<SEC-DOCUMENT>0000049071-24-000012.txt : 20240215
<SEC-HEADER>0000049071-24-000012.hdr.sgml : 20240215
<ACCEPTANCE-DATETIME>20240215165539
ACCESSION NUMBER:		0000049071-24-000012
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		132
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240215
DATE AS OF CHANGE:		20240215

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HUMANA INC
		CENTRAL INDEX KEY:			0000049071
		STANDARD INDUSTRIAL CLASSIFICATION:	HOSPITAL & MEDICAL SERVICE PLANS [6324]
		ORGANIZATION NAME:           	02 Finance
		IRS NUMBER:				610647538
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-05975
		FILM NUMBER:		24644596

	BUSINESS ADDRESS:	
		STREET 1:		500 W MAIN ST
		CITY:			LOUISVILLE
		STATE:			KY
		ZIP:			40202
		BUSINESS PHONE:		5025801000

	MAIL ADDRESS:	
		STREET 1:		500 W. MAIN ST
		CITY:			LOUISVILLE
		STATE:			KY
		ZIP:			40202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXTENDICARE INC
		DATE OF NAME CHANGE:	19740404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HERITAGE HOUSE OF AMERICA INC
		DATE OF NAME CHANGE:	19671129
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>hum-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:hum="http://www.humana.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>hum-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-32">0000049071</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-35">false</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-112">0.1667</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-113">0.1667</ix:nonFraction><ix:nonNumeric contextRef="c-7" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-117">http://fasb.org/us-gaap/2023#HealthCareMember</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-118">http://fasb.org/us-gaap/2023#HealthCareMember</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="f-119">http://fasb.org/us-gaap/2023#HealthCareMember</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1124">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="f-1125">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1128">http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1129">http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1132">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1133">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-428" name="hum:TRICAREManagedCareSupportContractBaseTerm" id="f-1748">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-428" name="hum:TRICAREManagedCareSupportContractTermWithOptionExercises" id="f-1750">P9Y</ix:nonNumeric><ix:nonFraction unitRef="usdPerShare" contextRef="c-616" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-2197">0.1667</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="c-617" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-2198">0.1667</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="hum-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:FederalGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">hum:ValueCreationInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">hum:ValueCreationInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">hum:ExitFromEmployerGroupCommercialMedicalProductsBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:ReinsuranceContractAxis"><us-gaap:ReinsuranceContractAxis.domain>CMS reinsurance subsidies and discounts</us-gaap:ReinsuranceContractAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:ReinsuranceContractAxis"><us-gaap:ReinsuranceContractAxis.domain>CMS brand name prescription drug discounts</us-gaap:ReinsuranceContractAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:ReinsuranceContractAxis"><us-gaap:ReinsuranceContractAxis.domain>CMS brand name prescription drug discounts</us-gaap:ReinsuranceContractAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">hum:HomeSolutionsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">hum:ProviderReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">hum:GentivaHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:TermLoanDueOctober2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">hum:GentivaHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-11</xbrli:startDate><xbrli:endDate>2022-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">hum:GentivaHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">hum:GentivaHospiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">hum:MedicareLicensesAndCertificatesOfNeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hum:KindredAtHomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hum:KindredAtHomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-17</xbrli:startDate><xbrli:endDate>2021-08-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">hum:KindredAtHomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">hum:KindredAtHomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">hum:KindredAtHomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">hum:KindredAtHomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">hum:KindredAtHomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">hum:KindredAtHomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">hum:KindredAtHomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-11</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WelshCarsonAndersonAndStoweMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="primary_care_center"><xbrli:measure>hum:primary_care_center</xbrli:measure></xbrli:unit><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WelshCarsonAndersonAndStoweMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WelshCarsonAndersonAndStoweMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WelshCarsonAndersonAndStoweCohortOfClinicsOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WelshCarsonAndersonAndStoweCohortOfClinicsOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">hum:GentivaHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">hum:GentivaHospiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">srt:StandardPoorsAAMinusRatingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>hum:position</xbrli:measure></xbrli:unit><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">hum:FairValueRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">hum:FairValueRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A5.88PercentSeniorNotesDueMarch2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A550PercentSeniorNotesDueMarch2053Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3.950PercentSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A5950PercentSeniorNotesDueMarch2034Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">hum:InterestRateSwapMaturing2032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">hum:InterestRateSwapMaturing2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">hum:InterestRateSwapMaturing2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">hum:InterestRateSwapMaturing2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">hum:TermLoanAndCommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hum:KindredAtHomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:CreditSpreadOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:CreditSpreadOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:CreditSpreadOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:CreditSpreadOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">hum:RevenueExitMultipleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">hum:RevenueExitMultipleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">hum:RevenueExitMultipleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">hum:RevenueExitMultipleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputLongTermRevenueGrowthRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputLongTermRevenueGrowthRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">hum:RiskCorridorSettlementsMedicarePartDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">hum:CmsSubsidiesOrDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">hum:RiskCorridorSettlementsMedicarePartDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">hum:CmsSubsidiesOrDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hum:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hum:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">hum:CertificateOfNeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">hum:CertificateOfNeedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">hum:NoncompetesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">hum:NoncompetesAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>hum:claim</xbrli:measure></xbrli:unit><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">hum:ShortDurationInsuranceContractAccidentYear2021AndPriorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">hum:ShortDurationInsuranceContractAccidentYear2021AndPriorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">hum:ShortDurationInsuranceContractAccidentYear2021AndPriorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3850PercentSeniorNotesDueOctober2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3850PercentSeniorNotesDueOctober2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A065PercentSeniorNotesDueAugust2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A065PercentSeniorNotesDueAugust2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A4.500PercentSeniorNotesDueApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A4.500PercentSeniorNotesDueApril2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A570PercentSeniorNotesDueMarch2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A570PercentSeniorNotesDueMarch2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A135PercentSeniorNotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A135PercentSeniorNotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3.95PercentSeniorNotesDueMarch2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3.95PercentSeniorNotesDueMarch2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A575PercentSeniorNotesDueMarch2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A575PercentSeniorNotesDueMarch2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A575PercentSeniorNotesDueDecember2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A575PercentSeniorNotesDueDecember2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A370PercentSeniorNotesDueMarch2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A370PercentSeniorNotesDueMarch2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A313PercentSeniorNotesDueAugust2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A313PercentSeniorNotesDueAugust2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A488PercentSeniorNotesDueApril2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A488PercentSeniorNotesDueApril2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A215PercentSeniorNotesDueFebruary2032Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A215PercentSeniorNotesDueFebruary2032Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A5.88PercentSeniorNotesDueMarch2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A5950PercentSeniorNotesDueMarch2034Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A8.15PercentSeniorNotesDueJune2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A8.15PercentSeniorNotesDueJune2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A463PercentSeniorNotesDueDecember2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A463PercentSeniorNotesDueDecember2042Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A4.95PercentSeniorNotesDueOctober2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A4.95PercentSeniorNotesDueOctober2044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A4.80PercentSeniorNotesDueMarch2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A4.80PercentSeniorNotesDueMarch2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3.95PercentSeniorNotesDueAugust2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3.95PercentSeniorNotesDueAugust2049Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A550PercentSeniorNotesDueMarch2053Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:DelayedDrawTermLoanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:DelayedDrawTermLoanMay2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A575PercentSeniorNotesDueDecember2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A5950PercentSeniorNotesDueMarch2034Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A570PercentSeniorNotesDueMarch2026Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A550PercentSeniorNotesDueMarch2053Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:DelayedDrawTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A135PercentSeniorNotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3.95PercentSeniorNotesDueMarch2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3700PercentSeniorNotesDueMarch2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3125PercentSeniorNotesDueAugust2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RepurchasePlanAugust2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A065PercentSeniorNotesDueAugust2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3850PercentSeniorNotesDueOctober2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RepurchasePlanMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A065PercentSeniorNotesDueAugust2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2021FiveYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2021FiveYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023OneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023OneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2022OneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2022OneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">hum:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023OneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">hum:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023OneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">hum:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">hum:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023OneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">hum:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023OneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">hum:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023OneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023OneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2021FiveYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2021OneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2021OneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:FederalHomeLoanBankAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:FederalHomeLoanBankAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:FederalHomeLoanBankAdvancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hum:A2011PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hum:A2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hum:A2011PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hum:A2011PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hum:A2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hum:A2019PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-07-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:CitibankNAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:JPMorganChaseBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-23</xbrli:startDate><xbrli:endDate>2020-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:JPMorganChaseBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-23</xbrli:startDate><xbrli:endDate>2020-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:CitibankNAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-23</xbrli:startDate><xbrli:endDate>2020-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:CitibankNAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-04</xbrli:startDate><xbrli:endDate>2021-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:JPMorganChaseBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-05</xbrli:startDate><xbrli:endDate>2021-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-22</xbrli:startDate><xbrli:endDate>2021-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-05</xbrli:startDate><xbrli:endDate>2021-05-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:MizuhoMarketsAmericasLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WellsFargoBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-12</xbrli:startDate><xbrli:endDate>2022-01-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WellsFargoBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-12</xbrli:startDate><xbrli:endDate>2022-01-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:MizuhoMarketsAmericasLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-12</xbrli:startDate><xbrli:endDate>2022-01-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:MizuhoMarketsAmericasLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-29</xbrli:startDate><xbrli:endDate>2022-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WellsFargoBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-30</xbrli:startDate><xbrli:endDate>2022-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-11</xbrli:startDate><xbrli:endDate>2022-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-29</xbrli:startDate><xbrli:endDate>2022-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:GoldmanSachsCoLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:MizuhoMarketsAmericasLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-02</xbrli:startDate><xbrli:endDate>2022-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:GoldmanSachsCoLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-02</xbrli:startDate><xbrli:endDate>2022-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:MizuhoMarketsAmericasLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-02</xbrli:startDate><xbrli:endDate>2022-11-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:GoldmanSachsCoLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-15</xbrli:startDate><xbrli:endDate>2022-12-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:MizuhoMarketsAmericasLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-16</xbrli:startDate><xbrli:endDate>2022-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-02</xbrli:startDate><xbrli:endDate>2022-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-15</xbrli:startDate><xbrli:endDate>2022-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:A2021ShareRepurchaseAuthorizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:A2023ShareRepurchaseAuthorizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:A2023ShareRepurchaseAuthorizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:A2023ShareRepurchaseAuthorizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:A2024ShareRepurchaseAuthorizationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:February2023ShareRepurchaseAuthorizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:February2023ShareRepurchaseAuthorizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:February2023ShareRepurchaseAuthorizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:February2023ShareRepurchaseAuthorizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:February2021ShareRepurchaseAuthorizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:February2021ShareRepurchaseAuthorizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:February2021ShareRepurchaseAuthorizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:February2021ShareRepurchaseAuthorizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="hum:TRICAREContractAxis">hum:TRICARE2017EastRegionContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hum:TRICAREContractAxis">hum:TRICARE2017EastRegionContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="state"><xbrli:measure>hum:state</xbrli:measure></xbrli:unit><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hum:TRICAREContractAxis">hum:TRICARE2017EastRegionContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="beneficiary"><xbrli:measure>hum:beneficiary</xbrli:measure></xbrli:unit><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hum:TRICAREContractAxis">hum:TRICAREManagedCareSupportContractEffective2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hum:TRICAREContractAxis">hum:TRICAREManagedCareSupportContractEffective2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="option_period"><xbrli:measure>hum:option_period</xbrli:measure></xbrli:unit><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>hum:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:FederalGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:FederalGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="hum:LongDurationInsuranceProductsAxis">hum:CoinsuranceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ProtectiveLifeInsuranceCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:AllOthersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="reinsurer"><xbrli:measure>hum:reinsurer</xbrli:measure></xbrli:unit><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000049071</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December&#160;31</ix:nonNumeric>, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.094%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from _____ to _____</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">1-5975</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">HUMANA INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:45.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.271%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.215%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">61-0647538</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation of organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">500 West Main Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Louisville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Kentucky</ix:nonNumeric>  <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">40202</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices, and zip code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">502</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">580-1000</ix:nonNumeric> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.290%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common stock, $0.16 2/3 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">HUM</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:  None</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.  <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744; </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9745; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744; </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.199%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9745;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#9745;</ix:nonNumeric></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of voting stock held by non-affiliates of the Registrant as of June&#160;30, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-29">55,096,895,366</ix:nonFraction> calculated using the average price on June&#160;30, 2023 of $445.24 per share.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares outstanding of the Registrant&#8217;s Common Stock as of January&#160;31, 2024 was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">120,653,315</ix:nonFraction>.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true">Parts II and III incorporate herein by reference portions of the Registrant&#8217;s Definitive Proxy Statement to be filed pursuant to Regulation 14A with respect to the Annual Meeting of Stockholders scheduled to be held on April&#160;18, 2024. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</ix:nonNumeric>  </span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_7"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HUMANA INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO ANNUAL REPORT ON FORM 10-K</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Year Ended December&#160;31, 2023 </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.340%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:72.340%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.020%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_19">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_67">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_67">22</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_70">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_70">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_2439">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_2439">36</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_73">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_73">37</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_76">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_76">38</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_79">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_79">38</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_85">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_85">39</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_88">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_88">42</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_94">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_94">43</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_118">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_118">67</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_121">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_121">69</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_208">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_208">124</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_211">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_211">124</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_214">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_214">125</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_217">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_217">125</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part III</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_223">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_223">126</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_226">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_226">127</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_229">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_229">127</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_232">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_232">128</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_235">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_235">128</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part IV</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_241">Exhibits, Financial Statement Schedule</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_241">129</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_286">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_286">141</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_289">Signatures and Certifications</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i7b1f484cd1dd4915aee01308d7de3d89_289">142</a></span></div></td></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_10"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Some of the statements under &#8220;Business,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and elsewhere in this report may contain forward-looking statements which reflect our current views with respect to future events and financial performance. These forward-looking statements are made within the meaning of Section&#160;27A of the Securities Act of 1933 and Section&#160;21E of the Securities Exchange Act of 1934, or the Exchange Act. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe harbor provisions. We have based these forward-looking statements on our current expectations and projections about future events, trends and uncertainties. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, including the information discussed under the section entitled &#8220;Risk Factors&#8221; in this report. In making these statements, we are not undertaking to address or update them in future filings or communications regarding our business or results. Our business is highly complicated, regulated and competitive with many different factors affecting results.</span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_13"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_16"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1. BUSINESS </span></div><div><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_19"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> General</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Louisville, Kentucky, Humana Inc. and its subsidiaries, referred to throughout this document as &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221; or &#8220;Humana,&#8221; is committed to putting health first &#8211; for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health &#8211; delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December&#160;31, 2023, we had approximately 17 million members in our medical benefit plans, as well as approximately 5&#160;million members in our specialty products. During 2023, 84% of our total premiums and services revenue were derived from contracts with the federal government, including 14% derived from our individual Medicare Advantage contracts in Florida with the Centers for Medicare and Medicaid Services, or CMS, under which we provide health insurance coverage to approximately 851,300 members as of December&#160;31, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humana Inc. was organized as a Delaware corporation in 1964. Our principal executive offices are located at 500 West Main Street, Louisville, Kentucky 40202, the telephone number at that address is (502)&#160;580-1000, and our website address is www.humana.com. We have made available free of charge through the Investor Relations section of our web site our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, and, if applicable, amendments to those reports filed or furnished pursuant to Section&#160;13(a) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K, or 2023 Form 10-K, contains both historical and forward-looking information. See Part I, Item&#160;1A, "Risk Factors" of this Form 10-K for a description of a number of factors that may adversely affect our results or business.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_22"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Segments</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2022, we realigned our businesses into two distinct segments: Insurance and CenterWell. The Insurance segment includes the businesses that were previously included in the Retail and Group and Specialty segments, as well as the Pharmacy Benefit Manager, or PBM, business which was previously included in the Healthcare Services segment. The CenterWell segment (formerly Healthcare Services) represents our payor-agnostic healthcare services offerings, including pharmacy solutions, primary care, and home solutions. In addition to the </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">new segment classifications being utilized to assess performance and allocate resources, we believe this simpler structure will create greater collaboration across the Insurance and CenterWell businesses and will accelerate work that is underway to centralize and integrate operations within the organization. 2021 segment financial information was recast to conform to the 2022 presentation. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our two</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources. For additional information on our business segments and segment financial information, refer to Note 18 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_25"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Products</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medical and specialty insurance products allow members to access health care services primarily through our networks of health care providers with whom we have contracted. These products may vary in the degree to which members have coverage. Health maintenance organizations, or HMOs, include comprehensive managed care benefits generally through a participating network of physicians, hospitals, and other providers. Preferred provider organizations, or PPOs, provide members the freedom to choose any health care provider. However, PPOs generally require the member to pay a greater portion of the provider&#8217;s fee in the event the member chooses not to use a provider participating in the PPO&#8217;s network. Point of Service, or POS, plans combine the advantages of HMO plans with the flexibility of PPO plans. In general, POS plans allow members to choose, at the time medical services are needed, to seek care from a provider within the plan&#8217;s network or outside the network. In addition, we offer services to our health plan members as well as to third parties that promote health and wellness, including pharmacy solutions, primary care, and home solutions, as well as services and capabilities to advance population health. At the core of our strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics. Three core elements of the model are to improve the consumer experience by simplifying the interaction with us, engaging members in clinical programs, and offering assistance to providers in transitioning from a fee-for-service, or FFS, to a value-based arrangement. Our approach to primary, physician-directed care for our members aims to provide quality care that is consistent, integrated, cost-effective, and member-focused. The model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering our members a simple, seamless healthcare experience. The discussion that follows describes the products offered by each of our segments.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_28"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Insurance Segment Products</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Insurance segment is comprised of products serving Medicare and state-based contract beneficiaries sold on a retail basis to individuals including medical and supplemental benefit plans. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision and life insurance benefits, as well as administrative services only, or ASO.  In addition, our Insurance segment includes our military services business as well as the operations of our PBM business. These products are described in the discussion that follows. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our premiums and services revenue for the Insurance segment by product for the year ended December&#160;31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:56.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.448%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance Segment<br/>Premiums and<br/>Services&#160;Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent of<br/>Consolidated<br/>Premiums and<br/>Services&#160;Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Insurance segment premiums and services revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,272&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have participated in the Medicare program for private health plans for over 30 years and have established a national presence, offering at least one type of Medicare plan in all 50 states. We have a geographically diverse membership base that we believe provides us with greater ability to expand our network of PPO and HMO providers. We employ strategies including health assessments and clinical guidance programs such as lifestyle and fitness programs for seniors to guide Medicare beneficiaries in making cost-effective decisions with respect to their health care. We believe these strategies result in cost savings that occur from making positive behavior changes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare is a federal program that provides persons age 65 and over and some disabled persons under the age of 65 certain hospital and medical insurance benefits. CMS, an agency of the United States Department of Health and Human Services, administers the Medicare program. Hospitalization benefits are provided under Part A, without the payment of any premium, for up to 90 days per incident of illness plus a lifetime reserve aggregating 60 days. Eligible beneficiaries are required to pay an annually adjusted premium to the federal government to be eligible for physician care and other services under Part B. Beneficiaries eligible for Part A and Part B coverage under traditional fee-for-service Medicare are still required to pay out-of-pocket deductibles and coinsurance. Throughout this document this program is referred to as Medicare FFS. As an alternative to Medicare FFS, in geographic areas where a managed care organization has contracted with CMS pursuant to the Medicare Advantage program, Medicare beneficiaries may choose to receive benefits from a Medicare Advantage organization under Medicare Part C. Pursuant to Medicare Part C, Medicare Advantage organizations contract with CMS to offer Medicare </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advantage plans to provide benefits at least comparable to those offered under Medicare FFS. Our Medicare Advantage, or MA, plans are discussed in the following sections. Prescription drug benefits are provided under Part D.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Individual Medicare Advantage Products</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with CMS under the Medicare Advantage program to provide a comprehensive array of health insurance benefits, including wellness programs, chronic care management, and care coordination, to Medicare eligible persons under HMO, PPO, Private Fee-For-Service, or PFFS, and Special Needs Plans, including Dual Eligible Special Needs, or D-SNP, plans in exchange for contractual payments received from CMS, usually a fixed payment per member per month. With each of these products, the beneficiary receives benefits in excess of Medicare FFS, typically including reduced cost sharing, enhanced prescription drug benefits, care coordination, data analysis techniques to help identify member needs, complex case management, tools to guide members in their health care decisions, care management programs, wellness and prevention programs and, in some instances, a reduced monthly Part B premium. Most Medicare Advantage plans offer the prescription drug benefit under Part D as part of the basic plan, subject to cost sharing and other limitations. Accordingly, all of the provisions of the Medicare Part D program described in connection with our stand-alone prescription drug plans in the following section also are applicable to most of our Medicare Advantage plans. Medicare Advantage plans may charge beneficiaries monthly premiums and other copayments for Medicare-covered services or for certain extra benefits. Generally, Medicare-eligible individuals enroll in one of our plan choices between October&#160;15 and December&#160;7 for coverage that begins on the following January&#160;1.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medicare HMO and PPO plans, which cover Medicare-eligible individuals residing in certain counties, may eliminate or reduce coinsurance or the level of deductibles on many other medical services while seeking care from participating in-network providers or in emergency situations. Except in emergency situations or as specified by the plan, most HMO plans provide no out-of-network benefits. PPO plans carry an out-of network benefit that is subject to higher member cost-sharing. In some cases, these beneficiaries are required to pay a monthly premium to the HMO or PPO plan in addition to the monthly Part B premium they are required to pay the Medicare program.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our Medicare PFFS plans are network-based products with in and out of network benefits due to a requirement that Medicare Advantage organizations establish adequate provider networks, except in geographic areas that CMS determines have fewer than two network-based Medicare Advantage plans. In these areas, we offer Medicare PFFS plans that have no preferred network. Individuals in these plans pay us a monthly premium to receive typical Medicare Advantage benefits along with the freedom to choose any health care provider that accepts individuals at rates equivalent to Medicare FFS payment rates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997 (BBA) and the Benefits Improvement and Protection Act of 2000 (BIPA), generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service (FFS) program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model. For additional information, </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">refer to Note 17 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" and Part I, Item 1A, "Risk Factors" of this Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, we provided health insurance coverage under CMS contracts to approximately 5,408,900 individual Medicare Advantage members, including approximately 851,300 members in Florida. These Florida contracts accounted for premiums revenue of approximately $14.9 billion, which represented approximately 19% of our individual Medicare Advantage premiums revenue, or 14% of our consolidated premiums and services revenue for the year ended December&#160;31, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our individual Medicare Advantage products covered under Medicare Advantage contracts with CMS are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May&#160;1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare Advantage products have been renewed for 2024, and all of our product offerings filed with CMS for 2024 have been approved.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Individual Medicare Stand-Alone Prescription Drug Products</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer stand-alone prescription drug plans, or PDPs, under Medicare Part D, including a PDP offering co-branded with Walmart Inc., or the Humana-Walmart plan. Generally, Medicare-eligible individuals enroll in one of our plan choices between October&#160;15 and December&#160;7 for coverage that begins on the following January&#160;1. Our stand-alone PDP offerings consist of plans offering basic coverage with benefits mandated by Congress, as well as plans providing enhanced coverage with varying degrees of out-of-pocket costs for premiums, deductibles, and co-insurance. Our revenues from CMS and the beneficiary are determined from our PDP bids submitted annually to CMS. These revenues also reflect the health status of the beneficiary and risk sharing provisions as more fully described in Note 2 to the audited Consolidated Financial Statements included in Item&#160;8. &#8211; Financial Statements and Supplementary Data, titled &#8220;Receivables and Revenue Recognition.&#8221; Our stand-alone PDP contracts with CMS are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May&#160;1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare stand-alone PDP products have been renewed for 2024, and all of our product offerings filed with CMS for 2024 have been approved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have administered CMS&#8217;s Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program since 2010. This program allows individuals who receive Medicare&#8217;s low-income subsidy to also receive immediate prescription drug coverage at the point of sale if they are not already enrolled in a Medicare Part D plan. CMS temporarily enrolls newly identified individuals with both Medicare and Medicaid into the LI-NET prescription drug plan program, and subsequently transitions each member into a Medicare Part D plan that may or may not be a Humana Medicare plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Group Medicare Advantage and Medicare Stand-Alone PDP</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer products that enable employers that provide post-retirement health care benefits to replace Medicare wrap or Medicare supplement products with Medicare Advantage or stand-alone PDPs from Humana. These products are primarily offered as PPO plans on the same Medicare platform as individual Medicare Advantage plans. These plans offer the same types of benefits and services available to members in our individual Medicare plans discussed previously, however, group Medicare Advantage plans typically have richer benefit offerings than individual Medicare Advantage plans, including prescription drug coverage in the gap, for instance, due to the desire of many customers to closely match their pre-retirement benefit structure.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Supplement</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer Medicare supplement products that help pay the medical expenses that Medicare FFS does not cover, such as copayments, coinsurance and deductibles.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State-based Contracts</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Through our state-based contracts, we serve members enrolled in Medicaid, a program funded by both the federal and state governments and administered by states to care for their most vulnerable populations. Within federal guidelines, states determine whom to cover, but general categories for traditional Medicaid programs include: children and parents receiving assistance through Temporary Assistance to Needy Families (TANF); Aged, Blind, and Disabled (ABD) individuals; and Medicaid Expansion adults. Through Medicaid Managed Long-Term Support Services (MLTSS) programs, states offer programs to deliver support services to people who receive home and community or institution-based services for long-term care. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have contracts in multiple states to serve Medicaid-eligible members, including Florida, Kentucky, Illinois, Louisiana, Ohio, South Carolina and Wisconsin. We were awarded new Medicaid contracts in Oklahoma and Indiana, which we expect to become effective April 1, 2024 and July 1, 2024, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also serve members who qualify for both Medicaid and Medicare, referred to as "dual eligible", through our Medicaid, Medicare Advantage, and stand-alone prescription drug plans. As the dual eligible population represents a disproportionate share of costs, Humana is participating in varied integration models designed to improve health outcomes and reduce avoidable costs. These programs largely operate separately from traditional Medicaid programs. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our individual Medicare Advantage products, we also offer Dual-Eligible Special Needs Plans (D-SNP). In connection with offering a D-SNP in a particular state, we are required to enter into a special coordinating contract with the applicable state Medicaid agency. To meet federal requirements that took effect in 2021, states have implemented new D-SNP requirements to strengthen Medicaid-Medicare integration requirements for D-SNPs. Some states are also moving to support the dual eligible population by linking D-SNP participation to enrollment in a plan that also participates in a state-based Medicaid program to coordinate and integrate both Medicare and Medicaid benefits.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Group Commercial Coverage </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. The exit from this line of business will be phased over the 18 to 24 months following our February 2023 announcement. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sell specialty and ancillary insurance benefits consisting of dental, vision, life and disability to employer groups.  In addition, we sell dental and vision specialty insurance benefits to individuals.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For in-force group commercial medical customers and members, our commercial products include a broad spectrum of major medical benefits with multiple in-network coinsurance levels and annual deductible choices that employers of all sizes can offer to their employees on either a fully-insured, through HMO, PPO, or POS plans, or self-funded basis. Our plans integrate clinical programs, plan designs, communication tools, and spending accounts. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ASO products are offered to small group and large group employers who self-insure their employee health plans. We receive fees to provide administrative services which generally include the processing of claims, offering access to our provider networks and clinical programs, and responding to customer service inquiries from members of self-funded employers. These products may include all of the same benefit and product design characteristics of our fully-insured HMO, PPO, or POS products described previously. Under ASO contracts, self-funded employers generally retain the risk of financing the costs of health benefits, with large group customers retaining a greater share and small group customers a smaller share of the cost of health benefits.  All small group ASO customers and many </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">large group ASO customers purchase stop loss insurance coverage from us to cover catastrophic claims or to limit aggregate annual costs.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Military Services</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our TRICARE contracts with the United States Department of Defense, or DoD, we provide administrative services to arrange health care services for active-duty and retired military personnel and their dependents. We have participated in the TRICARE program since 1996 under contracts with the DoD. Under our contracts, we provide administrative services while the federal government retains all of the risk of the cost of health benefits. Accordingly, we account for revenues under the current contract net of estimated health care costs similar to an administrative services fee only agreement. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2018, we began to deliver services under the T2017 East Region contract. The T2017 East Region contract comprises 32 states and approximately 6 million TRICARE beneficiaries. The T2017 East Region contract, which was originally set to expire on December 31, 2022, was subsequently extended by the DoD and is currently scheduled to expire on December 31, 2024, unless further extended. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we were awarded the next generation of TRICARE Managed Care Support Contracts, or T-5, for the updated TRICARE East Region by the Defense Health Agency of the DoD. The T-5 East Region contract comprises 24 states, and Washington D.C., and covers approximately 4.6&#160;million beneficiaries. The transition period for the T-5 contract began in January 2024 and will overlap the final year of the T2017 contract. The length of the contract is one transition year followed by eight annual option periods, which, if all options are exercised, would result in a total contract length of nine years. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_31"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our CenterWell Segment Products</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products offered by our CenterWell segment are key to our integrated care delivery model. This segment includes our pharmacy solutions, primary care, and home solutions operations. The CenterWell segment also includes our strategic partnerships with Welsh, Carson, Anderson &amp; Stowe, or WCAS, to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs. For information on our intersegment revenues, refer to Note 18 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our services revenue for the CenterWell segment by line of business for the year ended December&#160;31, 2023:</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:55.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.606%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell<br/>Segment<br/>Services Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent of<br/>Consolidated<br/>Premiums&#160;and<br/>Services&#160;Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intersegment revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External services revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external services revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,033&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n/a &#8211; not applicable</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmacy Solutions</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pharmacy solutions business includes the operations of CenterWell Pharmacy (our mail-order pharmacy business), CenterWell Specialty Pharmacy, and other retail pharmacies located within CenterWell Primary Care clinics for brand, generic, specialty drugs, over the counter medications and supplies, as well as hospice pharmacy drugs.&#160;</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Primary Care</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate full-service, value-based senior focused primary care centers in a number of states, including Georgia, Florida, Kansas, Louisiana, Missouri, Nevada, North Carolina, South Carolina, Texas, Arizona and Kentucky staffed by primary care providers and medical specialists with a primary focus on the senior population under our Primary Care Organization, or PCO. PCO operates these clinics primarily under the Conviva Care Centers and CenterWell Senior Primary Care brands. Our primary care subsidiaries operate our medical center business through both employed physicians and care providers, and through third party management service organizations with whom we contract to arrange for and manage certain clinical services. PCO currently operates 296 primary care clinics and employs approximately 890 primary care providers. PCO serves approximately 294,200 patients, primarily under risk sharing arrangements with Humana Medicare Advantage health plans, third party Medicare Advantage health plans and CMS administered risk sharing arrangements for Medicare FFS.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;PCO also operates a Medical Services Organization, or MSO, through Conviva that coordinates medical care for Medicare Advantage beneficiaries in Florida and Texas. This MSO provides resources in care coordination, financial risk management, clinical integration and patient engagement that help physicians improve the patient experience as well as care outcomes. Conviva&#8217;s MSO collaborates with physicians, medical groups and integrated delivery systems to successfully transition to value-based care by engaging, partnering and offering practical services and solutions.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, our Primary Care Organization entered into a strategic partnership with Welsh, Carson, Anderson &amp; Stowe, or WCAS, to accelerate the expansion of our primary care model. In May 2022, we established a second strategic partnership with WCAS to develop additional centers between 2023 and 2025. As of December 31, 2023, there were 108 primary care clinics operating under the partnership and we have capacity to open or acquire up to approximately 60 additional centers through the existing partnership agreements. For additional information, refer to Note 4 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Home Solutions </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CenterWell Home Health</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are actively involved in the care management of our customers with the greatest needs via in-home care. On August 17, 2021, we fully acquired Kindred at Home, or KAH, the nation&#8217;s largest home health and hospice provider with locations in 40 states, providing extensive geographic coverage with approximately 65% overlap with our individual Medicare Advantage membership. Our home solutions geographic scale and clinical breadth provides the opportunity to offer care beyond our health plan members. We have fully-integrated the home health operations, now branded CenterWell Home Health, allowing us to accelerate clinical innovation and the development and roll out of a value-based operating model at scale, more closely aligning incentives to focus on improving patient outcomes and reducing the total cost of care. This is critical to deploying a value-based, advanced home health model at scale that makes it easier for patients and providers to benefit from our full continuum of home-based capabilities, leveraging the best channel to deliver the right care needed at the right time.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Onehome</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onehome serves as the convener for the value-based model meeting the needs of health plans by serving their members through a full-risk model for integrated home-based services. Onehome manages a full range of post-acute patient needs, integrating and coordinating with physicians, hospitals and health plans for the provision of home health and infusion services as well as the distribution of durable medical equipment, or DME, at patients&#8217; homes. Onehome served 14% of our MA members with our value-based model as of December 31, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospice</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospice care is an important offering in the full continuum of care we offer patients, and we have been successful in delivering the desired patient experience and outcomes through partnership models, including through participation in the CMS hospice Value-Based Insurance Design, or VBID, model. As such, on August&#160;11, 2022, we completed the sale of a 60% interest in Gentiva (formerly Kindred) Hospice, to Clayton, Dubilier &amp; Rice, or CD&amp;R. Upon closing, Gentiva Hospice was restructured into a new stand-alone company. We continue to own a 35% minority ownership in Gentiva Hospice operations. For additional information on the sale of Gentiva Hospice, refer to Note 3 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_34"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Insurance Medical Membership</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total insurance medical membership (in thousands) at December&#160;31, 2023, by market and product:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.752%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.758%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Insurance Medical Membership</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Individual<br/>Medicare<br/>Advantage</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Group<br/>Medicare<br/>Advantage</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Medicare<br/>stand-<br/>alone&#160;PDP</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Medicare Supplement</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">State-<br/>based<br/>contracts and Other</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Fully-<br/>insured<br/>commercial<br/>Group</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">ASO</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Military services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Percent<br/>of&#160;Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Florida</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">851.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">656.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,764.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Texas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">446.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">762.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kentucky</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">653.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ohio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">502.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Georgia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">348.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">North Carolina</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">251.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">528.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Illinois</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tennessee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Louisiana</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">California</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Missouri/Kansas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Michigan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Wisconsin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">South Carolina</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indiana</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Virginia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">New York</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arizona</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pennsylvania</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mississippi</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TRICARE</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,960.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,960.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Others</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1010.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">946.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,185.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Totals</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,408.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">509.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,849.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,228.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">338.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,960.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,857.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_37"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provider Arrangements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide our members with access to health care services through our networks of health care providers whom we employ or with whom we have contracted, including hospitals and other independent facilities such as outpatient surgery centers, primary care providers, specialist physicians, dentists, and providers of ancillary health care services and facilities. These ancillary services and facilities include laboratories, ambulance services, medical equipment services, home health agencies, mental health providers, rehabilitation facilities, nursing homes, optical services, and pharmacies. Our membership base and the ability to influence where our members seek care generally enable us to obtain contractual discounts with providers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a variety of techniques to provide access to effective and efficient use of health care services for our members. These techniques include the coordination of care for our members, product and benefit designs, hospital inpatient management systems, the use of sophisticated analytics, and enrolling members into various care management programs. The focal point for health care services in many of our HMO networks is the primary care provider who, under contract with us, provides services to our members, and may control utilization of appropriate services by directing or approving hospitalization and referrals to specialists and other providers. Some physicians may have arrangements under which they can earn bonuses when certain target goals relating to the provision of quality patient care are met. We have available care management programs related to complex chronic conditions such as congestive heart failure and coronary artery disease. We also have programs for prenatal and premature infant care, asthma related illness, end stage renal disease, diabetes, cancer, and certain other conditions.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically contract with hospitals on either (1)&#160;a per diem rate, which is an all-inclusive rate per day, (2)&#160;a case rate for diagnosis-related groups (DRG), which is an all-inclusive rate per admission, or (3)&#160;a discounted charge for inpatient hospital services. Outpatient hospital services generally are contracted at a flat rate by type of service, ambulatory payment classifications, or APCs, or at a discounted charge. APCs are similar to flat rates except multiple services and procedures may be aggregated into one fixed payment. These contracts are often multi-year agreements, with rates that are adjusted for inflation annually based on the consumer price index, other nationally recognized inflation indexes, or specific negotiations with the provider. Outpatient surgery centers and other ancillary providers typically are contracted at flat rates per service provided or are reimbursed based upon a nationally recognized fee schedule such as the Medicare allowable fee schedule.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with physicians typically are renewed automatically each year, unless either party gives written notice, generally ranging from 90 to 120 days, to the other party of its intent to terminate the arrangement. Most of the physicians in our PPO networks and some of our physicians in our HMO networks are reimbursed based upon a fixed fee schedule, which typically provides for reimbursement based upon a percentage of the standard Medicare allowable fee schedule.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of our contracts with hospitals and physicians may also vary between Medicare and commercial business. A significant portion of our Medicare network contracts, including those with both hospitals and physicians, are tied to Medicare reimbursement levels and methodologies.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_40"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capitation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer providers a continuum of opportunities to increase the integration of care and offer assistance to providers in transitioning from a fee-for-service to a value-based arrangement. These include performance bonuses, shared savings and shared risk relationships. For some of our medical membership, we share risk with providers under capitation contracts where physicians and hospitals accept varying levels of financial risk for a defined set of membership, primarily HMO membership. Under the typical capitation arrangement, we prepay these providers a monthly fixed-fee per member, known as a capitation (per capita) payment, to cover all or a defined portion of the benefits provided to the capitated member.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these value-based arrangements represent a key element of our integrated care delivery model at the core of our strategy. Our health plan subsidiaries may enter into these value-based arrangements with third party providers or our owned provider subsidiaries.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, approximately 2,165,600 members, or 12.8% of our medical membership, were covered under shared risk value-based arrangements, which provide all member benefits, including 1,917,300 individual Medicare Advantage members, or 35.4% of our total individual Medicare Advantage membership. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians under capitation arrangements typically have stop loss coverage so that a physician&#8217;s financial risk for any single member is limited to a maximum amount on an annual basis. We typically process all claims and measure the financial performance of our capitated providers and require guarantees in certain instances.&#160;However, we delegated claim processing functions under capitation arrangements covering approximately 289,000 HMO members, including 288,300 individual Medicare Advantage members, or 15.0% of the 1,917,300 individual Medicare Advantage members covered under value-based contracts at December&#160;31, 2023, with the provider assuming substantially all the risk of coordinating the members&#8217; health care benefits.&#160;Capitation expense under delegated arrangements for which we have a limited view of the underlying claims experience was approximately $3.4 billion, or 3.9% of total benefits expense, for the year ended December&#160;31, 2023. We remain financially responsible for health care services to our members in the event our providers fail to provide such services.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_43"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accreditation Assessment</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accreditation assessment program consists of several internal programs, including those that credential providers and those designed to meet the audit standards of federal and state agencies as well as external accreditation standards. We also offer quality and outcome measurement and improvement programs such as the Health Care Effectiveness Data and Information Set, or HEDIS, which is used by employers, government purchasers </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the National Committee for Quality Assurance (NCQA) to evaluate health plans based on various criteria, including effectiveness of care and member satisfaction.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Providers participating in our networks must satisfy specific criteria, including licensing, patient access, office standards, after-hours coverage, and other factors. Most participating hospitals also meet accreditation criteria established by CMS and/or The Joint Commission.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recredentialing of participating providers occurs every three years, unless otherwise required by state or federal regulations. Recredentialing of participating providers includes verification of their medical licenses, review of their malpractice liability claims histories, review of their board certifications, if applicable, and review of applicable quality information. A committee composed of a peer group of providers reviews the applications of providers being considered for credentialing and recredentialing.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain accreditation for certain of our health plans and/or departments from NCQA, the Accreditation Association for Ambulatory Health Care (AAAHC), and/or URAC. Certain commercial businesses, such as those impacted by a third-party labor agreement or those where a request is made by the employer, may require or prefer accredited health plans.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NCQA reviews our compliance based on standards for quality improvement, population health management, credentialing, utilization management, network management, and member experience. We have achieved and maintained NCQA accreditation in many of our commercial, Medicare and Medicaid markets for HMO, POS, and PPO products, and our wellness program, Go365. Humana&#8217;s pharmacy organization is accredited by URAC.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_46"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We use various methods to market our products, including television, radio, the Internet, telemarketing, wholesale distributors (general agencies)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and direct mailings.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, we employed approximately 1,000 sales representatives, as well as approximately 2,500 telemarketing representatives who assisted in the marketing of Medicare products, including Medicare Advantage and PDP, and specialty products in our Insurance segment, including making appointments for sales representatives with prospective members. We have a marketing arrangement with Walmart Inc., or Walmart, for our individual Medicare stand-alone PDP offering. We also sell group Medicare Advantage products through large employers. In addition, we market our Medicare and individual specialty products through licensed independent brokers and agents. For our Medicare products, commissions paid to employed sales representatives and independent brokers and agents are based on a per unit commission structure, regulated in structure and amount by CMS. For our individual specialty products, we generally pay brokers a commission based on premiums, with commissions varying by market and premium volume. In addition to a commission based directly on premium volume for sales to particular customers, we also have programs that pay brokers and agents based on other metrics. These include commission bonuses based on sales that attain certain levels or involve particular products. We also pay additional commissions based on aggregate volumes of sales involving multiple customers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Insurance segment, we market our specialty products to individuals through their employers or other groups, which typically offer employees or members a selection of specialty products, pay for all or part of the premiums, and make payroll deductions for any premiums payable by the employees. We use licensed independent brokers, independent agents, digital insurance agencies, and employees to sell our specialty products. We pay brokers and agents using the same commission structure described above for our specialty products.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_49"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Underwriting</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2014, the Patient Protection and Affordability Care Act and The Health Care and Education Reconciliation Act of 2010, which we collectively refer to as the Health Care Reform Law, requires certain group health plans to guarantee issuance and renew coverage without pre-existing condition exclusions or health-status rating adjustments. Accordingly, certain group health plans are not subject to underwriting. Further, underwriting techniques are not employed in connection with our individual Medicare, military services, or Medicaid products because government regulations require us to accept all eligible applicants regardless of their health or medical history.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_52"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health benefits industry is highly competitive. Our competitors vary by local market and include other managed care companies, national insurance companies, and other HMOs and PPOs. Many of our competitors have a larger membership base and/or greater financial resources than our health plans in the markets in which we compete. Our ability to sell our products and to retain customers may be influenced by such factors as those described in Part I, Item&#160;1A, "Risk Factors" of this Form 10-K.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_55"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diverse legislative and regulatory initiatives at both the federal and state levels continue to affect aspects of the nation&#8217;s health care system, including the Health Care Reform Law at the federal level and laws in certain states limiting the entry of new providers or services though a certificate of need, or CON, process. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management works proactively to ensure compliance with all governmental laws and regulations affecting our business. We are unable to predict how existing federal or state laws and regulations may be changed or interpreted, what additional laws or regulations affecting our businesses may be enacted or proposed, when and which of the proposed laws will be adopted or what effect any such new laws and regulations will have on our results of operations, financial position, or cash flows.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of certain material current activities in the federal and state legislative areas, see Part I, Item&#160;1A, "Risk Factors" of this Form 10-K.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_58"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Other Services</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Captive Insurance Company</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We bear general business risks associated with operating our Company such as professional and general liability, employee workers&#8217; compensation, cybersecurity, and officer and director errors and omissions risks. Professional and general liability risks may include, for example, medical malpractice claims and disputes with members regarding benefit coverage. We retain certain of these risks through our wholly-owned, captive insurance subsidiary. We reduce exposure to these risks by insuring levels of coverage for losses in excess of our retained limits with a number of third-party insurance companies. We remain liable in the event these insurance companies are unable to pay their portion of the losses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Centralized Intercompany Services</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide centralized intercompany services to each of our health plans and to our business segments from our headquarters and service centers. These services include management information systems, product development and administration, finance, human resources, accounting, law, public relations, marketing, insurance, purchasing, risk management, internal audit, actuarial, underwriting, claims processing, billing/enrollment, and customer service. Through intercompany service agreements approved, if required, by state regulatory authorities, Humana Inc., our parent company, charges a services fee for reimbursement of certain centralized services provided to its subsidiaries to the extent that Humana Inc. is the service provider.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_61"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our associates are essential to our success in delivering on our core strategy, and creating positive healthcare experiences for our members. We are committed to recruiting, developing, and retaining strong, diverse teams, actively promoting a culture of inclusion and diversity. As of December 31, 2023, we had approximately 67,600 associates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Culture</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our members&#8217; experience is linked to our associates&#8217; experience and that engaged, productive associates are the key to building a healthy company and a caring environment where our associates go above and beyond for our members, driving innovation, and offering fulfilling experiences that incentivizes them to stay with us over the long-term. We provide opportunities for our associates to add to their personal well-being experiences that go beyond health to enhance their individual need for purpose, belonging and security. On average, our associates spend 7 years at our Company, which is a testament to our commitment to their growth, well-being, and our culture, a culture that is further reinforced by our voluntary turnover rate, or VTR. We believe our VTR is an important indicator of workforce satisfaction as our associates continue to choose us over other opportunities. During 2023, our VTR was 13.4%, representing a decrease from 17% in 2022. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly measure our success and seek opportunities to advance engagement through an Associate Experience Survey, or AES, and continuous listening campaigns. Continuous listening involves our proactive solicitation, analysis and response to associate feedback throughout the year by using pulse surveys. By regularly surveying samples of our workforce, we are able to continuously assess our effectiveness and act when needed, which in turn helps to strengthen our culture and support associate engagement. We aim to conduct a confidential, third-party administered AES on an annual basis and encourage all of our associates to participate. The AES is an in-depth survey covering eighteen dimensions that align to the Company&#8217;s strategy and employee engagement. We aggregate survey results, provide them to our entire associate population and encourage leaders to use the information to create open, honest action plans with their teams to build upon our collective engagement. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our culture is further strengthened by optimizing the well-being and effectiveness of our workforce. Through alternative work styles, such as home, hybrid home, office, hybrid office, and field, we help associates work more productively, communicate more easily and collaborate more freely. We encourage collaboration between leaders and their associates to identify and leverage the appropriate work style that both supports the achievement of business goals and personal work preferences. Alternate work styles enable associates to work from a job-appropriate location of their choice for all or some portion of their work schedule and to create a work schedule that better fits the diverse demands of today&#8217;s work environment. When managed effectively, alternative work styles can enhance a company&#8217;s employment brand, foster the development and effective delivery of innovative and diverse business solutions, right-size a company&#8217;s energy-consumption footprint, and increase associate engagement and well-being. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Inclusion and Diversity </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Office of Diversity, Equity &amp; Inclusion, or DEI Office, efforts are led by our Chief Diversity, Equity &amp; Inclusion Officer, who reports directly to the Chief Administrative Officer. The DEI Office connects to business groups across the enterprise to cultivate a diverse and inclusive culture that is representative of the communities we serve. By prioritizing DEI across our business, we enable associates to bring their whole selves to work, while also driving the innovation and insights needed to better serve our diverse members and communities. Together with key partners like our Chief Health Equity Officer, our Executive Diversity, Equity &amp; Inclusion Council, or the Council, our Network Resource Groups, or NRGs, and Culture &amp; Engagement professionals, we strive to expand our culture of inclusion to build deep relationships and create simple, personalized experiences for all of our stakeholders.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Council exists to help integrate inclusion, diversity, and equity into the fabric of the organization from the top down, connecting activities to a broader business-driven, results oriented strategy, and leverages leadership to advance DEI into the fabric of our culture. The Council reflects the diversity of our associates and communities we </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">serve. Chaired by our CEO, the Council sets its DEI objectives that complement our Talent and Diversity measure category and ensures transparency and accountability as they work towards them. We are committed to having diversity represented at all levels and have developed a pathway for diverse talent within our recruiting initiatives. We have also incorporated balanced interview panels into our interview process, through which we strategically engage a broad spectrum of interviewers that bring greater diversity and perspective. This proven best practice strengthens the candidate experience and hiring of diverse talent, ensuring we get the right talent for any given role, and minimizes the potential for personal blind spots when evaluating candidates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inclusion and diversity objectives also aim to build an awareness of biases and beliefs, identify differences and similarities of our multi-generational workforce and enable associates to leverage differences to drive innovation and create value. We are committed to growing our associates&#8217; inclusion skills and diversity knowledge and provide a variety of associate training programs and workshop opportunities. It is also our fundamental belief that every person has the right to a safe workplace. This includes having freedom of gender identity and expression, which we have included within our non-discrimination and anti-harassment policies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our associates&#8217; vast experiences and perceptions, unique characteristics, backgrounds and beliefs, drive the groundbreaking, strategic thinking that gives our Company its competitive edge in a diverse marketplace. Our approach fosters innovative thinking and creativity, expands insights and generates better business outcomes. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pay and Benefits Philosophy, Compensation and Financial Security</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e believe all of our associates have the right to receive a competitive wage and we are committed to maintaining a pay and benefits philosophy that is market-based and recognizes an associate&#8217;s contributions so that we can attract and retain an engaged, talented team. Further, we believe in fostering a fair and inclusive work environment, one where all associates receive equitable pay for their contributions. Each year, we conduct a comprehensive pay equity/gap analysis to identify and address potential pay disparities between associates performing similar work in similar capacities. Our pay and benefits structure is designed to motivate, incentivize and reward our associates, at all levels of the organization, for their skill development, demonstration of our values and performance. While our programs vary by location, associate type and business, they generally include: </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Financial</span></div></td></tr><tr style="height:17pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Competitive base pay, with additional incentive, supplemental, and/or recognition pay</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Tuition assistance program</span></div></td></tr><tr style="height:17pt"><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Paid internship </span></div></td></tr><tr style="height:17pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">401(k) retirement savings plans with Company match program</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Charitable gift matching program </span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Comprehensive financial well-being programs and support, including and employer-sponsored personal emergency savings account with matching funds from the Company</span></div></td></tr><tr style="height:18pt"><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Life insurance</span></div></td></tr><tr style="height:17pt"><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Short - and long-term disability insurance</span></div></td></tr><tr><td colspan="6" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Health</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Medical, dental and vision benefits</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Health savings account (HSA) and flexible savings account (FSA) contributions </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Supplemental health benefits</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">On-site health and fitness centers </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Long-term care insurance</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">On-site health screenings and vaccinations</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Whole-person well-being and rewards programs and platform </span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Weekly paid well-being time</span></div></td></tr><tr style="height:17pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Incentives for engaging in well-being programs</span></div></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">On-demand fitness classes, nutritional education through teaching kitchens, and digital coaching apps</span></div></td></tr><tr style="height:23pt"><td colspan="6" style="display:none"/></tr><tr><td colspan="6" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Life</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Paid time off, paid holidays, paid volunteer time off and jury duty pay</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Mental health support, including our robust Employee Assistance Program and Work-Life Services</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Adoption assistance</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Employee discount programs and services </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Paid parental leave program (6 weeks)</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Helping hands program</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Paid caregiver time off program (2 weeks)</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Transit services</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Nursing moms program with on-site lactation rooms </span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td></tr><tr><td colspan="6" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Learning and Development</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Diversity, equity, and inclusion training</span></div></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Access to degree and certification programs with tuition assistance </span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:12.53pt">Internal and external learning events </span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Talent Development and Growth Opportunities</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We champion the individual goals and development of our associates, and provide a number of programs and resources to support their efforts. The Humana Learning Center gives our associates the opportunity to earn professional certifications through continued education programs and to participate in instructor-led and online courses designed to strengthen soft and hard-skills and enhance leadership development. Our Career Cultivation team sponsors workshops and events to promote associate accountability within their personal and professional growth as part of overall career development. Our associates are also encouraged to participate in mentoring programs with people of various backgrounds and cultures. We view mentoring as an essential development tool for sharing skills and knowledge so we can all succeed. We also utilize development programs to enhance talent within our business segments through targeted internal initiatives, where we aim to upskill and reskill existing associates for opportunities in new career pathways. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information related to our human capital can be found by referencing our Definitive Proxy Statement of the Annual Meeting of Stockholders scheduled to be held on April 18, 2024 appearing under the caption "Human Capital Management." </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_64"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information About Our Executive Officers</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below are names and ages of all of our current executive officers as of February&#160;1, 2024, their positions, and the date first elected as an executive officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:22.854%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.848%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.507%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.051%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Position</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Elected<br/>Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bruce D. Broussard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer, Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vishal Agrawal, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Strategy and Corporate Development Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Samir M. Deshpande</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Information Officer </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07/17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Susan M. Diamond </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">07/19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John-Paul W. Felter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Accounting Officer and Controller</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">08/22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William K. Fleming, PharmD</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Corporate Affairs Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">03/17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy S. Huval</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Administrative Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James. A. Rechtin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Operating Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">01/24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">George Renaudin II</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Medicare &amp; Medicaid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sanjay K. Shetty, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, CenterWell</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">04/23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Ventura </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Legal Officer </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">02/19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Mr. Broussard currently serves as Director and Chief Executive Officer (Principal Executive Officer), having held these positions since January 1, 2013. Mr. Broussard was elected President upon joining the Company in December 2011 and served in that capacity through December 2012. Prior to joining the Company, Mr. Broussard was Chief Executive Officer of McKesson Specialty/US Oncology, Inc. US Oncology was purchased by McKesson in December 2010. At US Oncology, Mr. Broussard served in a number of senior executive roles, including Chief Financial Officer, Chief Executive Officer, and Chairman of the Board.</span></div><div style="margin-bottom:9pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Dr. Agrawal currently serves as Chief Strategy and Corporate Development Officer, having joined the Company in December 2018.&#160; Prior to joining the Company, Dr. Agrawal was Senior Advisor for The Carlyle Group L.P., having held that position from October 2017 to December 2018.&#160; Previously, Dr. Agrawal was President and Chief Growth Officer of Ciox Health, the largest health information exchange and release of information services organization in the U.S. from December of 2015 to October 2018.&#160; Prior to joining Ciox Health, Dr. Agrawal served as President of Harris Healthcare Solutions from January 2013 to December 2015. </span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Mr. Deshpande currently serves as Chief Information Officer, having been elected to this position in July 2021, from his prior role as Chief Technology and Risk Officer.  Before joining the Company in July 2017, Mr. Deshpande spent 17 years at Capital One in key leadership positions, most recently as Business Chief Risk Officer for the U.S. and international card business. He previously served as the Business Chief Risk Officer and Head of Enterprise Services for the Financial Services Division, responsible for Business Risk, Data Science, Data Quality, Process Excellence and Project Management. He also led marketing and analysis for the Home Loans, Auto Finance, and Credit Card businesses, with responsibilities for business strategy, credit, product and marketing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Ms. Diamond currently serves as Chief Financial Officer, having been elected to this position in June 2021, from her prior role as Segment President, Home Business. Ms. Diamond joined the Company in June 2004 </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:31.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and has spent the majority of her career in various leadership roles in the Medicare and Home businesses, with a particular passion and emphasis on growth and consumer segmentation strategies for the Company&#8217;s individual Medicare Advantage and Stand-Alone Part D offerings. Ms. Diamond also served for two and a half years as the Enterprise Vice President of Finance, where she was responsible for enterprise planning and forecasting, trend analytics and had responsibility for each of the Company&#8217;s line of business CFOs and controllers. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Mr. Felter currently serves as Senior Vice President, Chief Accounting Officer and Controller, having been elected to this position in August 2022. Before joining the Company, Mr. Felter served as Senior Director - Investment Finance for OneAmerica Financial Partners, Inc. in 2022.  Prior to OneAmerica, Mr. Felter spent nearly 11 years in multiple roles of increasing responsibility at Ernst &amp; Young LLP where he oversaw large audit engagements for public and private entities with a concentration in the health insurance sector.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Dr. Fleming currently serves as Chief Corporate Affairs Officer, having been elected to this position in April 2023, from his prior role as Segment President, Pharmacy Solutions and Chief Corporate Affairs Officer. Prior to that, Dr. Fleming held positions of Segment President, Clinical and Pharmacy Solutions, Segment President, Healthcare Services, and President of the Company&#8217;s pharmacy business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Fleming joined the Company in 1994.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Mr. Huval currently serves as Chief Administrative Officer, having been elected to this position in July 2019, from his previous role as Chief Human Resources Officer. Prior to joining the Company, Mr. Huval spent 10 years at Bank of America in multiple senior-level roles, including Human Resources executive and Chief Information Officer for Global Wealth &amp; Investment Management, as well as Human Resources executive for both Global Treasury Services and Technology &amp; Global Operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Mr. Rechtin currently serves as President and Chief Operating Officer, having been elected to this position in January 2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to joining the Company, Mr. Rechtin served as President and CEO at Envision Healthcare, having held that position from 2020 to 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Previously, Mr. Rechtin was President of OptumCare in 2019 after serving in multiple senior-level roles at Davita Medical Group from 2014 to 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(9)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Mr. Renaudin currently services as President, Medicare &amp; Medicaid, having been elected to this position in February 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Mr. Renaudin joined the Company in April 2004 and since then has held various leadership roles of increasing responsibility, most recently holding the position of President, Medicare.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(10)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:1.34pt">Dr. Shetty currently serves as President, CenterWell, having been elected to this position in April 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to joining the Company, Dr. Shetty spent nearly 13 years at Steward Health Care System in multiple senior-level roles, including President of Steward North America, President, Steward South Region and Executive Vice President, President, Steward Medical Group and Executive Vice President, Steward Health Care System, Executive Vice President for Corporate and Business Development, and President, Steward Health Care Network.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:1.34pt">Mr. Ventura currently serves as Chief Legal Officer. He joined the Company in January 2009 and since then has held various positions of increasing responsibility in the Company's Law Department, including most recently, Senior Vice President, Associate General Counsel &amp; Corporate Secretary from July 2017 until February 2019.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive officers are elected annually by our Board of Directors and serve until their successors are elected or until resignation or removal. Pursuant to our previously announced leadership succession plan, we expect that Mr. Broussard will step down as Chief Executive Officer in the latter half of 2024 and that Mr. Rechtin will become President and Chief Executive Officer at that time. There are no family relationships among any of our executive officers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_67"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.  RISK FACTORS</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Our Business</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not design and price our products properly and competitively, if the premiums we charge are insufficient to cover the cost of health care services delivered to our members, if we are unable to implement clinical initiatives to provide a better health care experience for our members, lower costs and appropriately document the risk profile of our members, or if our estimates of benefits expense are inadequate, our profitability may be materially adversely affected. We estimate the costs of our benefits expense payments, and design and price our products accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. These estimates involve extensive judgment, and have considerable inherent variability because they are extremely sensitive to changes in claim payment patterns and medical cost trends.  Accordingly, our reserves may be insufficient.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a substantial portion of our revenues to pay the costs of health care services delivered to our members, including claims payments, capitation payments to providers (predetermined amounts paid to cover services), estimates of future payments to hospitals and others for medical care provided to our members, and various other costs. Generally, premiums in the health care business are fixed for one-year periods. Accordingly, costs we incur in excess of our benefit cost projections generally are not recovered in the contract year through higher premiums. We estimate the costs of our future benefit claims and other expenses using actuarial methods and assumptions based upon claim payment patterns, medical inflation, historical developments, including claim inventory levels and claim receipt patterns, and other relevant factors. We also record benefits payable for future payments. We continually review estimates of future payments relating to benefit claims costs for services incurred in the current and prior periods and make necessary adjustments to our reserves, including premium deficiency reserves where appropriate. However, these estimates involve extensive judgment, and have considerable inherent variability that is sensitive to claim payment patterns and medical cost trends. Many factors may and often do cause actual health care costs to exceed what was estimated and used to set our premiums. These factors may include:</span></div><div style="margin-bottom:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased use of medical facilities and services, and the increased cost of such services;</span></div><div style="margin-bottom:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased use or cost of prescription drugs, including specialty prescription drugs;</span></div><div style="margin-bottom:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of new or costly treatments, prescription drugs, or new technologies; </span></div><div style="margin-bottom:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our membership mix;</span></div><div style="margin-bottom:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variances in actual versus estimated levels of cost associated with new products, benefits or lines of business, product changes or benefit level changes;</span></div><div style="margin-bottom:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the demographic characteristics of an account or market;</span></div><div style="margin-bottom:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes or reductions of our utilization management functions such as preauthorization of services, concurrent review or requirements for physician referrals; </span></div><div style="margin-bottom:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our purchase discounts or rebates received from manufacturers and wholesalers;</span></div><div style="margin-bottom:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pharmacy volume rebates received from drug manufacturers, which in Medicare Part D are fully reported to  CMS and factored into member premium pricing and CMS reimbursement to the plan;</span></div><div style="margin-bottom:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">catastrophes, including acts of terrorism, public health emergencies, epidemics or pandemics (such as  COVID-19), or natural disasters (such as hurricanes and earthquakes) which could occur more frequently or with more intense effects as a result of the impact of global climate change; </span></div><div style="margin-bottom:3pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">medical cost inflation; and</span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government mandated benefits, member eligibility criteria, or other legislative, judicial, or regulatory changes.</span></div><div style="padding-left:45pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Key to our operational strategy is the implementation of clinical initiatives that we believe provide a better health care experience for our members, lower the cost of healthcare services delivered to our members, and appropriately document the risk profile of our members. Our profitability and competitiveness depend in large part </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on our ability to appropriately manage health care costs through, among other things, the application of medical management programs such as our chronic care management program. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we proactively attempt to effectively manage our operating expenses, increases or decreases in staff-related expenses, any costs associated with exiting products, additional investment in new products (including our opportunities in the Medicare programs, state-based contracts, and expansion of clinical capabilities as part of our integrated care delivery model), investments in health and well-being product offerings, acquisitions, new taxes and assessments, inflation, and implementation of regulatory requirements may increase our operating expenses.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to adequately price our products or estimate sufficient benefits payable or effectively manage our operating expenses, may result in a material adverse effect on our results of operations, financial position, and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in a highly competitive industry. Some of our competitors are more established in the health care industry in terms of a larger market share and have greater financial resources than we do in some markets. In addition, other companies may enter our markets in the future, including emerging competitors in the Medicare program or competitors in the delivery of health care services. We believe that barriers to entry in our markets are not substantial, so the addition of new competitors can occur relatively easily, and customers enjoy significant flexibility in moving between competitors through the Medicare Annual Enrollment Period. While health plans compete on the basis of many factors, including service and the quality and depth of provider networks, we expect that price will continue to be a significant basis of competition. In addition to the challenge of controlling health care costs, we face intense competitive pressure to contain premium prices. Factors such as business consolidations, strategic alliances, legislative and regulatory reform, and marketing practices create pressure to contain premium price increases, despite being faced with increasing medical and administrative costs.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The policies and decisions of the federal and state governments regarding the Medicare Advantage and Prescription Drug Plans, military services and Medicaid programs in which we participate have a substantial impact on our profitability. These governmental policies and decisions, which we cannot predict with certainty, directly shape the premiums or other revenues to us under the programs, the eligibility and enrollment of our members, the services we provide to our members, and our administrative, health care services, and other costs associated with these programs. Legislative or regulatory actions, such as changes to the programs in which we participate, those resulting in a reduction in premium payments to us, an increase in our cost of administrative and health care services, or additional fees, taxes or assessments, may have a material adverse effect on our results of operations, financial position, and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium increases, introduction of new product designs, and our relationships with our providers in various markets, among other issues, could also affect our membership levels. Other actions that could affect membership levels include our possible exit from or entrance into Medicare or commercial markets, or the termination of a large contract. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not compete effectively in our markets, if we set rates too high or too low in highly competitive markets to keep or increase our market share, if membership does not increase as we expect, if membership declines, or if we lose membership with favorable medical cost experience while retaining or increasing membership with unfavorable medical cost experience, our results of operations, financial position, and cash flows may be materially adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to effectively implement our operational and strategic initiatives, including our Medicare initiatives, which are of particular importance given the concentration of our revenues in these products, our state-based contracts strategy, the growth of our CenterWell businesses, and our integrated care delivery model, our business may be materially adversely affected. In addition, there can be no assurances that we will be successful in maintaining or improving our Star ratings in future years.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future performance depends in large part upon our ability to execute our strategy, including opportunities created by the expansion of our Medicare programs, our strategy with respect to state-based contracts, including those covering members dually eligible for the Medicare and Medicaid programs, the growth of our pharmacy, </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">primary care, and home solutions businesses, and the successful implementation of our integrated care delivery model. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made substantial investments in the Medicare program to enhance our ability to participate in these programs. The growth of our Medicare products is an important part of our business strategy, and the attendant concentration of revenues intensifies the risks to us inherent in Medicare products. Any failure to achieve this growth may have a material adverse effect on our results of operations, financial position, or cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The achievement of star ratings of 4-star or higher qualifies Medicare Advantage plans for premium bonuses. Our Medicare Advantage plans' operating results may be significantly affected by their star ratings. Despite our operational efforts to improve our star ratings, there can be no assurances that we will be successful in maintaining or improving our star ratings in future years. In addition, audits of our performance for past or future periods may result in downgrades to our star ratings. Accordingly, our plans may not be eligible for full level quality bonuses, which could adversely affect the benefits such plans can offer, reduce membership and/or reduce profit margins.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to properly maintain the integrity of our data, to strategically maintain existing or implement new information systems, or to protect our proprietary rights to our systems, our business may be materially adversely affected. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends significantly on effective information systems and the integrity and timeliness of the data we use to run our business. Our business strategy involves providing members and providers with easy to use products that leverage our information to meet their needs. Our ability to adequately price our products and services, provide effective and efficient service to our customers, and to timely and accurately report our financial results depends significantly on the integrity of the data in our information systems. These systems require an ongoing commitment of significant resources to maintain, protect, and enhance existing systems and develop and integrate new systems to keep pace with continuing changes in information processing technology, evolving industry and regulatory standards, and changing customer preferences, and even with such resources there is no assurance that we will be able to do so. If the information we rely upon to run our businesses was found to be inaccurate or unreliable or if we fail to improve service levels or maintain effectively our information systems and data integrity, we could have operational disruptions, problems in determining medical cost estimates and establishing appropriate pricing, customer and health care provider disputes, regulatory or other legal problems, difficulty preventing and detecting fraud, have increases in operating expenses, loss of existing customers, difficulty in attracting new customers, or other adverse consequences, each of which may result in a material adverse effect on our results of operations, financial position, and cash flows. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on independent third parties for significant portions of our systems-related support, equipment, facilities, and certain data, including data center operations, data network, voice communication services and pharmacy data processing. This dependence makes our operations vulnerable to such third parties' failure to perform adequately under the contract, due to internal or external factors. A change in service providers could result in a decline in service quality and effectiveness or less favorable contract terms which may adversely affect our operating results. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our agreements with customers and service providers, confidentiality agreements with employees, and our trade secrets and copyrights to protect our proprietary rights. These legal protections and precautions may not prevent misappropriation of our proprietary information. The misappropriation of our proprietary information could hinder our ability to market and sell products and services and may result in a material adverse effect on our results of operations, financial position and cash flows.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we, and the third-party service providers on whom we rely, are unable to defend our information technology systems against cybersecurity attacks, contain such attacks when they occur, or prevent other privacy or data security incidents that result in security breaches that disrupt our operations or in the unintentional dissemination of sensitive personal information or proprietary or confidential information, we could be exposed to significant regulatory fines or penalties, liability or reputational damage, or experience a material adverse effect on our results of operations, financial position, and cash flows.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we process, store and transmit large amounts of data, and rely on third-party service providers to do the same, including sensitive personal information as well as proprietary or confidential information relating to our business or a third-party with which we do business. We have been, and will likely continue to be, regular targets of attempted cybersecurity attacks and other security threats and may be, and have been, subject to breaches of our information technology systems, including breaches of the information technology systems of third-party service providers. Although the impact of such attacks has not been material to our operations or results of operations, financial position, or cash flow through December 31, 2023, we can provide no assurance that we will be able to detect, prevent, or contain the effects of such cybersecurity attacks or other information security risks or threats, or that such an attack will not be material to our business, in the future. A cybersecurity attack may penetrate our layered security controls and lead to the misappropriation of or compromise of sensitive personal information or proprietary or confidential information, create system disruptions, cause shutdowns, or deploy viruses, ransomware, and other malicious software programs that attack our systems. A cybersecurity attack that bypasses our information technology systems, or the security of third-party service providers, could materially affect us due to the theft, destruction, loss, misappropriation or release of confidential information or intellectual property, operational or business delays resulting from the disruption of our IT systems, extortion attempts, or negative publicity resulting in reputation or brand damage with our members, customers, providers, and other stakeholders.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs to detect, prevent, eliminate or address cybersecurity threats and vulnerabilities before or after an incident could be substantial. Our remediation efforts may not be successful and could result in interruptions, delays, or cessation of service, and loss of existing or potential members.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, breaches of our security measures or the security measures of third-party service providers, and the unauthorized dissemination of sensitive personal information or proprietary or confidential information about us or our members or other third-parties, can expose our associates' or members&#8217; private information and result in the risk of financial or medical identity theft, or expose us or other third-parties to a risk of loss or misuse of this information, result in significant regulatory fines or penalties, litigation and potential liability for us, damage our brand and reputation, or otherwise harm our business.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are involved in various legal actions and governmental and internal investigations, any of which, if resolved unfavorably to us, could result in substantial monetary damages or changes in our business practices. Increased litigation and negative publicity could increase our cost of doing business.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are or may become a party to a variety of legal actions that affect our business, including breach of contract actions, employment compensation and other labor and employment practice suits, employee benefit claims, stockholder suits and other securities laws claims, intellectual and other property claims, and tort claims.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because of the nature of the health care business, we are subject to a variety of legal actions relating to our business operations, including the design, management, and offering of products and services. These include and could include in the future: claims relating to the methodologies for calculating premiums; claims relating to the denial of health care benefit payments; claims relating to the denial or rescission of insurance coverage; challenges to the use of some software products used in administering claims; claims relating to our administration of our Medicare Part D offerings; medical malpractice actions brought against our employed providers or affiliated physician-owned professional groups, or against our health plans based on our medical necessity decisions or brought against us on the theory that we are liable for a third-party providers' alleged malpractice; claims arising from any adverse medical consequences resulting from our recommendations about the appropriateness of providers&#8217; proposed medical treatment plans for patients; allegations of anti-competitive and unfair business activities; provider disputes over compensation or non-acceptance or termination of provider contracts; false claims litigation, such as qui tam lawsuits, brought by individuals who seek to sue on behalf of the government, alleging that we, as a government contractor, submitted false claims to the government or retained overpayments from the government, among other allegations, resulting from coding and review practices under the Medicare risk-adjustment model; claims related to the failure to disclose some business practices; claims relating to customer audits and contract performance; claims relating to dispensing of drugs associated with our in-house dispensing pharmacies; and professional liability claims arising out of the delivery of healthcare and related services to the public.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, substantial non-economic or punitive damages as well as treble damages under the federal False Claims Act, Racketeer Influenced and Corrupt Organizations Act and other statutes may be sought. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we currently have insurance coverage for some of these potential liabilities, other potential liabilities may not be covered by insurance, insurers may dispute coverage, or the amount of our insurance may not be enough to cover the damages awarded. In addition, some types of damages, like punitive damages, may not be covered by insurance. In some jurisdictions, coverage of punitive damages is prohibited. Insurance coverage for all or some forms of liability may become unavailable or prohibitively expensive in the future.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health benefits industry continues to receive significant negative publicity reflecting the public perception of the industry. This publicity and perception have been accompanied by increased litigation, including some large jury awards, legislative activity, regulation, and governmental review of industry practices. These factors may materially adversely affect our ability to market our products or services, may require us to change our products or services or otherwise change our business practices, may increase the regulatory burdens under which we operate, and may require us to pay large judgments or fines. Any combination of these factors could further increase our cost of doing business and adversely affect our results of operations, financial position, and cash flows.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Legal Proceedings and Certain Regulatory Matters" in Note 17 to the audited Consolidated Financial Statements included in Item 8. - Financial Statements and Supplementary Data. We cannot predict the outcome of these matters with certainty.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a government contractor, we are exposed to risks that may materially adversely affect our business or our willingness or ability to participate in government health care programs.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenues relates to federal and state government health care coverage programs, including the Medicare, military services, and Medicaid programs. These programs accounted for approximately 91% of our total premiums and services revenue for the year ended December 31, 2023. These programs involve various risks, as described further below.</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">At December 31, 2023, under our contracts with CMS we provided health insurance coverage to approximately 851,300 individual Medicare Advantage members in Florida. These contracts accounted for approximately 14% of our total premiums and services revenue for the year ended December 31, 2023. The loss of these and other CMS contracts (which are generally renewed annually) or significant changes in the Medicare Advantage and Prescription Drug Plan programs as a result of legislative or regulatory action, including changes to the Part D prescription drug benefit design (such as the changes to plan sponsor liability across the different Part D coverage phases that will apply beginning in plan year 2025) or reductions in premium payments to us or increases in member benefits or changes to member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows. </span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our military services business, which accounted for approximately 1% of our total premiums and services revenue for the year ended December 31, 2023, primarily consisted of the TRICARE T2017 East Region contract.  The T2017 East Region contract comprises 32 states and covers approximately 6.0&#160;million TRICARE beneficiaries, under which delivery of health care services commenced on January 1, 2018. The T2017 East Region contract, which was originally set to expire on December 31, 2022, was subsequently extended by the United States Department of Defense, or DoD, and is currently scheduled to expire on December 31, 2024 unless further extended. In December 2022, we were awarded the next generation of TRICARE Managed Care Support Contracts, or T-5, for the updated TRICARE East Region by the DoD. The T-5 East Region contract comprises 24 states and Washington, D.C., and covers approximately 4.6 million beneficiaries. The transition period for the T-5 contract began in January 2024 and will overlap the final year of the T2017 contract. The T-5 East Region contract includes certain provisions pursuant to which we have guaranteed certain discounts to expected costs over the life of the contract. The loss of the T2017 or T-5 East Region contracts, should either occur, or our failure to deliver </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the contractually agreed discounts, may have a material adverse effect on our results of operations, financial position, and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997 (BBA) and the Benefits Improvement and Protection Act of 2000 (BIPA), generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service (FFS) program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model.</span></div><div style="margin-bottom:9pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS and the Office of the Inspector General of Health and Human Services, or HHS-OIG, perform audits of various companies&#8217; risk adjustment diagnosis data submissions. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices that influence the calculation of health status-related premium payments to MA plans.  </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, CMS released an MA contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract&#8217;s entire health status-related risk adjusted premium amount for the year under audit.  In doing so, CMS recognized &#8220;that the documentation standard used in RADV audits to determine a contract&#8217;s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).&#8221;  To correct for this difference, CMS stated that it would apply a &#8220;Fee-for-Service Adjuster (FFS Adjuster)&#8221; as &#8220;an offset to the preliminary recovery amount.&#8221;  This adjuster would be &#8220;calculated by CMS based on a RADV-like review of records submitted to support FFS claims data.&#8221;  CMS stated that this methodology would apply to audits beginning with PY 2011.  Humana relied on CMS&#8217;s 2012 guidance in submitting MA bids to CMS.  Humana also launched a &#8220;Self-Audits&#8221; program in 2013 that applied CMS&#8217;s 2012 RADV audit methodology and included an estimated FFS Adjuster.  Humana completed Self-Audits for PYs 2011-2016 and reported results to CMS. </span></div><div style="margin-bottom:9pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, however, CMS issued a proposed rule announcing possible changes to the RADV audit methodology, including elimination of the FFS Adjuster.  CMS proposed applying its revised methodology, including extrapolated recoveries without application of a FFS Adjuster, to RADV audits dating back to PY 2011.  On January 30, 2023, CMS published a final rule related to the RADV audit methodology (Final RADV Rule).  The Final RADV Rule confirmed CMS&#8217;s decision to eliminate the FFS Adjuster. The Final RADV Rule states CMS&#8217;s intention to extrapolate results from CMS and HHS-OIG RADV audits beginning with PY 2018, rather than PY 2011 as proposed.  However, CMS&#8217;s Final RADV Rule does not adopt a specific sampling, extrapolation or audit methodology.  CMS instead stated its general plan to rely on &#8220;any statistically valid method . . . that is determined to be well-suited to a particular audit.&#8221;</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the Final RADV Rule fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act (&#8220;APA&#8221;). CMS failed to meet its legal obligations in the federal rulemaking process to give a reasoned justification for the rule or provide a meaningful opportunity for public comment. They also chose to apply the rule retroactively rather than prospectively, as required by law. Humana&#8217;s actuarially certified bids through PY 2023 preserved Humana&#8217;s position that CMS should apply an FFS Adjuster in any RADV audit that CMS intends to extrapolate. We expect CMS to apply the Final RADV Rule, including the first application of extrapolated audit results to determine audit settlements without a FFS Adjuster, to CMS and HHS-OIG RADV audits conducted for PY 2018 and subsequent years.  The Final RADV  Rule, including the lack of a FFS Adjuster, and any related regulatory, industry or company reactions, could have a material adverse effect on our results of operations, financial position, or cash flows.</span></div><div style="margin-bottom:9pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in connection with the risk adjustment model. These reviews may also result in the identification of errors and the submission of corrections to CMS that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows.</span></div><div style="padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. We remain committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members.  It is critical that MA plans are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows.</span></div><div style="padding-left:45pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our CMS contracts which cover members&#8217; prescription drugs under Medicare Part D contain provisions for risk sharing and certain payments for prescription drug costs for which we are not at risk. These provisions, certain of which are described below, affect our ultimate payments from CMS.</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The premiums from CMS are subject to risk corridor provisions which compare costs targeted in our annual bids to actual prescription drug costs, limited to actual costs that would have been incurred under the standard coverage as defined by CMS. Variances exceeding certain thresholds may result in CMS making additional payments to us or require us to refund to CMS a portion of the premiums we received (known as a &#8220;risk corridor&#8221;). We estimate and recognize an adjustment to premiums revenue related to the risk corridor payment settlement based upon pharmacy claims experience. The estimate of the settlement associated with these risk corridor provisions requires us to consider factors that may not be certain until CMS completes the applicable final payment year reconciliation, including member eligibility differences with CMS incurred allowable drug costs after rebates and other discounts, and low-income subsidy amounts. </span></div><div style="margin-bottom:6pt;padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reinsurance and low-income cost subsidies represent payments from CMS in connection with the Medicare Part D program for which we assume no risk. Reinsurance subsidies represent payments for CMS&#8217;s portion of claims costs which exceed the member&#8217;s out-of-pocket threshold, or the catastrophic coverage level. Low-income cost subsidies represent payments from CMS for all or a portion of the deductible, the coinsurance and co-payment amounts above the out-of-pocket threshold for low-income beneficiaries. Monthly prospective payments from CMS for reinsurance and low-income cost subsidies are based on assumptions submitted with our annual bid. A reconciliation and settlement of CMS&#8217;s prospective subsidies against actual prescription drug costs we paid is made after the end of the applicable year. </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:45pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlement of the reinsurance and low-income cost subsidies as well as the risk corridor payment is based on a reconciliation made approximately 9 months after the close of each calendar year. This reconciliation process requires us to submit claims data necessary for CMS to administer the program. Our claims data may not pass CMS&#8217;s claims edit processes due to various reasons, including discrepancies in eligibility or classification of low-income members. To the extent our data does not pass CMS&#8217;s claim edit processes, we may bear the risk for all or a portion of the claim which otherwise may have been subject to the risk corridor provision or payment which we would have otherwise received as a low-income subsidy or reinsurance claim. In addition, in the event the settlement represents an amount CMS owes us, there is a negative impact on our cash flows and financial condition as a result of financing CMS&#8217;s share of the risk. The opposite is true in the event the settlement represents an amount we owe CMS.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, legislative or regulatory changes to how actual prescription drug costs are reported or calculated or other changes to the Part D prescription drug benefit design may lower reinsurance or low-income cost subsidies paid by CMS and may have a material adverse effect on our results of operations, financial position, or cash flows.</span></div><div style="padding-left:45pt;text-align:justify"><span><br/></span></div><div style="padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our primary care and home health businesses derive a substantial portion of their revenues from third-party payors and directly from the federal and state governments through participation in fee-for-service Medicare. This concentration of revenues subjects these businesses to reductions in Medicare reimbursement rates or changes in the rules governing the Medicare program, including changes to CMS&#8217;s risk adjustment model that may apply to our primary care business through its contracts with third-party payors. It is reasonably possible that such changes in reimbursement rates or changes to the Medicare programs in which our primary care and home health business participate may have a material adverse effect on our results of operations, financial position, or cash flows.</span></div><div style="padding-left:45pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to various other governmental audits and investigations. Under state laws, our HMOs and health insurance companies are audited by state departments of insurance for financial and contractual compliance. Our HMOs are audited for compliance with health services by state departments of health. Audits and investigations, including audits of risk adjustment data, are also conducted by state attorneys general, CMS, HHS-OIG, the Office of Personnel Management, the Department of Justice, the Department of Labor, and the Defense Contract Audit Agency. All of these activities could result in the loss of licensure or temporary or permanent exclusion from participating in various government health care programs (such as Medicare and Medicaid), including a limitation on our ability to market or sell products, the imposition of fines, penalties and other civil and criminal sanctions, or changes in our business practices. The outcome of any current or future governmental or internal investigations cannot be accurately predicted, nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities. Nevertheless, it is reasonably possible that any such outcome of litigation, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows. Certain of these matters could also affect our reputation. In addition, disclosure of any adverse investigation or audit results or sanctions could negatively affect our industry or our reputation in various markets and make it more difficult for us to sell our products and services.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business activities are subject to substantial government regulation. New laws or regulations, or legislative, judicial, or regulatory changes in existing laws or regulations or their manner of application could increase our cost of doing business and may have a material adverse effect on our results of operations, or cash flows. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Laws or Regulations, or Future Legislative, Judicial or Regulatory Changes</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are and will continue to be regularly subject to new laws and regulations, changes to existing laws and regulations, and judicial determinations that impact the interpretation and applicability of those laws and regulations. The Patient Protection and Affordable Care Act and The Health Care and Education Reconciliation Act of 2010 (which we collectively refer to as the Health Care Reform Law), the Families First Coronavirus Response Act (the </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Families First Act&#8221;), the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;), and the Inflation Reduction Act of 2022 (the &#8220;Inflation Reduction Act&#8221;), and related regulations, are examples of laws which have enacted significant reforms to various aspects of the U.S. health insurance industry, including among others, mandated coverage requirements, mandated benefits and guarantee issuance associated with commercial medical insurance, rebates to policyholders based on minimum benefit ratios, adjustments to Medicare Advantage premiums, the establishment of federally facilitated or state-based exchanges coupled with programs designed to spread risk among insurers, the introduction of plan designs based on set actuarial values, and changes to the Part D prescription drug benefit design.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that these laws and regulations, as well as other current or future legislative, judicial or regulatory changes, including restrictions on our ability to manage our provider network, market and sell our products, or otherwise operate our business, or restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage business profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, increases in member benefits or changes to member eligibility criteria without corresponding increases in premium payments to us, increases in regulation of our prescription drug benefit businesses, or changes to the Part D prescription drug benefit design (and uncertainty arising from the implementation of these changes) may have a material adverse effect on our results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting our ability to expand into new markets, increasing our medical and operating costs, further lowering our Medicare payment rates and increasing our expenses associated with assessments); our financial position (including our ability to maintain the value of our goodwill); and our cash flows.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, potential legislative changes or judicial determinations, including activities to repeal or replace these laws and regulations, including the Health Care Reform Law or declare all or certain portions of these laws and regulations unconstitutional or contrary to law, create uncertainty for our business, and we cannot predict when, or in what form, such legislative changes or judicial determinations may occur.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Insurance Portability and Accountability Act (HIPAA) and the Health Information Technology for Economic and Clinical Health Act (HITECH Act)</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of individually identifiable health data by our business is regulated at federal and state levels. These laws and rules are changed frequently by legislation or administrative interpretation. Various state laws address the use and maintenance of individually identifiable health data. Most are derived from the privacy provisions in the federal Gramm-Leach-Bliley Act and the Health Insurance Portability and Accountability Act, or HIPAA. HIPAA includes administrative provisions directed at simplifying electronic data interchange through standardizing transactions, establishing uniform health care provider, payer, and employer identifiers, and seeking protections for the confidentiality and security of patient data. The rules do not provide for complete federal preemption of state laws, but rather preempt all inconsistent state laws unless the state law is more stringent. These regulations set standards for the security of electronic health information, including requirements that insurers provide customers with notice regarding how their non-public personal information is used, including an opportunity to "opt out" of certain disclosures. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HITECH Act, one part of the American Recovery and Reinvestment Act of 2009, significantly broadened and strengthened the scope of the privacy and security regulations of HIPAA and imposes additional limits on the use and disclosure of protected health information, or PHI. Among other requirements, the HITECH Act and HIPAA requires us and other covered entities to report any unauthorized release or use of or access to PHI to any impacted individuals and to HHS in those instances where the unauthorized activity poses a significant risk of financial, reputational or other harm to the individuals, and to notify the media in any states where 500 or more people are impacted by any unauthorized release or use of or access to PHI, requires business associates to comply with certain provisions of the HIPAA privacy and security rule, and grants enforcement authority to state attorneys general in addition to the HHS Office of Civil Rights. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are numerous federal and state laws and regulations addressing patient and consumer privacy concerns, including unauthorized access or theft of personal information. State statutes and regulations vary from state to state and could impose additional penalties. Violations of HIPAA or applicable federal or state laws or regulations could subject us to significant criminal or civil penalties, including significant monetary penalties. Compliance with HIPAA and other privacy regulations requires significant systems enhancements, training and administrative effort. HIPAA can also expose us to additional liability for violations by our business associates (e.g., entities that provide services to health plans and providers).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corporate Practice of Medicine and Other Laws </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a corporate entity, Humana Inc. is not licensed to practice medicine. Many states in which we operate through our subsidiaries limit the practice of medicine to licensed individuals or professional organizations comprised of licensed individuals, and business corporations generally may not exercise control over the medical decisions of physicians. Statutes and regulations relating to the practice of medicine, fee-splitting between physicians and referral sources, and similar issues vary widely from state to state. Under management agreements between certain of our subsidiaries and affiliated physician-owned professional groups, these groups retain sole responsibility for all medical decisions, as well as for hiring and managing physicians and other licensed healthcare providers, developing operating policies and procedures, implementing professional standards and controls, and maintaining malpractice insurance. We believe that our health services operations comply with applicable state statutes regarding corporate practice of medicine, fee-splitting, and similar issues. However, any enforcement actions by governmental officials alleging non-compliance with these statutes, which could subject us to penalties or restructuring or reorganization of our business, may result in a material adverse effect on our results of operations, financial position, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-Kickback, Physician Self-Referral, and Other Fraud and Abuse Laws </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various federal and state healthcare fraud and abuse laws including the federal False Claims Act (the &#8220;False Claims Act&#8221;), the federal anti-kickback statute (the &#8220;Anti-Kickback Statute&#8221;), the federal &#8220;Stark Law,&#8221; and related state laws. Potential sanctions for violating these laws include recoupment or reduction of government reimbursement amounts, civil penalties, treble damages, and exclusion from participating in the Medicare and Medicaid programs or other government healthcare programs. The False Claims Act prohibits knowingly submitting, conspiring to submit, or causing to be submitted, false claims, records, or statements to the federal government, or intentionally failing to return overpayments, in connection with reimbursement by federal government programs.  The Anti-Kickback Statute prohibits the offer, payment, solicitation, or receipt of any form of remuneration to induce, or in return for, the referral of business under Medicare or other governmental health program.  The Stark Law prohibits physicians from referring Medicare or Medicaid beneficiaries for certain services to any entity with which the physician, or an immediate family member of the physician, has a financial relationship, unless the financial relationship fits within a permissible exception.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many states also have enacted laws similar in scope and purpose to the Anti-Kickback Statute and, in more limited instances, the Stark Law, that are not limited to services for which Medicare or Medicaid payment is made. In addition, most states have statutes, regulations, or professional codes that restrict a physician from accepting various kinds of remuneration in exchange for making referrals. These laws vary from state to state and have seldom been interpreted by the courts or regulatory agencies. In states that have enacted these statutes, we believe that regulatory authorities and state courts interpreting these statutes may regard federal law under the Anti-Kickback Statute and the Stark Law as persuasive. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our operations comply with the Anti-Kickback Statute, the Stark Law, and similar federal or state laws addressing fraud and abuse. These laws are subject to modification and changes in interpretation, and are enforced by authorities vested with broad discretion. We continually monitor developments in this area. If these laws are interpreted in a manner contrary to our interpretation or are reinterpreted or amended, or if new legislation is enacted with respect to healthcare fraud and abuse, illegal remuneration, or similar issues, we may be required to restructure our affected operations to maintain compliance with applicable law. There can be no assurances that any </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such restructuring will be possible or, if possible, would not have a material adverse effect on our results of operations, financial position, or cash flows.  </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State Regulation of our Products and Services</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws in each of the states (and Puerto Rico) in which we operate our HMOs, PPOs and other health insurance-related services regulate our operations including: capital adequacy and other licensing requirements, policy language describing benefits, mandated benefits and processes, entry, withdrawal or re-entry into a state or market, rate increases, delivery systems, utilization review procedures, quality assurance, complaint systems, enrollment requirements, claim payments, marketing, and advertising. The HMO, PPO, and other health insurance-related products we offer are sold under licenses issued by the applicable insurance regulators.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our licensed insurance subsidiaries are also subject to regulation under state insurance holding company and Puerto Rico regulations. These regulations generally require, among other things, prior approval and/or notice of new products, rates, benefit changes, and certain material transactions, including dividend payments, purchases or sales of assets, intercompany agreements, and the filing of various financial and operational reports.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our healthcare services businesses require a Certificate of Need, or CON, to operate in certain states. These states restrict the entry of new providers or services and the expansion of existing providers or services in their state through a CON process, which is periodically evaluated and updated as required by applicable state law. To the extent that we require a CON or other similar approvals to expand our operations, our expansion could be adversely affected by our inability to obtain the necessary approval. To the extent laws in these CON states change, including the elimination of the CON requirement, the intangible value associated with these CONs may be impaired.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any failure by us to manage acquisitions, divestitures and other significant transactions successfully may have a material adverse effect on our results of operations, financial position, and cash flows. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we frequently engage in discussions with third parties regarding possible investments, acquisitions, divestitures, strategic alliances, joint ventures, and outsourcing transactions and often enter into agreements relating to such transactions in order to further our business objectives. In order to pursue our acquisition strategy successfully, we must identify suitable candidates for and successfully complete transactions, some of which may be large and complex, and manage post-closing issues such as the integration of acquired companies or employees. Integration and other risks can be more pronounced for larger and more complicated transactions, transactions outside of our core business space, or if multiple transactions are pursued simultaneously. The failure to successfully integrate acquired entities and businesses or failure to produce results consistent with the financial model used in the analysis of our transactions may cause asset write-offs, restructuring costs or other expenses and may have a material adverse effect on our results of operations, financial position, and cash flows. If we fail to identify and complete successfully transactions that further our strategic objectives, we may be required to expend resources to develop products and technology internally. In addition, from time to time, we evaluate alternatives for our businesses that do not meet our strategic, growth or profitability objectives, and we may divest or wind down such businesses. There can be no assurance that we will be able to complete any such divestiture on terms favorable to us, and the divestiture of certain businesses could result, individually or in the aggregate, in the recognition of material losses and a material adverse effect on our results of operations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to develop and maintain satisfactory relationships with the providers of care to our members, our business may be adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ or contract with physicians, hospitals and other providers to deliver health care to our members. Our products encourage or require our customers to use these contracted providers. A key component of our integrated care delivery strategy is to increase the number of providers who share medical cost risk with us or have financial incentives to deliver quality medical services in a cost-effective manner.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In any particular market, providers could refuse to contract with us, demand higher payments, or take other actions that could result in higher health care costs for us, less desirable products for customers and members or </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">difficulty meeting regulatory or accreditation requirements. In some markets, some providers, particularly hospitals, physician specialty groups, physician/hospital organizations, or multi-specialty physician groups, may have significant market positions and negotiating power. In addition, physician or practice management companies, which aggregate physician practices for administrative efficiency and marketing leverage, may compete directly with us. If these providers refuse to contract with us, use their market position to negotiate unfavorable contracts with us or place us at a competitive disadvantage, or do not enter into contracts with us that encourage the delivery of quality medical services in a cost-effective manner, our ability to market products or to be profitable in those areas may be adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some situations, we have contracts with individual or groups of primary care providers for an actuarially determined, fixed fee per month to provide a basket of required medical services to our members. This type of contract is referred to as a &#8220;capitation&#8221; contract. The inability of providers to properly manage costs under these capitation arrangements can result in the financial instability of these providers and the termination of their relationship with us. In addition, payment or other disputes between a primary care provider and specialists with whom the primary care provider contracts can result in a disruption in the provision of services to our members or a reduction in the services available to our members. The financial instability or failure of a primary care provider to pay other providers for services rendered could lead those other providers to demand payment from us even though we have made our regular fixed payments to the primary provider. There can be no assurance that providers with whom we contract will properly manage the costs of services, maintain financial solvency or avoid disputes with other providers. Any of these events may have a material adverse effect on the provision of services to our members and our results of operations, financial position, and cash flows.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our healthcare services businesses depends on our ability, and the ability of our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affiliated physician-owned professional groups </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and management services organizations, to recruit, hire, acquire, contract with, and retain physicians, nurses and other medical professionals who are experienced in providing care services to older adults.  The market to acquire or manage physician practices, and to employ or contract with individual physicians, nurses and other medical professionals is, and is expected to remain, highly competitive, and the performance of our healthcare services businesses may be adversely impacted if we, and our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affiliated physician-owned professional groups </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and management services organizations, are unable to attract, maintain satisfactory relationships with, and retain physicians, nurses and other medical professionals, or if these businesses are unable to retain patients following the departure of a physician, nurses or other medical professional. In addition, our healthcare services businesses contract with competitors of our health benefits businesses, and these businesses could be materially impacted if they are unable to maintain relationships with these companies, or fail to adequately negotiate the terms of their contracts with these third-party payers, including the price and other terms of fixed fee (or capitated) agreements under which our primary care business assumes the risk that the actual cost of a basket of services provided to a patient exceeds the reimbursement provided by the health plan third-party payers.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to our success, and our failure to do so could adversely affect our businesses, operating results and/or future performance.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends on our ability to attract, develop and retain qualified employees and executives, including those with diverse backgrounds, experiences and skill sets, to operate and expand our business. We face intense competition for qualified employees, and there can be no assurance that we will be able to attract and retain such employees or that such competition among potential employers will not result in increasing salaries.  In addition, while we have development and succession plans in place for our key employees and executives, these plans do not guarantee the services of our key employees and executives will continue to be available to us. If we are unable to attract, develop, retain and effectively manage the development and succession plans for key employees and executives, our business, results of operations and future performance could be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our pharmacy business is highly competitive and subjects us to regulations and distribution and supply chain risks in addition to those we face with our core health benefits businesses.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our in-house dispensing pharmacy business competes with locally owned drugstores, retail drugstore chains, supermarkets, discount retailers, membership clubs, internet companies and other mail-order and long-term care pharmacies. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pharmacy business also subjects us to extensive federal, state, and local regulation. The practice of pharmacy is generally regulated at the state level by state boards of pharmacy. Many of the states where we deliver pharmaceuticals, including controlled substances, have laws and regulations that require out-of-state mail-order pharmacies to register with that state&#8217;s board of pharmacy. Federal agencies further regulate our pharmacy operations, requiring registration with the U.S. Drug Enforcement Administration and individual state controlled substance authorities in order to dispense controlled substances. In addition, the FDA inspects facilities in connection with procedures to effect recalls of prescription drugs. The Federal Trade Commission also has requirements for mail-order sellers of goods. The U.S. Postal Service, or USPS, has statutory authority to restrict the transmission of drugs and medicines through the mail to a degree that may have an adverse effect on our mail-order operations. The USPS historically has exercised this statutory authority only with respect to controlled substances. If the USPS restricts our ability to deliver drugs through the mail, alternative means of delivery could be significantly more expensive. The U.S. Department of Transportation has regulatory authority to impose restrictions on drugs inserted in the stream of commerce. These regulations generally do not apply to the USPS and its operations. In addition, we are subject to CMS rules regarding the administration of our PDP plans and intercompany pricing between our PDP plans and our pharmacy business.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to risks inherent in the packaging and distribution of pharmaceuticals and other health care products, including the application of state laws and regulations related to the operation of internet and mail-order pharmacies, violations of which could expose us to civil and criminal penalties, and manufacturing, distribution or other supply chain disruptions (including disruptions that occur as a result of catastrophes, including acts of terrorism, public health emergencies, epidemics or pandemics (such as COVID-19), or natural disasters (such as hurricanes and earthquakes) which could occur more frequently or with more intense effects as a result of the impacts of global climate change), each of which could impact the availability or cost of supplying of such products.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in the prescription drug industry pricing benchmarks may adversely affect our financial performance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts in the prescription drug industry generally use certain published benchmarks to establish pricing for prescription drugs. These benchmarks include average wholesale price, which is referred to as &#8220;AWP,&#8221; average selling price, which is referred to as &#8220;ASP,&#8221; and wholesale acquisition cost. It is uncertain whether payors, pharmacy providers, pharmacy benefit managers, or PBMs, and others in the prescription drug industry will continue to utilize AWP as it has previously been calculated, or whether other pricing benchmarks will be adopted for establishing prices within the industry. Legislation may lead to changes in the pricing for Medicare and Medicaid programs. Regulators have conducted investigations into the use of AWP for federal program payment, and whether the use of AWP has inflated drug expenditures by the Medicare and Medicaid programs. Federal and state proposals have sought to change the basis for calculating payment of certain drugs by the Medicare and Medicaid programs. Adoption of ASP in lieu of AWP as the measure for determining payment by Medicare or Medicaid programs for the drugs sold in our in-house dispensing pharmacy business may reduce the revenues and gross margins of this business which may result in a material adverse effect on our results of operations, financial position, and cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to obtain funds from certain of our licensed subsidiaries is restricted by state insurance regulations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we operate as a holding company, we are dependent upon dividends and administrative expense reimbursements from our subsidiaries to fund the obligations of Humana Inc., our parent company. Certain of our </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insurance subsidiaries operate in states that regulate the payment of dividends, loans, administrative expense reimbursements or other cash transfers to Humana Inc., and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these insurance subsidiaries, without prior approval by state regulatory authorities, or ordinary dividends, is limited based on the entity's level of statutory income and statutory capital and surplus. In most states, prior notification is provided before paying a dividend even if approval is not required. Actual dividends paid may vary due to consideration of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix. Dividends from our non-insurance companies such as in our CenterWell segment are generally not restricted by Departments of Insurance. In the event that we are unable to provide sufficient capital to fund the obligations of Humana Inc., our results of operations, financial position, and cash flows may be materially adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Downgrades in our debt ratings, should they occur, may adversely affect our business, results of operations, and financial condition.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims paying ability, financial strength, and debt ratings by recognized rating organizations are an increasingly important factor in establishing the competitive position of insurance companies. Ratings information is broadly disseminated and generally used throughout the industry. Historically, rating agencies take action to lower ratings due to, among other things, perceived concerns about liquidity or solvency, the competitive environment in the insurance industry, the inherent uncertainty in determining reserves for future claims, the outcome of pending litigation and regulatory investigations, and possible changes in the methodology or criteria applied by the rating agencies. Each of the rating agencies reviews its ratings periodically and there can be no assurance that current ratings will be maintained in the future. Our ratings reflect each rating agency&#8217;s opinion of our financial strength, operating performance, and ability to meet our debt obligations or obligations to policyholders, but are not evaluations directed toward the protection of investors in our common stock and should not be relied upon as such. </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that certain of our customers place importance on our claims paying ability, financial strength, and debt ratings, and we may lose customers and compete less successfully if our ratings were to be downgraded. In addition, our credit ratings impact our ability to obtain future borrowings and investment capital on favorable terms. If our credit ratings were to be lowered, our cost of borrowing likely would increase, our sales and earnings could decrease, and our results of operations, financial position, and cash flows may be materially adversely affected.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Volatility or disruption in the securities and credit markets, including changes in interest rates, may significantly and adversely affect the value of our investment portfolio and the investment income that we derive from this portfolio. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ongoing volatility or disruption in the securities and credit markets, including changes in interest rates, may significantly and adversely affect the value of our significant investment portfolio and the investment income that we derive from this portfolio. We evaluate our investment securities for impairment on a quarterly basis. This review is subjective and requires a high degree of judgment. For the purpose of determining gross realized gains and losses, the cost of investment securities sold is based upon specific identification. For debt securities held, we recognize an impairment loss in income when the fair value of the debt security is less than the carrying value and we have the intent to sell the debt security or it is more likely than not that we will be required to sell the debt security before recovery of our amortized cost basis, or if a credit loss has occurred. When we do not intend to sell or are not required to sell a security in an unrealized loss position, potential credit related impairments are considered using a variety of factors, including the extent to which the fair value has been less than cost, adverse conditions specifically related to the industry, geographic area or financial condition of the issuer or underlying collateral of a security; payment structure of the security; changes in credit rating of the security by the rating agencies; the volatility of the fair value changes; and changes in fair value of the security after the balance sheet date. For debt securities, we take into account expectations of relevant market and economic data. We continuously review our investment portfolios and there is a continuing risk that declines in fair value may occur and additional material realized losses from sales or credit related impairments may be recorded in future periods.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our cash balances, investment securities, operating cash flows, and funds available under our credit agreement or from other public or private financing sources, taken together, provide adequate resources to fund ongoing operating and regulatory requirements, acquisitions, future expansion opportunities, and capital expenditures for at least the next twelve months, as well as to refinance or repay debt, and repurchase shares. However, continuing adverse securities and credit market conditions may significantly affect the availability of credit. While there is no assurance in the current economic environment, we have no reason to believe the lenders participating in our credit agreement will not be willing and able to provide financing in accordance with the terms of the agreement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our access to additional credit will depend on a variety of factors such as market conditions, the general availability of credit, both to the overall market and our industry, our credit ratings and debt capacity, as well as the possibility that customers or lenders could develop a negative perception of our long or short-term financial prospects. Similarly, our access to funds could be limited if regulatory authorities or rating agencies were to take negative actions against us. If a combination of these factors were to occur, we may not be able to successfully obtain additional financing on favorable terms or at all. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_70"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1B. UNRESOLVED STAFF COMMENTS</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_2439"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1C. CYBERSECURITY</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Management and Strategy</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we process, store and transmit large amounts of data, and rely on third-party service providers to do the same, including sensitive personal information as well as proprietary or confidential information relating to our business or a third-party. The protection of information and business processes is an integrated component in our overall risk management program, and reflected in our Code of Ethics, security standards, and privacy policies. We employ processes to safeguard information and protect our members&#8217; data, including by deploying both proactive and defensive practices against the evolving cyber threat landscape. Examples of these processes include:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Employing a qualified Chief Information Security Officer.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Maintaining tools to identify malicious cyber activity. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Monitoring risks posed by threat actors, including through partnerships with industry groups and government agencies. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Providing annual cybersecurity training to our associates. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Testing our associates&#8217; knowledge through internal phishing simulations. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.17pt">Engaging an independent third-party audit firm to perform an Annual Service Organizational Controls (SOC) 2 audit of enterprise claims platforms. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Reporting data breaches, as required by law, to the U.S. Department of Health and Human Services (HHS), Office for Civil Rights (OCR), and various state agencies; our reports are publicly available, free of charge, and can be obtained through the OCR Portal at https://ocrportal.hhs.gov/ocr/breach.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Maintaining a program to identify cybersecurity risks associated with certain third party vendors, which is one component of an overall vendor risk management program.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enhance our information technology infrastructure and security protocols to assess, identify, protect against, and manage material risks from cybersecurity threats following a risk-based approach. In addition, we conduct cybersecurity risk assessments at least annually, and periodically engage an independent auditor or other external assessors to aid in pro-active risk identification, prevention, detection, mitigation, and remediation.  Our efforts to manage against cybersecurity threats are further guided by Federal and state laws, as well as contractual </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commitments with third parties, which regulate our collection, use and disclosure of confidential information such as protected health information and personally identifiable information. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have been subject to breaches of our information technology systems, including breaches of the information technology systems of third-party service providers, the impact of such attacks has not been material to our business strategy, operations or results of operations, financial position, or cash flows through December 31, 2023. We do not believe that cybersecurity threats resulting from any previous cybersecurity incidents of which we are aware are reasonably likely to materially affect the Company. For additional information on the risks we face from cybersecurity threats, please refer to Part I, Item 1A, "Risk Factors" of this Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Governance</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its overall responsibility for oversight of our enterprise risk management, our Board of Directors reviews material risks to our Company, including risks from cybersecurity threats. The Board has designated our Audit Committee and Technology Committee with joint oversight over our information technology internal controls, cybersecurity, business continuity and disaster recovery programs.  </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for designing and implementing our governance framework and controls for managing our material risks from cybersecurity threats, under the oversight of our Board of Directors.  Our Chief Information Security Officer is responsible for assessing and managing identified cybersecurity risks, and evaluating and remediating cybersecurity incidents, and sharing information directly with the Audit Committee and Technology Committee, or full Board of Directors, when appropriate. Our Chief Information Security Officer reports to our Chief Information Officer, who is in turn responsible for the management of Humana&#8217;s data and information technology risks more generally. Our Chief Information Officer is a senior executive and industry leader in risk management practices in highly regulated fields. Our Chief Information Security Officer is an experienced cybersecurity executive and leader in the field, with many years of relevant experience working in highly regulated industries.  </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among our cybersecurity and risk teams, we utilize established governance mechanisms to enable a transparent and holistic approach to cybersecurity risk management, and the evaluation and remediation of cybersecurity incidents. These processes enable cross-functional engagement from our enterprise information protection, enterprise risk management, enterprise compliance, information technology, legal, privacy, and data governance teams.  </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a key component of this governance framework, the Audit Committee and Technology Committee also receive regular updates regarding our cybersecurity program and cybersecurity incidents from our Chief Information Security Officer.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_73"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2. PROPERTIES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive office is located in the Humana Building, 500 West Main Street, Louisville, Kentucky 40202. In addition to the headquarters in Louisville, Kentucky, we maintain other principal operating facilities used for customer service, enrollment, and/or claims processing and certain other corporate functions in Louisville, Kentucky; Green Bay, Wisconsin; Tampa, Florida; Cincinnati, Ohio; San Antonio, Texas; San Juan, Puerto Rico; and Austin, Texas.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We owned or leased numerous medical centers and administrative offices at December 31, 2023. The medical centers we operate are primarily located in Florida and Texas, including full-service, multi-specialty medical centers staffed by primary care providers and medical specialists. Of these medical centers, approximately 324 of these facilities are leased or subleased to our contracted providers to operate.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_76"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3. LEGAL PROCEEDINGS</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a variety of legal actions in the ordinary course of business, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate disputes, qui tam litigation brought by individuals seeking to sue on behalf of the government, failure to disclose network discounts and various other provider arrangements, general contractual matters, intellectual property matters, and challenges to subrogation practices. For a discussion of our material legal actions, including those not in the ordinary course of business, see &#8220;Legal Proceedings and Certain Regulatory Matters&#8221; in Note 17 to the audited Consolidated Financial Statements included in Item&#160;8. &#8211; Financial Statements and Supplementary Data. We cannot predict the outcome of these suits with certainty.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_79"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_82"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_85"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5. MARKET FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on the New York Stock Exchange under the symbol HUM. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of our Capital Stock</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January&#160;31, 2024, there were 1,602 holders of record of our common stock and 637,767 beneficial holders of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of dividend payments, excluding dividend equivalent rights, in 2022 and 2023, under our Board approved quarterly cash dividend policy:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.250%"><tr><td style="width:1.0%"/><td style="width:23.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.160%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.786%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.162%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Record<br/>Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment<br/>Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022 payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/31/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/28/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.7000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$90</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/31/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/29/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.7875</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/29/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.7875</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/30/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/28/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.7875</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$100</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/30/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/27/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.7875</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/31/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/28/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.8850</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$111</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/30/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/28/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.8850</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$110</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/29/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/27/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.8850</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$109</span></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><span><br/></span></div><div style="margin-bottom:1pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Board declared a cash dividend of $0.8850 per share payable on January&#160;26, 2024 to stockholders of record on December 29, 2023 for an aggregate amount of $108 million. In February 2024, the Board declared a cash dividend of $0.885 per share payable on April&#160;26, 2024 to stockholders of record on March&#160;29, 2024. Declaration and payment of future quarterly dividends is at the discretion of our Board and may be adjusted as business needs or market conditions change.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Total Return Performance</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares our total return to stockholders with the returns of the Standard&#160;&amp; Poor&#8217;s Composite 500 Index (&#8220;S&amp;P 500&#8221;) and the Dow Jones US Select Health Care Providers Index (&#8220;Peer Group&#8221;) for the five years ended December&#160;31, 2023. The graph assumes an investment of $100 in each of our common stock, the S&amp;P 500, and the Peer Group on December&#160;31, 2018, and that dividends were reinvested when paid.</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:24.75pt"><img src="hum-20231231_g1.jpg" alt="1101" style="height:337px;margin-bottom:5pt;vertical-align:text-bottom;width:573px"/></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:27.678%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.314%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.321%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HUM</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peer Group</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The stock price performance included in this graph is not necessarily indicative of future stock price performance.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about purchases by us during the three months ended December&#160;31, 2023 of equity securities that are registered by us pursuant to Section&#160;12 of the Exchange Act:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:24.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.774%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.777%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number<br/>of Shares<br/>Purchased (1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average<br/>Price&#160;Paid<br/>per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>as&#160;Part&#160;of&#160;Publicly<br/>Announced Plans<br/>or&#160;Programs&#160;(1)(2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar Value of<br/>Shares&#160;that&#160;May<br/>Yet&#160;Be&#160;Purchased<br/>Under the Plans<br/>or Programs (1) (2)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,917,683,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">860,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,150,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500,150,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080,505&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080,505&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:1pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Excludes 0.2 million shares repurchased in connection with employee stock plans.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On February&#160;15, 2023, the Board of Directors replaced the previous share repurchase authorization of up to $3&#160;billion (of which approximately $1&#160;billion remained unused) with a new authorization for repurchases of up to $3&#160;billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February&#160;15, 2026, which we refer to as the February 2023 repurchase authorization. Our remaining repurchase authorization under the February 2023 repurchase authorization was $824&#160;million as of February&#160;15, 2024.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_88"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6. [Reserved]</span></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_94"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_97"></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">For discussion of 2021 items and year-over-year comparisons between 2022 and 2021 that are not included in this 2023 Form 10-K, refer to "Item 7. &#8211; Management Discussion and Analysis of Financial Condition and Results of Operations" found in our Form 10-K for the year ended December 31, 2022, that was filed with the Securities and Exchange Commission on February 16, 2023.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Overview</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humana Inc., headquartered in Louisville, Kentucky, is committed to putting health first &#8211; for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health &#8211; delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our industry relies on two key statistics to measure performance. The benefit ratio, which is computed by taking total benefits expense as a percentage of premiums revenue, represents a statistic used to measure underwriting profitability. The operating cost ratio, which is computed by taking total operating costs, excluding depreciation and amortization, as a percentage of total revenue less investment income, represents a statistic used to measure administrative spending efficiency.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">Employer Group Commercial Medical Products Business Exit</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we announced our planned exit from the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings are materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans. The exit from this line of business will be phased over the 18 to 24 months following our February 2023 announcement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Hospice and Personal Care Divisions</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2022, we completed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the sale of a 60% i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nterest in Gentiva (formerly Kindred) Hospice to Clayton, Dubilier &amp; Rice, or CD&amp;R, for cash proceeds of approximately $2.7&#160;billion, net of cash disposed, including debt repayments from Gentiva Hospice to Humana of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.9&#160;billion. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale we recognized a pre-tax gain, net of transaction costs, of $237&#160;million, which was reported as a gain on sale of Gentiva Hospice in the accompanying consolidated statements of income for the year ended December 31, 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">COVID-19</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The emergence and spread of the novel coronavirus, or COVID-19, beginning in the first quarter of 2020 has impacted our business. Initially during periods of increased incidences of COVID-19, a reduction in non-COVID-19 hospital admissions for non-emergent and elective medical care resulted in lower overall healthcare system utilization. At the same time, COVID-19 treatment and testing costs increased utilization. During 2022, we experienced lower overall utilization of the healthcare system than anticipated, as the reduction in COVID-19 utilization following the increased incidence associated with the Omicron variant outpaced the increase in non-COVID-19 utilization. The significant disruption in utilization during 2020 also impacted our ability to implement clinical initiatives to manage health care costs and chronic conditions of our members, and appropriately document their risk profiles, and, as such, significantly affected our 2021 revenue under the risk adjustment payment model for Medicare Advantage plans. Finally, changes in utilization patterns and actions taken in 2021 as a result of the COVID-19 pandemic, including the suspension of certain financial recovery programs for a period of time and shifting the timing of claim payments and provider capitation surplus payments, impacted our claim reserve development and operating cash flows for 2021.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 National Emergency declared in 2020 was terminated on April 10, 2023 and the Public Health Emergency expired on May 11, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Value Creation Initiatives and Impairment Charges </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities beginning in 2022, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, we recorded charges of $436&#160;million and $473&#160;million in 2023 and 2022, respectively, within operating costs in the consolidated statements of income. These charges were recorded at the corporate level and not allocated to the segments. We expect to incur additional charges through the end of 2024. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value creation initiative charges primarily relate to $237&#160;million and $248&#160;million in asset impairments in 2023 and 2022, respectively, as well as $199&#160;million and $116&#160;million in severance charges in connection with workforce optimization in 2023 and 2022, respectively. The remainder of the 2022 charges primarily relate to external consulting fees. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, we also recorded severance charges of $70&#160;million within operating costs in our consolidated statement of income as a result of our exit from the Employer Group Commercial Medical Products business and impairment charges of $91&#160;million, including $55&#160;million relating to indefinite-lived intangibles. The indefinite-lived intangibles impairment charges were included within operating costs in our consolidated statement of income with the remaining impairment charges included within investment income.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Segments</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2022, we realigned our businesses into two distinct segments: Insurance and CenterWell. The Insurance segment includes the businesses that were previously included in the Retail and Group and Specialty segments, as well as the Pharmacy Benefit Manager, or PBM, business which was previously included in the Healthcare Services segment. The CenterWell segment (formerly Healthcare Services) represents our payor-agnostic healthcare services offerings, including pharmacy solutions, primary care, and home solutions. In addition to the new segment classifications being utilized to assess performance and allocate resources, we believe this simpler structure will create greater collaboration across the Insurance and CenterWell businesses and will accelerate work that is underway to centralize and integrate operations within the organization. 2021 segment financial information was recast to conform to the 2022 presentation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our two</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources. For segment financial information, refer to Note 18 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our military services business, primarily our T-2017 East Region contract, as well as the operations of our PBM business. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CenterWell segment includes our pharmacy solutions, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in Gentiva Hospice operations. Services offered by </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of each segment are measured by income (loss) from operations. Transactions between reportable segments primarily consist of sales of services rendered by our CenterWell segment, primarily pharmacy solutions, primary care, and home solutions, to our Insurance segment customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 disrupted the pattern of our quarterly earnings and operating cash flows largely due to the temporary deferral of non-essential care which resulted in reductions in non-COVID-19 hospital admissions and lower overall healthcare system utilization during higher levels of COVID-19 hospital admissions. At the same time, during periods of increased incidences of COVID-19, COVID-19 treatment and testing costs increase. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the product offerings of our Insurance segment is Medicare stand-alone prescription drug plans, or PDP, under the Medicare Part D program. Our quarterly Insurance segment earnings and operating cash flows are impacted by the Medicare Part D benefit design and changes in the composition of our membership. The Medicare Part D benefit design results in coverage that varies as a member&#8217;s cumulative out-of-pocket costs pass through successive stages of a member&#8217;s plan period, which begins annually on January 1 for renewals. These plan designs generally result in us sharing a greater portion of the responsibility for total prescription drug costs in the early stages and less in the latter stages. As a result, the PDP benefit ratio generally decreases as the year progresses. In addition, the number of low income senior members as well as year-over-year changes in the mix of membership in our standalone PDP products affects the quarterly benefit ratio pattern. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Insurance segment also experiences seasonality in the commercial fully-insured product offering. The effect on the Insurance segment benefit ratio is opposite of the Medicare stand-alone PDP impact, with the benefit ratio increasing as fully-insured members progress through their annual deductible and maximum out-of-pocket expenses. The Employer Group Commercial Fully-Insured business did not impact the Insurance segment benefit ratio for the year ended December&#160;31, 2023 and increased the Insurance segment benefit ratio by 10 basis points for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Insurance segment also experiences seasonality in the operating cost ratio as a result of costs incurred in the second half of the year associated with the Medicare marketing season. The Insurance segment may experience adverse impacts in the operating cost ratio as a result of our Employer Group Commercial Medical Products exit phased over the 18 to 24 months following our February 2023 announcement. The Employer Group Commercial Fully-Insured business increased the Insurance segment operating cost ratio by 30 basis points and increased the Insurance segment operating cost ratio by 40 basis points for the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Highlights </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our strategy offers our members affordable health care combined with a positive consumer experience in growing markets. At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics. Our approach to primary, physician-directed care for our members aims to provide quality care that is consistent, integrated, cost-effective, and member-focused, provided by both employed physicians and physicians with network contract arrangements. The model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering our members a simple, seamless healthcare experience. We believe this strategy is positioning us for long-term growth in both membership and earnings. We offer providers a continuum of opportunities to increase the integration of care and offer assistance to providers in transitioning from a fee-for-service to a value-based arrangement. These include performance bonuses, shared savings and shared risk relationships. At December&#160;31, 2023, approximately 3,764,300 members, or 70%, of our individual Medicare Advantage members were in value-based relationships under our integrated care delivery model, as compared to 3,175,500 members, or 70%, at December&#160;31, 2022.  </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On January 31, 2024, Centers for Medicare &amp; Medicaid Services, or CMS, issued its preliminary 2025 Medicare Advantage and Part D payment rates and proposed policy changes, collectively, the Advance Notice. CMS has invited public comment on the Advance Notice before publishing final rates on or before April 1, 2024, or the Final Notice. In the Advance Notice, CMS estimates Medicare Advantage plans across the sector will, on average, experience a 0.16% decrease in benchmark funding based on proposals included therein. As indicated by CMS, its estimate excludes the impact of fee-for-service county rebasing/re-pricing since the related impact is dependent upon finalization of certain data, which will be available with the publication of the Final Notice. Based on our preliminary analysis using the same factors included in CMS&#8217; estimate, the components of which are detailed on CMS&#8217; website, we anticipate the proposals in the Advance Notice would result in a change to our benchmark funding that is approximately 160 basis points worse than our expectation of a flat rate environment. This difference is primarily due to the proposed effective growth rate restatements, which we did not anticipate in light of the higher medical cost trends experienced across the industry, as well as the negative impact of CMS&#8217; proposed normalization factors. As part of our typical engagement with the agency, we will provide actuarial data with respect to our concerns regarding these items. We will continue to analyze the Advance Notice and will draw upon our program expertise to provide CMS formal commentary on the impact of the Advance Notice and the related impact upon Medicare beneficiaries&#8217; quality of care, affordability, and service to its members through the Medicare Advantage program.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net income attributable to Humana was $2.5 billion, or $20.00 per diluted common share, and $2.8 billion, or $22.08 per diluted common share, in  2023 and 2022, respectively. This comparison was significantly impacted by the gain on sale of Gentiva Hospice, put/call valuation adjustments associated with non-consolidating minority interest investments, transaction and integration costs,  the change in the fair market value of publicly-traded equity securities, an accrued charge related to certain litigation expenses, charges associated with value creation initiatives, and impairment charges. The impact of these adjustments to our consolidated income before income taxes and equity in net earnings and diluted earnings per common share was as follows for the 2023 and 2022 periods:</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated income before income taxes and equity in net (losses) earnings:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of Gentiva Hospice</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Put/call valuation adjustments associated with our non-consolidating minority interest investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction and integration costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of publicly-traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued charge related to certain anticipated litigation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value creation initiatives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted earnings per common share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of Gentiva Hospice</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Put/call valuation adjustments associated with our non-consolidating minority interest investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transaction and integration costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair market value of publicly-traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrual charge related to certain anticipated litigation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Value creation initiatives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net tax impact of transactions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.58&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.67&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Environment</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are and will continue to be regularly subject to new laws and regulations, changes to existing laws and regulations, and judicial determinations that impact the interpretation and applicability of those laws and regulations. The Health Care Reform Law, the Families First Act, the CARES Act, and the Inflation Reduction Act, and related regulations, are examples of laws which have</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enacted significant reforms to various aspects of the U.S. health insurance industry, including, among others, mandated coverage requirements, mandated benefits and guarantee issuance associated with insurance products, rebates to policyholders based on minimum benefit ratios, adjustments to Medicare Advantage premiums, the establishment of federally facilitated or state-based exchanges coupled with programs designed to spread risk among insurers, and the introduction of plan designs based on set actuarial values, and changes to the Part D prescription drug benefit design</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that these laws and regulations, as well as other current or future legislative, judicial or regulatory changes including restrictions on our ability to manage our provider network, manage and sell our products, or otherwise operate our business, or restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, increases in member benefits or changes to member eligibility criteria without corresponding increases in premium payments to us, increases in regulation of our prescription drug benefit businesses, or changes to the Part D prescription drug benefit design (and uncertainty arising from the implementation of these changes) in the aggregate may have a material adverse effect on our results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting our ability to expand into new markets, increasing our medical and operating costs, further lowering our Medicare payment rates and increasing our expenses associated with assessments); our financial position (including our ability to maintain the value of our goodwill); and our cash flows.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend for the discussion of our financial condition and results of operations that follows to assist in the understanding of our financial statements and related changes in certain key items in those financial statements from year to year, including the primary factors that accounted for those changes. Transactions between reportable segments primarily consist of sales of services rendered by our CenterWell segment, primarily pharmacy solutions, primary care, and home solutions, to our Insurance segment customers and are described in Note 18 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this  Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_100"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of Results of Operations for 2023 and 2022 </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion primarily details our results of operations for the year ended December 31, 2023, or the 2023 period, and the year ended December 31, 2022, or the 2022 period.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions, except per<br/>common share results)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance premiums</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,272&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(893)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,033&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,776&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(743)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,374&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,870&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,504&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,013&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,800&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of Gentiva Hospice</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes and equity in net losses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,383&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,568&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1475.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(318)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per common share</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.00&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.08&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.08)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit ratio (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cost ratio (b)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.41pt">Represents total benefits expense as a percentage of premiums revenue.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Represents total operating costs, excluding depreciation and amortization, as a percentage of total revenues less investment income.</span></div><div style="text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Premiums Revenue</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-13.5pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consolidated premiums revenue increased $13.6 billion, or 15.5%, from $87.7 billion in the 2022 period to $101.3 billion in the 2023 period primarily due to individual Medicare Advantage and state-based contracts membership growth and higher per member individual Medicare Advantage premiums. These factors were partially offset by the year-over-year decline in membership associated with group commercial medical, group Medicare Advantage and stand-alone PDP products, as well as the phase-out of COVID-19 sequestration relief in 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Services Revenue</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated services revenue decreased $0.7 billion, or 15.6%, from $4.8 billion in the 2022 period to $4.0 billion in the 2023 period primarily due to the divestiture of the 60% ownership of Gentiva Hospice in August 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Income</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income increased $0.7 billion, or 179.8%, from $0.4 billion in the 2022 period to $1.1 billion in the 2023 period primarily due to increase in interest income on our debt securities as well as the net unfavorable mark to market impact of our publicly-traded equity securities during the 2022 period.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefits Expense</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated benefits expense increased $12.7 billion, or 16.8%, from $75.7 billion in the 2022 period to $88.4 billion in the 2023 period. The consolidated benefit ratio increased 100 basis points from 86.3% in the 2022 period to 87.3% in the 2023 period primarily due to investments in the benefit design of our Medicare Advantage products for 2023, higher than anticipated Medicare Advantage utilization trends, which further increased in the fourth quarter of 2023, driven by inpatient utilization, primarily for the months of November and December, and non-inpatient trends, predominately in the categories of physician, outpatient surgeries and supplemental benefits, as well as the impact of continued individual Medicare Advantage growth following the 2023 Annual Election Period, or AEP, including a high proportion of age-ins, which typically have a higher benefits expense ratio initially than the average new member. These increases were partially offset by increased individual Medicare Advantage premiums, decreased average unit costs given the additional 20% payment on COVID-19 admissions during the Public Health Emergency, which expired on May 11, 2023, as well as higher favorable prior-period development in 2023. Further, the 2023 ratio continues to reflect a shift in line of business mix, with growth in individual Medicare Advantage and state-based contracts and other membership, which can carry a higher benefits expense ratio.   </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated benefits expense included $872 million of favorable prior-period medical claims reserve development in the 2023 period and $415 million of favorable prior-period medical claims reserve development in the 2022 period. Prior-period medical claims reserve development decreased the consolidated benefit ratio by approximately 90 basis points in the 2023 period and decreased the consolidated benefit ratio by approximately 50 basis points in the 2022 period.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Costs</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our segments incur both direct and shared indirect operating costs. We allocate the indirect costs shared by the segments primarily as a function of revenues. As a result, the profitability of each segment is interdependent.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated operating costs increased $0.5 billion, or 4.1%, from $12.7 billion in the 2022 period to $13.2 billion in the 2023 period. The consolidated operating cost ratio decreased 120 basis points from 13.7% in the 2022 period to 12.5% in the 2023 period. The ratio decrease was primarily due to the divestiture of the 60% ownership of Gentiva Hospice in August 2022, which carried a significantly higher operating cost ratio compared to the historical consolidated operating cost ratio, scale efficiencies associated with growth in individual Medicare Advantage membership, administrative cost efficiencies as a result of our value creation initiatives, as well as the impact of significantly reduced compensation accruals in 2023 for the annual incentive plan offered to employees across all levels of the company, in accordance with plan requirements, as our 2023 performance was negatively impacted by the previously-discussed higher Medicare Advantage utilization trends. These factors were partially offset by an </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase in commissions for brokers related to the individual Medicare Advantage membership growth in 2023, the impact of accelerated charges related to value creation initiatives in 2023 compared to 2022, impairment charges expensed in 2023, the phase-out of COVID-19 sequestration relief in 2022, and an accrual recorded in 2023 related to certain anticipated litigation expenses.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization increased $70 million, or 9.9%, from $709 million in the 2022 period to $779 million in the 2023 period primarily due to capital expenditures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased $92 million, or 22.9%, from $401 million in the 2022 period to $493 million in the 2023 period primarily due to higher average interest cost on outstanding borrowings.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate during 2023 was 25.2% compared to the effective tax rate of 21.4% in 2022. The year-over-year increase in the effective income tax rates is primarily due to the favorable adjustment in relation to tax basis over book basis for the sale of Gentiva Hospice recognized in 2022, which resulted in book income in excess of taxable gain, an increase in our federal and state audit reserves for 2023, as well as a reduction in the recognized value of certain net operating losses. For a complete reconciliation of the federal statutory rate to the effective tax rate, refer to Note 12 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance Segment</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Members</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Membership:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,408,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,565,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,849,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(702,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,767,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,682,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,200&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,600&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,400)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(217,600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,960,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,959,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medical Membership</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,857,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,079,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,400)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Specialty Membership</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,868,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,194,800&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326,500)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:1pt;margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:45.041%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Premiums and Services Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,895&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,157&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,738&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(862)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums and services revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,272&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from operations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit ratio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cost ratio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:1pt;margin-top:4pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from operations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance segment income from operations decreased $0.4 billion, or 12.2%, from $3.0 billion in the 2022 period to $2.6 billion in the 2023 period primarily due to the same factors impacting the segment's higher benefit ratio partially offset by the segment's lower operating cost ratio as more fully described below.</span></div><div><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Enrollment</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual Medicare Advantage membership increased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">843,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> members, or 18.5%, from 4,565,600 members as of December&#160;31, 2022 to 5,408,900 members as of December&#160;31, 2023 primarily due to membership additions associated with the 2023 AEP and continued growth in 2023. The year-ov</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">er-year growth was further impacted by continued enrollment resulting from special elections, age-ins, and Dual Eligible Special Need Plans, or D-SNP, membership. I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ndividual Medicare Advantage membership includes 871,300 D-SNP members as of December&#160;31, 2023, a net increase of 202,400 members, or 30.3%, from 668,900 members as of December&#160;31, 2022. </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the full year 2024, we anticipate a net membership growth in our individual Medicare Advantage offerings of approximately 100,000 members.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Group Medicare Advantage mem</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bership decreased 55,500 members, or 9.8%, from 565,100 members as of December&#160;31, 2022 to 509,600 members as of December&#160;31, 2023 reflecting the net loss of certain large accounts partially offset by continued growth in small group accounts.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the full year </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we anticipate a net membership growth in our group Medicare Advantage offerings of approximately 45,000 members.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medic</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are stand-alone PDP membership decreased 702,200 members, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19.8%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, from 3,551,300 members as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to 2,849,100 members as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023 primarily due to continued intensified competition for Medicare stand-alone PDP offerings. For the full year </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we anticipate a</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net membership decline in our Medicare stand-alone PDP offerings of approximately 650,000 members.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State-based contracts and other </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">membership increased 91,500 members, or 8.0%, from 1,137,300 members as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to 1,228,800 members as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023 reflecting the impact of membership additions associated with the implementation of the Louisiana and Ohio contracts effective January 2023 and February 2023, respectively, partially offset by ending the suspension of state eligibility redetermination efforts previously enacted as part of the Public Health Emergency. For the full year </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we anticipate a net membership growth in our state-based contracts of approximately </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250,000 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">members.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial fully-insured medical membership decreased 217,600 members, or 39.1%, from 556,300 members as of December&#160;31, 2022 to 338,700 members as of December&#160;31, 2023 and commercial ASO medical membership decreased 174,800 members, or 40.6%, from 430,100 members as of December&#160;31, 2022 to 255,300 members as of December&#160;31, 2023. These decreases reflect our planned exit of the Employer Group Commercial Medical Products business, which includes all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. The exit from this line of business will be phased over the 18 to 24 months following our February 2023 announcement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specialty membership decreased 326,500 members, or 6.3%, from 5,194,800 members as of December&#160;31, 2022 to 4,868,300 members as of December&#160;31, 2023 reflecting the decline in membership associated with our Optional Supplemental Benefit products as a result of enhanced mandatory dental and vision supplemental benefits on Medicare Advantage plans. In addition, the decline reflects loss of dental and vision individuals due to terminations as well as loss of dental and vision groups cross-sold with commercial medical products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Premiums revenue</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance segment premiums revenue increased $13.6 billion, or 15.5%, from $87.7 billion in the 2022 period to $101.3 billion in the 2023 period primarily due to individual Medicare Advantage and state-based contracts membership growth and higher per member individual Medicare Advantage premiums. These factors were partially offset by the year-over-year decline in membership associated with group commercial medical, group Medicare Advantage and stand-alone PDP products, as well as the phase-out of COVID-19 sequestration relief in 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Services revenue</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insurance segment services revenue increased $0.15 billion, or 17.6%, from $0.85 billion in the 2022 period to $1 billion in the 2023 period.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefits expense</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Insurance segment benefit ratio increased 140 basis points from 86.6% in the 2022 period to 88.0% in the 2023 period primarily due to investments in the benefit design of our Medicare Advantage products for 2023, higher than anticipated Medicare Advantage utilization trends, which further increased in the fourth quarter of 2023, driven by inpatient utilization, primarily for the months of November and December, and non-inpatient trends, predominately in the categories of physician, outpatient surgeries and supplemental benefits, as well as the impact of continued individual Medicare Advantage growth following the 2023 Annual Election Period, or AEP, including a high proportion of age-ins, which typically have a higher benefits expense ratio initially than the average new member. These increases were partially offset by increased individual Medicare Advantage premiums, decreased average unit costs given the additional 20% payment on COVID-19 admissions during the Public Health Emergency, which expired on May 11, 2023, as well as higher favorable prior-period development in 2023. Further, the 2023 ratio continues to reflect a shift in line of business mix, with growth in individual Medicare Advantage and state-based contracts and other membership, which can carry a higher benefits expense ratio. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Insurance segment benefits expense included $872 million of favorable prior-period medical claims reserve development in the 2023 period and $415 million of favorable prior-period medical claims reserve development in the 2022 period. Prior-period medical claims reserve development decreased the Insurance segment benefit ratio by approximately 90 basis points in the 2023 period and decreased the Insurance segment benefit ratio by approximately 50 basis points in the 2022 period.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating costs</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Insurance segment operating cost ratio decreased 20 basis points from 10.4% in the 2022 period to 10.2% in the 2023 period primarily due to scale efficiencies associated with growth in individual Medicare Advantage membership, administrative cost efficiencies as a result of our value creation initiatives, as well as the impact of significantly reduced compensation accruals in 2023 for the annual incentive plan offered to employees across all levels of the company, in accordance with plan requirements, as our 2023 performance was negatively impacted by the previously-discussed higher Medicare Advantage utilization trends. These factors were partially offset by an increase in commissions for brokers related to the individual Medicare Advantage membership growth in 2023, the phase-out of COVID-19 sequestration relief in 2022 and an accrual recorded in 2023 related to certain anticipated litigation expenses.</span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CenterWell Segment</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(991)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,033&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(893)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intersegment revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services and intersegment revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,299&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cost ratio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from operations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CenterWell segment income from operations increased $0.1 billion, or 8.8%, from $1.3 billion in the 2022 period to $1.4 billion in the 2023 period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Services revenue</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CenterWell segment services revenue decreased $0.9 billion, or 22.7%, from $3.9 billion in the 2022 period to $3.0 billion in the 2023 period primarily due to the divestiture of the 60% ownership of Gentiva Hospice in August 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intersegment revenues</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CenterWell segment intersegment revenues increased $2.0&#160;billion, or 14.9%, from $13.4&#160;billion in the 2022 period to $15.4&#160;billion in the 2023 period primarily due to individual Medicare Advantage membership growth, which led to higher pharmacy solutions revenues, higher revenues associated with growth in the primary care business, and greater revenues associated with the home solutions business as a result of the expansion of the value-based care home model in 2023 compared to 2022. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating costs</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CenterWell segment operating cost ratio decreased 30 basis points from 91.5% in the 2022 period to 91.2% in the 2023 period primarily due to an improving ratio in the primary care business driven by year-over-year medical costs favorability, administrative cost efficiencies related to the pharmacy solutions business, as well as the impact of significantly reduced compensation accruals in 2023 for the annual incentive plan offered to employees across all levels of the company, in accordance with plan requirements, as our 2023 performance was negatively impacted by the previously-discussed higher Medicare Advantage utilization trends. These factors were partially offset by the divestiture of the 60% ownership of Gentiva Hospice in August 2022, which carried a lower operating cost ratio compared to other businesses within the segment, the expansion of the value-based care model within the home solutions business, which carries a higher operating cost ratio compared to the core fee-for-service business, along with growth in Medicare Advantage episodes in the core fee-for-service business, as well as continued investments within the home solutions business to abate the pressures of the current nursing labor environment.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_106"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our primary sources of cash have included receipts of premiums, services revenue, and investment and other income, as well as proceeds from the sale or maturity of our investment securities, and borrowings. Our primary uses of cash historically have included disbursements for claims payments, operating costs, interest on borrowings, taxes, purchases of investment securities, acquisitions, capital expenditures, repayments on borrowings, dividends, and share repurchases. Because premiums generally are collected in advance of claim payments by a period of up to several months, our business normally should produce positive cash flows during periods of increasing premiums and enrollment. Conversely, cash flows would be negatively impacted during periods of decreasing premiums and enrollment. From period to period, our cash flows may also be affected by the timing of working capital items including premiums receivable, benefits payable, and other receivables and payables. Our cash flows are impacted by the timing of payments to and receipts from CMS associated with Medicare Part D subsidies for which we do not assume risk. The use of cash flows may be limited by regulatory requirements of state departments of insurance (or comparable state regulators) which require, among other items, that our regulated subsidiaries maintain minimum levels of capital and seek approval before paying dividends from the subsidiaries to the parent. Our use of cash flows derived from our non-insurance subsidiaries, such as in our CenterWell segment, is generally not restricted by state departments of insurance (or comparable state regulators).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our liquidity risk, please refer to Part I, Item&#160;1A, "Risk Factors" of this Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents decreased to $4.7&#160;billion at December&#160;31, 2023 from $5.1 billion at December&#160;31, 2022. The change in cash and cash equivalents for the years ended December&#160;31, 2023, 2022 and 2021 is summarized as follows:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.672%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,492)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,006)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,556)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,914)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in cash and cash equivalents</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,279)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow from Operating Activities</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by operations of $4.0&#160;billion in the 2023 period decreased $606&#160;million from cash flows provided by operations of $4.6&#160;billion in the 2022 period primarily due to lower earnings in the 2023 period compared to the 2022 period combined with the unfavorable impact of working capital changes. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant drivers of changes in our working capital are typically the timing of payments of benefits expense and receipts for premiums. Benefits expense includes claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care and other supplemental benefits provided on or prior to the balance sheet date. For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The detail of total net receivables was as follows at December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:58.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.505%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.505%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.505%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.447%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.505%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">549&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net receivables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation to cash flow statement:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables (acquired) disposed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in receivables per cash flow statement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The changes in Medicare receivables for both the 2023 period and the 2022 period reflect individual Medicare Advantage membership growth and the typical pattern caused by the timing of accruals and related collections associated with the CMS risk-adjustment model. The increase in Commercial and other receivables for the 2023 period is primarily related to Medicaid membership growth. The decrease in Commercial and other receivables for 2022 primarily relates to the Gentiva Hospice disposition. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow from Investing Activities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the 2022 period, we completed the sale of a 60% interest of Gentiva Hospice to CD&amp;R for cash proceeds of approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.7&#160;billion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, net of cash disposed, including debt repayments from Gentiva Hospice to Humana of $1.9&#160;billion. In connection with the sale we recognized a pre-tax gain, net of transaction costs, of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$237&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was reported as a gain on sale of Gentiva Hospice in the accompanying consolidated statement of income for the year ended December 31, 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the 2023 period and 2022 period, we acquired various businesses for approximately $233&#160;million and $337&#160;million, respectively, net of cash and cash equivalents received.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, we acquired Kindred at Home and other primary care businesses for cash consideration of approximately $4.2 billion, net of cash received. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ongoing capital expenditures primarily relate to our information technology initiatives, support of services in our primary care operations including medical and administrative facility improvements necessary for activities such as the provision of care to members, claims processing, billing and collections, wellness solutions, care coordination, regulatory compliance and customer service. Net capital expenditures, excluding acquisitions, were $794 million, $1.1 billion and $1.3 billion in the 2023, 2022 and 2021 periods, respectively. </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net purchases of investment securities were $2.5 billion, $2.3 billion and $1.1 billion in the 2023, 2022 and 2021 periods, respectively. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow from Financing Activities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financing cash flows are significantly impacted by the timing of claims payments and the related receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk. Monthly prospective payments from CMS for reinsurance and low-income cost subsidies are based on assumptions submitted with our annual bid. Settlement of the reinsurance and low-income cost subsidies is based on a reconciliation made approximately 9 months after the close of each calendar year. Receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk were higher than claim payments by $771 million and $2 billion in the 2023 and 2022 periods, respectively, and claim payments were higher than receipts from CMS associated with Medicare Part D claim subsidies for which we do not assume risk by $261 million in the 2021 period. Our net payable from CMS for subsidies and brand name prescription drug discounts was $1.3 billion at December 31, 2023 compared to a net payable of $540 million at December 31, 2022. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our administrative services only TRICARE contract, reimbursements from the federal government exceeded health care costs payments for which we do not assume risk by $57 million and $25 million in the 2023 and 2022 periods, respectively, and health care costs payments for which we do not assume risk exceeded reimbursements from the federal government by $45 million in the 2021 period.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, we issued $500 million of 5.750% unsecured senior notes due December 1, 2028 and $850 million of 5.950% unsecured senior notes due March 15, 2034. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $1.3 billion. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we issued $500&#160;million of 5.700% unsecured senior notes due March 13, 2026 and $750&#160;million of 5.500% unsecured senior notes due March 15, 2053. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $1.2&#160;billion. We used the net proceeds to repay outstanding amounts under our $500&#160;million Delayed Draw Term Loan. The remaining net proceeds were used for general corporate purposes, which included the repayment of existing indebtedness, including borrowings under our commercial paper program.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we issued $500&#160;million of 5.750% unsecured senior notes due March 1, 2028 and $750&#160;million of 5.875% unsecured senior notes due March 1, 2033. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $1.2&#160;billion. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we issued $750&#160;million of 3.700% unsecured senior notes due March 23, 2029. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $744&#160;million. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we issued $1.5&#160;billion of 0.650% unsecured senior notes due August 3, 2023, $750&#160;million of 1.350% unsecured senior notes due February 3, 2027 and $750&#160;million of 2.150% unsecured senior notes due February 3, 2032. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $3.0 billion. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $750&#160;million aggregate principal amount of 1.350% senior notes maturing in February 2027, our $600 million aggregate principal amount of 3.950% senior notes maturing in March 2027, our $750 million aggregate principal amount of 3.700% senior notes maturing in March 2029, and our $500 million aggregate principal amount of 3.125% senior notes maturing in August 2029 during the period beginning on August&#160;7, 2023 and ending on November&#160;15, 2023. For the year ended December 31, 2023, we repurchased $339 million principal amount of these senior notes for approximately $310 million cash.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $1.5&#160;billion aggregate principal amount of 0.650% senior notes maturing in August 2023 and our $600&#160;million aggregate principal amount of 3.850% senior notes maturing in October 2024 during the period beginning on March 13, 2023 and ending on July&#160;21, 2023. For the year ended December 31, 2023, we repurchased $361&#160;million principal amount </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of these senior notes for approximately $358&#160;million cash. We repaid the remaining $1.2&#160;billion aggregate principal amount of our 0.650% senior notes due on their maturity date of August&#160;3, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We repaid $600 million aggregate principal amount of our 3.150% senior notes due on their maturity date of December 1, 2022 and $400 million aggregate principal amount of our 2.900% senior notes due on their maturity date of December 15, 2022. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a commercial paper program in October 2014. Net proceeds from issuance of commercial paper were $211&#160;million in 2023 and the maximum principal amount outstanding at any one time during 2023 was $3.3&#160;billion. Net repayments from the issuance of commercial paper were $376&#160;million in 2022 and the maximum principal amount outstanding at any one time during 2022 was $1.5&#160;billion. Net proceeds from issuance of commercial paper were $352&#160;million in 2021 and the maximum principal amount outstanding at any one time during 2021 was $1.2 billion.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a short-term cash advance of $100 million from FHLB with certain of our marketable securities as collateral and subsequently repaid the outstanding balance in December 2023. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we repaid the $2.0&#160;billion October 2021 Term Loan Agreement without a prepayment penalty due.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we entered into a $2.0&#160;billion term loan agreement and applied the proceeds to finance the repayment in full of the outstanding assumed Kindred at Home debt.  </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we borrowed $500&#160;million under the delayed draw term loan agreement, which was used, in combination with other debt financing, to fund the approximate $5.8&#160;billion transaction price of Gentiva Hospice. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    We repurchased common shares for $1.6 billion, $2.1&#160;billion and $79&#160;million in 2023, 2022 and 2021, respectively, under share repurchase plans authorized by the Board of Directors and in connection with employee stock plans. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We paid dividends to stockholders of $431&#160;million in 2023, $392&#160;million in 2022, and $354&#160;million in 2021.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_109"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Sources and Uses of Liquidity</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a detailed discussion of dividends to stockholders, please refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchases</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a detailed discussion of stock repurchases, please refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a detailed discussion of our debt, including our senior notes, term loans, credit agreement and commercial paper program, please refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity Requirements</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our cash balances, investment securities, operating cash flows, and funds available under our credit agreement and our commercial paper program or from other public or private financing sources, taken together, provide adequate resources to fund ongoing operating and regulatory requirements, acquisitions, future expansion </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">opportunities, and capital expenditures for at least the next twelve months, as well as to refinance or repay debt, and repurchase shares.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse changes in our credit rating may increase the rate of interest we pay and may impact the amount of credit available to us in the future. Our investment-grade credit rating at December&#160;31, 2023 was BBB+ according to Standard&#160;&amp; Poor&#8217;s Rating Services, or S&amp;P, and Baa2 according to Moody&#8217;s Investors Services, Inc., or Moody&#8217;s. A downgrade by S&amp;P to BB+ or by Moody&#8217;s to Ba1 triggers an interest rate increase of 25 basis points with respect to $250 million of our senior notes. Successive one notch downgrades increase the interest rate an additional 25 basis points, or annual interest expense by $1 million, up to a maximum 100 basis points, or annual interest expense by $3 million.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we operate as a holding company in a highly regulated industry. Humana Inc., our parent company, is dependent upon dividends and administrative expense reimbursements from our subsidiaries, most of which are subject to regulatory restrictions. We continue to maintain significant levels of aggregate excess statutory capital and surplus in our state-regulated operating subsidiaries. Cash, cash equivalents, and short-term investments at the parent company decreased to $0.5 billion at December&#160;31, 2023 from $0.9 billion at December&#160;31, 2022. This decrease primarily reflects common stock repurchases, repayment of maturing senior notes, capital expenditures, capital contributions to certain subsidiaries, cash dividends to shareholders and acquisitions, partially offset by net proceeds from the senior notes, dividends from insurance subsidiaries, and cash from certain non-insurance subsidiaries within our CenterWell segment. Our use of operating cash derived from our non-insurance subsidiaries, such as our CenterWell segment, is generally not restricted by regulators. Our regulated insurance subsidiaries paid dividends to our parent company of $1.8 billion in 2023, $1.3 billion in 2022, and $1.6 billion in 2021. Subsidiary capital requirements from significant premium growth has impacted the amount of regulated subsidiary dividends over the last two years. Refer to our parent company financial statements and accompanying notes in Schedule I - Parent Company Financial Information. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of ordinary dividends that may be paid to our parent company in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.1 billion, in the aggregate. Actual dividends paid may vary due to consideration of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Requirements</span></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a detailed discussion of our regulatory requirements, including aggregate statutory capital and surplus as well as dividends paid from the subsidiaries to our parent, please refer to Note 16 to the to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="margin-top:14pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we were not involved in any special purpose entity, or SPE, transactions. For a detailed discussion of off-balance sheet arrangements, please refer to Note 17 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a detailed discussion of our guarantees and indemnifications, please refer to Note 17 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Contracts</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a detailed discussion of our government contracts, including our Medicare, military services, and Medicaid and state-based contracts, please refer to Note 17  to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_115"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis of our financial condition and results of operations is based upon our consolidated financial statements and accompanying notes, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements and accompanying notes requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. We continuously evaluate our estimates and those critical accounting policies primarily related to benefits expense and revenue recognition as well as accounting for impairments related to our investment securities, goodwill, indefinite-lived and long-lived assets. These estimates are based on knowledge of current events and anticipated future events and, accordingly, actual results ultimately may differ from those estimates. We believe the following critical accounting policies involve the most significant judgments and estimates used in the preparation of our consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefits Expense Recognition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefits expense is recognized in the period in which services are provided and includes an estimate of the cost of services which have been incurred but not yet reported, or IBNR. Our reserving practice is to consistently recognize the actuarial best point estimate within a level of confidence required by actuarial standards. For further discussion of our reserving methodology, including our use of completion and claims per member per month trend factors to estimate IBNR, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The completion and claims per member per month trend factors are the most significant factors impacting the IBNR estimate. The portion of IBNR estimated using completion factors for claims incurred prior to the most recent two months is generally less variable than the portion of IBNR estimated using trend factors. The following table illustrates the sensitivity of these factors assuming moderately adverse experience and the estimated potential impact on our operating results caused by reasonably likely changes in these factors based on December&#160;31, 2023 data:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:464.25pt"><tr><td style="width:1.0pt"/><td style="width:111.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:111.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:111.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:111.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Completion Factor (a):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claims Trend Factor (b):</span></td></tr><tr style="height:20pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Factor<br/>Change (c)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Decrease in<br/>Benefits Payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Factor<br/>Change (c)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Decrease&#160;in<br/>Benefits Payable</span></td></tr><tr style="height:12pt"><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$707</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.80%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$628</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$709</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.70%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$550</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$667</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.60%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$471</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$625</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$393</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$584</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.40%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$314</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$542</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$236</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$157</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$459</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$417</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.05%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$39</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$375</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.00%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$333</span></td></tr></table></div><div style="margin-bottom:3pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Reflects estimated potential changes in benefits payable at December&#160;31, 2023 caused by changes in completion factors for incurred months prior to the most recent two months.</span></div><div style="margin-bottom:3pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Reflects estimated potential changes in benefits payable at December&#160;31, 2023 caused by changes in annualized claims trend used for the estimation of per member per month incurred claims for the most recent two months.</span></div><div style="margin-bottom:9pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The factor change indicated represents the percentage point change.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a historical perspective regarding the accrual and payment of our benefits payable. Components of the total incurred claims for each year include amounts accrued for current year estimated benefits </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense as well as adjustments to prior year estimated accruals. Refer to Note 11 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K for information about incurred and paid claims development as of December&#160;31, 2023 as well as cumulative claim frequency and the total of IBNR included within the net incurred claims amounts.</span></div><div style="margin-bottom:7pt;text-align:center;text-indent:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:56.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.404%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.404%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances at January&#160;1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,394&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,690&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,199&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,946)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,479)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,715)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,095)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances at December&#160;31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,241&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,289&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in estimate for incurred claims related to prior years attributable to our key assumptions. As previously described, our key assumptions consist of trend and completion factors estimated using an assumption of moderately adverse conditions. The amounts below represent the difference between our original estimates and the actual benefits expense ultimately incurred as determined from subsequent claim payments.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.355%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Favorable Development by Changes in Key Assumptions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Factor<br/>Change&#160;(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Factor<br/>Change&#160;(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Factor<br/>Change&#160;(a)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trend factors</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(361)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Completion factors</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(464)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(872)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The factor change indicated represents the percentage point change.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. We experienced favorable medical claims reserve development related to prior fiscal years of $872 million in 2023, $415 million in 2022, and $825 million in 2021. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable medical claims reserve development for 2023, 2022, and 2021 primarily reflects the consistent application of trend and completion factors estimated using an assumption of moderately adverse conditions. The favorable development recognized in 2023 and 2021 primarily resulted from trend factors developing more favorably than originally expected as well as for 2021 completion factors developing faster than expected. The favorable development recognized in 2022 resulted primarily from completion factors remaining largely unchanged, resulting in lower overall development as compared to 2023 and 2021.</span></div><div style="margin-bottom:9pt;margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our favorable development for each of the years presented above is discussed further in Note 11 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually adjust our historical trend and completion factor experience with our knowledge of recent events that may impact current trends and completion factors when establishing our reserves. Because our reserving practice is to consistently recognize the actuarial best point estimate using an assumption of moderately adverse conditions as required by actuarial standards, there is a reasonable possibility that variances between actual trend and completion factors and those assumed in our December&#160;31, 2023 estimates would fall towards the middle of the ranges previously presented in our sensitivity table. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally establish one-year commercial membership contracts with employer groups, subject to cancellation by the employer group on 30-day written notice. Our Medicare contracts with CMS renew annually. Our military services contracts with the federal government and certain contracts with various state Medicaid programs generally are multi-year contracts subject to annual renewal provisions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive monthly premiums from the federal government and various states according to government specified payment rates and various contractual terms. We bill and collect premiums from employer groups and members in our Medicare and other individual products monthly.  Changes in premium revenues resulting from the periodic changes in risk-adjustment scores derived from medical diagnoses for our membership are estimated by projecting the ultimate annual premium and recognized ratably during the year with adjustments each period to reflect changes in the ultimate premium. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premiums revenue is estimated by multiplying the membership covered under the various contracts by the contractual rates. Premiums revenue is recognized as income in the period members are entitled to receive services, and is net of estimated uncollectible amounts, retroactive membership adjustments, and adjustments to recognize rebates under the minimum benefit ratios required under the Health Care Reform Law. We estimate policyholder rebates by projecting calendar year minimum benefit ratios for the small group and large group markets, as defined by the Health Care Reform Law using a methodology prescribed by HHS, separately by state and legal entity. Medicare Advantage products are also subject to minimum benefit ratio requirements under the Health Care Reform Law. Estimated calendar year rebates recognized ratably during the year are revised each period to reflect current experience. Retroactive membership adjustments result from enrollment changes not yet processed, or not yet reported by an employer group or the government. We routinely monitor the collectability of specific accounts, the aging of receivables, historical retroactivity trends, estimated rebates, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. Premiums received prior to the service period are recorded as unearned revenues.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Risk-Adjustment Provisions </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997 (BBA) and the Benefits Improvement and Protection Act of 2000 (BIPA), generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service (FFS) program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model. For additional information, refer to Note 17 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" and Part I, Item 1A, "Risk Factors" of this Form 10-K.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Securities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities totaled $17.0 billion, or 36% of total assets at December&#160;31, 2023, and $14.3 billion, or 33% of total assets at December&#160;31, 2022. The investment portfolio was primarily comprised of debt securities, detailed below, at December&#160;31, 2023 and December 31, 2022. The fair value of investment securities were as follows at December&#160;31, 2023 and 2022:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:40.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.565%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.893%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage<br/>of Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/31/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percentage<br/>of Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>&#160;&#160;&#160;&#160;corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,254&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investment securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,261&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 97% of our debt securities were investment-grade quality, with a weighted average credit rating of AA- by S&amp;P at December&#160;31, 2023. Most of the debt securities that were below investment-grade were rated B+, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">exceeding approximately 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross unrealized losses and fair values aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position were as follows at December&#160;31, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:35.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.745%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;than&#160;12&#160;months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 months or more</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr style="height:15pt"><td colspan="36" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>&#160;&#160;&#160;&#160;corporations and agencies:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(592)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,621&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,046&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,300)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,667&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the current expected credit losses model, or CECL, expected losses on available for sale debt securities are recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities. For debt securities whose fair value is less than their amortized cost which we do not intend to sell or are not required to sell, we evaluate the expected cash flows to be received as compared to amortized cost and determine if an expected credit loss has occurred. In the event of an expected credit loss, only the amount of the impairment associated with the expected credit loss is recognized in income with the remainder, if any, of the loss recognized in other comprehensive income.  To the extent we have the intent to sell the debt security or it is more likely than not we will be required to sell the debt security before recovery of our amortized cost basis, we recognize an impairment loss in income in an amount equal to the full difference between the amortized cost basis and the fair value.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential expected credit loss impairment is considered using a variety of factors, including the extent to which the fair value has been less than cost; adverse conditions specifically related to the industry, geographic area or financial condition of the issuer or underlying collateral of a debt security; changes in the quality of the debt security's credit enhancement; payment structure of the debt security; changes in credit rating of the debt security by the rating agencies; failure of the issuer to make scheduled principal or interest payments on the debt security and changes in prepayment speeds. For debt securities, we take into account expectations of relevant market and economic data. For example, with respect to mortgage and asset-backed securities, such data includes underlying loan level data and structural features such as seniority and other forms of credit enhancements. We estimate the amount of the expected credit loss component of a debt security as the difference between the amortized cost and the present value of the expected cash flows of the security. The present value is determined using the best estimate of future cash flows discounted at the implicit interest rate at the date of purchase. The expected credit loss cannot exceed the full difference between the amortized cost basis and the fair value. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks inherent in assessing the impairment of an investment include the risk that market factors may differ from our expectations, facts and circumstances factored into our assessment may change with the passage of time, or we may decide to subsequently sell the investment. The determination of whether a decline in the value of an investment is related to a credit event requires us to exercise significant diligence and judgment. The discovery of new information and the passage of time can significantly change these judgments. The status of the general </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">economic environment and significant changes in the national securities markets influence the determination of fair value and the assessment of investment impairment. There is a continuing risk that declines in fair value may occur and additional material realized losses from sales or expected credit loss impairments may be recorded in future periods.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All issuers of debt securities we own that were trading at an unrealized loss at December&#160;31, 2023 remain current on all contractual payments. After taking into account these and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time the debt securities were purchased. At December&#160;31, 2023, we did not intend to sell any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. Additionally, we did not record any material credit allowances for debt securities that were in an unrealized loss position at December&#160;31, 2023,  2022 or 2021.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Indefinite-lived and Long-lived Assets</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, goodwill, indefinite-lived and other long-lived assets represented 30% of total assets and 87% of total stockholders&#8217; equity, compared to 33% and 92%, respectively, at December&#160;31, 2022. The decrease in goodwill, indefinite-lived and other long-lived assets as a percentage of total assets is primarily attributable to the increase in investment securities.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For goodwill, we are required to test at least annually for impairment at a level of reporting referred to as the reporting unit, and more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. A reporting unit either is our operating segments or one level below the operating segments, referred to as a component, which comprise our reportable segments. A component is considered a reporting unit if the component constitutes a business for which discrete financial information is available that is regularly reviewed by management. We are required to aggregate the components of an operating segment into one reporting unit if they have similar economic characteristics. Goodwill is assigned to the reporting unit that is expected to benefit from a specific acquisition. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform a quantitative assessment to review goodwill for impairment to determine both the existence and amount of goodwill impairment, if any. Our strategy, long-range business plan, and annual planning process support our goodwill impairment tests. These tests are performed, at a minimum, annually in the fourth quarter, and are based on an evaluation of future discounted cash flows. We rely on this discounted cash flow analysis to determine fair value. However, outcomes from the discounted cash flow analysis are compared to other market approach valuation methodologies for reasonableness. We use discount rates that correspond to a market-based weighted-average cost of capital and terminal growth rates that correspond to long-term growth prospects, consistent with the long-term inflation rate. Key assumptions in our cash flow projections, including changes in membership, premium yields, medical and operating cost trends, and certain government contract extensions, are consistent with those utilized in our long-range business plan and annual planning process. If these assumptions differ from actual, including the impact of the Health Care Reform Law or changes in government reimbursement rates, the estimates underlying our goodwill impairment tests could be adversely affected. The fair value of our reporting units with significant goodwill exceeded carrying amounts by a substantial margin. However, unfavorable changes in key assumptions or combinations of assumptions including a significant increase in the discount rate, decrease in the long-term growth rate or substantial reduction in our underlying cash flow assumptions, including revenue growth rates, medical and operating cost trends, and projected operating income could have a significant negative impact on the estimated fair value of our home solutions and primary care reporting units, which accounted for $4.4&#160;billion and $1.2&#160;billion of goodwill, respectively. Impairment tests completed for 2023, 2022, and 2021 did not result in an impairment loss.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets relate to Certificate of Needs (CON) and Medicare licenses acquired in connection with our August 2021 KAH acquisition with a carrying value of $1.4&#160;billion at December&#160;31, 2023. Like goodwill, we are required to test at least annually for impairment and more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. These tests are performed, at a minimum, annually in the fourth quarter. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss is recognized. Fair values of indefinite-lived intangible assets are determined based on the income approach. Impairment tests completed for 2023 and 2022 did not result in material impairment losses. These charges reflect the amount by which the carrying value exceeded its estimated fair value. Impairment tests completed for 2021 did not result in an impairment loss. The fair values of the assets were measured using Level 3 inputs, such as projected revenues and operating cash flows. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property and equipment and other definite-lived intangible assets. These assets are depreciated or amortized over their estimated useful life, and are subject to impairment reviews. We periodically review long-lived assets whenever adverse events or changes in circumstances indicate the carrying value of the asset may not be recoverable. In assessing recoverability, we must make assumptions regarding estimated future cash flows and other factors to determine if an impairment loss may exist, and, if so, estimate fair value. We also must estimate and make assumptions regarding the useful life we assign to our long-lived assets. If these estimates or their related assumptions change in the future, we may be required to record impairment losses or change the useful life, including accelerating depreciation or amortization for these assets. Other than the impairment charges as described in Footnote 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K, there were no other impairment losses in the last three years.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our earnings and financial position are exposed to financial market risk, including those resulting from changes in interest rates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The level of our pretax earnings is subject to market risk due to changes in interest rates and the resulting impact on investment income and interest expense.  In the past we have, and in the future we may enter into interest rate swap agreements depending on market conditions and other factors. Under the revolving credit agreements, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at either LIBOR plus a spread or the base rate plus a spread. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based on LIBOR, at our option. The revolving credit agreements provide for the transition from LIBOR and do not require amendment in connection with such transition. There were no borrowings outstanding under our credit agreements at December&#160;31, 2023 or December&#160;31, 2022.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk also represents a market risk factor affecting our consolidated financial position due to our significant investment portfolio, consisting primarily of fixed maturity securities of investment-grade quality with a weighted average S&amp;P credit rating of AA- at December&#160;31, 2023. Our net unrealized position increased $0.4 billion from a net unrealized loss position of $1.7 billion at December&#160;31, 2022 to a net unrealized loss position of $1.3 billion at December&#160;31, 2023. At December&#160;31, 2023, we had gross unrealized losses of $1.3 billion on our investment portfolio primarily due to an increase in market interest rates since the time the securities were purchased.  We did not record any material credit allowances for debt securities that were in an unrealized loss position during 2023 and 2022. While we believe that these impairments will be recovered and we currently do not have the intent to sell such securities, given the current market conditions and the significant judgments involved, there is a continuing risk that future declines in fair value may occur and material realized losses from sales or credit loss impairments may be recorded in future periods.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Duration is the time-weighted average of the present value of the bond portfolio&#8217;s cash flow. Duration is indicative of the relationship between changes in fair value and changes in interest rates, providing a general indication of the sensitivity of the fair values of our fixed maturity securities to changes in interest rates. However, actual fair values may differ significantly from estimates based on duration. The average duration of our investment portfolio, including cash and cash equivalents, was approximately 3.0 years as of December&#160;31, 2023 and 3.2 years as of December&#160;31, 2022. Based on the duration including cash equivalents, a 1% increase in interest rates would generally decrease the December&#160;31, 2023 fair value of our securities by approximately $656 million.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also evaluated the impact on our investment income and interest expense resulting from a hypothetical change in interest rates of 100, 200, and 300 basis points over the next twelve-month period, as reflected in the </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">following table. The evaluation was based on our investment portfolio and our outstanding indebtedness at December&#160;31, 2023 and 2022. Our investment portfolio consists of cash, cash equivalents, and investment securities. The modeling technique used to calculate the pro forma net change in pretax earnings considered the cash flows related to fixed income investments and debt, which are subject to interest rate changes during a prospective twelve-month period. This evaluation measures parallel shifts in interest rates and may not account for certain unpredictable events that may affect interest income, including unexpected changes of cash flows into and out of the portfolio, changes in the asset allocation, including shifts between taxable and tax-exempt securities, spread changes specific to various investment categories and the mix of short-term versus long-term debt. In the past ten years, changes in 10 year US treasury rates during the year have not exceeded 300 basis points, have changed between 200 and 300 basis points one time, have changed between 100 and 200 basis points four times, and have changed by less than 100 basis points five times.</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.278%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (decrease) in<br/>pretax&#160;earnings&#160;given&#160;an<br/>interest&#160;rate&#160;decrease&#160;of<br/>X basis points</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (decrease) in<br/>pretax earnings given an<br/>interest rate increase of<br/>X basis points</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(300)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(200)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(100)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">100</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">200</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">300</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income (a)</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income (a)</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense (b)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(220)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;margin-top:4pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">As of December&#160;31, 2023, none of our investments had interest rates below 1%. As of December&#160;31, 2022, some of our investments had interest rates below 1%, so the assumed hypothetical change in pretax earnings does not reflect the full 1% point reduction.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The interest rate under our senior notes, which represent 93% of total debt, is fixed, unaffected by changes in interest rates. We did not have any variable rate term loans at December&#160;31, 2023 and had $0.5&#160;billion of variable rate term loans at December&#160;31, 2022 which were used to fund the August 2021 KAH acquisition. There were no borrowings outstanding under the credit agreement at December&#160;31, 2023 or December&#160;31, 2022. There was $871 million and $595 million outstanding under our commercial paper program at December&#160;31, 2023 and 2022, respectively.  As of December&#160;31, 2023 and December&#160;31, 2022, our interest rates under our commercial paper program was not less than 1%.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_121"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_124"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except<br/>share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-36">4,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-37">5,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-38">16,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="f-39">13,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net of allowances of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-40">88</ix:nonFraction> in 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-41">70</ix:nonFraction> in 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-42">2,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-43">1,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-44">6,631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-45">5,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-46">29,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-47">26,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-48">3,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-49">3,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="f-50">382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="f-51">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-52">9,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-53">9,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:EquityMethodInvestments" scale="6" id="f-54">740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:EquityMethodInvestments" scale="6" id="f-55">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-56">3,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-57">3,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-58">47,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-59">43,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-60">10,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-61">9,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-62">6,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-63">5,238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Book overdraft</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="hum:BookOverdraftLiability" scale="6" id="f-64">353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="hum:BookOverdraftLiability" scale="6" id="f-65">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-66">266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-67">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-68">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-69">2,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-70">18,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-71">17,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-72">10,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-73">9,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-74">1,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-75">1,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-76">30,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-77">27,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 17)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-78"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-79"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-80"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-81">1</ix:nonFraction></ix:nonFraction> par; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-82"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-83">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-84"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-85">none</ix:nonFraction></ix:nonFraction> issued</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.16 2/3 par; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-88"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-89">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized; </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-90">198,690,082</ix:nonFraction> shares issued at December 31, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-91">198,666,598</ix:nonFraction> shares issued at December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="f-92">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="f-93">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital in excess of par value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-94">3,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-95">3,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-96">27,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-97">25,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-98">999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-99">1,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-100">76,465,862</ix:nonFraction> shares at December 31, 2023</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-101">73,691,955</ix:nonFraction> shares at December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="f-102">13,658</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="f-103">12,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-104">16,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-105">15,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="f-106">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="f-107">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-108">16,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-109">15,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-110">47,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-111">43,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_130"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:48.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions, except per share results)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-114">101,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-115">87,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-116">79,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-117"><span style="-sec-ix-hidden:f-118"><span style="-sec-ix-hidden:f-119">Services</span></span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-120">4,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-121">4,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-122">3,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="6" id="f-123">1,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-124">382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-125">187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-126">106,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-127">92,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-128">83,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" format="ixt:num-dot-decimal" scale="6" id="f-129">88,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" format="ixt:num-dot-decimal" scale="6" id="f-130">75,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" format="ixt:num-dot-decimal" scale="6" id="f-131">69,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-132">13,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-133">12,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-134">10,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-135">779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-136">709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-137">596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-138">102,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-139">89,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-140">79,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-141">4,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-142">3,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-143">3,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of Gentiva Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="f-144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-145">237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="f-146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-147">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-148">401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-149">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-150">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-151">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-152">532</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes and equity in net earnings</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-153">3,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-154">3,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-155">3,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-156">836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-157">762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-158">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net (losses) earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-159">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-160">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-161">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-162">2,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-163">2,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-164">2,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-165">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-166">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-167">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Humana</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-168">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-169">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-170">2,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-171">20.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-172">22.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-173">22.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-174">20.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-175">22.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-176">22.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_133"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:54.758%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.025%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.025%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Humana</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-177">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-178">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-179">2,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in gross unrealized investment gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="f-180">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-181">1,819</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="f-182">356</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of income taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="f-183">85</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="f-184">418</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="f-185">81</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total change in unrealized investment  <br/>&#160;&#160;&#160;&#160;&#160;gains (losses), net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-186">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-187">1,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-188">275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustment for net realized <br/>&#160;losses (gains) included in investment income </span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="f-189">25</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="f-190">72</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="f-191">103</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="f-192">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="f-193">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="f-194">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassification adjustment, net of tax</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="f-195">18</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="f-196">55</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="f-197">80</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-198">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="f-199">1,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-200">355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to equity method<br/>&#160;&#160;investments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-201">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-202">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments" scale="6" id="f-203">6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to Humana</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-204">2,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-205">1,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-206">2,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_136"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.050%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.050%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.249%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.050%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.317%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.317%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.084%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.317%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.094%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Capital&#160;In<br/>Excess&#160;of<br/>Par Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Treasury<br/>Stock</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Total Stockholders'<br/>Equity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Total<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Issued<br/>Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.25pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="51" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions, share amounts in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-207">198,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-208">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-209">2,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-210">20,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-211">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-212">9,918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-213">13,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-215">13,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-216">2,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-217">2,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-218">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-219">2,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="f-220">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="f-221">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-222">349</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-223">349</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-224">349</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" sign="-" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-225">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-226">341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-227">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-228">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends and dividend <br/>&#160;&#160;&#160;equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-229">364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-230">364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-231">364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-232">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-233">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-234">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock unit vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="6" id="f-235">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="6" id="f-236">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="6" id="f-237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-238">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-239">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-240">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-241">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances, December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-242">198,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-243">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-244">3,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-245">23,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-246">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-247">10,163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-248">16,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-249">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-250">16,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-251">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-252">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-253">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-254">2,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution to noncontrolling interest holders, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-6" sign="-" name="hum:NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders" scale="6" id="f-255">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="hum:NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders" scale="6" id="f-256">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of Gentiva Hospice</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-6" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" scale="6" id="f-257">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" scale="6" id="f-258">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-6" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="f-259">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="f-260">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-261">1,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-262">1,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-263">1,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock repurchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-264">2,096</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-265">2,096</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-266">2,096</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends and dividend <br/>&#160;&#160;&#160;equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-267">400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-268">400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-269">400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-270">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-271">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-272">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock unit vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-273">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="6" id="f-274">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="6" id="f-275">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="6" id="f-276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="6" id="f-277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-278">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-279">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-280">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-281">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-282">198,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-283">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-284">3,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-285">25,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-286">1,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-287">12,156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-288">15,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-289">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-290">15,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-291">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-292">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="f-293">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-294">2,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution from noncontrolling interest holders, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-6" name="hum:NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders" scale="6" id="f-295">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="hum:NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders" scale="6" id="f-296">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="f-297">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="6" id="f-298">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-299">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-300">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-301">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock repurchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-302">1,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-303">1,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-304">1,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends and dividend <br/>&#160;&#160;&#160;equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-305">441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-306">441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-307">441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-308">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-309">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-310">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock unit vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-311">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="6" id="f-312">80</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="6" id="f-313">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="6" id="f-314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock option exercises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-315">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-316">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-317">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="f-318">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balances, December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-319">198,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-320">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-321">3,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-322">27,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-323">999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-324">13,658</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-325">16,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-326">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-327">16,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.&#160;&#160;&#160;&#160;</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_139"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOW</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.371%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.375%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-328">2,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-329">2,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-330">2,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of Gentiva Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="f-331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-332">237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="f-333">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on investment securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DebtAndEquitySecuritiesGainLoss" scale="6" id="f-334">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:DebtAndEquitySecuritiesGainLoss" scale="6" id="f-335">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:DebtAndEquitySecuritiesGainLoss" scale="6" id="f-336">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on Kindred at Home equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:fixed-zero" scale="6" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:fixed-zero" scale="6" id="f-338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="f-339">1,129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity in net losses (earnings)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-340">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-341">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-342">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-343">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-344">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="f-345">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-346">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-347">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-348">640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="f-349">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="f-350">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="f-351">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:TangibleAssetImpairmentCharges" scale="6" id="f-352">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:TangibleAssetImpairmentCharges" scale="6" id="f-353">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="f-354">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="f-355">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="f-356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-358">167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-359">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="6" id="f-360">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of effect of businesses acquired and dispositions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="f-361">337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="f-362">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="f-363">280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="f-364">1,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="f-365">463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="f-366">491</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Benefits payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities" scale="6" id="f-367">915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities" scale="6" id="f-368">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities" scale="6" id="f-369">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="f-370">841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="f-371">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="f-372">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unearned revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-373">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-374">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-375">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="f-376">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="f-377">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="f-378">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-379">3,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-380">4,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-381">2,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of Gentiva Hospice, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" format="ixt:fixed-zero" scale="6" id="f-382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" format="ixt:num-dot-decimal" scale="6" id="f-383">2,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" format="ixt:fixed-zero" scale="6" id="f-384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions, net of cash and cash equivalents acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="f-385">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="f-386">337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="f-387">4,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-388">1,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-389">1,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-390">1,342</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="f-391">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="f-392">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="f-393">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-394">7,552</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-395">6,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-396">7,197</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities of investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-397">1,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-398">1,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="f-399">2,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sales of investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-400">3,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-401">2,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-402">3,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-403">3,492</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-404">1,006</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-405">6,556</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receipts (withdrawals) from contract deposits, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="hum:PaymentsForProceedsFromContractDeposits" scale="6" id="f-406">828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="hum:PaymentsForProceedsFromContractDeposits" format="ixt:num-dot-decimal" scale="6" id="f-407">1,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:PaymentsForProceedsFromContractDeposits" scale="6" id="f-408">306</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of senior notes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-409">2,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-410">1,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-411">2,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="f-412">1,832</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="f-413">1,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:fixed-zero" scale="6" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds (repayments) from issuance of commercial paper, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfCommercialPaper" scale="6" id="f-415">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfCommercialPaper" scale="6" id="f-416">376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfCommercialPaper" scale="6" id="f-417">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="f-418">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="6" id="f-419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="6" id="f-420">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="f-421">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="6" id="f-422">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="6" id="f-423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" format="ixt:fixed-zero" scale="6" id="f-424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" format="ixt:fixed-zero" scale="6" id="f-425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfUnsecuredDebt" format="ixt:num-dot-decimal" scale="6" id="f-426">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of term loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RepaymentsOfUnsecuredDebt" scale="6" id="f-427">500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:RepaymentsOfUnsecuredDebt" format="ixt:num-dot-decimal" scale="6" id="f-428">2,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RepaymentsOfUnsecuredDebt" format="ixt:num-dot-decimal" scale="6" id="f-429">2,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="f-430">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="f-431">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="f-432">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-433">1,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-434">2,096</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-435">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="f-436">431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="f-437">392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="f-438">354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in book overdraft</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInBookOverdrafts" scale="6" id="f-439">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInBookOverdrafts" scale="6" id="f-440">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncreaseDecreaseInBookOverdrafts" scale="6" id="f-441">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-442">151</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-443">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-444">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-445">856</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-446">1,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-447">3,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-448">367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-449">1,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-450">1,279</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-451">5,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-452">3,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-453">4,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-454">4,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-455">5,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-456">3,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOW&#8212;(Continued)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:62.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.636%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest payments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="f-457">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="f-458">354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="f-459">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax payments, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="f-460">997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="f-461">758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="f-462">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Details of businesses acquired in purchase transactions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of assets acquired, net of cash acquired</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="f-463">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="f-464">460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:FairValueOfAssetsAcquired" format="ixt:num-dot-decimal" scale="6" id="f-465">9,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:LiabilitiesAssumed1" scale="6" id="f-466">234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:LiabilitiesAssumed1" scale="6" id="f-467">70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:LiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="f-468">3,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Noncontrolling interests acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="hum:NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired" scale="6" id="f-469">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="hum:NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired" scale="6" id="f-470">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired" scale="6" id="f-471">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Remeasured existing Kindred at Home equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="hum:NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment" format="ixt:fixed-zero" scale="6" id="f-472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="hum:NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment" format="ixt:fixed-zero" scale="6" id="f-473">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment" format="ixt:num-dot-decimal" scale="6" id="f-474">2,360</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for acquired businesses, net of cash acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="f-475">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="f-476">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="f-477">4,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the consolidated financial statements.</span></div><div style="height:49.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_142"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_145"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-478" continuedAt="f-478-1" escape="true">REPORTING ENTITY</ix:nonNumeric></span></div><ix:continuation id="f-478-1"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Operations</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humana Inc., headquartered in Louisville, Kentucky, is committed to putting health first &#8211; for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health &#8211; delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. References throughout these notes to consolidated financial statements to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Company,&#8221; and &#8220;Humana,&#8221; mean Humana Inc. and its subsidiaries. We derived approximately <ix:nonFraction unitRef="number" contextRef="c-58" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-479">84</ix:nonFraction>% of our total premiums and services revenue from contracts with the federal government in 2023, including <ix:nonFraction unitRef="number" contextRef="c-59" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-480">14</ix:nonFraction>% related to our federal government contracts with the Centers for Medicare and Medicaid Services, or CMS, to provide health insurance coverage for individual Medicare Advantage members in Florida. CMS is the federal government&#8217;s agency responsible for administering the Medicare program.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_148"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-481" continuedAt="f-481-1" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-481-1" continuedAt="f-481-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-482" escape="true"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. Our consolidated financial statements include the accounts of Humana Inc. and subsidiaries that the Company controls, including variable interest entities associated with medical practices for which we are the primary beneficiary. We do not own many of our medical practices but instead enter into exclusive management agreements with the affiliated Professional Associations, or P.A.s, that operate these medical practices. Based upon the provisions of these agreements, these affiliated P.A.s are variable interest entities and we are the primary beneficiary, and accordingly we consolidate the affiliated P.A.s. All significant intercompany balances and transactions have been eliminated.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Value Creation Initiatives and Impairment Charges </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities beginning in 2022, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, we recorded charges of $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-6" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-483">436</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:RestructuringCostsAndAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-484">473</ix:nonFraction>&#160;million in 2023 and 2022, respectively, within operating costs in the consolidated statements of income. These charges were recorded at the corporate level and not allocated to the segments. We expect to incur additional charges through the end of 2024. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value creation initiative charges primarily relate to $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="f-485">237</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="f-486">248</ix:nonFraction>&#160;million in asset impairments in 2023 and 2022, respectively, as well as $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-6" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-487">199</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-488">116</ix:nonFraction>&#160;million in severance charges in connection with workforce optimization in 2023 and 2022, respectively. The remainder of the 2022 charges primarily relate to external consulting fees. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, we also recorded severance charges of $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="f-489">70</ix:nonFraction>&#160;million within operating costs in our consolidated statement of income as a result of our exit from the Employer Group Commercial Medical Products business and impairment charges of $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="f-490">91</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-491">55</ix:nonFraction>&#160;million relating to indefinite-lived intangibles. The indefinite-</span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-481-2" continuedAt="f-481-3"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lived intangibles impairment charges were included within operating costs in our consolidated statement of income with the remaining impairment charges included within investment income.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">COVID-19</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The emergence and spread of the novel coronavirus, or COVID-19, beginning in the first quarter of 2020 has impacted our business. Initially during periods of increased incidences of COVID-19, a reduction in non-COVID-19 hospital admissions for non-emergent and elective medical care resulted in lower overall healthcare system utilization. At the same time, COVID-19 treatment and testing costs increased utilization. During 2022, we experienced lower overall utilization of the healthcare system than anticipated, as the reduction in COVID-19 utilization following the increased incidence associated with the Omicron variant outpaced the increase in non-COVID-19 utilization. The significant disruption in utilization during 2020 also impacted our ability to implement clinical initiatives to manage health care costs and chronic conditions of our members, and appropriately document their risk profiles, and, as such, significantly affected our 2021 revenue under the risk adjustment payment model for Medicare Advantage plans. Finally, changes in utilization patterns and actions taken in 2021 as a result of the COVID-19 pandemic, including the suspension of certain financial recovery programs for a period of time and shifting the timing of claim payments and provider capitation surplus payments, impacted our claim reserve development and operating cash flows for 2021.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 National Emergency declared in 2020 was terminated on April 10, 2023 and the Public Health Emergency expired on May 11, 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-492" escape="true"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include cash, time deposits, money market funds, commercial paper, other money market instruments, and certain U.S. Government securities with an original maturity of three months or less. Carrying value approximates fair value due to the short-term maturity of the investments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-493" continuedAt="f-493-1" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Securities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities, which consist of debt and equity securities, are stated at fair value. Our debt securities have been categorized as available for sale. Debt securities available for current operations, as well as our equity securities, are classified as current assets, and debt securities available to fund our professional and other self-insurance liability requirements, as well as restricted statutory deposits, are classified as long-term assets. For the purpose of determining realized gross gains and losses for debt securities sold, that are included as a component of investment income in the consolidated statements of income, the cost of investment securities sold is based upon specific identification. Unrealized holding gains and losses for debt securities, net of applicable deferred taxes, are included in other comprehensive income or loss as a component of stockholders&#8217; equity until realized from a sale or an expected credit loss is recognized. For the purpose of determining gross gains and losses for equity securities, changes in fair value at the reporting date are included as a component of investment income in the consolidated statements of income.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the current expected credit losses model, or CECL, expected losses on available for sale debt securities are recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities. For debt securities whose fair value is less than their amortized cost which we do not intend to sell or are not required to sell, we evaluate the expected cash flows to be received as compared to amortized cost and determine if an expected credit loss has occurred. In the event of an expected credit loss, only the amount of the impairment associated with the expected credit loss is recognized in income with the remainder, if any, of the loss recognized in other comprehensive income.  To the extent we have the intent to sell the debt security or it is more likely than not we will be required to sell the debt security before recovery of our amortized cost basis, we recognize an impairment loss in income in an amount equal to the full difference between the amortized cost basis and the fair value.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential expected credit loss impairment is considered using a variety of factors, including the extent to which the fair value has been less than cost; adverse conditions specifically related to the industry, geographic area or financial condition of the issuer or underlying collateral of a debt security; changes in the quality of the debt </span></div></ix:nonNumeric></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-481-3" continuedAt="f-481-4"><ix:continuation id="f-493-1"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">security's credit enhancement; payment structure of the debt security; changes in credit rating of the debt security by the rating agencies; failure of the issuer to make scheduled principal or interest payments on the debt security and changes in prepayment speeds. For debt securities, we take into account expectations of relevant market and economic data. For example, with respect to mortgage and asset-backed securities, such data includes underlying loan level data and structural features such as seniority and other forms of credit enhancements. We estimate the amount of the expected credit loss component of a debt security as the difference between the amortized cost and the present value of the expected cash flows of the security. The present value is determined using the best estimate of future cash flows discounted at the implicit interest rate at the date of purchase. The expected credit loss cannot exceed the full difference between the amortized cost basis and the fair value.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables and Revenue Recognition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally establish <ix:nonNumeric contextRef="c-1" name="hum:CommercialMembershipContractTerm" format="ixt-sec:durwordsen" id="f-494">one-year</ix:nonNumeric> commercial membership contracts with employer groups, subject to cancellation by the employer group on <ix:nonNumeric contextRef="c-1" name="hum:NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies" format="ixt-sec:durday" id="f-495">30</ix:nonNumeric>-day written notice. Our Medicare contracts with CMS renew annually. Our military services contracts with the federal government and certain contracts with various state Medicaid programs generally are multi-year contracts subject to annual renewal provisions.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InsurancePremiumsRevenueRecognitionPolicy" id="f-496" continuedAt="f-496-1" escape="true"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Premiums Revenue</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive monthly premiums from the federal government and various states according to government specified payment rates and various contractual terms. We bill and collect premium from employer groups and members in our Medicare and other individual products monthly.  Changes in premium revenues resulting from the periodic changes in risk-adjustment scores derived from medical diagnoses for our membership are estimated by projecting the ultimate annual premium and are recognized ratably during the year, with adjustments each period to reflect changes in the ultimate premium. Receivables or payables are classified as current or long-term in our consolidated balance sheet based on the timing of the expected settlement. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premiums revenue is estimated by multiplying the membership covered under the various contracts by the contractual rates. Premiums revenue is recognized as income in the period members are entitled to receive services and is net of estimated uncollectible amounts, retroactive membership adjustments, and adjustments to recognize rebates under the minimum benefit ratios required under the Health Care Reform Law. We estimate policyholder rebates by projecting calendar year minimum benefit ratios for the small group and large group markets, as defined by the Health Care Reform Law using a methodology prescribed by Health and Human Services, or HHS, separately by state and legal entity. Medicare Advantage and Medicaid products are also subject to minimum benefit ratio requirements. Estimated calendar year rebates recognized ratably during the year are revised each period to reflect current experience. Retroactive membership adjustments result from enrollment changes not yet processed, or not yet reported by an employer group or the government. We routinely monitor the collectability of specific accounts, the aging of receivables, historical retroactivity trends, estimated rebates, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. Premiums received prior to the service period are recorded as unearned revenues.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Part D</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with CMS. The payments we receive monthly from CMS and members, which are determined from our annual bid, represent amounts for providing prescription drug insurance coverage. We recognize premiums revenue for providing this insurance coverage ratably over the term of our annual contract. Our CMS payment is subject to risk sharing through the Medicare Part D risk corridor provisions. In addition, receipts for reinsurance and low-income cost subsidies as well as receipts for certain discounts on brand name prescription drugs in the coverage gap represent payments for prescription drug costs for which we are not at risk.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk corridor provisions compare costs targeted in our bids to actual prescription drug costs, limited to actual costs that would have been incurred under the standard coverage as defined by CMS. Variances exceeding certain thresholds may result in CMS making additional payments to us or require us to refund to CMS a portion of the premiums we received. As risk corridor provisions are considered in our overall annual bid process, we estimate </span></div></ix:nonNumeric></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-481-4" continuedAt="f-481-5"><ix:continuation id="f-496-1" continuedAt="f-496-2"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and recognize an adjustment to premiums revenue related to these provisions based upon pharmacy claims experience. We record a receivable or payable at the contract level and classify the amount as current or long-term in our consolidated balance sheets based on the timing of expected settlement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reinsurance and low-income cost subsidies represent funding from CMS in connection with the Medicare Part D program for which we assume no risk. Reinsurance subsidies represent funding from CMS for its portion of prescription drug costs which exceed the member&#8217;s out-of-pocket threshold, or the catastrophic coverage level. Low-income cost subsidies represent funding from CMS for all or a portion of the deductible, the coinsurance and co-payment amounts above the out-of-pocket threshold for low-income beneficiaries. Monthly prospective payments from CMS for reinsurance and low-income cost subsidies are based on assumptions submitted with our annual bid. A reconciliation and related settlement of CMS&#8217;s prospective subsidies against actual prescription drug costs we paid is made after the end of the year. The Health Care Reform Law mandates consumer discounts of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="hum:ConsumerDiscountsOnBrandNamePrescriptionDrugs" scale="-2" id="f-497">50</ix:nonFraction>% on brand name prescription drugs for Part D plan participants in the coverage gap. These discounts are funded by CMS and pharmaceutical manufacturers while we administer the application of these funds. <ix:nonNumeric contextRef="c-1" name="hum:ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock" id="f-498" continuedAt="f-498-1" escape="true">We account for these subsidies and discounts as a deposit in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits, net in our consolidated statements of cash flows. </ix:nonNumeric></span></div><ix:continuation id="f-498-1" continuedAt="f-498-2"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"/><td style="width:56.896%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.470%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.470%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.472%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part D subsidy/discount payments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="hum:SubsidyAndDiscountPayments" format="ixt:num-dot-decimal" scale="6" id="f-499">17,582</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="hum:SubsidyAndDiscountPayments" format="ixt:num-dot-decimal" scale="6" id="f-500">16,530</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:SubsidyAndDiscountPayments" format="ixt:num-dot-decimal" scale="6" id="f-501">14,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part D subsidy/discount reimbursements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="hum:SubsidyAndDiscountReimbursements" format="ixt:num-dot-decimal" scale="6" id="f-502">18,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="hum:SubsidyAndDiscountReimbursements" format="ixt:num-dot-decimal" scale="6" id="f-503">18,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:SubsidyAndDiscountReimbursements" format="ixt:num-dot-decimal" scale="6" id="f-504">14,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net reimbursements (payments)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="hum:SubsidyAndDiscountPaymentsInExcessOfReimbursements" scale="6" id="f-505">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="hum:SubsidyAndDiscountPaymentsInExcessOfReimbursements" format="ixt:num-dot-decimal" scale="6" id="f-506">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:SubsidyAndDiscountPaymentsInExcessOfReimbursements" scale="6" id="f-507">261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not recognize premiums revenue or benefit expenses for these subsidies or discounts. Receipt and payment activity is accumulated at the contract level and recorded in our consolidated balance sheets in other current assets or trade accounts payable and accrued expenses depending on the contract balance at the end of the reporting period.</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-496-2">Settlement of the reinsurance and low-income cost subsidies as well as the risk corridor payment is based on a reconciliation made approximately <ix:nonNumeric contextRef="c-63" name="hum:SubsidyAndDiscountsSettlementPeriodAfterClose" format="ixt-sec:durmonth" id="f-508">9</ix:nonNumeric> months after the close of each calendar year. Settlement with CMS for brand name prescription drug discounts is based on a reconciliation made approximately <ix:nonNumeric contextRef="c-64" name="hum:SubsidyAndDiscountsSettlementPeriodAfterClose" format="ixt-sec:durmonth" id="f-509">14</ix:nonNumeric> to <ix:nonNumeric contextRef="c-65" name="hum:SubsidyAndDiscountsSettlementPeriodAfterClose" format="ixt-sec:durmonth" id="f-510">18</ix:nonNumeric> months after the close of each calendar year. We continue to revise our estimates with respect to the risk corridor provisions based on subsequent period pharmacy claims data. For additional information regarding amounts recorded to our consolidated balance sheets related to the risk corridor settlement and subsidies from CMS with respect to the Medicare Part D program, refer to Note 7 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-511" continuedAt="f-511-1" escape="true"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient services revenue </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient services include services related to pharmacy solutions, primary care, and home solutions and other services and capabilities to promote wellness and advance population health. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our pharmacy solutions business, external pharmacy revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments for drugs dispensed through our CenterWell Pharmacy (our mail-order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Services revenues related to product revenues from dispensing prescriptions are recorded when the prescription or product is shipped.</span></div></ix:nonNumeric></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-511-1"><ix:continuation id="f-481-5" continuedAt="f-481-6"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary care business recognizes revenues for certain value-based arrangements. Under these value-based arrangements, we enter into agreements with health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our patients. In exchange, we receive a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our patients. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home solutions businesses, revenues include net patient services revenue recorded based upon established billing rates, net of contractual allowances, discounts, or other implicit price concessions, and are recognized as performance obligations are satisfied, which is in the period services are rendered.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the&#160;year ended December&#160;31, 2023, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price), was not material. Further, revenue expected to be recognized in any future year related to remaining performance obligations is not material.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Administrative services fees </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative services fees cover the processing of claims, offering access to our provider networks and clinical programs, and responding to customer service inquiries from members of self-funded groups. Revenues from providing administration services, also known as administrative services only, or ASO, are recognized in the period services are performed and are net of estimated uncollectible amounts. ASO fees are estimated by multiplying the membership covered under the various contracts by the contractual rates. Under ASO contracts, self-funded employers retain the risk of financing substantially all of the cost of health benefits. However, many ASO customers purchase stop loss insurance coverage from us to cover catastrophic claims or to limit aggregate annual costs. Accordingly, we have recorded premiums revenue and benefits expense related to these stop loss insurance contracts. We routinely monitor the collectability of specific accounts, the aging of receivables, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. ASO fees received prior to the service period are recorded as unearned revenues.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under our TRICARE contracts with the Department of Defense (DoD) we provide administrative services, including offering access to our provider networks and clinical programs, claim processing, customer service, enrollment, and other services, while the federal government retains all of the risk of the cost of health benefits. We account for revenues under our contracts net of estimated health care costs similar to an administrative services fee only agreement. Our contracts include fixed administrative services fees and incentive fees and penalties. Administrative services fees are recognized as services are performed.&#160;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our TRICARE members are served by both in-network and out-of-network providers in accordance with our contracts. We pay health care costs related to these services to the providers and are subsequently reimbursed by the DoD for such payments. <ix:continuation id="f-498-2" continuedAt="f-498-3">We account for the payments of the federal government&#8217;s claims and the related reimbursements under deposit accounting in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits, net in our consolidated statements of cash flows.  </ix:continuation></span></div><ix:continuation id="f-498-3"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:56.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.448%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.450%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost payments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="hum:HealthCareCostPayments" format="ixt:num-dot-decimal" scale="6" id="f-512">7,073</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="hum:HealthCareCostPayments" format="ixt:num-dot-decimal" scale="6" id="f-513">7,110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:HealthCareCostPayments" format="ixt:num-dot-decimal" scale="6" id="f-514">6,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost reimbursements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="hum:HealthCareCostReimbursements" format="ixt:num-dot-decimal" scale="6" id="f-515">7,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="hum:HealthCareCostReimbursements" format="ixt:num-dot-decimal" scale="6" id="f-516">7,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:HealthCareCostReimbursements" format="ixt:num-dot-decimal" scale="6" id="f-517">6,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net reimbursements (payments)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="hum:HealthCareCostPaymentsAndReimbursementsNet" scale="6" id="f-518">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="hum:HealthCareCostPaymentsAndReimbursementsNet" scale="6" id="f-519">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:HealthCareCostPaymentsAndReimbursementsNet" scale="6" id="f-520">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:continuation></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-481-6" continuedAt="f-481-7"><ix:nonNumeric contextRef="c-1" name="us-gaap:ReceivablesPolicyTextBlock" id="f-521" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, including premium receivables, patient services revenue receivables, and ASO fee receivables, are shown net of allowances for estimated uncollectible accounts, retroactive membership adjustments, and contractual allowances.</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At&#160;December&#160;31, 2023 and 2022, accounts receivable related to services were $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-522">357</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-523">291</ix:nonFraction> million, respectively. For the&#160;years ended December&#160;31, 2023, 2022 and 2021, we had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the consolidated balance sheet at&#160;December&#160;31, 2023 and 2022.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="hum:OtherCurrentAssetsPolicyTextBlock" id="f-524" continuedAt="f-524-1" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets</span></div></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-524-1">Other current assets include amounts associated with Medicare Part D, rebates due from pharmaceutical manufacturers and other amounts due within one year.  We accrue pharmaceutical rebates as they are earned based on contractual terms and usage of the product.</ix:continuation>  The balance of pharmaceutical rebates receivable was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-8" name="hum:AccruedPharmaceuticalRebatesCurrent" format="ixt:num-dot-decimal" scale="9" id="f-525">2.3</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-8" name="hum:AccruedPharmaceuticalRebatesCurrent" format="ixt:num-dot-decimal" scale="9" id="f-526">2.0</ix:nonFraction>&#160;billion at December&#160;31, 2023 and 2022, respectively. For additional information regarding amounts associated with Medicare Part D, refer to Note 7 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InsuranceContractAcquisitionCostPolicyTextBlock" id="f-527" escape="true"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policy Acquisition Costs</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Policy acquisition costs are those costs that relate directly to the successful acquisition of new and renewal insurance policies. Such costs include commissions, costs of policy issuance and underwriting, and other costs we incur to acquire new business or renew existing business. We expense policy acquisition costs related to our employer-group prepaid health services policies as incurred. These short-duration employer-group prepaid health services policies typically have a <ix:nonNumeric contextRef="c-1" name="hum:TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies" format="ixt-sec:duryear" id="f-528">1</ix:nonNumeric>-year term and may be canceled upon <ix:nonNumeric contextRef="c-1" name="hum:NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies" format="ixt-sec:durday" id="f-529">30</ix:nonNumeric> days notice by the employer group.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-530" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at cost. Gains and losses on sales or disposals of property and equipment are included in operating costs in our consolidated income statements. Certain costs related to the development or purchase of internal-use software are capitalized. Depreciation is computed using the straight-line method over estimated useful lives ranging from <ix:nonNumeric contextRef="c-68" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-531">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-69" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-532">10</ix:nonNumeric> years for equipment, <ix:nonNumeric contextRef="c-70" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-533">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-71" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-534">5</ix:nonNumeric> years for computer software, and <ix:nonNumeric contextRef="c-72" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-535">10</ix:nonNumeric> to <ix:nonNumeric contextRef="c-73" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-536">20</ix:nonNumeric> years for buildings. Improvements to leased facilities are depreciated over the shorter of the remaining lease term or the anticipated life of the improvement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review long-lived assets, including property and equipment and other definite-lived intangible assets, for impairment whenever adverse events or changes in circumstances indicate the carrying value of the asset may not be recoverable. Losses are recognized for a long-lived asset to be held and used in our operations when the undiscounted future cash flows expected to result from the use of the asset are less than its carrying value. We recognize an impairment loss based on the excess of the carrying value over the fair value of the asset. A long-lived asset held for sale is reported at the lower of the carrying amount or fair value less costs to sell. Depreciation expense is not recognized on assets held for sale. Losses are recognized for a long-lived asset to be abandoned when the asset ceases to be used. In addition, we periodically review the estimated lives of all long-lived assets for reasonableness.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsPolicy" id="f-537" continuedAt="f-537-1" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investments</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method of accounting for equity investments in companies where we are able to exercise significant influence, but not control, over operating and financial policies of the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as our ownership interest, representation on the board of directors, organizational structure, participation in policy-making decisions and material intra-entity transactions.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-481-7" continuedAt="f-481-8"><ix:continuation id="f-537-1"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, under the equity method, original investments in these entities are recorded at cost and subsequently adjusted by our share of equity in income or losses after the date of acquisition as well as capital contributions to and distributions from these companies. Our proportionate share of the net income or loss of these companies is included in consolidated net income.  Investment amounts in excess of our share of an investee&#8217;s net assets are amortized over the life of the related asset creating the excess. Excess goodwill is not amortized. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered by us when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than carrying value, the investee&#8217;s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.</span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our equity method investments, refer to Note 4 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-538" continuedAt="f-538-1" escape="true"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the unamortized excess of cost over the fair value of the net tangible and other intangible assets acquired. We are required to test at least annually for impairment at a level of reporting referred to as the reporting unit, and more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. A reporting unit either is our operating segments or one level below the operating segments, referred to as a component, which comprise our reportable segments. A component is considered a reporting unit if the component constitutes a business for which discrete financial information is available that is regularly reviewed by management. We aggregate the components of an operating segment into one reporting unit if they have similar economic characteristics. Goodwill is assigned to the reporting units that are expected to benefit from the specific synergies of the business combination.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform a quantitative assessment to review goodwill for impairment to determine both the existence and amount of goodwill impairment, if any. Impairment tests are performed, at a minimum, in the fourth quarter of each year supported by our long-range business plan and annual planning process. We rely on an evaluation of future discounted cash flows to determine fair value of our reporting units. The fair value of our reporting units with significant goodwill exceeded carrying amounts. However, unfavorable changes in key assumptions or combinations of assumptions including a significant increase in the discount rate, decrease in the long-term growth rate or substantial reduction in our underlying cash flow assumptions, including revenue growth rates, medical and operating cost trends, and projected operating income could have a significant negative impact on the estimated fair value of our home solutions and primary care reporting units, which accounted for $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="f-539">4.4</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="f-540">1.2</ix:nonFraction>&#160;billion of goodwill, respectively. Impairment tests completed for 2023, 2022, and 2021 did <ix:nonFraction unitRef="usd" contextRef="c-7" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-541"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-542"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-543">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t result in an impairment loss. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with indefinite lives relate to Certificate of Needs (CON) and Medicare licenses acquired as part of our acquisition of Kindred at Home, or KAH, and are included within other long-term assets in the consolidated balance sheet at December&#160;31, 2023 and December&#160;31, 2022. For additional information regarding our acquisition of KAH, refer to Note 3 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K. We are required to annually compare the fair values of other indefinite-lived intangible assets to their carrying amounts. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized. Fair values of indefinite-lived intangible assets are determined based on the income approach. Impairment tests completed for 2023 and 2022 did not result in material impairment losses. These charges reflect the amount by which the carrying value exceeded its estimated fair value. Impairment tests completed for 2021 did not result in an impairment loss. The fair values of the assets were measured using Level 3 inputs, such as projected revenues and operating cash flows. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Definite-lived intangible assets primarily relate to acquired customer contracts/relationships and are included with other long-term assets in the consolidated balance sheets. Definite-lived intangible assets are amortized over the </span></div></ix:nonNumeric></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-481-8" continuedAt="f-481-9"><ix:continuation id="f-538-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">useful life generally using the straight-line method. We review definite-lived intangible assets for impairment under our long-lived asset policy.</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="hum:BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock" id="f-544" continuedAt="f-544-1" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefits Payable and Benefits Expense Recognition</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefits expense includes claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care and other supplemental benefits provided on or prior to the balance sheet date. Capitation payments represent monthly contractual fees disbursed to primary care and other providers who are responsible for providing medical care to members. Pharmacy costs represent payments for members&#8217; prescription drug benefits, net of rebates from drug manufacturers. Receivables for such pharmacy rebates are included in other current assets in our consolidated balance sheets. Other supplemental benefits include dental, vision, and other supplemental health products.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the costs of our benefits expense payments using actuarial methods and assumptions based upon claim payment patterns, medical cost inflation, historical developments such as claim inventory levels and claim receipt patterns, and other relevant factors, and record benefit reserves for future payments. We continually review estimates of future payments relating to claims costs for services incurred in the current and prior periods and make necessary adjustments to our reserves.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefits expense is recognized in the period in which services are provided and includes an estimate of the cost of services which have been incurred but not yet reported, or IBNR. Our reserving practice is to consistently recognize the actuarial best point estimate within a level of confidence required by actuarial standards. Actuarial standards of practice generally require a level of confidence such that the liabilities established for IBNR have a greater probability of being adequate versus being insufficient, or such that the liabilities established for IBNR are sufficient to cover obligations under an assumption of moderately adverse conditions. Adverse conditions are situations in which the actual claims are expected to be higher than the otherwise estimated value of such claims at the time of the estimate. Therefore, in many situations, the claim amounts ultimately settled will be less than the estimate that satisfies the actuarial standards of practice.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We develop our estimate for IBNR using actuarial methodologies and assumptions, primarily based upon historical claim experience. Depending on the period for which incurred claims are estimated, we apply a different method in determining our estimate. For periods prior to the most recent two months, a completion factor method uses historical paid claims patterns to estimate the percentage of claims incurred during a given period that have historically been adjudicated as of the reporting period. Changes in claim inventory levels and known changes in claim payment processes are taken into account in these estimates. For the most recent two months, the incurred claims are estimated primarily from a trend analysis based upon per member per month claims trends developed from our historical experience in the preceding months, adjusted for known changes in estimates of hospital admissions, recent hospital and drug utilization data, provider contracting changes, changes in benefit levels, changes in member cost sharing, changes in medical management processes, product mix, and workday seasonality.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The completion factor method is used for the months of incurred claims prior to the most recent two months because the historical percentage of claims processed for those months is at a level sufficient to produce a consistently reliable result. Conversely, for the most recent two months of incurred claims, the volume of claims processed historically is not at a level sufficient to produce a reliable result, which therefore requires us to examine historical trend patterns as the primary method of evaluation. Changes in claim processes, including recoveries of overpayments, receipt cycle times, claim inventory levels, outsourcing, system conversions, and processing disruptions due to weather or other events affect views regarding the reasonable choice of completion factors. Claim payments to providers for services rendered are often net of overpayment recoveries for claims paid previously, as contractually allowed. Claim overpayment recoveries can result from many different factors, including retroactive enrollment activity, audits of provider billings, and/or payment errors. Changes in patterns of claim overpayment recoveries can be unpredictable and result in completion factor volatility, as they often impact older dates of service. The receipt cycle time measures the average length of time between when a medical claim was initially incurred and </span></div></ix:nonNumeric></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-481-9" continuedAt="f-481-10"><ix:continuation id="f-544-1"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when the claim form was received. Increases in electronic claim submissions from providers decrease the receipt cycle time. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claim may be more (less) complete than originally estimated using our completion factors, which may result in reserves that are higher (lower) than required.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical cost trends potentially are more volatile than other segments of the economy. The drivers of medical cost trends include increases in the utilization of hospital facilities, physician services, new higher priced technologies and medical procedures, and new prescription drugs and therapies, as well as the inflationary effect on the cost per unit of each of these expense components. Other external factors such as government-mandated benefits or other regulatory changes, the tort liability system, increases in medical services capacity, direct to consumer advertising for prescription drugs and medical services, an aging population, lifestyle changes including diet and smoking, catastrophes, public health emergencies, epidemics and pandemics (such as COVID-19) also may impact medical cost trends. Internal factors such as system conversions, claims processing cycle times, changes in medical management practices and changes in provider contracts also may impact our ability to accurately predict estimates of historical completion factors or medical cost trends. All of these factors are considered in estimating IBNR and in estimating the per member per month claims trend for purposes of determining the reserve for the most recent two months. Additionally, we continually prepare and review follow-up studies to assess the reasonableness of the estimates generated by our process and methods over time. The results of these studies are also considered in determining the reserve for the most recent two months. Each of these factors requires significant judgment by management.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reassess the profitability of our contracts for providing insurance coverage to our members when current operating results or forecasts indicate probable future losses. We establish a premium deficiency reserve in current operations to the extent that the sum of expected future costs, claim adjustment expenses, and maintenance costs exceeds related future premiums under contracts. For purposes of determining premium deficiencies, contracts are grouped in a manner consistent with our method of acquiring, servicing, and measuring the profitability of such contracts. Losses recognized as a premium deficiency result in a beneficial effect in subsequent periods as operating losses under these contracts are charged to the liability previously established. Because the majority of our member contracts renew annually, we would not record a material premium deficiency reserve, except when unanticipated adverse events or changes in circumstances indicate otherwise.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our benefits payable are adequate to cover future claims payments required. However, such estimates are based on knowledge of current events and anticipated future events. Therefore, the actual liability could differ materially from the amounts provided.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="hum:FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock" id="f-545" escape="true"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future policy benefits payable</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future policy benefits payable includes liabilities for long-duration insurance policies primarily related to certain blocks of insurance assumed in acquisitions, primarily life and annuities in run-off status, and are included in our consolidated balance sheet within other long-term liabilities. Most of these policies are subject to reinsurance. For additional information regarding reinsurance, refer to Note 19 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="hum:BookOverdraftPolicyPolicyTextBlock" id="f-546" escape="true"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Book Overdraft</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our cash management system, checks issued but not yet presented to banks that would result in negative bank balances when presented are classified as a current liability in the consolidated balance sheets. Changes in book overdrafts from period to period are reported in the consolidated statement of cash flows as a financing activity.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-547" continuedAt="f-547-1" escape="true"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets or liabilities and their reported amounts in the consolidated financial statements. These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or </span></div></ix:nonNumeric></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-481-10" continuedAt="f-481-11"><ix:continuation id="f-547-1"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities are recovered or settled. We also recognize the future tax benefits such as net operating and capital loss carryforwards as deferred tax assets. A valuation allowance is provided against these deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized. Future years&#8217; tax expense may be increased or decreased by adjustments to the valuation allowance or to the estimated accrual for income taxes. Deferred tax assets and deferred tax liabilities are further adjusted for changes in the enacted tax rates. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record tax benefits when it is more likely than not that the tax return position taken with respect to a particular transaction will be sustained. A liability, if recorded, is not considered resolved until the statute of limitations for the relevant taxing authority to examine and challenge the tax position has expired, or the tax position is ultimately settled through examination, negotiation, or litigation. We classify interest and penalties associated with uncertain tax positions in our provision for income taxes.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="f-548" escape="true"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include all assets, liabilities, revenues and expenses of less than 100% owned affiliates that we control. Accordingly, we record noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interest holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interest holders&#8217; balances. Noncontrolling interests, which relate to the minority ownership held by third party investors in certain of our businesses within our Insurance and CenterWell segments, are reported below net income under the heading &#8220;Net income attributable to noncontrolling interests&#8221; in the consolidated statements of income and presented as a component of equity in the consolidated balance sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="f-549" continuedAt="f-549-1" escape="true"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-549-1">We generally recognize stock-based compensation expense, as determined on the date of grant at fair value, on a straight-line basis over the period during which an employee is required to provide service in exchange for the award (the vesting period). In addition, for awards with both time and performance-based conditions, we generally recognize compensation expense on a straight line basis over the vesting period when it is probable that the performance condition will be achieved. We estimate expected forfeitures and recognize compensation expense only for those awards which are expected to vest. We estimate the grant-date fair value of stock options using the Black-Scholes option-pricing model.</ix:continuation> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For additional information regarding our stock-based compensation plans, refer to Note 14 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-550" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Common Share</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compute basic earnings per common share on the basis of the weighted-average number of unrestricted common shares outstanding. Diluted earnings per common share is computed on the basis of the weighted-average number of unrestricted common shares outstanding plus the dilutive effect of outstanding employee stock options and restricted shares, or units, using the treasury stock method.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our earnings per share, refer to Note 15 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-551" continuedAt="f-551-1" escape="true"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are categorized into a fair value hierarchy based on whether the inputs to valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our own assumptions about the assumptions market participants would use. The fair value hierarchy includes three levels of inputs that may be used to measure fair value as described below.</span></div></ix:nonNumeric></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-481-11" continuedAt="f-481-12"><ix:continuation id="f-551-1"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities include securities that are traded in an active exchange market.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8211; Observable inputs other than Level 1 prices such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less frequently than exchange-traded instruments as well as debt securities whose value is determined using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes assets and liabilities whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting our own assumptions about the assumptions market participants would use as well as those requiring significant management judgment.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of actively traded debt and equity securities are based on quoted market prices. Fair value of other debt securities are based on quoted market prices of identical or similar securities or based on observable inputs like interest rates generally using a market valuation approach, or, less frequently, an income valuation approach and are generally classified as Level 2. Fair value of privately held investment grade debt securities are estimated using a variety of valuation methodologies, including both market and income approaches, where an observable quoted market does not exist and are generally classified as Level 3. For privately-held investment grade debt securities, such methodologies include reviewing the value ascribed to the most recent financing, comparing the security with securities of publicly-traded companies in similar lines of business with similar credit characteristics, and reviewing the underlying financial performance including estimating discounted cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain at least one price for each security from a third party pricing service. These prices are generally derived from recently reported trades for identical or similar securities, including adjustments through the reporting date based upon observable market information. When quoted prices are not available, the third party pricing service may use quoted market prices of comparable securities or discounted cash flow analysis, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include benchmark yields, reported trades, credit spreads, broker quotes, default rates, and prepayment speeds. We are responsible for the determination of fair value and as such we perform analysis on the prices received from the third party pricing service to determine whether the prices are reasonable estimates of fair value. Our analysis includes a review of monthly price fluctuations as well as a quarterly comparison of the prices received from the pricing service to prices reported by our third party investment adviser. In addition, on a quarterly basis we examine the underlying inputs and assumptions for a sample of individual securities across asset classes, credit rating levels, and various durations.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-552" continuedAt="f-552-1" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services&#8212;Insurance (Topic 944): Effective Date and Early Application (&#8220;ASU 2020-11&#8221;). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services&#8212;Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (&#8220;ASU 2018-12&#8221;), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The new guidance relates to accounting for long-duration contracts of insurers which revises key elements of the measurement models and disclosure requirements for long-duration contracts issued by insurers, including the amortization of deferred contract acquisition costs and the measurement of liabilities for future policy benefits using current, rather than locked-in, assumptions. The new guidance, limited to our Medicare Supplement product which represents less than <ix:nonFraction unitRef="number" contextRef="c-76" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-553">1</ix:nonFraction>% of consolidated premiums and services revenue, became effective for us </span></div></ix:nonNumeric></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-552-1"><ix:continuation id="f-481-12"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beginning January 1, 2023 and was applied to contracts in force on the basis of their existing carrying value amounts at the beginning of the earliest period presented. The adoption of the new standard in 2023 did not have a material impact on our consolidated results of operations, financial position or cash flows.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Pronouncements Effective in Future Periods</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting &#8212; Improvements to Reportable Segment Disclosures. The new guidance requires incremental disclosures related to a public entity&#8217;s reportable segments but does not change the definition of a segment, the method for determining segments, or the criteria for aggregating operating segments into reportable segments. The new guidance requires a public entity to disclose its significant segment expense categories and amounts for each reportable segment. The new guidance will be effective for us beginning with our annual 2024 year-end financial statements. We are currently evaluating the impact on our segment information footnote disclosures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-09 &#8212; Income Taxes (Topic 740): Improvements to Income Tax Disclosures.  The new guidance requires significant additional disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be effective for us beginning with our annual 2025 year-end financial statements, with early adoption permitted.  We are currently evaluating the impact on our income tax footnote disclosures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.</span></div></ix:continuation></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_151"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="f-554" continuedAt="f-554-1" escape="true">ACQUISITIONS AND DIVESTITURES</ix:nonNumeric></span><ix:continuation id="f-554-1" continuedAt="f-554-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span></ix:continuation></div><ix:continuation id="f-554-2" continuedAt="f-554-3"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;11, 2022, we completed the sale of a <ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="hum:DisposalGroupIncludingDiscontinuedOperationEquityInterestSold" scale="-2" id="f-555">60</ix:nonFraction>% i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nterest in Gentiva (formerly Kindred) Hospice to Clayton, Dubilier &amp; Rice, or CD&amp;R, for cash proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-8" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="9" id="f-556">2.7</ix:nonFraction>&#160;billion, net of cash disposed, including debt repayments from Gentiva Hospice to Humana of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-8" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="9" id="f-557">1.9</ix:nonFraction>&#160;billion. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale, we recognized a pre-tax gain, net of transaction costs, of $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="f-558">237</ix:nonFraction>&#160;million which was reported as a gain on sale of Gentiva Hospice in the accompanying consolidated statement of income for the year ended December 31, 2022. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we classified Gentiva Hospice as held-for-sale and aggregated Gentiva Hospice&#8217;s assets and liabilities separately on the balance sheet. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-559" continuedAt="f-559-1" escape="true">The assets, liabilities and noncontrolling interest disposed of on August 11, 2022 were as follows:</ix:nonNumeric></span></div><ix:continuation id="f-559-1"><div style="padding-left:36pt;padding-right:36pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:77.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.928%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="6" id="f-560">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Receivables, net of allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="6" id="f-561">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" scale="6" id="f-562">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" scale="6" id="f-563">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-564">2,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" scale="6" id="f-565">960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="f-566">3,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trade accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-567">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" scale="6" id="f-568">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="f-569">530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Noncontrolling interest</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="hum:DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest" scale="6" id="f-570">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:continuation><div style="padding-left:36pt;padding-right:36pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets included $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-571">866</ix:nonFraction>&#160;million identifiable intangibles consisting of Medicare licenses and CON. </span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-554-3"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale of a <ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="hum:DisposalGroupIncludingDiscontinuedOperationEquityInterestSold" scale="-2" id="f-572">60</ix:nonFraction>% interest in Gentiva Hospice on August 11, 2022, as discussed above, Gentiva Hospice revenues and pretax earnings through the date of sale for the year ended December 31, 2022, were $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="f-573">958</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax" format="ixt:num-dot-decimal" scale="6" id="f-574">150</ix:nonFraction>&#160;million, respectively.  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, we acquired the remaining <ix:nonFraction unitRef="number" contextRef="c-81" decimals="2" name="hum:BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage" scale="-2" id="f-575">60</ix:nonFraction>% interest in Kindred at Home, or KAH,  from TPG Capital and Welsh, Carson, Anderson &amp; Stowe, or WCAS, two private equity funds, for an enterprise value of $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-8" name="hum:BusinessCombinationTotalEnterpriseValueOfAcquiree" format="ixt:num-dot-decimal" scale="9" id="f-576">8.2</ix:nonFraction>&#160;billion, which included our equity value of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-8" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" format="ixt:num-dot-decimal" scale="9" id="f-577">2.4</ix:nonFraction>&#160;billion associated with our <ix:nonFraction unitRef="number" contextRef="c-81" decimals="2" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" id="f-578">40</ix:nonFraction>% minority ownership interest. The remeasurement to fair value of our previously held <ix:nonFraction unitRef="number" contextRef="c-81" decimals="2" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" id="f-579">40</ix:nonFraction>% equity method investment with a carrying value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="f-580">1.3</ix:nonFraction>&#160;billion, resulted in a $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-8" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" format="ixt:num-dot-decimal" scale="9" id="f-581">1.1</ix:nonFraction>&#160;billion gain recognized in "Other (income) expense, net" </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the accompanying consolidated statement of income for the year ended December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We paid the approximate $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-8" name="hum:BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest" format="ixt:num-dot-decimal" scale="9" id="f-582">5.8</ix:nonFraction>&#160;billion transaction price (net of our existing equity stake) through a combination of debt financing, the assumption of existing KAH indebtedness and parent company cash.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, 2022, and 2021, we acquired other health and wellness related businesses which other than the impacts to goodwill, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows.  The results of operations and financial condition of these businesses have been included in our consolidated statements of income and consolidated balance sheets from the respective acquisition dates. Acquisition-related costs recognized in each of 2023, 2022 and 2021 were not material to our results of operations. For asset acquisitions the goodwill acquired is partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the year of acquisition, were not material for disclosure purposes.</span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_154"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="f-583" continuedAt="f-583-1" escape="true">EQUITY METHOD INVESTMENT</ix:nonNumeric></span></div><ix:continuation id="f-583-1"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our acquisition of KAH in August 2021, we accounted for our <ix:nonFraction unitRef="number" contextRef="c-83" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-584">40</ix:nonFraction>%&#160;investment in KAH using the equity method of accounting. Our share of income or loss was reported as equity in net (losses) earnings in our consolidated statements of income.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed the sale of a <ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="hum:DisposalGroupIncludingDiscontinuedOperationEquityInterestSold" scale="-2" id="f-585">60</ix:nonFraction>% interest in Gentiva Hospice on August 11, 2022 and we account for our remaining minority ownership in Gentiva Hospice using the equity method of accounting. At December&#160;31, 2023 and 2022 we owned <ix:nonFraction unitRef="number" contextRef="c-84" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-586">35</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-85" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-587">40</ix:nonFraction>%, respectively. This investment was reflected in equity method investments in our December&#160;31, 2023 and 2022 consolidated balance sheets, with our share of income or loss reported as equity in net (losses) earnings in our consolidated statements of income.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsTextBlock" id="f-588" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summarized balance sheets and statements of income at December&#160;31, 2023 and 2022 of Gentiva Hospice were as follows:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:55.210%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.746%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance sheet</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:AssetsCurrent" scale="6" id="f-589">415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:AssetsCurrent" scale="6" id="f-590">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-591">4,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-592">3,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-593">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-594">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-595">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-596">2,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-597">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-598">1,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"/><td style="width:53.916%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.393%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31, 2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">August 11, 2022 through December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-599">1,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-600">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" name="hum:Expenses" format="ixt:num-dot-decimal" scale="6" id="f-601">1,873</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-6" name="hum:Expenses" scale="6" id="f-602">652</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-603">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="f-604">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other equity method investments</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, our Primary Care Organization entered into a strategic partnership with Welsh, Carson, Anderson &amp; Stowe, or WCAS, to accelerate the expansion of our primary care model. In May 2022, we established a second strategic partnership with WCAS to develop additional centers between 2023 and 2025. As of December 31, 2023, there were <ix:nonFraction unitRef="primary_care_center" contextRef="c-90" decimals="INF" name="hum:StrategicPartnershipAgreementNumberOfPrimaryCareCenters" scale="0" id="f-605">108</ix:nonFraction> primary care clinics operating under the partnership and we have capacity to open or acquire up to approximately <ix:nonFraction unitRef="primary_care_center" contextRef="c-90" decimals="0" name="hum:StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened" scale="0" id="f-606">60</ix:nonFraction> additional centers through the existing partnership agreements. In addition, the agreements include a series of put and call options through which WCAS may require us to purchase their interest in the entity, and through which we may acquire WCAS&#8217;s interest, over the next <ix:nonNumeric contextRef="c-91" name="hum:StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity" format="ixt-sec:duryear" id="f-607">2</ix:nonNumeric> to <ix:nonNumeric contextRef="c-92" name="hum:StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity" format="ixt-sec:duryear" id="f-608">9</ix:nonNumeric> years. We have the option to purchase the first cohort of clinics in 2025 for approximately $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-6" name="hum:StrategicPartnershipAgreementCallOptionStrikePrice" format="ixt:num-dot-decimal" scale="6" id="f-609">550</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-6" name="hum:StrategicPartnershipAgreementCallOptionStrikePrice" format="ixt:num-dot-decimal" scale="6" id="f-610">650</ix:nonFraction>&#160;million based on current projections. All existing cohorts can be called by us from 2025 to 2030 and could require $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-8" name="hum:StrategicPartnershipAgreementCallOptionStrikePrice" format="ixt:num-dot-decimal" scale="9" id="f-611">2.0</ix:nonFraction>&#160;billion to $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-8" name="hum:StrategicPartnershipAgreementCallOptionStrikePrice" format="ixt:num-dot-decimal" scale="9" id="f-612">3.0</ix:nonFraction>&#160;billion based on current projections. These estimates are dependent on multiple factors including the actual timing of when the put or call options are exercised, expected revenue growth at each center within the respective cohort and future capital contributions, among other factors. For additional information on inputs relevant to these put and call options, refer to Note 6 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several individually immaterial equity method investments, including our strategic partnership with WCAS as described above, included within equity method investments in our consolidated balance sheets as of December&#160;31, 2023 and 2022 with our share of income or loss reported as equity in net (losses) earnings in our consolidated statements of income for the years ended December&#160;31, 2023, 2022 and 2021.</span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_157"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-613" continuedAt="f-613-1" escape="true">INVESTMENT SECURITIES</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="f-614" escape="true"><ix:continuation id="f-613-1" continuedAt="f-613-2"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities classified as current and long-term were as follows at December&#160;31, 2023 and 2022, respectively:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.682%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.646%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>&#160;&#160;&#160;&#160;corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-615">2,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-616">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-617">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-618">2,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-619">3,946</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-620">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-621">425</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-622">3,522</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-623">879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-624">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-625">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-626">858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-627">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-628">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-629">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-630">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-631">1,471</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-632">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-633">126</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-634">1,345</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-635">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-636">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-637">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-638">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-639">7,011</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-640">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-641">594</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-642">6,445</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-643">18,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-644">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-645">1,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-646">17,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="f-647">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investment securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-648">17,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>&#160;&#160;&#160;&#160;corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-649">1,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-650">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-651">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-652">1,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-653">3,697</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-654">4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-655">471</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-656">3,230</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-657">765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-658">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-659">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-660">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-661">477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-662">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-663">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-664">401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-665">1,554</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-666">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-667">155</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-668">1,399</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-669">1,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-670">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-671">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-672">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-673">6,551</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-674">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-675">828</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-676">5,726</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-677">15,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-678">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-679">1,701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-680">14,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-681">7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investment securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:Investments" format="ixt:num-dot-decimal" scale="6" id="f-682">14,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-613-2" continuedAt="f-613-3"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own certain corporate debt securities of Gentiva Hospice. The book value and fair value are $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-683">379</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-684">398</ix:nonFraction>&#160;million, respectively, at December&#160;31, 2023. The book value and fair value were $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-685">280</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-686">278</ix:nonFraction>&#160;million, respectively, at December&#160;31, 2022.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="f-687" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross unrealized losses and fair values aggregated by investment category and length of time that individual debt securities have been in a continuous unrealized loss position were as follows at December&#160;31, 2023 and 2022, respectively:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;than&#160;12&#160;months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 months or more</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr style="height:15pt"><td colspan="36" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>&#160;&#160;&#160;&#160;corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="f-688">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-689">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-690">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-691">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-692">2,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-693">51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-694">958</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-695">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-696">2,269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-697">413</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-698">3,227</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-699">425</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-700">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-701">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-702">523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-703">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-704">683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-705">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:fixed-zero" scale="6" id="f-706">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-707">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-708">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-709">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-710">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-711">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-712">18</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="f-713">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-714">1,303</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-715">126</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-716">1,321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-717">126</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-718">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-719">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-720">1,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-721">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-722">1,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-723">44</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-724">466</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-725">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-726">4,783</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-727">592</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-728">5,249</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-729">594</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="f-730">3,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-731">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-732">11,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="f-733">1,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-734">14,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="f-735">1,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>&#160;&#160;&#160;&#160;corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-736">512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-737">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-738">397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-739">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-740">909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-741">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="f-742">1,231</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-743">104</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-744">1,683</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-745">367</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-746">2,914</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-747">471</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-748">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-749">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-750">615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-751">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-752">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-753">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-754">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-755">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="f-756">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-757">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="f-758">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-759">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-760">243</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-761">13</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-762">1,157</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-763">142</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-764">1,400</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-765">155</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="f-766">620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-767">32</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-768">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-769">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-770">1,631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-771">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="f-772">1,625</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-773">98</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-774">3,825</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="f-775">730</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-776">5,450</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-777">828</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="f-778">4,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="f-779">270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="f-780">8,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="f-781">1,431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="6" id="f-782">13,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" format="ixt:num-dot-decimal" scale="6" id="f-783">1,701</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="number" contextRef="c-113" decimals="2" name="hum:PercentageOfTotalDebtSecuritiesInvestmentGradeQuality" scale="-2" id="f-784">97</ix:nonFraction>% of our debt securities were investment-grade quality, with a weighted average credit rating of AA- by S&amp;P at December&#160;31, 2023. Most of the debt securities that were below investment-grade were rated B+, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding approximately <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="hum:MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities" scale="-2" id="f-785">1</ix:nonFraction>% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types. &#160;&#160;&#160;&#160;</span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-613-3"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unrealized loss from all debt securities was generated from approximately <ix:nonFraction unitRef="position" contextRef="c-4" decimals="0" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="f-786">1,560</ix:nonFraction> positions out of a total of approximately <ix:nonFraction unitRef="position" contextRef="c-4" decimals="0" name="hum:DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="f-787">2,060</ix:nonFraction> positions at December&#160;31, 2023. All issuers of debt securities we own that were trading at an unrealized loss at December&#160;31, 2023 remain current on all contractual payments. After taking into account these and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time the debt securities were purchased. At December&#160;31, 2023, we did not intend to sell any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. Additionally, we did not record any material credit allowances for debt securities that were in an unrealized loss position at December&#160;31, 2023, 2022 or 2021.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRealizedGainLossTableTextBlock" id="f-788" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The detail of realized gains (losses) related to investment securities and included within investment income was as follows for the years ended December&#160;31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:7pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:57.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.226%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains on investment securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="hum:DebtAndEquitySecuritiesRealizedGain" scale="6" id="f-789">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="hum:DebtAndEquitySecuritiesRealizedGain" scale="6" id="f-790">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:DebtAndEquitySecuritiesRealizedGain" scale="6" id="f-791">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses on investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="hum:DebtAndEquitySecuritiesRealizedLoss" scale="6" id="f-792">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="hum:DebtAndEquitySecuritiesRealizedLoss" scale="6" id="f-793">144</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:DebtAndEquitySecuritiesRealizedLoss" scale="6" id="f-794">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGain" scale="6" id="f-795">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGain" scale="6" id="f-796">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGain" scale="6" id="f-797">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedLoss" format="ixt:fixed-zero" scale="6" id="f-798">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedLoss" scale="6" id="f-799">174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedLoss" scale="6" id="f-800">364</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net recognized losses on investment securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DebtAndEquitySecuritiesGainLoss" scale="6" id="f-801">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:DebtAndEquitySecuritiesGainLoss" scale="6" id="f-802">205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:DebtAndEquitySecuritiesGainLoss" scale="6" id="f-803">130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GainLossOnInvestmentsTextBlock" id="f-804" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains and losses related to equity securities for the years ended December&#160;31, 2023, 2022 and 2021 was as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.517%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains (losses) recognized on equity securities during the period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-805">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-806">123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-807">341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net gains (losses) recognized on equity securities sold during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-808">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-809">105</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-810">13</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses recognized on equity securities still held at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:fixed-zero" scale="6" id="f-811">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-812">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-813">328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-814" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of debt securities available for sale at December&#160;31, 2023, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:75.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.995%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-815">1,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="f-816">1,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-817">5,279</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="f-818">5,112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-819">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="f-820">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-821">1,149</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="f-822">962</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="f-823">7,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" format="ixt:num-dot-decimal" scale="6" id="f-824">7,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-825">18,302</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-826">17,008</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_160"></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-827" continuedAt="f-827-1" escape="true">FAIR VALUE</ix:nonNumeric></span></div><ix:continuation id="f-827-1" continuedAt="f-827-2"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="f-828" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our fair value measurements at December&#160;31, 2023 and 2022, respectively, for financial assets measured at fair value on a recurring basis:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:45.127%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.741%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.744%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-829">4,582</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-830">4,582</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-831">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-832">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-833">2,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-834">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-835">2,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-836">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-837">3,522</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-838">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-839">3,522</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-840">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-841">858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-842">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-843">858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-845">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-846">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-847">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-848">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-849">1,345</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-850">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-851">1,345</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-852">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-853">1,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-855">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-856">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-857">6,445</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-858">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-859">6,269</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-860">176</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-861">17,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-862">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-863">16,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-864">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="f-865">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="f-866">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="f-867">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="f-868">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total invested assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-869">21,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-870">4,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-871">16,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-872">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-873">4,832</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-874">4,832</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-875">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-876">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-877">1,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-879">1,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-880">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-881">3,230</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-882">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-883">3,230</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-884">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-885">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-886">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-887">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-889">401</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-890">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-891">401</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-892">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-893">1,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-894">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-895">1,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-897">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-898">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-899">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-900">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-901">5,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-902">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-903">5,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-904">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-905">14,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-906">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="f-907">14,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-908">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-909">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-910">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="f-911">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="f-912">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total invested assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-913">19,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-914">4,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-915">14,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-916">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-827-2" continuedAt="f-827-3"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Level 3 assets had fair values of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="6" id="f-917">218</ix:nonFraction> million, or <ix:nonFraction unitRef="number" contextRef="c-178" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-918">1.0</ix:nonFraction>% of total invested assets, and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="6" id="f-919">101</ix:nonFraction> million, or <ix:nonFraction unitRef="number" contextRef="c-179" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-920">0.5</ix:nonFraction>% of total invested assets, at December&#160;31, 2023 and 2022, respectively. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-921" continuedAt="f-921-1" escape="true">During the years ended December&#160;31, 2023 and 2022, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:</ix:nonNumeric></span></div><ix:continuation id="f-921-1"><div style="margin-bottom:9pt;text-align:center;text-indent:11.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:54.277%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.211%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.212%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December&#160;31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December&#160;31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Private<br/>Placements</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January&#160;1</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="f-922">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="f-923">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gains or losses:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="f-924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:fixed-zero" scale="6" id="f-925">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized in other comprehensive&#160;income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="f-926">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" scale="6" id="f-927">14</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="f-928">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" scale="6" id="f-929">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" format="ixt:fixed-zero" scale="6" id="f-930">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" format="ixt:fixed-zero" scale="6" id="f-931">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="f-932">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="f-933">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers Out</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" scale="6" id="f-934">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" format="ixt:fixed-zero" scale="6" id="f-935">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers In</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" scale="6" id="f-936">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" format="ixt:fixed-zero" scale="6" id="f-937">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="f-938">218</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="6" id="f-939">101</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Swaps</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, we entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on our $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-940">750</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="c-180" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-941">5.875</ix:nonFraction>% senior notes, our $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-942">750</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="c-181" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-943">5.500</ix:nonFraction>% senior notes, our $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-944">500</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="c-182" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-945">3.950</ix:nonFraction>% senior notes and our $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-946">850</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="c-183" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-947">5.950</ix:nonFraction>% from fixed rates to variable rates to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities. Our swap agreements, which are considered derivative instruments, exchange the fixed interest rate under our <ix:nonFraction unitRef="number" contextRef="c-180" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-948">5.875</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-181" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-949">5.500</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-182" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-950">3.950</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-183" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-951">5.950</ix:nonFraction>% senior notes for a variable interest rate based on SOFR. Interest rate swaps with notional amounts of $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-952">650</ix:nonFraction>&#160;million, maturing September 1, 2032, $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-953">300</ix:nonFraction>&#160;million, maturing March 15, 2033, $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-954">450</ix:nonFraction>&#160;million  maturing August 15, 2049 and $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-955">400</ix:nonFraction>&#160;million, maturing March 15, 2034, were outstanding on our <ix:nonFraction unitRef="number" contextRef="c-180" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-956">5.875</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-181" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-957">5.500</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-182" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-958">3.950</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-183" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-959">5.950</ix:nonFraction>% senior notes, respectively, at December&#160;31, 2023. These swap agreements were qualified and designated as a fair value hedge. Our interest rate swaps are recognized in other assets or other liabilities, as appropriate, in our consolidated balance sheets at fair value as of the reporting date.  Our interest rate swaps are highly effective at reflecting the fair value of our hedged fixed rate senior notes payable. We utilize market-based financing rates, forward yield curves and discount rates in determining fair value of these swaps at each reporting date, a Level 2 measure within the fair value hierarchy.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The swap asset, included within other long-term assets on our consolidated balance sheet, was approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:InterestRateFairValueHedgeAssetAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-960">68</ix:nonFraction>&#160;million at December&#160;31, 2023. We include the gain or loss on the swap agreements in interest expense on our consolidated statement of income, the same line item as the offsetting loss or gain on the related senior notes. The gain or loss due to hedge ineffectiveness was not material for the year ended December&#160;31, 2023.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Liabilities</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our debt is recorded at carrying value in our consolidated balance sheets. The carrying value of our senior notes debt outstanding, net of unamortized debt issuance costs, was $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="f-961">10.8</ix:nonFraction>&#160;billion at December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="f-962">10.0</ix:nonFraction> billion at December&#160;31, 2022. The fair value of our senior note debt was $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="f-963">10.6</ix:nonFraction> billion at December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="f-964">9.4</ix:nonFraction> billion at December&#160;31, 2022. The fair value of our senior note debt is determined based on Level 2 inputs, including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities. Carrying value approximates </span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-827-3" continuedAt="f-827-4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair value for our term loans and commercial paper borrowings. The commercial paper borrowings&#160;were $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-8" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="9" id="f-965">0.9</ix:nonFraction>&#160;billion at December&#160;31, 2023 and the term loan and commercial paper borrowings were $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-8" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="9" id="f-966">1.1</ix:nonFraction> billion at December&#160;31, 2022.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Put and Call Options Measured at Fair Value</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our put and call options associated with our equity method investments are measured at fair value each period using a Monte Carlo simulation. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 27, 2021, with the signing of the definitive agreement to acquire the remaining <ix:nonFraction unitRef="number" contextRef="c-194" decimals="2" name="hum:DefinitiveAgreementEquityInterestToBeAcquiredPercentage" scale="-2" id="f-967">60</ix:nonFraction>% interest of KAH, the respective put and call options were terminated. As such, the $<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-6" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-968">63</ix:nonFraction>&#160;million put and $<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="hum:FinancialAssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-969">440</ix:nonFraction>&#160;million call fair values as of the first quarter of 2021 were reduced to <ix:nonFraction unitRef="usd" contextRef="c-197" decimals="INF" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-970"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="INF" name="hum:FinancialAssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="f-971">zero</ix:nonFraction></ix:nonFraction>, resulting in $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:LossOnTerminationOfDerivatives" format="ixt:num-dot-decimal" scale="6" id="f-972">377</ix:nonFraction>&#160;million in other expense (income), net in our consolidated statements of income for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The put and call options fair values associated with our Primary Care Organization strategic partnership with WCAS, which are exercisable at a fixed revenue exit multiple and provide a minimum return on WCAS' investment if exercised, are measured at fair value each reporting period using a Monte Carlo simulation. The put and call options fair values, derived from the Monte Carlo simulation, were $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-973">595</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="hum:FinancialAssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-974">18</ix:nonFraction> million, respectively, at December&#160;31, 2023. The put and call options fair values, derived from the Monte Carlo simulation, were $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-6" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-975">267</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-6" name="hum:FinancialAssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-976">10</ix:nonFraction> million, respectively, at December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant unobservable inputs utilized in these Level 3 fair value measurements (and selected values) include the enterprise value, annualized volatility and credit spread. Enterprise value was derived from a discounted cash flow model, which utilized significant unobservable inputs for long-term revenue, to measure underlying cash flows, weighted average cost of capital and long term growth rate. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-977" continuedAt="f-977-1" escape="true">The table below presents the assumptions used for December&#160;31, 2023 and 2022, respectively: </ix:nonNumeric></span></div><ix:continuation id="f-977-1"><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:59.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.837%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-203" decimals="3" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="-2" id="f-978">16.1</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-204" decimals="3" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="-2" id="f-979">17.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-205" decimals="3" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="-2" id="f-980">16.7</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-206" decimals="3" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="-2" id="f-981">20.8</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit spread</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-207" decimals="3" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="-2" id="f-982">0.9</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-208" decimals="3" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="-2" id="f-983">1.1</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-209" decimals="3" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="-2" id="f-984">1.3</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-210" decimals="3" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="-2" id="f-985">1.5</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue exit multiple</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-211" decimals="1" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="0" id="f-986">1.5</ix:nonFraction>x - <ix:nonFraction unitRef="number" contextRef="c-212" decimals="1" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="0" id="f-987">2.5</ix:nonFraction>x </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-213" decimals="1" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="0" id="f-988">1.5</ix:nonFraction>x - <ix:nonFraction unitRef="number" contextRef="c-214" decimals="1" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="0" id="f-989">2.5</ix:nonFraction>x</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average cost of capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-215" decimals="3" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="-2" id="f-990">11.0</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-216" decimals="3" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="-2" id="f-991">12.5</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-217" decimals="3" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="-2" id="f-992">11.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-218" decimals="3" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="-2" id="f-993">12.5</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term growth rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-219" decimals="3" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="-2" id="f-994">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-220" decimals="3" name="us-gaap:DerivativeAssetLiabilityNetMeasurementInput" scale="-2" id="f-995">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for annualized volatility, credit spread and weighted average cost of capital reflect the lowest and highest values where they differ significantly across the series of put and call options due to their expected exercise dates.</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are measured at fair value on a non-recurring basis subject to fair value adjustment only in certain circumstances.  As disclosed in Note 3, &#8220;Acquisitions&#8221;, we completed our acquisition of KAH during the third quarter of 2021. The net assets acquired and resulting goodwill and other intangible assets were recorded at fair value primarily using Level 3 inputs.  The net tangible assets including receivables and accrued liabilities were recorded at their carrying value which approximated their fair value due to their short term nature. The fair value of goodwill and other intangible assets were internally estimated based on the income approach.  The income approach estimates fair value based on the present value of cash flow that the assets could be expected to generate in the future. We developed internal estimates for expected cash flows in the present value calculation using inputs and significant assumptions that include historical revenues and earnings, long-term growth rate, discount rate, contributory asset charges and future tax rates, among others.  The excess purchase price over the fair value of assets and liabilities acquired is recorded as goodwill.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in Note 3, we completed the sale of a <ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="hum:DisposalGroupIncludingDiscontinuedOperationEquityInterestSold" scale="-2" id="f-996">60</ix:nonFraction>% interest in Gentiva Hospice on August 11, 2022. The carrying value of the assets and liabilities of Gentiva Hospice disposed approximates fair value. The amount of </span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-827-4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">goodwill included in the carrying value is based on the relative fair value of Gentiva Hospice as compared to the total fair value of our home solutions reporting unit included within the CenterWell segment.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as disclosed in Note 3, we completed our acquisitions of certain health and wellness related businesses during 2023, 2022, and 2021. The values of net tangible assets acquired and the resulting goodwill and other intangible assets were recorded at fair value using Level 3 inputs. The majority of the related tangible assets acquired and liabilities assumed were recorded at their carrying values as of the respective dates of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in these acquisitions were internally estimated primarily based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets are expected to generate in the future. We developed internal estimates for the expected cash flows and discount rates in the present value calculations. Other than assets acquired and liabilities assumed in these acquisitions, there were no material assets or liabilities measured at fair value on a nonrecurring basis during 2023, 2022, or 2021.</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_163"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="hum:MedicarePartDDisclosureTextBlock" id="f-997" continuedAt="f-997-1" escape="true">MEDICARE PART D</ix:nonNumeric></span></div><ix:continuation id="f-997-1"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with CMS. <ix:nonNumeric contextRef="c-1" name="hum:BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock" id="f-998" continuedAt="f-998-1" escape="true">The accompanying consolidated balance sheets include the following amounts associated with Medicare Part D as of December&#160;31, 2023 and 2022. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</ix:nonNumeric></span></div><ix:continuation id="f-998-1"><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk<br/>Corridor<br/>Settlement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CMS<br/>Subsidies/<br/>Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk<br/>Corridor<br/>Settlement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CMS<br/>Subsidies/<br/>Discounts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-999">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-1000">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-1001">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-1002">696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-1003">232</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1004">1,825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-1005">166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1006">1,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current (liability) asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" sign="-" name="hum:NetCurrentLiabilityAsset" scale="6" id="f-1007">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" sign="-" name="hum:NetCurrentLiabilityAsset" format="ixt:num-dot-decimal" scale="6" id="f-1008">1,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="hum:NetCurrentLiabilityAsset" scale="6" id="f-1009">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" sign="-" name="hum:NetCurrentLiabilityAsset" scale="6" id="f-1010">540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-1011">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1012">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-1013">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1014">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-1015">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1016">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-1017">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1018">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net long-term liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" sign="-" name="hum:NetNoncurrentAssetLiability" scale="6" id="f-1019">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="hum:NetNoncurrentAssetLiability" format="ixt:fixed-zero" scale="6" id="f-1020">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" sign="-" name="hum:NetNoncurrentAssetLiability" scale="6" id="f-1021">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" name="hum:NetNoncurrentAssetLiability" format="ixt:fixed-zero" scale="6" id="f-1022">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total net (liability) asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" sign="-" name="hum:NetAssetLiability" scale="6" id="f-1023">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" sign="-" name="hum:NetAssetLiability" format="ixt:num-dot-decimal" scale="6" id="f-1024">1,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="hum:NetAssetLiability" scale="6" id="f-1025">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-6" sign="-" name="hum:NetAssetLiability" scale="6" id="f-1026">540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_166"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-1027" continuedAt="f-1027-1" escape="true">PROPERTY AND EQUIPMENT, NET</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-1028" escape="true"><ix:continuation id="f-1027-1" continuedAt="f-1027-2"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment was comprised of the following at December&#160;31, 2023 and 2022. </span></div><div style="margin-bottom:1pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:75.786%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.656%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-1029">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-1030">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-1031">1,002</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-1032">1,143</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-1033">1,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-1034">1,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-1035">3,546</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-1036">3,951</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-1037">5,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="f-1038">6,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1039">2,854</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1040">3,136</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-1041">3,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-1042">3,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1027-2"><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DepreciationNonproduction" format="ixt:num-dot-decimal" scale="6" id="f-1043">831</ix:nonFraction>&#160;million in 2023, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:DepreciationNonproduction" format="ixt:num-dot-decimal" scale="6" id="f-1044">749</ix:nonFraction> million in 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:DepreciationNonproduction" format="ixt:num-dot-decimal" scale="6" id="f-1045">640</ix:nonFraction> million in 2021, including amortization expense for capitalized internally developed and purchased software of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="f-1046">589</ix:nonFraction> million in 2023, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="f-1047">525</ix:nonFraction> million in 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="f-1048">443</ix:nonFraction> million in 2021.</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_169"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 9. <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-1049" continuedAt="f-1049-1" escape="true">GOODWILL AND OTHER INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="f-1049-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-1050" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill for our reportable segments for the years ended December&#160;31, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:53.635%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1051">2,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1052">8,802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1053">11,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1054">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1055">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1056">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dispositions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="f-1057">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="6" id="f-1058">2,331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="6" id="f-1059">2,331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1060">2,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1061">6,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1062">9,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1063">191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1064">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="f-1065">408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1066">2,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1067">6,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1068">9,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-1069" escape="true"><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of our other intangible assets included in other long-term assets in the accompanying consolidated balance sheets at December&#160;31, 2023 and 2022:</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.791%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.592%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.957%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.116%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1070">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1071">1,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1072">1,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1073">1,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1074">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1075">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1076">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1077">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-247" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1078">9.4</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-1079">956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1080">718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-1081">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-1082">929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1083">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-1084">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-249" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1085">6.7</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-1086">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1087">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-1088">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-1089">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1090">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-1091">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-251" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1092">11.9</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-1093">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1094">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-1095">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-1096">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1097">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-1098">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetes and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-253" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1099">8.4</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-1100">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1101">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-1102">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-1103">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1104">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-1105">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1106">9.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1107">2,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1108">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1109">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1110">2,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-1111">883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1112">1,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for other intangible assets was approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1113">67</ix:nonFraction> million in 2023, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1114">81</ix:nonFraction>&#160;million in 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-1115">65</ix:nonFraction>&#160;million in 2021. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023 we recorded impairment charges of $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1116">55</ix:nonFraction>&#160;million relating to indefinite-lived intangibles.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-1117" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our estimate of amortization expense for each of the five next succeeding fiscal years: </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:81.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.614%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="f-1118">60</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="f-1119">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="f-1120">43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="f-1121">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="f-1122">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_172"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-1123" continuedAt="f-1123-1" escape="true">LEASES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-1123-1" continuedAt="f-1123-2"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if a contract contains a lease by evaluating the nature and substance of the agreement. We lease facilities, computer hardware, and other furniture and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. For new lease agreements, we combine lease and nonlease components for all of our asset classes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When portions of the lease payments are not fixed or depend on an index or rate, we consider those payments to be variable in nature. Our variable lease payments include, but are not limited to, common area maintenance, taxes and insurance which are not dependent upon an index or rate. Variable lease payments are recorded in the period in which the obligation for the payment is incurred. Most leases include options to renew, with renewal terms that can extend the lease term. The exercise of lease renewal options is at our sole discretion. Certain leases also include options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets included within <span style="-sec-ix-hidden:f-1124"><span style="-sec-ix-hidden:f-1125">other long-term assets</span></span> in our consolidated balance sheets were $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-1126">510</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-1127">515</ix:nonFraction> million at December&#160;31, 2023 and December&#160;31, 2022, respectively. Operating lease liabilities included within <span style="-sec-ix-hidden:f-1128"><span style="-sec-ix-hidden:f-1129">trade accounts payable and accrued expenses</span></span> in our consolidated balance sheets were $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1130">149</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1131">152</ix:nonFraction> million at December&#160;31, 2023 and December&#160;31, 2022, respectively. Additionally, operating lease liabilities included within <span style="-sec-ix-hidden:f-1132"><span style="-sec-ix-hidden:f-1133">other long-term liabilities</span></span> in our consolidated balance sheets were $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1134">444</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1135">456</ix:nonFraction> million at December&#160;31, 2023 and December&#160;31, 2022, respectively. The classification of our operating lease liabilities is based on the remaining lease term.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021, total fixed operating lease costs, excluding short-term lease costs, were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-1136">145</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-1137">183</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-1138">159</ix:nonFraction> million, respectively, and are included within operating costs in our consolidated statements of income. Short-term lease costs were not material for the years ended December&#160;31, 2023, 2022 and 2021. In addition, for the years ended December&#160;31, 2023, 2022 and 2021, total variable operating lease costs were</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-1139">120</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-1140">101</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-1141">94</ix:nonFraction> million, respectively, and are included within operating costs in our consolidated statements of income. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sublease facilities or partial facilities to third party tenants for space not used in our operations. For the years ended December&#160;31, 2023, 2022 and 2021, sublease rental income was</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-1142">66</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-1143">52</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="6" id="f-1144">43</ix:nonFraction> million, respectively, and is included within operating costs in our consolidated statements of income.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term is <ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1145"><ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1146">5.4</ix:nonNumeric></ix:nonNumeric> years at December&#160;31, 2023 and December&#160;31, 2022. The weighted average discount rate is <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1147">3.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1148">3.2</ix:nonFraction>% at December&#160;31, 2023 and December&#160;31, 2022, respectively. For the years ended December&#160;31, 2023, 2022 and 2021, cash paid for amounts included in the measurement of lease liabilities included within our operating cash flows was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-1149">166</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-1150">191</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="6" id="f-1151">165</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-1152" escape="true"><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:80.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity of&#160;Lease&#160;Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="f-1153">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="f-1154">145</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="f-1155">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="f-1156">75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="f-1157">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="f-1158">108</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="f-1159">653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="f-1160">60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-1161">593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><span><br/></span></div><ix:continuation id="f-1123-2"><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate, as adjusted for collateralized borrowings, based on the information available at date of adoption or commencement date in determining the present value of lease payments.</span></div></ix:continuation><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_175"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:InsuranceDisclosureTextBlock" id="f-1162" continuedAt="f-1162-1" escape="true">BENEFITS PAYABLE</ix:nonNumeric></span></div><ix:continuation id="f-1162-1" continuedAt="f-1162-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="f-1163" escape="true"><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:54.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.868%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances at January&#160;1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1164">9,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1165">8,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1166">8,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" scale="6" id="f-1167">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="6" id="f-1168">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" scale="6" id="f-1169">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1170">89,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1171">76,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1172">70,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-1173">872</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-1174">415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="f-1175">825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="f-1176">88,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="f-1177">75,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="f-1178">69,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="f-1179">79,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="f-1180">67,287</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="f-1181">62,149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="f-1182">7,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="f-1183">7,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="f-1184">6,946</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1185">87,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1186">74,715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1187">69,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances at December&#160;31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1188">10,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1189">9,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1190">8,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:1pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimate of benefits payable for claims incurred but not reported, or IBNR, is included within the net </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incurred claims amounts. At December&#160;31, 2023 and 2022, benefits payable included IBNR of approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-8" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount" format="ixt:num-dot-decimal" scale="9" id="f-1191">6.6</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-8" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount" format="ixt:num-dot-decimal" scale="9" id="f-1192">5.7</ix:nonFraction>&#160;billion, primarily associated with claims incurred in each respective year. The cumulative number of reported claims as of December&#160;31, 2023 was approximately <ix:nonFraction unitRef="claim" contextRef="c-255" decimals="-5" name="hum:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported" format="ixt:num-dot-decimal" scale="6" id="f-1193">200.0</ix:nonFraction>&#160;million for claims incurred in 2023, <ix:nonFraction unitRef="claim" contextRef="c-256" decimals="-5" name="hum:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported" format="ixt:num-dot-decimal" scale="6" id="f-1194">182.4</ix:nonFraction>&#160;million for claims incurred in 2022, and <ix:nonFraction unitRef="claim" contextRef="c-257" decimals="-5" name="hum:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported" format="ixt:num-dot-decimal" scale="6" id="f-1195">173.7</ix:nonFraction>&#160;million for claims incurred in 2021.</span></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Amounts incurred related to prior years vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. We experienced favorable medical claims reserve development related to prior fiscal years of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="hum:FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears" format="ixt:num-dot-decimal" scale="6" id="f-1196">872</ix:nonFraction> million in 2023, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="hum:FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears" format="ixt:num-dot-decimal" scale="6" id="f-1197">415</ix:nonFraction> million in 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears" format="ixt:num-dot-decimal" scale="6" id="f-1198">825</ix:nonFraction> million in 2021.</span></div><div style="margin-bottom:12pt;margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical claims reserve development for 2023, 2022, and 2021 primarily reflects the consistent application of trend and completion factors estimated using an assumption of moderately adverse conditions. The favorable development recognized in 2023 and 2021 primarily resulted from trend factors developing more favorably than originally expected as well as for 2021 completion factors developing faster than expected. The favorable development recognized in 2022 resulted primarily from completion factors remaining largely unchanged, resulting in lower overall development as compared to 2023 and 2021.</span></div><div style="margin-bottom:12pt;margin-top:4pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         </span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1162-2"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incurred and Paid Claims Development</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion provides information about incurred and paid claims development as of December&#160;31, 2023, net of reinsurance, as well as cumulative claim frequency and the total of IBNR included within the net incurred claims amounts. The information about incurred and paid claims development for the years ended December 31, 2022 and 2021 is presented as supplementary information.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Claims frequency is measured as medical fee-for-service claims for each service encounter with a unique provider identification number. Our claims frequency measure includes claims covered by deductibles as well as claims under capitated arrangements. Claim counts may vary based on product mix and the percentage of delegated capitation arrangements.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" id="f-1199" continuedAt="f-1199-1" escape="true">The following tables provide information about incurred and paid claims development as of December&#160;31, 2023, net of reinsurance.</ix:nonNumeric></span></div><ix:continuation id="f-1199-1"><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:54.527%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.890%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurred Claims, Net of Reinsurance</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claims Incurred Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021<br/>Unaudited</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022<br/>Unaudited</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-1200">70,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-1201">69,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-1202">69,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-1203">76,105</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-1204">75,447</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-1205">89,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-1206">234,259</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:53.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.246%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.891%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Paid Claims, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claims Incurred Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021<br/>Unaudited</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022<br/>Unaudited</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-1207">62,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-1208">69,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-1209">69,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-1210">67,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-1211">74,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-1212">79,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-1213">224,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All outstanding benefit liabilities before 2021, net of reinsurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits payable, net of reinsurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="f-1214">10,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.</span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_178"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1215" continuedAt="f-1215-1" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="f-1215-1" continuedAt="f-1215-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1216" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes consisted of the following for the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:1pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:55.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.868%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-1217">915</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-1218">755</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-1219">466</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States and Puerto Rico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-1220">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-1221">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-1222">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1223">1,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-1224">862</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-1225">470</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1226">164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1227">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-1228">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1229">836</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1230">762</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1231">485</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1232" continuedAt="f-1232-1" escape="true"><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes was different from the amount computed using the federal statutory rate for the years ended December&#160;31, 2023, 2022 and 2021 due to the following:</span></div></ix:nonNumeric><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><ix:continuation id="f-1232-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:55.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.868%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision at federal statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="f-1233">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="f-1234">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="f-1235">718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, net of federal benefit, and Puerto Rico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-1236">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-1237">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-1238">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax exempt investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" scale="6" id="f-1239">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" scale="6" id="f-1240">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxExemptIncome" scale="6" id="f-1241">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="f-1242">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="f-1243">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="f-1244">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable KAH gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="hum:EffectiveIncomeTaxReconciliationNonTaxableKAHGain" format="ixt:fixed-zero" scale="6" id="f-1245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="hum:EffectiveIncomeTaxReconciliationNonTaxableKAHGain" format="ixt:fixed-zero" scale="6" id="f-1246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:EffectiveIncomeTaxReconciliationNonTaxableKAHGain" scale="6" id="f-1247">264</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax effect from sale of Gentiva Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" format="ixt:fixed-zero" scale="6" id="f-1248">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" scale="6" id="f-1249">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" format="ixt:fixed-zero" scale="6" id="f-1250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Tax Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="6" id="f-1251">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:fixed-zero" scale="6" id="f-1252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:fixed-zero" scale="6" id="f-1253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="f-1254">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="f-1255">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="f-1256">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1257">836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1258">762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1259">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax balances reflect the impact of temporary differences between the tax bases of assets or liabilities and their reported amounts in our consolidated financial statements, and are stated at enacted tax rates expected to be in effect when the reported amounts are actually recovered or settled. </span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1215-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1260" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal components of our net deferred tax balances at December&#160;31, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:70.168%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.866%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets&#160;(Liabilities)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="f-1261">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="f-1262">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and other accrued expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" scale="6" id="f-1263">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" scale="6" id="f-1264">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="f-1265">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="f-1266">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred acquisition costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="hum:DeferredTaxAssetsDeferredPolicyAcquisitionCost" scale="6" id="f-1267">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="hum:DeferredTaxAssetsDeferredPolicyAcquisitionCost" scale="6" id="f-1268">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jobs tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="hum:DeferredTaxAssetJobsTaxCredit" format="ixt:fixed-zero" scale="6" id="f-1269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="hum:DeferredTaxAssetJobsTaxCredit" scale="6" id="f-1270">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="f-1271">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="f-1272">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve" scale="6" id="f-1273">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve" scale="6" id="f-1274">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsInvestments" scale="6" id="f-1275">419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsInvestments" scale="6" id="f-1276">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="f-1277">935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="f-1278">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-1279">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-1280">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="f-1281">862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="f-1282">851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property and intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="hum:DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets" scale="6" id="f-1283">642</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="hum:DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets" scale="6" id="f-1284">740</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="6" id="f-1285">156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="6" id="f-1286">132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="f-1287">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="f-1288">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="f-1289">814</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="f-1290">878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred income tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="f-1291">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DeferredTaxLiabilities" scale="6" id="f-1292">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All deferred tax assets and liabilities are classified as noncurrent in our consolidated balance sheets as other long-term assets and liabilities at December 31, 2023  and 2022, respectively. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, we had approximately $<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1293">7</ix:nonFraction> million of federal net operating losses and approximately $<ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-8" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="9" id="f-1294">1.2</ix:nonFraction> billion of pre-apportioned state and Puerto Rico net operating losses to carry forward. A portion of these loss carryforwards, if not used to offset future taxable income, will expire from 2024 through 2041. The balance of the net operating loss carryforwards has no expiration date. Due to limitations and uncertainty regarding our ability to use some of the loss carryforwards and certain other deferred tax assets, a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-1295">73</ix:nonFraction> million was established. For the remainder of the net operating loss carryforwards and other cumulative temporary differences, based on our historical record of producing taxable income and profitability, we have concluded that future operating income will be sufficient to recover these deferred tax assets. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We file income tax returns in the United States and Puerto Rico.&#160;The U.S. Internal Revenue Service, or IRS, has completed its examinations of our consolidated income tax returns for 2021 and prior years. Our 2022 tax return is in the post-filing review period under the Compliance Assurance Process, or CAP. Our 2023 tax return is under advance review by the IRS under CAP. With a few exceptions, which are immaterial in the aggregate, we are no longer subject to state, local and foreign tax examinations for years before 2020.&#160;We are not aware of any material adjustments that may be proposed as a result of any ongoing or future examinations. We do not have material uncertain tax positions reflected in our consolidated balance sheets.</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_181"></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-1296" continuedAt="f-1296-1" escape="true">DEBT</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-1297" escape="true"><ix:continuation id="f-1296-1" continuedAt="f-1296-2"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of debt outstanding was as follows at December&#160;31, 2023 and 2022:</span></div><div style="margin-bottom:1pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:61.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.877%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-6" name="us-gaap:ShortTermBorrowings" scale="6" id="f-1298">871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-6" name="us-gaap:ShortTermBorrowings" scale="6" id="f-1299">595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1300">600</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-265" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1301">3.850</ix:nonFraction>% due October 1, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-1302">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="f-1303">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1304">1.5</ix:nonFraction> billion, <ix:nonFraction unitRef="number" contextRef="c-267" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1305">0.650</ix:nonFraction>% due August 3, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="f-1306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1307">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior notes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-6" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-1308">572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1309">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1310">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1311">2,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior notes:</span></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1312">600</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-265" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1313">3.850</ix:nonFraction>% due October 1, 2024</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1314">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1315">599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-271" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1316">600</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-271" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1317">4.500</ix:nonFraction>% due April 1, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1318">598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1319">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-273" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1320">500</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-273" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1321">5.700</ix:nonFraction>% due March 13, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1322">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-275" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1324">750</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-275" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1325">1.350</ix:nonFraction>% due February 3, 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1326">688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1327">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1328">600</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-277" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1329">3.950</ix:nonFraction>% due March 15, 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1330">537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1331">597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-279" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1332">500</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-279" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1333">5.750</ix:nonFraction>% due March 1, 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1334">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1335">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-281" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1336">500</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-281" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1337">5.750</ix:nonFraction>% due December 1, 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1338">495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1340">750</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-283" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1341">3.700</ix:nonFraction>% due March 23, 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1342">590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1343">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1344">500</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-285" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1345">3.125</ix:nonFraction>% due August 15, 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1346">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1347">496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-287" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1348">500</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-287" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1349">4.875</ix:nonFraction>% due April 1, 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1350">496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1351">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-289" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1352">750</ix:nonFraction> million <ix:nonFraction unitRef="number" contextRef="c-289" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1353">2.150</ix:nonFraction>% due February 3, 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1354">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1355">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1356">750</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-180" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1357">5.875</ix:nonFraction>% due March 1, 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1358">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1359">739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1360">850</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-183" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1361">5.950</ix:nonFraction>% due March 15, 2034</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1362">840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1364">250</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-293" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1365">8.150</ix:nonFraction>% due June&#160;15, 2038</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1366">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1367">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-295" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1368">400</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-295" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1369">4.625</ix:nonFraction>% due December&#160;1, 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1370">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1371">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-297" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1372">750</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-297" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1373">4.950</ix:nonFraction>% due October 1, 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1374">740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1375">740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1376">400</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-299" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1377">4.800</ix:nonFraction>% due March 15, 2047</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1378">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1379">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-301" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1380">500</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-301" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1381">3.950</ix:nonFraction>% due August 15, 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1382">529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1383">493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1384">750</ix:nonFraction> million, <ix:nonFraction unitRef="number" contextRef="c-181" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1385">5.500</ix:nonFraction>% due March 15, 2053</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1386">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;text-indent:-9.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior notes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1388">10,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1389">8,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loans:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delayed draw term loan, due May 28, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1390">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-1391">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:8.99pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1392">10,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1393">9,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1296-2" continuedAt="f-1296-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-1394" escape="true"><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the short-term and long-term debt for the years ending December 31, are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:79.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.094%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-1395">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="f-1396">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="f-1397">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="f-1398">1,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="f-1399">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="f-1400">6,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior notes, which are unsecured, may be redeemed at our option at any time at <ix:nonFraction unitRef="number" contextRef="c-306" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-1401">100</ix:nonFraction>% of the principal amount plus accrued interest and a specified make-whole amount. The <ix:nonFraction unitRef="number" contextRef="c-293" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1402">8.150</ix:nonFraction>% senior notes are subject to an interest rate adjustment if the debt ratings assigned to the notes are downgraded (or subsequently upgraded). In addition, our senior notes contain a change of control provision that may require us to purchase the notes under certain circumstances. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we issued $<ix:nonFraction unitRef="usd" contextRef="c-307" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1403">500</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="c-307" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1404">5.750</ix:nonFraction>% unsecured senior notes due December 1, 2028 and $<ix:nonFraction unitRef="usd" contextRef="c-308" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1405">850</ix:nonFraction>&#160;million of our <ix:nonFraction unitRef="number" contextRef="c-308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1406">5.950</ix:nonFraction>% unsecured senior notes due March 15, 2034. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $<ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-8" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="f-1407">1.3</ix:nonFraction>&#160;billion. We used the net proceeds for general corporate purposes, which included the repayment of existing indebtedness, including borrowings under our commercial paper program.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we issued $<ix:nonFraction unitRef="usd" contextRef="c-310" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1408">500</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="c-310" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1409">5.700</ix:nonFraction>% unsecured senior notes due March 13, 2026 and $<ix:nonFraction unitRef="usd" contextRef="c-311" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1410">750</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="c-311" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1411">5.500</ix:nonFraction>% unsecured senior notes due March 15, 2053. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $<ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-8" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="f-1412">1.2</ix:nonFraction>&#160;billion. We used the net proceeds to repay outstanding amounts under our $<ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1413">500</ix:nonFraction>&#160;million Delayed Draw Term Loan. The remaining net proceeds were used for general corporate purposes, which included the repayment of existing indebtedness, including borrowings under our commercial paper program.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $<ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1414">750</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-314" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1415">1.350</ix:nonFraction>% senior notes maturing in February 2027, our $<ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1416">600</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-315" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1417">3.950</ix:nonFraction>% senior notes maturing in March 2027, our $<ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1418">750</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-316" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1419">3.700</ix:nonFraction>% senior notes maturing in March 2029, and our $<ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1420">500</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-317" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1421">3.125</ix:nonFraction>% senior notes maturing in August 2029 during the period beginning on August&#160;7, 2023 and ending on November&#160;15, 2023. For the year ended December 31, 2023, we repurchased $<ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-6" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1422">339</ix:nonFraction>&#160;million principal amount of these senior notes for approximately $<ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-6" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="f-1423">310</ix:nonFraction>&#160;million cash.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $<ix:nonFraction unitRef="usd" contextRef="c-319" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1424">1.5</ix:nonFraction>&#160;billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-319" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1425">0.650</ix:nonFraction>% senior notes maturing in August 2023 and our $<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1426">600</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-320" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1427">3.850</ix:nonFraction>% senior notes maturing in October 2024 during the period beginning on March 13, 2023 and ending on July&#160;21, 2023. For the year ended December 31, 2023, we repurchased $<ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-6" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1428">361</ix:nonFraction>&#160;million principal amount of these senior notes for approximately $<ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-6" name="us-gaap:DebtInstrumentRepurchaseAmount" format="ixt:num-dot-decimal" scale="6" id="f-1429">358</ix:nonFraction>&#160;million cash. We repaid the remaining $<ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-8" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="9" id="f-1430">1.2</ix:nonFraction>&#160;billion aggregate principal amount of our <ix:nonFraction unitRef="number" contextRef="c-319" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1431">0.650</ix:nonFraction>% senior notes due on their maturity date of August&#160;3, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, we entered into interest rate swap agreements to exchange the fixed interest rate under our <ix:nonFraction unitRef="number" contextRef="c-180" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1432">5.875</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-181" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1433">5.500</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-182" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1434">3.950</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-183" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1435">5.950</ix:nonFraction>% senior notes for a variable interest rate based on SOFR, as further described in Note 6. As a result, the carrying value of these senior notes has been adjusted to reflect changes in value caused by an increase or decrease in interest rates. The cumulative, aggregate adjustment to the carrying value of the <ix:nonFraction unitRef="number" contextRef="c-180" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1436">5.875</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-181" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1437">5.500</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-182" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1438">3.950</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-183" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1439">5.950</ix:nonFraction>% senior notes was $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="hum:LongTermDebtAggregateCarryingValueAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-1440">9</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="hum:LongTermDebtAggregateCarryingValueAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-1441">13</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-6" name="hum:LongTermDebtAggregateCarryingValueAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-1442">36</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-6" name="hum:LongTermDebtAggregateCarryingValueAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-1443">10</ix:nonFraction>&#160;million respectively, at December 31, 2023.</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1296-3" continuedAt="f-1296-4"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revolving Credit Agreements</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into an amended and restated <ix:nonNumeric contextRef="c-323" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1444">5-year</ix:nonNumeric>, $<ix:nonFraction unitRef="usd" contextRef="c-324" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-1445">2.5</ix:nonFraction>&#160;billion unsecured revolving credit agreement (replacing the <ix:nonNumeric contextRef="c-325" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1446">5-year</ix:nonNumeric>, $<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-1447">2.5</ix:nonFraction>&#160;billion unsecured revolving credit agreement entered in June 2021) and entered into a <ix:nonNumeric contextRef="c-327" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1448">364-day</ix:nonNumeric> $<ix:nonFraction unitRef="usd" contextRef="c-328" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-1449">1.5</ix:nonFraction>&#160;billion unsecured revolving credit agreement (replacing the <ix:nonNumeric contextRef="c-329" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1450">364-day</ix:nonNumeric> $<ix:nonFraction unitRef="usd" contextRef="c-330" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-1451">1.5</ix:nonFraction>&#160;billion unsecured revolving credit agreement entered into in June 2022, which expired in accordance with its terms). </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the credit agreements, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at Term SOFR or the base rate plus a spread. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based Term SOFR, at our option. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SOFR spread, currently <ix:nonFraction unitRef="number" contextRef="c-331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="f-1452">103.5</ix:nonFraction> basis points under the <ix:nonNumeric contextRef="c-332" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1453">5-year</ix:nonNumeric> revolving credit agreement and <ix:nonFraction unitRef="number" contextRef="c-333" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="f-1454">105.5</ix:nonFraction> basis points under the <ix:nonNumeric contextRef="c-334" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1455">364-day</ix:nonNumeric> revolving credit agreement, varies depending on our credit ratings ranging from <ix:nonFraction unitRef="number" contextRef="c-335" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="f-1456">92.0</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="c-336" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="f-1457">130.0</ix:nonFraction> basis points under the <ix:nonNumeric contextRef="c-332" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1458">5-year</ix:nonNumeric> revolving credit agreement and from <ix:nonFraction unitRef="number" contextRef="c-337" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="f-1459">94.0</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="c-338" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-4" id="f-1460">135.0</ix:nonFraction> basis points under the <ix:nonNumeric contextRef="c-334" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1461">364-day</ix:nonNumeric> revolving credit agreement. We also pay an annual facility fee regardless of utilization. This facility fee, currently <ix:nonFraction unitRef="number" contextRef="c-332" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-4" id="f-1462">9.0</ix:nonFraction> basis points, under the <ix:nonNumeric contextRef="c-332" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1463">5-year</ix:nonNumeric> revolving credit agreement and <ix:nonFraction unitRef="number" contextRef="c-334" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-4" id="f-1464">7.0</ix:nonFraction> basis points under the <ix:nonNumeric contextRef="c-334" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1465">364-day</ix:nonNumeric> revolving agreement, varies depending on our credit ratings ranging from <ix:nonFraction unitRef="number" contextRef="c-339" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-4" id="f-1466">8.0</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="c-340" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-4" id="f-1467">20.0</ix:nonFraction> basis points under the <ix:nonNumeric contextRef="c-332" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1468">5-year</ix:nonNumeric> revolving credit agreement and from <ix:nonFraction unitRef="number" contextRef="c-341" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-4" id="f-1469">6.0</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="c-342" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-4" id="f-1470">15.0</ix:nonFraction> basis points under the <ix:nonNumeric contextRef="c-334" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1471">364-day</ix:nonNumeric> revolving credit agreement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the revolving credit agreements include standard provisions related to conditions of borrowing which could limit our ability to borrow additional funds. In addition, the credit agreements contain customary restrictive covenants and a financial covenant regarding maximum debt to capitalization of <ix:nonFraction unitRef="number" contextRef="c-343" decimals="INF" name="hum:DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum" scale="-2" id="f-1472">60</ix:nonFraction>%, as well as customary events of default. We are in compliance with this financial covenant, with actual debt to capitalization of <ix:nonFraction unitRef="number" contextRef="c-344" decimals="3" name="hum:DebtInstrumentCovenantDebtToCapitalizationPercentageActual" scale="-2" id="f-1473">41.8</ix:nonFraction>% as measured in accordance with the revolving credit agreements as of December&#160;31, 2023. Upon our agreement with one or more financial institutions, we may expand the aggregate commitments under the revolving credit agreements by up to $<ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-6" name="hum:LineOfCreditFacilityUncommittedIncrementalCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1474">750</ix:nonFraction>&#160;million in the aggregate, to a maximum of $<ix:nonFraction unitRef="usd" contextRef="c-343" decimals="INF" name="hum:LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity" format="ixt:num-dot-decimal" scale="9" id="f-1475">4.75</ix:nonFraction>&#160;billion, across the <ix:nonNumeric contextRef="c-345" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1476">5</ix:nonNumeric>-year and <ix:nonNumeric contextRef="c-346" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durday" id="f-1477">364</ix:nonNumeric>-day revolving credit agreements. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, we had <ix:nonFraction unitRef="usd" contextRef="c-343" decimals="INF" name="us-gaap:LinesOfCreditCurrent" format="ixt:fixed-zero" scale="0" id="f-1478">no</ix:nonFraction> borrowings and approximately $<ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-6" name="us-gaap:LinesOfCreditCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1479">18</ix:nonFraction>&#160;million of letters of credit outstanding under the revolving credit agreements. Accordingly, as of December&#160;31, 2023, we had $<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-6" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-1480">2.482</ix:nonFraction>&#160;billion of remaining borrowing capacity under the <ix:nonNumeric contextRef="c-345" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1481">5-year</ix:nonNumeric> revolving credit agreement and $<ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-8" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-1482">1.5</ix:nonFraction>&#160;billion of remaining borrowing capacity under the <ix:nonNumeric contextRef="c-346" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1483">364-day</ix:nonNumeric> revolving credit agreement (which excludes the uncommitted $<ix:nonFraction unitRef="usd" contextRef="c-343" decimals="INF" name="hum:LineOfCreditFacilityUncommittedIncrementalCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1484">750</ix:nonFraction>&#160;million of incremental loan facilities), none of which would be restricted by our financial covenant compliance requirement. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have other customary relationships, including financial advisory and banking, with some parties to the revolving credit agreements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Paper</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     Under our commercial paper program we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers at any time. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The maximum principal amount outstanding at any one time during the year ended&#160;December&#160;31, 2023&#160;was $<ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-8" name="us-gaap:ShorttermDebtMaximumAmountOutstandingDuringPeriod" format="ixt:num-dot-decimal" scale="9" id="f-1485">3.3</ix:nonFraction>&#160;billion, with $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-1486">871</ix:nonFraction> million outstanding at December&#160;31, 2023 compared to $<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="f-1487">595</ix:nonFraction> million outstanding at December 31, 2022. The outstanding commercial paper at December&#160;31, 2023 had a weighted average annual interest rate of <ix:nonFraction unitRef="number" contextRef="c-192" decimals="4" name="us-gaap:ShortTermDebtWeightedAverageInterestRate" scale="-2" id="f-1488">5.68</ix:nonFraction>%.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Short-Term Borrowings</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a member, through one subsidiary, of the Federal Home Loan Bank of Cincinnati, or FHLB. As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We received a short-term cash advance of $<ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1489"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-1490">100</ix:nonFraction></ix:nonFraction>&#160;million from FHLB with certain of our marketable securities as </span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1296-4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collateral and subsequently repaid the outstanding balance in December 2023. As of December&#160;31, 2023 and December&#160;31, 2022, we had <ix:nonFraction unitRef="usd" contextRef="c-352" decimals="INF" name="us-gaap:ShortTermBorrowings" format="ixt:fixed-zero" scale="0" id="f-1491"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="INF" name="us-gaap:ShortTermBorrowings" format="ixt:fixed-zero" scale="0" id="f-1492">no</ix:nonFraction></ix:nonFraction> outstanding short-term FHLB borrowings.</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_184"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="hum:DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock" id="f-1493" continuedAt="f-1493-1" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="f-1493-1" continuedAt="f-1493-2"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Savings Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have defined contribution retirement savings plans covering eligible employees which include matching contributions based on the amount of our employees&#8217; contributions to the plans. The cost of these plans amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1494">278</ix:nonFraction> million in 2023, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1495">286</ix:nonFraction> million in 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1496">259</ix:nonFraction> million in 2021. The Company&#8217;s cash match is invested pursuant to the participant&#8217;s contribution direction. Based on the closing price of our common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="hum:CompanyCommonStockClosingSharePrice" scale="0" id="f-1497">457.81</ix:nonFraction> on December&#160;31, 2023, approximately <ix:nonFraction unitRef="number" contextRef="c-4" decimals="2" name="hum:DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock" scale="-2" id="f-1498">8</ix:nonFraction>% of the retirement and savings plan&#8217;s assets were invested in our common stock, or approximately <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="hum:DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares" format="ixt:num-dot-decimal" scale="6" id="f-1499">1.3</ix:nonFraction> million shares, representing approximately <ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="hum:DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding" scale="-2" id="f-1500">1.1</ix:nonFraction>% of the shares outstanding as of December&#160;31, 2023. At December&#160;31, 2023, approximately <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-5" name="hum:DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance" format="ixt:num-dot-decimal" scale="6" id="f-1501">5.5</ix:nonFraction> million shares of our common stock were reserved for issuance under our defined contribution retirement savings plans.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have plans under which options to purchase our common stock and restricted stock units have been granted to executive officers, directors and key employees. Awards generally require both a change in control and termination of employment within <ix:nonNumeric contextRef="c-1" name="hum:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod" format="ixt-sec:duryear" id="f-1502">2</ix:nonNumeric> years of the date of the change in control to accelerate the vesting, including those granted to retirement-eligible participants. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms and vesting schedules for stock-based awards vary by type of grant. Generally, the awards vest upon time-based conditions. We have also granted awards to certain employees that vest upon a combination of time and performance-based conditions. The stock awards of retirement-eligible participants are generally earned ratably over the service period for each tranche. Accordingly, upon retirement the earned portion of the current tranche will continue to vest on the originally scheduled vest date and any remaining unearned portion of the award will be forfeited. Our equity award program includes a retirement provision that generally treats employees with a combination of age and years of services with the Company totaling <ix:nonNumeric contextRef="c-1" name="hum:CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram" format="ixt-sec:duryear" id="f-1503">65</ix:nonNumeric> or greater, with a minimum required age of <ix:nonNumeric contextRef="c-1" name="hum:MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram" format="ixt-sec:duryear" id="f-1504">55</ix:nonNumeric> and a minimum requirement of <ix:nonNumeric contextRef="c-1" name="hum:MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram" format="ixt-sec:duryear" id="f-1505">5</ix:nonNumeric> years of service, as retirement-eligible. Upon exercise, stock-based compensation awards are settled with authorized but unissued company stock or treasury stock. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-1506" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation expense that has been charged against income for these plans was as follows for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:55.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.868%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by type:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1507">168</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1508">207</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1509">171</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1510">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-358" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1511">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1512">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1513">175</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1514">216</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1515">180</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1516">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1517">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1518">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense, net of tax</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1519">147</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1520">188</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1521">165</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit recognized in our consolidated financial statements is based on the amount of compensation expense recorded for book purposes, subject to limitations on the deductibility of annual compensation in excess of $500,000 per employee as mandated by the Health Care Reform Law. The actual tax benefit realized in our tax return is based on the intrinsic value, or the excess of the market value over the exercise or purchase price, of stock options exercised and restricted stock vested during the period, subject to limitations on the deductibility of annual compensation in excess of $500,000 per employee as mandated by the Health Care Reform Law. The actual tax benefit realized for the deductions taken on our tax returns from option exercises and restricted stock vesting totaled </span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1493-2" continuedAt="f-1493-3"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="hum:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting" format="ixt:num-dot-decimal" scale="6" id="f-1522">30</ix:nonFraction> million in 2023, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="hum:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting" format="ixt:num-dot-decimal" scale="6" id="f-1523">31</ix:nonFraction>&#160;million in 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting" format="ixt:num-dot-decimal" scale="6" id="f-1524">28</ix:nonFraction> million in 2021. There was <ix:nonFraction unitRef="usd" contextRef="c-7" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="f-1525"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="f-1526"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="f-1527">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> capitalized stock-based compensation expense during these years.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, there were approximately <ix:nonFraction unitRef="shares" contextRef="c-360" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-1528">11.0</ix:nonFraction> million shares reserved for stock award plans under the Humana Inc. 2011 Stock Incentive Plan, or 2011 Plan, and approximately <ix:nonFraction unitRef="shares" contextRef="c-361" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-1529">14.8</ix:nonFraction> million shares reserved for stock award plans under the Humana Inc. 2019 Stock Incentive Plan, or 2019 Plan. These reserved shares included giving effect to, under the 2011 Plan, <ix:nonFraction unitRef="shares" contextRef="c-362" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1530">3.3</ix:nonFraction> million shares of common stock available for future grants assuming all stock options were granted or <ix:nonFraction unitRef="shares" contextRef="c-363" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1531">1.4</ix:nonFraction> million shares available for future grants assuming all restricted stock were granted.&#160;These reserved shares included giving effect to, under the 2019 Plan, <ix:nonFraction unitRef="shares" contextRef="c-364" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1532">9.7</ix:nonFraction> million shares of common stock available for future grants assuming all stock options were granted or <ix:nonFraction unitRef="shares" contextRef="c-365" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1533">2.9</ix:nonFraction> million shares available for future grants assuming all restricted stock were granted. Shares may be issued from authorized but unissued company stock or treasury stock.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock is granted with a fair value equal to the market price of our common stock on the date of grant and generally vests in equal annual tranches over a <ix:nonNumeric contextRef="c-354" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1534">three year</ix:nonNumeric> period from the date of grant. Certain of our restricted stock grants also include performance-based conditions generally associated with return on invested capital and strategic membership growth. Restricted stock units have forfeitable dividend equivalent rights equal to the dividend paid on common stock. The weighted-average grant date fair value of our restricted stock was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-354" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1535">508.23</ix:nonFraction> in 2023, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-355" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1536">430.06</ix:nonFraction> in 2022, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-356" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1537">381.34</ix:nonFraction> in 2021. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-1538" continuedAt="f-1538-1" escape="true">Activity for our restricted stock was as follows for the year ended December&#160;31, 2023:</ix:nonNumeric></span></div><ix:continuation id="f-1538-1"><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:70.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.889%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(shares in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested restricted stock at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-366" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-1539">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-366" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1540">429.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-354" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-1541">437</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-354" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1542">508.23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-354" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-1543">428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-354" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1544">389.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-354" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-1545">68</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-354" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1546">441.20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested restricted stock at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-367" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-1547">754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-367" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1548">488.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="number" contextRef="c-367" decimals="2" name="hum:ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions" scale="-2" id="f-1549">37</ix:nonFraction>% of the nonvested restricted stock at December 31, 2023 included performance-based conditions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares vested was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1550">236</ix:nonFraction> million during 2023, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1551">244</ix:nonFraction> million during 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1552">236</ix:nonFraction> million during 2021. Total compensation expense not yet recognized related to nonvested restricted stock was $<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-1553">181</ix:nonFraction> million at December&#160;31, 2023. We expect to recognize this compensation expense over a weighted-average period of approximately <ix:nonNumeric contextRef="c-354" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1554">1.7</ix:nonNumeric> years. There are no other contractual terms covering restricted stock once vested.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options are granted with an exercise price equal to the fair market value of the underlying common stock on the date of grant. Our stock plans, as approved by the Board of Directors and stockholders, define fair market value as the average of the highest and lowest stock prices reported on the composite tape by the New York Stock Exchange on a given date. Exercise provisions vary, but most options vest in whole or in part <ix:nonNumeric contextRef="c-368" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-1555">1</ix:nonNumeric> to <ix:nonNumeric contextRef="c-369" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="f-1556">3</ix:nonNumeric> years after grant and expire <ix:nonNumeric contextRef="c-357" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-1557">7</ix:nonNumeric> years after grant.</span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1493-3"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value of each option granted during 2023, 2022, and 2021 is provided below. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1558" continuedAt="f-1558-1" escape="true">The fair value was estimated on the date of grant using the Black-Scholes pricing model with the weighted-average assumptions indicated below:</ix:nonNumeric></span></div><ix:continuation id="f-1558-1"><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:55.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.868%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value at grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-357" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1559">130.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-358" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1560">113.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-359" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1561">92.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option life (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-357" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1562">3.0</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-358" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1563">3.6</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-359" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1564">3.7</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-357" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1565">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-358" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1566">36.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-359" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1567">33.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate at grant date</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-357" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1568">4.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-358" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1569">1.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-359" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1570">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-357" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1571">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-358" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1572">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-359" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1573">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate the expected term for our employee stock options based on historical employee exercise behavior and base the risk-free interest rate on a traded zero-coupon U.S. Treasury bond with a term substantially equal to the option&#8217;s expected term.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The volatility used to value employee stock options is based on historical volatility. We calculate historical volatility using a simple-average calculation methodology based on daily price intervals as measured over the expected term of the option.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-1574" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for our option plans was as follows for the year ended December&#160;31, 2023:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:70.168%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.866%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160; Under<br/>Option</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(shares in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="f-1575">204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1576">381.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" id="f-1577">63</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1578">508.80</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-1579">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1580">371.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="f-1581">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1582">491.82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="f-1583">242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1584">415.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at December&#160;31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="f-1585">112</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1586">366.69</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of  December&#160;31, 2023, outstanding stock options, substantially all of which are expected to vest, had an aggregate intrinsic value of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1587">13</ix:nonFraction> million, and a weighted-average remaining contractual term of <ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1588">4.5</ix:nonNumeric> years. As of December&#160;31, 2023, exercisable stock options had an aggregate intrinsic value of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="f-1589">10</ix:nonFraction> million, and a weighted-average remaining contractual term of <ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1590">3.6</ix:nonNumeric> years. The total intrinsic value of stock options exercised during 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1591">3</ix:nonFraction> million, compared with $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1592">32</ix:nonFraction> million during 2022 and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-1593">18</ix:nonFraction> million during 2021. Cash received from stock option exercises totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-1594">9</ix:nonFraction> million in 2023, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-1595">51</ix:nonFraction> million in 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-1596">30</ix:nonFraction> million in 2021.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense not yet recognized related to nonvested options was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-1597">9</ix:nonFraction> million at December&#160;31, 2023. We expect to recognize this compensation expense over a weighted-average period of approximately <ix:nonNumeric contextRef="c-357" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1598">1.7</ix:nonNumeric> years.</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_187"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1599" continuedAt="f-1599-1" escape="true">EARNINGS PER COMMON SHARE COMPUTATION</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1600" escape="true"><ix:continuation id="f-1599-1"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detail supporting the computation of basic and diluted earnings per common share was as follows for the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.470%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions, except&#160;per<br/>common share results, number&#160;of<br/>shares/options in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available for common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1601">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1602">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1603">2,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average outstanding shares of common stock used to <br/>&#160;&#160;&#160;&#160;compute basic earnings per common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1604">123,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1605">126,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1606">128,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-357" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-1607">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-358" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-1608">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-359" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-1609">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-354" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-1610">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-355" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-1611">625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-356" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-1612">644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used to compute diluted earnings per&#160;common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1613">124,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1614">127,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1615">129,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1616">20.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1617">22.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1618">22.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per common share</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1619">20.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1620">22.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1621">22.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of antidilutive stock options and restricted stock&#160;awards <br/>&#160;&#160;&#160;&#160;excluded from computation</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-1622">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-1623">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-1624">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_190"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1625" continuedAt="f-1625-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="f-1625-1" continuedAt="f-1625-2"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DividendsDeclaredTableTextBlock" id="f-1626" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of dividend payments, excluding dividend equivalent rights, in 2021, 2022, and 2023, under our Board approved quarterly cash dividend policy:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"/><td style="width:64.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.486%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.605%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.487%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-1627">2.73</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:Dividends" scale="6" id="f-1628">351</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-1629">3.06</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:Dividends" scale="6" id="f-1630">390</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="f-1631">3.44</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Dividends" scale="6" id="f-1632">428</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:1pt;text-align:center"><span><br/></span></div><div style="margin-bottom:1pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Board declared a cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-370" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-1633">0.885</ix:nonFraction> per share payable on January&#160;26, 2024 to stockholders of record on December&#160;29, 2023 for an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-6" name="us-gaap:DividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-1634">108</ix:nonFraction> million. In February 2024, the Board declared a cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-371" decimals="4" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-1635">0.885</ix:nonFraction> per share payable on April&#160;26, 2024 to stockholders of record on March&#160;29, 2024. Declaration and payment of future quarterly dividends is at the discretion of our Board and may be adjusted as business needs or market conditions change.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchases</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors may authorize the purchase of our common shares. Under our share repurchase authorization, shares may have been purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or in privately-negotiated transactions (including pursuant to accelerated share repurchase agreements with investment banks), subject to certain regulatory restrictions on volume, pricing, and timing. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2020, we entered into separate accelerated stock repurchase agreements, the December 2020 ASR Agreements, with Citibank, N.A., or Citi, and JPMorgan Chase Bank, or JPM, to repurchase $<ix:nonFraction unitRef="usd" contextRef="c-372" decimals="INF" name="hum:AcceleratedShareRepurchasesAgreementAmount" format="ixt:num-dot-decimal" scale="9" id="f-1636">1.75</ix:nonFraction>&#160;billion of our common stock as part of the $<ix:nonFraction unitRef="usd" contextRef="c-373" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1637">3</ix:nonFraction>&#160;billion repurchase program authorized by the Board of Directors on July 30, </span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1625-2" continuedAt="f-1625-3"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019. On December 23, 2020, in accordance with the December 2020 ASR Agreements, we made a payment of $<ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-7" sign="-" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" format="ixt:num-dot-decimal" scale="9" id="f-1638">1.75</ix:nonFraction>&#160;billion ($<ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-6" sign="-" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" format="ixt:num-dot-decimal" scale="6" id="f-1639">875</ix:nonFraction>&#160;million to Citi and $<ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-6" sign="-" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" format="ixt:num-dot-decimal" scale="6" id="f-1640">875</ix:nonFraction>&#160;million to JPM) and received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="c-377" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1641">3.8</ix:nonFraction>&#160;million shares of our common stock (<ix:nonFraction unitRef="shares" contextRef="c-378" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1642"><ix:nonFraction unitRef="shares" contextRef="c-379" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1643">1.9</ix:nonFraction></ix:nonFraction>&#160;million shares each from Citi and JPM). We recorded the payments to Citi and JPM as a reduction to stockholders&#8217; equity, consisting of an $<ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="f-1644">1.5</ix:nonFraction>&#160;billion increase in treasury stock, which reflects the value of the initial <ix:nonFraction unitRef="shares" contextRef="c-377" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1645">3.8</ix:nonFraction>&#160;million shares received upon initial settlement, and a $<ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-5" name="hum:TreasuryStockDecreaseInCapitalInExcessOfParValue" format="ixt:num-dot-decimal" scale="6" id="f-1646">262.5</ix:nonFraction>&#160;million decrease in capital in excess of par value, which reflects the value of stock held back by Citi and JPM pending final settlement of the December 2020 ASR Agreements. Upon final settlement of the December 2020 ASR agreements with Citi and JPM on May 4, 2021 and May 5, 2021, respectively, we received an additional <ix:nonFraction unitRef="shares" contextRef="c-380" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1647">0.3</ix:nonFraction>&#160;million shares and <ix:nonFraction unitRef="shares" contextRef="c-381" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1648">0.3</ix:nonFraction>&#160;million shares, respectively, as determined by the average daily volume weighted-averages share price of our common stock during the term of the agreement, less a discount, of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-380" decimals="2" name="us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare" scale="0" id="f-1649">400.07</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-381" decimals="2" name="us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare" scale="0" id="f-1650">401.49</ix:nonFraction>, respectively, bringing the total shares received under the December 2020 ASR agreements to <ix:nonFraction unitRef="shares" contextRef="c-382" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1651">4.4</ix:nonFraction>&#160;million. In addition, upon settlement we reclassified the $<ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-5" name="hum:CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue" format="ixt:num-dot-decimal" scale="6" id="f-1652">262.5</ix:nonFraction>&#160;million value of stock initially held back by Citi and JPM from capital in excess of par value to treasury stock.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2021, the Board of Directors replaced the previous share repurchase authorization of up to $<ix:nonFraction unitRef="usd" contextRef="c-384" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1653">3</ix:nonFraction>&#160;billion (of which approximately $<ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-9" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1654">1</ix:nonFraction>&#160;billion remained unused) with a new authorization for repurchases of up to $<ix:nonFraction unitRef="usd" contextRef="c-384" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1655">3</ix:nonFraction>&#160;billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 18, 2024.  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we entered into separate accelerated stock repurchase agreements, the January 2022 ASR Agreements, with Mizuho Markets Americas LLC, or Mizuho, and Wells Fargo Bank, or Wells Fargo, to repurchase $<ix:nonFraction unitRef="usd" contextRef="c-385" decimals="INF" name="hum:AcceleratedShareRepurchasesAgreementAmount" format="ixt:num-dot-decimal" scale="9" id="f-1656">1</ix:nonFraction>&#160;billion of our common stock as part of the $<ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-9" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1657">3</ix:nonFraction>&#160;billion repurchase program authorized by the Board of Directors on February 18, 2021. On January 12, 2022, in accordance with the January 2022 ASR Agreements, we made a payment of $<ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-9" sign="-" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" format="ixt:num-dot-decimal" scale="9" id="f-1658">1</ix:nonFraction>&#160;billion ($<ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-6" sign="-" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" format="ixt:num-dot-decimal" scale="6" id="f-1659">500</ix:nonFraction>&#160;million to Mizuho and $<ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-6" sign="-" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" format="ixt:num-dot-decimal" scale="6" id="f-1660">500</ix:nonFraction>&#160;million to Wells Fargo) and received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="c-389" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1661">2.2</ix:nonFraction>&#160;million shares of our common stock (<ix:nonFraction unitRef="shares" contextRef="c-390" decimals="-4" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1662"><ix:nonFraction unitRef="shares" contextRef="c-391" decimals="-4" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1663">1.08</ix:nonFraction></ix:nonFraction>&#160;million shares each from Mizuho and Wells Fargo). We recorded the payments to Mizuho and Wells Fargo as a reduction to stockholders&#8217; equity, consisting of an $<ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-1664">850</ix:nonFraction>&#160;million increase in treasury stock, which reflects the value of the initial <ix:nonFraction unitRef="shares" contextRef="c-389" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1665">2.2</ix:nonFraction>&#160;million shares received upon initial settlement, and a $<ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-6" name="hum:TreasuryStockDecreaseInCapitalInExcessOfParValue" format="ixt:num-dot-decimal" scale="6" id="f-1666">150</ix:nonFraction>&#160;million decrease in capital in excess of par value, which reflects the value of stock held back by Mizuho and Wells Fargo pending final settlement of the January 2022 ASR Agreements. Upon final settlement of the January 2022 ASR Agreements with Mizuho and Wells Fargo on March 29, 2022 and March 30, 2022, respectively, we received an additional <ix:nonFraction unitRef="shares" contextRef="c-392" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1667">0.1</ix:nonFraction>&#160;million shares and <ix:nonFraction unitRef="shares" contextRef="c-393" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1668">0.1</ix:nonFraction>&#160;million shares, respectively, as determined by the average daily volume weighted-averages share price of our common stock during the term of the agreement, less a discount, of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-392" decimals="2" name="us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare" scale="0" id="f-1669">410.96</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-393" decimals="2" name="us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare" scale="0" id="f-1670">411.66</ix:nonFraction>, respectively, bringing the total shares received under the January 2022 ASR Agreements to <ix:nonFraction unitRef="shares" contextRef="c-394" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1671">2.4</ix:nonFraction>&#160;million. In addition, upon settlement we reclassified the $<ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-6" name="hum:CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue" format="ixt:num-dot-decimal" scale="6" id="f-1672">150</ix:nonFraction>&#160;million value of stock initially held back by Mizuho and Wells Fargo from capital in excess of par value to treasury stock. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 2, 2022, we entered into separate accelerated stock repurchase agreements, the November 2022 ASR Agreements, with Goldman Sachs &amp; Co. LLC, or Goldman Sachs, and Mizuho Markets Americas LLC, or Mizuho, to repurchase $<ix:nonFraction unitRef="usd" contextRef="c-396" decimals="INF" name="hum:AcceleratedShareRepurchasesAgreementAmount" format="ixt:num-dot-decimal" scale="9" id="f-1673">1</ix:nonFraction>&#160;billion of our common stock as part of the $<ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-9" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1674">3</ix:nonFraction>&#160;billion repurchase program authorized by the Board of Directors on February 18, 2021. In accordance with the November 2022 ASR Agreements, we made a payment of $<ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-9" sign="-" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" format="ixt:num-dot-decimal" scale="9" id="f-1675">1</ix:nonFraction>&#160;billion ($<ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-6" sign="-" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" format="ixt:num-dot-decimal" scale="6" id="f-1676">500</ix:nonFraction>&#160;million to Goldman Sachs on November 3, 2022 and $<ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-6" sign="-" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" format="ixt:num-dot-decimal" scale="6" id="f-1677">500</ix:nonFraction>&#160;million to Mizuho on November 4, 2022) and received an initial delivery of <ix:nonFraction unitRef="shares" contextRef="c-399" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1678">1.5</ix:nonFraction>&#160;million shares of our common stock (<ix:nonFraction unitRef="shares" contextRef="c-400" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1679"><ix:nonFraction unitRef="shares" contextRef="c-401" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1680">0.760</ix:nonFraction></ix:nonFraction>&#160;million shares each from Goldman Sachs and Mizuho). We recorded the payments to Goldman Sachs and Mizuho as a reduction to stockholders&#8217; equity, consisting of an $<ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-1681">850</ix:nonFraction>&#160;million increase in treasury stock, which reflects the value of the initial <ix:nonFraction unitRef="shares" contextRef="c-399" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1682">1.5</ix:nonFraction>&#160;million shares received upon initial settlement, and a $<ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-6" name="hum:TreasuryStockDecreaseInCapitalInExcessOfParValue" format="ixt:num-dot-decimal" scale="6" id="f-1683">150</ix:nonFraction>&#160;million decrease in capital in excess of par value, which reflects the value of stock held back by Goldman Sachs and Mizuho pending final settlement of the November 2022 ASR Agreements. Upon final settlement of the November 2022 ASR Agreements with Goldman Sachs and Mizuho on December 15, 2022 and December 16, 2022, respectively, we received an additional <ix:nonFraction unitRef="shares" contextRef="c-402" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1684">0.177</ix:nonFraction>&#160;million shares and <ix:nonFraction unitRef="shares" contextRef="c-403" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1685">0.177</ix:nonFraction>&#160;million shares, respectively,  as determined by the average daily volume weighted-averages share price of our common stock during the term of the agreement, less a discount, of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-402" decimals="2" name="us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare" scale="0" id="f-1686">534.16</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-403" decimals="2" name="us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare" scale="0" id="f-1687">533.87</ix:nonFraction>, respectively, bringing the total shares received under the November 2022 ASR Agreements to <ix:nonFraction unitRef="shares" contextRef="c-404" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1688">1.8</ix:nonFraction>&#160;million. In addition, upon settlement we reclassified the $<ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-6" name="hum:CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue" format="ixt:num-dot-decimal" scale="6" id="f-1689">150</ix:nonFraction>&#160;million value of stock initially held back by Goldman Sachs and Mizuho from capital in excess of par value to treasury stock. </span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1625-3"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, the Board of Directors replaced the previous share repurchase authorization of up to $<ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-9" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1690">3</ix:nonFraction>&#160;billion (of which approximately $<ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-9" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1691">1</ix:nonFraction>&#160;billion remained unused) with a new authorization for repurchases of up to $<ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-9" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1692">3</ix:nonFraction>&#160;billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2026, which we refer to as the February 2023 repurchase authorization. During the year ended December&#160;31, 2023, we repurchased <ix:nonFraction unitRef="shares" contextRef="c-408" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-1693">3.1</ix:nonFraction>&#160;million common shares in open market transactions for $<ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-8" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="9" id="f-1694">1.5</ix:nonFraction>&#160;billion at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-408" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-1695">482.27</ix:nonFraction> under the current share repurchase authorization. During the years ended December&#160;31, 2022 and December&#160;31, 2021, we did <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="0" id="f-1696"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="0" id="f-1697">not</ix:nonFraction></ix:nonFraction> repurchase shares in open market transactions.  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 16, 2024, the Board of Directors replaced the February 2023 repurchase authorization (of which approximately $<ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-6" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="6" id="f-1698">824</ix:nonFraction>&#160;million remained unused) with a new share repurchase authorization for repurchases of up to $<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-9" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1699">3</ix:nonFraction>&#160;billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2027, which we refer to as the 2024 repurchase authorization. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="f-1700" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding shares acquired in connection with employee stock plans, share repurchases were as follows during the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:38.546%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.296%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.129%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorization Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchase Not to Exceed</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-411" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-1701">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-412" decimals="-4" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-1702">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-1703">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-413" decimals="-4" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="f-1704">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="f-1705">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-414" decimals="-4" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="f-1706">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="f-1707">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-415" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="f-1708">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-416" decimals="-4" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="f-1709">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="f-1710">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-417" decimals="-4" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-1711">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-1712">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-418" decimals="-4" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="f-1713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="f-1714">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repurchases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-419" decimals="-4" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-1715">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-1716">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-420" decimals="-4" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-1717">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="f-1718">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-421" decimals="-4" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="6" id="f-1719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="6" id="f-1720">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with employee stock plans, we acquired <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares" format="ixt:num-dot-decimal" scale="6" id="f-1721">0.2</ix:nonFraction> million common shares for $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue" format="ixt:num-dot-decimal" scale="6" id="f-1722">73</ix:nonFraction> million in 2023, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares" format="ixt:num-dot-decimal" scale="6" id="f-1723">0.2</ix:nonFraction> million common shares for $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue" format="ixt:num-dot-decimal" scale="6" id="f-1724">96</ix:nonFraction> million in 2022, and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares" format="ixt:num-dot-decimal" scale="6" id="f-1725">0.2</ix:nonFraction> million common shares for $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue" format="ixt:num-dot-decimal" scale="6" id="f-1726">79</ix:nonFraction> million in 2021.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our stockholders' equity, refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Requirements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our subsidiaries operate in states that regulate the payment of dividends, loans, or other cash transfers to Humana Inc., our parent company, and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these subsidiaries, without prior approval by state regulatory authorities, or ordinary dividends, is limited based on the entity&#8217;s level of statutory income and statutory capit</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">al and surplus. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, it is generally considered an extraordinary dividend requiring prior regulatory approval. In most states, prior notification is provided before paying a dividend even if approval is not required. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although minimum required levels of equity are largely based on premium volume, product mix, and the quality of assets held, minimum requirements vary significantly at the state level. Our state regulated insurance subsidiaries had aggregate statutory capital and surplus of approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" format="ixt:num-dot-decimal" scale="9" id="f-1727">12.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" format="ixt:num-dot-decimal" scale="9" id="f-1728">11.3</ix:nonFraction> billion as of December&#160;31, 2023 and 2022, respectively, which exceeded aggregate minimum regulatory requirements of </span><span style="background-color:#ffffff;color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" format="ixt:num-dot-decimal" scale="9" id="f-1729">9.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" format="ixt:num-dot-decimal" scale="9" id="f-1730">8.4</ix:nonFraction> billion, respectively.  The amount of ordinary dividends that may be paid to our parent company in 2024 is approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval" format="ixt:num-dot-decimal" scale="9" id="f-1731">1.1</ix:nonFraction> billion in the aggregate. The amount, timing and mix of ordinary and extraordinary dividend payments will vary due to state </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory requirements, the level of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix. Actual dividends that were paid to our parent company were approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="hum:DividendsToParentWithoutPriorStateRegulatoryApproval" format="ixt:num-dot-decimal" scale="9" id="f-1732">1.8</ix:nonFraction> billion in 2023, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-8" name="hum:DividendsToParentWithoutPriorStateRegulatoryApproval" format="ixt:num-dot-decimal" scale="9" id="f-1733">1.3</ix:nonFraction> billion in 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-8" name="hum:DividendsToParentWithoutPriorStateRegulatoryApproval" format="ixt:num-dot-decimal" scale="9" id="f-1734">1.6</ix:nonFraction> billion in 2021.</span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_193"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-1735" continuedAt="f-1735-1" escape="true">COMMITMENTS, GUARANTEES AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-1735-1" continuedAt="f-1735-2"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">     Purchase Obligations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreements to purchase services, primarily information technology related services, or to make improvements to real estate, in each case that are enforceable and legally binding on us and that specify all significant terms, including: fixed or minimum levels of service to be purchased; fixed, minimum or variable price provisions; and the appropriate timing of the transaction. We have purchase obligation commitments of</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" format="ixt:num-dot-decimal" scale="6" id="f-1736">829</ix:nonFraction> million in 2024, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" format="ixt:num-dot-decimal" scale="6" id="f-1737">518</ix:nonFraction> million in 2025, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" format="ixt:num-dot-decimal" scale="6" id="f-1738">354</ix:nonFraction> million in 2026, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" format="ixt:num-dot-decimal" scale="6" id="f-1739">273</ix:nonFraction> million in 2027, and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" format="ixt:num-dot-decimal" scale="6" id="f-1740">209</ix:nonFraction> million in 2028. Purchase obligations exclude agreements that are cancellable without penalty.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our ongoing business, we do not participate or knowingly seek to participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, or SPEs, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As of December&#160;31, 2023, we were not involved in any SPE transactions.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through indemnity agreements approved by the state regulatory authorities, certain of our regulated subsidiaries generally are guaranteed by Humana Inc., our parent company, in the event of insolvency for (1)&#160;member coverage for which premium payment has been made prior to insolvency; (2)&#160;benefits for members then hospitalized until discharged; and (3)&#160;payment to providers for services rendered prior to insolvency. Our parent also has guaranteed the obligations of certain of our non-regulated subsidiaries and funding to maintain required statutory capital levels of certain regulated subsidiaries.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we enter into contractual arrangements under which we may agree to indemnify a third party to such arrangement from any losses incurred relating to the services they perform on behalf of us, or for losses arising from certain events as defined within the particular contract, which may include, for example, litigation or claims relating to past performance. Such indemnification obligations may not be subject to maximum loss clauses. Historically, payments made related to these indemnifications have been immaterial.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Contracts</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medicare products, which accounted for approximately <ix:nonFraction unitRef="number" contextRef="c-422" decimals="2" name="hum:PercentageOfTotalPremiumAndServicesRevenues" scale="-2" id="f-1741">83</ix:nonFraction>% of our total premiums and services revenue for the year ended December&#160;31, 2023, primarily consisted of products covered under the Medicare Advantage and Medicare Part D Prescription Drug Plan contracts with the federal government. These contracts are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare products have been renewed for 2024, and all of our product offerings filed with CMS for 2024 have been approved.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997 (BBA) and the Benefits Improvement and Protection Act of 2000 (BIPA), generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium </span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1735-2" continuedAt="f-1735-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service (FFS) program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS and the Office of the Inspector General of Health and Human Services, or HHS-OIG, perform audits of various companies&#8217; risk adjustment diagnosis data submissions. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices that influence the calculation of health status-related premium payments to MA plans.  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, CMS released an MA contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract&#8217;s entire health status-related risk adjusted premium amount for the year under audit.  In doing so, CMS recognized &#8220;that the documentation standard used in RADV audits to determine a contract&#8217;s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).&#8221;  To correct for this difference, CMS stated that it would apply a &#8220;Fee-for-Service Adjuster (FFS Adjuster)&#8221; as &#8220;an offset to the preliminary recovery amount.&#8221;  This adjuster would be &#8220;calculated by CMS based on a RADV-like review of records submitted to support FFS claims data.&#8221;  CMS stated that this methodology would apply to audits beginning with PY 2011.  Humana relied on CMS&#8217;s 2012 guidance in submitting MA bids to CMS.  Humana also launched a &#8220;Self-Audits&#8221; program in 2013 that applied CMS&#8217;s 2012 RADV audit methodology and included an estimated FFS Adjuster.  Humana completed Self-Audits for PYs 2011-2016 and reported results to CMS.  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, however, CMS issued a proposed rule announcing possible changes to the RADV audit methodology, including elimination of the FFS Adjuster.  CMS proposed applying its revised methodology, including extrapolated recoveries without application of a FFS Adjuster, to RADV audits dating back to PY 2011.  On January 30, 2023, CMS published a final rule related to the RADV audit methodology (Final RADV Rule).  The Final RADV Rule confirmed CMS&#8217;s decision to eliminate the FFS Adjuster. The Final RADV Rule states CMS&#8217;s intention to extrapolate results from CMS and HHS-OIG RADV audits beginning with PY 2018, rather than PY 2011 as proposed.  However, CMS&#8217;s Final RADV Rule does not adopt a specific sampling, extrapolation or audit methodology.  CMS instead stated its general plan to rely on &#8220;any statistically valid method . . . that is determined to be well-suited to a particular audit.&#8221;  </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the Final RADV Rule fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act (&#8220;APA&#8221;). CMS failed to meet its legal obligations in the federal rulemaking process to give a reasoned justification for the rule or provide a meaningful opportunity for public comment. They also chose to apply the rule retroactively rather than prospectively, as required by law. Humana&#8217;s actuarially certified bids through PY 2023 preserved Humana&#8217;s position that CMS should apply an FFS Adjuster in any RADV audit that CMS intends to extrapolate. We expect CMS to apply the Final RADV Rule, including the first application of extrapolated audit results to determine audit settlements without a FFS Adjuster, to CMS and HHS-OIG RADV audits conducted for PY 2018 and subsequent years.  The Final RADV  Rule, including the lack of a FFS Adjuster, and any related regulatory, industry or company reactions, could have a material adverse effect on our results of operations, financial position, or cash flows.  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in connection with the risk adjustment model. These reviews may also result in the identification of errors and the submission of corrections to CMS that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows. </span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1735-3" continuedAt="f-1735-4"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. We remain committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members.  It is critical that MA plans are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows. </span></div><div style="margin-bottom:9pt;margin-top:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state-based Medicaid business accounted for approximately <ix:nonFraction unitRef="number" contextRef="c-423" decimals="2" name="hum:PercentageOfTotalPremiumAndServicesRevenues" scale="-2" id="f-1742">7</ix:nonFraction>% of our total premiums and services revenue for the year ended December 31, 2023 primarily serving members enrolled in Medicaid, and in certain circumstances members who qualify for both Medicaid and Medicare, under contracts with various states. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     Our military services business, which accounted for approximately <ix:nonFraction unitRef="number" contextRef="c-424" decimals="2" name="hum:PercentageOfTotalPremiumAndServicesRevenues" scale="-2" id="f-1743">1</ix:nonFraction>% of our total premiums and services revenue for the year ended December 31, 2023, primarily consisted of the TRICARE T2017 East Region contract. The T2017 East Region contract comprises <ix:nonFraction unitRef="state" contextRef="c-425" decimals="INF" name="hum:NumberOfStatesComprisingTRICAREBeneficiaries" scale="0" id="f-1744">32</ix:nonFraction> states and approximately <ix:nonFraction unitRef="beneficiary" contextRef="c-426" decimals="-5" name="hum:NumberOfTRICAREBeneficiaries" format="ixt:num-dot-decimal" scale="6" id="f-1745">6.0</ix:nonFraction>&#160;million TRICARE beneficiaries, under which delivery of health care services commenced on January 1, 2018. The T2017 East Region contract, which was originally set to expire on December 31, 2022, was subsequently extended by the DoD and is currently scheduled to expire on December 31, 2024, unless further extended.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we were awarded the next generation of TRICARE Managed Care Support Contracts, or T-5, for the updated TRICARE East Region by the Defense Health Agency of the DoD.The T-5 East Region contract comprises <ix:nonFraction unitRef="state" contextRef="c-427" decimals="INF" name="hum:NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries" scale="0" id="f-1746">24</ix:nonFraction> states, and Washington D.C., and covers approximately <ix:nonFraction unitRef="beneficiary" contextRef="c-428" decimals="INF" name="hum:NumberOfTRICAREManagedCareSupportContractBeneficiaries" format="ixt:num-dot-decimal" scale="6" id="f-1747">4.6</ix:nonFraction>&#160;million beneficiaries. The transition period for the T-5 contract began in January 2024 and will overlap the final year of the T2017 contract. The length of the contract is <span style="-sec-ix-hidden:f-1748">one</span> transition year followed by <ix:nonFraction unitRef="option_period" contextRef="c-427" decimals="INF" name="hum:TRICAREManagedCareSupportContractNumberOfOptionPeriods" format="ixt-sec:numwordsen" scale="0" id="f-1749">eight</ix:nonFraction> annual option periods, which, if all options are exercised, would result in a total contract length of <span style="-sec-ix-hidden:f-1750">nine years.</span> </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss of any of the contracts above or significant changes in these programs as a result of legislative or regulatory action, including reductions in premium payments to us, regulatory restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, or increases in member benefits or member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings and Certain Regulatory Matters</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, the Civil Division of the United States Department of Justice provided us with an information request in December 2014, concerning our Medicare Part C risk adjustment practices. The request relates to our oversight and submission of risk adjustment data generated by providers in our Medicare Advantage network, as well as to our business and compliance practices related to risk adjustment data generated by our providers and by us, including medical record reviews conducted as part of our data and payment accuracy compliance efforts, the use of health and well-being assessments, and our fraud detection efforts. We believe that this request for information is in connection with a wider review of Medicare Risk Adjustment generally that includes a number of Medicare Advantage plans, providers and vendors. We cooperated with the Department of Justice, and we have not heard from the Department of Justice on this matter since 2020. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on January 19, 2016, an individual filed a qui tam suit captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States of America ex rel. Steven Scott v. Humana, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, currently pending in United States District Court, Western District of Kentucky, Louisville Division. The complaint alleges certain civil violations by us in connection with the actuarial equivalence of the plan benefits under Humana&#8217;s Basic PDP plan, a prescription drug plan offered by us under Medicare Part D. The action seeks damages and penalties on behalf of the United States under the False Claims Act. The court ordered the qui tam action unsealed on September 13, 2017, so that the relator could proceed, following notice from the U.S. Government that it was not intervening at that time. On March 31, 2022, the Court denied the parties' Motions for Summary Judgement. We take seriously our obligations to comply with applicable CMS </span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1735-4" continuedAt="f-1735-5"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements and actuarial standards of practice, and continue to vigorously defend against these allegations. During 2023, we have accrued certain anticipated expenses in connection with this matter.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside.  There is no assurance that we will prevail in the lawsuit. See &#8220;Government Contracts&#8221; in this Note 17 for additional information regarding this matter.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Lawsuits and Regulatory Matters</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our current and past business practices are subject to review or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance, health care delivery and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, statutory capital requirements, provider contracting, risk adjustment, competitive practices, commission payments, privacy issues, utilization management practices, pharmacy benefits, access to care, sales practices, and provision of care by our healthcare services businesses, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are involved in various other lawsuits that arise, for the most part, in the ordinary course of our business operations, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate and payment disputes, including disputes over reimbursement rates required by statute, disputes arising from competitive procurement process, general contractual matters, intellectual property matters, and challenges to subrogation practices. Under state guaranty assessment laws, including those related to state cooperative failures in the industry, we may be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business as we do.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a government contractor, we may also be subject to false claims litigation, such as qui tam lawsuits brought by individuals who seek to sue on behalf of the government, alleging that the government contractor submitted false claims to the government or related overpayments from the government, including, among other allegations, those resulting from coding and review practices under the Medicare risk adjustment model. Qui tam litigation is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the individual may continue to prosecute the action on his or her own, on behalf of the government. We also are subject to other allegations of nonperformance of contractual obligations to providers, members, and others, including failure to properly pay claims, improper policy terminations, challenges to our implementation of the Medicare Part D prescription drug program and other litigation.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A limited number of the claims asserted against us are subject to insurance coverage. Personal injury claims, claims for extra contractual damages, care delivery malpractice, and claims arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for the contingencies discussed in the sections above to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters specifically described above because of the inherently unpredictable nature of legal proceedings, which also may be exacerbated by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or </span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1735-5"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting judgments, penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities or as a result of actions by third parties. Nevertheless, it is reasonably possible that any such outcome of litigation, judgments, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows, and may also affect our reputation.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_196"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1751" continuedAt="f-1751-1" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-1751-1" continuedAt="f-1751-2"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2022, we realigned our businesses into <ix:nonFraction unitRef="segment" contextRef="c-429" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1752">two</ix:nonFraction> distinct segments: Insurance and CenterWell. The Insurance segment includes the businesses that were previously included in the Retail and Group and Specialty segments, as well as the Pharmacy Benefit Manager, or PBM, business which was previously included in the Healthcare Services segment. The CenterWell segment (formerly Healthcare Services) represents our payor-agnostic healthcare services offerings, including pharmacy solutions, primary care, and home solutions. In addition to the new segment classifications being utilized to assess performance and allocate resources, we believe this simpler structure will create greater collaboration across the Insurance and CenterWell businesses and will accelerate work that is underway to centralize and integrate operations within the organization. 2021 segment financial information was recast to conform to the 2022 presentation. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1753">two</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our military services business, primarily our T-2017 East Region contract, as well as the operations of our PBM business. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CenterWell segment includes our pharmacy solutions, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in Gentiva Hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CenterWell intersegment revenues primarily relate to the operations of CenterWell Pharmacy (our mail-order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics. </span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1751-2" continuedAt="f-1751-3"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our CenterWell intersegment revenues includes revenues earned by certain owned providers (CenterWell Senior Primary Care) derived from certain value-based arrangements with our health plans. Under these value-based arrangements, our owned providers enter into agreements with our health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our members. In exchange, the owned provider receives a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our members. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We present our consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="hum:GovernmentAndHealthPlanMemberSubsidiesAmount" format="ixt:num-dot-decimal" scale="9" id="f-1754">20.7</ix:nonFraction> billion in 2023, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-8" name="hum:GovernmentAndHealthPlanMemberSubsidiesAmount" format="ixt:num-dot-decimal" scale="9" id="f-1755">19.7</ix:nonFraction> billion in 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-8" name="hum:GovernmentAndHealthPlanMemberSubsidiesAmount" format="ixt:num-dot-decimal" scale="9" id="f-1756">18.1</ix:nonFraction> billion in 2021. In addition, depreciation and amortization expense associated with certain businesses delivering benefits to our members, primarily associated with our primary care and pharmacy operations, are included with benefits expense. The amount of this expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="hum:DepreciationAndAmortizationClassifiedAsBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="f-1757">138</ix:nonFraction>&#160;million in 2023, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="hum:DepreciationAndAmortizationClassifiedAsBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="f-1758">122</ix:nonFraction>&#160;million in 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:DepreciationAndAmortizationClassifiedAsBenefitExpense" format="ixt:num-dot-decimal" scale="6" id="f-1759">108</ix:nonFraction>&#160;million in 2021. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than those described previously, the accounting policies of each segment are the same and are described in Note 2. Transactions between reportable segments primarily consist of sales of services rendered by our CenterWell segment, primarily pharmacy solutions, primary care, and home solutions, to our Insurance segment customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium and services revenues derived from our contracts with the federal government, as a percentage of our total premium and services revenues, were approximately <ix:nonFraction unitRef="number" contextRef="c-58" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1760">84</ix:nonFraction>% for 2023, <ix:nonFraction unitRef="number" contextRef="c-430" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1761">82</ix:nonFraction>% for 2022 and <ix:nonFraction unitRef="number" contextRef="c-431" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1762">83</ix:nonFraction>% for 2021.</span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1763" continuedAt="f-1763-1" escape="true"><ix:continuation id="f-1751-3" continuedAt="f-1751-4"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.861%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1764">78,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-434" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1766">78,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-435" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1767">6,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-436" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1769">6,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-438" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1770">2,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-439" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1772">2,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1773">87,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1774">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1775">87,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1776">3,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1777">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1778">3,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1779">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1780">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1781">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-1782">735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1783">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-1784">735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1785">8,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-454" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-455" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1787">8,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-456" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1788">101,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-457" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1790">101,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1791">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1792">1,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1793">1,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1795">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1796">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-465" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1797">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-466" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1798">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-467" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1799">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-468" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1800">763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-469" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1801">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1802">763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-471" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1803">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-472" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1804">849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-473" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1805">849</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-474" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1806">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-475" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1807">3,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-476" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1808">4,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1809">102,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1810">3,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-479" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1811">105,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-1812">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-481" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1813">4,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-482" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1814">4,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-1815">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-484" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1816">10,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-485" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1817">10,451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-1818">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1819">15,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1820">15,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-1821">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:fixed-zero" scale="6" id="f-1822">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-1823">518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="6" id="f-1824">1,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1825">102,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1826">18,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1827">14,885</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1828">106,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" format="ixt:num-dot-decimal" scale="6" id="f-1829">89,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" format="ixt:fixed-zero" scale="6" id="f-1830">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" sign="-" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" scale="6" id="f-1831">706</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" format="ixt:num-dot-decimal" scale="6" id="f-1832">88,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1833">10,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1834">16,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1835">14,011</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1836">13,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-1837">692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-1838">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" sign="-" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-1839">123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-1840">779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1841">100,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1842">17,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" sign="-" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1843">14,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1844">102,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1845">2,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1846">1,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-1847">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1848">4,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="6" id="f-1849">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-1850">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-1851">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-1852">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="f-1853">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="f-1854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1855">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1856">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net losses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1857">2,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1858">1,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="f-1859">672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1860">3,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-1861">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-1862">57</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-1863">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-1864">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1865">2,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1866">1,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1867">672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1868">3,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-1869">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-1870">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-1871">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-1872">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-6" name="hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="f-1873">2,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-6" name="hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="f-1874">1,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-6" sign="-" name="hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" scale="6" id="f-1875">672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="f-1876">3,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1763-1" continuedAt="f-1763-2"><ix:continuation id="f-1751-4" continuedAt="f-1751-5"><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1877">65,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1879">65,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-495" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1880">7,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-496" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1881">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-497" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1882">7,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-498" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1883">2,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-499" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1884">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-500" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1885">2,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-501" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1886">75,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-502" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1887">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1888">75,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1889">4,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1890">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1891">4,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-507" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1892">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1893">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1894">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-1895">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-1897">743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1898">6,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1899">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-515" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1900">6,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-516" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1901">87,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-517" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1902">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1903">87,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-519" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1904">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1905">2,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1906">2,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1907">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1908">568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1909">568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1910">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1911">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1912">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-528" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1913">550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-529" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1914">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-530" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1915">550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-1916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-532" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1917">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-533" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1918">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-534" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-1919">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-535" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1920">3,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-536" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1921">4,776</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1922">88,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-538" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1923">3,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-539" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1924">92,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-1925">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-541" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1926">3,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-542" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1927">3,588</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-1928">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1929">9,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-545" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1930">9,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-1931">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-547" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1932">13,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-548" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1933">13,429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-1934">223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-1935">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-1936">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-1937">382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1938">88,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1939">17,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1940">13,278</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1941">92,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" format="ixt:num-dot-decimal" scale="6" id="f-1942">75,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" format="ixt:fixed-zero" scale="6" id="f-1943">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" sign="-" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" scale="6" id="f-1944">244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" format="ixt:num-dot-decimal" scale="6" id="f-1945">75,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1946">9,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1947">15,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1948">12,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1949">12,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-1950">634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-1951">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" sign="-" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-1952">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-1953">709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1954">85,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1955">16,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" sign="-" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1956">12,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-1957">89,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1958">3,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1959">1,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-1960">513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1961">3,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of Gentiva Hospice</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="f-1962">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-1963">237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="6" id="f-1964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:GainLossOnSaleOfBusiness" scale="6" id="f-1965">237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="6" id="f-1966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="6" id="f-1967">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-1968">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-1969">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="f-1970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="f-1971">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1972">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1973">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net earnings (losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1974">3,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1975">1,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="f-1976">982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-1977">3,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net earnings (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-1978">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-1979">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-1980">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-1981">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1982">3,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1983">1,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-1984">982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-1985">3,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-1986">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-1987">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-1988">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-1989">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-549" decimals="-6" name="hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="f-1990">3,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-6" name="hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="f-1991">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-6" sign="-" name="hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" scale="6" id="f-1992">982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="f-1993">3,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><ix:continuation id="f-1763-2"><ix:continuation id="f-1751-5"><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1994">58,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-553" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1995">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1996">58,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1997">6,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-1998">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-557" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-1999">6,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-558" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2000">2,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-559" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-2001">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-560" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2002">2,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-561" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2003">67,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-2004">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2005">67,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2006">4,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-565" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-2007">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-566" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2008">4,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2009">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-2010">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2011">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-2012">731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-2013">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-572" decimals="-6" name="us-gaap:PremiumsEarnedNet" scale="6" id="f-2014">731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2015">5,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-2016">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-575" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2017">5,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-576" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2018">79,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-577" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:fixed-zero" scale="6" id="f-2019">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-578" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="f-2020">79,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-579" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-2021">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-580" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2022">1,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-581" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2023">1,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-582" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-2024">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-583" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-2025">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-584" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-2026">413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-585" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-2027">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-586" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-2028">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-587" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-2029">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-588" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-2030">547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-589" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-2031">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-2032">547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="6" id="f-2033">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-2034">623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-593" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-2035">623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-594" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" id="f-2036">853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2037">2,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-2038">3,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-597" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2039">80,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2040">2,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-599" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2041">82,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-600" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-2042">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-601" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2043">2,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-602" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2044">2,869</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-603" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-2045">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-604" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2046">9,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-605" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2047">9,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-606" decimals="-6" name="us-gaap:Revenues" scale="6" id="f-2048">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-607" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2049">11,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-608" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2050">11,893</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-2051">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-2052">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" sign="-" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-2053">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:InvestmentIncomeInterestAndDividend" scale="6" id="f-2054">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2055">80,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2056">14,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2057">11,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2058">83,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" format="ixt:num-dot-decimal" scale="6" id="f-2059">69,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" format="ixt:fixed-zero" scale="6" id="f-2060">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" sign="-" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" scale="6" id="f-2061">440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" format="ixt:num-dot-decimal" scale="6" id="f-2062">69,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2063">8,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2064">12,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2065">11,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2066">10,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-2067">539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-2068">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" sign="-" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-2069">95</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-2070">596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-2071">78,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-2072">13,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" sign="-" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-2073">11,722</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:BenefitsLossesAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-2074">79,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2075">2,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-2076">938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-2077">202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2078">3,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="6" id="f-2079">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="6" id="f-2080">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-2081">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-2082">326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="f-2083">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="f-2084">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-2085">532</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-2086">532</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes and equity in net earnings</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-2087">2,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="f-2088">938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="f-2089">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-2090">3,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2091">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-2092">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2093">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-2094">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2095">2,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2096">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-2097">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-2098">3,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-2099">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-2100">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-2101">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-2102">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings attributable to Humana</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-6" name="hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="f-2103">2,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-6" name="hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="f-2104">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-6" name="hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" scale="6" id="f-2105">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="f-2106">3,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_199"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:3pt;text-align:center;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)</span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:ReinsuranceTextBlock" id="f-2107" continuedAt="f-2107-1" escape="true">REINSURANCE </ix:nonNumeric></span></div><ix:continuation id="f-2107-1"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain blocks of insurance assumed in acquisitions, primarily life and annuities in run-off status are subject to reinsurance where some or all of the underwriting risk related to these policies has been ceded to a third party. In addition, a large portion of our reinsurance takes the form of 100% coinsurance agreements where, in addition to all of the underwriting risk, all administrative responsibilities, including premium collections and claim payment, have also been ceded to a third party. We acquired these policies and related reinsurance agreements with the purchase of stock of companies in which the policies were originally written. We acquired these companies for business reasons unrelated to these particular policies, including the companies&#8217; other products and licenses necessary to fulfill strategic plans. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reinsurance agreement between two entities transfers the underwriting risk of policyholder liabilities to a reinsurer while the primary insurer retains the contractual relationship with the ultimate insured. As such, these reinsurance agreements do not completely relieve us of our potential liability to the ultimate insured. However, given the transfer of underwriting risk, our potential liability is limited to the credit exposure which exists should the reinsurer be unable to meet its obligations assumed under these reinsurance agreements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reinsurance recoverables represent the portion of future policy benefits payable and benefits payable that are covered by reinsurance. Reinsurance recoverables, included in other long-term assets, were $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ReinsuranceRecoverables" format="ixt:num-dot-decimal" scale="6" id="f-2108">173</ix:nonFraction> million at December&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ReinsuranceRecoverables" format="ixt:num-dot-decimal" scale="6" id="f-2109">181</ix:nonFraction> million at December&#160;31, 2022. The amount of these reinsurance recoverables resulting from <ix:nonFraction unitRef="number" contextRef="c-612" decimals="INF" name="hum:PercentageOfCoinsuranceAgreement" scale="-2" id="f-2110">100</ix:nonFraction>% coinsurance agreements was approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="us-gaap:ReinsuranceRecoverables" format="ixt:num-dot-decimal" scale="6" id="f-2111">173</ix:nonFraction> million at December&#160;31, 2023 and approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-6" name="us-gaap:ReinsuranceRecoverables" format="ixt:num-dot-decimal" scale="6" id="f-2112">181</ix:nonFraction> million at December&#160;31, 2022. Premiums ceded were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CededPremiumsWritten" format="ixt:num-dot-decimal" scale="6" id="f-2113">1</ix:nonFraction> million in 2023, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:CededPremiumsWritten" format="ixt:num-dot-decimal" scale="6" id="f-2114">5</ix:nonFraction> million in 2022 and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:CededPremiumsWritten" format="ixt:num-dot-decimal" scale="6" id="f-2115">6</ix:nonFraction> million in 2021. Benefits ceded were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" format="ixt:num-dot-decimal" scale="6" id="f-2116">3</ix:nonFraction> million in 2023, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" format="ixt:num-dot-decimal" scale="6" id="f-2117">2</ix:nonFraction> million in 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" format="ixt:num-dot-decimal" scale="6" id="f-2118">2</ix:nonFraction> million in 2021. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate the financial condition of our reinsurers on a regular basis. Protective Life Insurance Company with $<ix:nonFraction unitRef="usd" contextRef="c-613" decimals="-6" name="us-gaap:ReinsuranceRecoverables" format="ixt:num-dot-decimal" scale="6" id="f-2119">159</ix:nonFraction> million in reinsurance recoverables is well-known and well-established with a AM Best rating of A+ at December&#160;31, 2023. The remaining reinsurance recoverables of $<ix:nonFraction unitRef="usd" contextRef="c-614" decimals="-6" name="us-gaap:ReinsuranceRecoverables" format="ixt:num-dot-decimal" scale="6" id="f-2120">15</ix:nonFraction> million are divided between <ix:nonFraction unitRef="reinsurer" contextRef="c-1" decimals="INF" name="hum:NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance" scale="0" id="f-2121">8</ix:nonFraction> other reinsurers, with $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="hum:AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer" format="ixt:num-dot-decimal" scale="6" id="f-2122">0.4</ix:nonFraction> million subject to funds withheld accounts or other financial guarantees supporting the repayment of these amounts.</span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_202"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of Humana Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Humana Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, and the related consolidated statements of income, of comprehensive income, of stockholders&#8217; equity and of cash flow for each of the three years in the period ended December 31, 2023, including the related notes and financial statement schedule listed in the index appearing under Item 15(a)(2) (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013) issued by the COSO.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Report on Internal Control over Financial Reporting appearing under Item 9A. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Incurred but not yet Reported Benefits Payable</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Notes 2 and 11 to the consolidated financial statements, the Company&#8217;s incurred but not yet reported benefits payable (IBNR) was $6.6 billion as of December 31, 2023. Management develops its estimate for IBNR using actuarial methodologies and assumptions, primarily based upon historical claim experience. Actuarial standards of practice generally require a level of confidence such that the liabilities established for IBNR have a greater probability of being adequate versus being insufficient, or such that the liabilities established for IBNR are sufficient to cover obligations under an assumption of moderately adverse conditions. As described by management, for the periods prior to the most recent two months, a completion factor method uses historical paid claims patterns to estimate the percentage of claims incurred during a given period that have historically been adjudicated as of the reporting period. Changes in claim inventory levels and known changes in claim payment processes are taken into account in these estimates. For the most recent two months, the incurred claims are estimated primarily from a trend analysis based upon per member per month claims trends developed from historical experience in the preceding months, adjusted for known changes in estimates of hospital admissions, recent hospital and drug utilization data, provider contracting changes, changes in benefit levels, changes in member cost sharing, changes in medical management processes, product mix and workday seasonality.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to the valuation of IBNR is a critical audit matter are the significant judgment by management when developing the estimate of IBNR, which in turn led to a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating the actuarial methodologies and significant assumptions related to completion factors, per member per month claims trends, and the potential for moderately adverse conditions. Also, the audit effort involved the use of professionals with specialized skill and knowledge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to the valuation of IBNR, including controls over the actuarial methodologies and development of significant assumptions related to completion factors, per member per month claims trends, and the potential for moderately adverse conditions. These procedures also included, among others, the involvement of professionals with </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specialized skill and knowledge to assist in developing an independent estimate of IBNR. This independent estimate includes a range of reasonable outcomes, including outcomes under moderately adverse conditions, which are compared to management&#8217;s estimate of IBNR. Developing the independent estimate involved developing independent completion factors and per member per month claims trends assumptions using management&#8217;s data, testing the completeness and accuracy of data provided by management, and evaluating the reasonableness of management&#8217;s assumptions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill Impairment Assessments &#8211; Home Solutions and Primary Care Reporting Units</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Notes 2 and 9 to the consolidated financial statements, the Company&#8217;s consolidated goodwill balance was $9.6 billion as of December 31, 2023, and the goodwill associated with the Home Solutions and Primary Care Reporting Units was $4.4 billion and $1.2 billion, respectively. Management conducts an impairment test in the fourth quarter of each year and more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. Management relies on an evaluation of future discounted cash flows analysis to determine fair value and uses discount rates that correspond to a market-based weighted-average cost of capital, and terminal growth rates that correspond to long-term growth prospects, consistent with the long-term inflation rate. Key assumptions in management&#8217;s cash flow projections, including revenue growth rates, medical and operating cost trends, and projected operating income, are supported with management&#8217;s long-range business plan and annual planning process.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to the goodwill impairment assessments of the Home Solutions and Primary Care reporting units is a critical audit matter are the significant judgment by management when determining the fair value of the reporting units, which in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management&#8217;s significant assumptions related to the revenue and terminal growth rates, projected operating income, and the discount rates. Also, the audit effort involved the use of professionals with specialized skill and knowledge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s goodwill impairment assessments, including controls over the significant assumptions used in the valuation of the Home Solutions and Primary Care reporting units. These procedures also included, among others, testing management's process for determining the fair value estimate of the reporting units; evaluating the appropriateness of the discounted cash flows analysis; testing the completeness and accuracy of underlying data used in the analysis; and evaluating the reasonableness of the significant assumptions used by management related to the revenue and terminal growth rates, projected operating income, and the discount rates. Evaluating management&#8217;s assumptions related to revenue and terminal growth rates and projected operating income involved considering the past performance of the reporting units and whether the assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in the evaluation of the appropriateness of the Company&#8217;s discounted cash flows analysis and the reasonableness of the significant assumptions related to the terminal growth rates and the discount rates. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-2123">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-2124">Louisville, Kentucky</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;15, 2024</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1968.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_208"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_211"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9A. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Responsibility for Financial Statements and Other Information</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for the preparation and integrity of the consolidated financial statements appearing in our Annual Report. The consolidated financial statements were prepared in conformity with accounting principles generally accepted in the United States and include amounts based on our estimates and judgments. All other financial information in this report has been presented on a basis consistent with the information included in the financial statements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our control environment is the foundation for our system of internal control over financial reporting and is embodied in our Code of Ethics and Business Conduct, which we currently refer to as the Humana Inc. Ethics Every Day. It sets the tone of our organization and includes factors such as integrity and ethical values. Our internal control over financial reporting is supported by formal policies and procedures which are reviewed, modified and improved as changes occur in business conditions and operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee of the Board of Directors, which is composed solely of independent outside directors, meets periodically with members of management, the internal auditors and our independent registered public accounting firm to review and discuss internal controls over financial reporting and accounting and financial reporting matters. Our independent registered public accounting firm and internal auditors report to the Audit Committee and accordingly have full and free access to the Audit Committee at any time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established disclosure controls and procedures to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to members of senior management and the Board of Directors.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our evaluation as of December&#160;31, 2023, we as the principal executive officer, the principal financial officer and the principal accounting officer of the Company have concluded that the Company&#8217;s disclosure controls and procedures (as defined in the Securities Exchange Act of 1934) are effective to ensure that the information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported as specified in Securities and Exchange Commission rules and forms.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for establishing and maintaining effective internal control over financial reporting as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934. The Company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2023. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)&#160;in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8211; Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2013). Based on our assessment, we determined that, as of December&#160;31, 2023, the Company&#8217;s internal control over financial reporting was effective based on those criteria.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December&#160;31, 2023 has been audited by PricewaterhouseCoopers LLP, our independent registered public accounting firm, who also audited the Company&#8217;s consolidated financial statements included in our Annual Report on Form 10-K, as stated in their report which appears on pages 121-123.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in the Company&#8217;s internal control over financial reporting during the quarter ended December&#160;31, 2023 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_214"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9B. OTHER INFORMATION</span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) None.</span></div><div><span><br/></span></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) During the three months ended December 31, 2023, no director or officer of the Company <ix:nonNumeric contextRef="c-615" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-2125"><ix:nonNumeric contextRef="c-615" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-2126">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-615" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-2127"><ix:nonNumeric contextRef="c-615" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-2128">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(a) of Regulation S-K.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_217"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_220"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_223"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Directors</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is herein incorporated by reference from our Definitive Proxy Statement for the Annual Meeting of Stockholders scheduled to be held on April&#160;18, 2024 appearing under the caption &#8220;Proposal One: Election of Directors&#8221; in such Definitive Proxy Statement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Officers of the Registrant</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A list of our executive officers and biographical information appears in Part I, Item 1, "Business" of this Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Code of Conduct for Chief Executive Officer and Senior Financial Officers</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Conduct for the Chief Executive Officer and Senior Financial Officers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> violations of which should be reported to the Audit Committee. The code may be viewed through the Investor Relations section of our web site at www.humana.com. Any amendment to or waiver of the application of the Code of Conduct for the Chief Executive Officer and Senior Financial Officers will be promptly disclosed through the Investor Relations section of our web site at www.humana.com.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Code of Business Conduct and Ethics</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 1995, we have operated under an omnibus Code of Ethics and Business Conduct, currently known as the Humana Inc. Ethics Every Day (the &#8220;Code&#8221;). All employees and directors are required to annually affirm in writing their acceptance of the Code. The Code was adopted by our Board of Directors in June 2014, replacing a previous iteration, known as the Humana Inc. Principles of Business Ethics, as the document to comply with the New York Stock Exchange Corporate Governance Standard 303A.10. The Code is available on the Investor Relations section of our web site at www.humana.com, and any waiver of the application of the Code with respect to directors or executive officers must be made by the Board of Directors and will be promptly disclosed on our web site at www.humana.com.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Governance Items</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made available free of charge on or through the Investor Relations section of our web site at www.humana.com our annual reports on Form 10-K, quarterly reports on Form 10-Q, proxy statements, and all of our other reports, and, if applicable, amendments to those reports filed or furnished pursuant to Section&#160;13(a) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Also available on the Investor Relations section of our Internet web site at www.humana.com is information about our corporate governance, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination of independence for each member of our Board of Directors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the name, membership, role, and charter of each of the various committees of our Board of Directors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the name(s) of the directors designated as a financial expert under rules and regulations promulgated by the SEC;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the responsibility of the Company&#8217;s Lead Independent Director, if applicable, to convene, set the agenda for, and lead executive sessions of the non-management directors, pursuant to our Corporate Governance Guidelines;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pre-approval process of non-audit services provided by our independent accountants;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our By-laws and Certificate of Incorporation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our Majority Vote policy, pursuant to our By-laws;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our Related Persons Transaction Policy;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the process by which interested parties can communicate with directors;</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the process by which stockholders can make director nominations (pursuant to our By-laws);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our Corporate Governance Guidelines;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our Policy Regarding Transactions in Company Securities, Inside Information and Confidentiality;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Stock Ownership Guidelines for directors and for executive officers;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Humana Inc. Ethics Every Day and any waivers thereto; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Code of Conduct for the Chief Executive Officer and Senior Financial Officers and any waivers thereto.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information about these items can be found in, and is incorporated by reference to, our Definitive Proxy Statement for the Annual Meeting of Stockholders scheduled to be held on April&#160;18, 2024.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Changes to the Procedures by which Security Holders May Recommend Nominees to the Registrant&#8217;s Board of Directors</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee Financial Expert</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is herein incorporated by reference from our Definitive Proxy Statement for the Annual Meeting of Stockholders scheduled to be held on April&#160;18, 2024 appearing under the caption &#8220;Corporate Governance &#8211; Audit Committee&#8221; of such Definitive Proxy Statement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee Composition and Independence</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is herein incorporated by reference from our Definitive Proxy Statement for the Annual Meeting of Stockholders scheduled to be held on April&#160;18, 2024 appearing under the caption &#8220;Corporate Governance &#8211; Committee Membership and Attendance&#8221; of such Definitive Proxy Statement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_226"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;11. EXECUTIVE COMPENSATION</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information required by this Item is incorporated herein by reference from our Definitive Proxy Statement for the Annual Meeting of Stockholders scheduled to be held on April&#160;18, 2024.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_229"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity compensation plan information</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain plans under which options to purchase our common stock and awards of restricted stock may be made to officers, directors, and key employees. Stock options are granted with an exercise price equal to the fair market value of the underlying common stock on the date of grant. Our stock plans, as approved by the Board of Directors and stockholders, define fair market value as the average of the highest and lowest stock prices reported on the composite tape by the New York Stock Exchange on a given date. Exercise provisions vary, but most options vest in whole or in part 1 to 3 years after grant and expire up to 7 years after grant.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information concerning stock option awards and the number of securities remaining available for future issuance under our equity compensation plans in effect as of December&#160;31, 2023 follows:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.957%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.329%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.124%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.489%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.198%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(a)<br/>Number&#160;of&#160; securities<br/>to be issued upon<br/>exercise&#160;of&#160;outstanding<br/>options, warrants<br/>and rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(b)<br/>Weighted-average<br/>exercise price of<br/>outstanding<br/>options, warrants<br/>and rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(c)<br/>Number&#160;of&#160; securities<br/>remaining&#160;available&#160;for<br/>future issuance under<br/>equity&#160;compensation&#160;<br/>plans<br/>(excluding securities<br/>reflected in column(a))</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by <br/>&#160;&#160;&#160;&#160;security holders (1)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,006</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,036,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)(3)(4)&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved <br/>&#160;&#160;&#160;&#160;by security holders</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.178&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,036,391&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The above table does not include awards of shares of restricted stock or restricted stock units. For information concerning these awards, see Note 14.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Humana Inc. 2011 Stock Incentive Plan was approved by stockholders at the Annual Meeting held on April&#160;21, 2011. On July&#160;5, 2011, 18.5&#160;million shares were registered with the Securities and Exchange Commission on Form S-8.</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Humana Inc. Amended and Restated Stock Incentive Plan was approved by stockholders at the Annual Meeting held on April 18, 2019. On May 1, 2019, 16&#160;million shares were registered with the Securities and Exchange Commission on Form S-8.</span></div><div style="margin-bottom:9pt;padding-left:31.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Of the number listed above, 4,348,987 (1,445,965 from the 2011 Plan and 2,903,023 from the Amended and Restated Plan) can be issued as restricted stock at December&#160;31, 2023 (giving effect to the provision that one restricted share is equivalent to 2.29 stock options in the 2011 Plan and 3.35 stock options in the Amended and Restated Plan).</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information under the captions &#8220;Stock Ownership Information - Security Ownership of Certain Beneficial Owners of Company Common Stock&#8221; and &#8220;Stock Ownership Information - Security Ownership of Directors and Executive Officers&#8221; in our Definitive Proxy Statement for the Annual Meeting of Stockholders scheduled to be held on April&#160;18, 2024, is herein incorporated by reference.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_232"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is herein incorporated by reference from our Definitive Proxy Statement for the Annual Meeting of Stockholders scheduled to be held on April&#160;18, 2024 appearing under the captions &#8220;Certain Transactions with Management and Others&#8221; and &#8220;Corporate Governance &#8211; Director Independence&#8221; of such Definitive Proxy Statement.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_235"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;14. PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is herein incorporated by reference from our Definitive Proxy Statement for the Annual Meeting of Stockholders scheduled to be held on April&#160;18, 2024 appearing under the caption &#8220;Audit Committee Report&#8221; of such Definitive Proxy Statement.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_238"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_241"></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;15. EXHIBITS, FINANCIAL STATEMENT SCHEDULE</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:9.975%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.912%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.270%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.643%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.270%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.270%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.932%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The financial statements, Report of Independent Registered Public Accounting Firm (PCAOB ID <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-2129">238</ix:nonNumeric>), financial statement schedule and exhibits set forth below are filed as part of this report.</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements &#8211; The response to this portion of Item&#160;15 is submitted as Item&#160;8 of Part II of this report.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following Consolidated Financial Statement Schedule is included herein:</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="12" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Schedule I</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Parent Company Condensed Financial Information at December 31, 2023 and 2022 and for the years ended December 31, 2023, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All other schedules have been omitted because they are not applicable.</span></div><div style="padding-left:31.5pt;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Exhibits:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restated Certificate of Incorporation of Humana Inc. filed with the Secretary of State of Delaware on November 9, 1989, as restated to incorporate the amendment of January 9, 1992, and the correction of March 23, 1992 (incorporated herein by reference to Exhibit 4(i) to Humana Inc.&#8217;s Post-Effective Amendment No.1 to the Registration Statement on Form S-8 (Reg. No.&#160;33-49305) filed February 2, 1994).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000004907123000070/exhibit3bhumanaincamendeda.htm">(b)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Inc. Amended and Restated By-laws, effective as of December 7, 2023 (incorporated herein by reference to Exhibit 3(b) to Humana Inc.&#8217;s Current Report on Form 8-K filed on December 7, 2023).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312503073141/dex41.htm">4(a)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indenture, dated as of August 5, 2003, by and between Humana Inc. and The Bank of New York, as trustee (incorporated herein by reference to Exhibit 4.1 to Humana Inc.'s Quarterly Report on Form 10-Q for the quarter ended September 30, 2003, File No. 001-05975). </span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312508128893/dex43.htm">(b)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourth Supplemental Indenture, dated as of June 5, 2008, by and between Humana Inc. and The Bank of New York Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit&#160;4.3 to Humana Inc.&#8217;s Current Report on Form 8-K filed on June 5, 2008).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000089534506000406/ex4_2.txt">(c)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indenture, dated as of March 30, 2006, by and between Humana Inc. and The Bank of New York Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.2 to Humana Inc.&#8217;s Registration Statement on Form S-3 filed on March 31, 2006, Req. No. 333-132878).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">There are no instruments defining the rights of holders with respect to long-term debt in excess of 10 percent of the total assets of Humana Inc. on a consolidated basis. Other long-term indebtedness of Humana Inc. is described herein in Note 13 to Consolidated Financial Statements. Humana Inc. agrees to furnish copies of all such instruments defining the rights of the holders of such indebtedness not otherwise filed as an Exhibit to this Annual Report on Form 10-K to the Commission upon request.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312512496959/d451705dex43.htm">(e)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sixth Supplemental Indenture, dated as of December 10, 2012, by and between Humana Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.3 to Humana Inc.&#8217;s Current Report on Form 8-K filed on December 10, 2012).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312514347186/d792515dex44.htm">(f)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eighth Supplemental Indenture, dated as of September 19, 2014, by and between Humana Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.4 to Humana Inc.&#8217;s Current Report on Form 8-K filed on September 19, 2014).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312514347186/d792515dex46.htm">(g)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ninth Supplemental Indenture, dated as of September 19, 2014, by and between Humana Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.6 to Humana Inc.&#8217;s Current Report on Form 8-K filed on September 19, 2014).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312517085551/d335535dex42.htm">(h)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenth Supplemental Indenture, dated March 16, 2017, between Humana Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.2 to Humana Inc.&#8217;s Current Report on Form 8-K filed on March 16, 2017).</span></td></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.484%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312517085551/d335535dex44.htm">(i)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eleventh Supplemental Indenture, dated March 16, 2017, between Humana Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.4 to Humana Inc.&#8217;s Current Report on Form 8-K filed on March 16, 2017).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312519222527/d793619dex42.htm">(j)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fourteenth Supplemental Indenture, dated August 15, 2019, between Humana Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.2 to Humana Inc.&#8217;s Current Report on Form 8-K filed on August 15, 2019). </span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312519222527/d793619dex44.htm">(k)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fifteenth Supplemental Indenture, dated August 15, 2019, between Humana Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.4 to Humana Inc.&#8217;s Current Report on Form 8-K filed on August 15, 2019). </span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907120000071/form8kex4x2linked.htm">(l)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sixteenth Supplemental Indenture, dated March 26, 2020, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.2 to Humana Inc.&#8217;s Current Report on Form 8-K, filed March 27, 2020).</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000004907120000071/form8kex4x4linked.htm">(m)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seventeenth Supplemental Indenture, dated March 26, 2020, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.4 to Humana Inc.&#8217;s Current Report on Form 8-K, filed March 27, 2020).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000119312521235039/d161015dex44.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000119312521235039/d161015dex44.htm">n</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000119312521235039/d161015dex44.htm">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nineteenth Supplemental Indenture, dated August 3, 2021, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.4 to Humana Inc.&#8217;s Current Report on Form 8-K filed on August 3, 2021).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000119312521235039/d161015dex46.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000119312521235039/d161015dex46.htm">o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000119312521235039/d161015dex46.htm">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Twentieth Supplemental Indenture, dated August 3, 2021, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.6 to Humana Inc.&#8217;s Current Report on Form 8-K filed on August 3, 2021).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312522082811/d335183dex42.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312522082811/d335183dex42.htm">p</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312522082811/d335183dex42.htm">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Twenty-First Supplemental Indenture, dated March 23, 2022, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.2 to Humana Inc.&#8217;s Current Report on Form 8-K filed on March 23, 2022).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312522291138/d383861dex42.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312522291138/d383861dex42.htm">q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312522291138/d383861dex42.htm">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Twenty-Second Supplemental Indenture, dated November 22, 2022, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.2 to Humana Inc.&#8217;s Current Report on Form 8-K filed on November 22, 2022).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312522291138/d383861dex44.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312522291138/d383861dex44.htm">r</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312522291138/d383861dex44.htm">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Twenty-Third Supplemental Indenture, dated November 22, 2022, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.4 to Humana Inc.&#8217;s Current Report on Form 8-K filed on November 22, 2022).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312523069153/d484848dex42.htm">(s)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Twenty-Fourth Supplemental Indenture, dated March 13, 2023, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.2 to Humana Inc.&#8217;s Current Report on Form 8-K filed on March 13, 2023).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312523069153/d484848dex44.htm">(t)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Twenty-Fifth Supplemental Indenture, dated March 13, 2023, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.4 to Humana Inc.&#8217;s Current Report on Form 8-K filed on March 13, 2023).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000162828023038312/exhibit42-closing8xk.htm">(u)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Twenty-Sixth Supplemental Indenture, dated November 9, 2023, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.2 to Humana Inc.&#8217;s Current Report on Form 8-K filed on November 9, 2023).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000162828023038312/exhibit44-closing8xk.htm">(v)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Twenty-Seventh Supplemental Indenture, dated November 9, 2023, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated herein by reference to Exhibit 4.4 to Humana Inc.&#8217;s Current Report on Form 8-K filed on November 9, 2023).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907120000032/hum-20191231x10kxex4o.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907120000032/hum-20191231x10kxex4o.htm">w</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907120000032/hum-20191231x10kxex4o.htm">)</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Description of Securities (incorporated herein by reference to Exhibit 4(o) to Humana Inc.&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019).</span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10bexecutiveaip.htm">10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10bexecutiveaip.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10bexecutiveaip.htm">a</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10bexecutiveaip.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Inc. Executive Incentive Compensation Plan, as amended and restated January 1, 2020 (incorporated herein by reference to Exhibit 10(b) to Humana Inc.'s Annual Report on Form 10-K for the fiscal year ended December 31, 2020).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trust under Humana Inc. Deferred Compensation Plans (incorporated herein by reference to Exhibit 10(p) to Humana Inc.&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 1999, File No. 001-05975).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312513069911/d446200dex10m.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312513069911/d446200dex10m.htm">c</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312513069911/d446200dex10m.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Humana Inc. Deferred Compensation Plan for Non-Employee Directors (as amended on October 18, 2012) (incorporated herein by reference to Exhibit 10(m) to Humana Inc.&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2012).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000004907123000025/humanaseverancepolicyfinal.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000004907123000025/humanaseverancepolicyfinal.htm">d</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000004907123000025/humanaseverancepolicyfinal.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Inc. Executive Severance Policy, effective as of March 1, 2023 (incorporated herein by reference to Exhibit 10.3 to Humana Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907111000014/exhibit4-1.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907111000014/exhibit4-1.htm">e</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907111000014/exhibit4-1.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Inc. Deferred Compensation Plan (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-8 (Reg. No. 333-171616), filed on January 7, 2011).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312511039288/dex10p.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312511039288/dex10p.htm">f</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312511039288/dex10p.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Retirement Equalization Plan, as amended and restated as of January 1, 2011 (incorporated herein by reference to Exhibit 10(p) to Humana Inc.&#8217;s Annual Report on Form 10-K filed on February 18, 2011).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Letter agreement with Humana Inc. officers concerning health insurance availability (incorporated herein by reference to Exhibit 10(mm) to Humana Inc.&#8217;s Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 1994, File No. 001-05975).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312504188013/dex10a.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312504188013/dex10a.htm">h</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312504188013/dex10a.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Long-Term Disability Program (incorporated herein by reference to Exhibit 10(a) to Humana Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2004).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)*</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indemnity Agreement (incorporated herein by reference to Appendix B to Humana Inc.&#8217;s Proxy Statement with respect to the Annual Meeting of Stockholders held on January 8, 1987).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312513069911/d446200dex10v.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312513069911/d446200dex10v.htm">j</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312513069911/d446200dex10v.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summary of the Company&#8217;s Financial Planning Program for our executive officers (incorporated herein by reference to Exhibit 10(v) to Humana&#8217;s Inc.&#8217;s Annual Report on Form 10-K filed on February 22, 2013).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312523159869/d507342dex101.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312523159869/d507342dex101.htm">k</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312523159869/d507342dex101.htm">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Five-Year $2.5 Billion Amended and Restated Credit Agreement, dated as of June 2, 2023, among Humana Inc., and JPMorgan Chase Bank, N.A. as Agent, Bank of America, N.A. as Syndication Agent, Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Documentation Agents, and JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Joint Lead Arrangers and Joint Bookrunners (incorporated herein by reference to Exhibit 10.1 to Humana Inc.&#8217;s Current Report on Form 8-K filed on June 2, 2023)).</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312523159869/d507342dex102.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312523159869/d507342dex102.htm">l</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/49071/000119312523159869/d507342dex102.htm">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364-Day $1.5 Billion Revolving Credit Agreement, dated as of June 2, 2023, among Humana Inc., and JPMorgan Chase Bank, N.A. as Agent, Bank of America, N.A. as Syndication Agent, Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Documentation Agents, and JPMorgan Chase Bank, N.A., BofA Securities, Inc., Citibank, N.A., Goldman Sachs Bank USA, PNC Capital Markets LLC, U.S. Bank, National Association and Wells Fargo Securities, LLC, as Joint Lead Arrangers and Joint Bookrunners (incorporated herein by reference to Exhibit 10.2 to Humana Inc.&#8217;s Current Report on Form 8-K filed on June 2, 2023).</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex101.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex101.htm">m</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex101.htm">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of CMS Coordinated Care Plan Agreement (incorporated herein by reference to Exhibit 10.1 to Humana Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2005, File No. 001-05975).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex102.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex102.htm">n</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex102.htm">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of CMS Private Fee for Service Agreement (incorporated herein by reference to Exhibit 10.2 to Humana Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2005, File No. 001-05975).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex103.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex103.htm">o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex103.htm">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addendum to Agreement Providing for the Operation of a Medicare Voluntary Prescription Drug Plan (incorporated herein by reference to Exhibit 10.3 to Humana Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2005, File No. 001-05975).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex104.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex104.htm">p</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex104.htm">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addendum to Agreement Providing for the Operation of an Employer/Union-only Group Medicare Advantage Prescription Drug Plan (incorporated herein by reference to Exhibit 10.4 to Humana Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2005, File No. 001-05975).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex105.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex105.htm">q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex105.htm">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addendum to Agreement Providing for the Operation of an Employer/Union-only Group Medicare Advantage-Only Plan (incorporated herein by reference to Exhibit 10.5 to Humana Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2005, File No. 001-05975).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex106.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex106.htm">r</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312505218181/dex106.htm">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Addendum to Agreement Providing for the Operation of a Medicare Advantage Regional Coordinated Care Plan (incorporated herein by reference to Exhibit 10.6 to Humana Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2005, File No. 001-05975).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312506045135/dex10nn.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312506045135/dex10nn.htm">s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312506045135/dex10nn.htm">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Explanatory Note regarding Medicare Prescription Drug Plan Contracts between Humana and CMS (incorporated herein by reference to Exhibit 10(nn) to Humana Inc.&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2005, File No. 001-05975).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312511057037/ddef14a.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312511057037/ddef14a.htm">t</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312511057037/ddef14a.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Inc. 2011 Stock Incentive Plan (incorporated herein by reference to Appendix A to Humana Inc.&#8217;s Proxy Statement with respect to the Annual Meeting of Stockholders held on April 21, 2011).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907114000053/humana8-k02282014ex10.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907114000053/humana8-k02282014ex10.htm">u</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907114000053/humana8-k02282014ex10.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Employment Agreement, dated as of February 27, 2014, by and between Humana Inc. and Bruce D. Broussard (incorporated herein by reference to Exhibit 10.1 to Humana Inc.&#8217;s current report on Form 8-K filed on February 28, 2014).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312515249229/d41670dex101.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312515249229/d41670dex101.htm">v</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312515249229/d41670dex101.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment to the Amended and Restated Employment Agreement between Humana Inc. and Bruce D. Broussard, dated July 2, 2015 (incorporated herein by reference to Exhibit 10.1 to Humana Inc.&#8217;s current report on Form 8-K filed on July 9, 2015).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312518253067/d603469dex101.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312518253067/d603469dex101.htm">w</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312518253067/d603469dex101.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment No. 2, dated as of August 16, 2018, to the Amended and Restated Employment Agreement between Humana Inc. and Bruce D. Broussard, dated as of February 27, 2014 (incorporated herein by reference to Exhibit 10.1 to Humana Inc.s Current Report on Form 8-K, filed on August 20, 2018).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907119000023/hum-20181231x10kxex10aa.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907119000023/hum-20181231x10kxex10aa.htm">x</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907119000023/hum-20181231x10kxex10aa.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Inc. Change in Control Policy, effective March 1, 2019 (incorporated herein by reference to Exhibit 10(aa) to Humana Inc.&#8217;s Annual Report on Form 10-K filed on February 21, 2019).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907114000121/humana8-k10062014ex10.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907114000121/humana8-k10062014ex10.htm">y</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907114000121/humana8-k10062014ex10.htm">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Commercial Paper Dealer Agreement between Humana Inc., as Issuer, and the Dealer party thereto (incorporated herein by reference to Exhibit 10.1 to Humana Inc.&#8217;s current report on Form 8-K filed on October 7, 2014).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907116000117/hum-20151231x10kxex10jj.htm">(z)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Company's Stock Option Agreement under the 2011 Stock Incentive Plan (Incentive Stock Options) (incorporated herein by reference to Exhibit 10(jj) to Humana Inc.&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2015).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907116000117/hum-20151231x10kxex10kk.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907116000117/hum-20151231x10kxex10kk.htm">aa</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907116000117/hum-20151231x10kxex10kk.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Company's Stock Option Agreement under the 2011 Stock Incentive Plan (Non-Qualified Stock Options with Non-Compete/Non-Solicit) (incorporated herein by reference to Exhibit 10(kk) to Humana Inc.&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2015).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907119000023/hum-20181231x10kxex10hh.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907119000023/hum-20181231x10kxex10hh.htm">bb</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907119000023/hum-20181231x10kxex10hh.htm">)*</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Company&#8217;s Incentive Stock Option Agreement and Agreement not to Compete or Solicit under the 2011 Stock Incentive Plan (incorporated herein by reference to Exhibit 10(hh) to Humana Inc.&#8217;s Annual Report on Form 10-K filed on February 21, 2019).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907119000023/hum-20181231x10kxex10ii.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907119000023/hum-20181231x10kxex10ii.htm">cc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907119000023/hum-20181231x10kxex10ii.htm">)*</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Company&#8217;s Stock Option Agreement and Agreement not to Compete or Solicit under the 2011 Stock Incentive Plan (Non-Qualified Stock Options) (incorporated herein by reference to Exhibit 10(ii) to Humana Inc.&#8217;s Annual Report on Form 10-K filed on February 21, 2019).</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312519064676/d662496ddef14a.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312519064676/d662496ddef14a.htm">dd</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312519064676/d662496ddef14a.htm">)*</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Humana Inc. Stock Incentive Plan (incorporated herein by reference to Appendix A to Humana Inc.&#8217;s Proxy Statement with respect to the Annual Meeting of Stockholders held on April 18, 2019).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10ee-firstamendment.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10ee-firstamendment.htm">ee</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10ee-firstamendment.htm">)*&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Amendment to the Amended and Restated Humana Inc. Stock Incentive Plan.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907119000061/hum20190331ex105.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907119000061/hum20190331ex105.htm">ff</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907119000061/hum20190331ex105.htm">)*</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Company&#8217;s Incentive Stock Option Agreement and Agreement not to Compete or Solicit under the Amended and Restated Humana Inc. Stock Incentive Plan (incorporated herein by reference to Exhibit 10.5 to Humana Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019).</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907119000061/hum20190331ex106.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907119000061/hum20190331ex106.htm">gg</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000004907119000061/hum20190331ex106.htm">)*</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Company&#8217;s Stock Option Agreement and Agreement not to Compete or Solicit under the Amended and Restated Humana Inc. Stock Incentive Plan (Non-Qualified Stock Options) (incorporated herein by reference to Exhibit 10.6 to Humana Inc.&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019).</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10nn-annualnq3yr33.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10nn-annualnq3yr33.htm">hh</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10nn-annualnq3yr33.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Form of Company&#8217;s Stock Option Agreement and Agreement not to Compete or Solicit under the Amended and Restated Humana Inc. Stock Incentive Plan (Non-Qualified Stock Options) (incorporated herein by reference to Exhibit 10(nn) to Humana Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10oo-annualiso3yr33.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10oo-annualiso3yr33.htm">ii</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10oo-annualiso3yr33.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Form of Company&#8217;s Incentive Stock Option Agreement and Agreement not to Compete or Solicit under the Amended and Restated Humana Inc. Stock Incentive Plan (incorporated herein by reference to Exhibit 10(oo) to Humana Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10pp-annualpsu100at3yr.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10pp-annualpsu100at3yr.htm">jj</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10pp-annualpsu100at3yr.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Form of Company&#8217;s Restricted Stock Unit Agreement with Performance Vesting and Agreement not to Compete or Solicit under the Amended and Restated Humana Inc. Stock Incentive Plan (incorporated herein by reference to Exhibit 10(pp) to Humana Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10qq-newhirersu3yr33.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10qq-newhirersu3yr33.htm">kk</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10qq-newhirersu3yr33.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Form of Company&#8217;s Restricted Stock Unit Agreement and Agreement not to Compete or Solicit under the Amended and Restated Humana Inc. Stock Incentive Plan (without retirement provisions) (incorporated herein by reference to Exhibit 10(qq) to Humana Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020).</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10rr-annualrsu3yr33.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10rr-annualrsu3yr33.htm">ll</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0000049071/000004907121000039/ex10rr-annualrsu3yr33.htm">)*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Form of Company&#8217;s Restricted Stock Unit Agreement and Agreement not to Compete or Solicit under the Amended and Restated Humana Inc. Stock Incentive Plan (with retirement provisions) (incorporated herein by reference to Exhibit 10(rr) to Humana Inc.&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020).</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10mm-annualrsu3yr33.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10mm-annualrsu3yr33.htm">mm</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10mm-annualrsu3yr33.htm">)*&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Company&#8217;s Restricted Stock Unit Agreement and Agreement not to Compete or Solicit under the Amended and Restated Humana Inc. Stock Incentive Plan.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10nn-annualpsu100at.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10nn-annualpsu100at.htm">nn</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10nn-annualpsu100at.htm">)*&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Company&#8217;s Restricted Stock Unit Agreement with Performance Vesting and Agreement not to Compete or Solicit under the Amended and Restated Humana Inc. Stock Incentive Plan.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10oo-annualiso3yr33.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10oo-annualiso3yr33.htm">oo</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10oo-annualiso3yr33.htm">)*&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Company&#8217;s Incentive Stock Option Agreement and Agreement not to Compete or Solicit under the Amended and Restated Humana Inc. Stock Incentive Plan.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10pp-annualnq3yr33n.htm">(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10pp-annualnq3yr33n.htm">pp</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit10pp-annualnq3yr33n.htm">)*&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Company&#8217;s Stock Option Agreement and Agreement not to Compete or Solicit under the Amended and Restated Humana Inc. Stock Incentive Plan (Non-Qualified Stock Options).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/49071/000119312504035443/dex14.htm">14</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Code of Conduct for Chief Executive Officer &amp; Senior Financial Officers (incorporated herein by reference to Exhibit 14 to Humana Inc.&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2003).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="hum-20231231x10kxex21.htm">21 &#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">List of subsidiaries.</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="hum-20231231x10kxex23.htm">23 &#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of PricewaterhouseCoopers LLP.</span></td></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.484%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="hum-20231231x10kxex311.htm">31.1 &#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CEO certification pursuant to Rule 13a-14(a)/15d-14(a).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="hum-20231231x10kxex312.htm">31.2 &#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CFO certification pursuant to Rule 13a-14(a)/15d-14(a).</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="hum-20231231x10kxex32.htm">32 &#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes &#8211; Oxley Act of 2002.</span></td></tr></table></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit97-humanarecoupment.htm">97*&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     Humana Inc. Compensation Recoupment Policy, effective October 2, 2023 </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101&#160;&#160;&#160;&#160;The following materials from Humana Inc.'s Annual Report on Form 10-K formatted in iXBRL (Inline Extensible Business Reporting Language): (i)&#160;the Consolidated Balance Sheets at December&#160;31, 2023 and 2022; (ii)&#160;the Consolidated Statements of Income for the&#160;years ended December&#160;31, 2023, 2022 and 2021; (iii)&#160;the Consolidated Statements of Comprehensive Income for the years ended December&#160;31, 2023, 2022 and 2021; (iv)&#160;the Consolidated Statements of Stockholders&#8217; Equity as of December&#160;31, 2023, 2022, and 2021; (v)&#160;the Consolidated Statements of Cash Flows for the years ended December&#160;31, 2023, 2022 and 2021; and (vi)&#160;Notes to Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104 &#160;&#160;&#160;&#160;Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Exhibits 10(a) through and including 10(j), and Exhibits 10(t) through and including 10(x), as well as Exhibits 10(z) through and including Exhibit 10(pp) are compensatory plans or management contracts.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**Pursuant to Rule 24b-2 of the Exchange Act, confidential portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;Submitted electronically with this report.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_244"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" id="f-2130" continuedAt="f-2130-1" escape="true"><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE I&#8212;PARENT COMPANY FINANCIAL INFORMATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"/><td style="width:63.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.344%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions,&#160;except&#160;share<br/>amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-2131">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-2132">614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-2133">260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="f-2134">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Receivable from operating subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2135">2,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-619" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2136">1,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-2137">717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-2138">577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2139">3,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2140">3,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2141">2,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-2142">2,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="hum:InvestmentInRelatedPartiesAndSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-2143">29,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="hum:InvestmentInRelatedPartiesAndSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-2144">27,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-2145">348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-2146">282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2147">35,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-2148">33,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payable to operating subsidiaries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2149">5,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-619" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2150">5,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2151">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2152">2,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable to operating subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-6" name="us-gaap:NotesPayableCurrent" scale="6" id="f-2153">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-619" decimals="-6" name="us-gaap:NotesPayableCurrent" scale="6" id="f-2154">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Book overdraft</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="hum:BookOverdraftLiability" scale="6" id="f-2155">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="hum:BookOverdraftLiability" scale="6" id="f-2156">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2157">1,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2158">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2159">8,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-2160">9,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-2161">10,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-2162">9,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-2163">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-2164">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-2165">19,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-2166">18,587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-616" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-2167"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-617" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-2168"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-616" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-2169"><ix:nonFraction unitRef="usdPerShare" contextRef="c-617" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-2170">1</ix:nonFraction></ix:nonFraction> par; <ix:nonFraction unitRef="shares" contextRef="c-616" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-2171"><ix:nonFraction unitRef="shares" contextRef="c-617" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-2172">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-616" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-2173"><ix:nonFraction unitRef="shares" contextRef="c-617" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-2174">none</ix:nonFraction></ix:nonFraction> issued</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-2175">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-2176">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.16 2/3 par; <ix:nonFraction unitRef="shares" contextRef="c-616" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-2177"><ix:nonFraction unitRef="shares" contextRef="c-617" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-2178">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-616" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2179">198,690,082</ix:nonFraction> shares issued at December&#160;31, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-617" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-2180">198,666,598</ix:nonFraction> shares issued at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="f-2181">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="f-2182">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Capital in excess of par value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-2183">3,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-2184">3,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-2185">27,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-2186">25,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-2187">999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2188">1,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="c-616" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-2189">76,465,862</ix:nonFraction> shares at December&#160;31, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-617" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-2190">73,691,955</ix:nonFraction> shares at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="f-2191">13,658</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="f-2192">12,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-2193">16,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-2194">15,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-2195">35,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-2196">33,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the parent company financial statements.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_250"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><ix:continuation id="f-2130-1" continuedAt="f-2130-2"><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE I&#8212;PARENT COMPANY FINANCIAL INFORMATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF INCOME</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"/><td style="width:58.224%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.926%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fees charged to operating subsidiaries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="hum:ManagementFeesChargedToOperatingSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-2199">2,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="hum:ManagementFeesChargedToOperatingSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-2200">1,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="hum:ManagementFeesChargedToOperatingSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-2201">1,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other (loss) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="hum:InvestmentAndOtherIncomeNet" scale="6" id="f-2202">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" sign="-" name="hum:InvestmentAndOtherIncomeNet" scale="6" id="f-2203">88</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" sign="-" name="hum:InvestmentAndOtherIncomeNet" scale="6" id="f-2204">266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2205">2,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2206">1,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-2207">1,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Operating costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2208">2,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2209">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-2210">1,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2211">656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2212">581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-2213">488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-2214">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-2215">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-2216">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-2217">3,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-2218">2,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-2219">2,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-2220">184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="f-2221">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-2222">672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and equity in net earnings of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" sign="-" name="hum:IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries" scale="6" id="f-2223">860</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" sign="-" name="hum:IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-2224">1,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" sign="-" name="hum:IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries" scale="6" id="f-2225">166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-2226">146</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-2227">266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-2228">259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before equity in net earnings of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" sign="-" name="hum:IncomeLossBeforeEquityInNetEarningsOfSubsidiaries" scale="6" id="f-2229">714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" sign="-" name="hum:IncomeLossBeforeEquityInNetEarningsOfSubsidiaries" scale="6" id="f-2230">949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="hum:IncomeLossBeforeEquityInNetEarningsOfSubsidiaries" scale="6" id="f-2231">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net earnings of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="hum:EquityInNetEarningsOfSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-2232">3,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="hum:EquityInNetEarningsOfSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-2233">3,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="hum:EquityInNetEarningsOfSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-2234">2,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net earnings of equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-2237">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Humana</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-2238">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-2239">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-2240">2,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the parent company financial statements.</span></div></ix:continuation><div><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_253"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><ix:continuation id="f-2130-2" continuedAt="f-2130-3"><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE I&#8212;PARENT COMPANY FINANCIAL INFORMATION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:54.758%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.025%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.025%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.188%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Humana</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2241">2,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2242">2,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-2243">2,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in gross unrealized investment gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="f-2244">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-2245">1,819</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="f-2246">356</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of income taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="f-2247">85</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="f-2248">418</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="f-2249">81</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total change in unrealized investment  <br/>&#160;&#160;&#160;&#160;&#160;gains (losses), net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-2250">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2251">1,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="f-2252">275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustment for net realized <br/>&#160;losses (gains) included in investment income </span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="f-2253">25</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="f-2254">72</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" scale="6" id="f-2255">103</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="f-2256">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="f-2257">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" scale="6" id="f-2258">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassification adjustment, net of tax</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="f-2259">18</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="f-2260">55</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" scale="6" id="f-2261">80</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-2262">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="f-2263">1,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-2264">355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to equity method<br/>&#160;&#160;investments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2265">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-2266">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments" scale="6" id="f-2267">6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to Humana</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2268">2,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2269">1,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-2270">2,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the parent company financial statements.</span></div></ix:continuation><div><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_256"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><ix:continuation id="f-2130-3" continuedAt="f-2130-4"><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE I&#8212;PARENT COMPANY FINANCIAL INFORMATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:52.993%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2271">3,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2272">4,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2273">2,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="f-2274">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="f-2275">337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="f-2276">4,187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital contributions to operating subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="hum:CapitalContributionsToOperatingSubsidiaries" scale="6" id="f-2277">792</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="hum:CapitalContributionsToOperatingSubsidiaries" scale="6" id="f-2278">484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="hum:CapitalContributionsToOperatingSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="f-2279">2,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Purchases of property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-2280">761</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-2281">931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-2282">958</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="f-2283">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="f-2284">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="f-2285">200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="f-2286">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="f-2287">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="6" id="f-2288">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="f-2289">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="f-2290">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="6" id="f-2291">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2292">1,695</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2293">1,317</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2294">7,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of senior notes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-2295">2,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-2296">1,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-2297">2,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Repayments of senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="f-2298">1,832</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="f-2299">1,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:fixed-zero" scale="6" id="f-2300">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds (repayments) from issuance of commercial paper, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfCommercialPaper" scale="6" id="f-2301">211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfCommercialPaper" scale="6" id="f-2302">376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfCommercialPaper" scale="6" id="f-2303">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Proceeds from issuance of term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="6" id="f-2304">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="6" id="f-2305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:ProceedsFromNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-2306">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of term loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:RepaymentsOfNotesPayable" scale="6" id="f-2307">500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-2308">2,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:fixed-zero" scale="6" id="f-2309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Change in book overdraft</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:IncreaseDecreaseInBookOverdrafts" scale="6" id="f-2310">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:IncreaseDecreaseInBookOverdrafts" scale="6" id="f-2311">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInBookOverdrafts" scale="6" id="f-2312">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Common stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-2313">1,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-2314">2,096</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-2315">79</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="f-2316">431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="f-2317">392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:PaymentsOfDividends" scale="6" id="f-2318">354</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" sign="-" name="hum:ProceedsFromStockOptionsExercisedAndOther" scale="6" id="f-2319">125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" name="hum:ProceedsFromStockOptionsExercisedAndOther" scale="6" id="f-2320">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="hum:ProceedsFromStockOptionsExercisedAndOther" scale="6" id="f-2321">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2322">1,711</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2323">3,843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-2324">5,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-2325">364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-2326">292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-2327">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-2328">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-2329">906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-624" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-2330">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-2331">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-2332">614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-2333">906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the parent company financial statements.</span></div></ix:continuation><div><span><br/></span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_259"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><ix:continuation id="f-2130-4" continuedAt="f-2130-5"><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE I&#8212;PARENT COMPANY FINANCIAL INFORMATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></div></ix:continuation><div><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_262"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;<ix:continuation id="f-2130-5" continuedAt="f-2130-6">BASIS OF PRESENTATION</ix:continuation></span></div><ix:continuation id="f-2130-6" continuedAt="f-2130-7"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parent company financial information has been derived from our consolidated financial statements and excludes the accounts of all operating subsidiaries. This information should be read in conjunction with our consolidated financial statements.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_265"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 2.&#160;<ix:continuation id="f-2130-7" continuedAt="f-2130-8">TRANSACTIONS WITH SUBSIDIARIES</ix:continuation></span></div><ix:continuation id="f-2130-8" continuedAt="f-2130-9"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Services Fee</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through intercompany service agreements approved, if required, by state regulatory authorities, Humana Inc., our parent company, charges a services fee for reimbursement of certain centralized services provided to its subsidiaries including information systems, disbursement, investment and cash administration, marketing, legal, finance, and medical and executive management oversight.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash dividends received from subsidiaries and included as a component of net cash provided by operating activities were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="hum:DividendsToParentWithoutPriorStateRegulatoryApproval" format="ixt:num-dot-decimal" scale="9" id="f-2334">1.8</ix:nonFraction> billion in 2023, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-8" name="hum:DividendsToParentWithoutPriorStateRegulatoryApproval" format="ixt:num-dot-decimal" scale="9" id="f-2335">1.3</ix:nonFraction> billion in 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-8" name="hum:DividendsToParentWithoutPriorStateRegulatoryApproval" format="ixt:num-dot-decimal" scale="9" id="f-2336">1.6</ix:nonFraction> billion in 2021.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantee</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through indemnity agreements approved by state regulatory authorities, certain of our regulated subsidiaries generally are guaranteed by our parent company in the event of insolvency for: (1) member coverage for which premium payment has been made prior to insolvency; (2) benefits for members then hospitalized until discharged; and (3)&#160;payment to providers for services rendered prior to insolvency. Our parent has also guaranteed the obligations of our military services subsidiaries and funding to maintain required statutory capital levels of certain other regulated subsidiaries.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_268"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  3.&#160;<ix:continuation id="f-2130-9" continuedAt="f-2130-10">REGULATORY REQUIREMENTS</ix:continuation></span></div><ix:continuation id="f-2130-10" continuedAt="f-2130-11"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our subsidiaries operate in states that regulate the payment of dividends, loans, or other cash transfers to Humana Inc., our parent company, and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these subsidiaries, without prior approval by state regulatory authorities, or ordinary dividends, is limited based on the entity&#8217;s level of statutory income and statutory capit</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">al and surplus. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, it is generally considered an extraordinary dividend requiring prior regulatory approval. In most states, prior notification is provided before paying a dividend even if approval is not required.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although minimum required levels of equity are largely based on premium volume, product mix, and the quality of assets held, minimum requirements vary significantly at the state level. Our state regulated insurance subsidiaries had aggregate statutory capital and surplus of approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" format="ixt:num-dot-decimal" scale="9" id="f-2337">12.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" format="ixt:num-dot-decimal" scale="9" id="f-2338">11.3</ix:nonFraction> billion as of December&#160;31, 2023 and 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, which exceeded aggregate minimum regulatory requirements of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" format="ixt:num-dot-decimal" scale="9" id="f-2339">9.8</ix:nonFraction> billion</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" format="ixt:num-dot-decimal" scale="9" id="f-2340">8.4</ix:nonFraction> billion, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of ordinary dividends that may be paid to our parent company in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval" format="ixt:num-dot-decimal" scale="9" id="f-2341">1.1</ix:nonFraction> billion </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the aggregate. The amount, timing and mix of ordinary and extraordinary dividend payments will vary due to state </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory requirements, the level of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix. Actual dividends that were paid to our parent company were approximately  $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="hum:DividendsToParentWithoutPriorStateRegulatoryApproval" format="ixt:num-dot-decimal" scale="9" id="f-2342">1.8</ix:nonFraction> billion in 2023, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-8" name="hum:DividendsToParentWithoutPriorStateRegulatoryApproval" format="ixt:num-dot-decimal" scale="9" id="f-2343">1.3</ix:nonFraction> billion in 2022, and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-8" name="hum:DividendsToParentWithoutPriorStateRegulatoryApproval" format="ixt:num-dot-decimal" scale="9" id="f-2344">1.6</ix:nonFraction> billion in 2021.</span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Humana Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE I&#8212;PARENT COMPANY FINANCIAL INFORMATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED FINANCIAL STATEMENTS&#8212;(Continued)</span></div><div><span><br/></span></div></div><ix:continuation id="f-2130-11" continuedAt="f-2130-12"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our use of operating cash flows derived from our non-insurance subsidiaries, such as in our Healthcare Services segment, is generally not restricted by state departments of insurance (or comparable state regulators).</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_271"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;<ix:continuation id="f-2130-12" continuedAt="f-2130-13">ACQUISITIONS</ix:continuation></span></div><ix:continuation id="f-2130-13" continuedAt="f-2130-14"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 3 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K for a description of certain acquisitions.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_274"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;<ix:continuation id="f-2130-14" continuedAt="f-2130-15">INCOME TAXES</ix:continuation></span></div><ix:continuation id="f-2130-15" continuedAt="f-2130-16"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K for a description of income taxes.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_277"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;<ix:continuation id="f-2130-16" continuedAt="f-2130-17">DEBT</ix:continuation></span></div><ix:continuation id="f-2130-17" continuedAt="f-2130-18"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K for a description of debt.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_280"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;<ix:continuation id="f-2130-18" continuedAt="f-2130-19">STOCKHOLDERS' EQUITY</ix:continuation></span></div><ix:continuation id="f-2130-19"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K for a description of stockholders&#8217; equity, including stock repurchases and stockholder dividends.</span></div></ix:continuation><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_286"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;16. FORM 10-K SUMMARY</span></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><div id="i7b1f484cd1dd4915aee01308d7de3d89_289"></div><hr style="page-break-after:always"/><div style="min-height:94.5pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Sections 13 or 15(d) of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.360%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UMANA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;SUSAN M. DIAMOND</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Susan M. Diamond</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chief Financial Officer<br/>&#160;(Principal Financial Officer)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the date indicated.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.717%"><tr><td style="width:1.0%"/><td style="width:30.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;SUSAN M. DIAMOND</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer<br/>(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Susan M. Diamond</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JOHN-PAUL W. FELTER</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President, Chief Accounting Officer and Controller (Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">John-Paul W. Felter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;BRUCE D. BROUSSARD</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer, Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Bruce D. Broussard</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;KURT J. HILZINGER</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Kurt J. Hilzinger</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;RAQUEL C. BONO, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Raquel C. Bono, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;FRANK A. D&#8217;AMELIO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Frank A. D&#8217;Amelio</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;DAVID T. FEINBERG, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">David T. Feinberg, M.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;WAYNE A. I. FREDERICK, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wayne A. I. Frederick, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JOHN W. GARRATT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">John W. Garratt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;KAREN W. KATZ</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Karen W. Katz</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;MARCY S. KLEVORN</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marcy S. Klevorn</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;WILLIAM&#160;J. MCDONALD</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">William J. McDonald</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JORGE S. MESQUITA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jorge S. Mesquita</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;BRAD D. SMITH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Brad D. Smith</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.EE
<SEQUENCE>2
<FILENAME>exhibit10ee-firstamendment.htm
<DESCRIPTION>EX-10.EE
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i442d4b12bf9a413b9910432b01947e59_1"></div><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">FIRST AMENDMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TO THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">HUMANA INC.<br>STOCK INCENTIVE PLAN </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This First Amendment (this &#8220;Amendment&#8221;) to the Amended and Restated Humana Inc. Stock Incentive Plan (the &#8220;Plan&#8221;) is effective as of February 24, 2024.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Plan provides for different treatment of the continued vesting of Options, Stock Appreciation Rights, and unvested shares of Restricted Stock and Restricted Stock Units in connection with (a) a Participant&#8217;s Retirement and (b) and the termination of a Participant&#8217;s employment, directorship or consultancy due to a Workforce Reduction or a Position Elimination&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company wishes to amend the Plan to provide for the same continued vesting treatment in connection with (a) a Participant&#8217;s Retirement and (b) and the termination of a Participant&#8217;s employment, directorship or consultancy due to a Workforce Reduction or a Position Elimination&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that the Participant has held an applicable Award for at least twelve (12) months from the original date of grant&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Plan may be amended by the Board, subject to the restrictions set forth in Section 14 of the Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Plan is hereby amended as follows&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Section 13(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Section 13(c) is hereby amended and restated in its entirety as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;(c) In the event of the Participant&#8217;s Retirement&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.69pt">(A)&#160;To the extent any Option or Stock Appreciation Right (or portion thereof) is exercisable on the date of such Retirement, the Option or Stock Appreciation Right shall be exercisable for the two (2) year period after the date of such Retirement, but in no event beyond the expiration date of the Option or Stock Appreciation Right, and only to the extent the Option or Stock Appreciation Right (or portion hereof) was exercisable on the date of the Participant&#8217;s Retirement and (B) (I) to the extent that the Option or Stock Appreciation Right (or portion thereof) (x) is not exercisable as of the date of such Retirement and (y) has been held by the Participant for at least twelve (12) months from the original date of grant, the unvested portion of the Option or Stock Appreciation Right shall continue to vest and become exercisable upon the regular vesting dates (as set forth in the Award Agreement) that would occur during the twelve (12) month period immediately following the date of such Retirement as if the Participant continued to be employed by the Company, and (II) to the extent that the Option or Stock Appreciation Right (or portion thereof) (x) is not exercisable as of the date of such Retirement and (y) has not been held by the Participant for at least twelve (12) months from the original date of grant, a prorated portion of the Option or Stock Appreciation Right that would have vested on the next scheduled vesting date (as set forth in the Award Agreement) shall vest and become exercisable upon the next scheduled vesting date, with the proration to be determined by calculating the product of (A) the quotient of (x) the number of completed months the Participant has been employed since the date of grant of the Option or Stock Appreciation Right or the most recent vesting date, as </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:90pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">applicable, divided by (y) the number of months in the current vesting period, multiplied by (B) the total number of Options or Stock Appreciation Rights that were scheduled to vest and become exercisable on the next scheduled vesting date&#59; provided, that, the Committee may determine, in its sole discretion, that the restrictions on some or all of the Options or Stock Appreciation Rights held by the Participant as of the date of Retirement shall immediately lapse. The portion of the Option or Stock Appreciation Right that vests pursuant to clause (B) of this Section 13(c)(i) shall be exercisable at any time within two (2) years following the vesting date of such Option or Stock Appreciation Right, but in no event beyond the expiration date of the Option or Stock Appreciation Right.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:12.36pt">(A) The portion of any unvested Shares of Restricted Stock or Restricted Stock Units (and related Dividend Equivalent Rights) that (x) the Participant has held for at least twelve (12) months from the original date of grant and (y) would ordinarily vest within twelve (12) months of the date of Retirement shall continue to vest on regularly scheduled vesting dates (as set forth in the Award Agreement) in the same manner as if the Participant continued to be employed by the Company through the applicable vesting dates, and (B) a prorated portion of any unvested Shares of Restricted Stock or Restricted Stock Units (and related Dividend Equivalent Rights) that (x) the Participant has held for less than twelve (12) months from the original date of grant and (y) would ordinarily vest within twelve (12) months of the date of Retirement shall continue to vest on regularly scheduled vesting (as set forth in the Award Agreement), with the proration to be determined by calculating the product of (i) the quotient of (x) the number of completed months the Participant has been employed since the date of grant or the most recent vesting date, as applicable, divided by (y) the number of months in the current restricted vesting period, multiplied by (ii) the total number of Shares of Restricted Stock or Restricted Stock Units that were scheduled to vest on the next scheduled vesting date&#59; provided, that, the Committee may determine, in its sole discretion, that the restrictions on some or all of the Shares of Restricted Stock or Restricted Stock Units held by the Participant as of the date of termination of employment shall immediately lapse.  </font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:9.03pt">A prorated portion of any  unvested Performance Awards that would have vested on the next scheduled vesting date (as set forth in the Award Agreement) shall vest on the next scheduled vesting date, with the proration to be determined by calculating the product of (i) the quotient of (x) the number of completed months the Participant has been employed since the date of grant or the most recent vesting date, as applicable, divided by (y) the number of months in the current restricted vesting period, multiplied by (ii) the total number of Performance Awards that were scheduled to vest on the next scheduled vesting date (taking into account achievement of applicable performance goals) &#59; provided, that, the Committee may determine, in its sole discretion, that the restrictions on some or all of the Performance Awards held by the Participant as of the date of Retirement shall immediately lapse. For purposes of the foregoing calculation, a month is complete on the day in the following month that corresponds to the date of grant.&#8221;  </font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Effect of Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as expressly set forth herein, this Amendment shall not alter, modify, amend or in any way affect any of the terms, conditions, obligations or agreements contained in the Plan, all of which are hereby ratified and affirmed in all respects and shall continue in full force and effect.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Terms used but not defined herein have the meanings assigned to them in the Plan.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(As adopted by the Board on December 7, 2023.) </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.MM
<SEQUENCE>3
<FILENAME>exhibit10mm-annualrsu3yr33.htm
<DESCRIPTION>EX-10.MM
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i57b15f73ac8b4268bdac06d62f48c560_1"></div><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-4.5pt"><font><br></font></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">HUMANA INC.</font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RESTRICTED STOCK UNIT AGREEMENT</font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AND AGREEMENT NOT TO COMPETE OR SOLICIT</font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">UNDER THE AMENDED AND RESTATED STOCK INCENTIVE PLAN</font></div><div style="padding-right:-2.25pt;text-align:center"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;THIS RESTRICTED STOCK UNIT AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#34;Agreement&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">) made as of &#60;award_date&#62; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Date of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">HUMANA INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, a corporation duly organized and existing under the laws of the State of Delaware (hereinafter referred to as the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">), and &#60;first_name&#62; &#60;middle_name&#62; &#60;last_name&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">an employee of the Company (hereinafter referred to as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#34;Grantee&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">).</font></div><div style="padding-right:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;WITNESSETH&#58;</font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> the Amended and Restated Humana Inc. Stock Incentive Plan (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#34;Plan&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">) was approved by the Company's Board of Directors and stockholders&#59; and</font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> the Company desires to award to Grantee Restricted Stock Units in accordance with the Plan.</font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> in consideration of the award of Restricted Stock Units to Grantee, the promises and mutual covenants hereinafter set forth, and other good and valuable consideration, the Company and Grantee agree as follows&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">RESTRICTED STOCK UNIT GRANT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  Subject to the terms and conditions hereinafter set forth, and in accordance with the provisions of the Plan, the Company hereby grants to Grantee, and Grantee hereby accepts from the Company &#60;shares_awarded&#62; Restricted Stock Units.  Each Restricted Stock Unit represents the right of Grantee to receive one (1) Share on the date of distribution provided for in Section I(E)</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.  In addition, Grantee shall also have the right to receive all of the cash or in-kind dividends that are paid with respect to the Shares represented by the Restricted Stock Units to which this award relates (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">DERs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221;).  Dividend equivalents with respect to any such Share shall be paid on the same date that such Share is issued to Grantee pursuant to Section I(E) hereof.  The DERs shall be subject to the same terms and conditions applicable to the Restricted Stock Units, including, without limitation, the restrictions and non-transferability, vesting, forfeiture and distribution provisions contained in Sections I(B) through I(E), inclusive, of this Agreement.  In the event that the Restricted Stock Units are forfeited pursuant to Section I(D) hereof, the related DER shall also be forfeited.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Restrictions and Non-Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  The Restricted Stock Units and DERs may not be sold, transferred, pledged, assigned or otherwise alienated or hypothecated.  In addition, such Restricted Stock Units and DERs shall be subject to forfeiture in accordance with the provisions of Section I(D).  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Vesting of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">The Restricted Stock Units shall vest in three equal installments, with the first installment vesting on December 15 of the year in which the Date of Grant occurs, and the next two installments vesting on December 15 of each of the next two years (each such date, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Vesting Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; and the period between each Vesting Date or between the Date of Grant and a Vesting Date, as applicable, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Vesting Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221;) subject to Grantee&#8217;s continued employment with the Company through each such Vesting Date&#59; However, notwithstanding the foregoing, upon certain terminations of employment (as set forth below), all or a portion of the unvested Restricted Stock Units and DERs will vest in accordance with Sections 12 and 13 of the Plan. </font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;Except as set forth in Sections 12 and 13 of the Plan, upon the Last Day, but prior to the time the Restricted Stock Units and DERs have vested, the Restricted Stock Units and DERs shall be forfeited immediately by Grantee.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  The Company shall issue to Grantee (or, if applicable, Grantee&#8217;s estate or personal representative) Shares (or such other securities or other property into which the Shares have been converted, with any partial Shares or other securities to be settled in cash) with respect to Grantee&#8217;s Restricted Stock Units and dividend equivalents accrued pursuant to the DERs with respect to such Restricted Stock Units, within 30 days of the date that the Restricted Stock Units vest in accordance with Section I(C) hereof&#59; provided, however, that, to the extent that the Restricted Stock Units are considered deferred compensation subject to Section 409A of the Code and the Restricted Stock Units vest in connection with Grantee&#8217;s Change in Control Termination (defined below), then unless the Change in Control is a Section 409A Change in Control, the distribution of  Shares (or such other securities or other property into which the Shares have been converted) shall not be accelerated to the vesting date but such distribution shall instead occur based on the Vesting Dates set forth in Section I(C) hereof.  A &#8220;Section 409A Change in Control&#8221; shall mean a Change in Control that also constitutes a &#8220;change in ownership or effective control&#8221; of the Company or a &#8220;change in ownership of a substantial portion of the assets of&#8221; the Company, in each case within the meaning of Section 409A of the Code.  Notwithstanding anything to the contrary contained herein, no Shares may be transferred to any person other than Grantee unless such other person demonstrates to the reasonable satisfaction of the Company such person&#8217;s right to the transfer.   </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">F.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  Federal, state and local income and employment taxes and other amounts as may be required by law to be collected by the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221;) in connection with the distribution of Shares, cash or other property or, to the extent applicable, vesting of the Restricted Stock Units or DERs hereunder, shall be paid by Grantee at such time.  Notwithstanding the foregoing, the Company shall withhold delivery of a number of Shares with a Fair Market Value as of the distribution date equal to the Withholding Taxes required to be withheld in connection with such distribution.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">II.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">AGREEMENT NOT TO COMPETE AND AGREEMENT NOT TO SOLICIT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Grantee agrees and understands that the Company&#8217;s business is a profit-generating business operating in a highly competitive business environment and that the Company has a legitimate business interest in, among other things, its confidential information and trade secrets (including as protected in other agreements and policies between the Company and Grantee) that it is providing Grantee, and in the significant time, money, training, team building and other efforts it expends to develop Grantee&#8217;s skills to assist in performing Grantee&#8217;s duties for the Company, including with respect to establishing, developing and maintaining the goodwill and business relationships with Protected Relationships (defined below) and employees, each of which Grantee agrees are valuable assets of the Company to which it has devoted substantial resources. Grantee acknowledges that the grant Grantee is receiving under the Plan is a meaningful way that the Company entrusts Grantee with its goodwill and aligns Grantee with the Company objective of increasing the value of the Company&#8217;s business.  Accordingly, Grantee acknowledges the importance of protecting the value of the Company&#8217;s business through, among other things, covenants to restrict Grantee from engaging in activities that would adversely affect the value of the Company and its goodwill.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Agreement Not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> </font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1. &#160;&#160;&#160;&#160;Grantee agrees that during the Restricted Period (defined below) and within the Restricted Geographic Area (defined below), Grantee will not, directly or indirectly, perform or engage in Competitive Product or Services (defined below) with a Competitor (defined below). Grantee may not accept employment with a Competitor (defined below) unless the Competitor&#8217;s business is diversified and the Company receives Written Assurances from the Competitor and Grantee that are satisfactory to the Company that Grantee, during the Restricted Period, will not work on or provide Competitive Products or Services or otherwise use or disclose the Company&#8217;s confidential information or trade secrets.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2. &#160;&#160;&#160;&#160;For Section II(A), such &#8220;Written Assurances&#8221; must contain a written statement detailing the identity of the Competitor and the nature of the services that Grantee will provide to the Competitor with sufficient detail to allow the Company to independently assess whether Grantee is or will be in violation of the Agreement.  The Company must also receive such &#8220;Written Assurances&#8221; at least ten business days before Grantee commences employment for the Competitor.  Such &#8220;Written Assurances&#8221; shall be delivered to the Company&#8217;s Chief Human Resource Officer or his&#47;her authorized delegate.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">3. &#160;&#160;&#160;&#160;Nothing in this Agreement is intended to prevent Grantee from investing Grantee&#8217;s funds in securities of a person engaged in a business that is directly competitive with the Company if the securities of such a person are listed for trading on a registered securities exchange or actively traded in an over-the-counter market and Grantee&#8217;s holdings represent less than one percent (1%) of the total number of outstanding shares or principal amount of the securities of such a person.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Agreement Not to Solicit Protected Relationships</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> During the Restricted Period (defined below) and in connection with a Competitive Product or Service (defined below), Grantee shall not, individually or jointly with others, directly or indirectly, or by assisting others, (1) Solicit (defined below) any Protected Relationships (defined below)&#59; or (2) Solicit any Protected Relationships to terminate a relationship with the Company, its subsidiaries, and&#47;or its affiliates, reduce the volume of their business dealings with the Company, its subsidiaries, and&#47;or its affiliates, or to otherwise cease to accept services or products from the Company, its subsidiaries, and&#47;or its affiliates.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Agreement Not to Solicit Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">During the Restricted Period, Grantee shall not, individually or jointly with others, directly or indirectly, or by assisting others, (1) Solicit any employees or former employees of the Company, its subsidiaries, and&#47;or its affiliates with whom Grantee worked, had business contact, or about which Grantee gained non-public or confidential information (&#8220;Employees or Former Employees&#8221;)&#59; (2) contact or communicate with Employees or Former Employees for the purpose of Soliciting them to terminate their employment or find employment or work with another person or entity&#59; (3) provide, share, or pass along to any person or entity the name, contact and&#47;or background information about any Employees or Former Employees or provide references or any other information about them&#59; (4) provide, share, or pass along to Employees or Former Employees any information regarding potential jobs or entities or persons to work for, including but not limited to job openings, job postings, or the names or contact information of individuals or companies hiring people or accepting job applications&#59; and&#47;or (5) offer employment or work to any Employees or Former Employees.  For purposes of this covenant, &#8220;Former Employees&#8221; shall refer to employees who are not employed by the Company, its subsidiaries, and&#47;or its affiliates at the time of the attempted recruiting or hiring, but were employed by, or working for the Company, its subsidiaries, and&#47;or its affiliates in the three months prior to the time of the attempted recruiting or hiring and&#47;or interference.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Effect of a Change in Control Termination on Agreements Not to Compete and Not to Solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.&#160;&#160;&#160;&#160;In the event of a Change in Control Termination, the prohibitions on Grantee set forth in Section II(A) shall remain in full force and effect only if the acquirer or successor to the Company following the Change in Control shall, solely at its option, pay, within thirty (30) days following the Last Day (with the Company or its successor), to Grantee the Non-Compete Payment.  Notwithstanding any previous agreement between Grantee and the Company relating to the prohibitions on Grantee set forth in Section II.A, the &#8220;Non-Compete Payment&#8221; shall be an amount at least equal to Grantee&#8217;s then current annual base salary.  Such amount shall be in addition to any other amounts paid or payable to Grantee with respect to other severance plans or policies maintained by the Company.  For the avoidance of doubt, the provisions of this Section II(D) shall supersede any agreement between Grantee and the Company relating to the prohibitions on Grantee set forth in Section II(A), with the exception of any similar agreement contained in (i) any employment agreement between Grantee and the Company, (ii) any agreement between Grantee and the Company not related to the employment of Grantee by the Company, (iii) any severance plan or policy of the Company and (iv) any change in control severance plan or policy of the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2.&#160;&#160;&#160;&#160;In the event of a Change in Control Termination, the prohibitions on Grantee set forth in Sections II(B) and II(C) shall remain in full force and effect.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">E. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Violation of Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  This subsection sets forth the circumstances under which Grantee shall forfeit all or a portion of any vested or unvested Restricted Stock Units without payment and&#47;or be required to repay or otherwise reimburse the Company for the gain or value realized in respect of all or a portion of the Restricted Stock Units.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1. &#160;&#160;&#160;&#160;If Grantee violates any provisions of Section II of this Agreement (a &#8220;Forfeiture Event&#8221;), Grantee shall immediately forfeit as of the date that the violation first occurs all unvested Restricted Stock Units without payment..  This provision does not alter the circumstances for forfeiture of unvested Restricted Stock Units as described in Section I(D) of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2.&#160;&#160;&#160;&#160;For any Restricted Stock Units that vested during the 12 month period prior to the Forfeiture Event or at any time after the Forfeiture event, Grantee shall be required to repay or otherwise reimburse the Company, immediately upon demand, an amount in Cash or Humana Inc. common stock equal to (i) equal to the aggregate Fair Market Value of the shares of Stock underlying such Restricted Stock Units on the date the Restricted Stock Units became vested and (ii) any dividend or DER amounts paid in respect of Shares.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">3.&#160;&#160;&#160;&#160;The relief provided in this Section II(F) of the Agreement does not constitute the Company&#8217;s exclusive remedy for the Grantee&#8217;s violation of any of the provisions of Section II of the Agreement.  As any forfeiture and repayment provisions are not adequate remedies at law, including because they do not repair the irreparable harm the Company will suffer from Grantee&#8217;s breaches of this Agreement, the Company may seek any additional legal or equitable remedy, including injunctive relief, for such violations.  The provisions in this section are essential economic conditions to the Company&#8217;s grant of Restricted Stock Units.  By receiving the Restricted Stock Units, Grantee agrees upon Grantee&#8217;s violation of Section II of this Agreement that the Company may, subject to applicable state law, deduct from any amounts the Company owes the Grantee following the Last Day any amounts Grantee owes the Company under Section II(F). </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">4.&#160;&#160;&#160;&#160;The provisions under this Section II(F) of the Agreement and any amounts repayable by Grantee hereunder are intended to be in addition to any rights to repayment the Company may have under Section 304 of the Sarbanes-Oxley Act of 2002 and other applicable law. </font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">5.&#160;&#160;&#160;&#160;In addition, if Grantee realizes any amounts in excess of what Grantee should have received under the terms of any Restricted Stock Units for any reason due to mistake in calculations or other administrative error, then Grantee shall be required to repay or reimburse any such excess amounts to the Company within thirty (30) days following the Company&#8217;s written demand for repayment.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> Notwithstanding any other provision herein to the contrary, the provisions of this Section II of the Agreement shall be governed by, and construed in accordance with, the laws of the Commonwealth of Kentucky without regard to its conflicts or choice of laws rules or principles that might otherwise refer construction or interpretation of this Section II to the substantive law of another jurisdiction.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Injunctive Relief&#59; Invalidity of Any Provision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  Grantee acknowledges that (1) his or her services to the Company, its subsidiaries, and&#47;or its affiliates are of a special, unique and extraordinary character, (2) his or her position with the Company, its subsidiaries, and&#47;or its affiliates will place him or her in a position of confidence and trust with respect to the operations of the Company, its subsidiaries, and&#47;or its affiliates, (3) he or she will benefit from continued employment with the Company, its subsidiaries, and&#47;or its affiliates, (4) the nature and periods of restrictions imposed by the covenants contained in this Section II are fair, reasonable and necessary to protect the Company, its subsidiaries, and&#47;or its affiliates, (5) the Company, its subsidiaries, and&#47;or its affiliates would sustain immediate and irreparable loss and damage from Grantee&#8217;s wrongful use or disclosure of the Company, its subsidiaries, and&#47;or its affiliates&#8217; confidential information or trade secrets and from Grantee&#8217;s unfair competition or wrongful Solicitation of Protected Relationships, including with respect to the impairment of the Company&#8217;s, its subsidiaries&#8217;, and&#47;or its affiliates&#8217; goodwill in its Protected Relationships, and (6) for the same reason, the Company&#8217;s remedy at law (including under any forfeiture under Section II(F) above) for any such breach will be inadequate.  Accordingly, Grantee agrees and consents that the Company, in addition to the recovery of damages and all other remedies available to it, at law or in equity, shall be entitled to seek temporary, preliminary, and permanent injunctions to prevent and&#47;or halt a breach or threatened breach by Grantee of any covenant contained in Section II hereof.  If any part or provision of this Section II is determined by a court of competent jurisdiction to be invalid in whole or in part, it shall be deemed to have been amended (and the court is authorized to amend), whether as to time, area covered or otherwise, as and to the extent required for its validity under applicable law, and as so amended, shall be enforceable.  The parties further agree to execute all documents necessary to evidence such amendment.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">H.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Notice of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  Grantee agrees that, during the Restricted Period, Grantee will tell any prospective new employer, partner, in a business venture, investors and&#47;or any entity seeking to engage Grantee&#8217;s services, prior to accepting employment, engagement as a consultant or contractor, or engaging in a business venture that this Agreement exists, and further, Grantee agrees to provide a true and correct copy of this Agreement to any such individual or entity prior to accepting any such employment or entering into any such employment or business venture. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Tolling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">In the event Grantee violates one of the time-limited restrictions in Section II of this Agreement, the Company reserves the right to request as a form or equitable relief, and Grantee will not object, that a court of competent jurisdiction extend the time period for such violated restriction by one day for each day Grantee violated the restriction, up to the maximum extension equal to the length of the original period of the time-limited restrictions in Section II of this Agreement.</font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">III.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">MISCELLANEOUS PROVISIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Binding Effect &#38; Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;This Agreement shall be binding and conclusive upon each successor and assign of the Company.  Grantee&#8217;s obligations hereunder shall not be assignable to any other person or entity. It is the intent of the parties to this Agreement that the benefits of any appreciation of the underlying Shares during the term of the Award shall be preserved in any event, including but not limited to a recapitalization, merger, consolidation, reorganization, stock dividend, stock split, reverse stock split, spin-off or similar transaction, or other change in corporate structure affecting the Shares, as more fully described in Sections 4.6 and 11 of the Plan.  All obligations imposed upon Grantee and all rights granted to Grantee and to the Company shall be binding upon Grantee's heirs and legal representatives.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.  This Agreement may only be amended by a writing executed by each of the parties hereto.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  Except as to matters of federal law and the provisions of Section II hereof, this Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware without regard to its conflict of laws rules. This Agreement shall also be governed by, and construed in accordance with, the terms of the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">No Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.  Nothing herein confers on Grantee any rights with respect to the continuance of employment or other service with the Company, nor will it interfere with any right the Company would otherwise have to terminate or modify the terms of Grantee's employment or other service at any time.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">E.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">If any provision of this Agreement is or becomes or is deemed invalid, illegal or unenforceable in any relevant jurisdiction, or would disqualify this Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan, it shall be stricken and the remainder of the Agreement shall remain in full force and effect.</font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">F.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.   </font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Any term used herein and not otherwise defined herein shall have the same meaning as in the Plan.  Any conflict between this Agreement and the Plan will be resolved in favor of the Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Any disputes or questions of right or obligation which shall result from or relate to any interpretation of this Agreement shall be determined by the Committee.  Any such determination shall be binding and conclusive upon Grantee and any person or persons claiming through Grantee as to any rights hereunder.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2.&#160;&#160;&#160;&#160;For the purposes of this Agreement, the following terms shall have the following meaning&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(i) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Change in Control Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means, in the event unvested Restricted Stock Units and DERs are assumed, converted, continued or substituted in connection with a Change in Control in accordance with Section 11.1 of the Plan, if the employment of Grantee is terminated within two years following the Change in Control (a) by the Company or its acquirer or successor for any reason other than Cause or (b) by Grantee with Good Reason.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;(ii) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Competitive Product or Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means any product, process, system or service (in existence or under development) of any person or organization other than the Company that is the same as, similar to, or competes with, a product, process, system or service (in existence or under development) upon which Grantee worked, had direct or indirect responsibilities, or had confidential information about at the Company during the twenty-four (24) months prior to the Grantee&#8217;s Last Day (defined below).</font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iii) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means Grantee or any other person or organization, other than the Company or any of its subsidiaries, engaged in, or about to become engaged in, research or development, production, marketing, leasing, selling, or servicing of a Competitive Product or Service. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iv) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Last Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means Grantee&#8217;s last day of employment with the Company, its subsidiaries, and&#47;or its affiliates (or immediate successor) regardless of the reason for Grantee&#8217;s separation.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;(v) &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Protected Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means, but is not necessarily limited to, vendors, healthcare providers, hospitals, hospital systems, lobbyists, state Medicaid agencies, long-term care facilities, pharmaceutical manufacturers, policyholders, agents, brokers, dealers, distributers, customers, and&#47;or other sources of supply or customers with whom within twenty-four months prior to the Last Day, Grantee, directly or indirectly (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, through employees whom Grantee supervised) had material business contact and&#47;or about whom Grantee obtained confidential information and trade secrets.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;(vi) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Restricted Geographic Area</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means the territory (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#58; (i) state(s), (ii) county(ies), or (iii) city(ies)) in which, during the twenty-four (24) months prior to the Last Day, Grantee provided material services on behalf of the Company (or in which Grantee supervised directly, indirectly, in whole or in part, the servicing activities).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;(vii) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means the period of Grantee&#8217;s employment with the Company, its subsidiaries, and&#47;or its affiliates and a period of twelve (12) months after the Last Day.  Grantee recognizes that the durational term is reasonably and narrowly tailored to the Company&#8217;s, its subsidiaries&#8217;, and&#47;or its affiliates&#8217; legitimate business interest and need for protection with each position.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;(viii) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means to hire, entice, encourage, persuade, recruit, or solicit, or attempt to hire, entice, encourage, persuade, recruit, or solicit, either directly by Grantee or indirectly through another individual. </font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">G.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Execution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">If Grantee shall fail to execute this Agreement, either manually with a paper document, or through the online grant agreement procedure with the Company&#8217;s designated broker&#8211;dealer, and, if manually executed, return the executed original to the Secretary of the Company, the Award shall be null and void.  The choice of form will be at the Company&#8217;s discretion.</font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">H.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;All Restricted Stock Units granted pursuant to this Agreement are intended either to be exempt from Section 409A of the Code, or, if subject to Section 409A of the Code, to be administered, operated and construed in compliance with Section 409A of the Code and any guidance issued thereunder.  This Agreement and the Plan shall be administered in a manner consistent with this intent and any provision that would cause the Agreement or Plan to fail to satisfy the first sentence of this section shall have no force and effect. Notwithstanding anything contained herein to the contrary, Restricted Stock Units (and related DERs) that (a)&#160;constitute &#8220;nonqualified deferred compensation&#8221; as defined under Section&#160;409A of the Code and (b)&#160;vest as a consequence of Grantee&#8217;s termination of employment, shall not be delivered until the date that Grantee incurs a &#8220;separation from service&#8221; within the meaning of Section&#160;409A of the Code (or, if Grantee is a &#8220;specified employee&#8221; within the meaning of Section&#160;409A of the Code and any guidance issued thereunder, the date that is six months and one day following the date of such &#8220;separation from service&#8221; (or on the date of Grantee&#8217;s death, if earlier)).  In addition, each amount to be paid or benefit to be provided to Grantee pursuant to this Agreement that constitutes deferred compensation subject to Section&#160;409A of the Code, shall be construed as a separate identified payment for purposes of Section&#160;409A of the Code.  </font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">GRANTEE CERTIFIES THAT GRANTEE HAS READ AND UNDERSTANDS THIS AGREEMENT AND THE RESTRICTIONS CONTAINED THEREIN, AND HAS HAD AN OPPORTUNITY TO CONSULT WITH LEGAL COUNSEL PRIOR TO SIGNING.  GRANTEE ACKNOWLEDGES THAT THIS AGREEMENT MAY BE ACCEPTED ELECTRONICALLY BY GRANTEE, AND THAT AN ELECTRONIC COPY, HARD COPY, OR ACKNOWLEDGEMENT IS AS ENFORCEABLE AS AN ORIGINAL.  GRANTEE ACKNOWLEDGES THAT GRANTEE HAD ABILITY TO PRINT A COPY OF THIS AGREEMENT AND TIME TO REVIEW IT PRIOR TO SIGNING. </font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, Company has caused this Agreement to be executed on its behalf by its duly authorized officer, and Grantee has executed this Agreement, each as of the day first above written.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#34;Company&#34;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ATTEST&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;HUMANA INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:40.32pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BY&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;BY&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JOSEPH C. VENTURA&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BRUCE D. BROUSSARD</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Chief Legal Officer                                                            President &#38; Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;Grantee&#8221;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:180pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#60;first_name&#62; &#60;middle_name&#62; &#60;last_name&#62;</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:53.28pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.NN
<SEQUENCE>4
<FILENAME>exhibit10nn-annualpsu100at.htm
<DESCRIPTION>EX-10.NN
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i24cfb990530f41e1b4fb8b14522206a0_1"></div><div style="min-height:45.36pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font><br></font></div><div style="padding-left:6.75pt;padding-right:6.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">HUMANA INC.</font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RESTRICTED STOCK UNIT AGREEMENT WITH PERFORMANCE VESTING</font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AND AGREEMENT NOT TO COMPETE OR SOLICIT</font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">UNDER THE AMENDED AND RESTATED STOCK INCENTIVE PLAN</font></div><div style="padding-right:-2.25pt;text-align:center"><font><br></font></div><div style="padding-right:-2.25pt;text-align:center"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">THIS RESTRICTED STOCK UNIT AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#34;Agreement&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">) made as of &#60;award_date&#62; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Date of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">HUMANA INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, a corporation duly organized and existing under the laws of the State of Delaware (hereinafter referred to as the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">), and &#60;first_name&#62; &#60;middle_name&#62; &#60;last_name&#62;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">an employee of the Company (hereinafter referred to as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#34;Grantee&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">).</font></div><div style="padding-right:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;WITNESSETH&#58;</font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> the Amended and Restated Humana Inc. Stock Incentive Plan (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#34;Plan&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">) was approved by the Company's Board of Directors and stockholders&#59; and</font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> the Company desires to award to Grantee Restricted Stock Units in accordance with the Plan.</font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> in consideration of the award of Restricted Stock Units to Grantee, the promises and mutual covenants hereinafter set forth, and other good and valuable consideration, the Company and Grantee agree as follows&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">RESTRICTED STOCK UNIT GRANT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  Subject to the terms and conditions hereinafter set forth, and in accordance with the provisions of the Plan, the Company hereby grants to Grantee, and Grantee hereby accepts from the Company &#60;shares_awarded&#62; Performance-Based Restricted Stock Units (the &#8220;Restricted Stock Units&#8221;) (which represents the target amount of shares available as set out on Appendix A).  Each Restricted Stock Unit represents the right of Grantee to receive (i) one (1) Share on the date of distribution provided for in Section I(E).  In addition, Grantee shall also have the right to receive all of the cash or in-kind dividends that are paid with respect to the Shares represented by the Restricted Stock Units to which this award relates (&#8220;DERs&#8221;).   Dividend equivalents with respect to any such Share shall be paid on the same date that such Share is issued to Grantee pursuant to Section I(E). hereof.  The DERs shall be subject to the same terms and conditions applicable to the Restricted Stock Units, including, without limitation, the restrictions and non-transferability, vesting, forfeiture and distribution provisions contained in Sections I(B) through I(E), inclusive, of this Agreement.  In the event that the Restricted Stock Units are forfeited pursuant to Section I(D) hereof, the related DER shall also be forfeited.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Restrictions and Non-Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  The Restricted Stock Units and DERs may not be sold, transferred, pledged, assigned or otherwise alienated or hypothecated.  In addition, such Restricted Stock Units and DERs shall be subject to forfeiture in accordance with the provisions of Section I(D).  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Vesting of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Subject to the terms set forth below, if as of the third anniversary of the Date of Grant (the &#8220;Vesting Date&#8221;), Grantee and the Company have achieved the performance goals to be set forth in Appendix A, the Restricted Stock Units and related DERs shall vest to the extent such performance goals have been achieved.  Effective on the Vesting Date, any portion of the Restricted Stock Units and the related DERs for which the performance goals set forth in Appendix A have not been satisfied shall be immediately forfeited. However, notwithstanding the foregoing, upon </font></div><div style="height:41.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">certain terminations of employment (as set forth below), all or a portion of the unvested Restricted Stock Units and DERs will vest in accordance with Sections 12 and 13 of the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;Except as set forth in Sections 12 and 13 of the Plan, upon the termination of Grantee's employment with the Company prior to the time the Restricted Stock Units and DERs have vested, the Restricted Stock Units and DERs shall be forfeited immediately by Grantee.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Distributions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.  The Company shall issue to Grantee (or, if applicable, Grantee&#8217;s estate or personal representative) Shares (or such other securities or other property into which the Shares have been converted, with any partial Shares or other securities to be settled in cash) with respect to Grantee&#8217;s Restricted Stock Units and dividend equivalents accrued pursuant to the DERs with respect to such Restricted Stock Units, within 30 days of the date that the Restricted Stock Units vest in accordance with Section I(C) hereof&#59; provided, however, that, to the extent that the Restricted Stock Units are considered deferred compensation subject to Section 409A of the Code and the Restricted Stock Units vest in connection with Grantee&#8217;s Change in Control Termination (defined below), then unless the Change in Control is a Section 409A Change in Control, the distribution of  Shares (or such other securities or other property into which the Shares have been converted) shall not be accelerated to the vesting date but such distribution shall instead occur based on the Vesting Dates set forth in Section I(C) hereof.  A &#8220;Section 409A Change in Control&#8221; shall mean a Change in Control that also constitutes a &#8220;change in ownership or effective control&#8221; of the Company or a &#8220;change in ownership of a substantial portion of the assets of&#8221; the Company, in each case within the meaning of Section 409A of the Code.  Notwithstanding anything to the contrary contained herein, no Shares may be transferred to any person other than Grantee unless such other person demonstrates to the reasonable satisfaction of the Company such person&#8217;s right to the transfer.   </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">F.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.  Federal, state and local income and employment taxes and other amounts as may be required by law to be collected by the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Withholding Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221;) in connection with the distribution of Shares, cash or other property or, to the extent applicable, vesting of the Restricted Stock Units or DERs hereunder, shall be paid by Grantee at such time.  Notwithstanding the foregoing, the Company shall withhold delivery of a number of Shares with a Fair Market Value as of the distribution date equal to the Withholding Taxes required to be withheld in connection with such distribution.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">II.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">AGREEMENT NOT TO COMPETE AND AGREEMENT NOT TO SOLICIT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Grantee agrees and understands that the Company&#8217;s business is a profit-generating business operating in a highly competitive business environment and that the Company has a legitimate business interest in, among other things, its confidential information and trade secrets (including as protected in other agreements and policies between the Company and Grantee) that it is providing Grantee, and in the significant time, money, training, team building and other efforts it expends to develop Grantee&#8217;s skills to assist in performing Grantee&#8217;s duties for the Company, including with respect to establishing, developing and maintaining the goodwill and business relationships with Protected Relationships (defined below) and employees, each of which Grantee agrees are valuable assets of the Company to which it has devoted substantial resources. Grantee acknowledges that the grant Grantee is receiving under the Plan is a meaningful way that the Company entrusts Grantee with its goodwill and aligns Grantee with the Company objective of increasing the value of the Company&#8217;s business.  Accordingly, Grantee acknowledges the importance of protecting the value of the Company&#8217;s </font></div><div style="height:41.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">business through, among other things, covenants to restrict Grantee from engaging in activities that would adversely affect the value of the Company and its goodwill.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Agreement Not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1. &#160;&#160;&#160;&#160;Grantee agrees that during the Restricted Period (defined below) and within the Restricted Geographic Area (defined below), Grantee will not, directly or indirectly, perform or engage in Competitive Product or Services (defined below) with a Competitor (defined below). Grantee may not accept employment with a Competitor (defined below) unless the Competitor&#8217;s business is diversified and the Company receives Written Assurances from the Competitor and Grantee that are satisfactory to the Company that Grantee, during the Restricted Period, will not work on or provide Competitive Products or Services or otherwise use or disclose the Company&#8217;s confidential information or trade secrets.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2. &#160;&#160;&#160;&#160;For Section II(A), such &#8220;Written Assurances&#8221; must contain a written statement detailing the identity of the Competitor and the nature of the services that Grantee will provide to the Competitor with sufficient detail to allow the Company to independently assess whether Grantee is or will be in violation of the Agreement.  The Company must also receive such &#8220;Written Assurances&#8221; at least ten business days before Grantee commences employment for the Competitor.  Such &#8220;Written Assurances&#8221; shall be delivered to the Company&#8217;s Chief Human Resource Officer or his&#47;her authorized delegate.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">3. &#160;&#160;&#160;&#160;Nothing in this Agreement is intended to prevent Grantee from investing Grantee&#8217;s funds in securities of a person engaged in a business that is directly competitive with the Company if the securities of such a person are listed for trading on a registered securities exchange or actively traded in an over-the-counter market and Grantee&#8217;s holdings represent less than one percent (1%) of the total number of outstanding shares or principal amount of the securities of such a person.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Agreement Not to Solicit Protected Relationships</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> During the Restricted Period (defined below) and in connection with a Competitive Product or Service (defined below), Grantee shall not, individually or jointly with others, directly or indirectly, or by assisting others, (1) Solicit (defined below) any Protected Relationships (defined below)&#59; or (2) Solicit any Protected Relationships to terminate a relationship with the Company, its subsidiaries, and&#47;or its affiliates, reduce the volume of their business dealings with the Company, its subsidiaries, and&#47;or its affiliates, or to otherwise cease to accept services or products from the Company, its subsidiaries, and&#47;or its affiliates.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Agreement Not to Solicit Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">During the Restricted Period, Grantee shall not, individually or jointly with others, directly or indirectly, or by assisting others, (1) Solicit any employees or former employees of the Company, its subsidiaries, and&#47;or its affiliates with whom Grantee worked, had business contact, or about which Grantee gained non-public or confidential information (&#8220;Employees or Former Employees&#8221;)&#59; (2) contact or communicate with Employees or Former Employees for the purpose of Soliciting them to terminate their employment or find employment or work with another person or entity&#59; (3) provide, share, or pass along to any person or entity the name, contact and&#47;or background information about any Employees or Former Employees or provide references or any other information about them&#59; (4) provide, share, or pass along to Employees or Former Employees any information regarding potential jobs or entities or persons to work for, including but not limited to job openings, job postings, or the names or contact information of individuals or companies hiring people or accepting job applications&#59; and&#47;or (5) offer employment or work to any Employees or Former Employees.  For purposes of this covenant, &#8220;Former Employees&#8221; shall refer to employees who are </font></div><div style="height:41.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">not employed by the Company, its subsidiaries, and&#47;or its affiliates at the time of the attempted recruiting or hiring, but were employed by, or working for the Company, its subsidiaries, and&#47;or its affiliates in the three months prior to the time of the attempted recruiting or hiring and&#47;or interference.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Effect of a Change in Control Termination on Agreements Not to Compete and Not to Solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.&#160;&#160;&#160;&#160;In the event of a Change in Control Termination, the prohibitions on Grantee set forth in Section II(A) shall remain in full force and effect only if the acquirer or successor to the Company following the Change in Control shall, solely at its option, pay, within thirty (30) days following the Last Day (with the Company or its successor), to Grantee the Non-Compete Payment.  Notwithstanding any previous agreement between Grantee and the Company relating to the prohibitions on Grantee set forth in Section II(A), the &#8220;Non-Compete Payment&#8221; shall be an amount at least equal to Grantee&#8217;s then current annual base salary.  Such amount shall be in addition to any other amounts paid or payable to Grantee with respect to other severance plans or policies maintained by the Company.  For the avoidance of doubt, the provisions of this Section II(D) shall supersede any agreement between Grantee and the Company relating to the prohibitions on Grantee set forth in Section II(A), with the exception of any similar agreement contained in (i) any employment agreement between Grantee and the Company, (ii) any agreement between Grantee and the Company not related to the employment of Grantee by the Company, (iii) any severance plan or policy of the Company and (iv) any change in control severance plan or policy of the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2.&#160;&#160;&#160;&#160;In the event of a Change in Control Termination, the prohibitions on Grantee set forth in Sections II(B) and II(C) shall remain in full force and effect.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">E. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Violation of Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  This subsection sets forth the circumstances under which Grantee shall forfeit all or a portion of any vested or unvested Restricted Stock Units without payment and&#47;or be required to repay or otherwise reimburse the Company any gain or value realized in respect of all or a portion of the Restricted Stock Units.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1. &#160;&#160;&#160;&#160;If Grantee violates any provisions of Section II of this Agreement (a &#8220;Forfeiture Event&#8221;), Grantee shall immediately forfeit as of the date that the violation first occurs all unvested Restricted Stock Units.  This provision does not alter the circumstances for forfeiture of unvested Restricted Stock Units as described in Section I(D) of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2.&#160;&#160;&#160;&#160;For any Restricted Stock Units that vested during the 12 month period prior to the Forfeiture Event or at any time after the Forfeiture event, Grantee shall be required to repay or otherwise reimburse the Company, immediately upon demand, an amount in Cash or Humana Inc. common stock equal to (i) equal to the aggregate Fair Market Value of the shares of Stock underlying such Restricted Stock Units on the date the Restricted Stock Units became vested and (ii) any dividend or DER amounts paid in respect of Shares.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">3.&#160;&#160;&#160;&#160;The relief provided in this Section II(F) of the Agreement does not constitute the Company&#8217;s exclusive remedy for the Grantee&#8217;s violation of any of the provisions of Section II of the Agreement.  As any forfeiture and repayment provisions are not adequate remedies at law, including because they do not repair the irreparable harm the Company will suffer from Grantee&#8217;s breaches of this Agreement, the Company may seek any additional legal or equitable remedy, including injunctive relief, for such violations.  The provisions in this section are essential economic conditions to the Company&#8217;s grant of Restricted Stock Units.  By receiving the Restricted Stock Units, Grantee agrees upon Grantee&#8217;s </font></div><div style="height:41.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">violation of Section II of this Agreement that the Company may, subject to applicable state law, deduct from any amounts the Company owes Grantee following the Last Day any amounts Grantee owes the Company under Section II(F). </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">4.&#160;&#160;&#160;&#160;The provisions under this Section II(F) of the Agreement and any amounts repayable by Grantee hereunder are intended to be in addition to any rights to repayment the Company may have under Section 304 of the Sarbanes-Oxley Act of 2002 and other applicable law. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">5.&#160;&#160;&#160;&#160;In addition, if Grantee realizes any amounts in excess of what Grantee should have received under the terms of any Restricted Stock Units for any reason due to mistake in calculations or other administrative error, then Grantee shall be required to repay or reimburse any such excess amounts to the Company within thirty (30) days following the Company&#8217;s written demand for repayment.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> Notwithstanding any other provision herein to the contrary, the provisions of this Section II of the Agreement shall be governed by, and construed in accordance with, the laws of the Commonwealth of Kentucky without regard to its conflicts or choice of laws rules or principles that might otherwise refer construction or interpretation of this Section II to the substantive law of another jurisdiction.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Injunctive Relief&#59; Invalidity of Any Provision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  Grantee acknowledges that (1) his or her services to the Company, its subsidiaries, and&#47;or its affiliates are of a special, unique and extraordinary character, (2) his or her position with the Company, its subsidiaries, and&#47;or its affiliates will place him or her in a position of confidence and trust with respect to the operations of the Company, its subsidiaries, and&#47;or its affiliates, (3) he or she will benefit from continued employment with the Company, its subsidiaries, and&#47;or its affiliates, (4) the nature and periods of restrictions imposed by the covenants contained in this Section II are fair, reasonable and necessary to protect the Company, its subsidiaries, and&#47;or its affiliates, (5) the Company, its subsidiaries, and&#47;or its affiliates would sustain immediate and irreparable loss and damage from Grantee&#8217;s wrongful use or disclosure of the Company, its subsidiaries, and&#47;or its affiliates&#8217; confidential information or trade secrets and from Grantee&#8217;s unfair competition or wrongful Solicitation of Protected Relationships, including with respect to the impairment of the Company&#8217;s, its subsidiaries&#8217;, and&#47;or its affiliates&#8217; goodwill in its Protected Relationships, and (6) for the same reason, the Company&#8217;s remedy at law (including under any forfeiture under Section II(F) above) for any such breach will be inadequate.  Accordingly, Grantee agrees and consents that the Company, in addition to the recovery of damages and all other remedies available to it, at law or in equity, shall be entitled to seek temporary, preliminary, and permanent injunctions to prevent and&#47;or halt a breach or threatened breach by Grantee of any covenant contained in Section II hereof.  If any part or provision of this Section II is determined by a court of competent jurisdiction to be invalid in whole or in part, it shall be deemed to have been amended (and the court is authorized to amend), whether as to time, area covered or otherwise, as and to the extent required for its validity under applicable law, and as so amended, shall be enforceable.  The parties further agree to execute all documents necessary to evidence such amendment.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">H.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Notice of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  Grantee agrees that, during the Restricted Period, Grantee will tell any prospective new employer, partner, in a business venture, investors and&#47;or any entity seeking to engage Grantee&#8217;s services, prior to accepting employment, engagement as a consultant or contractor, or engaging in a business venture that this Agreement exists, and further, Grantee agrees to provide a true and correct copy of this Agreement to any such individual or entity prior to accepting any such employment or entering into any such employment or business venture. </font></div><div style="height:41.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Tolling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">In the event Grantee violates one of the time-limited restrictions in Section II of this Agreement, the Company reserves the right to request as a form or equitable relief, and Grantee will not object, that a court of competent jurisdiction extend the time period for such violated restriction by one day for each day Grantee violated the restriction, up to the maximum extension equal to the length of the original period of the time-limited restrictions in Section II of this Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">III.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">MISCELLANEOUS PROVISIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Binding Effect &#38; Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;This Agreement shall be binding and conclusive upon each successor and assign of the Company.  Grantee&#8217;s obligations hereunder shall not be assignable to any other person or entity. It is the intent of the parties to this Agreement that the benefits of any appreciation of the underlying Shares during the term of the Award shall be preserved in any event, including but not limited to a recapitalization, merger, consolidation, reorganization, stock dividend, stock split, reverse stock split, spin-off or similar transaction, or other change in corporate structure affecting the Shares, as more fully described in Sections 4.6 and 11 of the Plan.  All obligations imposed upon Grantee and all rights granted to Grantee and to the Company shall be binding upon Grantee's heirs and legal representatives.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.  This Agreement may only be amended by a writing executed by each of the parties hereto.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  Except as to matters of federal law and the provisions of Section II hereof, this Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware without regard to its conflict of laws rules. This Agreement shall also be governed by, and construed in accordance with, the terms of the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">No Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.  Nothing herein confers on Grantee any rights with respect to the continuance of employment or other service with the Company, nor will it interfere with any right the Company would otherwise have to terminate or modify the terms of Grantee's employment or other service at any time.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">E.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">If any provision of this Agreement is or becomes or is deemed invalid, illegal or unenforceable in any relevant jurisdiction, or would disqualify this Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan, it shall be stricken and the remainder of the Agreement shall remain in full force and effect.</font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">F.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.   </font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Any term used herein and not otherwise defined herein shall have the same meaning as in the Plan.  Any conflict between this Agreement and the Plan will be resolved in favor of the Plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Any disputes or questions of right or obligation which shall result from or relate to any interpretation of this Agreement shall be determined by the Committee.  Any such determination shall be binding and conclusive upon Grantee and any person or persons claiming through Grantee as to any rights hereunder.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2.&#160;&#160;&#160;&#160;For the purposes of this Agreement, the following terms shall have the following meaning&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(i) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Change in Control Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means, in the event unvested Restricted Stock Units and DERs are assumed, converted, continued or substituted in connection with a Change in Control in accordance with Section 11.1 of the Plan, if the employment of Grantee is terminated within two years following the Change in Control (a) by the Company or its acquirer or successor for any reason other than Cause or (b) by Grantee with Good Reason.</font></div><div style="height:41.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;(ii) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Competitive Product or Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means any product, process, system or service (in existence or under development) of any person or organization other than the Company that is the same as, similar to, or competes with, a product, process, system or service (in existence or under development) upon which Grantee worked, had direct or indirect responsibilities, or had confidential information about at the Company during the twenty-four (24) months prior to the Grantee&#8217;s Last Day (defined below).</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iii) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means Grantee or any other person or organization, other than the Company or any of its subsidiaries, engaged in, or about to become engaged in, research or development, production, marketing, leasing, selling, or servicing of a Competitive Product or Service. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iv) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Last Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means Grantee&#8217;s last day of employment with the Company, its subsidiaries, and&#47;or its affiliates (or immediate successor) regardless of the reason for Grantee&#8217;s separation.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;(v) &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Protected Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means, but is not necessarily limited to, vendors, healthcare providers, hospitals, hospital systems, lobbyists, state Medicaid agencies, long-term care facilities, pharmaceutical manufacturers, policyholders, agents, brokers, dealers, distributers, customers, and&#47;or other sources of supply or customers with whom within twenty-four months prior to the Last Day, Grantee, directly or indirectly (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, through employees whom Grantee supervised) had material business contact and&#47;or about whom Grantee obtained confidential information and trade secrets.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;(vi) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Restricted Geographic Area</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means the territory (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#58; (i) state(s), (ii) county(ies), or (iii) city(ies)) in which, during the twenty-four (24) months prior to the Last Day, Grantee provided material services on behalf of the Company (or in which Grantee supervised directly, indirectly, in whole or in part, the servicing activities).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;(vii) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means the period of Grantee&#8217;s employment with the Company, its subsidiaries, and&#47;or its affiliates and a period of twelve (12) months after the Last Day.  Grantee recognizes that the durational term is reasonably and narrowly tailored to the Company&#8217;s, its subsidiaries&#8217;, and&#47;or its affiliates&#8217; legitimate business interest and need for protection with each position.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;(viii) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means to hire, entice, encourage, persuade, recruit, or solicit, or attempt to hire, entice, encourage, persuade, recruit, or solicit, either directly by Grantee or indirectly through another individual. </font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">G.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Execution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">If Grantee shall fail to execute this Agreement, either manually with a paper document, or through the online grant agreement procedure with the Company&#8217;s designated broker&#8211;dealer, and, if manually executed, return the executed original to the Secretary of the Company, the Award shall be null and void.  The choice of form will be at the Company&#8217;s discretion.</font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">H.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;All Restricted Stock Units granted pursuant to this Agreement are intended either to be exempt from Section 409A of the Code, or, if subject to Section 409A of the Code, to be administered, operated and construed in compliance with Section 409A of the Code and any guidance issued thereunder.  This Agreement and the Plan shall be administered in a manner consistent with this intent and any provision that would cause the Agreement or Plan to fail to satisfy the first sentence of this section shall have no force and effect. Notwithstanding anything contained herein to the contrary, Restricted Stock Units (and related DERs) that (a)&#160;constitute &#8220;nonqualified deferred compensation&#8221; as defined under Section&#160;409A of the Code and (b)&#160;vest as a consequence of Grantee&#8217;s termination of employment, shall not be delivered until the date that Grantee incurs a &#8220;separation from service&#8221; within the meaning of Section&#160;409A of the Code (or, if Grantee is a &#8220;specified employee&#8221; within the meaning of Section&#160;409A of the Code and any guidance issued </font></div><div style="height:41.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-4.5pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">thereunder, the date that is six months and one day following the date of such &#8220;separation from service&#8221; (or on the date of Grantee&#8217;s death, if earlier)).  In addition, each amount to be paid or benefit to be provided to Grantee pursuant to this Agreement that constitutes deferred compensation subject to Section&#160;409A of the Code, shall be construed as a separate identified payment for purposes of Section&#160;409A of the Code.  </font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">GRANTEE CERTIFIES THAT GRANTEE HAS READ AND UNDERSTANDS THIS AGREEMENT AND THE RESTRICTIONS CONTAINED THEREIN, AND HAS HAD AN OPPORTUNITY TO CONSULT WITH LEGAL COUNSEL PRIOR TO SIGNING.  GRANTEE ACKNOWLEDGES THAT THIS AGREEMENT MAY BE ACCEPTED ELECTRONICALLY BY GRANTEE, AND THAT AN ELECTRONIC COPY, HARD COPY, OR ACKNOWLEDGEMENT IS AS ENFORCEABLE AS AN ORIGINAL.  GRANTEE ACKNOWLEDGES THAT GRANTEE HAD ABILITY TO PRINT A COPY OF THIS AGREEMENT AND TIME TO REVIEW IT PRIOR TO SIGNING. </font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, Company has caused this Agreement to be executed on its behalf by its duly authorized officer, and Grantee has executed this Agreement, each as of the day first above written.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#34;Company&#34;</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ATTEST&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;HUMANA INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BY&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;BY&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JOSEPH C. VENTURA&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BRUCE D. BROUSSARD</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Chief Legal Officer&#160;&#160;&#160;&#160;                                                    President &#38; Chief Executive Officer</font></div><div style="padding-right:-18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;Grantee&#8221;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#60;first_name&#62; &#60;middle_name&#62; &#60;last_name&#62;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:41.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i24cfb990530f41e1b4fb8b14522206a0_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.OO
<SEQUENCE>5
<FILENAME>exhibit10oo-annualiso3yr33.htm
<DESCRIPTION>EX-10.OO
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ie26bb14c361141debf6e73273b91f334_1"></div><div style="min-height:47.52pt;width:100%"><div><font><br></font></div></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">HUMANA INC.</font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INCENTIVE STOCK OPTION AGREEMENT</font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AND AGREEMENT NOT TO COMPETE OR SOLICIT</font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">UNDER THE AMENDED AND RESTATED STOCK INCENTIVE PLAN</font></div><div style="padding-right:-2.25pt;text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">THIS AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#8220;Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">) made as of &#60;award_date&#62; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Date of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">HUMANA INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, a corporation duly organized and existing under the laws of the State of Delaware (hereinafter referred to as the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">), and &#60;first_name&#62; &#60;middle_name&#62; &#60;last_name&#62;, an employee of the Company (hereinafter referred to as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#34;Optionee&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">).</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;WITNESSETH</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> the Amended and Restated Humana Inc. Stock Incentive Plan (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#34;Plan&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">), was approved by the Company&#8217;s Board of Directors and stockholders&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> the Company desires to grant to Optionee an option to purchase shares of common stock of the Company in accordance with the Plan&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> in consideration of the premises and mutual covenants hereinafter set forth, and other good and valuable consideration, the Company and Optionee agree as follows&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">OPTION GRANT</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">The Company hereby grants to Optionee, as a matter of separate inducement and agreement and not in lieu of salary or other compensation for services, an Incentive Stock Option to purchase &#60;shares_awarded&#62; shares of the $.16-2&#47;3 par value common stock of the Company (&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#34;) at the purchase price of $&#60;award_price&#62; per share (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#34;) exercisable on the terms and conditions set forth herein.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">The term of the Option shall commence upon the Date of Grant, and shall expire on &#60;expire_Date&#62; (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#8220;Expiration Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">).</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Vesting of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.  Except as otherwise set forth herein, the Option shall be exercisable by Optionee or his&#47;her personal representative on and after the first anniversary of the Date of Grant in cumulative annual installments of one-third of the number of Shares covered hereby.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Effect of Termination of Employment on Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> If the employment of Optionee by the Company is terminated for Cause, all the rights of Optionee under this Agreement, whether or not exercisable, shall terminate immediately.  If the employment of Optionee is terminated for any reason other than for Cause, the Option shall vest and remain exercisable in accordance with Sections 12 and 13 of the Plan, but in no event beyond the Expiration Date.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">E.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1. &#160;&#160;&#160;&#160;The Option shall be exercisable only by written notice to the Secretary of the Company at the Company's principal executive offices, or through the online procedure to such broker-dealer as designated by the Company, Optionee or his&#47;her legal representative as herein provided.  Such notice shall state the number of Shares with respect to which the Option is being exercised and shall be signed, or authorized electronically, by Optionee or his&#47;her legal representative, as applicable.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2. &#160;&#160;&#160;&#160;The purchase price shall be paid as follows&#58; (i) In full in cash upon the exercise of the Option&#59; (ii) By tendering to the Company Shares owned by Optionee prior to the date of exercise and having an aggregate Fair Market Value equal to the cash exercise price applicable to the Option&#59; or (iii) A combination of I(E)(2)(i) and I(E)(2)(ii) above.</font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:47.52pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">3. &#160;&#160;&#160;&#160;Federal, state and local income and employment taxes and other amounts as may be required by law to be collected by the Company (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#8220;Withholding Taxes&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">) in connection with the exercise of the Option shall be paid pursuant to the Plan by Optionee prior to the delivery of any Common Stock under this Agreement.  The Company shall, at Optionee&#8217;s election, withhold delivery of a number of Shares with a Fair Market Value as of the exercise date equal to the Withholding Taxes in satisfaction of Optionee&#8217;s obligations hereunder.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">II.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">AGREEMENT NOT TO COMPETE AND AGREEMENT NOT TO SOLICIT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Optionee agrees and understands that the Company&#8217;s business is a profit-generating business operating in a highly competitive business environment and that the Company has a legitimate business interest in, among other things, its confidential information and trade secrets (including as protected in other agreements and policies between the Company and Optionee) that it is providing Optionee, and in the significant time, money, training, team building and other efforts it expends to develop Optionee&#8217;s skills to assist in performing Optionee&#8217;s duties for the Company, including with respect to establishing, developing and maintaining the goodwill and business relationships with Protected Relationships (defined below) and employees, each of which Optionee agrees are valuable assets of the Company to which it has devoted substantial resources. Optionee acknowledges that the grant Optionee is receiving under the Plan is a meaningful way that the Company entrusts Optionee with its goodwill and aligns Optionee with the Company objective of increasing the value of the Company&#8217;s business.  Accordingly, Optionee acknowledges the importance of protecting the value of the Company&#8217;s business through, among other things, covenants to restrict Optionee from engaging in activities that would adversely affect the value of the Company and its goodwill.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Agreement Not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1. &#160;&#160;&#160;&#160;Optionee agrees that during the Restricted Period (defined below) and within the Restricted Geographic Area (defined below), Optionee will not, directly or indirectly, perform or engage in Competitive Product or Services (defined below) with a Competitor (defined below). Optionee may not accept employment with a Competitor (defined below) unless the Competitor&#8217;s business is diversified and the Company receives Written Assurances from the Competitor and Optionee that are satisfactory to the Company that Optionee, during the Restricted Period, will not work on or provide Competitive Products or Services or otherwise use or disclose the Company&#8217;s confidential information or trade secrets.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2. &#160;&#160;&#160;&#160;For Section II(A), such &#8220;Written Assurances&#8221; must contain a written statement detailing the identity of the Competitor and the nature of the services that Optionee will provide to the Competitor with sufficient detail to allow the Company to independently assess whether Optionee is or will be in violation of the Agreement.  The Company must also receive such &#8220;Written Assurances&#8221; at least ten business days before Optionee commences employment for the Competitor.  Such &#8220;Written Assurances&#8221; shall be delivered to the Company&#8217;s Chief Human Resource Officer or his&#47;her authorized delegate.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">3. &#160;&#160;&#160;&#160;Nothing in this Agreement is intended to prevent Optionee from investing Optionee&#8217;s funds in securities of a person engaged in a business that is directly competitive with the Company if the securities of such a person are listed for trading on a registered securities exchange or actively traded in an over-the-counter market and Optionee&#8217;s holdings represent less than one percent (1%) of the total number of outstanding shares or principal amount of the securities of such a person.</font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:47.52pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;B. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Agreement Not to Solicit Protected Relationships</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> During the Restricted Period (defined below) and in connection with a Competitive Product or Service (defined below), Optionee shall not, individually or jointly with others, directly or indirectly, or by assisting others, (1) Solicit (defined below) any Protected Relationships (defined below)&#59; or (2) Solicit any Protected Relationships to terminate a relationship with the Company, its subsidiaries, and&#47;or its affiliates, reduce the volume of their business dealings with the Company, its subsidiaries, and&#47;or its affiliates, or to otherwise cease to accept services or products from the Company, its subsidiaries, and&#47;or its affiliates.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Agreement Not to Solicit Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">During the Restricted Period, Optionee shall not, individually or jointly with others, directly or indirectly, or by assisting others, (1) Solicit any employees or former employees of the Company, its subsidiaries, and&#47;or its affiliates with whom Optionee worked, had business contact, or about which Optionee gained non-public or confidential information (&#8220;Employees or Former Employees&#8221;)&#59; (2) contact or communicate with Employees or Former Employees for the purpose of Soliciting them to terminate their employment or find employment or work with another person or entity&#59; (3) provide, share, or pass along to any person or entity the name, contact and&#47;or background information about any Employees or Former Employees or provide references or any other information about them&#59; (4) provide, share, or pass along to Employees or Former Employees any information regarding potential jobs or entities or persons to work for, including but not limited to job openings, job postings, or the names or contact information of individuals or companies hiring people or accepting job applications&#59; and&#47;or (5) offer employment or work to any Employees or Former Employees.  For purposes of this covenant, &#8220;Former Employees&#8221; shall refer to employees who are not employed by the Company, its subsidiaries, and&#47;or its affiliates at the time of the attempted recruiting or hiring, but were employed by, or working for the Company, its subsidiaries, and&#47;or its affiliates in the three months prior to the time of the attempted recruiting or hiring and&#47;or interference.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Effect of a Change in Control Termination on Agreements Not to Compete and Not to Solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.&#160;&#160;&#160;&#160; In the event of a Change in Control Termination, the prohibitions on Optionee set forth in Section II(A) shall remain in full force and effect only if the acquirer or successor to the Company following the Change in Control shall, solely at its option, pay, within thirty (30) days following the Last Day (with the Company or its successor), to Optionee the Non-Compete Payment.  Notwithstanding any previous agreement between Optionee and the Company relating to the prohibitions on Optionee set forth in Section II(A), the &#8220;Non-Compete Payment&#8221; shall be an amount at least equal to Optionee&#8217;s then current annual base salary.  Such amount shall be in addition to any other amounts paid or payable to Optionee with respect to other severance plans or policies maintained by the Company.  For the avoidance of doubt, the provisions of this Section II(D) shall supersede any agreement between Optionee and the Company relating to the prohibitions on Optionee set forth in Section II(A), with the exception of any similar agreement contained in (i) any employment agreement between Optionee and the Company, (ii) any agreement between Optionee and the Company not related to the employment of Optionee by the Company, (iii) any severance plan or policy of the Company and (iv) any change in control severance plan or policy of the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2.&#160;&#160;&#160;&#160;In the event of a Change in Control Termination, the prohibitions on Optionee set forth in Sections II(B) and II(C) shall remain in full force and effect.</font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:47.52pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">E. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Violation of Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  This subsection sets forth the circumstances under which Optionee shall forfeit all or a portion of any vested or unvested Options held by Optionee without payment and&#47;or be required to repay or otherwise reimburse the Company for the gain or value realized in respect of all or a portion of any exercised Options.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1. &#160;&#160;&#160;&#160;If Optionee violates any provisions of Section II of this Agreement (a &#8220;Forfeiture Event&#8221;), Optionee shall immediately forfeit as of the date that the violation first occurs all unexercised Options described above in Section I(A) (whether vested or unvested) without payment.  This provision does not alter the circumstances for forfeiture of unexercised Options as described in Section I(D) of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2.&#160;&#160;&#160;&#160;If Optionee has exercised any of the Options prior to the Forfeiture Event, then for any Option that has been exercised during the 12 month period prior to the Forfeiture Event or at any time after the Forfeiture event, Optionee shall be required to repay or otherwise reimburse the Company, immediately upon demand, an amount in Cash or Humana Inc. common stock equal to the amount described below. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">To the extent that (i) any Shares related to exercised Options have been sold or transferred, the amount shall be the aggregate gross proceeds realized by Optionee from such sale or transfer of the net Shares acquired after payment of the exercise price and any applicable taxes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Net Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221;) (or, in the case of any disposition or transfer of the Net Shares for less than the Fair Market Value of such Net Shares, Optionee will repay or reimburse to the Company an amount equal to the Fair Market Value of such Net Shares) or (ii) if the Net Shares have not been sold at the time Company demand is made, the amount shall be the aggregate Fair Market Value of the Net Shares on the date the Options were exercised.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">3.&#160;&#160;&#160;&#160;The relief provided in this Section II(F) of the Agreement does not constitute the Company&#8217;s exclusive remedy for the Optionee&#8217;s violation of any of the provisions of Section II of the Agreement.  As any forfeiture and repayment provisions are not adequate remedies at law, including because they do not repair the irreparable harm the Company will suffer from Optionee&#8217;s breaches of this Agreement, the Company may seek any additional legal or equitable remedy, including injunctive relief, for such violations.  The provisions in this section are essential economic conditions to the Company&#8217;s grant of Options.  By receiving the Options, Optionee agrees upon Optionee&#8217;s violation of Section II of this Agreement that the Company may, subject to applicable state law, deduct from any amounts the Company owes Optionee following the Last Day any amounts Optionee owes the Company under Section II(F). </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">4.&#160;&#160;&#160;&#160;The provisions under this Section II(F) of the Agreement and any amounts repayable by Optionee hereunder are intended to be in addition to any rights to repayment the Company may have under Section 304 of the Sarbanes-Oxley Act of 2002 and other applicable law. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">5.&#160;&#160;&#160;&#160;In addition, if Optionee realizes any amounts in excess of what he or she should have received under the terms of any Options for any reason due to mistake in calculations or other administrative error, then Optionee shall be required to repay or reimburse any such excess amounts to the Company within thirty (30) days following the Company&#8217;s written demand for repayment.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> Notwithstanding any other provision herein to the contrary, the provisions of this Section II of the Agreement shall be governed by, and construed in accordance with, the laws of the Commonwealth of </font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:47.52pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Kentucky without regard to its conflicts or choice of laws rules or principles that might otherwise refer construction or interpretation of this Section II to the substantive law of another jurisdiction.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Injunctive Relief&#59; Invalidity of Any Provision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  Optionee acknowledges that (1) his or her services to the Company, its subsidiaries, and&#47;or its affiliates are of a special, unique and extraordinary character, (2) his or her position with the Company, its subsidiaries, and&#47;or its affiliates will place him or her in a position of confidence and trust with respect to the operations of the Company, its subsidiaries, and&#47;or its affiliates, (3) he or she will benefit from continued employment with the Company, its subsidiaries, and&#47;or its affiliates, (4) the nature and periods of restrictions imposed by the covenants contained in this Section II are fair, reasonable and necessary to protect the Company, its subsidiaries, and&#47;or its affiliates, (5) the Company, its subsidiaries, and&#47;or its affiliates would sustain immediate and irreparable loss and damage from Optionee&#8217;s wrongful use or disclosure of the Company, its subsidiaries, and&#47;or its affiliates&#8217; confidential information or trade secrets and from Optionee&#8217;s unfair competition or wrongful Solicitation of Protected Relationships, including with respect to the impairment of the Company&#8217;s, its subsidiaries&#8217;, and&#47;or its affiliates&#8217; goodwill in its Protected Relationships, and (6) for the same reason, the Company&#8217;s remedy at law (including under any forfeiture under Section II(F) above) for any such breach will be inadequate.  Accordingly, Optionee agrees and consents that the Company, in addition to the recovery of damages and all other remedies available to it, at law or in equity, shall be entitled to seek temporary, preliminary, and permanent injunctions to prevent and&#47;or halt a breach or threatened breach by Optionee of any covenant contained in Section II hereof.  If any part or provision of this Section II is determined by a court of competent jurisdiction to be invalid in whole or in part, it shall be deemed to have been amended (and the court is authorized to amend), whether as to time, area covered or otherwise, as and to the extent required for its validity under applicable law, and as so amended, shall be enforceable.  The parties further agree to execute all documents necessary to evidence such amendment.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">H.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Notice of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  Optionee agrees that, during the Restricted Period, Optionee will tell any prospective new employer, partner, in a business venture, investors and&#47;or any entity seeking to engage Optionee&#8217;s services, prior to accepting employment, engagement as a consultant or contractor, or engaging in a business venture that this Agreement exists, and further, Optionee agrees to provide a true and correct copy of this Agreement to any such individual or entity prior to accepting any such employment or entering into any such employment or business venture. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Tolling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">In the event Optionee violates one of the time-limited restrictions in Section II of this Agreement, the Company reserves the right to request as a form or equitable relief, and Optionee will not object, that a court of competent jurisdiction extend the time period for such violated restriction by one day for each day Optionee violated the restriction, up to the maximum extension equal to the length of the original period of the time-limited restrictions in Section II of this Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">III.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">MISCELLANEOUS PROVISIONS</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Binding Effect &#38; Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;This Agreement shall be binding and conclusive upon each successor and assign of the Company.  Optionee&#8217;s obligations hereunder shall not be assignable to any other person or entity. It is the intent of the parties to this Agreement that the benefits of any appreciation of the underlying Common Stock during the term of the Award shall be preserved in any event, including but not limited to a recapitalization, merger, consolidation, </font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:47.52pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">reorganization, stock dividend, stock split, reverse stock split, spin-off or similar transaction, or other change in corporate structure affecting the Shares, as more fully described in Sections 4.6 and 11 of the Plan.  All obligations imposed upon Optionee and all rights granted to Optionee and to the Company shall be binding upon Optionee's heirs and legal representatives.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.  This Agreement may only be amended by a writing executed by each of the parties hereto.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  Except as to matters of federal law and the provisions of Section II hereof, this Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware without regard to its conflict of laws rules. This Agreement shall also be governed by, and construed in accordance with, the terms of the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Jurisdiction&#59; Service of Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.  Any action or proceeding seeking to enforce any provision of, or based on any right arising out of, this Agreement may be brought against any of the parties in the courts of the Commonwealth of Kentucky, County of Jefferson, or, if it has or can acquire jurisdiction, in the United States District Court for the Western District of Kentucky, and each of the parties consents to the jurisdiction of such courts (and of the appropriate appellate courts) in any such action or proceeding and waives any objection to venue laid therein.  Process in any action or proceeding referred to in the preceding sentence may be served on any party anywhere in the world.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">No Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.  Nothing herein confers on Optionee any rights with respect to the continuance of employment or other service with the Company, nor will it interfere with any right the Company would otherwise have to terminate or modify the terms of Optionee's employment or other service at any time.</font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">F.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">If any provision of this Agreement is or becomes or is deemed invalid, illegal or unenforceable in any relevant jurisdiction, or would disqualify this Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan, it shall be stricken and the remainder of the Agreement shall remain in full force and effect. Any provision in this Agreement determined by competent authority to be in conflict with 422 of the Internal Revenue Code of 1986, as amended, or its successor, in regard to qualifying this Option as an incentive stock option shall be ineffective ab initio to the extent of such conflict. </font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  The Option granted under this Agreement to Optionee may not be assigned, transferred, pledged, alienated or hypothecated in any manner during Optionee's lifetime, but shall be solely and exclusively the right of Optionee to exercise during his&#47;her lifetime.  Should Optionee attempt to assign, transfer, pledge, alienate or hypothecate the Option or any rights hereunder in any manner whatsoever, such action shall constitute a breach of the covenants hereunder and the Company may terminate the Option as to any then unexercised shares.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">H.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.   </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Any term used herein and not otherwise defined herein shall have the same meaning as in the Plan.  Any conflict between this Agreement and the Plan will be resolved in favor of the Plan.  Any disputes or questions of right or obligation which shall result from or relate to any interpretation of this Agreement shall be determined by the Committee.  Any such determination shall be binding and conclusive upon Optionee and any person or persons claiming through Optionee as to any rights hereunder.  </font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:47.52pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;2. &#160;&#160;&#160;&#160;For the purposes of this Agreement, the following terms shall have the following meaning&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Change in Control Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means, in the event the Option is assumed, converted, continued or substituted in connection with a Change in Control in accordance with Section 11.1 of the Plan, if the employment of Optionee is terminated within two (2) years following the Change in Control (a) by the Company or its acquirer or successor for any reason other than Cause or (b) by Optionee with Good Reason.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(ii) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Competitive Product or Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means any product, process, system or service (in existence or under development) of any person or organization other than the Company that is the same as, similar to, or competes with, a product, process, system or service (in existence or under development) upon which Optionee worked or for which Optionee had direct or indirect responsibilities, or had confidential information about at the Company during the twenty-four (24) months prior to the Optionee&#8217;s Last Day (as defined below).</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iii) &#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means Optionee or any other person or organization, other than the Company or any of its subsidiaries, engaged in, or about to become engaged in, research or development, production, marketing, leasing, selling, or servicing of a Competitive Product or Service.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iv)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Last Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means Optionee&#8217;s last day of employment with the Company, its subsidiaries, and&#47;or its affiliates (or immediate successor) regardless of the reason for Optionee&#8217;s separation.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(v)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Protected Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means, but is not necessarily limited to, vendors, healthcare providers, hospitals, hospital systems, lobbyists, long-term care facilities, state Medicaid agencies, pharmaceutical manufacturers, policyholders, agents, brokers, dealers, distributers, customers, and&#47;or sources of supply or customers with whom, within twenty-four (24) months prior to the Last Day, Optionee, directly or indirectly (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, through employees whom Optionee supervised) had material business contact and&#47;or about whom Optionee obtained confidential information and trade secrets.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(vi)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Restricted Geographic Area</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means the territory (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#58; (i) state(s), (ii) county(ies), or (iii) city(ies)) in which, during the twenty-four (24) months prior to the Last Day, Optionee provided material services on behalf of the Company (or in which Optionee supervised directly, indirectly, in whole or in part, the servicing activities). </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(vii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means the period of Optionee&#8217;s employment with the Company, its subsidiaries&#8217;, and&#47;or its affiliates&#8217; and a period of twelve (12) months after the Last Day.  Optionee recognizes that the durational term is reasonably and narrowly tailored to the Company&#8217;s, its subsidiaries&#8217;, and&#47;or its affiliates&#8217; legitimate business interest and need for protection with each position.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(viii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means to hire, entice, encourage, persuade, recruit, or solicit, or attempt to hire, entice, encourage, persuade, recruit, or solicit, either directly by Optionee or indirectly through another individual. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Execution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">If Optionee shall fail to execute this Agreement, either manually with a paper document, or through the online grant agreement procedure with the Company&#8217;s designated broker&#8211;dealer, and, if manually executed, return the executed original to the Secretary of the Company, the Award shall be null and void.  The choice of form will be at the Company&#8217;s discretion.</font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:47.52pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, Company has caused this Agreement to be executed on its behalf by its duly authorized officer, and Optionee has executed this Agreement, each as of the day first above written.</font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#34;Company&#34;</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ATTEST&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;HUMANA INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BY&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;BY&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JOSEPH C. VENTURA&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BRUCE D. BROUSSARD</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Chief Legal Officer                                                           President &#38; Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;Optionee&#8221;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#60;first_name&#62; &#60;middle_name&#62; &#60;last_name&#62;</font></div><div style="padding-left:216pt;text-align:right"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:47.52pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.PP
<SEQUENCE>6
<FILENAME>exhibit10pp-annualnq3yr33n.htm
<DESCRIPTION>EX-10.PP
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ia8a7ac0db71848ff9672f87e3d9593d5_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">HUMANA INC.</font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">STOCK OPTION AGREEMENT</font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">AND AGREEMENT NOT TO COMPETE OR SOLICIT</font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">UNDER THE AMENDED AND RESTATED STOCK INCENTIVE PLAN</font></div><div style="padding-right:-2.25pt;text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">THIS AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#8220;Agreement&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">) made as of &#60;award_date&#62; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Date of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221;) by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">HUMANA INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, a corporation duly organized and existing under the laws of the State of Delaware (hereinafter referred to as the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">), and &#60;first_name&#62; &#60;middle_name&#62; &#60;last_name&#62;, an employee of the Company (hereinafter referred to as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#34;Optionee&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">).</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">WITNESSETH</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> the Amended and Restated Humana Inc. Stock Incentive Plan (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#34;Plan&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">), was approved by the Company&#8217;s Board of Directors and stockholders&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> the Company desires to grant to Optionee an option to purchase shares of common stock of the Company in accordance with the Plan&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">NOW, THEREFORE,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> in consideration of the premises and mutual covenants hereinafter set forth, and other good and valuable consideration, the Company and Optionee agree as follows&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">OPTION GRANT</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">The Company hereby grants to Optionee, as a matter of separate inducement and agreement and not in lieu of salary or other compensation for services, a Non-Qualified Stock Option to purchase &#60;shares_awarded&#62; shares of the $.16-2&#47;3 par value common stock of the Company (&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#34;) at the purchase price of &#60;award_price&#62; per share (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#34;) exercisable on the terms and conditions set forth herein.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">The term of the Option shall commence upon the Date of Grant, and shall expire on &#60;expire_Date&#62;.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Vesting of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.  Except as otherwise set forth herein, the Option shall be exercisable by Optionee or his&#47;her personal representative on and after the first anniversary of the Date of Grant in cumulative annual installments of one-third of the number of Shares covered hereby.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">D.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Effect of Termination of Employment on Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> If the employment of Optionee by the Company is terminated for Cause, all the rights of Optionee under this Agreement, whether or not exercisable, shall terminate immediately.  If the employment of Optionee is terminated for any reason other than for Cause, the Option shall vest and remain exercisable in accordance with Sections 12 and 13 of the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">E.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font></div><div style="height:66.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NQ &#8211; NCNS - RE</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;1.&#160;&#160;&#160;&#160;The Option shall be exercisable only by written notice to the Secretary of the Company at the Company's principal executive offices, or through the online procedure to such broker-dealer as designated by the Company, Optionee or his&#47;her legal representative as herein provided.  Such notice shall state the number of Shares with respect to which the Option is being exercised and shall be signed, or authorized electronically, by Optionee or his&#47;her legal representative, as applicable.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;2. &#160;&#160;&#160;&#160;The purchase price shall be paid as follows&#58; (a) In full in cash upon the exercise of the Option&#59; (b) By tendering to the Company Shares owned by Optionee prior to the date of exercise and having an aggregate Fair Market Value equal to the cash exercise price applicable to the Option&#59; (c) A combination of I(E)(2)(a) and I(E)(2)(b) above&#59; or (d) Through the cashless exercise provisions of the designated broker-dealer as described in the procedures communicated to Optionee by the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">3. &#160;&#160;&#160;&#160;Federal, state and local income and employment taxes and other amounts as may be required by law to be collected by the Company (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#8220;Withholding Taxes&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">) in connection with the exercise of the Option shall be paid pursuant to the Plan by Optionee prior to the delivery of any Common Stock under this Agreement.  The Company shall, at Optionee&#8217;s election, withhold delivery of a number of Shares with a Fair Market Value as of the exercise date equal to the Withholding Taxes in satisfaction of Optionee&#8217;s obligations hereunder.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">II.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">AGREEMENT NOT TO COMPETE AND AGREEMENT NOT TO SOLICIT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Optionee agrees and understands that the Company&#8217;s business is a profit-generating business operating in a highly competitive business environment and that the Company has a legitimate business interest in, among other things, its confidential information and trade secrets (including as protected in other agreements and policies between the Company and Optionee) that it is providing Optionee, and in the significant time, money, training, team building and other efforts it expends to develop Optionee&#8217;s skills to assist in performing Optionee&#8217;s duties for the Company, including with respect to establishing, developing and maintaining the goodwill and business relationships with Protected Relationships (defined below) and employees, each of which Optionee agrees are valuable assets of the Company to which it has devoted substantial resources. Optionee acknowledges that the grant Optionee is receiving under the Plan is a meaningful way that the Company entrusts Optionee with its goodwill and aligns Optionee with the Company objective of increasing the value of the Company&#8217;s business.  Accordingly, Optionee acknowledges the importance of protecting the value of the Company&#8217;s business through, among other things, covenants to restrict Optionee from engaging in activities that would adversely affect the value of the Company and its goodwill.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Agreement Not to Compete</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> </font></div><div style="height:66.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="margin-top:0.95pt;padding-left:0.7pt;padding-right:0.7pt"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1. &#160;&#160;&#160;&#160;Optionee agrees that during the Restricted Period (defined below) and within the Restricted Geographic Area (defined below), Optionee will not, directly or indirectly, perform or engage in Competitive Product or Services (defined below) with a Competitor (defined below). Optionee may not accept employment with a Competitor (defined below) unless the Competitor&#8217;s business is diversified and the Company receives Written Assurances from the Competitor and Optionee that are satisfactory to the Company that Optionee, during the Restricted Period, will not work on or provide Competitive Products or Services or otherwise use or disclose the Company&#8217;s confidential information or trade secrets.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2. &#160;&#160;&#160;&#160;For Section II(A), such &#8220;Written Assurances&#8221; must contain a written statement detailing the identity of the Competitor and the nature of the services that Optionee will provide to the Competitor with sufficient detail to allow the Company to independently assess whether Optionee is or will be in violation of the Agreement.  The Company must also receive such &#8220;Written Assurances&#8221; at least ten business days before Optionee commences employment for the Competitor.  Such &#8220;Written Assurances&#8221; shall be delivered to the Company&#8217;s Chief Human Resource Officer or his&#47;her authorized delegate.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">3. &#160;&#160;&#160;&#160;Nothing in this Agreement is intended to prevent Optionee from investing Optionee&#8217;s funds in securities of a person engaged in a business that is directly competitive with the Company if the securities of such a person are listed for trading on a registered securities exchange or actively traded in an over-the-counter market and Optionee&#8217;s holdings represent less than one percent (1%) of the total number of outstanding shares or principal amount of the securities of such a person.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;B.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Agreement Not to Solicit Protected Relationships</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> During the Restricted Period (defined below) and in connection with a Competitive Product or Service (defined below), Optionee shall not, individually or jointly with others, directly or indirectly, or by assisting others, (1) Solicit (defined below) any Protected Relationships (defined below)&#59; or (2) Solicit any Protected Relationships to terminate a relationship with the Company, its subsidiaries, and&#47;or its affiliates, reduce the volume of their business dealings with the Company, its subsidiaries, and&#47;or its affiliates, or to otherwise cease to accept services or products from the Company, its subsidiaries, and&#47;or its affiliates.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Agreement Not to Solicit Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">During the Restricted Period, Optionee shall not, individually or jointly with others, directly or indirectly, or by assisting others, (1) Solicit any employees or former employees of the Company, its subsidiaries, and&#47;or its affiliates with whom Optionee worked, had business contact, or about which Optionee gained non-public or confidential information (&#8220;Employees or Former Employees&#8221;)&#59; (2) contact or communicate with Employees or Former Employees for the purpose of Soliciting them to terminate their employment or find employment or work with another person or entity&#59; (3) provide, share, or pass along to any person or entity the name, contact and&#47;or background information about any Employees or Former Employees or provide references or any other information about them&#59; (4) provide, share, or pass along to Employees or Former Employees any </font></div><div style="height:66.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="margin-top:0.95pt;padding-left:0.7pt;padding-right:0.7pt"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">information regarding potential jobs or entities or persons to work for, including but not limited to job openings, job postings, or the names or contact information of individuals or companies hiring people or accepting job applications&#59; and&#47;or (5) offer employment or work to any Employees or Former Employees.  For purposes of this covenant, &#8220;Former Employees&#8221; shall refer to employees who are not employed by the Company, its subsidiaries, and&#47;or its affiliates at the time of the attempted recruiting or hiring, but were employed by, or working for the Company, its subsidiaries, and&#47;or its affiliates in the three months prior to the time of the attempted recruiting or hiring and&#47;or interference.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Effect of a Change in Control Termination on Agreements Not to Compete and Not to Solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.&#160;&#160;&#160;&#160; In the event of a Change in Control Termination, the prohibitions on Optionee set forth in Section II(A) shall remain in full force and effect only if the acquirer or successor to the Company following the Change in Control shall, solely at its option, pay, within thirty (30) days following the Last Day (with the Company or its successor), to Optionee the Non-Compete Payment.  Notwithstanding any previous agreement between Optionee and the Company relating to the prohibitions on Optionee set forth in Section II(A), the &#8220;Non-Compete Payment&#8221; shall be an amount at least equal to Optionee&#8217;s then current annual base salary.  Such amount shall be in addition to any other amounts paid or payable to Optionee with respect to other severance plans or policies maintained by the Company.  For the avoidance of doubt, the provisions of this Section II(D) shall supersede any agreement between Optionee and the Company relating to the prohibitions on Optionee set forth in Section II(A), with the exception of any similar agreement contained in (i) any employment agreement between Optionee and the Company, (ii) any agreement between Optionee and the Company not related to the employment of Optionee by the Company, (iii) any severance plan or policy of the Company and (iv) any change in control severance plan or policy of the Company.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2.&#160;&#160;&#160;&#160;In the event of a Change in Control Termination, the prohibitions on Optionee set forth in Sections II(B) and II(C) shall remain in full force and effect.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">E. &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Violation of Restrictive Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  This subsection sets forth the circumstances under which Optionee shall forfeit all or a portion of any vested or unvested Options held by Optionee without payment and&#47;or be required to repay or otherwise reimburse the Company for the gain or value realized in respect of all or a portion of any exercised Options.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1. &#160;&#160;&#160;&#160;If Optionee violates any provisions of Section II of this Agreement (a &#8220;Forfeiture Event&#8221;), Optionee shall immediately forfeit as of the date that the violation first occurs all unexercised Options described above in Section I(A) (whether vested or unvested) without payment.  This provision </font></div><div style="height:66.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="margin-top:0.95pt;padding-left:0.7pt;padding-right:0.7pt"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">does not alter the circumstances for forfeiture of unexercised Options as described in Section I(D) of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2.&#160;&#160;&#160;&#160;If Optionee has exercised any of the Options prior to the Forfeiture Event, then for any Option that has been exercised during the 12 month period prior to the Forfeiture Event or at any time after the Forfeiture event, Optionee shall be required to repay or otherwise reimburse the Company, immediately upon demand, an amount in Cash or Humana Inc. common stock equal to the amount described below. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">To the extent that (i) any Shares related to exercised Options have been sold or transferred, the amount shall be the aggregate gross proceeds realized by Optionee from such sale or transfer of the net Shares acquired after payment of the exercise price and any applicable taxes  (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Net Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221;) (or, in the case of any disposition or transfer of the Net Shares for less than the Fair Market Value of such Net Shares, Optionee will repay or reimburse to the Company an amount equal to the Fair Market Value of such Net Shares) or (ii) if the Net Shares have not been sold at the time Company demand is made, the amount shall be the aggregate Fair Market Value of the Net Shares on the date the Options were exercised.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">3.&#160;&#160;&#160;&#160;The relief provided in this Section II(F) of the Agreement does not constitute the Company&#8217;s exclusive remedy for the Optionee&#8217;s violation of any of the provisions of Section II of the Agreement.  As any forfeiture and repayment provisions are not adequate remedies at law, including because they do not repair the irreparable harm the Company will suffer from Optionee&#8217;s breaches of this Agreement, the Company may seek any additional legal or equitable remedy, including injunctive relief, for such violations.  The provisions in this section are essential economic conditions to the Company&#8217;s grant of Options.  By receiving the Options, Optionee agrees upon Optionee&#8217;s violation of Section II of this Agreement that the Company may, subject to applicable state law, deduct from any amounts the Company owes Optionee following the Last Day any amounts Optionee owes the Company under Section II(F). </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">4.&#160;&#160;&#160;&#160;The provisions under this Section II(F) of the Agreement and any amounts repayable by Optionee hereunder are intended to be in addition to any rights to repayment the Company may have under Section 304 of the Sarbanes-Oxley Act of 2002 and other applicable law. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">5.&#160;&#160;&#160;&#160;In addition, if Optionee realizes any amounts in excess of what he or she should have received under the terms of any Options for any reason due to mistake in calculations or other administrative error, then Optionee shall be required to repay or reimburse any such excess amounts to the Company within thirty (30) days following the Company&#8217;s written demand for repayment.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">F</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%"> Notwithstanding any other provision herein to the contrary, the provisions of this Section II of the Agreement shall be governed by, and construed in accordance with, the </font></div><div style="height:66.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="margin-top:0.95pt;padding-left:0.7pt;padding-right:0.7pt"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">laws of the Commonwealth of Kentucky without regard to Kentucky&#8217;s conflicts or choice of laws rules or principles that might otherwise refer construction or interpretation of this Section II to the substantive law of another jurisdiction.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;G</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Injunctive Relief&#59; Invalidity of Any Provision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  Optionee acknowledges that (1) his or her services to the Company, its subsidiaries, and&#47;or its affiliates are of a special, unique and extraordinary character, (2) his or her position with the Company, its subsidiaries, and&#47;or its affiliates will place him or her in a position of confidence and trust with respect to the operations of the Company, its subsidiaries, and&#47;or its affiliates, (3) he or she will benefit from continued employment with the Company, its subsidiaries, and&#47;or its affiliates, (4) the nature and periods of restrictions imposed by the covenants contained in this Section II are fair, reasonable and necessary to protect the Company, its subsidiaries, and&#47;or its affiliates, (5) the Company, its subsidiaries, and&#47;or its affiliates would sustain immediate and irreparable loss and damage from Optionee&#8217;s wrongful use or disclosure of the Company, its subsidiaries, and&#47;or its affiliates&#8217; confidential information or trade secrets and from Optionee&#8217;s unfair competition or wrongful Solicitation of Protected Relationships, including with respect to the impairment of the Company&#8217;s, its subsidiaries&#8217;, and&#47;or its affiliates&#8217; goodwill in its Protected Relationships, and (6) for the same reason, the Company&#8217;s remedy at law (including under any forfeiture under Section II(F) above) for any such breach will be inadequate.  Accordingly, Optionee agrees and consents that the Company, in addition to the recovery of damages and all other remedies available to it, at law or in equity, shall be entitled to seek temporary, preliminary, and permanent injunctions to prevent and&#47;or halt a breach or threatened breach by Optionee of any covenant contained in Section II hereof.  If any part or provision of this Section II is determined by a court of competent jurisdiction to be invalid in whole or in part, it shall be deemed to have been amended (and the court is authorized to amend), whether as to time, area covered or otherwise, as and to the extent required for its validity under applicable law, and as so amended, shall be enforceable.  The parties further agree to execute all documents necessary to evidence such amendment.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">H.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Notice of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  Optionee agrees that, during the Restricted Period, Optionee will tell any prospective new employer, partner, in a business venture, investors and&#47;or any entity seeking to engage Optionee&#8217;s services, prior to accepting employment, engagement as a consultant or contractor, or engaging in a business venture that this Agreement exists, and further, Optionee agrees to provide a true and correct copy of this Agreement to any such individual or entity prior to accepting any such employment or entering into any such employment or business venture. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Tolling</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">In the event Optionee violates one of the time-limited restrictions in Section II of this Agreement, the Company reserves the right to request as a form or equitable relief, and Optionee will not object, that a court of competent jurisdiction extend the time period for such violated restriction </font></div><div style="height:66.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="margin-top:0.95pt;padding-left:0.7pt;padding-right:0.7pt"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">by one day for each day Optionee violated the restriction, up to the maximum extension equal to the length of the original period of the time-limited restrictions in Section II of this Agreement.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">III.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">MISCELLANEOUS PROVISIONS</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">A.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Binding Effect &#38; Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;This Agreement shall be binding and conclusive upon each successor and assign of the Company.  Optionee&#8217;s obligations hereunder shall not be assignable to any other person or entity. It is the intent of the parties to this Agreement that the benefits of any appreciation of the underlying Common Stock during the term of the Award shall be preserved in any event, including but not limited to a recapitalization, merger, consolidation, reorganization, stock dividend, stock split, reverse stock split, spin-off or similar transaction, or other change in corporate structure affecting the Shares, as more fully described in Sections 4.6 and 11 of the Plan.  All obligations imposed upon Optionee and all rights granted to Optionee and to the Company shall be binding upon Optionee's heirs and legal representatives.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.  This Agreement may only be amended by a writing executed by each of the parties hereto.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  Except as to matters of federal law and the provisions of Section II hereof, this Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware without regard to its conflict of laws rules. This Agreement shall also be governed by, and construed in accordance with, the terms of the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Jurisdiction&#59; Service of Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.  Any action or proceeding seeking to enforce any provision of, or based on any right arising out of, this Agreement may be brought against any of the parties in the courts of the Commonwealth of Kentucky, County of Jefferson, or, if it has or can acquire jurisdiction, in the United States District Court for the Western District of Kentucky, and each of the parties consents to the jurisdiction of such courts (and of the appropriate appellate courts) in any such action or proceeding and waives any objection to venue laid therein.  Process in any action or proceeding referred to in the preceding sentence may be served on any party anywhere in the world.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">No Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">.  Nothing herein confers on Optionee any rights with respect to the continuance of employment or other service with the Company, nor will it interfere with any right the Company would otherwise have to terminate or modify the terms of Optionee's employment or other service at any time.</font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">F.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">If any provision of this Agreement is or becomes or is deemed invalid, illegal or unenforceable in any relevant jurisdiction, or would disqualify this Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to applicable laws or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan, it shall be stricken and the remainder of the </font></div><div style="height:66.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="margin-top:0.95pt;padding-left:0.7pt;padding-right:0.7pt"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="padding-right:-4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Agreement shall remain in full force and effect. Any provision in this Agreement determined by competent authority to be in conflict with 422 of the Internal Revenue Code of 1986, as amended, or its successor, in regard to qualifying this Option as an incentive stock option shall be ineffective ab initio to the extent of such conflict. </font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">  The Option granted under this Agreement to Optionee may not be assigned, transferred, pledged, alienated or hypothecated in any manner during Optionee's lifetime, but shall be solely and exclusively the right of Optionee to exercise during his&#47;her lifetime.  Should Optionee attempt to assign, transfer, pledge, alienate or hypothecate the Option or any rights hereunder in any manner whatsoever, such action shall constitute a breach of the covenants hereunder and the Company may terminate the Option as to any then unexercised shares.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">H.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.   </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">Any term used herein and not otherwise defined herein shall have the same meaning as in the Plan.  Any conflict between this Agreement and the Plan will be resolved in favor of the Plan.  Any disputes or questions of right or obligation which shall result from or relate to any interpretation of this Agreement shall be determined by the Committee.  Any such determination shall be binding and conclusive upon Optionee and any person or persons claiming through Optionee as to any rights hereunder.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">2.&#160;&#160;&#160;&#160;For the purposes of this Agreement, the following terms shall have the following meaning&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Change in Control Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means, in the event the Option is assumed, converted, continued or substituted in connection with a Change in Control in accordance with Section 11.1 of the Plan, if the employment of Optionee is terminated within two (2) years following the Change in Control (a) by the Company or its acquirer or successor for any reason other than Cause or (b) by Optionee with Good Reason.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(ii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Competitive Product or Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means any product, process, system or service (in existence or under development) of any person or organization other than the Company that is the same as, similar to, or competes with, a product, process, system or service (in existence or under development) upon which Optionee worked or for which Optionee had direct or indirect responsibilities, or had confidential information about at the Company during the twenty-four (24) months prior to the Optionee&#8217;s Last Day (as defined below).</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Competitor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means Optionee or any other person or organization, other than the Company or any of its subsidiaries, engaged in, or about to become engaged in, research or development, production, marketing, leasing, selling, or servicing of a Competitive Product or Service.</font></div><div style="height:66.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="margin-top:0.95pt;padding-left:0.7pt;padding-right:0.7pt"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(iv)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Last Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means Optionee&#8217;s last day of employment with the Company, its subsidiaries, and&#47;or its affiliates (or immediate successor)  regardless of the reason for Optionee&#8217;s separation.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(v)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Protected Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means, but is not necessarily limited to, vendors, healthcare providers, hospitals, hospital systems, lobbyists, long-term care facilities, state Medicaid agencies, pharmaceutical manufacturers, policyholders, agents, brokers, dealers, distributers, customers, and&#47;or sources of supply or customers with whom, within twenty-four (24) months prior to the Last Day, Optionee, directly or indirectly (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, through employees whom Optionee supervised) had material business contact and&#47;or about whom Optionee obtained confidential information and trade secrets.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(vi)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Restricted Geographic Area</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means the territory (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:174%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#58; (i) state(s), (ii) county(ies), or (iii) c  ity(ies)) in which, during the twenty-four (24) months prior to the Last Day, Optionee provided material services on behalf of the Company (or in which Optionee supervised directly, indirectly, in whole or in part, the servicing activities).</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(vii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means the period of Optionee&#8217;s employment with the Company, its subsidiaries&#8217;, and&#47;or its affiliates&#8217; and a period of twelve (12) months after the Last Day.  Optionee recognizes that the durational term is reasonably and narrowly tailored to the Company&#8217;s, its subsidiaries&#8217;, and&#47;or its affiliates&#8217; legitimate business interest and need for protection with each position.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">(viii)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">Solicit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">&#8221; means to hire, entice, encourage, persuade, recruit, or solicit, or attempt to hire, entice, encourage, persuade, recruit, or solicit, either directly by Optionee or indirectly through another individual. </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;text-decoration:underline">Execution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">If Optionee shall fail to execute this Agreement, either manually with a paper document, or through the online grant agreement procedure with the Company&#8217;s designated broker&#8211;dealer, and, if manually executed, return the executed original to the Secretary of the Company, the Award shall be null and void.  The choice of form will be at the Company&#8217;s discretion.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:174%">, Company has caused this Agreement to be executed on its behalf by its duly authorized officer, and Optionee has executed this Agreement, each as of the day first above written.</font></div><div style="padding-right:-4.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#34;Company&#34;</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="height:66.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="margin-top:0.95pt;padding-left:0.7pt;padding-right:0.7pt"><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ATTEST&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;HUMANA INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">           </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">BY&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;BY&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">JOSEPH C. VENTURA&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;BRUCE D. BROUSSARD</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Chief Legal Officer                                                               President &#38; Chief Executive Officer</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8220;Optionee&#8221;</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#60;first_name&#62; &#60;middle_name&#62; &#60;last_name</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="height:66.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="margin-top:0.95pt;padding-left:0.7pt;padding-right:0.7pt"><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>7
<FILENAME>hum-20231231x10kxex21.htm
<DESCRIPTION>EX-21
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4453ebe5c02b429baa797e2fa347345f_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 21</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HUMANA INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SUBSIDIARY LIST</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">ALABAMA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mid-South Home Health Agency, LLC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">ARKANSAS</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Regional Health Plan, Inc.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">CALIFORNIA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asian American Home Care, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Health Plan of California, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Healthcare at Home, LLC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">COLORADO</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpine Home Health Care, LLC</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">DELAWARE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Access Home Health of Florida, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amazing Home Health Holdings, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">American Homecare Management Corp.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CDO 1, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CDO 2, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell Care Solutions, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell Certified Healthcare Corp.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell Health Services (Certified), Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell Health Services (USA) LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell Health Services Holding Corp.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell Health Services, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell Home Health Services, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell Pharmacy, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CompBenefits Corporation</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CompBenefits Direct, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conviva Care Solutions, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conviva Care Solutions II, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conviva Group Holdings, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conviva Health Management, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conviva Health MSO of Texas, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conviva Medical Center Management, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eagle NY Rx, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eagle Rx Holdco, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eagle Rx, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Echo Primary Care Holdings, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edge Health MSO, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emphesys, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enclara Pharmacia, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FPG Acquisition Corp.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FPG Acquisition Holdings Corp.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FPG Holding Company, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Go365, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harden Healthcare Holdings, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harden Home Health, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Value Management, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthfield Operating Group, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthfield, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HHS Healthcare Corp.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hospice Pharmacy Solutions, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HP Solutions Holdings, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HUM Provider Holdings, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana at Home, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Digital Health and Analytics Platform Services, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Direct Contracting Entity, Inc.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Government Business, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Innovation Enterprises, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana WellWorks LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HumanaDental, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integracare Holdings, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integracare Intermediate Holdings, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KAH Development 10, L.L.C.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KAH Development 12, L.L.C.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KAH Development 14, L.L.C.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KAH Development 4, L.L.C.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kentucky Homecare Holdings, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kentucky Homecare Parent Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KND Development 50, L.L.C.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mid-South Home Health, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">North Region Providers, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One Home Medical Equipment NC, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One Home Medical Equipment VA, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One Infusion Pharmacy NC, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One Infusion Pharmacy TX, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One Infusion Pharmacy VA, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outcome Resources, </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PBM Holding Co.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PBM Plus Mail Service Pharmacy, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PF Development 10, L.L.C.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PF Development 15, L.L.C.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PF Development 16, L.L.C.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PF Development 21, L.L.C.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PF Development 5, L.L.C.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PF Development 7, L.L.C.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PF Development 9, L.L.C.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharaoh JV, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHH Acquisition Corp.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHHC Acquisition Corp.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary Care Holdings II, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prime West JV Holdings, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Healthcare, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SHC Holding, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transcend Population Health Management II, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trilogy Home Healthcare NE FL, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trilogy Home Healthcare SW FL, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vitality HHS Holdings, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vitality Home Care, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Voyager Home Health, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Voyager Hospicecare, Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">DOMINICAN REPUBLIC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trueshore S.R. I.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">FLORIDA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A &#38; A HomeCare, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredited Home Health of Broward, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Oncology Services, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All About Home Care Management, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Altercare LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Altercare of Palm Beach County, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amazing Home Health Care, Inc. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amicus Medical Center LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amicus Medical Group, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amicus Medical Services Organization, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Care Hope Holdings, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Care Hope Home Health Agency, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Care Partners Home Care, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CarePlus Health Plans, Inc.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell Accountable Care, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell Senior Primary Care (FL), Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CompBenefits Company</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Complex Clinical Management, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conviva Physician Group, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conviva Specialty, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elite Health Medical Centers, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elite Health Primary Care, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FPG Senior Services, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Homecare Holdings, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HUM-e-FL, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana At Home 1, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Dental Company</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Health Insurance Company of Florida, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Medical Plan, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med. Tech. Services of South Florida, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medstar Home Health, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med-Tech Services of Dade, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Med-Tech Services of Palm Beach, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">METCARE of Florida, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metropolitan Health Networks, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M-SAC, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">On the Way Home Care, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One Home Health Holdings, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One Home Medical Equipment, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One Homecare Solutions, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One Homecare Systems, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One Infusion Pharmacy, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One Nursing Care, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One TPA Systems, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality Living Home Health Care LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SeniorBridge Family Companies (FL), Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Home Care, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Florida Cardiology Associates, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trident Home Health, LLC </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trueshore BPO, LLC</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">GEORGIA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital Care Resources of South Carolina, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital Care Resources, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital Health Management Group, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chattahoochee Valley Home Care Services, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chattahoochee Valley Home Health, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHMG Acquisition LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHMG of Atlanta, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHMG of Griffin, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthfield Home Health, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthfield of Southwest Georgia, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthfield of Statesboro, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthfield of Tennessee, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Employers Health Plan of Georgia, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mid-South Home Health of Gadsden, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Care Home Health of Louisburg, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Care Home Health of North Carolina, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Care Home Health of South Carolina, LLC</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">ILLINOIS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CompBenefits Dental, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dental Care Plus Management, Corp.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Benefit Plan of Illinois, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Healthcare Research, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%;text-decoration:underline">IOWA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hawkeye Health Services, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">KENTUCKY</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516-526 West Main Street Condominium Council of Co-Owners, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CHA HMO, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Active Outlook, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Health Plan, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Insurance Company of Kentucky</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana MarketPOINT, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Pharmacy Solutions, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Real Estate Company</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humco, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Dental Concern, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">LOUISIANA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Health Benefit Plan of Louisiana, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergy Home Care-Acadiana Region, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergy Home Care-Capitol Region, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergy Home Care-Central Region, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergy Home Care-Northeastern Region, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergy Home Care-Northshore Region, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergy Home Care-Northwestern Region, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergy Home Care-Southeastern Region, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Synergy, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">MICHIGAN</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell IPA Solutions, LLC </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Medical Plan of Michigan, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prime Accountable Care West, LLC</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">MISSISSIPPI</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gilbert's Home Health Agency, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health Care Affiliates of Central Mississippi, L.L.C.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health Care Affiliates of Mississippi, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health Care Affiliates, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Van Winkle Home Health Care, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">MISSOURI</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Missouri Home Care of Rolla, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NEVADA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nevada Independent Physicians, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southern Nevada Home Health Care, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NEW YORK</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander Infusion, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CenterWell Services of New York, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harris, Rothenberg International Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Health Company of New York, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Insurance Company of New York</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York Healthcare Services, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SeniorBridge Family Companies (NY), Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QC-Medi New York, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality Care - USA, Inc.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NORTH CAROLINA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eastern Carolina Home Health Agency, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare Planning of America, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health Care of Carteret County, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Innovative Financial Group Holdings, LLC</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Innovative Financial Partners, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rees Financial LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TAR Heel Health Care Services, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Lead Store LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Versa Management LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wake Forest Baptist Health Care at Home, LLC</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">OHIO</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Health Plan of Ohio, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hummingbird Coaching Systems LLC</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">PENNSYLVANIA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Medical Plan of Pennsylvania, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">PUERTO RICO</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Health Plans of Puerto Rico, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Insurance of Puerto Rico, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Management Services of Puerto Rico, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana MarketPOINT of Puerto Rico, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">SOUTH CAROLINA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Benefit Plan of South Carolina, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">TENNESSEE</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cariten Health Plan Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PHP Companies, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred Health Partnership, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">TEXAS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aberdeen Holdings, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Able Home Healthcare, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BWB Sunbelt Home Health Services, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California Hospice, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CompBenefits Insurance Company</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corpus Christi Home Care, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DentiCare, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emphesys Insurance Company</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Focus Care Health Resources, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GBA Holding, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GBA West, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia Hospice, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harden Clinical Services, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harden HC Texas Holdco, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harden Healthcare, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harden Hospice, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health of Rural Texas, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Horizon Health Care Services, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana At Home (Dallas), Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana At Home (Houston), Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana At Home (San Antonio), Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana At Home (TLC), Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Benefit Plan of Texas, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Health Plan of Texas, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integracare Home Health Services, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integracare of Albany, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integracare of Athens-Home Health, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integracare of Olney Home Health, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integracare of Texas, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integracare of West Texas-Home Health, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Integracare of Wichita Falls, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lighthouse Hospice - Metroplex, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lighthouse Hospice Management, LLC</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lighthouse Hospice-San Antonio, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One Home Health Holdings CCTX, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One Home Medical Equipment TX, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outreach Health Services of North Texas, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROHC, L.L.C.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas Dental Plans, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vernon Home Health Care Agency, LLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Voyager Acquisition, L.P.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">UTAH</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home Health Services, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Medical Plan of Utah, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">VERMONT</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed Care Indemnity, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">WASHINGTON</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arcadian Health Plan, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">WEST VIRGINIA</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Home Health, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nursing Care-Home Health Agency, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">WISCONSIN</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CareNetwork, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GuidantRx, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Insurance Company</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humana Wisconsin Health Organization Insurance Corporation</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HumanaDental Insurance Company</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Independent Care Health Plan</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>8
<FILENAME>hum-20231231x10kxex23.htm
<DESCRIPTION>EX-23
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i12d28804f3d64ba7ac4da0c6484a788b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statements on Form</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">S-3 (No. 333-254041)</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and Form S-8 (Nos. 033-49305, 333-04435, 333-57095, 333-86801, 333-41408, 333-86280, 333-105622, 333-134887, 333-162747, 333-171616, 333-175350, 333-231154, and 033-264543) of Humana Inc. of our report dated February&#160;15, 2024 relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font></div><div style="text-indent:18pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Louisville, Kentucky </font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;15, 2024 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>hum-20231231x10kxex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i951a1530ef384cb79b6da60501cdd265_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">I, Bruce D. Broussard, principal executive officer of Humana Inc., certify that&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.           I have reviewed this annual report on Form 10-K of Humana Inc.&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.           Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.           The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d) &#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.           The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="padding-left:40.5pt"><font><br></font></div><div style="padding-left:40.5pt"><font><br></font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.091%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.093%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; BRUCE D. BROUSSARD</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bruce D. Broussard<br>Principal Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>hum-20231231x10kxex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="id50cf76352d544fcb0c06923ae4b2ef9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Susan M. Diamond, principal financial officer of Humana Inc., certify that&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. &#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of Humana Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. &#160;&#160;&#160;&#160;Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. &#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. &#160;&#160;&#160;&#160;The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160; Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160; Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) &#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) &#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. &#160;&#160;&#160;&#160;The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) &#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) &#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:9pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:18.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.155%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 15, 2024</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; SUSAN M. DIAMOND</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Susan M. Diamond<br>Principal Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>11
<FILENAME>hum-20231231x10kxex32.htm
<DESCRIPTION>EX-32
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i2bafb2aeea634fbd9c82a7d433597850_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Humana Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned hereby certifies, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Humana Inc., that&#58;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; BRUCE D. BROUSSARD</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bruce D. Broussard<br>Chief Executive Officer (Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> February&#160;15, 2024 </font></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; SUSAN M. DIAMOND</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Susan M. Diamond<br>Chief Financial Officer (Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> February&#160;15, 2024 </font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to Humana Inc. and will be retained by Humana Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>12
<FILENAME>exhibit97-humanarecoupment.htm
<DESCRIPTION>EX-97
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i5cccf29f3caf486c909efcc32186f47d_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">HUMANA INC.<br>COMPENSATION RECOUPMENT POLICY<br>(Effective October 2, 2023)</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This Humana Inc. Compensation Recoupment Policy (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) has been adopted by the Board of Humana Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;). This Policy provides for the recoupment of certain executive compensation in the event of (i) an accounting restatement resulting from material noncompliance with financial reporting requirements under U.S. federal securities laws in accordance with the terms and conditions set forth herein&#59; and&#47;or (ii) the Administrator&#8217;s determination that an Executive has engaged in Improper Conduct within the meaning of this Policy. This Policy is intended to comply with the requirements of Section 10D of the Exchange Act (as defined below) and Section 303A.14 of the NYSE Listed Company Manual. This Compensation Recoupment Policy is intended to supersede and override the Humana Compensation Recoupment Policy which was approved by the Board on February 21, 2019.</font></div><div style="margin-bottom:10pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. For the purposes of this Policy, the following terms shall have the meanings set forth below. </font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Board of Directors of the Company.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Board, the Compensation Committee or such other committee of the Board that, at the relevant time, has authority for making determinations as to the compensation of senior executives. </font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Organization &#38; Compensation Committee of the Board.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Covered Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any current or former Executive Officer.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the U.S. Securities Exchange Act of 1934, as amended. </font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.01pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means, with respect to the Company, any individual who serves as a current or former &#8220;Officer&#8221; within the meaning set forth in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), as applied by the Administrator from time to time. The determination as to an individual&#8217;s status as an Executive Officer shall be made by the Administrator and such determination shall be final, conclusive and binding on such individual and all other interested persons.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Incentive-based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any compensation &#8220;received&#8221; by a Covered Executive during the applicable Recoupment Period&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that&#58;</font></div><div style="margin-bottom:10pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:8.57pt">the compensation is granted, earned and&#47;or vested based wholly or in part upon the achievement of a Financial Reporting Measure (including, for the avoidance of doubt, any cash or equity or equity-based compensation, whether deferred or current). For purposes of this Policy, &#8220;Financial Incentive-based Compensation&#8221; shall also be deemed to include any amounts which were determined based on (or were otherwise calculated by reference to) Financial Incentive-based Compensation (including, without limitation, any amounts under any long-term disability, life insurance or supplemental retirement or severance plan or agreement or any notional account that is based on Financial Incentive-based Compensation, as well as any earnings accrued thereon)&#59;</font></div><div style="margin-bottom:10pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:5.8pt">such Financial Incentive-based Compensation was received by such Covered Executive (A) after October 2, 2023, (B) after he or she commenced service as an Executive Officer and (C) while the Company had a class of securities publicly listed on a United States national securities exchange&#59; and </font></div><div style="margin-bottom:10pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:3.03pt">such Covered Executive served as an Executive Officer at any time during the performance period applicable to such Financial Incentive-based Compensation. </font></div><div style="margin-bottom:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For purposes of this Policy, Financial Incentive-based Compensation is &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">received</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; by a Covered Executive during the fiscal period in which the Financial Reporting Measure applicable to such Financial Incentive-based Compensation (or portion thereof) is attained, even if the payment or grant of such Financial Incentive-based Compensation is made thereafter.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Reporting Measure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any (i) measure that is determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, (ii) stock price measure or (iii)&#160;total shareholder return measure (and any measures that are derived wholly or in part from any measure referenced in clause (i), (ii) or (iii) above). For the avoidance of doubt, any such measure does not need to </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.384%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">be presented within the Company&#8217;s financial statements or included in a filing with the U.S. Securities and Exchange Commission to constitute a Financial Reporting Measure. </font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a restatement of the Company&#8217;s financial statements due to the Company&#8217;s material noncompliance with any financial reporting requirement under U.S. federal securities laws that is required in order to correct&#58;</font></div><div style="margin-bottom:10pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:8.57pt">an error in previously issued financial statements that is material to the previously issued financial statements&#59; or</font></div><div style="margin-bottom:10pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:5.8pt">an error that would result in a material misstatement if (A) the error were corrected in the current period or (B) left uncorrected in the current period. </font></div><div style="margin-bottom:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For purposes of this Policy, a Financial Restatement shall not be deemed to occur in the event of a revision of the Company&#8217;s financial statements due to an out-of-period adjustment (i.e., when the error is immaterial to the previously issued financial statements and the correction of the error is also immaterial to the current period) or a retrospective (1) application of a change in accounting principles&#59; (2) revision to reportable segment information due to a change in the structure of the Company&#8217;s internal organization&#59; (3) reclassification due to a discontinued operation&#59; (4) application of a change in reporting entity, such as from a reorganization of entities under common control&#59; or (5) revision for stock splits, reverse stock splits, stock dividends or other changes in capital structure.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Improper Conduct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the following conduct that, in the sole discretion of the Administrator, is likely to cause or has caused material financial, operational, or reputational harm to the Company, materially disrupt, damage, impair or interfere with the business of the Company or its affiliates, or have a significant, adverse reputational or economic impact on the Company or any of its affiliates or divisions&#58; </font></div><div style="margin-bottom:10pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:8.57pt">the commission of an act of fraud, misappropriation or embezzlement in the course of employment (or actual knowledge of the fraud, misappropriation, or embezzlement in the course of employment of another person)&#59;</font></div><div style="margin-bottom:10pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:5.8pt">the commission of a criminal act, whether or not in the workplace, that in the Administrator&#8217;s sole discretion, constitutes a felony or crime of comparable magnitude&#59;</font></div><div style="margin-bottom:10pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:3.03pt">the material violation of a non-compete, non-solicitation, or confidentiality agreement&#59; or</font></div><div style="margin-bottom:10pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:3.57pt">the willful and material breach of a Covered Executive&#8217;s obligations under the Company&#8217;s code of conduct relating to compliance with law or regulation.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incentive Compensation&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> means (i) Financial Incentive-based Compensation&#59; (ii) time-vesting awards&#59; (iii) compensation awarded on the basis of the achievement of metrics that are not Financial Reporting Measures&#59; and (iv) any compensation awarded solely at the discretion of the Administrator or the Board. </font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(l)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NYSE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the New York Stock Exchange, or any successor thereof.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(m)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.57pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recoupment Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means (i) with respect to a recoupment triggered by a Financial Restatement, the three fiscal years completed immediately preceding the date of any applicable Recoupment Trigger Date and (ii) with respect to a recoupment triggered by Improper Conduct, the three fiscal years immediately preceding the Administrator&#8217;s determination that Improper Conduct has occurred. Notwithstanding the foregoing, with respect to clawbacks triggered by Financial Restatements, the Recoupment Period additionally includes any transition period (that results from a change in the Company&#8217;s fiscal year) within or immediately following those three completed fiscal years, provided that a transition period between the last day of the Company&#8217;s previous fiscal year end and the first day of its new fiscal year that comprises a period of nine (9) to twelve (12) months would be deemed a completed fiscal year.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(n)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Recoupment Trigger Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means (i) with respect to a recoupment triggered by a Financial Restatement, the earlier of (A)&#160;the date that the Board (or a committee thereof or the officer(s) of the Company authorized to take such action if Board action is not required) concludes, or reasonably should have concluded, that the Company is required to prepare a Financial Restatement, and (B) the date on which a court, regulator or other legally authorized body directs the Company to prepare a Financial Restatement&#59; and (ii) with respect to a recoupment triggered by Improper Conduct, the date on which the Administrator determines that the Improper Conduct occurred.</font></div><div style="margin-bottom:10pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt;text-decoration:underline">Recoupment of Erroneously Awarded Compensation in Connection with a Financial Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.384%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">In the event of a Financial Restatement, if the amount of any Financial Incentive-based Compensation received by a Covered Executive on or after October 2, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Awarded Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;) exceeds the amount of such Financial Incentive-based Compensation that would have otherwise been received by such Covered Executive if calculated based on the Financial Restatement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;), the Company shall reasonably promptly recover from such Covered Executive an amount equal to the excess of the Awarded Compensation over the Adjusted Compensation, each calculated on a pre-tax basis (such excess amount, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Erroneously Awarded Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">If (i)&#160;the Financial Reporting Measure applicable to the relevant Financial Incentive-based Compensation is stock price or total shareholder return (or any measure derived wholly or in part from either of such measures) and (ii)&#160;the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in the Financial Restatement, then the amount of Erroneously Awarded Compensation shall be determined (on a pre-tax basis) based on the Company&#8217;s reasonable estimate of the effect of the Financial Restatement on the Company&#8217;s stock price or total shareholder return (or the derivative measure thereof) upon which such Financial Incentive-based Compensation was received. </font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">The Company&#8217;s obligation to recover Erroneously Awarded Compensation is not dependent on (i) if or when the restated financial statements are filed or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii) any fault of any Covered Executive for the accounting errors or other actions leading to a Financial Restatement. </font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">Notwithstanding anything to the contrary in Sections&#160;2(a) through (c) hereof, the Company shall not be required to recover any Erroneously Awarded Compensation if both (x) the conditions set forth in either of the following clauses (i) or (ii) are satisfied and (y) the Administrator (or a majority of the independent directors serving on the Board) has determined that recovery of the Erroneously Awarded Compensation would be impracticable&#58;</font></div><div style="margin-bottom:10pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:8.57pt">the direct expense paid to a third party to assist in enforcing the recovery of the Erroneously Awarded Compensation under this Policy would exceed the amount of such Erroneously Awarded Compensation to be recovered&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that, before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation pursuant to this Section&#160;2(d), the Company shall have first made a reasonable attempt to recover such Erroneously Awarded Compensation, document such reasonable attempt(s) to make such recovery and provide that documentation to the NYSE&#59; or</font></div><div style="margin-bottom:10pt;padding-left:90pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:5.8pt">recovery of the Erroneously Awarded Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Sections 401(a)(13) or 411(a) of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">The Company shall not indemnify any Covered Executive, directly or indirectly, for any losses that such Covered Executive may incur in connection with the recovery of Erroneously Awarded Compensation pursuant to this Policy, including through the payment of insurance premiums or gross-up payments.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.01pt">Notwithstanding anything to the contrary herein, the Company has no obligation to seek recoupment of amounts paid to a Covered Executive which are granted, vested or earned based solely upon the occurrence or non-occurrence of nonfinancial events. Such exempt compensation includes, without limitation, base salary, time-vesting awards, compensation awarded on the basis of the achievement of metrics that are not Financial Reporting Measures or compensation awarded solely at the discretion of the Administrator or the Board, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">such amounts are in no way contingent on, and were not in any way granted on the basis of, the achievement of any Financial Reporting Measure performance goal.</font></div><div style="margin-bottom:10pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt;text-decoration:underline">Recoupment of Incentive Compensation for Improper Conduct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">In the event the Administrator determines that a Covered Executive engaged in Improper Conduct, the Administrator may, in its sole discretion, recover all or any portion of the Incentive Compensation paid to a Covered Executive during the Recoupment Period. </font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">The Administrator may consider any and all facts it considers relevant under all of the circumstances, including without limitation&#58; (A) whether or not the Covered Executive engaged in Improper Conduct&#59; (B) the likelihood of success of any recovery under this Policy under governing law as compared to the cost and effort involved&#59; (C) whether the assertion of a claim may prejudice the interests of the Company, including in any related proceeding or investigation&#59; (D) the passage of time since the occurrence of the Improper Conduct</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> and (E) any pending legal proceeding relating to the Improper Conduct. </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.384%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">In no event will the amount of the Recoverable Incentive exceed the total amount of Incentive Compensation paid or granted during the Applicable Period.</font></div><div style="margin-bottom:10pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">This Policy shall be administered by the Administrator.  All decisions of the Administrator shall be final, conclusive and binding upon the Company and the Covered Executives, their beneficiaries, executors, administrators and any other legal representative. The Administrator shall have full power and authority to (i)&#160;administer and interpret this Policy&#59; (ii) correct any defect, supply any omission and reconcile any inconsistency in this Policy&#59; and (iii) make any other determination and take any other action that the Administrator deems necessary or desirable for the administration of this Policy and to comply with applicable law (including Section 10D of the Exchange Act) and applicable stock market or exchange rules and regulations. Notwithstanding anything to the contrary contained herein, to the extent permitted by Section 10D of the Exchange Act and Section 303A.14 of the NYSE Listed Company Manual, the Board may, in its sole discretion, at any time and from time to time, administer this Policy in the same manner as the Administrator.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">The Administrator shall determine, in its sole discretion, the manner and timing in which any Incentive Compensation shall be recovered from a Covered Executive in accordance with applicable law, including, without limitation, by (i) requiring reimbursement of Financial Incentive-based Compensation previously paid in cash&#59; (ii)seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition of any equity or equity-based awards&#59; (iii) offsetting the Incentive Compensation amount from any compensation otherwise owed by the Company or any of its affiliates to the Covered Executive&#59; (iv) cancelling outstanding vested or unvested equity or equity-based awards&#59; and&#47;or (v) taking any other remedial and recovery action permitted by applicable law. For the avoidance of doubt, except as set forth in Section&#160;2(d), in no event may the Company accept an amount that is less than the amount of Erroneously Awarded Compensation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> that, to the extent necessary to avoid any adverse tax consequences to the Covered Executive pursuant to Section 409A of the Code, any offsets against amounts under any nonqualified deferred compensation plans (as defined under Section 409A of the Code) shall be made in compliance with Section 409A of the Code.</font></div><div style="margin-bottom:10pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt;text-decoration:underline">Amendment&#47;Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Subject to Section 10D of the Exchange Act and Section 303A.14 of the NYSE Listed Company Manual, this Policy may be amended or terminated by the Administrator at any time. To the extent that any applicable law, or stock market or exchange rules or regulations require recovery of Erroneously Awarded Compensation in circumstances in addition to those specified herein, nothing in this Policy shall be deemed to limit or restrict the right or obligation of the Company to recover Erroneously Awarded Compensation to the fullest extent required by such applicable law, stock market or exchange rules and regulations. </font></div><div style="margin-bottom:10pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding anything to the contrary herein, this Policy is intended to comply with the requirements of Section 10D of the Exchange Act and Section 303A.14 of the NYSE Listed Company Manual (and any applicable regulations, administrative interpretations or stock market or exchange rules and regulations adopted in connection therewith). The provisions of this Policy shall be interpreted in a manner that satisfies such requirements and this Policy shall be operated accordingly. If any provision of this Policy would otherwise frustrate or conflict with this intent, the provision shall be interpreted and deemed amended so as to avoid such conflict.</font></div><div style="margin-bottom:10pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt;text-decoration:underline">No Double Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Any amounts recouped or clawed back pursuant to the Company&#8217;s obligation to recover Erroneously Awarded Compensation shall count toward amounts recouped or clawed back pursuant to the Company&#8217;s right to recover Incentive Compensation other than Erroneously Awarded Compensation and vice versa.</font></div><div style="margin-bottom:10pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt;text-decoration:underline">Other Compensation Clawback&#47;Recoupment Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies, rights or requirements with respect to the clawback or recoupment of any compensation that may be available to the Company pursuant to the terms of any other recoupment or clawback policy of the Company (or any of its affiliates) that may be in effect from time to time, any provisions in any employment agreement, offer letter, equity plan, equity award agreement or similar plan or agreement, and any other legal remedies available to the Company, as well as applicable law, stock market or exchange rules, listing standards or regulations&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">, that any amounts recouped or clawed back under any other policy that would be recoupable under this Policy shall count toward any required clawback or recoupment under this Policy and vice versa. </font></div><div style="margin-bottom:10pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt;text-decoration:underline">Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The circumstances of any recoupment of Erroneously Awarded Compensation pursuant to a Financial Restatement will be publicly disclosed where required by Section 10D of the Exchange Act, Items 402 and 601(b) of Regulation S-K and Section 303A.14 of the NYSE Listed Company Manual. For the avoidance of doubt, the Company has no obligation pursuant to this Policy to publicly disclose any recoupment of Incentive Compensation that is not Erroneously Awarded Compensation. </font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.384%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt"><font><br></font></div></td></tr></table></div></div><div style="margin-bottom:10pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:5.5pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">Any applicable award agreement or other document setting forth the terms and conditions of any compensation covered by this Policy shall be deemed to include the restrictions imposed herein and incorporate this Policy by reference and, in the event of any inconsistency, the terms of this Policy will govern. For the avoidance of doubt, this Policy applies to all compensation that is received on or after (i) October 2, 2023, with respect to a recoupment triggered by a Financial Restatement or (ii) February 21, 2019, with respect to a recoupment triggered by Improper Conduct, regardless of the date on which the award agreement or other document setting forth the terms and conditions of the Covered Executive&#8217;s compensation became effective, including, without limitation, compensation received under the Humana Inc. 2011 Stock Incentive Plan, the 2019 Amended and Restated Humana Inc. Stock Incentive Plan, the Humana Inc. Executive Incentive Compensation Plan and any successor plan to each of the foregoing. </font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.34pt">This Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.</font></div><div style="margin-bottom:10pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:24.91pt">If any provision of this Policy is determined to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted by applicable law and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:84.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>hum-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:7bfbafa3-a477-4092-82f1-790bd65455d7,g:6b53bb4a-2282-4b95-aa2c-e78c6730e17d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:hum="http://www.humana.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.humana.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hum-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hum-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hum-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hum-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.humana.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.humana.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.humana.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOW" roleURI="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOW</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REPORTINGENTITY" roleURI="http://www.humana.com/role/REPORTINGENTITY">
        <link:definition>0000009 - Disclosure - REPORTING ENTITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSANDDIVESTITURES" roleURI="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURES">
        <link:definition>0000011 - Disclosure - ACQUISITIONS AND DIVESTITURES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYMETHODINVESTMENT" roleURI="http://www.humana.com/role/EQUITYMETHODINVESTMENT">
        <link:definition>0000012 - Disclosure - EQUITY METHOD INVESTMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSECURITIES" roleURI="http://www.humana.com/role/INVESTMENTSECURITIES">
        <link:definition>0000013 - Disclosure - INVESTMENT SECURITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUE" roleURI="http://www.humana.com/role/FAIRVALUE">
        <link:definition>0000014 - Disclosure - FAIR VALUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MEDICAREPARTD" roleURI="http://www.humana.com/role/MEDICAREPARTD">
        <link:definition>0000015 - Disclosure - MEDICARE PART D</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNET" roleURI="http://www.humana.com/role/PROPERTYANDEQUIPMENTNET">
        <link:definition>0000016 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETS" roleURI="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETS">
        <link:definition>0000017 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.humana.com/role/LEASES">
        <link:definition>0000018 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BENEFITSPAYABLE" roleURI="http://www.humana.com/role/BENEFITSPAYABLE">
        <link:definition>0000019 - Disclosure - BENEFITS PAYABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.humana.com/role/INCOMETAXES">
        <link:definition>0000020 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://www.humana.com/role/DEBT">
        <link:definition>0000021 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANS" roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANS">
        <link:definition>0000022 - Disclosure - EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERCOMMONSHARECOMPUTATION" roleURI="http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATION">
        <link:definition>0000023 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.humana.com/role/STOCKHOLDERSEQUITY">
        <link:definition>0000024 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSGUARANTEESANDCONTINGENCIES" roleURI="http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIES">
        <link:definition>0000025 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.humana.com/role/SEGMENTINFORMATION">
        <link:definition>0000026 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REINSURANCE" roleURI="http://www.humana.com/role/REINSURANCE">
        <link:definition>0000027 - Disclosure - REINSURANCE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIPARENTCOMPANYFINANCIALINFORMATION" roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATION">
        <link:definition>0000028 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSANDDIVESTITURESTables" roleURI="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESTables">
        <link:definition>9954473 - Disclosure - ACQUISITIONS AND DIVESTITURES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYMETHODINVESTMENTTables" roleURI="http://www.humana.com/role/EQUITYMETHODINVESTMENTTables">
        <link:definition>9954474 - Disclosure - EQUITY METHOD INVESTMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSECURITIESTables" roleURI="http://www.humana.com/role/INVESTMENTSECURITIESTables">
        <link:definition>9954475 - Disclosure - INVESTMENT SECURITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUETables" roleURI="http://www.humana.com/role/FAIRVALUETables">
        <link:definition>9954476 - Disclosure - FAIR VALUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MEDICAREPARTDTables" roleURI="http://www.humana.com/role/MEDICAREPARTDTables">
        <link:definition>9954477 - Disclosure - MEDICARE PART D (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNETTables" roleURI="http://www.humana.com/role/PROPERTYANDEQUIPMENTNETTables">
        <link:definition>9954478 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSTables" roleURI="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables">
        <link:definition>9954479 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.humana.com/role/LEASESTables">
        <link:definition>9954480 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BENEFITSPAYABLETables" roleURI="http://www.humana.com/role/BENEFITSPAYABLETables">
        <link:definition>9954481 - Disclosure - BENEFITS PAYABLE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.humana.com/role/INCOMETAXESTables">
        <link:definition>9954482 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://www.humana.com/role/DEBTTables">
        <link:definition>9954483 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSTables" roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSTables">
        <link:definition>9954484 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERCOMMONSHARECOMPUTATIONTables" roleURI="http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONTables">
        <link:definition>9954485 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.humana.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>9954486 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.humana.com/role/SEGMENTINFORMATIONTables">
        <link:definition>9954487 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REPORTINGENTITYDetails" roleURI="http://www.humana.com/role/REPORTINGENTITYDetails">
        <link:definition>9954488 - Disclosure - REPORTING ENTITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails_1" roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails_1">
        <link:definition>9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPartDSubsidyDiscountPaymentsNetDetails" roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPartDSubsidyDiscountPaymentsNetDetails">
        <link:definition>9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Part D Subsidy/Discount Payments, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESHealthCareCostPaymentsNetDetails" roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESHealthCareCostPaymentsNetDetails">
        <link:definition>9954491 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Health Care Cost Payments, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSANDDIVESTITURESNarrativeDetails" roleURI="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails">
        <link:definition>9954492 - Disclosure - ACQUISITIONS AND DIVESTITURES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails" roleURI="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails">
        <link:definition>9954493 - Disclosure - ACQUISITIONS AND DIVESTITURES - Assets, Liabilities And Noncontrolling Interest Disposed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYMETHODINVESTMENTNarrativeDetails" roleURI="http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails">
        <link:definition>9954494 - Disclosure - EQUITY METHOD INVESTMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails" roleURI="http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails">
        <link:definition>9954495 - Disclosure - EQUITY METHOD INVESTMENT - Summarized Balance Sheets and Statements of Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails" roleURI="http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails">
        <link:definition>9954496 - Disclosure - INVESTMENT SECURITIES - Classified as Current and Long-Term (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSECURITIESNarrativeDetails" roleURI="http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails">
        <link:definition>9954497 - Disclosure - INVESTMENT SECURITIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" roleURI="http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails">
        <link:definition>9954498 - Disclosure - INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails" roleURI="http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails">
        <link:definition>9954499 - Disclosure - INVESTMENT SECURITIES - Realized Gains (Losses) Included Within Investment Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSECURITIESGainsLossesonEquitySecuritiesDetails" roleURI="http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesonEquitySecuritiesDetails">
        <link:definition>9954500 - Disclosure - INVESTMENT SECURITIES - Gains (Losses) on Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" roleURI="http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails">
        <link:definition>9954501 - Disclosure - INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" roleURI="http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails">
        <link:definition>9954502 - Disclosure - FAIR VALUE - Financial Assets Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUENarrativeDetails" roleURI="http://www.humana.com/role/FAIRVALUENarrativeDetails">
        <link:definition>9954503 - Disclosure - FAIR VALUE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUESignificantUnobservableInputsLevel3Details" roleURI="http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details">
        <link:definition>9954504 - Disclosure - FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" roleURI="http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails">
        <link:definition>9954505 - Disclosure - FAIR VALUE - Put and Call Options Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MEDICAREPARTDDetails" roleURI="http://www.humana.com/role/MEDICAREPARTDDetails">
        <link:definition>9954506 - Disclosure - MEDICARE PART D (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails" roleURI="http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails">
        <link:definition>9954507 - Disclosure - PROPERTY AND EQUIPMENT, NET - Property and Equipment Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNETNarrativeDetails" roleURI="http://www.humana.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails">
        <link:definition>9954508 - Disclosure - PROPERTY AND EQUIPMENT, NET - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails" roleURI="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails">
        <link:definition>9954509 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Changes in Carrying Amount of Goodwill by Reportable Segments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails" roleURI="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails">
        <link:definition>9954510 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Details of Intangible Assets Included in Other Long-Term Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" roleURI="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails">
        <link:definition>9954511 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDOTHERINTANGIBLEASSETSEstimateofAmortizationExpenseDetails" roleURI="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSEstimateofAmortizationExpenseDetails">
        <link:definition>9954512 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Estimate of Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.humana.com/role/LEASESNarrativeDetails">
        <link:definition>9954513 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESMaturityofLeaseLiabilitiesDetails" roleURI="http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails">
        <link:definition>9954514 - Disclosure - LEASES - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESMaturityofLeaseLiabilitiesDetails_1" roleURI="http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails_1">
        <link:definition>9954514 - Disclosure - LEASES - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BENEFITSPAYABLEActivityinBenefitsPayableDetails" roleURI="http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails">
        <link:definition>9954515 - Disclosure - BENEFITS PAYABLE - Activity in Benefits Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BENEFITSPAYABLENarrativeDetails" roleURI="http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails">
        <link:definition>9954516 - Disclosure - BENEFITS PAYABLE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails" roleURI="http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails">
        <link:definition>9954517 - Disclosure - BENEFITS PAYABLE - Incurred and Paid Claims Development (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESProvisionforIncomeTaxesDetails" roleURI="http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails">
        <link:definition>9954518 - Disclosure - INCOME TAXES - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESProvisionforIncomeTaxesReconciliationDetails" roleURI="http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails">
        <link:definition>9954519 - Disclosure - INCOME TAXES - Provision for Income Taxes Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails" roleURI="http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails">
        <link:definition>9954520 - Disclosure - INCOME TAXES - Principal Components of Net Deferred Tax Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.humana.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>9954521 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTDebtOutstandingDetails" roleURI="http://www.humana.com/role/DEBTDebtOutstandingDetails">
        <link:definition>9954522 - Disclosure - DEBT - Debt Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTMaturitiesofDebtDetails" roleURI="http://www.humana.com/role/DEBTMaturitiesofDebtDetails">
        <link:definition>9954523 - Disclosure - DEBT - Maturities of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTSeniorNotesDetails" roleURI="http://www.humana.com/role/DEBTSeniorNotesDetails">
        <link:definition>9954524 - Disclosure - DEBT - Senior Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTRevolvingCreditAgreementsDetails" roleURI="http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails">
        <link:definition>9954525 - Disclosure - DEBT - Revolving Credit Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTCommercialPaperandOtherShortTermBorrowingsDetails" roleURI="http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails">
        <link:definition>9954526 - Disclosure - DEBT - Commercial Paper and Other Short-Term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSNarrativeDetails" roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails">
        <link:definition>9954527 - Disclosure - EMPLOYEE BENEFIT PLANS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails" roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails">
        <link:definition>9954528 - Disclosure - EMPLOYEE BENEFIT PLANS - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails" roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails">
        <link:definition>9954529 - Disclosure - EMPLOYEE BENEFIT PLANS - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails" roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails">
        <link:definition>9954530 - Disclosure - EMPLOYEE BENEFIT PLANS - Weighted-Average Fair Value Assumptions for Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSOptionPlansActivityDetails" roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails">
        <link:definition>9954531 - Disclosure - EMPLOYEE BENEFIT PLANS - Option Plans Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSPERCOMMONSHARECOMPUTATIONDetails" roleURI="http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails">
        <link:definition>9954532 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYDividendPaymentsDetails" roleURI="http://www.humana.com/role/STOCKHOLDERSEQUITYDividendPaymentsDetails">
        <link:definition>9954533 - Disclosure - STOCKHOLDERS' EQUITY - Dividend Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>9954534 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYShareRepurchasesDetails" roleURI="http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails">
        <link:definition>9954535 - Disclosure - STOCKHOLDERS' EQUITY - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" roleURI="http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails">
        <link:definition>9954536 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>9954537 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONSegmentResultsDetails" roleURI="http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails">
        <link:definition>9954538 - Disclosure - SEGMENT INFORMATION - Segment Results (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REINSURANCEDetails" roleURI="http://www.humana.com/role/REINSURANCEDetails">
        <link:definition>9954539 - Disclosure - REINSURANCE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails" roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails">
        <link:definition>9954540 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Balance Sheets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails" roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails">
        <link:definition>9954541 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Balance Sheets Share Data) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails" roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails">
        <link:definition>9954542 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails" roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails">
        <link:definition>9954543 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Comprehensive Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails" roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails">
        <link:definition>9954544 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Cash Flows) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONNotestoCondensedFinancialStatementsDetails" roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONNotestoCondensedFinancialStatementsDetails">
        <link:definition>9954545 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Notes to Condensed Financial Statements) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="hum_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_SubsidyAndDiscountReimbursements" abstract="false" name="SubsidyAndDiscountReimbursements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality" abstract="false" name="PercentageOfTotalDebtSecuritiesInvestmentGradeQuality" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="hum_BookOverdraftPolicyPolicyTextBlock" abstract="false" name="BookOverdraftPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="hum_DepreciationAndAmortizationClassifiedAsBenefitExpense" abstract="false" name="DepreciationAndAmortizationClassifiedAsBenefitExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member" abstract="true" name="A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_RevolvingCreditAgreementJune2022OneYearMember" abstract="true" name="RevolvingCreditAgreementJune2022OneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired" abstract="false" name="NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments" abstract="false" name="ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_A3.95PercentSeniorNotesDueAugust2049Member" abstract="true" name="A3.95PercentSeniorNotesDueAugust2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_InvestmentAndOtherIncomeNet" abstract="false" name="InvestmentAndOtherIncomeNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_A313PercentSeniorNotesDueAugust2029Member" abstract="true" name="A313PercentSeniorNotesDueAugust2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_CommercialMembershipContractTerm" abstract="false" name="CommercialMembershipContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer" abstract="false" name="AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_InvestmentInRelatedPartiesAndSubsidiaries" abstract="false" name="InvestmentInRelatedPartiesAndSubsidiaries" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum" abstract="false" name="DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="hum_A488PercentSeniorNotesDueApril2030Member" abstract="true" name="A488PercentSeniorNotesDueApril2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_A2019PlanMember" abstract="true" name="A2019PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock" abstract="false" name="DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="hum_MedicareAdvantageMember" abstract="true" name="MedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_SpecialtyBenefitsMember" abstract="true" name="SpecialtyBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual" abstract="false" name="DebtInstrumentCovenantDebtToCapitalizationPercentageActual" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="hum_HealthCareCostPaymentsAndReimbursementsNet" abstract="false" name="HealthCareCostPaymentsAndReimbursementsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_BuildingsAndLeaseholdImprovementsMember" abstract="true" name="BuildingsAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member" abstract="true" name="A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_NoncompetesAndOtherMember" abstract="true" name="NoncompetesAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_A5.88PercentSeniorNotesDueMarch2033Member" abstract="true" name="A5.88PercentSeniorNotesDueMarch2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_A570PercentSeniorNotesDueMarch2026Member" abstract="true" name="A570PercentSeniorNotesDueMarch2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember" abstract="true" name="WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_BusinessCombinationTotalEnterpriseValueOfAcquiree" abstract="false" name="BusinessCombinationTotalEnterpriseValueOfAcquiree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_A3700PercentSeniorNotesDueMarch2029Member" abstract="true" name="A3700PercentSeniorNotesDueMarch2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears" abstract="false" name="FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_OtherCurrentAssetsPolicyTextBlock" abstract="false" name="OtherCurrentAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="hum_BookOverdraftLiability" abstract="false" name="BookOverdraftLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_PaymentsForProceedsFromContractDeposits" abstract="false" name="PaymentsForProceedsFromContractDeposits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_CitibankNAMember" abstract="true" name="CitibankNAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_ValueCreationInitiativesMember" abstract="true" name="ValueCreationInitiativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain" abstract="false" name="EffectiveIncomeTaxReconciliationNonTaxableKAHGain" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_RevolvingCreditAgreementJune2023FiveYearMember" abstract="true" name="RevolvingCreditAgreementJune2023FiveYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram" abstract="false" name="CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries" abstract="false" name="NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="hum_NetCurrentLiabilityAsset" abstract="false" name="NetCurrentLiabilityAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_AccruedPharmaceuticalRebatesCurrent" abstract="false" name="AccruedPharmaceuticalRebatesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions" abstract="false" name="ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened" abstract="false" name="StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries" abstract="false" name="IncomeLossBeforeEquityInNetEarningsOfSubsidiaries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_FinancialAssetsFairValueDisclosure" abstract="false" name="FinancialAssetsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_TRICAREManagedCareSupportContractEffective2024Member" abstract="true" name="TRICAREManagedCareSupportContractEffective2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_ExternalRevenuesMember" abstract="true" name="ExternalRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares" abstract="false" name="DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="hum_MedicareLicensesAndCertificatesOfNeedMember" abstract="true" name="MedicareLicensesAndCertificatesOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember" abstract="true" name="ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_PharmacySolutionsMember" abstract="true" name="PharmacySolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_CertificateOfNeedMember" abstract="true" name="CertificateOfNeedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_LossOnTerminationOfDerivatives" abstract="false" name="LossOnTerminationOfDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_A2021ShareRepurchaseAuthorizationMember" abstract="true" name="A2021ShareRepurchaseAuthorizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_A3125PercentSeniorNotesDueAugust2029Member" abstract="true" name="A3125PercentSeniorNotesDueAugust2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="hum_Expenses" abstract="false" name="Expenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions" abstract="false" name="DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="hum_PercentageOfTotalPremiumAndServicesRevenues" abstract="false" name="PercentageOfTotalPremiumAndServicesRevenues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="hum_TermLoanDueOctober2023Member" abstract="true" name="TermLoanDueOctober2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_FederalGovernmentMember" abstract="true" name="FederalGovernmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_RevolvingCreditAgreementJune2023OneYearMember" abstract="true" name="RevolvingCreditAgreementJune2023OneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_RevenueExitMultipleMember" abstract="true" name="RevenueExitMultipleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue" abstract="false" name="CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_StrategicPartnershipAgreementCallOptionStrikePrice" abstract="false" name="StrategicPartnershipAgreementCallOptionStrikePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares" abstract="false" name="ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="hum_A4.95PercentSeniorNotesDueOctober2044Member" abstract="true" name="A4.95PercentSeniorNotesDueOctober2044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram" abstract="false" name="MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember" abstract="true" name="WelshCarsonAndersonAndStoweCohortOfClinicsOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance" abstract="false" name="NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities" abstract="false" name="MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" abstract="false" name="IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries" abstract="false" name="IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue" abstract="false" name="ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding" abstract="false" name="DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram" abstract="false" name="MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hum_PercentageOfCoinsuranceAgreement" abstract="false" name="PercentageOfCoinsuranceAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="hum_LongDurationInsuranceProductsAxis" abstract="true" name="LongDurationInsuranceProductsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="hum_NetAssetLiability" abstract="false" name="NetAssetLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_A3.95PercentSeniorNotesDueMarch2027Member" abstract="true" name="A3.95PercentSeniorNotesDueMarch2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock" abstract="false" name="ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hum_ReinsuranceTable" abstract="true" name="ReinsuranceTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="hum_A2011PlanMember" abstract="true" name="A2011PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_NumberOfTRICAREBeneficiaries" abstract="false" name="NumberOfTRICAREBeneficiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="hum_CommercialASOMember" abstract="true" name="CommercialASOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported" abstract="false" name="LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="hum_GentivaHospiceMember" abstract="true" name="GentivaHospiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_StateBasedContractsAndOtherMember" abstract="true" name="StateBasedContractsAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_PrimaryCareMember" abstract="true" name="PrimaryCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_GroupMedicareAdvantageMember" abstract="true" name="GroupMedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_TermLoanAndCommercialPaperMember" abstract="true" name="TermLoanAndCommercialPaperMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements" abstract="false" name="SubsidyAndDiscountPaymentsInExcessOfReimbursements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_MedicareStandAlonePrescriptionDrugPlanMember" abstract="true" name="MedicareStandAlonePrescriptionDrugPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract" abstract="true" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="hum_WellsFargoBankMember" abstract="true" name="WellsFargoBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_InterestRateSwapMaturing2034Member" abstract="true" name="InterestRateSwapMaturing2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_ManagementFeesChargedToOperatingSubsidiaries" abstract="false" name="ManagementFeesChargedToOperatingSubsidiaries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_EquityInNetEarningsOfSubsidiaries" abstract="false" name="EquityInNetEarningsOfSubsidiaries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_DividendsToParentWithoutPriorStateRegulatoryApproval" abstract="false" name="DividendsToParentWithoutPriorStateRegulatoryApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_A370PercentSeniorNotesDueMarch2029Member" abstract="true" name="A370PercentSeniorNotesDueMarch2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_MedicareSupplementProductMember" abstract="true" name="MedicareSupplementProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest" abstract="false" name="BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember" abstract="true" name="ShortDurationInsuranceContractAccidentYear2021AndPriorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_RiskCorridorSettlementsMedicarePartDMember" abstract="true" name="RiskCorridorSettlementsMedicarePartDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_A215PercentSeniorNotesDueFebruary2032Member" abstract="true" name="A215PercentSeniorNotesDueFebruary2032Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_NumberOfStatesComprisingTRICAREBeneficiaries" abstract="false" name="NumberOfStatesComprisingTRICAREBeneficiaries" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="hum_A3.950PercentSeniorNotesMember" abstract="true" name="A3.950PercentSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="hum_DelayedDrawTermLoanMember" abstract="true" name="DelayedDrawTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance" abstract="false" name="DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_MilitaryAndOtherMember" abstract="true" name="MilitaryAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_ProtectiveLifeInsuranceCompanyMember" abstract="true" name="ProtectiveLifeInsuranceCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_AcceleratedShareRepurchasesAgreementAmount" abstract="false" name="AcceleratedShareRepurchasesAgreementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_RepurchasePlanMarch2023Member" abstract="true" name="RepurchasePlanMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_TRICARE2017EastRegionContractMember" abstract="true" name="TRICARE2017EastRegionContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_LongTermDebtAggregateCarryingValueAdjustment" abstract="false" name="LongTermDebtAggregateCarryingValueAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_HealthCareCostPayments" abstract="false" name="HealthCareCostPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationEquityInterestSold" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="hum_A4.80PercentSeniorNotesDueMarch2047Member" abstract="true" name="A4.80PercentSeniorNotesDueMarch2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment" abstract="false" name="NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock" abstract="false" name="FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="hum_TRICAREContractDomain" abstract="true" name="TRICAREContractDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_MizuhoMarketsAmericasLLCMember" abstract="true" name="MizuhoMarketsAmericasLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_ProceedsFromStockOptionsExercisedAndOther" abstract="false" name="ProceedsFromStockOptionsExercisedAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_NetNoncurrentAssetLiability" abstract="false" name="NetNoncurrentAssetLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_CapitalContributionsToOperatingSubsidiaries" abstract="false" name="CapitalContributionsToOperatingSubsidiaries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_DeferredTaxAssetJobsTaxCredit" abstract="false" name="DeferredTaxAssetJobsTaxCredit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_RepurchasePlanAugust2023Member" abstract="true" name="RepurchasePlanAugust2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_DebtAndEquitySecuritiesRealizedLoss" abstract="false" name="DebtAndEquitySecuritiesRealizedLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember" abstract="true" name="FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_A135PercentSeniorNotesDueFebruary2027Member" abstract="true" name="A135PercentSeniorNotesDueFebruary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries" abstract="false" name="NumberOfTRICAREManagedCareSupportContractBeneficiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="hum_JPMorganChaseBankMember" abstract="true" name="JPMorganChaseBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_A575PercentSeniorNotesDueDecember2028Member" abstract="true" name="A575PercentSeniorNotesDueDecember2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_SubsidyAndDiscountPayments" abstract="false" name="SubsidyAndDiscountPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_CorporateAndEliminationsMember" abstract="true" name="CorporateAndEliminationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_A2024ShareRepurchaseAuthorizationMember" abstract="true" name="A2024ShareRepurchaseAuthorizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_TRICAREManagedCareSupportContractBaseTerm" abstract="false" name="TRICAREManagedCareSupportContractBaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hum_CommercialFullyInsuredMember" abstract="true" name="CommercialFullyInsuredMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_A575PercentSeniorNotesDueMarch2028Member" abstract="true" name="A575PercentSeniorNotesDueMarch2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_HealthCareCostReimbursements" abstract="false" name="HealthCareCostReimbursements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_MilitaryServiceMember" abstract="true" name="MilitaryServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets" abstract="false" name="DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_InterestRateSwapMaturing2049Member" abstract="true" name="InterestRateSwapMaturing2049Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_InterestRateSwapMaturing2032Member" abstract="true" name="InterestRateSwapMaturing2032Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_HomeSolutionsMember" abstract="true" name="HomeSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods" abstract="false" name="TRICAREManagedCareSupportContractNumberOfOptionPeriods" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="hum_LongDurationInsuranceProductsDomain" abstract="true" name="LongDurationInsuranceProductsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_GovernmentAndHealthPlanMemberSubsidiesAmount" abstract="false" name="GovernmentAndHealthPlanMemberSubsidiesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock" abstract="false" name="BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="hum_KindredAtHomeMember" abstract="true" name="KindredAtHomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_A3850PercentSeniorNotesDueOctober2024Member" abstract="true" name="A3850PercentSeniorNotesDueOctober2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_CenterWellSegmentMember" abstract="true" name="CenterWellSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies" abstract="false" name="NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hum_DebtAndEquitySecuritiesRealizedGain" abstract="false" name="DebtAndEquitySecuritiesRealizedGain" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_AllOthersMember" abstract="true" name="AllOthersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies" abstract="false" name="TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hum_A8.15PercentSeniorNotesDueJune2038Member" abstract="true" name="A8.15PercentSeniorNotesDueJune2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_HomeSolutionsReportingUnitMember" abstract="true" name="HomeSolutionsReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_February2023ShareRepurchaseAuthorizationMember" abstract="true" name="February2023ShareRepurchaseAuthorizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_A550PercentSeniorNotesDueMarch2053Member" abstract="true" name="A550PercentSeniorNotesDueMarch2053Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_WelshCarsonAndersonAndStoweMember" abstract="true" name="WelshCarsonAndersonAndStoweMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_January2022AcceleratedShareRepurchaseAgreementMember" abstract="true" name="January2022AcceleratedShareRepurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_A463PercentSeniorNotesDueDecember2042Member" abstract="true" name="A463PercentSeniorNotesDueDecember2042Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember" abstract="true" name="ExitFromEmployerGroupCommercialMedicalProductsBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters" abstract="false" name="StrategicPartnershipAgreementNumberOfPrimaryCareCenters" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="hum_RevolvingCreditAgreementJune2021FiveYearMember" abstract="true" name="RevolvingCreditAgreementJune2021FiveYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_GoldmanSachsCoLLCMember" abstract="true" name="GoldmanSachsCoLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_SecuredOvernightFinancingRateSOFRMember" abstract="true" name="SecuredOvernightFinancingRateSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting" abstract="false" name="EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_InsuranceSegmentMember" abstract="true" name="InsuranceSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_InterestRateSwapMaturing2033Member" abstract="true" name="InterestRateSwapMaturing2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_CoinsuranceAgreementMember" abstract="true" name="CoinsuranceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock" abstract="false" name="BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity" abstract="false" name="LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage" abstract="false" name="BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="hum_FairValueRiskMember" abstract="true" name="FairValueRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_CompanyCommonStockClosingSharePrice" abstract="false" name="CompanyCommonStockClosingSharePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="hum_TRICAREContractAxis" abstract="true" name="TRICAREContractAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="hum_MedicarePartDDisclosureTextBlock" abstract="false" name="MedicarePartDDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="hum_A065PercentSeniorNotesDueAugust2023Member" abstract="true" name="A065PercentSeniorNotesDueAugust2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_ProviderReportingUnitMember" abstract="true" name="ProviderReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost" abstract="false" name="DeferredTaxAssetsDeferredPolicyAcquisitionCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders" abstract="false" name="NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_CmsSubsidiesOrDiscountsMember" abstract="true" name="CmsSubsidiesOrDiscountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock" abstract="false" name="DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="hum_TRICAREManagedCareSupportContractTermWithOptionExercises" abstract="false" name="TRICAREManagedCareSupportContractTermWithOptionExercises" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hum_SubsidyAndDiscountsSettlementPeriodAfterClose" abstract="false" name="SubsidyAndDiscountsSettlementPeriodAfterClose" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs" abstract="false" name="ConsumerDiscountsOnBrandNamePrescriptionDrugs" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="hum_LineOfCreditFacilityUncommittedIncrementalCapacity" abstract="false" name="LineOfCreditFacilityUncommittedIncrementalCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_December2020AcceleratedShareRepurchaseAgreementMember" abstract="true" name="December2020AcceleratedShareRepurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_November2022AcceleratedShareRepurchaseProgramMember" abstract="true" name="November2022AcceleratedShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage" abstract="false" name="DefinitiveAgreementEquityInterestToBeAcquiredPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="hum_A5950PercentSeniorNotesDueMarch2034Member" abstract="true" name="A5950PercentSeniorNotesDueMarch2034Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_A4.500PercentSeniorNotesDueApril2025Member" abstract="true" name="A4.500PercentSeniorNotesDueApril2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_TreasuryStockDecreaseInCapitalInExcessOfParValue" abstract="false" name="TreasuryStockDecreaseInCapitalInExcessOfParValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="hum_RevolvingCreditAgreementJune2021OneYearMember" abstract="true" name="RevolvingCreditAgreementJune2021OneYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_DelayedDrawTermLoanMay2024Member" abstract="true" name="DelayedDrawTermLoanMay2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="hum_A2023ShareRepurchaseAuthorizationMember" abstract="true" name="A2023ShareRepurchaseAuthorizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity" abstract="false" name="StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="hum_February2021ShareRepurchaseAuthorizationMember" abstract="true" name="February2021ShareRepurchaseAuthorizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>hum-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:7bfbafa3-a477-4092-82f1-790bd65455d7,g:6b53bb4a-2282-4b95-aa2c-e78c6730e17d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="hum-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7909a044-2e69-47d3-a38f-f3a77e145636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_88694b16-b84f-4f03-9fc8-14f2d5fab966" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7909a044-2e69-47d3-a38f-f3a77e145636" xlink:to="loc_us-gaap_LiabilitiesCurrent_88694b16-b84f-4f03-9fc8-14f2d5fab966" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3fd3f188-74a0-4b43-9e31-f3bf1dc66697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7909a044-2e69-47d3-a38f-f3a77e145636" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3fd3f188-74a0-4b43-9e31-f3bf1dc66697" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_1dc6c1b8-879c-44c4-aa77-452c79dcd3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7909a044-2e69-47d3-a38f-f3a77e145636" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_1dc6c1b8-879c-44c4-aa77-452c79dcd3ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a732d52d-e085-4288-93bc-513ac0d5ef7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6ab254b5-c9e6-4577-97ab-d4a15627c4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a732d52d-e085-4288-93bc-513ac0d5ef7a" xlink:to="loc_us-gaap_AssetsCurrent_6ab254b5-c9e6-4577-97ab-d4a15627c4fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9e43e23d-cc2e-4ef3-a79e-28c2bda3bb05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a732d52d-e085-4288-93bc-513ac0d5ef7a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9e43e23d-cc2e-4ef3-a79e-28c2bda3bb05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_de144bfe-eacc-4b75-809e-9e73b1202b44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a732d52d-e085-4288-93bc-513ac0d5ef7a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_de144bfe-eacc-4b75-809e-9e73b1202b44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_543f56da-eb70-471b-b96c-30668aa86ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a732d52d-e085-4288-93bc-513ac0d5ef7a" xlink:to="loc_us-gaap_Goodwill_543f56da-eb70-471b-b96c-30668aa86ec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_dfd8606b-cb13-46ec-b3c6-cbea1fc92c31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a732d52d-e085-4288-93bc-513ac0d5ef7a" xlink:to="loc_us-gaap_EquityMethodInvestments_dfd8606b-cb13-46ec-b3c6-cbea1fc92c31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4bf9337d-8cf5-497e-9842-f725e0e446ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a732d52d-e085-4288-93bc-513ac0d5ef7a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4bf9337d-8cf5-497e-9842-f725e0e446ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4437da3f-c039-406a-8eaa-f0acbf89aab3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c82ce778-a9d0-4c19-9c17-1729e012c92a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4437da3f-c039-406a-8eaa-f0acbf89aab3" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c82ce778-a9d0-4c19-9c17-1729e012c92a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cc633685-0d3f-4aee-85a7-93ba50dc8f95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4437da3f-c039-406a-8eaa-f0acbf89aab3" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cc633685-0d3f-4aee-85a7-93ba50dc8f95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BookOverdraftLiability_59cdb0c4-4cc4-44e6-9733-a09c9f8e65c1" xlink:href="hum-20231231.xsd#hum_BookOverdraftLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4437da3f-c039-406a-8eaa-f0acbf89aab3" xlink:to="loc_hum_BookOverdraftLiability_59cdb0c4-4cc4-44e6-9733-a09c9f8e65c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_50d841be-86b0-471d-b5e6-368bbb30c33f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4437da3f-c039-406a-8eaa-f0acbf89aab3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_50d841be-86b0-471d-b5e6-368bbb30c33f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_76fa64f9-5d9c-448c-a1c6-e834d4c76f26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4437da3f-c039-406a-8eaa-f0acbf89aab3" xlink:to="loc_us-gaap_DebtCurrent_76fa64f9-5d9c-448c-a1c6-e834d4c76f26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9b7d0b6d-4bd6-4a7d-bf9a-e7010295a7c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_b81613b9-1d65-4ab0-a635-e3246718296b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b7d0b6d-4bd6-4a7d-bf9a-e7010295a7c6" xlink:to="loc_us-gaap_TreasuryStockCommonValue_b81613b9-1d65-4ab0-a635-e3246718296b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_938d7116-ff0b-4e75-b5e2-9a9ef8469b16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b7d0b6d-4bd6-4a7d-bf9a-e7010295a7c6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_938d7116-ff0b-4e75-b5e2-9a9ef8469b16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e66941e9-0946-4cd2-abe0-c0300d63ee36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b7d0b6d-4bd6-4a7d-bf9a-e7010295a7c6" xlink:to="loc_us-gaap_CommonStockValue_e66941e9-0946-4cd2-abe0-c0300d63ee36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_dda5ec7a-f1c2-44e6-8bc9-12129624d9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b7d0b6d-4bd6-4a7d-bf9a-e7010295a7c6" xlink:to="loc_us-gaap_PreferredStockValue_dda5ec7a-f1c2-44e6-8bc9-12129624d9a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_db798963-ed7d-4788-8ef5-357b31004099" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b7d0b6d-4bd6-4a7d-bf9a-e7010295a7c6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_db798963-ed7d-4788-8ef5-357b31004099" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0a6e7c43-c84a-4fce-891a-484150cdd48c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b7d0b6d-4bd6-4a7d-bf9a-e7010295a7c6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0a6e7c43-c84a-4fce-891a-484150cdd48c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_301e4df8-cf15-48ca-9380-9ff3803b96b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_12767570-1bf7-42d6-a7bc-a16de3ded18b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_301e4df8-cf15-48ca-9380-9ff3803b96b2" xlink:to="loc_us-gaap_CommitmentsAndContingencies_12767570-1bf7-42d6-a7bc-a16de3ded18b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_af667941-aad4-46c8-a67a-1ba5a4b70dff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_301e4df8-cf15-48ca-9380-9ff3803b96b2" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_af667941-aad4-46c8-a67a-1ba5a4b70dff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d1844032-0c64-4d39-aa09-6917b476d9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_301e4df8-cf15-48ca-9380-9ff3803b96b2" xlink:to="loc_us-gaap_Liabilities_d1844032-0c64-4d39-aa09-6917b476d9ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5ee33a92-6842-441d-a714-201543b84583" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_51c82d04-57ec-4061-8927-0ecde6a66513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5ee33a92-6842-441d-a714-201543b84583" xlink:to="loc_us-gaap_MinorityInterest_51c82d04-57ec-4061-8927-0ecde6a66513" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c3119b07-d14d-45d8-b0fe-5568ab2eb93e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5ee33a92-6842-441d-a714-201543b84583" xlink:to="loc_us-gaap_StockholdersEquity_c3119b07-d14d-45d8-b0fe-5568ab2eb93e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4eca4fc5-3ecd-4459-9d65-9f4a3f017d97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_76182a44-bac9-481c-97f0-51935bef893b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4eca4fc5-3ecd-4459-9d65-9f4a3f017d97" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_76182a44-bac9-481c-97f0-51935bef893b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_227306fa-7d8f-4f0c-8569-9debf7f6b5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4eca4fc5-3ecd-4459-9d65-9f4a3f017d97" xlink:to="loc_us-gaap_ShortTermInvestments_227306fa-7d8f-4f0c-8569-9debf7f6b5d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_cc2356c8-a8a2-44c2-b924-62c58f3a812f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4eca4fc5-3ecd-4459-9d65-9f4a3f017d97" xlink:to="loc_us-gaap_ReceivablesNetCurrent_cc2356c8-a8a2-44c2-b924-62c58f3a812f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_9790733d-d369-4192-9273-47b9bfab2f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4eca4fc5-3ecd-4459-9d65-9f4a3f017d97" xlink:to="loc_us-gaap_OtherAssetsCurrent_9790733d-d369-4192-9273-47b9bfab2f7a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="hum-20231231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bc1cb660-8d55-4a49-b5e8-9381882de695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_f1691524-8382-4712-bf96-663a9e370111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_bc1cb660-8d55-4a49-b5e8-9381882de695" xlink:to="loc_us-gaap_PremiumsEarnedNet_f1691524-8382-4712-bf96-663a9e370111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_f11b56ea-cfda-458e-8765-33e5dbb3f3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_bc1cb660-8d55-4a49-b5e8-9381882de695" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_f11b56ea-cfda-458e-8765-33e5dbb3f3d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_db7228cc-7fb0-424e-a8be-d26f4791974c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_bc1cb660-8d55-4a49-b5e8-9381882de695" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_db7228cc-7fb0-424e-a8be-d26f4791974c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c96fd842-954a-4468-b956-29d81b111623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c65f687b-2b54-4a4b-b9ad-6a3d8ff0e1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c96fd842-954a-4468-b956-29d81b111623" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c65f687b-2b54-4a4b-b9ad-6a3d8ff0e1a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_382a11fd-6112-4dff-b5ce-4b7b959f7e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c96fd842-954a-4468-b956-29d81b111623" xlink:to="loc_us-gaap_ProfitLoss_382a11fd-6112-4dff-b5ce-4b7b959f7e1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_5b2c4af9-573a-4196-9a65-b4c7359c27bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_4a5d548d-408a-40ed-82bc-cdba8c37ce06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_5b2c4af9-573a-4196-9a65-b4c7359c27bb" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_4a5d548d-408a-40ed-82bc-cdba8c37ce06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9dd27a0e-a149-4cf5-951c-8551f1e48874" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_5b2c4af9-573a-4196-9a65-b4c7359c27bb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9dd27a0e-a149-4cf5-951c-8551f1e48874" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_af1f2f7c-1ebb-44d2-91d5-7a78a72100fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses_5b2c4af9-573a-4196-9a65-b4c7359c27bb" xlink:to="loc_us-gaap_DepreciationAndAmortization_af1f2f7c-1ebb-44d2-91d5-7a78a72100fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ecd9dd67-512f-4926-b6fd-0e94578144c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_44e3cc60-d2f3-4e3f-a7f1-06491149d0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ecd9dd67-512f-4926-b6fd-0e94578144c6" xlink:to="loc_us-gaap_Revenues_44e3cc60-d2f3-4e3f-a7f1-06491149d0ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_d6b8b50b-16b1-4a5a-906a-f5bb106c98f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ecd9dd67-512f-4926-b6fd-0e94578144c6" xlink:to="loc_us-gaap_BenefitsLossesAndExpenses_d6b8b50b-16b1-4a5a-906a-f5bb106c98f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_788f0fed-d316-45f2-87be-fe181c6b5b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_cb8e1bb7-c673-4224-afa5-bec4d33fd99f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_788f0fed-d316-45f2-87be-fe181c6b5b6c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_cb8e1bb7-c673-4224-afa5-bec4d33fd99f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_85c9c23c-5a0d-40a8-8ff9-7954b205a0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_788f0fed-d316-45f2-87be-fe181c6b5b6c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_85c9c23c-5a0d-40a8-8ff9-7954b205a0d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f6e9ee5d-532b-4c86-9f1c-47f3ba64a3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_788f0fed-d316-45f2-87be-fe181c6b5b6c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_f6e9ee5d-532b-4c86-9f1c-47f3ba64a3a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_86061e01-08f3-4ca6-a903-d193e45b6162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_03a575fd-da85-4eed-8d00-2d25c351e571" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_86061e01-08f3-4ca6-a903-d193e45b6162" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_03a575fd-da85-4eed-8d00-2d25c351e571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_920ed8bf-4ab1-47c0-886e-72e6300917db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_86061e01-08f3-4ca6-a903-d193e45b6162" xlink:to="loc_us-gaap_InterestExpense_920ed8bf-4ab1-47c0-886e-72e6300917db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_08803753-5bc0-4c16-a0a7-a828f0db7494" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_86061e01-08f3-4ca6-a903-d193e45b6162" xlink:to="loc_us-gaap_OperatingIncomeLoss_08803753-5bc0-4c16-a0a7-a828f0db7494" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_989022d6-99f0-40f6-93cf-f79e8d51e814" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_86061e01-08f3-4ca6-a903-d193e45b6162" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_989022d6-99f0-40f6-93cf-f79e8d51e814" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="hum-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e68e8ac8-3c0b-4288-91bc-394148deec57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_941a11de-949e-4531-ae80-e5119d107341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e68e8ac8-3c0b-4288-91bc-394148deec57" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_941a11de-949e-4531-ae80-e5119d107341" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_c43cb385-7cfb-43d8-8c57-554891440c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e68e8ac8-3c0b-4288-91bc-394148deec57" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_c43cb385-7cfb-43d8-8c57-554891440c2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_f69a0815-fce1-4dba-9a78-847e5e24e083" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_fb3fcf33-c1a4-4176-ad40-41d3e5d3600a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_f69a0815-fce1-4dba-9a78-847e5e24e083" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_fb3fcf33-c1a4-4176-ad40-41d3e5d3600a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_3b609578-ee43-40be-b973-b4ea699fab22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_f69a0815-fce1-4dba-9a78-847e5e24e083" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_3b609578-ee43-40be-b973-b4ea699fab22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_92194a50-b6f0-4dc8-8365-114281693ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a5dd3840-f6a9-4fad-92b0-393397f04b78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_92194a50-b6f0-4dc8-8365-114281693ffc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a5dd3840-f6a9-4fad-92b0-393397f04b78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_93980512-512c-4f03-8ff5-15902ccfbd9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_92194a50-b6f0-4dc8-8365-114281693ffc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_93980512-512c-4f03-8ff5-15902ccfbd9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_569129b5-74ab-4cde-b94e-71bcbebdc8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_422180f1-981b-4441-b221-ab97b6314f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_569129b5-74ab-4cde-b94e-71bcbebdc8f6" xlink:to="loc_us-gaap_NetIncomeLoss_422180f1-981b-4441-b221-ab97b6314f4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4ce44a31-13df-4e3e-b8cc-1a27efb4a3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_569129b5-74ab-4cde-b94e-71bcbebdc8f6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_4ce44a31-13df-4e3e-b8cc-1a27efb4a3e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments_ce556696-ebb7-4491-bfa9-47d1b0e7c21c" xlink:href="hum-20231231.xsd#hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_569129b5-74ab-4cde-b94e-71bcbebdc8f6" xlink:to="loc_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments_ce556696-ebb7-4491-bfa9-47d1b0e7c21c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" xlink:type="simple" xlink:href="hum-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOW"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_174b25b7-f6a3-482a-97e3-56cb1b64f8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_dc42801f-9309-459c-b8e5-2f90970a2c43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_174b25b7-f6a3-482a-97e3-56cb1b64f8ce" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_dc42801f-9309-459c-b8e5-2f90970a2c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ae1ffa46-993c-4bd3-ad28-108ac31d1938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_174b25b7-f6a3-482a-97e3-56cb1b64f8ce" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_ae1ffa46-993c-4bd3-ad28-108ac31d1938" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_145398e5-0bbe-44bc-8cff-d670b9e48b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_174b25b7-f6a3-482a-97e3-56cb1b64f8ce" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_145398e5-0bbe-44bc-8cff-d670b9e48b5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_5b1fb67f-04fd-4ee8-bedf-76d4550e71ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_174b25b7-f6a3-482a-97e3-56cb1b64f8ce" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_5b1fb67f-04fd-4ee8-bedf-76d4550e71ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_1f7df831-9469-4f73-9979-80ab68c5e9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_174b25b7-f6a3-482a-97e3-56cb1b64f8ce" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_1f7df831-9469-4f73-9979-80ab68c5e9bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_cae1d55c-29b5-4d71-89ae-2f2322cb45ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_174b25b7-f6a3-482a-97e3-56cb1b64f8ce" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_cae1d55c-29b5-4d71-89ae-2f2322cb45ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1408ccef-35e7-48fc-9303-e40357e3b7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_174b25b7-f6a3-482a-97e3-56cb1b64f8ce" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1408ccef-35e7-48fc-9303-e40357e3b7cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d959de-12dd-420c-956c-c08718b822b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0b6b23bf-385f-4111-b2c6-7c3ba54c60a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d959de-12dd-420c-956c-c08718b822b0" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0b6b23bf-385f-4111-b2c6-7c3ba54c60a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_1e8e72b1-1243-49a5-a965-258063a16de3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d959de-12dd-420c-956c-c08718b822b0" xlink:to="loc_us-gaap_PaymentsOfDividends_1e8e72b1-1243-49a5-a965-258063a16de3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PaymentsForProceedsFromContractDeposits_79b4a48a-7f01-45e1-8692-77c1f4e9aa35" xlink:href="hum-20231231.xsd#hum_PaymentsForProceedsFromContractDeposits"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d959de-12dd-420c-956c-c08718b822b0" xlink:to="loc_hum_PaymentsForProceedsFromContractDeposits_79b4a48a-7f01-45e1-8692-77c1f4e9aa35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_85ba3395-ceb0-4181-b2fe-cb25c65ec1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d959de-12dd-420c-956c-c08718b822b0" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_85ba3395-ceb0-4181-b2fe-cb25c65ec1d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_b0498c2e-01c5-4310-b791-0cadb5c19a69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d959de-12dd-420c-956c-c08718b822b0" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_b0498c2e-01c5-4310-b791-0cadb5c19a69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt_5ef3a8cc-6007-423f-b0e2-2346f563223e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d959de-12dd-420c-956c-c08718b822b0" xlink:to="loc_us-gaap_RepaymentsOfUnsecuredDebt_5ef3a8cc-6007-423f-b0e2-2346f563223e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_6dffad2f-66d0-43cc-9c13-52337ea0fcee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d959de-12dd-420c-956c-c08718b822b0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_6dffad2f-66d0-43cc-9c13-52337ea0fcee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_e55e3e85-b5ce-4133-8646-d61bde4cc37e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d959de-12dd-420c-956c-c08718b822b0" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_e55e3e85-b5ce-4133-8646-d61bde4cc37e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_0f03296a-bd43-46d9-9929-c2fb63837363" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d959de-12dd-420c-956c-c08718b822b0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_0f03296a-bd43-46d9-9929-c2fb63837363" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8d74543a-0319-4b02-88f9-22a6bbaa3ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d959de-12dd-420c-956c-c08718b822b0" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_8d74543a-0319-4b02-88f9-22a6bbaa3ab6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_2ad84f8c-1395-41eb-82af-8134d42a20db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfCommercialPaper"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d959de-12dd-420c-956c-c08718b822b0" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_2ad84f8c-1395-41eb-82af-8134d42a20db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInBookOverdrafts_cdaf60ed-f942-4b00-9671-35b6cceeb67b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInBookOverdrafts"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d959de-12dd-420c-956c-c08718b822b0" xlink:to="loc_us-gaap_IncreaseDecreaseInBookOverdrafts_cdaf60ed-f942-4b00-9671-35b6cceeb67b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4f9a1c4b-0c85-469f-bddf-10c89b54a493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_59d959de-12dd-420c-956c-c08718b822b0" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_4f9a1c4b-0c85-469f-bddf-10c89b54a493" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e58926ca-c005-4934-a2d6-ab3b1082def5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fc4cdbb-d1af-4140-a90e-caddcbe631c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e58926ca-c005-4934-a2d6-ab3b1082def5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8fc4cdbb-d1af-4140-a90e-caddcbe631c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bbf2c058-31d5-485d-8776-42b8487bc5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e58926ca-c005-4934-a2d6-ab3b1082def5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bbf2c058-31d5-485d-8776-42b8487bc5ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e301365c-9b14-4d23-9485-95a21c792170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e58926ca-c005-4934-a2d6-ab3b1082def5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e301365c-9b14-4d23-9485-95a21c792170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_283ef90f-de9d-4128-8c84-fc35c0e0823d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_283ef90f-de9d-4128-8c84-fc35c0e0823d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_f8ba6e44-4653-4713-afed-589142e0d0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_f8ba6e44-4653-4713-afed-589142e0d0ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_73c7a948-e1b4-4b21-8d16-f84706b24d41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_73c7a948-e1b4-4b21-8d16-f84706b24d41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_e27994bb-420d-463f-aa9f-1f354ad5f1df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_e27994bb-420d-463f-aa9f-1f354ad5f1df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_8ac99b80-5dc8-4907-a487-3d335c7750a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndEquitySecuritiesGainLoss"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_8ac99b80-5dc8-4907-a487-3d335c7750a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_eabb084d-bdae-4af7-ad81-2725f45627ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_eabb084d-bdae-4af7-ad81-2725f45627ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_74e178d2-e90f-4c55-a8e4-fbe5681443ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_74e178d2-e90f-4c55-a8e4-fbe5681443ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3d542500-1dc0-4cfc-b2e1-91ca1c1f152f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_ShareBasedCompensation_3d542500-1dc0-4cfc-b2e1-91ca1c1f152f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_2ac3b426-97e9-41df-ac64-c0a5c5fc125e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_2ac3b426-97e9-41df-ac64-c0a5c5fc125e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_4350b1af-7c47-46b2-b8fc-4100e0754759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_4350b1af-7c47-46b2-b8fc-4100e0754759" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_07bb6360-6e80-413e-b622-448a33f729bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_Depreciation_07bb6360-6e80-413e-b622-448a33f729bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_c947b1da-3267-4d4f-8986-37076730eea9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_c947b1da-3267-4d4f-8986-37076730eea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_c8436e73-a684-45ac-a650-efe543f0aed3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_AdjustmentForAmortization_c8436e73-a684-45ac-a650-efe543f0aed3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_75e5a0a2-5611-450b-a7e9-5032d108dc83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_75e5a0a2-5611-450b-a7e9-5032d108dc83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_57119749-32f1-49a2-afd2-c7f6e8e1139f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_ProfitLoss_57119749-32f1-49a2-afd2-c7f6e8e1139f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_88080a3b-43b4-4c5b-aad2-c6b36b188b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_88080a3b-43b4-4c5b-aad2-c6b36b188b5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_81a40244-d105-486d-bd8a-d7b9b4e83b68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46284e38-ab0e-49a3-9c8a-b295029a18d6" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_81a40244-d105-486d-bd8a-d7b9b4e83b68" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPartDSubsidyDiscountPaymentsNetDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPartDSubsidyDiscountPaymentsNetDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPartDSubsidyDiscountPaymentsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements_ecaabcbd-f280-49be-aafd-003cd2421854" xlink:href="hum-20231231.xsd#hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SubsidyAndDiscountPayments_658aca31-82a7-4d0a-9e7a-2d69355f3203" xlink:href="hum-20231231.xsd#hum_SubsidyAndDiscountPayments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements_ecaabcbd-f280-49be-aafd-003cd2421854" xlink:to="loc_hum_SubsidyAndDiscountPayments_658aca31-82a7-4d0a-9e7a-2d69355f3203" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SubsidyAndDiscountReimbursements_82c062a3-f690-4fc3-94e6-5a9868bef229" xlink:href="hum-20231231.xsd#hum_SubsidyAndDiscountReimbursements"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements_ecaabcbd-f280-49be-aafd-003cd2421854" xlink:to="loc_hum_SubsidyAndDiscountReimbursements_82c062a3-f690-4fc3-94e6-5a9868bef229" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESHealthCareCostPaymentsNetDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESHealthCareCostPaymentsNetDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESHealthCareCostPaymentsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_hum_HealthCareCostPaymentsAndReimbursementsNet_ac4a70c6-eae4-4cac-aac8-3b798751b037" xlink:href="hum-20231231.xsd#hum_HealthCareCostPaymentsAndReimbursementsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_HealthCareCostPayments_6ad29d3a-8439-44ae-a629-dd58d9a43eeb" xlink:href="hum-20231231.xsd#hum_HealthCareCostPayments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_HealthCareCostPaymentsAndReimbursementsNet_ac4a70c6-eae4-4cac-aac8-3b798751b037" xlink:to="loc_hum_HealthCareCostPayments_6ad29d3a-8439-44ae-a629-dd58d9a43eeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_HealthCareCostReimbursements_cb1ccb37-3df1-4b89-b933-7a9924b9e90a" xlink:href="hum-20231231.xsd#hum_HealthCareCostReimbursements"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_HealthCareCostPaymentsAndReimbursementsNet_ac4a70c6-eae4-4cac-aac8-3b798751b037" xlink:to="loc_hum_HealthCareCostReimbursements_cb1ccb37-3df1-4b89-b933-7a9924b9e90a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_9bfc2eb8-4bf7-47c4-94b7-8f0b92142863" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_c6b69b1c-b687-43a9-bc57-78d056e54a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_9bfc2eb8-4bf7-47c4-94b7-8f0b92142863" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_c6b69b1c-b687-43a9-bc57-78d056e54a23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_96b9b8ff-194a-4b3f-b484-657b5d4b58ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_9bfc2eb8-4bf7-47c4-94b7-8f0b92142863" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_96b9b8ff-194a-4b3f-b484-657b5d4b58ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_71f833ea-2a20-4e77-9dff-869ae3dd808e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_9bfc2eb8-4bf7-47c4-94b7-8f0b92142863" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_71f833ea-2a20-4e77-9dff-869ae3dd808e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_4bcd9ee2-4f3f-40ec-b642-e22ffd833c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_9bfc2eb8-4bf7-47c4-94b7-8f0b92142863" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_4bcd9ee2-4f3f-40ec-b642-e22ffd833c4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_e65c98e3-11f6-4b9c-9417-f994d796cf97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_9bfc2eb8-4bf7-47c4-94b7-8f0b92142863" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_e65c98e3-11f6-4b9c-9417-f994d796cf97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_d916657b-a1b9-4dfb-bf8c-5285de3b2314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_9bfc2eb8-4bf7-47c4-94b7-8f0b92142863" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_d916657b-a1b9-4dfb-bf8c-5285de3b2314" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_8a6266a7-3e11-4b0f-bf34-59a82ee1f5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_be9fc5fb-36f8-45b1-ad6e-4437cb539d95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_8a6266a7-3e11-4b0f-bf34-59a82ee1f5a7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_be9fc5fb-36f8-45b1-ad6e-4437cb539d95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_6d11790a-e37d-4628-b930-5d28dd7e1183" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_8a6266a7-3e11-4b0f-bf34-59a82ee1f5a7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_6d11790a-e37d-4628-b930-5d28dd7e1183" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_0e29da49-848f-4b97-a51e-ec6287fdfc42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_862b6322-5502-4f88-aa0f-33c777b903af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Investments_0e29da49-848f-4b97-a51e-ec6287fdfc42" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_862b6322-5502-4f88-aa0f-33c777b903af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_5bce2bc0-2cb9-4135-8289-d95e434953ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Investments_0e29da49-848f-4b97-a51e-ec6287fdfc42" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_5bce2bc0-2cb9-4135-8289-d95e434953ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2b080091-94e3-48cb-997d-d6126ebd34b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_67c72035-b9fb-46ed-8123-356a8fe1a327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2b080091-94e3-48cb-997d-d6126ebd34b3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_67c72035-b9fb-46ed-8123-356a8fe1a327" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ac862f0d-f029-428e-b479-9979cdb70fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2b080091-94e3-48cb-997d-d6126ebd34b3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ac862f0d-f029-428e-b479-9979cdb70fb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5c822c9d-456e-416d-8e88-dd8adbd30068" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2b080091-94e3-48cb-997d-d6126ebd34b3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5c822c9d-456e-416d-8e88-dd8adbd30068" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_381bb619-aba5-4492-a410-e9c885a52b22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_8d1fd81f-76b9-4dff-9ccd-159a91ba519c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_381bb619-aba5-4492-a410-e9c885a52b22" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_8d1fd81f-76b9-4dff-9ccd-159a91ba519c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_2297c4f2-c643-4ae5-9679-abb8444d70ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_381bb619-aba5-4492-a410-e9c885a52b22" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_2297c4f2-c643-4ae5-9679-abb8444d70ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a8cc344d-2158-4f30-90bb-028f9e01d5df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_f520db49-31ea-45e3-be72-99bad20c6af1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a8cc344d-2158-4f30-90bb-028f9e01d5df" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_f520db49-31ea-45e3-be72-99bad20c6af1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b9489105-8e5a-4de1-820f-be849134d8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_a8cc344d-2158-4f30-90bb-028f9e01d5df" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b9489105-8e5a-4de1-820f-be849134d8c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_49add69a-e441-4bf3-907f-82246bbf7600" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndEquitySecuritiesGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DebtAndEquitySecuritiesRealizedGain_4c71eba0-5f22-4ed4-b1af-c801624ec1b5" xlink:href="hum-20231231.xsd#hum_DebtAndEquitySecuritiesRealizedGain"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_49add69a-e441-4bf3-907f-82246bbf7600" xlink:to="loc_hum_DebtAndEquitySecuritiesRealizedGain_4c71eba0-5f22-4ed4-b1af-c801624ec1b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DebtAndEquitySecuritiesRealizedLoss_1a6903c0-e26e-40f1-baff-64d5819522ef" xlink:href="hum-20231231.xsd#hum_DebtAndEquitySecuritiesRealizedLoss"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_49add69a-e441-4bf3-907f-82246bbf7600" xlink:to="loc_hum_DebtAndEquitySecuritiesRealizedLoss_1a6903c0-e26e-40f1-baff-64d5819522ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_f56896e9-bf60-46d7-b19e-a36aa4d984cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGain"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_49add69a-e441-4bf3-907f-82246bbf7600" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_f56896e9-bf60-46d7-b19e-a36aa4d984cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedLoss_ac9f8955-6afd-46a1-8b24-c995f7ef370f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedLoss"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_49add69a-e441-4bf3-907f-82246bbf7600" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedLoss_ac9f8955-6afd-46a1-8b24-c995f7ef370f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesonEquitySecuritiesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INVESTMENTSECURITIESGainsLossesonEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesonEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d5d26da2-806c-4bb8-9bf9-571b762f22e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_7067a0ed-b052-4022-9688-5d36a39d7af2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d5d26da2-806c-4bb8-9bf9-571b762f22e0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_7067a0ed-b052-4022-9688-5d36a39d7af2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_67c71c86-fda7-40d3-828c-15856b35ce9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d5d26da2-806c-4bb8-9bf9-571b762f22e0" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_67c71c86-fda7-40d3-828c-15856b35ce9c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_efba33de-c2ea-4eb0-be47-68f9dea5d9af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_38e80095-8cb6-4901-8bb8-cb474a4867b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_efba33de-c2ea-4eb0-be47-68f9dea5d9af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_38e80095-8cb6-4901-8bb8-cb474a4867b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5892cad2-b4b2-4f85-800e-1b9e47e0a020" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_efba33de-c2ea-4eb0-be47-68f9dea5d9af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5892cad2-b4b2-4f85-800e-1b9e47e0a020" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_6ad40c95-2dd3-4416-ad98-328bc62bd8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_efba33de-c2ea-4eb0-be47-68f9dea5d9af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_6ad40c95-2dd3-4416-ad98-328bc62bd8fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_407c365d-3101-441c-a9cd-55b631433c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_efba33de-c2ea-4eb0-be47-68f9dea5d9af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_407c365d-3101-441c-a9cd-55b631433c5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_b5d5961b-25c6-4408-85f5-706faffe5cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_efba33de-c2ea-4eb0-be47-68f9dea5d9af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_b5d5961b-25c6-4408-85f5-706faffe5cd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea32f4f9-f652-4a84-96b4-f6ccf7e3fa22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c803e02d-be6d-494a-8fe9-e2253e0018a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea32f4f9-f652-4a84-96b4-f6ccf7e3fa22" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c803e02d-be6d-494a-8fe9-e2253e0018a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3a9ac34b-7566-49ad-bf0f-205d16c69713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea32f4f9-f652-4a84-96b4-f6ccf7e3fa22" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_3a9ac34b-7566-49ad-bf0f-205d16c69713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_e839dbb4-cb60-437b-b963-24d75998ac53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea32f4f9-f652-4a84-96b4-f6ccf7e3fa22" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_e839dbb4-cb60-437b-b963-24d75998ac53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_2557dc44-b8bc-4bb4-8e99-a50b25d2c90a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea32f4f9-f652-4a84-96b4-f6ccf7e3fa22" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_2557dc44-b8bc-4bb4-8e99-a50b25d2c90a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_7dc7744f-b9f0-4034-834c-9cb7f79e7b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ea32f4f9-f652-4a84-96b4-f6ccf7e3fa22" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_7dc7744f-b9f0-4034-834c-9cb7f79e7b2b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_287da967-6daa-4097-85e2-5914b2d73d97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0408d5fe-a7e6-4edc-aee5-8dc4537d1ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_287da967-6daa-4097-85e2-5914b2d73d97" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0408d5fe-a7e6-4edc-aee5-8dc4537d1ec0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_59301a51-4c71-4fd5-9114-9f2fca341659" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_287da967-6daa-4097-85e2-5914b2d73d97" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_59301a51-4c71-4fd5-9114-9f2fca341659" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_45ff3853-134c-424b-9810-da7e8caced61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_287da967-6daa-4097-85e2-5914b2d73d97" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_45ff3853-134c-424b-9810-da7e8caced61" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/MEDICAREPARTDDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#MEDICAREPARTDDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/MEDICAREPARTDDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_hum_NetNoncurrentAssetLiability_77ec2810-c89b-43e5-92e4-abcfce40c5c0" xlink:href="hum-20231231.xsd#hum_NetNoncurrentAssetLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c8e20110-b72c-49e8-91e0-106ed3c913b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_NetNoncurrentAssetLiability_77ec2810-c89b-43e5-92e4-abcfce40c5c0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c8e20110-b72c-49e8-91e0-106ed3c913b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3b93ba52-8673-4782-a948-94dc048a2710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_NetNoncurrentAssetLiability_77ec2810-c89b-43e5-92e4-abcfce40c5c0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3b93ba52-8673-4782-a948-94dc048a2710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NetCurrentLiabilityAsset_a6f62fca-4ce7-40ec-a4ee-8204e0869108" xlink:href="hum-20231231.xsd#hum_NetCurrentLiabilityAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_8346737b-78a0-42ee-a817-5291f48b709e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_NetCurrentLiabilityAsset_a6f62fca-4ce7-40ec-a4ee-8204e0869108" xlink:to="loc_us-gaap_OtherAssetsCurrent_8346737b-78a0-42ee-a817-5291f48b709e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d6eea528-befb-4aba-bf8c-4eab12e03c46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_NetCurrentLiabilityAsset_a6f62fca-4ce7-40ec-a4ee-8204e0869108" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_d6eea528-befb-4aba-bf8c-4eab12e03c46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NetAssetLiability_0fc63107-163f-4d8a-9d0f-eecdd0c26b0f" xlink:href="hum-20231231.xsd#hum_NetAssetLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NetCurrentLiabilityAsset_354e8bfb-79b4-4418-8c48-d3343beea380" xlink:href="hum-20231231.xsd#hum_NetCurrentLiabilityAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_NetAssetLiability_0fc63107-163f-4d8a-9d0f-eecdd0c26b0f" xlink:to="loc_hum_NetCurrentLiabilityAsset_354e8bfb-79b4-4418-8c48-d3343beea380" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NetNoncurrentAssetLiability_a5a8c3aa-5847-4dc1-9307-7f09ddd2b61e" xlink:href="hum-20231231.xsd#hum_NetNoncurrentAssetLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_NetAssetLiability_0fc63107-163f-4d8a-9d0f-eecdd0c26b0f" xlink:to="loc_hum_NetNoncurrentAssetLiability_a5a8c3aa-5847-4dc1-9307-7f09ddd2b61e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_38e14732-7b9d-49de-abff-5e3cbe015fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7b827268-c1a5-4c04-9c32-59b17dddacf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_38e14732-7b9d-49de-abff-5e3cbe015fb9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7b827268-c1a5-4c04-9c32-59b17dddacf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8f48de49-b71d-4431-a9a7-92bcad59f120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_38e14732-7b9d-49de-abff-5e3cbe015fb9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8f48de49-b71d-4431-a9a7-92bcad59f120" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b05c7471-2ba5-4485-bccf-75bd277ec0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8fea069d-683a-4b57-98cc-594779e185b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b05c7471-2ba5-4485-bccf-75bd277ec0a3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8fea069d-683a-4b57-98cc-594779e185b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_01142d68-2d12-49ee-b6c9-0849ef102932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b05c7471-2ba5-4485-bccf-75bd277ec0a3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_01142d68-2d12-49ee-b6c9-0849ef102932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d96c13ad-f30d-4b2f-9f15-749711019960" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7810e7da-c33c-4cf9-bacb-44802f5d0d49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d96c13ad-f30d-4b2f-9f15-749711019960" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7810e7da-c33c-4cf9-bacb-44802f5d0d49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_03f73202-2f8b-4837-ba36-b4186b9bffd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_d96c13ad-f30d-4b2f-9f15-749711019960" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_03f73202-2f8b-4837-ba36-b4186b9bffd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f3764f5c-db5d-481c-bad8-1995c8c31f12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c4ead773-2156-4733-99d0-825b88f9c41f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f3764f5c-db5d-481c-bad8-1995c8c31f12" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c4ead773-2156-4733-99d0-825b88f9c41f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_23ccae70-6020-4bc6-8180-a9d144217d22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f3764f5c-db5d-481c-bad8-1995c8c31f12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_23ccae70-6020-4bc6-8180-a9d144217d22" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#LEASESMaturityofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_48f95cf1-ae82-40d7-8481-e84949c69ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_810bf2d1-24b8-41c6-94bc-15bc90acfd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_48f95cf1-ae82-40d7-8481-e84949c69ca2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_810bf2d1-24b8-41c6-94bc-15bc90acfd6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2cf7edeb-4db5-4f52-aaf2-a5dd25d9bb19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_48f95cf1-ae82-40d7-8481-e84949c69ca2" xlink:to="loc_us-gaap_OperatingLeaseLiability_2cf7edeb-4db5-4f52-aaf2-a5dd25d9bb19" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="hum-20231231.xsd#LEASESMaturityofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1bd511a1-1e4f-4fcf-a50c-144465aa7a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2b61100a-2ea5-4338-be56-08a3632dbf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1bd511a1-1e4f-4fcf-a50c-144465aa7a7f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2b61100a-2ea5-4338-be56-08a3632dbf2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a1c9fe42-94f5-4f47-ab7d-424248c4ba28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1bd511a1-1e4f-4fcf-a50c-144465aa7a7f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a1c9fe42-94f5-4f47-ab7d-424248c4ba28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cc5cbe16-73e3-45fa-8a2b-dffec901e8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1bd511a1-1e4f-4fcf-a50c-144465aa7a7f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_cc5cbe16-73e3-45fa-8a2b-dffec901e8ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3ea013b4-c5f3-4cd7-a7d1-13b731b3680b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1bd511a1-1e4f-4fcf-a50c-144465aa7a7f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3ea013b4-c5f3-4cd7-a7d1-13b731b3680b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8d1f4419-e389-4079-91bd-923051c8900e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1bd511a1-1e4f-4fcf-a50c-144465aa7a7f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8d1f4419-e389-4079-91bd-923051c8900e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d8e9ef41-1045-4749-80fa-2396377e824b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1bd511a1-1e4f-4fcf-a50c-144465aa7a7f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_d8e9ef41-1045-4749-80fa-2396377e824b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#BENEFITSPAYABLEActivityinBenefitsPayableDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_f621b44b-4bde-4677-8034-2ffb17b3a1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_d795e2b2-753d-409f-b58e-dcef648810cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_f621b44b-4bde-4677-8034-2ffb17b3a1c2" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_d795e2b2-753d-409f-b58e-dcef648810cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_84fe3655-6dd7-4ed9-af62-948eab7569e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_f621b44b-4bde-4677-8034-2ffb17b3a1c2" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_84fe3655-6dd7-4ed9-af62-948eab7569e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_8592635f-1c57-45de-a985-bd36959667f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_578e4b78-922a-4db5-9d24-747a79d51e50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_8592635f-1c57-45de-a985-bd36959667f2" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_578e4b78-922a-4db5-9d24-747a79d51e50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_c467ae10-ffac-4f05-a02e-ed6e8e2502a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_8592635f-1c57-45de-a985-bd36959667f2" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_c467ae10-ffac-4f05-a02e-ed6e8e2502a7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_84d88f4e-0365-4df5-9ba7-8868abc24194" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_36db5683-77c3-4f50-a1b3-1f49d83854a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_84d88f4e-0365-4df5-9ba7-8868abc24194" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_36db5683-77c3-4f50-a1b3-1f49d83854a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_1afcfe35-9c12-44f7-be11-1453d17797af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_84d88f4e-0365-4df5-9ba7-8868abc24194" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_1afcfe35-9c12-44f7-be11-1453d17797af" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INCOMETAXESProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_77473de4-09f0-46a2-900a-ee63ed8f56d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_cbd7e968-2fa9-41ed-90b3-db501e6bc8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_77473de4-09f0-46a2-900a-ee63ed8f56d4" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_cbd7e968-2fa9-41ed-90b3-db501e6bc8c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c3c98c33-ad01-415a-a20a-11197e7ac4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_77473de4-09f0-46a2-900a-ee63ed8f56d4" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c3c98c33-ad01-415a-a20a-11197e7ac4ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2e67096c-7512-4c57-8458-ba16bb2f82fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0deb8fa8-c87d-4d09-ae74-d4c4a667d602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2e67096c-7512-4c57-8458-ba16bb2f82fe" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_0deb8fa8-c87d-4d09-ae74-d4c4a667d602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_572ce64e-e093-468a-b87f-97d5e8877426" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_2e67096c-7512-4c57-8458-ba16bb2f82fe" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_572ce64e-e093-468a-b87f-97d5e8877426" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INCOMETAXESProvisionforIncomeTaxesReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a8fdcd4b-9d72-43a0-883e-a5552e406291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_526305f4-d518-4d24-8fcd-a1bfca187ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a8fdcd4b-9d72-43a0-883e-a5552e406291" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_526305f4-d518-4d24-8fcd-a1bfca187ffb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7e4c95e4-dabf-489a-bbb9-4d787c72a2f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a8fdcd4b-9d72-43a0-883e-a5552e406291" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7e4c95e4-dabf-489a-bbb9-4d787c72a2f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain_2dd3982c-0854-4bed-bfb5-3d9c079476b8" xlink:href="hum-20231231.xsd#hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a8fdcd4b-9d72-43a0-883e-a5552e406291" xlink:to="loc_hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain_2dd3982c-0854-4bed-bfb5-3d9c079476b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome_cf911ef4-b376-47b9-8b7d-dfca6acd0253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a8fdcd4b-9d72-43a0-883e-a5552e406291" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome_cf911ef4-b376-47b9-8b7d-dfca6acd0253" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_3c96a4f9-4323-4b33-b9cc-3ab0f0ddd4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a8fdcd4b-9d72-43a0-883e-a5552e406291" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_3c96a4f9-4323-4b33-b9cc-3ab0f0ddd4ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_558de95a-01ac-495c-8602-efd19cce39ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a8fdcd4b-9d72-43a0-883e-a5552e406291" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_558de95a-01ac-495c-8602-efd19cce39ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_88384bf2-6908-4367-9af9-130f08ff920c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a8fdcd4b-9d72-43a0-883e-a5552e406291" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_88384bf2-6908-4367-9af9-130f08ff920c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_813fd13b-ab99-4d0b-935a-610662e424b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a8fdcd4b-9d72-43a0-883e-a5552e406291" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_813fd13b-ab99-4d0b-935a-610662e424b0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_cc8d435c-5ace-4cb2-ba18-fc1bcaa21d00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets_83c95e10-b664-4bd9-bf53-f90d7901a8f3" xlink:href="hum-20231231.xsd#hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_cc8d435c-5ace-4cb2-ba18-fc1bcaa21d00" xlink:to="loc_hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets_83c95e10-b664-4bd9-bf53-f90d7901a8f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_d25168fd-5070-40de-94a4-c326f064869b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_cc8d435c-5ace-4cb2-ba18-fc1bcaa21d00" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_d25168fd-5070-40de-94a4-c326f064869b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_286885e9-eb9e-4813-9def-fe32c74a648d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_cc8d435c-5ace-4cb2-ba18-fc1bcaa21d00" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_286885e9-eb9e-4813-9def-fe32c74a648d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_d7c32eda-813b-4f78-80de-179dce85530e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_04aa6e27-5b53-4ed2-b604-4dae955563d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_d7c32eda-813b-4f78-80de-179dce85530e" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_04aa6e27-5b53-4ed2-b604-4dae955563d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_9a965b9c-5fd0-48af-b102-3623acc9a5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_d7c32eda-813b-4f78-80de-179dce85530e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_9a965b9c-5fd0-48af-b102-3623acc9a5f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8d85065b-80bf-4b6e-9303-b7746c00f1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_710979bb-5e19-41e2-892a-37b347d04f71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8d85065b-80bf-4b6e-9303-b7746c00f1b7" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_710979bb-5e19-41e2-892a-37b347d04f71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_14685125-127e-4942-a5c5-732ce5f29212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8d85065b-80bf-4b6e-9303-b7746c00f1b7" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_14685125-127e-4942-a5c5-732ce5f29212" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1769ccb3-ff35-43ce-9bb7-a1f7a6528c91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_3f1a2452-10cd-457a-a4d7-8b16fd032023" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1769ccb3-ff35-43ce-9bb7-a1f7a6528c91" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_3f1a2452-10cd-457a-a4d7-8b16fd032023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a22d719a-8617-48dd-b441-87ea264912db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_1769ccb3-ff35-43ce-9bb7-a1f7a6528c91" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a22d719a-8617-48dd-b441-87ea264912db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_5ae42f8a-9df2-4c5a-a9e9-a2d601582454" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_9a056b6c-eec1-40be-a0b5-2c444ddb142c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5ae42f8a-9df2-4c5a-a9e9-a2d601582454" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_9a056b6c-eec1-40be-a0b5-2c444ddb142c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_cbb00912-94b2-46d6-b788-b7887eb5862c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5ae42f8a-9df2-4c5a-a9e9-a2d601582454" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_cbb00912-94b2-46d6-b788-b7887eb5862c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f15dbdcb-a5df-4676-b3e4-dac78d742ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5ae42f8a-9df2-4c5a-a9e9-a2d601582454" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_f15dbdcb-a5df-4676-b3e4-dac78d742ef6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve_3fea6574-b19d-4ae0-ab96-817cf2ea1301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5ae42f8a-9df2-4c5a-a9e9-a2d601582454" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve_3fea6574-b19d-4ae0-ab96-817cf2ea1301" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost_34716c47-f362-4972-8890-9fc43b3dab87" xlink:href="hum-20231231.xsd#hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5ae42f8a-9df2-4c5a-a9e9-a2d601582454" xlink:to="loc_hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost_34716c47-f362-4972-8890-9fc43b3dab87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DeferredTaxAssetJobsTaxCredit_1a9e493e-ab09-468d-8505-28034ce8ef28" xlink:href="hum-20231231.xsd#hum_DeferredTaxAssetJobsTaxCredit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5ae42f8a-9df2-4c5a-a9e9-a2d601582454" xlink:to="loc_hum_DeferredTaxAssetJobsTaxCredit_1a9e493e-ab09-468d-8505-28034ce8ef28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_d0d7eef6-bdc3-4352-97d0-417ed82074c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5ae42f8a-9df2-4c5a-a9e9-a2d601582454" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_d0d7eef6-bdc3-4352-97d0-417ed82074c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_887e6e1e-71e8-4cfb-b689-aef552c7d263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_5ae42f8a-9df2-4c5a-a9e9-a2d601582454" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_887e6e1e-71e8-4cfb-b689-aef552c7d263" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/DEBTDebtOutstandingDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#DEBTDebtOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/DEBTDebtOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_fe945e14-9fc2-48d7-a799-055abd6c80f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_84f2212d-7127-4905-ba74-172a23a522df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_fe945e14-9fc2-48d7-a799-055abd6c80f6" xlink:to="loc_us-gaap_ShortTermBorrowings_84f2212d-7127-4905-ba74-172a23a522df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_56402061-5cc3-474e-af4a-19ba98a61a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_fe945e14-9fc2-48d7-a799-055abd6c80f6" xlink:to="loc_us-gaap_LongTermDebtCurrent_56402061-5cc3-474e-af4a-19ba98a61a5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6c2f9b50-ed14-451e-b3ca-53e13ba8fbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_02614856-5601-4844-8570-544037d6e798" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6c2f9b50-ed14-451e-b3ca-53e13ba8fbcd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_02614856-5601-4844-8570-544037d6e798" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_4776180b-68b8-4f74-b3bb-23198138bfad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6c2f9b50-ed14-451e-b3ca-53e13ba8fbcd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_4776180b-68b8-4f74-b3bb-23198138bfad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EARNINGSPERCOMMONSHARECOMPUTATIONDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_25ec5e3d-ff8e-444d-9b84-b3500867a90c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_25440cb6-042e-460e-aaba-bf27668ee4d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_25ec5e3d-ff8e-444d-9b84-b3500867a90c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_25440cb6-042e-460e-aaba-bf27668ee4d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_133503dd-636e-4e8d-85d4-47b68f9e6e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_25ec5e3d-ff8e-444d-9b84-b3500867a90c" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_133503dd-636e-4e8d-85d4-47b68f9e6e1a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SEGMENTINFORMATIONSegmentResultsDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b28926bf-576c-4b87-910f-386dff14e924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ce7d8d27-8f4c-443c-b88b-9ef9ec1aff6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b28926bf-576c-4b87-910f-386dff14e924" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ce7d8d27-8f4c-443c-b88b-9ef9ec1aff6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_21972247-2d34-4042-857a-e9f8a3eb6067" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b28926bf-576c-4b87-910f-386dff14e924" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_21972247-2d34-4042-857a-e9f8a3eb6067" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent_578e611b-3788-43a1-8c7b-4eb938898bb6" xlink:href="hum-20231231.xsd#hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6818a3a0-8d64-40b7-bafd-a95cd94561f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent_578e611b-3788-43a1-8c7b-4eb938898bb6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6818a3a0-8d64-40b7-bafd-a95cd94561f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0f43bd69-fef2-4921-b7b4-c6be869b9fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent_578e611b-3788-43a1-8c7b-4eb938898bb6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0f43bd69-fef2-4921-b7b4-c6be869b9fc2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0454b221-cbce-40d4-8587-9a22a3193452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InvestmentInRelatedPartiesAndSubsidiaries_d8e0c44c-51f4-47b5-975b-f57d9042e0e7" xlink:href="hum-20231231.xsd#hum_InvestmentInRelatedPartiesAndSubsidiaries"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0454b221-cbce-40d4-8587-9a22a3193452" xlink:to="loc_hum_InvestmentInRelatedPartiesAndSubsidiaries_d8e0c44c-51f4-47b5-975b-f57d9042e0e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4551d19a-63c2-42c4-85f5-75d96696ea77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0454b221-cbce-40d4-8587-9a22a3193452" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4551d19a-63c2-42c4-85f5-75d96696ea77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5ce73828-18a9-4ddf-8d68-5647c92a753a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0454b221-cbce-40d4-8587-9a22a3193452" xlink:to="loc_us-gaap_AssetsCurrent_5ce73828-18a9-4ddf-8d68-5647c92a753a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8a162fb7-6789-4f14-bfa6-02ceb9481ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0454b221-cbce-40d4-8587-9a22a3193452" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8a162fb7-6789-4f14-bfa6-02ceb9481ebc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2ea0b1f1-3d8b-4ae0-8da2-4326c5444f61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_63f595f4-7e40-4527-b3fa-038cdd4a7a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ea0b1f1-3d8b-4ae0-8da2-4326c5444f61" xlink:to="loc_us-gaap_DebtCurrent_63f595f4-7e40-4527-b3fa-038cdd4a7a1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_b2e556d1-fe15-4fc3-8101-8cf95d714dee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ea0b1f1-3d8b-4ae0-8da2-4326c5444f61" xlink:to="loc_us-gaap_NotesPayableCurrent_b2e556d1-fe15-4fc3-8101-8cf95d714dee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BookOverdraftLiability_431347ca-c59a-461c-a22b-25407746751e" xlink:href="hum-20231231.xsd#hum_BookOverdraftLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ea0b1f1-3d8b-4ae0-8da2-4326c5444f61" xlink:to="loc_hum_BookOverdraftLiability_431347ca-c59a-461c-a22b-25407746751e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_91e45489-35d3-49e4-afb6-c0efd1b4f9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ea0b1f1-3d8b-4ae0-8da2-4326c5444f61" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_91e45489-35d3-49e4-afb6-c0efd1b4f9a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7e6f8c98-3a3f-485a-9fbf-b7174680f097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ea0b1f1-3d8b-4ae0-8da2-4326c5444f61" xlink:to="loc_us-gaap_AccountsPayableCurrent_7e6f8c98-3a3f-485a-9fbf-b7174680f097" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries_81f84394-5b81-4d9e-aa76-a4ec9122439d" xlink:href="hum-20231231.xsd#hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4141d167-7994-45b6-9850-929384c12990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries_81f84394-5b81-4d9e-aa76-a4ec9122439d" xlink:to="loc_us-gaap_CostsAndExpenses_4141d167-7994-45b6-9850-929384c12990" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_c30a037c-4ba4-43ee-8e85-4cce4c65a6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries_81f84394-5b81-4d9e-aa76-a4ec9122439d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_c30a037c-4ba4-43ee-8e85-4cce4c65a6ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d118e746-c1fa-4ee9-9b78-cfd6a58842f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries_81f84394-5b81-4d9e-aa76-a4ec9122439d" xlink:to="loc_us-gaap_Revenues_d118e746-c1fa-4ee9-9b78-cfd6a58842f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5b9b4012-71d2-4930-878c-07f06c12ee8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InvestmentAndOtherIncomeNet_aa509115-5e67-4620-8b99-16ac3bf23e56" xlink:href="hum-20231231.xsd#hum_InvestmentAndOtherIncomeNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_5b9b4012-71d2-4930-878c-07f06c12ee8c" xlink:to="loc_hum_InvestmentAndOtherIncomeNet_aa509115-5e67-4620-8b99-16ac3bf23e56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ManagementFeesChargedToOperatingSubsidiaries_45f8f3cd-df7b-4d80-8623-0141ca2c1f96" xlink:href="hum-20231231.xsd#hum_ManagementFeesChargedToOperatingSubsidiaries"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_5b9b4012-71d2-4930-878c-07f06c12ee8c" xlink:to="loc_hum_ManagementFeesChargedToOperatingSubsidiaries_45f8f3cd-df7b-4d80-8623-0141ca2c1f96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1602768f-637b-4186-8bc7-59850e0ecdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8b46ef16-631e-44c4-93a9-c0e82248b75d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1602768f-637b-4186-8bc7-59850e0ecdf1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8b46ef16-631e-44c4-93a9-c0e82248b75d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_EquityInNetEarningsOfSubsidiaries_32d37eff-afe6-407c-953d-93abc5988109" xlink:href="hum-20231231.xsd#hum_EquityInNetEarningsOfSubsidiaries"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1602768f-637b-4186-8bc7-59850e0ecdf1" xlink:to="loc_hum_EquityInNetEarningsOfSubsidiaries_32d37eff-afe6-407c-953d-93abc5988109" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries_50691509-de52-44d9-96bb-45663883b358" xlink:href="hum-20231231.xsd#hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1602768f-637b-4186-8bc7-59850e0ecdf1" xlink:to="loc_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries_50691509-de52-44d9-96bb-45663883b358" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries_c40db0ce-fb0e-446b-9312-338f23e1c85c" xlink:href="hum-20231231.xsd#hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries_02568035-25fc-4e75-80c0-14de82286eaf" xlink:href="hum-20231231.xsd#hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries_c40db0ce-fb0e-446b-9312-338f23e1c85c" xlink:to="loc_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries_02568035-25fc-4e75-80c0-14de82286eaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_10e845bc-ee14-461a-93d4-635861cf98d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries_c40db0ce-fb0e-446b-9312-338f23e1c85c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_10e845bc-ee14-461a-93d4-635861cf98d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_dcede01b-f306-4e02-932a-521eddf48354" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c147cdce-0727-40d6-8eb8-4e71f2a54c82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dcede01b-f306-4e02-932a-521eddf48354" xlink:to="loc_us-gaap_InterestExpense_c147cdce-0727-40d6-8eb8-4e71f2a54c82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_bad3293d-74c8-4c3c-99b7-64383da7baf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dcede01b-f306-4e02-932a-521eddf48354" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_bad3293d-74c8-4c3c-99b7-64383da7baf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1209bc62-b6be-4bf9-8a97-ac9d56d8389b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_dcede01b-f306-4e02-932a-521eddf48354" xlink:to="loc_us-gaap_Depreciation_1209bc62-b6be-4bf9-8a97-ac9d56d8389b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"/>
  <link:calculationLink xlink:role="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08125581-fd56-4b6f-9479-cd632315a301" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_8ace05a1-bd0d-4961-b4b9-b0d1cb8ca8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfCommercialPaper"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08125581-fd56-4b6f-9479-cd632315a301" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_8ace05a1-bd0d-4961-b4b9-b0d1cb8ca8d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b2ffd7a6-3f3a-4611-9be5-6340c44339e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08125581-fd56-4b6f-9479-cd632315a301" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b2ffd7a6-3f3a-4611-9be5-6340c44339e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInBookOverdrafts_a81698fd-6099-44ee-9872-cfbc1bdcb9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInBookOverdrafts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08125581-fd56-4b6f-9479-cd632315a301" xlink:to="loc_us-gaap_IncreaseDecreaseInBookOverdrafts_a81698fd-6099-44ee-9872-cfbc1bdcb9c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ProceedsFromStockOptionsExercisedAndOther_4a48b6bb-9ec6-4631-bbf2-1c248028ea4f" xlink:href="hum-20231231.xsd#hum_ProceedsFromStockOptionsExercisedAndOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08125581-fd56-4b6f-9479-cd632315a301" xlink:to="loc_hum_ProceedsFromStockOptionsExercisedAndOther_4a48b6bb-9ec6-4631-bbf2-1c248028ea4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_b801ae91-4b15-4eda-a1a0-58595ebfdd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08125581-fd56-4b6f-9479-cd632315a301" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_b801ae91-4b15-4eda-a1a0-58595ebfdd7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_d0448b12-11f2-4951-8017-d836784f9a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08125581-fd56-4b6f-9479-cd632315a301" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_d0448b12-11f2-4951-8017-d836784f9a5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_ab0fdd1b-8b05-431e-a544-350dbc113006" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08125581-fd56-4b6f-9479-cd632315a301" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_ab0fdd1b-8b05-431e-a544-350dbc113006" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_d5cffaaa-d586-4451-ad07-16c5a5097143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08125581-fd56-4b6f-9479-cd632315a301" xlink:to="loc_us-gaap_PaymentsOfDividends_d5cffaaa-d586-4451-ad07-16c5a5097143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_6db3225d-a147-4d3d-b815-1be5c3a27c03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_08125581-fd56-4b6f-9479-cd632315a301" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_6db3225d-a147-4d3d-b815-1be5c3a27c03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ec7b426-bb3b-421c-bae0-07b16fa5e6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CapitalContributionsToOperatingSubsidiaries_e7473277-20d0-4fff-90af-e628bdd7eec5" xlink:href="hum-20231231.xsd#hum_CapitalContributionsToOperatingSubsidiaries"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ec7b426-bb3b-421c-bae0-07b16fa5e6f8" xlink:to="loc_hum_CapitalContributionsToOperatingSubsidiaries_e7473277-20d0-4fff-90af-e628bdd7eec5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_6fb77f5d-24ff-41ab-9a3a-2c7b8ef902c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ec7b426-bb3b-421c-bae0-07b16fa5e6f8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_6fb77f5d-24ff-41ab-9a3a-2c7b8ef902c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5b26cae4-2897-4e21-bd98-dc4224bf0b50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ec7b426-bb3b-421c-bae0-07b16fa5e6f8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5b26cae4-2897-4e21-bd98-dc4224bf0b50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_506c48dd-be8d-450d-98bf-c5aabcdf0544" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ec7b426-bb3b-421c-bae0-07b16fa5e6f8" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_506c48dd-be8d-450d-98bf-c5aabcdf0544" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_da4982c4-18c1-4fac-981c-043705d592a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ec7b426-bb3b-421c-bae0-07b16fa5e6f8" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_da4982c4-18c1-4fac-981c-043705d592a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0cdc5860-e427-433b-8da6-bd52e74a5bce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ec7b426-bb3b-421c-bae0-07b16fa5e6f8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0cdc5860-e427-433b-8da6-bd52e74a5bce" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>hum-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:7bfbafa3-a477-4092-82f1-790bd65455d7,g:6b53bb4a-2282-4b95-aa2c-e78c6730e17d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="hum-20231231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bb8e3e2f-c7ea-43f9-9980-18a85f3f604a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1637d3d6-b14c-4c6d-a7ef-b23a0e383ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_bb8e3e2f-c7ea-43f9-9980-18a85f3f604a" xlink:to="loc_us-gaap_StatementTable_1637d3d6-b14c-4c6d-a7ef-b23a0e383ba8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_73f38c9c-6af7-4b47-ba27-10eded29c140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1637d3d6-b14c-4c6d-a7ef-b23a0e383ba8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_73f38c9c-6af7-4b47-ba27-10eded29c140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_73f38c9c-6af7-4b47-ba27-10eded29c140_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_73f38c9c-6af7-4b47-ba27-10eded29c140" xlink:to="loc_us-gaap_EquityComponentDomain_73f38c9c-6af7-4b47-ba27-10eded29c140_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_749423b0-1181-4226-a1a3-86a876364b47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_73f38c9c-6af7-4b47-ba27-10eded29c140" xlink:to="loc_us-gaap_EquityComponentDomain_749423b0-1181-4226-a1a3-86a876364b47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_a964ffc7-155e-4511-ba30-81c53c58a41c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_749423b0-1181-4226-a1a3-86a876364b47" xlink:to="loc_us-gaap_ParentMember_a964ffc7-155e-4511-ba30-81c53c58a41c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_030a02f0-b19a-4ad5-b7f7-b80f78db8ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_a964ffc7-155e-4511-ba30-81c53c58a41c" xlink:to="loc_us-gaap_CommonStockMember_030a02f0-b19a-4ad5-b7f7-b80f78db8ea9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_07c3b27f-3f01-42e3-8476-905495c93480" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_a964ffc7-155e-4511-ba30-81c53c58a41c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_07c3b27f-3f01-42e3-8476-905495c93480" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1ec0afb1-9387-4d65-b5a9-697faeedec18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_a964ffc7-155e-4511-ba30-81c53c58a41c" xlink:to="loc_us-gaap_RetainedEarningsMember_1ec0afb1-9387-4d65-b5a9-697faeedec18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8b552557-9093-454d-8804-a704d8997f41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_a964ffc7-155e-4511-ba30-81c53c58a41c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8b552557-9093-454d-8804-a704d8997f41" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_95564c4f-ae68-475c-9ec2-67ef8a40c132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_a964ffc7-155e-4511-ba30-81c53c58a41c" xlink:to="loc_us-gaap_TreasuryStockCommonMember_95564c4f-ae68-475c-9ec2-67ef8a40c132" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_a12cc832-bced-4dc9-a561-0730def7714d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_749423b0-1181-4226-a1a3-86a876364b47" xlink:to="loc_us-gaap_NoncontrollingInterestMember_a12cc832-bced-4dc9-a561-0730def7714d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_bb8e3e2f-c7ea-43f9-9980-18a85f3f604a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c80c6ba8-4e1e-409f-9d97-7d509013c705" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c80c6ba8-4e1e-409f-9d97-7d509013c705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b19d5ed-14da-4172-94a4-ba93d0fd34df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b19d5ed-14da-4172-94a4-ba93d0fd34df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8777224b-8293-435a-9208-84ec2ba781fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_ProfitLoss_8777224b-8293-435a-9208-84ec2ba781fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders_cb3ebebd-73ac-472d-918e-3376ddfafe1a" xlink:href="hum-20231231.xsd#hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders_cb3ebebd-73ac-472d-918e-3376ddfafe1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_a3c07dc5-a330-4a0b-9e5e-a29468f99e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_a3c07dc5-a330-4a0b-9e5e-a29468f99e4f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_80e93217-fdeb-456c-bd5f-6fb6ad8cb146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_80e93217-fdeb-456c-bd5f-6fb6ad8cb146" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_784707a1-58d6-402d-ae9d-954f43c58555" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_784707a1-58d6-402d-ae9d-954f43c58555" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f67aa063-88ca-45c4-8b91-7f9db9f5bdd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f67aa063-88ca-45c4-8b91-7f9db9f5bdd3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_f6ba7b02-0f7a-4d4b-8af8-0cbe173b0c95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_DividendsCommonStockCash_f6ba7b02-0f7a-4d4b-8af8-0cbe173b0c95" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f0cdd302-1e31-45f4-9b5d-dd43180039b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f0cdd302-1e31-45f4-9b5d-dd43180039b5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_98e64a5f-b96d-420c-8158-d9214ea5a136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_98e64a5f-b96d-420c-8158-d9214ea5a136" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_98321690-e5a2-4abf-90a9-5798f8fa6404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_98321690-e5a2-4abf-90a9-5798f8fa6404" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e8d88a9d-b516-4651-a47a-6e4b31dc3645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e8d88a9d-b516-4651-a47a-6e4b31dc3645" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_056a2475-61e7-42f8-b60d-b291e97469a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ef487393-6f8f-4647-80e9-fcf756d2fec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/REPORTINGENTITYDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#REPORTINGENTITYDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/REPORTINGENTITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_d9fecca3-a5f9-40d0-bc84-5c8b39e10849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_8d3add52-6029-4b7c-b835-88f4b4de14f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d9fecca3-a5f9-40d0-bc84-5c8b39e10849" xlink:to="loc_us-gaap_ConcentrationRiskTable_8d3add52-6029-4b7c-b835-88f4b4de14f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_208753b0-ea65-441e-a642-9cbdc5073c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8d3add52-6029-4b7c-b835-88f4b4de14f0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_208753b0-ea65-441e-a642-9cbdc5073c5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_208753b0-ea65-441e-a642-9cbdc5073c5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_208753b0-ea65-441e-a642-9cbdc5073c5f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_208753b0-ea65-441e-a642-9cbdc5073c5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_63a1d8d4-0f0e-48e6-b09f-f77b0699ed2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_208753b0-ea65-441e-a642-9cbdc5073c5f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_63a1d8d4-0f0e-48e6-b09f-f77b0699ed2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_bd35fa49-a5d1-40bb-9dad-2a9ddccf84a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_63a1d8d4-0f0e-48e6-b09f-f77b0699ed2a" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_bd35fa49-a5d1-40bb-9dad-2a9ddccf84a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_95c526ac-f0cd-425e-8713-0380d46267fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8d3add52-6029-4b7c-b835-88f4b4de14f0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_95c526ac-f0cd-425e-8713-0380d46267fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_95c526ac-f0cd-425e-8713-0380d46267fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_95c526ac-f0cd-425e-8713-0380d46267fb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_95c526ac-f0cd-425e-8713-0380d46267fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5a37b9b7-ff08-47d7-bdd7-c50655ab24df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_95c526ac-f0cd-425e-8713-0380d46267fb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5a37b9b7-ff08-47d7-bdd7-c50655ab24df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_888e3d90-e8c8-47bb-aee7-e2b3f541b07b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5a37b9b7-ff08-47d7-bdd7-c50655ab24df" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_888e3d90-e8c8-47bb-aee7-e2b3f541b07b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7fe989de-2ecd-48ea-8169-2eae1b024c5b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_8d3add52-6029-4b7c-b835-88f4b4de14f0" xlink:to="loc_srt_MajorCustomersAxis_7fe989de-2ecd-48ea-8169-2eae1b024c5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7fe989de-2ecd-48ea-8169-2eae1b024c5b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_7fe989de-2ecd-48ea-8169-2eae1b024c5b" xlink:to="loc_srt_NameOfMajorCustomerDomain_7fe989de-2ecd-48ea-8169-2eae1b024c5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4f11e22d-e3b8-4c3a-a870-f7ba897ffc1a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_7fe989de-2ecd-48ea-8169-2eae1b024c5b" xlink:to="loc_srt_NameOfMajorCustomerDomain_4f11e22d-e3b8-4c3a-a870-f7ba897ffc1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FederalGovernmentMember_787bf5a6-cabe-4604-894f-d76096387034" xlink:href="hum-20231231.xsd#hum_FederalGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4f11e22d-e3b8-4c3a-a870-f7ba897ffc1a" xlink:to="loc_hum_FederalGovernmentMember_787bf5a6-cabe-4604-894f-d76096387034" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember_59a70101-69cc-408f-836c-56a996148fa2" xlink:href="hum-20231231.xsd#hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4f11e22d-e3b8-4c3a-a870-f7ba897ffc1a" xlink:to="loc_hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember_59a70101-69cc-408f-836c-56a996148fa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_83a3d2af-7075-49f4-aac1-bcc598607099" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d9fecca3-a5f9-40d0-bc84-5c8b39e10849" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_83a3d2af-7075-49f4-aac1-bcc598607099" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:href="hum-20231231.xsd#hum_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:href="hum-20231231.xsd#hum_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceContractAxis_3cf54e77-2f94-46cc-94a6-45d4fda0bcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceContractAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_ReinsuranceContractAxis_3cf54e77-2f94-46cc-94a6-45d4fda0bcfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6603a9c8-3394-49f7-a538-642637fa879f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_srt_ProductOrServiceAxis_6603a9c8-3394-49f7-a538-642637fa879f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6603a9c8-3394-49f7-a538-642637fa879f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6603a9c8-3394-49f7-a538-642637fa879f" xlink:to="loc_srt_ProductsAndServicesDomain_6603a9c8-3394-49f7-a538-642637fa879f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e6fc3aad-ce7d-4aaf-9315-0469eb49a814" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6603a9c8-3394-49f7-a538-642637fa879f" xlink:to="loc_srt_ProductsAndServicesDomain_e6fc3aad-ce7d-4aaf-9315-0469eb49a814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_7224520c-8c68-4f13-ad6b-4e935848ac47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6fc3aad-ce7d-4aaf-9315-0469eb49a814" xlink:to="loc_us-gaap_ServiceMember_7224520c-8c68-4f13-ad6b-4e935848ac47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareSupplementProductMember_029f5517-d785-4fc9-8407-cf2f07ca28f7" xlink:href="hum-20231231.xsd#hum_MedicareSupplementProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6fc3aad-ce7d-4aaf-9315-0469eb49a814" xlink:to="loc_hum_MedicareSupplementProductMember_029f5517-d785-4fc9-8407-cf2f07ca28f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb43270b-61c1-42c5-9834-121f75353bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb43270b-61c1-42c5-9834-121f75353bb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb43270b-61c1-42c5-9834-121f75353bb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb43270b-61c1-42c5-9834-121f75353bb9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb43270b-61c1-42c5-9834-121f75353bb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a98b60c-3e70-4c18-98b2-96729a557aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb43270b-61c1-42c5-9834-121f75353bb9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a98b60c-3e70-4c18-98b2-96729a557aa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_19210c79-5c9e-4af2-a10d-83454a4a189c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a98b60c-3e70-4c18-98b2-96729a557aa9" xlink:to="loc_us-gaap_EquipmentMember_19210c79-5c9e-4af2-a10d-83454a4a189c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_12b89f2a-983e-4eb7-933a-6db4e8dc4363" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a98b60c-3e70-4c18-98b2-96729a557aa9" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_12b89f2a-983e-4eb7-933a-6db4e8dc4363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_0f7c15e5-ee32-404a-851a-7910c4aa3e09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a98b60c-3e70-4c18-98b2-96729a557aa9" xlink:to="loc_us-gaap_BuildingMember_0f7c15e5-ee32-404a-851a-7910c4aa3e09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_0835bc40-bb5d-4306-8309-cee423e256ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_ReportingUnitAxis_0835bc40-bb5d-4306-8309-cee423e256ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_0835bc40-bb5d-4306-8309-cee423e256ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_0835bc40-bb5d-4306-8309-cee423e256ab" xlink:to="loc_us-gaap_ReportingUnitDomain_0835bc40-bb5d-4306-8309-cee423e256ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_6061b16d-aaea-4da0-b91a-ed0593c982a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_0835bc40-bb5d-4306-8309-cee423e256ab" xlink:to="loc_us-gaap_ReportingUnitDomain_6061b16d-aaea-4da0-b91a-ed0593c982a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_HomeSolutionsReportingUnitMember_a3fd08d7-ef9c-4278-8c35-8fb0131c4e1b" xlink:href="hum-20231231.xsd#hum_HomeSolutionsReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_6061b16d-aaea-4da0-b91a-ed0593c982a5" xlink:to="loc_hum_HomeSolutionsReportingUnitMember_a3fd08d7-ef9c-4278-8c35-8fb0131c4e1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ProviderReportingUnitMember_c3740ffc-fe7a-449a-9f90-02bb6e8b5076" xlink:href="hum-20231231.xsd#hum_ProviderReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_6061b16d-aaea-4da0-b91a-ed0593c982a5" xlink:to="loc_hum_ProviderReportingUnitMember_c3740ffc-fe7a-449a-9f90-02bb6e8b5076" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3f8a9f31-f0f3-4b19-b54b-49f18872fb00" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_srt_RangeAxis_3f8a9f31-f0f3-4b19-b54b-49f18872fb00" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f8a9f31-f0f3-4b19-b54b-49f18872fb00_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3f8a9f31-f0f3-4b19-b54b-49f18872fb00" xlink:to="loc_srt_RangeMember_3f8a9f31-f0f3-4b19-b54b-49f18872fb00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c30ecab-354a-471d-97e9-0fdeaa81994f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3f8a9f31-f0f3-4b19-b54b-49f18872fb00" xlink:to="loc_srt_RangeMember_2c30ecab-354a-471d-97e9-0fdeaa81994f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6b3d4d5e-0029-441a-93c7-3035449af3b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2c30ecab-354a-471d-97e9-0fdeaa81994f" xlink:to="loc_srt_MinimumMember_6b3d4d5e-0029-441a-93c7-3035449af3b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1c9a82b9-9ba4-4663-8cdb-996ef8145abb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2c30ecab-354a-471d-97e9-0fdeaa81994f" xlink:to="loc_srt_MaximumMember_1c9a82b9-9ba4-4663-8cdb-996ef8145abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd9cc172-63e9-4361-9b9b-4620adb7afba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd9cc172-63e9-4361-9b9b-4620adb7afba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cd9cc172-63e9-4361-9b9b-4620adb7afba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd9cc172-63e9-4361-9b9b-4620adb7afba" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cd9cc172-63e9-4361-9b9b-4620adb7afba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f383a13a-1617-4319-b699-5573fb1acb08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd9cc172-63e9-4361-9b9b-4620adb7afba" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f383a13a-1617-4319-b699-5573fb1acb08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_07ad6d8f-fe61-43b1-8077-88be2280fc27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f383a13a-1617-4319-b699-5573fb1acb08" xlink:to="loc_us-gaap_SalesRevenueNetMember_07ad6d8f-fe61-43b1-8077-88be2280fc27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5ac49e92-cc4d-426b-867a-5342ecdfa7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5ac49e92-cc4d-426b-867a-5342ecdfa7c7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5ac49e92-cc4d-426b-867a-5342ecdfa7c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5ac49e92-cc4d-426b-867a-5342ecdfa7c7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5ac49e92-cc4d-426b-867a-5342ecdfa7c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c44aa83a-b5d1-4f63-90e6-2d48efae2c07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5ac49e92-cc4d-426b-867a-5342ecdfa7c7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c44aa83a-b5d1-4f63-90e6-2d48efae2c07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_c94a1e6b-7498-440f-ad9b-65b7fe5fefe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c44aa83a-b5d1-4f63-90e6-2d48efae2c07" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_c94a1e6b-7498-440f-ad9b-65b7fe5fefe1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_bd4ff641-be13-47fb-8357-8a95c16fc919" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_RestructuringPlanAxis_bd4ff641-be13-47fb-8357-8a95c16fc919" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_bd4ff641-be13-47fb-8357-8a95c16fc919_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_bd4ff641-be13-47fb-8357-8a95c16fc919" xlink:to="loc_us-gaap_RestructuringPlanDomain_bd4ff641-be13-47fb-8357-8a95c16fc919_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_ee9233d5-42c1-40dc-b8d9-4e87645360d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_bd4ff641-be13-47fb-8357-8a95c16fc919" xlink:to="loc_us-gaap_RestructuringPlanDomain_ee9233d5-42c1-40dc-b8d9-4e87645360d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ValueCreationInitiativesMember_26bbc550-c786-48cb-a1a3-b5456d269ecc" xlink:href="hum-20231231.xsd#hum_ValueCreationInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_ee9233d5-42c1-40dc-b8d9-4e87645360d6" xlink:to="loc_hum_ValueCreationInitiativesMember_26bbc550-c786-48cb-a1a3-b5456d269ecc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember_d0175efe-6b23-41f6-ad64-0b7e26d4319d" xlink:href="hum-20231231.xsd#hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_ee9233d5-42c1-40dc-b8d9-4e87645360d6" xlink:to="loc_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember_d0175efe-6b23-41f6-ad64-0b7e26d4319d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_97938347-29d4-4022-8c51-a80cc9acc1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_97938347-29d4-4022-8c51-a80cc9acc1b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_0d532744-6a69-4677-8fdb-1f3f8413bb84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_0d532744-6a69-4677-8fdb-1f3f8413bb84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_bd707659-46a6-43a2-abeb-e265f2de2f67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_SeveranceCosts1_bd707659-46a6-43a2-abeb-e265f2de2f67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a4d8dfe3-823b-4f03-b56c-f7dd1cd130ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_AssetImpairmentCharges_a4d8dfe3-823b-4f03-b56c-f7dd1cd130ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3fc7d31c-9018-4240-ac81-2151c275b24a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3fc7d31c-9018-4240-ac81-2151c275b24a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CommercialMembershipContractTerm_bef85b80-9d7f-42c8-8642-1c5cf1cac8cb" xlink:href="hum-20231231.xsd#hum_CommercialMembershipContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_CommercialMembershipContractTerm_bef85b80-9d7f-42c8-8642-1c5cf1cac8cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies_a21bd6cd-f6c4-4fde-82a7-fdd35354f641" xlink:href="hum-20231231.xsd#hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies_a21bd6cd-f6c4-4fde-82a7-fdd35354f641" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs_66c50444-0e75-4e59-b362-10c3c0e3fda8" xlink:href="hum-20231231.xsd#hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs_66c50444-0e75-4e59-b362-10c3c0e3fda8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SubsidyAndDiscountsSettlementPeriodAfterClose_a6cba838-7b7d-4b7c-be76-bf01cf0da63a" xlink:href="hum-20231231.xsd#hum_SubsidyAndDiscountsSettlementPeriodAfterClose"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_SubsidyAndDiscountsSettlementPeriodAfterClose_a6cba838-7b7d-4b7c-be76-bf01cf0da63a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_03e996f7-b5ef-4e8e-9783-b8fc6edd092f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_03e996f7-b5ef-4e8e-9783-b8fc6edd092f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_AccruedPharmaceuticalRebatesCurrent_c82a0e1d-4b72-4517-bf8b-1efde6058081" xlink:href="hum-20231231.xsd#hum_AccruedPharmaceuticalRebatesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_AccruedPharmaceuticalRebatesCurrent_c82a0e1d-4b72-4517-bf8b-1efde6058081" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies_9a765624-8085-4f1f-9cdf-17f87f7cfafc" xlink:href="hum-20231231.xsd#hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies_9a765624-8085-4f1f-9cdf-17f87f7cfafc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_911cafc7-c9fb-4ec4-b32f-73e0ed9c1158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_911cafc7-c9fb-4ec4-b32f-73e0ed9c1158" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c942c0ad-e899-4649-b2e7-0c01036ce7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_Goodwill_c942c0ad-e899-4649-b2e7-0c01036ce7d0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_31664f9f-bc13-42db-8d4c-e638da765f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_31664f9f-bc13-42db-8d4c-e638da765f1f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0ea618ba-c00c-462d-86c2-7da7e49f93f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_0ea618ba-c00c-462d-86c2-7da7e49f93f2" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails_1" xlink:type="simple" xlink:href="hum-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails_1"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:href="hum-20231231.xsd#hum_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:href="hum-20231231.xsd#hum_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6603a9c8-3394-49f7-a538-642637fa879f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_srt_ProductOrServiceAxis_6603a9c8-3394-49f7-a538-642637fa879f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6603a9c8-3394-49f7-a538-642637fa879f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6603a9c8-3394-49f7-a538-642637fa879f" xlink:to="loc_srt_ProductsAndServicesDomain_6603a9c8-3394-49f7-a538-642637fa879f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e6fc3aad-ce7d-4aaf-9315-0469eb49a814" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6603a9c8-3394-49f7-a538-642637fa879f" xlink:to="loc_srt_ProductsAndServicesDomain_e6fc3aad-ce7d-4aaf-9315-0469eb49a814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_7224520c-8c68-4f13-ad6b-4e935848ac47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6fc3aad-ce7d-4aaf-9315-0469eb49a814" xlink:to="loc_us-gaap_ServiceMember_7224520c-8c68-4f13-ad6b-4e935848ac47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareSupplementProductMember_029f5517-d785-4fc9-8407-cf2f07ca28f7" xlink:href="hum-20231231.xsd#hum_MedicareSupplementProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e6fc3aad-ce7d-4aaf-9315-0469eb49a814" xlink:to="loc_hum_MedicareSupplementProductMember_029f5517-d785-4fc9-8407-cf2f07ca28f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb43270b-61c1-42c5-9834-121f75353bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb43270b-61c1-42c5-9834-121f75353bb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb43270b-61c1-42c5-9834-121f75353bb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb43270b-61c1-42c5-9834-121f75353bb9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cb43270b-61c1-42c5-9834-121f75353bb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a98b60c-3e70-4c18-98b2-96729a557aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb43270b-61c1-42c5-9834-121f75353bb9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a98b60c-3e70-4c18-98b2-96729a557aa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_19210c79-5c9e-4af2-a10d-83454a4a189c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a98b60c-3e70-4c18-98b2-96729a557aa9" xlink:to="loc_us-gaap_EquipmentMember_19210c79-5c9e-4af2-a10d-83454a4a189c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_12b89f2a-983e-4eb7-933a-6db4e8dc4363" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a98b60c-3e70-4c18-98b2-96729a557aa9" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_12b89f2a-983e-4eb7-933a-6db4e8dc4363" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_0f7c15e5-ee32-404a-851a-7910c4aa3e09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a98b60c-3e70-4c18-98b2-96729a557aa9" xlink:to="loc_us-gaap_BuildingMember_0f7c15e5-ee32-404a-851a-7910c4aa3e09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_0835bc40-bb5d-4306-8309-cee423e256ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_ReportingUnitAxis_0835bc40-bb5d-4306-8309-cee423e256ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_0835bc40-bb5d-4306-8309-cee423e256ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_0835bc40-bb5d-4306-8309-cee423e256ab" xlink:to="loc_us-gaap_ReportingUnitDomain_0835bc40-bb5d-4306-8309-cee423e256ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_6061b16d-aaea-4da0-b91a-ed0593c982a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_0835bc40-bb5d-4306-8309-cee423e256ab" xlink:to="loc_us-gaap_ReportingUnitDomain_6061b16d-aaea-4da0-b91a-ed0593c982a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_HomeSolutionsReportingUnitMember_a3fd08d7-ef9c-4278-8c35-8fb0131c4e1b" xlink:href="hum-20231231.xsd#hum_HomeSolutionsReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_6061b16d-aaea-4da0-b91a-ed0593c982a5" xlink:to="loc_hum_HomeSolutionsReportingUnitMember_a3fd08d7-ef9c-4278-8c35-8fb0131c4e1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ProviderReportingUnitMember_c3740ffc-fe7a-449a-9f90-02bb6e8b5076" xlink:href="hum-20231231.xsd#hum_ProviderReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_6061b16d-aaea-4da0-b91a-ed0593c982a5" xlink:to="loc_hum_ProviderReportingUnitMember_c3740ffc-fe7a-449a-9f90-02bb6e8b5076" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3f8a9f31-f0f3-4b19-b54b-49f18872fb00" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_srt_RangeAxis_3f8a9f31-f0f3-4b19-b54b-49f18872fb00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f8a9f31-f0f3-4b19-b54b-49f18872fb00_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3f8a9f31-f0f3-4b19-b54b-49f18872fb00" xlink:to="loc_srt_RangeMember_3f8a9f31-f0f3-4b19-b54b-49f18872fb00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c30ecab-354a-471d-97e9-0fdeaa81994f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3f8a9f31-f0f3-4b19-b54b-49f18872fb00" xlink:to="loc_srt_RangeMember_2c30ecab-354a-471d-97e9-0fdeaa81994f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6b3d4d5e-0029-441a-93c7-3035449af3b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2c30ecab-354a-471d-97e9-0fdeaa81994f" xlink:to="loc_srt_MinimumMember_6b3d4d5e-0029-441a-93c7-3035449af3b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1c9a82b9-9ba4-4663-8cdb-996ef8145abb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2c30ecab-354a-471d-97e9-0fdeaa81994f" xlink:to="loc_srt_MaximumMember_1c9a82b9-9ba4-4663-8cdb-996ef8145abb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd9cc172-63e9-4361-9b9b-4620adb7afba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd9cc172-63e9-4361-9b9b-4620adb7afba" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cd9cc172-63e9-4361-9b9b-4620adb7afba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd9cc172-63e9-4361-9b9b-4620adb7afba" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cd9cc172-63e9-4361-9b9b-4620adb7afba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f383a13a-1617-4319-b699-5573fb1acb08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd9cc172-63e9-4361-9b9b-4620adb7afba" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f383a13a-1617-4319-b699-5573fb1acb08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_07ad6d8f-fe61-43b1-8077-88be2280fc27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f383a13a-1617-4319-b699-5573fb1acb08" xlink:to="loc_us-gaap_SalesRevenueNetMember_07ad6d8f-fe61-43b1-8077-88be2280fc27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5ac49e92-cc4d-426b-867a-5342ecdfa7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5ac49e92-cc4d-426b-867a-5342ecdfa7c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5ac49e92-cc4d-426b-867a-5342ecdfa7c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5ac49e92-cc4d-426b-867a-5342ecdfa7c7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5ac49e92-cc4d-426b-867a-5342ecdfa7c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c44aa83a-b5d1-4f63-90e6-2d48efae2c07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5ac49e92-cc4d-426b-867a-5342ecdfa7c7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c44aa83a-b5d1-4f63-90e6-2d48efae2c07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_c94a1e6b-7498-440f-ad9b-65b7fe5fefe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c44aa83a-b5d1-4f63-90e6-2d48efae2c07" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_c94a1e6b-7498-440f-ad9b-65b7fe5fefe1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_bd4ff641-be13-47fb-8357-8a95c16fc919" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_RestructuringPlanAxis_bd4ff641-be13-47fb-8357-8a95c16fc919" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_bd4ff641-be13-47fb-8357-8a95c16fc919_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_bd4ff641-be13-47fb-8357-8a95c16fc919" xlink:to="loc_us-gaap_RestructuringPlanDomain_bd4ff641-be13-47fb-8357-8a95c16fc919_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_ee9233d5-42c1-40dc-b8d9-4e87645360d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_bd4ff641-be13-47fb-8357-8a95c16fc919" xlink:to="loc_us-gaap_RestructuringPlanDomain_ee9233d5-42c1-40dc-b8d9-4e87645360d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ValueCreationInitiativesMember_26bbc550-c786-48cb-a1a3-b5456d269ecc" xlink:href="hum-20231231.xsd#hum_ValueCreationInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_ee9233d5-42c1-40dc-b8d9-4e87645360d6" xlink:to="loc_hum_ValueCreationInitiativesMember_26bbc550-c786-48cb-a1a3-b5456d269ecc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember_d0175efe-6b23-41f6-ad64-0b7e26d4319d" xlink:href="hum-20231231.xsd#hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_ee9233d5-42c1-40dc-b8d9-4e87645360d6" xlink:to="loc_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember_d0175efe-6b23-41f6-ad64-0b7e26d4319d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_97938347-29d4-4022-8c51-a80cc9acc1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_97938347-29d4-4022-8c51-a80cc9acc1b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_0d532744-6a69-4677-8fdb-1f3f8413bb84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_0d532744-6a69-4677-8fdb-1f3f8413bb84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_bd707659-46a6-43a2-abeb-e265f2de2f67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_SeveranceCosts1_bd707659-46a6-43a2-abeb-e265f2de2f67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a4d8dfe3-823b-4f03-b56c-f7dd1cd130ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_AssetImpairmentCharges_a4d8dfe3-823b-4f03-b56c-f7dd1cd130ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3fc7d31c-9018-4240-ac81-2151c275b24a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3fc7d31c-9018-4240-ac81-2151c275b24a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CommercialMembershipContractTerm_bef85b80-9d7f-42c8-8642-1c5cf1cac8cb" xlink:href="hum-20231231.xsd#hum_CommercialMembershipContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_CommercialMembershipContractTerm_bef85b80-9d7f-42c8-8642-1c5cf1cac8cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies_a21bd6cd-f6c4-4fde-82a7-fdd35354f641" xlink:href="hum-20231231.xsd#hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies_a21bd6cd-f6c4-4fde-82a7-fdd35354f641" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs_66c50444-0e75-4e59-b362-10c3c0e3fda8" xlink:href="hum-20231231.xsd#hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs_66c50444-0e75-4e59-b362-10c3c0e3fda8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SubsidyAndDiscountsSettlementPeriodAfterClose_a6cba838-7b7d-4b7c-be76-bf01cf0da63a" xlink:href="hum-20231231.xsd#hum_SubsidyAndDiscountsSettlementPeriodAfterClose"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_SubsidyAndDiscountsSettlementPeriodAfterClose_a6cba838-7b7d-4b7c-be76-bf01cf0da63a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_03e996f7-b5ef-4e8e-9783-b8fc6edd092f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_03e996f7-b5ef-4e8e-9783-b8fc6edd092f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_AccruedPharmaceuticalRebatesCurrent_c82a0e1d-4b72-4517-bf8b-1efde6058081" xlink:href="hum-20231231.xsd#hum_AccruedPharmaceuticalRebatesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_AccruedPharmaceuticalRebatesCurrent_c82a0e1d-4b72-4517-bf8b-1efde6058081" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies_9a765624-8085-4f1f-9cdf-17f87f7cfafc" xlink:href="hum-20231231.xsd#hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies_9a765624-8085-4f1f-9cdf-17f87f7cfafc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_911cafc7-c9fb-4ec4-b32f-73e0ed9c1158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_911cafc7-c9fb-4ec4-b32f-73e0ed9c1158" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c942c0ad-e899-4649-b2e7-0c01036ce7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_Goodwill_c942c0ad-e899-4649-b2e7-0c01036ce7d0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_31664f9f-bc13-42db-8d4c-e638da765f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_31664f9f-bc13-42db-8d4c-e638da765f1f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0ea618ba-c00c-462d-86c2-7da7e49f93f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_0ea618ba-c00c-462d-86c2-7da7e49f93f2" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#ACQUISITIONSANDDIVESTITURESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9367279a-e97d-4302-8615-d67268fe5d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9367279a-e97d-4302-8615-d67268fe5d4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9367279a-e97d-4302-8615-d67268fe5d4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9367279a-e97d-4302-8615-d67268fe5d4b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9367279a-e97d-4302-8615-d67268fe5d4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5058b129-2e7f-4589-8488-5840c1de0050" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9367279a-e97d-4302-8615-d67268fe5d4b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5058b129-2e7f-4589-8488-5840c1de0050" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ee2ac2c1-3f22-4315-b44a-cbeab0be6b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_5058b129-2e7f-4589-8488-5840c1de0050" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ee2ac2c1-3f22-4315-b44a-cbeab0be6b2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7d8c92e-6f0f-4e8e-8437-829918075501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7d8c92e-6f0f-4e8e-8437-829918075501" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7d8c92e-6f0f-4e8e-8437-829918075501_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7d8c92e-6f0f-4e8e-8437-829918075501" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e7d8c92e-6f0f-4e8e-8437-829918075501_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1b19b5ac-effc-46b0-9a2d-97ff2c2052c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7d8c92e-6f0f-4e8e-8437-829918075501" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1b19b5ac-effc-46b0-9a2d-97ff2c2052c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GentivaHospiceMember_9c5e5f16-831a-49b4-bd65-33b0b3208b84" xlink:href="hum-20231231.xsd#hum_GentivaHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1b19b5ac-effc-46b0-9a2d-97ff2c2052c0" xlink:to="loc_hum_GentivaHospiceMember_9c5e5f16-831a-49b4-bd65-33b0b3208b84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e4ba5dba-3889-4f0a-b610-0f2e21616141" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:to="loc_us-gaap_DebtInstrumentAxis_e4ba5dba-3889-4f0a-b610-0f2e21616141" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e4ba5dba-3889-4f0a-b610-0f2e21616141_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e4ba5dba-3889-4f0a-b610-0f2e21616141" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e4ba5dba-3889-4f0a-b610-0f2e21616141_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6c647c9b-ac8c-4f57-a28f-c3ff2d780386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e4ba5dba-3889-4f0a-b610-0f2e21616141" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6c647c9b-ac8c-4f57-a28f-c3ff2d780386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TermLoanDueOctober2023Member_e40a1924-521a-44f3-99c1-f0c53d60445f" xlink:href="hum-20231231.xsd#hum_TermLoanDueOctober2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6c647c9b-ac8c-4f57-a28f-c3ff2d780386" xlink:to="loc_hum_TermLoanDueOctober2023Member_e40a1924-521a-44f3-99c1-f0c53d60445f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_76f17288-fa7e-4cb9-a60b-2cd6b9feac10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_76f17288-fa7e-4cb9-a60b-2cd6b9feac10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_76f17288-fa7e-4cb9-a60b-2cd6b9feac10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_76f17288-fa7e-4cb9-a60b-2cd6b9feac10" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_76f17288-fa7e-4cb9-a60b-2cd6b9feac10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5bff05a6-bd43-400d-83f3-292807e9cb25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_76f17288-fa7e-4cb9-a60b-2cd6b9feac10" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5bff05a6-bd43-400d-83f3-292807e9cb25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_9c4ab56f-5e7e-47c8-9a19-5996812d3332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5bff05a6-bd43-400d-83f3-292807e9cb25" xlink:to="loc_us-gaap_LoansPayableMember_9c4ab56f-5e7e-47c8-9a19-5996812d3332" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_881a91f5-bf72-4953-bcec-60b14c76fdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_881a91f5-bf72-4953-bcec-60b14c76fdfa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_881a91f5-bf72-4953-bcec-60b14c76fdfa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_881a91f5-bf72-4953-bcec-60b14c76fdfa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_881a91f5-bf72-4953-bcec-60b14c76fdfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_735787b6-fefa-411a-b2eb-e350fff7410a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_881a91f5-bf72-4953-bcec-60b14c76fdfa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_735787b6-fefa-411a-b2eb-e350fff7410a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareLicensesAndCertificatesOfNeedMember_aa6fd562-e301-4b14-a50d-6cdb82848940" xlink:href="hum-20231231.xsd#hum_MedicareLicensesAndCertificatesOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_735787b6-fefa-411a-b2eb-e350fff7410a" xlink:to="loc_hum_MedicareLicensesAndCertificatesOfNeedMember_aa6fd562-e301-4b14-a50d-6cdb82848940" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e2961f2c-e995-4fa4-854c-1bab65f5bae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e2961f2c-e995-4fa4-854c-1bab65f5bae3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e2961f2c-e995-4fa4-854c-1bab65f5bae3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e2961f2c-e995-4fa4-854c-1bab65f5bae3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e2961f2c-e995-4fa4-854c-1bab65f5bae3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_977b2493-2678-4484-bf80-4c550d23fc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e2961f2c-e995-4fa4-854c-1bab65f5bae3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_977b2493-2678-4484-bf80-4c550d23fc9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_KindredAtHomeMember_87d53386-c1cb-47c1-af30-ae4fd8966378" xlink:href="hum-20231231.xsd#hum_KindredAtHomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_977b2493-2678-4484-bf80-4c550d23fc9b" xlink:to="loc_hum_KindredAtHomeMember_87d53386-c1cb-47c1-af30-ae4fd8966378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold_0b532cf1-539b-4170-abb4-b67a6a4a0256" xlink:href="hum-20231231.xsd#hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold_0b532cf1-539b-4170-abb4-b67a6a4a0256" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_42e0dc04-f9a9-49ae-afa5-c018db0b9276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_42e0dc04-f9a9-49ae-afa5-c018db0b9276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_4b94323f-4e84-4dfc-a312-cb90bef5f171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_RepaymentsOfDebt_4b94323f-4e84-4dfc-a312-cb90bef5f171" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_b5575efd-5284-454a-95b4-29d69826c5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_b5575efd-5284-454a-95b4-29d69826c5b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_0a05aa82-17f5-4389-8555-0a2cd48c537c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_0a05aa82-17f5-4389-8555-0a2cd48c537c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_cbf3efb4-ae78-430e-aab1-2f87efa291a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_cbf3efb4-ae78-430e-aab1-2f87efa291a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax_6a4abdad-a486-432d-862f-3b0898f70bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax_6a4abdad-a486-432d-862f-3b0898f70bf8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage_feeac632-837f-4149-95f8-3e05d5803a7c" xlink:href="hum-20231231.xsd#hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage_feeac632-837f-4149-95f8-3e05d5803a7c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BusinessCombinationTotalEnterpriseValueOfAcquiree_2ab3ea39-639f-45e9-92ee-4c2e72294090" xlink:href="hum-20231231.xsd#hum_BusinessCombinationTotalEnterpriseValueOfAcquiree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_hum_BusinessCombinationTotalEnterpriseValueOfAcquiree_2ab3ea39-639f-45e9-92ee-4c2e72294090" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_26c81bd5-7888-482f-982d-cf67b947dc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_26c81bd5-7888-482f-982d-cf67b947dc5f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_c06d01fe-1e75-409d-94e2-73014c3421f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_c06d01fe-1e75-409d-94e2-73014c3421f1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_95b851ab-03f5-4122-8876-3c393599f909" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_EquityMethodInvestments_95b851ab-03f5-4122-8876-3c393599f909" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_5be23974-a85c-4567-ab28-8d2457e1c3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_5be23974-a85c-4567-ab28-8d2457e1c3fb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest_2ced3cdf-76f3-4635-80d3-d7e6b0b20207" xlink:href="hum-20231231.xsd#hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest_2ced3cdf-76f3-4635-80d3-d7e6b0b20207" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e378ad8-d2e7-4f67-8b5b-7b22ddf56dda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e378ad8-d2e7-4f67-8b5b-7b22ddf56dda" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_8bf8ac17-e955-4341-9ee7-fbcc64a943ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e378ad8-d2e7-4f67-8b5b-7b22ddf56dda" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_8bf8ac17-e955-4341-9ee7-fbcc64a943ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8bf8ac17-e955-4341-9ee7-fbcc64a943ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8bf8ac17-e955-4341-9ee7-fbcc64a943ae" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8bf8ac17-e955-4341-9ee7-fbcc64a943ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0eb4f15c-0d9c-4a32-8a0d-40d6c431d9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8bf8ac17-e955-4341-9ee7-fbcc64a943ae" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0eb4f15c-0d9c-4a32-8a0d-40d6c431d9fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f310f48b-4c0c-41a5-9a26-1cb573736338" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0eb4f15c-0d9c-4a32-8a0d-40d6c431d9fc" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f310f48b-4c0c-41a5-9a26-1cb573736338" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ee71f7cb-83a6-42b9-bec0-4a2bc85dc64e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e378ad8-d2e7-4f67-8b5b-7b22ddf56dda" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ee71f7cb-83a6-42b9-bec0-4a2bc85dc64e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ee71f7cb-83a6-42b9-bec0-4a2bc85dc64e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ee71f7cb-83a6-42b9-bec0-4a2bc85dc64e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_ee71f7cb-83a6-42b9-bec0-4a2bc85dc64e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08837979-735a-4862-85a9-b65ee2baf062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ee71f7cb-83a6-42b9-bec0-4a2bc85dc64e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08837979-735a-4862-85a9-b65ee2baf062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GentivaHospiceMember_87588a1b-2fc7-4b34-8a84-83c080634425" xlink:href="hum-20231231.xsd#hum_GentivaHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08837979-735a-4862-85a9-b65ee2baf062" xlink:to="loc_hum_GentivaHospiceMember_87588a1b-2fc7-4b34-8a84-83c080634425" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_dee68405-9027-43ab-957b-1c10e4f26f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_dee68405-9027-43ab-957b-1c10e4f26f6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_feb4dab0-5f93-47d9-bbe3-c379e9bada9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_feb4dab0-5f93-47d9-bbe3-c379e9bada9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_f090b3ab-7d26-4588-8b10-7e782fdc1dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_f090b3ab-7d26-4588-8b10-7e782fdc1dc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_a6cab79e-d72a-43d2-8113-7eca3db638e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_a6cab79e-d72a-43d2-8113-7eca3db638e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_6f7f0270-5ae1-43dc-aae3-cda1f8fb8583" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_6f7f0270-5ae1-43dc-aae3-cda1f8fb8583" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_dd07245f-e3eb-4f8c-81eb-68a11d3c22b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_dd07245f-e3eb-4f8c-81eb-68a11d3c22b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_263798da-fce0-4b59-8aba-8c088ff34bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_263798da-fce0-4b59-8aba-8c088ff34bd2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_db8fb163-797e-45a9-b18a-dd8928c0dfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_db8fb163-797e-45a9-b18a-dd8928c0dfb0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_79fabdf9-10ed-4218-bcd9-d23530592881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_79fabdf9-10ed-4218-bcd9-d23530592881" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_98ca81ba-3505-471a-9624-ca79dbf89d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_98ca81ba-3505-471a-9624-ca79dbf89d7b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest_a73b4a04-70ab-4bdf-becb-2ac39f98ebe3" xlink:href="hum-20231231.xsd#hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest_a73b4a04-70ab-4bdf-becb-2ac39f98ebe3" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EQUITYMETHODINVESTMENTNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fdf8eb0-8564-40fa-bbdf-55afbd003d41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1997eeb2-eb88-4b35-9750-c9b94502b50d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fdf8eb0-8564-40fa-bbdf-55afbd003d41" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1997eeb2-eb88-4b35-9750-c9b94502b50d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2dce153d-3032-4b2d-a50a-c7a82f634e0b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1997eeb2-eb88-4b35-9750-c9b94502b50d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2dce153d-3032-4b2d-a50a-c7a82f634e0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2dce153d-3032-4b2d-a50a-c7a82f634e0b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2dce153d-3032-4b2d-a50a-c7a82f634e0b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2dce153d-3032-4b2d-a50a-c7a82f634e0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_af1c5712-71e1-4184-ac07-c498eee285b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2dce153d-3032-4b2d-a50a-c7a82f634e0b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_af1c5712-71e1-4184-ac07-c498eee285b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_KindredAtHomeMember_4bcf3527-dcc7-481a-8d6c-62676c107821" xlink:href="hum-20231231.xsd#hum_KindredAtHomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_af1c5712-71e1-4184-ac07-c498eee285b9" xlink:to="loc_hum_KindredAtHomeMember_4bcf3527-dcc7-481a-8d6c-62676c107821" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fba61c8e-77ab-4b4f-85e7-48f7de4b180e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1997eeb2-eb88-4b35-9750-c9b94502b50d" xlink:to="loc_srt_CounterpartyNameAxis_fba61c8e-77ab-4b4f-85e7-48f7de4b180e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fba61c8e-77ab-4b4f-85e7-48f7de4b180e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_fba61c8e-77ab-4b4f-85e7-48f7de4b180e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fba61c8e-77ab-4b4f-85e7-48f7de4b180e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f1cbea12-ba00-4679-b1b8-2aeaa4c271c3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_fba61c8e-77ab-4b4f-85e7-48f7de4b180e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f1cbea12-ba00-4679-b1b8-2aeaa4c271c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_WelshCarsonAndersonAndStoweMember_ed7f2c3d-c45f-4ede-882a-05f4050a9b67" xlink:href="hum-20231231.xsd#hum_WelshCarsonAndersonAndStoweMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f1cbea12-ba00-4679-b1b8-2aeaa4c271c3" xlink:to="loc_hum_WelshCarsonAndersonAndStoweMember_ed7f2c3d-c45f-4ede-882a-05f4050a9b67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember_955848de-ab6a-4ca8-a102-266b090861dc" xlink:href="hum-20231231.xsd#hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_WelshCarsonAndersonAndStoweMember_ed7f2c3d-c45f-4ede-882a-05f4050a9b67" xlink:to="loc_hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember_955848de-ab6a-4ca8-a102-266b090861dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember_b7b8f601-68c8-4dad-9356-ec68b7e18c92" xlink:href="hum-20231231.xsd#hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_WelshCarsonAndersonAndStoweMember_ed7f2c3d-c45f-4ede-882a-05f4050a9b67" xlink:to="loc_hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember_b7b8f601-68c8-4dad-9356-ec68b7e18c92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_de9d4c82-5801-4325-9f2a-6d6fdfef8545" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1997eeb2-eb88-4b35-9750-c9b94502b50d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_de9d4c82-5801-4325-9f2a-6d6fdfef8545" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_de9d4c82-5801-4325-9f2a-6d6fdfef8545_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_de9d4c82-5801-4325-9f2a-6d6fdfef8545" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_de9d4c82-5801-4325-9f2a-6d6fdfef8545_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b40ee8d2-f8df-476f-a593-a9e0c670949e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_de9d4c82-5801-4325-9f2a-6d6fdfef8545" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b40ee8d2-f8df-476f-a593-a9e0c670949e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_53ee61d7-290b-4242-9caf-c551c07a00b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_b40ee8d2-f8df-476f-a593-a9e0c670949e" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_53ee61d7-290b-4242-9caf-c551c07a00b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_60712b16-2b62-4224-86fa-80aac4702880" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1997eeb2-eb88-4b35-9750-c9b94502b50d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_60712b16-2b62-4224-86fa-80aac4702880" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_60712b16-2b62-4224-86fa-80aac4702880_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_60712b16-2b62-4224-86fa-80aac4702880" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_60712b16-2b62-4224-86fa-80aac4702880_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5836f827-e49e-4e60-94ec-357c990b7fee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_60712b16-2b62-4224-86fa-80aac4702880" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5836f827-e49e-4e60-94ec-357c990b7fee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GentivaHospiceMember_4b40b13e-3661-44d0-aa53-4858379230ee" xlink:href="hum-20231231.xsd#hum_GentivaHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5836f827-e49e-4e60-94ec-357c990b7fee" xlink:to="loc_hum_GentivaHospiceMember_4b40b13e-3661-44d0-aa53-4858379230ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ff5d386a-2e9b-495c-a58c-ab4467d85812" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1997eeb2-eb88-4b35-9750-c9b94502b50d" xlink:to="loc_srt_RangeAxis_ff5d386a-2e9b-495c-a58c-ab4467d85812" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ff5d386a-2e9b-495c-a58c-ab4467d85812_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ff5d386a-2e9b-495c-a58c-ab4467d85812" xlink:to="loc_srt_RangeMember_ff5d386a-2e9b-495c-a58c-ab4467d85812_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fe6cc2ba-e9af-4ad3-8cba-f3f7a72a77a0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ff5d386a-2e9b-495c-a58c-ab4467d85812" xlink:to="loc_srt_RangeMember_fe6cc2ba-e9af-4ad3-8cba-f3f7a72a77a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8a144eda-5808-4e45-bab1-5f05a7724215" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fe6cc2ba-e9af-4ad3-8cba-f3f7a72a77a0" xlink:to="loc_srt_MinimumMember_8a144eda-5808-4e45-bab1-5f05a7724215" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ac010efd-a726-4920-869f-441206488ebb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fe6cc2ba-e9af-4ad3-8cba-f3f7a72a77a0" xlink:to="loc_srt_MaximumMember_ac010efd-a726-4920-869f-441206488ebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9fd5a4fe-64c3-4371-a1d3-5d600793d7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fdf8eb0-8564-40fa-bbdf-55afbd003d41" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9fd5a4fe-64c3-4371-a1d3-5d600793d7d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold_d1b421fa-adc5-48b5-a356-322e1eb933ec" xlink:href="hum-20231231.xsd#hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fdf8eb0-8564-40fa-bbdf-55afbd003d41" xlink:to="loc_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold_d1b421fa-adc5-48b5-a356-322e1eb933ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters_923a8c2f-7992-46fd-b85f-d69a559389e4" xlink:href="hum-20231231.xsd#hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fdf8eb0-8564-40fa-bbdf-55afbd003d41" xlink:to="loc_hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters_923a8c2f-7992-46fd-b85f-d69a559389e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened_5936e93e-d01c-4e1f-b8a5-238602c2abfb" xlink:href="hum-20231231.xsd#hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fdf8eb0-8564-40fa-bbdf-55afbd003d41" xlink:to="loc_hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened_5936e93e-d01c-4e1f-b8a5-238602c2abfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity_12d98fac-8e1e-4f33-a6a0-7811b0f83ff7" xlink:href="hum-20231231.xsd#hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fdf8eb0-8564-40fa-bbdf-55afbd003d41" xlink:to="loc_hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity_12d98fac-8e1e-4f33-a6a0-7811b0f83ff7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_StrategicPartnershipAgreementCallOptionStrikePrice_1dbec8d8-ba26-4bb4-a476-76e011433f55" xlink:href="hum-20231231.xsd#hum_StrategicPartnershipAgreementCallOptionStrikePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fdf8eb0-8564-40fa-bbdf-55afbd003d41" xlink:to="loc_hum_StrategicPartnershipAgreementCallOptionStrikePrice_1dbec8d8-ba26-4bb4-a476-76e011433f55" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_52132a65-0bdd-4142-8d6e-c8b90040362e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_48cb2100-3bee-4f2d-8763-4d5c3954f897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_52132a65-0bdd-4142-8d6e-c8b90040362e" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_48cb2100-3bee-4f2d-8763-4d5c3954f897" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_eca198ee-d37a-4f05-a777-c682b17012b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_48cb2100-3bee-4f2d-8763-4d5c3954f897" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_eca198ee-d37a-4f05-a777-c682b17012b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_eca198ee-d37a-4f05-a777-c682b17012b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_eca198ee-d37a-4f05-a777-c682b17012b0" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_eca198ee-d37a-4f05-a777-c682b17012b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b8adb716-a7eb-4794-a13c-527deadb3f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_eca198ee-d37a-4f05-a777-c682b17012b0" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b8adb716-a7eb-4794-a13c-527deadb3f51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_KindredAtHomeMember_56691bb9-2951-471d-b16e-4aa965f38b70" xlink:href="hum-20231231.xsd#hum_KindredAtHomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b8adb716-a7eb-4794-a13c-527deadb3f51" xlink:to="loc_hum_KindredAtHomeMember_56691bb9-2951-471d-b16e-4aa965f38b70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d1bfba8a-312d-4492-b0e4-aedea19af712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_52132a65-0bdd-4142-8d6e-c8b90040362e" xlink:to="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d1bfba8a-312d-4492-b0e4-aedea19af712" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_687739dc-2cc7-48d0-95b2-c6343949c7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d1bfba8a-312d-4492-b0e4-aedea19af712" xlink:to="loc_us-gaap_AssetsCurrent_687739dc-2cc7-48d0-95b2-c6343949c7ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_923f9495-a138-45f8-803c-d8d2d82bc75b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d1bfba8a-312d-4492-b0e4-aedea19af712" xlink:to="loc_us-gaap_AssetsNoncurrent_923f9495-a138-45f8-803c-d8d2d82bc75b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b23306fa-1a07-45e3-9ff8-3527ce67e8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d1bfba8a-312d-4492-b0e4-aedea19af712" xlink:to="loc_us-gaap_LiabilitiesCurrent_b23306fa-1a07-45e3-9ff8-3527ce67e8d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_c0721dc8-e8b1-435b-a126-b1a832ff58b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d1bfba8a-312d-4492-b0e4-aedea19af712" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_c0721dc8-e8b1-435b-a126-b1a832ff58b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_de4bbb51-3b43-4849-aa0b-bdf0d9aa9c61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d1bfba8a-312d-4492-b0e4-aedea19af712" xlink:to="loc_us-gaap_StockholdersEquity_de4bbb51-3b43-4849-aa0b-bdf0d9aa9c61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_eb076c91-5dad-41c4-9463-323a4c423e27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementRelatedDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_52132a65-0bdd-4142-8d6e-c8b90040362e" xlink:to="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_eb076c91-5dad-41c4-9463-323a4c423e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_40210c76-8e43-420a-bffa-34e564e66a61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_eb076c91-5dad-41c4-9463-323a4c423e27" xlink:to="loc_us-gaap_Revenues_40210c76-8e43-420a-bffa-34e564e66a61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_Expenses_c41b2bb2-cc36-42b6-bffe-dcc870e4f867" xlink:href="hum-20231231.xsd#hum_Expenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_eb076c91-5dad-41c4-9463-323a4c423e27" xlink:to="loc_hum_Expenses_c41b2bb2-cc36-42b6-bffe-dcc870e4f867" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_50cc382d-c967-4aa4-9647-fd568edb474d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_eb076c91-5dad-41c4-9463-323a4c423e27" xlink:to="loc_us-gaap_NetIncomeLoss_50cc382d-c967-4aa4-9647-fd568edb474d" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e29ec88c-b33a-4d9c-b2c4-5ab2f8b2a787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e5a04013-7eec-416a-8fd2-6a6304095a63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e29ec88c-b33a-4d9c-b2c4-5ab2f8b2a787" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e5a04013-7eec-416a-8fd2-6a6304095a63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_24e90025-449d-49c0-98c1-16764117a2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e5a04013-7eec-416a-8fd2-6a6304095a63" xlink:to="loc_us-gaap_FinancialInstrumentAxis_24e90025-449d-49c0-98c1-16764117a2d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24e90025-449d-49c0-98c1-16764117a2d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_24e90025-449d-49c0-98c1-16764117a2d8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_24e90025-449d-49c0-98c1-16764117a2d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_24e90025-449d-49c0-98c1-16764117a2d8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_a791f7e6-cd49-403a-8d8c-4d052b3b1468" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_a791f7e6-cd49-403a-8d8c-4d052b3b1468" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_d142cecf-1da4-4e1e-8c5d-327528a8eb59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_d142cecf-1da4-4e1e-8c5d-327528a8eb59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontaxableMunicipalNotesMember_99f29528-544e-4627-af24-06e68698c06e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontaxableMunicipalNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:to="loc_us-gaap_NontaxableMunicipalNotesMember_99f29528-544e-4627-af24-06e68698c06e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_7811fad3-7052-496c-94aa-9b9ba921de22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_7811fad3-7052-496c-94aa-9b9ba921de22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_3e74b2a0-ea59-4050-8d3c-9a4bef34fb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_3e74b2a0-ea59-4050-8d3c-9a4bef34fb8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_c8b8669b-52e4-4d35-8455-b59acff914f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_c8b8669b-52e4-4d35-8455-b59acff914f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3d9afad6-98a7-41cf-819e-1b941d67f213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3d9afad6-98a7-41cf-819e-1b941d67f213" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9ad82394-2930-4574-aafe-57678cd41934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e29ec88c-b33a-4d9c-b2c4-5ab2f8b2a787" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9ad82394-2930-4574-aafe-57678cd41934" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_283c8124-3474-4658-bbf7-30caccb4154b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9ad82394-2930-4574-aafe-57678cd41934" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_283c8124-3474-4658-bbf7-30caccb4154b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_84396d52-2dbb-4e39-a71d-7c7a821b2e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9ad82394-2930-4574-aafe-57678cd41934" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_84396d52-2dbb-4e39-a71d-7c7a821b2e3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_62410856-22bd-44b1-8ce5-90801060926c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9ad82394-2930-4574-aafe-57678cd41934" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_62410856-22bd-44b1-8ce5-90801060926c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_897767a0-cd79-4dab-a51e-5a20d4beb821" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9ad82394-2930-4574-aafe-57678cd41934" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_897767a0-cd79-4dab-a51e-5a20d4beb821" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_db3be93b-811c-49d3-9be3-172996622f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9ad82394-2930-4574-aafe-57678cd41934" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_db3be93b-811c-49d3-9be3-172996622f79" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_4e92052c-0b40-417a-8b02-918dbe01ab35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9ad82394-2930-4574-aafe-57678cd41934" xlink:to="loc_us-gaap_Investments_4e92052c-0b40-417a-8b02-918dbe01ab35" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INVESTMENTSECURITIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems_c37472ff-81df-4abb-9d4b-1218fc4dd747" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_156bf20e-3ab9-49ce-973b-fdf855acdf18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems_c37472ff-81df-4abb-9d4b-1218fc4dd747" xlink:to="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_156bf20e-3ab9-49ce-973b-fdf855acdf18" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_5d777f81-a123-4926-965b-d731ea89cc40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_156bf20e-3ab9-49ce-973b-fdf855acdf18" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_5d777f81-a123-4926-965b-d731ea89cc40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5d777f81-a123-4926-965b-d731ea89cc40_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_5d777f81-a123-4926-965b-d731ea89cc40" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5d777f81-a123-4926-965b-d731ea89cc40_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_034e66d4-4204-4358-b78c-c1585f84fd75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_5d777f81-a123-4926-965b-d731ea89cc40" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_034e66d4-4204-4358-b78c-c1585f84fd75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_a0d4ce1b-4549-4a43-9370-c089ed258a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_034e66d4-4204-4358-b78c-c1585f84fd75" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_a0d4ce1b-4549-4a43-9370-c089ed258a8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_84fecc26-8201-4adf-8b80-2b0971567082" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_156bf20e-3ab9-49ce-973b-fdf855acdf18" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_84fecc26-8201-4adf-8b80-2b0971567082" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_84fecc26-8201-4adf-8b80-2b0971567082_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_84fecc26-8201-4adf-8b80-2b0971567082" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_84fecc26-8201-4adf-8b80-2b0971567082_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_75ce1235-62e4-4040-a941-d48c2428083b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_84fecc26-8201-4adf-8b80-2b0971567082" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_75ce1235-62e4-4040-a941-d48c2428083b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GentivaHospiceMember_110c35b4-8b4c-41d4-812e-e02e78aedd90" xlink:href="hum-20231231.xsd#hum_GentivaHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_75ce1235-62e4-4040-a941-d48c2428083b" xlink:to="loc_hum_GentivaHospiceMember_110c35b4-8b4c-41d4-812e-e02e78aedd90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CreditRatingStandardPoorsAxis_71e877c5-55c3-408c-bb3c-798f78eca6d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CreditRatingStandardPoorsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_156bf20e-3ab9-49ce-973b-fdf855acdf18" xlink:to="loc_srt_CreditRatingStandardPoorsAxis_71e877c5-55c3-408c-bb3c-798f78eca6d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExternalCreditRatingStandardPoorsMember_71e877c5-55c3-408c-bb3c-798f78eca6d3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExternalCreditRatingStandardPoorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CreditRatingStandardPoorsAxis_71e877c5-55c3-408c-bb3c-798f78eca6d3" xlink:to="loc_srt_ExternalCreditRatingStandardPoorsMember_71e877c5-55c3-408c-bb3c-798f78eca6d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExternalCreditRatingStandardPoorsMember_25b1c694-3102-4606-b0b4-9cb4a4afcdd1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExternalCreditRatingStandardPoorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CreditRatingStandardPoorsAxis_71e877c5-55c3-408c-bb3c-798f78eca6d3" xlink:to="loc_srt_ExternalCreditRatingStandardPoorsMember_25b1c694-3102-4606-b0b4-9cb4a4afcdd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StandardPoorsAAMinusRatingMember_ac6f0dbf-48ce-40eb-b4f5-ab83616eae89" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StandardPoorsAAMinusRatingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ExternalCreditRatingStandardPoorsMember_25b1c694-3102-4606-b0b4-9cb4a4afcdd1" xlink:to="loc_srt_StandardPoorsAAMinusRatingMember_ac6f0dbf-48ce-40eb-b4f5-ab83616eae89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c836eef5-be48-417c-8b5d-24eed5eac28a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems_c37472ff-81df-4abb-9d4b-1218fc4dd747" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c836eef5-be48-417c-8b5d-24eed5eac28a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f7d7f27f-a240-4f1e-9f13-45bba7928d11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems_c37472ff-81df-4abb-9d4b-1218fc4dd747" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f7d7f27f-a240-4f1e-9f13-45bba7928d11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality_eca8d72e-0385-4651-bec9-610335b484aa" xlink:href="hum-20231231.xsd#hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems_c37472ff-81df-4abb-9d4b-1218fc4dd747" xlink:to="loc_hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality_eca8d72e-0385-4651-bec9-610335b484aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities_70c8b128-495a-4e58-bb3b-b0c46e549a5d" xlink:href="hum-20231231.xsd#hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems_c37472ff-81df-4abb-9d4b-1218fc4dd747" xlink:to="loc_hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities_70c8b128-495a-4e58-bb3b-b0c46e549a5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_6b698192-db1c-44e2-9cac-06ee8d8a4521" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems_c37472ff-81df-4abb-9d4b-1218fc4dd747" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_6b698192-db1c-44e2-9cac-06ee8d8a4521" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions_1e7cae70-5594-4699-a2bc-08ebd51b3346" xlink:href="hum-20231231.xsd#hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems_c37472ff-81df-4abb-9d4b-1218fc4dd747" xlink:to="loc_hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions_1e7cae70-5594-4699-a2bc-08ebd51b3346" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_7735fd87-c92f-4063-8f56-29930788bee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_f28f42af-e7e0-4ea1-9454-9ceba0223414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_7735fd87-c92f-4063-8f56-29930788bee3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_f28f42af-e7e0-4ea1-9454-9ceba0223414" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_937ffa91-5b09-4182-969d-62013c57752f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_f28f42af-e7e0-4ea1-9454-9ceba0223414" xlink:to="loc_us-gaap_FinancialInstrumentAxis_937ffa91-5b09-4182-969d-62013c57752f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_937ffa91-5b09-4182-969d-62013c57752f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_937ffa91-5b09-4182-969d-62013c57752f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_937ffa91-5b09-4182-969d-62013c57752f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_937ffa91-5b09-4182-969d-62013c57752f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_d2d35651-632b-47c3-8f3e-535dcbc0dc04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_d2d35651-632b-47c3-8f3e-535dcbc0dc04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_3e1fe275-f1dd-42dd-b5e7-673ae52a1a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_3e1fe275-f1dd-42dd-b5e7-673ae52a1a1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontaxableMunicipalNotesMember_50c1de99-6531-4943-8cba-87a3286c5fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontaxableMunicipalNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:to="loc_us-gaap_NontaxableMunicipalNotesMember_50c1de99-6531-4943-8cba-87a3286c5fd9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_9a44fb07-8956-4674-a63b-c8c7529d6f83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_9a44fb07-8956-4674-a63b-c8c7529d6f83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_6af85ecb-2eaa-4ff2-88ab-9705212b4ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_6af85ecb-2eaa-4ff2-88ab-9705212b4ae6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_c5fa1465-67cb-4872-bba3-52dc71c4d7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_c5fa1465-67cb-4872-bba3-52dc71c4d7d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c612ad5c-384d-4394-883b-5f92975f179d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c612ad5c-384d-4394-883b-5f92975f179d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_79eef231-8afa-4e5f-a0cf-36bba0850575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_7735fd87-c92f-4063-8f56-29930788bee3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_79eef231-8afa-4e5f-a0cf-36bba0850575" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_aee1b743-6095-49e5-8803-df7f23dacf85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_79eef231-8afa-4e5f-a0cf-36bba0850575" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_aee1b743-6095-49e5-8803-df7f23dacf85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_691b0128-da7f-4497-81d3-9b49c7ee53c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_79eef231-8afa-4e5f-a0cf-36bba0850575" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_691b0128-da7f-4497-81d3-9b49c7ee53c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_187a2265-76c3-45f1-b5a4-63d37715eda6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_79eef231-8afa-4e5f-a0cf-36bba0850575" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_187a2265-76c3-45f1-b5a4-63d37715eda6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_360dccd7-e177-4d9d-8828-398c0af97d27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_7735fd87-c92f-4063-8f56-29930788bee3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_360dccd7-e177-4d9d-8828-398c0af97d27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9756c4a0-b6df-4e35-85fc-db9e54b784b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_360dccd7-e177-4d9d-8828-398c0af97d27" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9756c4a0-b6df-4e35-85fc-db9e54b784b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_385a3127-cef8-4c04-9cc3-8ab85f7feb02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_360dccd7-e177-4d9d-8828-398c0af97d27" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_385a3127-cef8-4c04-9cc3-8ab85f7feb02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_73f3f014-805b-43d6-8c64-6d284d3a32b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_360dccd7-e177-4d9d-8828-398c0af97d27" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_73f3f014-805b-43d6-8c64-6d284d3a32b1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_abefc34f-621e-46c1-90aa-3ee7c6005e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f7cde86-c001-408e-ac21-5486b4f805d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_abefc34f-621e-46c1-90aa-3ee7c6005e6a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f7cde86-c001-408e-ac21-5486b4f805d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ae8eda6-fe8f-4e18-b4e2-68f25ab36798" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f7cde86-c001-408e-ac21-5486b4f805d0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ae8eda6-fe8f-4e18-b4e2-68f25ab36798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8ae8eda6-fe8f-4e18-b4e2-68f25ab36798_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ae8eda6-fe8f-4e18-b4e2-68f25ab36798" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8ae8eda6-fe8f-4e18-b4e2-68f25ab36798_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4dbd73c9-326e-4727-b020-926cacbda3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ae8eda6-fe8f-4e18-b4e2-68f25ab36798" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4dbd73c9-326e-4727-b020-926cacbda3b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a9d4c87f-501a-455c-aaf6-1e99add9d593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4dbd73c9-326e-4727-b020-926cacbda3b5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a9d4c87f-501a-455c-aaf6-1e99add9d593" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d77a5344-a39d-4539-908b-da75fd00efc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f7cde86-c001-408e-ac21-5486b4f805d0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d77a5344-a39d-4539-908b-da75fd00efc3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d77a5344-a39d-4539-908b-da75fd00efc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d77a5344-a39d-4539-908b-da75fd00efc3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d77a5344-a39d-4539-908b-da75fd00efc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a1e9d89-5b4a-4b37-b521-4602df049a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d77a5344-a39d-4539-908b-da75fd00efc3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a1e9d89-5b4a-4b37-b521-4602df049a4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4d02afb0-29c0-4d2c-8f2f-b4bf658949b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a1e9d89-5b4a-4b37-b521-4602df049a4d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4d02afb0-29c0-4d2c-8f2f-b4bf658949b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8cd7df3b-05b3-4f5f-a4db-d49bab9eb267" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a1e9d89-5b4a-4b37-b521-4602df049a4d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8cd7df3b-05b3-4f5f-a4db-d49bab9eb267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_832d80b2-9c4f-40b9-90ea-f126592fb49b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a1e9d89-5b4a-4b37-b521-4602df049a4d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_832d80b2-9c4f-40b9-90ea-f126592fb49b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2afb42c9-f518-4a51-8f1d-600992c54e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f7cde86-c001-408e-ac21-5486b4f805d0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2afb42c9-f518-4a51-8f1d-600992c54e0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2afb42c9-f518-4a51-8f1d-600992c54e0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2afb42c9-f518-4a51-8f1d-600992c54e0e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2afb42c9-f518-4a51-8f1d-600992c54e0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2afb42c9-f518-4a51-8f1d-600992c54e0e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_6e186890-49b6-462c-8dba-52d3ae4c7475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_6e186890-49b6-462c-8dba-52d3ae4c7475" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_6b55abdb-dd63-4ae2-afdb-c6a4426ba079" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_6b55abdb-dd63-4ae2-afdb-c6a4426ba079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontaxableMunicipalNotesMember_34d6b7e4-47ee-4f4b-8768-d11a147a20c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontaxableMunicipalNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:to="loc_us-gaap_NontaxableMunicipalNotesMember_34d6b7e4-47ee-4f4b-8768-d11a147a20c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_a1c28ba3-207e-4c1d-b9ff-36cfdc5c7c23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_a1c28ba3-207e-4c1d-b9ff-36cfdc5c7c23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_49ba713f-432b-49a6-905c-c8bd33297d60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_49ba713f-432b-49a6-905c-c8bd33297d60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_de40654e-01bd-4698-9d56-4a24293ef237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_de40654e-01bd-4698-9d56-4a24293ef237" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c5ee4921-9f9b-4dbc-b9ad-5cdfa1ea1b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c5ee4921-9f9b-4dbc-b9ad-5cdfa1ea1b2f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ae98cde6-1bac-420b-b435-96a4d0813793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_abefc34f-621e-46c1-90aa-3ee7c6005e6a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ae98cde6-1bac-420b-b435-96a4d0813793" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6db19344-34d7-441b-b51b-9f0a2c2d8ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_abefc34f-621e-46c1-90aa-3ee7c6005e6a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6db19344-34d7-441b-b51b-9f0a2c2d8ae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_e327c2c7-96fe-4ec8-94b7-ebc14ef84eda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_abefc34f-621e-46c1-90aa-3ee7c6005e6a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_e327c2c7-96fe-4ec8-94b7-ebc14ef84eda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_cf2ab967-0c65-4def-9301-913022c21240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_abefc34f-621e-46c1-90aa-3ee7c6005e6a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_cf2ab967-0c65-4def-9301-913022c21240" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/FAIRVALUENarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#FAIRVALUENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/FAIRVALUENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d0f51bb2-177e-4cdd-b8fd-ae43082a2023" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_DebtInstrumentAxis_d0f51bb2-177e-4cdd-b8fd-ae43082a2023" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d0f51bb2-177e-4cdd-b8fd-ae43082a2023_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d0f51bb2-177e-4cdd-b8fd-ae43082a2023" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d0f51bb2-177e-4cdd-b8fd-ae43082a2023_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fbc5bfce-7adc-45c8-a4ef-c4de3c6f7ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d0f51bb2-177e-4cdd-b8fd-ae43082a2023" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fbc5bfce-7adc-45c8-a4ef-c4de3c6f7ac5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5.88PercentSeniorNotesDueMarch2033Member_cd7eadc9-3c49-4860-bbdd-17b12bb9e146" xlink:href="hum-20231231.xsd#hum_A5.88PercentSeniorNotesDueMarch2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fbc5bfce-7adc-45c8-a4ef-c4de3c6f7ac5" xlink:to="loc_hum_A5.88PercentSeniorNotesDueMarch2033Member_cd7eadc9-3c49-4860-bbdd-17b12bb9e146" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A550PercentSeniorNotesDueMarch2053Member_0b420dbf-6470-4943-a92d-52e4b2e7a132" xlink:href="hum-20231231.xsd#hum_A550PercentSeniorNotesDueMarch2053Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fbc5bfce-7adc-45c8-a4ef-c4de3c6f7ac5" xlink:to="loc_hum_A550PercentSeniorNotesDueMarch2053Member_0b420dbf-6470-4943-a92d-52e4b2e7a132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3.950PercentSeniorNotesMember_b5a307dd-4aaa-4d88-926e-c19719b772bf" xlink:href="hum-20231231.xsd#hum_A3.950PercentSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fbc5bfce-7adc-45c8-a4ef-c4de3c6f7ac5" xlink:to="loc_hum_A3.950PercentSeniorNotesMember_b5a307dd-4aaa-4d88-926e-c19719b772bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5950PercentSeniorNotesDueMarch2034Member_05ef3aa4-9c28-4ebb-84b4-d8d105aec1ea" xlink:href="hum-20231231.xsd#hum_A5950PercentSeniorNotesDueMarch2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fbc5bfce-7adc-45c8-a4ef-c4de3c6f7ac5" xlink:to="loc_hum_A5950PercentSeniorNotesDueMarch2034Member_05ef3aa4-9c28-4ebb-84b4-d8d105aec1ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_df37ab99-30f1-46bb-a3d3-5b2084825316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_df37ab99-30f1-46bb-a3d3-5b2084825316" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_df37ab99-30f1-46bb-a3d3-5b2084825316_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_df37ab99-30f1-46bb-a3d3-5b2084825316" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_df37ab99-30f1-46bb-a3d3-5b2084825316_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6d47b982-fda1-4fab-b5f5-551259f9d829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_df37ab99-30f1-46bb-a3d3-5b2084825316" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6d47b982-fda1-4fab-b5f5-551259f9d829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_139a154a-9362-45d5-b21e-461e13a202cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6d47b982-fda1-4fab-b5f5-551259f9d829" xlink:to="loc_us-gaap_SeniorNotesMember_139a154a-9362-45d5-b21e-461e13a202cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b0ec71f1-b575-4609-95e5-9f0ce77a9edf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b0ec71f1-b575-4609-95e5-9f0ce77a9edf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b0ec71f1-b575-4609-95e5-9f0ce77a9edf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b0ec71f1-b575-4609-95e5-9f0ce77a9edf" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b0ec71f1-b575-4609-95e5-9f0ce77a9edf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7818c062-5e42-4cc5-af45-e1d2f0c312f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b0ec71f1-b575-4609-95e5-9f0ce77a9edf" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7818c062-5e42-4cc5-af45-e1d2f0c312f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InterestRateSwapMaturing2032Member_ebb07d3b-6002-4dd8-a9f6-28e161fba495" xlink:href="hum-20231231.xsd#hum_InterestRateSwapMaturing2032Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7818c062-5e42-4cc5-af45-e1d2f0c312f8" xlink:to="loc_hum_InterestRateSwapMaturing2032Member_ebb07d3b-6002-4dd8-a9f6-28e161fba495" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InterestRateSwapMaturing2033Member_f6aef42a-4e6c-4dbc-a9e5-e7156f3770c5" xlink:href="hum-20231231.xsd#hum_InterestRateSwapMaturing2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7818c062-5e42-4cc5-af45-e1d2f0c312f8" xlink:to="loc_hum_InterestRateSwapMaturing2033Member_f6aef42a-4e6c-4dbc-a9e5-e7156f3770c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InterestRateSwapMaturing2049Member_7d7a3d8f-8970-42c5-bb8a-50540e662200" xlink:href="hum-20231231.xsd#hum_InterestRateSwapMaturing2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7818c062-5e42-4cc5-af45-e1d2f0c312f8" xlink:to="loc_hum_InterestRateSwapMaturing2049Member_7d7a3d8f-8970-42c5-bb8a-50540e662200" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InterestRateSwapMaturing2034Member_03c74717-6b69-4171-bf6b-e6ded7f8e4fc" xlink:href="hum-20231231.xsd#hum_InterestRateSwapMaturing2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7818c062-5e42-4cc5-af45-e1d2f0c312f8" xlink:to="loc_hum_InterestRateSwapMaturing2034Member_03c74717-6b69-4171-bf6b-e6ded7f8e4fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_30f5efb5-320f-47a7-bc7a-b3d3498f96e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_FinancialInstrumentAxis_30f5efb5-320f-47a7-bc7a-b3d3498f96e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_30f5efb5-320f-47a7-bc7a-b3d3498f96e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_30f5efb5-320f-47a7-bc7a-b3d3498f96e8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_30f5efb5-320f-47a7-bc7a-b3d3498f96e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77f8193a-1e87-46fa-b077-8be0814dd288" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_30f5efb5-320f-47a7-bc7a-b3d3498f96e8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77f8193a-1e87-46fa-b077-8be0814dd288" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_7c782e45-5dd6-491d-b4f2-3dc33ca0ccb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77f8193a-1e87-46fa-b077-8be0814dd288" xlink:to="loc_us-gaap_InterestRateSwapMember_7c782e45-5dd6-491d-b4f2-3dc33ca0ccb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_37444d59-b0c3-4185-978c-fc2c7f4c899c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_37444d59-b0c3-4185-978c-fc2c7f4c899c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_37444d59-b0c3-4185-978c-fc2c7f4c899c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_37444d59-b0c3-4185-978c-fc2c7f4c899c" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_37444d59-b0c3-4185-978c-fc2c7f4c899c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ab4a8539-95d1-40a4-8d1f-da2819fd5275" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_37444d59-b0c3-4185-978c-fc2c7f4c899c" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ab4a8539-95d1-40a4-8d1f-da2819fd5275" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_097851ac-88a4-4805-90cd-3ac117fb3aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ab4a8539-95d1-40a4-8d1f-da2819fd5275" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_097851ac-88a4-4805-90cd-3ac117fb3aa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_38b25f5e-f854-4b12-85c5-e9b790437581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_097851ac-88a4-4805-90cd-3ac117fb3aa2" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_38b25f5e-f854-4b12-85c5-e9b790437581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_84394076-babd-4a38-a18d-550c39b263ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_097851ac-88a4-4805-90cd-3ac117fb3aa2" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_84394076-babd-4a38-a18d-550c39b263ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_b6a700b2-c400-4d40-8e3b-c309e610fbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_b6a700b2-c400-4d40-8e3b-c309e610fbc0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_b6a700b2-c400-4d40-8e3b-c309e610fbc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_b6a700b2-c400-4d40-8e3b-c309e610fbc0" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_b6a700b2-c400-4d40-8e3b-c309e610fbc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_4a83dab1-0ecc-470d-89ba-a51b5f662dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_b6a700b2-c400-4d40-8e3b-c309e610fbc0" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_4a83dab1-0ecc-470d-89ba-a51b5f662dc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4f7c7809-ab0f-4524-9f35-083296fe4548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_4a83dab1-0ecc-470d-89ba-a51b5f662dc1" xlink:to="loc_us-gaap_CommercialPaperMember_4f7c7809-ab0f-4524-9f35-083296fe4548" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TermLoanAndCommercialPaperMember_975629c0-9e5d-4bcf-83bd-eaf34987bceb" xlink:href="hum-20231231.xsd#hum_TermLoanAndCommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_4a83dab1-0ecc-470d-89ba-a51b5f662dc1" xlink:to="loc_hum_TermLoanAndCommercialPaperMember_975629c0-9e5d-4bcf-83bd-eaf34987bceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cff2e505-f4c5-4c24-88a6-d9c24139eefc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cff2e505-f4c5-4c24-88a6-d9c24139eefc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cff2e505-f4c5-4c24-88a6-d9c24139eefc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cff2e505-f4c5-4c24-88a6-d9c24139eefc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cff2e505-f4c5-4c24-88a6-d9c24139eefc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4efff02-e052-424f-b1a6-784bbf8910cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cff2e505-f4c5-4c24-88a6-d9c24139eefc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4efff02-e052-424f-b1a6-784bbf8910cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_KindredAtHomeMember_31dc338b-6ecb-4b3e-8de4-82a5cc9213cb" xlink:href="hum-20231231.xsd#hum_KindredAtHomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4efff02-e052-424f-b1a6-784bbf8910cc" xlink:to="loc_hum_KindredAtHomeMember_31dc338b-6ecb-4b3e-8de4-82a5cc9213cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8b94662b-8ccc-483d-ba2f-d2bb477c4b28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8b94662b-8ccc-483d-ba2f-d2bb477c4b28" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_8b94662b-8ccc-483d-ba2f-d2bb477c4b28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8b94662b-8ccc-483d-ba2f-d2bb477c4b28" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_8b94662b-8ccc-483d-ba2f-d2bb477c4b28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_aedee3bb-f9e9-4fa9-bfe3-c604a3c417c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8b94662b-8ccc-483d-ba2f-d2bb477c4b28" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_aedee3bb-f9e9-4fa9-bfe3-c604a3c417c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8b4e624c-df61-4316-96c8-fbdb2fe88dde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_aedee3bb-f9e9-4fa9-bfe3-c604a3c417c5" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8b4e624c-df61-4316-96c8-fbdb2fe88dde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_e04b122c-caa9-49a6-846f-1c801e9fe810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_aedee3bb-f9e9-4fa9-bfe3-c604a3c417c5" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_e04b122c-caa9-49a6-846f-1c801e9fe810" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_7895562a-705f-4c8b-9d4c-919d64e0cafe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_7895562a-705f-4c8b-9d4c-919d64e0cafe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_7895562a-705f-4c8b-9d4c-919d64e0cafe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_7895562a-705f-4c8b-9d4c-919d64e0cafe" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_7895562a-705f-4c8b-9d4c-919d64e0cafe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_125465fc-8e8f-4c3e-896d-be0cbe1d0ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_7895562a-705f-4c8b-9d4c-919d64e0cafe" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_125465fc-8e8f-4c3e-896d-be0cbe1d0ea8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember_17a3bcd8-a3a7-4fe9-b89f-a3ce98cf4cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PutOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_125465fc-8e8f-4c3e-896d-be0cbe1d0ea8" xlink:to="loc_us-gaap_PutOptionMember_17a3bcd8-a3a7-4fe9-b89f-a3ce98cf4cfd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember_c8cc10be-5594-400b-b8e2-38df9f164c85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_125465fc-8e8f-4c3e-896d-be0cbe1d0ea8" xlink:to="loc_us-gaap_CallOptionMember_c8cc10be-5594-400b-b8e2-38df9f164c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_39868dd2-1969-47cd-84e4-6648baa009ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_39868dd2-1969-47cd-84e4-6648baa009ad" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_39868dd2-1969-47cd-84e4-6648baa009ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_39868dd2-1969-47cd-84e4-6648baa009ad" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_39868dd2-1969-47cd-84e4-6648baa009ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_bd84b28d-4982-426f-ae9c-5abaa1e1750c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_39868dd2-1969-47cd-84e4-6648baa009ad" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_bd84b28d-4982-426f-ae9c-5abaa1e1750c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FairValueRiskMember_2fe9bed9-c8a3-44b6-88a7-1f01c462393e" xlink:href="hum-20231231.xsd#hum_FairValueRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_bd84b28d-4982-426f-ae9c-5abaa1e1750c" xlink:to="loc_hum_FairValueRiskMember_2fe9bed9-c8a3-44b6-88a7-1f01c462393e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67b3f5b7-5142-4a8a-bfb0-92bf46db672f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67b3f5b7-5142-4a8a-bfb0-92bf46db672f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67b3f5b7-5142-4a8a-bfb0-92bf46db672f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67b3f5b7-5142-4a8a-bfb0-92bf46db672f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_67b3f5b7-5142-4a8a-bfb0-92bf46db672f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6daab656-2dbc-4603-9d63-8b35693926ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67b3f5b7-5142-4a8a-bfb0-92bf46db672f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6daab656-2dbc-4603-9d63-8b35693926ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5473cc43-23d3-4898-a867-89e3e35cc01e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6daab656-2dbc-4603-9d63-8b35693926ab" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5473cc43-23d3-4898-a867-89e3e35cc01e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_701a897f-b4d2-4517-8b76-562726078e83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_701a897f-b4d2-4517-8b76-562726078e83" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_701a897f-b4d2-4517-8b76-562726078e83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_701a897f-b4d2-4517-8b76-562726078e83" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_701a897f-b4d2-4517-8b76-562726078e83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d59db2c0-a173-4c4a-9fde-4acbd519d8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_701a897f-b4d2-4517-8b76-562726078e83" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d59db2c0-a173-4c4a-9fde-4acbd519d8a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_47a9d39c-0e28-43db-9805-6b746e9e5fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d59db2c0-a173-4c4a-9fde-4acbd519d8a8" xlink:to="loc_us-gaap_InvestmentsMember_47a9d39c-0e28-43db-9805-6b746e9e5fe4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_afdc4ac5-042a-4a02-9ce1-c18977b5f33d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_afdc4ac5-042a-4a02-9ce1-c18977b5f33d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_afdc4ac5-042a-4a02-9ce1-c18977b5f33d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_afdc4ac5-042a-4a02-9ce1-c18977b5f33d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_afdc4ac5-042a-4a02-9ce1-c18977b5f33d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4d3b60f6-90a4-409c-a5da-5cc249a663c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_afdc4ac5-042a-4a02-9ce1-c18977b5f33d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4d3b60f6-90a4-409c-a5da-5cc249a663c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_4f814af4-d4fc-47ab-a72d-a416fcf58cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4d3b60f6-90a4-409c-a5da-5cc249a663c3" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_4f814af4-d4fc-47ab-a72d-a416fcf58cd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d2a6e014-e834-4c14-bda6-63046eb94c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d2a6e014-e834-4c14-bda6-63046eb94c4c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d2a6e014-e834-4c14-bda6-63046eb94c4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d2a6e014-e834-4c14-bda6-63046eb94c4c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d2a6e014-e834-4c14-bda6-63046eb94c4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c8ced13-c1c2-4229-b232-fe38972e79dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d2a6e014-e834-4c14-bda6-63046eb94c4c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c8ced13-c1c2-4229-b232-fe38972e79dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GentivaHospiceMember_28a37d54-2b22-40bb-91ef-66d812e1f0e4" xlink:href="hum-20231231.xsd#hum_GentivaHospiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c8ced13-c1c2-4229-b232-fe38972e79dd" xlink:to="loc_hum_GentivaHospiceMember_28a37d54-2b22-40bb-91ef-66d812e1f0e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_fe580a47-9a0e-4716-85ca-a5c678a41990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_fe580a47-9a0e-4716-85ca-a5c678a41990" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_864b0f5c-e1a6-4cc4-8b3f-ae8f35aea361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_864b0f5c-e1a6-4cc4-8b3f-ae8f35aea361" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_402ffd28-7756-4914-a90c-370f6e813bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_402ffd28-7756-4914-a90c-370f6e813bd8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d74e161a-0753-4816-8a6a-467a092fc89c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d74e161a-0753-4816-8a6a-467a092fc89c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_9bd5cfda-f7c9-4f84-818d-2f22b6ea729c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_DerivativeNotionalAmount_9bd5cfda-f7c9-4f84-818d-2f22b6ea729c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_9e5d7bee-6b58-41ab-8171-c863489e4b23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_9e5d7bee-6b58-41ab-8171-c863489e4b23" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_1cc22528-4447-4aa5-aaf4-7022916e0ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_DebtInstrumentFairValue_1cc22528-4447-4aa5-aaf4-7022916e0ab6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_339bc723-fdc3-4b15-9665-ecda61200106" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_ShortTermBorrowings_339bc723-fdc3-4b15-9665-ecda61200106" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage_529f3522-a866-491a-8377-8b98076bf815" xlink:href="hum-20231231.xsd#hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage_529f3522-a866-491a-8377-8b98076bf815" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_a49ceaed-8768-43b7-afd2-29b9e3956e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_a49ceaed-8768-43b7-afd2-29b9e3956e8b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FinancialAssetsFairValueDisclosure_bdd3d0be-e5a1-460b-8d35-b1d4f1b62152" xlink:href="hum-20231231.xsd#hum_FinancialAssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_hum_FinancialAssetsFairValueDisclosure_bdd3d0be-e5a1-460b-8d35-b1d4f1b62152" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LossOnTerminationOfDerivatives_0a3f4d8d-e7f4-4476-b0bf-15250ca6703a" xlink:href="hum-20231231.xsd#hum_LossOnTerminationOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_hum_LossOnTerminationOfDerivatives_0a3f4d8d-e7f4-4476-b0bf-15250ca6703a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold_378808da-b133-4f54-838e-17dbbad03ee9" xlink:href="hum-20231231.xsd#hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold_378808da-b133-4f54-838e-17dbbad03ee9" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ac112038-aa47-4c40-b5bd-898706aa80e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_226aaf37-cba1-4dd1-b6dd-20661f213802" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ac112038-aa47-4c40-b5bd-898706aa80e3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_226aaf37-cba1-4dd1-b6dd-20661f213802" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7d767645-2b0e-48b1-9573-1e80742ad4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_226aaf37-cba1-4dd1-b6dd-20661f213802" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7d767645-2b0e-48b1-9573-1e80742ad4c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7d767645-2b0e-48b1-9573-1e80742ad4c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7d767645-2b0e-48b1-9573-1e80742ad4c9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7d767645-2b0e-48b1-9573-1e80742ad4c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b965127-26e7-492b-921d-06fa98b07559" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7d767645-2b0e-48b1-9573-1e80742ad4c9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b965127-26e7-492b-921d-06fa98b07559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionOnSecuritiesMember_6319809d-e58e-4c9a-a793-89a3d2394010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionOnSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b965127-26e7-492b-921d-06fa98b07559" xlink:to="loc_us-gaap_OptionOnSecuritiesMember_6319809d-e58e-4c9a-a793-89a3d2394010" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7b1d0a1e-9ff8-4c32-9589-1f75c1a72db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_226aaf37-cba1-4dd1-b6dd-20661f213802" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7b1d0a1e-9ff8-4c32-9589-1f75c1a72db3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b1d0a1e-9ff8-4c32-9589-1f75c1a72db3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7b1d0a1e-9ff8-4c32-9589-1f75c1a72db3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7b1d0a1e-9ff8-4c32-9589-1f75c1a72db3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_22dfc938-1ad1-4313-8889-184761031789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7b1d0a1e-9ff8-4c32-9589-1f75c1a72db3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_22dfc938-1ad1-4313-8889-184761031789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d9748b84-d184-42cc-816f-919d9c8074f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_22dfc938-1ad1-4313-8889-184761031789" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d9748b84-d184-42cc-816f-919d9c8074f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1e662b60-4b3f-475c-8dbe-b9c226c9a51d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_226aaf37-cba1-4dd1-b6dd-20661f213802" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1e662b60-4b3f-475c-8dbe-b9c226c9a51d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1e662b60-4b3f-475c-8dbe-b9c226c9a51d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1e662b60-4b3f-475c-8dbe-b9c226c9a51d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1e662b60-4b3f-475c-8dbe-b9c226c9a51d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_74f1d133-4992-45e4-ae24-3310f23c4ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1e662b60-4b3f-475c-8dbe-b9c226c9a51d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_74f1d133-4992-45e4-ae24-3310f23c4ca2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_72d81228-458e-41c5-99c9-18469818bb82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_74f1d133-4992-45e4-ae24-3310f23c4ca2" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_72d81228-458e-41c5-99c9-18469818bb82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditSpreadOptionMember_14fa5c71-170a-401e-8244-68831a79ba33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditSpreadOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_74f1d133-4992-45e4-ae24-3310f23c4ca2" xlink:to="loc_us-gaap_CreditSpreadOptionMember_14fa5c71-170a-401e-8244-68831a79ba33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevenueExitMultipleMember_0b194492-d4ff-44f3-b9d8-673655faaabf" xlink:href="hum-20231231.xsd#hum_RevenueExitMultipleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_74f1d133-4992-45e4-ae24-3310f23c4ca2" xlink:to="loc_hum_RevenueExitMultipleMember_0b194492-d4ff-44f3-b9d8-673655faaabf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_653fd415-d84f-4450-af61-c622875fa18b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_74f1d133-4992-45e4-ae24-3310f23c4ca2" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_653fd415-d84f-4450-af61-c622875fa18b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputLongTermRevenueGrowthRateMember_67a72adf-577b-4ebe-bcfa-6926d06de992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputLongTermRevenueGrowthRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_74f1d133-4992-45e4-ae24-3310f23c4ca2" xlink:to="loc_us-gaap_MeasurementInputLongTermRevenueGrowthRateMember_67a72adf-577b-4ebe-bcfa-6926d06de992" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9ea8adff-00f3-47c0-968e-f36a3bae71ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_226aaf37-cba1-4dd1-b6dd-20661f213802" xlink:to="loc_srt_RangeAxis_9ea8adff-00f3-47c0-968e-f36a3bae71ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9ea8adff-00f3-47c0-968e-f36a3bae71ce_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9ea8adff-00f3-47c0-968e-f36a3bae71ce" xlink:to="loc_srt_RangeMember_9ea8adff-00f3-47c0-968e-f36a3bae71ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d06e9d7a-e4e9-479b-bf34-8178829a538f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9ea8adff-00f3-47c0-968e-f36a3bae71ce" xlink:to="loc_srt_RangeMember_d06e9d7a-e4e9-479b-bf34-8178829a538f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8d1f8cc4-3f27-4e73-897a-ce415fe0ad6e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d06e9d7a-e4e9-479b-bf34-8178829a538f" xlink:to="loc_srt_MinimumMember_8d1f8cc4-3f27-4e73-897a-ce415fe0ad6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_29f649dc-2f93-40b0-8e44-8229f1be8978" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d06e9d7a-e4e9-479b-bf34-8178829a538f" xlink:to="loc_srt_MaximumMember_29f649dc-2f93-40b0-8e44-8229f1be8978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetLiabilityNetMeasurementInput_c43639c0-faab-4dae-8cc9-9c9d6900fba2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetLiabilityNetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ac112038-aa47-4c40-b5bd-898706aa80e3" xlink:to="loc_us-gaap_DerivativeAssetLiabilityNetMeasurementInput_c43639c0-faab-4dae-8cc9-9c9d6900fba2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/MEDICAREPARTDDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#MEDICAREPARTDDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/MEDICAREPARTDDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8b86583a-596a-42e7-9750-8aca58a6362a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8b86583a-596a-42e7-9750-8aca58a6362a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ccea5c05-cfdb-4e03-9ef6-dd52e4a9e15a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8b86583a-596a-42e7-9750-8aca58a6362a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ccea5c05-cfdb-4e03-9ef6-dd52e4a9e15a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ccea5c05-cfdb-4e03-9ef6-dd52e4a9e15a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ccea5c05-cfdb-4e03-9ef6-dd52e4a9e15a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ccea5c05-cfdb-4e03-9ef6-dd52e4a9e15a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca0a5df7-6ef6-475d-8b68-3f701d058280" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ccea5c05-cfdb-4e03-9ef6-dd52e4a9e15a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca0a5df7-6ef6-475d-8b68-3f701d058280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RiskCorridorSettlementsMedicarePartDMember_f9a5f4ea-c59a-40b8-b7fd-17d34bc22653" xlink:href="hum-20231231.xsd#hum_RiskCorridorSettlementsMedicarePartDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca0a5df7-6ef6-475d-8b68-3f701d058280" xlink:to="loc_hum_RiskCorridorSettlementsMedicarePartDMember_f9a5f4ea-c59a-40b8-b7fd-17d34bc22653" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CmsSubsidiesOrDiscountsMember_e915f599-2c39-4f86-ae3d-07aea74a550f" xlink:href="hum-20231231.xsd#hum_CmsSubsidiesOrDiscountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca0a5df7-6ef6-475d-8b68-3f701d058280" xlink:to="loc_hum_CmsSubsidiesOrDiscountsMember_e915f599-2c39-4f86-ae3d-07aea74a550f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_6e21d864-a659-4c3a-951c-f3890da5ba61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:to="loc_us-gaap_OtherAssetsCurrent_6e21d864-a659-4c3a-951c-f3890da5ba61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b55e13d-e373-4a05-ad25-9324407e6e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b55e13d-e373-4a05-ad25-9324407e6e2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NetCurrentLiabilityAsset_c53807e3-010c-45d8-bb5c-372a0133f971" xlink:href="hum-20231231.xsd#hum_NetCurrentLiabilityAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:to="loc_hum_NetCurrentLiabilityAsset_c53807e3-010c-45d8-bb5c-372a0133f971" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b85ff79d-050a-4095-80e8-db4e7f1117a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b85ff79d-050a-4095-80e8-db4e7f1117a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_92a7503a-a0ca-449e-b5ff-a41b7615cd95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_92a7503a-a0ca-449e-b5ff-a41b7615cd95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NetNoncurrentAssetLiability_a9536b43-9d8c-4945-8eaf-69ee82f94ae9" xlink:href="hum-20231231.xsd#hum_NetNoncurrentAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:to="loc_hum_NetNoncurrentAssetLiability_a9536b43-9d8c-4945-8eaf-69ee82f94ae9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NetAssetLiability_d0cfe685-df02-4533-8af3-f40e88f16ed3" xlink:href="hum-20231231.xsd#hum_NetAssetLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:to="loc_hum_NetAssetLiability_d0cfe685-df02-4533-8af3-f40e88f16ed3" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0c482842-2d76-413e-b765-d330edbc8f32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_398e6a5d-e58a-446b-b36d-7d09f15d0f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0c482842-2d76-413e-b765-d330edbc8f32" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_398e6a5d-e58a-446b-b36d-7d09f15d0f9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_642ee14a-0a49-494d-a301-7a0dc1533b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_398e6a5d-e58a-446b-b36d-7d09f15d0f9c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_642ee14a-0a49-494d-a301-7a0dc1533b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_642ee14a-0a49-494d-a301-7a0dc1533b5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_642ee14a-0a49-494d-a301-7a0dc1533b5b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_642ee14a-0a49-494d-a301-7a0dc1533b5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a61cba4b-c773-4346-8e26-2018cb6bc0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_642ee14a-0a49-494d-a301-7a0dc1533b5b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a61cba4b-c773-4346-8e26-2018cb6bc0d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_5f048448-15c5-49fc-b02d-e2baf63d1437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a61cba4b-c773-4346-8e26-2018cb6bc0d8" xlink:to="loc_us-gaap_LandMember_5f048448-15c5-49fc-b02d-e2baf63d1437" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BuildingsAndLeaseholdImprovementsMember_ccf1520e-3db9-465c-9b2c-1249854bdefc" xlink:href="hum-20231231.xsd#hum_BuildingsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a61cba4b-c773-4346-8e26-2018cb6bc0d8" xlink:to="loc_hum_BuildingsAndLeaseholdImprovementsMember_ccf1520e-3db9-465c-9b2c-1249854bdefc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6a0e17aa-3409-4de5-b520-9693159a1f90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a61cba4b-c773-4346-8e26-2018cb6bc0d8" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_6a0e17aa-3409-4de5-b520-9693159a1f90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_7bb28935-3367-4cdf-8029-778c6e3a3e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a61cba4b-c773-4346-8e26-2018cb6bc0d8" xlink:to="loc_us-gaap_ComputerEquipmentMember_7bb28935-3367-4cdf-8029-778c6e3a3e6c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_275f2b50-93e1-42eb-9aca-47f75d1b5a29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0c482842-2d76-413e-b765-d330edbc8f32" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_275f2b50-93e1-42eb-9aca-47f75d1b5a29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e6ad56b8-84d2-4977-90e4-e1405068aa44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0c482842-2d76-413e-b765-d330edbc8f32" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e6ad56b8-84d2-4977-90e4-e1405068aa44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dacd7420-601e-4f27-8749-0cf7e83ff885" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0c482842-2d76-413e-b765-d330edbc8f32" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dacd7420-601e-4f27-8749-0cf7e83ff885" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_f8292800-d774-4639-8e79-8d433ae029c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_a6ea9d9e-b44a-4adc-a123-f18ce4fc680e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_f8292800-d774-4639-8e79-8d433ae029c9" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_a6ea9d9e-b44a-4adc-a123-f18ce4fc680e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_28049685-6b96-47f0-86b8-111de393b31c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a6ea9d9e-b44a-4adc-a123-f18ce4fc680e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_28049685-6b96-47f0-86b8-111de393b31c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_28049685-6b96-47f0-86b8-111de393b31c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_28049685-6b96-47f0-86b8-111de393b31c" xlink:to="loc_us-gaap_SegmentDomain_28049685-6b96-47f0-86b8-111de393b31c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9631c051-0600-4ff2-9bc3-3e39ccc3289e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_28049685-6b96-47f0-86b8-111de393b31c" xlink:to="loc_us-gaap_SegmentDomain_9631c051-0600-4ff2-9bc3-3e39ccc3289e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InsuranceSegmentMember_bfdceaeb-d297-479e-9f83-9a0126af0416" xlink:href="hum-20231231.xsd#hum_InsuranceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9631c051-0600-4ff2-9bc3-3e39ccc3289e" xlink:to="loc_hum_InsuranceSegmentMember_bfdceaeb-d297-479e-9f83-9a0126af0416" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CenterWellSegmentMember_8dc35d78-7dea-4cc4-b4c9-681761a64afd" xlink:href="hum-20231231.xsd#hum_CenterWellSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9631c051-0600-4ff2-9bc3-3e39ccc3289e" xlink:to="loc_hum_CenterWellSegmentMember_8dc35d78-7dea-4cc4-b4c9-681761a64afd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_09c42a18-6179-427f-b9b5-66a8d5670688" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_f8292800-d774-4639-8e79-8d433ae029c9" xlink:to="loc_us-gaap_GoodwillRollForward_09c42a18-6179-427f-b9b5-66a8d5670688" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_82ce74bb-9f5d-412c-9c24-dced6b27b7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_09c42a18-6179-427f-b9b5-66a8d5670688" xlink:to="loc_us-gaap_Goodwill_82ce74bb-9f5d-412c-9c24-dced6b27b7f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_884d775d-bf2e-4d2f-9f23-5e3ea8db7630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_09c42a18-6179-427f-b9b5-66a8d5670688" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_884d775d-bf2e-4d2f-9f23-5e3ea8db7630" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_eeffcbfb-2b7d-4cc0-b2ed-bf28a0dac913" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_09c42a18-6179-427f-b9b5-66a8d5670688" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_eeffcbfb-2b7d-4cc0-b2ed-bf28a0dac913" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bac8b5b5-5511-46fc-a467-bdb1d284bcc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7d40d32c-f937-45dd-b92e-6fe12ffcfe7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8c8e02c6-27ef-4ec2-a886-34c27d9d7d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7d40d32c-f937-45dd-b92e-6fe12ffcfe7e" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8c8e02c6-27ef-4ec2-a886-34c27d9d7d3f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_03136658-28f6-4908-9ae9-8735be86c29b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8c8e02c6-27ef-4ec2-a886-34c27d9d7d3f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_03136658-28f6-4908-9ae9-8735be86c29b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_03136658-28f6-4908-9ae9-8735be86c29b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_03136658-28f6-4908-9ae9-8735be86c29b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_03136658-28f6-4908-9ae9-8735be86c29b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8ac5ec12-b283-4f63-9bd0-766f5b8aec07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_03136658-28f6-4908-9ae9-8735be86c29b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8ac5ec12-b283-4f63-9bd0-766f5b8aec07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CertificateOfNeedMember_efad89df-b347-4642-8678-893eaa32acc3" xlink:href="hum-20231231.xsd#hum_CertificateOfNeedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8ac5ec12-b283-4f63-9bd0-766f5b8aec07" xlink:to="loc_hum_CertificateOfNeedMember_efad89df-b347-4642-8678-893eaa32acc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_5bdd6ded-dbbf-4fb9-82e4-c331e35216ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8ac5ec12-b283-4f63-9bd0-766f5b8aec07" xlink:to="loc_us-gaap_LicensingAgreementsMember_5bdd6ded-dbbf-4fb9-82e4-c331e35216ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_815a4e22-7655-4494-bc57-68c4c1be35b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7d40d32c-f937-45dd-b92e-6fe12ffcfe7e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_815a4e22-7655-4494-bc57-68c4c1be35b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_900e80ba-176d-4329-82de-3a66ef5faadd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d74d79f9-65cf-4019-b30c-55036734bea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_900e80ba-176d-4329-82de-3a66ef5faadd" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d74d79f9-65cf-4019-b30c-55036734bea8" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d23e1e8f-d861-4ae8-b21d-f22d0cd95cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d74d79f9-65cf-4019-b30c-55036734bea8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d23e1e8f-d861-4ae8-b21d-f22d0cd95cb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d23e1e8f-d861-4ae8-b21d-f22d0cd95cb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d23e1e8f-d861-4ae8-b21d-f22d0cd95cb4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d23e1e8f-d861-4ae8-b21d-f22d0cd95cb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6920a2ad-034a-46d5-a096-cbc4a25f4256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d23e1e8f-d861-4ae8-b21d-f22d0cd95cb4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6920a2ad-034a-46d5-a096-cbc4a25f4256" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerContractsMember_b8b32d67-e97e-4d10-8584-65b85f81bb44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6920a2ad-034a-46d5-a096-cbc4a25f4256" xlink:to="loc_us-gaap_CustomerContractsMember_b8b32d67-e97e-4d10-8584-65b85f81bb44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_ea8bc493-70cf-42a9-b426-85d0f7aa3008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6920a2ad-034a-46d5-a096-cbc4a25f4256" xlink:to="loc_us-gaap_TradeNamesMember_ea8bc493-70cf-42a9-b426-85d0f7aa3008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_778b0288-cde2-4de1-aa2c-53610b3f2efa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6920a2ad-034a-46d5-a096-cbc4a25f4256" xlink:to="loc_us-gaap_ContractualRightsMember_778b0288-cde2-4de1-aa2c-53610b3f2efa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NoncompetesAndOtherMember_0ec39f5d-7b07-4d4a-a19c-aef7404226fc" xlink:href="hum-20231231.xsd#hum_NoncompetesAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6920a2ad-034a-46d5-a096-cbc4a25f4256" xlink:to="loc_hum_NoncompetesAndOtherMember_0ec39f5d-7b07-4d4a-a19c-aef7404226fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a85ac6f2-e77a-4419-9fee-1acc779d8815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_900e80ba-176d-4329-82de-3a66ef5faadd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a85ac6f2-e77a-4419-9fee-1acc779d8815" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fd3cf4b9-73a5-4216-9d32-530f569dde6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a85ac6f2-e77a-4419-9fee-1acc779d8815" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fd3cf4b9-73a5-4216-9d32-530f569dde6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ece11d8f-366d-439b-a6a5-d5e922c240bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a85ac6f2-e77a-4419-9fee-1acc779d8815" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ece11d8f-366d-439b-a6a5-d5e922c240bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5a047e81-46f9-47dc-9eae-6297baf11c04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a85ac6f2-e77a-4419-9fee-1acc779d8815" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5a047e81-46f9-47dc-9eae-6297baf11c04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_49e4000a-c66d-4d25-891c-2838bc761979" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a85ac6f2-e77a-4419-9fee-1acc779d8815" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_49e4000a-c66d-4d25-891c-2838bc761979" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8cfda045-456c-47ac-a4cc-94dd92601822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a85ac6f2-e77a-4419-9fee-1acc779d8815" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8cfda045-456c-47ac-a4cc-94dd92601822" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_699a18f7-211b-4482-ae4f-ab644d9414a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a85ac6f2-e77a-4419-9fee-1acc779d8815" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_699a18f7-211b-4482-ae4f-ab644d9414a4" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_019825f8-2c9e-4187-9d27-a500e59630b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_ec35a641-b2cf-4ca7-b432-8cfe5aa140b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_019825f8-2c9e-4187-9d27-a500e59630b0" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_ec35a641-b2cf-4ca7-b432-8cfe5aa140b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_22b44a4d-be16-4dfb-a0ad-37a611cbcd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_ec35a641-b2cf-4ca7-b432-8cfe5aa140b8" xlink:to="loc_us-gaap_RestructuringPlanAxis_22b44a4d-be16-4dfb-a0ad-37a611cbcd9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_22b44a4d-be16-4dfb-a0ad-37a611cbcd9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_22b44a4d-be16-4dfb-a0ad-37a611cbcd9b" xlink:to="loc_us-gaap_RestructuringPlanDomain_22b44a4d-be16-4dfb-a0ad-37a611cbcd9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6c6f2bc3-e2c8-49e1-aa79-fd4a306bbcca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_22b44a4d-be16-4dfb-a0ad-37a611cbcd9b" xlink:to="loc_us-gaap_RestructuringPlanDomain_6c6f2bc3-e2c8-49e1-aa79-fd4a306bbcca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember_f191b603-c484-430c-aede-48f38186747f" xlink:href="hum-20231231.xsd#hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_6c6f2bc3-e2c8-49e1-aa79-fd4a306bbcca" xlink:to="loc_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember_f191b603-c484-430c-aede-48f38186747f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_45b34b4d-a4e0-417f-bd3b-90291fd61824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_019825f8-2c9e-4187-9d27-a500e59630b0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_45b34b4d-a4e0-417f-bd3b-90291fd61824" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_a32e8c17-499a-4e76-8025-9936b70d5e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_019825f8-2c9e-4187-9d27-a500e59630b0" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_a32e8c17-499a-4e76-8025-9936b70d5e23" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#BENEFITSPAYABLENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClaimsDevelopmentLineItems_b58ba5d4-dfbf-4dab-846f-331b154b877f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClaimsDevelopmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_0dbb93c0-149d-4406-93a7-1383faef2858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_b58ba5d4-dfbf-4dab-846f-331b154b877f" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_0dbb93c0-149d-4406-93a7-1383faef2858" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_718e9c15-ab7c-4f26-bb43-018195fea68e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_0dbb93c0-149d-4406-93a7-1383faef2858" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_718e9c15-ab7c-4f26-bb43-018195fea68e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_718e9c15-ab7c-4f26-bb43-018195fea68e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_718e9c15-ab7c-4f26-bb43-018195fea68e" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_718e9c15-ab7c-4f26-bb43-018195fea68e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a902b7cc-ca46-4470-8711-4360ec057773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_718e9c15-ab7c-4f26-bb43-018195fea68e" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a902b7cc-ca46-4470-8711-4360ec057773" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member_9fb1c9e4-4ad1-414c-82e1-7ea8b6f3b89e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a902b7cc-ca46-4470-8711-4360ec057773" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member_9fb1c9e4-4ad1-414c-82e1-7ea8b6f3b89e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_e0d519de-9df5-4a02-9efb-424bed564a37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a902b7cc-ca46-4470-8711-4360ec057773" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_e0d519de-9df5-4a02-9efb-424bed564a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member_338ca7d6-451b-4d8f-865c-a400bf528222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a902b7cc-ca46-4470-8711-4360ec057773" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member_338ca7d6-451b-4d8f-865c-a400bf528222" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount_c166c768-f303-4a51-ae2f-fdc3d3b4fe36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_b58ba5d4-dfbf-4dab-846f-331b154b877f" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount_c166c768-f303-4a51-ae2f-fdc3d3b4fe36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported_64fcdb89-d14b-4200-a051-75872f250103" xlink:href="hum-20231231.xsd#hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_b58ba5d4-dfbf-4dab-846f-331b154b877f" xlink:to="loc_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported_64fcdb89-d14b-4200-a051-75872f250103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears_74ed9cbf-557b-4045-83e1-2741dd43e560" xlink:href="hum-20231231.xsd#hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_b58ba5d4-dfbf-4dab-846f-331b154b877f" xlink:to="loc_hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears_74ed9cbf-557b-4045-83e1-2741dd43e560" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClaimsDevelopmentLineItems_fbd0749a-7d29-4596-9116-067b607f7461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClaimsDevelopmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_dad3db8c-524f-4d0e-b756-733fcbedc027" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_fbd0749a-7d29-4596-9116-067b607f7461" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_dad3db8c-524f-4d0e-b756-733fcbedc027" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_1cb23d32-2343-46bb-85c1-715cd7f5750d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_dad3db8c-524f-4d0e-b756-733fcbedc027" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_1cb23d32-2343-46bb-85c1-715cd7f5750d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_1cb23d32-2343-46bb-85c1-715cd7f5750d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_1cb23d32-2343-46bb-85c1-715cd7f5750d" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_1cb23d32-2343-46bb-85c1-715cd7f5750d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_d2d9dbec-d489-401d-83da-e93b2cc2b408" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_1cb23d32-2343-46bb-85c1-715cd7f5750d" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_d2d9dbec-d489-401d-83da-e93b2cc2b408" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember_6ee7a4e4-dfb4-4e32-a7ac-32b08a8c0ded" xlink:href="hum-20231231.xsd#hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_d2d9dbec-d489-401d-83da-e93b2cc2b408" xlink:to="loc_hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember_6ee7a4e4-dfb4-4e32-a7ac-32b08a8c0ded" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_07f0f349-681a-4c62-8a5e-7826d6ef793f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_d2d9dbec-d489-401d-83da-e93b2cc2b408" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_07f0f349-681a-4c62-8a5e-7826d6ef793f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member_1c951ee1-46a6-4b86-906a-f57061e98a42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_d2d9dbec-d489-401d-83da-e93b2cc2b408" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member_1c951ee1-46a6-4b86-906a-f57061e98a42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_72028435-3232-49ce-8bfe-9e181c8b096e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_fbd0749a-7d29-4596-9116-067b607f7461" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_72028435-3232-49ce-8bfe-9e181c8b096e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_d2d19d0a-9f40-468b-97e7-805a375fdae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_fbd0749a-7d29-4596-9116-067b607f7461" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_d2d19d0a-9f40-468b-97e7-805a375fdae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_3d5e4936-f81e-4919-8fe3-803dbeb44150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_fbd0749a-7d29-4596-9116-067b607f7461" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_3d5e4936-f81e-4919-8fe3-803dbeb44150" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_37425bba-07c9-4d79-af55-04359a17b868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_013cc35c-e39f-4569-80de-d63b1aeb055b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_37425bba-07c9-4d79-af55-04359a17b868" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_013cc35c-e39f-4569-80de-d63b1aeb055b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_21f1a8ed-3c4c-4982-8355-50ca59340505" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_013cc35c-e39f-4569-80de-d63b1aeb055b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_21f1a8ed-3c4c-4982-8355-50ca59340505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_21f1a8ed-3c4c-4982-8355-50ca59340505_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_21f1a8ed-3c4c-4982-8355-50ca59340505" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_21f1a8ed-3c4c-4982-8355-50ca59340505_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e430da20-5a31-4ec6-839d-f65c61bd566f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_21f1a8ed-3c4c-4982-8355-50ca59340505" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e430da20-5a31-4ec6-839d-f65c61bd566f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_73968146-0b7e-4fe9-8879-ac11806ca644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e430da20-5a31-4ec6-839d-f65c61bd566f" xlink:to="loc_us-gaap_DomesticCountryMember_73968146-0b7e-4fe9-8879-ac11806ca644" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_89e9eb21-e9ef-48e6-9225-504e6c7e2377" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e430da20-5a31-4ec6-839d-f65c61bd566f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_89e9eb21-e9ef-48e6-9225-504e6c7e2377" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_7e906c5a-5a1d-4a5d-b6fe-d47e457dd233" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_37425bba-07c9-4d79-af55-04359a17b868" xlink:to="loc_us-gaap_OperatingLossCarryforwards_7e906c5a-5a1d-4a5d-b6fe-d47e457dd233" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b9897482-2d40-4ca0-adb7-65928a22b149" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_37425bba-07c9-4d79-af55-04359a17b868" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b9897482-2d40-4ca0-adb7-65928a22b149" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/DEBTDebtOutstandingDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#DEBTDebtOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/DEBTDebtOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6805204f-d980-47cd-9c12-7bea413b5c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_74384b4d-54ff-4f0f-bf13-87d2eac436d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6805204f-d980-47cd-9c12-7bea413b5c66" xlink:to="loc_us-gaap_DebtInstrumentTable_74384b4d-54ff-4f0f-bf13-87d2eac436d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_71d368ea-5245-48b4-ade7-d1c9dd7af689" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_74384b4d-54ff-4f0f-bf13-87d2eac436d1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_71d368ea-5245-48b4-ade7-d1c9dd7af689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_71d368ea-5245-48b4-ade7-d1c9dd7af689_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_71d368ea-5245-48b4-ade7-d1c9dd7af689" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_71d368ea-5245-48b4-ade7-d1c9dd7af689_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_7f81aea5-278f-4c37-b2ac-6370161351dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_71d368ea-5245-48b4-ade7-d1c9dd7af689" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_7f81aea5-278f-4c37-b2ac-6370161351dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_44217676-1dc2-497a-91aa-5dfdcd04a0be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_7f81aea5-278f-4c37-b2ac-6370161351dc" xlink:to="loc_us-gaap_CommercialPaperMember_44217676-1dc2-497a-91aa-5dfdcd04a0be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bfecce00-47c0-4c3d-83b0-10b4affd4bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_74384b4d-54ff-4f0f-bf13-87d2eac436d1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bfecce00-47c0-4c3d-83b0-10b4affd4bc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bfecce00-47c0-4c3d-83b0-10b4affd4bc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfecce00-47c0-4c3d-83b0-10b4affd4bc8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bfecce00-47c0-4c3d-83b0-10b4affd4bc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_07358603-8da7-48b2-9a07-19184b7170c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfecce00-47c0-4c3d-83b0-10b4affd4bc8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_07358603-8da7-48b2-9a07-19184b7170c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e196cd23-77c7-4cc8-a259-268c8493011d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_07358603-8da7-48b2-9a07-19184b7170c5" xlink:to="loc_us-gaap_SeniorNotesMember_e196cd23-77c7-4cc8-a259-268c8493011d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_6df2267a-0751-440f-a152-0e3b014eb96c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_07358603-8da7-48b2-9a07-19184b7170c5" xlink:to="loc_us-gaap_LoansPayableMember_6df2267a-0751-440f-a152-0e3b014eb96c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bf0ccb2a-8399-4849-8841-804128604473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_74384b4d-54ff-4f0f-bf13-87d2eac436d1" xlink:to="loc_us-gaap_DebtInstrumentAxis_bf0ccb2a-8399-4849-8841-804128604473" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bf0ccb2a-8399-4849-8841-804128604473_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_bf0ccb2a-8399-4849-8841-804128604473" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bf0ccb2a-8399-4849-8841-804128604473_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_bf0ccb2a-8399-4849-8841-804128604473" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3850PercentSeniorNotesDueOctober2024Member_86505d07-d7c4-4b44-b398-0864b7c94db6" xlink:href="hum-20231231.xsd#hum_A3850PercentSeniorNotesDueOctober2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A3850PercentSeniorNotesDueOctober2024Member_86505d07-d7c4-4b44-b398-0864b7c94db6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A065PercentSeniorNotesDueAugust2023Member_817f1971-6f20-4719-a4ee-b25c9d03beda" xlink:href="hum-20231231.xsd#hum_A065PercentSeniorNotesDueAugust2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A065PercentSeniorNotesDueAugust2023Member_817f1971-6f20-4719-a4ee-b25c9d03beda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A4.500PercentSeniorNotesDueApril2025Member_2ad7beff-0b50-40e2-a7a9-9eba7e09bddd" xlink:href="hum-20231231.xsd#hum_A4.500PercentSeniorNotesDueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A4.500PercentSeniorNotesDueApril2025Member_2ad7beff-0b50-40e2-a7a9-9eba7e09bddd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A570PercentSeniorNotesDueMarch2026Member_d11c7395-24d7-4db1-afb9-fc3460a6ce6a" xlink:href="hum-20231231.xsd#hum_A570PercentSeniorNotesDueMarch2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A570PercentSeniorNotesDueMarch2026Member_d11c7395-24d7-4db1-afb9-fc3460a6ce6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A135PercentSeniorNotesDueFebruary2027Member_95910699-c048-4dc3-9f70-978fce37c002" xlink:href="hum-20231231.xsd#hum_A135PercentSeniorNotesDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A135PercentSeniorNotesDueFebruary2027Member_95910699-c048-4dc3-9f70-978fce37c002" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3.95PercentSeniorNotesDueMarch2027Member_30f089dc-b219-423d-ac57-a711dc7e9b4e" xlink:href="hum-20231231.xsd#hum_A3.95PercentSeniorNotesDueMarch2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A3.95PercentSeniorNotesDueMarch2027Member_30f089dc-b219-423d-ac57-a711dc7e9b4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A575PercentSeniorNotesDueMarch2028Member_7ddc2603-47e8-4a15-b3d6-7d4eaf17049f" xlink:href="hum-20231231.xsd#hum_A575PercentSeniorNotesDueMarch2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A575PercentSeniorNotesDueMarch2028Member_7ddc2603-47e8-4a15-b3d6-7d4eaf17049f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A575PercentSeniorNotesDueDecember2028Member_0e852f45-4d47-453f-9dfd-86ebd0b04dd1" xlink:href="hum-20231231.xsd#hum_A575PercentSeniorNotesDueDecember2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A575PercentSeniorNotesDueDecember2028Member_0e852f45-4d47-453f-9dfd-86ebd0b04dd1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A370PercentSeniorNotesDueMarch2029Member_7cf39daf-6fa7-4523-8e3b-3e775b43c0cf" xlink:href="hum-20231231.xsd#hum_A370PercentSeniorNotesDueMarch2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A370PercentSeniorNotesDueMarch2029Member_7cf39daf-6fa7-4523-8e3b-3e775b43c0cf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A313PercentSeniorNotesDueAugust2029Member_02cbf33c-70db-4579-bf42-9ce26277186b" xlink:href="hum-20231231.xsd#hum_A313PercentSeniorNotesDueAugust2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A313PercentSeniorNotesDueAugust2029Member_02cbf33c-70db-4579-bf42-9ce26277186b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A488PercentSeniorNotesDueApril2030Member_4840d2d6-69e9-4dbf-95ad-888b5bf42dac" xlink:href="hum-20231231.xsd#hum_A488PercentSeniorNotesDueApril2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A488PercentSeniorNotesDueApril2030Member_4840d2d6-69e9-4dbf-95ad-888b5bf42dac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A215PercentSeniorNotesDueFebruary2032Member_bd1048d1-0c36-4104-90ad-afbf3dc693bc" xlink:href="hum-20231231.xsd#hum_A215PercentSeniorNotesDueFebruary2032Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A215PercentSeniorNotesDueFebruary2032Member_bd1048d1-0c36-4104-90ad-afbf3dc693bc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5.88PercentSeniorNotesDueMarch2033Member_42633433-e9bc-4b0b-97da-265b517ff684" xlink:href="hum-20231231.xsd#hum_A5.88PercentSeniorNotesDueMarch2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A5.88PercentSeniorNotesDueMarch2033Member_42633433-e9bc-4b0b-97da-265b517ff684" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5950PercentSeniorNotesDueMarch2034Member_c9380a4a-3e27-44e3-8f6c-27d4c27783d7" xlink:href="hum-20231231.xsd#hum_A5950PercentSeniorNotesDueMarch2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A5950PercentSeniorNotesDueMarch2034Member_c9380a4a-3e27-44e3-8f6c-27d4c27783d7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A8.15PercentSeniorNotesDueJune2038Member_e6fd2184-6696-4357-b927-0d67f98b94bc" xlink:href="hum-20231231.xsd#hum_A8.15PercentSeniorNotesDueJune2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A8.15PercentSeniorNotesDueJune2038Member_e6fd2184-6696-4357-b927-0d67f98b94bc" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A463PercentSeniorNotesDueDecember2042Member_47d143b0-9576-4a46-aff8-6d9d1179bee4" xlink:href="hum-20231231.xsd#hum_A463PercentSeniorNotesDueDecember2042Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A463PercentSeniorNotesDueDecember2042Member_47d143b0-9576-4a46-aff8-6d9d1179bee4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A4.95PercentSeniorNotesDueOctober2044Member_55fb862d-8ca8-4002-a68b-902bfba03d69" xlink:href="hum-20231231.xsd#hum_A4.95PercentSeniorNotesDueOctober2044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A4.95PercentSeniorNotesDueOctober2044Member_55fb862d-8ca8-4002-a68b-902bfba03d69" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A4.80PercentSeniorNotesDueMarch2047Member_9db18ed9-2eb9-4b0c-826f-8317d3f053b5" xlink:href="hum-20231231.xsd#hum_A4.80PercentSeniorNotesDueMarch2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A4.80PercentSeniorNotesDueMarch2047Member_9db18ed9-2eb9-4b0c-826f-8317d3f053b5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3.95PercentSeniorNotesDueAugust2049Member_d630032a-d2a4-4ff7-9401-320c251cb3df" xlink:href="hum-20231231.xsd#hum_A3.95PercentSeniorNotesDueAugust2049Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A3.95PercentSeniorNotesDueAugust2049Member_d630032a-d2a4-4ff7-9401-320c251cb3df" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A550PercentSeniorNotesDueMarch2053Member_6b418e03-64b1-4886-9752-67492636a06a" xlink:href="hum-20231231.xsd#hum_A550PercentSeniorNotesDueMarch2053Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A550PercentSeniorNotesDueMarch2053Member_6b418e03-64b1-4886-9752-67492636a06a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DelayedDrawTermLoanMay2024Member_8c8ed2fc-3bbc-48dc-a761-404418c9e272" xlink:href="hum-20231231.xsd#hum_DelayedDrawTermLoanMay2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_DelayedDrawTermLoanMay2024Member_8c8ed2fc-3bbc-48dc-a761-404418c9e272" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_57ce3209-d2be-4790-93ea-b0062c9729d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6805204f-d980-47cd-9c12-7bea413b5c66" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_57ce3209-d2be-4790-93ea-b0062c9729d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_57ad544d-2060-4870-ab47-469d3a173516" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6805204f-d980-47cd-9c12-7bea413b5c66" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_57ad544d-2060-4870-ab47-469d3a173516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_afa80906-ec15-4bd7-a9e3-474e91ee3ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6805204f-d980-47cd-9c12-7bea413b5c66" xlink:to="loc_us-gaap_ShortTermBorrowings_afa80906-ec15-4bd7-a9e3-474e91ee3ae8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_0c0dfacb-dc5d-4e09-82c4-028844c89197" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6805204f-d980-47cd-9c12-7bea413b5c66" xlink:to="loc_us-gaap_LongTermDebtCurrent_0c0dfacb-dc5d-4e09-82c4-028844c89197" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_04a21320-d935-4c24-bd26-e0b9ac5eb48e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6805204f-d980-47cd-9c12-7bea413b5c66" xlink:to="loc_us-gaap_DebtCurrent_04a21320-d935-4c24-bd26-e0b9ac5eb48e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_092f043b-9ecc-4ecd-997f-d022e8a40807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6805204f-d980-47cd-9c12-7bea413b5c66" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_092f043b-9ecc-4ecd-997f-d022e8a40807" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/DEBTSeniorNotesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#DEBTSeniorNotesDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/DEBTSeniorNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_11095ed3-22a3-4fe2-aa14-8e5e124e98d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_us-gaap_DebtInstrumentTable_11095ed3-22a3-4fe2-aa14-8e5e124e98d6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9f46ad03-11cf-4e04-9cd8-c7f894a044e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11095ed3-22a3-4fe2-aa14-8e5e124e98d6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9f46ad03-11cf-4e04-9cd8-c7f894a044e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9f46ad03-11cf-4e04-9cd8-c7f894a044e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9f46ad03-11cf-4e04-9cd8-c7f894a044e6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9f46ad03-11cf-4e04-9cd8-c7f894a044e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b3fa66f5-5979-44a1-aa97-2c172bb3388d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9f46ad03-11cf-4e04-9cd8-c7f894a044e6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b3fa66f5-5979-44a1-aa97-2c172bb3388d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_81eb9129-9e6e-49df-8e7d-43af32e0cba1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b3fa66f5-5979-44a1-aa97-2c172bb3388d" xlink:to="loc_us-gaap_SeniorNotesMember_81eb9129-9e6e-49df-8e7d-43af32e0cba1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_cd1078fe-18c9-406e-9c91-43a9351b8285" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b3fa66f5-5979-44a1-aa97-2c172bb3388d" xlink:to="loc_us-gaap_LoansPayableMember_cd1078fe-18c9-406e-9c91-43a9351b8285" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_02d7daa8-8298-4e63-99a2-e4638660a8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_11095ed3-22a3-4fe2-aa14-8e5e124e98d6" xlink:to="loc_us-gaap_DebtInstrumentAxis_02d7daa8-8298-4e63-99a2-e4638660a8c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_02d7daa8-8298-4e63-99a2-e4638660a8c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_02d7daa8-8298-4e63-99a2-e4638660a8c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_02d7daa8-8298-4e63-99a2-e4638660a8c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_02d7daa8-8298-4e63-99a2-e4638660a8c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A8.15PercentSeniorNotesDueJune2038Member_37ade16c-728b-4d8b-aa84-42babdbaa864" xlink:href="hum-20231231.xsd#hum_A8.15PercentSeniorNotesDueJune2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:to="loc_hum_A8.15PercentSeniorNotesDueJune2038Member_37ade16c-728b-4d8b-aa84-42babdbaa864" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member_b424c6b8-2fb1-43c7-a043-c0eb53fb8332" xlink:href="hum-20231231.xsd#hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:to="loc_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member_b424c6b8-2fb1-43c7-a043-c0eb53fb8332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A575PercentSeniorNotesDueDecember2028Member_6d43d929-d7d9-4fad-b942-84a9a25ff2d7" xlink:href="hum-20231231.xsd#hum_A575PercentSeniorNotesDueDecember2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member_b424c6b8-2fb1-43c7-a043-c0eb53fb8332" xlink:to="loc_hum_A575PercentSeniorNotesDueDecember2028Member_6d43d929-d7d9-4fad-b942-84a9a25ff2d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5950PercentSeniorNotesDueMarch2034Member_c75c8a44-29de-4ddc-bb05-49266b95cf44" xlink:href="hum-20231231.xsd#hum_A5950PercentSeniorNotesDueMarch2034Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member_b424c6b8-2fb1-43c7-a043-c0eb53fb8332" xlink:to="loc_hum_A5950PercentSeniorNotesDueMarch2034Member_c75c8a44-29de-4ddc-bb05-49266b95cf44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member_e7943292-18a1-43f0-a70c-772be4bc144f" xlink:href="hum-20231231.xsd#hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:to="loc_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member_e7943292-18a1-43f0-a70c-772be4bc144f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A570PercentSeniorNotesDueMarch2026Member_e05062f4-8818-4b8f-801a-9ee4e7fe2cd8" xlink:href="hum-20231231.xsd#hum_A570PercentSeniorNotesDueMarch2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member_e7943292-18a1-43f0-a70c-772be4bc144f" xlink:to="loc_hum_A570PercentSeniorNotesDueMarch2026Member_e05062f4-8818-4b8f-801a-9ee4e7fe2cd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A550PercentSeniorNotesDueMarch2053Member_5fa9d778-53cf-4cbe-96b2-75ca8211da90" xlink:href="hum-20231231.xsd#hum_A550PercentSeniorNotesDueMarch2053Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member_e7943292-18a1-43f0-a70c-772be4bc144f" xlink:to="loc_hum_A550PercentSeniorNotesDueMarch2053Member_5fa9d778-53cf-4cbe-96b2-75ca8211da90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DelayedDrawTermLoanMember_81ded253-7e92-4241-856c-a59508112acc" xlink:href="hum-20231231.xsd#hum_DelayedDrawTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:to="loc_hum_DelayedDrawTermLoanMember_81ded253-7e92-4241-856c-a59508112acc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RepurchasePlanAugust2023Member_9634a6a3-f35f-4ad8-ba7c-ea0c1a36117a" xlink:href="hum-20231231.xsd#hum_RepurchasePlanAugust2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:to="loc_hum_RepurchasePlanAugust2023Member_9634a6a3-f35f-4ad8-ba7c-ea0c1a36117a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A135PercentSeniorNotesDueFebruary2027Member_5c82cc67-2b61-46d9-b4f1-f2459a559aaa" xlink:href="hum-20231231.xsd#hum_A135PercentSeniorNotesDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_RepurchasePlanAugust2023Member_9634a6a3-f35f-4ad8-ba7c-ea0c1a36117a" xlink:to="loc_hum_A135PercentSeniorNotesDueFebruary2027Member_5c82cc67-2b61-46d9-b4f1-f2459a559aaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3.95PercentSeniorNotesDueMarch2027Member_8457f946-928d-4224-8b70-bf6b068f0254" xlink:href="hum-20231231.xsd#hum_A3.95PercentSeniorNotesDueMarch2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_RepurchasePlanAugust2023Member_9634a6a3-f35f-4ad8-ba7c-ea0c1a36117a" xlink:to="loc_hum_A3.95PercentSeniorNotesDueMarch2027Member_8457f946-928d-4224-8b70-bf6b068f0254" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3700PercentSeniorNotesDueMarch2029Member_53fcb329-4b7a-4857-8ae0-492a45fa8a04" xlink:href="hum-20231231.xsd#hum_A3700PercentSeniorNotesDueMarch2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_RepurchasePlanAugust2023Member_9634a6a3-f35f-4ad8-ba7c-ea0c1a36117a" xlink:to="loc_hum_A3700PercentSeniorNotesDueMarch2029Member_53fcb329-4b7a-4857-8ae0-492a45fa8a04" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3125PercentSeniorNotesDueAugust2029Member_d68e1348-6404-418a-9404-9efb6971e919" xlink:href="hum-20231231.xsd#hum_A3125PercentSeniorNotesDueAugust2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_RepurchasePlanAugust2023Member_9634a6a3-f35f-4ad8-ba7c-ea0c1a36117a" xlink:to="loc_hum_A3125PercentSeniorNotesDueAugust2029Member_d68e1348-6404-418a-9404-9efb6971e919" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RepurchasePlanMarch2023Member_f1891886-b97e-48ab-9fc4-0874bd83c3db" xlink:href="hum-20231231.xsd#hum_RepurchasePlanMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:to="loc_hum_RepurchasePlanMarch2023Member_f1891886-b97e-48ab-9fc4-0874bd83c3db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A065PercentSeniorNotesDueAugust2023Member_7eac0a49-1e81-4453-b0f4-bff394dae539" xlink:href="hum-20231231.xsd#hum_A065PercentSeniorNotesDueAugust2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_RepurchasePlanMarch2023Member_f1891886-b97e-48ab-9fc4-0874bd83c3db" xlink:to="loc_hum_A065PercentSeniorNotesDueAugust2023Member_7eac0a49-1e81-4453-b0f4-bff394dae539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3850PercentSeniorNotesDueOctober2024Member_b43957af-925d-428d-9fa5-acf0ce70b593" xlink:href="hum-20231231.xsd#hum_A3850PercentSeniorNotesDueOctober2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_RepurchasePlanMarch2023Member_f1891886-b97e-48ab-9fc4-0874bd83c3db" xlink:to="loc_hum_A3850PercentSeniorNotesDueOctober2024Member_b43957af-925d-428d-9fa5-acf0ce70b593" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5.88PercentSeniorNotesDueMarch2033Member_1083ef93-1bb0-4857-9f2e-cd07d06c289e" xlink:href="hum-20231231.xsd#hum_A5.88PercentSeniorNotesDueMarch2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:to="loc_hum_A5.88PercentSeniorNotesDueMarch2033Member_1083ef93-1bb0-4857-9f2e-cd07d06c289e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3.950PercentSeniorNotesMember_c43047ad-7ab4-4fca-9be9-0931f819dd5e" xlink:href="hum-20231231.xsd#hum_A3.950PercentSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:to="loc_hum_A3.950PercentSeniorNotesMember_c43047ad-7ab4-4fca-9be9-0931f819dd5e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9d4cd2c7-36c5-461c-9aa9-9d6b7e8ebb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9d4cd2c7-36c5-461c-9aa9-9d6b7e8ebb5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f8e7cdc1-7317-42c6-a340-03944db82322" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f8e7cdc1-7317-42c6-a340-03944db82322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ce217388-6098-4389-b5e7-fc9a87a93dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ce217388-6098-4389-b5e7-fc9a87a93dd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_ee96ef75-af51-4254-a418-2bf998c7ef66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_ee96ef75-af51-4254-a418-2bf998c7ef66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_76e9b0c3-322d-4ea0-9377-21767ec25c34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_76e9b0c3-322d-4ea0-9377-21767ec25c34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_44a1772d-5811-4685-a594-271a19a5868a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_44a1772d-5811-4685-a594-271a19a5868a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_5eb30f78-672e-4607-83fe-ebefef2a6991" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_5eb30f78-672e-4607-83fe-ebefef2a6991" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LongTermDebtAggregateCarryingValueAdjustment_8241cb87-bfb6-4046-b7a5-e2b26d41933d" xlink:href="hum-20231231.xsd#hum_LongTermDebtAggregateCarryingValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_hum_LongTermDebtAggregateCarryingValueAdjustment_8241cb87-bfb6-4046-b7a5-e2b26d41933d" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#DEBTRevolvingCreditAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_1a8d5dfe-4b4a-4595-9121-1e93c5472e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_1a8d5dfe-4b4a-4595-9121-1e93c5472e0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ed491fbc-df9b-44d8-94eb-5087321592b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1a8d5dfe-4b4a-4595-9121-1e93c5472e0a" xlink:to="loc_us-gaap_CreditFacilityAxis_ed491fbc-df9b-44d8-94eb-5087321592b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_ed491fbc-df9b-44d8-94eb-5087321592b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_ed491fbc-df9b-44d8-94eb-5087321592b0" xlink:to="loc_us-gaap_CreditFacilityDomain_ed491fbc-df9b-44d8-94eb-5087321592b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bdef70ba-c8b1-4186-abb7-2c11620153c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_ed491fbc-df9b-44d8-94eb-5087321592b0" xlink:to="loc_us-gaap_CreditFacilityDomain_bdef70ba-c8b1-4186-abb7-2c11620153c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_154e7c32-a52a-4c3d-88c5-02471eb5edd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_bdef70ba-c8b1-4186-abb7-2c11620153c2" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_154e7c32-a52a-4c3d-88c5-02471eb5edd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_f34d0174-38fe-499c-99e0-f2cc238ff608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_bdef70ba-c8b1-4186-abb7-2c11620153c2" xlink:to="loc_us-gaap_LetterOfCreditMember_f34d0174-38fe-499c-99e0-f2cc238ff608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_524ff4e4-c25c-488b-ae09-ee543dbf808a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1a8d5dfe-4b4a-4595-9121-1e93c5472e0a" xlink:to="loc_us-gaap_DebtInstrumentAxis_524ff4e4-c25c-488b-ae09-ee543dbf808a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_524ff4e4-c25c-488b-ae09-ee543dbf808a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_524ff4e4-c25c-488b-ae09-ee543dbf808a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_524ff4e4-c25c-488b-ae09-ee543dbf808a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_26637f62-e82f-4728-958e-17352ffc8f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_524ff4e4-c25c-488b-ae09-ee543dbf808a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_26637f62-e82f-4728-958e-17352ffc8f2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevolvingCreditAgreementJune2021FiveYearMember_4e026cb8-91df-4ad1-8da9-b1c06dc5f3b9" xlink:href="hum-20231231.xsd#hum_RevolvingCreditAgreementJune2021FiveYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26637f62-e82f-4728-958e-17352ffc8f2c" xlink:to="loc_hum_RevolvingCreditAgreementJune2021FiveYearMember_4e026cb8-91df-4ad1-8da9-b1c06dc5f3b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevolvingCreditAgreementJune2021OneYearMember_a79ab679-9087-4eff-a5ff-7ecb1064fabc" xlink:href="hum-20231231.xsd#hum_RevolvingCreditAgreementJune2021OneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26637f62-e82f-4728-958e-17352ffc8f2c" xlink:to="loc_hum_RevolvingCreditAgreementJune2021OneYearMember_a79ab679-9087-4eff-a5ff-7ecb1064fabc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevolvingCreditAgreementJune2023FiveYearMember_1ac03cf8-0fd8-4e92-8f9e-1c6f00e2f2f6" xlink:href="hum-20231231.xsd#hum_RevolvingCreditAgreementJune2023FiveYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26637f62-e82f-4728-958e-17352ffc8f2c" xlink:to="loc_hum_RevolvingCreditAgreementJune2023FiveYearMember_1ac03cf8-0fd8-4e92-8f9e-1c6f00e2f2f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevolvingCreditAgreementJune2023OneYearMember_19a096c0-03fc-49d3-a7ec-105933841fd2" xlink:href="hum-20231231.xsd#hum_RevolvingCreditAgreementJune2023OneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26637f62-e82f-4728-958e-17352ffc8f2c" xlink:to="loc_hum_RevolvingCreditAgreementJune2023OneYearMember_19a096c0-03fc-49d3-a7ec-105933841fd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevolvingCreditAgreementJune2022OneYearMember_443e5233-678d-415b-a7c4-1765c8e6b135" xlink:href="hum-20231231.xsd#hum_RevolvingCreditAgreementJune2022OneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26637f62-e82f-4728-958e-17352ffc8f2c" xlink:to="loc_hum_RevolvingCreditAgreementJune2022OneYearMember_443e5233-678d-415b-a7c4-1765c8e6b135" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8549f5b9-688e-451c-9398-7ec1030830b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1a8d5dfe-4b4a-4595-9121-1e93c5472e0a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8549f5b9-688e-451c-9398-7ec1030830b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8549f5b9-688e-451c-9398-7ec1030830b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8549f5b9-688e-451c-9398-7ec1030830b1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8549f5b9-688e-451c-9398-7ec1030830b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_417010fe-e8a7-4246-8d9e-49dc420312b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8549f5b9-688e-451c-9398-7ec1030830b1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_417010fe-e8a7-4246-8d9e-49dc420312b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_c3783200-9664-4a46-bb7b-281b67000f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_417010fe-e8a7-4246-8d9e-49dc420312b6" xlink:to="loc_us-gaap_LoansPayableMember_c3783200-9664-4a46-bb7b-281b67000f6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_edba5cf5-cce9-488d-9513-895b1f9719f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1a8d5dfe-4b4a-4595-9121-1e93c5472e0a" xlink:to="loc_us-gaap_VariableRateAxis_edba5cf5-cce9-488d-9513-895b1f9719f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_edba5cf5-cce9-488d-9513-895b1f9719f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_edba5cf5-cce9-488d-9513-895b1f9719f9" xlink:to="loc_us-gaap_VariableRateDomain_edba5cf5-cce9-488d-9513-895b1f9719f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0f75a4fa-5f00-42f0-93cb-9c542dca26cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_edba5cf5-cce9-488d-9513-895b1f9719f9" xlink:to="loc_us-gaap_VariableRateDomain_0f75a4fa-5f00-42f0-93cb-9c542dca26cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SecuredOvernightFinancingRateSOFRMember_27acd031-0437-4104-b4b4-c30ad3f48a77" xlink:href="hum-20231231.xsd#hum_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0f75a4fa-5f00-42f0-93cb-9c542dca26cc" xlink:to="loc_hum_SecuredOvernightFinancingRateSOFRMember_27acd031-0437-4104-b4b4-c30ad3f48a77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3d931ae5-3a8e-4ce9-90a3-98a28aa9964f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1a8d5dfe-4b4a-4595-9121-1e93c5472e0a" xlink:to="loc_srt_RangeAxis_3d931ae5-3a8e-4ce9-90a3-98a28aa9964f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3d931ae5-3a8e-4ce9-90a3-98a28aa9964f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3d931ae5-3a8e-4ce9-90a3-98a28aa9964f" xlink:to="loc_srt_RangeMember_3d931ae5-3a8e-4ce9-90a3-98a28aa9964f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_165c2cbb-9f08-43db-b0b5-5be24a0824c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3d931ae5-3a8e-4ce9-90a3-98a28aa9964f" xlink:to="loc_srt_RangeMember_165c2cbb-9f08-43db-b0b5-5be24a0824c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c281a1f9-1598-4254-8f4d-b87a936f473e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_165c2cbb-9f08-43db-b0b5-5be24a0824c0" xlink:to="loc_srt_MinimumMember_c281a1f9-1598-4254-8f4d-b87a936f473e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bdd11c53-b692-4e31-b04f-feb60ae4a280" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_165c2cbb-9f08-43db-b0b5-5be24a0824c0" xlink:to="loc_srt_MaximumMember_bdd11c53-b692-4e31-b04f-feb60ae4a280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_1ab1e68a-ce00-4898-b853-3f76800d7d62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_us-gaap_DebtInstrumentTerm_1ab1e68a-ce00-4898-b853-3f76800d7d62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_45fe1c6b-b095-4fe2-acba-a3c24dd78d32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_45fe1c6b-b095-4fe2-acba-a3c24dd78d32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9cd16edd-cbbe-4f0c-8a66-32f670a8896f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9cd16edd-cbbe-4f0c-8a66-32f670a8896f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7b36c005-af3c-4c28-aee5-e602c3168044" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7b36c005-af3c-4c28-aee5-e602c3168044" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum_e6ec3e52-efa6-4b3a-9340-ef0945af0ca1" xlink:href="hum-20231231.xsd#hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum_e6ec3e52-efa6-4b3a-9340-ef0945af0ca1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual_964e74ef-f0fb-41d7-84a9-ff96eaebc03a" xlink:href="hum-20231231.xsd#hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual_964e74ef-f0fb-41d7-84a9-ff96eaebc03a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LineOfCreditFacilityUncommittedIncrementalCapacity_10bce201-dcc3-496c-aa6a-43b32131d4ec" xlink:href="hum-20231231.xsd#hum_LineOfCreditFacilityUncommittedIncrementalCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_hum_LineOfCreditFacilityUncommittedIncrementalCapacity_10bce201-dcc3-496c-aa6a-43b32131d4ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity_a7bbf84f-243b-481c-a35a-aa027d3f03fa" xlink:href="hum-20231231.xsd#hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity_a7bbf84f-243b-481c-a35a-aa027d3f03fa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_4d82144a-aedb-4551-99bd-69df541e3d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_us-gaap_LinesOfCreditCurrent_4d82144a-aedb-4551-99bd-69df541e3d8f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_b5e9f8b0-86eb-4adc-9baa-5f42a988ca7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_b5e9f8b0-86eb-4adc-9baa-5f42a988ca7f" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#DEBTCommercialPaperandOtherShortTermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_852de6c5-db79-49fe-91cf-7c2e45e48aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_3c7d307b-362c-4c06-974c-69c03ac69bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_852de6c5-db79-49fe-91cf-7c2e45e48aa8" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_3c7d307b-362c-4c06-974c-69c03ac69bbe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_76d0ffa2-836d-4f2d-b81d-b7cb5e351fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_3c7d307b-362c-4c06-974c-69c03ac69bbe" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_76d0ffa2-836d-4f2d-b81d-b7cb5e351fa4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_76d0ffa2-836d-4f2d-b81d-b7cb5e351fa4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_76d0ffa2-836d-4f2d-b81d-b7cb5e351fa4" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_76d0ffa2-836d-4f2d-b81d-b7cb5e351fa4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_16cd56e9-b3f7-4d97-b106-735848bbfbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_76d0ffa2-836d-4f2d-b81d-b7cb5e351fa4" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_16cd56e9-b3f7-4d97-b106-735848bbfbd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_63666180-57c8-484c-9ba6-e563e95c1292" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_16cd56e9-b3f7-4d97-b106-735848bbfbd2" xlink:to="loc_us-gaap_CommercialPaperMember_63666180-57c8-484c-9ba6-e563e95c1292" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesMember_5eeaf3be-567b-4103-9203-e003530d3ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalHomeLoanBankAdvancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_16cd56e9-b3f7-4d97-b106-735848bbfbd2" xlink:to="loc_us-gaap_FederalHomeLoanBankAdvancesMember_5eeaf3be-567b-4103-9203-e003530d3ac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod_eac97c9d-d95f-4caf-8f21-ee51d9236b97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_852de6c5-db79-49fe-91cf-7c2e45e48aa8" xlink:to="loc_us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod_eac97c9d-d95f-4caf-8f21-ee51d9236b97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_f573fb30-55f4-4cdb-8609-c73809564798" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_852de6c5-db79-49fe-91cf-7c2e45e48aa8" xlink:to="loc_us-gaap_ShortTermBorrowings_f573fb30-55f4-4cdb-8609-c73809564798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_e2566b28-274c-459e-86aa-00eb5b2a5318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_852de6c5-db79-49fe-91cf-7c2e45e48aa8" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_e2566b28-274c-459e-86aa-00eb5b2a5318" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_0648f419-7a5c-4673-bf46-e3f2476fe799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_852de6c5-db79-49fe-91cf-7c2e45e48aa8" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_0648f419-7a5c-4673-bf46-e3f2476fe799" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_0a2b6f8d-7df4-4674-96dc-178b4636c3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_852de6c5-db79-49fe-91cf-7c2e45e48aa8" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_0a2b6f8d-7df4-4674-96dc-178b4636c3b4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EMPLOYEEBENEFITPLANSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eec6b747-bf7f-44ae-af2b-0cdf843c778b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eec6b747-bf7f-44ae-af2b-0cdf843c778b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_26e7481a-54ed-4c95-83c6-559f2acea708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eec6b747-bf7f-44ae-af2b-0cdf843c778b" xlink:to="loc_us-gaap_PlanNameAxis_26e7481a-54ed-4c95-83c6-559f2acea708" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_26e7481a-54ed-4c95-83c6-559f2acea708_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_26e7481a-54ed-4c95-83c6-559f2acea708" xlink:to="loc_us-gaap_PlanNameDomain_26e7481a-54ed-4c95-83c6-559f2acea708_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_74d34329-ded1-4a23-bacd-fe4c706bfa82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_26e7481a-54ed-4c95-83c6-559f2acea708" xlink:to="loc_us-gaap_PlanNameDomain_74d34329-ded1-4a23-bacd-fe4c706bfa82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A2011PlanMember_92887407-0dc4-4ee2-b9b0-50cfd21bfb5f" xlink:href="hum-20231231.xsd#hum_A2011PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_74d34329-ded1-4a23-bacd-fe4c706bfa82" xlink:to="loc_hum_A2011PlanMember_92887407-0dc4-4ee2-b9b0-50cfd21bfb5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A2019PlanMember_746bfa5c-cfc4-4828-a719-88b52f04f77e" xlink:href="hum-20231231.xsd#hum_A2019PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_74d34329-ded1-4a23-bacd-fe4c706bfa82" xlink:to="loc_hum_A2019PlanMember_746bfa5c-cfc4-4828-a719-88b52f04f77e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c781dc11-a304-4fca-b547-543a9f42e618" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eec6b747-bf7f-44ae-af2b-0cdf843c778b" xlink:to="loc_us-gaap_AwardTypeAxis_c781dc11-a304-4fca-b547-543a9f42e618" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c781dc11-a304-4fca-b547-543a9f42e618_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c781dc11-a304-4fca-b547-543a9f42e618" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c781dc11-a304-4fca-b547-543a9f42e618_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85a33c89-4c5b-4997-a957-b57e22dae402" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c781dc11-a304-4fca-b547-543a9f42e618" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85a33c89-4c5b-4997-a957-b57e22dae402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b795707e-231b-4c71-947e-6e8bbfff92fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85a33c89-4c5b-4997-a957-b57e22dae402" xlink:to="loc_us-gaap_RestrictedStockMember_b795707e-231b-4c71-947e-6e8bbfff92fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_15c2ac2b-4391-462a-adcc-ce29975fad2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85a33c89-4c5b-4997-a957-b57e22dae402" xlink:to="loc_us-gaap_EmployeeStockOptionMember_15c2ac2b-4391-462a-adcc-ce29975fad2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1cb9fd1b-ffce-4ebe-aa8c-e0a726efccb9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eec6b747-bf7f-44ae-af2b-0cdf843c778b" xlink:to="loc_srt_RangeAxis_1cb9fd1b-ffce-4ebe-aa8c-e0a726efccb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1cb9fd1b-ffce-4ebe-aa8c-e0a726efccb9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1cb9fd1b-ffce-4ebe-aa8c-e0a726efccb9" xlink:to="loc_srt_RangeMember_1cb9fd1b-ffce-4ebe-aa8c-e0a726efccb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cf7f6039-d1b2-43c9-8a11-28a959c414c3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1cb9fd1b-ffce-4ebe-aa8c-e0a726efccb9" xlink:to="loc_srt_RangeMember_cf7f6039-d1b2-43c9-8a11-28a959c414c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fa811842-070c-4b71-a51b-e6a6ee622dcf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cf7f6039-d1b2-43c9-8a11-28a959c414c3" xlink:to="loc_srt_MinimumMember_fa811842-070c-4b71-a51b-e6a6ee622dcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_546afdf0-6acd-4213-8934-9b500ac3c969" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cf7f6039-d1b2-43c9-8a11-28a959c414c3" xlink:to="loc_srt_MaximumMember_546afdf0-6acd-4213-8934-9b500ac3c969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_0278e2df-9da8-421a-a16d-cad1f00e7f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_0278e2df-9da8-421a-a16d-cad1f00e7f3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CompanyCommonStockClosingSharePrice_a4c37262-9e17-4e69-bd87-6ca2e83e959f" xlink:href="hum-20231231.xsd#hum_CompanyCommonStockClosingSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_CompanyCommonStockClosingSharePrice_a4c37262-9e17-4e69-bd87-6ca2e83e959f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock_e1f47a16-be13-43b7-bf5d-9d5468f3ada6" xlink:href="hum-20231231.xsd#hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock_e1f47a16-be13-43b7-bf5d-9d5468f3ada6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares_1a3dd60f-eafd-4e97-bc9e-72c9deee693e" xlink:href="hum-20231231.xsd#hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares_1a3dd60f-eafd-4e97-bc9e-72c9deee693e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding_54126ebc-f300-40ae-b5d2-9e93e19b878e" xlink:href="hum-20231231.xsd#hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding_54126ebc-f300-40ae-b5d2-9e93e19b878e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance_3707b818-4134-4a00-a868-96efe2031129" xlink:href="hum-20231231.xsd#hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance_3707b818-4134-4a00-a868-96efe2031129" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod_f9ca8f42-944e-420b-8e43-c506b1acdcd3" xlink:href="hum-20231231.xsd#hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod_f9ca8f42-944e-420b-8e43-c506b1acdcd3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram_164c05e6-9f7d-4732-a3ac-7d309c59febd" xlink:href="hum-20231231.xsd#hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram_164c05e6-9f7d-4732-a3ac-7d309c59febd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram_5aaa1d24-77b0-4c13-9561-be2e395f140b" xlink:href="hum-20231231.xsd#hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram_5aaa1d24-77b0-4c13-9561-be2e395f140b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram_cd25a7b9-ddc6-4cbd-9da6-fc562932d548" xlink:href="hum-20231231.xsd#hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram_cd25a7b9-ddc6-4cbd-9da6-fc562932d548" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting_29ce670c-ed8a-46db-a1d7-724874b5e174" xlink:href="hum-20231231.xsd#hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting_29ce670c-ed8a-46db-a1d7-724874b5e174" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_12f69eaa-7381-4c8f-9e52-fa98190a9136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_12f69eaa-7381-4c8f-9e52-fa98190a9136" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_503a5a87-ce76-40dc-8f94-08a633c9a0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_503a5a87-ce76-40dc-8f94-08a633c9a0b7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f81177ed-3c03-4355-96ec-8f567bc5e3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f81177ed-3c03-4355-96ec-8f567bc5e3d6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7ff86303-2f5f-4058-b580-9e24dbeaa8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7ff86303-2f5f-4058-b580-9e24dbeaa8aa" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_465c797c-c3de-4ac2-a447-b0862d40657e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_465c797c-c3de-4ac2-a447-b0862d40657e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions_05ab306a-9c73-4f51-96cb-842c56f79a6c" xlink:href="hum-20231231.xsd#hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions_05ab306a-9c73-4f51-96cb-842c56f79a6c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7768c622-fffd-4726-8ca7-b31331f55acb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7768c622-fffd-4726-8ca7-b31331f55acb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5e7dfc88-fcaa-429e-a4d5-4d9f23b3c107" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5e7dfc88-fcaa-429e-a4d5-4d9f23b3c107" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fdb95739-2ac5-4041-809a-56d2f7c33c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fdb95739-2ac5-4041-809a-56d2f7c33c2f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bdb165f8-7c7a-4161-b5ef-7ead4e898ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bdb165f8-7c7a-4161-b5ef-7ead4e898ad6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_81d23d6a-94e7-4902-a0f5-5a477d06a231" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_81d23d6a-94e7-4902-a0f5-5a477d06a231" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_81d85a6f-b636-4b47-bae3-e80c2a609c20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_81d85a6f-b636-4b47-bae3-e80c2a609c20" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_131ea365-a82f-498f-9ea2-24fd292c4b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_131ea365-a82f-498f-9ea2-24fd292c4b7b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_48409d52-53f4-453d-9ae1-21f216c99d88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_48409d52-53f4-453d-9ae1-21f216c99d88" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c0b70724-8b13-4b40-b38a-fb5dd37005ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c0b70724-8b13-4b40-b38a-fb5dd37005ed" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2576b4e2-9488-4458-820a-ed2e4c232d02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2576b4e2-9488-4458-820a-ed2e4c232d02" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b46729c5-0976-4dba-bf93-7edc79c1c4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b46729c5-0976-4dba-bf93-7edc79c1c4b3" xlink:type="arc" order="27"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6c4f3de0-6389-4d79-aba1-0a2472f7340c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b965fa56-cca8-40b0-86c4-e7a4236ae58e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6c4f3de0-6389-4d79-aba1-0a2472f7340c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b965fa56-cca8-40b0-86c4-e7a4236ae58e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f5dbb8dd-147d-4324-8788-0b2e923e31f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b965fa56-cca8-40b0-86c4-e7a4236ae58e" xlink:to="loc_us-gaap_AwardTypeAxis_f5dbb8dd-147d-4324-8788-0b2e923e31f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5dbb8dd-147d-4324-8788-0b2e923e31f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f5dbb8dd-147d-4324-8788-0b2e923e31f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5dbb8dd-147d-4324-8788-0b2e923e31f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382e3f33-7d68-45eb-a711-fb58a2305d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f5dbb8dd-147d-4324-8788-0b2e923e31f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382e3f33-7d68-45eb-a711-fb58a2305d39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_04e0a87f-5f91-4c14-8c10-59c5ff335bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382e3f33-7d68-45eb-a711-fb58a2305d39" xlink:to="loc_us-gaap_RestrictedStockMember_04e0a87f-5f91-4c14-8c10-59c5ff335bd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2c76b351-4da0-4a61-9d1c-2da39250443a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382e3f33-7d68-45eb-a711-fb58a2305d39" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2c76b351-4da0-4a61-9d1c-2da39250443a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a3bbe442-dd43-474c-84b0-778043eb05aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6c4f3de0-6389-4d79-aba1-0a2472f7340c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a3bbe442-dd43-474c-84b0-778043eb05aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_99d9eb19-6b85-4fdf-97df-b48f7c83af15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6c4f3de0-6389-4d79-aba1-0a2472f7340c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_99d9eb19-6b85-4fdf-97df-b48f7c83af15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4d53043f-2566-471e-a76c-f84819437c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6c4f3de0-6389-4d79-aba1-0a2472f7340c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4d53043f-2566-471e-a76c-f84819437c1c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41b43629-c570-440f-86b7-80d89110581e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d43081a-df9e-4fd0-b0da-607a8bdacf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41b43629-c570-440f-86b7-80d89110581e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d43081a-df9e-4fd0-b0da-607a8bdacf7a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_99961227-4bdd-4827-aaef-d850060ee380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d43081a-df9e-4fd0-b0da-607a8bdacf7a" xlink:to="loc_us-gaap_AwardTypeAxis_99961227-4bdd-4827-aaef-d850060ee380" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99961227-4bdd-4827-aaef-d850060ee380_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_99961227-4bdd-4827-aaef-d850060ee380" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_99961227-4bdd-4827-aaef-d850060ee380_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e18ca81-3020-4752-bcb4-725924c4d3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_99961227-4bdd-4827-aaef-d850060ee380" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e18ca81-3020-4752-bcb4-725924c4d3a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_57eac0ee-237a-45ad-8064-e4c5415ac76f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e18ca81-3020-4752-bcb4-725924c4d3a9" xlink:to="loc_us-gaap_RestrictedStockMember_57eac0ee-237a-45ad-8064-e4c5415ac76f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_80ced98d-6aed-42ff-ba88-700d15d6ee8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41b43629-c570-440f-86b7-80d89110581e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_80ced98d-6aed-42ff-ba88-700d15d6ee8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_49eb5d5e-8ec6-4561-ac15-73a714df919b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_80ced98d-6aed-42ff-ba88-700d15d6ee8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_49eb5d5e-8ec6-4561-ac15-73a714df919b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d473fe93-d213-4f32-8d9b-f10826526da9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_80ced98d-6aed-42ff-ba88-700d15d6ee8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d473fe93-d213-4f32-8d9b-f10826526da9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e8f34106-87c3-4457-86ce-97efaca1fbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_80ced98d-6aed-42ff-ba88-700d15d6ee8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e8f34106-87c3-4457-86ce-97efaca1fbb7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_463cab28-d75c-4b62-90a6-55abaf58a1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_80ced98d-6aed-42ff-ba88-700d15d6ee8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_463cab28-d75c-4b62-90a6-55abaf58a1d8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7b82b2aa-c122-4c54-8e93-4890fd025fea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03581ed2-4c9b-44ba-a7a0-e3198362ff90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41b43629-c570-440f-86b7-80d89110581e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03581ed2-4c9b-44ba-a7a0-e3198362ff90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a0df52f0-efa2-4c7d-921b-b4b9031b17b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03581ed2-4c9b-44ba-a7a0-e3198362ff90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a0df52f0-efa2-4c7d-921b-b4b9031b17b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_df03a14d-4158-4a68-9f41-d0b544520554" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03581ed2-4c9b-44ba-a7a0-e3198362ff90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_df03a14d-4158-4a68-9f41-d0b544520554" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_603c15f2-fc94-451b-ab55-02973b48d356" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03581ed2-4c9b-44ba-a7a0-e3198362ff90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_603c15f2-fc94-451b-ab55-02973b48d356" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0bb6eba7-312f-43c8-a3c2-3d3fb6daf95e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03581ed2-4c9b-44ba-a7a0-e3198362ff90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0bb6eba7-312f-43c8-a3c2-3d3fb6daf95e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f2fd6290-3bd2-49e9-91d7-0d58adafce33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81e3d0c2-3760-42c8-a480-b34d07c9d6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_194df487-41bf-4820-884f-8a6d005c9093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81e3d0c2-3760-42c8-a480-b34d07c9d6a7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_194df487-41bf-4820-884f-8a6d005c9093" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bd87448c-d24d-48c0-b40a-f70b640e559b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_194df487-41bf-4820-884f-8a6d005c9093" xlink:to="loc_us-gaap_AwardTypeAxis_bd87448c-d24d-48c0-b40a-f70b640e559b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd87448c-d24d-48c0-b40a-f70b640e559b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bd87448c-d24d-48c0-b40a-f70b640e559b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bd87448c-d24d-48c0-b40a-f70b640e559b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20238bec-0367-4982-b264-06a580aa70bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bd87448c-d24d-48c0-b40a-f70b640e559b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20238bec-0367-4982-b264-06a580aa70bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1ded3dff-cfde-4003-85ba-4c200e6b76cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20238bec-0367-4982-b264-06a580aa70bc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1ded3dff-cfde-4003-85ba-4c200e6b76cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c5df7591-f1cf-4caf-b2f4-c1fce89a53f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81e3d0c2-3760-42c8-a480-b34d07c9d6a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c5df7591-f1cf-4caf-b2f4-c1fce89a53f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0d0a4ff3-f56c-4e56-b714-31651317ac61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81e3d0c2-3760-42c8-a480-b34d07c9d6a7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0d0a4ff3-f56c-4e56-b714-31651317ac61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2f5894fe-2507-4247-b752-b28a592e1ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81e3d0c2-3760-42c8-a480-b34d07c9d6a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2f5894fe-2507-4247-b752-b28a592e1ddf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cb80dfcc-0aa8-4236-b8e0-69d9d95367d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81e3d0c2-3760-42c8-a480-b34d07c9d6a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cb80dfcc-0aa8-4236-b8e0-69d9d95367d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9e5e7e6b-6669-4077-9344-b3cf53c6ed2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81e3d0c2-3760-42c8-a480-b34d07c9d6a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9e5e7e6b-6669-4077-9344-b3cf53c6ed2f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EARNINGSPERCOMMONSHARECOMPUTATIONDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_bbc305be-6529-4b7a-909f-f858361d7d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_bbc305be-6529-4b7a-909f-f858361d7d0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f0983805-2395-4880-91af-4222fea9c0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_bbc305be-6529-4b7a-909f-f858361d7d0a" xlink:to="loc_us-gaap_AwardTypeAxis_f0983805-2395-4880-91af-4222fea9c0e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0983805-2395-4880-91af-4222fea9c0e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f0983805-2395-4880-91af-4222fea9c0e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f0983805-2395-4880-91af-4222fea9c0e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d63caad7-d112-43c9-a661-33ee2a5b557a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f0983805-2395-4880-91af-4222fea9c0e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d63caad7-d112-43c9-a661-33ee2a5b557a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_94786675-30d7-4bbd-b720-502069ecd685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d63caad7-d112-43c9-a661-33ee2a5b557a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_94786675-30d7-4bbd-b720-502069ecd685" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5cfd7afb-8a3b-491f-8f2b-0c080ff59a04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d63caad7-d112-43c9-a661-33ee2a5b557a" xlink:to="loc_us-gaap_RestrictedStockMember_5cfd7afb-8a3b-491f-8f2b-0c080ff59a04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3cacedec-4f37-4322-aa25-8606e38be6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:to="loc_us-gaap_NetIncomeLoss_3cacedec-4f37-4322-aa25-8606e38be6e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e99991b7-f3cb-4d8b-bd1d-e53db598b199" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e99991b7-f3cb-4d8b-bd1d-e53db598b199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_55c686fc-5d58-4dd3-83da-73ecf32b51d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_55c686fc-5d58-4dd3-83da-73ecf32b51d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0d227fbd-030d-4aa5-ad78-0b5dd073cb31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0d227fbd-030d-4aa5-ad78-0b5dd073cb31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cc275f8a-248f-4d80-b306-d1a13a2e4ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:to="loc_us-gaap_EarningsPerShareBasic_cc275f8a-248f-4d80-b306-d1a13a2e4ca4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c8fef28c-9aa5-4413-8c8d-dc1e668f7f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c8fef28c-9aa5-4413-8c8d-dc1e668f7f1f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8f10fc7e-1a30-4fcf-948e-b9bb431623c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8f10fc7e-1a30-4fcf-948e-b9bb431623c0" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_2c6f3b71-7f86-4ea9-a41f-aa22c4907e50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_2c6f3b71-7f86-4ea9-a41f-aa22c4907e50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_369ffa12-72ca-4d65-a298-e2efcbd2c993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_2c6f3b71-7f86-4ea9-a41f-aa22c4907e50" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_369ffa12-72ca-4d65-a298-e2efcbd2c993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_369ffa12-72ca-4d65-a298-e2efcbd2c993_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_369ffa12-72ca-4d65-a298-e2efcbd2c993" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_369ffa12-72ca-4d65-a298-e2efcbd2c993_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_f6b0745e-ca27-4e45-9675-1793318bfadb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_369ffa12-72ca-4d65-a298-e2efcbd2c993" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_f6b0745e-ca27-4e45-9675-1793318bfadb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_December2020AcceleratedShareRepurchaseAgreementMember_951a7c69-8257-47f9-86b1-120fbdb27746" xlink:href="hum-20231231.xsd#hum_December2020AcceleratedShareRepurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_f6b0745e-ca27-4e45-9675-1793318bfadb" xlink:to="loc_hum_December2020AcceleratedShareRepurchaseAgreementMember_951a7c69-8257-47f9-86b1-120fbdb27746" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_January2022AcceleratedShareRepurchaseAgreementMember_723510a7-3f8e-494b-af0a-4150163732c8" xlink:href="hum-20231231.xsd#hum_January2022AcceleratedShareRepurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_f6b0745e-ca27-4e45-9675-1793318bfadb" xlink:to="loc_hum_January2022AcceleratedShareRepurchaseAgreementMember_723510a7-3f8e-494b-af0a-4150163732c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_November2022AcceleratedShareRepurchaseProgramMember_24befae7-060c-4dac-932d-554bc34d945d" xlink:href="hum-20231231.xsd#hum_November2022AcceleratedShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_f6b0745e-ca27-4e45-9675-1793318bfadb" xlink:to="loc_hum_November2022AcceleratedShareRepurchaseProgramMember_24befae7-060c-4dac-932d-554bc34d945d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8c8dedd4-a069-4562-8370-9cb73555e2c9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_2c6f3b71-7f86-4ea9-a41f-aa22c4907e50" xlink:to="loc_srt_CounterpartyNameAxis_8c8dedd4-a069-4562-8370-9cb73555e2c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c8dedd4-a069-4562-8370-9cb73555e2c9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8c8dedd4-a069-4562-8370-9cb73555e2c9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8c8dedd4-a069-4562-8370-9cb73555e2c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd454951-74a8-4fa3-94d9-3c27d5016f6a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8c8dedd4-a069-4562-8370-9cb73555e2c9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd454951-74a8-4fa3-94d9-3c27d5016f6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CitibankNAMember_029157fc-7a29-4b4e-9fab-6b28bc0a5859" xlink:href="hum-20231231.xsd#hum_CitibankNAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd454951-74a8-4fa3-94d9-3c27d5016f6a" xlink:to="loc_hum_CitibankNAMember_029157fc-7a29-4b4e-9fab-6b28bc0a5859" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_JPMorganChaseBankMember_1d8bff28-0f9a-4345-b2f0-98a8ab714679" xlink:href="hum-20231231.xsd#hum_JPMorganChaseBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd454951-74a8-4fa3-94d9-3c27d5016f6a" xlink:to="loc_hum_JPMorganChaseBankMember_1d8bff28-0f9a-4345-b2f0-98a8ab714679" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MizuhoMarketsAmericasLLCMember_31d56e4a-de7e-45bd-8b43-c444e2b62578" xlink:href="hum-20231231.xsd#hum_MizuhoMarketsAmericasLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd454951-74a8-4fa3-94d9-3c27d5016f6a" xlink:to="loc_hum_MizuhoMarketsAmericasLLCMember_31d56e4a-de7e-45bd-8b43-c444e2b62578" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_WellsFargoBankMember_2291afb8-a276-452c-a703-ab32a12eb12f" xlink:href="hum-20231231.xsd#hum_WellsFargoBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd454951-74a8-4fa3-94d9-3c27d5016f6a" xlink:to="loc_hum_WellsFargoBankMember_2291afb8-a276-452c-a703-ab32a12eb12f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GoldmanSachsCoLLCMember_ea8b9862-b82a-49f7-9cef-fcfd7678e6b4" xlink:href="hum-20231231.xsd#hum_GoldmanSachsCoLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd454951-74a8-4fa3-94d9-3c27d5016f6a" xlink:to="loc_hum_GoldmanSachsCoLLCMember_ea8b9862-b82a-49f7-9cef-fcfd7678e6b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_ba0d92bb-1d53-49c7-a521-5147dd143715" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_2c6f3b71-7f86-4ea9-a41f-aa22c4907e50" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_ba0d92bb-1d53-49c7-a521-5147dd143715" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_ba0d92bb-1d53-49c7-a521-5147dd143715_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_ba0d92bb-1d53-49c7-a521-5147dd143715" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_ba0d92bb-1d53-49c7-a521-5147dd143715_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b575d8e0-f7a4-431c-9362-8f139ab33111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_ba0d92bb-1d53-49c7-a521-5147dd143715" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b575d8e0-f7a4-431c-9362-8f139ab33111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A2021ShareRepurchaseAuthorizationMember_7da1df75-383d-4498-8e16-3bee9cf1a67e" xlink:href="hum-20231231.xsd#hum_A2021ShareRepurchaseAuthorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b575d8e0-f7a4-431c-9362-8f139ab33111" xlink:to="loc_hum_A2021ShareRepurchaseAuthorizationMember_7da1df75-383d-4498-8e16-3bee9cf1a67e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A2023ShareRepurchaseAuthorizationMember_00dbedd3-3407-4982-832e-06cc24939835" xlink:href="hum-20231231.xsd#hum_A2023ShareRepurchaseAuthorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b575d8e0-f7a4-431c-9362-8f139ab33111" xlink:to="loc_hum_A2023ShareRepurchaseAuthorizationMember_00dbedd3-3407-4982-832e-06cc24939835" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A2024ShareRepurchaseAuthorizationMember_57d6375c-b640-4b39-bfb9-bd736282f8df" xlink:href="hum-20231231.xsd#hum_A2024ShareRepurchaseAuthorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b575d8e0-f7a4-431c-9362-8f139ab33111" xlink:to="loc_hum_A2024ShareRepurchaseAuthorizationMember_57d6375c-b640-4b39-bfb9-bd736282f8df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_676ff7cf-172f-4196-8b60-630841390cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_2c6f3b71-7f86-4ea9-a41f-aa22c4907e50" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_676ff7cf-172f-4196-8b60-630841390cb9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_676ff7cf-172f-4196-8b60-630841390cb9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_676ff7cf-172f-4196-8b60-630841390cb9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_676ff7cf-172f-4196-8b60-630841390cb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b2b3cf44-cbd7-4e3a-ae6d-c331347700ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_676ff7cf-172f-4196-8b60-630841390cb9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b2b3cf44-cbd7-4e3a-ae6d-c331347700ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ad0aa68c-f88f-4d9d-8856-e7941087ea2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b2b3cf44-cbd7-4e3a-ae6d-c331347700ea" xlink:to="loc_us-gaap_SubsequentEventMember_ad0aa68c-f88f-4d9d-8856-e7941087ea2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_4b9def43-6cea-4d67-91ea-5a0975901373" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_2c6f3b71-7f86-4ea9-a41f-aa22c4907e50" xlink:to="loc_srt_StatementScenarioAxis_4b9def43-6cea-4d67-91ea-5a0975901373" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_4b9def43-6cea-4d67-91ea-5a0975901373_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_4b9def43-6cea-4d67-91ea-5a0975901373" xlink:to="loc_srt_ScenarioUnspecifiedDomain_4b9def43-6cea-4d67-91ea-5a0975901373_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ca96930d-db54-4729-8342-ed0812ff921a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_4b9def43-6cea-4d67-91ea-5a0975901373" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ca96930d-db54-4729-8342-ed0812ff921a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d3b4544e-5af3-46ff-8f63-aefd67ee66a6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_ca96930d-db54-4729-8342-ed0812ff921a" xlink:to="loc_srt_ScenarioForecastMember_d3b4544e-5af3-46ff-8f63-aefd67ee66a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_65628584-1e1e-421d-a404-52e3d02fad43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_65628584-1e1e-421d-a404-52e3d02fad43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_ebba5812-e4ee-47ef-a20c-66d29101dd66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_DividendsCommonStock_ebba5812-e4ee-47ef-a20c-66d29101dd66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_AcceleratedShareRepurchasesAgreementAmount_4e49707d-0a02-46d3-970e-4ad1153423d7" xlink:href="hum-20231231.xsd#hum_AcceleratedShareRepurchasesAgreementAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_hum_AcceleratedShareRepurchasesAgreementAmount_4e49707d-0a02-46d3-970e-4ad1153423d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_f5b3fc9f-ed3d-4080-92e8-01bd20037884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_f5b3fc9f-ed3d-4080-92e8-01bd20037884" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_132b0835-792a-4c56-944a-d2fe86650142" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_132b0835-792a-4c56-944a-d2fe86650142" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_32f712bd-c8e7-4bdd-a708-031177be890e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_32f712bd-c8e7-4bdd-a708-031177be890e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_4edaa9e5-e868-45cf-9b6c-54132ce89b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_4edaa9e5-e868-45cf-9b6c-54132ce89b5e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue_69c4e9fe-e72e-4095-9213-17c3ed7d08da" xlink:href="hum-20231231.xsd#hum_TreasuryStockDecreaseInCapitalInExcessOfParValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue_69c4e9fe-e72e-4095-9213-17c3ed7d08da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_4b3c6bf9-a562-48af-8925-0016673a68c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_4b3c6bf9-a562-48af-8925-0016673a68c2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue_f396c25d-f4d2-41c6-b755-41b9a140ec5d" xlink:href="hum-20231231.xsd#hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue_f396c25d-f4d2-41c6-b755-41b9a140ec5d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_5ba0aa7e-adfa-4157-8443-3df5d4d61736" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_5ba0aa7e-adfa-4157-8443-3df5d4d61736" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_f7fa9986-5416-4f59-85e3-4f417b4dc33f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_f7fa9986-5416-4f59-85e3-4f417b4dc33f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares_874f277d-becd-412e-a45a-825af2f0d199" xlink:href="hum-20231231.xsd#hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares_874f277d-becd-412e-a45a-825af2f0d199" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue_aad40180-2e33-4119-a1fa-1db7abcec89d" xlink:href="hum-20231231.xsd#hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue_aad40180-2e33-4119-a1fa-1db7abcec89d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_3e378ad0-de8c-43c7-a5ec-0a847a9335a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_3e378ad0-de8c-43c7-a5ec-0a847a9335a7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_ed01a72d-ffe2-401c-8fcf-b71c30bbdb73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_ed01a72d-ffe2-401c-8fcf-b71c30bbdb73" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval_b01a55ad-4b64-4cad-964d-ae0b02c7ac4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval_b01a55ad-4b64-4cad-964d-ae0b02c7ac4b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DividendsToParentWithoutPriorStateRegulatoryApproval_48d3ffe9-3ed4-4c6d-b909-8b6a6a0ccbf1" xlink:href="hum-20231231.xsd#hum_DividendsToParentWithoutPriorStateRegulatoryApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_hum_DividendsToParentWithoutPriorStateRegulatoryApproval_48d3ffe9-3ed4-4c6d-b909-8b6a6a0ccbf1" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#STOCKHOLDERSEQUITYShareRepurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b4905eb1-23ce-4367-b051-a6df46eb07ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_44409618-3082-4746-8cb1-b9b2d580dcd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b4905eb1-23ce-4367-b051-a6df46eb07ad" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_44409618-3082-4746-8cb1-b9b2d580dcd6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_a4ea7fea-d3e6-45b8-a383-babdf95f3a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_44409618-3082-4746-8cb1-b9b2d580dcd6" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_a4ea7fea-d3e6-45b8-a383-babdf95f3a7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_a4ea7fea-d3e6-45b8-a383-babdf95f3a7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_a4ea7fea-d3e6-45b8-a383-babdf95f3a7e" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_a4ea7fea-d3e6-45b8-a383-babdf95f3a7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_388841c9-5da3-4582-97f9-3f19257af89d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_a4ea7fea-d3e6-45b8-a383-babdf95f3a7e" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_388841c9-5da3-4582-97f9-3f19257af89d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember_276a5ff6-00b3-4093-b5cf-dce66e5041e5" xlink:href="hum-20231231.xsd#hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_388841c9-5da3-4582-97f9-3f19257af89d" xlink:to="loc_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember_276a5ff6-00b3-4093-b5cf-dce66e5041e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_February2023ShareRepurchaseAuthorizationMember_8b4e2306-ff69-4d26-b862-4db1800f035b" xlink:href="hum-20231231.xsd#hum_February2023ShareRepurchaseAuthorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember_276a5ff6-00b3-4093-b5cf-dce66e5041e5" xlink:to="loc_hum_February2023ShareRepurchaseAuthorizationMember_8b4e2306-ff69-4d26-b862-4db1800f035b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_February2021ShareRepurchaseAuthorizationMember_09511956-0c71-4139-858a-c4b3a51165f1" xlink:href="hum-20231231.xsd#hum_February2021ShareRepurchaseAuthorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember_276a5ff6-00b3-4093-b5cf-dce66e5041e5" xlink:to="loc_hum_February2021ShareRepurchaseAuthorizationMember_09511956-0c71-4139-858a-c4b3a51165f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bf41aaf6-1800-4c85-86a1-62c06e54bea0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b4905eb1-23ce-4367-b051-a6df46eb07ad" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bf41aaf6-1800-4c85-86a1-62c06e54bea0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_c7dcd41f-85fd-4947-86fa-2a2d5b2d377c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b4905eb1-23ce-4367-b051-a6df46eb07ad" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_c7dcd41f-85fd-4947-86fa-2a2d5b2d377c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0afd3a71-594b-4d3e-a12f-f52dd4bfbf90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b4905eb1-23ce-4367-b051-a6df46eb07ad" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0afd3a71-594b-4d3e-a12f-f52dd4bfbf90" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_57acc890-36c5-4d84-b7fa-5661d08d152f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_us-gaap_LossContingenciesTable_57acc890-36c5-4d84-b7fa-5661d08d152f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_837c9787-7c54-4102-b922-80435ccbfab6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_57acc890-36c5-4d84-b7fa-5661d08d152f" xlink:to="loc_srt_MajorCustomersAxis_837c9787-7c54-4102-b922-80435ccbfab6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_837c9787-7c54-4102-b922-80435ccbfab6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_837c9787-7c54-4102-b922-80435ccbfab6" xlink:to="loc_srt_NameOfMajorCustomerDomain_837c9787-7c54-4102-b922-80435ccbfab6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_8fdfb6f8-65b2-42ef-a9ec-75ced6b351c9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_837c9787-7c54-4102-b922-80435ccbfab6" xlink:to="loc_srt_NameOfMajorCustomerDomain_8fdfb6f8-65b2-42ef-a9ec-75ced6b351c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareMember_46d37560-d677-42f8-9b72-a053da83583c" xlink:href="hum-20231231.xsd#hum_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fdfb6f8-65b2-42ef-a9ec-75ced6b351c9" xlink:to="loc_hum_MedicareMember_46d37560-d677-42f8-9b72-a053da83583c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicaidMember_f4c37842-d2a9-450e-88f8-e20df543582e" xlink:href="hum-20231231.xsd#hum_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fdfb6f8-65b2-42ef-a9ec-75ced6b351c9" xlink:to="loc_hum_MedicaidMember_f4c37842-d2a9-450e-88f8-e20df543582e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MilitaryServiceMember_755bc970-99cb-47f8-8541-5c64c6a79fb2" xlink:href="hum-20231231.xsd#hum_MilitaryServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fdfb6f8-65b2-42ef-a9ec-75ced6b351c9" xlink:to="loc_hum_MilitaryServiceMember_755bc970-99cb-47f8-8541-5c64c6a79fb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREContractAxis_b6371c3d-cdb8-4074-8c5b-50bd70b5a16b" xlink:href="hum-20231231.xsd#hum_TRICAREContractAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_57acc890-36c5-4d84-b7fa-5661d08d152f" xlink:to="loc_hum_TRICAREContractAxis_b6371c3d-cdb8-4074-8c5b-50bd70b5a16b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREContractDomain_b6371c3d-cdb8-4074-8c5b-50bd70b5a16b_default" xlink:href="hum-20231231.xsd#hum_TRICAREContractDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_hum_TRICAREContractAxis_b6371c3d-cdb8-4074-8c5b-50bd70b5a16b" xlink:to="loc_hum_TRICAREContractDomain_b6371c3d-cdb8-4074-8c5b-50bd70b5a16b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREContractDomain_81cc08ba-84d0-4009-ba64-869387dde1cb" xlink:href="hum-20231231.xsd#hum_TRICAREContractDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_hum_TRICAREContractAxis_b6371c3d-cdb8-4074-8c5b-50bd70b5a16b" xlink:to="loc_hum_TRICAREContractDomain_81cc08ba-84d0-4009-ba64-869387dde1cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICARE2017EastRegionContractMember_f8915fe3-8fc7-459e-878c-d039bfef9570" xlink:href="hum-20231231.xsd#hum_TRICARE2017EastRegionContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_TRICAREContractDomain_81cc08ba-84d0-4009-ba64-869387dde1cb" xlink:to="loc_hum_TRICARE2017EastRegionContractMember_f8915fe3-8fc7-459e-878c-d039bfef9570" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREManagedCareSupportContractEffective2024Member_f22d5b90-e79c-4ae5-9ed6-a108f80b8db2" xlink:href="hum-20231231.xsd#hum_TRICAREManagedCareSupportContractEffective2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_TRICAREContractDomain_81cc08ba-84d0-4009-ba64-869387dde1cb" xlink:to="loc_hum_TRICAREManagedCareSupportContractEffective2024Member_f22d5b90-e79c-4ae5-9ed6-a108f80b8db2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_22d9db03-87fb-4f04-9f3c-ee2157c4b486" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_22d9db03-87fb-4f04-9f3c-ee2157c4b486" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_369205ca-9077-4f29-bafb-2ed33426cfe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_369205ca-9077-4f29-bafb-2ed33426cfe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_4a3e3a0d-0573-444a-a01e-192f36ad2918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_4a3e3a0d-0573-444a-a01e-192f36ad2918" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_29f14b87-0154-4c49-8010-145945071542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_29f14b87-0154-4c49-8010-145945071542" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_2445f373-0ce3-4065-aae1-6c82ce56181f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_2445f373-0ce3-4065-aae1-6c82ce56181f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PercentageOfTotalPremiumAndServicesRevenues_ca42fb9c-3271-4f1c-9f45-b2b6f26c4b01" xlink:href="hum-20231231.xsd#hum_PercentageOfTotalPremiumAndServicesRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_hum_PercentageOfTotalPremiumAndServicesRevenues_ca42fb9c-3271-4f1c-9f45-b2b6f26c4b01" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfStatesComprisingTRICAREBeneficiaries_936cd9f4-5d02-4111-b4cf-1f69654a6fca" xlink:href="hum-20231231.xsd#hum_NumberOfStatesComprisingTRICAREBeneficiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_hum_NumberOfStatesComprisingTRICAREBeneficiaries_936cd9f4-5d02-4111-b4cf-1f69654a6fca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfTRICAREBeneficiaries_3dd18530-b96b-4ec4-b54f-baf309e1ed75" xlink:href="hum-20231231.xsd#hum_NumberOfTRICAREBeneficiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_hum_NumberOfTRICAREBeneficiaries_3dd18530-b96b-4ec4-b54f-baf309e1ed75" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries_2c5cea28-899e-4e48-a164-b7f8c59e1681" xlink:href="hum-20231231.xsd#hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries_2c5cea28-899e-4e48-a164-b7f8c59e1681" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries_f950eca0-4115-41ac-a629-da647a9bc825" xlink:href="hum-20231231.xsd#hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries_f950eca0-4115-41ac-a629-da647a9bc825" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREManagedCareSupportContractBaseTerm_b93003e0-6a62-4b97-9e5f-3c8e07f3adce" xlink:href="hum-20231231.xsd#hum_TRICAREManagedCareSupportContractBaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_hum_TRICAREManagedCareSupportContractBaseTerm_b93003e0-6a62-4b97-9e5f-3c8e07f3adce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods_a71c58e2-938c-4488-8c14-5ed510b5d92d" xlink:href="hum-20231231.xsd#hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods_a71c58e2-938c-4488-8c14-5ed510b5d92d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREManagedCareSupportContractTermWithOptionExercises_8ab94a07-a327-4d46-9c28-b100af8e3461" xlink:href="hum-20231231.xsd#hum_TRICAREManagedCareSupportContractTermWithOptionExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_hum_TRICAREManagedCareSupportContractTermWithOptionExercises_8ab94a07-a327-4d46-9c28-b100af8e3461" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_4023d123-6108-4969-97e6-b528b2ef68f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_62097919-3804-4bdb-8c4b-447500e3b4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4023d123-6108-4969-97e6-b528b2ef68f1" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_62097919-3804-4bdb-8c4b-447500e3b4e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_809c8f19-c7ab-453e-af9e-78cc1fce5aee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_62097919-3804-4bdb-8c4b-447500e3b4e2" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_809c8f19-c7ab-453e-af9e-78cc1fce5aee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_809c8f19-c7ab-453e-af9e-78cc1fce5aee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_809c8f19-c7ab-453e-af9e-78cc1fce5aee" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_809c8f19-c7ab-453e-af9e-78cc1fce5aee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ff1c7e6a-840b-4086-8547-e7b68d317f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_809c8f19-c7ab-453e-af9e-78cc1fce5aee" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ff1c7e6a-840b-4086-8547-e7b68d317f2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_97d40de2-af2a-433b-9a62-a8e366fd0d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ff1c7e6a-840b-4086-8547-e7b68d317f2e" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_97d40de2-af2a-433b-9a62-a8e366fd0d0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ba6a7fd6-58a4-49de-b3b6-bee2011b4cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_62097919-3804-4bdb-8c4b-447500e3b4e2" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ba6a7fd6-58a4-49de-b3b6-bee2011b4cc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ba6a7fd6-58a4-49de-b3b6-bee2011b4cc1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ba6a7fd6-58a4-49de-b3b6-bee2011b4cc1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ba6a7fd6-58a4-49de-b3b6-bee2011b4cc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2cbef317-d8a7-4d14-b47c-19b1e9647bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ba6a7fd6-58a4-49de-b3b6-bee2011b4cc1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2cbef317-d8a7-4d14-b47c-19b1e9647bf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_54ae70c6-425c-4f71-9b5b-3ff5b0e49cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2cbef317-d8a7-4d14-b47c-19b1e9647bf3" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_54ae70c6-425c-4f71-9b5b-3ff5b0e49cc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_638fa89e-161a-449f-b0ca-c09f804d6212" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_62097919-3804-4bdb-8c4b-447500e3b4e2" xlink:to="loc_srt_MajorCustomersAxis_638fa89e-161a-449f-b0ca-c09f804d6212" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_638fa89e-161a-449f-b0ca-c09f804d6212_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_638fa89e-161a-449f-b0ca-c09f804d6212" xlink:to="loc_srt_NameOfMajorCustomerDomain_638fa89e-161a-449f-b0ca-c09f804d6212_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_985abda3-175b-4ca3-8f37-90c63c10123d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_638fa89e-161a-449f-b0ca-c09f804d6212" xlink:to="loc_srt_NameOfMajorCustomerDomain_985abda3-175b-4ca3-8f37-90c63c10123d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FederalGovernmentMember_79ec9050-b3d5-42cc-b89a-7a20c5708b90" xlink:href="hum-20231231.xsd#hum_FederalGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_985abda3-175b-4ca3-8f37-90c63c10123d" xlink:to="loc_hum_FederalGovernmentMember_79ec9050-b3d5-42cc-b89a-7a20c5708b90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_28f1bb34-60a5-4cb8-9e18-44baee482f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4023d123-6108-4969-97e6-b528b2ef68f1" xlink:to="loc_us-gaap_NumberOfReportableSegments_28f1bb34-60a5-4cb8-9e18-44baee482f6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GovernmentAndHealthPlanMemberSubsidiesAmount_055dc7dc-260a-49c4-8b23-ce40e90583e0" xlink:href="hum-20231231.xsd#hum_GovernmentAndHealthPlanMemberSubsidiesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4023d123-6108-4969-97e6-b528b2ef68f1" xlink:to="loc_hum_GovernmentAndHealthPlanMemberSubsidiesAmount_055dc7dc-260a-49c4-8b23-ce40e90583e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DepreciationAndAmortizationClassifiedAsBenefitExpense_4d7cd938-b67b-4975-a93b-620488654a80" xlink:href="hum-20231231.xsd#hum_DepreciationAndAmortizationClassifiedAsBenefitExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4023d123-6108-4969-97e6-b528b2ef68f1" xlink:to="loc_hum_DepreciationAndAmortizationClassifiedAsBenefitExpense_4d7cd938-b67b-4975-a93b-620488654a80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_316fb9c6-c91c-476b-b7cf-b9b744628f52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4023d123-6108-4969-97e6-b528b2ef68f1" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_316fb9c6-c91c-476b-b7cf-b9b744628f52" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SEGMENTINFORMATIONSegmentResultsDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3de02c05-85f2-4eec-b177-98aae6c5ada2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3de02c05-85f2-4eec-b177-98aae6c5ada2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b4f2f74c-1ed4-485e-b6ed-82ea62f3a9b3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3de02c05-85f2-4eec-b177-98aae6c5ada2" xlink:to="loc_srt_ConsolidationItemsAxis_b4f2f74c-1ed4-485e-b6ed-82ea62f3a9b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b4f2f74c-1ed4-485e-b6ed-82ea62f3a9b3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_b4f2f74c-1ed4-485e-b6ed-82ea62f3a9b3" xlink:to="loc_srt_ConsolidationItemsDomain_b4f2f74c-1ed4-485e-b6ed-82ea62f3a9b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_3e3c9fb0-2f47-4ac1-a26e-73ee1be3074f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_b4f2f74c-1ed4-485e-b6ed-82ea62f3a9b3" xlink:to="loc_srt_ConsolidationItemsDomain_3e3c9fb0-2f47-4ac1-a26e-73ee1be3074f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_fc620a6a-f463-48ac-a413-0fde675e6344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_3e3c9fb0-2f47-4ac1-a26e-73ee1be3074f" xlink:to="loc_us-gaap_OperatingSegmentsMember_fc620a6a-f463-48ac-a413-0fde675e6344" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CorporateAndEliminationsMember_3b449347-2fad-446d-9926-5879a88e8f34" xlink:href="hum-20231231.xsd#hum_CorporateAndEliminationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_3e3c9fb0-2f47-4ac1-a26e-73ee1be3074f" xlink:to="loc_hum_CorporateAndEliminationsMember_3b449347-2fad-446d-9926-5879a88e8f34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_388f14d5-04a5-453b-863e-ddf534d090b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_3e3c9fb0-2f47-4ac1-a26e-73ee1be3074f" xlink:to="loc_us-gaap_IntersegmentEliminationMember_388f14d5-04a5-453b-863e-ddf534d090b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_25933a62-3446-405a-a8d4-27c8364f2473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3de02c05-85f2-4eec-b177-98aae6c5ada2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_25933a62-3446-405a-a8d4-27c8364f2473" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_25933a62-3446-405a-a8d4-27c8364f2473_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_25933a62-3446-405a-a8d4-27c8364f2473" xlink:to="loc_us-gaap_SegmentDomain_25933a62-3446-405a-a8d4-27c8364f2473_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2fd9dd2b-c5c8-4646-9579-226425403dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_25933a62-3446-405a-a8d4-27c8364f2473" xlink:to="loc_us-gaap_SegmentDomain_2fd9dd2b-c5c8-4646-9579-226425403dfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InsuranceSegmentMember_d5c93b79-c999-4bfd-b567-bd805ce3fb56" xlink:href="hum-20231231.xsd#hum_InsuranceSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2fd9dd2b-c5c8-4646-9579-226425403dfd" xlink:to="loc_hum_InsuranceSegmentMember_d5c93b79-c999-4bfd-b567-bd805ce3fb56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CenterWellSegmentMember_25df3f62-e0e8-4f35-b7eb-86a867cb4a50" xlink:href="hum-20231231.xsd#hum_CenterWellSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2fd9dd2b-c5c8-4646-9579-226425403dfd" xlink:to="loc_hum_CenterWellSegmentMember_25df3f62-e0e8-4f35-b7eb-86a867cb4a50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_242b7cfe-920f-4263-a8ec-626f14116d3a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3de02c05-85f2-4eec-b177-98aae6c5ada2" xlink:to="loc_srt_MajorCustomersAxis_242b7cfe-920f-4263-a8ec-626f14116d3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_242b7cfe-920f-4263-a8ec-626f14116d3a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_242b7cfe-920f-4263-a8ec-626f14116d3a" xlink:to="loc_srt_NameOfMajorCustomerDomain_242b7cfe-920f-4263-a8ec-626f14116d3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_242b7cfe-920f-4263-a8ec-626f14116d3a" xlink:to="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareMember_b5471474-f1fc-4827-9f9b-677add71a004" xlink:href="hum-20231231.xsd#hum_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_MedicareMember_b5471474-f1fc-4827-9f9b-677add71a004" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareAdvantageMember_d6da628e-a0fa-4f0a-a817-dccfbb4cc02a" xlink:href="hum-20231231.xsd#hum_MedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_MedicareMember_b5471474-f1fc-4827-9f9b-677add71a004" xlink:to="loc_hum_MedicareAdvantageMember_d6da628e-a0fa-4f0a-a817-dccfbb4cc02a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GroupMedicareAdvantageMember_22d71a47-3b14-42e3-9919-01299db07d64" xlink:href="hum-20231231.xsd#hum_GroupMedicareAdvantageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_MedicareMember_b5471474-f1fc-4827-9f9b-677add71a004" xlink:to="loc_hum_GroupMedicareAdvantageMember_22d71a47-3b14-42e3-9919-01299db07d64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareStandAlonePrescriptionDrugPlanMember_b7d892e5-a981-40cd-bc6f-eba3f4dcc78c" xlink:href="hum-20231231.xsd#hum_MedicareStandAlonePrescriptionDrugPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_MedicareMember_b5471474-f1fc-4827-9f9b-677add71a004" xlink:to="loc_hum_MedicareStandAlonePrescriptionDrugPlanMember_b7d892e5-a981-40cd-bc6f-eba3f4dcc78c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CommercialFullyInsuredMember_51993ca5-f5c9-4fb1-8d01-35f33a80e0b0" xlink:href="hum-20231231.xsd#hum_CommercialFullyInsuredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_CommercialFullyInsuredMember_51993ca5-f5c9-4fb1-8d01-35f33a80e0b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SpecialtyBenefitsMember_2ecfb153-cefb-4e2c-adb7-52c9f5efa495" xlink:href="hum-20231231.xsd#hum_SpecialtyBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_SpecialtyBenefitsMember_2ecfb153-cefb-4e2c-adb7-52c9f5efa495" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareSupplementProductMember_aa206014-d880-4a5a-96df-172229bb7b29" xlink:href="hum-20231231.xsd#hum_MedicareSupplementProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_MedicareSupplementProductMember_aa206014-d880-4a5a-96df-172229bb7b29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_StateBasedContractsAndOtherMember_4cf67329-1531-4876-8dff-f7dba2f1346c" xlink:href="hum-20231231.xsd#hum_StateBasedContractsAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_StateBasedContractsAndOtherMember_4cf67329-1531-4876-8dff-f7dba2f1346c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_HomeSolutionsMember_cfc1fe7d-18f8-4d0d-ab57-04cb3ea56114" xlink:href="hum-20231231.xsd#hum_HomeSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_HomeSolutionsMember_cfc1fe7d-18f8-4d0d-ab57-04cb3ea56114" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PrimaryCareMember_62222d2c-a462-4461-b12f-d4fce8737acf" xlink:href="hum-20231231.xsd#hum_PrimaryCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_PrimaryCareMember_62222d2c-a462-4461-b12f-d4fce8737acf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CommercialASOMember_a1d108d4-9580-4056-9a99-12ae545f1d05" xlink:href="hum-20231231.xsd#hum_CommercialASOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_CommercialASOMember_a1d108d4-9580-4056-9a99-12ae545f1d05" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MilitaryAndOtherMember_c466fcf8-a74c-4796-9e8c-37b7fb316e27" xlink:href="hum-20231231.xsd#hum_MilitaryAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_MilitaryAndOtherMember_c466fcf8-a74c-4796-9e8c-37b7fb316e27" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PharmacySolutionsMember_7936704c-19eb-4849-bdd1-e54bc7de1fe4" xlink:href="hum-20231231.xsd#hum_PharmacySolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_PharmacySolutionsMember_7936704c-19eb-4849-bdd1-e54bc7de1fe4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_75e1b911-8410-4563-baf7-f03f53e71582" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3de02c05-85f2-4eec-b177-98aae6c5ada2" xlink:to="loc_srt_ProductOrServiceAxis_75e1b911-8410-4563-baf7-f03f53e71582" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_75e1b911-8410-4563-baf7-f03f53e71582_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_75e1b911-8410-4563-baf7-f03f53e71582" xlink:to="loc_srt_ProductsAndServicesDomain_75e1b911-8410-4563-baf7-f03f53e71582_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_da5a41d9-3b93-4dc5-9d7c-d895b4b4200c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_75e1b911-8410-4563-baf7-f03f53e71582" xlink:to="loc_srt_ProductsAndServicesDomain_da5a41d9-3b93-4dc5-9d7c-d895b4b4200c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_adf9dfc4-3950-4f28-a23a-edefa18c46fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_da5a41d9-3b93-4dc5-9d7c-d895b4b4200c" xlink:to="loc_us-gaap_ProductMember_adf9dfc4-3950-4f28-a23a-edefa18c46fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_d98812cb-2cdf-4647-9aeb-2de6f62ac933" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_da5a41d9-3b93-4dc5-9d7c-d895b4b4200c" xlink:to="loc_us-gaap_ServiceMember_d98812cb-2cdf-4647-9aeb-2de6f62ac933" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ExternalRevenuesMember_ee2726de-029a-46b3-801d-92619946d5f7" xlink:href="hum-20231231.xsd#hum_ExternalRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_da5a41d9-3b93-4dc5-9d7c-d895b4b4200c" xlink:to="loc_hum_ExternalRevenuesMember_ee2726de-029a-46b3-801d-92619946d5f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_81858ba0-c15e-407d-83e8-8d55f2fd39bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_PremiumsEarnedNet_81858ba0-c15e-407d-83e8-8d55f2fd39bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6e65ec70-09b2-492d-bf54-5d8abdb2fbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6e65ec70-09b2-492d-bf54-5d8abdb2fbb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1be06ad8-6b0d-4b60-9e94-561ca80d396f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_Revenues_1be06ad8-6b0d-4b60-9e94-561ca80d396f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_eb3b0fbf-1f57-429d-b49f-365b041f4f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_eb3b0fbf-1f57-429d-b49f-365b041f4f7f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_b8afe302-2119-416f-9d6a-d345f207aae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_b8afe302-2119-416f-9d6a-d345f207aae3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7a61a221-38b7-4388-8600-e33b78025dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7a61a221-38b7-4388-8600-e33b78025dc5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_07daa953-ee65-4c15-95ae-550c938300d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_DepreciationAndAmortization_07daa953-ee65-4c15-95ae-550c938300d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_b6ea8677-c5bb-4b74-af9b-9f98e9716900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_BenefitsLossesAndExpenses_b6ea8677-c5bb-4b74-af9b-9f98e9716900" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1e1a48d6-9141-4418-b52c-b52298d0049e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_OperatingIncomeLoss_1e1a48d6-9141-4418-b52c-b52298d0049e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_15bae60c-ea6a-431c-892d-e48a32bca75c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_15bae60c-ea6a-431c-892d-e48a32bca75c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6f83aba1-aaa4-42e3-9b33-5aeec7d9efa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_InterestExpense_6f83aba1-aaa4-42e3-9b33-5aeec7d9efa0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d56183ad-9a43-4d1c-8097-ed226cf030d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d56183ad-9a43-4d1c-8097-ed226cf030d5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a04bab88-8f2b-4065-b3a5-a0d75c28a11a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a04bab88-8f2b-4065-b3a5-a0d75c28a11a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_213ebb45-9b16-4d20-9476-8e04bec441c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_213ebb45-9b16-4d20-9476-8e04bec441c1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9b02788a-60d6-4ea5-bd45-1e33ed76fa44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9b02788a-60d6-4ea5-bd45-1e33ed76fa44" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_eff0cc01-0f03-43e2-a99e-3ac2e158be37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_eff0cc01-0f03-43e2-a99e-3ac2e158be37" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent_5cc9170b-0e31-4c11-b8f0-1c38d63c8cbf" xlink:href="hum-20231231.xsd#hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent_5cc9170b-0e31-4c11-b8f0-1c38d63c8cbf" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/REINSURANCEDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#REINSURANCEDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/REINSURANCEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceLineItems_4498fb98-ac8f-474d-b060-0664e3cb37b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectsOfReinsuranceLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ReinsuranceTable_132952d5-6d46-4aeb-98b3-0c55590d58a5" xlink:href="hum-20231231.xsd#hum_ReinsuranceTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_4498fb98-ac8f-474d-b060-0664e3cb37b2" xlink:to="loc_hum_ReinsuranceTable_132952d5-6d46-4aeb-98b3-0c55590d58a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LongDurationInsuranceProductsAxis_352099fe-1b6a-4c72-8070-38d3478050bc" xlink:href="hum-20231231.xsd#hum_LongDurationInsuranceProductsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_ReinsuranceTable_132952d5-6d46-4aeb-98b3-0c55590d58a5" xlink:to="loc_hum_LongDurationInsuranceProductsAxis_352099fe-1b6a-4c72-8070-38d3478050bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LongDurationInsuranceProductsDomain_352099fe-1b6a-4c72-8070-38d3478050bc_default" xlink:href="hum-20231231.xsd#hum_LongDurationInsuranceProductsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_hum_LongDurationInsuranceProductsAxis_352099fe-1b6a-4c72-8070-38d3478050bc" xlink:to="loc_hum_LongDurationInsuranceProductsDomain_352099fe-1b6a-4c72-8070-38d3478050bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LongDurationInsuranceProductsDomain_3d1ee5ea-1c6a-4eb4-8b2d-70100bfde09f" xlink:href="hum-20231231.xsd#hum_LongDurationInsuranceProductsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_hum_LongDurationInsuranceProductsAxis_352099fe-1b6a-4c72-8070-38d3478050bc" xlink:to="loc_hum_LongDurationInsuranceProductsDomain_3d1ee5ea-1c6a-4eb4-8b2d-70100bfde09f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CoinsuranceAgreementMember_1f1cebbb-fa3e-441a-a980-b5f6f8926fb5" xlink:href="hum-20231231.xsd#hum_CoinsuranceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_hum_LongDurationInsuranceProductsDomain_3d1ee5ea-1c6a-4eb4-8b2d-70100bfde09f" xlink:to="loc_hum_CoinsuranceAgreementMember_1f1cebbb-fa3e-441a-a980-b5f6f8926fb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_31b4fc3d-8eec-462c-8101-74389989f990" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_hum_ReinsuranceTable_132952d5-6d46-4aeb-98b3-0c55590d58a5" xlink:to="loc_srt_ProductOrServiceAxis_31b4fc3d-8eec-462c-8101-74389989f990" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_31b4fc3d-8eec-462c-8101-74389989f990_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_31b4fc3d-8eec-462c-8101-74389989f990" xlink:to="loc_srt_ProductsAndServicesDomain_31b4fc3d-8eec-462c-8101-74389989f990_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e618bc02-7918-4ac0-9c30-90dddd8075d7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_31b4fc3d-8eec-462c-8101-74389989f990" xlink:to="loc_srt_ProductsAndServicesDomain_e618bc02-7918-4ac0-9c30-90dddd8075d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ProtectiveLifeInsuranceCompanyMember_69ce0490-dc34-45e0-83d8-a530a69a5efd" xlink:href="hum-20231231.xsd#hum_ProtectiveLifeInsuranceCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e618bc02-7918-4ac0-9c30-90dddd8075d7" xlink:to="loc_hum_ProtectiveLifeInsuranceCompanyMember_69ce0490-dc34-45e0-83d8-a530a69a5efd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_AllOthersMember_c8e1fad5-d7bb-40e5-92b3-4a27200a59ff" xlink:href="hum-20231231.xsd#hum_AllOthersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e618bc02-7918-4ac0-9c30-90dddd8075d7" xlink:to="loc_hum_AllOthersMember_c8e1fad5-d7bb-40e5-92b3-4a27200a59ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverables_261d980e-125f-4e52-8fbf-c3f45bd6766f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceRecoverables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_4498fb98-ac8f-474d-b060-0664e3cb37b2" xlink:to="loc_us-gaap_ReinsuranceRecoverables_261d980e-125f-4e52-8fbf-c3f45bd6766f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PercentageOfCoinsuranceAgreement_47d1bbfa-3d58-4023-a73c-43a3c77e5cf1" xlink:href="hum-20231231.xsd#hum_PercentageOfCoinsuranceAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_4498fb98-ac8f-474d-b060-0664e3cb37b2" xlink:to="loc_hum_PercentageOfCoinsuranceAgreement_47d1bbfa-3d58-4023-a73c-43a3c77e5cf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsWritten_8e6d2567-0024-4964-a9d7-53419a0fff20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededPremiumsWritten"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_4498fb98-ac8f-474d-b060-0664e3cb37b2" xlink:to="loc_us-gaap_CededPremiumsWritten_8e6d2567-0024-4964-a9d7-53419a0fff20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_841a60a9-61c5-4042-a994-f3149f6292e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_4498fb98-ac8f-474d-b060-0664e3cb37b2" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_841a60a9-61c5-4042-a994-f3149f6292e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance_c804ffeb-7d21-4881-bd63-5d74f15fb70d" xlink:href="hum-20231231.xsd#hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_4498fb98-ac8f-474d-b060-0664e3cb37b2" xlink:to="loc_hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance_c804ffeb-7d21-4881-bd63-5d74f15fb70d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer_68e13347-483e-449a-9d79-6378917b0604" xlink:href="hum-20231231.xsd#hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_4498fb98-ac8f-474d-b060-0664e3cb37b2" xlink:to="loc_hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer_68e13347-483e-449a-9d79-6378917b0604" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_c5c6e68f-bdc6-4ab6-b326-2e42a5ef70b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_b763d5d5-769f-40f2-bebd-f98aff5460c3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_c5c6e68f-bdc6-4ab6-b326-2e42a5ef70b5" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_b763d5d5-769f-40f2-bebd-f98aff5460c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_90285b7e-df79-4e60-ac84-90d67204b29b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_b763d5d5-769f-40f2-bebd-f98aff5460c3" xlink:to="loc_srt_ConsolidatedEntitiesAxis_90285b7e-df79-4e60-ac84-90d67204b29b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_90285b7e-df79-4e60-ac84-90d67204b29b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_90285b7e-df79-4e60-ac84-90d67204b29b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_90285b7e-df79-4e60-ac84-90d67204b29b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_18858562-a86a-4beb-9e68-f1dcb654cd97" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_90285b7e-df79-4e60-ac84-90d67204b29b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_18858562-a86a-4beb-9e68-f1dcb654cd97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_b9ac1860-d8cd-4f7e-934e-9b6985945936" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_18858562-a86a-4beb-9e68-f1dcb654cd97" xlink:to="loc_srt_ParentCompanyMember_b9ac1860-d8cd-4f7e-934e-9b6985945936" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_44b961cf-e104-40e5-b586-135063fe3994" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_b763d5d5-769f-40f2-bebd-f98aff5460c3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_44b961cf-e104-40e5-b586-135063fe3994" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_44b961cf-e104-40e5-b586-135063fe3994_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_44b961cf-e104-40e5-b586-135063fe3994" xlink:to="loc_us-gaap_RelatedPartyDomain_44b961cf-e104-40e5-b586-135063fe3994_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f71c9431-d576-4fc7-a9dd-4e5c42c471fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_44b961cf-e104-40e5-b586-135063fe3994" xlink:to="loc_us-gaap_RelatedPartyDomain_f71c9431-d576-4fc7-a9dd-4e5c42c471fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_c429c1ce-4398-499b-ab62-f665a9e44e9d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f71c9431-d576-4fc7-a9dd-4e5c42c471fc" xlink:to="loc_srt_SubsidiariesMember_c429c1ce-4398-499b-ab62-f665a9e44e9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9d5f00aa-ad0b-48df-91e2-c4f723102f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_c5c6e68f-bdc6-4ab6-b326-2e42a5ef70b5" xlink:to="loc_us-gaap_AssetsAbstract_9d5f00aa-ad0b-48df-91e2-c4f723102f5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e5dc6f54-af2b-4381-9bba-253f2f182da4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_9d5f00aa-ad0b-48df-91e2-c4f723102f5e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e5dc6f54-af2b-4381-9bba-253f2f182da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f376df72-68f7-4394-ae3a-5f6462744c56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e5dc6f54-af2b-4381-9bba-253f2f182da4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f376df72-68f7-4394-ae3a-5f6462744c56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_91b99ff0-abe4-4c6b-88d9-a04a9bf6d56c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e5dc6f54-af2b-4381-9bba-253f2f182da4" xlink:to="loc_us-gaap_ShortTermInvestments_91b99ff0-abe4-4c6b-88d9-a04a9bf6d56c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_e476a30d-b636-43fb-af33-2423601a0cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e5dc6f54-af2b-4381-9bba-253f2f182da4" xlink:to="loc_us-gaap_ReceivablesNetCurrent_e476a30d-b636-43fb-af33-2423601a0cd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_93514851-ca28-4b7d-a119-8d6ee2629333" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e5dc6f54-af2b-4381-9bba-253f2f182da4" xlink:to="loc_us-gaap_OtherAssetsCurrent_93514851-ca28-4b7d-a119-8d6ee2629333" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6c3ee1db-75ae-4ec8-b971-03a4f12b2f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e5dc6f54-af2b-4381-9bba-253f2f182da4" xlink:to="loc_us-gaap_AssetsCurrent_6c3ee1db-75ae-4ec8-b971-03a4f12b2f75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_347a9025-15bd-43b7-94f8-bac5c3fdb215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_9d5f00aa-ad0b-48df-91e2-c4f723102f5e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_347a9025-15bd-43b7-94f8-bac5c3fdb215" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InvestmentInRelatedPartiesAndSubsidiaries_9f2d4acd-5a82-4a1c-bf5b-8ec3cbbaec0e" xlink:href="hum-20231231.xsd#hum_InvestmentInRelatedPartiesAndSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_9d5f00aa-ad0b-48df-91e2-c4f723102f5e" xlink:to="loc_hum_InvestmentInRelatedPartiesAndSubsidiaries_9f2d4acd-5a82-4a1c-bf5b-8ec3cbbaec0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_dfe4771a-9101-474d-94ad-8f0b9388cb27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_9d5f00aa-ad0b-48df-91e2-c4f723102f5e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_dfe4771a-9101-474d-94ad-8f0b9388cb27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3f86b0e7-5c29-41f8-afe2-f981f113b114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_9d5f00aa-ad0b-48df-91e2-c4f723102f5e" xlink:to="loc_us-gaap_Assets_3f86b0e7-5c29-41f8-afe2-f981f113b114" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_c5c6e68f-bdc6-4ab6-b326-2e42a5ef70b5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d248ac83-709d-488f-96a5-68f13fd53a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d248ac83-709d-488f-96a5-68f13fd53a8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2b7b865f-1c29-45d6-b254-190548ef7047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d248ac83-709d-488f-96a5-68f13fd53a8c" xlink:to="loc_us-gaap_AccountsPayableCurrent_2b7b865f-1c29-45d6-b254-190548ef7047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_612bac0a-ac3d-45fd-b1f9-f441d267206b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d248ac83-709d-488f-96a5-68f13fd53a8c" xlink:to="loc_us-gaap_DebtCurrent_612bac0a-ac3d-45fd-b1f9-f441d267206b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_7429c827-f3cd-4797-b56e-ccb68e82f723" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d248ac83-709d-488f-96a5-68f13fd53a8c" xlink:to="loc_us-gaap_NotesPayableCurrent_7429c827-f3cd-4797-b56e-ccb68e82f723" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BookOverdraftLiability_a166175f-2886-4198-96e6-dfb7221a9f75" xlink:href="hum-20231231.xsd#hum_BookOverdraftLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d248ac83-709d-488f-96a5-68f13fd53a8c" xlink:to="loc_hum_BookOverdraftLiability_a166175f-2886-4198-96e6-dfb7221a9f75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_447ef71b-4c43-450a-810f-f1eab5426bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d248ac83-709d-488f-96a5-68f13fd53a8c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_447ef71b-4c43-450a-810f-f1eab5426bf2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d145d43f-1092-45b1-8d8c-6f1ee0eac15d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d248ac83-709d-488f-96a5-68f13fd53a8c" xlink:to="loc_us-gaap_LiabilitiesCurrent_d145d43f-1092-45b1-8d8c-6f1ee0eac15d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9ed3f27a-787f-4a0c-a927-35720c46d92a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9ed3f27a-787f-4a0c-a927-35720c46d92a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b2d36da3-4585-43ee-99b3-2be376b36c34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b2d36da3-4585-43ee-99b3-2be376b36c34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_53f477b4-d47b-4979-9186-76aa677113e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:to="loc_us-gaap_Liabilities_53f477b4-d47b-4979-9186-76aa677113e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_79459295-144e-455d-9f7d-96dac5e0bd42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:to="loc_us-gaap_CommitmentsAndContingencies_79459295-144e-455d-9f7d-96dac5e0bd42" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:to="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a5a60fda-73bb-437c-b951-9d4d37ff2605" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:to="loc_us-gaap_PreferredStockValue_a5a60fda-73bb-437c-b951-9d4d37ff2605" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0ae2dd0d-de62-4727-8a65-a353d98fef50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:to="loc_us-gaap_CommonStockValue_0ae2dd0d-de62-4727-8a65-a353d98fef50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_20bb8705-ea1c-4e31-a181-7d2f033d7111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_20bb8705-ea1c-4e31-a181-7d2f033d7111" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7bd704e2-fa55-4607-946a-7c1360709a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7bd704e2-fa55-4607-946a-7c1360709a8b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1d413c19-6a0d-4fd4-b0f8-e2cbf56300a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1d413c19-6a0d-4fd4-b0f8-e2cbf56300a8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_b6ee371b-064f-4232-a4bd-5b74ce06da33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:to="loc_us-gaap_TreasuryStockCommonValue_b6ee371b-064f-4232-a4bd-5b74ce06da33" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dcd86040-905c-495c-b485-893042a35824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:to="loc_us-gaap_StockholdersEquity_dcd86040-905c-495c-b485-893042a35824" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_70e72cdb-edf0-4c7a-8748-dd9249e1a91e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_70e72cdb-edf0-4c7a-8748-dd9249e1a91e" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_7075b706-6a02-4dcf-8b29-efa23cbab084" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_7075b706-6a02-4dcf-8b29-efa23cbab084" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_d62c6174-8193-4391-9ba1-4bf7cab15f76" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_7075b706-6a02-4dcf-8b29-efa23cbab084" xlink:to="loc_srt_ConsolidatedEntitiesAxis_d62c6174-8193-4391-9ba1-4bf7cab15f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d62c6174-8193-4391-9ba1-4bf7cab15f76_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_d62c6174-8193-4391-9ba1-4bf7cab15f76" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d62c6174-8193-4391-9ba1-4bf7cab15f76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_e04dfbf4-f126-46eb-a486-cd3e4c41f1c4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_d62c6174-8193-4391-9ba1-4bf7cab15f76" xlink:to="loc_srt_ConsolidatedEntitiesDomain_e04dfbf4-f126-46eb-a486-cd3e4c41f1c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_6475e1a9-2637-41ed-be53-2495f7cf033c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_e04dfbf4-f126-46eb-a486-cd3e4c41f1c4" xlink:to="loc_srt_ParentCompanyMember_6475e1a9-2637-41ed-be53-2495f7cf033c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_384a70c0-3a7b-4e34-808b-6ec279978459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_384a70c0-3a7b-4e34-808b-6ec279978459" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_01f939e2-7e2d-4731-92a7-cc79d62c6fda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_01f939e2-7e2d-4731-92a7-cc79d62c6fda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_cafc3ced-2cbc-4196-aff0-bced62ce6760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_cafc3ced-2cbc-4196-aff0-bced62ce6760" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ec641615-2b78-4b1b-a492-2ff99e101ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ec641615-2b78-4b1b-a492-2ff99e101ba0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_80352ad1-c48e-42d6-ba7e-dc457d483334" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_80352ad1-c48e-42d6-ba7e-dc457d483334" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1919020e-9245-4517-96b6-4733937ef111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:to="loc_us-gaap_CommonStockSharesIssued_1919020e-9245-4517-96b6-4733937ef111" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_b588b40c-d265-4640-bca0-521dada236db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_b588b40c-d265-4640-bca0-521dada236db" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_969d3095-aa0f-49f2-9001-4bead8dd9835" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_969d3095-aa0f-49f2-9001-4bead8dd9835" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_331c44b8-e077-491e-ad50-cec89433cd93" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_969d3095-aa0f-49f2-9001-4bead8dd9835" xlink:to="loc_srt_ConsolidatedEntitiesAxis_331c44b8-e077-491e-ad50-cec89433cd93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_331c44b8-e077-491e-ad50-cec89433cd93_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_331c44b8-e077-491e-ad50-cec89433cd93" xlink:to="loc_srt_ConsolidatedEntitiesDomain_331c44b8-e077-491e-ad50-cec89433cd93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_36548ada-e31a-48e9-818d-ab2dfa3c794a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_331c44b8-e077-491e-ad50-cec89433cd93" xlink:to="loc_srt_ConsolidatedEntitiesDomain_36548ada-e31a-48e9-818d-ab2dfa3c794a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_ddb1096c-eba7-4129-9450-56f6443f2295" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_36548ada-e31a-48e9-818d-ab2dfa3c794a" xlink:to="loc_srt_ParentCompanyMember_ddb1096c-eba7-4129-9450-56f6443f2295" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_b0c9fce9-ff0a-4b8a-ac23-90152a91457c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_us-gaap_RevenuesAbstract_b0c9fce9-ff0a-4b8a-ac23-90152a91457c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ManagementFeesChargedToOperatingSubsidiaries_92b61f11-c110-4384-9d32-7c1a7e2e1268" xlink:href="hum-20231231.xsd#hum_ManagementFeesChargedToOperatingSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_b0c9fce9-ff0a-4b8a-ac23-90152a91457c" xlink:to="loc_hum_ManagementFeesChargedToOperatingSubsidiaries_92b61f11-c110-4384-9d32-7c1a7e2e1268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InvestmentAndOtherIncomeNet_fa27471c-f0b8-4b10-9b20-04404fffa08f" xlink:href="hum-20231231.xsd#hum_InvestmentAndOtherIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_b0c9fce9-ff0a-4b8a-ac23-90152a91457c" xlink:to="loc_hum_InvestmentAndOtherIncomeNet_fa27471c-f0b8-4b10-9b20-04404fffa08f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b1d99615-287b-4a47-91fa-81535b962222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_b0c9fce9-ff0a-4b8a-ac23-90152a91457c" xlink:to="loc_us-gaap_Revenues_b1d99615-287b-4a47-91fa-81535b962222" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4623aaa7-861f-4741-bf68-b9d86c966634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4623aaa7-861f-4741-bf68-b9d86c966634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_74efcfe1-5363-4b11-ba8a-d33c990cb3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4623aaa7-861f-4741-bf68-b9d86c966634" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_74efcfe1-5363-4b11-ba8a-d33c990cb3fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_49439831-7eca-432d-ae73-b8bbb261b59b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4623aaa7-861f-4741-bf68-b9d86c966634" xlink:to="loc_us-gaap_Depreciation_49439831-7eca-432d-ae73-b8bbb261b59b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_233fe462-88c0-4389-b29b-e30a932c58a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4623aaa7-861f-4741-bf68-b9d86c966634" xlink:to="loc_us-gaap_InterestExpense_233fe462-88c0-4389-b29b-e30a932c58a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_47e98238-94cb-4b5e-9a82-237dc186bd81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4623aaa7-861f-4741-bf68-b9d86c966634" xlink:to="loc_us-gaap_CostsAndExpenses_47e98238-94cb-4b5e-9a82-237dc186bd81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1af0be3f-10e2-4528-8cc5-11f9a0bbc16e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1af0be3f-10e2-4528-8cc5-11f9a0bbc16e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries_c7133cfc-f6aa-4d9d-9fae-7fdfa9a85419" xlink:href="hum-20231231.xsd#hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries_c7133cfc-f6aa-4d9d-9fae-7fdfa9a85419" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c8b44794-a702-44a0-b164-ca87f1e969cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c8b44794-a702-44a0-b164-ca87f1e969cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries_9a27a66c-5f8a-4727-94d9-2f635171b7dd" xlink:href="hum-20231231.xsd#hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries_9a27a66c-5f8a-4727-94d9-2f635171b7dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_EquityInNetEarningsOfSubsidiaries_fe20429f-4e6a-44fb-a7cd-82e8a260c07b" xlink:href="hum-20231231.xsd#hum_EquityInNetEarningsOfSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_hum_EquityInNetEarningsOfSubsidiaries_fe20429f-4e6a-44fb-a7cd-82e8a260c07b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_565dc812-3dda-4d28-a4cd-aa210c88af86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_565dc812-3dda-4d28-a4cd-aa210c88af86" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f0e4faab-18d9-45e2-9c34-72fd4f3070a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_us-gaap_ProfitLoss_f0e4faab-18d9-45e2-9c34-72fd4f3070a4" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7d31242b-c77c-4b6e-a841-136a52017e6e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_dc8c44db-378e-40ef-8594-1a830123a288" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7d31242b-c77c-4b6e-a841-136a52017e6e" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_dc8c44db-378e-40ef-8594-1a830123a288" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1ec0017f-8e2f-43a6-8c34-1ea71c5a687a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_dc8c44db-378e-40ef-8594-1a830123a288" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1ec0017f-8e2f-43a6-8c34-1ea71c5a687a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1ec0017f-8e2f-43a6-8c34-1ea71c5a687a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1ec0017f-8e2f-43a6-8c34-1ea71c5a687a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1ec0017f-8e2f-43a6-8c34-1ea71c5a687a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d1b1eed5-8cca-4d8f-84dc-2eaf844f1a30" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1ec0017f-8e2f-43a6-8c34-1ea71c5a687a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d1b1eed5-8cca-4d8f-84dc-2eaf844f1a30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_f7522d50-37be-4ae5-a36f-79e934d0ffa1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_d1b1eed5-8cca-4d8f-84dc-2eaf844f1a30" xlink:to="loc_srt_ParentCompanyMember_f7522d50-37be-4ae5-a36f-79e934d0ffa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1b5e19cf-5546-4cd7-99e2-0631ba5c498b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7d31242b-c77c-4b6e-a841-136a52017e6e" xlink:to="loc_us-gaap_NetIncomeLoss_1b5e19cf-5546-4cd7-99e2-0631ba5c498b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7d31242b-c77c-4b6e-a841-136a52017e6e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_39744d99-78c2-418e-9565-1e1e3a7d009b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_39744d99-78c2-418e-9565-1e1e3a7d009b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_edcb57f6-b18d-455e-baf1-c66a47cc7553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_edcb57f6-b18d-455e-baf1-c66a47cc7553" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_055d1ed4-e572-4ac9-b868-ff139e6d6dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_055d1ed4-e572-4ac9-b868-ff139e6d6dc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_80c95a39-133b-4e4d-a4bc-aea5902256e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_80c95a39-133b-4e4d-a4bc-aea5902256e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_b35effcf-5b8a-421e-a864-d70b6fea1ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_b35effcf-5b8a-421e-a864-d70b6fea1ad0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_ac3123f2-c009-455c-8969-a60a18cdf26d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_ac3123f2-c009-455c-8969-a60a18cdf26d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_88066031-8c52-4eb8-8143-107754de3278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_88066031-8c52-4eb8-8143-107754de3278" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments_918e7be8-0f26-4b5b-9cf6-983ebc0811a3" xlink:href="hum-20231231.xsd#hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7d31242b-c77c-4b6e-a841-136a52017e6e" xlink:to="loc_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments_918e7be8-0f26-4b5b-9cf6-983ebc0811a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_595f0716-6013-4f7b-a75a-befbd4f52296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7d31242b-c77c-4b6e-a841-136a52017e6e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_595f0716-6013-4f7b-a75a-befbd4f52296" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_262fb949-289c-4712-b661-ee89b9d42da2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_56ee6185-228d-4cad-860d-f57445e7a3cb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_262fb949-289c-4712-b661-ee89b9d42da2" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_56ee6185-228d-4cad-860d-f57445e7a3cb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_9f346d72-e72f-4a49-b253-40c18156f7a5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_56ee6185-228d-4cad-860d-f57445e7a3cb" xlink:to="loc_srt_ConsolidatedEntitiesAxis_9f346d72-e72f-4a49-b253-40c18156f7a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_9f346d72-e72f-4a49-b253-40c18156f7a5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_9f346d72-e72f-4a49-b253-40c18156f7a5" xlink:to="loc_srt_ConsolidatedEntitiesDomain_9f346d72-e72f-4a49-b253-40c18156f7a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_aa9c4494-b070-45a1-999f-87f71a338de0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_9f346d72-e72f-4a49-b253-40c18156f7a5" xlink:to="loc_srt_ConsolidatedEntitiesDomain_aa9c4494-b070-45a1-999f-87f71a338de0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_38605569-e434-4942-b015-a0cade767a85" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_aa9c4494-b070-45a1-999f-87f71a338de0" xlink:to="loc_srt_ParentCompanyMember_38605569-e434-4942-b015-a0cade767a85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2aa91fb9-5e39-4bd8-88c8-fcfca40f509b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_262fb949-289c-4712-b661-ee89b9d42da2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2aa91fb9-5e39-4bd8-88c8-fcfca40f509b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_262fb949-289c-4712-b661-ee89b9d42da2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8c13c686-ccac-489f-89cb-ebc220364c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8c13c686-ccac-489f-89cb-ebc220364c1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CapitalContributionsToOperatingSubsidiaries_2a75f0a7-142b-4e6d-8ba2-75552e1117ab" xlink:href="hum-20231231.xsd#hum_CapitalContributionsToOperatingSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:to="loc_hum_CapitalContributionsToOperatingSubsidiaries_2a75f0a7-142b-4e6d-8ba2-75552e1117ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7ff6a4f7-2d59-4b43-817a-0ff46cd2172a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7ff6a4f7-2d59-4b43-817a-0ff46cd2172a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4e02efcc-23ec-417c-9a8e-b82fae94da53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4e02efcc-23ec-417c-9a8e-b82fae94da53" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_11ace372-4886-4090-b378-58d615e24b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_11ace372-4886-4090-b378-58d615e24b6f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_932c3ee4-90d7-4967-b11b-59b9bc849892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_932c3ee4-90d7-4967-b11b-59b9bc849892" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fe4fdb89-18ae-4435-a79c-53f896a2cddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fe4fdb89-18ae-4435-a79c-53f896a2cddd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_262fb949-289c-4712-b661-ee89b9d42da2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_10a7ee60-e2aa-415c-b9c7-a886b35a63ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_10a7ee60-e2aa-415c-b9c7-a886b35a63ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_730828fb-bf22-4798-abed-0679d5a12bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_730828fb-bf22-4798-abed-0679d5a12bf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_eb37bf0c-ab3f-4039-9858-8b80962bab42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfCommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_eb37bf0c-ab3f-4039-9858-8b80962bab42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_9e54461d-f35d-4fa9-9e0a-73cedfe44936" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_9e54461d-f35d-4fa9-9e0a-73cedfe44936" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_b922b09d-8a6a-4944-8943-9ffcb2a69bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_b922b09d-8a6a-4944-8943-9ffcb2a69bc3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInBookOverdrafts_160106f1-1b3d-4a59-8bb8-cfc7a129d465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInBookOverdrafts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_IncreaseDecreaseInBookOverdrafts_160106f1-1b3d-4a59-8bb8-cfc7a129d465" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f4cc872-cfbe-4ca4-a91c-1eace1039e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f4cc872-cfbe-4ca4-a91c-1eace1039e4c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_c5f08b09-ad12-4936-b93d-45620c7d23c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_PaymentsOfDividends_c5f08b09-ad12-4936-b93d-45620c7d23c1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ProceedsFromStockOptionsExercisedAndOther_67754aa3-9591-4bea-9703-be6bea76808f" xlink:href="hum-20231231.xsd#hum_ProceedsFromStockOptionsExercisedAndOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_hum_ProceedsFromStockOptionsExercisedAndOther_67754aa3-9591-4bea-9703-be6bea76808f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_310be386-afa4-4dbe-a92e-1c1ad450cb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_310be386-afa4-4dbe-a92e-1c1ad450cb8e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b1064fde-dd73-4117-925f-6cadae4f7476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_262fb949-289c-4712-b661-ee89b9d42da2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b1064fde-dd73-4117-925f-6cadae4f7476" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4dfdc63-d671-46e2-b9b0-9995877f2c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_262fb949-289c-4712-b661-ee89b9d42da2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4dfdc63-d671-46e2-b9b0-9995877f2c6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef97f5ee-61e8-421f-acef-6b2307c1e95f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>hum-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:7bfbafa3-a477-4092-82f1-790bd65455d7,g:6b53bb4a-2282-4b95-aa2c-e78c6730e17d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_9dff7480-eac8-4017-93ff-c1f43d9eb93c_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of investment securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_49f6126f-8eff-480e-9f9b-8f2be45ecca1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of investment securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_cd5d39e5-a753-4e60-90ac-c476a2102090_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3e8aa2ae-1025-489b-a5a3-bec338352d35_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements_344f8d47-4994-48aa-bffa-d5b783f95821_negatedTotalLabel_en-US" xlink:label="lab_hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net reimbursements (payments)</link:label>
    <link:label id="lab_hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements_label_en-US" xlink:label="lab_hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidy And Discount Payments In Excess Of Reimbursements</link:label>
    <link:label id="lab_hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements_documentation_en-US" xlink:label="lab_hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidy And Discount Payments In Excess Of Reimbursements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements" xlink:href="hum-20231231.xsd#hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements" xlink:to="lab_hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9c31be61-241e-49b9-a1ba-ef93e7bf6e1c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of effect of businesses acquired and dispositions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ce525c51-9702-49fe-b18e-28ae1abb3a15_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cc61b841-f455-4f2a-b89b-05f4bcae773d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_72c47d59-96aa-44ad-8f34-df356ac1e40f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod_54175998-2a24-433e-bac8-79dc859c92b9_terseLabel_en-US" xlink:label="lab_hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated vesting, termination of employment period</link:label>
    <link:label id="lab_hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod_label_en-US" xlink:label="lab_hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Termination Of Employment Period</link:label>
    <link:label id="lab_hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod_documentation_en-US" xlink:label="lab_hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Termination Of Employment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod" xlink:href="hum-20231231.xsd#hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod" xlink:to="lab_hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_06aa94bf-0c01-4475-b663-53b0ed38c9bd_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ReinsuranceTable_19700ce0-977f-4fe1-9b21-1b358d7d6509_terseLabel_en-US" xlink:label="lab_hum_ReinsuranceTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance [Table]</link:label>
    <link:label id="lab_hum_ReinsuranceTable_label_en-US" xlink:label="lab_hum_ReinsuranceTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance [Table]</link:label>
    <link:label id="lab_hum_ReinsuranceTable_documentation_en-US" xlink:label="lab_hum_ReinsuranceTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ReinsuranceTable" xlink:href="hum-20231231.xsd#hum_ReinsuranceTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ReinsuranceTable" xlink:to="lab_hum_ReinsuranceTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_0c0acbfd-de14-4e6c-a926-422d3474f0d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of short-term borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_51f56e8a-9082-4d70-b707-8f5708469679_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of short-term borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_caaef881-b6d6-4099-b8d0-537121388f15_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ProtectiveLifeInsuranceCompanyMember_a99155cd-6179-4856-a20c-89c396e0e562_verboseLabel_en-US" xlink:label="lab_hum_ProtectiveLifeInsuranceCompanyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Protective Life Insurance Company</link:label>
    <link:label id="lab_hum_ProtectiveLifeInsuranceCompanyMember_label_en-US" xlink:label="lab_hum_ProtectiveLifeInsuranceCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Protective Life Insurance Company [Member]</link:label>
    <link:label id="lab_hum_ProtectiveLifeInsuranceCompanyMember_documentation_en-US" xlink:label="lab_hum_ProtectiveLifeInsuranceCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Protective Life Insurance Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ProtectiveLifeInsuranceCompanyMember" xlink:href="hum-20231231.xsd#hum_ProtectiveLifeInsuranceCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ProtectiveLifeInsuranceCompanyMember" xlink:to="lab_hum_ProtectiveLifeInsuranceCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_8f95cf54-b499-45b2-bbbe-9cb3cb9ff20e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_d443733a-9f0d-447f-bf54-d32e85d448ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investment Securities Classified as Current and Long-Term</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_TermLoanDueOctober2023Member_83db8e74-e761-4596-8fd1-fdc756816d4e_terseLabel_en-US" xlink:label="lab_hum_TermLoanDueOctober2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Due October 2023</link:label>
    <link:label id="lab_hum_TermLoanDueOctober2023Member_label_en-US" xlink:label="lab_hum_TermLoanDueOctober2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Due October 2023 [Member]</link:label>
    <link:label id="lab_hum_TermLoanDueOctober2023Member_documentation_en-US" xlink:label="lab_hum_TermLoanDueOctober2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Due October 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TermLoanDueOctober2023Member" xlink:href="hum-20231231.xsd#hum_TermLoanDueOctober2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_TermLoanDueOctober2023Member" xlink:to="lab_hum_TermLoanDueOctober2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_MedicareStandAlonePrescriptionDrugPlanMember_af5fac8d-49ed-4509-a59c-3d624a8d7d07_terseLabel_en-US" xlink:label="lab_hum_MedicareStandAlonePrescriptionDrugPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare stand-alone PDP</link:label>
    <link:label id="lab_hum_MedicareStandAlonePrescriptionDrugPlanMember_label_en-US" xlink:label="lab_hum_MedicareStandAlonePrescriptionDrugPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Stand Alone Prescription Drug Plan [Member]</link:label>
    <link:label id="lab_hum_MedicareStandAlonePrescriptionDrugPlanMember_documentation_en-US" xlink:label="lab_hum_MedicareStandAlonePrescriptionDrugPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Stand Alone Prescription Drug Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareStandAlonePrescriptionDrugPlanMember" xlink:href="hum-20231231.xsd#hum_MedicareStandAlonePrescriptionDrugPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_MedicareStandAlonePrescriptionDrugPlanMember" xlink:to="lab_hum_MedicareStandAlonePrescriptionDrugPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_1629d22d-452e-4ccf-909a-7c3b5c9dc400_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_23dfcb97-f852-4ebc-8ab0-03539b3b1f6b_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance at January&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_4c9e4e2c-18ed-48da-9415-043f42874c4a_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December&#160;31</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_TRICAREManagedCareSupportContractEffective2024Member_1c676277-c15d-4c55-a0c5-eecf7eb681d0_terseLabel_en-US" xlink:label="lab_hum_TRICAREManagedCareSupportContractEffective2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE Managed Care Support Contract, Effective 2024</link:label>
    <link:label id="lab_hum_TRICAREManagedCareSupportContractEffective2024Member_label_en-US" xlink:label="lab_hum_TRICAREManagedCareSupportContractEffective2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE Managed Care Support Contract, Effective 2024 [Member]</link:label>
    <link:label id="lab_hum_TRICAREManagedCareSupportContractEffective2024Member_documentation_en-US" xlink:label="lab_hum_TRICAREManagedCareSupportContractEffective2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE Managed Care Support Contract, Effective 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREManagedCareSupportContractEffective2024Member" xlink:href="hum-20231231.xsd#hum_TRICAREManagedCareSupportContractEffective2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_TRICAREManagedCareSupportContractEffective2024Member" xlink:to="lab_hum_TRICAREManagedCareSupportContractEffective2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A3.95PercentSeniorNotesDueAugust2049Member_7bdba129-95a1-499d-aa49-b0a095ff00d0_terseLabel_en-US" xlink:label="lab_hum_A3.95PercentSeniorNotesDueAugust2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million, 3.950% due August 15, 2049</link:label>
    <link:label id="lab_hum_A3.95PercentSeniorNotesDueAugust2049Member_label_en-US" xlink:label="lab_hum_A3.95PercentSeniorNotesDueAugust2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95 Percent Senior Notes Due August 2049 [Member]</link:label>
    <link:label id="lab_hum_A3.95PercentSeniorNotesDueAugust2049Member_documentation_en-US" xlink:label="lab_hum_A3.95PercentSeniorNotesDueAugust2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A 3.95 Percent Senior Notes Due August 2049 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3.95PercentSeniorNotesDueAugust2049Member" xlink:href="hum-20231231.xsd#hum_A3.95PercentSeniorNotesDueAugust2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A3.95PercentSeniorNotesDueAugust2049Member" xlink:to="lab_hum_A3.95PercentSeniorNotesDueAugust2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_27cffd4d-264d-4c08-81a0-9f028a79dafa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member_338638e3-0d90-43e6-a197-03fe491fe9e5_terseLabel_en-US" xlink:label="lab_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.70 Percent Senior Notes Due March 2026 And 5.50 Percent Senior Notes Due March 2053</link:label>
    <link:label id="lab_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member_label_en-US" xlink:label="lab_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.70 Percent Senior Notes Due March 2026 And 5.50 Percent Senior Notes Due March 2053 [Member]</link:label>
    <link:label id="lab_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member_documentation_en-US" xlink:label="lab_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.70 Percent Senior Notes Due March 2026 And 5.50 Percent Senior Notes Due March 2053</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member" xlink:href="hum-20231231.xsd#hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member" xlink:to="lab_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_16105972-bd08-4815-9c12-b36f80b255e7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_741a8ecf-af40-446a-abc2-4f53621e9e2d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod_94050f6f-d007-49e7-ab4e-25d424cb8987_terseLabel_en-US" xlink:label="lab_us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount outstanding during period</link:label>
    <link:label id="lab_us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod_label_en-US" xlink:label="lab_us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Maximum Amount Outstanding During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod" xlink:to="lab_us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_fa40d14e-42a7-45cb-97c0-24b1f099b002_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_54b1f4e7-f8ae-4419-aeb5-36fe1baa303a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock_f4337821-7ee6-43ed-9d6c-82de78ea2ddc_terseLabel_en-US" xlink:label="lab_hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits Payable and Benefits Expense Recognition</link:label>
    <link:label id="lab_hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock_label_en-US" xlink:label="lab_hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits Payable And Benefit Expense Recognition Policy [Policy Text Block]</link:label>
    <link:label id="lab_hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes the entity's accounting policies, methodologies, and assumptions for estimating its liability as of the balance sheet date for the cost of settling reported and unreported claims.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock" xlink:href="hum-20231231.xsd#hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock" xlink:to="lab_hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_GovernmentAndHealthPlanMemberSubsidiesAmount_fa47e92d-4a3b-4da6-8b63-353f48c062f2_terseLabel_en-US" xlink:label="lab_hum_GovernmentAndHealthPlanMemberSubsidiesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member co-share amounts and government subsidies</link:label>
    <link:label id="lab_hum_GovernmentAndHealthPlanMemberSubsidiesAmount_label_en-US" xlink:label="lab_hum_GovernmentAndHealthPlanMemberSubsidiesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government And Health Plan Member Subsidies Amount</link:label>
    <link:label id="lab_hum_GovernmentAndHealthPlanMemberSubsidiesAmount_documentation_en-US" xlink:label="lab_hum_GovernmentAndHealthPlanMemberSubsidiesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of member co-share amounts and government subsidies that are excluded from benefits expense because the health plans do not bear responsibility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GovernmentAndHealthPlanMemberSubsidiesAmount" xlink:href="hum-20231231.xsd#hum_GovernmentAndHealthPlanMemberSubsidiesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_GovernmentAndHealthPlanMemberSubsidiesAmount" xlink:to="lab_hum_GovernmentAndHealthPlanMemberSubsidiesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_b0bd4561-93af-4402-90a4-7e3f932bffb6_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_61fac2c1-bc30-4d1b-9882-4df04be412f7_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of financial liability</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_735eb9f0-aa0a-4c05-8779-ac40902d3bf4_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_017bbc94-de3e-4fab-9a8b-029cc32b5505_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_February2021ShareRepurchaseAuthorizationMember_6a5ad254-ee12-4fa4-976b-e34e6fc00eb5_terseLabel_en-US" xlink:label="lab_hum_February2021ShareRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February 2021 Authorization</link:label>
    <link:label id="lab_hum_February2021ShareRepurchaseAuthorizationMember_label_en-US" xlink:label="lab_hum_February2021ShareRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February 2021 Share Repurchase Authorization [Member]</link:label>
    <link:label id="lab_hum_February2021ShareRepurchaseAuthorizationMember_documentation_en-US" xlink:label="lab_hum_February2021ShareRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February 2021 Share Repurchase Authorization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_February2021ShareRepurchaseAuthorizationMember" xlink:href="hum-20231231.xsd#hum_February2021ShareRepurchaseAuthorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_February2021ShareRepurchaseAuthorizationMember" xlink:to="lab_hum_February2021ShareRepurchaseAuthorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_7d52b202-3e95-4078-9636-adf2f83ae062_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $1 par; 10,000,000 shares authorized; none issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_27873f0d-7719-429f-b575-084a41f74140_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditSpreadOptionMember_1c7375ab-c571-4784-98d1-f7b5622452ae_terseLabel_en-US" xlink:label="lab_us-gaap_CreditSpreadOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit spread</link:label>
    <link:label id="lab_us-gaap_CreditSpreadOptionMember_label_en-US" xlink:label="lab_us-gaap_CreditSpreadOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Spread Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditSpreadOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditSpreadOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditSpreadOptionMember" xlink:to="lab_us-gaap_CreditSpreadOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_307d4e65-845c-485d-9b65-d0173b162c61_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0973d34b-ffc2-4ff0-94ed-b319831f7036_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_FederalGovernmentMember_03df1cf3-4271-46f8-9ce1-a172e910c8c9_terseLabel_en-US" xlink:label="lab_hum_FederalGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal government contracts</link:label>
    <link:label id="lab_hum_FederalGovernmentMember_label_en-US" xlink:label="lab_hum_FederalGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Government [Member]</link:label>
    <link:label id="lab_hum_FederalGovernmentMember_documentation_en-US" xlink:label="lab_hum_FederalGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FederalGovernmentMember" xlink:href="hum-20231231.xsd#hum_FederalGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_FederalGovernmentMember" xlink:to="lab_hum_FederalGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_cdebeb36-33ef-4ba6-bc41-4f2c378064b3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_fa1f3de0-f964-4826-8f25-20170b835739_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligations in 2028</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain_bdb31491-9dde-4e5b-8924-5ded180d6406_negatedTerseLabel_en-US" xlink:label="lab_hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-taxable KAH gain</link:label>
    <link:label id="lab_hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain_label_en-US" xlink:label="lab_hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Non-Taxable KAH Gain</link:label>
    <link:label id="lab_hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain_documentation_en-US" xlink:label="lab_hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Non-Taxable KAH Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain" xlink:href="hum-20231231.xsd#hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain" xlink:to="lab_hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3f6c2727-cbcf-4691-aa62-7f5a975f1c0e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_2e1d07db-7e07-417c-b1f6-e5a86d586e78_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_PaymentsForProceedsFromContractDeposits_a1044261-a3f2-4a44-b51e-6bb5066b5fa4_negatedTerseLabel_en-US" xlink:label="lab_hum_PaymentsForProceedsFromContractDeposits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipts (withdrawals) from contract deposits, net</link:label>
    <link:label id="lab_hum_PaymentsForProceedsFromContractDeposits_label_en-US" xlink:label="lab_hum_PaymentsForProceedsFromContractDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Contract Deposits</link:label>
    <link:label id="lab_hum_PaymentsForProceedsFromContractDeposits_documentation_en-US" xlink:label="lab_hum_PaymentsForProceedsFromContractDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Contract Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PaymentsForProceedsFromContractDeposits" xlink:href="hum-20231231.xsd#hum_PaymentsForProceedsFromContractDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_PaymentsForProceedsFromContractDeposits" xlink:to="lab_hum_PaymentsForProceedsFromContractDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a7d68424-4b97-4736-bc94-71b575b340b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_1cb8521d-2456-4ae8-9eca-312ec41505fe_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8e8cb9fa-92a6-4423-b3ae-f8d56a920ffc_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_c2e4e092-4e55-4fcb-a92b-66708586a13c_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A3125PercentSeniorNotesDueAugust2029Member_baa44477-363c-48b0-8ca1-1ca967eee9a7_terseLabel_en-US" xlink:label="lab_hum_A3125PercentSeniorNotesDueAugust2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.125 Percent Senior Notes Due August 2029</link:label>
    <link:label id="lab_hum_A3125PercentSeniorNotesDueAugust2029Member_label_en-US" xlink:label="lab_hum_A3125PercentSeniorNotesDueAugust2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.125 Percent Senior Notes Due August 2029 [Member]</link:label>
    <link:label id="lab_hum_A3125PercentSeniorNotesDueAugust2029Member_documentation_en-US" xlink:label="lab_hum_A3125PercentSeniorNotesDueAugust2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A 3.125 Percent Senior Notes Due August 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3125PercentSeniorNotesDueAugust2029Member" xlink:href="hum-20231231.xsd#hum_A3125PercentSeniorNotesDueAugust2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A3125PercentSeniorNotesDueAugust2029Member" xlink:to="lab_hum_A3125PercentSeniorNotesDueAugust2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_07af84a5-26fc-4083-951c-22262c4d0d1f_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other intangible assets, cost</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentContractsConcentrationRiskMember_2bf7c51a-aad9-4922-aef4-567043481d1a_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government contracts concentration risk</link:label>
    <link:label id="lab_us-gaap_GovernmentContractsConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Contracts Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:to="lab_us-gaap_GovernmentContractsConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_d34f5750-8b44-496c-8525-c23048bb7ed4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember_1b9db9ad-2b5e-4e00-9fde-4433f09edcae_terseLabel_en-US" xlink:label="lab_hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Existing Cohorts</link:label>
    <link:label id="lab_hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember_label_en-US" xlink:label="lab_hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Welsh Carson Anderson And Stowe, Cohort Of Clinics Two [Member]</link:label>
    <link:label id="lab_hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember_documentation_en-US" xlink:label="lab_hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Welsh Carson Anderson And Stowe, Cohort Of Clinics Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember" xlink:href="hum-20231231.xsd#hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember" xlink:to="lab_hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_02e62ed0-4949-4122-8e1a-9e326207ff72_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTMENT SECURITIES</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_12407ed1-729d-45f6-b555-80a15e30e06f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears_178ecce1-8c34-446e-ad76-f5531f6aa387_terseLabel_en-US" xlink:label="lab_hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable&#160;medical&#160;claims&#160;reserve development related to prior fiscal years</link:label>
    <link:label id="lab_hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears_label_en-US" xlink:label="lab_hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable Medical Claims Reserve Development Related To Prior Fiscal Years</link:label>
    <link:label id="lab_hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears_documentation_en-US" xlink:label="lab_hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Favorable medical claims reserve development related to prior fiscal years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears" xlink:href="hum-20231231.xsd#hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears" xlink:to="lab_hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_cc755ee8-2a46-4722-87aa-2ea90f34dfbb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Earnings Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A370PercentSeniorNotesDueMarch2029Member_420bb067-1bc3-45b2-acd2-be59fd6adfbd_terseLabel_en-US" xlink:label="lab_hum_A370PercentSeniorNotesDueMarch2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$750 million, 3.700% due March 23, 2029</link:label>
    <link:label id="lab_hum_A370PercentSeniorNotesDueMarch2029Member_label_en-US" xlink:label="lab_hum_A370PercentSeniorNotesDueMarch2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70 Percent Senior Notes Due March 2029 [Member]</link:label>
    <link:label id="lab_hum_A370PercentSeniorNotesDueMarch2029Member_documentation_en-US" xlink:label="lab_hum_A370PercentSeniorNotesDueMarch2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70 Percent Senior Notes Due March 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A370PercentSeniorNotesDueMarch2029Member" xlink:href="hum-20231231.xsd#hum_A370PercentSeniorNotesDueMarch2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A370PercentSeniorNotesDueMarch2029Member" xlink:to="lab_hum_A370PercentSeniorNotesDueMarch2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_MilitaryServiceMember_6e1dcc5b-dfe3-44df-a360-beb75e9a7f90_terseLabel_en-US" xlink:label="lab_hum_MilitaryServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Military services</link:label>
    <link:label id="lab_hum_MilitaryServiceMember_label_en-US" xlink:label="lab_hum_MilitaryServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Military Service [Member]</link:label>
    <link:label id="lab_hum_MilitaryServiceMember_documentation_en-US" xlink:label="lab_hum_MilitaryServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Military Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MilitaryServiceMember" xlink:href="hum-20231231.xsd#hum_MilitaryServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_MilitaryServiceMember" xlink:to="lab_hum_MilitaryServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CededPremiumsWritten_10a924b3-e5b2-4973-ac9c-c9ba5daf57f7_terseLabel_en-US" xlink:label="lab_us-gaap_CededPremiumsWritten" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums ceded</link:label>
    <link:label id="lab_us-gaap_CededPremiumsWritten_label_en-US" xlink:label="lab_us-gaap_CededPremiumsWritten" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ceded Premiums Written</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsWritten" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededPremiumsWritten"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CededPremiumsWritten" xlink:to="lab_us-gaap_CededPremiumsWritten" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6c135389-463c-4c26-82a6-72063915c77c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3b3aeaaf-571a-4d68-9055-8370975dbdb5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_f0972578-0e4f-41a8-929b-958212db1cee_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_678be21a-0697-49bb-a35b-42480b07dd5e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d812bc30-20d7-4e92-8a75-b528bfee6464_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_2585c8f2-176e-4f5d-8770-55750717a54d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax assets, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_26ef31bc-41f6-4237-9609-ea6387c8a001_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_650e068e-19c4-4d9f-b330-40c383be2ae8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ed111038-88fc-41fb-86e9-e23f2617a9c2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_08ea4288-3505-4e43-ad03-cc8570eefd38_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6983b60d-1c02-47d6-b453-01910c1d09ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grants assuming all stock options or restricted stock are granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_StateBasedContractsAndOtherMember_cb47f12c-5fdb-4e32-bb58-342921476a14_terseLabel_en-US" xlink:label="lab_hum_StateBasedContractsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State-based contracts and other</link:label>
    <link:label id="lab_hum_StateBasedContractsAndOtherMember_label_en-US" xlink:label="lab_hum_StateBasedContractsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State-Based Contracts and Other [Member]</link:label>
    <link:label id="lab_hum_StateBasedContractsAndOtherMember_documentation_en-US" xlink:label="lab_hum_StateBasedContractsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State-Based Contracts and Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_StateBasedContractsAndOtherMember" xlink:href="hum-20231231.xsd#hum_StateBasedContractsAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_StateBasedContractsAndOtherMember" xlink:to="lab_hum_StateBasedContractsAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_22d6f0ab-f9c1-4be9-ade3-1f9a3da3b060_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8c6d8319-8be9-4948-b292-1825354a4f91_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_EquityInNetEarningsOfSubsidiaries_06c94626-7248-48b3-ab82-4faf69a17ccc_terseLabel_en-US" xlink:label="lab_hum_EquityInNetEarningsOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net earnings of subsidiaries</link:label>
    <link:label id="lab_hum_EquityInNetEarningsOfSubsidiaries_label_en-US" xlink:label="lab_hum_EquityInNetEarningsOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity In Net Earnings Of Subsidiaries</link:label>
    <link:label id="lab_hum_EquityInNetEarningsOfSubsidiaries_documentation_en-US" xlink:label="lab_hum_EquityInNetEarningsOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net earnings of subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_EquityInNetEarningsOfSubsidiaries" xlink:href="hum-20231231.xsd#hum_EquityInNetEarningsOfSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_EquityInNetEarningsOfSubsidiaries" xlink:to="lab_hum_EquityInNetEarningsOfSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_2e9f9fd3-4f53-4a57-94d5-dc15c4f74f98_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_37b6119c-41a9-4169-bf7f-e3aa6db63712_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_468c3bd2-9627-4074-8be6-3b2170ea2f74_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_f86af47a-5e27-4be8-8f28-7400dd7d7cd5_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_MedicareLicensesAndCertificatesOfNeedMember_20c9db87-0c87-4ac7-a49d-7d1a53cbb044_terseLabel_en-US" xlink:label="lab_hum_MedicareLicensesAndCertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Licenses And Certificates Of Need</link:label>
    <link:label id="lab_hum_MedicareLicensesAndCertificatesOfNeedMember_label_en-US" xlink:label="lab_hum_MedicareLicensesAndCertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Licenses And Certificates Of Need [Member]</link:label>
    <link:label id="lab_hum_MedicareLicensesAndCertificatesOfNeedMember_documentation_en-US" xlink:label="lab_hum_MedicareLicensesAndCertificatesOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Licenses And Certificates Of Need [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareLicensesAndCertificatesOfNeedMember" xlink:href="hum-20231231.xsd#hum_MedicareLicensesAndCertificatesOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_MedicareLicensesAndCertificatesOfNeedMember" xlink:to="lab_hum_MedicareLicensesAndCertificatesOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_1413e864-8407-4228-bb49-3f9ccedd69c8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_83c72237-249f-42d6-9841-c99fdbb7eacc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceLineItems_ccbe2eaa-e373-43f2-80c9-bca0fbccc6c1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Reinsurance [Line Items]</link:label>
    <link:label id="lab_us-gaap_EffectsOfReinsuranceLineItems_label_en-US" xlink:label="lab_us-gaap_EffectsOfReinsuranceLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Reinsurance [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectsOfReinsuranceLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems" xlink:to="lab_us-gaap_EffectsOfReinsuranceLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_ecbd03d5-0357-40c6-8ad0-183acec5503d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Awards Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_3c785b82-1c29-4731-92a8-898d770e5214_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1331ab68-ac2d-4176-af07-bb5773177a04_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible executive compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_bb00f1b7-638b-4949-a632-4e5e3a99dc46_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_63c55503-30cb-43e0-9447-409593e332b4_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_601dfa53-6e90-42f0-ba4a-29245ce29413_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract_590707d6-300b-4b41-bb41-bae46e02e5c1_terseLabel_en-US" xlink:label="lab_hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gains or losses:</link:label>
    <link:label id="lab_hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract_label_en-US" xlink:label="lab_hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) [Abstract]</link:label>
    <link:label id="lab_hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract_documentation_en-US" xlink:label="lab_hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract" xlink:href="hum-20231231.xsd#hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract" xlink:to="lab_hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_15328404-f7fb-457c-ad8d-cbe5ebe17d6f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_baee76ef-135f-46d5-bf9b-51fcf0feacc6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments_a915b3a5-1663-40ae-b65f-4c64b19da8b9_terseLabel_en-US" xlink:label="lab_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to equity method investments</link:label>
    <link:label id="lab_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments_c8cd1c82-bcb0-4631-bb79-0002ea46e0a7_verboseLabel_en-US" xlink:label="lab_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to equity method investments</link:label>
    <link:label id="lab_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments_label_en-US" xlink:label="lab_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable To Equity Method Investments</link:label>
    <link:label id="lab_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments_documentation_en-US" xlink:label="lab_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable To Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments" xlink:href="hum-20231231.xsd#hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments" xlink:to="lab_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries_2a5ae805-241a-44c1-b22d-d5d57f57626f_terseLabel_en-US" xlink:label="lab_hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of TRICARE Managed Care Support Contract beneficiaries</link:label>
    <link:label id="lab_hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries_label_en-US" xlink:label="lab_hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of TRICARE Managed Care Support Contract Beneficiaries</link:label>
    <link:label id="lab_hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries_documentation_en-US" xlink:label="lab_hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of TRICARE Managed Care Support Contract Beneficiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries" xlink:href="hum-20231231.xsd#hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries" xlink:to="lab_hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_8cfbed69-218a-493f-a252-8185d2275183_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_Expenses_a7d6d080-92d1-47ec-b193-fa9271e0521a_terseLabel_en-US" xlink:label="lab_hum_Expenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_hum_Expenses_label_en-US" xlink:label="lab_hum_Expenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_hum_Expenses_documentation_en-US" xlink:label="lab_hum_Expenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_Expenses" xlink:href="hum-20231231.xsd#hum_Expenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_Expenses" xlink:to="lab_hum_Expenses" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A5.88PercentSeniorNotesDueMarch2033Member_6e62f670-a7a3-4475-909f-f66b5815ec48_terseLabel_en-US" xlink:label="lab_hum_A5.88PercentSeniorNotesDueMarch2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$750 million, 5.875% due March 1, 2033</link:label>
    <link:label id="lab_hum_A5.88PercentSeniorNotesDueMarch2033Member_label_en-US" xlink:label="lab_hum_A5.88PercentSeniorNotesDueMarch2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.88 Percent Senior Notes Due March 2033 [Member]</link:label>
    <link:label id="lab_hum_A5.88PercentSeniorNotesDueMarch2033Member_documentation_en-US" xlink:label="lab_hum_A5.88PercentSeniorNotesDueMarch2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.88 Percent Senior Notes Due March 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5.88PercentSeniorNotesDueMarch2033Member" xlink:href="hum-20231231.xsd#hum_A5.88PercentSeniorNotesDueMarch2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A5.88PercentSeniorNotesDueMarch2033Member" xlink:to="lab_hum_A5.88PercentSeniorNotesDueMarch2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_652acbf7-900e-4550-bc7e-b09f037c8bc4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_1294e197-eb13-46fe-bac0-d8da54c55871_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_4a12f1fa-eb23-474b-a47d-22b2bf6ed450_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_8a55590b-045f-4834-8f30-b6df07fdc723_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold_b71d6c2a-cb19-4d3a-a52b-6805bf957c29_terseLabel_en-US" xlink:label="lab_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest to be sold</link:label>
    <link:label id="lab_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold_label_en-US" xlink:label="lab_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Equity Interest Sold</link:label>
    <link:label id="lab_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold_documentation_en-US" xlink:label="lab_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Equity Interest Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold" xlink:href="hum-20231231.xsd#hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold" xlink:to="lab_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DepreciationAndAmortizationClassifiedAsBenefitExpense_10dcdb60-1507-4060-aa3c-efdd34433944_terseLabel_en-US" xlink:label="lab_hum_DepreciationAndAmortizationClassifiedAsBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization classified as benefit expense</link:label>
    <link:label id="lab_hum_DepreciationAndAmortizationClassifiedAsBenefitExpense_label_en-US" xlink:label="lab_hum_DepreciationAndAmortizationClassifiedAsBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization Classified As Benefit Expense</link:label>
    <link:label id="lab_hum_DepreciationAndAmortizationClassifiedAsBenefitExpense_documentation_en-US" xlink:label="lab_hum_DepreciationAndAmortizationClassifiedAsBenefitExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense that has been reclassified to be included with benefit expenses. The reclassification is the result of depreciation and amortization expense associated primarily from the delivery of pharmacy services by our wholly-owned pharmacy business included in our Healthcare Services segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DepreciationAndAmortizationClassifiedAsBenefitExpense" xlink:href="hum-20231231.xsd#hum_DepreciationAndAmortizationClassifiedAsBenefitExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DepreciationAndAmortizationClassifiedAsBenefitExpense" xlink:to="lab_hum_DepreciationAndAmortizationClassifiedAsBenefitExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_0b428852-12dd-4d2e-b084-62bb146d211a_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum_49fb5924-0689-46cb-9cda-ed1a43233d97_terseLabel_en-US" xlink:label="lab_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt to capitalization percentage, maximum</link:label>
    <link:label id="lab_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum_label_en-US" xlink:label="lab_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt To Capitalization Percentage, Maximum</link:label>
    <link:label id="lab_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum_documentation_en-US" xlink:label="lab_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt To Capitalization Percentage, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum" xlink:href="hum-20231231.xsd#hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum" xlink:to="lab_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_8634019e-5608-41e7-9b1c-1775bbd3c469_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits</link:label>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_label_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Net, Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare" xlink:to="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_82e2e993-1b6f-45e7-bcde-2465707217c6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of antidilutive stock options and restricted stock&#160;awards excluded from computation (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_dbb4133a-056d-4580-b4b0-6ff005d880bb_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7982bdd5-24f3-4e95-92a3-21feb012ecea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceContractAxis_2817aa7c-31c4-4106-82f8-ef711360081b_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceContractAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Policy, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ReinsuranceContractAxis_label_en-US" xlink:label="lab_us-gaap_ReinsuranceContractAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Contract [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceContractAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceContractAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceContractAxis" xlink:to="lab_us-gaap_ReinsuranceContractAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_dac16f0b-cfb7-4ae1-a4ff-c33b7884b77c_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStock_3197d5bf-00b6-4ff0-9f9d-c4c9ebd5b45b_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStock" xlink:to="lab_us-gaap_DividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_a0e0dff3-9ca8-4dff-9243-37b20bc974a6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ecf22c8b-88a4-4388-be64-5d9fcb210cec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened_8ba337d3-3ff0-4985-8264-ca4b846855a6_terseLabel_en-US" xlink:label="lab_hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional primary care centers expected to be opened in strategic partnership</link:label>
    <link:label id="lab_hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened_label_en-US" xlink:label="lab_hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Partnership Agreement, Number Of Additional Primary Care Centers Expected To Be Opened</link:label>
    <link:label id="lab_hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened_documentation_en-US" xlink:label="lab_hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Partnership Agreement, Number Of Additional Primary Care Centers Expected To Be Opened</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened" xlink:href="hum-20231231.xsd#hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened" xlink:to="lab_hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_956003bd-d77e-4c61-b4b9-0abb5b511689_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_f1525582-7d6f-40b7-856b-368b60246f00_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_90746a0e-9180-4b4c-b463-7a2474190c54_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_eedda523-004c-4e27-b5d4-1ae6ebd127ef_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Details of Dividend Payments</link:label>
    <link:label id="lab_us-gaap_DividendsDeclaredTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Declared [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDeclaredTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsDeclaredTableTextBlock" xlink:to="lab_us-gaap_DividendsDeclaredTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_15380904-2b84-4a5c-afd3-9a67dfb348cf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_78a764ba-7068-4577-a1c4-a31db091f73f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net of allowances</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_dd8799ea-ae84-43c6-8442-2d69c4fac673_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_39083544-85b0-47a8-a6c2-5c20b0084704_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities included within trade accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member_ba936498-1d1a-41cb-83f4-4b9bcc808c0c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Claims Incurred Year</link:label>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member_label_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contract, Accident Year 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member" xlink:to="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue_6921776b-9e8f-48e8-8f46-e3547ee42e22_terseLabel_en-US" xlink:label="lab_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares acquired in connection with employee stock plans, amount</link:label>
    <link:label id="lab_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue_label_en-US" xlink:label="lab_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchases Related To Employee Stock Based Compensation Awards Value</link:label>
    <link:label id="lab_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue_documentation_en-US" xlink:label="lab_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of common stock that were repurchased in the administration of our employee share-based compensation plans. Under the terms of these plans, we accept shares of common stock from option holders if they elect to surrender previously-owned shares upon exercise of the option to cover the exercise price of the options or, in the case of restricted shares of common stock, the withholding of shares to satisfy tax withholding obligations associated with the vesting of such shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue" xlink:href="hum-20231231.xsd#hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue" xlink:to="lab_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_88528829-9dfe-496b-b193-a0a4534b36a6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_AllOthersMember_b76c32b0-8513-42ad-b20e-f97b57f36c18_verboseLabel_en-US" xlink:label="lab_hum_AllOthersMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All others</link:label>
    <link:label id="lab_hum_AllOthersMember_label_en-US" xlink:label="lab_hum_AllOthersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Others [Member]</link:label>
    <link:label id="lab_hum_AllOthersMember_documentation_en-US" xlink:label="lab_hum_AllOthersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Others</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_AllOthersMember" xlink:href="hum-20231231.xsd#hum_AllOthersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_AllOthersMember" xlink:to="lab_hum_AllOthersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_49e67598-86fd-4271-b811-57f95f92e039_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_2fc90846-85fa-4058-b6a6-5eef9e236a24_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_09d5db4a-bca8-4ca8-8a1a-04ed100cfc36_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Pronouncements and Accounting Pronouncements Effective in Future Periods</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_a6666111-1e5f-4dd9-ac7c-03e86509acfc_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase average price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_ee1d6946-3a28-41e5-b728-e0e4edc91839_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits payable</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_356d8821-8a10-4a81-aae2-405dce2c65b9_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_76223918-21f1-4aa1-a002-595889387cca_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f5274ff9-f639-45d8-b692-48518c038de1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A570PercentSeniorNotesDueMarch2026Member_38ed3d39-7878-4f01-a3b7-2924549f1900_terseLabel_en-US" xlink:label="lab_hum_A570PercentSeniorNotesDueMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million, 5.700% due March 13, 2026</link:label>
    <link:label id="lab_hum_A570PercentSeniorNotesDueMarch2026Member_label_en-US" xlink:label="lab_hum_A570PercentSeniorNotesDueMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.70 Percent Senior Notes Due March 2026 [Member]</link:label>
    <link:label id="lab_hum_A570PercentSeniorNotesDueMarch2026Member_documentation_en-US" xlink:label="lab_hum_A570PercentSeniorNotesDueMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.70 Percent Senior Notes Due March 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A570PercentSeniorNotesDueMarch2026Member" xlink:href="hum-20231231.xsd#hum_A570PercentSeniorNotesDueMarch2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A570PercentSeniorNotesDueMarch2026Member" xlink:to="lab_hum_A570PercentSeniorNotesDueMarch2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceAbstract_58c190f4-2038-4cb1-b7df-521283146f85_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:label id="lab_us-gaap_InsuranceAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAbstract" xlink:to="lab_us-gaap_InsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_fc8e2458-03de-46f2-9510-26e4bb4575a5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ExternalRevenuesMember_7ba6f396-3679-4484-86f1-d66456f3c4ce_terseLabel_en-US" xlink:label="lab_hum_ExternalRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Revenues</link:label>
    <link:label id="lab_hum_ExternalRevenuesMember_label_en-US" xlink:label="lab_hum_ExternalRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Revenues [Member]</link:label>
    <link:label id="lab_hum_ExternalRevenuesMember_documentation_en-US" xlink:label="lab_hum_ExternalRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ExternalRevenuesMember" xlink:href="hum-20231231.xsd#hum_ExternalRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ExternalRevenuesMember" xlink:to="lab_hum_ExternalRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_TRICAREContractDomain_32214a3a-870c-44eb-a035-8402ef05f1e4_terseLabel_en-US" xlink:label="lab_hum_TRICAREContractDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE Contract [Domain]</link:label>
    <link:label id="lab_hum_TRICAREContractDomain_label_en-US" xlink:label="lab_hum_TRICAREContractDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE Contract [Domain]</link:label>
    <link:label id="lab_hum_TRICAREContractDomain_documentation_en-US" xlink:label="lab_hum_TRICAREContractDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREContractDomain" xlink:href="hum-20231231.xsd#hum_TRICAREContractDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_TRICAREContractDomain" xlink:to="lab_hum_TRICAREContractDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_23570989-c2fa-476e-925d-8ba1796a4d2e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility fee (percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_3d7e4bfa-2faf-47b9-b048-1aae6cac89fc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a3919b0d-8bd5-4019-8a55-98130a8a17b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Fair Value Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1b818c8d-1fd1-4de0-970e-9fed713a1c6e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_a4fac1e5-7e82-4b03-b00c-dbead27e3e8c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating costs</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_56e99585-0f03-45bf-82d9-7c7acf58ba98_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_9da657e4-be87-40cc-ac39-778191870013_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d99308bf-ad67-4d39-918f-60739f7c5776_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_AuditInformationAbstract_label_en-US" xlink:label="lab_hum_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_hum_AuditInformationAbstract_documentation_en-US" xlink:label="lab_hum_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_AuditInformationAbstract" xlink:href="hum-20231231.xsd#hum_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_AuditInformationAbstract" xlink:to="lab_hum_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_da338a44-5652-4082-a9f6-07b4dda614f1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ProceedsFromStockOptionsExercisedAndOther_7d594d13-095b-425e-b968-f98dcf330dab_verboseLabel_en-US" xlink:label="lab_hum_ProceedsFromStockOptionsExercisedAndOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_hum_ProceedsFromStockOptionsExercisedAndOther_label_en-US" xlink:label="lab_hum_ProceedsFromStockOptionsExercisedAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised And Other</link:label>
    <link:label id="lab_hum_ProceedsFromStockOptionsExercisedAndOther_documentation_en-US" xlink:label="lab_hum_ProceedsFromStockOptionsExercisedAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ProceedsFromStockOptionsExercisedAndOther" xlink:href="hum-20231231.xsd#hum_ProceedsFromStockOptionsExercisedAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ProceedsFromStockOptionsExercisedAndOther" xlink:to="lab_hum_ProceedsFromStockOptionsExercisedAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_6001f7af-b14e-4778-a130-377851c695f6_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_c9c11d44-22d0-4428-8118-8e5945a269f6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, repurchased face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7f5aa37e-5526-44c6-8f4a-f0ddd4adaa5e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_8f09e754-fffa-4c2f-a03c-bc3bba4e1009_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_371d87fa-128c-4d1b-8314-4506e179ddb1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_a35ceefa-3881-46f6-b9d9-ac1ed7efe77f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligations in 2027</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BenefitsLossesAndExpenses_1c2d6f54-40c3-45b6-9b96-26eabbc1a363_totalLabel_en-US" xlink:label="lab_us-gaap_BenefitsLossesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_BenefitsLossesAndExpenses_label_en-US" xlink:label="lab_us-gaap_BenefitsLossesAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits, Losses and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BenefitsLossesAndExpenses" xlink:to="lab_us-gaap_BenefitsLossesAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_41700969-1333-4326-9a18-51e29fab1287_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock repurchases</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_033b77ee-7232-4ecc-9bab-41bfaf762cac_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in treasury stock from share repurchases</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_acc5f498-48d8-4299-acd2-c2a0ce5fa183_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of repurchases</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6af7e2c4-68ed-42a4-88e3-0190fd1715af_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndEquitySecuritiesGainLoss_905a30ba-6c5e-4931-93bd-a95cba08a22d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on investment securities, net</link:label>
    <link:label id="lab_us-gaap_DebtAndEquitySecuritiesGainLoss_11946236-25db-4993-ae2c-a784009afcac_totalLabel_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net recognized losses on investment securities</link:label>
    <link:label id="lab_us-gaap_DebtAndEquitySecuritiesGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Equity Securities, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndEquitySecuritiesGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:to="lab_us-gaap_DebtAndEquitySecuritiesGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_d19c0d82-0232-478a-a11e-ce08c32fc8c2_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_84b0c277-d8e0-4741-9b43-e7e9471fb90e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_10924072-4085-4235-82b0-fcc403c8efa7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Kindred at Home equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_5472dea5-2144-4b14-88ad-52a1db7504af_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investment securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_LossOnTerminationOfDerivatives_09653e5c-1d60-4c7b-9c68-ec64e4551ab0_terseLabel_en-US" xlink:label="lab_hum_LossOnTerminationOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination of put and call options</link:label>
    <link:label id="lab_hum_LossOnTerminationOfDerivatives_label_en-US" xlink:label="lab_hum_LossOnTerminationOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss On Termination Of Derivatives</link:label>
    <link:label id="lab_hum_LossOnTerminationOfDerivatives_documentation_en-US" xlink:label="lab_hum_LossOnTerminationOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss On Termination Of Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LossOnTerminationOfDerivatives" xlink:href="hum-20231231.xsd#hum_LossOnTerminationOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_LossOnTerminationOfDerivatives" xlink:to="lab_hum_LossOnTerminationOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_330e7665-a81d-48b0-a01c-5f0d579f6740_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b27b0840-1337-4458-8519-e79dfd6e6368_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net of allowances</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_December2020AcceleratedShareRepurchaseAgreementMember_466b9bb8-3798-4803-98b8-e2ff50edfe8d_terseLabel_en-US" xlink:label="lab_hum_December2020AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ASR</link:label>
    <link:label id="lab_hum_December2020AcceleratedShareRepurchaseAgreementMember_label_en-US" xlink:label="lab_hum_December2020AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 Accelerated Share Repurchase Agreement [Member]</link:label>
    <link:label id="lab_hum_December2020AcceleratedShareRepurchaseAgreementMember_documentation_en-US" xlink:label="lab_hum_December2020AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 Accelerated Share Repurchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_December2020AcceleratedShareRepurchaseAgreementMember" xlink:href="hum-20231231.xsd#hum_December2020AcceleratedShareRepurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_December2020AcceleratedShareRepurchaseAgreementMember" xlink:to="lab_hum_December2020AcceleratedShareRepurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_488c1ed8-1c9b-4ed6-8da9-339dc263fb4b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_435ce2f5-6c78-4a87-9ef8-3e9a005fb713_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_b77b92b6-9cc6-408d-8846-5d190a1157cd_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0197a9b2-8a7b-4488-9e22-d68aac5bf895_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_04a90755-cdb9-4068-b13b-9f629ee8c87b_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_f604f4e0-4dd1-4d0b-99d2-4d9d57373cb3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities Amortized Cost to Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_e4fbcdc6-9242-47dc-bd7e-32bb196e3cba_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_c0fe48d9-90bb-43f7-92f5-34d0b4d67ffb_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease rental income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e7d84255-f04b-45e0-8e4a-276c0fa057bb_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_HealthCareCostPayments_c720a0da-7cb1-44c6-935b-3c729eb9d0b0_negatedTerseLabel_en-US" xlink:label="lab_hum_HealthCareCostPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health care cost payments</link:label>
    <link:label id="lab_hum_HealthCareCostPayments_label_en-US" xlink:label="lab_hum_HealthCareCostPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Payments</link:label>
    <link:label id="lab_hum_HealthCareCostPayments_documentation_en-US" xlink:label="lab_hum_HealthCareCostPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health care cost payments associated with the TRICARE South Region contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_HealthCareCostPayments" xlink:href="hum-20231231.xsd#hum_HealthCareCostPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_HealthCareCostPayments" xlink:to="lab_hum_HealthCareCostPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_0521fc2a-4b5d-4b74-92e1-413c22848022_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_9797ae08-4b9d-4457-b05f-baa1a25f5218_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_dab6e775-de5c-4086-aa39-d48771cf205e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested restricted stock, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_03b3654e-3e2e-4bb9-835f-08737e937a1b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested restricted stock, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_3142b289-f0b7-4f0f-b16d-db4066ef53f7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_03e3006e-cf1b-4eba-96f7-205a2cc61ddf_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Fair value of liabilities assumed</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_0bc63b95-58cd-4177-b3e0-89c9286206e8_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1131601f-de9e-4575-9771-dba4c370ff28_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_27b57f8b-08f8-4757-b03b-faacfd78666c_terseLabel_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Claims Incurred Year</link:label>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_label_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contract, Accident Year 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member" xlink:to="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_3ee8e5d8-adf0-413b-83c0-b04b198b3bf2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Gentiva Hospice</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance_e5c09f66-68db-41ba-a9a2-c78c642203a5_terseLabel_en-US" xlink:label="lab_hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reinsurers comprising other reinsurance recoverables balance</link:label>
    <link:label id="lab_hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance_label_en-US" xlink:label="lab_hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Reinsurers Comprising Other Reinsurance Recoverables Balance</link:label>
    <link:label id="lab_hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance_documentation_en-US" xlink:label="lab_hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reinsurers comprising other reinsurance recoverables balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance" xlink:href="hum-20231231.xsd#hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance" xlink:to="lab_hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_24766832-5c0f-489e-a636-3a36654dcdd5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_71340d68-5b34-4d06-a1b4-df241676981c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DelayedDrawTermLoanMay2024Member_3c738d34-e2d9-4230-884c-98b77c317be8_terseLabel_en-US" xlink:label="lab_hum_DelayedDrawTermLoanMay2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed draw term loan, due May 28, 2024</link:label>
    <link:label id="lab_hum_DelayedDrawTermLoanMay2024Member_label_en-US" xlink:label="lab_hum_DelayedDrawTermLoanMay2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan May 2024 [Member]</link:label>
    <link:label id="lab_hum_DelayedDrawTermLoanMay2024Member_documentation_en-US" xlink:label="lab_hum_DelayedDrawTermLoanMay2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan May 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DelayedDrawTermLoanMay2024Member" xlink:href="hum-20231231.xsd#hum_DelayedDrawTermLoanMay2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DelayedDrawTermLoanMay2024Member" xlink:to="lab_hum_DelayedDrawTermLoanMay2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_73db49b2-766d-4265-a83c-b2cee80c1aec_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerContractsMember_a49c2d5a-78a4-48b4-833a-db68fe8b3de2_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerContractsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer contracts/relationships</link:label>
    <link:label id="lab_us-gaap_CustomerContractsMember_label_en-US" xlink:label="lab_us-gaap_CustomerContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Contracts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerContractsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerContractsMember" xlink:to="lab_us-gaap_CustomerContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_8b24e0b7-3819-4616-8a0b-a608f02de63d_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_656c1878-ded8-4e15-bea8-05738cbbd752_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRealizedGainLossTableTextBlock_de1e41d7-38c6-4551-b48e-81be7e134f35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Realized Gains (Losses) Related to Investment Securities Included Within Investment Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRealizedGainLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Realized Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRealizedGainLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRealizedGainLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_ef3bd46b-931b-4792-8a35-e44498592548_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_f8c7fddd-02aa-4fc5-92a5-9be3de11d700_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_1be57bcd-7994-416c-a000-8d94fbce26d3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_114749a0-fe97-417f-bae5-b50a09b8bac8_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost_72ba85d4-16ed-4379-9f13-1e2f1b86846d_terseLabel_en-US" xlink:label="lab_hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred acquisition costs</link:label>
    <link:label id="lab_hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost_label_en-US" xlink:label="lab_hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Policy Acquisition Cost</link:label>
    <link:label id="lab_hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost_documentation_en-US" xlink:label="lab_hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of deferred tax balance as it relates to deferred acquisition costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost" xlink:href="hum-20231231.xsd#hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost" xlink:to="lab_hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_49501eb7-f656-4cc2-b119-19edb1196ac1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9f5fdfa9-dc03-49de-9dd6-ad42f363bc5a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_b6394da7-807f-40b8-90aa-ef682e1d9d4f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_13d75f44-ce59-4ae7-8f98-9afba44daba2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_NetNoncurrentAssetLiability_37a62ef1-8a3d-432a-bb2c-b7af65977faa_totalLabel_en-US" xlink:label="lab_hum_NetNoncurrentAssetLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net long-term liability</link:label>
    <link:label id="lab_hum_NetNoncurrentAssetLiability_label_en-US" xlink:label="lab_hum_NetNoncurrentAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Noncurrent Asset (Liability)</link:label>
    <link:label id="lab_hum_NetNoncurrentAssetLiability_documentation_en-US" xlink:label="lab_hum_NetNoncurrentAssetLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Noncurrent Asset (Liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NetNoncurrentAssetLiability" xlink:href="hum-20231231.xsd#hum_NetNoncurrentAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_NetNoncurrentAssetLiability" xlink:to="lab_hum_NetNoncurrentAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_0f5255f6-5240-419a-890b-3f97faa61f1b_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2ddfb565-2148-44b5-bfac-d701737ca668_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Principal Components of Net Deferred Tax Balances</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_8cb74e02-86fc-48f2-9190-88ca470ace5a_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6a43371b-cd78-4145-bfa8-a0b099517598_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_ccf555a6-fa14-46d5-b6f3-e5ea3a26d4dd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cash payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_34051025-3d78-4ca1-ab47-72573ffaa0ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_February2023ShareRepurchaseAuthorizationMember_a3446c9c-087d-404e-89a7-99acf4a9c33a_terseLabel_en-US" xlink:label="lab_hum_February2023ShareRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February 2023</link:label>
    <link:label id="lab_hum_February2023ShareRepurchaseAuthorizationMember_label_en-US" xlink:label="lab_hum_February2023ShareRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February 2023 Share Repurchase Authorization [Member]</link:label>
    <link:label id="lab_hum_February2023ShareRepurchaseAuthorizationMember_documentation_en-US" xlink:label="lab_hum_February2023ShareRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">February 2023 Share Repurchase Authorization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_February2023ShareRepurchaseAuthorizationMember" xlink:href="hum-20231231.xsd#hum_February2023ShareRepurchaseAuthorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_February2023ShareRepurchaseAuthorizationMember" xlink:to="lab_hum_February2023ShareRepurchaseAuthorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_f9015ec5-8bb9-4d63-a065-ab814eca10d9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4593aa41-0bd1-4fde-a0ea-bedd9da7121b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_PercentageOfCoinsuranceAgreement_956edfac-65f2-46db-a9eb-b60efe49518b_terseLabel_en-US" xlink:label="lab_hum_PercentageOfCoinsuranceAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of coinsurance agreement</link:label>
    <link:label id="lab_hum_PercentageOfCoinsuranceAgreement_label_en-US" xlink:label="lab_hum_PercentageOfCoinsuranceAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Coinsurance Agreement</link:label>
    <link:label id="lab_hum_PercentageOfCoinsuranceAgreement_documentation_en-US" xlink:label="lab_hum_PercentageOfCoinsuranceAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Coinsurance Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PercentageOfCoinsuranceAgreement" xlink:href="hum-20231231.xsd#hum_PercentageOfCoinsuranceAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_PercentageOfCoinsuranceAgreement" xlink:to="lab_hum_PercentageOfCoinsuranceAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceRecoverables_1d8c60ed-49e5-46ad-ae9f-39504b736929_verboseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance recoverables</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverables_label_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverables, Including Reinsurance Premium Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceRecoverables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceRecoverables" xlink:to="lab_us-gaap_ReinsuranceRecoverables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_3dc95fae-f4b5-496d-be4a-4b7ca3f4118e_terseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Amount</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries_b5bb6685-f2f0-4bec-b79c-2b36f9f0a7be_terseLabel_en-US" xlink:label="lab_hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states comprising TRICARE Managed Care Support Contract beneficiaries</link:label>
    <link:label id="lab_hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries_label_en-US" xlink:label="lab_hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of States Comprising Of TRICARE Managed Care Support Contract Beneficiaries</link:label>
    <link:label id="lab_hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries_documentation_en-US" xlink:label="lab_hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of States Comprising Of TRICARE Managed Care Support Contract Beneficiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries" xlink:href="hum-20231231.xsd#hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries" xlink:to="lab_hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_f473947f-777d-4934-9f2b-467eef4af792_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_42e1f1a4-8e87-48db-b90f-9dba599eae33_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_6448cd1e-df16-4eb5-9c93-fe415bb7a5d7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_CommercialMembershipContractTerm_5e77e7e1-26e8-4ed4-b17d-710bc43b0479_terseLabel_en-US" xlink:label="lab_hum_CommercialMembershipContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health services term</link:label>
    <link:label id="lab_hum_CommercialMembershipContractTerm_label_en-US" xlink:label="lab_hum_CommercialMembershipContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Membership Contract Term</link:label>
    <link:label id="lab_hum_CommercialMembershipContractTerm_documentation_en-US" xlink:label="lab_hum_CommercialMembershipContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Membership Contract Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CommercialMembershipContractTerm" xlink:href="hum-20231231.xsd#hum_CommercialMembershipContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_CommercialMembershipContractTerm" xlink:to="lab_hum_CommercialMembershipContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_eebcff4b-0db7-40f7-8e4f-7083d5e493d8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_0d27a16a-663a-4fd7-b827-91d334fc1b00_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">States, net of federal benefit, and Puerto Rico</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CallOptionMember_6bf2054a-3945-471c-8e47-2e91b840ce4e_terseLabel_en-US" xlink:label="lab_us-gaap_CallOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call option</link:label>
    <link:label id="lab_us-gaap_CallOptionMember_label_en-US" xlink:label="lab_us-gaap_CallOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CallOptionMember" xlink:to="lab_us-gaap_CallOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e498975e-6bce-4ed4-b50e-344e1dc4d06d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member_aa147db8-2a28-4da9-a658-c80fe2a96153_terseLabel_en-US" xlink:label="lab_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.750 Percent Senior Notes Due December 2028 And 5.50 Percent Senior Notes Due March 2034</link:label>
    <link:label id="lab_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member_label_en-US" xlink:label="lab_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.750 Percent Senior Notes Due December 2028 And 5.50 Percent Senior Notes Due March 2034 [Member]</link:label>
    <link:label id="lab_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member_documentation_en-US" xlink:label="lab_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.750 Percent Senior Notes Due December 2028 And 5.50 Percent Senior Notes Due March 2034</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member" xlink:href="hum-20231231.xsd#hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member" xlink:to="lab_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4b30b1a-ab4b-4927-bf75-4626131bbf93_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_02275760-e20d-45ac-9305-f291a1a96b4f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_67abdb6c-9660-47ca-91ff-ef3596169391_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8030d50d-ac6f-4182-9411-6ec1791340e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities in unrealized loss position, number of positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_9c44798b-0a6c-4352-8beb-d0aacd8a6301_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_18f10976-d542-4afb-9fd3-62e62bfef576_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_0a4baa0c-0822-4863-8089-6666761f6360_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_08a30fce-68c8-4735-b284-c5c828682635_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_b3d921c8-5d7d-48c9-ad99-ea06942c7737_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_6b811ab2-4b97-4304-a93a-782fb3b68a4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e693388b-064e-45b7-ad4e-99bf30ca3912_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_55774c0a-827e-48b6-a89d-2861c54f21e2_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_173f4d13-2f19-4730-9e38-944a82cc7082_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_19851063-e22c-4bf5-8092-ed531ec00be7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance sheet</link:label>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_2cf478e7-e29a-49c9-b3ee-b3d575879735_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (repayments) from issuance of commercial paper, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfCommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfCommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_37bdf8aa-ffae-41da-96ee-5eed5bf04c73_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_CmsSubsidiesOrDiscountsMember_08cff2c1-b07c-46ea-ba47-8f7a25831c60_terseLabel_en-US" xlink:label="lab_hum_CmsSubsidiesOrDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS Subsidies/ Discounts</link:label>
    <link:label id="lab_hum_CmsSubsidiesOrDiscountsMember_label_en-US" xlink:label="lab_hum_CmsSubsidiesOrDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cms Subsidies Or Discounts [Member]</link:label>
    <link:label id="lab_hum_CmsSubsidiesOrDiscountsMember_documentation_en-US" xlink:label="lab_hum_CmsSubsidiesOrDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS Subsidies Or Discounts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CmsSubsidiesOrDiscountsMember" xlink:href="hum-20231231.xsd#hum_CmsSubsidiesOrDiscountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_CmsSubsidiesOrDiscountsMember" xlink:to="lab_hum_CmsSubsidiesOrDiscountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_0ca7cc78-4fc7-4ddb-a0b6-c301f6b042bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a792991c-c64a-4298-9207-78fc1850fa1f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_ce6c82fd-d433-4a5c-a02b-901d6bb2b025_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost, Rolling Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_fd723248-90ca-4bb5-8b7a-b31186898689_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligations in 2024</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_44e2c656-0181-4389-a625-b134a02f5ccc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_3c1e54c0-42dd-4573-bb8f-36df47478191_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_fedaee5a-81d5-4eff-a26f-a98f9043e7d9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposed of by sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_GoldmanSachsCoLLCMember_df102ca7-72cd-4154-904c-f4ff40415f27_terseLabel_en-US" xlink:label="lab_hum_GoldmanSachsCoLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goldman Sachs</link:label>
    <link:label id="lab_hum_GoldmanSachsCoLLCMember_label_en-US" xlink:label="lab_hum_GoldmanSachsCoLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goldman Sachs &amp; Co. LLC [Member]</link:label>
    <link:label id="lab_hum_GoldmanSachsCoLLCMember_documentation_en-US" xlink:label="lab_hum_GoldmanSachsCoLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goldman Sachs &amp; Co. LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GoldmanSachsCoLLCMember" xlink:href="hum-20231231.xsd#hum_GoldmanSachsCoLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_GoldmanSachsCoLLCMember" xlink:to="lab_hum_GoldmanSachsCoLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_182f4f1f-6044-484f-9a35-6b4f8356af36_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annualized volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_363fc7bf-8517-406c-9246-480e9dc8d0e2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less&#160;than&#160;12&#160;months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_28e35447-402b-4d89-afdb-ef9ca228b37e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Accident Year [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Accident Year [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_5c3b9214-6d19-4631-80d6-7811f050b982_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average annual interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock_1179b09a-29cf-4c3b-b6b5-56dcf8dac1f5_terseLabel_en-US" xlink:label="lab_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets invested in Company common stock (percent)</link:label>
    <link:label id="lab_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock_label_en-US" xlink:label="lab_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Plan Assets Invested In Company Common Stock</link:label>
    <link:label id="lab_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock_documentation_en-US" xlink:label="lab_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Plan Assets Invested In Company Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock" xlink:href="hum-20231231.xsd#hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock" xlink:to="lab_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_29ea2759-cfe0-49d0-a5d8-73ed3366c586_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">States and Puerto Rico</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A463PercentSeniorNotesDueDecember2042Member_9ac10731-b994-4ddc-be1e-4effc8ee4584_terseLabel_en-US" xlink:label="lab_hum_A463PercentSeniorNotesDueDecember2042Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$400 million, 4.625% due December&#160;1, 2042</link:label>
    <link:label id="lab_hum_A463PercentSeniorNotesDueDecember2042Member_label_en-US" xlink:label="lab_hum_A463PercentSeniorNotesDueDecember2042Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.63 Percent Senior Notes Due December 2042 [Member]</link:label>
    <link:label id="lab_hum_A463PercentSeniorNotesDueDecember2042Member_documentation_en-US" xlink:label="lab_hum_A463PercentSeniorNotesDueDecember2042Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.625 Percent Senior Notes Due December 2042 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A463PercentSeniorNotesDueDecember2042Member" xlink:href="hum-20231231.xsd#hum_A463PercentSeniorNotesDueDecember2042Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A463PercentSeniorNotesDueDecember2042Member" xlink:to="lab_hum_A463PercentSeniorNotesDueDecember2042Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_84be26a9-3b05-4268-bdba-ec5a0c2e1c77_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_c5356a28-5447-4720-8597-90b957e6b90b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_fca857d5-c962-4659-bf4f-949cdc80fa9c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_a231cea8-3af0-4110-aa7e-285460266624_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-Backed Securities, Issued by US Government Sponsored Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_89dc62c0-99ea-40bd-ac9c-162014c9b7ac_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_d2d27d71-11cb-491a-b3b5-0471cc3b3583_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StandardPoorsAAMinusRatingMember_132849fd-cbf3-456a-a47a-e61db339821e_terseLabel_en-US" xlink:label="lab_srt_StandardPoorsAAMinusRatingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard &amp; Poor's, AA- Rating</link:label>
    <link:label id="lab_srt_StandardPoorsAAMinusRatingMember_label_en-US" xlink:label="lab_srt_StandardPoorsAAMinusRatingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard &amp; Poor's, AA- Rating [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StandardPoorsAAMinusRatingMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StandardPoorsAAMinusRatingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StandardPoorsAAMinusRatingMember" xlink:to="lab_srt_StandardPoorsAAMinusRatingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_9c9135ce-c9cc-405e-9c3e-48d9055fc1ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_11b05034-6db1-455c-9a50-c3f36e1a4fa3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f1808d53-f469-4715-92a5-c5b2d7bf26c6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL AND OTHER INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue_35abfa19-d31f-4272-9a80-1089c45c55be_terseLabel_en-US" xlink:label="lab_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from capital in excess of par value to treasury stock</link:label>
    <link:label id="lab_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue_label_en-US" xlink:label="lab_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Reclassified From Capital In Excess Of Par Value To Treasury Stock Upon Repurchase, Value</link:label>
    <link:label id="lab_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue_documentation_en-US" xlink:label="lab_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Reclassified From Capital In Excess Of Par Value To Treasury Stock Upon Repurchase, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue" xlink:href="hum-20231231.xsd#hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue" xlink:to="lab_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_34646a6f-4e6b-4a80-99be-1a712c653dec_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_345bb0df-6c66-4954-b316-29fc7c2e85ee_totalLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total investment securities</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_17e3e8d6-c00e-4e6d-9699-4740a33826b6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_581d422e-1029-440a-9c6a-7e33ebf78749_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_90cf6a50-3718-425a-826b-2ec161ce6c76_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_34148ff3-5cea-4002-bc2d-277c3c646a5a_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and agency obligations</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_1b06ef7a-b38f-4528-b4d2-54172430d443_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_3116ebd0-05de-4d91-9cac-c31008f4bd74_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligations in 2025</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_febb70cb-dd84-475a-9c6f-452c1de131e8_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_df71ddf4-faaf-45a5-ad2b-00c6ada4dac3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_16fbdac1-3672-4df1-98b2-012c2f6fc89f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5b13df51-566c-4b46-ade5-83a79c5f3c76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimate of Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_ce682459-c804-4ef6-87e9-67218add8b24_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY METHOD INVESTMENT</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_82c2ceb0-974c-494b-baf0-df56db2e243c_terseLabel_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, outstanding borrowings</link:label>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_label_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LinesOfCreditCurrent" xlink:to="lab_us-gaap_LinesOfCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member_7ff0fad3-4dc9-4a18-8c06-84b01fa52783_terseLabel_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Claims Incurred Year</link:label>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member_label_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contract, Accident Year 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member" xlink:to="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_76f10a21-1198-489a-adf6-cdabb5c5c9a1_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate statutory capital and surplus in our state regulated insurance subsidiaries</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices, Statutory Capital and Surplus, Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:to="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_072ce6ad-57fd-4088-b848-9f6195257c22_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember_230e4554-7cd9-4672-bf55-3c3b490e9b53_terseLabel_en-US" xlink:label="lab_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excluding Employee Stock Plans and ASR</link:label>
    <link:label id="lab_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember_label_en-US" xlink:label="lab_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excluding Employee Stock Plans And Accelerated Share Repurchase Agreement [Member]</link:label>
    <link:label id="lab_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember_documentation_en-US" xlink:label="lab_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excluding Employee Stock Plans And Accelerated Share Repurchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember" xlink:href="hum-20231231.xsd#hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember" xlink:to="lab_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A550PercentSeniorNotesDueMarch2053Member_2573e637-0b86-4ba9-bd58-484d90de6929_terseLabel_en-US" xlink:label="lab_hum_A550PercentSeniorNotesDueMarch2053Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$750 million, 5.500% due March 15, 2053</link:label>
    <link:label id="lab_hum_A550PercentSeniorNotesDueMarch2053Member_label_en-US" xlink:label="lab_hum_A550PercentSeniorNotesDueMarch2053Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50 Percent Senior Notes Due March 2053 [Member]</link:label>
    <link:label id="lab_hum_A550PercentSeniorNotesDueMarch2053Member_documentation_en-US" xlink:label="lab_hum_A550PercentSeniorNotesDueMarch2053Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50 Percent Senior Notes Due March 2053</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A550PercentSeniorNotesDueMarch2053Member" xlink:href="hum-20231231.xsd#hum_A550PercentSeniorNotesDueMarch2053Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A550PercentSeniorNotesDueMarch2053Member" xlink:to="lab_hum_A550PercentSeniorNotesDueMarch2053Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_297ec9a5-0a95-4f44-a70f-694f31313e57_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_1fa756f2-e4a1-46ef-a6c6-48212dfc8f17_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_8f5a6778-1e6c-4d5a-b14b-305dc3796f05_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_db6f25ef-1f33-48c4-8603-5812247e3c79_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_a3a39ac3-f82e-4c4f-bb4d-c6e7e8e36416_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment securities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_59d8b4a3-dfb0-44ef-91b4-8094d64c305f_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_be0800c7-b90e-4d1c-a076-9e6a01dd0889_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowances on net operating loss carryforwards related to prior acquisitions</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7fbcf928-c199-438e-81ad-3c010985f328_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_FinancialAssetsFairValueDisclosure_16ab4399-1549-4caf-a838-604d33630769_terseLabel_en-US" xlink:label="lab_hum_FinancialAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of financial asset</link:label>
    <link:label id="lab_hum_FinancialAssetsFairValueDisclosure_label_en-US" xlink:label="lab_hum_FinancialAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets, Fair Value Disclosure</link:label>
    <link:label id="lab_hum_FinancialAssetsFairValueDisclosure_documentation_en-US" xlink:label="lab_hum_FinancialAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FinancialAssetsFairValueDisclosure" xlink:href="hum-20231231.xsd#hum_FinancialAssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_FinancialAssetsFairValueDisclosure" xlink:to="lab_hum_FinancialAssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_PercentageOfTotalPremiumAndServicesRevenues_07c67ee4-248c-40a1-ab57-95097bcb97fc_terseLabel_en-US" xlink:label="lab_hum_PercentageOfTotalPremiumAndServicesRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of premiums and services revenue</link:label>
    <link:label id="lab_hum_PercentageOfTotalPremiumAndServicesRevenues_label_en-US" xlink:label="lab_hum_PercentageOfTotalPremiumAndServicesRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Total Premium And Services Revenues</link:label>
    <link:label id="lab_hum_PercentageOfTotalPremiumAndServicesRevenues_documentation_en-US" xlink:label="lab_hum_PercentageOfTotalPremiumAndServicesRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Total Premium And Services Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PercentageOfTotalPremiumAndServicesRevenues" xlink:href="hum-20231231.xsd#hum_PercentageOfTotalPremiumAndServicesRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_PercentageOfTotalPremiumAndServicesRevenues" xlink:to="lab_hum_PercentageOfTotalPremiumAndServicesRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_TRICAREManagedCareSupportContractBaseTerm_f84dd02b-c25c-44ce-9f51-6008996eacd7_terseLabel_en-US" xlink:label="lab_hum_TRICAREManagedCareSupportContractBaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract base term</link:label>
    <link:label id="lab_hum_TRICAREManagedCareSupportContractBaseTerm_label_en-US" xlink:label="lab_hum_TRICAREManagedCareSupportContractBaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE Managed Care Support Contract, Base Term</link:label>
    <link:label id="lab_hum_TRICAREManagedCareSupportContractBaseTerm_documentation_en-US" xlink:label="lab_hum_TRICAREManagedCareSupportContractBaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE Managed Care Support Contract, Base Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREManagedCareSupportContractBaseTerm" xlink:href="hum-20231231.xsd#hum_TRICAREManagedCareSupportContractBaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_TRICAREManagedCareSupportContractBaseTerm" xlink:to="lab_hum_TRICAREManagedCareSupportContractBaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram_a6e1d72c-79fb-4a69-bf70-a28c0c0cceae_terseLabel_en-US" xlink:label="lab_hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum number of years of service for retirement eligibility as related to our equity award program</link:label>
    <link:label id="lab_hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram_label_en-US" xlink:label="lab_hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Number Of Years Of Service For Retirement Eligibility As Related To Our Equity Award Program</link:label>
    <link:label id="lab_hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram_documentation_en-US" xlink:label="lab_hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum number of years of service for retirement eligibility as related to our equity award program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram" xlink:href="hum-20231231.xsd#hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram" xlink:to="lab_hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities_dad14495-5582-4b35-833b-8e6cb578d564_terseLabel_en-US" xlink:label="lab_hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum individual state general bond obligation as a percentage of total debt securities (percent)</link:label>
    <link:label id="lab_hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities_label_en-US" xlink:label="lab_hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Individual State General Bond Obligation, As Percentage Of Total Debt Securities</link:label>
    <link:label id="lab_hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities_documentation_en-US" xlink:label="lab_hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Individual State General Bond Obligation, As Percentage Of Total Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities" xlink:href="hum-20231231.xsd#hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities" xlink:to="lab_hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c13ef9bd-8b16-48f1-b5c5-c76aeef3d6bd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_SubsidyAndDiscountReimbursements_f98ef6ba-fc07-4bb4-b422-d7f5ab0aa350_terseLabel_en-US" xlink:label="lab_hum_SubsidyAndDiscountReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Part D subsidy/discount reimbursements</link:label>
    <link:label id="lab_hum_SubsidyAndDiscountReimbursements_label_en-US" xlink:label="lab_hum_SubsidyAndDiscountReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidy And Discount Reimbursements</link:label>
    <link:label id="lab_hum_SubsidyAndDiscountReimbursements_documentation_en-US" xlink:label="lab_hum_SubsidyAndDiscountReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidy And Discount Reimbursements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SubsidyAndDiscountReimbursements" xlink:href="hum-20231231.xsd#hum_SubsidyAndDiscountReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_SubsidyAndDiscountReimbursements" xlink:to="lab_hum_SubsidyAndDiscountReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets_00ee643c-6dcc-40cc-a7b6-997d76f238c7_negatedLabel_en-US" xlink:label="lab_hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciable property and intangible assets</link:label>
    <link:label id="lab_hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets_label_en-US" xlink:label="lab_hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities Depreciable Property And Intangible Assets</link:label>
    <link:label id="lab_hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets_documentation_en-US" xlink:label="lab_hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of deferred tax balance as it relates to depreciable property and intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets" xlink:href="hum-20231231.xsd#hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets" xlink:to="lab_hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_InterestRateSwapMaturing2033Member_a5e14de8-6938-4416-97f5-ba7eb7e4be2d_terseLabel_en-US" xlink:label="lab_hum_InterestRateSwapMaturing2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap Maturing 2033</link:label>
    <link:label id="lab_hum_InterestRateSwapMaturing2033Member_label_en-US" xlink:label="lab_hum_InterestRateSwapMaturing2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap Maturing 2033 [Member]</link:label>
    <link:label id="lab_hum_InterestRateSwapMaturing2033Member_documentation_en-US" xlink:label="lab_hum_InterestRateSwapMaturing2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap Maturing 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InterestRateSwapMaturing2033Member" xlink:href="hum-20231231.xsd#hum_InterestRateSwapMaturing2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_InterestRateSwapMaturing2033Member" xlink:to="lab_hum_InterestRateSwapMaturing2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4069bd5e-2559-4670-8193-e9c37e2adf73_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_049c24d1-c31b-403d-bda1-9596a3e9573c_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_39fa9dd5-fe01-4f57-9e5f-a4c9704c7b09_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_bc31f93b-ea38-4447-aade-99d9847ba494_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting_945751f2-7c1b-45af-a469-9ac0509425c6_terseLabel_en-US" xlink:label="lab_hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual realized tax benefit on tax returns from option exercises and restricted stock vesting</link:label>
    <link:label id="lab_hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting_label_en-US" xlink:label="lab_hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options And Restricted Stock Vesting</link:label>
    <link:label id="lab_hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting_documentation_en-US" xlink:label="lab_hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of the aggregate tax benefit realized from the exercise of stock options and vesting of restricted stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting" xlink:href="hum-20231231.xsd#hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting" xlink:to="lab_hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_8ed07a58-8b84-49b4-8e9c-01f83a9d993e_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_c8cc541e-b0ed-45a7-b178-7d603b397b22_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_50728270-55ea-4a6b-9077-d7ce209e450c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_7d7ef956-9b0f-4c1f-a122-ef963e506eca_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_HomeSolutionsMember_ec6b9a6f-b7c1-4fa1-8cfd-7eab1be22d48_terseLabel_en-US" xlink:label="lab_hum_HomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home solutions</link:label>
    <link:label id="lab_hum_HomeSolutionsMember_label_en-US" xlink:label="lab_hum_HomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Solutions [Member]</link:label>
    <link:label id="lab_hum_HomeSolutionsMember_documentation_en-US" xlink:label="lab_hum_HomeSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_HomeSolutionsMember" xlink:href="hum-20231231.xsd#hum_HomeSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_HomeSolutionsMember" xlink:to="lab_hum_HomeSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9d7b83d7-276a-4673-bd65-15c456e85766_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember_e57fa477-6dac-4fc0-9f61-c6758468d058_terseLabel_en-US" xlink:label="lab_hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 and Prior Claims Incurred Year</link:label>
    <link:label id="lab_hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember_label_en-US" xlink:label="lab_hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contract, Accident Year 2021 And Prior [Member]</link:label>
    <link:label id="lab_hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember_documentation_en-US" xlink:label="lab_hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contract, Accident Year 2021 And Prior</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember" xlink:href="hum-20231231.xsd#hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember" xlink:to="lab_hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_OtherCurrentAssetsPolicyTextBlock_3dd8e987-2580-4438-bd41-81c7cb486651_terseLabel_en-US" xlink:label="lab_hum_OtherCurrentAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets</link:label>
    <link:label id="lab_hum_OtherCurrentAssetsPolicyTextBlock_label_en-US" xlink:label="lab_hum_OtherCurrentAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Policy Text Block]</link:label>
    <link:label id="lab_hum_OtherCurrentAssetsPolicyTextBlock_documentation_en-US" xlink:label="lab_hum_OtherCurrentAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_OtherCurrentAssetsPolicyTextBlock" xlink:href="hum-20231231.xsd#hum_OtherCurrentAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_OtherCurrentAssetsPolicyTextBlock" xlink:to="lab_hum_OtherCurrentAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_RevolvingCreditAgreementJune2023OneYearMember_1baee86e-51d5-4601-900d-46f1aefa0ace_terseLabel_en-US" xlink:label="lab_hum_RevolvingCreditAgreementJune2023OneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement June 2023 One Year</link:label>
    <link:label id="lab_hum_RevolvingCreditAgreementJune2023OneYearMember_label_en-US" xlink:label="lab_hum_RevolvingCreditAgreementJune2023OneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement June 2023 One Year [Member]</link:label>
    <link:label id="lab_hum_RevolvingCreditAgreementJune2023OneYearMember_documentation_en-US" xlink:label="lab_hum_RevolvingCreditAgreementJune2023OneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement June 2023 One Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevolvingCreditAgreementJune2023OneYearMember" xlink:href="hum-20231231.xsd#hum_RevolvingCreditAgreementJune2023OneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_RevolvingCreditAgreementJune2023OneYearMember" xlink:to="lab_hum_RevolvingCreditAgreementJune2023OneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval_e3ce81b7-b72e-40be-a31a-ebaff1c1f648_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ordinary dividends that may be paid to parent company</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices, Statutory Amount Available for Dividend Payments without Regulatory Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval" xlink:to="lab_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_315225ca-da66-461d-966a-5044ee3b2e9b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_35209825-ae66-428a-8152-2b7078c7a0c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_365f8c9b-a671-4fba-b015-f765773ef351_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investment securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7597d13e-66b1-4a4a-93a3-85d3b73d61fa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_cd9e2934-4144-4e19-9015-ed4749df351f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_6eb9053a-639c-4870-82ee-65a57be9fcc7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome_5618bc08-8a20-4a96-8c6e-a780162e7bdb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax exempt investment income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxExemptIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_86242c4e-a44e-43c8-af15-fa35bcd0b023_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d4a31ff8-2bd6-4c30-8bf7-ce3fad1f8b8e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_377b23c3-3e00-4854-aa06-0311d03dcadd_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_01840fa6-02e8-460b-b620-1064e698c9c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated share repurchase payment</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Settlement (Payment) or Receipt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_adde1127-731a-42a1-946b-3048260bf006_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9b04d616-0bc1-494c-8741-dcae8230ba66_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2a1ab81b-c2c3-470d-95fe-588c3128df6d_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_9d299195-ee97-4f8a-a15f-1ba4ccf38e2b_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net of allowances of $88 in 2023 and $70 in 2022</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_7ee5e881-78d0-452b-a932-524361893cfc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_ca434ca1-d99b-41f6-8479-6030f39f522f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_518cbd7e-dbb6-4e9b-a1ad-e2153c6d50e2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_fc776f6f-0c54-4707-b2c2-97e86c68d9a8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_689426c9-9fe2-410e-922c-cc405ef885f7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_38e30096-70d3-4229-8814-5d893f89ff33_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_66a956f8-500a-47dd-a056-485f23b7d82f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total incurred</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_abf7edb6-0732-4f2c-b2e5-1fff2fc12925_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_741b49be-71e7-42c4-908e-171301c7b08b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries_1e233e57-71fa-469f-b23e-5c0e69911a29_totalLabel_en-US" xlink:label="lab_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes and equity in net earnings of subsidiaries</link:label>
    <link:label id="lab_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries_label_en-US" xlink:label="lab_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Before Income Taxes And Equity In Net Earnings Of Subsidiaries</link:label>
    <link:label id="lab_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries_documentation_en-US" xlink:label="lab_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Before Income Taxes And Equity In Net Earnings Of Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries" xlink:href="hum-20231231.xsd#hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries" xlink:to="lab_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a1494616-0d58-4c1b-8e40-6d4392d82be0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f32a9488-e8ec-45b1-ab07-6b4e569655c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS, GUARANTEES AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_InvestmentInRelatedPartiesAndSubsidiaries_fcd382da-e130-4681-b7cf-2fce8011ad6d_terseLabel_en-US" xlink:label="lab_hum_InvestmentInRelatedPartiesAndSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in subsidiaries</link:label>
    <link:label id="lab_hum_InvestmentInRelatedPartiesAndSubsidiaries_label_en-US" xlink:label="lab_hum_InvestmentInRelatedPartiesAndSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In Related Parties And Subsidiaries</link:label>
    <link:label id="lab_hum_InvestmentInRelatedPartiesAndSubsidiaries_documentation_en-US" xlink:label="lab_hum_InvestmentInRelatedPartiesAndSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in related parties and subsidiaries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InvestmentInRelatedPartiesAndSubsidiaries" xlink:href="hum-20231231.xsd#hum_InvestmentInRelatedPartiesAndSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_InvestmentInRelatedPartiesAndSubsidiaries" xlink:to="lab_hum_InvestmentInRelatedPartiesAndSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_182a2ae8-47fe-4564-a8fd-35b627344fab_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_LongDurationInsuranceProductsDomain_bfc2e0fd-9932-46c8-8eeb-27ba1e39c3a8_terseLabel_en-US" xlink:label="lab_hum_LongDurationInsuranceProductsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Duration Insurance Products [Domain]</link:label>
    <link:label id="lab_hum_LongDurationInsuranceProductsDomain_label_en-US" xlink:label="lab_hum_LongDurationInsuranceProductsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Duration Insurance Products [Domain]</link:label>
    <link:label id="lab_hum_LongDurationInsuranceProductsDomain_documentation_en-US" xlink:label="lab_hum_LongDurationInsuranceProductsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Duration Insurance Products [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LongDurationInsuranceProductsDomain" xlink:href="hum-20231231.xsd#hum_LongDurationInsuranceProductsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_LongDurationInsuranceProductsDomain" xlink:to="lab_hum_LongDurationInsuranceProductsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_e738c686-448c-4f24-b8b6-e45ec4cb8813_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total senior notes</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A2011PlanMember_43269d88-894a-481d-969a-acdcb78f6736_terseLabel_en-US" xlink:label="lab_hum_A2011PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 Plan</link:label>
    <link:label id="lab_hum_A2011PlanMember_label_en-US" xlink:label="lab_hum_A2011PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 Plan [Member]</link:label>
    <link:label id="lab_hum_A2011PlanMember_documentation_en-US" xlink:label="lab_hum_A2011PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2011 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A2011PlanMember" xlink:href="hum-20231231.xsd#hum_A2011PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A2011PlanMember" xlink:to="lab_hum_A2011PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_HealthCareCostPaymentsAndReimbursementsNet_47c6b0ad-3f95-4802-aa49-6bf1e8b02ba3_negatedTotalLabel_en-US" xlink:label="lab_hum_HealthCareCostPaymentsAndReimbursementsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net reimbursements (payments)</link:label>
    <link:label id="lab_hum_HealthCareCostPaymentsAndReimbursementsNet_label_en-US" xlink:label="lab_hum_HealthCareCostPaymentsAndReimbursementsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Payments And Reimbursements, Net</link:label>
    <link:label id="lab_hum_HealthCareCostPaymentsAndReimbursementsNet_documentation_en-US" xlink:label="lab_hum_HealthCareCostPaymentsAndReimbursementsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The difference between health care cost payments and reimbursements related to the TRICARE South Region contract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_HealthCareCostPaymentsAndReimbursementsNet" xlink:href="hum-20231231.xsd#hum_HealthCareCostPaymentsAndReimbursementsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_HealthCareCostPaymentsAndReimbursementsNet" xlink:to="lab_hum_HealthCareCostPaymentsAndReimbursementsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_35eeb937-1529-49ed-ad9b-4bbb0ca10f19_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_136bcb15-aa17-42e9-8021-9c056c234ed4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_66bc8b83-57c9-4cd8-b262-b5a0c148ccd1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_8ad16995-98f0-49ce-9909-3b850ee8ccfb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_359ebb61-0ad1-463c-9eeb-a7022dababc2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net deferred income tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dd1ad84f-9d38-4336-a2a9-2f9abf968124_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of stock options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_SecuredOvernightFinancingRateSOFRMember_04df20be-1d12-4083-88f8-f811b8d43ff1_terseLabel_en-US" xlink:label="lab_hum_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR</link:label>
    <link:label id="lab_hum_SecuredOvernightFinancingRateSOFRMember_label_en-US" xlink:label="lab_hum_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:label id="lab_hum_SecuredOvernightFinancingRateSOFRMember_documentation_en-US" xlink:label="lab_hum_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SecuredOvernightFinancingRateSOFRMember" xlink:href="hum-20231231.xsd#hum_SecuredOvernightFinancingRateSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_SecuredOvernightFinancingRateSOFRMember" xlink:to="lab_hum_SecuredOvernightFinancingRateSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A313PercentSeniorNotesDueAugust2029Member_0463d616-8579-4d62-b79d-dd30c04e8180_terseLabel_en-US" xlink:label="lab_hum_A313PercentSeniorNotesDueAugust2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million, 3.125% due August 15, 2029</link:label>
    <link:label id="lab_hum_A313PercentSeniorNotesDueAugust2029Member_label_en-US" xlink:label="lab_hum_A313PercentSeniorNotesDueAugust2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.13 Percent Senior Notes Due August 2029 [Member]</link:label>
    <link:label id="lab_hum_A313PercentSeniorNotesDueAugust2029Member_documentation_en-US" xlink:label="lab_hum_A313PercentSeniorNotesDueAugust2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.13 Percent Senior Notes Due August 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A313PercentSeniorNotesDueAugust2029Member" xlink:href="hum-20231231.xsd#hum_A313PercentSeniorNotesDueAugust2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A313PercentSeniorNotesDueAugust2029Member" xlink:to="lab_hum_A313PercentSeniorNotesDueAugust2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_b90a184e-31f2-4d94-91fd-3964c5e4d7ce_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_06a7815c-c76a-493e-9757-49164033f503_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_NumberOfTRICAREBeneficiaries_db013685-6ea8-46d1-8c4a-9168dc3ef334_terseLabel_en-US" xlink:label="lab_hum_NumberOfTRICAREBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of TRICARE beneficiaries</link:label>
    <link:label id="lab_hum_NumberOfTRICAREBeneficiaries_label_en-US" xlink:label="lab_hum_NumberOfTRICAREBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of TRICARE Beneficiaries</link:label>
    <link:label id="lab_hum_NumberOfTRICAREBeneficiaries_documentation_en-US" xlink:label="lab_hum_NumberOfTRICAREBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of TRICARE Beneficiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfTRICAREBeneficiaries" xlink:href="hum-20231231.xsd#hum_NumberOfTRICAREBeneficiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_NumberOfTRICAREBeneficiaries" xlink:to="lab_hum_NumberOfTRICAREBeneficiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_a047608a-84d2-4416-b401-2fcea772b34b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A4.80PercentSeniorNotesDueMarch2047Member_dfd79c58-d9d8-4453-8ff1-0b2ac9afb72d_terseLabel_en-US" xlink:label="lab_hum_A4.80PercentSeniorNotesDueMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$400 million, 4.800% due March 15, 2047</link:label>
    <link:label id="lab_hum_A4.80PercentSeniorNotesDueMarch2047Member_label_en-US" xlink:label="lab_hum_A4.80PercentSeniorNotesDueMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80 Percent Senior Notes Due March 2047 [Member]</link:label>
    <link:label id="lab_hum_A4.80PercentSeniorNotesDueMarch2047Member_documentation_en-US" xlink:label="lab_hum_A4.80PercentSeniorNotesDueMarch2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.80 Percent Senior Notes Due March 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A4.80PercentSeniorNotesDueMarch2047Member" xlink:href="hum-20231231.xsd#hum_A4.80PercentSeniorNotesDueMarch2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A4.80PercentSeniorNotesDueMarch2047Member" xlink:to="lab_hum_A4.80PercentSeniorNotesDueMarch2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_TermLoanAndCommercialPaperMember_2f0849b6-4b3f-44c4-b8ef-cd09203d3363_terseLabel_en-US" xlink:label="lab_hum_TermLoanAndCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan and Commercial Paper</link:label>
    <link:label id="lab_hum_TermLoanAndCommercialPaperMember_label_en-US" xlink:label="lab_hum_TermLoanAndCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan And Commercial Paper [Member]</link:label>
    <link:label id="lab_hum_TermLoanAndCommercialPaperMember_documentation_en-US" xlink:label="lab_hum_TermLoanAndCommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan And Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TermLoanAndCommercialPaperMember" xlink:href="hum-20231231.xsd#hum_TermLoanAndCommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_TermLoanAndCommercialPaperMember" xlink:to="lab_hum_TermLoanAndCommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0a63bb68-ba37-49a4-9f8e-6f0606a92f6d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_NoncompetesAndOtherMember_81f09843-3731-45be-80f5-02afe87c89a3_terseLabel_en-US" xlink:label="lab_hum_NoncompetesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompetes and other</link:label>
    <link:label id="lab_hum_NoncompetesAndOtherMember_label_en-US" xlink:label="lab_hum_NoncompetesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompetes And Other [Member]</link:label>
    <link:label id="lab_hum_NoncompetesAndOtherMember_documentation_en-US" xlink:label="lab_hum_NoncompetesAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncompetes and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NoncompetesAndOtherMember" xlink:href="hum-20231231.xsd#hum_NoncompetesAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_NoncompetesAndOtherMember" xlink:to="lab_hum_NoncompetesAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f8bcc05d-44a6-465a-9b5f-2fd9321183a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_e77ee365-89ba-4042-9f39-b017df4c68dd_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Health Care Insurance Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_7d1615de-eb14-4a13-bcc9-c78d6a927a07_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Paid related to:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_c447bb02-9189-410c-8c1e-16179fc8b5a4_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_TRICAREManagedCareSupportContractTermWithOptionExercises_dc307506-0b9e-4817-91ad-cdfe08a14af5_terseLabel_en-US" xlink:label="lab_hum_TRICAREManagedCareSupportContractTermWithOptionExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term with exercises</link:label>
    <link:label id="lab_hum_TRICAREManagedCareSupportContractTermWithOptionExercises_label_en-US" xlink:label="lab_hum_TRICAREManagedCareSupportContractTermWithOptionExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE Managed Care Support Contract, Term With Option Exercises</link:label>
    <link:label id="lab_hum_TRICAREManagedCareSupportContractTermWithOptionExercises_documentation_en-US" xlink:label="lab_hum_TRICAREManagedCareSupportContractTermWithOptionExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE Managed Care Support Contract, Term With Option Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREManagedCareSupportContractTermWithOptionExercises" xlink:href="hum-20231231.xsd#hum_TRICAREManagedCareSupportContractTermWithOptionExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_TRICAREManagedCareSupportContractTermWithOptionExercises" xlink:to="lab_hum_TRICAREManagedCareSupportContractTermWithOptionExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_01c37fbd-ab16-40e0-bc3f-610defb4ba98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGain_b59cf3d7-9790-4a35-91ce-dcaa921c9ff1_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross gains on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGain_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalHomeLoanBankAdvancesMember_71d1b560-8b43-49d9-8803-84420c662394_terseLabel_en-US" xlink:label="lab_us-gaap_FederalHomeLoanBankAdvancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Home Loan Bank Advances</link:label>
    <link:label id="lab_us-gaap_FederalHomeLoanBankAdvancesMember_label_en-US" xlink:label="lab_us-gaap_FederalHomeLoanBankAdvancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Home Loan Bank Advances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalHomeLoanBankAdvancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalHomeLoanBankAdvancesMember" xlink:to="lab_us-gaap_FederalHomeLoanBankAdvancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_9843076e-3f78-4334-b5e1-e386b0fda33c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_08507a94-a8c2-49e5-9817-3ca8c8d98fb7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage_e7a85fab-ce21-419c-aab9-fa150af597e0_terseLabel_en-US" xlink:label="lab_hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest to be acquired per agreement (percent)</link:label>
    <link:label id="lab_hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage_label_en-US" xlink:label="lab_hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definitive Agreement, Equity Interest To Be Acquired, Percentage</link:label>
    <link:label id="lab_hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage_documentation_en-US" xlink:label="lab_hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definitive Agreement, Equity Interest To Be Acquired, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage" xlink:href="hum-20231231.xsd#hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage" xlink:to="lab_hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_SignificantAccountingPoliciesLineItems_20d9e217-ea72-4ea5-a1eb-ff7b572a9f66_terseLabel_en-US" xlink:label="lab_hum_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_hum_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_hum_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_hum_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_hum_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SignificantAccountingPoliciesLineItems" xlink:href="hum-20231231.xsd#hum_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems" xlink:to="lab_hum_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_4387bea7-d5a5-4b58-a2d2-69106085e955_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders_b3905c3d-ee1f-4db7-8a8a-16f94a0304b0_terseLabel_en-US" xlink:label="lab_hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution from (to) noncontrolling interest holders, net</link:label>
    <link:label id="lab_hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase (Decrease) From Contributions Or Distributions To Noncontrolling Interest Holders</link:label>
    <link:label id="lab_hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders_documentation_en-US" xlink:label="lab_hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase (Decrease) From Contributions Or Distributions To Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders" xlink:href="hum-20231231.xsd#hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders" xlink:to="lab_hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_c333793a-c09f-4502-b4e6-00a882cff6da_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swap asset</link:label>
    <link:label id="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Fair Value Hedge Asset at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:to="lab_us-gaap_InterestRateFairValueHedgeAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_6c2f2f5e-349a-4c73-a79d-d8872384df7a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue_e3b0dbd2-d845-4cd8-bcdb-6f0070fb3cab_terseLabel_en-US" xlink:label="lab_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in capital in excess of par value</link:label>
    <link:label id="lab_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue_label_en-US" xlink:label="lab_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Decrease In Capital In Excess Of Par Value</link:label>
    <link:label id="lab_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue_documentation_en-US" xlink:label="lab_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Decrease In Capital In Excess Of Par Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue" xlink:href="hum-20231231.xsd#hum_TreasuryStockDecreaseInCapitalInExcessOfParValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue" xlink:to="lab_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired_4c5b7320-0363-40c1-b839-5cd227655191_negatedTerseLabel_en-US" xlink:label="lab_hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Noncontrolling interests acquired</link:label>
    <link:label id="lab_hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired_label_en-US" xlink:label="lab_hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Acquisition Noncontrolling Interest Acquired</link:label>
    <link:label id="lab_hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired_documentation_en-US" xlink:label="lab_hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Acquisition Noncontrolling Interest Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired" xlink:href="hum-20231231.xsd#hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired" xlink:to="lab_hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A8.15PercentSeniorNotesDueJune2038Member_3cb19d16-bccc-4be5-8252-72ced8ddf447_terseLabel_en-US" xlink:label="lab_hum_A8.15PercentSeniorNotesDueJune2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$250 million, 8.150% due June&#160;15, 2038</link:label>
    <link:label id="lab_hum_A8.15PercentSeniorNotesDueJune2038Member_label_en-US" xlink:label="lab_hum_A8.15PercentSeniorNotesDueJune2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.15 Percent Senior Notes Due June 2038 [Member]</link:label>
    <link:label id="lab_hum_A8.15PercentSeniorNotesDueJune2038Member_documentation_en-US" xlink:label="lab_hum_A8.15PercentSeniorNotesDueJune2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.15 Percent Senior Notes Due June 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A8.15PercentSeniorNotesDueJune2038Member" xlink:href="hum-20231231.xsd#hum_A8.15PercentSeniorNotesDueJune2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A8.15PercentSeniorNotesDueJune2038Member" xlink:to="lab_hum_A8.15PercentSeniorNotesDueJune2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e2b1a836-d00b-4158-abdc-7769a26d7267_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_47eabba3-25a6-4ec2-a4ae-69e51f75923f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock unit vesting</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_343fc300-1526-41d3-b6db-118a711099bb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred (benefit) expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_ec58685a-b351-4e8f-a44e-e0d07f937ac0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_cbe00b10-4d9d-46dd-bb52-65e48594259b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_53ebe613-a85e-4dbc-981e-c3bef7ddff52_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementRelatedDisclosuresAbstract_14cac327-a90d-48c3-b791-9441027c0605_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Related Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_757bfc4d-972e-4da2-9d5c-12e29b63a309_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2a611278-4a4c-4c26-92e4-5a19ac2f3eec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_94ac6063-eb03-4dbe-8c65-abcf537207ba_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8a91af4c-361e-4ef9-8fc8-9ab8e46fd56c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_7593db44-d7e8-4e2e-8766-1e0e6a43dc39_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_CapitalContributionsToOperatingSubsidiaries_2db4e31d-168d-4149-a73b-91fec0acea89_negatedLabel_en-US" xlink:label="lab_hum_CapitalContributionsToOperatingSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contributions to operating subsidiaries</link:label>
    <link:label id="lab_hum_CapitalContributionsToOperatingSubsidiaries_label_en-US" xlink:label="lab_hum_CapitalContributionsToOperatingSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Contributions To Operating Subsidiaries</link:label>
    <link:label id="lab_hum_CapitalContributionsToOperatingSubsidiaries_documentation_en-US" xlink:label="lab_hum_CapitalContributionsToOperatingSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contributions to operating subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CapitalContributionsToOperatingSubsidiaries" xlink:href="hum-20231231.xsd#hum_CapitalContributionsToOperatingSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_CapitalContributionsToOperatingSubsidiaries" xlink:to="lab_hum_CapitalContributionsToOperatingSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9fece949-c986-4ca3-a977-a91f28f21337_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_90e0bcf4-a303-469e-826a-ac15d1ccfcfa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_21c48753-8f9a-4a44-8ae2-5652ff140c4f_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of employee stock options and restricted stock (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_73214112-67ba-446f-86ac-9817b99e7c55_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies_fae52d73-721a-4396-b12e-2ec80eebcbda_terseLabel_en-US" xlink:label="lab_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of days notice for employer group to cancel short-duration prepaid health services policies</link:label>
    <link:label id="lab_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies_label_en-US" xlink:label="lab_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Days Notice For Employer Group To Cancel Short Duration Prepaid Health Services Policies</link:label>
    <link:label id="lab_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies_documentation_en-US" xlink:label="lab_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Days Notice For Employer Group To Cancel Short Duration Prepaid Health Services Policies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies" xlink:href="hum-20231231.xsd#hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies" xlink:to="lab_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_dae863ea-0650-4788-915f-41a3703edd65_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses recognized on equity securities still held at the end of the period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_30c2a8cd-51a7-4081-96d2-68f44d9d2e96_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_19d3899d-f3ea-411c-bdc3-fa2e37ed7bb8_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInBookOverdrafts_e572cf2c-79d2-4255-849d-18d7da3ac71c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInBookOverdrafts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in book overdraft</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInBookOverdrafts_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInBookOverdrafts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Book Overdrafts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInBookOverdrafts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInBookOverdrafts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInBookOverdrafts" xlink:to="lab_us-gaap_IncreaseDecreaseInBookOverdrafts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_051cf410-f783-4633-aab2-310f16779632_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_dacf8077-8e8a-4b6e-b21e-7cfd4e2abf13_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_e1dfcf81-17cc-43e6-992b-d33ef4a6baa8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7ef88da1-be09-4074-aefe-928fefd63daf_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_b95385a8-a03f-4ced-9771-87d57763a444_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_174c3a4f-3bce-45af-8dc9-7761cb372aee_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock_3049e689-b489-422f-a15d-bd9743676673_terseLabel_en-US" xlink:label="lab_hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future policy benefits payable</link:label>
    <link:label id="lab_hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock_label_en-US" xlink:label="lab_hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Policy And Benefits Payable Policy [Policy Text Block]</link:label>
    <link:label id="lab_hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of policies associated with the accounting treatment of future policy benefits payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock" xlink:href="hum-20231231.xsd#hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock" xlink:to="lab_hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_90cde0e1-b130-45c0-b624-718be91227a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_b3c9d8a2-3672-4dec-acf2-7cce38956ec3_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for abandonment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_437620cc-4bca-460f-ad64-41c3c9a44a71_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 months or more</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_ab31bf08-0308-4811-979f-33d97b9635ca_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_569fe98f-0c20-44b4-b6ff-05a62d33d1db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_0dd8f773-bedf-4489-b467-cf8bb50390ee_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reclassification adjustment, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_5deb0253-df83-4c44-b171-5d43ffc9011d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A3850PercentSeniorNotesDueOctober2024Member_01411525-ff64-4cf3-b0d0-dac7ddd2959a_terseLabel_en-US" xlink:label="lab_hum_A3850PercentSeniorNotesDueOctober2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$600 million, 3.850% due October 1, 2024</link:label>
    <link:label id="lab_hum_A3850PercentSeniorNotesDueOctober2024Member_label_en-US" xlink:label="lab_hum_A3850PercentSeniorNotesDueOctober2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.850 Percent Senior Notes Due October 2024 [Member]</link:label>
    <link:label id="lab_hum_A3850PercentSeniorNotesDueOctober2024Member_documentation_en-US" xlink:label="lab_hum_A3850PercentSeniorNotesDueOctober2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.850 Percent Senior Notes Due October 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3850PercentSeniorNotesDueOctober2024Member" xlink:href="hum-20231231.xsd#hum_A3850PercentSeniorNotesDueOctober2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A3850PercentSeniorNotesDueOctober2024Member" xlink:to="lab_hum_A3850PercentSeniorNotesDueOctober2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DebtAndEquitySecuritiesRealizedLoss_4586b7e1-10dc-4148-b662-a20608a35e83_negatedTerseLabel_en-US" xlink:label="lab_hum_DebtAndEquitySecuritiesRealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross losses on investment securities</link:label>
    <link:label id="lab_hum_DebtAndEquitySecuritiesRealizedLoss_label_en-US" xlink:label="lab_hum_DebtAndEquitySecuritiesRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt And Equity Securities, Realized Loss</link:label>
    <link:label id="lab_hum_DebtAndEquitySecuritiesRealizedLoss_documentation_en-US" xlink:label="lab_hum_DebtAndEquitySecuritiesRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt And Equity Securities, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DebtAndEquitySecuritiesRealizedLoss" xlink:href="hum-20231231.xsd#hum_DebtAndEquitySecuritiesRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DebtAndEquitySecuritiesRealizedLoss" xlink:to="lab_hum_DebtAndEquitySecuritiesRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_a7b97f36-511d-4b36-a5b1-65a1fa1c13b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less&#160;than&#160;12&#160;months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_15f2432d-128f-480f-ba96-60652c7f6f26_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_ebe2e11a-276b-48a3-8014-f1b45b07a375_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7b5ba0bd-75d7-4077-9687-1398e87d259b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash and cash equivalents acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1a41e65d-b934-4104-b442-dc7fad8fd365_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquired businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_86341b12-5534-4c48-b872-46e16a2e87ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Credit Quality Indicator [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Credit Quality Indicator [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable" xlink:to="lab_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_58b7eaf5-f883-4f07-a690-b6aefba560c8_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_0bea881f-5336-4f6d-a685-618dc656e562_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_81427c3e-6e7d-442f-9cc6-ced78219f5ef_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_BookOverdraftPolicyPolicyTextBlock_bb0635e0-db0a-4bde-8144-5a92432957a0_terseLabel_en-US" xlink:label="lab_hum_BookOverdraftPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Book Overdraft</link:label>
    <link:label id="lab_hum_BookOverdraftPolicyPolicyTextBlock_label_en-US" xlink:label="lab_hum_BookOverdraftPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Book Overdraft Policy [Policy Text Block]</link:label>
    <link:label id="lab_hum_BookOverdraftPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_hum_BookOverdraftPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of policies associated with the accounting treatment of book overdraft</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BookOverdraftPolicyPolicyTextBlock" xlink:href="hum-20231231.xsd#hum_BookOverdraftPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_BookOverdraftPolicyPolicyTextBlock" xlink:to="lab_hum_BookOverdraftPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_InterestRateSwapMaturing2034Member_7402ff9b-002b-4e0a-ac1c-7c96c0c73a45_terseLabel_en-US" xlink:label="lab_hum_InterestRateSwapMaturing2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap Maturing 2034</link:label>
    <link:label id="lab_hum_InterestRateSwapMaturing2034Member_label_en-US" xlink:label="lab_hum_InterestRateSwapMaturing2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap Maturing 2034 [Member]</link:label>
    <link:label id="lab_hum_InterestRateSwapMaturing2034Member_documentation_en-US" xlink:label="lab_hum_InterestRateSwapMaturing2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap Maturing 2034</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InterestRateSwapMaturing2034Member" xlink:href="hum-20231231.xsd#hum_InterestRateSwapMaturing2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_InterestRateSwapMaturing2034Member" xlink:to="lab_hum_InterestRateSwapMaturing2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_32801b04-5dc0-4400-b0cc-019a7e7f3830_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis points spread on variable rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_62981463-33b3-4bc4-8f3a-4ca3a7d6b688_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets estimated useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_9de3dc2b-004a-4d1b-9dfc-feea43cbb08a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Unsecured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_CertificateOfNeedMember_e0dda258-181b-424a-8d14-1d78b64fecbe_terseLabel_en-US" xlink:label="lab_hum_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of need</link:label>
    <link:label id="lab_hum_CertificateOfNeedMember_label_en-US" xlink:label="lab_hum_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate Of Need [Member]</link:label>
    <link:label id="lab_hum_CertificateOfNeedMember_documentation_en-US" xlink:label="lab_hum_CertificateOfNeedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate Of Need</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CertificateOfNeedMember" xlink:href="hum-20231231.xsd#hum_CertificateOfNeedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_CertificateOfNeedMember" xlink:to="lab_hum_CertificateOfNeedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_RepurchasePlanMarch2023Member_d95d3d98-f0d8-49be-843b-ef14f624904f_terseLabel_en-US" xlink:label="lab_hum_RepurchasePlanMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Plan, March 2023</link:label>
    <link:label id="lab_hum_RepurchasePlanMarch2023Member_label_en-US" xlink:label="lab_hum_RepurchasePlanMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Plan, March 2023 [Member]</link:label>
    <link:label id="lab_hum_RepurchasePlanMarch2023Member_documentation_en-US" xlink:label="lab_hum_RepurchasePlanMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Plan, March 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RepurchasePlanMarch2023Member" xlink:href="hum-20231231.xsd#hum_RepurchasePlanMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_RepurchasePlanMarch2023Member" xlink:to="lab_hum_RepurchasePlanMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_HomeSolutionsReportingUnitMember_896fb794-a1bb-4491-8e23-8889acd4e36c_terseLabel_en-US" xlink:label="lab_hum_HomeSolutionsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Solutions Reporting Unit</link:label>
    <link:label id="lab_hum_HomeSolutionsReportingUnitMember_label_en-US" xlink:label="lab_hum_HomeSolutionsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Solutions Reporting Unit [Member]</link:label>
    <link:label id="lab_hum_HomeSolutionsReportingUnitMember_documentation_en-US" xlink:label="lab_hum_HomeSolutionsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Home Solutions Reporting Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_HomeSolutionsReportingUnitMember" xlink:href="hum-20231231.xsd#hum_HomeSolutionsReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_HomeSolutionsReportingUnitMember" xlink:to="lab_hum_HomeSolutionsReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_NetAssetLiability_ae5264d5-3127-4cc2-95bb-77bf63e008c4_totalLabel_en-US" xlink:label="lab_hum_NetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net (liability) asset</link:label>
    <link:label id="lab_hum_NetAssetLiability_label_en-US" xlink:label="lab_hum_NetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Asset (Liability)</link:label>
    <link:label id="lab_hum_NetAssetLiability_documentation_en-US" xlink:label="lab_hum_NetAssetLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Asset (Liability)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NetAssetLiability" xlink:href="hum-20231231.xsd#hum_NetAssetLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_NetAssetLiability" xlink:to="lab_hum_NetAssetLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_28da5cdb-9e2d-4e02-b33a-bcd977317a10_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital in excess of par value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_fe7aab2d-b94b-4c26-a6f5-5c67b115681f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_d716068d-cc86-4d59-8e98-e3c0b89a8d70_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital&#160;In Excess&#160;of Par Value</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_ff1ccfc5-a0c2-4768-9e6e-0a1e549bcea2_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_966dde5e-bb71-45e9-bb7c-7794141fd6b6_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_0a0d77f7-9eeb-4e57-adb5-f923bef4ff1f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net gains (losses) recognized on equity securities sold during the period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfUnsecuredDebt_35140114-887c-4543-86dc-90e0f580d962_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfUnsecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Unsecured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfUnsecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfUnsecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_d45ca74f-b67e-4031-8eb2-3021d36d6e0e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net (losses) earnings</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_336e02a0-ed3f-4960-913d-bad675174b64_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net losses (earnings)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_7771e778-1ec1-4d3f-806f-504309af3511_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net losses</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_9352a768-762a-46c7-be94-04c3081513f8_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_5af282f0-86c5-4a98-80f4-66f51bdffd08_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3cb1f092-ddcf-4abb-a711-336e876523bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_78823352-2cca-4b32-bf14-982630f4c8e7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_c1fae0c4-f8ea-4a86-acf9-9a8a3b4274d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_ac422ce5-aee0-42d3-99a4-f8961332d614_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_782ceb5d-5b63-4843-8fcb-cf36cd246342_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_b37742c4-2f5c-4bd3-9baa-5dc93160d620_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_83fdbda2-64e7-4c40-957e-3d4de27b5673_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_a06af775-44eb-4144-a007-29dd8d2532bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment securities</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_TRICAREContractAxis_966bfe8c-ee78-4f70-aac3-7d4a254664b6_terseLabel_en-US" xlink:label="lab_hum_TRICAREContractAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE Contract [Axis]</link:label>
    <link:label id="lab_hum_TRICAREContractAxis_label_en-US" xlink:label="lab_hum_TRICAREContractAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE Contract [Axis]</link:label>
    <link:label id="lab_hum_TRICAREContractAxis_documentation_en-US" xlink:label="lab_hum_TRICAREContractAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREContractAxis" xlink:href="hum-20231231.xsd#hum_TRICAREContractAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_TRICAREContractAxis" xlink:to="lab_hum_TRICAREContractAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_a80b198c-d245-497c-a682-d67d619c833f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_6dc19bf6-71b4-44a3-bb2e-9d1d44bd675a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_993d8739-f730-4bb5-8d3c-69693870ba1b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_NetCurrentLiabilityAsset_4a66428f-1144-444e-b755-923591f9c4f8_totalLabel_en-US" xlink:label="lab_hum_NetCurrentLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net current (liability) asset</link:label>
    <link:label id="lab_hum_NetCurrentLiabilityAsset_label_en-US" xlink:label="lab_hum_NetCurrentLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Current (Liability) Asset</link:label>
    <link:label id="lab_hum_NetCurrentLiabilityAsset_documentation_en-US" xlink:label="lab_hum_NetCurrentLiabilityAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net current (liability) asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NetCurrentLiabilityAsset" xlink:href="hum-20231231.xsd#hum_NetCurrentLiabilityAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_NetCurrentLiabilityAsset" xlink:to="lab_hum_NetCurrentLiabilityAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_MedicaidMember_13c6ce20-da53-4177-90b4-7b031991a0c8_terseLabel_en-US" xlink:label="lab_hum_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_hum_MedicaidMember_label_en-US" xlink:label="lab_hum_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_hum_MedicaidMember_documentation_en-US" xlink:label="lab_hum_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicaidMember" xlink:href="hum-20231231.xsd#hum_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_MedicaidMember" xlink:to="lab_hum_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_eea3bed1-65a5-4294-8b06-866fdcf0669a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_RevenueExitMultipleMember_e74cfcaa-ac63-4ba1-98e5-4b04b2013fff_terseLabel_en-US" xlink:label="lab_hum_RevenueExitMultipleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue exit multiple</link:label>
    <link:label id="lab_hum_RevenueExitMultipleMember_label_en-US" xlink:label="lab_hum_RevenueExitMultipleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Exit Multiple [Member]</link:label>
    <link:label id="lab_hum_RevenueExitMultipleMember_documentation_en-US" xlink:label="lab_hum_RevenueExitMultipleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Exit Multiple</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevenueExitMultipleMember" xlink:href="hum-20231231.xsd#hum_RevenueExitMultipleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_RevenueExitMultipleMember" xlink:to="lab_hum_RevenueExitMultipleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_WelshCarsonAndersonAndStoweMember_586e3829-abe9-4854-834e-577fc381263f_terseLabel_en-US" xlink:label="lab_hum_WelshCarsonAndersonAndStoweMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WCAS</link:label>
    <link:label id="lab_hum_WelshCarsonAndersonAndStoweMember_label_en-US" xlink:label="lab_hum_WelshCarsonAndersonAndStoweMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Welsh Carson Anderson And Stowe [Member]</link:label>
    <link:label id="lab_hum_WelshCarsonAndersonAndStoweMember_documentation_en-US" xlink:label="lab_hum_WelshCarsonAndersonAndStoweMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Welsh Carson Anderson And Stowe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_WelshCarsonAndersonAndStoweMember" xlink:href="hum-20231231.xsd#hum_WelshCarsonAndersonAndStoweMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_WelshCarsonAndersonAndStoweMember" xlink:to="lab_hum_WelshCarsonAndersonAndStoweMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_1726bf0d-e37e-4639-94b1-3fc3092adc42_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Puerto Rico</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_e9f5d973-daa0-4631-9380-07eac0eaf8cd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d4853561-6060-40ad-98d5-ede54a12a7f4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_93200cf7-82db-47b6-83ce-f1f472463d94_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_05623a92-88b8-4e47-8a7b-711d12520c46_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_566f4c11-79de-463e-a758-eaebff73360e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_7464fe8a-e321-46f1-93f9-6d1c53deef6c_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_c940185c-04b6-4a97-87a7-f8356bd4493f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_77468ddb-4b6e-497f-acc8-6b8fcfa119d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram_d1282354-019b-4b2c-950b-88725decde81_terseLabel_en-US" xlink:label="lab_hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum age required for retirement eligibility as related to our equity award program</link:label>
    <link:label id="lab_hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram_label_en-US" xlink:label="lab_hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Age Required For Retirement Eligibility As Related To Our Equity Award Program</link:label>
    <link:label id="lab_hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram_documentation_en-US" xlink:label="lab_hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum age required for retirement eligibility as related to our equity award program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram" xlink:href="hum-20231231.xsd#hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram" xlink:to="lab_hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_2eac1113-81a7-4c3a-b01d-dc45e1770d55_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_2a5433cd-206a-4bec-955b-fd9c21d50fe3_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_0079f123-45bb-4ec5-9b39-1ac600af8f68_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance_e7024b2a-fe86-43b9-9d63-6935d57ac61a_terseLabel_en-US" xlink:label="lab_hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock reserved for issuance under defined contribution retirement savings plan (in shares)</link:label>
    <link:label id="lab_hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance_label_en-US" xlink:label="lab_hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Number Of Shares Of Common Stock Reserved For Issuance</link:label>
    <link:label id="lab_hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance_documentation_en-US" xlink:label="lab_hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Number Of Shares Of Common Stock Reserved For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance" xlink:href="hum-20231231.xsd#hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance" xlink:to="lab_hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_65acbeca-dec4-40c4-813f-97c56047f050_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate minimum regulatory requirements of statutory capital and surplus</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices, Statutory Capital and Surplus Required</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:to="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_f3fca2df-6334-47d1-9f7d-3067eb36f51e_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DelayedDrawTermLoanMember_8fdc0169-d318-4bfe-bc8f-e4e23ebfcb81_terseLabel_en-US" xlink:label="lab_hum_DelayedDrawTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan</link:label>
    <link:label id="lab_hum_DelayedDrawTermLoanMember_label_en-US" xlink:label="lab_hum_DelayedDrawTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan [Member]</link:label>
    <link:label id="lab_hum_DelayedDrawTermLoanMember_documentation_en-US" xlink:label="lab_hum_DelayedDrawTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DelayedDrawTermLoanMember" xlink:href="hum-20231231.xsd#hum_DelayedDrawTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DelayedDrawTermLoanMember" xlink:to="lab_hum_DelayedDrawTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_129ee2b7-3053-4a2b-940d-4fac958a65b3_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_62672932-08be-45da-801c-408e4f597103_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_2e49eda4-c231-475f-8e9f-867c4c892f94_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e842ba83-dd67-417e-a9b8-e86eac0fe239_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (income) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_24a5d519-ad63-4e5c-9e77-f044777394bf_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (income) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_a531781d-eac7-4c45-8937-ea806f4a1bc7_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a16886b3-bd08-43e7-a556-e540fb9781d8_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4246339c-0da5-4290-ba82-2e6604d778ac_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested restricted stock, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6d1d4338-9d83-4d20-bf45-1b02f04dc881_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested restricted stock, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_TRICARE2017EastRegionContractMember_bffeb475-476a-461a-a595-11c49d63591d_terseLabel_en-US" xlink:label="lab_hum_TRICARE2017EastRegionContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE 2017 East Region Contract</link:label>
    <link:label id="lab_hum_TRICARE2017EastRegionContractMember_label_en-US" xlink:label="lab_hum_TRICARE2017EastRegionContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE 2017 East Region Contract [Member]</link:label>
    <link:label id="lab_hum_TRICARE2017EastRegionContractMember_documentation_en-US" xlink:label="lab_hum_TRICARE2017EastRegionContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE 2017 East Region Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICARE2017EastRegionContractMember" xlink:href="hum-20231231.xsd#hum_TRICARE2017EastRegionContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_TRICARE2017EastRegionContractMember" xlink:to="lab_hum_TRICARE2017EastRegionContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve_7ee5c237-b0d7-4c99-b733-c084e58e94d6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned revenues</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Unearned Premiums Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_449ab821-710f-4b52-9a2e-cb9c40acdb43_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_dd10c01f-479b-4779-b61f-4557043dcd35_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c5f3d19e-a671-49db-b6a0-c40d2771e7f5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_01949ce8-d2f6-4d64-bcf1-4ec1f0ec1398_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetLiabilityNetMeasurementInput_1c85e36e-25b2-4ff3-b3b0-f9911ebadbdc_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetLiabilityNetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetLiabilityNetMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetLiabilityNetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset (Liability) Net, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetLiabilityNetMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetLiabilityNetMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetLiabilityNetMeasurementInput" xlink:to="lab_us-gaap_DerivativeAssetLiabilityNetMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_a4d85236-45d4-4a45-9c80-f67c1acb065b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_fb4538ac-3d93-4504-b2ff-bffa6de4fea5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable to operating subsidiaries</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_9fa2fd5e-359a-4c0b-aa49-1b2579461507_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_672f396b-8fb3-4cf1-a61e-02d03d5744df_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term of exercisable options (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_45070338-5c47-4ea8-9d48-583a35eecc88_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_dadc8732-1d33-42ea-bbe5-53faf74c0d61_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers Out</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_7b7ac82e-fb3d-419a-abea-925223727f32_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_176112cd-9304-4e2b-9d96-113e919e6d64_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_a48390d5-f262-4b37-a979-ce630d271ed7_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_13a9f9a8-2fc7-456f-aa77-623be675de05_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 17)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_10ae0fb2-96ae-4eb4-8576-a272c4e1ea1d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies_f758d887-203d-48d1-b00e-afa9527f1144_terseLabel_en-US" xlink:label="lab_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Typical term (in years) of short-duration employer-group prepaid health services policies</link:label>
    <link:label id="lab_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies_label_en-US" xlink:label="lab_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Typical Term In Years Of Short Duration Employer Group Prepaid Health Services Policies</link:label>
    <link:label id="lab_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies_documentation_en-US" xlink:label="lab_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Typical Term (In Years) Of Short-Duration Employer-Group Prepaid Health Services Policies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies" xlink:href="hum-20231231.xsd#hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies" xlink:to="lab_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_03916610-2830-47d0-9469-9cffdbb636c6_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_641a00aa-bcfc-4d21-8892-df4d498c05bd_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_1eea0303-02b3-46b2-927c-eb3c8dd18309_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_45289fbd-848b-4fa1-9643-bfb586ce79e4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_690c9b97-33a4-49c7-9bdb-28fdd6b6d0b7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d8666192-0639-4844-9519-612c607a8452_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances, beginning of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_bfbd21fb-a06e-4c4c-b4af-1afcecab55fb_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balances, end of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_InterestRateSwapMaturing2032Member_4b59260b-418c-4d35-999a-205b2a20d076_terseLabel_en-US" xlink:label="lab_hum_InterestRateSwapMaturing2032Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap Maturing 2032</link:label>
    <link:label id="lab_hum_InterestRateSwapMaturing2032Member_label_en-US" xlink:label="lab_hum_InterestRateSwapMaturing2032Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap Maturing 2032 [Member]</link:label>
    <link:label id="lab_hum_InterestRateSwapMaturing2032Member_documentation_en-US" xlink:label="lab_hum_InterestRateSwapMaturing2032Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap Maturing 2032</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InterestRateSwapMaturing2032Member" xlink:href="hum-20231231.xsd#hum_InterestRateSwapMaturing2032Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_InterestRateSwapMaturing2032Member" xlink:to="lab_hum_InterestRateSwapMaturing2032Member" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember_2d70d85c-dc52-424e-982d-5a9d4672fe62_terseLabel_en-US" xlink:label="lab_hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS, coverage for individual Medicare Advantage members in Florida</link:label>
    <link:label id="lab_hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember_label_en-US" xlink:label="lab_hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Government, Centers For Medicare And Medicaid Services, Florida Medicare Advantage [Member]</link:label>
    <link:label id="lab_hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember_documentation_en-US" xlink:label="lab_hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Government, Centers For Medicare And Medicaid Services, Florida Medicare Advantage [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember" xlink:href="hum-20231231.xsd#hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember" xlink:to="lab_hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_36e85856-654e-427c-83ed-a3342613cbc9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned revenues</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A135PercentSeniorNotesDueFebruary2027Member_050f9f86-93d6-4f76-a9f7-8ce192664330_terseLabel_en-US" xlink:label="lab_hum_A135PercentSeniorNotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$750 million, 1.350% due February 3, 2027</link:label>
    <link:label id="lab_hum_A135PercentSeniorNotesDueFebruary2027Member_label_en-US" xlink:label="lab_hum_A135PercentSeniorNotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.35 Percent Senior Notes Due February 2027 [Member]</link:label>
    <link:label id="lab_hum_A135PercentSeniorNotesDueFebruary2027Member_documentation_en-US" xlink:label="lab_hum_A135PercentSeniorNotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.35 Percent Senior Notes Due February 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A135PercentSeniorNotesDueFebruary2027Member" xlink:href="hum-20231231.xsd#hum_A135PercentSeniorNotesDueFebruary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A135PercentSeniorNotesDueFebruary2027Member" xlink:to="lab_hum_A135PercentSeniorNotesDueFebruary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_d9935357-084c-4bcb-b529-4c530dd215f9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_97212553-f082-4be2-8f76-4a17df3ed476_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Accident Year [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Accident Year [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_cecbdd9b-8188-4e32-b37b-b9de879ece31_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_04e1c1b6-62e0-4e78-89f4-33f259a2176f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6bfba282-610e-4e3f-82ad-840cd7c33abf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant-Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_LongDurationInsuranceProductsAxis_ba19ad6d-e646-4c91-842e-fe001a18a2a7_terseLabel_en-US" xlink:label="lab_hum_LongDurationInsuranceProductsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Duration Insurance Products [Axis]</link:label>
    <link:label id="lab_hum_LongDurationInsuranceProductsAxis_label_en-US" xlink:label="lab_hum_LongDurationInsuranceProductsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Duration Insurance Products [Axis]</link:label>
    <link:label id="lab_hum_LongDurationInsuranceProductsAxis_documentation_en-US" xlink:label="lab_hum_LongDurationInsuranceProductsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Duration Insurance Products [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LongDurationInsuranceProductsAxis" xlink:href="hum-20231231.xsd#hum_LongDurationInsuranceProductsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_LongDurationInsuranceProductsAxis" xlink:to="lab_hum_LongDurationInsuranceProductsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_65e919db-f0ed-4eff-9969-2b8d2ddeec84_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_b87141b8-eef7-4407-8d56-53910549999c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement gain</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A065PercentSeniorNotesDueAugust2023Member_86279a21-18c9-45f3-9af8-dcf40e3b7252_terseLabel_en-US" xlink:label="lab_hum_A065PercentSeniorNotesDueAugust2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1.5 billion, 0.650% due August 3, 2023</link:label>
    <link:label id="lab_hum_A065PercentSeniorNotesDueAugust2023Member_label_en-US" xlink:label="lab_hum_A065PercentSeniorNotesDueAugust2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.65 Percent Senior Notes Due August 2023 [Member]</link:label>
    <link:label id="lab_hum_A065PercentSeniorNotesDueAugust2023Member_documentation_en-US" xlink:label="lab_hum_A065PercentSeniorNotesDueAugust2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.65 Percent Senior Notes Due August 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A065PercentSeniorNotesDueAugust2023Member" xlink:href="hum-20231231.xsd#hum_A065PercentSeniorNotesDueAugust2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A065PercentSeniorNotesDueAugust2023Member" xlink:to="lab_hum_A065PercentSeniorNotesDueAugust2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3021649e-95e6-4de6-8d8f-f3e5fa1690fa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_0ac71519-ebf2-48ff-be6f-10b1996924ba_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_cd6d5863-da21-4527-b220-2340946e1d8f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3106ad9d-79d2-41ec-85d5-c0defc717855_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3 fair value measurement</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_f3249784-968c-4c3e-a400-f4809c76da51_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClaimsDevelopmentLineItems_d4c3b04d-7d2e-4b36-a026-047fbcbb5297_terseLabel_en-US" xlink:label="lab_us-gaap_ClaimsDevelopmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims Development [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClaimsDevelopmentLineItems_label_en-US" xlink:label="lab_us-gaap_ClaimsDevelopmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims Development [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClaimsDevelopmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClaimsDevelopmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems" xlink:to="lab_us-gaap_ClaimsDevelopmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4badef31-a329-47d8-81b6-162036b37068_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d7cd91aa-3ec5-4def-9265-9a79553f07f6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_5af8ff6c-0b16-40ce-9503-e0762f94551a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_985a01a5-6729-4332-bd32-c970125f7678_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_0fa14318-5519-479e-ac6d-6cc56560be8f_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0c74aea7-1645-421a-bd8e-8d66d005e9c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value at grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_a54dac12-64ae-4270-8c9a-4e2363e4c441_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Humana</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_487aaf5d-be65-4eee-b31d-2d24b2c3269f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Humana</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c5ccb2de-70ab-4ce1-b8ef-8c1135837994_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income available for common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_bacbc400-b235-464f-b942-99818e9baf96_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2077dec0-2f6c-4e6f-8b10-b601b6de6802_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_4f9f2709-5537-4fc8-945b-52df75556267_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_93617667-011c-45f1-adbf-9f99a21690de_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_d3688462-1631-4110-a5fe-74df2a619038_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_7e24874c-6b4e-42cc-a24f-4e6ec0d53975_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_November2022AcceleratedShareRepurchaseProgramMember_261d9511-3fa0-4bfa-b1fd-e5f43a5cf435_terseLabel_en-US" xlink:label="lab_hum_November2022AcceleratedShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2022 ASR</link:label>
    <link:label id="lab_hum_November2022AcceleratedShareRepurchaseProgramMember_label_en-US" xlink:label="lab_hum_November2022AcceleratedShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2022 Accelerated Share Repurchase Program [Member]</link:label>
    <link:label id="lab_hum_November2022AcceleratedShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_hum_November2022AcceleratedShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">November 2022 Accelerated Share Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_November2022AcceleratedShareRepurchaseProgramMember" xlink:href="hum-20231231.xsd#hum_November2022AcceleratedShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_November2022AcceleratedShareRepurchaseProgramMember" xlink:to="lab_hum_November2022AcceleratedShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0618d9e7-bc32-4be3-b2e7-5bae75c12abf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ee20c18b-226e-4375-ac44-475281c21c91_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_efe59ce0-6ee6-468b-91de-982d25587130_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_0384d88f-9040-4890-b1a0-602ab437c27e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Paid Claims, Net of Reinsurance</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_71d980f4-f1df-4186-9a27-dc743bab53b6_terseLabel_en-US" xlink:label="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION</link:label>
    <link:label id="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information of Parent Company Only Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c42bf2ba-1c51-44bc-8840-41aa30e5b4d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_ce7ec63f-2065-44a3-9e6c-86e54b1bf0cc_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a08883a3-d637-4a75-bb62-0592f497915a_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_17fa6bf2-29f3-465a-ad7b-c7830a813b50_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported_2028781c-0776-478e-8d60-9fddf427dcb3_terseLabel_en-US" xlink:label="lab_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative number of reported claims</link:label>
    <link:label id="lab_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported_label_en-US" xlink:label="lab_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Unpaid Claims And Claims Adjustment Expense, Cumulative Number Of Claims, Reported</link:label>
    <link:label id="lab_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported_documentation_en-US" xlink:label="lab_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Unpaid Claims And Claims Adjustment Expense, Cumulative Number Of Claims, Reported</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported" xlink:href="hum-20231231.xsd#hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported" xlink:to="lab_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_9d29432d-34f6-4078-b4d0-a89a884f94f3_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DebtAndEquitySecuritiesRealizedGain_e635bf06-611f-4a0c-8860-96ec1b4a03bb_terseLabel_en-US" xlink:label="lab_hum_DebtAndEquitySecuritiesRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross gains on investment securities</link:label>
    <link:label id="lab_hum_DebtAndEquitySecuritiesRealizedGain_label_en-US" xlink:label="lab_hum_DebtAndEquitySecuritiesRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt And Equity Securities, Realized Gain</link:label>
    <link:label id="lab_hum_DebtAndEquitySecuritiesRealizedGain_documentation_en-US" xlink:label="lab_hum_DebtAndEquitySecuritiesRealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt And Equity Securities, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DebtAndEquitySecuritiesRealizedGain" xlink:href="hum-20231231.xsd#hum_DebtAndEquitySecuritiesRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DebtAndEquitySecuritiesRealizedGain" xlink:to="lab_hum_DebtAndEquitySecuritiesRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest_4c17cde4-db5d-4af4-a522-27b636a813ec_terseLabel_en-US" xlink:label="lab_hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction amount, net of existing equity stake</link:label>
    <link:label id="lab_hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest_label_en-US" xlink:label="lab_hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Per Agreement, Net Of Existing Equity Interest</link:label>
    <link:label id="lab_hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest_documentation_en-US" xlink:label="lab_hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Per Agreement, Net Of Existing Equity Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest" xlink:href="hum-20231231.xsd#hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest" xlink:to="lab_hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19427d10-4deb-4eb8-a387-37eb374e65b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_InvestmentAndOtherIncomeNet_908e4e4e-8fd3-49c8-b948-7881dc7627a9_terseLabel_en-US" xlink:label="lab_hum_InvestmentAndOtherIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment and other (loss) income, net</link:label>
    <link:label id="lab_hum_InvestmentAndOtherIncomeNet_label_en-US" xlink:label="lab_hum_InvestmentAndOtherIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment And Other Income Net</link:label>
    <link:label id="lab_hum_InvestmentAndOtherIncomeNet_documentation_en-US" xlink:label="lab_hum_InvestmentAndOtherIncomeNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment and other income, net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InvestmentAndOtherIncomeNet" xlink:href="hum-20231231.xsd#hum_InvestmentAndOtherIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_InvestmentAndOtherIncomeNet" xlink:to="lab_hum_InvestmentAndOtherIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_bed2e175-447b-42c2-8d9b-fd7ce289dc50_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligations in 2026</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_04befdb3-4bdd-4038-bf9f-2f7330ca4075_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_bcebb6cf-e587-468d-827a-f78031187fc6_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_ca71811b-a1a2-4753-b992-af9d0b78ea5b_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax_eade903d-afd9-4e8c-a281-f41e6714ae46_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax earnings</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Individually Significant Component Disposed of or Held-for-Sale, Excluding Discontinued Operations, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax" xlink:to="lab_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_108a81ce-5b34-403d-9cc9-19bebe988ff5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares_a82a2690-e6b1-42cd-b96a-8e8bfb66925b_terseLabel_en-US" xlink:label="lab_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets invested in Company common stock (in shares)</link:label>
    <link:label id="lab_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares_label_en-US" xlink:label="lab_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Plan Assets Invested In Company Common Stock, Shares</link:label>
    <link:label id="lab_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares_documentation_en-US" xlink:label="lab_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Plan Assets Invested In Company Common Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares" xlink:href="hum-20231231.xsd#hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares" xlink:to="lab_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_fffda127-0aed-462d-9a5f-7cf447bae806_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_SignificantAccountingPoliciesTable_75b25df8-f5f1-43d2-8343-ca75c4ae47e2_terseLabel_en-US" xlink:label="lab_hum_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_hum_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_hum_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_hum_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_hum_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SignificantAccountingPoliciesTable" xlink:href="hum-20231231.xsd#hum_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_SignificantAccountingPoliciesTable" xlink:to="lab_hum_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsurancePremiumsRevenueRecognitionPolicy_61b97b57-bc79-43b9-b576-ca7288a0c8a6_terseLabel_en-US" xlink:label="lab_us-gaap_InsurancePremiumsRevenueRecognitionPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Revenue</link:label>
    <link:label id="lab_us-gaap_InsurancePremiumsRevenueRecognitionPolicy_label_en-US" xlink:label="lab_us-gaap_InsurancePremiumsRevenueRecognitionPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Premiums Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsurancePremiumsRevenueRecognitionPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsurancePremiumsRevenueRecognitionPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsurancePremiumsRevenueRecognitionPolicy" xlink:to="lab_us-gaap_InsurancePremiumsRevenueRecognitionPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_b832f2ef-9ef6-4978-89b9-1756e21b36d5_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_9d926f9e-f9d0-404c-9b85-04c3398b554e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_87911611-47de-4b1f-ada6-711ad038ed7e_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SubsidiariesMember_ccf852b1-7969-4013-b1ae-2cce9bc7af55_terseLabel_en-US" xlink:label="lab_srt_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiaries</link:label>
    <link:label id="lab_srt_SubsidiariesMember_label_en-US" xlink:label="lab_srt_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiaries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SubsidiariesMember" xlink:to="lab_srt_SubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_fa887383-c1bc-438b-b0d9-fd1d081b9907_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividend declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ed8160c1-117c-4677-98f6-e868e8d7c061_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total change in unrealized investment gains (losses), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_cf14dbb5-0cdd-40a5-85f5-fa9eabe473ea_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities included within other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_b003ec13-623a-4fde-84eb-e30db9d18e8c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred related to:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_89cadb10-8e88-4afa-acd7-f6441884a95e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contractual Maturities of Debt Securities Available for Sale</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_StrategicPartnershipAgreementCallOptionStrikePrice_5618c9fa-d875-4dcb-b34b-e317b21f939b_terseLabel_en-US" xlink:label="lab_hum_StrategicPartnershipAgreementCallOptionStrikePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call option strike price</link:label>
    <link:label id="lab_hum_StrategicPartnershipAgreementCallOptionStrikePrice_label_en-US" xlink:label="lab_hum_StrategicPartnershipAgreementCallOptionStrikePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Partnership Agreement, Call Option Strike Price</link:label>
    <link:label id="lab_hum_StrategicPartnershipAgreementCallOptionStrikePrice_documentation_en-US" xlink:label="lab_hum_StrategicPartnershipAgreementCallOptionStrikePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Partnership Agreement, Call Option Strike Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_StrategicPartnershipAgreementCallOptionStrikePrice" xlink:href="hum-20231231.xsd#hum_StrategicPartnershipAgreementCallOptionStrikePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_StrategicPartnershipAgreementCallOptionStrikePrice" xlink:to="lab_hum_StrategicPartnershipAgreementCallOptionStrikePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_CommercialASOMember_d19eef81-f608-4003-89f7-3c2e747e5e82_terseLabel_en-US" xlink:label="lab_hum_CommercialASOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial ASO</link:label>
    <link:label id="lab_hum_CommercialASOMember_label_en-US" xlink:label="lab_hum_CommercialASOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial ASO [Member]</link:label>
    <link:label id="lab_hum_CommercialASOMember_documentation_en-US" xlink:label="lab_hum_CommercialASOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial ASO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CommercialASOMember" xlink:href="hum-20231231.xsd#hum_CommercialASOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_CommercialASOMember" xlink:to="lab_hum_CommercialASOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_16c52204-c986-4e56-84cf-8b9746a2936d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument term (in years)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1fa58791-effe-473a-a870-35e3cf8141e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_028e828b-1dae-4d85-8705-c1cc813ad739_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_52a990ca-d16e-41df-922b-a9039ebc6a41_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issue costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_c1fdcbb0-6edf-49a9-bcff-1f88b3fd0b34_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e3216032-277f-4fc8-a392-dca15232a753_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_784f8cb3-5d18-4a85-b1d1-4728327882f8_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_08cfa24c-a488-4976-ac92-a8c50181513b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_55bb3719-e875-4172-8f78-72587ef5081f_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_c86a0832-53d1-49b7-9844-231b9c3f8e0e_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions_7e2c3b4e-39f5-4758-b65f-9ea9a58d144b_terseLabel_en-US" xlink:label="lab_hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities, number of positions</link:label>
    <link:label id="lab_hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions_label_en-US" xlink:label="lab_hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Securities, Available-For-Sale, Securities, Number Of Positions</link:label>
    <link:label id="lab_hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions_documentation_en-US" xlink:label="lab_hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Securities, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions" xlink:href="hum-20231231.xsd#hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions" xlink:to="lab_hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a887a920-e955-4b06-b380-a5aef534ee4c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fc4ce868-982a-4606-a291-b50cd8501b42_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A2021ShareRepurchaseAuthorizationMember_9c4378c6-9640-483c-a080-d7e2399c71e1_terseLabel_en-US" xlink:label="lab_hum_A2021ShareRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Authorization</link:label>
    <link:label id="lab_hum_A2021ShareRepurchaseAuthorizationMember_label_en-US" xlink:label="lab_hum_A2021ShareRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Authorization [Member]</link:label>
    <link:label id="lab_hum_A2021ShareRepurchaseAuthorizationMember_documentation_en-US" xlink:label="lab_hum_A2021ShareRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Share Repurchase Authorization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A2021ShareRepurchaseAuthorizationMember" xlink:href="hum-20231231.xsd#hum_A2021ShareRepurchaseAuthorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A2021ShareRepurchaseAuthorizationMember" xlink:to="lab_hum_A2021ShareRepurchaseAuthorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_January2022AcceleratedShareRepurchaseAgreementMember_8928d89f-d25c-44cd-aaa6-3bbeacfe6641_terseLabel_en-US" xlink:label="lab_hum_January2022AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2022 ASR</link:label>
    <link:label id="lab_hum_January2022AcceleratedShareRepurchaseAgreementMember_label_en-US" xlink:label="lab_hum_January2022AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2022 Accelerated Share Repurchase Agreement [Member]</link:label>
    <link:label id="lab_hum_January2022AcceleratedShareRepurchaseAgreementMember_documentation_en-US" xlink:label="lab_hum_January2022AcceleratedShareRepurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">January 2022 Accelerated Share Repurchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_January2022AcceleratedShareRepurchaseAgreementMember" xlink:href="hum-20231231.xsd#hum_January2022AcceleratedShareRepurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_January2022AcceleratedShareRepurchaseAgreementMember" xlink:to="lab_hum_January2022AcceleratedShareRepurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_4f8b6b6d-0246-4a68-8584-7697d0a4dd2e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_ca07d022-9d68-487b-bd48-d184746be69a_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_80c9e9a2-87c0-43e4-afd2-4b3b01f07a3f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_3303c23b-7d6f-4ed2-a616-7c88b04fe182_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total compensation expense not yet recognized related to nonvested awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_86060eae-6732-4312-8030-68d6c62edc99_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangibles</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_23d2e105-3e96-4e8a-8840-4446b931b89f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares reserved for stock award plans (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock_5e7f72c9-0c48-456d-9dbd-2f247060963b_terseLabel_en-US" xlink:label="lab_hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Health Care Cost Payments and Reimbursements</link:label>
    <link:label id="lab_hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock_label_en-US" xlink:label="lab_hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Health Care Cost Payments and Reimbursements [Table Text Block]</link:label>
    <link:label id="lab_hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock_documentation_en-US" xlink:label="lab_hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Health Care Cost Payments and Reimbursements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock" xlink:href="hum-20231231.xsd#hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock" xlink:to="lab_hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b7a30c80-bfb2-4f68-bf2c-e8678eec4653_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual term of outstanding options (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_c3dfbb1c-ab9a-4f47-b55b-02a45351f340_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6a57cebd-ba45-4f05-b34b-d96ea09f93e8_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_d45ee8e5-ecf7-4a16-8a96-2108903ddd74_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f2f2ba7f-8892-4195-86d5-e5ad5cbd491b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_f148e2fb-eb63-445c-8128-15cff5f9a23a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average cost of capital</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4831512c-711c-4bd9-9a63-576c6f0b8ee7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_ae4eeccb-b372-4049-878a-92df86a2f453_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_6e1d10fa-9481-4e0f-b916-2e9fedec62de_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_CorporateAndEliminationsMember_472a668a-c9ec-4a08-9a2d-d22966c1b832_terseLabel_en-US" xlink:label="lab_hum_CorporateAndEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eliminations/ Corporate</link:label>
    <link:label id="lab_hum_CorporateAndEliminationsMember_label_en-US" xlink:label="lab_hum_CorporateAndEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate And Eliminations [Member]</link:label>
    <link:label id="lab_hum_CorporateAndEliminationsMember_documentation_en-US" xlink:label="lab_hum_CorporateAndEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate And Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CorporateAndEliminationsMember" xlink:href="hum-20231231.xsd#hum_CorporateAndEliminationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_CorporateAndEliminationsMember" xlink:to="lab_hum_CorporateAndEliminationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_72340d38-7408-4b65-a2e4-aafedc33d33b_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense for other intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_6425d0b2-d733-4a73-a081-67343498bd67_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_2bbe5d58-0cd3-4d41-a08a-df7c01cc1b30_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_b30f0957-6395-4919-b364-751242b526b5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a07de5e-a135-4c69-8fc4-a73ce73a902c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d07d82c5-cccf-4061-916d-17d99a867390_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedLoss_dfa5ba3b-cddf-4c22-b4fc-1ff15d8fadd3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross losses on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer_d06b2754-81f5-4cb9-a9ac-9576cb6b4b5f_terseLabel_en-US" xlink:label="lab_hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and securities in trusts held by certain reinsurers</link:label>
    <link:label id="lab_hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer_label_en-US" xlink:label="lab_hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Held In Cash And Securities In Trust At Least Equal To Recoverable From Reinsurer</link:label>
    <link:label id="lab_hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer_documentation_en-US" xlink:label="lab_hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount held in cash and securities in trust, at least equal to the recoverable from the reinsurer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer" xlink:href="hum-20231231.xsd#hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer" xlink:to="lab_hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_f613e8c3-1cb1-4936-b9e5-4e53844f3841_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_4e278676-be7f-4b5a-a5b0-a12be45d4fa5_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_4699aabb-04ea-442d-be6f-10a02e2d5c8f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_79d9cd96-3d4f-4ff9-b6e0-c95d6bca36d5_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_9ca23ec7-c3df-4a3f-b218-b9711d433414_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">12 months or more</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_d940bec1-1290-4ea8-b9d3-b12994415e47_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7d97588c-ffec-4933-b912-b8b663b8ef1d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_7abcecc6-511a-4ddf-8382-c257ff0a5029_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_dfac4741-fac3-446b-b760-db069de774aa_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_53025a73-e343-4d97-b0dc-e61515ad1dfc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Gross Unrealized Losses and Fair Value of Securities</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_78af20bc-67f4-49f9-aed0-45c10466a7c4_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost, 76,465,862 shares at December 31, 2023 and 73,691,955 shares at December 31, 2022</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_128ae2a1-15df-4950-b43d-8c8e1f73007c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total invested assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_4ed55260-8392-4747-9d0c-f2b3a3ddb804_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_BusinessCombinationTotalEnterpriseValueOfAcquiree_eb54b3d3-ddbd-4b2d-aa3a-db95c5cd1c55_terseLabel_en-US" xlink:label="lab_hum_BusinessCombinationTotalEnterpriseValueOfAcquiree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Enterprise value of acquiree including existing equity value</link:label>
    <link:label id="lab_hum_BusinessCombinationTotalEnterpriseValueOfAcquiree_label_en-US" xlink:label="lab_hum_BusinessCombinationTotalEnterpriseValueOfAcquiree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Total Enterprise Value Of Acquiree</link:label>
    <link:label id="lab_hum_BusinessCombinationTotalEnterpriseValueOfAcquiree_documentation_en-US" xlink:label="lab_hum_BusinessCombinationTotalEnterpriseValueOfAcquiree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Total Enterprise Value Of Acquiree</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BusinessCombinationTotalEnterpriseValueOfAcquiree" xlink:href="hum-20231231.xsd#hum_BusinessCombinationTotalEnterpriseValueOfAcquiree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_BusinessCombinationTotalEnterpriseValueOfAcquiree" xlink:to="lab_hum_BusinessCombinationTotalEnterpriseValueOfAcquiree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_676f1320-a708-4ead-b83b-d7649dfad340_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A3.95PercentSeniorNotesDueMarch2027Member_e66f9732-9a1a-484f-aa78-a1f68a5dbaae_terseLabel_en-US" xlink:label="lab_hum_A3.95PercentSeniorNotesDueMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$600 million, 3.950% due March 15, 2027</link:label>
    <link:label id="lab_hum_A3.95PercentSeniorNotesDueMarch2027Member_label_en-US" xlink:label="lab_hum_A3.95PercentSeniorNotesDueMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95 Percent Senior Notes Due March 2027 [Member]</link:label>
    <link:label id="lab_hum_A3.95PercentSeniorNotesDueMarch2027Member_documentation_en-US" xlink:label="lab_hum_A3.95PercentSeniorNotesDueMarch2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95 Percent Senior Notes Due March 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3.95PercentSeniorNotesDueMarch2027Member" xlink:href="hum-20231231.xsd#hum_A3.95PercentSeniorNotesDueMarch2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A3.95PercentSeniorNotesDueMarch2027Member" xlink:to="lab_hum_A3.95PercentSeniorNotesDueMarch2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual_5d3482ef-f5dd-45ac-9464-e0534e5e8a08_terseLabel_en-US" xlink:label="lab_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual debt to capitalization percentage</link:label>
    <link:label id="lab_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual_label_en-US" xlink:label="lab_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt To Capitalization Percentage, Actual</link:label>
    <link:label id="lab_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual_documentation_en-US" xlink:label="lab_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt To Capitalization Percentage, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual" xlink:href="hum-20231231.xsd#hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual" xlink:to="lab_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_86355e49-e322-4bf3-a322-88959c850c9c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation expense recognition over a weighted-average period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_afe451df-6e3a-4c57-a022-5c9c3eae5031_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0cbc356c-cad4-4a80-a639-a6b53d037ff9_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to Humana</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_RepurchasePlanAugust2023Member_0adafb30-eae6-4aa9-9985-c71724f92bef_terseLabel_en-US" xlink:label="lab_hum_RepurchasePlanAugust2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Plan, August 2023</link:label>
    <link:label id="lab_hum_RepurchasePlanAugust2023Member_label_en-US" xlink:label="lab_hum_RepurchasePlanAugust2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Plan, August 2023 [Member]</link:label>
    <link:label id="lab_hum_RepurchasePlanAugust2023Member_documentation_en-US" xlink:label="lab_hum_RepurchasePlanAugust2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Plan, August 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RepurchasePlanAugust2023Member" xlink:href="hum-20231231.xsd#hum_RepurchasePlanAugust2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_RepurchasePlanAugust2023Member" xlink:to="lab_hum_RepurchasePlanAugust2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_b851d40b-5d6a-4866-b478-a7ead385c830_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ExternalCreditRatingStandardPoorsMember_6853cbe0-2c9e-4e4f-97ae-1a297370e95e_terseLabel_en-US" xlink:label="lab_srt_ExternalCreditRatingStandardPoorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Credit Rating, Standard &amp; Poor's [Domain]</link:label>
    <link:label id="lab_srt_ExternalCreditRatingStandardPoorsMember_label_en-US" xlink:label="lab_srt_ExternalCreditRatingStandardPoorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">External Credit Rating, Standard &amp; Poor's [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExternalCreditRatingStandardPoorsMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExternalCreditRatingStandardPoorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExternalCreditRatingStandardPoorsMember" xlink:to="lab_srt_ExternalCreditRatingStandardPoorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_6dca7b0e-3bbf-4789-adfd-3299dc2623ab_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8f11fcf5-f68c-4fa2-b470-50a526f2264b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract_8654d328-2941-40d3-a325-98b329fa8e35_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details of businesses acquired in purchase transactions:</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_NumberOfStatesComprisingTRICAREBeneficiaries_6bb62f41-5556-468b-a1f0-0be47a03e946_terseLabel_en-US" xlink:label="lab_hum_NumberOfStatesComprisingTRICAREBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states comprising TRICARE beneficiaries</link:label>
    <link:label id="lab_hum_NumberOfStatesComprisingTRICAREBeneficiaries_label_en-US" xlink:label="lab_hum_NumberOfStatesComprisingTRICAREBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of States Comprising TRICARE Beneficiaries</link:label>
    <link:label id="lab_hum_NumberOfStatesComprisingTRICAREBeneficiaries_documentation_en-US" xlink:label="lab_hum_NumberOfStatesComprisingTRICAREBeneficiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of States Comprising TRICARE Beneficiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfStatesComprisingTRICAREBeneficiaries" xlink:href="hum-20231231.xsd#hum_NumberOfStatesComprisingTRICAREBeneficiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_NumberOfStatesComprisingTRICAREBeneficiaries" xlink:to="lab_hum_NumberOfStatesComprisingTRICAREBeneficiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A575PercentSeniorNotesDueMarch2028Member_b83427f3-e732-4fad-975b-daee67c558db_terseLabel_en-US" xlink:label="lab_hum_A575PercentSeniorNotesDueMarch2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million, 5.750% due March 1, 2028</link:label>
    <link:label id="lab_hum_A575PercentSeniorNotesDueMarch2028Member_label_en-US" xlink:label="lab_hum_A575PercentSeniorNotesDueMarch2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75 Percent Senior Notes Due March 2028 [Member]</link:label>
    <link:label id="lab_hum_A575PercentSeniorNotesDueMarch2028Member_documentation_en-US" xlink:label="lab_hum_A575PercentSeniorNotesDueMarch2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75 Percent Senior Notes Due March 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A575PercentSeniorNotesDueMarch2028Member" xlink:href="hum-20231231.xsd#hum_A575PercentSeniorNotesDueMarch2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A575PercentSeniorNotesDueMarch2028Member" xlink:to="lab_hum_A575PercentSeniorNotesDueMarch2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares_47af1abe-7ab4-4fc2-90e6-e5b68f69cf97_terseLabel_en-US" xlink:label="lab_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares acquired in connection with employee stock plans (in shares)</link:label>
    <link:label id="lab_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares_label_en-US" xlink:label="lab_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchases Related To Employee Stock Based Compensation Awards Shares</link:label>
    <link:label id="lab_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares_documentation_en-US" xlink:label="lab_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of common stock that were repurchased in the administration of our employee share-based compensation plans. Under the terms of these plans, we accept shares of common stock from option holders if they elect to surrender previously-owned shares upon exercise of the option to cover the exercise price of the options or, in the case of restricted shares of common stock, the withholding of shares to satisfy tax withholding obligations associated with the vesting of such shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares" xlink:href="hum-20231231.xsd#hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares" xlink:to="lab_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4fb885a7-30fa-454e-842a-a949bab02e89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_7ade25e2-2376-4706-959e-4cace3a02dab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DividendsToParentWithoutPriorStateRegulatoryApproval_022548e1-ae18-44d1-ba5e-f8498a3c0298_terseLabel_en-US" xlink:label="lab_hum_DividendsToParentWithoutPriorStateRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual dividends paid to parent company</link:label>
    <link:label id="lab_hum_DividendsToParentWithoutPriorStateRegulatoryApproval_label_en-US" xlink:label="lab_hum_DividendsToParentWithoutPriorStateRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends To Parent Without Prior State Regulatory Approval</link:label>
    <link:label id="lab_hum_DividendsToParentWithoutPriorStateRegulatoryApproval_documentation_en-US" xlink:label="lab_hum_DividendsToParentWithoutPriorStateRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of dividends paid to our parent company without prior approval by state regulatory authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DividendsToParentWithoutPriorStateRegulatoryApproval" xlink:href="hum-20231231.xsd#hum_DividendsToParentWithoutPriorStateRegulatoryApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DividendsToParentWithoutPriorStateRegulatoryApproval" xlink:to="lab_hum_DividendsToParentWithoutPriorStateRegulatoryApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_565a0b36-e795-4f20-9821-67fd784fbea8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_CitibankNAMember_55dcf399-6184-4da8-bc08-68697abc5c4e_terseLabel_en-US" xlink:label="lab_hum_CitibankNAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Citi</link:label>
    <link:label id="lab_hum_CitibankNAMember_label_en-US" xlink:label="lab_hum_CitibankNAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Citibank NA [Member]</link:label>
    <link:label id="lab_hum_CitibankNAMember_documentation_en-US" xlink:label="lab_hum_CitibankNAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Citibank NA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CitibankNAMember" xlink:href="hum-20231231.xsd#hum_CitibankNAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_CitibankNAMember" xlink:to="lab_hum_CitibankNAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_4c007b78-12f4-499e-b3a2-1a404fc1bfbe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses to carryforward related to prior acquisitions</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A488PercentSeniorNotesDueApril2030Member_799f2d17-c2a4-4715-99bf-2b99d3f54d35_terseLabel_en-US" xlink:label="lab_hum_A488PercentSeniorNotesDueApril2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million, 4.875% due April 1, 2030</link:label>
    <link:label id="lab_hum_A488PercentSeniorNotesDueApril2030Member_label_en-US" xlink:label="lab_hum_A488PercentSeniorNotesDueApril2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.88 Percent Senior Notes Due April 2030 [Member]</link:label>
    <link:label id="lab_hum_A488PercentSeniorNotesDueApril2030Member_documentation_en-US" xlink:label="lab_hum_A488PercentSeniorNotesDueApril2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.88 Percent Senior Notes Due April 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A488PercentSeniorNotesDueApril2030Member" xlink:href="hum-20231231.xsd#hum_A488PercentSeniorNotesDueApril2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A488PercentSeniorNotesDueApril2030Member" xlink:to="lab_hum_A488PercentSeniorNotesDueApril2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_8d0c9158-8a12-4f8a-8399-7a05aebf7d83_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_f9f8dfc5-8097-4a6a-98c6-3f176fd71464_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets Included in Other Long-Term Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_a367e354-59f4-411b-8956-a9f03c0ce1f0_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average daily volume weighted-average share price of common stock during term of agreement (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Final Price Paid Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_31617eec-2b6b-4818-8a9e-1c0ddea97814_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionOnSecuritiesMember_16845bab-b627-4558-bbf9-3b2868d3f425_terseLabel_en-US" xlink:label="lab_us-gaap_OptionOnSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_OptionOnSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OptionOnSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option on Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionOnSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionOnSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionOnSecuritiesMember" xlink:to="lab_us-gaap_OptionOnSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_436f6139-91b8-42a2-a4f7-d4c7c35addb6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableRecordedInvestmentLineItems_033bf1bd-96b0-4800-9e4c-7a3115f49ec1_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Credit Quality Indicator [Line Items]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableRecordedInvestmentLineItems_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableRecordedInvestmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Credit Quality Indicator [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems" xlink:to="lab_us-gaap_FinancingReceivableRecordedInvestmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_2258a2f2-b51d-4ee7-ba93-55e5310ca59f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_f12d8bb4-601b-4ade-89c0-6afd86eb9542_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_d60661a2-4d76-4fdc-94ca-cdcfc0353d12_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7c14328d-151a-4a04-b5b8-380ae0706fb3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision at federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_3dc73ff9-cfc6-4dd0-8456-3ebc9fd6fda8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity in Benefits Payable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceTextBlock_d905a545-e08a-41ab-826a-9f7cf03adb6a_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REINSURANCE</link:label>
    <link:label id="lab_us-gaap_ReinsuranceTextBlock_label_en-US" xlink:label="lab_us-gaap_ReinsuranceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceTextBlock" xlink:to="lab_us-gaap_ReinsuranceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_3cb235f7-2772-4f1c-a785-ff96add416bf_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A3700PercentSeniorNotesDueMarch2029Member_40f94f8f-59ba-4c6a-8562-9cd8099e0157_terseLabel_en-US" xlink:label="lab_hum_A3700PercentSeniorNotesDueMarch2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.700 Percent Senior Notes Due March 2029</link:label>
    <link:label id="lab_hum_A3700PercentSeniorNotesDueMarch2029Member_label_en-US" xlink:label="lab_hum_A3700PercentSeniorNotesDueMarch2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.700 Percent Senior Notes Due March 2029 [Member]</link:label>
    <link:label id="lab_hum_A3700PercentSeniorNotesDueMarch2029Member_documentation_en-US" xlink:label="lab_hum_A3700PercentSeniorNotesDueMarch2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.700 Percent Senior Notes Due March 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3700PercentSeniorNotesDueMarch2029Member" xlink:href="hum-20231231.xsd#hum_A3700PercentSeniorNotesDueMarch2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A3700PercentSeniorNotesDueMarch2029Member" xlink:to="lab_hum_A3700PercentSeniorNotesDueMarch2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_38833aa0-8f0c-46ec-be10-1cae883279e8_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_fc4e1a6a-1a43-43e0-b8f9-4d0c7a1527a4_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_fa5bc9f6-800b-4983-a26f-dc286580b090_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock repurchases</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7c7cfc38-7efe-438a-a61d-07b9af74dca0_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_bdacbee6-9253-4d21-a2e9-6f3ad8a42705_totalLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits payable, net of reinsurance</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges_5a44ba7b-c0bc-4fd5-a15d-edde4afb2af0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and impairment charge</link:label>
    <link:label id="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_RestructuringCostsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_BookOverdraftLiability_6f3fbba1-fbbf-4acb-a6ac-3edf57f8be5b_terseLabel_en-US" xlink:label="lab_hum_BookOverdraftLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Book overdraft</link:label>
    <link:label id="lab_hum_BookOverdraftLiability_label_en-US" xlink:label="lab_hum_BookOverdraftLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Book Overdraft Liability</link:label>
    <link:label id="lab_hum_BookOverdraftLiability_documentation_en-US" xlink:label="lab_hum_BookOverdraftLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Book Overdraft Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BookOverdraftLiability" xlink:href="hum-20231231.xsd#hum_BookOverdraftLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_BookOverdraftLiability" xlink:to="lab_hum_BookOverdraftLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_e7b3287d-279b-48c2-867e-3f3cd70f1c43_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS AND DIVESTITURES</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_fbbb684e-1f49-477e-a438-1d386b3154c6_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_ac571d44-eb56-4af3-b846-438342df8029_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_f272acbc-652d-4f41-834b-16174cabeb29_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationNonproduction_278c014c-86b5-4b08-9c67-dab4ee7437f7_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationNonproduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_DepreciationNonproduction_label_en-US" xlink:label="lab_us-gaap_DepreciationNonproduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationNonproduction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationNonproduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationNonproduction" xlink:to="lab_us-gaap_DepreciationNonproduction" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_ec33aeff-4e82-455c-aa63-23fc885cddf6_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputLongTermRevenueGrowthRateMember_b8b2fa81-3cef-4054-809c-ab04c68ca9a5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputLongTermRevenueGrowthRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term growth rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputLongTermRevenueGrowthRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputLongTermRevenueGrowthRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Long-Term Revenue Growth Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputLongTermRevenueGrowthRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputLongTermRevenueGrowthRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputLongTermRevenueGrowthRateMember" xlink:to="lab_us-gaap_MeasurementInputLongTermRevenueGrowthRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b9694c23-00c0-4133-8468-d7abcc9c7b63_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_d7045f0c-d6c2-4566-9352-5e7b7ff7dfa3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock unit vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_579941eb-de6e-4523-b7f8-a547b1cd2759_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEFITS PAYABLE</link:label>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:to="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_c159fd48-c636-49bf-929b-3668fc033ac9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfers In</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_KindredAtHomeMember_a1aba32e-73ae-4d0e-bbca-6e7d3c416cc1_terseLabel_en-US" xlink:label="lab_hum_KindredAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kindred at Home</link:label>
    <link:label id="lab_hum_KindredAtHomeMember_label_en-US" xlink:label="lab_hum_KindredAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kindred At Home [Member]</link:label>
    <link:label id="lab_hum_KindredAtHomeMember_documentation_en-US" xlink:label="lab_hum_KindredAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kindred At Home [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_KindredAtHomeMember" xlink:href="hum-20231231.xsd#hum_KindredAtHomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_KindredAtHomeMember" xlink:to="lab_hum_KindredAtHomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_c2490ba1-b1df-49a9-9dc4-a418f7c98d60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_6a9c1d98-9abd-48da-825f-e82649be3176_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Claims Development [Table]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Claims Development [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NontaxableMunicipalNotesMember_aa90cf9f-5d3e-4e26-bd75-19f5607fffbd_verboseLabel_en-US" xlink:label="lab_us-gaap_NontaxableMunicipalNotesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax-exempt municipal securities</link:label>
    <link:label id="lab_us-gaap_NontaxableMunicipalNotesMember_label_en-US" xlink:label="lab_us-gaap_NontaxableMunicipalNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nontaxable Municipal Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontaxableMunicipalNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontaxableMunicipalNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NontaxableMunicipalNotesMember" xlink:to="lab_us-gaap_NontaxableMunicipalNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4b0a9526-81f4-4313-96c2-8ba02da04df9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_109c389c-3c26-4f4b-bea0-1dc1b320434f_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_498356ef-6100-4e9b-a841-56f9b6a2a7ac_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_f4306e2d-98db-4782-94da-5712dc34b015_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_3993b274-4b10-418d-8d5d-06b0b84b298b_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6f50b81a-cb4e-4ad3-8485-40995d59028d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_75e2d7cd-3521-449f-82f0-4e76b7cf2d31_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember_01f47918-53f5-4216-b532-988c3d1c041a_terseLabel_en-US" xlink:label="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential</link:label>
    <link:label id="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Residential Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_ResidentialMortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters_9961d059-78c5-4937-93fe-5f6055109531_terseLabel_en-US" xlink:label="lab_hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of primary care centers in strategic partnership</link:label>
    <link:label id="lab_hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters_label_en-US" xlink:label="lab_hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Partnership Agreement, Number Of Primary Care Centers</link:label>
    <link:label id="lab_hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters_documentation_en-US" xlink:label="lab_hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Partnership Agreement, Number Of Primary Care Centers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters" xlink:href="hum-20231231.xsd#hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters" xlink:to="lab_hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_554ab245-b7e9-4cb7-845c-d5b85be4d82a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investment securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_aea39905-2bf5-4439-b83c-8f4b2a862239_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A2023ShareRepurchaseAuthorizationMember_87518e1d-21b3-41b3-8f32-ca9f59fce66d_terseLabel_en-US" xlink:label="lab_hum_A2023ShareRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Share Repurchase Authorization</link:label>
    <link:label id="lab_hum_A2023ShareRepurchaseAuthorizationMember_label_en-US" xlink:label="lab_hum_A2023ShareRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Share Repurchase Authorization [Member]</link:label>
    <link:label id="lab_hum_A2023ShareRepurchaseAuthorizationMember_documentation_en-US" xlink:label="lab_hum_A2023ShareRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Share Repurchase Authorization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A2023ShareRepurchaseAuthorizationMember" xlink:href="hum-20231231.xsd#hum_A2023ShareRepurchaseAuthorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A2023ShareRepurchaseAuthorizationMember" xlink:to="lab_hum_A2023ShareRepurchaseAuthorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_HealthCareCostReimbursements_d6232865-9d0f-43ca-a0ba-e8d1f4f6529c_terseLabel_en-US" xlink:label="lab_hum_HealthCareCostReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health care cost reimbursements</link:label>
    <link:label id="lab_hum_HealthCareCostReimbursements_label_en-US" xlink:label="lab_hum_HealthCareCostReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Cost Reimbursements</link:label>
    <link:label id="lab_hum_HealthCareCostReimbursements_documentation_en-US" xlink:label="lab_hum_HealthCareCostReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reimbursements for health care cost payments associated with the TRICARE South Region contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_HealthCareCostReimbursements" xlink:href="hum-20231231.xsd#hum_HealthCareCostReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_HealthCareCostReimbursements" xlink:to="lab_hum_HealthCareCostReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_60ca01fb-2e29-4493-a4f1-b3970145dbc5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock_b239f913-80d5-4173-b846-ecc864829fb6_terseLabel_en-US" xlink:label="lab_hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock_label_en-US" xlink:label="lab_hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Compensation Related Costs Share Based Payments And Compensation And Retirement Disclosure [Text Block]</link:label>
    <link:label id="lab_hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock_documentation_en-US" xlink:label="lab_hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure Of Compensation Related Costs Share Based Payments And Compensation And Retirement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock" xlink:href="hum-20231231.xsd#hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock" xlink:to="lab_hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_7ca99aa3-df19-44f0-a98d-4f88677ff6bb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_f242f386-00b1-4450-8d3c-db4710c30147_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_565cffdb-79a8-4dd5-b6cd-2261ffb1ba09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares&#160; Under Option</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_91109327-141a-47ae-a02c-98bf450609c2_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_75c7f10b-a201-4c59-800b-02ef94aa4598_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_f03f5c66-f991-42b5-9e0b-1c29698be8b7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in gross unrealized investment gains (losses)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember_e50d559f-9c80-407a-8d2d-d539baa6a97c_terseLabel_en-US" xlink:label="lab_hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Cohort of Clinics</link:label>
    <link:label id="lab_hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember_label_en-US" xlink:label="lab_hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Welsh Carson Anderson And Stowe, Cohort Of Clinics One [Member]</link:label>
    <link:label id="lab_hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember_documentation_en-US" xlink:label="lab_hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Welsh Carson Anderson And Stowe, Cohort Of Clinics One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember" xlink:href="hum-20231231.xsd#hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember" xlink:to="lab_hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_fea93e10-6228-4dbf-8e2c-8c44166a8cf7_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DeferredTaxAssetJobsTaxCredit_4bf060ea-2a35-4135-b369-2fa35aba1f35_terseLabel_en-US" xlink:label="lab_hum_DeferredTaxAssetJobsTaxCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jobs tax credits</link:label>
    <link:label id="lab_hum_DeferredTaxAssetJobsTaxCredit_label_en-US" xlink:label="lab_hum_DeferredTaxAssetJobsTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Jobs Tax Credit</link:label>
    <link:label id="lab_hum_DeferredTaxAssetJobsTaxCredit_documentation_en-US" xlink:label="lab_hum_DeferredTaxAssetJobsTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Jobs Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DeferredTaxAssetJobsTaxCredit" xlink:href="hum-20231231.xsd#hum_DeferredTaxAssetJobsTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DeferredTaxAssetJobsTaxCredit" xlink:to="lab_hum_DeferredTaxAssetJobsTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_17e856f5-c2ac-4948-a6a3-f3d9bd3dff3c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_886fc7a9-b8e9-4bd0-99ca-5482cf75ac02_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration to be received</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ef41b21b-ebf3-4889-be34-334aa3342c7a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_FairValueRiskMember_d7177832-7594-4b3a-96bf-0576066c0d48_terseLabel_en-US" xlink:label="lab_hum_FairValueRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Risk</link:label>
    <link:label id="lab_hum_FairValueRiskMember_label_en-US" xlink:label="lab_hum_FairValueRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Risk [Member]</link:label>
    <link:label id="lab_hum_FairValueRiskMember_documentation_en-US" xlink:label="lab_hum_FairValueRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FairValueRiskMember" xlink:href="hum-20231231.xsd#hum_FairValueRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_FairValueRiskMember" xlink:to="lab_hum_FairValueRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_910531dd-2657-448b-8084-6bce487ec275_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority ownership prior to acquisition (percent)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_03085da5-9d86-4c6c-a7cb-3ed5add1f2af_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee retirement and savings plan cost</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_547cd14c-0a27-41a4-8427-f469bc83faf5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A3.950PercentSeniorNotesMember_6f99c549-f2bd-4370-b589-21da8c78c624_terseLabel_en-US" xlink:label="lab_hum_A3.950PercentSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.950 Percent Senior Notes</link:label>
    <link:label id="lab_hum_A3.950PercentSeniorNotesMember_label_en-US" xlink:label="lab_hum_A3.950PercentSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.950 Percent Senior Notes [Member]</link:label>
    <link:label id="lab_hum_A3.950PercentSeniorNotesMember_documentation_en-US" xlink:label="lab_hum_A3.950PercentSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.950 Percent Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3.950PercentSeniorNotesMember" xlink:href="hum-20231231.xsd#hum_A3.950PercentSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A3.950PercentSeniorNotesMember" xlink:to="lab_hum_A3.950PercentSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_bf13dca4-c302-4888-8697-4022db28b1c1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_3ba3d25d-f420-49c1-a537-56bcdfb22f0e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_56af8592-ff9a-41bf-b1a2-c89903087eab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_c7d57506-9523-42b5-bd52-c804d535b2bf_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_633092c2-c3c4-4ab4-86e5-d20c7ab440f1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_b20bf4a4-84a0-450a-9c59-0e6d8bd3a861_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of senior notes, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Senior Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_3f2685dc-eaa3-4745-9b81-12bb0fbc7949_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,690,082 shares issued at December 31, 2023 and 198,666,598 shares issued at December 31, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_360b4213-d6bf-460a-9471-54c09de514ee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A215PercentSeniorNotesDueFebruary2032Member_5282c356-b0ff-4bdb-abe9-95fcc0767a32_terseLabel_en-US" xlink:label="lab_hum_A215PercentSeniorNotesDueFebruary2032Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$750 million 2.150% due February 3, 2032</link:label>
    <link:label id="lab_hum_A215PercentSeniorNotesDueFebruary2032Member_label_en-US" xlink:label="lab_hum_A215PercentSeniorNotesDueFebruary2032Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.15 Percent Senior Notes Due February 2032 [Member]</link:label>
    <link:label id="lab_hum_A215PercentSeniorNotesDueFebruary2032Member_documentation_en-US" xlink:label="lab_hum_A215PercentSeniorNotesDueFebruary2032Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.15 Percent Senior Notes Due February 2032</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A215PercentSeniorNotesDueFebruary2032Member" xlink:href="hum-20231231.xsd#hum_A215PercentSeniorNotesDueFebruary2032Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A215PercentSeniorNotesDueFebruary2032Member" xlink:to="lab_hum_A215PercentSeniorNotesDueFebruary2032Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_8ef225dc-b488-4ac2-affa-2ce50d042c00_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a915a0d4-7139-4f2b-a4f3-bab19c70d705_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_9df2f8f2-9631-4d7f-90ba-dda0c4d27c74_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade names and technology</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_cfe6f369-dcd8-4f3c-9d7d-1a1e310355b5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceContractAcquisitionCostPolicyTextBlock_2f10f013-e8b0-43dd-80c6-f2b49eb01b52_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceContractAcquisitionCostPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policy Acquisition Costs</link:label>
    <link:label id="lab_us-gaap_InsuranceContractAcquisitionCostPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InsuranceContractAcquisitionCostPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Contract, Acquisition Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceContractAcquisitionCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceContractAcquisitionCostPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceContractAcquisitionCostPolicyTextBlock" xlink:to="lab_us-gaap_InsuranceContractAcquisitionCostPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions_d43508c1-676d-428f-88ca-1b10689be147_terseLabel_en-US" xlink:label="lab_hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of restricted stock with performance-based conditions</link:label>
    <link:label id="lab_hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions_label_en-US" xlink:label="lab_hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation By Share Based Payment Award, Equity Instruments Other Than Options, Percent Of Stock With Performance Based Conditions</link:label>
    <link:label id="lab_hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions_documentation_en-US" xlink:label="lab_hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation By Share Based Payment Award, Equity Instruments Other Than Options, Percent Of Stock With Performance Based Conditions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions" xlink:href="hum-20231231.xsd#hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions" xlink:to="lab_hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_bcdbbe67-9eb1-4f29-b566-8041b3449271_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_70dbe44b-59d8-4f40-af4a-636dc63d0e04_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Incurred and Paid Claims Development</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Claims Development [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_MedicareAdvantageMember_1a3ee427-95da-464c-a8b8-2c7dcdd5f18b_terseLabel_en-US" xlink:label="lab_hum_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Medicare Advantage</link:label>
    <link:label id="lab_hum_MedicareAdvantageMember_label_en-US" xlink:label="lab_hum_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:label id="lab_hum_MedicareAdvantageMember_documentation_en-US" xlink:label="lab_hum_MedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Advantage [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareAdvantageMember" xlink:href="hum-20231231.xsd#hum_MedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_MedicareAdvantageMember" xlink:to="lab_hum_MedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_7c155e30-b3ea-4f3d-8b00-bda43f341f35_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_75ce525d-c31d-4d13-a536-dea372e71ec7_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b8432a46-cf23-418f-8af5-1a09add04b00_negatedNetLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_122b7ed3-ed2c-45b9-a76d-319a7f93e529_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_de1a62d0-e681-4e6e-be5e-7939d6e95d38_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_b282ecc4-1d87-4654-9ed7-5535c5cdb843_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share Repurchases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4c964a4d-cfbc-41c9-8493-5f519bae561a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_5ee13ce7-abb5-4f41-8f6c-039e30595250_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_RevolvingCreditAgreementJune2021OneYearMember_4cd3777d-ef75-4fbf-b254-9f386934b98e_terseLabel_en-US" xlink:label="lab_hum_RevolvingCreditAgreementJune2021OneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement June 2021 One Year</link:label>
    <link:label id="lab_hum_RevolvingCreditAgreementJune2021OneYearMember_label_en-US" xlink:label="lab_hum_RevolvingCreditAgreementJune2021OneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement June 2021 One Year [Member]</link:label>
    <link:label id="lab_hum_RevolvingCreditAgreementJune2021OneYearMember_documentation_en-US" xlink:label="lab_hum_RevolvingCreditAgreementJune2021OneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement June 2021 One Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevolvingCreditAgreementJune2021OneYearMember" xlink:href="hum-20231231.xsd#hum_RevolvingCreditAgreementJune2021OneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_RevolvingCreditAgreementJune2021OneYearMember" xlink:to="lab_hum_RevolvingCreditAgreementJune2021OneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_17984db5-7c89-4bd8-8c25-52a4e4b79e58_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchase authorization</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_CompanyCommonStockClosingSharePrice_fe49582e-8810-43c3-91d2-e0bb11f7c764_terseLabel_en-US" xlink:label="lab_hum_CompanyCommonStockClosingSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company common stock closing price (in dollars per share)</link:label>
    <link:label id="lab_hum_CompanyCommonStockClosingSharePrice_label_en-US" xlink:label="lab_hum_CompanyCommonStockClosingSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Common Stock, Closing Share Price</link:label>
    <link:label id="lab_hum_CompanyCommonStockClosingSharePrice_documentation_en-US" xlink:label="lab_hum_CompanyCommonStockClosingSharePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Common Stock, Closing Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CompanyCommonStockClosingSharePrice" xlink:href="hum-20231231.xsd#hum_CompanyCommonStockClosingSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_CompanyCommonStockClosingSharePrice" xlink:to="lab_hum_CompanyCommonStockClosingSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f06c85d0-31e4-4e3c-b723-b42ac86571ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Provision for Income Taxes Using Federal Statutory Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_643f3511-24aa-422c-b68e-ca383fb314e9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_6df84a89-d294-4f6b-9f88-00ca682134e0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_8d3b22e4-6aa7-4d49-9514-15ad39fe92f9_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_label_en-US" xlink:label="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1a0c2630-6f9e-4616-b858-0d4ea5c88b17_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_e1c05e65-e2bb-4e63-aa70-89ba07364129_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_b4c93d15-8322-446a-8545-a119fb9583ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Carrying Amount of Goodwill By Reportable Segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualRightsMember_8232f3ea-d7a6-4e45-b629-86b93e1fd9de_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider contracts</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_label_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualRightsMember" xlink:to="lab_us-gaap_ContractualRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_baa3bc0e-60c9-4064-ad3a-69e8ec61723b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized in other comprehensive&#160;income</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesDateAxis_f7753c13-5b27-4bbc-9e9e-eba676ce78db_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesDateAxis_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_87dc1826-979e-4ac8-99be-fe575b8c71c8_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_205ab5a0-0886-40cf-a482-b9381e70e7f2_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REPORTING ENTITY</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_b3d18902-0eac-42e7-87b3-5487e64324a6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_0ebe7076-e0e0-4268-8327-60f017e33b0f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_97493b20-d756-468e-a552-1629498268c4_negatedLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality_fce1bc56-e94e-41f7-9512-ff3143a85c14_terseLabel_en-US" xlink:label="lab_hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of debt securities considered to be of investment-grade (percent)</link:label>
    <link:label id="lab_hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality_label_en-US" xlink:label="lab_hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Total Debt Securities, Investment Grade Quality</link:label>
    <link:label id="lab_hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality_documentation_en-US" xlink:label="lab_hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Total Debt Securities, Investment Grade Quality</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality" xlink:href="hum-20231231.xsd#hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality" xlink:to="lab_hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_fb931928-b2d6-4036-ae56-81cd82946531_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_55115d30-479c-42c5-9137-4787e28ff56c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of Gentiva Hospice</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_20f5fc05-d233-4a07-b50c-8ac9679d680b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_45814045-c066-4d45-ac1b-1ca0a49d538e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_31baa7d4-d529-4586-961a-debd7b9f185d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs_365465fb-921a-487d-9abd-c97b16afb014_terseLabel_en-US" xlink:label="lab_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer discounts on brand name prescription drugs</link:label>
    <link:label id="lab_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs_label_en-US" xlink:label="lab_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Discounts On Brand Name Prescription Drugs</link:label>
    <link:label id="lab_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs_documentation_en-US" xlink:label="lab_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning in 2011, the Health Reform Legislation mandates consumer discounts of 50% on brand name prescription drugs for Part D plan participants in the coverage gap. These discounts are funded by CMS and pharmaceutical manufacturers while we administer the application of these funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs" xlink:href="hum-20231231.xsd#hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs" xlink:to="lab_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_389e33d9-d317-4701-a2c7-2fa39eeb0367_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums</link:label>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_label_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsEarnedNet" xlink:to="lab_us-gaap_PremiumsEarnedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_12434e17-a5d1-4ced-a5e4-5555199a1532_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_ca6bb0f6-d70c-4417-923c-b93c0d8871ef_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_e39c18ba-c3a1-465a-b85a-081633bf71c3_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_03f76ee6-7c4a-4255-a339-1e5b7d633b91_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used For Inputs In Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4b12c62a-4d96-43aa-9bee-303f8de14b8f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_MizuhoMarketsAmericasLLCMember_1de4d7d4-fe85-4444-87c8-72836f555138_terseLabel_en-US" xlink:label="lab_hum_MizuhoMarketsAmericasLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mizuho Markets Americas LLC</link:label>
    <link:label id="lab_hum_MizuhoMarketsAmericasLLCMember_label_en-US" xlink:label="lab_hum_MizuhoMarketsAmericasLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mizuho Markets Americas LLC [Member]</link:label>
    <link:label id="lab_hum_MizuhoMarketsAmericasLLCMember_documentation_en-US" xlink:label="lab_hum_MizuhoMarketsAmericasLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mizuho Markets Americas LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MizuhoMarketsAmericasLLCMember" xlink:href="hum-20231231.xsd#hum_MizuhoMarketsAmericasLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_MizuhoMarketsAmericasLLCMember" xlink:to="lab_hum_MizuhoMarketsAmericasLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_RevolvingCreditAgreementJune2022OneYearMember_6aa8efce-2b3e-4e4e-8a52-e5b91b3cee62_terseLabel_en-US" xlink:label="lab_hum_RevolvingCreditAgreementJune2022OneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement June 2022 One Year</link:label>
    <link:label id="lab_hum_RevolvingCreditAgreementJune2022OneYearMember_label_en-US" xlink:label="lab_hum_RevolvingCreditAgreementJune2022OneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement June 2022 One Year [Member]</link:label>
    <link:label id="lab_hum_RevolvingCreditAgreementJune2022OneYearMember_documentation_en-US" xlink:label="lab_hum_RevolvingCreditAgreementJune2022OneYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement June 2022 One Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevolvingCreditAgreementJune2022OneYearMember" xlink:href="hum-20231231.xsd#hum_RevolvingCreditAgreementJune2022OneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_RevolvingCreditAgreementJune2022OneYearMember" xlink:to="lab_hum_RevolvingCreditAgreementJune2022OneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_6f2869d0-7eb6-4731-ba9a-2501e34af46d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a351e268-3b3f-4362-8ef3-65380e8c72c6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected option life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0444a3bc-b408-4e5a-9fdc-0b5dfa89d615_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment earnings (loss)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_4521446b-eec4-4a93-81d0-0d9cae3f6299_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_d4c63a81-3a7b-41ef-8784-b7fbab96b697_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of property and equipment</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1509bb59-1237-432b-bd3c-c9feeb448833_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_d9baf2a1-6327-4d59-b597-68ef11600c90_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CreditRatingStandardPoorsAxis_6c88aad8-e16c-48c7-ad69-cd76b084dc46_terseLabel_en-US" xlink:label="lab_srt_CreditRatingStandardPoorsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Rating, Standard &amp; Poor's [Axis]</link:label>
    <link:label id="lab_srt_CreditRatingStandardPoorsAxis_label_en-US" xlink:label="lab_srt_CreditRatingStandardPoorsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Rating, Standard &amp; Poor's [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CreditRatingStandardPoorsAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CreditRatingStandardPoorsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CreditRatingStandardPoorsAxis" xlink:to="lab_srt_CreditRatingStandardPoorsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_PharmacySolutionsMember_f5fb05fd-5ee1-4eec-9608-375db85a5492_terseLabel_en-US" xlink:label="lab_hum_PharmacySolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy solutions</link:label>
    <link:label id="lab_hum_PharmacySolutionsMember_label_en-US" xlink:label="lab_hum_PharmacySolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Solutions [Member]</link:label>
    <link:label id="lab_hum_PharmacySolutionsMember_documentation_en-US" xlink:label="lab_hum_PharmacySolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Solutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PharmacySolutionsMember" xlink:href="hum-20231231.xsd#hum_PharmacySolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_PharmacySolutionsMember" xlink:to="lab_hum_PharmacySolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PutOptionMember_4fd70081-b4d9-49b9-84b0-c29be9acc1fe_terseLabel_en-US" xlink:label="lab_us-gaap_PutOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put option</link:label>
    <link:label id="lab_us-gaap_PutOptionMember_label_en-US" xlink:label="lab_us-gaap_PutOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Put Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PutOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PutOptionMember" xlink:to="lab_us-gaap_PutOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_BuildingsAndLeaseholdImprovementsMember_59aa96a2-0cc3-4900-a0ab-7048890378fc_terseLabel_en-US" xlink:label="lab_hum_BuildingsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and leasehold improvements</link:label>
    <link:label id="lab_hum_BuildingsAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_hum_BuildingsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings And Leasehold Improvements [Member]</link:label>
    <link:label id="lab_hum_BuildingsAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_hum_BuildingsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings And Leasehold Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BuildingsAndLeaseholdImprovementsMember" xlink:href="hum-20231231.xsd#hum_BuildingsAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_BuildingsAndLeaseholdImprovementsMember" xlink:to="lab_hum_BuildingsAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_9dcaada8-7c06-4c6f-a6a2-db1e4c83a07f_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest_189ea976-cfc8-48ce-ac6f-062fd493b1f3_terseLabel_en-US" xlink:label="lab_hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest_label_en-US" xlink:label="lab_hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Noncontrolling interest</link:label>
    <link:label id="lab_hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest_documentation_en-US" xlink:label="lab_hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Noncontrolling interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest" xlink:href="hum-20231231.xsd#hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest" xlink:to="lab_hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4c61dd0a-db15-44fc-8e0d-1d84ca3b938f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2911fb86-b555-433b-a09b-65949fa5a9d1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f9315057-cc62-455d-a697-a2cd34e18af3_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_4f1e7387-d8cf-4f5e-9db7-9aa41de0da6a_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits ceded</link:label>
    <link:label id="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_label_en-US" xlink:label="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Ceded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:to="lab_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_c5df6587-49b0-41fc-b6df-b23dd244f0bc_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a5ce91c4-ffc1-4bcf-a574-801878e1e278_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4a2a605c-5a91-49e1-aa60-a7991ecbf14f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9d679367-6bcc-434d-a51d-d1095ffc75bc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_52e16350-046e-470b-a615-c79712c7f657_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_AccruedPharmaceuticalRebatesCurrent_4555e57a-8ff3-4ef7-98fb-8ec15f4703cb_terseLabel_en-US" xlink:label="lab_hum_AccruedPharmaceuticalRebatesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical rebates</link:label>
    <link:label id="lab_hum_AccruedPharmaceuticalRebatesCurrent_label_en-US" xlink:label="lab_hum_AccruedPharmaceuticalRebatesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Pharmaceutical Rebates, Current</link:label>
    <link:label id="lab_hum_AccruedPharmaceuticalRebatesCurrent_documentation_en-US" xlink:label="lab_hum_AccruedPharmaceuticalRebatesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Pharmaceutical Rebates, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_AccruedPharmaceuticalRebatesCurrent" xlink:href="hum-20231231.xsd#hum_AccruedPharmaceuticalRebatesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_AccruedPharmaceuticalRebatesCurrent" xlink:to="lab_hum_AccruedPharmaceuticalRebatesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e1c32db0-d9c4-41c0-b590-eef487f2bc22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_SubsidyAndDiscountPayments_b791a853-9024-4e51-aa0b-430e5d645d64_negatedTerseLabel_en-US" xlink:label="lab_hum_SubsidyAndDiscountPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Part D subsidy/discount payments</link:label>
    <link:label id="lab_hum_SubsidyAndDiscountPayments_label_en-US" xlink:label="lab_hum_SubsidyAndDiscountPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidy And Discount Payments</link:label>
    <link:label id="lab_hum_SubsidyAndDiscountPayments_documentation_en-US" xlink:label="lab_hum_SubsidyAndDiscountPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidy And Discount Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SubsidyAndDiscountPayments" xlink:href="hum-20231231.xsd#hum_SubsidyAndDiscountPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_SubsidyAndDiscountPayments" xlink:to="lab_hum_SubsidyAndDiscountPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_bec48a93-796c-4dde-880b-c7254132918c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, repurchase amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_4bdc7a28-f3be-4627-8193-b2f26af5ce95_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred Claims, Net of Reinsurance</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram_698f0c8e-c4d6-4fd7-a384-4efdc6a356e0_terseLabel_en-US" xlink:label="lab_hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combination of age and years necessary for retirement provision as related to our equity award program</link:label>
    <link:label id="lab_hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram_label_en-US" xlink:label="lab_hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combination Of Age And Years Necessary For Retirement Provision As Related To Our Equity Award Program</link:label>
    <link:label id="lab_hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram_documentation_en-US" xlink:label="lab_hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combination of age and years necessary for retirement provision as related to our equity award program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram" xlink:href="hum-20231231.xsd#hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram" xlink:to="lab_hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a14550df-fedf-40b0-a6f8-e2bea3d8bc66_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_d61e3c51-2991-4db6-9783-1decbbe79379_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_8fcc1a94-9e9e-43c2-adec-741e8afe2a80_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS PER COMMON SHARE COMPUTATION</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_d7a35f14-f352-4c8c-a3f4-762c662c914f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment ownership (percent)</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c2e510fd-ea4e-4367-8f2a-8d6295fa197c_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_b1f58059-e75c-48e4-8603-ee2cd7d09243_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_a956d1c8-5600-4263-b756-cc6a875d0598_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_JPMorganChaseBankMember_e041e3fe-74a6-4b12-8d13-ed7f7edf0f37_terseLabel_en-US" xlink:label="lab_hum_JPMorganChaseBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JPM</link:label>
    <link:label id="lab_hum_JPMorganChaseBankMember_label_en-US" xlink:label="lab_hum_JPMorganChaseBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JPMorgan Chase Bank [Member]</link:label>
    <link:label id="lab_hum_JPMorganChaseBankMember_documentation_en-US" xlink:label="lab_hum_JPMorganChaseBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JPMorgan Chase Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_JPMorganChaseBankMember" xlink:href="hum-20231231.xsd#hum_JPMorganChaseBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_JPMorganChaseBankMember" xlink:to="lab_hum_JPMorganChaseBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_6876dc5e-1b99-449f-96ae-55e309594a5d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A2024ShareRepurchaseAuthorizationMember_8fdca07e-178e-49d9-bd79-ca3f556ba9b0_terseLabel_en-US" xlink:label="lab_hum_A2024ShareRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Share Repurchase Authorization</link:label>
    <link:label id="lab_hum_A2024ShareRepurchaseAuthorizationMember_label_en-US" xlink:label="lab_hum_A2024ShareRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Share Repurchase Authorization [Member]</link:label>
    <link:label id="lab_hum_A2024ShareRepurchaseAuthorizationMember_documentation_en-US" xlink:label="lab_hum_A2024ShareRepurchaseAuthorizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Share Repurchase Authorization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A2024ShareRepurchaseAuthorizationMember" xlink:href="hum-20231231.xsd#hum_A2024ShareRepurchaseAuthorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A2024ShareRepurchaseAuthorizationMember" xlink:to="lab_hum_A2024ShareRepurchaseAuthorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2b1b15e2-6d6c-4c19-8347-dd230c2d7f33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity for Option Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_293d8dea-8135-4b9c-be5c-2513fbdea27d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A5950PercentSeniorNotesDueMarch2034Member_45ef2b1a-ce9d-4e98-a906-1396d5032866_terseLabel_en-US" xlink:label="lab_hum_A5950PercentSeniorNotesDueMarch2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$850 million, 5.950% due March 15, 2034</link:label>
    <link:label id="lab_hum_A5950PercentSeniorNotesDueMarch2034Member_label_en-US" xlink:label="lab_hum_A5950PercentSeniorNotesDueMarch2034Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.950 Percent Senior Notes Due March 2034 [Member]</link:label>
    <link:label id="lab_hum_A5950PercentSeniorNotesDueMarch2034Member_documentation_en-US" xlink:label="lab_hum_A5950PercentSeniorNotesDueMarch2034Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.950 Percent Senior Notes Due March 2034</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5950PercentSeniorNotesDueMarch2034Member" xlink:href="hum-20231231.xsd#hum_A5950PercentSeniorNotesDueMarch2034Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A5950PercentSeniorNotesDueMarch2034Member" xlink:to="lab_hum_A5950PercentSeniorNotesDueMarch2034Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_42c5d7b3-1e52-400a-9499-5560afba4d20_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_24cbbd58-5310-428d-80a6-808c20a29013_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends and dividend equivalents</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_36037523-4cd2-45c9-8c82-92f79311d097_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_847104dc-e567-477b-bbcd-852cfde9c3bf_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_MedicarePartDDisclosureTextBlock_5f0dd22f-6600-4ea5-a36d-0652180dcc48_terseLabel_en-US" xlink:label="lab_hum_MedicarePartDDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEDICARE PART D</link:label>
    <link:label id="lab_hum_MedicarePartDDisclosureTextBlock_label_en-US" xlink:label="lab_hum_MedicarePartDDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Part D Disclosure [Text Block]</link:label>
    <link:label id="lab_hum_MedicarePartDDisclosureTextBlock_documentation_en-US" xlink:label="lab_hum_MedicarePartDDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance sheet amounts associated with Medicare Part D.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicarePartDDisclosureTextBlock" xlink:href="hum-20231231.xsd#hum_MedicarePartDDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_MedicarePartDDisclosureTextBlock" xlink:to="lab_hum_MedicarePartDDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity_a0830308-6cc3-4d90-886f-ea4009877fd4_terseLabel_en-US" xlink:label="lab_hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time frame for put and call option activity per partnership agreement</link:label>
    <link:label id="lab_hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity_label_en-US" xlink:label="lab_hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Partnership Agreement, Timeframe For Put And Call Option Activity</link:label>
    <link:label id="lab_hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity_documentation_en-US" xlink:label="lab_hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Partnership Agreement, Timeframe For Put And Call Option Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity" xlink:href="hum-20231231.xsd#hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity" xlink:to="lab_hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries_a481f7c5-2efd-47b7-80a0-2ff510862ab7_totalLabel_en-US" xlink:label="lab_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income before equity in net earnings of subsidiaries</link:label>
    <link:label id="lab_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries_label_en-US" xlink:label="lab_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss Before Equity In Net Earnings Of Subsidiaries</link:label>
    <link:label id="lab_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries_documentation_en-US" xlink:label="lab_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before equity in net earnings of subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries" xlink:href="hum-20231231.xsd#hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries" xlink:to="lab_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_d24ed8d5-25ae-4ecf-aa63-c0d537902d81_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_df8de31c-86c1-43e7-9020-b45ca56e0890_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_dfcddf7c-58e3-435c-ac47-99aaddcc623f_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_e88300d4-0db6-4ba2-9496-9768b2c11012_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax payments, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_9c7bfcdd-2140-4339-8ea4-aceadad445d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_08cea0ec-d0b7-4944-ae6c-bcc3a1da7eb4_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0540f646-0fbf-4cfb-89bb-cf49a52f1de9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ae3de67a-2bc3-4234-939d-72d64a8ace25_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3034c690-657d-48bc-9090-2070328db2fc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Book value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_beaa18dc-21cb-409f-82f1-31f894096cd3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5f8e2948-b680-4919-9b39-c4fa656fb184_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate at grant date</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_374dd573-5ac1-443c-8d8d-c2bda64d2699_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets included within other long-term assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_ffd8ce26-82d5-401d-98f9-9ca452e9f15c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_InterestRateSwapMaturing2049Member_81972b20-cd0f-4d83-b5ce-a688f413fc5d_terseLabel_en-US" xlink:label="lab_hum_InterestRateSwapMaturing2049Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap Maturing 2049</link:label>
    <link:label id="lab_hum_InterestRateSwapMaturing2049Member_label_en-US" xlink:label="lab_hum_InterestRateSwapMaturing2049Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap Maturing 2049 [Member]</link:label>
    <link:label id="lab_hum_InterestRateSwapMaturing2049Member_documentation_en-US" xlink:label="lab_hum_InterestRateSwapMaturing2049Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap Maturing 2049</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InterestRateSwapMaturing2049Member" xlink:href="hum-20231231.xsd#hum_InterestRateSwapMaturing2049Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_InterestRateSwapMaturing2049Member" xlink:to="lab_hum_InterestRateSwapMaturing2049Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a649f024-c82a-46eb-af11-ae45b26ae3df_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_5fa1b69f-8079-422b-8dbc-72c2637c99c9_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax gain, net of transaction costs</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f6a758df-6188-4765-97c5-2551c769527d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent_5e41876d-49d4-4de5-a43e-0b59d8acfa27_totalLabel_en-US" xlink:label="lab_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment earnings (loss) attributable to Humana</link:label>
    <link:label id="lab_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent_label_en-US" xlink:label="lab_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss From Continuing Operations Before Income Taxes Attributable To Parent</link:label>
    <link:label id="lab_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent_documentation_en-US" xlink:label="lab_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Loss From Continuing Operations Before Income Taxes Attributable To Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" xlink:href="hum-20231231.xsd#hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" xlink:to="lab_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_SpecialtyBenefitsMember_c2afa818-8a95-4d82-8a4c-745f9105d041_terseLabel_en-US" xlink:label="lab_hum_SpecialtyBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty benefits</link:label>
    <link:label id="lab_hum_SpecialtyBenefitsMember_label_en-US" xlink:label="lab_hum_SpecialtyBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Benefits [Member]</link:label>
    <link:label id="lab_hum_SpecialtyBenefitsMember_documentation_en-US" xlink:label="lab_hum_SpecialtyBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SpecialtyBenefitsMember" xlink:href="hum-20231231.xsd#hum_SpecialtyBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_SpecialtyBenefitsMember" xlink:to="lab_hum_SpecialtyBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_3c73f039-77a0-404d-8d16-1ca5ae1384f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, By Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_cb9839dc-2e5f-4c90-8b66-691818b85d91_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_e596ded4-07e1-4761-b0dd-dd2c2fd1f573_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Existing equity value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity_2b0e8c4a-9ff6-46ea-ae07-3f412e9c61b7_terseLabel_en-US" xlink:label="lab_hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity including uncommitted incremental loan facility</link:label>
    <link:label id="lab_hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity_label_en-US" xlink:label="lab_hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Maximum Borrowing Capacity Including Uncommitted Incremental Capacity</link:label>
    <link:label id="lab_hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity_documentation_en-US" xlink:label="lab_hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity under the credit facility including uncommitted incremental capacity and without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity" xlink:href="hum-20231231.xsd#hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity" xlink:to="lab_hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_ab312fb8-e002-427e-a5c0-090a35b30482_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_370cfeaa-150f-4faa-83ee-ab8b1f33501c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_09fb5a16-f746-431a-8e84-2d76beb76b73_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_c56ac905-c9f9-4577-bdbf-36837507e947_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c23e5e4d-6b77-4543-86b2-0fb170afeaf3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_6e2efb06-c770-4fc4-bbe8-3de75410b1d9_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense for capitalized internally developed and purchased software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_08cfcf06-32f7-4261-9fdb-3cf570bbe169_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8bece95b-ac32-48f5-a1df-3fade56d1b84_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_09882ac1-175b-43cd-b6a0-45b7d0ed3386_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_InsuranceSegmentMember_e8e634b0-507c-47a5-9a89-0f45d96dc6c3_terseLabel_en-US" xlink:label="lab_hum_InsuranceSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance</link:label>
    <link:label id="lab_hum_InsuranceSegmentMember_label_en-US" xlink:label="lab_hum_InsuranceSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Segment [Member]</link:label>
    <link:label id="lab_hum_InsuranceSegmentMember_documentation_en-US" xlink:label="lab_hum_InsuranceSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InsuranceSegmentMember" xlink:href="hum-20231231.xsd#hum_InsuranceSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_InsuranceSegmentMember" xlink:to="lab_hum_InsuranceSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_9f6a6792-bf31-432a-b05d-babc5932f331_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_a18520de-0929-4cc4-a8d2-b17d73a1b8fa_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt outstanding</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fcc0ec41-3fce-4648-b0c7-83dd568eda37_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_aa899950-8321-4c98-9158-7b79f4561d43_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) recognized on equity securities during the period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_b7fcce05-99bc-4af3-932d-8348e6818553_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_1ccd28a9-38e3-49ae-bcfd-8f1441ae8b50_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_SubsidyAndDiscountsSettlementPeriodAfterClose_f1cf5fab-3511-4fc2-b528-76db6b939998_terseLabel_en-US" xlink:label="lab_hum_SubsidyAndDiscountsSettlementPeriodAfterClose" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement period after close</link:label>
    <link:label id="lab_hum_SubsidyAndDiscountsSettlementPeriodAfterClose_label_en-US" xlink:label="lab_hum_SubsidyAndDiscountsSettlementPeriodAfterClose" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidy And Discounts, Settlement Period After Close</link:label>
    <link:label id="lab_hum_SubsidyAndDiscountsSettlementPeriodAfterClose_documentation_en-US" xlink:label="lab_hum_SubsidyAndDiscountsSettlementPeriodAfterClose" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidy And Discounts, Settlement Period After Close</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SubsidyAndDiscountsSettlementPeriodAfterClose" xlink:href="hum-20231231.xsd#hum_SubsidyAndDiscountsSettlementPeriodAfterClose"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_SubsidyAndDiscountsSettlementPeriodAfterClose" xlink:to="lab_hum_SubsidyAndDiscountsSettlementPeriodAfterClose" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ecdfeebf-7e17-405d-b4fe-37addd90c01c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_c90db8af-d70b-418e-aef2-3e41c4cfb240_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_f93abbdb-1e49-4a62-932c-923e80a6e994_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of notes payable to operating subsidiaries</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_RiskCorridorSettlementsMedicarePartDMember_2a15373c-7715-42a5-a9ba-58f020449fca_terseLabel_en-US" xlink:label="lab_hum_RiskCorridorSettlementsMedicarePartDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Corridor Settlement</link:label>
    <link:label id="lab_hum_RiskCorridorSettlementsMedicarePartDMember_label_en-US" xlink:label="lab_hum_RiskCorridorSettlementsMedicarePartDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Corridor Settlements Medicare Part D [Member]</link:label>
    <link:label id="lab_hum_RiskCorridorSettlementsMedicarePartDMember_documentation_en-US" xlink:label="lab_hum_RiskCorridorSettlementsMedicarePartDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Corridor Settlements - Medicare Part D [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RiskCorridorSettlementsMedicarePartDMember" xlink:href="hum-20231231.xsd#hum_RiskCorridorSettlementsMedicarePartDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_RiskCorridorSettlementsMedicarePartDMember" xlink:to="lab_hum_RiskCorridorSettlementsMedicarePartDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_MedicareMember_c66706ef-a9fa-4a52-8c7a-dd57d7564e40_verboseLabel_en-US" xlink:label="lab_hum_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_hum_MedicareMember_bef3805b-4e30-44bc-8763-bfbc06cdcb41_terseLabel_en-US" xlink:label="lab_hum_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Medicare</link:label>
    <link:label id="lab_hum_MedicareMember_label_en-US" xlink:label="lab_hum_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_hum_MedicareMember_documentation_en-US" xlink:label="lab_hum_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareMember" xlink:href="hum-20231231.xsd#hum_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_MedicareMember" xlink:to="lab_hum_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_GentivaHospiceMember_d6874547-4f26-49f1-9b1f-8d13cada349c_terseLabel_en-US" xlink:label="lab_hum_GentivaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gentiva Hospice</link:label>
    <link:label id="lab_hum_GentivaHospiceMember_label_en-US" xlink:label="lab_hum_GentivaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gentiva Hospice [Member]</link:label>
    <link:label id="lab_hum_GentivaHospiceMember_documentation_en-US" xlink:label="lab_hum_GentivaHospiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gentiva Hospice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GentivaHospiceMember" xlink:href="hum-20231231.xsd#hum_GentivaHospiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_GentivaHospiceMember" xlink:to="lab_hum_GentivaHospiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_3fa8fec1-34d3-4d0c-9187-119dff9a893c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and other accrued expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_3fca16d4-ea10-4ea7-bf25-e11980e0a2b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_af9b2ec6-3daa-4be5-b5fa-5a1d8a6625c4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_5ee02996-51e9-452b-805c-2490bf858278_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_f1e6c4af-88a3-4238-8419-e90c2f58718a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_LineOfCreditFacilityUncommittedIncrementalCapacity_7a9008bf-1e04-4bc1-a35c-058938d57d7d_terseLabel_en-US" xlink:label="lab_hum_LineOfCreditFacilityUncommittedIncrementalCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncommitted incremental loan facility</link:label>
    <link:label id="lab_hum_LineOfCreditFacilityUncommittedIncrementalCapacity_label_en-US" xlink:label="lab_hum_LineOfCreditFacilityUncommittedIncrementalCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Uncommitted Incremental Capacity</link:label>
    <link:label id="lab_hum_LineOfCreditFacilityUncommittedIncrementalCapacity_documentation_en-US" xlink:label="lab_hum_LineOfCreditFacilityUncommittedIncrementalCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Uncommitted Incremental Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LineOfCreditFacilityUncommittedIncrementalCapacity" xlink:href="hum-20231231.xsd#hum_LineOfCreditFacilityUncommittedIncrementalCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_LineOfCreditFacilityUncommittedIncrementalCapacity" xlink:to="lab_hum_LineOfCreditFacilityUncommittedIncrementalCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_CoinsuranceAgreementMember_eb5cab6b-1bcf-40e1-a76c-9c8711c79130_terseLabel_en-US" xlink:label="lab_hum_CoinsuranceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">100% coinsurance agreements</link:label>
    <link:label id="lab_hum_CoinsuranceAgreementMember_label_en-US" xlink:label="lab_hum_CoinsuranceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coinsurance Agreement [Member]</link:label>
    <link:label id="lab_hum_CoinsuranceAgreementMember_documentation_en-US" xlink:label="lab_hum_CoinsuranceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coinsurance Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CoinsuranceAgreementMember" xlink:href="hum-20231231.xsd#hum_CoinsuranceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_CoinsuranceAgreementMember" xlink:to="lab_hum_CoinsuranceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3032b571-0182-4392-8f46-4b9507168355_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_915de712-2b10-460c-a417-4f1f01e04482_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_33583b82-0b79-4a29-9b32-687d78c21f98_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_b431a62f-a78a-48d4-ad76-8cf1e3689ed2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_b16cbb76-ade4-4fc0-be2d-fa5fe9c2a52e_totalLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total short-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_98bd9717-f940-4983-95f3-813a92431b94_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_71265495-7c32-4c72-a00c-630631ade8bd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_de36d9e8-73ba-478f-bdf6-2130903b017b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of Gentiva Hospice, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_945e9ca5-21d3-43ff-b884-898d6a2c8b0e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of stock options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ProviderReportingUnitMember_04227627-0acd-4539-bcfc-25e6ab9fa279_terseLabel_en-US" xlink:label="lab_hum_ProviderReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider reporting unit</link:label>
    <link:label id="lab_hum_ProviderReportingUnitMember_label_en-US" xlink:label="lab_hum_ProviderReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider Reporting Unit [Member]</link:label>
    <link:label id="lab_hum_ProviderReportingUnitMember_documentation_en-US" xlink:label="lab_hum_ProviderReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider Reporting Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ProviderReportingUnitMember" xlink:href="hum-20231231.xsd#hum_ProviderReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ProviderReportingUnitMember" xlink:to="lab_hum_ProviderReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5ee1339a-1420-466c-91fc-18a9e1850e53_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ValueCreationInitiativesMember_bb94923f-fcc2-4a98-be3e-c018a9e755bb_terseLabel_en-US" xlink:label="lab_hum_ValueCreationInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Creation Initiatives</link:label>
    <link:label id="lab_hum_ValueCreationInitiativesMember_label_en-US" xlink:label="lab_hum_ValueCreationInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Creation Initiatives [Member]</link:label>
    <link:label id="lab_hum_ValueCreationInitiativesMember_documentation_en-US" xlink:label="lab_hum_ValueCreationInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Creation Initiatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ValueCreationInitiativesMember" xlink:href="hum-20231231.xsd#hum_ValueCreationInitiativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ValueCreationInitiativesMember" xlink:to="lab_hum_ValueCreationInitiativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_0db38a1a-74d2-4001-939d-09e8130cbefb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_55878db0-f726-41f4-89b0-484240ade474_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_d9a9705a-6bff-4cbf-bc9d-3c0bcb537ae5_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_a6898590-59dc-4a9d-9860-cdce27dc84ec_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount_81cceb20-7ac2-4316-a15a-fc4dd7843fc1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total IBNR</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0f4e2337-a6a1-48d0-807d-53499a64e5da_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b9041c6c-d9d9-4a9b-849d-b1fe3087692d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6920875c-6a7a-4d60-a356-f233a2ef885b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_e0a28c3d-b6b1-4225-8afd-ec8002f0e006_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5338dda1-8f1a-46a6-9f99-d95858d84b90_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_1daafec8-5493-40f4-8660-ada536fb0141_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized in earnings</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d672b184-6691-440a-b232-075d77861c42_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_7ca0364b-c2c8-47e1-9a76-b5c319de56e6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortizable intangible assets, cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_PrimaryCareMember_05abc5eb-5661-4510-856d-c63e84ac4b2a_terseLabel_en-US" xlink:label="lab_hum_PrimaryCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary care</link:label>
    <link:label id="lab_hum_PrimaryCareMember_label_en-US" xlink:label="lab_hum_PrimaryCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary Care [Member]</link:label>
    <link:label id="lab_hum_PrimaryCareMember_documentation_en-US" xlink:label="lab_hum_PrimaryCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary Care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PrimaryCareMember" xlink:href="hum-20231231.xsd#hum_PrimaryCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_PrimaryCareMember" xlink:to="lab_hum_PrimaryCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_1ad19560-3129-49f6-9378-b2f2750c7eca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_GroupMedicareAdvantageMember_7b2ca8f2-a7a9-4392-a0bb-059eb325f09d_terseLabel_en-US" xlink:label="lab_hum_GroupMedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Group Medicare Advantage</link:label>
    <link:label id="lab_hum_GroupMedicareAdvantageMember_label_en-US" xlink:label="lab_hum_GroupMedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Group Medicare Advantage [Member]</link:label>
    <link:label id="lab_hum_GroupMedicareAdvantageMember_documentation_en-US" xlink:label="lab_hum_GroupMedicareAdvantageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Group Medicare Advantage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GroupMedicareAdvantageMember" xlink:href="hum-20231231.xsd#hum_GroupMedicareAdvantageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_GroupMedicareAdvantageMember" xlink:to="lab_hum_GroupMedicareAdvantageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_ca9d14d8-0ef4-42ea-a53e-00dcea28b87b_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_WellsFargoBankMember_efb7cce5-10a4-4ddb-84e1-6dec613763c9_terseLabel_en-US" xlink:label="lab_hum_WellsFargoBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wells Fargo Bank</link:label>
    <link:label id="lab_hum_WellsFargoBankMember_label_en-US" xlink:label="lab_hum_WellsFargoBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wells Fargo Bank [Member]</link:label>
    <link:label id="lab_hum_WellsFargoBankMember_documentation_en-US" xlink:label="lab_hum_WellsFargoBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wells Fargo Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_WellsFargoBankMember" xlink:href="hum-20231231.xsd#hum_WellsFargoBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_WellsFargoBankMember" xlink:to="lab_hum_WellsFargoBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c6ed0e94-742f-40fb-b630-c21b5d4771a7_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_RevolvingCreditAgreementJune2021FiveYearMember_c2ad6682-0c3a-4397-b85f-741e22497aa9_terseLabel_en-US" xlink:label="lab_hum_RevolvingCreditAgreementJune2021FiveYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement June 2021 Five Year</link:label>
    <link:label id="lab_hum_RevolvingCreditAgreementJune2021FiveYearMember_label_en-US" xlink:label="lab_hum_RevolvingCreditAgreementJune2021FiveYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement June 2021 Five Year [Member]</link:label>
    <link:label id="lab_hum_RevolvingCreditAgreementJune2021FiveYearMember_documentation_en-US" xlink:label="lab_hum_RevolvingCreditAgreementJune2021FiveYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement June 2021 Five Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevolvingCreditAgreementJune2021FiveYearMember" xlink:href="hum-20231231.xsd#hum_RevolvingCreditAgreementJune2021FiveYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_RevolvingCreditAgreementJune2021FiveYearMember" xlink:to="lab_hum_RevolvingCreditAgreementJune2021FiveYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_MilitaryAndOtherMember_49f6121f-349a-42ef-8e6e-f7f25c15acf2_terseLabel_en-US" xlink:label="lab_hum_MilitaryAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Military services and other</link:label>
    <link:label id="lab_hum_MilitaryAndOtherMember_label_en-US" xlink:label="lab_hum_MilitaryAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Military And Other [Member]</link:label>
    <link:label id="lab_hum_MilitaryAndOtherMember_documentation_en-US" xlink:label="lab_hum_MilitaryAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Military And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MilitaryAndOtherMember" xlink:href="hum-20231231.xsd#hum_MilitaryAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_MilitaryAndOtherMember" xlink:to="lab_hum_MilitaryAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_c2d72a2f-a990-4026-818e-5e00a4552b38_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1308e5f5-7392-4761-af19-8e372743767b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ManagementFeesChargedToOperatingSubsidiaries_3b743a98-7060-4146-8299-4fc49f282cf8_terseLabel_en-US" xlink:label="lab_hum_ManagementFeesChargedToOperatingSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fees charged to operating subsidiaries</link:label>
    <link:label id="lab_hum_ManagementFeesChargedToOperatingSubsidiaries_label_en-US" xlink:label="lab_hum_ManagementFeesChargedToOperatingSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Fees Charged To Operating Subsidiaries</link:label>
    <link:label id="lab_hum_ManagementFeesChargedToOperatingSubsidiaries_documentation_en-US" xlink:label="lab_hum_ManagementFeesChargedToOperatingSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Through intercompany service agreements approved, if required, by state regulatory authorities, Humana Inc., our parent company, charges a management fee for reimbursement of certain centralized services provided to its subsidiaries, including information systems, disbursement, investment and cash administration, marketing, legal, finance, and medical and executive management oversight</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ManagementFeesChargedToOperatingSubsidiaries" xlink:href="hum-20231231.xsd#hum_ManagementFeesChargedToOperatingSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ManagementFeesChargedToOperatingSubsidiaries" xlink:to="lab_hum_ManagementFeesChargedToOperatingSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_edadbf22-3795-4a6f-bd50-189e353c207c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock_4e375be0-d6b1-415f-b2bb-fe86b3301485_terseLabel_en-US" xlink:label="lab_hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Balance Sheet Amounts Associated With Medicare Part D</link:label>
    <link:label id="lab_hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock_label_en-US" xlink:label="lab_hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Account Associated With Medicare Part D [Table Text Block]</link:label>
    <link:label id="lab_hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock_documentation_en-US" xlink:label="lab_hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Account Associated With Medicare Part D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock" xlink:href="hum-20231231.xsd#hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock" xlink:to="lab_hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_cb64cc13-3669-48d1-8560-8dfe57e43378_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification adjustment for net realized losses (gains) included in investment income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A4.95PercentSeniorNotesDueOctober2044Member_cffa9f02-cf65-46da-9718-cd9d614354e5_terseLabel_en-US" xlink:label="lab_hum_A4.95PercentSeniorNotesDueOctober2044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$750 million, 4.950% due October 1, 2044</link:label>
    <link:label id="lab_hum_A4.95PercentSeniorNotesDueOctober2044Member_label_en-US" xlink:label="lab_hum_A4.95PercentSeniorNotesDueOctober2044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95 Percent Senior Notes Due October 2044 [Member]</link:label>
    <link:label id="lab_hum_A4.95PercentSeniorNotesDueOctober2044Member_documentation_en-US" xlink:label="lab_hum_A4.95PercentSeniorNotesDueOctober2044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95 Percent Senior Notes Due October 2044 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A4.95PercentSeniorNotesDueOctober2044Member" xlink:href="hum-20231231.xsd#hum_A4.95PercentSeniorNotesDueOctober2044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A4.95PercentSeniorNotesDueOctober2044Member" xlink:to="lab_hum_A4.95PercentSeniorNotesDueOctober2044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_debe21a7-744b-4256-b56d-0f1854cec40b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate (percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_0b939320-9939-48d7-99e7-f2d0fc92d4fe_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_87dcba42-57cd-4e38-b843-17b627fcabcf_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest payments</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_50abe642-58e0-43e7-91b1-c335b8635d14_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_95e3cb31-e8cb-47b3-b44b-8c49850af29f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_cb018ebc-da67-412c-9243-436756b404f8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_3489dcdf-1d87-4d4b-a8b5-e54b5b07abdf_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_acefb0ec-3c4d-481a-be2e-aa09b07ea1df_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net deferred income tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_df9c11b6-4fc3-455c-927f-17d147cc565e_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Gain (Loss) on Equity Securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_113673b1-6d86-4ba9-887e-571db58451f6_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used to compute diluted earnings per&#160;common share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_0afb44f6-71cb-428f-9e5a-149867c78b62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dispositions</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b03523b2-10ad-4d11-8915-3e73739a16ec_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_780f1243-1c41-4f8d-8261-237d11310c2f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_4cd27cda-3c32-464a-bf8c-d06644d224be_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums and services revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueProductLineMember" xlink:to="lab_us-gaap_SalesRevenueProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesDateDomain_6f5206fe-cb8c-47c6-83ba-425845445b53_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesDateDomain_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7cadbffe-196a-4c27-8e92-b4a43d7bc55d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_93bdd4c3-fbe7-4676-a2c3-50cec0f297bc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_RevolvingCreditAgreementJune2023FiveYearMember_df6b6c21-0a17-42fb-bfd9-9aee9620ecb6_terseLabel_en-US" xlink:label="lab_hum_RevolvingCreditAgreementJune2023FiveYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement June 2023 Five Year</link:label>
    <link:label id="lab_hum_RevolvingCreditAgreementJune2023FiveYearMember_label_en-US" xlink:label="lab_hum_RevolvingCreditAgreementJune2023FiveYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement June 2023 Five Year [Member]</link:label>
    <link:label id="lab_hum_RevolvingCreditAgreementJune2023FiveYearMember_documentation_en-US" xlink:label="lab_hum_RevolvingCreditAgreementJune2023FiveYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement June 2023 Five Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevolvingCreditAgreementJune2023FiveYearMember" xlink:href="hum-20231231.xsd#hum_RevolvingCreditAgreementJune2023FiveYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_RevolvingCreditAgreementJune2023FiveYearMember" xlink:to="lab_hum_RevolvingCreditAgreementJune2023FiveYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_170d2bae-0b0b-4816-8114-ac169fd2f611_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_148ac454-f2f0-47a0-a998-5e8da4ff3179_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_CenterWellSegmentMember_315dc202-7888-4032-beaa-c47ab90d68c0_terseLabel_en-US" xlink:label="lab_hum_CenterWellSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CenterWell</link:label>
    <link:label id="lab_hum_CenterWellSegmentMember_label_en-US" xlink:label="lab_hum_CenterWellSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CenterWell Segment [Member]</link:label>
    <link:label id="lab_hum_CenterWellSegmentMember_documentation_en-US" xlink:label="lab_hum_CenterWellSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CenterWell Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CenterWellSegmentMember" xlink:href="hum-20231231.xsd#hum_CenterWellSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_CenterWellSegmentMember" xlink:to="lab_hum_CenterWellSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_7be548b1-668c-4d15-95fb-6b9e7f8ac7fe_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_65012df6-f9f5-44b3-9120-17e9b93d0f77_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_bc1ba325-007e-413d-b33a-2bd57b69d9ca_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1a2699c2-1e5b-4ee9-9e09-d32ef75aa95d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_4c5749fd-b95a-4701-ad40-cd13e9e670cc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax effect from sale of Gentiva Hospice</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:to="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_MedicareSupplementProductMember_02109c89-5a2d-4777-9cbd-2b98a641ed0d_terseLabel_en-US" xlink:label="lab_hum_MedicareSupplementProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Supplement</link:label>
    <link:label id="lab_hum_MedicareSupplementProductMember_label_en-US" xlink:label="lab_hum_MedicareSupplementProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Supplement Product [Member]</link:label>
    <link:label id="lab_hum_MedicareSupplementProductMember_documentation_en-US" xlink:label="lab_hum_MedicareSupplementProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Supplement Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareSupplementProductMember" xlink:href="hum-20231231.xsd#hum_MedicareSupplementProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_MedicareSupplementProductMember" xlink:to="lab_hum_MedicareSupplementProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ea9ae2d4-27a9-4d56-a81b-f5c8251f6da1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_d7ffe7eb-2547-4573-814b-ee7ad09868a3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e0389d16-08ed-49ca-b66d-c299e8f8afc8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ede35f1a-0e94-45f4-b39b-b63bfdd5ad2b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes and equity in net earnings</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_551323e5-f64c-4c87-9289-302ec5ef0f4f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes and equity in net earnings (losses)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A4.500PercentSeniorNotesDueApril2025Member_81846ad0-941e-427e-afe4-10897ec58566_terseLabel_en-US" xlink:label="lab_hum_A4.500PercentSeniorNotesDueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$600 million, 4.500% due April 1, 2025</link:label>
    <link:label id="lab_hum_A4.500PercentSeniorNotesDueApril2025Member_label_en-US" xlink:label="lab_hum_A4.500PercentSeniorNotesDueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.500 Percent Senior Notes Due April 2025 [Member]</link:label>
    <link:label id="lab_hum_A4.500PercentSeniorNotesDueApril2025Member_documentation_en-US" xlink:label="lab_hum_A4.500PercentSeniorNotesDueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.500 Percent Senior Notes Due April 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A4.500PercentSeniorNotesDueApril2025Member" xlink:href="hum-20231231.xsd#hum_A4.500PercentSeniorNotesDueApril2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A4.500PercentSeniorNotesDueApril2025Member" xlink:to="lab_hum_A4.500PercentSeniorNotesDueApril2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_88972f92-6b21-4c63-894e-77398e9bbc81_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4fecd807-6654-4247-aace-519c06666c0a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average outstanding shares of common stock used to compute basic earnings per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_8bea0913-edc6-42a2-8606-19429087fc48_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1799e606-5331-47c8-b8e2-ecdf430d3f7e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A575PercentSeniorNotesDueDecember2028Member_92433823-d700-42db-a945-75b09798b7fe_terseLabel_en-US" xlink:label="lab_hum_A575PercentSeniorNotesDueDecember2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$500 million, 5.750% due December 1, 2028</link:label>
    <link:label id="lab_hum_A575PercentSeniorNotesDueDecember2028Member_label_en-US" xlink:label="lab_hum_A575PercentSeniorNotesDueDecember2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75 Percent Senior Notes Due December 2028 [Member]</link:label>
    <link:label id="lab_hum_A575PercentSeniorNotesDueDecember2028Member_documentation_en-US" xlink:label="lab_hum_A575PercentSeniorNotesDueDecember2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.75 Percent Senior Notes Due December 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A575PercentSeniorNotesDueDecember2028Member" xlink:href="hum-20231231.xsd#hum_A575PercentSeniorNotesDueDecember2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A575PercentSeniorNotesDueDecember2028Member" xlink:to="lab_hum_A575PercentSeniorNotesDueDecember2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_AcceleratedShareRepurchasesAgreementAmount_19adfd80-0df0-428c-bfd4-7f5a3d8a582c_terseLabel_en-US" xlink:label="lab_hum_AcceleratedShareRepurchasesAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated share repurchase agreement amount</link:label>
    <link:label id="lab_hum_AcceleratedShareRepurchasesAgreementAmount_label_en-US" xlink:label="lab_hum_AcceleratedShareRepurchasesAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Agreement Amount</link:label>
    <link:label id="lab_hum_AcceleratedShareRepurchasesAgreementAmount_documentation_en-US" xlink:label="lab_hum_AcceleratedShareRepurchasesAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases, Agreement Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_AcceleratedShareRepurchasesAgreementAmount" xlink:href="hum-20231231.xsd#hum_AcceleratedShareRepurchasesAgreementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_AcceleratedShareRepurchasesAgreementAmount" xlink:to="lab_hum_AcceleratedShareRepurchasesAgreementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_06365b20-98d3-499b-9031-396e903a4309_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_A2019PlanMember_5af937ad-de90-4da6-afcc-8c06eb61a3fc_terseLabel_en-US" xlink:label="lab_hum_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Plan</link:label>
    <link:label id="lab_hum_A2019PlanMember_label_en-US" xlink:label="lab_hum_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2019 Plan [Member]</link:label>
    <link:label id="lab_hum_A2019PlanMember_documentation_en-US" xlink:label="lab_hum_A2019PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2019 Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A2019PlanMember" xlink:href="hum-20231231.xsd#hum_A2019PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_A2019PlanMember" xlink:to="lab_hum_A2019PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_1785883b-7887-493f-8259-6a3701c16668_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_38e63291-5d0a-44b6-9011-0f602d0552a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_02e2ed20-ba04-452a-8ee6-38f18451eae5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_LongTermDebtAggregateCarryingValueAdjustment_ec12bd13-e5bb-4430-b497-23ed6a0f4276_terseLabel_en-US" xlink:label="lab_hum_LongTermDebtAggregateCarryingValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate carrying value adjustment</link:label>
    <link:label id="lab_hum_LongTermDebtAggregateCarryingValueAdjustment_label_en-US" xlink:label="lab_hum_LongTermDebtAggregateCarryingValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Aggregate Carrying Value Adjustment</link:label>
    <link:label id="lab_hum_LongTermDebtAggregateCarryingValueAdjustment_documentation_en-US" xlink:label="lab_hum_LongTermDebtAggregateCarryingValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Aggregate Carrying Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LongTermDebtAggregateCarryingValueAdjustment" xlink:href="hum-20231231.xsd#hum_LongTermDebtAggregateCarryingValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_LongTermDebtAggregateCarryingValueAdjustment" xlink:to="lab_hum_LongTermDebtAggregateCarryingValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_08c38303-1d18-463b-9875-67386cc2ec6e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_66ba6bcd-c40a-4fec-bb13-022e0a1bac8e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment_d45226d4-ecc4-480d-bc7c-99963a2ec952_negatedTerseLabel_en-US" xlink:label="lab_hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Remeasured existing Kindred at Home equity method investment</link:label>
    <link:label id="lab_hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment_label_en-US" xlink:label="lab_hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Acquisition Remeasurement Of Equity Investment</link:label>
    <link:label id="lab_hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment_documentation_en-US" xlink:label="lab_hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Acquisition Remeasurement Of Equity Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment" xlink:href="hum-20231231.xsd#hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment" xlink:to="lab_hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember_2a82c9b7-3f6b-4767-9fc0-a540e21ba479_terseLabel_en-US" xlink:label="lab_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit From Employer Group Commercial Medical Products Business</link:label>
    <link:label id="lab_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember_label_en-US" xlink:label="lab_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit From Employer Group Commercial Medical Products Business [Member]</link:label>
    <link:label id="lab_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember_documentation_en-US" xlink:label="lab_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit From Employer Group Commercial Medical Products Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember" xlink:href="hum-20231231.xsd#hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember" xlink:to="lab_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_6b3e076e-e9de-45f7-ba2e-cbbcf60e72e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Value of Debt Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_d17b2897-4885-4ec9-a9cf-e2fb031a568e_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods_232f9e18-5708-480b-9543-c3a22ccc41e9_terseLabel_en-US" xlink:label="lab_hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual option periods</link:label>
    <link:label id="lab_hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods_label_en-US" xlink:label="lab_hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE Managed Care Support Contract, Number Of Option Periods</link:label>
    <link:label id="lab_hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods_documentation_en-US" xlink:label="lab_hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRICARE Managed Care Support Contract, Number Of Option Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods" xlink:href="hum-20231231.xsd#hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods" xlink:to="lab_hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding_be6a4c53-ab63-41da-8b2c-242a84334d8a_terseLabel_en-US" xlink:label="lab_hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock plan assets as percentage of shares outstanding</link:label>
    <link:label id="lab_hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding_label_en-US" xlink:label="lab_hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Shares Of Common Stock In Plan As Percentage Of Shares Outstanding</link:label>
    <link:label id="lab_hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding_documentation_en-US" xlink:label="lab_hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Shares Of Common Stock In Plan As Percentage Of Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding" xlink:href="hum-20231231.xsd#hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding" xlink:to="lab_hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage_74c6d147-0f86-4597-9f12-6639afbd2bc0_terseLabel_en-US" xlink:label="lab_hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining ownership percentage acquired</link:label>
    <link:label id="lab_hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage_label_en-US" xlink:label="lab_hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Subsequent Acquisition, Percentage</link:label>
    <link:label id="lab_hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage_documentation_en-US" xlink:label="lab_hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Subsequent Acquisition, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage" xlink:href="hum-20231231.xsd#hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage" xlink:to="lab_hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_2b476633-85c0-4f33-8743-633d3fe851b9_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_hum_CommercialFullyInsuredMember_4b2e6bec-2f25-4979-b1e7-ff67934b8d2a_terseLabel_en-US" xlink:label="lab_hum_CommercialFullyInsuredMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial fully-insured</link:label>
    <link:label id="lab_hum_CommercialFullyInsuredMember_label_en-US" xlink:label="lab_hum_CommercialFullyInsuredMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Fully-Insured [Member]</link:label>
    <link:label id="lab_hum_CommercialFullyInsuredMember_documentation_en-US" xlink:label="lab_hum_CommercialFullyInsuredMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Fully-Insured</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CommercialFullyInsuredMember" xlink:href="hum-20231231.xsd#hum_CommercialFullyInsuredMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_hum_CommercialFullyInsuredMember" xlink:to="lab_hum_CommercialFullyInsuredMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareMember_label_en-US" xlink:label="lab_us-gaap_HealthCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareMember" xlink:to="lab_us-gaap_HealthCareMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>hum-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:7bfbafa3-a477-4092-82f1-790bd65455d7,g:6b53bb4a-2282-4b95-aa2c-e78c6730e17d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.humana.com/role/Cover" xlink:type="simple" xlink:href="hum-20231231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_87e231ae-aab4-48ba-9d24-568f00acc4db" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_DocumentType_87e231ae-aab4-48ba-9d24-568f00acc4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_f053b34e-0ba1-49be-a5a9-debf14ff0f88" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_DocumentAnnualReport_f053b34e-0ba1-49be-a5a9-debf14ff0f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ea18fe53-edbe-4259-9a7c-85fcda207da4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_DocumentPeriodEndDate_ea18fe53-edbe-4259-9a7c-85fcda207da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a1d596b6-cb01-4e5c-a5d2-cbf7fa21b96c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_CurrentFiscalYearEndDate_a1d596b6-cb01-4e5c-a5d2-cbf7fa21b96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_f53a411a-59d5-408f-8f6c-07079f69b2b3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_DocumentTransitionReport_f53a411a-59d5-408f-8f6c-07079f69b2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_6c17e8ab-730e-47fd-b237-ba67d11e90fb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityFileNumber_6c17e8ab-730e-47fd-b237-ba67d11e90fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_66aeec75-e0c8-442c-a733-ef1848996c72" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityRegistrantName_66aeec75-e0c8-442c-a733-ef1848996c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_512fbf72-b297-474c-996f-3aa4a4aa6fb8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityIncorporationStateCountryCode_512fbf72-b297-474c-996f-3aa4a4aa6fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_0ce0cb90-e319-4614-b84d-956adfb7a771" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityTaxIdentificationNumber_0ce0cb90-e319-4614-b84d-956adfb7a771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_003ae155-7fd2-44be-9893-ec4f8ff3b991" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityAddressAddressLine1_003ae155-7fd2-44be-9893-ec4f8ff3b991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_496d6b3b-804b-43ac-851b-f03799c1ae33" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityAddressCityOrTown_496d6b3b-804b-43ac-851b-f03799c1ae33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c74e968b-89ac-4760-8b31-02f57c306cfb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityAddressStateOrProvince_c74e968b-89ac-4760-8b31-02f57c306cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_384f560b-d9a3-4015-903d-551f96b60e88" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityAddressPostalZipCode_384f560b-d9a3-4015-903d-551f96b60e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ce893e2e-bdab-4551-8d1f-6ddcd313a4cf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_CityAreaCode_ce893e2e-bdab-4551-8d1f-6ddcd313a4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_98a084ef-5e78-4890-959d-8547f9608866" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_LocalPhoneNumber_98a084ef-5e78-4890-959d-8547f9608866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_de136254-e6d0-4f8d-8b66-e0a3fd73aa8a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_Security12bTitle_de136254-e6d0-4f8d-8b66-e0a3fd73aa8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f93dabf6-cf3e-4f78-ac4e-85e65f636e07" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_TradingSymbol_f93dabf6-cf3e-4f78-ac4e-85e65f636e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b95ba527-84c7-4e3e-becf-21af1c7cae22" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_SecurityExchangeName_b95ba527-84c7-4e3e-becf-21af1c7cae22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_dff6099b-5c9d-425e-999f-fe8562933d52" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_dff6099b-5c9d-425e-999f-fe8562933d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_c066fd81-60aa-4474-9c19-0f1f2b60da49" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityVoluntaryFilers_c066fd81-60aa-4474-9c19-0f1f2b60da49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_842e34cd-170c-42bf-a530-24b26259cc4b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityCurrentReportingStatus_842e34cd-170c-42bf-a530-24b26259cc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f9b4a2e8-b92c-4e18-a472-e3c725a433cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityInteractiveDataCurrent_f9b4a2e8-b92c-4e18-a472-e3c725a433cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_52d5456f-0802-4fd1-b6da-75932879d14b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityFilerCategory_52d5456f-0802-4fd1-b6da-75932879d14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7d56831a-0aac-462f-8f15-acbd57db18f3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntitySmallBusiness_7d56831a-0aac-462f-8f15-acbd57db18f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_fb0b381f-7155-42a3-9bd7-acec76ee9614" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityEmergingGrowthCompany_fb0b381f-7155-42a3-9bd7-acec76ee9614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_caca227a-5d01-4d6e-8b91-15e9718f8f60" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_IcfrAuditorAttestationFlag_caca227a-5d01-4d6e-8b91-15e9718f8f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_55e53c69-5201-4824-870e-c60ad42dbc3b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_55e53c69-5201-4824-870e-c60ad42dbc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_27187978-be97-4978-ab88-47d41cbb4dcd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityShellCompany_27187978-be97-4978-ab88-47d41cbb4dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_864e2182-0616-46b0-a40d-65ead9af82c6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityPublicFloat_864e2182-0616-46b0-a40d-65ead9af82c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_5d9c95d6-7af7-4900-9282-1bc7b5cfad4e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_5d9c95d6-7af7-4900-9282-1bc7b5cfad4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_86193df3-661b-4944-929f-81bbcc238af0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_86193df3-661b-4944-929f-81bbcc238af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3810df30-3140-41b5-9b88-de23c959f1d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_EntityCentralIndexKey_3810df30-3140-41b5-9b88-de23c959f1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4f713030-8c6e-4bbd-804b-e8d107103542" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_DocumentFiscalYearFocus_4f713030-8c6e-4bbd-804b-e8d107103542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_726cd4d8-35a1-4eae-8489-0d1a23b2f708" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_DocumentFiscalPeriodFocus_726cd4d8-35a1-4eae-8489-0d1a23b2f708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8c7299d3-ddcc-4159-90ea-ff53b11fd0f3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e29c7a8e-bac6-4bfe-aa26-ba7d90a32314" xlink:to="loc_dei_AmendmentFlag_8c7299d3-ddcc-4159-90ea-ff53b11fd0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/AuditInformation" xlink:type="simple" xlink:href="hum-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_hum_AuditInformationAbstract_f7d57220-5ed6-4967-b402-9c95eeabb2db" xlink:href="hum-20231231.xsd#hum_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_7a348206-ae6e-4fa1-9f0a-02030d5b79f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_AuditInformationAbstract_f7d57220-5ed6-4967-b402-9c95eeabb2db" xlink:to="loc_dei_AuditorName_7a348206-ae6e-4fa1-9f0a-02030d5b79f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_dcdf0c30-4930-4551-bb1b-9a442032aca1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_AuditInformationAbstract_f7d57220-5ed6-4967-b402-9c95eeabb2db" xlink:to="loc_dei_AuditorLocation_dcdf0c30-4930-4551-bb1b-9a442032aca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_838e6869-2bf9-4c33-88f8-b4fa4b332138" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_AuditInformationAbstract_f7d57220-5ed6-4967-b402-9c95eeabb2db" xlink:to="loc_dei_AuditorFirmId_838e6869-2bf9-4c33-88f8-b4fa4b332138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="hum-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_eaff4ba8-2d86-4bb1-bb46-010f5932adfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_14dd16f9-8bc4-47e5-95cb-4e14892ceda7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eaff4ba8-2d86-4bb1-bb46-010f5932adfb" xlink:to="loc_us-gaap_AssetsAbstract_14dd16f9-8bc4-47e5-95cb-4e14892ceda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_b6bfcfca-43e9-414e-a775-990a2e72744d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_14dd16f9-8bc4-47e5-95cb-4e14892ceda7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_b6bfcfca-43e9-414e-a775-990a2e72744d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_883f30dd-8f9d-42f5-a6db-583494802495" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b6bfcfca-43e9-414e-a775-990a2e72744d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_883f30dd-8f9d-42f5-a6db-583494802495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_5bd2a9ab-45ea-4b44-8ec8-46a46b8376db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b6bfcfca-43e9-414e-a775-990a2e72744d" xlink:to="loc_us-gaap_ShortTermInvestments_5bd2a9ab-45ea-4b44-8ec8-46a46b8376db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_89765643-d3d9-40ea-ab95-46d78431a618" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b6bfcfca-43e9-414e-a775-990a2e72744d" xlink:to="loc_us-gaap_ReceivablesNetCurrent_89765643-d3d9-40ea-ab95-46d78431a618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_552d1315-dac5-4f4c-b4c2-a2b2fdfe7a59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b6bfcfca-43e9-414e-a775-990a2e72744d" xlink:to="loc_us-gaap_OtherAssetsCurrent_552d1315-dac5-4f4c-b4c2-a2b2fdfe7a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_378c74c2-11ff-4d7f-9e23-5958795bf99d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b6bfcfca-43e9-414e-a775-990a2e72744d" xlink:to="loc_us-gaap_AssetsCurrent_378c74c2-11ff-4d7f-9e23-5958795bf99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_daff33d7-538d-4213-9aab-943d42f13dac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_14dd16f9-8bc4-47e5-95cb-4e14892ceda7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_daff33d7-538d-4213-9aab-943d42f13dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_764f5700-3171-4b48-83d5-b2c7f035ecb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_14dd16f9-8bc4-47e5-95cb-4e14892ceda7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_764f5700-3171-4b48-83d5-b2c7f035ecb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6ff99ebb-9992-43cd-b003-75d93a98c5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_14dd16f9-8bc4-47e5-95cb-4e14892ceda7" xlink:to="loc_us-gaap_Goodwill_6ff99ebb-9992-43cd-b003-75d93a98c5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ed90eaca-83f5-441b-b150-f292153332b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_14dd16f9-8bc4-47e5-95cb-4e14892ceda7" xlink:to="loc_us-gaap_EquityMethodInvestments_ed90eaca-83f5-441b-b150-f292153332b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d8ba83dc-96b8-4d89-8728-c52f3af09a40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_14dd16f9-8bc4-47e5-95cb-4e14892ceda7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d8ba83dc-96b8-4d89-8728-c52f3af09a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3c5df1a7-e8fb-453b-879a-8ff8bf6e8ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_14dd16f9-8bc4-47e5-95cb-4e14892ceda7" xlink:to="loc_us-gaap_Assets_3c5df1a7-e8fb-453b-879a-8ff8bf6e8ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_864f464c-b774-4d22-9a86-83b0294dfb30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_eaff4ba8-2d86-4bb1-bb46-010f5932adfb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_864f464c-b774-4d22-9a86-83b0294dfb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_ddb44501-97a7-4344-adf7-0fa2481115a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_864f464c-b774-4d22-9a86-83b0294dfb30" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_ddb44501-97a7-4344-adf7-0fa2481115a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_b9c436de-1b88-4996-8ad4-39c87c87c923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ddb44501-97a7-4344-adf7-0fa2481115a0" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_b9c436de-1b88-4996-8ad4-39c87c87c923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1e6161dc-d1e4-48da-a2d4-5fe7fdc718ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ddb44501-97a7-4344-adf7-0fa2481115a0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1e6161dc-d1e4-48da-a2d4-5fe7fdc718ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BookOverdraftLiability_d16534ae-f88b-41c8-83ea-fe6d51eccbdb" xlink:href="hum-20231231.xsd#hum_BookOverdraftLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ddb44501-97a7-4344-adf7-0fa2481115a0" xlink:to="loc_hum_BookOverdraftLiability_d16534ae-f88b-41c8-83ea-fe6d51eccbdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5c43638a-aaf1-4f1c-a0f6-e0772c327370" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ddb44501-97a7-4344-adf7-0fa2481115a0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5c43638a-aaf1-4f1c-a0f6-e0772c327370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_5e3e2c48-5e32-45f9-90a7-81119d1b113d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ddb44501-97a7-4344-adf7-0fa2481115a0" xlink:to="loc_us-gaap_DebtCurrent_5e3e2c48-5e32-45f9-90a7-81119d1b113d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1222221b-8faa-46a6-bdbe-c94ab36093eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_ddb44501-97a7-4344-adf7-0fa2481115a0" xlink:to="loc_us-gaap_LiabilitiesCurrent_1222221b-8faa-46a6-bdbe-c94ab36093eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7600dca0-2c5e-4a17-b753-7d138d4ce0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_864f464c-b774-4d22-9a86-83b0294dfb30" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7600dca0-2c5e-4a17-b753-7d138d4ce0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ee56a57d-f50d-40e2-a9a1-a153feb83ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_864f464c-b774-4d22-9a86-83b0294dfb30" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ee56a57d-f50d-40e2-a9a1-a153feb83ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b7cd8601-1813-4058-a867-994b66dbba2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_864f464c-b774-4d22-9a86-83b0294dfb30" xlink:to="loc_us-gaap_Liabilities_b7cd8601-1813-4058-a867-994b66dbba2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b8754ddf-4df2-452e-b02e-f899b33266b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_864f464c-b774-4d22-9a86-83b0294dfb30" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b8754ddf-4df2-452e-b02e-f899b33266b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_dc5fbd78-b7b2-42da-98c1-6bc9b60b4773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_864f464c-b774-4d22-9a86-83b0294dfb30" xlink:to="loc_us-gaap_StockholdersEquityAbstract_dc5fbd78-b7b2-42da-98c1-6bc9b60b4773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_8e55f735-8990-4f8c-88ea-a97f771f5417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc5fbd78-b7b2-42da-98c1-6bc9b60b4773" xlink:to="loc_us-gaap_PreferredStockValue_8e55f735-8990-4f8c-88ea-a97f771f5417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_47a7ac11-69ac-4af3-98d4-fbec6ad87984" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc5fbd78-b7b2-42da-98c1-6bc9b60b4773" xlink:to="loc_us-gaap_CommonStockValue_47a7ac11-69ac-4af3-98d4-fbec6ad87984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0ae55858-e2cd-42b1-b46e-84c54a76dc50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc5fbd78-b7b2-42da-98c1-6bc9b60b4773" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0ae55858-e2cd-42b1-b46e-84c54a76dc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0cf55f75-655a-417a-867a-decbe2312d79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc5fbd78-b7b2-42da-98c1-6bc9b60b4773" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0cf55f75-655a-417a-867a-decbe2312d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0319ad3a-f156-420e-8bf9-55456a12c795" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc5fbd78-b7b2-42da-98c1-6bc9b60b4773" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0319ad3a-f156-420e-8bf9-55456a12c795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_5a53a582-9920-4b42-9de8-be0132b75e13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc5fbd78-b7b2-42da-98c1-6bc9b60b4773" xlink:to="loc_us-gaap_TreasuryStockCommonValue_5a53a582-9920-4b42-9de8-be0132b75e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fb499e48-8284-4847-b518-a2960e4b05de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc5fbd78-b7b2-42da-98c1-6bc9b60b4773" xlink:to="loc_us-gaap_StockholdersEquity_fb499e48-8284-4847-b518-a2960e4b05de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_10a46880-4984-4e89-8358-d3612ab33d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc5fbd78-b7b2-42da-98c1-6bc9b60b4773" xlink:to="loc_us-gaap_MinorityInterest_10a46880-4984-4e89-8358-d3612ab33d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ea1c0f1a-66d8-4d59-8af6-c7a6489bc369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dc5fbd78-b7b2-42da-98c1-6bc9b60b4773" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ea1c0f1a-66d8-4d59-8af6-c7a6489bc369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3b731d9f-41f5-473b-948a-92d086c47313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_864f464c-b774-4d22-9a86-83b0294dfb30" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3b731d9f-41f5-473b-948a-92d086c47313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="hum-20231231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a7652b76-d035-4cc0-a214-65d4d307e6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f6fb8e78-3ee3-4846-8856-fa6dc6adef80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a7652b76-d035-4cc0-a214-65d4d307e6fa" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_f6fb8e78-3ee3-4846-8856-fa6dc6adef80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a7f40923-e644-47f2-a56f-97eff092edee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a7652b76-d035-4cc0-a214-65d4d307e6fa" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a7f40923-e644-47f2-a56f-97eff092edee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_72c6ec66-ecfe-4d57-8449-de38343232cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a7652b76-d035-4cc0-a214-65d4d307e6fa" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_72c6ec66-ecfe-4d57-8449-de38343232cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_67b1f1d9-ec04-4088-9a1d-f73258b9505f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a7652b76-d035-4cc0-a214-65d4d307e6fa" xlink:to="loc_us-gaap_PreferredStockSharesIssued_67b1f1d9-ec04-4088-9a1d-f73258b9505f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_0d7d8302-3012-434a-9265-b8906427e961" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a7652b76-d035-4cc0-a214-65d4d307e6fa" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_0d7d8302-3012-434a-9265-b8906427e961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6640eda7-0f22-4942-ae65-07798383c46e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a7652b76-d035-4cc0-a214-65d4d307e6fa" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6640eda7-0f22-4942-ae65-07798383c46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e9600994-17a1-4dd8-ae47-bb8eef041f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a7652b76-d035-4cc0-a214-65d4d307e6fa" xlink:to="loc_us-gaap_CommonStockSharesIssued_e9600994-17a1-4dd8-ae47-bb8eef041f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_5bd72d6b-2211-4376-b0af-55aa4b9772aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a7652b76-d035-4cc0-a214-65d4d307e6fa" xlink:to="loc_us-gaap_TreasuryStockCommonShares_5bd72d6b-2211-4376-b0af-55aa4b9772aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="hum-20231231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_782d253c-f39d-44a5-89df-7d542f68760a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_8ca1e5c4-b828-4533-ad6d-478fa7bbf2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_782d253c-f39d-44a5-89df-7d542f68760a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_8ca1e5c4-b828-4533-ad6d-478fa7bbf2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_bcc0e2cd-6f88-4fce-85f6-7a6f8a7dfe44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_782d253c-f39d-44a5-89df-7d542f68760a" xlink:to="loc_us-gaap_RevenuesAbstract_bcc0e2cd-6f88-4fce-85f6-7a6f8a7dfe44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_755485c5-b990-4aca-82a4-e225c25493b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_bcc0e2cd-6f88-4fce-85f6-7a6f8a7dfe44" xlink:to="loc_us-gaap_PremiumsEarnedNet_755485c5-b990-4aca-82a4-e225c25493b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ba84b287-b2e6-4c5c-8538-8543467efb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_bcc0e2cd-6f88-4fce-85f6-7a6f8a7dfe44" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_ba84b287-b2e6-4c5c-8538-8543467efb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_66f214b3-8e67-46a9-b829-692325089ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_bcc0e2cd-6f88-4fce-85f6-7a6f8a7dfe44" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_66f214b3-8e67-46a9-b829-692325089ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9ae7a106-52b3-4e16-93f9-a51637979df6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_bcc0e2cd-6f88-4fce-85f6-7a6f8a7dfe44" xlink:to="loc_us-gaap_Revenues_9ae7a106-52b3-4e16-93f9-a51637979df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8eaffa58-fc22-4a8e-a3f0-1adce5b1c405" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_782d253c-f39d-44a5-89df-7d542f68760a" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8eaffa58-fc22-4a8e-a3f0-1adce5b1c405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_3f2e2d7b-5004-468a-955b-fa45c2097134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8eaffa58-fc22-4a8e-a3f0-1adce5b1c405" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_3f2e2d7b-5004-468a-955b-fa45c2097134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_096ff51b-cfb0-4d74-b553-7aba94482200" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8eaffa58-fc22-4a8e-a3f0-1adce5b1c405" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_096ff51b-cfb0-4d74-b553-7aba94482200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_364ac86f-4d9d-46ae-b23d-1eb869e4d9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8eaffa58-fc22-4a8e-a3f0-1adce5b1c405" xlink:to="loc_us-gaap_DepreciationAndAmortization_364ac86f-4d9d-46ae-b23d-1eb869e4d9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_daf0af20-5f57-458d-a0cc-c7ae50f1a561" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8eaffa58-fc22-4a8e-a3f0-1adce5b1c405" xlink:to="loc_us-gaap_BenefitsLossesAndExpenses_daf0af20-5f57-458d-a0cc-c7ae50f1a561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5f2c9140-2075-4402-b0eb-21d30eebfb17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_782d253c-f39d-44a5-89df-7d542f68760a" xlink:to="loc_us-gaap_OperatingIncomeLoss_5f2c9140-2075-4402-b0eb-21d30eebfb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_c44f6db1-0333-4187-bde5-18479f93641c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_782d253c-f39d-44a5-89df-7d542f68760a" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_c44f6db1-0333-4187-bde5-18479f93641c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_10f55371-a0f4-4ba7-b62e-1118d1098aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_782d253c-f39d-44a5-89df-7d542f68760a" xlink:to="loc_us-gaap_InterestExpense_10f55371-a0f4-4ba7-b62e-1118d1098aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f8408be0-7014-419b-8a12-86135065f396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_782d253c-f39d-44a5-89df-7d542f68760a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f8408be0-7014-419b-8a12-86135065f396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ffc8ad1a-acfc-481f-be46-3af12508542e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_782d253c-f39d-44a5-89df-7d542f68760a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ffc8ad1a-acfc-481f-be46-3af12508542e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_15a7fa63-2398-4492-9a29-beedfa9b5508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_782d253c-f39d-44a5-89df-7d542f68760a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_15a7fa63-2398-4492-9a29-beedfa9b5508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6e21065d-1de4-40f7-b3b3-bfe83f58e914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_782d253c-f39d-44a5-89df-7d542f68760a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_6e21065d-1de4-40f7-b3b3-bfe83f58e914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e650ada8-6730-4ba9-8855-3bd625039b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_782d253c-f39d-44a5-89df-7d542f68760a" xlink:to="loc_us-gaap_ProfitLoss_e650ada8-6730-4ba9-8855-3bd625039b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f5a1c257-bdfb-4c25-bb1e-09e87a129347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_782d253c-f39d-44a5-89df-7d542f68760a" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f5a1c257-bdfb-4c25-bb1e-09e87a129347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_316e8d91-2fab-43b1-a4a0-639a42deb355" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_782d253c-f39d-44a5-89df-7d542f68760a" xlink:to="loc_us-gaap_NetIncomeLoss_316e8d91-2fab-43b1-a4a0-639a42deb355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_62ca6019-3b7d-4b5e-8615-1139fda0a55c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_782d253c-f39d-44a5-89df-7d542f68760a" xlink:to="loc_us-gaap_EarningsPerShareBasic_62ca6019-3b7d-4b5e-8615-1139fda0a55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a605aa9f-6db6-4c20-b251-f42cb1254d17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_782d253c-f39d-44a5-89df-7d542f68760a" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a605aa9f-6db6-4c20-b251-f42cb1254d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="hum-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6199200f-f41d-4ca6-a34c-615fcb1f222d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1d8b9e32-e835-4b29-90a2-6d149f37b439" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6199200f-f41d-4ca6-a34c-615fcb1f222d" xlink:to="loc_us-gaap_NetIncomeLoss_1d8b9e32-e835-4b29-90a2-6d149f37b439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f4069021-dd18-48df-bdd7-3ec1dd7239bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6199200f-f41d-4ca6-a34c-615fcb1f222d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f4069021-dd18-48df-bdd7-3ec1dd7239bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_c88f6ff5-5c22-41a3-85b2-d69133e19de7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f4069021-dd18-48df-bdd7-3ec1dd7239bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_c88f6ff5-5c22-41a3-85b2-d69133e19de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_afc30bb9-4e78-4bbf-bea8-043e51616303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f4069021-dd18-48df-bdd7-3ec1dd7239bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_afc30bb9-4e78-4bbf-bea8-043e51616303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8810d24f-4610-45ba-a2df-3fafd4719e62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f4069021-dd18-48df-bdd7-3ec1dd7239bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_8810d24f-4610-45ba-a2df-3fafd4719e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_b6a95e87-3c87-4702-8bdd-6d25889138c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f4069021-dd18-48df-bdd7-3ec1dd7239bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_b6a95e87-3c87-4702-8bdd-6d25889138c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_2adefd81-2d3c-4179-a228-a16620edf32c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f4069021-dd18-48df-bdd7-3ec1dd7239bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_2adefd81-2d3c-4179-a228-a16620edf32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_a138e690-c143-447b-898d-42a9f18352f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f4069021-dd18-48df-bdd7-3ec1dd7239bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_a138e690-c143-447b-898d-42a9f18352f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a20df299-ae9b-4288-9dd2-da8c4fedfa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_f4069021-dd18-48df-bdd7-3ec1dd7239bc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a20df299-ae9b-4288-9dd2-da8c4fedfa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments_a0d91ea4-2b6a-46f9-8f74-8b446032473a" xlink:href="hum-20231231.xsd#hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6199200f-f41d-4ca6-a34c-615fcb1f222d" xlink:to="loc_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments_a0d91ea4-2b6a-46f9-8f74-8b446032473a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_715d70c3-e133-4af2-bf68-90d0e7bbe20f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6199200f-f41d-4ca6-a34c-615fcb1f222d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_715d70c3-e133-4af2-bf68-90d0e7bbe20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="hum-20231231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_78afaaaa-5483-4abb-8125-9e8a35f47030" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1637d3d6-b14c-4c6d-a7ef-b23a0e383ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_78afaaaa-5483-4abb-8125-9e8a35f47030" xlink:to="loc_us-gaap_StatementTable_1637d3d6-b14c-4c6d-a7ef-b23a0e383ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_73f38c9c-6af7-4b47-ba27-10eded29c140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1637d3d6-b14c-4c6d-a7ef-b23a0e383ba8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_73f38c9c-6af7-4b47-ba27-10eded29c140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_749423b0-1181-4226-a1a3-86a876364b47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_73f38c9c-6af7-4b47-ba27-10eded29c140" xlink:to="loc_us-gaap_EquityComponentDomain_749423b0-1181-4226-a1a3-86a876364b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_a964ffc7-155e-4511-ba30-81c53c58a41c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_749423b0-1181-4226-a1a3-86a876364b47" xlink:to="loc_us-gaap_ParentMember_a964ffc7-155e-4511-ba30-81c53c58a41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_030a02f0-b19a-4ad5-b7f7-b80f78db8ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_a964ffc7-155e-4511-ba30-81c53c58a41c" xlink:to="loc_us-gaap_CommonStockMember_030a02f0-b19a-4ad5-b7f7-b80f78db8ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_07c3b27f-3f01-42e3-8476-905495c93480" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_a964ffc7-155e-4511-ba30-81c53c58a41c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_07c3b27f-3f01-42e3-8476-905495c93480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1ec0afb1-9387-4d65-b5a9-697faeedec18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_a964ffc7-155e-4511-ba30-81c53c58a41c" xlink:to="loc_us-gaap_RetainedEarningsMember_1ec0afb1-9387-4d65-b5a9-697faeedec18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8b552557-9093-454d-8804-a704d8997f41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_a964ffc7-155e-4511-ba30-81c53c58a41c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8b552557-9093-454d-8804-a704d8997f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_95564c4f-ae68-475c-9ec2-67ef8a40c132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_a964ffc7-155e-4511-ba30-81c53c58a41c" xlink:to="loc_us-gaap_TreasuryStockCommonMember_95564c4f-ae68-475c-9ec2-67ef8a40c132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_a12cc832-bced-4dc9-a561-0730def7714d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_749423b0-1181-4226-a1a3-86a876364b47" xlink:to="loc_us-gaap_NoncontrollingInterestMember_a12cc832-bced-4dc9-a561-0730def7714d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_bb8e3e2f-c7ea-43f9-9980-18a85f3f604a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1637d3d6-b14c-4c6d-a7ef-b23a0e383ba8" xlink:to="loc_us-gaap_StatementLineItems_bb8e3e2f-c7ea-43f9-9980-18a85f3f604a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_bb8e3e2f-c7ea-43f9-9980-18a85f3f604a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c80c6ba8-4e1e-409f-9d97-7d509013c705" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c80c6ba8-4e1e-409f-9d97-7d509013c705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b19d5ed-14da-4172-94a4-ba93d0fd34df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8b19d5ed-14da-4172-94a4-ba93d0fd34df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8777224b-8293-435a-9208-84ec2ba781fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_ProfitLoss_8777224b-8293-435a-9208-84ec2ba781fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders_cb3ebebd-73ac-472d-918e-3376ddfafe1a" xlink:href="hum-20231231.xsd#hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders_cb3ebebd-73ac-472d-918e-3376ddfafe1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_a3c07dc5-a330-4a0b-9e5e-a29468f99e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_a3c07dc5-a330-4a0b-9e5e-a29468f99e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_80e93217-fdeb-456c-bd5f-6fb6ad8cb146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_80e93217-fdeb-456c-bd5f-6fb6ad8cb146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_784707a1-58d6-402d-ae9d-954f43c58555" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_784707a1-58d6-402d-ae9d-954f43c58555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f67aa063-88ca-45c4-8b91-7f9db9f5bdd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_f67aa063-88ca-45c4-8b91-7f9db9f5bdd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_f6ba7b02-0f7a-4d4b-8af8-0cbe173b0c95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_DividendsCommonStockCash_f6ba7b02-0f7a-4d4b-8af8-0cbe173b0c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f0cdd302-1e31-45f4-9b5d-dd43180039b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f0cdd302-1e31-45f4-9b5d-dd43180039b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_98e64a5f-b96d-420c-8158-d9214ea5a136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_98e64a5f-b96d-420c-8158-d9214ea5a136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_98321690-e5a2-4abf-90a9-5798f8fa6404" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_98321690-e5a2-4abf-90a9-5798f8fa6404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e8d88a9d-b516-4651-a47a-6e4b31dc3645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_e8d88a9d-b516-4651-a47a-6e4b31dc3645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_056a2475-61e7-42f8-b60d-b291e97469a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_056a2475-61e7-42f8-b60d-b291e97469a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ef487393-6f8f-4647-80e9-fcf756d2fec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e79e56e2-362d-42d0-afc4-cd571eeede0f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ef487393-6f8f-4647-80e9-fcf756d2fec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" xlink:type="simple" xlink:href="hum-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOW"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f9e1b0db-840f-4ac9-b2e3-240f014d0b99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7f11c98-4d2c-44eb-9dba-a74670869943" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9e1b0db-840f-4ac9-b2e3-240f014d0b99" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7f11c98-4d2c-44eb-9dba-a74670869943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_70ba0fc5-162e-4ba0-aba1-f94b919c1fde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7f11c98-4d2c-44eb-9dba-a74670869943" xlink:to="loc_us-gaap_ProfitLoss_70ba0fc5-162e-4ba0-aba1-f94b919c1fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e19d686-ed6e-44f2-9f49-d82995518f58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7f11c98-4d2c-44eb-9dba-a74670869943" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e19d686-ed6e-44f2-9f49-d82995518f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_657d569e-753f-4e83-a01a-a1c92993d1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e19d686-ed6e-44f2-9f49-d82995518f58" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_657d569e-753f-4e83-a01a-a1c92993d1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_00ef2c6f-bac0-426d-8ca9-c67ab465d17d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndEquitySecuritiesGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e19d686-ed6e-44f2-9f49-d82995518f58" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_00ef2c6f-bac0-426d-8ca9-c67ab465d17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_4e553f91-4201-420d-ab4b-089d19942152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e19d686-ed6e-44f2-9f49-d82995518f58" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_4e553f91-4201-420d-ab4b-089d19942152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_58f0ab50-ce89-4f7f-b452-cff5e15c8b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e19d686-ed6e-44f2-9f49-d82995518f58" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_58f0ab50-ce89-4f7f-b452-cff5e15c8b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_60ec88aa-69f3-4ade-b88a-6824349f51b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e19d686-ed6e-44f2-9f49-d82995518f58" xlink:to="loc_us-gaap_ShareBasedCompensation_60ec88aa-69f3-4ade-b88a-6824349f51b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_18d3ebda-ee4f-4b49-b2e1-57dec44716ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e19d686-ed6e-44f2-9f49-d82995518f58" xlink:to="loc_us-gaap_Depreciation_18d3ebda-ee4f-4b49-b2e1-57dec44716ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_7c414895-3492-40de-a7e3-85de4275887b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e19d686-ed6e-44f2-9f49-d82995518f58" xlink:to="loc_us-gaap_AdjustmentForAmortization_7c414895-3492-40de-a7e3-85de4275887b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_e9fa20a3-260f-4a88-a382-95178b7d4b18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e19d686-ed6e-44f2-9f49-d82995518f58" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_e9fa20a3-260f-4a88-a382-95178b7d4b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_223f090f-2a4d-449d-8283-77717a15a701" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e19d686-ed6e-44f2-9f49-d82995518f58" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_223f090f-2a4d-449d-8283-77717a15a701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_baf921db-d5f2-4c78-963f-d79518af7013" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e19d686-ed6e-44f2-9f49-d82995518f58" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_baf921db-d5f2-4c78-963f-d79518af7013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c899035-a7e7-4aa0-8e04-31fe53bab55d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e19d686-ed6e-44f2-9f49-d82995518f58" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c899035-a7e7-4aa0-8e04-31fe53bab55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_18c382a4-c9ad-47bc-8fbe-bfe113dd6b98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c899035-a7e7-4aa0-8e04-31fe53bab55d" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_18c382a4-c9ad-47bc-8fbe-bfe113dd6b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_de31c448-19c5-4258-8ce6-d2f8901d808a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c899035-a7e7-4aa0-8e04-31fe53bab55d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_de31c448-19c5-4258-8ce6-d2f8901d808a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_754c4254-6d71-41f9-accb-6941d3762e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c899035-a7e7-4aa0-8e04-31fe53bab55d" xlink:to="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_754c4254-6d71-41f9-accb-6941d3762e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_481e4421-c9d6-49b2-9a82-ae213039be78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c899035-a7e7-4aa0-8e04-31fe53bab55d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_481e4421-c9d6-49b2-9a82-ae213039be78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8a6722b6-df7f-4ec4-8bbb-9b375843e83b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4c899035-a7e7-4aa0-8e04-31fe53bab55d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8a6722b6-df7f-4ec4-8bbb-9b375843e83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_73973e65-0eef-4459-934b-cd27c574e6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0e19d686-ed6e-44f2-9f49-d82995518f58" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_73973e65-0eef-4459-934b-cd27c574e6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d9a1bb0-7753-4f4f-a59c-932cde70d7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e7f11c98-4d2c-44eb-9dba-a74670869943" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d9a1bb0-7753-4f4f-a59c-932cde70d7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8c1d8cf4-377e-451c-9a63-7cc82352d77f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9e1b0db-840f-4ac9-b2e3-240f014d0b99" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8c1d8cf4-377e-451c-9a63-7cc82352d77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_f63c2bcf-98ab-4f89-9203-dd03631e1f58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8c1d8cf4-377e-451c-9a63-7cc82352d77f" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_f63c2bcf-98ab-4f89-9203-dd03631e1f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_90541c51-ac8a-486b-b2dc-df9458752078" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8c1d8cf4-377e-451c-9a63-7cc82352d77f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_90541c51-ac8a-486b-b2dc-df9458752078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20502cf0-6b96-4406-9db1-216fe0746053" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8c1d8cf4-377e-451c-9a63-7cc82352d77f" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_20502cf0-6b96-4406-9db1-216fe0746053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_74667c07-3572-4c79-a4da-2321346c69da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8c1d8cf4-377e-451c-9a63-7cc82352d77f" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_74667c07-3572-4c79-a4da-2321346c69da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2ba1e402-2f28-49dd-940d-79e142b6045f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8c1d8cf4-377e-451c-9a63-7cc82352d77f" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2ba1e402-2f28-49dd-940d-79e142b6045f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7d934513-5011-495a-9a67-20a05fa324f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8c1d8cf4-377e-451c-9a63-7cc82352d77f" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_7d934513-5011-495a-9a67-20a05fa324f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_227e53a3-a36f-45e2-8017-d76ffc5fdffc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8c1d8cf4-377e-451c-9a63-7cc82352d77f" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_227e53a3-a36f-45e2-8017-d76ffc5fdffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cf57a246-799f-4f03-b8aa-6d6287309cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8c1d8cf4-377e-451c-9a63-7cc82352d77f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cf57a246-799f-4f03-b8aa-6d6287309cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_278dc30b-71f5-496d-a7fe-a53783d998dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9e1b0db-840f-4ac9-b2e3-240f014d0b99" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_278dc30b-71f5-496d-a7fe-a53783d998dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PaymentsForProceedsFromContractDeposits_218471a4-b3fc-4840-af12-faa15b5a9f5e" xlink:href="hum-20231231.xsd#hum_PaymentsForProceedsFromContractDeposits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_278dc30b-71f5-496d-a7fe-a53783d998dc" xlink:to="loc_hum_PaymentsForProceedsFromContractDeposits_218471a4-b3fc-4840-af12-faa15b5a9f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_a5c8dd86-5379-46ec-8578-fd40ccf59591" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_278dc30b-71f5-496d-a7fe-a53783d998dc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_a5c8dd86-5379-46ec-8578-fd40ccf59591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_25f18ef3-0225-4b03-8d9e-102d2c76bbf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_278dc30b-71f5-496d-a7fe-a53783d998dc" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_25f18ef3-0225-4b03-8d9e-102d2c76bbf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_701bed93-ea5a-47af-b2ea-043129c4019a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfCommercialPaper"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_278dc30b-71f5-496d-a7fe-a53783d998dc" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_701bed93-ea5a-47af-b2ea-043129c4019a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_c8742048-b193-4670-a386-aa413ff0d4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_278dc30b-71f5-496d-a7fe-a53783d998dc" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_c8742048-b193-4670-a386-aa413ff0d4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_8ef314a4-6baf-45c5-8734-d12ce8c1f732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_278dc30b-71f5-496d-a7fe-a53783d998dc" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_8ef314a4-6baf-45c5-8734-d12ce8c1f732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_2ea248d7-6c68-4dea-bfcb-20cb4b563623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_278dc30b-71f5-496d-a7fe-a53783d998dc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt_2ea248d7-6c68-4dea-bfcb-20cb4b563623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfUnsecuredDebt_2cab2887-061a-41dc-9e5a-4cedca133e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfUnsecuredDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_278dc30b-71f5-496d-a7fe-a53783d998dc" xlink:to="loc_us-gaap_RepaymentsOfUnsecuredDebt_2cab2887-061a-41dc-9e5a-4cedca133e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_72b45ce9-578a-4893-bb3f-81618c319abd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_278dc30b-71f5-496d-a7fe-a53783d998dc" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_72b45ce9-578a-4893-bb3f-81618c319abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_70510da5-fea7-4760-a654-7679636a8897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_278dc30b-71f5-496d-a7fe-a53783d998dc" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_70510da5-fea7-4760-a654-7679636a8897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_b28e832b-98d2-4994-bd85-94ca4a49e6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_278dc30b-71f5-496d-a7fe-a53783d998dc" xlink:to="loc_us-gaap_PaymentsOfDividends_b28e832b-98d2-4994-bd85-94ca4a49e6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInBookOverdrafts_d5db103a-585b-4f24-9ebf-5428c97a3086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInBookOverdrafts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_278dc30b-71f5-496d-a7fe-a53783d998dc" xlink:to="loc_us-gaap_IncreaseDecreaseInBookOverdrafts_d5db103a-585b-4f24-9ebf-5428c97a3086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_76fe0da3-72b2-4c82-b875-42d08b2c8ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_278dc30b-71f5-496d-a7fe-a53783d998dc" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_76fe0da3-72b2-4c82-b875-42d08b2c8ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec5101fa-8cfa-449e-b091-e14cac27854d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_278dc30b-71f5-496d-a7fe-a53783d998dc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ec5101fa-8cfa-449e-b091-e14cac27854d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b6a1242e-4115-4522-8cc5-c42d1814fde5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9e1b0db-840f-4ac9-b2e3-240f014d0b99" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b6a1242e-4115-4522-8cc5-c42d1814fde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6685dde8-ecea-49a0-853b-5dbe663fae96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9e1b0db-840f-4ac9-b2e3-240f014d0b99" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6685dde8-ecea-49a0-853b-5dbe663fae96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c0e6ea23-8c9c-4ef1-a004-9b1dd268cd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9e1b0db-840f-4ac9-b2e3-240f014d0b99" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c0e6ea23-8c9c-4ef1-a004-9b1dd268cd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6548bd87-903c-4c32-9e32-c60bff3fbf4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9e1b0db-840f-4ac9-b2e3-240f014d0b99" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6548bd87-903c-4c32-9e32-c60bff3fbf4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_54b705bf-c717-4a6f-a898-bfd8d4934a37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6548bd87-903c-4c32-9e32-c60bff3fbf4b" xlink:to="loc_us-gaap_InterestPaidNet_54b705bf-c717-4a6f-a898-bfd8d4934a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_470c203c-db7d-4943-9f11-45588d850e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6548bd87-903c-4c32-9e32-c60bff3fbf4b" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_470c203c-db7d-4943-9f11-45588d850e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract_b17b5792-52ff-4236-ac55-b232c9ab5d00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6548bd87-903c-4c32-9e32-c60bff3fbf4b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract_b17b5792-52ff-4236-ac55-b232c9ab5d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_36345f27-44f3-4805-a25c-440a55e8b841" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract_b17b5792-52ff-4236-ac55-b232c9ab5d00" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_36345f27-44f3-4805-a25c-440a55e8b841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_29130e6c-54c2-4536-8107-148f13084c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract_b17b5792-52ff-4236-ac55-b232c9ab5d00" xlink:to="loc_us-gaap_LiabilitiesAssumed1_29130e6c-54c2-4536-8107-148f13084c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired_f0d6b09f-8444-4676-ad17-b039a2b8cfc9" xlink:href="hum-20231231.xsd#hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract_b17b5792-52ff-4236-ac55-b232c9ab5d00" xlink:to="loc_hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired_f0d6b09f-8444-4676-ad17-b039a2b8cfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment_99136df1-fbb5-4082-8656-2765867345e7" xlink:href="hum-20231231.xsd#hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract_b17b5792-52ff-4236-ac55-b232c9ab5d00" xlink:to="loc_hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment_99136df1-fbb5-4082-8656-2765867345e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2dd032c8-1b8e-4506-96c2-de20588ccdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract_b17b5792-52ff-4236-ac55-b232c9ab5d00" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2dd032c8-1b8e-4506-96c2-de20588ccdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/REPORTINGENTITY" xlink:type="simple" xlink:href="hum-20231231.xsd#REPORTINGENTITY"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/REPORTINGENTITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f5fb7829-f618-481f-9773-1d9c7926f0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_a24cf10b-3dfe-43bd-94e3-321cdcf51a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f5fb7829-f618-481f-9773-1d9c7926f0b2" xlink:to="loc_us-gaap_NatureOfOperations_a24cf10b-3dfe-43bd-94e3-321cdcf51a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="hum-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d8e006c9-3a7c-4269-b725-6ac919cb6613" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6568a7aa-7eda-46eb-8e55-34f9d667204d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d8e006c9-3a7c-4269-b725-6ac919cb6613" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6568a7aa-7eda-46eb-8e55-34f9d667204d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURES" xlink:type="simple" xlink:href="hum-20231231.xsd#ACQUISITIONSANDDIVESTITURES"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c4295d91-641c-480f-9462-9dbfdcd93179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_18e3b609-0b7d-4a76-840b-fe76a8f01ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c4295d91-641c-480f-9462-9dbfdcd93179" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_18e3b609-0b7d-4a76-840b-fe76a8f01ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/EQUITYMETHODINVESTMENT" xlink:type="simple" xlink:href="hum-20231231.xsd#EQUITYMETHODINVESTMENT"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/EQUITYMETHODINVESTMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_95824219-ddef-4a12-9ee4-14d60aa28e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_737f9276-93d1-4763-9125-0518a96f1ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_95824219-ddef-4a12-9ee4-14d60aa28e5e" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_737f9276-93d1-4763-9125-0518a96f1ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INVESTMENTSECURITIES" xlink:type="simple" xlink:href="hum-20231231.xsd#INVESTMENTSECURITIES"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/INVESTMENTSECURITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2143d89e-c8e2-4d50-8780-2fa173438b56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0bbe5c81-bb07-4cde-9471-49c8c9ebe8af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2143d89e-c8e2-4d50-8780-2fa173438b56" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_0bbe5c81-bb07-4cde-9471-49c8c9ebe8af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/FAIRVALUE" xlink:type="simple" xlink:href="hum-20231231.xsd#FAIRVALUE"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/FAIRVALUE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c972e098-8164-4c18-a4f1-bf8da3cba548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5b0489d6-1b25-490a-b059-4a33429f3f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c972e098-8164-4c18-a4f1-bf8da3cba548" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5b0489d6-1b25-490a-b059-4a33429f3f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/MEDICAREPARTD" xlink:type="simple" xlink:href="hum-20231231.xsd#MEDICAREPARTD"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/MEDICAREPARTD" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_e2706ec1-051f-42f5-84a1-f5f616da7acb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicarePartDDisclosureTextBlock_e45ccf88-eee6-49fb-a03c-59ed9c7857f7" xlink:href="hum-20231231.xsd#hum_MedicarePartDDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_e2706ec1-051f-42f5-84a1-f5f616da7acb" xlink:to="loc_hum_MedicarePartDDisclosureTextBlock_e45ccf88-eee6-49fb-a03c-59ed9c7857f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/PROPERTYANDEQUIPMENTNET" xlink:type="simple" xlink:href="hum-20231231.xsd#PROPERTYANDEQUIPMENTNET"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/PROPERTYANDEQUIPMENTNET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_00954b5b-84d4-4dbb-bc09-26e8124fd688" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5d1c49a0-994b-4197-9c5a-10b780ebd839" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_00954b5b-84d4-4dbb-bc09-26e8124fd688" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5d1c49a0-994b-4197-9c5a-10b780ebd839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" xlink:type="simple" xlink:href="hum-20231231.xsd#GOODWILLANDOTHERINTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_aff98ed7-87bf-443e-83ce-bb5f1f2c7efd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_05c3b8b3-beab-4ef5-9863-02e169c5e4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_aff98ed7-87bf-443e-83ce-bb5f1f2c7efd" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_05c3b8b3-beab-4ef5-9863-02e169c5e4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/LEASES" xlink:type="simple" xlink:href="hum-20231231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a9b4a9b8-2a5e-4af2-9b1f-a88e741f7631" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_17fe6f05-cab1-4b14-9fd5-4af1f1a3e3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a9b4a9b8-2a5e-4af2-9b1f-a88e741f7631" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_17fe6f05-cab1-4b14-9fd5-4af1f1a3e3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/BENEFITSPAYABLE" xlink:type="simple" xlink:href="hum-20231231.xsd#BENEFITSPAYABLE"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/BENEFITSPAYABLE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_671587a1-80c7-4b19-9cd8-77910b06369a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock_6a11703e-02c7-4c02-b244-c9c562238ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_671587a1-80c7-4b19-9cd8-77910b06369a" xlink:to="loc_us-gaap_InsuranceDisclosureTextBlock_6a11703e-02c7-4c02-b244-c9c562238ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INCOMETAXES" xlink:type="simple" xlink:href="hum-20231231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5d622058-1ca4-4f46-853a-bd4bfb125437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_826c0e54-a0e5-44fd-96c9-772a98203230" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5d622058-1ca4-4f46-853a-bd4bfb125437" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_826c0e54-a0e5-44fd-96c9-772a98203230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/DEBT" xlink:type="simple" xlink:href="hum-20231231.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bdb7d3ae-2b3c-468d-bab5-253a482deac7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_17812f77-7644-4df7-b1a4-437b595e54e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bdb7d3ae-2b3c-468d-bab5-253a482deac7" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_17812f77-7644-4df7-b1a4-437b595e54e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="hum-20231231.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_60eeb1ad-70da-4c2b-b7e7-1196cfb986e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock_969d0bd4-67c7-48c6-a744-69587390a84d" xlink:href="hum-20231231.xsd#hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_60eeb1ad-70da-4c2b-b7e7-1196cfb986e6" xlink:to="loc_hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock_969d0bd4-67c7-48c6-a744-69587390a84d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATION" xlink:type="simple" xlink:href="hum-20231231.xsd#EARNINGSPERCOMMONSHARECOMPUTATION"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_54f3ceab-b59f-46e9-9e60-b3315ec68f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_4bb59786-810b-4a3f-81b5-4badd19f56c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_54f3ceab-b59f-46e9-9e60-b3315ec68f0e" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_4bb59786-810b-4a3f-81b5-4badd19f56c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="hum-20231231.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2e1c137c-cdc2-40d3-a228-c53500a55db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ae2e05b2-c055-4a1c-92c0-872922745e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2e1c137c-cdc2-40d3-a228-c53500a55db3" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_ae2e05b2-c055-4a1c-92c0-872922745e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIES" xlink:type="simple" xlink:href="hum-20231231.xsd#COMMITMENTSGUARANTEESANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c0541059-c2fc-424a-aedf-4c6eccbb7d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9c53e83a-98e2-4ad6-88f9-4d6d5caa65a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c0541059-c2fc-424a-aedf-4c6eccbb7d4e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9c53e83a-98e2-4ad6-88f9-4d6d5caa65a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="hum-20231231.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7215b757-bf97-432a-8c62-a1c6c1184d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_5285967b-0155-4fc9-a290-796ec038a436" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7215b757-bf97-432a-8c62-a1c6c1184d1b" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_5285967b-0155-4fc9-a290-796ec038a436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/REINSURANCE" xlink:type="simple" xlink:href="hum-20231231.xsd#REINSURANCE"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/REINSURANCE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_2c9ca402-0a62-4bfe-b548-96b4e9368701" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceTextBlock_dc2f7d6c-8694-4a3f-be45-46ae21ac7d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_2c9ca402-0a62-4bfe-b548-96b4e9368701" xlink:to="loc_us-gaap_ReinsuranceTextBlock_dc2f7d6c-8694-4a3f-be45-46ae21ac7d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATION" xlink:type="simple" xlink:href="hum-20231231.xsd#SCHEDULEIPARENTCOMPANYFINANCIALINFORMATION"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2b1379cd-7448-46c5-a7d9-10be35d70d2d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_cb5129be-bae6-4e5f-ba6f-98432f6c96ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2b1379cd-7448-46c5-a7d9-10be35d70d2d" xlink:to="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_cb5129be-bae6-4e5f-ba6f-98432f6c96ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="hum-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d2df1ba3-017f-481d-986a-5fb87fdf0d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d2df1ba3-017f-481d-986a-5fb87fdf0d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ba3bb7be-00b3-4e01-b955-8540db9be611" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_ba3bb7be-00b3-4e01-b955-8540db9be611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_148e6f8a-60c5-4179-bc3e-34cba4208b70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_148e6f8a-60c5-4179-bc3e-34cba4208b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsurancePremiumsRevenueRecognitionPolicy_3c94d73e-621b-4cf4-829c-8dc4309e7205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsurancePremiumsRevenueRecognitionPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_us-gaap_InsurancePremiumsRevenueRecognitionPolicy_3c94d73e-621b-4cf4-829c-8dc4309e7205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8e43512b-883f-462c-8b2b-74c7f9373ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8e43512b-883f-462c-8b2b-74c7f9373ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_ae3b51df-e1d1-4789-9b2a-ff318714122b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_ae3b51df-e1d1-4789-9b2a-ff318714122b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_OtherCurrentAssetsPolicyTextBlock_a3d64163-5cfe-4a97-8010-20ae4c98d257" xlink:href="hum-20231231.xsd#hum_OtherCurrentAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_hum_OtherCurrentAssetsPolicyTextBlock_a3d64163-5cfe-4a97-8010-20ae4c98d257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceContractAcquisitionCostPolicyTextBlock_1e4216d6-aa10-4b32-a396-c780b7958a85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceContractAcquisitionCostPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_us-gaap_InsuranceContractAcquisitionCostPolicyTextBlock_1e4216d6-aa10-4b32-a396-c780b7958a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_fc57a4fd-61b6-4a4e-96ab-69d30aa2a317" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_fc57a4fd-61b6-4a4e-96ab-69d30aa2a317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_6ae7e150-9465-4493-9d6a-473506b6f302" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_6ae7e150-9465-4493-9d6a-473506b6f302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_b2c4551b-2521-4b61-82a6-14058f83a433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_b2c4551b-2521-4b61-82a6-14058f83a433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock_8c2db552-f2fb-4903-94ef-da89fc5dbac8" xlink:href="hum-20231231.xsd#hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock_8c2db552-f2fb-4903-94ef-da89fc5dbac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock_5aed90c9-ecbd-4474-881e-d22e9cabf79a" xlink:href="hum-20231231.xsd#hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock_5aed90c9-ecbd-4474-881e-d22e9cabf79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BookOverdraftPolicyPolicyTextBlock_3d5f2514-d054-458a-a7db-141dd474c6f5" xlink:href="hum-20231231.xsd#hum_BookOverdraftPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_hum_BookOverdraftPolicyPolicyTextBlock_3d5f2514-d054-458a-a7db-141dd474c6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_44382cd0-8626-49f9-b480-885d3757759c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_44382cd0-8626-49f9-b480-885d3757759c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_eae36ed6-b3a8-4376-b947-d28de6a88ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_eae36ed6-b3a8-4376-b947-d28de6a88ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_9fc050db-ee69-4fd4-be7d-6fca1960122b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_9fc050db-ee69-4fd4-be7d-6fca1960122b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_bbf63af6-d4b1-4006-8887-ddfc8a130a36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_bbf63af6-d4b1-4006-8887-ddfc8a130a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_b1ba8c51-ed88-43f9-a0a5-baea9c4efbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_b1ba8c51-ed88-43f9-a0a5-baea9c4efbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16151565-4fdd-411c-8c1e-f8d45bf45da4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9e6f4453-ebd3-41b0-9c5f-bcb3a280c5dd" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16151565-4fdd-411c-8c1e-f8d45bf45da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="hum-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8153364c-0148-47a9-aa52-7307a207695a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock_486bde08-0716-4fe2-a6d9-9309f329f2dc" xlink:href="hum-20231231.xsd#hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8153364c-0148-47a9-aa52-7307a207695a" xlink:to="loc_hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock_486bde08-0716-4fe2-a6d9-9309f329f2dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESTables" xlink:type="simple" xlink:href="hum-20231231.xsd#ACQUISITIONSANDDIVESTITURESTables"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9b3ddb02-6728-43aa-b061-990f193a4e68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1c32c392-e039-4302-969b-7a0ad713d654" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9b3ddb02-6728-43aa-b061-990f193a4e68" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_1c32c392-e039-4302-969b-7a0ad713d654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/EQUITYMETHODINVESTMENTTables" xlink:type="simple" xlink:href="hum-20231231.xsd#EQUITYMETHODINVESTMENTTables"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/EQUITYMETHODINVESTMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_322ed90e-3b23-4011-b9ef-f3dcd8bc0dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_89405cff-ef88-4dcf-aa81-a1dec11716e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_322ed90e-3b23-4011-b9ef-f3dcd8bc0dc5" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_89405cff-ef88-4dcf-aa81-a1dec11716e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INVESTMENTSECURITIESTables" xlink:type="simple" xlink:href="hum-20231231.xsd#INVESTMENTSECURITIESTables"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/INVESTMENTSECURITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3b9f5871-6c07-4c6b-bb60-f5ff6de1364c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_ec190206-0d6f-41d1-a546-fb602efd3cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3b9f5871-6c07-4c6b-bb60-f5ff6de1364c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_ec190206-0d6f-41d1-a546-fb602efd3cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_e250d461-28fa-49c9-8049-089e8d2ee229" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3b9f5871-6c07-4c6b-bb60-f5ff6de1364c" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_e250d461-28fa-49c9-8049-089e8d2ee229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRealizedGainLossTableTextBlock_f1b8adc3-49ac-4ab5-931d-47af49f88485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRealizedGainLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3b9f5871-6c07-4c6b-bb60-f5ff6de1364c" xlink:to="loc_us-gaap_ScheduleOfRealizedGainLossTableTextBlock_f1b8adc3-49ac-4ab5-931d-47af49f88485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_ca763f7f-5699-4804-81fb-a0a193cdf87b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3b9f5871-6c07-4c6b-bb60-f5ff6de1364c" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_ca763f7f-5699-4804-81fb-a0a193cdf87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_fa995381-c9ad-43e0-a2ca-ce5a74c32949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3b9f5871-6c07-4c6b-bb60-f5ff6de1364c" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_fa995381-c9ad-43e0-a2ca-ce5a74c32949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/FAIRVALUETables" xlink:type="simple" xlink:href="hum-20231231.xsd#FAIRVALUETables"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/FAIRVALUETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_88464a57-ac1f-41e7-95c1-93376d44916d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_c1ea70f2-b5bf-4c38-8aa3-5a42559e9f85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_88464a57-ac1f-41e7-95c1-93376d44916d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_c1ea70f2-b5bf-4c38-8aa3-5a42559e9f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_3b85bff2-197a-48e1-a991-b412c7edf6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_88464a57-ac1f-41e7-95c1-93376d44916d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_3b85bff2-197a-48e1-a991-b412c7edf6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_da2d0c8a-ace4-45c0-b3bd-b3b939e63257" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_88464a57-ac1f-41e7-95c1-93376d44916d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_da2d0c8a-ace4-45c0-b3bd-b3b939e63257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/MEDICAREPARTDTables" xlink:type="simple" xlink:href="hum-20231231.xsd#MEDICAREPARTDTables"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/MEDICAREPARTDTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_368609a6-b624-4a30-8b0e-c0532c1ca6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock_73c5c600-241a-4ad5-950c-5cf638ab2e68" xlink:href="hum-20231231.xsd#hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_368609a6-b624-4a30-8b0e-c0532c1ca6f5" xlink:to="loc_hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock_73c5c600-241a-4ad5-950c-5cf638ab2e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/PROPERTYANDEQUIPMENTNETTables" xlink:type="simple" xlink:href="hum-20231231.xsd#PROPERTYANDEQUIPMENTNETTables"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/PROPERTYANDEQUIPMENTNETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_82a96ca6-5ee0-4344-b311-7d919a76dd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ef7cd5b1-1a1f-482a-9ed3-ccc9fa336e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_82a96ca6-5ee0-4344-b311-7d919a76dd9a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ef7cd5b1-1a1f-482a-9ed3-ccc9fa336e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="hum-20231231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d1357c61-5e84-42c9-8159-24e02064e3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_a686b725-de99-4d1b-9e99-3e094ce38de4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d1357c61-5e84-42c9-8159-24e02064e3c4" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_a686b725-de99-4d1b-9e99-3e094ce38de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0846b179-680c-45ac-973b-14f3b5a07ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d1357c61-5e84-42c9-8159-24e02064e3c4" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0846b179-680c-45ac-973b-14f3b5a07ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_810f3d1d-8448-4758-aec6-df68660e9420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d1357c61-5e84-42c9-8159-24e02064e3c4" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_810f3d1d-8448-4758-aec6-df68660e9420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/LEASESTables" xlink:type="simple" xlink:href="hum-20231231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_dc113d95-e21b-4578-9111-91507699a1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ee8a21a5-e09c-4ce3-85c8-5281dbf92f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dc113d95-e21b-4578-9111-91507699a1d1" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ee8a21a5-e09c-4ce3-85c8-5281dbf92f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/BENEFITSPAYABLETables" xlink:type="simple" xlink:href="hum-20231231.xsd#BENEFITSPAYABLETables"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/BENEFITSPAYABLETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_7cf0d2c6-6617-4ac4-a4b3-ebb210e49c81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_a0fab4c0-a57f-4b0c-8519-ce5d9a059539" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_7cf0d2c6-6617-4ac4-a4b3-ebb210e49c81" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_a0fab4c0-a57f-4b0c-8519-ce5d9a059539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_e4fd3d1c-8a72-457c-8df0-568abce5ca52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_7cf0d2c6-6617-4ac4-a4b3-ebb210e49c81" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_e4fd3d1c-8a72-457c-8df0-568abce5ca52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="hum-20231231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a677a926-2d17-4ce9-b4d0-f8dd020bdddf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_bf5872d2-9f56-4fdc-b30b-124c4c68f775" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a677a926-2d17-4ce9-b4d0-f8dd020bdddf" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_bf5872d2-9f56-4fdc-b30b-124c4c68f775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_855dc476-6a2f-4987-b17d-9e2fed48a5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a677a926-2d17-4ce9-b4d0-f8dd020bdddf" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_855dc476-6a2f-4987-b17d-9e2fed48a5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3e4bc980-cdea-4b16-b725-6035a8555f78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a677a926-2d17-4ce9-b4d0-f8dd020bdddf" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3e4bc980-cdea-4b16-b725-6035a8555f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/DEBTTables" xlink:type="simple" xlink:href="hum-20231231.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d444532b-6f81-4e85-848b-8041a2aebe6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_819cf449-9f72-45bf-80e7-b2c18d98a1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d444532b-6f81-4e85-848b-8041a2aebe6f" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_819cf449-9f72-45bf-80e7-b2c18d98a1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ebaa35c2-3f0a-4bf2-83d0-9be5f99409e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d444532b-6f81-4e85-848b-8041a2aebe6f" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_ebaa35c2-3f0a-4bf2-83d0-9be5f99409e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSTables" xlink:type="simple" xlink:href="hum-20231231.xsd#EMPLOYEEBENEFITPLANSTables"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/EMPLOYEEBENEFITPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_aadd8ac7-0126-4c3b-b778-9e750e942715" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1544b149-4e80-4ef6-9eab-c9ad05daff94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_aadd8ac7-0126-4c3b-b778-9e750e942715" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1544b149-4e80-4ef6-9eab-c9ad05daff94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_933c562c-38a7-462c-b0e0-0ef26c410097" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_aadd8ac7-0126-4c3b-b778-9e750e942715" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_933c562c-38a7-462c-b0e0-0ef26c410097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f49b155c-8073-4fcf-aebc-9d80c53c36d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_aadd8ac7-0126-4c3b-b778-9e750e942715" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f49b155c-8073-4fcf-aebc-9d80c53c36d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_728f47dc-e402-4993-a1fd-3044d8cca520" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_aadd8ac7-0126-4c3b-b778-9e750e942715" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_728f47dc-e402-4993-a1fd-3044d8cca520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONTables" xlink:type="simple" xlink:href="hum-20231231.xsd#EARNINGSPERCOMMONSHARECOMPUTATIONTables"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_84c03d8c-0673-4b47-9b9f-706ffc58b703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_76afe9ef-9255-45a7-87b9-ccebf78573fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_84c03d8c-0673-4b47-9b9f-706ffc58b703" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_76afe9ef-9255-45a7-87b9-ccebf78573fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="hum-20231231.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_624d165c-cf15-4958-a5b7-bd2bb0c454f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsDeclaredTableTextBlock_78499f9f-2891-47fe-b6ef-a053e3ce9a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsDeclaredTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_624d165c-cf15-4958-a5b7-bd2bb0c454f3" xlink:to="loc_us-gaap_DividendsDeclaredTableTextBlock_78499f9f-2891-47fe-b6ef-a053e3ce9a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_22943918-8745-4305-a590-921747f2ca9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_624d165c-cf15-4958-a5b7-bd2bb0c454f3" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_22943918-8745-4305-a590-921747f2ca9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="hum-20231231.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_63227155-cb1f-4600-995c-c1938bf772ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_2d974ed4-868f-4ef4-87d4-69e95a58b8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_63227155-cb1f-4600-995c-c1938bf772ec" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_2d974ed4-868f-4ef4-87d4-69e95a58b8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/REPORTINGENTITYDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#REPORTINGENTITYDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/REPORTINGENTITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0b06ebe8-ebb1-449b-949a-5464b8c83658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_8d3add52-6029-4b7c-b835-88f4b4de14f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0b06ebe8-ebb1-449b-949a-5464b8c83658" xlink:to="loc_us-gaap_ConcentrationRiskTable_8d3add52-6029-4b7c-b835-88f4b4de14f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_208753b0-ea65-441e-a642-9cbdc5073c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8d3add52-6029-4b7c-b835-88f4b4de14f0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_208753b0-ea65-441e-a642-9cbdc5073c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_63a1d8d4-0f0e-48e6-b09f-f77b0699ed2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_208753b0-ea65-441e-a642-9cbdc5073c5f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_63a1d8d4-0f0e-48e6-b09f-f77b0699ed2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_bd35fa49-a5d1-40bb-9dad-2a9ddccf84a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_63a1d8d4-0f0e-48e6-b09f-f77b0699ed2a" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_bd35fa49-a5d1-40bb-9dad-2a9ddccf84a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_95c526ac-f0cd-425e-8713-0380d46267fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8d3add52-6029-4b7c-b835-88f4b4de14f0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_95c526ac-f0cd-425e-8713-0380d46267fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5a37b9b7-ff08-47d7-bdd7-c50655ab24df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_95c526ac-f0cd-425e-8713-0380d46267fb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5a37b9b7-ff08-47d7-bdd7-c50655ab24df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_888e3d90-e8c8-47bb-aee7-e2b3f541b07b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5a37b9b7-ff08-47d7-bdd7-c50655ab24df" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_888e3d90-e8c8-47bb-aee7-e2b3f541b07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7fe989de-2ecd-48ea-8169-2eae1b024c5b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8d3add52-6029-4b7c-b835-88f4b4de14f0" xlink:to="loc_srt_MajorCustomersAxis_7fe989de-2ecd-48ea-8169-2eae1b024c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4f11e22d-e3b8-4c3a-a870-f7ba897ffc1a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7fe989de-2ecd-48ea-8169-2eae1b024c5b" xlink:to="loc_srt_NameOfMajorCustomerDomain_4f11e22d-e3b8-4c3a-a870-f7ba897ffc1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FederalGovernmentMember_787bf5a6-cabe-4604-894f-d76096387034" xlink:href="hum-20231231.xsd#hum_FederalGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4f11e22d-e3b8-4c3a-a870-f7ba897ffc1a" xlink:to="loc_hum_FederalGovernmentMember_787bf5a6-cabe-4604-894f-d76096387034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember_59a70101-69cc-408f-836c-56a996148fa2" xlink:href="hum-20231231.xsd#hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4f11e22d-e3b8-4c3a-a870-f7ba897ffc1a" xlink:to="loc_hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember_59a70101-69cc-408f-836c-56a996148fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_d9fecca3-a5f9-40d0-bc84-5c8b39e10849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_8d3add52-6029-4b7c-b835-88f4b4de14f0" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_d9fecca3-a5f9-40d0-bc84-5c8b39e10849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_83a3d2af-7075-49f4-aac1-bcc598607099" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_d9fecca3-a5f9-40d0-bc84-5c8b39e10849" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_83a3d2af-7075-49f4-aac1-bcc598607099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7bce4978-41f9-4ee3-904f-7a32fbdcc501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:href="hum-20231231.xsd#hum_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7bce4978-41f9-4ee3-904f-7a32fbdcc501" xlink:to="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceContractAxis_3cf54e77-2f94-46cc-94a6-45d4fda0bcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceContractAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_ReinsuranceContractAxis_3cf54e77-2f94-46cc-94a6-45d4fda0bcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6603a9c8-3394-49f7-a538-642637fa879f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_srt_ProductOrServiceAxis_6603a9c8-3394-49f7-a538-642637fa879f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e6fc3aad-ce7d-4aaf-9315-0469eb49a814" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6603a9c8-3394-49f7-a538-642637fa879f" xlink:to="loc_srt_ProductsAndServicesDomain_e6fc3aad-ce7d-4aaf-9315-0469eb49a814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_7224520c-8c68-4f13-ad6b-4e935848ac47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6fc3aad-ce7d-4aaf-9315-0469eb49a814" xlink:to="loc_us-gaap_ServiceMember_7224520c-8c68-4f13-ad6b-4e935848ac47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareSupplementProductMember_029f5517-d785-4fc9-8407-cf2f07ca28f7" xlink:href="hum-20231231.xsd#hum_MedicareSupplementProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e6fc3aad-ce7d-4aaf-9315-0469eb49a814" xlink:to="loc_hum_MedicareSupplementProductMember_029f5517-d785-4fc9-8407-cf2f07ca28f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb43270b-61c1-42c5-9834-121f75353bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb43270b-61c1-42c5-9834-121f75353bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a98b60c-3e70-4c18-98b2-96729a557aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cb43270b-61c1-42c5-9834-121f75353bb9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a98b60c-3e70-4c18-98b2-96729a557aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_19210c79-5c9e-4af2-a10d-83454a4a189c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a98b60c-3e70-4c18-98b2-96729a557aa9" xlink:to="loc_us-gaap_EquipmentMember_19210c79-5c9e-4af2-a10d-83454a4a189c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_12b89f2a-983e-4eb7-933a-6db4e8dc4363" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a98b60c-3e70-4c18-98b2-96729a557aa9" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_12b89f2a-983e-4eb7-933a-6db4e8dc4363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_0f7c15e5-ee32-404a-851a-7910c4aa3e09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9a98b60c-3e70-4c18-98b2-96729a557aa9" xlink:to="loc_us-gaap_BuildingMember_0f7c15e5-ee32-404a-851a-7910c4aa3e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_0835bc40-bb5d-4306-8309-cee423e256ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_ReportingUnitAxis_0835bc40-bb5d-4306-8309-cee423e256ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_6061b16d-aaea-4da0-b91a-ed0593c982a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_0835bc40-bb5d-4306-8309-cee423e256ab" xlink:to="loc_us-gaap_ReportingUnitDomain_6061b16d-aaea-4da0-b91a-ed0593c982a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_HomeSolutionsReportingUnitMember_a3fd08d7-ef9c-4278-8c35-8fb0131c4e1b" xlink:href="hum-20231231.xsd#hum_HomeSolutionsReportingUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_6061b16d-aaea-4da0-b91a-ed0593c982a5" xlink:to="loc_hum_HomeSolutionsReportingUnitMember_a3fd08d7-ef9c-4278-8c35-8fb0131c4e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ProviderReportingUnitMember_c3740ffc-fe7a-449a-9f90-02bb6e8b5076" xlink:href="hum-20231231.xsd#hum_ProviderReportingUnitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_6061b16d-aaea-4da0-b91a-ed0593c982a5" xlink:to="loc_hum_ProviderReportingUnitMember_c3740ffc-fe7a-449a-9f90-02bb6e8b5076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3f8a9f31-f0f3-4b19-b54b-49f18872fb00" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_srt_RangeAxis_3f8a9f31-f0f3-4b19-b54b-49f18872fb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2c30ecab-354a-471d-97e9-0fdeaa81994f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3f8a9f31-f0f3-4b19-b54b-49f18872fb00" xlink:to="loc_srt_RangeMember_2c30ecab-354a-471d-97e9-0fdeaa81994f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6b3d4d5e-0029-441a-93c7-3035449af3b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2c30ecab-354a-471d-97e9-0fdeaa81994f" xlink:to="loc_srt_MinimumMember_6b3d4d5e-0029-441a-93c7-3035449af3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1c9a82b9-9ba4-4663-8cdb-996ef8145abb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2c30ecab-354a-471d-97e9-0fdeaa81994f" xlink:to="loc_srt_MaximumMember_1c9a82b9-9ba4-4663-8cdb-996ef8145abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd9cc172-63e9-4361-9b9b-4620adb7afba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd9cc172-63e9-4361-9b9b-4620adb7afba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f383a13a-1617-4319-b699-5573fb1acb08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cd9cc172-63e9-4361-9b9b-4620adb7afba" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f383a13a-1617-4319-b699-5573fb1acb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_07ad6d8f-fe61-43b1-8077-88be2280fc27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f383a13a-1617-4319-b699-5573fb1acb08" xlink:to="loc_us-gaap_SalesRevenueNetMember_07ad6d8f-fe61-43b1-8077-88be2280fc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5ac49e92-cc4d-426b-867a-5342ecdfa7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5ac49e92-cc4d-426b-867a-5342ecdfa7c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c44aa83a-b5d1-4f63-90e6-2d48efae2c07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5ac49e92-cc4d-426b-867a-5342ecdfa7c7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c44aa83a-b5d1-4f63-90e6-2d48efae2c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_c94a1e6b-7498-440f-ad9b-65b7fe5fefe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c44aa83a-b5d1-4f63-90e6-2d48efae2c07" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_c94a1e6b-7498-440f-ad9b-65b7fe5fefe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_bd4ff641-be13-47fb-8357-8a95c16fc919" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_us-gaap_RestructuringPlanAxis_bd4ff641-be13-47fb-8357-8a95c16fc919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_ee9233d5-42c1-40dc-b8d9-4e87645360d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_bd4ff641-be13-47fb-8357-8a95c16fc919" xlink:to="loc_us-gaap_RestructuringPlanDomain_ee9233d5-42c1-40dc-b8d9-4e87645360d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ValueCreationInitiativesMember_26bbc550-c786-48cb-a1a3-b5456d269ecc" xlink:href="hum-20231231.xsd#hum_ValueCreationInitiativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_ee9233d5-42c1-40dc-b8d9-4e87645360d6" xlink:to="loc_hum_ValueCreationInitiativesMember_26bbc550-c786-48cb-a1a3-b5456d269ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember_d0175efe-6b23-41f6-ad64-0b7e26d4319d" xlink:href="hum-20231231.xsd#hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_ee9233d5-42c1-40dc-b8d9-4e87645360d6" xlink:to="loc_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember_d0175efe-6b23-41f6-ad64-0b7e26d4319d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:href="hum-20231231.xsd#hum_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesTable_b53f9fe3-ca59-4309-90ac-af2e3f8fb6b5" xlink:to="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_97938347-29d4-4022-8c51-a80cc9acc1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostsAndAssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_RestructuringCostsAndAssetImpairmentCharges_97938347-29d4-4022-8c51-a80cc9acc1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_0d532744-6a69-4677-8fdb-1f3f8413bb84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_0d532744-6a69-4677-8fdb-1f3f8413bb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_bd707659-46a6-43a2-abeb-e265f2de2f67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_SeveranceCosts1_bd707659-46a6-43a2-abeb-e265f2de2f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a4d8dfe3-823b-4f03-b56c-f7dd1cd130ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_AssetImpairmentCharges_a4d8dfe3-823b-4f03-b56c-f7dd1cd130ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3fc7d31c-9018-4240-ac81-2151c275b24a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_3fc7d31c-9018-4240-ac81-2151c275b24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CommercialMembershipContractTerm_bef85b80-9d7f-42c8-8642-1c5cf1cac8cb" xlink:href="hum-20231231.xsd#hum_CommercialMembershipContractTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_CommercialMembershipContractTerm_bef85b80-9d7f-42c8-8642-1c5cf1cac8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies_a21bd6cd-f6c4-4fde-82a7-fdd35354f641" xlink:href="hum-20231231.xsd#hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies_a21bd6cd-f6c4-4fde-82a7-fdd35354f641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs_66c50444-0e75-4e59-b362-10c3c0e3fda8" xlink:href="hum-20231231.xsd#hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs_66c50444-0e75-4e59-b362-10c3c0e3fda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SubsidyAndDiscountsSettlementPeriodAfterClose_a6cba838-7b7d-4b7c-be76-bf01cf0da63a" xlink:href="hum-20231231.xsd#hum_SubsidyAndDiscountsSettlementPeriodAfterClose"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_SubsidyAndDiscountsSettlementPeriodAfterClose_a6cba838-7b7d-4b7c-be76-bf01cf0da63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_03e996f7-b5ef-4e8e-9783-b8fc6edd092f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_03e996f7-b5ef-4e8e-9783-b8fc6edd092f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_AccruedPharmaceuticalRebatesCurrent_c82a0e1d-4b72-4517-bf8b-1efde6058081" xlink:href="hum-20231231.xsd#hum_AccruedPharmaceuticalRebatesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_AccruedPharmaceuticalRebatesCurrent_c82a0e1d-4b72-4517-bf8b-1efde6058081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies_9a765624-8085-4f1f-9cdf-17f87f7cfafc" xlink:href="hum-20231231.xsd#hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies_9a765624-8085-4f1f-9cdf-17f87f7cfafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_911cafc7-c9fb-4ec4-b32f-73e0ed9c1158" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_911cafc7-c9fb-4ec4-b32f-73e0ed9c1158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c942c0ad-e899-4649-b2e7-0c01036ce7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_Goodwill_c942c0ad-e899-4649-b2e7-0c01036ce7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_31664f9f-bc13-42db-8d4c-e638da765f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_31664f9f-bc13-42db-8d4c-e638da765f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0ea618ba-c00c-462d-86c2-7da7e49f93f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_SignificantAccountingPoliciesLineItems_eb39e677-1787-482f-b2b3-64ef453b943c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_0ea618ba-c00c-462d-86c2-7da7e49f93f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails_1" xlink:type="simple" xlink:href="hum-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails_1"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPartDSubsidyDiscountPaymentsNetDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPartDSubsidyDiscountPaymentsNetDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPartDSubsidyDiscountPaymentsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_19ffa1fb-a968-4237-967d-ee39d38211b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SubsidyAndDiscountPayments_eea1703f-8731-4d9a-9329-db895000d9df" xlink:href="hum-20231231.xsd#hum_SubsidyAndDiscountPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_19ffa1fb-a968-4237-967d-ee39d38211b1" xlink:to="loc_hum_SubsidyAndDiscountPayments_eea1703f-8731-4d9a-9329-db895000d9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SubsidyAndDiscountReimbursements_b7e6e0b8-2939-45be-af21-ea7d093f343c" xlink:href="hum-20231231.xsd#hum_SubsidyAndDiscountReimbursements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_19ffa1fb-a968-4237-967d-ee39d38211b1" xlink:to="loc_hum_SubsidyAndDiscountReimbursements_b7e6e0b8-2939-45be-af21-ea7d093f343c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements_fde46870-ac1a-4b74-9968-a4b9aadbf95d" xlink:href="hum-20231231.xsd#hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_19ffa1fb-a968-4237-967d-ee39d38211b1" xlink:to="loc_hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements_fde46870-ac1a-4b74-9968-a4b9aadbf95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESHealthCareCostPaymentsNetDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESHealthCareCostPaymentsNetDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESHealthCareCostPaymentsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3a4617e2-7284-4d82-8dd7-bed9c35d82bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_HealthCareCostPayments_51f0ff3e-5418-4f0f-949d-b8c0160b7766" xlink:href="hum-20231231.xsd#hum_HealthCareCostPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a4617e2-7284-4d82-8dd7-bed9c35d82bd" xlink:to="loc_hum_HealthCareCostPayments_51f0ff3e-5418-4f0f-949d-b8c0160b7766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_HealthCareCostReimbursements_495f2fa3-16e6-4cfe-9740-39612c3e554a" xlink:href="hum-20231231.xsd#hum_HealthCareCostReimbursements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a4617e2-7284-4d82-8dd7-bed9c35d82bd" xlink:to="loc_hum_HealthCareCostReimbursements_495f2fa3-16e6-4cfe-9740-39612c3e554a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_HealthCareCostPaymentsAndReimbursementsNet_7ab7dc4e-b519-4917-8118-6ee51d86986e" xlink:href="hum-20231231.xsd#hum_HealthCareCostPaymentsAndReimbursementsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3a4617e2-7284-4d82-8dd7-bed9c35d82bd" xlink:to="loc_hum_HealthCareCostPaymentsAndReimbursementsNet_7ab7dc4e-b519-4917-8118-6ee51d86986e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#ACQUISITIONSANDDIVESTITURESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c87391c8-6146-4674-8eae-8555cb6210d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c87391c8-6146-4674-8eae-8555cb6210d7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9367279a-e97d-4302-8615-d67268fe5d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9367279a-e97d-4302-8615-d67268fe5d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_5058b129-2e7f-4589-8488-5840c1de0050" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9367279a-e97d-4302-8615-d67268fe5d4b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_5058b129-2e7f-4589-8488-5840c1de0050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ee2ac2c1-3f22-4315-b44a-cbeab0be6b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_5058b129-2e7f-4589-8488-5840c1de0050" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ee2ac2c1-3f22-4315-b44a-cbeab0be6b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7d8c92e-6f0f-4e8e-8437-829918075501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7d8c92e-6f0f-4e8e-8437-829918075501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1b19b5ac-effc-46b0-9a2d-97ff2c2052c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e7d8c92e-6f0f-4e8e-8437-829918075501" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1b19b5ac-effc-46b0-9a2d-97ff2c2052c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GentivaHospiceMember_9c5e5f16-831a-49b4-bd65-33b0b3208b84" xlink:href="hum-20231231.xsd#hum_GentivaHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1b19b5ac-effc-46b0-9a2d-97ff2c2052c0" xlink:to="loc_hum_GentivaHospiceMember_9c5e5f16-831a-49b4-bd65-33b0b3208b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e4ba5dba-3889-4f0a-b610-0f2e21616141" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:to="loc_us-gaap_DebtInstrumentAxis_e4ba5dba-3889-4f0a-b610-0f2e21616141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6c647c9b-ac8c-4f57-a28f-c3ff2d780386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e4ba5dba-3889-4f0a-b610-0f2e21616141" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6c647c9b-ac8c-4f57-a28f-c3ff2d780386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TermLoanDueOctober2023Member_e40a1924-521a-44f3-99c1-f0c53d60445f" xlink:href="hum-20231231.xsd#hum_TermLoanDueOctober2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6c647c9b-ac8c-4f57-a28f-c3ff2d780386" xlink:to="loc_hum_TermLoanDueOctober2023Member_e40a1924-521a-44f3-99c1-f0c53d60445f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_76f17288-fa7e-4cb9-a60b-2cd6b9feac10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_76f17288-fa7e-4cb9-a60b-2cd6b9feac10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5bff05a6-bd43-400d-83f3-292807e9cb25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_76f17288-fa7e-4cb9-a60b-2cd6b9feac10" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5bff05a6-bd43-400d-83f3-292807e9cb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_9c4ab56f-5e7e-47c8-9a19-5996812d3332" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5bff05a6-bd43-400d-83f3-292807e9cb25" xlink:to="loc_us-gaap_LoansPayableMember_9c4ab56f-5e7e-47c8-9a19-5996812d3332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_881a91f5-bf72-4953-bcec-60b14c76fdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_881a91f5-bf72-4953-bcec-60b14c76fdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_735787b6-fefa-411a-b2eb-e350fff7410a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_881a91f5-bf72-4953-bcec-60b14c76fdfa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_735787b6-fefa-411a-b2eb-e350fff7410a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareLicensesAndCertificatesOfNeedMember_aa6fd562-e301-4b14-a50d-6cdb82848940" xlink:href="hum-20231231.xsd#hum_MedicareLicensesAndCertificatesOfNeedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_735787b6-fefa-411a-b2eb-e350fff7410a" xlink:to="loc_hum_MedicareLicensesAndCertificatesOfNeedMember_aa6fd562-e301-4b14-a50d-6cdb82848940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e2961f2c-e995-4fa4-854c-1bab65f5bae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e2961f2c-e995-4fa4-854c-1bab65f5bae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_977b2493-2678-4484-bf80-4c550d23fc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e2961f2c-e995-4fa4-854c-1bab65f5bae3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_977b2493-2678-4484-bf80-4c550d23fc9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_KindredAtHomeMember_87d53386-c1cb-47c1-af30-ae4fd8966378" xlink:href="hum-20231231.xsd#hum_KindredAtHomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_977b2493-2678-4484-bf80-4c550d23fc9b" xlink:to="loc_hum_KindredAtHomeMember_87d53386-c1cb-47c1-af30-ae4fd8966378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_386ade08-6b7f-483c-9383-01c55c019468" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold_0b532cf1-539b-4170-abb4-b67a6a4a0256" xlink:href="hum-20231231.xsd#hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold_0b532cf1-539b-4170-abb4-b67a6a4a0256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_42e0dc04-f9a9-49ae-afa5-c018db0b9276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_42e0dc04-f9a9-49ae-afa5-c018db0b9276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_4b94323f-4e84-4dfc-a312-cb90bef5f171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_RepaymentsOfDebt_4b94323f-4e84-4dfc-a312-cb90bef5f171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_b5575efd-5284-454a-95b4-29d69826c5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_b5575efd-5284-454a-95b4-29d69826c5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_0a05aa82-17f5-4389-8555-0a2cd48c537c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_0a05aa82-17f5-4389-8555-0a2cd48c537c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_cbf3efb4-ae78-430e-aab1-2f87efa291a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_cbf3efb4-ae78-430e-aab1-2f87efa291a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax_6a4abdad-a486-432d-862f-3b0898f70bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax_6a4abdad-a486-432d-862f-3b0898f70bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage_feeac632-837f-4149-95f8-3e05d5803a7c" xlink:href="hum-20231231.xsd#hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage_feeac632-837f-4149-95f8-3e05d5803a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BusinessCombinationTotalEnterpriseValueOfAcquiree_2ab3ea39-639f-45e9-92ee-4c2e72294090" xlink:href="hum-20231231.xsd#hum_BusinessCombinationTotalEnterpriseValueOfAcquiree"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_hum_BusinessCombinationTotalEnterpriseValueOfAcquiree_2ab3ea39-639f-45e9-92ee-4c2e72294090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_26c81bd5-7888-482f-982d-cf67b947dc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_26c81bd5-7888-482f-982d-cf67b947dc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_c06d01fe-1e75-409d-94e2-73014c3421f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_c06d01fe-1e75-409d-94e2-73014c3421f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_95b851ab-03f5-4122-8876-3c393599f909" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_EquityMethodInvestments_95b851ab-03f5-4122-8876-3c393599f909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_5be23974-a85c-4567-ab28-8d2457e1c3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain_5be23974-a85c-4567-ab28-8d2457e1c3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest_2ced3cdf-76f3-4635-80d3-d7e6b0b20207" xlink:href="hum-20231231.xsd#hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_39fee491-0c6a-4e64-af11-a5e70c207889" xlink:to="loc_hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest_2ced3cdf-76f3-4635-80d3-d7e6b0b20207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7cfa8192-a5bf-40d9-a2e4-d7262fd85add" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e378ad8-d2e7-4f67-8b5b-7b22ddf56dda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7cfa8192-a5bf-40d9-a2e4-d7262fd85add" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e378ad8-d2e7-4f67-8b5b-7b22ddf56dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_8bf8ac17-e955-4341-9ee7-fbcc64a943ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e378ad8-d2e7-4f67-8b5b-7b22ddf56dda" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_8bf8ac17-e955-4341-9ee7-fbcc64a943ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0eb4f15c-0d9c-4a32-8a0d-40d6c431d9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8bf8ac17-e955-4341-9ee7-fbcc64a943ae" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0eb4f15c-0d9c-4a32-8a0d-40d6c431d9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f310f48b-4c0c-41a5-9a26-1cb573736338" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0eb4f15c-0d9c-4a32-8a0d-40d6c431d9fc" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_f310f48b-4c0c-41a5-9a26-1cb573736338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ee71f7cb-83a6-42b9-bec0-4a2bc85dc64e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e378ad8-d2e7-4f67-8b5b-7b22ddf56dda" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ee71f7cb-83a6-42b9-bec0-4a2bc85dc64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08837979-735a-4862-85a9-b65ee2baf062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ee71f7cb-83a6-42b9-bec0-4a2bc85dc64e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08837979-735a-4862-85a9-b65ee2baf062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GentivaHospiceMember_87588a1b-2fc7-4b34-8a84-83c080634425" xlink:href="hum-20231231.xsd#hum_GentivaHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_08837979-735a-4862-85a9-b65ee2baf062" xlink:to="loc_hum_GentivaHospiceMember_87588a1b-2fc7-4b34-8a84-83c080634425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4e378ad8-d2e7-4f67-8b5b-7b22ddf56dda" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_dee68405-9027-43ab-957b-1c10e4f26f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_dee68405-9027-43ab-957b-1c10e4f26f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_feb4dab0-5f93-47d9-bbe3-c379e9bada9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_feb4dab0-5f93-47d9-bbe3-c379e9bada9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_f090b3ab-7d26-4588-8b10-7e782fdc1dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_f090b3ab-7d26-4588-8b10-7e782fdc1dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_a6cab79e-d72a-43d2-8113-7eca3db638e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_a6cab79e-d72a-43d2-8113-7eca3db638e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_6f7f0270-5ae1-43dc-aae3-cda1f8fb8583" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent_6f7f0270-5ae1-43dc-aae3-cda1f8fb8583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_dd07245f-e3eb-4f8c-81eb-68a11d3c22b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_dd07245f-e3eb-4f8c-81eb-68a11d3c22b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_263798da-fce0-4b59-8aba-8c088ff34bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_263798da-fce0-4b59-8aba-8c088ff34bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_db8fb163-797e-45a9-b18a-dd8928c0dfb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent_db8fb163-797e-45a9-b18a-dd8928c0dfb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_79fabdf9-10ed-4218-bcd9-d23530592881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_79fabdf9-10ed-4218-bcd9-d23530592881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_98ca81ba-3505-471a-9624-ca79dbf89d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_98ca81ba-3505-471a-9624-ca79dbf89d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest_a73b4a04-70ab-4bdf-becb-2ac39f98ebe3" xlink:href="hum-20231231.xsd#hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2bc0ee85-ae74-4bff-a5ac-ca53e934725a" xlink:to="loc_hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest_a73b4a04-70ab-4bdf-becb-2ac39f98ebe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EQUITYMETHODINVESTMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_49e336ca-56e6-4f88-add9-8f8205db1879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1997eeb2-eb88-4b35-9750-c9b94502b50d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_49e336ca-56e6-4f88-add9-8f8205db1879" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1997eeb2-eb88-4b35-9750-c9b94502b50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2dce153d-3032-4b2d-a50a-c7a82f634e0b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1997eeb2-eb88-4b35-9750-c9b94502b50d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2dce153d-3032-4b2d-a50a-c7a82f634e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_af1c5712-71e1-4184-ac07-c498eee285b9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2dce153d-3032-4b2d-a50a-c7a82f634e0b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_af1c5712-71e1-4184-ac07-c498eee285b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_KindredAtHomeMember_4bcf3527-dcc7-481a-8d6c-62676c107821" xlink:href="hum-20231231.xsd#hum_KindredAtHomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_af1c5712-71e1-4184-ac07-c498eee285b9" xlink:to="loc_hum_KindredAtHomeMember_4bcf3527-dcc7-481a-8d6c-62676c107821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fba61c8e-77ab-4b4f-85e7-48f7de4b180e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1997eeb2-eb88-4b35-9750-c9b94502b50d" xlink:to="loc_srt_CounterpartyNameAxis_fba61c8e-77ab-4b4f-85e7-48f7de4b180e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f1cbea12-ba00-4679-b1b8-2aeaa4c271c3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_fba61c8e-77ab-4b4f-85e7-48f7de4b180e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f1cbea12-ba00-4679-b1b8-2aeaa4c271c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_WelshCarsonAndersonAndStoweMember_ed7f2c3d-c45f-4ede-882a-05f4050a9b67" xlink:href="hum-20231231.xsd#hum_WelshCarsonAndersonAndStoweMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f1cbea12-ba00-4679-b1b8-2aeaa4c271c3" xlink:to="loc_hum_WelshCarsonAndersonAndStoweMember_ed7f2c3d-c45f-4ede-882a-05f4050a9b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember_955848de-ab6a-4ca8-a102-266b090861dc" xlink:href="hum-20231231.xsd#hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_WelshCarsonAndersonAndStoweMember_ed7f2c3d-c45f-4ede-882a-05f4050a9b67" xlink:to="loc_hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember_955848de-ab6a-4ca8-a102-266b090861dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember_b7b8f601-68c8-4dad-9356-ec68b7e18c92" xlink:href="hum-20231231.xsd#hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_WelshCarsonAndersonAndStoweMember_ed7f2c3d-c45f-4ede-882a-05f4050a9b67" xlink:to="loc_hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember_b7b8f601-68c8-4dad-9356-ec68b7e18c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_de9d4c82-5801-4325-9f2a-6d6fdfef8545" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1997eeb2-eb88-4b35-9750-c9b94502b50d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_de9d4c82-5801-4325-9f2a-6d6fdfef8545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b40ee8d2-f8df-476f-a593-a9e0c670949e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_de9d4c82-5801-4325-9f2a-6d6fdfef8545" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b40ee8d2-f8df-476f-a593-a9e0c670949e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_53ee61d7-290b-4242-9caf-c551c07a00b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_b40ee8d2-f8df-476f-a593-a9e0c670949e" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_53ee61d7-290b-4242-9caf-c551c07a00b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_60712b16-2b62-4224-86fa-80aac4702880" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1997eeb2-eb88-4b35-9750-c9b94502b50d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_60712b16-2b62-4224-86fa-80aac4702880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5836f827-e49e-4e60-94ec-357c990b7fee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_60712b16-2b62-4224-86fa-80aac4702880" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5836f827-e49e-4e60-94ec-357c990b7fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GentivaHospiceMember_4b40b13e-3661-44d0-aa53-4858379230ee" xlink:href="hum-20231231.xsd#hum_GentivaHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_5836f827-e49e-4e60-94ec-357c990b7fee" xlink:to="loc_hum_GentivaHospiceMember_4b40b13e-3661-44d0-aa53-4858379230ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ff5d386a-2e9b-495c-a58c-ab4467d85812" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1997eeb2-eb88-4b35-9750-c9b94502b50d" xlink:to="loc_srt_RangeAxis_ff5d386a-2e9b-495c-a58c-ab4467d85812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fe6cc2ba-e9af-4ad3-8cba-f3f7a72a77a0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ff5d386a-2e9b-495c-a58c-ab4467d85812" xlink:to="loc_srt_RangeMember_fe6cc2ba-e9af-4ad3-8cba-f3f7a72a77a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8a144eda-5808-4e45-bab1-5f05a7724215" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fe6cc2ba-e9af-4ad3-8cba-f3f7a72a77a0" xlink:to="loc_srt_MinimumMember_8a144eda-5808-4e45-bab1-5f05a7724215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ac010efd-a726-4920-869f-441206488ebb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fe6cc2ba-e9af-4ad3-8cba-f3f7a72a77a0" xlink:to="loc_srt_MaximumMember_ac010efd-a726-4920-869f-441206488ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fdf8eb0-8564-40fa-bbdf-55afbd003d41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_1997eeb2-eb88-4b35-9750-c9b94502b50d" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fdf8eb0-8564-40fa-bbdf-55afbd003d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9fd5a4fe-64c3-4371-a1d3-5d600793d7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fdf8eb0-8564-40fa-bbdf-55afbd003d41" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9fd5a4fe-64c3-4371-a1d3-5d600793d7d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold_d1b421fa-adc5-48b5-a356-322e1eb933ec" xlink:href="hum-20231231.xsd#hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fdf8eb0-8564-40fa-bbdf-55afbd003d41" xlink:to="loc_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold_d1b421fa-adc5-48b5-a356-322e1eb933ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters_923a8c2f-7992-46fd-b85f-d69a559389e4" xlink:href="hum-20231231.xsd#hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fdf8eb0-8564-40fa-bbdf-55afbd003d41" xlink:to="loc_hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters_923a8c2f-7992-46fd-b85f-d69a559389e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened_5936e93e-d01c-4e1f-b8a5-238602c2abfb" xlink:href="hum-20231231.xsd#hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fdf8eb0-8564-40fa-bbdf-55afbd003d41" xlink:to="loc_hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened_5936e93e-d01c-4e1f-b8a5-238602c2abfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity_12d98fac-8e1e-4f33-a6a0-7811b0f83ff7" xlink:href="hum-20231231.xsd#hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fdf8eb0-8564-40fa-bbdf-55afbd003d41" xlink:to="loc_hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity_12d98fac-8e1e-4f33-a6a0-7811b0f83ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_StrategicPartnershipAgreementCallOptionStrikePrice_1dbec8d8-ba26-4bb4-a476-76e011433f55" xlink:href="hum-20231231.xsd#hum_StrategicPartnershipAgreementCallOptionStrikePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_8fdf8eb0-8564-40fa-bbdf-55afbd003d41" xlink:to="loc_hum_StrategicPartnershipAgreementCallOptionStrikePrice_1dbec8d8-ba26-4bb4-a476-76e011433f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_83b2a2cf-89da-46a4-b4ab-dd6d3f17cfda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_48cb2100-3bee-4f2d-8763-4d5c3954f897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_83b2a2cf-89da-46a4-b4ab-dd6d3f17cfda" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_48cb2100-3bee-4f2d-8763-4d5c3954f897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_eca198ee-d37a-4f05-a777-c682b17012b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_48cb2100-3bee-4f2d-8763-4d5c3954f897" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_eca198ee-d37a-4f05-a777-c682b17012b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b8adb716-a7eb-4794-a13c-527deadb3f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_eca198ee-d37a-4f05-a777-c682b17012b0" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b8adb716-a7eb-4794-a13c-527deadb3f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_KindredAtHomeMember_56691bb9-2951-471d-b16e-4aa965f38b70" xlink:href="hum-20231231.xsd#hum_KindredAtHomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_b8adb716-a7eb-4794-a13c-527deadb3f51" xlink:to="loc_hum_KindredAtHomeMember_56691bb9-2951-471d-b16e-4aa965f38b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_52132a65-0bdd-4142-8d6e-c8b90040362e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_48cb2100-3bee-4f2d-8763-4d5c3954f897" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_52132a65-0bdd-4142-8d6e-c8b90040362e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d1bfba8a-312d-4492-b0e4-aedea19af712" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_52132a65-0bdd-4142-8d6e-c8b90040362e" xlink:to="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d1bfba8a-312d-4492-b0e4-aedea19af712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_687739dc-2cc7-48d0-95b2-c6343949c7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d1bfba8a-312d-4492-b0e4-aedea19af712" xlink:to="loc_us-gaap_AssetsCurrent_687739dc-2cc7-48d0-95b2-c6343949c7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_923f9495-a138-45f8-803c-d8d2d82bc75b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d1bfba8a-312d-4492-b0e4-aedea19af712" xlink:to="loc_us-gaap_AssetsNoncurrent_923f9495-a138-45f8-803c-d8d2d82bc75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b23306fa-1a07-45e3-9ff8-3527ce67e8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d1bfba8a-312d-4492-b0e4-aedea19af712" xlink:to="loc_us-gaap_LiabilitiesCurrent_b23306fa-1a07-45e3-9ff8-3527ce67e8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_c0721dc8-e8b1-435b-a126-b1a832ff58b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d1bfba8a-312d-4492-b0e4-aedea19af712" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_c0721dc8-e8b1-435b-a126-b1a832ff58b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_de4bbb51-3b43-4849-aa0b-bdf0d9aa9c61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_d1bfba8a-312d-4492-b0e4-aedea19af712" xlink:to="loc_us-gaap_StockholdersEquity_de4bbb51-3b43-4849-aa0b-bdf0d9aa9c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_eb076c91-5dad-41c4-9463-323a4c423e27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementRelatedDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_52132a65-0bdd-4142-8d6e-c8b90040362e" xlink:to="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_eb076c91-5dad-41c4-9463-323a4c423e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_40210c76-8e43-420a-bffa-34e564e66a61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_eb076c91-5dad-41c4-9463-323a4c423e27" xlink:to="loc_us-gaap_Revenues_40210c76-8e43-420a-bffa-34e564e66a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_Expenses_c41b2bb2-cc36-42b6-bffe-dcc870e4f867" xlink:href="hum-20231231.xsd#hum_Expenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_eb076c91-5dad-41c4-9463-323a4c423e27" xlink:to="loc_hum_Expenses_c41b2bb2-cc36-42b6-bffe-dcc870e4f867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_50cc382d-c967-4aa4-9647-fd568edb474d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementRelatedDisclosuresAbstract_eb076c91-5dad-41c4-9463-323a4c423e27" xlink:to="loc_us-gaap_NetIncomeLoss_50cc382d-c967-4aa4-9647-fd568edb474d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d72b9974-3e06-478d-836b-7bfaf24affd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e5a04013-7eec-416a-8fd2-6a6304095a63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d72b9974-3e06-478d-836b-7bfaf24affd8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e5a04013-7eec-416a-8fd2-6a6304095a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_24e90025-449d-49c0-98c1-16764117a2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e5a04013-7eec-416a-8fd2-6a6304095a63" xlink:to="loc_us-gaap_FinancialInstrumentAxis_24e90025-449d-49c0-98c1-16764117a2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_24e90025-449d-49c0-98c1-16764117a2d8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_a791f7e6-cd49-403a-8d8c-4d052b3b1468" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_a791f7e6-cd49-403a-8d8c-4d052b3b1468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_d142cecf-1da4-4e1e-8c5d-327528a8eb59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_d142cecf-1da4-4e1e-8c5d-327528a8eb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontaxableMunicipalNotesMember_99f29528-544e-4627-af24-06e68698c06e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontaxableMunicipalNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:to="loc_us-gaap_NontaxableMunicipalNotesMember_99f29528-544e-4627-af24-06e68698c06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_7811fad3-7052-496c-94aa-9b9ba921de22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_7811fad3-7052-496c-94aa-9b9ba921de22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_3e74b2a0-ea59-4050-8d3c-9a4bef34fb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_3e74b2a0-ea59-4050-8d3c-9a4bef34fb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_c8b8669b-52e4-4d35-8455-b59acff914f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_c8b8669b-52e4-4d35-8455-b59acff914f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3d9afad6-98a7-41cf-819e-1b941d67f213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cecdf417-531a-4481-827a-ce55ec219233" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3d9afad6-98a7-41cf-819e-1b941d67f213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e29ec88c-b33a-4d9c-b2c4-5ab2f8b2a787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_e5a04013-7eec-416a-8fd2-6a6304095a63" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e29ec88c-b33a-4d9c-b2c4-5ab2f8b2a787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9ad82394-2930-4574-aafe-57678cd41934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e29ec88c-b33a-4d9c-b2c4-5ab2f8b2a787" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9ad82394-2930-4574-aafe-57678cd41934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_283c8124-3474-4658-bbf7-30caccb4154b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9ad82394-2930-4574-aafe-57678cd41934" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_283c8124-3474-4658-bbf7-30caccb4154b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_84396d52-2dbb-4e39-a71d-7c7a821b2e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9ad82394-2930-4574-aafe-57678cd41934" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_84396d52-2dbb-4e39-a71d-7c7a821b2e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_62410856-22bd-44b1-8ce5-90801060926c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9ad82394-2930-4574-aafe-57678cd41934" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_62410856-22bd-44b1-8ce5-90801060926c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_897767a0-cd79-4dab-a51e-5a20d4beb821" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9ad82394-2930-4574-aafe-57678cd41934" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_897767a0-cd79-4dab-a51e-5a20d4beb821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_db3be93b-811c-49d3-9be3-172996622f79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9ad82394-2930-4574-aafe-57678cd41934" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_db3be93b-811c-49d3-9be3-172996622f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_4e92052c-0b40-417a-8b02-918dbe01ab35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Investments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_9ad82394-2930-4574-aafe-57678cd41934" xlink:to="loc_us-gaap_Investments_4e92052c-0b40-417a-8b02-918dbe01ab35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INVESTMENTSECURITIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_02ed44a6-d4a5-48ef-8bf0-246c39bb04b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_156bf20e-3ab9-49ce-973b-fdf855acdf18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_02ed44a6-d4a5-48ef-8bf0-246c39bb04b9" xlink:to="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_156bf20e-3ab9-49ce-973b-fdf855acdf18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_5d777f81-a123-4926-965b-d731ea89cc40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_156bf20e-3ab9-49ce-973b-fdf855acdf18" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_5d777f81-a123-4926-965b-d731ea89cc40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_034e66d4-4204-4358-b78c-c1585f84fd75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_5d777f81-a123-4926-965b-d731ea89cc40" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_034e66d4-4204-4358-b78c-c1585f84fd75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_a0d4ce1b-4549-4a43-9370-c089ed258a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_034e66d4-4204-4358-b78c-c1585f84fd75" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_a0d4ce1b-4549-4a43-9370-c089ed258a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_84fecc26-8201-4adf-8b80-2b0971567082" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_156bf20e-3ab9-49ce-973b-fdf855acdf18" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_84fecc26-8201-4adf-8b80-2b0971567082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_75ce1235-62e4-4040-a941-d48c2428083b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_84fecc26-8201-4adf-8b80-2b0971567082" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_75ce1235-62e4-4040-a941-d48c2428083b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GentivaHospiceMember_110c35b4-8b4c-41d4-812e-e02e78aedd90" xlink:href="hum-20231231.xsd#hum_GentivaHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_75ce1235-62e4-4040-a941-d48c2428083b" xlink:to="loc_hum_GentivaHospiceMember_110c35b4-8b4c-41d4-812e-e02e78aedd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CreditRatingStandardPoorsAxis_71e877c5-55c3-408c-bb3c-798f78eca6d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CreditRatingStandardPoorsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_156bf20e-3ab9-49ce-973b-fdf855acdf18" xlink:to="loc_srt_CreditRatingStandardPoorsAxis_71e877c5-55c3-408c-bb3c-798f78eca6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExternalCreditRatingStandardPoorsMember_25b1c694-3102-4606-b0b4-9cb4a4afcdd1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ExternalCreditRatingStandardPoorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CreditRatingStandardPoorsAxis_71e877c5-55c3-408c-bb3c-798f78eca6d3" xlink:to="loc_srt_ExternalCreditRatingStandardPoorsMember_25b1c694-3102-4606-b0b4-9cb4a4afcdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StandardPoorsAAMinusRatingMember_ac6f0dbf-48ce-40eb-b4f5-ab83616eae89" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StandardPoorsAAMinusRatingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ExternalCreditRatingStandardPoorsMember_25b1c694-3102-4606-b0b4-9cb4a4afcdd1" xlink:to="loc_srt_StandardPoorsAAMinusRatingMember_ac6f0dbf-48ce-40eb-b4f5-ab83616eae89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems_c37472ff-81df-4abb-9d4b-1218fc4dd747" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancingReceivableRecordedInvestmentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable_156bf20e-3ab9-49ce-973b-fdf855acdf18" xlink:to="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems_c37472ff-81df-4abb-9d4b-1218fc4dd747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c836eef5-be48-417c-8b5d-24eed5eac28a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems_c37472ff-81df-4abb-9d4b-1218fc4dd747" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_c836eef5-be48-417c-8b5d-24eed5eac28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f7d7f27f-a240-4f1e-9f13-45bba7928d11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems_c37472ff-81df-4abb-9d4b-1218fc4dd747" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f7d7f27f-a240-4f1e-9f13-45bba7928d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality_eca8d72e-0385-4651-bec9-610335b484aa" xlink:href="hum-20231231.xsd#hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems_c37472ff-81df-4abb-9d4b-1218fc4dd747" xlink:to="loc_hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality_eca8d72e-0385-4651-bec9-610335b484aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities_70c8b128-495a-4e58-bb3b-b0c46e549a5d" xlink:href="hum-20231231.xsd#hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems_c37472ff-81df-4abb-9d4b-1218fc4dd747" xlink:to="loc_hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities_70c8b128-495a-4e58-bb3b-b0c46e549a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_6b698192-db1c-44e2-9cac-06ee8d8a4521" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems_c37472ff-81df-4abb-9d4b-1218fc4dd747" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_6b698192-db1c-44e2-9cac-06ee8d8a4521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions_1e7cae70-5594-4699-a2bc-08ebd51b3346" xlink:href="hum-20231231.xsd#hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivableRecordedInvestmentLineItems_c37472ff-81df-4abb-9d4b-1218fc4dd747" xlink:to="loc_hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions_1e7cae70-5594-4699-a2bc-08ebd51b3346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_21968876-5e19-490d-92c7-49e3f72e4bae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_f28f42af-e7e0-4ea1-9454-9ceba0223414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_21968876-5e19-490d-92c7-49e3f72e4bae" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_f28f42af-e7e0-4ea1-9454-9ceba0223414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_937ffa91-5b09-4182-969d-62013c57752f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_f28f42af-e7e0-4ea1-9454-9ceba0223414" xlink:to="loc_us-gaap_FinancialInstrumentAxis_937ffa91-5b09-4182-969d-62013c57752f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_937ffa91-5b09-4182-969d-62013c57752f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_d2d35651-632b-47c3-8f3e-535dcbc0dc04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_d2d35651-632b-47c3-8f3e-535dcbc0dc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_3e1fe275-f1dd-42dd-b5e7-673ae52a1a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_3e1fe275-f1dd-42dd-b5e7-673ae52a1a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontaxableMunicipalNotesMember_50c1de99-6531-4943-8cba-87a3286c5fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontaxableMunicipalNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:to="loc_us-gaap_NontaxableMunicipalNotesMember_50c1de99-6531-4943-8cba-87a3286c5fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_9a44fb07-8956-4674-a63b-c8c7529d6f83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_9a44fb07-8956-4674-a63b-c8c7529d6f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_6af85ecb-2eaa-4ff2-88ab-9705212b4ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_6af85ecb-2eaa-4ff2-88ab-9705212b4ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_c5fa1465-67cb-4872-bba3-52dc71c4d7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_c5fa1465-67cb-4872-bba3-52dc71c4d7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c612ad5c-384d-4394-883b-5f92975f179d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8dcb65e8-f7c7-40be-9f9f-10307b56b49d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c612ad5c-384d-4394-883b-5f92975f179d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_7735fd87-c92f-4063-8f56-29930788bee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_f28f42af-e7e0-4ea1-9454-9ceba0223414" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_7735fd87-c92f-4063-8f56-29930788bee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_79eef231-8afa-4e5f-a0cf-36bba0850575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_7735fd87-c92f-4063-8f56-29930788bee3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_79eef231-8afa-4e5f-a0cf-36bba0850575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_aee1b743-6095-49e5-8803-df7f23dacf85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_79eef231-8afa-4e5f-a0cf-36bba0850575" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_aee1b743-6095-49e5-8803-df7f23dacf85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_691b0128-da7f-4497-81d3-9b49c7ee53c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_79eef231-8afa-4e5f-a0cf-36bba0850575" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_691b0128-da7f-4497-81d3-9b49c7ee53c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_187a2265-76c3-45f1-b5a4-63d37715eda6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract_79eef231-8afa-4e5f-a0cf-36bba0850575" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_187a2265-76c3-45f1-b5a4-63d37715eda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_360dccd7-e177-4d9d-8828-398c0af97d27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_7735fd87-c92f-4063-8f56-29930788bee3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_360dccd7-e177-4d9d-8828-398c0af97d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9756c4a0-b6df-4e35-85fc-db9e54b784b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_360dccd7-e177-4d9d-8828-398c0af97d27" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9756c4a0-b6df-4e35-85fc-db9e54b784b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_385a3127-cef8-4c04-9cc3-8ab85f7feb02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_360dccd7-e177-4d9d-8828-398c0af97d27" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_385a3127-cef8-4c04-9cc3-8ab85f7feb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_73f3f014-805b-43d6-8c64-6d284d3a32b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_360dccd7-e177-4d9d-8828-398c0af97d27" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_73f3f014-805b-43d6-8c64-6d284d3a32b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_01bc5eb6-0963-4711-98c3-d5c2a032b30d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DebtAndEquitySecuritiesRealizedGain_7732db57-1653-4128-a04f-80e235ef43f3" xlink:href="hum-20231231.xsd#hum_DebtAndEquitySecuritiesRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_01bc5eb6-0963-4711-98c3-d5c2a032b30d" xlink:to="loc_hum_DebtAndEquitySecuritiesRealizedGain_7732db57-1653-4128-a04f-80e235ef43f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DebtAndEquitySecuritiesRealizedLoss_c864e68d-68e8-47eb-80f7-b83f8432a006" xlink:href="hum-20231231.xsd#hum_DebtAndEquitySecuritiesRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_01bc5eb6-0963-4711-98c3-d5c2a032b30d" xlink:to="loc_hum_DebtAndEquitySecuritiesRealizedLoss_c864e68d-68e8-47eb-80f7-b83f8432a006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_3f3340a8-f114-4b85-9a04-d2778a8c8277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGain"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_01bc5eb6-0963-4711-98c3-d5c2a032b30d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_3f3340a8-f114-4b85-9a04-d2778a8c8277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedLoss_e3f42476-4fb0-4aa3-b03f-a6042b7bb6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_01bc5eb6-0963-4711-98c3-d5c2a032b30d" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedLoss_e3f42476-4fb0-4aa3-b03f-a6042b7bb6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_02c5d195-a749-43ac-af75-dfe8a72033f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndEquitySecuritiesGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_01bc5eb6-0963-4711-98c3-d5c2a032b30d" xlink:to="loc_us-gaap_DebtAndEquitySecuritiesGainLoss_02c5d195-a749-43ac-af75-dfe8a72033f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesonEquitySecuritiesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INVESTMENTSECURITIESGainsLossesonEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesonEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_242d46f2-0eae-47b5-b7b9-7f3cb1b803fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_ef0e6a86-2552-403a-b47d-efb3a16e9c33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_242d46f2-0eae-47b5-b7b9-7f3cb1b803fe" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_ef0e6a86-2552-403a-b47d-efb3a16e9c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f1f9f0f2-98b2-458a-aee1-c07cc8fdc819" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_242d46f2-0eae-47b5-b7b9-7f3cb1b803fe" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f1f9f0f2-98b2-458a-aee1-c07cc8fdc819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_086dda55-20fb-4ea7-a72b-90c3ab6bd1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_242d46f2-0eae-47b5-b7b9-7f3cb1b803fe" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_086dda55-20fb-4ea7-a72b-90c3ab6bd1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9d58acb8-3a7c-468e-97d8-8d53ec5a977a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_33281020-6dec-48de-8254-5f1c6df67519" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9d58acb8-3a7c-468e-97d8-8d53ec5a977a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_33281020-6dec-48de-8254-5f1c6df67519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3ef1a155-e4a8-4f32-a228-c4124f027d80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_33281020-6dec-48de-8254-5f1c6df67519" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_3ef1a155-e4a8-4f32-a228-c4124f027d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c452afcd-9e11-433e-a1de-98cad5d6f238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_33281020-6dec-48de-8254-5f1c6df67519" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_c452afcd-9e11-433e-a1de-98cad5d6f238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_3cacc4f6-a00a-4bb7-99bf-e6285acf47fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_33281020-6dec-48de-8254-5f1c6df67519" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_3cacc4f6-a00a-4bb7-99bf-e6285acf47fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_b7df2650-5d2d-4bbc-8489-7f192a3dbb99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_33281020-6dec-48de-8254-5f1c6df67519" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_b7df2650-5d2d-4bbc-8489-7f192a3dbb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_96fabbc2-3f91-411d-b966-22869eea8e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_33281020-6dec-48de-8254-5f1c6df67519" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost_96fabbc2-3f91-411d-b966-22869eea8e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9e726748-169e-49ac-9995-cf6f88fdfc20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract_33281020-6dec-48de-8254-5f1c6df67519" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9e726748-169e-49ac-9995-cf6f88fdfc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8edad22e-b959-42d2-a7fd-91a788a78cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9d58acb8-3a7c-468e-97d8-8d53ec5a977a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8edad22e-b959-42d2-a7fd-91a788a78cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c47bc883-921c-474b-b103-43cc6c1faf05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8edad22e-b959-42d2-a7fd-91a788a78cbd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c47bc883-921c-474b-b103-43cc6c1faf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_75b5489b-d5f8-4a2d-acf5-96433433c247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8edad22e-b959-42d2-a7fd-91a788a78cbd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_75b5489b-d5f8-4a2d-acf5-96433433c247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_48109e21-9a4c-4a52-8d29-3db355e98836" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8edad22e-b959-42d2-a7fd-91a788a78cbd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_48109e21-9a4c-4a52-8d29-3db355e98836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_f0604931-924d-44f4-b54f-9bfc4d0e9310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8edad22e-b959-42d2-a7fd-91a788a78cbd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_f0604931-924d-44f4-b54f-9bfc4d0e9310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_23dae7a1-5672-449d-bd73-c50ba3768a40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8edad22e-b959-42d2-a7fd-91a788a78cbd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_23dae7a1-5672-449d-bd73-c50ba3768a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c81c373f-3c40-44b8-9b75-7672bf138a90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_8edad22e-b959-42d2-a7fd-91a788a78cbd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c81c373f-3c40-44b8-9b75-7672bf138a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_464f260a-366a-4d86-a5d9-a61ec45f53fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f7cde86-c001-408e-ac21-5486b4f805d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_464f260a-366a-4d86-a5d9-a61ec45f53fa" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f7cde86-c001-408e-ac21-5486b4f805d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ae8eda6-fe8f-4e18-b4e2-68f25ab36798" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f7cde86-c001-408e-ac21-5486b4f805d0" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ae8eda6-fe8f-4e18-b4e2-68f25ab36798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4dbd73c9-326e-4727-b020-926cacbda3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8ae8eda6-fe8f-4e18-b4e2-68f25ab36798" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4dbd73c9-326e-4727-b020-926cacbda3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a9d4c87f-501a-455c-aaf6-1e99add9d593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_4dbd73c9-326e-4727-b020-926cacbda3b5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a9d4c87f-501a-455c-aaf6-1e99add9d593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d77a5344-a39d-4539-908b-da75fd00efc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f7cde86-c001-408e-ac21-5486b4f805d0" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d77a5344-a39d-4539-908b-da75fd00efc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a1e9d89-5b4a-4b37-b521-4602df049a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d77a5344-a39d-4539-908b-da75fd00efc3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a1e9d89-5b4a-4b37-b521-4602df049a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4d02afb0-29c0-4d2c-8f2f-b4bf658949b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a1e9d89-5b4a-4b37-b521-4602df049a4d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4d02afb0-29c0-4d2c-8f2f-b4bf658949b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_8cd7df3b-05b3-4f5f-a4db-d49bab9eb267" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a1e9d89-5b4a-4b37-b521-4602df049a4d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_8cd7df3b-05b3-4f5f-a4db-d49bab9eb267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_832d80b2-9c4f-40b9-90ea-f126592fb49b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2a1e9d89-5b4a-4b37-b521-4602df049a4d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_832d80b2-9c4f-40b9-90ea-f126592fb49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2afb42c9-f518-4a51-8f1d-600992c54e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f7cde86-c001-408e-ac21-5486b4f805d0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2afb42c9-f518-4a51-8f1d-600992c54e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2afb42c9-f518-4a51-8f1d-600992c54e0e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_6e186890-49b6-462c-8dba-52d3ae4c7475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_6e186890-49b6-462c-8dba-52d3ae4c7475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_6b55abdb-dd63-4ae2-afdb-c6a4426ba079" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_6b55abdb-dd63-4ae2-afdb-c6a4426ba079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NontaxableMunicipalNotesMember_34d6b7e4-47ee-4f4b-8768-d11a147a20c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NontaxableMunicipalNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:to="loc_us-gaap_NontaxableMunicipalNotesMember_34d6b7e4-47ee-4f4b-8768-d11a147a20c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_a1c28ba3-207e-4c1d-b9ff-36cfdc5c7c23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResidentialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:to="loc_us-gaap_ResidentialMortgageBackedSecuritiesMember_a1c28ba3-207e-4c1d-b9ff-36cfdc5c7c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_49ba713f-432b-49a6-905c-c8bd33297d60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_49ba713f-432b-49a6-905c-c8bd33297d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_de40654e-01bd-4698-9d56-4a24293ef237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_de40654e-01bd-4698-9d56-4a24293ef237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c5ee4921-9f9b-4dbc-b9ad-5cdfa1ea1b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e12243e5-2ec7-4962-8525-a3cfa2cc9a6a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c5ee4921-9f9b-4dbc-b9ad-5cdfa1ea1b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_abefc34f-621e-46c1-90aa-3ee7c6005e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4f7cde86-c001-408e-ac21-5486b4f805d0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_abefc34f-621e-46c1-90aa-3ee7c6005e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ae98cde6-1bac-420b-b435-96a4d0813793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_abefc34f-621e-46c1-90aa-3ee7c6005e6a" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ae98cde6-1bac-420b-b435-96a4d0813793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6db19344-34d7-441b-b51b-9f0a2c2d8ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_abefc34f-621e-46c1-90aa-3ee7c6005e6a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6db19344-34d7-441b-b51b-9f0a2c2d8ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_e327c2c7-96fe-4ec8-94b7-ebc14ef84eda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_abefc34f-621e-46c1-90aa-3ee7c6005e6a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_e327c2c7-96fe-4ec8-94b7-ebc14ef84eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_cf2ab967-0c65-4def-9301-913022c21240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_abefc34f-621e-46c1-90aa-3ee7c6005e6a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_cf2ab967-0c65-4def-9301-913022c21240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/FAIRVALUENarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#FAIRVALUENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/FAIRVALUENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c3219cf1-6c6a-46d8-8c6d-3b8aa77a5227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c3219cf1-6c6a-46d8-8c6d-3b8aa77a5227" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d0f51bb2-177e-4cdd-b8fd-ae43082a2023" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_DebtInstrumentAxis_d0f51bb2-177e-4cdd-b8fd-ae43082a2023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fbc5bfce-7adc-45c8-a4ef-c4de3c6f7ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d0f51bb2-177e-4cdd-b8fd-ae43082a2023" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fbc5bfce-7adc-45c8-a4ef-c4de3c6f7ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5.88PercentSeniorNotesDueMarch2033Member_cd7eadc9-3c49-4860-bbdd-17b12bb9e146" xlink:href="hum-20231231.xsd#hum_A5.88PercentSeniorNotesDueMarch2033Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fbc5bfce-7adc-45c8-a4ef-c4de3c6f7ac5" xlink:to="loc_hum_A5.88PercentSeniorNotesDueMarch2033Member_cd7eadc9-3c49-4860-bbdd-17b12bb9e146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A550PercentSeniorNotesDueMarch2053Member_0b420dbf-6470-4943-a92d-52e4b2e7a132" xlink:href="hum-20231231.xsd#hum_A550PercentSeniorNotesDueMarch2053Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fbc5bfce-7adc-45c8-a4ef-c4de3c6f7ac5" xlink:to="loc_hum_A550PercentSeniorNotesDueMarch2053Member_0b420dbf-6470-4943-a92d-52e4b2e7a132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3.950PercentSeniorNotesMember_b5a307dd-4aaa-4d88-926e-c19719b772bf" xlink:href="hum-20231231.xsd#hum_A3.950PercentSeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fbc5bfce-7adc-45c8-a4ef-c4de3c6f7ac5" xlink:to="loc_hum_A3.950PercentSeniorNotesMember_b5a307dd-4aaa-4d88-926e-c19719b772bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5950PercentSeniorNotesDueMarch2034Member_05ef3aa4-9c28-4ebb-84b4-d8d105aec1ea" xlink:href="hum-20231231.xsd#hum_A5950PercentSeniorNotesDueMarch2034Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_fbc5bfce-7adc-45c8-a4ef-c4de3c6f7ac5" xlink:to="loc_hum_A5950PercentSeniorNotesDueMarch2034Member_05ef3aa4-9c28-4ebb-84b4-d8d105aec1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_df37ab99-30f1-46bb-a3d3-5b2084825316" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_df37ab99-30f1-46bb-a3d3-5b2084825316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6d47b982-fda1-4fab-b5f5-551259f9d829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_df37ab99-30f1-46bb-a3d3-5b2084825316" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6d47b982-fda1-4fab-b5f5-551259f9d829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_139a154a-9362-45d5-b21e-461e13a202cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6d47b982-fda1-4fab-b5f5-551259f9d829" xlink:to="loc_us-gaap_SeniorNotesMember_139a154a-9362-45d5-b21e-461e13a202cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b0ec71f1-b575-4609-95e5-9f0ce77a9edf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b0ec71f1-b575-4609-95e5-9f0ce77a9edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7818c062-5e42-4cc5-af45-e1d2f0c312f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b0ec71f1-b575-4609-95e5-9f0ce77a9edf" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7818c062-5e42-4cc5-af45-e1d2f0c312f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InterestRateSwapMaturing2032Member_ebb07d3b-6002-4dd8-a9f6-28e161fba495" xlink:href="hum-20231231.xsd#hum_InterestRateSwapMaturing2032Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7818c062-5e42-4cc5-af45-e1d2f0c312f8" xlink:to="loc_hum_InterestRateSwapMaturing2032Member_ebb07d3b-6002-4dd8-a9f6-28e161fba495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InterestRateSwapMaturing2033Member_f6aef42a-4e6c-4dbc-a9e5-e7156f3770c5" xlink:href="hum-20231231.xsd#hum_InterestRateSwapMaturing2033Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7818c062-5e42-4cc5-af45-e1d2f0c312f8" xlink:to="loc_hum_InterestRateSwapMaturing2033Member_f6aef42a-4e6c-4dbc-a9e5-e7156f3770c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InterestRateSwapMaturing2049Member_7d7a3d8f-8970-42c5-bb8a-50540e662200" xlink:href="hum-20231231.xsd#hum_InterestRateSwapMaturing2049Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7818c062-5e42-4cc5-af45-e1d2f0c312f8" xlink:to="loc_hum_InterestRateSwapMaturing2049Member_7d7a3d8f-8970-42c5-bb8a-50540e662200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InterestRateSwapMaturing2034Member_03c74717-6b69-4171-bf6b-e6ded7f8e4fc" xlink:href="hum-20231231.xsd#hum_InterestRateSwapMaturing2034Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7818c062-5e42-4cc5-af45-e1d2f0c312f8" xlink:to="loc_hum_InterestRateSwapMaturing2034Member_03c74717-6b69-4171-bf6b-e6ded7f8e4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_30f5efb5-320f-47a7-bc7a-b3d3498f96e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_FinancialInstrumentAxis_30f5efb5-320f-47a7-bc7a-b3d3498f96e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77f8193a-1e87-46fa-b077-8be0814dd288" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_30f5efb5-320f-47a7-bc7a-b3d3498f96e8" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77f8193a-1e87-46fa-b077-8be0814dd288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_7c782e45-5dd6-491d-b4f2-3dc33ca0ccb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_77f8193a-1e87-46fa-b077-8be0814dd288" xlink:to="loc_us-gaap_InterestRateSwapMember_7c782e45-5dd6-491d-b4f2-3dc33ca0ccb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_37444d59-b0c3-4185-978c-fc2c7f4c899c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_37444d59-b0c3-4185-978c-fc2c7f4c899c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ab4a8539-95d1-40a4-8d1f-da2819fd5275" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_37444d59-b0c3-4185-978c-fc2c7f4c899c" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ab4a8539-95d1-40a4-8d1f-da2819fd5275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_097851ac-88a4-4805-90cd-3ac117fb3aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_ab4a8539-95d1-40a4-8d1f-da2819fd5275" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_097851ac-88a4-4805-90cd-3ac117fb3aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_38b25f5e-f854-4b12-85c5-e9b790437581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_097851ac-88a4-4805-90cd-3ac117fb3aa2" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_38b25f5e-f854-4b12-85c5-e9b790437581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_84394076-babd-4a38-a18d-550c39b263ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_097851ac-88a4-4805-90cd-3ac117fb3aa2" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_84394076-babd-4a38-a18d-550c39b263ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_b6a700b2-c400-4d40-8e3b-c309e610fbc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_b6a700b2-c400-4d40-8e3b-c309e610fbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_4a83dab1-0ecc-470d-89ba-a51b5f662dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_b6a700b2-c400-4d40-8e3b-c309e610fbc0" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_4a83dab1-0ecc-470d-89ba-a51b5f662dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_4f7c7809-ab0f-4524-9f35-083296fe4548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_4a83dab1-0ecc-470d-89ba-a51b5f662dc1" xlink:to="loc_us-gaap_CommercialPaperMember_4f7c7809-ab0f-4524-9f35-083296fe4548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TermLoanAndCommercialPaperMember_975629c0-9e5d-4bcf-83bd-eaf34987bceb" xlink:href="hum-20231231.xsd#hum_TermLoanAndCommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_4a83dab1-0ecc-470d-89ba-a51b5f662dc1" xlink:to="loc_hum_TermLoanAndCommercialPaperMember_975629c0-9e5d-4bcf-83bd-eaf34987bceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_cff2e505-f4c5-4c24-88a6-d9c24139eefc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_cff2e505-f4c5-4c24-88a6-d9c24139eefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4efff02-e052-424f-b1a6-784bbf8910cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_cff2e505-f4c5-4c24-88a6-d9c24139eefc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4efff02-e052-424f-b1a6-784bbf8910cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_KindredAtHomeMember_31dc338b-6ecb-4b3e-8de4-82a5cc9213cb" xlink:href="hum-20231231.xsd#hum_KindredAtHomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4efff02-e052-424f-b1a6-784bbf8910cc" xlink:to="loc_hum_KindredAtHomeMember_31dc338b-6ecb-4b3e-8de4-82a5cc9213cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_8b94662b-8ccc-483d-ba2f-d2bb477c4b28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_8b94662b-8ccc-483d-ba2f-d2bb477c4b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_aedee3bb-f9e9-4fa9-bfe3-c604a3c417c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_8b94662b-8ccc-483d-ba2f-d2bb477c4b28" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_aedee3bb-f9e9-4fa9-bfe3-c604a3c417c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8b4e624c-df61-4316-96c8-fbdb2fe88dde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_aedee3bb-f9e9-4fa9-bfe3-c604a3c417c5" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8b4e624c-df61-4316-96c8-fbdb2fe88dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_e04b122c-caa9-49a6-846f-1c801e9fe810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_aedee3bb-f9e9-4fa9-bfe3-c604a3c417c5" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_e04b122c-caa9-49a6-846f-1c801e9fe810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_7895562a-705f-4c8b-9d4c-919d64e0cafe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_7895562a-705f-4c8b-9d4c-919d64e0cafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_125465fc-8e8f-4c3e-896d-be0cbe1d0ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_7895562a-705f-4c8b-9d4c-919d64e0cafe" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_125465fc-8e8f-4c3e-896d-be0cbe1d0ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PutOptionMember_17a3bcd8-a3a7-4fe9-b89f-a3ce98cf4cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PutOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_125465fc-8e8f-4c3e-896d-be0cbe1d0ea8" xlink:to="loc_us-gaap_PutOptionMember_17a3bcd8-a3a7-4fe9-b89f-a3ce98cf4cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CallOptionMember_c8cc10be-5594-400b-b8e2-38df9f164c85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CallOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_125465fc-8e8f-4c3e-896d-be0cbe1d0ea8" xlink:to="loc_us-gaap_CallOptionMember_c8cc10be-5594-400b-b8e2-38df9f164c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_39868dd2-1969-47cd-84e4-6648baa009ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_39868dd2-1969-47cd-84e4-6648baa009ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_bd84b28d-4982-426f-ae9c-5abaa1e1750c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_39868dd2-1969-47cd-84e4-6648baa009ad" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_bd84b28d-4982-426f-ae9c-5abaa1e1750c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FairValueRiskMember_2fe9bed9-c8a3-44b6-88a7-1f01c462393e" xlink:href="hum-20231231.xsd#hum_FairValueRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_bd84b28d-4982-426f-ae9c-5abaa1e1750c" xlink:to="loc_hum_FairValueRiskMember_2fe9bed9-c8a3-44b6-88a7-1f01c462393e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67b3f5b7-5142-4a8a-bfb0-92bf46db672f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67b3f5b7-5142-4a8a-bfb0-92bf46db672f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6daab656-2dbc-4603-9d63-8b35693926ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_67b3f5b7-5142-4a8a-bfb0-92bf46db672f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6daab656-2dbc-4603-9d63-8b35693926ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_5473cc43-23d3-4898-a867-89e3e35cc01e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6daab656-2dbc-4603-9d63-8b35693926ab" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_5473cc43-23d3-4898-a867-89e3e35cc01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_701a897f-b4d2-4517-8b76-562726078e83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_701a897f-b4d2-4517-8b76-562726078e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d59db2c0-a173-4c4a-9fde-4acbd519d8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_701a897f-b4d2-4517-8b76-562726078e83" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d59db2c0-a173-4c4a-9fde-4acbd519d8a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_47a9d39c-0e28-43db-9805-6b746e9e5fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d59db2c0-a173-4c4a-9fde-4acbd519d8a8" xlink:to="loc_us-gaap_InvestmentsMember_47a9d39c-0e28-43db-9805-6b746e9e5fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_afdc4ac5-042a-4a02-9ce1-c18977b5f33d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_afdc4ac5-042a-4a02-9ce1-c18977b5f33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4d3b60f6-90a4-409c-a5da-5cc249a663c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_afdc4ac5-042a-4a02-9ce1-c18977b5f33d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4d3b60f6-90a4-409c-a5da-5cc249a663c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_4f814af4-d4fc-47ab-a72d-a416fcf58cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4d3b60f6-90a4-409c-a5da-5cc249a663c3" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_4f814af4-d4fc-47ab-a72d-a416fcf58cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d2a6e014-e834-4c14-bda6-63046eb94c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d2a6e014-e834-4c14-bda6-63046eb94c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c8ced13-c1c2-4229-b232-fe38972e79dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d2a6e014-e834-4c14-bda6-63046eb94c4c" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c8ced13-c1c2-4229-b232-fe38972e79dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GentivaHospiceMember_28a37d54-2b22-40bb-91ef-66d812e1f0e4" xlink:href="hum-20231231.xsd#hum_GentivaHospiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9c8ced13-c1c2-4229-b232-fe38972e79dd" xlink:to="loc_hum_GentivaHospiceMember_28a37d54-2b22-40bb-91ef-66d812e1f0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d067b505-4667-4470-bef3-2a7f9969b2fe" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_fe580a47-9a0e-4716-85ca-a5c678a41990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_fe580a47-9a0e-4716-85ca-a5c678a41990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_864b0f5c-e1a6-4cc4-8b3f-ae8f35aea361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_864b0f5c-e1a6-4cc4-8b3f-ae8f35aea361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_402ffd28-7756-4914-a90c-370f6e813bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_402ffd28-7756-4914-a90c-370f6e813bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d74e161a-0753-4816-8a6a-467a092fc89c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d74e161a-0753-4816-8a6a-467a092fc89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_9bd5cfda-f7c9-4f84-818d-2f22b6ea729c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_DerivativeNotionalAmount_9bd5cfda-f7c9-4f84-818d-2f22b6ea729c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_9e5d7bee-6b58-41ab-8171-c863489e4b23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateFairValueHedgeAssetAtFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_InterestRateFairValueHedgeAssetAtFairValue_9e5d7bee-6b58-41ab-8171-c863489e4b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_1cc22528-4447-4aa5-aaf4-7022916e0ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_DebtInstrumentFairValue_1cc22528-4447-4aa5-aaf4-7022916e0ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_339bc723-fdc3-4b15-9665-ecda61200106" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_ShortTermBorrowings_339bc723-fdc3-4b15-9665-ecda61200106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage_529f3522-a866-491a-8377-8b98076bf815" xlink:href="hum-20231231.xsd#hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage_529f3522-a866-491a-8377-8b98076bf815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_a49ceaed-8768-43b7-afd2-29b9e3956e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_a49ceaed-8768-43b7-afd2-29b9e3956e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FinancialAssetsFairValueDisclosure_bdd3d0be-e5a1-460b-8d35-b1d4f1b62152" xlink:href="hum-20231231.xsd#hum_FinancialAssetsFairValueDisclosure"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_hum_FinancialAssetsFairValueDisclosure_bdd3d0be-e5a1-460b-8d35-b1d4f1b62152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LossOnTerminationOfDerivatives_0a3f4d8d-e7f4-4476-b0bf-15250ca6703a" xlink:href="hum-20231231.xsd#hum_LossOnTerminationOfDerivatives"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_hum_LossOnTerminationOfDerivatives_0a3f4d8d-e7f4-4476-b0bf-15250ca6703a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold_378808da-b133-4f54-838e-17dbbad03ee9" xlink:href="hum-20231231.xsd#hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_40f21590-c81b-4998-a35b-250c758856a8" xlink:to="loc_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold_378808da-b133-4f54-838e-17dbbad03ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" xlink:type="simple" xlink:href="hum-20231231.xsd#FAIRVALUESignificantUnobservableInputsLevel3Details"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_480866a0-bdbf-4a42-88dd-6cc58c22629d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8bedb52-68b4-4aba-9166-6b63910f19eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_480866a0-bdbf-4a42-88dd-6cc58c22629d" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8bedb52-68b4-4aba-9166-6b63910f19eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_4371b66d-1d4b-46aa-b101-524d22579768" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8bedb52-68b4-4aba-9166-6b63910f19eb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_4371b66d-1d4b-46aa-b101-524d22579768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract_597d1c87-31f9-47f5-a356-fda93a5341b1" xlink:href="hum-20231231.xsd#hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8bedb52-68b4-4aba-9166-6b63910f19eb" xlink:to="loc_hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract_597d1c87-31f9-47f5-a356-fda93a5341b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_dd556dae-ebb9-4e0a-9447-d54502c6fa17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract_597d1c87-31f9-47f5-a356-fda93a5341b1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_dd556dae-ebb9-4e0a-9447-d54502c6fa17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_0bf4ec08-b397-49a7-ac7f-f8c47773b0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract_597d1c87-31f9-47f5-a356-fda93a5341b1" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss_0bf4ec08-b397-49a7-ac7f-f8c47773b0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_00c616ae-256a-429b-a6a5-fb5074ecf1df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8bedb52-68b4-4aba-9166-6b63910f19eb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_00c616ae-256a-429b-a6a5-fb5074ecf1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_6699d90f-c81e-4dd3-b593-5eaf40a6748c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8bedb52-68b4-4aba-9166-6b63910f19eb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales_6699d90f-c81e-4dd3-b593-5eaf40a6748c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_2b23cb3c-1753-4124-b145-5bdd2b4e03f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8bedb52-68b4-4aba-9166-6b63910f19eb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_2b23cb3c-1753-4124-b145-5bdd2b4e03f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_705d85e8-f1f4-4eb1-8702-d45c005b507b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8bedb52-68b4-4aba-9166-6b63910f19eb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_705d85e8-f1f4-4eb1-8702-d45c005b507b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_3a402eca-9ce8-467a-bd89-f815c9e63416" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8bedb52-68b4-4aba-9166-6b63910f19eb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_3a402eca-9ce8-467a-bd89-f815c9e63416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_85fc59da-3240-41d4-a00a-42cf77f7f405" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d8bedb52-68b4-4aba-9166-6b63910f19eb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_85fc59da-3240-41d4-a00a-42cf77f7f405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e5cad84f-99d1-4091-baba-20899bfc8f07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_226aaf37-cba1-4dd1-b6dd-20661f213802" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e5cad84f-99d1-4091-baba-20899bfc8f07" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_226aaf37-cba1-4dd1-b6dd-20661f213802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7d767645-2b0e-48b1-9573-1e80742ad4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_226aaf37-cba1-4dd1-b6dd-20661f213802" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7d767645-2b0e-48b1-9573-1e80742ad4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b965127-26e7-492b-921d-06fa98b07559" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7d767645-2b0e-48b1-9573-1e80742ad4c9" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b965127-26e7-492b-921d-06fa98b07559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionOnSecuritiesMember_6319809d-e58e-4c9a-a793-89a3d2394010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionOnSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b965127-26e7-492b-921d-06fa98b07559" xlink:to="loc_us-gaap_OptionOnSecuritiesMember_6319809d-e58e-4c9a-a793-89a3d2394010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7b1d0a1e-9ff8-4c32-9589-1f75c1a72db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_226aaf37-cba1-4dd1-b6dd-20661f213802" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7b1d0a1e-9ff8-4c32-9589-1f75c1a72db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_22dfc938-1ad1-4313-8889-184761031789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7b1d0a1e-9ff8-4c32-9589-1f75c1a72db3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_22dfc938-1ad1-4313-8889-184761031789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d9748b84-d184-42cc-816f-919d9c8074f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_22dfc938-1ad1-4313-8889-184761031789" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d9748b84-d184-42cc-816f-919d9c8074f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1e662b60-4b3f-475c-8dbe-b9c226c9a51d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_226aaf37-cba1-4dd1-b6dd-20661f213802" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1e662b60-4b3f-475c-8dbe-b9c226c9a51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_74f1d133-4992-45e4-ae24-3310f23c4ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1e662b60-4b3f-475c-8dbe-b9c226c9a51d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_74f1d133-4992-45e4-ae24-3310f23c4ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_72d81228-458e-41c5-99c9-18469818bb82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_74f1d133-4992-45e4-ae24-3310f23c4ca2" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_72d81228-458e-41c5-99c9-18469818bb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditSpreadOptionMember_14fa5c71-170a-401e-8244-68831a79ba33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditSpreadOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_74f1d133-4992-45e4-ae24-3310f23c4ca2" xlink:to="loc_us-gaap_CreditSpreadOptionMember_14fa5c71-170a-401e-8244-68831a79ba33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevenueExitMultipleMember_0b194492-d4ff-44f3-b9d8-673655faaabf" xlink:href="hum-20231231.xsd#hum_RevenueExitMultipleMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_74f1d133-4992-45e4-ae24-3310f23c4ca2" xlink:to="loc_hum_RevenueExitMultipleMember_0b194492-d4ff-44f3-b9d8-673655faaabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_653fd415-d84f-4450-af61-c622875fa18b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_74f1d133-4992-45e4-ae24-3310f23c4ca2" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_653fd415-d84f-4450-af61-c622875fa18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputLongTermRevenueGrowthRateMember_67a72adf-577b-4ebe-bcfa-6926d06de992" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputLongTermRevenueGrowthRateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_74f1d133-4992-45e4-ae24-3310f23c4ca2" xlink:to="loc_us-gaap_MeasurementInputLongTermRevenueGrowthRateMember_67a72adf-577b-4ebe-bcfa-6926d06de992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9ea8adff-00f3-47c0-968e-f36a3bae71ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_226aaf37-cba1-4dd1-b6dd-20661f213802" xlink:to="loc_srt_RangeAxis_9ea8adff-00f3-47c0-968e-f36a3bae71ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d06e9d7a-e4e9-479b-bf34-8178829a538f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9ea8adff-00f3-47c0-968e-f36a3bae71ce" xlink:to="loc_srt_RangeMember_d06e9d7a-e4e9-479b-bf34-8178829a538f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8d1f8cc4-3f27-4e73-897a-ce415fe0ad6e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d06e9d7a-e4e9-479b-bf34-8178829a538f" xlink:to="loc_srt_MinimumMember_8d1f8cc4-3f27-4e73-897a-ce415fe0ad6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_29f649dc-2f93-40b0-8e44-8229f1be8978" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d06e9d7a-e4e9-479b-bf34-8178829a538f" xlink:to="loc_srt_MaximumMember_29f649dc-2f93-40b0-8e44-8229f1be8978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ac112038-aa47-4c40-b5bd-898706aa80e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_226aaf37-cba1-4dd1-b6dd-20661f213802" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ac112038-aa47-4c40-b5bd-898706aa80e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetLiabilityNetMeasurementInput_c43639c0-faab-4dae-8cc9-9c9d6900fba2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetLiabilityNetMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_ac112038-aa47-4c40-b5bd-898706aa80e3" xlink:to="loc_us-gaap_DerivativeAssetLiabilityNetMeasurementInput_c43639c0-faab-4dae-8cc9-9c9d6900fba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/MEDICAREPARTDDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#MEDICAREPARTDDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/MEDICAREPARTDDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_8994f013-847a-44db-8605-7ff8c48a9af1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8b86583a-596a-42e7-9750-8aca58a6362a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_8994f013-847a-44db-8605-7ff8c48a9af1" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8b86583a-596a-42e7-9750-8aca58a6362a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ccea5c05-cfdb-4e03-9ef6-dd52e4a9e15a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8b86583a-596a-42e7-9750-8aca58a6362a" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ccea5c05-cfdb-4e03-9ef6-dd52e4a9e15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca0a5df7-6ef6-475d-8b68-3f701d058280" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ccea5c05-cfdb-4e03-9ef6-dd52e4a9e15a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca0a5df7-6ef6-475d-8b68-3f701d058280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RiskCorridorSettlementsMedicarePartDMember_f9a5f4ea-c59a-40b8-b7fd-17d34bc22653" xlink:href="hum-20231231.xsd#hum_RiskCorridorSettlementsMedicarePartDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca0a5df7-6ef6-475d-8b68-3f701d058280" xlink:to="loc_hum_RiskCorridorSettlementsMedicarePartDMember_f9a5f4ea-c59a-40b8-b7fd-17d34bc22653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CmsSubsidiesOrDiscountsMember_e915f599-2c39-4f86-ae3d-07aea74a550f" xlink:href="hum-20231231.xsd#hum_CmsSubsidiesOrDiscountsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca0a5df7-6ef6-475d-8b68-3f701d058280" xlink:to="loc_hum_CmsSubsidiesOrDiscountsMember_e915f599-2c39-4f86-ae3d-07aea74a550f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_8b86583a-596a-42e7-9750-8aca58a6362a" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_6e21d864-a659-4c3a-951c-f3890da5ba61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:to="loc_us-gaap_OtherAssetsCurrent_6e21d864-a659-4c3a-951c-f3890da5ba61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b55e13d-e373-4a05-ad25-9324407e6e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_8b55e13d-e373-4a05-ad25-9324407e6e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NetCurrentLiabilityAsset_c53807e3-010c-45d8-bb5c-372a0133f971" xlink:href="hum-20231231.xsd#hum_NetCurrentLiabilityAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:to="loc_hum_NetCurrentLiabilityAsset_c53807e3-010c-45d8-bb5c-372a0133f971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b85ff79d-050a-4095-80e8-db4e7f1117a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b85ff79d-050a-4095-80e8-db4e7f1117a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_92a7503a-a0ca-449e-b5ff-a41b7615cd95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_92a7503a-a0ca-449e-b5ff-a41b7615cd95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NetNoncurrentAssetLiability_a9536b43-9d8c-4945-8eaf-69ee82f94ae9" xlink:href="hum-20231231.xsd#hum_NetNoncurrentAssetLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:to="loc_hum_NetNoncurrentAssetLiability_a9536b43-9d8c-4945-8eaf-69ee82f94ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NetAssetLiability_d0cfe685-df02-4533-8af3-f40e88f16ed3" xlink:href="hum-20231231.xsd#hum_NetAssetLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_6e52d968-7266-46a9-badf-1fe5864f78d1" xlink:to="loc_hum_NetAssetLiability_d0cfe685-df02-4533-8af3-f40e88f16ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_23527d74-1356-4179-99a0-502a29df6005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_398e6a5d-e58a-446b-b36d-7d09f15d0f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_23527d74-1356-4179-99a0-502a29df6005" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_398e6a5d-e58a-446b-b36d-7d09f15d0f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_642ee14a-0a49-494d-a301-7a0dc1533b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_398e6a5d-e58a-446b-b36d-7d09f15d0f9c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_642ee14a-0a49-494d-a301-7a0dc1533b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a61cba4b-c773-4346-8e26-2018cb6bc0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_642ee14a-0a49-494d-a301-7a0dc1533b5b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a61cba4b-c773-4346-8e26-2018cb6bc0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_5f048448-15c5-49fc-b02d-e2baf63d1437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a61cba4b-c773-4346-8e26-2018cb6bc0d8" xlink:to="loc_us-gaap_LandMember_5f048448-15c5-49fc-b02d-e2baf63d1437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BuildingsAndLeaseholdImprovementsMember_ccf1520e-3db9-465c-9b2c-1249854bdefc" xlink:href="hum-20231231.xsd#hum_BuildingsAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a61cba4b-c773-4346-8e26-2018cb6bc0d8" xlink:to="loc_hum_BuildingsAndLeaseholdImprovementsMember_ccf1520e-3db9-465c-9b2c-1249854bdefc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_6a0e17aa-3409-4de5-b520-9693159a1f90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a61cba4b-c773-4346-8e26-2018cb6bc0d8" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_6a0e17aa-3409-4de5-b520-9693159a1f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_7bb28935-3367-4cdf-8029-778c6e3a3e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a61cba4b-c773-4346-8e26-2018cb6bc0d8" xlink:to="loc_us-gaap_ComputerEquipmentMember_7bb28935-3367-4cdf-8029-778c6e3a3e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0c482842-2d76-413e-b765-d330edbc8f32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_398e6a5d-e58a-446b-b36d-7d09f15d0f9c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0c482842-2d76-413e-b765-d330edbc8f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_275f2b50-93e1-42eb-9aca-47f75d1b5a29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0c482842-2d76-413e-b765-d330edbc8f32" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_275f2b50-93e1-42eb-9aca-47f75d1b5a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e6ad56b8-84d2-4977-90e4-e1405068aa44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0c482842-2d76-413e-b765-d330edbc8f32" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_e6ad56b8-84d2-4977-90e4-e1405068aa44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dacd7420-601e-4f27-8749-0cf7e83ff885" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0c482842-2d76-413e-b765-d330edbc8f32" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dacd7420-601e-4f27-8749-0cf7e83ff885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#PROPERTYANDEQUIPMENTNETNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3c0fa11a-1650-4c83-84dc-42c808d2c64c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationNonproduction_591f703d-6b6d-4bbb-87fc-cfd3dc4376c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationNonproduction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3c0fa11a-1650-4c83-84dc-42c808d2c64c" xlink:to="loc_us-gaap_DepreciationNonproduction_591f703d-6b6d-4bbb-87fc-cfd3dc4376c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_c35e9c4e-dc30-429d-825c-0f75a7bd3b79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_3c0fa11a-1650-4c83-84dc-42c808d2c64c" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_c35e9c4e-dc30-429d-825c-0f75a7bd3b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a9149da2-5b7e-40fe-9389-c1f997053583" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_a6ea9d9e-b44a-4adc-a123-f18ce4fc680e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a9149da2-5b7e-40fe-9389-c1f997053583" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_a6ea9d9e-b44a-4adc-a123-f18ce4fc680e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_28049685-6b96-47f0-86b8-111de393b31c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a6ea9d9e-b44a-4adc-a123-f18ce4fc680e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_28049685-6b96-47f0-86b8-111de393b31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9631c051-0600-4ff2-9bc3-3e39ccc3289e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_28049685-6b96-47f0-86b8-111de393b31c" xlink:to="loc_us-gaap_SegmentDomain_9631c051-0600-4ff2-9bc3-3e39ccc3289e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InsuranceSegmentMember_bfdceaeb-d297-479e-9f83-9a0126af0416" xlink:href="hum-20231231.xsd#hum_InsuranceSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9631c051-0600-4ff2-9bc3-3e39ccc3289e" xlink:to="loc_hum_InsuranceSegmentMember_bfdceaeb-d297-479e-9f83-9a0126af0416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CenterWellSegmentMember_8dc35d78-7dea-4cc4-b4c9-681761a64afd" xlink:href="hum-20231231.xsd#hum_CenterWellSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9631c051-0600-4ff2-9bc3-3e39ccc3289e" xlink:to="loc_hum_CenterWellSegmentMember_8dc35d78-7dea-4cc4-b4c9-681761a64afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_f8292800-d774-4639-8e79-8d433ae029c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a6ea9d9e-b44a-4adc-a123-f18ce4fc680e" xlink:to="loc_us-gaap_GoodwillLineItems_f8292800-d774-4639-8e79-8d433ae029c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_09c42a18-6179-427f-b9b5-66a8d5670688" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_f8292800-d774-4639-8e79-8d433ae029c9" xlink:to="loc_us-gaap_GoodwillRollForward_09c42a18-6179-427f-b9b5-66a8d5670688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_82ce74bb-9f5d-412c-9c24-dced6b27b7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_09c42a18-6179-427f-b9b5-66a8d5670688" xlink:to="loc_us-gaap_Goodwill_82ce74bb-9f5d-412c-9c24-dced6b27b7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_884d775d-bf2e-4d2f-9f23-5e3ea8db7630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_09c42a18-6179-427f-b9b5-66a8d5670688" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_884d775d-bf2e-4d2f-9f23-5e3ea8db7630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_eeffcbfb-2b7d-4cc0-b2ed-bf28a0dac913" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_09c42a18-6179-427f-b9b5-66a8d5670688" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_eeffcbfb-2b7d-4cc0-b2ed-bf28a0dac913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bac8b5b5-5511-46fc-a467-bdb1d284bcc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_09c42a18-6179-427f-b9b5-66a8d5670688" xlink:to="loc_us-gaap_Goodwill_bac8b5b5-5511-46fc-a467-bdb1d284bcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_232c4e92-f394-4b9a-955d-087ff7dacaad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8c8e02c6-27ef-4ec2-a886-34c27d9d7d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_232c4e92-f394-4b9a-955d-087ff7dacaad" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8c8e02c6-27ef-4ec2-a886-34c27d9d7d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_03136658-28f6-4908-9ae9-8735be86c29b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8c8e02c6-27ef-4ec2-a886-34c27d9d7d3f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_03136658-28f6-4908-9ae9-8735be86c29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8ac5ec12-b283-4f63-9bd0-766f5b8aec07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_03136658-28f6-4908-9ae9-8735be86c29b" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8ac5ec12-b283-4f63-9bd0-766f5b8aec07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CertificateOfNeedMember_efad89df-b347-4642-8678-893eaa32acc3" xlink:href="hum-20231231.xsd#hum_CertificateOfNeedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8ac5ec12-b283-4f63-9bd0-766f5b8aec07" xlink:to="loc_hum_CertificateOfNeedMember_efad89df-b347-4642-8678-893eaa32acc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_5bdd6ded-dbbf-4fb9-82e4-c331e35216ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8ac5ec12-b283-4f63-9bd0-766f5b8aec07" xlink:to="loc_us-gaap_LicensingAgreementsMember_5bdd6ded-dbbf-4fb9-82e4-c331e35216ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7d40d32c-f937-45dd-b92e-6fe12ffcfe7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8c8e02c6-27ef-4ec2-a886-34c27d9d7d3f" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7d40d32c-f937-45dd-b92e-6fe12ffcfe7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_815a4e22-7655-4494-bc57-68c4c1be35b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_7d40d32c-f937-45dd-b92e-6fe12ffcfe7e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_815a4e22-7655-4494-bc57-68c4c1be35b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d74d79f9-65cf-4019-b30c-55036734bea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_232c4e92-f394-4b9a-955d-087ff7dacaad" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d74d79f9-65cf-4019-b30c-55036734bea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d23e1e8f-d861-4ae8-b21d-f22d0cd95cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d74d79f9-65cf-4019-b30c-55036734bea8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d23e1e8f-d861-4ae8-b21d-f22d0cd95cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6920a2ad-034a-46d5-a096-cbc4a25f4256" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d23e1e8f-d861-4ae8-b21d-f22d0cd95cb4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6920a2ad-034a-46d5-a096-cbc4a25f4256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerContractsMember_b8b32d67-e97e-4d10-8584-65b85f81bb44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerContractsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6920a2ad-034a-46d5-a096-cbc4a25f4256" xlink:to="loc_us-gaap_CustomerContractsMember_b8b32d67-e97e-4d10-8584-65b85f81bb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_ea8bc493-70cf-42a9-b426-85d0f7aa3008" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6920a2ad-034a-46d5-a096-cbc4a25f4256" xlink:to="loc_us-gaap_TradeNamesMember_ea8bc493-70cf-42a9-b426-85d0f7aa3008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_778b0288-cde2-4de1-aa2c-53610b3f2efa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6920a2ad-034a-46d5-a096-cbc4a25f4256" xlink:to="loc_us-gaap_ContractualRightsMember_778b0288-cde2-4de1-aa2c-53610b3f2efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NoncompetesAndOtherMember_0ec39f5d-7b07-4d4a-a19c-aef7404226fc" xlink:href="hum-20231231.xsd#hum_NoncompetesAndOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6920a2ad-034a-46d5-a096-cbc4a25f4256" xlink:to="loc_hum_NoncompetesAndOtherMember_0ec39f5d-7b07-4d4a-a19c-aef7404226fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_900e80ba-176d-4329-82de-3a66ef5faadd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d74d79f9-65cf-4019-b30c-55036734bea8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_900e80ba-176d-4329-82de-3a66ef5faadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a85ac6f2-e77a-4419-9fee-1acc779d8815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_900e80ba-176d-4329-82de-3a66ef5faadd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a85ac6f2-e77a-4419-9fee-1acc779d8815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fd3cf4b9-73a5-4216-9d32-530f569dde6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a85ac6f2-e77a-4419-9fee-1acc779d8815" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fd3cf4b9-73a5-4216-9d32-530f569dde6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ece11d8f-366d-439b-a6a5-d5e922c240bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a85ac6f2-e77a-4419-9fee-1acc779d8815" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ece11d8f-366d-439b-a6a5-d5e922c240bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5a047e81-46f9-47dc-9eae-6297baf11c04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a85ac6f2-e77a-4419-9fee-1acc779d8815" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5a047e81-46f9-47dc-9eae-6297baf11c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_49e4000a-c66d-4d25-891c-2838bc761979" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a85ac6f2-e77a-4419-9fee-1acc779d8815" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_49e4000a-c66d-4d25-891c-2838bc761979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8cfda045-456c-47ac-a4cc-94dd92601822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a85ac6f2-e77a-4419-9fee-1acc779d8815" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_8cfda045-456c-47ac-a4cc-94dd92601822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_699a18f7-211b-4482-ae4f-ab644d9414a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_a85ac6f2-e77a-4419-9fee-1acc779d8815" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_699a18f7-211b-4482-ae4f-ab644d9414a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_98586fa5-1975-4a1f-8f13-f6b5ae04a80c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_ec35a641-b2cf-4ca7-b432-8cfe5aa140b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_98586fa5-1975-4a1f-8f13-f6b5ae04a80c" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_ec35a641-b2cf-4ca7-b432-8cfe5aa140b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_22b44a4d-be16-4dfb-a0ad-37a611cbcd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_ec35a641-b2cf-4ca7-b432-8cfe5aa140b8" xlink:to="loc_us-gaap_RestructuringPlanAxis_22b44a4d-be16-4dfb-a0ad-37a611cbcd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_6c6f2bc3-e2c8-49e1-aa79-fd4a306bbcca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_22b44a4d-be16-4dfb-a0ad-37a611cbcd9b" xlink:to="loc_us-gaap_RestructuringPlanDomain_6c6f2bc3-e2c8-49e1-aa79-fd4a306bbcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember_f191b603-c484-430c-aede-48f38186747f" xlink:href="hum-20231231.xsd#hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_6c6f2bc3-e2c8-49e1-aa79-fd4a306bbcca" xlink:to="loc_hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember_f191b603-c484-430c-aede-48f38186747f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_019825f8-2c9e-4187-9d27-a500e59630b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_ec35a641-b2cf-4ca7-b432-8cfe5aa140b8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_019825f8-2c9e-4187-9d27-a500e59630b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_45b34b4d-a4e0-417f-bd3b-90291fd61824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_019825f8-2c9e-4187-9d27-a500e59630b0" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_45b34b4d-a4e0-417f-bd3b-90291fd61824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_a32e8c17-499a-4e76-8025-9936b70d5e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_019825f8-2c9e-4187-9d27-a500e59630b0" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_a32e8c17-499a-4e76-8025-9936b70d5e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSEstimateofAmortizationExpenseDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#GOODWILLANDOTHERINTANGIBLEASSETSEstimateofAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSEstimateofAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_be536309-741d-4c7e-8a56-c7ae8f8cbbec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_359a98df-d076-4b1c-873f-7668e83a263d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_be536309-741d-4c7e-8a56-c7ae8f8cbbec" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_359a98df-d076-4b1c-873f-7668e83a263d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e2211309-22d2-4539-be8e-5d21b8755d53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_359a98df-d076-4b1c-873f-7668e83a263d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e2211309-22d2-4539-be8e-5d21b8755d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ad76584f-46d7-4579-8c41-1c2e9d144254" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_359a98df-d076-4b1c-873f-7668e83a263d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ad76584f-46d7-4579-8c41-1c2e9d144254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3e3ca69d-abe2-4636-a794-79e0017552fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_359a98df-d076-4b1c-873f-7668e83a263d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3e3ca69d-abe2-4636-a794-79e0017552fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4ddca6d6-a987-45eb-bfb2-baa8faf59ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_359a98df-d076-4b1c-873f-7668e83a263d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4ddca6d6-a987-45eb-bfb2-baa8faf59ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ab2b9bb9-0eb4-4731-b87d-4b17d82a9b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_359a98df-d076-4b1c-873f-7668e83a263d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_ab2b9bb9-0eb4-4731-b87d-4b17d82a9b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d36d7ac6-50a6-46ff-a9f2-768b0fd92683" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_8921864e-6ec3-4c30-8ad2-f69f51236711" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d36d7ac6-50a6-46ff-a9f2-768b0fd92683" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_8921864e-6ec3-4c30-8ad2-f69f51236711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a51ef8e8-fec8-4cbe-8a83-40068340f08d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d36d7ac6-50a6-46ff-a9f2-768b0fd92683" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a51ef8e8-fec8-4cbe-8a83-40068340f08d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1f17b23b-ed6a-4116-96b8-596b3ca1f981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d36d7ac6-50a6-46ff-a9f2-768b0fd92683" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_1f17b23b-ed6a-4116-96b8-596b3ca1f981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6551178e-4f36-4902-8b1c-0abfa3e7e1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d36d7ac6-50a6-46ff-a9f2-768b0fd92683" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6551178e-4f36-4902-8b1c-0abfa3e7e1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_1cc7e6d6-4584-4edf-a328-f573964bc754" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d36d7ac6-50a6-46ff-a9f2-768b0fd92683" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_1cc7e6d6-4584-4edf-a328-f573964bc754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9caca5c5-d90b-4d00-9047-9251212ac2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d36d7ac6-50a6-46ff-a9f2-768b0fd92683" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9caca5c5-d90b-4d00-9047-9251212ac2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_9ff3197f-23da-4f45-b34d-b94c86862f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d36d7ac6-50a6-46ff-a9f2-768b0fd92683" xlink:to="loc_us-gaap_OperatingLeaseCost_9ff3197f-23da-4f45-b34d-b94c86862f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_75f77546-9c1c-48a6-9371-4c5dcc07f897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d36d7ac6-50a6-46ff-a9f2-768b0fd92683" xlink:to="loc_us-gaap_VariableLeaseCost_75f77546-9c1c-48a6-9371-4c5dcc07f897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_4c3cd414-4d66-4b01-a3d5-3240f2dd6398" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d36d7ac6-50a6-46ff-a9f2-768b0fd92683" xlink:to="loc_us-gaap_SubleaseIncome_4c3cd414-4d66-4b01-a3d5-3240f2dd6398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_442b30c5-3ac7-4309-b7ec-76a86b4184bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d36d7ac6-50a6-46ff-a9f2-768b0fd92683" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_442b30c5-3ac7-4309-b7ec-76a86b4184bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_016688e2-44df-4fc2-b3ee-5d005a13471f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d36d7ac6-50a6-46ff-a9f2-768b0fd92683" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_016688e2-44df-4fc2-b3ee-5d005a13471f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_3d41def2-9f0d-4aeb-b556-e2f3bd187ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d36d7ac6-50a6-46ff-a9f2-768b0fd92683" xlink:to="loc_us-gaap_OperatingLeasePayments_3d41def2-9f0d-4aeb-b556-e2f3bd187ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#LEASESMaturityofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_76a32415-5caa-449c-841d-9c64812a6c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_dc916967-60f9-43be-a49b-ed7e1ae3aadf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_76a32415-5caa-449c-841d-9c64812a6c2a" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_dc916967-60f9-43be-a49b-ed7e1ae3aadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1eefb743-644c-4f40-b4a4-bfd5107d21d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_dc916967-60f9-43be-a49b-ed7e1ae3aadf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1eefb743-644c-4f40-b4a4-bfd5107d21d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_50ef9eb1-d58a-4dca-9880-db7ff7cd754a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_dc916967-60f9-43be-a49b-ed7e1ae3aadf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_50ef9eb1-d58a-4dca-9880-db7ff7cd754a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_471a59f7-653d-4df6-a9bf-b8c722fd8b13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_dc916967-60f9-43be-a49b-ed7e1ae3aadf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_471a59f7-653d-4df6-a9bf-b8c722fd8b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2177192b-32bd-4403-b6a1-9f39d20fafc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_dc916967-60f9-43be-a49b-ed7e1ae3aadf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2177192b-32bd-4403-b6a1-9f39d20fafc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f53b4956-1843-45ea-a267-bdb1218d42cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_dc916967-60f9-43be-a49b-ed7e1ae3aadf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f53b4956-1843-45ea-a267-bdb1218d42cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c661d931-bfd5-4f4c-8ea5-1f676a603290" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_dc916967-60f9-43be-a49b-ed7e1ae3aadf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c661d931-bfd5-4f4c-8ea5-1f676a603290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_02126197-0c1c-4011-a08c-66d8140dcb12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_dc916967-60f9-43be-a49b-ed7e1ae3aadf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_02126197-0c1c-4011-a08c-66d8140dcb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1e98f453-d55b-48e6-8a2d-a1c1ceebd86a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_dc916967-60f9-43be-a49b-ed7e1ae3aadf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1e98f453-d55b-48e6-8a2d-a1c1ceebd86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_eff113fa-b030-4799-a703-bf9f0c43414c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_dc916967-60f9-43be-a49b-ed7e1ae3aadf" xlink:to="loc_us-gaap_OperatingLeaseLiability_eff113fa-b030-4799-a703-bf9f0c43414c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="hum-20231231.xsd#LEASESMaturityofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#BENEFITSPAYABLEActivityinBenefitsPayableDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_b92457e1-fc2b-401f-8a7f-aa902726f40e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_d0448339-bcc6-4611-9a9f-aa17c0c60358" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_b92457e1-fc2b-401f-8a7f-aa902726f40e" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_d0448339-bcc6-4611-9a9f-aa17c0c60358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c95d31fa-e951-45cc-9d06-6dcba45ea5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_d0448339-bcc6-4611-9a9f-aa17c0c60358" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c95d31fa-e951-45cc-9d06-6dcba45ea5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_cd0e5444-fe01-41c5-841d-866d48d474f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_d0448339-bcc6-4611-9a9f-aa17c0c60358" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_cd0e5444-fe01-41c5-841d-866d48d474f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_ceacab87-e925-4466-b245-cc7f9bf14e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_d0448339-bcc6-4611-9a9f-aa17c0c60358" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_ceacab87-e925-4466-b245-cc7f9bf14e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_02b8c9ac-5075-43e2-8bb3-4ac233c3717f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_ceacab87-e925-4466-b245-cc7f9bf14e23" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_02b8c9ac-5075-43e2-8bb3-4ac233c3717f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_028aff96-189e-4552-bed3-8e358445d6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_ceacab87-e925-4466-b245-cc7f9bf14e23" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_028aff96-189e-4552-bed3-8e358445d6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_856a9f10-0868-48ef-97ec-9aed800955e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_ceacab87-e925-4466-b245-cc7f9bf14e23" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_856a9f10-0868-48ef-97ec-9aed800955e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_dfc55941-995e-4be9-a4c9-035438de768f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_d0448339-bcc6-4611-9a9f-aa17c0c60358" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_dfc55941-995e-4be9-a4c9-035438de768f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_0a1794de-c8ee-4659-855f-9e8ab5ab59f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_dfc55941-995e-4be9-a4c9-035438de768f" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_0a1794de-c8ee-4659-855f-9e8ab5ab59f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_1ab4ec26-977e-4d64-bca2-de2f73a51a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_dfc55941-995e-4be9-a4c9-035438de768f" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_1ab4ec26-977e-4d64-bca2-de2f73a51a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_82143e65-5a35-4816-8c9e-eda9f1664105" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_dfc55941-995e-4be9-a4c9-035438de768f" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_82143e65-5a35-4816-8c9e-eda9f1664105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c5c0eb93-cc60-4024-85b8-6047f64c6eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_d0448339-bcc6-4611-9a9f-aa17c0c60358" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c5c0eb93-cc60-4024-85b8-6047f64c6eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#BENEFITSPAYABLENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_a343c2af-9fc8-4f16-8d8b-8b3fb6859697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_0dbb93c0-149d-4406-93a7-1383faef2858" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_a343c2af-9fc8-4f16-8d8b-8b3fb6859697" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_0dbb93c0-149d-4406-93a7-1383faef2858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_718e9c15-ab7c-4f26-bb43-018195fea68e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_0dbb93c0-149d-4406-93a7-1383faef2858" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_718e9c15-ab7c-4f26-bb43-018195fea68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a902b7cc-ca46-4470-8711-4360ec057773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_718e9c15-ab7c-4f26-bb43-018195fea68e" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a902b7cc-ca46-4470-8711-4360ec057773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member_9fb1c9e4-4ad1-414c-82e1-7ea8b6f3b89e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a902b7cc-ca46-4470-8711-4360ec057773" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member_9fb1c9e4-4ad1-414c-82e1-7ea8b6f3b89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_e0d519de-9df5-4a02-9efb-424bed564a37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a902b7cc-ca46-4470-8711-4360ec057773" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_e0d519de-9df5-4a02-9efb-424bed564a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member_338ca7d6-451b-4d8f-865c-a400bf528222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2021Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a902b7cc-ca46-4470-8711-4360ec057773" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member_338ca7d6-451b-4d8f-865c-a400bf528222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClaimsDevelopmentLineItems_b58ba5d4-dfbf-4dab-846f-331b154b877f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClaimsDevelopmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_0dbb93c0-149d-4406-93a7-1383faef2858" xlink:to="loc_us-gaap_ClaimsDevelopmentLineItems_b58ba5d4-dfbf-4dab-846f-331b154b877f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount_c166c768-f303-4a51-ae2f-fdc3d3b4fe36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_b58ba5d4-dfbf-4dab-846f-331b154b877f" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount_c166c768-f303-4a51-ae2f-fdc3d3b4fe36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported_64fcdb89-d14b-4200-a051-75872f250103" xlink:href="hum-20231231.xsd#hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_b58ba5d4-dfbf-4dab-846f-331b154b877f" xlink:to="loc_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported_64fcdb89-d14b-4200-a051-75872f250103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears_74ed9cbf-557b-4045-83e1-2741dd43e560" xlink:href="hum-20231231.xsd#hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_b58ba5d4-dfbf-4dab-846f-331b154b877f" xlink:to="loc_hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears_74ed9cbf-557b-4045-83e1-2741dd43e560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_02173f7b-d0f3-436e-b069-5ae8a86d7e44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_dad3db8c-524f-4d0e-b756-733fcbedc027" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_02173f7b-d0f3-436e-b069-5ae8a86d7e44" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_dad3db8c-524f-4d0e-b756-733fcbedc027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_1cb23d32-2343-46bb-85c1-715cd7f5750d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_dad3db8c-524f-4d0e-b756-733fcbedc027" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_1cb23d32-2343-46bb-85c1-715cd7f5750d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_d2d9dbec-d489-401d-83da-e93b2cc2b408" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_1cb23d32-2343-46bb-85c1-715cd7f5750d" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_d2d9dbec-d489-401d-83da-e93b2cc2b408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember_6ee7a4e4-dfb4-4e32-a7ac-32b08a8c0ded" xlink:href="hum-20231231.xsd#hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_d2d9dbec-d489-401d-83da-e93b2cc2b408" xlink:to="loc_hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember_6ee7a4e4-dfb4-4e32-a7ac-32b08a8c0ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_07f0f349-681a-4c62-8a5e-7826d6ef793f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_d2d9dbec-d489-401d-83da-e93b2cc2b408" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_07f0f349-681a-4c62-8a5e-7826d6ef793f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member_1c951ee1-46a6-4b86-906a-f57061e98a42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_d2d9dbec-d489-401d-83da-e93b2cc2b408" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2023Member_1c951ee1-46a6-4b86-906a-f57061e98a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClaimsDevelopmentLineItems_fbd0749a-7d29-4596-9116-067b607f7461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClaimsDevelopmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable_dad3db8c-524f-4d0e-b756-733fcbedc027" xlink:to="loc_us-gaap_ClaimsDevelopmentLineItems_fbd0749a-7d29-4596-9116-067b607f7461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_72028435-3232-49ce-8bfe-9e181c8b096e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_fbd0749a-7d29-4596-9116-067b607f7461" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet_72028435-3232-49ce-8bfe-9e181c8b096e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_d2d19d0a-9f40-468b-97e7-805a375fdae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_fbd0749a-7d29-4596-9116-067b607f7461" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_d2d19d0a-9f40-468b-97e7-805a375fdae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_3d5e4936-f81e-4919-8fe3-803dbeb44150" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClaimsDevelopmentLineItems_fbd0749a-7d29-4596-9116-067b607f7461" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_3d5e4936-f81e-4919-8fe3-803dbeb44150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INCOMETAXESProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_25ed7e9e-3023-4b58-a225-bbba13ea377e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_cea9b375-525e-4212-a3cf-7f289754a65c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_25ed7e9e-3023-4b58-a225-bbba13ea377e" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_cea9b375-525e-4212-a3cf-7f289754a65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_97addbed-b6c8-415a-8f1d-9134a519b3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_25ed7e9e-3023-4b58-a225-bbba13ea377e" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_97addbed-b6c8-415a-8f1d-9134a519b3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5f27d365-b5ad-438a-8655-3ef66c302d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_25ed7e9e-3023-4b58-a225-bbba13ea377e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5f27d365-b5ad-438a-8655-3ef66c302d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cff967b2-2dd5-4535-8ba1-4a498e7a0f89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_25ed7e9e-3023-4b58-a225-bbba13ea377e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_cff967b2-2dd5-4535-8ba1-4a498e7a0f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_91be82fe-14a8-44fb-bd86-e687afa8f80e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_25ed7e9e-3023-4b58-a225-bbba13ea377e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_91be82fe-14a8-44fb-bd86-e687afa8f80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INCOMETAXESProvisionforIncomeTaxesReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_12f8042e-e20b-4723-be98-158376c0c830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_582e5f89-2ce0-4267-9153-4feddb87f6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_12f8042e-e20b-4723-be98-158376c0c830" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_582e5f89-2ce0-4267-9153-4feddb87f6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_44efaf6f-8508-4414-83d2-445ee9e4bc96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_12f8042e-e20b-4723-be98-158376c0c830" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_44efaf6f-8508-4414-83d2-445ee9e4bc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome_9cf93293-f7bc-4207-8803-0e383c7e8911" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxExemptIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_12f8042e-e20b-4723-be98-158376c0c830" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxExemptIncome_9cf93293-f7bc-4207-8803-0e383c7e8911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_4718f12e-8521-44eb-bc49-91a62714d2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_12f8042e-e20b-4723-be98-158376c0c830" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_4718f12e-8521-44eb-bc49-91a62714d2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain_a043f0e3-2df7-4010-8f9f-6d1e414c8290" xlink:href="hum-20231231.xsd#hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_12f8042e-e20b-4723-be98-158376c0c830" xlink:to="loc_hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain_a043f0e3-2df7-4010-8f9f-6d1e414c8290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_b5a0bab0-d568-4e44-827d-97fd9c99e6da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_12f8042e-e20b-4723-be98-158376c0c830" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_b5a0bab0-d568-4e44-827d-97fd9c99e6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_19762305-06ae-4595-9120-ef3e4ad3628d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_12f8042e-e20b-4723-be98-158376c0c830" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_19762305-06ae-4595-9120-ef3e4ad3628d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b1c4abe9-2c18-445c-803b-dbc0e6cc8f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_12f8042e-e20b-4723-be98-158376c0c830" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b1c4abe9-2c18-445c-803b-dbc0e6cc8f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_02123ca7-92f5-4ee7-b325-ee8cae1732ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_12f8042e-e20b-4723-be98-158376c0c830" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_02123ca7-92f5-4ee7-b325-ee8cae1732ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_58e64b2a-66c9-45a6-ba5b-5ee7adda7d96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_58e64b2a-66c9-45a6-ba5b-5ee7adda7d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_f132547c-d37d-49ba-aea2-c34deabd47ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_f132547c-d37d-49ba-aea2-c34deabd47ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_4506cadc-6d6e-4651-aef6-36b88007e0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_4506cadc-6d6e-4651-aef6-36b88007e0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost_e8aed86d-eb0d-4377-94f2-4c27e25eb128" xlink:href="hum-20231231.xsd#hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost_e8aed86d-eb0d-4377-94f2-4c27e25eb128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DeferredTaxAssetJobsTaxCredit_5fcc9ca9-e52b-4d59-a6f9-dfb9d010027b" xlink:href="hum-20231231.xsd#hum_DeferredTaxAssetJobsTaxCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_hum_DeferredTaxAssetJobsTaxCredit_5fcc9ca9-e52b-4d59-a6f9-dfb9d010027b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_8aae17aa-a62c-4625-a62e-40a800f9de45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_8aae17aa-a62c-4625-a62e-40a800f9de45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve_3c816be1-6448-4814-af0a-38440b6afc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve_3c816be1-6448-4814-af0a-38440b6afc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_19944b2f-852a-4496-b799-324b054b5b02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_19944b2f-852a-4496-b799-324b054b5b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a1b480b4-0525-4a4f-9c1b-88048c39622d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_a1b480b4-0525-4a4f-9c1b-88048c39622d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cbf1d481-4047-473b-9a68-0a7fd746e551" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_cbf1d481-4047-473b-9a68-0a7fd746e551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_562f7fc8-7696-45ab-918a-a69bff6020a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_562f7fc8-7696-45ab-918a-a69bff6020a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets_9dbbc73a-b0df-44ae-839b-aca73adb58b5" xlink:href="hum-20231231.xsd#hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets_9dbbc73a-b0df-44ae-839b-aca73adb58b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_6731d6b9-942e-4f58-aa45-9130020ea93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_6731d6b9-942e-4f58-aa45-9130020ea93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_6ea1f4e5-8a8e-402a-90a9-aceb6836f1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_6ea1f4e5-8a8e-402a-90a9-aceb6836f1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_c6fb3c87-eee9-4633-8408-a225eb73ca86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_c6fb3c87-eee9-4633-8408-a225eb73ca86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b2dc6ada-49c8-432e-a765-fc9ced060b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b2dc6ada-49c8-432e-a765-fc9ced060b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_eb69dd65-f95b-4e7b-bab1-b17739a6712a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_511df459-ebe5-4ac2-9a0c-adbeda07ed25" xlink:to="loc_us-gaap_DeferredTaxLiabilities_eb69dd65-f95b-4e7b-bab1-b17739a6712a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7503ed0e-1fa5-4169-869b-702b95436b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_013cc35c-e39f-4569-80de-d63b1aeb055b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7503ed0e-1fa5-4169-869b-702b95436b6f" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_013cc35c-e39f-4569-80de-d63b1aeb055b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_21f1a8ed-3c4c-4982-8355-50ca59340505" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_013cc35c-e39f-4569-80de-d63b1aeb055b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_21f1a8ed-3c4c-4982-8355-50ca59340505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e430da20-5a31-4ec6-839d-f65c61bd566f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_21f1a8ed-3c4c-4982-8355-50ca59340505" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e430da20-5a31-4ec6-839d-f65c61bd566f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_73968146-0b7e-4fe9-8879-ac11806ca644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e430da20-5a31-4ec6-839d-f65c61bd566f" xlink:to="loc_us-gaap_DomesticCountryMember_73968146-0b7e-4fe9-8879-ac11806ca644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_89e9eb21-e9ef-48e6-9225-504e6c7e2377" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e430da20-5a31-4ec6-839d-f65c61bd566f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_89e9eb21-e9ef-48e6-9225-504e6c7e2377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_37425bba-07c9-4d79-af55-04359a17b868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_013cc35c-e39f-4569-80de-d63b1aeb055b" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_37425bba-07c9-4d79-af55-04359a17b868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_7e906c5a-5a1d-4a5d-b6fe-d47e457dd233" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_37425bba-07c9-4d79-af55-04359a17b868" xlink:to="loc_us-gaap_OperatingLossCarryforwards_7e906c5a-5a1d-4a5d-b6fe-d47e457dd233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b9897482-2d40-4ca0-adb7-65928a22b149" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_37425bba-07c9-4d79-af55-04359a17b868" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b9897482-2d40-4ca0-adb7-65928a22b149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/DEBTDebtOutstandingDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#DEBTDebtOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/DEBTDebtOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_29fa7e7e-2cf3-436c-bf1b-642e2cd5420c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_74384b4d-54ff-4f0f-bf13-87d2eac436d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_29fa7e7e-2cf3-436c-bf1b-642e2cd5420c" xlink:to="loc_us-gaap_DebtInstrumentTable_74384b4d-54ff-4f0f-bf13-87d2eac436d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_71d368ea-5245-48b4-ade7-d1c9dd7af689" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_74384b4d-54ff-4f0f-bf13-87d2eac436d1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_71d368ea-5245-48b4-ade7-d1c9dd7af689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_7f81aea5-278f-4c37-b2ac-6370161351dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_71d368ea-5245-48b4-ade7-d1c9dd7af689" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_7f81aea5-278f-4c37-b2ac-6370161351dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_44217676-1dc2-497a-91aa-5dfdcd04a0be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_7f81aea5-278f-4c37-b2ac-6370161351dc" xlink:to="loc_us-gaap_CommercialPaperMember_44217676-1dc2-497a-91aa-5dfdcd04a0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bfecce00-47c0-4c3d-83b0-10b4affd4bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_74384b4d-54ff-4f0f-bf13-87d2eac436d1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bfecce00-47c0-4c3d-83b0-10b4affd4bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_07358603-8da7-48b2-9a07-19184b7170c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bfecce00-47c0-4c3d-83b0-10b4affd4bc8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_07358603-8da7-48b2-9a07-19184b7170c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e196cd23-77c7-4cc8-a259-268c8493011d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_07358603-8da7-48b2-9a07-19184b7170c5" xlink:to="loc_us-gaap_SeniorNotesMember_e196cd23-77c7-4cc8-a259-268c8493011d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_6df2267a-0751-440f-a152-0e3b014eb96c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_07358603-8da7-48b2-9a07-19184b7170c5" xlink:to="loc_us-gaap_LoansPayableMember_6df2267a-0751-440f-a152-0e3b014eb96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bf0ccb2a-8399-4849-8841-804128604473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_74384b4d-54ff-4f0f-bf13-87d2eac436d1" xlink:to="loc_us-gaap_DebtInstrumentAxis_bf0ccb2a-8399-4849-8841-804128604473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_bf0ccb2a-8399-4849-8841-804128604473" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3850PercentSeniorNotesDueOctober2024Member_86505d07-d7c4-4b44-b398-0864b7c94db6" xlink:href="hum-20231231.xsd#hum_A3850PercentSeniorNotesDueOctober2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A3850PercentSeniorNotesDueOctober2024Member_86505d07-d7c4-4b44-b398-0864b7c94db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A065PercentSeniorNotesDueAugust2023Member_817f1971-6f20-4719-a4ee-b25c9d03beda" xlink:href="hum-20231231.xsd#hum_A065PercentSeniorNotesDueAugust2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A065PercentSeniorNotesDueAugust2023Member_817f1971-6f20-4719-a4ee-b25c9d03beda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A4.500PercentSeniorNotesDueApril2025Member_2ad7beff-0b50-40e2-a7a9-9eba7e09bddd" xlink:href="hum-20231231.xsd#hum_A4.500PercentSeniorNotesDueApril2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A4.500PercentSeniorNotesDueApril2025Member_2ad7beff-0b50-40e2-a7a9-9eba7e09bddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A570PercentSeniorNotesDueMarch2026Member_d11c7395-24d7-4db1-afb9-fc3460a6ce6a" xlink:href="hum-20231231.xsd#hum_A570PercentSeniorNotesDueMarch2026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A570PercentSeniorNotesDueMarch2026Member_d11c7395-24d7-4db1-afb9-fc3460a6ce6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A135PercentSeniorNotesDueFebruary2027Member_95910699-c048-4dc3-9f70-978fce37c002" xlink:href="hum-20231231.xsd#hum_A135PercentSeniorNotesDueFebruary2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A135PercentSeniorNotesDueFebruary2027Member_95910699-c048-4dc3-9f70-978fce37c002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3.95PercentSeniorNotesDueMarch2027Member_30f089dc-b219-423d-ac57-a711dc7e9b4e" xlink:href="hum-20231231.xsd#hum_A3.95PercentSeniorNotesDueMarch2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A3.95PercentSeniorNotesDueMarch2027Member_30f089dc-b219-423d-ac57-a711dc7e9b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A575PercentSeniorNotesDueMarch2028Member_7ddc2603-47e8-4a15-b3d6-7d4eaf17049f" xlink:href="hum-20231231.xsd#hum_A575PercentSeniorNotesDueMarch2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A575PercentSeniorNotesDueMarch2028Member_7ddc2603-47e8-4a15-b3d6-7d4eaf17049f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A575PercentSeniorNotesDueDecember2028Member_0e852f45-4d47-453f-9dfd-86ebd0b04dd1" xlink:href="hum-20231231.xsd#hum_A575PercentSeniorNotesDueDecember2028Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A575PercentSeniorNotesDueDecember2028Member_0e852f45-4d47-453f-9dfd-86ebd0b04dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A370PercentSeniorNotesDueMarch2029Member_7cf39daf-6fa7-4523-8e3b-3e775b43c0cf" xlink:href="hum-20231231.xsd#hum_A370PercentSeniorNotesDueMarch2029Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A370PercentSeniorNotesDueMarch2029Member_7cf39daf-6fa7-4523-8e3b-3e775b43c0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A313PercentSeniorNotesDueAugust2029Member_02cbf33c-70db-4579-bf42-9ce26277186b" xlink:href="hum-20231231.xsd#hum_A313PercentSeniorNotesDueAugust2029Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A313PercentSeniorNotesDueAugust2029Member_02cbf33c-70db-4579-bf42-9ce26277186b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A488PercentSeniorNotesDueApril2030Member_4840d2d6-69e9-4dbf-95ad-888b5bf42dac" xlink:href="hum-20231231.xsd#hum_A488PercentSeniorNotesDueApril2030Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A488PercentSeniorNotesDueApril2030Member_4840d2d6-69e9-4dbf-95ad-888b5bf42dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A215PercentSeniorNotesDueFebruary2032Member_bd1048d1-0c36-4104-90ad-afbf3dc693bc" xlink:href="hum-20231231.xsd#hum_A215PercentSeniorNotesDueFebruary2032Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A215PercentSeniorNotesDueFebruary2032Member_bd1048d1-0c36-4104-90ad-afbf3dc693bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5.88PercentSeniorNotesDueMarch2033Member_42633433-e9bc-4b0b-97da-265b517ff684" xlink:href="hum-20231231.xsd#hum_A5.88PercentSeniorNotesDueMarch2033Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A5.88PercentSeniorNotesDueMarch2033Member_42633433-e9bc-4b0b-97da-265b517ff684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5950PercentSeniorNotesDueMarch2034Member_c9380a4a-3e27-44e3-8f6c-27d4c27783d7" xlink:href="hum-20231231.xsd#hum_A5950PercentSeniorNotesDueMarch2034Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A5950PercentSeniorNotesDueMarch2034Member_c9380a4a-3e27-44e3-8f6c-27d4c27783d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A8.15PercentSeniorNotesDueJune2038Member_e6fd2184-6696-4357-b927-0d67f98b94bc" xlink:href="hum-20231231.xsd#hum_A8.15PercentSeniorNotesDueJune2038Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A8.15PercentSeniorNotesDueJune2038Member_e6fd2184-6696-4357-b927-0d67f98b94bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A463PercentSeniorNotesDueDecember2042Member_47d143b0-9576-4a46-aff8-6d9d1179bee4" xlink:href="hum-20231231.xsd#hum_A463PercentSeniorNotesDueDecember2042Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A463PercentSeniorNotesDueDecember2042Member_47d143b0-9576-4a46-aff8-6d9d1179bee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A4.95PercentSeniorNotesDueOctober2044Member_55fb862d-8ca8-4002-a68b-902bfba03d69" xlink:href="hum-20231231.xsd#hum_A4.95PercentSeniorNotesDueOctober2044Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A4.95PercentSeniorNotesDueOctober2044Member_55fb862d-8ca8-4002-a68b-902bfba03d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A4.80PercentSeniorNotesDueMarch2047Member_9db18ed9-2eb9-4b0c-826f-8317d3f053b5" xlink:href="hum-20231231.xsd#hum_A4.80PercentSeniorNotesDueMarch2047Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A4.80PercentSeniorNotesDueMarch2047Member_9db18ed9-2eb9-4b0c-826f-8317d3f053b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3.95PercentSeniorNotesDueAugust2049Member_d630032a-d2a4-4ff7-9401-320c251cb3df" xlink:href="hum-20231231.xsd#hum_A3.95PercentSeniorNotesDueAugust2049Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A3.95PercentSeniorNotesDueAugust2049Member_d630032a-d2a4-4ff7-9401-320c251cb3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A550PercentSeniorNotesDueMarch2053Member_6b418e03-64b1-4886-9752-67492636a06a" xlink:href="hum-20231231.xsd#hum_A550PercentSeniorNotesDueMarch2053Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_A550PercentSeniorNotesDueMarch2053Member_6b418e03-64b1-4886-9752-67492636a06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DelayedDrawTermLoanMay2024Member_8c8ed2fc-3bbc-48dc-a761-404418c9e272" xlink:href="hum-20231231.xsd#hum_DelayedDrawTermLoanMay2024Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_eeeea6ab-dea2-4cf9-984b-f73bcc1cc25c" xlink:to="loc_hum_DelayedDrawTermLoanMay2024Member_8c8ed2fc-3bbc-48dc-a761-404418c9e272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6805204f-d980-47cd-9c12-7bea413b5c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_74384b4d-54ff-4f0f-bf13-87d2eac436d1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6805204f-d980-47cd-9c12-7bea413b5c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_57ce3209-d2be-4790-93ea-b0062c9729d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6805204f-d980-47cd-9c12-7bea413b5c66" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_57ce3209-d2be-4790-93ea-b0062c9729d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_57ad544d-2060-4870-ab47-469d3a173516" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6805204f-d980-47cd-9c12-7bea413b5c66" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_57ad544d-2060-4870-ab47-469d3a173516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_afa80906-ec15-4bd7-a9e3-474e91ee3ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6805204f-d980-47cd-9c12-7bea413b5c66" xlink:to="loc_us-gaap_ShortTermBorrowings_afa80906-ec15-4bd7-a9e3-474e91ee3ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_0c0dfacb-dc5d-4e09-82c4-028844c89197" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6805204f-d980-47cd-9c12-7bea413b5c66" xlink:to="loc_us-gaap_LongTermDebtCurrent_0c0dfacb-dc5d-4e09-82c4-028844c89197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_04a21320-d935-4c24-bd26-e0b9ac5eb48e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6805204f-d980-47cd-9c12-7bea413b5c66" xlink:to="loc_us-gaap_DebtCurrent_04a21320-d935-4c24-bd26-e0b9ac5eb48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_092f043b-9ecc-4ecd-997f-d022e8a40807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6805204f-d980-47cd-9c12-7bea413b5c66" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_092f043b-9ecc-4ecd-997f-d022e8a40807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/DEBTMaturitiesofDebtDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#DEBTMaturitiesofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/DEBTMaturitiesofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2c39bd34-1ace-44a1-966c-8b9ae3c410a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_d86458cc-6846-40b6-912f-a3ca9d4726a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2c39bd34-1ace-44a1-966c-8b9ae3c410a0" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_d86458cc-6846-40b6-912f-a3ca9d4726a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ea56512b-bc51-4156-a739-80f0e3fbadad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_d86458cc-6846-40b6-912f-a3ca9d4726a6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ea56512b-bc51-4156-a739-80f0e3fbadad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ae414713-5b96-4550-89d2-7573adbf3a00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_d86458cc-6846-40b6-912f-a3ca9d4726a6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ae414713-5b96-4550-89d2-7573adbf3a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9ffb68d3-404a-496e-a247-97c8eb555906" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_d86458cc-6846-40b6-912f-a3ca9d4726a6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_9ffb68d3-404a-496e-a247-97c8eb555906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_de36f719-9653-4a44-b622-78480109260e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_d86458cc-6846-40b6-912f-a3ca9d4726a6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_de36f719-9653-4a44-b622-78480109260e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9219b54e-7411-4af1-b79d-6e5c5d18b63d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_d86458cc-6846-40b6-912f-a3ca9d4726a6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9219b54e-7411-4af1-b79d-6e5c5d18b63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_8072f53b-cd19-4dc5-b3b2-fe818b19c608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_d86458cc-6846-40b6-912f-a3ca9d4726a6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_8072f53b-cd19-4dc5-b3b2-fe818b19c608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/DEBTSeniorNotesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#DEBTSeniorNotesDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/DEBTSeniorNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6747de44-efb2-4c42-a926-7068e5213304" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_11095ed3-22a3-4fe2-aa14-8e5e124e98d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6747de44-efb2-4c42-a926-7068e5213304" xlink:to="loc_us-gaap_DebtInstrumentTable_11095ed3-22a3-4fe2-aa14-8e5e124e98d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_9f46ad03-11cf-4e04-9cd8-c7f894a044e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11095ed3-22a3-4fe2-aa14-8e5e124e98d6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_9f46ad03-11cf-4e04-9cd8-c7f894a044e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b3fa66f5-5979-44a1-aa97-2c172bb3388d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_9f46ad03-11cf-4e04-9cd8-c7f894a044e6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b3fa66f5-5979-44a1-aa97-2c172bb3388d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_81eb9129-9e6e-49df-8e7d-43af32e0cba1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b3fa66f5-5979-44a1-aa97-2c172bb3388d" xlink:to="loc_us-gaap_SeniorNotesMember_81eb9129-9e6e-49df-8e7d-43af32e0cba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_cd1078fe-18c9-406e-9c91-43a9351b8285" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b3fa66f5-5979-44a1-aa97-2c172bb3388d" xlink:to="loc_us-gaap_LoansPayableMember_cd1078fe-18c9-406e-9c91-43a9351b8285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_02d7daa8-8298-4e63-99a2-e4638660a8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11095ed3-22a3-4fe2-aa14-8e5e124e98d6" xlink:to="loc_us-gaap_DebtInstrumentAxis_02d7daa8-8298-4e63-99a2-e4638660a8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_02d7daa8-8298-4e63-99a2-e4638660a8c6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A8.15PercentSeniorNotesDueJune2038Member_37ade16c-728b-4d8b-aa84-42babdbaa864" xlink:href="hum-20231231.xsd#hum_A8.15PercentSeniorNotesDueJune2038Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:to="loc_hum_A8.15PercentSeniorNotesDueJune2038Member_37ade16c-728b-4d8b-aa84-42babdbaa864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member_b424c6b8-2fb1-43c7-a043-c0eb53fb8332" xlink:href="hum-20231231.xsd#hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:to="loc_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member_b424c6b8-2fb1-43c7-a043-c0eb53fb8332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A575PercentSeniorNotesDueDecember2028Member_6d43d929-d7d9-4fad-b942-84a9a25ff2d7" xlink:href="hum-20231231.xsd#hum_A575PercentSeniorNotesDueDecember2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member_b424c6b8-2fb1-43c7-a043-c0eb53fb8332" xlink:to="loc_hum_A575PercentSeniorNotesDueDecember2028Member_6d43d929-d7d9-4fad-b942-84a9a25ff2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5950PercentSeniorNotesDueMarch2034Member_c75c8a44-29de-4ddc-bb05-49266b95cf44" xlink:href="hum-20231231.xsd#hum_A5950PercentSeniorNotesDueMarch2034Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member_b424c6b8-2fb1-43c7-a043-c0eb53fb8332" xlink:to="loc_hum_A5950PercentSeniorNotesDueMarch2034Member_c75c8a44-29de-4ddc-bb05-49266b95cf44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member_e7943292-18a1-43f0-a70c-772be4bc144f" xlink:href="hum-20231231.xsd#hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:to="loc_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member_e7943292-18a1-43f0-a70c-772be4bc144f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A570PercentSeniorNotesDueMarch2026Member_e05062f4-8818-4b8f-801a-9ee4e7fe2cd8" xlink:href="hum-20231231.xsd#hum_A570PercentSeniorNotesDueMarch2026Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member_e7943292-18a1-43f0-a70c-772be4bc144f" xlink:to="loc_hum_A570PercentSeniorNotesDueMarch2026Member_e05062f4-8818-4b8f-801a-9ee4e7fe2cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A550PercentSeniorNotesDueMarch2053Member_5fa9d778-53cf-4cbe-96b2-75ca8211da90" xlink:href="hum-20231231.xsd#hum_A550PercentSeniorNotesDueMarch2053Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member_e7943292-18a1-43f0-a70c-772be4bc144f" xlink:to="loc_hum_A550PercentSeniorNotesDueMarch2053Member_5fa9d778-53cf-4cbe-96b2-75ca8211da90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DelayedDrawTermLoanMember_81ded253-7e92-4241-856c-a59508112acc" xlink:href="hum-20231231.xsd#hum_DelayedDrawTermLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:to="loc_hum_DelayedDrawTermLoanMember_81ded253-7e92-4241-856c-a59508112acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RepurchasePlanAugust2023Member_9634a6a3-f35f-4ad8-ba7c-ea0c1a36117a" xlink:href="hum-20231231.xsd#hum_RepurchasePlanAugust2023Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:to="loc_hum_RepurchasePlanAugust2023Member_9634a6a3-f35f-4ad8-ba7c-ea0c1a36117a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A135PercentSeniorNotesDueFebruary2027Member_5c82cc67-2b61-46d9-b4f1-f2459a559aaa" xlink:href="hum-20231231.xsd#hum_A135PercentSeniorNotesDueFebruary2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_RepurchasePlanAugust2023Member_9634a6a3-f35f-4ad8-ba7c-ea0c1a36117a" xlink:to="loc_hum_A135PercentSeniorNotesDueFebruary2027Member_5c82cc67-2b61-46d9-b4f1-f2459a559aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3.95PercentSeniorNotesDueMarch2027Member_8457f946-928d-4224-8b70-bf6b068f0254" xlink:href="hum-20231231.xsd#hum_A3.95PercentSeniorNotesDueMarch2027Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_RepurchasePlanAugust2023Member_9634a6a3-f35f-4ad8-ba7c-ea0c1a36117a" xlink:to="loc_hum_A3.95PercentSeniorNotesDueMarch2027Member_8457f946-928d-4224-8b70-bf6b068f0254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3700PercentSeniorNotesDueMarch2029Member_53fcb329-4b7a-4857-8ae0-492a45fa8a04" xlink:href="hum-20231231.xsd#hum_A3700PercentSeniorNotesDueMarch2029Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_RepurchasePlanAugust2023Member_9634a6a3-f35f-4ad8-ba7c-ea0c1a36117a" xlink:to="loc_hum_A3700PercentSeniorNotesDueMarch2029Member_53fcb329-4b7a-4857-8ae0-492a45fa8a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3125PercentSeniorNotesDueAugust2029Member_d68e1348-6404-418a-9404-9efb6971e919" xlink:href="hum-20231231.xsd#hum_A3125PercentSeniorNotesDueAugust2029Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_RepurchasePlanAugust2023Member_9634a6a3-f35f-4ad8-ba7c-ea0c1a36117a" xlink:to="loc_hum_A3125PercentSeniorNotesDueAugust2029Member_d68e1348-6404-418a-9404-9efb6971e919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RepurchasePlanMarch2023Member_f1891886-b97e-48ab-9fc4-0874bd83c3db" xlink:href="hum-20231231.xsd#hum_RepurchasePlanMarch2023Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:to="loc_hum_RepurchasePlanMarch2023Member_f1891886-b97e-48ab-9fc4-0874bd83c3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A065PercentSeniorNotesDueAugust2023Member_7eac0a49-1e81-4453-b0f4-bff394dae539" xlink:href="hum-20231231.xsd#hum_A065PercentSeniorNotesDueAugust2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_RepurchasePlanMarch2023Member_f1891886-b97e-48ab-9fc4-0874bd83c3db" xlink:to="loc_hum_A065PercentSeniorNotesDueAugust2023Member_7eac0a49-1e81-4453-b0f4-bff394dae539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3850PercentSeniorNotesDueOctober2024Member_b43957af-925d-428d-9fa5-acf0ce70b593" xlink:href="hum-20231231.xsd#hum_A3850PercentSeniorNotesDueOctober2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_RepurchasePlanMarch2023Member_f1891886-b97e-48ab-9fc4-0874bd83c3db" xlink:to="loc_hum_A3850PercentSeniorNotesDueOctober2024Member_b43957af-925d-428d-9fa5-acf0ce70b593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A5.88PercentSeniorNotesDueMarch2033Member_1083ef93-1bb0-4857-9f2e-cd07d06c289e" xlink:href="hum-20231231.xsd#hum_A5.88PercentSeniorNotesDueMarch2033Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:to="loc_hum_A5.88PercentSeniorNotesDueMarch2033Member_1083ef93-1bb0-4857-9f2e-cd07d06c289e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A3.950PercentSeniorNotesMember_c43047ad-7ab4-4fca-9be9-0931f819dd5e" xlink:href="hum-20231231.xsd#hum_A3.950PercentSeniorNotesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2e536b73-5ff3-46b9-91da-86edb54044d8" xlink:to="loc_hum_A3.950PercentSeniorNotesMember_c43047ad-7ab4-4fca-9be9-0931f819dd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_11095ed3-22a3-4fe2-aa14-8e5e124e98d6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9d4cd2c7-36c5-461c-9aa9-9d6b7e8ebb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9d4cd2c7-36c5-461c-9aa9-9d6b7e8ebb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f8e7cdc1-7317-42c6-a340-03944db82322" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f8e7cdc1-7317-42c6-a340-03944db82322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ce217388-6098-4389-b5e7-fc9a87a93dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ce217388-6098-4389-b5e7-fc9a87a93dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_ee96ef75-af51-4254-a418-2bf998c7ef66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_ee96ef75-af51-4254-a418-2bf998c7ef66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_76e9b0c3-322d-4ea0-9377-21767ec25c34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_76e9b0c3-322d-4ea0-9377-21767ec25c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_44a1772d-5811-4685-a594-271a19a5868a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_44a1772d-5811-4685-a594-271a19a5868a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_5eb30f78-672e-4607-83fe-ebefef2a6991" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_5eb30f78-672e-4607-83fe-ebefef2a6991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LongTermDebtAggregateCarryingValueAdjustment_8241cb87-bfb6-4046-b7a5-e2b26d41933d" xlink:href="hum-20231231.xsd#hum_LongTermDebtAggregateCarryingValueAdjustment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_425ee70a-4b15-4162-ab07-15276d003080" xlink:to="loc_hum_LongTermDebtAggregateCarryingValueAdjustment_8241cb87-bfb6-4046-b7a5-e2b26d41933d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#DEBTRevolvingCreditAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a17984f0-592b-4f29-a587-548e527022ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_1a8d5dfe-4b4a-4595-9121-1e93c5472e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a17984f0-592b-4f29-a587-548e527022ae" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_1a8d5dfe-4b4a-4595-9121-1e93c5472e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_ed491fbc-df9b-44d8-94eb-5087321592b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1a8d5dfe-4b4a-4595-9121-1e93c5472e0a" xlink:to="loc_us-gaap_CreditFacilityAxis_ed491fbc-df9b-44d8-94eb-5087321592b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_bdef70ba-c8b1-4186-abb7-2c11620153c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_ed491fbc-df9b-44d8-94eb-5087321592b0" xlink:to="loc_us-gaap_CreditFacilityDomain_bdef70ba-c8b1-4186-abb7-2c11620153c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_154e7c32-a52a-4c3d-88c5-02471eb5edd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_bdef70ba-c8b1-4186-abb7-2c11620153c2" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_154e7c32-a52a-4c3d-88c5-02471eb5edd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_f34d0174-38fe-499c-99e0-f2cc238ff608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_bdef70ba-c8b1-4186-abb7-2c11620153c2" xlink:to="loc_us-gaap_LetterOfCreditMember_f34d0174-38fe-499c-99e0-f2cc238ff608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_524ff4e4-c25c-488b-ae09-ee543dbf808a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1a8d5dfe-4b4a-4595-9121-1e93c5472e0a" xlink:to="loc_us-gaap_DebtInstrumentAxis_524ff4e4-c25c-488b-ae09-ee543dbf808a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_26637f62-e82f-4728-958e-17352ffc8f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_524ff4e4-c25c-488b-ae09-ee543dbf808a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_26637f62-e82f-4728-958e-17352ffc8f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevolvingCreditAgreementJune2021FiveYearMember_4e026cb8-91df-4ad1-8da9-b1c06dc5f3b9" xlink:href="hum-20231231.xsd#hum_RevolvingCreditAgreementJune2021FiveYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26637f62-e82f-4728-958e-17352ffc8f2c" xlink:to="loc_hum_RevolvingCreditAgreementJune2021FiveYearMember_4e026cb8-91df-4ad1-8da9-b1c06dc5f3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevolvingCreditAgreementJune2021OneYearMember_a79ab679-9087-4eff-a5ff-7ecb1064fabc" xlink:href="hum-20231231.xsd#hum_RevolvingCreditAgreementJune2021OneYearMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26637f62-e82f-4728-958e-17352ffc8f2c" xlink:to="loc_hum_RevolvingCreditAgreementJune2021OneYearMember_a79ab679-9087-4eff-a5ff-7ecb1064fabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevolvingCreditAgreementJune2023FiveYearMember_1ac03cf8-0fd8-4e92-8f9e-1c6f00e2f2f6" xlink:href="hum-20231231.xsd#hum_RevolvingCreditAgreementJune2023FiveYearMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26637f62-e82f-4728-958e-17352ffc8f2c" xlink:to="loc_hum_RevolvingCreditAgreementJune2023FiveYearMember_1ac03cf8-0fd8-4e92-8f9e-1c6f00e2f2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevolvingCreditAgreementJune2023OneYearMember_19a096c0-03fc-49d3-a7ec-105933841fd2" xlink:href="hum-20231231.xsd#hum_RevolvingCreditAgreementJune2023OneYearMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26637f62-e82f-4728-958e-17352ffc8f2c" xlink:to="loc_hum_RevolvingCreditAgreementJune2023OneYearMember_19a096c0-03fc-49d3-a7ec-105933841fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_RevolvingCreditAgreementJune2022OneYearMember_443e5233-678d-415b-a7c4-1765c8e6b135" xlink:href="hum-20231231.xsd#hum_RevolvingCreditAgreementJune2022OneYearMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26637f62-e82f-4728-958e-17352ffc8f2c" xlink:to="loc_hum_RevolvingCreditAgreementJune2022OneYearMember_443e5233-678d-415b-a7c4-1765c8e6b135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8549f5b9-688e-451c-9398-7ec1030830b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1a8d5dfe-4b4a-4595-9121-1e93c5472e0a" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8549f5b9-688e-451c-9398-7ec1030830b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_417010fe-e8a7-4246-8d9e-49dc420312b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8549f5b9-688e-451c-9398-7ec1030830b1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_417010fe-e8a7-4246-8d9e-49dc420312b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_c3783200-9664-4a46-bb7b-281b67000f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_417010fe-e8a7-4246-8d9e-49dc420312b6" xlink:to="loc_us-gaap_LoansPayableMember_c3783200-9664-4a46-bb7b-281b67000f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_edba5cf5-cce9-488d-9513-895b1f9719f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1a8d5dfe-4b4a-4595-9121-1e93c5472e0a" xlink:to="loc_us-gaap_VariableRateAxis_edba5cf5-cce9-488d-9513-895b1f9719f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0f75a4fa-5f00-42f0-93cb-9c542dca26cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_edba5cf5-cce9-488d-9513-895b1f9719f9" xlink:to="loc_us-gaap_VariableRateDomain_0f75a4fa-5f00-42f0-93cb-9c542dca26cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SecuredOvernightFinancingRateSOFRMember_27acd031-0437-4104-b4b4-c30ad3f48a77" xlink:href="hum-20231231.xsd#hum_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0f75a4fa-5f00-42f0-93cb-9c542dca26cc" xlink:to="loc_hum_SecuredOvernightFinancingRateSOFRMember_27acd031-0437-4104-b4b4-c30ad3f48a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3d931ae5-3a8e-4ce9-90a3-98a28aa9964f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1a8d5dfe-4b4a-4595-9121-1e93c5472e0a" xlink:to="loc_srt_RangeAxis_3d931ae5-3a8e-4ce9-90a3-98a28aa9964f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_165c2cbb-9f08-43db-b0b5-5be24a0824c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3d931ae5-3a8e-4ce9-90a3-98a28aa9964f" xlink:to="loc_srt_RangeMember_165c2cbb-9f08-43db-b0b5-5be24a0824c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c281a1f9-1598-4254-8f4d-b87a936f473e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_165c2cbb-9f08-43db-b0b5-5be24a0824c0" xlink:to="loc_srt_MinimumMember_c281a1f9-1598-4254-8f4d-b87a936f473e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bdd11c53-b692-4e31-b04f-feb60ae4a280" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_165c2cbb-9f08-43db-b0b5-5be24a0824c0" xlink:to="loc_srt_MaximumMember_bdd11c53-b692-4e31-b04f-feb60ae4a280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1a8d5dfe-4b4a-4595-9121-1e93c5472e0a" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_1ab1e68a-ce00-4898-b853-3f76800d7d62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_us-gaap_DebtInstrumentTerm_1ab1e68a-ce00-4898-b853-3f76800d7d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_45fe1c6b-b095-4fe2-acba-a3c24dd78d32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_45fe1c6b-b095-4fe2-acba-a3c24dd78d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9cd16edd-cbbe-4f0c-8a66-32f670a8896f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9cd16edd-cbbe-4f0c-8a66-32f670a8896f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7b36c005-af3c-4c28-aee5-e602c3168044" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7b36c005-af3c-4c28-aee5-e602c3168044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum_e6ec3e52-efa6-4b3a-9340-ef0945af0ca1" xlink:href="hum-20231231.xsd#hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum_e6ec3e52-efa6-4b3a-9340-ef0945af0ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual_964e74ef-f0fb-41d7-84a9-ff96eaebc03a" xlink:href="hum-20231231.xsd#hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual_964e74ef-f0fb-41d7-84a9-ff96eaebc03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LineOfCreditFacilityUncommittedIncrementalCapacity_10bce201-dcc3-496c-aa6a-43b32131d4ec" xlink:href="hum-20231231.xsd#hum_LineOfCreditFacilityUncommittedIncrementalCapacity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_hum_LineOfCreditFacilityUncommittedIncrementalCapacity_10bce201-dcc3-496c-aa6a-43b32131d4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity_a7bbf84f-243b-481c-a35a-aa027d3f03fa" xlink:href="hum-20231231.xsd#hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity_a7bbf84f-243b-481c-a35a-aa027d3f03fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_4d82144a-aedb-4551-99bd-69df541e3d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_us-gaap_LinesOfCreditCurrent_4d82144a-aedb-4551-99bd-69df541e3d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_b5e9f8b0-86eb-4adc-9baa-5f42a988ca7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_42d7fe09-f165-4b0b-92d8-e3e027a8cb7c" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_b5e9f8b0-86eb-4adc-9baa-5f42a988ca7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#DEBTCommercialPaperandOtherShortTermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f1889b9c-c813-4cf1-9338-c1360c1cd6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_3c7d307b-362c-4c06-974c-69c03ac69bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f1889b9c-c813-4cf1-9338-c1360c1cd6fc" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_3c7d307b-362c-4c06-974c-69c03ac69bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_76d0ffa2-836d-4f2d-b81d-b7cb5e351fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_3c7d307b-362c-4c06-974c-69c03ac69bbe" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_76d0ffa2-836d-4f2d-b81d-b7cb5e351fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_16cd56e9-b3f7-4d97-b106-735848bbfbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_76d0ffa2-836d-4f2d-b81d-b7cb5e351fa4" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_16cd56e9-b3f7-4d97-b106-735848bbfbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_63666180-57c8-484c-9ba6-e563e95c1292" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_16cd56e9-b3f7-4d97-b106-735848bbfbd2" xlink:to="loc_us-gaap_CommercialPaperMember_63666180-57c8-484c-9ba6-e563e95c1292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalHomeLoanBankAdvancesMember_5eeaf3be-567b-4103-9203-e003530d3ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalHomeLoanBankAdvancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_16cd56e9-b3f7-4d97-b106-735848bbfbd2" xlink:to="loc_us-gaap_FederalHomeLoanBankAdvancesMember_5eeaf3be-567b-4103-9203-e003530d3ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_852de6c5-db79-49fe-91cf-7c2e45e48aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_3c7d307b-362c-4c06-974c-69c03ac69bbe" xlink:to="loc_us-gaap_ShortTermDebtLineItems_852de6c5-db79-49fe-91cf-7c2e45e48aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod_eac97c9d-d95f-4caf-8f21-ee51d9236b97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_852de6c5-db79-49fe-91cf-7c2e45e48aa8" xlink:to="loc_us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod_eac97c9d-d95f-4caf-8f21-ee51d9236b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_f573fb30-55f4-4cdb-8609-c73809564798" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_852de6c5-db79-49fe-91cf-7c2e45e48aa8" xlink:to="loc_us-gaap_ShortTermBorrowings_f573fb30-55f4-4cdb-8609-c73809564798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_e2566b28-274c-459e-86aa-00eb5b2a5318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_852de6c5-db79-49fe-91cf-7c2e45e48aa8" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_e2566b28-274c-459e-86aa-00eb5b2a5318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_0648f419-7a5c-4673-bf46-e3f2476fe799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_852de6c5-db79-49fe-91cf-7c2e45e48aa8" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_0648f419-7a5c-4673-bf46-e3f2476fe799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_0a2b6f8d-7df4-4674-96dc-178b4636c3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_852de6c5-db79-49fe-91cf-7c2e45e48aa8" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_0a2b6f8d-7df4-4674-96dc-178b4636c3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EMPLOYEEBENEFITPLANSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a4fe1cdf-da30-4325-84d3-46b292787d76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eec6b747-bf7f-44ae-af2b-0cdf843c778b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a4fe1cdf-da30-4325-84d3-46b292787d76" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eec6b747-bf7f-44ae-af2b-0cdf843c778b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_26e7481a-54ed-4c95-83c6-559f2acea708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eec6b747-bf7f-44ae-af2b-0cdf843c778b" xlink:to="loc_us-gaap_PlanNameAxis_26e7481a-54ed-4c95-83c6-559f2acea708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_74d34329-ded1-4a23-bacd-fe4c706bfa82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_26e7481a-54ed-4c95-83c6-559f2acea708" xlink:to="loc_us-gaap_PlanNameDomain_74d34329-ded1-4a23-bacd-fe4c706bfa82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A2011PlanMember_92887407-0dc4-4ee2-b9b0-50cfd21bfb5f" xlink:href="hum-20231231.xsd#hum_A2011PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_74d34329-ded1-4a23-bacd-fe4c706bfa82" xlink:to="loc_hum_A2011PlanMember_92887407-0dc4-4ee2-b9b0-50cfd21bfb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A2019PlanMember_746bfa5c-cfc4-4828-a719-88b52f04f77e" xlink:href="hum-20231231.xsd#hum_A2019PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_74d34329-ded1-4a23-bacd-fe4c706bfa82" xlink:to="loc_hum_A2019PlanMember_746bfa5c-cfc4-4828-a719-88b52f04f77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c781dc11-a304-4fca-b547-543a9f42e618" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eec6b747-bf7f-44ae-af2b-0cdf843c778b" xlink:to="loc_us-gaap_AwardTypeAxis_c781dc11-a304-4fca-b547-543a9f42e618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85a33c89-4c5b-4997-a957-b57e22dae402" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c781dc11-a304-4fca-b547-543a9f42e618" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85a33c89-4c5b-4997-a957-b57e22dae402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b795707e-231b-4c71-947e-6e8bbfff92fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85a33c89-4c5b-4997-a957-b57e22dae402" xlink:to="loc_us-gaap_RestrictedStockMember_b795707e-231b-4c71-947e-6e8bbfff92fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_15c2ac2b-4391-462a-adcc-ce29975fad2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_85a33c89-4c5b-4997-a957-b57e22dae402" xlink:to="loc_us-gaap_EmployeeStockOptionMember_15c2ac2b-4391-462a-adcc-ce29975fad2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1cb9fd1b-ffce-4ebe-aa8c-e0a726efccb9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eec6b747-bf7f-44ae-af2b-0cdf843c778b" xlink:to="loc_srt_RangeAxis_1cb9fd1b-ffce-4ebe-aa8c-e0a726efccb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cf7f6039-d1b2-43c9-8a11-28a959c414c3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1cb9fd1b-ffce-4ebe-aa8c-e0a726efccb9" xlink:to="loc_srt_RangeMember_cf7f6039-d1b2-43c9-8a11-28a959c414c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fa811842-070c-4b71-a51b-e6a6ee622dcf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cf7f6039-d1b2-43c9-8a11-28a959c414c3" xlink:to="loc_srt_MinimumMember_fa811842-070c-4b71-a51b-e6a6ee622dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_546afdf0-6acd-4213-8934-9b500ac3c969" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cf7f6039-d1b2-43c9-8a11-28a959c414c3" xlink:to="loc_srt_MaximumMember_546afdf0-6acd-4213-8934-9b500ac3c969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_eec6b747-bf7f-44ae-af2b-0cdf843c778b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_0278e2df-9da8-421a-a16d-cad1f00e7f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_0278e2df-9da8-421a-a16d-cad1f00e7f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CompanyCommonStockClosingSharePrice_a4c37262-9e17-4e69-bd87-6ca2e83e959f" xlink:href="hum-20231231.xsd#hum_CompanyCommonStockClosingSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_CompanyCommonStockClosingSharePrice_a4c37262-9e17-4e69-bd87-6ca2e83e959f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock_e1f47a16-be13-43b7-bf5d-9d5468f3ada6" xlink:href="hum-20231231.xsd#hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock_e1f47a16-be13-43b7-bf5d-9d5468f3ada6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares_1a3dd60f-eafd-4e97-bc9e-72c9deee693e" xlink:href="hum-20231231.xsd#hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares_1a3dd60f-eafd-4e97-bc9e-72c9deee693e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding_54126ebc-f300-40ae-b5d2-9e93e19b878e" xlink:href="hum-20231231.xsd#hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding_54126ebc-f300-40ae-b5d2-9e93e19b878e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance_3707b818-4134-4a00-a868-96efe2031129" xlink:href="hum-20231231.xsd#hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance_3707b818-4134-4a00-a868-96efe2031129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod_f9ca8f42-944e-420b-8e43-c506b1acdcd3" xlink:href="hum-20231231.xsd#hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod_f9ca8f42-944e-420b-8e43-c506b1acdcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram_164c05e6-9f7d-4732-a3ac-7d309c59febd" xlink:href="hum-20231231.xsd#hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram_164c05e6-9f7d-4732-a3ac-7d309c59febd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram_5aaa1d24-77b0-4c13-9561-be2e395f140b" xlink:href="hum-20231231.xsd#hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram_5aaa1d24-77b0-4c13-9561-be2e395f140b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram_cd25a7b9-ddc6-4cbd-9da6-fc562932d548" xlink:href="hum-20231231.xsd#hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram_cd25a7b9-ddc6-4cbd-9da6-fc562932d548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting_29ce670c-ed8a-46db-a1d7-724874b5e174" xlink:href="hum-20231231.xsd#hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting_29ce670c-ed8a-46db-a1d7-724874b5e174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_12f69eaa-7381-4c8f-9e52-fa98190a9136" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_12f69eaa-7381-4c8f-9e52-fa98190a9136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_503a5a87-ce76-40dc-8f94-08a633c9a0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_503a5a87-ce76-40dc-8f94-08a633c9a0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f81177ed-3c03-4355-96ec-8f567bc5e3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f81177ed-3c03-4355-96ec-8f567bc5e3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7ff86303-2f5f-4058-b580-9e24dbeaa8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7ff86303-2f5f-4058-b580-9e24dbeaa8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_465c797c-c3de-4ac2-a447-b0862d40657e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_465c797c-c3de-4ac2-a447-b0862d40657e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions_05ab306a-9c73-4f51-96cb-842c56f79a6c" xlink:href="hum-20231231.xsd#hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions_05ab306a-9c73-4f51-96cb-842c56f79a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7768c622-fffd-4726-8ca7-b31331f55acb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_7768c622-fffd-4726-8ca7-b31331f55acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5e7dfc88-fcaa-429e-a4d5-4d9f23b3c107" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5e7dfc88-fcaa-429e-a4d5-4d9f23b3c107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fdb95739-2ac5-4041-809a-56d2f7c33c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_fdb95739-2ac5-4041-809a-56d2f7c33c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bdb165f8-7c7a-4161-b5ef-7ead4e898ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_bdb165f8-7c7a-4161-b5ef-7ead4e898ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_81d23d6a-94e7-4902-a0f5-5a477d06a231" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_81d23d6a-94e7-4902-a0f5-5a477d06a231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_81d85a6f-b636-4b47-bae3-e80c2a609c20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_81d85a6f-b636-4b47-bae3-e80c2a609c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_131ea365-a82f-498f-9ea2-24fd292c4b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_131ea365-a82f-498f-9ea2-24fd292c4b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_48409d52-53f4-453d-9ae1-21f216c99d88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_48409d52-53f4-453d-9ae1-21f216c99d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c0b70724-8b13-4b40-b38a-fb5dd37005ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c0b70724-8b13-4b40-b38a-fb5dd37005ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_2576b4e2-9488-4458-820a-ed2e4c232d02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_2576b4e2-9488-4458-820a-ed2e4c232d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b46729c5-0976-4dba-bf93-7edc79c1c4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bedb6042-cdcf-4988-a8a0-ee5e13219954" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_b46729c5-0976-4dba-bf93-7edc79c1c4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1e08b60a-54b8-40bf-a774-dfaa0f17c668" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b965fa56-cca8-40b0-86c4-e7a4236ae58e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1e08b60a-54b8-40bf-a774-dfaa0f17c668" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b965fa56-cca8-40b0-86c4-e7a4236ae58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f5dbb8dd-147d-4324-8788-0b2e923e31f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b965fa56-cca8-40b0-86c4-e7a4236ae58e" xlink:to="loc_us-gaap_AwardTypeAxis_f5dbb8dd-147d-4324-8788-0b2e923e31f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382e3f33-7d68-45eb-a711-fb58a2305d39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f5dbb8dd-147d-4324-8788-0b2e923e31f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382e3f33-7d68-45eb-a711-fb58a2305d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_04e0a87f-5f91-4c14-8c10-59c5ff335bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382e3f33-7d68-45eb-a711-fb58a2305d39" xlink:to="loc_us-gaap_RestrictedStockMember_04e0a87f-5f91-4c14-8c10-59c5ff335bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2c76b351-4da0-4a61-9d1c-2da39250443a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_382e3f33-7d68-45eb-a711-fb58a2305d39" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2c76b351-4da0-4a61-9d1c-2da39250443a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6c4f3de0-6389-4d79-aba1-0a2472f7340c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b965fa56-cca8-40b0-86c4-e7a4236ae58e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6c4f3de0-6389-4d79-aba1-0a2472f7340c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a3bbe442-dd43-474c-84b0-778043eb05aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6c4f3de0-6389-4d79-aba1-0a2472f7340c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a3bbe442-dd43-474c-84b0-778043eb05aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_99d9eb19-6b85-4fdf-97df-b48f7c83af15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6c4f3de0-6389-4d79-aba1-0a2472f7340c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_99d9eb19-6b85-4fdf-97df-b48f7c83af15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4d53043f-2566-471e-a76c-f84819437c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6c4f3de0-6389-4d79-aba1-0a2472f7340c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_4d53043f-2566-471e-a76c-f84819437c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7fbebc0d-dddb-4c8b-9491-dbd62f13510a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d43081a-df9e-4fd0-b0da-607a8bdacf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7fbebc0d-dddb-4c8b-9491-dbd62f13510a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d43081a-df9e-4fd0-b0da-607a8bdacf7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_99961227-4bdd-4827-aaef-d850060ee380" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d43081a-df9e-4fd0-b0da-607a8bdacf7a" xlink:to="loc_us-gaap_AwardTypeAxis_99961227-4bdd-4827-aaef-d850060ee380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e18ca81-3020-4752-bcb4-725924c4d3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_99961227-4bdd-4827-aaef-d850060ee380" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e18ca81-3020-4752-bcb4-725924c4d3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_57eac0ee-237a-45ad-8064-e4c5415ac76f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3e18ca81-3020-4752-bcb4-725924c4d3a9" xlink:to="loc_us-gaap_RestrictedStockMember_57eac0ee-237a-45ad-8064-e4c5415ac76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41b43629-c570-440f-86b7-80d89110581e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0d43081a-df9e-4fd0-b0da-607a8bdacf7a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41b43629-c570-440f-86b7-80d89110581e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_80ced98d-6aed-42ff-ba88-700d15d6ee8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41b43629-c570-440f-86b7-80d89110581e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_80ced98d-6aed-42ff-ba88-700d15d6ee8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_49eb5d5e-8ec6-4561-ac15-73a714df919b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_80ced98d-6aed-42ff-ba88-700d15d6ee8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_49eb5d5e-8ec6-4561-ac15-73a714df919b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d473fe93-d213-4f32-8d9b-f10826526da9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_80ced98d-6aed-42ff-ba88-700d15d6ee8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_d473fe93-d213-4f32-8d9b-f10826526da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e8f34106-87c3-4457-86ce-97efaca1fbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_80ced98d-6aed-42ff-ba88-700d15d6ee8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e8f34106-87c3-4457-86ce-97efaca1fbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_463cab28-d75c-4b62-90a6-55abaf58a1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_80ced98d-6aed-42ff-ba88-700d15d6ee8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_463cab28-d75c-4b62-90a6-55abaf58a1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7b82b2aa-c122-4c54-8e93-4890fd025fea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_80ced98d-6aed-42ff-ba88-700d15d6ee8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7b82b2aa-c122-4c54-8e93-4890fd025fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03581ed2-4c9b-44ba-a7a0-e3198362ff90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_41b43629-c570-440f-86b7-80d89110581e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03581ed2-4c9b-44ba-a7a0-e3198362ff90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a0df52f0-efa2-4c7d-921b-b4b9031b17b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03581ed2-4c9b-44ba-a7a0-e3198362ff90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a0df52f0-efa2-4c7d-921b-b4b9031b17b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_df03a14d-4158-4a68-9f41-d0b544520554" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03581ed2-4c9b-44ba-a7a0-e3198362ff90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_df03a14d-4158-4a68-9f41-d0b544520554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_603c15f2-fc94-451b-ab55-02973b48d356" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03581ed2-4c9b-44ba-a7a0-e3198362ff90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_603c15f2-fc94-451b-ab55-02973b48d356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0bb6eba7-312f-43c8-a3c2-3d3fb6daf95e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03581ed2-4c9b-44ba-a7a0-e3198362ff90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0bb6eba7-312f-43c8-a3c2-3d3fb6daf95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f2fd6290-3bd2-49e9-91d7-0d58adafce33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03581ed2-4c9b-44ba-a7a0-e3198362ff90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f2fd6290-3bd2-49e9-91d7-0d58adafce33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8264de8c-7a27-46dc-9e8a-732d85336373" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_194df487-41bf-4820-884f-8a6d005c9093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8264de8c-7a27-46dc-9e8a-732d85336373" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_194df487-41bf-4820-884f-8a6d005c9093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bd87448c-d24d-48c0-b40a-f70b640e559b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_194df487-41bf-4820-884f-8a6d005c9093" xlink:to="loc_us-gaap_AwardTypeAxis_bd87448c-d24d-48c0-b40a-f70b640e559b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20238bec-0367-4982-b264-06a580aa70bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bd87448c-d24d-48c0-b40a-f70b640e559b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20238bec-0367-4982-b264-06a580aa70bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1ded3dff-cfde-4003-85ba-4c200e6b76cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_20238bec-0367-4982-b264-06a580aa70bc" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1ded3dff-cfde-4003-85ba-4c200e6b76cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81e3d0c2-3760-42c8-a480-b34d07c9d6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_194df487-41bf-4820-884f-8a6d005c9093" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81e3d0c2-3760-42c8-a480-b34d07c9d6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c5df7591-f1cf-4caf-b2f4-c1fce89a53f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81e3d0c2-3760-42c8-a480-b34d07c9d6a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c5df7591-f1cf-4caf-b2f4-c1fce89a53f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0d0a4ff3-f56c-4e56-b714-31651317ac61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81e3d0c2-3760-42c8-a480-b34d07c9d6a7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0d0a4ff3-f56c-4e56-b714-31651317ac61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2f5894fe-2507-4247-b752-b28a592e1ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81e3d0c2-3760-42c8-a480-b34d07c9d6a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2f5894fe-2507-4247-b752-b28a592e1ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cb80dfcc-0aa8-4236-b8e0-69d9d95367d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81e3d0c2-3760-42c8-a480-b34d07c9d6a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_cb80dfcc-0aa8-4236-b8e0-69d9d95367d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9e5e7e6b-6669-4077-9344-b3cf53c6ed2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_81e3d0c2-3760-42c8-a480-b34d07c9d6a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9e5e7e6b-6669-4077-9344-b3cf53c6ed2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EMPLOYEEBENEFITPLANSOptionPlansActivityDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f605c2f2-3efd-4dd6-9547-dd87a6ad1cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_25ee471b-af2f-4bb2-a92a-3885d982ebe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f605c2f2-3efd-4dd6-9547-dd87a6ad1cf1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_25ee471b-af2f-4bb2-a92a-3885d982ebe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d549955f-d4d0-4797-815b-a6b047cd9a12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_25ee471b-af2f-4bb2-a92a-3885d982ebe4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d549955f-d4d0-4797-815b-a6b047cd9a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_501782cf-cb90-4fd5-89d9-fc790e9e0059" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_25ee471b-af2f-4bb2-a92a-3885d982ebe4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_501782cf-cb90-4fd5-89d9-fc790e9e0059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9fa78d8-6aae-4e1c-bace-a5215a083192" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_25ee471b-af2f-4bb2-a92a-3885d982ebe4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c9fa78d8-6aae-4e1c-bace-a5215a083192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_002ea4bf-72d5-4f1e-97b6-fe3f72afd922" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_25ee471b-af2f-4bb2-a92a-3885d982ebe4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_002ea4bf-72d5-4f1e-97b6-fe3f72afd922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9d9a26b6-f347-4078-b827-ab3cb5527cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_25ee471b-af2f-4bb2-a92a-3885d982ebe4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9d9a26b6-f347-4078-b827-ab3cb5527cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e8f93fc8-c3b3-4294-a1c6-a43a15ffbf4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f605c2f2-3efd-4dd6-9547-dd87a6ad1cf1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e8f93fc8-c3b3-4294-a1c6-a43a15ffbf4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_11bbe7a6-871a-4172-9f34-98c1137cb70c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f605c2f2-3efd-4dd6-9547-dd87a6ad1cf1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_11bbe7a6-871a-4172-9f34-98c1137cb70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_88c36d2a-9eb3-47c9-a10b-adcffbb3916c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_11bbe7a6-871a-4172-9f34-98c1137cb70c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_88c36d2a-9eb3-47c9-a10b-adcffbb3916c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c0a913a5-aedd-4930-b90d-e45e4d015c50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_11bbe7a6-871a-4172-9f34-98c1137cb70c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c0a913a5-aedd-4930-b90d-e45e4d015c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f7f6aec6-0c5f-41c8-9d1e-825ae9937d35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_11bbe7a6-871a-4172-9f34-98c1137cb70c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f7f6aec6-0c5f-41c8-9d1e-825ae9937d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e7caccaa-87e0-40ce-8cea-f8c660f28fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_11bbe7a6-871a-4172-9f34-98c1137cb70c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e7caccaa-87e0-40ce-8cea-f8c660f28fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18a29f9d-3d17-449a-a065-5e3012d3f0df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_11bbe7a6-871a-4172-9f34-98c1137cb70c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18a29f9d-3d17-449a-a065-5e3012d3f0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_12be725f-ef67-4422-a43f-9c53d2211f70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f605c2f2-3efd-4dd6-9547-dd87a6ad1cf1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_12be725f-ef67-4422-a43f-9c53d2211f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#EARNINGSPERCOMMONSHARECOMPUTATIONDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1415b517-564a-4b1d-b03f-d8dbe7db8b39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_bbc305be-6529-4b7a-909f-f858361d7d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1415b517-564a-4b1d-b03f-d8dbe7db8b39" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_bbc305be-6529-4b7a-909f-f858361d7d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f0983805-2395-4880-91af-4222fea9c0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_bbc305be-6529-4b7a-909f-f858361d7d0a" xlink:to="loc_us-gaap_AwardTypeAxis_f0983805-2395-4880-91af-4222fea9c0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d63caad7-d112-43c9-a661-33ee2a5b557a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f0983805-2395-4880-91af-4222fea9c0e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d63caad7-d112-43c9-a661-33ee2a5b557a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_94786675-30d7-4bbd-b720-502069ecd685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d63caad7-d112-43c9-a661-33ee2a5b557a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_94786675-30d7-4bbd-b720-502069ecd685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5cfd7afb-8a3b-491f-8f2b-0c080ff59a04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d63caad7-d112-43c9-a661-33ee2a5b557a" xlink:to="loc_us-gaap_RestrictedStockMember_5cfd7afb-8a3b-491f-8f2b-0c080ff59a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_bbc305be-6529-4b7a-909f-f858361d7d0a" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3cacedec-4f37-4322-aa25-8606e38be6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:to="loc_us-gaap_NetIncomeLoss_3cacedec-4f37-4322-aa25-8606e38be6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e99991b7-f3cb-4d8b-bd1d-e53db598b199" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e99991b7-f3cb-4d8b-bd1d-e53db598b199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_55c686fc-5d58-4dd3-83da-73ecf32b51d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_55c686fc-5d58-4dd3-83da-73ecf32b51d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0d227fbd-030d-4aa5-ad78-0b5dd073cb31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0d227fbd-030d-4aa5-ad78-0b5dd073cb31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cc275f8a-248f-4d80-b306-d1a13a2e4ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:to="loc_us-gaap_EarningsPerShareBasic_cc275f8a-248f-4d80-b306-d1a13a2e4ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_c8fef28c-9aa5-4413-8c8d-dc1e668f7f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:to="loc_us-gaap_EarningsPerShareDiluted_c8fef28c-9aa5-4413-8c8d-dc1e668f7f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8f10fc7e-1a30-4fcf-948e-b9bb431623c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_b4e2baa7-de37-4a7f-8152-fa18fee3e143" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8f10fc7e-1a30-4fcf-948e-b9bb431623c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/STOCKHOLDERSEQUITYDividendPaymentsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#STOCKHOLDERSEQUITYDividendPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/STOCKHOLDERSEQUITYDividendPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2509700e-eace-4f44-91af-b23ddfd66a24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_e777041f-25c0-4d69-b855-0dcc1274584b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2509700e-eace-4f44-91af-b23ddfd66a24" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_e777041f-25c0-4d69-b855-0dcc1274584b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_39bcca24-c27b-4f6d-98c3-acc02914c3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2509700e-eace-4f44-91af-b23ddfd66a24" xlink:to="loc_us-gaap_Dividends_39bcca24-c27b-4f6d-98c3-acc02914c3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_94a9ef8d-3f01-4087-8bec-08614fe6f837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_2c6f3b71-7f86-4ea9-a41f-aa22c4907e50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_94a9ef8d-3f01-4087-8bec-08614fe6f837" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_2c6f3b71-7f86-4ea9-a41f-aa22c4907e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_369ffa12-72ca-4d65-a298-e2efcbd2c993" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_2c6f3b71-7f86-4ea9-a41f-aa22c4907e50" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_369ffa12-72ca-4d65-a298-e2efcbd2c993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_f6b0745e-ca27-4e45-9675-1793318bfadb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateAxis_369ffa12-72ca-4d65-a298-e2efcbd2c993" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_f6b0745e-ca27-4e45-9675-1793318bfadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_December2020AcceleratedShareRepurchaseAgreementMember_951a7c69-8257-47f9-86b1-120fbdb27746" xlink:href="hum-20231231.xsd#hum_December2020AcceleratedShareRepurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_f6b0745e-ca27-4e45-9675-1793318bfadb" xlink:to="loc_hum_December2020AcceleratedShareRepurchaseAgreementMember_951a7c69-8257-47f9-86b1-120fbdb27746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_January2022AcceleratedShareRepurchaseAgreementMember_723510a7-3f8e-494b-af0a-4150163732c8" xlink:href="hum-20231231.xsd#hum_January2022AcceleratedShareRepurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_f6b0745e-ca27-4e45-9675-1793318bfadb" xlink:to="loc_hum_January2022AcceleratedShareRepurchaseAgreementMember_723510a7-3f8e-494b-af0a-4150163732c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_November2022AcceleratedShareRepurchaseProgramMember_24befae7-060c-4dac-932d-554bc34d945d" xlink:href="hum-20231231.xsd#hum_November2022AcceleratedShareRepurchaseProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesDateDomain_f6b0745e-ca27-4e45-9675-1793318bfadb" xlink:to="loc_hum_November2022AcceleratedShareRepurchaseProgramMember_24befae7-060c-4dac-932d-554bc34d945d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8c8dedd4-a069-4562-8370-9cb73555e2c9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_2c6f3b71-7f86-4ea9-a41f-aa22c4907e50" xlink:to="loc_srt_CounterpartyNameAxis_8c8dedd4-a069-4562-8370-9cb73555e2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd454951-74a8-4fa3-94d9-3c27d5016f6a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8c8dedd4-a069-4562-8370-9cb73555e2c9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd454951-74a8-4fa3-94d9-3c27d5016f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CitibankNAMember_029157fc-7a29-4b4e-9fab-6b28bc0a5859" xlink:href="hum-20231231.xsd#hum_CitibankNAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd454951-74a8-4fa3-94d9-3c27d5016f6a" xlink:to="loc_hum_CitibankNAMember_029157fc-7a29-4b4e-9fab-6b28bc0a5859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_JPMorganChaseBankMember_1d8bff28-0f9a-4345-b2f0-98a8ab714679" xlink:href="hum-20231231.xsd#hum_JPMorganChaseBankMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd454951-74a8-4fa3-94d9-3c27d5016f6a" xlink:to="loc_hum_JPMorganChaseBankMember_1d8bff28-0f9a-4345-b2f0-98a8ab714679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MizuhoMarketsAmericasLLCMember_31d56e4a-de7e-45bd-8b43-c444e2b62578" xlink:href="hum-20231231.xsd#hum_MizuhoMarketsAmericasLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd454951-74a8-4fa3-94d9-3c27d5016f6a" xlink:to="loc_hum_MizuhoMarketsAmericasLLCMember_31d56e4a-de7e-45bd-8b43-c444e2b62578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_WellsFargoBankMember_2291afb8-a276-452c-a703-ab32a12eb12f" xlink:href="hum-20231231.xsd#hum_WellsFargoBankMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd454951-74a8-4fa3-94d9-3c27d5016f6a" xlink:to="loc_hum_WellsFargoBankMember_2291afb8-a276-452c-a703-ab32a12eb12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GoldmanSachsCoLLCMember_ea8b9862-b82a-49f7-9cef-fcfd7678e6b4" xlink:href="hum-20231231.xsd#hum_GoldmanSachsCoLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fd454951-74a8-4fa3-94d9-3c27d5016f6a" xlink:to="loc_hum_GoldmanSachsCoLLCMember_ea8b9862-b82a-49f7-9cef-fcfd7678e6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_ba0d92bb-1d53-49c7-a521-5147dd143715" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_2c6f3b71-7f86-4ea9-a41f-aa22c4907e50" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_ba0d92bb-1d53-49c7-a521-5147dd143715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_b575d8e0-f7a4-431c-9362-8f139ab33111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_ba0d92bb-1d53-49c7-a521-5147dd143715" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_b575d8e0-f7a4-431c-9362-8f139ab33111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A2021ShareRepurchaseAuthorizationMember_7da1df75-383d-4498-8e16-3bee9cf1a67e" xlink:href="hum-20231231.xsd#hum_A2021ShareRepurchaseAuthorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b575d8e0-f7a4-431c-9362-8f139ab33111" xlink:to="loc_hum_A2021ShareRepurchaseAuthorizationMember_7da1df75-383d-4498-8e16-3bee9cf1a67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A2023ShareRepurchaseAuthorizationMember_00dbedd3-3407-4982-832e-06cc24939835" xlink:href="hum-20231231.xsd#hum_A2023ShareRepurchaseAuthorizationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b575d8e0-f7a4-431c-9362-8f139ab33111" xlink:to="loc_hum_A2023ShareRepurchaseAuthorizationMember_00dbedd3-3407-4982-832e-06cc24939835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_A2024ShareRepurchaseAuthorizationMember_57d6375c-b640-4b39-bfb9-bd736282f8df" xlink:href="hum-20231231.xsd#hum_A2024ShareRepurchaseAuthorizationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_b575d8e0-f7a4-431c-9362-8f139ab33111" xlink:to="loc_hum_A2024ShareRepurchaseAuthorizationMember_57d6375c-b640-4b39-bfb9-bd736282f8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_676ff7cf-172f-4196-8b60-630841390cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_2c6f3b71-7f86-4ea9-a41f-aa22c4907e50" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_676ff7cf-172f-4196-8b60-630841390cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b2b3cf44-cbd7-4e3a-ae6d-c331347700ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_676ff7cf-172f-4196-8b60-630841390cb9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b2b3cf44-cbd7-4e3a-ae6d-c331347700ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ad0aa68c-f88f-4d9d-8856-e7941087ea2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_b2b3cf44-cbd7-4e3a-ae6d-c331347700ea" xlink:to="loc_us-gaap_SubsequentEventMember_ad0aa68c-f88f-4d9d-8856-e7941087ea2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_4b9def43-6cea-4d67-91ea-5a0975901373" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_2c6f3b71-7f86-4ea9-a41f-aa22c4907e50" xlink:to="loc_srt_StatementScenarioAxis_4b9def43-6cea-4d67-91ea-5a0975901373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ca96930d-db54-4729-8342-ed0812ff921a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_4b9def43-6cea-4d67-91ea-5a0975901373" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ca96930d-db54-4729-8342-ed0812ff921a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d3b4544e-5af3-46ff-8f63-aefd67ee66a6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_ca96930d-db54-4729-8342-ed0812ff921a" xlink:to="loc_srt_ScenarioForecastMember_d3b4544e-5af3-46ff-8f63-aefd67ee66a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_2c6f3b71-7f86-4ea9-a41f-aa22c4907e50" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_65628584-1e1e-421d-a404-52e3d02fad43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_65628584-1e1e-421d-a404-52e3d02fad43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStock_ebba5812-e4ee-47ef-a20c-66d29101dd66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_DividendsCommonStock_ebba5812-e4ee-47ef-a20c-66d29101dd66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_AcceleratedShareRepurchasesAgreementAmount_4e49707d-0a02-46d3-970e-4ad1153423d7" xlink:href="hum-20231231.xsd#hum_AcceleratedShareRepurchasesAgreementAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_hum_AcceleratedShareRepurchasesAgreementAmount_4e49707d-0a02-46d3-970e-4ad1153423d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_f5b3fc9f-ed3d-4080-92e8-01bd20037884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_f5b3fc9f-ed3d-4080-92e8-01bd20037884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_132b0835-792a-4c56-944a-d2fe86650142" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_132b0835-792a-4c56-944a-d2fe86650142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_32f712bd-c8e7-4bdd-a708-031177be890e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_32f712bd-c8e7-4bdd-a708-031177be890e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_4edaa9e5-e868-45cf-9b6c-54132ce89b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_4edaa9e5-e868-45cf-9b6c-54132ce89b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue_69c4e9fe-e72e-4095-9213-17c3ed7d08da" xlink:href="hum-20231231.xsd#hum_TreasuryStockDecreaseInCapitalInExcessOfParValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue_69c4e9fe-e72e-4095-9213-17c3ed7d08da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_4b3c6bf9-a562-48af-8925-0016673a68c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_4b3c6bf9-a562-48af-8925-0016673a68c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue_f396c25d-f4d2-41c6-b755-41b9a140ec5d" xlink:href="hum-20231231.xsd#hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue_f396c25d-f4d2-41c6-b755-41b9a140ec5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_5ba0aa7e-adfa-4157-8443-3df5d4d61736" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_5ba0aa7e-adfa-4157-8443-3df5d4d61736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_f7fa9986-5416-4f59-85e3-4f417b4dc33f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_f7fa9986-5416-4f59-85e3-4f417b4dc33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares_874f277d-becd-412e-a45a-825af2f0d199" xlink:href="hum-20231231.xsd#hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares_874f277d-becd-412e-a45a-825af2f0d199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue_aad40180-2e33-4119-a1fa-1db7abcec89d" xlink:href="hum-20231231.xsd#hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue_aad40180-2e33-4119-a1fa-1db7abcec89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_3e378ad0-de8c-43c7-a5ec-0a847a9335a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_3e378ad0-de8c-43c7-a5ec-0a847a9335a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_ed01a72d-ffe2-401c-8fcf-b71c30bbdb73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_ed01a72d-ffe2-401c-8fcf-b71c30bbdb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval_b01a55ad-4b64-4cad-964d-ae0b02c7ac4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval_b01a55ad-4b64-4cad-964d-ae0b02c7ac4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DividendsToParentWithoutPriorStateRegulatoryApproval_48d3ffe9-3ed4-4c6d-b909-8b6a6a0ccbf1" xlink:href="hum-20231231.xsd#hum_DividendsToParentWithoutPriorStateRegulatoryApproval"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_ca0c3e53-75bd-4ab3-a07e-988deef256ed" xlink:to="loc_hum_DividendsToParentWithoutPriorStateRegulatoryApproval_48d3ffe9-3ed4-4c6d-b909-8b6a6a0ccbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#STOCKHOLDERSEQUITYShareRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8dd9fd0d-91f6-4741-9b4b-d5491395e5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_44409618-3082-4746-8cb1-b9b2d580dcd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8dd9fd0d-91f6-4741-9b4b-d5491395e5dd" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_44409618-3082-4746-8cb1-b9b2d580dcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_a4ea7fea-d3e6-45b8-a383-babdf95f3a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_44409618-3082-4746-8cb1-b9b2d580dcd6" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_a4ea7fea-d3e6-45b8-a383-babdf95f3a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_388841c9-5da3-4582-97f9-3f19257af89d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_a4ea7fea-d3e6-45b8-a383-babdf95f3a7e" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_388841c9-5da3-4582-97f9-3f19257af89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember_276a5ff6-00b3-4093-b5cf-dce66e5041e5" xlink:href="hum-20231231.xsd#hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_388841c9-5da3-4582-97f9-3f19257af89d" xlink:to="loc_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember_276a5ff6-00b3-4093-b5cf-dce66e5041e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_February2023ShareRepurchaseAuthorizationMember_8b4e2306-ff69-4d26-b862-4db1800f035b" xlink:href="hum-20231231.xsd#hum_February2023ShareRepurchaseAuthorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember_276a5ff6-00b3-4093-b5cf-dce66e5041e5" xlink:to="loc_hum_February2023ShareRepurchaseAuthorizationMember_8b4e2306-ff69-4d26-b862-4db1800f035b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_February2021ShareRepurchaseAuthorizationMember_09511956-0c71-4139-858a-c4b3a51165f1" xlink:href="hum-20231231.xsd#hum_February2021ShareRepurchaseAuthorizationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember_276a5ff6-00b3-4093-b5cf-dce66e5041e5" xlink:to="loc_hum_February2021ShareRepurchaseAuthorizationMember_09511956-0c71-4139-858a-c4b3a51165f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b4905eb1-23ce-4367-b051-a6df46eb07ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_44409618-3082-4746-8cb1-b9b2d580dcd6" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b4905eb1-23ce-4367-b051-a6df46eb07ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bf41aaf6-1800-4c85-86a1-62c06e54bea0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b4905eb1-23ce-4367-b051-a6df46eb07ad" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_bf41aaf6-1800-4c85-86a1-62c06e54bea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_c7dcd41f-85fd-4947-86fa-2a2d5b2d377c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b4905eb1-23ce-4367-b051-a6df46eb07ad" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_c7dcd41f-85fd-4947-86fa-2a2d5b2d377c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0afd3a71-594b-4d3e-a12f-f52dd4bfbf90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_b4905eb1-23ce-4367-b051-a6df46eb07ad" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0afd3a71-594b-4d3e-a12f-f52dd4bfbf90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa21d097-e3e1-492b-9fe8-cd87cbea6079" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_57acc890-36c5-4d84-b7fa-5661d08d152f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa21d097-e3e1-492b-9fe8-cd87cbea6079" xlink:to="loc_us-gaap_LossContingenciesTable_57acc890-36c5-4d84-b7fa-5661d08d152f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_837c9787-7c54-4102-b922-80435ccbfab6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_57acc890-36c5-4d84-b7fa-5661d08d152f" xlink:to="loc_srt_MajorCustomersAxis_837c9787-7c54-4102-b922-80435ccbfab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_8fdfb6f8-65b2-42ef-a9ec-75ced6b351c9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_837c9787-7c54-4102-b922-80435ccbfab6" xlink:to="loc_srt_NameOfMajorCustomerDomain_8fdfb6f8-65b2-42ef-a9ec-75ced6b351c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareMember_46d37560-d677-42f8-9b72-a053da83583c" xlink:href="hum-20231231.xsd#hum_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fdfb6f8-65b2-42ef-a9ec-75ced6b351c9" xlink:to="loc_hum_MedicareMember_46d37560-d677-42f8-9b72-a053da83583c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicaidMember_f4c37842-d2a9-450e-88f8-e20df543582e" xlink:href="hum-20231231.xsd#hum_MedicaidMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fdfb6f8-65b2-42ef-a9ec-75ced6b351c9" xlink:to="loc_hum_MedicaidMember_f4c37842-d2a9-450e-88f8-e20df543582e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MilitaryServiceMember_755bc970-99cb-47f8-8541-5c64c6a79fb2" xlink:href="hum-20231231.xsd#hum_MilitaryServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_8fdfb6f8-65b2-42ef-a9ec-75ced6b351c9" xlink:to="loc_hum_MilitaryServiceMember_755bc970-99cb-47f8-8541-5c64c6a79fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREContractAxis_b6371c3d-cdb8-4074-8c5b-50bd70b5a16b" xlink:href="hum-20231231.xsd#hum_TRICAREContractAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_57acc890-36c5-4d84-b7fa-5661d08d152f" xlink:to="loc_hum_TRICAREContractAxis_b6371c3d-cdb8-4074-8c5b-50bd70b5a16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREContractDomain_81cc08ba-84d0-4009-ba64-869387dde1cb" xlink:href="hum-20231231.xsd#hum_TRICAREContractDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_TRICAREContractAxis_b6371c3d-cdb8-4074-8c5b-50bd70b5a16b" xlink:to="loc_hum_TRICAREContractDomain_81cc08ba-84d0-4009-ba64-869387dde1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICARE2017EastRegionContractMember_f8915fe3-8fc7-459e-878c-d039bfef9570" xlink:href="hum-20231231.xsd#hum_TRICARE2017EastRegionContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_TRICAREContractDomain_81cc08ba-84d0-4009-ba64-869387dde1cb" xlink:to="loc_hum_TRICARE2017EastRegionContractMember_f8915fe3-8fc7-459e-878c-d039bfef9570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREManagedCareSupportContractEffective2024Member_f22d5b90-e79c-4ae5-9ed6-a108f80b8db2" xlink:href="hum-20231231.xsd#hum_TRICAREManagedCareSupportContractEffective2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_TRICAREContractDomain_81cc08ba-84d0-4009-ba64-869387dde1cb" xlink:to="loc_hum_TRICAREManagedCareSupportContractEffective2024Member_f22d5b90-e79c-4ae5-9ed6-a108f80b8db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_57acc890-36c5-4d84-b7fa-5661d08d152f" xlink:to="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_22d9db03-87fb-4f04-9f3c-ee2157c4b486" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary_22d9db03-87fb-4f04-9f3c-ee2157c4b486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_369205ca-9077-4f29-bafb-2ed33426cfe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary_369205ca-9077-4f29-bafb-2ed33426cfe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_4a3e3a0d-0573-444a-a01e-192f36ad2918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary_4a3e3a0d-0573-444a-a01e-192f36ad2918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_29f14b87-0154-4c49-8010-145945071542" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary_29f14b87-0154-4c49-8010-145945071542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_2445f373-0ce3-4065-aae1-6c82ce56181f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary_2445f373-0ce3-4065-aae1-6c82ce56181f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PercentageOfTotalPremiumAndServicesRevenues_ca42fb9c-3271-4f1c-9f45-b2b6f26c4b01" xlink:href="hum-20231231.xsd#hum_PercentageOfTotalPremiumAndServicesRevenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_hum_PercentageOfTotalPremiumAndServicesRevenues_ca42fb9c-3271-4f1c-9f45-b2b6f26c4b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfStatesComprisingTRICAREBeneficiaries_936cd9f4-5d02-4111-b4cf-1f69654a6fca" xlink:href="hum-20231231.xsd#hum_NumberOfStatesComprisingTRICAREBeneficiaries"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_hum_NumberOfStatesComprisingTRICAREBeneficiaries_936cd9f4-5d02-4111-b4cf-1f69654a6fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfTRICAREBeneficiaries_3dd18530-b96b-4ec4-b54f-baf309e1ed75" xlink:href="hum-20231231.xsd#hum_NumberOfTRICAREBeneficiaries"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_hum_NumberOfTRICAREBeneficiaries_3dd18530-b96b-4ec4-b54f-baf309e1ed75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries_2c5cea28-899e-4e48-a164-b7f8c59e1681" xlink:href="hum-20231231.xsd#hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries_2c5cea28-899e-4e48-a164-b7f8c59e1681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries_f950eca0-4115-41ac-a629-da647a9bc825" xlink:href="hum-20231231.xsd#hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries_f950eca0-4115-41ac-a629-da647a9bc825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREManagedCareSupportContractBaseTerm_b93003e0-6a62-4b97-9e5f-3c8e07f3adce" xlink:href="hum-20231231.xsd#hum_TRICAREManagedCareSupportContractBaseTerm"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_hum_TRICAREManagedCareSupportContractBaseTerm_b93003e0-6a62-4b97-9e5f-3c8e07f3adce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods_a71c58e2-938c-4488-8c14-5ed510b5d92d" xlink:href="hum-20231231.xsd#hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods_a71c58e2-938c-4488-8c14-5ed510b5d92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_TRICAREManagedCareSupportContractTermWithOptionExercises_8ab94a07-a327-4d46-9c28-b100af8e3461" xlink:href="hum-20231231.xsd#hum_TRICAREManagedCareSupportContractTermWithOptionExercises"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_5d35afa7-a0d2-4e5e-a414-aef00f008096" xlink:to="loc_hum_TRICAREManagedCareSupportContractTermWithOptionExercises_8ab94a07-a327-4d46-9c28-b100af8e3461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8f048d74-904e-4eea-ad42-48c6ef720e84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_62097919-3804-4bdb-8c4b-447500e3b4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8f048d74-904e-4eea-ad42-48c6ef720e84" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_62097919-3804-4bdb-8c4b-447500e3b4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_809c8f19-c7ab-453e-af9e-78cc1fce5aee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_62097919-3804-4bdb-8c4b-447500e3b4e2" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_809c8f19-c7ab-453e-af9e-78cc1fce5aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ff1c7e6a-840b-4086-8547-e7b68d317f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_809c8f19-c7ab-453e-af9e-78cc1fce5aee" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ff1c7e6a-840b-4086-8547-e7b68d317f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentContractsConcentrationRiskMember_97d40de2-af2a-433b-9a62-a8e366fd0d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentContractsConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ff1c7e6a-840b-4086-8547-e7b68d317f2e" xlink:to="loc_us-gaap_GovernmentContractsConcentrationRiskMember_97d40de2-af2a-433b-9a62-a8e366fd0d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ba6a7fd6-58a4-49de-b3b6-bee2011b4cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_62097919-3804-4bdb-8c4b-447500e3b4e2" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ba6a7fd6-58a4-49de-b3b6-bee2011b4cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2cbef317-d8a7-4d14-b47c-19b1e9647bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_ba6a7fd6-58a4-49de-b3b6-bee2011b4cc1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2cbef317-d8a7-4d14-b47c-19b1e9647bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_54ae70c6-425c-4f71-9b5b-3ff5b0e49cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2cbef317-d8a7-4d14-b47c-19b1e9647bf3" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_54ae70c6-425c-4f71-9b5b-3ff5b0e49cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_638fa89e-161a-449f-b0ca-c09f804d6212" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_62097919-3804-4bdb-8c4b-447500e3b4e2" xlink:to="loc_srt_MajorCustomersAxis_638fa89e-161a-449f-b0ca-c09f804d6212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_985abda3-175b-4ca3-8f37-90c63c10123d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_638fa89e-161a-449f-b0ca-c09f804d6212" xlink:to="loc_srt_NameOfMajorCustomerDomain_985abda3-175b-4ca3-8f37-90c63c10123d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_FederalGovernmentMember_79ec9050-b3d5-42cc-b89a-7a20c5708b90" xlink:href="hum-20231231.xsd#hum_FederalGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_985abda3-175b-4ca3-8f37-90c63c10123d" xlink:to="loc_hum_FederalGovernmentMember_79ec9050-b3d5-42cc-b89a-7a20c5708b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_4023d123-6108-4969-97e6-b528b2ef68f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_62097919-3804-4bdb-8c4b-447500e3b4e2" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_4023d123-6108-4969-97e6-b528b2ef68f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_28f1bb34-60a5-4cb8-9e18-44baee482f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4023d123-6108-4969-97e6-b528b2ef68f1" xlink:to="loc_us-gaap_NumberOfReportableSegments_28f1bb34-60a5-4cb8-9e18-44baee482f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GovernmentAndHealthPlanMemberSubsidiesAmount_055dc7dc-260a-49c4-8b23-ce40e90583e0" xlink:href="hum-20231231.xsd#hum_GovernmentAndHealthPlanMemberSubsidiesAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4023d123-6108-4969-97e6-b528b2ef68f1" xlink:to="loc_hum_GovernmentAndHealthPlanMemberSubsidiesAmount_055dc7dc-260a-49c4-8b23-ce40e90583e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DepreciationAndAmortizationClassifiedAsBenefitExpense_4d7cd938-b67b-4975-a93b-620488654a80" xlink:href="hum-20231231.xsd#hum_DepreciationAndAmortizationClassifiedAsBenefitExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4023d123-6108-4969-97e6-b528b2ef68f1" xlink:to="loc_hum_DepreciationAndAmortizationClassifiedAsBenefitExpense_4d7cd938-b67b-4975-a93b-620488654a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_316fb9c6-c91c-476b-b7cf-b9b744628f52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4023d123-6108-4969-97e6-b528b2ef68f1" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_316fb9c6-c91c-476b-b7cf-b9b744628f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SEGMENTINFORMATIONSegmentResultsDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f9e5665b-1a71-44a7-853f-7e3230831860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3de02c05-85f2-4eec-b177-98aae6c5ada2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f9e5665b-1a71-44a7-853f-7e3230831860" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3de02c05-85f2-4eec-b177-98aae6c5ada2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b4f2f74c-1ed4-485e-b6ed-82ea62f3a9b3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3de02c05-85f2-4eec-b177-98aae6c5ada2" xlink:to="loc_srt_ConsolidationItemsAxis_b4f2f74c-1ed4-485e-b6ed-82ea62f3a9b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_3e3c9fb0-2f47-4ac1-a26e-73ee1be3074f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_b4f2f74c-1ed4-485e-b6ed-82ea62f3a9b3" xlink:to="loc_srt_ConsolidationItemsDomain_3e3c9fb0-2f47-4ac1-a26e-73ee1be3074f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_fc620a6a-f463-48ac-a413-0fde675e6344" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_3e3c9fb0-2f47-4ac1-a26e-73ee1be3074f" xlink:to="loc_us-gaap_OperatingSegmentsMember_fc620a6a-f463-48ac-a413-0fde675e6344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CorporateAndEliminationsMember_3b449347-2fad-446d-9926-5879a88e8f34" xlink:href="hum-20231231.xsd#hum_CorporateAndEliminationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_3e3c9fb0-2f47-4ac1-a26e-73ee1be3074f" xlink:to="loc_hum_CorporateAndEliminationsMember_3b449347-2fad-446d-9926-5879a88e8f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_388f14d5-04a5-453b-863e-ddf534d090b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_3e3c9fb0-2f47-4ac1-a26e-73ee1be3074f" xlink:to="loc_us-gaap_IntersegmentEliminationMember_388f14d5-04a5-453b-863e-ddf534d090b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_25933a62-3446-405a-a8d4-27c8364f2473" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3de02c05-85f2-4eec-b177-98aae6c5ada2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_25933a62-3446-405a-a8d4-27c8364f2473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2fd9dd2b-c5c8-4646-9579-226425403dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_25933a62-3446-405a-a8d4-27c8364f2473" xlink:to="loc_us-gaap_SegmentDomain_2fd9dd2b-c5c8-4646-9579-226425403dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InsuranceSegmentMember_d5c93b79-c999-4bfd-b567-bd805ce3fb56" xlink:href="hum-20231231.xsd#hum_InsuranceSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2fd9dd2b-c5c8-4646-9579-226425403dfd" xlink:to="loc_hum_InsuranceSegmentMember_d5c93b79-c999-4bfd-b567-bd805ce3fb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CenterWellSegmentMember_25df3f62-e0e8-4f35-b7eb-86a867cb4a50" xlink:href="hum-20231231.xsd#hum_CenterWellSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2fd9dd2b-c5c8-4646-9579-226425403dfd" xlink:to="loc_hum_CenterWellSegmentMember_25df3f62-e0e8-4f35-b7eb-86a867cb4a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_242b7cfe-920f-4263-a8ec-626f14116d3a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3de02c05-85f2-4eec-b177-98aae6c5ada2" xlink:to="loc_srt_MajorCustomersAxis_242b7cfe-920f-4263-a8ec-626f14116d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_242b7cfe-920f-4263-a8ec-626f14116d3a" xlink:to="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareMember_b5471474-f1fc-4827-9f9b-677add71a004" xlink:href="hum-20231231.xsd#hum_MedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_MedicareMember_b5471474-f1fc-4827-9f9b-677add71a004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareAdvantageMember_d6da628e-a0fa-4f0a-a817-dccfbb4cc02a" xlink:href="hum-20231231.xsd#hum_MedicareAdvantageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_MedicareMember_b5471474-f1fc-4827-9f9b-677add71a004" xlink:to="loc_hum_MedicareAdvantageMember_d6da628e-a0fa-4f0a-a817-dccfbb4cc02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_GroupMedicareAdvantageMember_22d71a47-3b14-42e3-9919-01299db07d64" xlink:href="hum-20231231.xsd#hum_GroupMedicareAdvantageMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_MedicareMember_b5471474-f1fc-4827-9f9b-677add71a004" xlink:to="loc_hum_GroupMedicareAdvantageMember_22d71a47-3b14-42e3-9919-01299db07d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareStandAlonePrescriptionDrugPlanMember_b7d892e5-a981-40cd-bc6f-eba3f4dcc78c" xlink:href="hum-20231231.xsd#hum_MedicareStandAlonePrescriptionDrugPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_MedicareMember_b5471474-f1fc-4827-9f9b-677add71a004" xlink:to="loc_hum_MedicareStandAlonePrescriptionDrugPlanMember_b7d892e5-a981-40cd-bc6f-eba3f4dcc78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CommercialFullyInsuredMember_51993ca5-f5c9-4fb1-8d01-35f33a80e0b0" xlink:href="hum-20231231.xsd#hum_CommercialFullyInsuredMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_CommercialFullyInsuredMember_51993ca5-f5c9-4fb1-8d01-35f33a80e0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_SpecialtyBenefitsMember_2ecfb153-cefb-4e2c-adb7-52c9f5efa495" xlink:href="hum-20231231.xsd#hum_SpecialtyBenefitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_SpecialtyBenefitsMember_2ecfb153-cefb-4e2c-adb7-52c9f5efa495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MedicareSupplementProductMember_aa206014-d880-4a5a-96df-172229bb7b29" xlink:href="hum-20231231.xsd#hum_MedicareSupplementProductMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_MedicareSupplementProductMember_aa206014-d880-4a5a-96df-172229bb7b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_StateBasedContractsAndOtherMember_4cf67329-1531-4876-8dff-f7dba2f1346c" xlink:href="hum-20231231.xsd#hum_StateBasedContractsAndOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_StateBasedContractsAndOtherMember_4cf67329-1531-4876-8dff-f7dba2f1346c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_HomeSolutionsMember_cfc1fe7d-18f8-4d0d-ab57-04cb3ea56114" xlink:href="hum-20231231.xsd#hum_HomeSolutionsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_HomeSolutionsMember_cfc1fe7d-18f8-4d0d-ab57-04cb3ea56114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PrimaryCareMember_62222d2c-a462-4461-b12f-d4fce8737acf" xlink:href="hum-20231231.xsd#hum_PrimaryCareMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_PrimaryCareMember_62222d2c-a462-4461-b12f-d4fce8737acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CommercialASOMember_a1d108d4-9580-4056-9a99-12ae545f1d05" xlink:href="hum-20231231.xsd#hum_CommercialASOMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_CommercialASOMember_a1d108d4-9580-4056-9a99-12ae545f1d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_MilitaryAndOtherMember_c466fcf8-a74c-4796-9e8c-37b7fb316e27" xlink:href="hum-20231231.xsd#hum_MilitaryAndOtherMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_MilitaryAndOtherMember_c466fcf8-a74c-4796-9e8c-37b7fb316e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PharmacySolutionsMember_7936704c-19eb-4849-bdd1-e54bc7de1fe4" xlink:href="hum-20231231.xsd#hum_PharmacySolutionsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1dff2b6f-8970-4ff9-8a9e-8018f2bc515e" xlink:to="loc_hum_PharmacySolutionsMember_7936704c-19eb-4849-bdd1-e54bc7de1fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_75e1b911-8410-4563-baf7-f03f53e71582" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3de02c05-85f2-4eec-b177-98aae6c5ada2" xlink:to="loc_srt_ProductOrServiceAxis_75e1b911-8410-4563-baf7-f03f53e71582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_da5a41d9-3b93-4dc5-9d7c-d895b4b4200c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_75e1b911-8410-4563-baf7-f03f53e71582" xlink:to="loc_srt_ProductsAndServicesDomain_da5a41d9-3b93-4dc5-9d7c-d895b4b4200c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_adf9dfc4-3950-4f28-a23a-edefa18c46fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_da5a41d9-3b93-4dc5-9d7c-d895b4b4200c" xlink:to="loc_us-gaap_ProductMember_adf9dfc4-3950-4f28-a23a-edefa18c46fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_d98812cb-2cdf-4647-9aeb-2de6f62ac933" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_da5a41d9-3b93-4dc5-9d7c-d895b4b4200c" xlink:to="loc_us-gaap_ServiceMember_d98812cb-2cdf-4647-9aeb-2de6f62ac933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ExternalRevenuesMember_ee2726de-029a-46b3-801d-92619946d5f7" xlink:href="hum-20231231.xsd#hum_ExternalRevenuesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_da5a41d9-3b93-4dc5-9d7c-d895b4b4200c" xlink:to="loc_hum_ExternalRevenuesMember_ee2726de-029a-46b3-801d-92619946d5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_3de02c05-85f2-4eec-b177-98aae6c5ada2" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_81858ba0-c15e-407d-83e8-8d55f2fd39bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_PremiumsEarnedNet_81858ba0-c15e-407d-83e8-8d55f2fd39bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6e65ec70-09b2-492d-bf54-5d8abdb2fbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_6e65ec70-09b2-492d-bf54-5d8abdb2fbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_1be06ad8-6b0d-4b60-9e94-561ca80d396f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_Revenues_1be06ad8-6b0d-4b60-9e94-561ca80d396f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_eb3b0fbf-1f57-429d-b49f-365b041f4f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_eb3b0fbf-1f57-429d-b49f-365b041f4f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_b8afe302-2119-416f-9d6a-d345f207aae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_b8afe302-2119-416f-9d6a-d345f207aae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7a61a221-38b7-4388-8600-e33b78025dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7a61a221-38b7-4388-8600-e33b78025dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_07daa953-ee65-4c15-95ae-550c938300d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_DepreciationAndAmortization_07daa953-ee65-4c15-95ae-550c938300d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BenefitsLossesAndExpenses_b6ea8677-c5bb-4b74-af9b-9f98e9716900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BenefitsLossesAndExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_BenefitsLossesAndExpenses_b6ea8677-c5bb-4b74-af9b-9f98e9716900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1e1a48d6-9141-4418-b52c-b52298d0049e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_OperatingIncomeLoss_1e1a48d6-9141-4418-b52c-b52298d0049e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_15bae60c-ea6a-431c-892d-e48a32bca75c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_15bae60c-ea6a-431c-892d-e48a32bca75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6f83aba1-aaa4-42e3-9b33-5aeec7d9efa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_InterestExpense_6f83aba1-aaa4-42e3-9b33-5aeec7d9efa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d56183ad-9a43-4d1c-8097-ed226cf030d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d56183ad-9a43-4d1c-8097-ed226cf030d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a04bab88-8f2b-4065-b3a5-a0d75c28a11a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a04bab88-8f2b-4065-b3a5-a0d75c28a11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_213ebb45-9b16-4d20-9476-8e04bec441c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_213ebb45-9b16-4d20-9476-8e04bec441c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9b02788a-60d6-4ea5-bd45-1e33ed76fa44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9b02788a-60d6-4ea5-bd45-1e33ed76fa44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_eff0cc01-0f03-43e2-a99e-3ac2e158be37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_eff0cc01-0f03-43e2-a99e-3ac2e158be37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent_5cc9170b-0e31-4c11-b8f0-1c38d63c8cbf" xlink:href="hum-20231231.xsd#hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_5b33992d-0296-401b-ae6b-3eec846b201c" xlink:to="loc_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent_5cc9170b-0e31-4c11-b8f0-1c38d63c8cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/REINSURANCEDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#REINSURANCEDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/REINSURANCEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_79fc5b86-11a8-46d5-a4bc-f9e2a3e4dd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ReinsuranceTable_132952d5-6d46-4aeb-98b3-0c55590d58a5" xlink:href="hum-20231231.xsd#hum_ReinsuranceTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_79fc5b86-11a8-46d5-a4bc-f9e2a3e4dd3b" xlink:to="loc_hum_ReinsuranceTable_132952d5-6d46-4aeb-98b3-0c55590d58a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LongDurationInsuranceProductsAxis_352099fe-1b6a-4c72-8070-38d3478050bc" xlink:href="hum-20231231.xsd#hum_LongDurationInsuranceProductsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_ReinsuranceTable_132952d5-6d46-4aeb-98b3-0c55590d58a5" xlink:to="loc_hum_LongDurationInsuranceProductsAxis_352099fe-1b6a-4c72-8070-38d3478050bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_LongDurationInsuranceProductsDomain_3d1ee5ea-1c6a-4eb4-8b2d-70100bfde09f" xlink:href="hum-20231231.xsd#hum_LongDurationInsuranceProductsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_LongDurationInsuranceProductsAxis_352099fe-1b6a-4c72-8070-38d3478050bc" xlink:to="loc_hum_LongDurationInsuranceProductsDomain_3d1ee5ea-1c6a-4eb4-8b2d-70100bfde09f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CoinsuranceAgreementMember_1f1cebbb-fa3e-441a-a980-b5f6f8926fb5" xlink:href="hum-20231231.xsd#hum_CoinsuranceAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_LongDurationInsuranceProductsDomain_3d1ee5ea-1c6a-4eb4-8b2d-70100bfde09f" xlink:to="loc_hum_CoinsuranceAgreementMember_1f1cebbb-fa3e-441a-a980-b5f6f8926fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_31b4fc3d-8eec-462c-8101-74389989f990" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_ReinsuranceTable_132952d5-6d46-4aeb-98b3-0c55590d58a5" xlink:to="loc_srt_ProductOrServiceAxis_31b4fc3d-8eec-462c-8101-74389989f990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e618bc02-7918-4ac0-9c30-90dddd8075d7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_31b4fc3d-8eec-462c-8101-74389989f990" xlink:to="loc_srt_ProductsAndServicesDomain_e618bc02-7918-4ac0-9c30-90dddd8075d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ProtectiveLifeInsuranceCompanyMember_69ce0490-dc34-45e0-83d8-a530a69a5efd" xlink:href="hum-20231231.xsd#hum_ProtectiveLifeInsuranceCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e618bc02-7918-4ac0-9c30-90dddd8075d7" xlink:to="loc_hum_ProtectiveLifeInsuranceCompanyMember_69ce0490-dc34-45e0-83d8-a530a69a5efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_AllOthersMember_c8e1fad5-d7bb-40e5-92b3-4a27200a59ff" xlink:href="hum-20231231.xsd#hum_AllOthersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e618bc02-7918-4ac0-9c30-90dddd8075d7" xlink:to="loc_hum_AllOthersMember_c8e1fad5-d7bb-40e5-92b3-4a27200a59ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectsOfReinsuranceLineItems_4498fb98-ac8f-474d-b060-0664e3cb37b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectsOfReinsuranceLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_hum_ReinsuranceTable_132952d5-6d46-4aeb-98b3-0c55590d58a5" xlink:to="loc_us-gaap_EffectsOfReinsuranceLineItems_4498fb98-ac8f-474d-b060-0664e3cb37b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverables_261d980e-125f-4e52-8fbf-c3f45bd6766f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceRecoverables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_4498fb98-ac8f-474d-b060-0664e3cb37b2" xlink:to="loc_us-gaap_ReinsuranceRecoverables_261d980e-125f-4e52-8fbf-c3f45bd6766f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_PercentageOfCoinsuranceAgreement_47d1bbfa-3d58-4023-a73c-43a3c77e5cf1" xlink:href="hum-20231231.xsd#hum_PercentageOfCoinsuranceAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_4498fb98-ac8f-474d-b060-0664e3cb37b2" xlink:to="loc_hum_PercentageOfCoinsuranceAgreement_47d1bbfa-3d58-4023-a73c-43a3c77e5cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CededPremiumsWritten_8e6d2567-0024-4964-a9d7-53419a0fff20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CededPremiumsWritten"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_4498fb98-ac8f-474d-b060-0664e3cb37b2" xlink:to="loc_us-gaap_CededPremiumsWritten_8e6d2567-0024-4964-a9d7-53419a0fff20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_841a60a9-61c5-4042-a994-f3149f6292e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_4498fb98-ac8f-474d-b060-0664e3cb37b2" xlink:to="loc_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded_841a60a9-61c5-4042-a994-f3149f6292e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance_c804ffeb-7d21-4881-bd63-5d74f15fb70d" xlink:href="hum-20231231.xsd#hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_4498fb98-ac8f-474d-b060-0664e3cb37b2" xlink:to="loc_hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance_c804ffeb-7d21-4881-bd63-5d74f15fb70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer_68e13347-483e-449a-9d79-6378917b0604" xlink:href="hum-20231231.xsd#hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectsOfReinsuranceLineItems_4498fb98-ac8f-474d-b060-0664e3cb37b2" xlink:to="loc_hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer_68e13347-483e-449a-9d79-6378917b0604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_e79df484-e9c4-4bfa-8b6d-c23b77a2d5b8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_b763d5d5-769f-40f2-bebd-f98aff5460c3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_e79df484-e9c4-4bfa-8b6d-c23b77a2d5b8" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_b763d5d5-769f-40f2-bebd-f98aff5460c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_90285b7e-df79-4e60-ac84-90d67204b29b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_b763d5d5-769f-40f2-bebd-f98aff5460c3" xlink:to="loc_srt_ConsolidatedEntitiesAxis_90285b7e-df79-4e60-ac84-90d67204b29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_18858562-a86a-4beb-9e68-f1dcb654cd97" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_90285b7e-df79-4e60-ac84-90d67204b29b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_18858562-a86a-4beb-9e68-f1dcb654cd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_b9ac1860-d8cd-4f7e-934e-9b6985945936" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_18858562-a86a-4beb-9e68-f1dcb654cd97" xlink:to="loc_srt_ParentCompanyMember_b9ac1860-d8cd-4f7e-934e-9b6985945936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_44b961cf-e104-40e5-b586-135063fe3994" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_b763d5d5-769f-40f2-bebd-f98aff5460c3" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_44b961cf-e104-40e5-b586-135063fe3994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f71c9431-d576-4fc7-a9dd-4e5c42c471fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_44b961cf-e104-40e5-b586-135063fe3994" xlink:to="loc_us-gaap_RelatedPartyDomain_f71c9431-d576-4fc7-a9dd-4e5c42c471fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_c429c1ce-4398-499b-ab62-f665a9e44e9d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f71c9431-d576-4fc7-a9dd-4e5c42c471fc" xlink:to="loc_srt_SubsidiariesMember_c429c1ce-4398-499b-ab62-f665a9e44e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_c5c6e68f-bdc6-4ab6-b326-2e42a5ef70b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_b763d5d5-769f-40f2-bebd-f98aff5460c3" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_c5c6e68f-bdc6-4ab6-b326-2e42a5ef70b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9d5f00aa-ad0b-48df-91e2-c4f723102f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_c5c6e68f-bdc6-4ab6-b326-2e42a5ef70b5" xlink:to="loc_us-gaap_AssetsAbstract_9d5f00aa-ad0b-48df-91e2-c4f723102f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e5dc6f54-af2b-4381-9bba-253f2f182da4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d5f00aa-ad0b-48df-91e2-c4f723102f5e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e5dc6f54-af2b-4381-9bba-253f2f182da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f376df72-68f7-4394-ae3a-5f6462744c56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e5dc6f54-af2b-4381-9bba-253f2f182da4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f376df72-68f7-4394-ae3a-5f6462744c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_91b99ff0-abe4-4c6b-88d9-a04a9bf6d56c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e5dc6f54-af2b-4381-9bba-253f2f182da4" xlink:to="loc_us-gaap_ShortTermInvestments_91b99ff0-abe4-4c6b-88d9-a04a9bf6d56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_e476a30d-b636-43fb-af33-2423601a0cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e5dc6f54-af2b-4381-9bba-253f2f182da4" xlink:to="loc_us-gaap_ReceivablesNetCurrent_e476a30d-b636-43fb-af33-2423601a0cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_93514851-ca28-4b7d-a119-8d6ee2629333" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e5dc6f54-af2b-4381-9bba-253f2f182da4" xlink:to="loc_us-gaap_OtherAssetsCurrent_93514851-ca28-4b7d-a119-8d6ee2629333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6c3ee1db-75ae-4ec8-b971-03a4f12b2f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e5dc6f54-af2b-4381-9bba-253f2f182da4" xlink:to="loc_us-gaap_AssetsCurrent_6c3ee1db-75ae-4ec8-b971-03a4f12b2f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_347a9025-15bd-43b7-94f8-bac5c3fdb215" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d5f00aa-ad0b-48df-91e2-c4f723102f5e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_347a9025-15bd-43b7-94f8-bac5c3fdb215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InvestmentInRelatedPartiesAndSubsidiaries_9f2d4acd-5a82-4a1c-bf5b-8ec3cbbaec0e" xlink:href="hum-20231231.xsd#hum_InvestmentInRelatedPartiesAndSubsidiaries"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d5f00aa-ad0b-48df-91e2-c4f723102f5e" xlink:to="loc_hum_InvestmentInRelatedPartiesAndSubsidiaries_9f2d4acd-5a82-4a1c-bf5b-8ec3cbbaec0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_dfe4771a-9101-474d-94ad-8f0b9388cb27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d5f00aa-ad0b-48df-91e2-c4f723102f5e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_dfe4771a-9101-474d-94ad-8f0b9388cb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3f86b0e7-5c29-41f8-afe2-f981f113b114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d5f00aa-ad0b-48df-91e2-c4f723102f5e" xlink:to="loc_us-gaap_Assets_3f86b0e7-5c29-41f8-afe2-f981f113b114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_c5c6e68f-bdc6-4ab6-b326-2e42a5ef70b5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_d248ac83-709d-488f-96a5-68f13fd53a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_d248ac83-709d-488f-96a5-68f13fd53a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2b7b865f-1c29-45d6-b254-190548ef7047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d248ac83-709d-488f-96a5-68f13fd53a8c" xlink:to="loc_us-gaap_AccountsPayableCurrent_2b7b865f-1c29-45d6-b254-190548ef7047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_612bac0a-ac3d-45fd-b1f9-f441d267206b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d248ac83-709d-488f-96a5-68f13fd53a8c" xlink:to="loc_us-gaap_DebtCurrent_612bac0a-ac3d-45fd-b1f9-f441d267206b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_7429c827-f3cd-4797-b56e-ccb68e82f723" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d248ac83-709d-488f-96a5-68f13fd53a8c" xlink:to="loc_us-gaap_NotesPayableCurrent_7429c827-f3cd-4797-b56e-ccb68e82f723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_BookOverdraftLiability_a166175f-2886-4198-96e6-dfb7221a9f75" xlink:href="hum-20231231.xsd#hum_BookOverdraftLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d248ac83-709d-488f-96a5-68f13fd53a8c" xlink:to="loc_hum_BookOverdraftLiability_a166175f-2886-4198-96e6-dfb7221a9f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_447ef71b-4c43-450a-810f-f1eab5426bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d248ac83-709d-488f-96a5-68f13fd53a8c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_447ef71b-4c43-450a-810f-f1eab5426bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d145d43f-1092-45b1-8d8c-6f1ee0eac15d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_d248ac83-709d-488f-96a5-68f13fd53a8c" xlink:to="loc_us-gaap_LiabilitiesCurrent_d145d43f-1092-45b1-8d8c-6f1ee0eac15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9ed3f27a-787f-4a0c-a927-35720c46d92a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9ed3f27a-787f-4a0c-a927-35720c46d92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_b2d36da3-4585-43ee-99b3-2be376b36c34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_b2d36da3-4585-43ee-99b3-2be376b36c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_53f477b4-d47b-4979-9186-76aa677113e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:to="loc_us-gaap_Liabilities_53f477b4-d47b-4979-9186-76aa677113e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_79459295-144e-455d-9f7d-96dac5e0bd42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:to="loc_us-gaap_CommitmentsAndContingencies_79459295-144e-455d-9f7d-96dac5e0bd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:to="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a5a60fda-73bb-437c-b951-9d4d37ff2605" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:to="loc_us-gaap_PreferredStockValue_a5a60fda-73bb-437c-b951-9d4d37ff2605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0ae2dd0d-de62-4727-8a65-a353d98fef50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:to="loc_us-gaap_CommonStockValue_0ae2dd0d-de62-4727-8a65-a353d98fef50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_20bb8705-ea1c-4e31-a181-7d2f033d7111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_20bb8705-ea1c-4e31-a181-7d2f033d7111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7bd704e2-fa55-4607-946a-7c1360709a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7bd704e2-fa55-4607-946a-7c1360709a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1d413c19-6a0d-4fd4-b0f8-e2cbf56300a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1d413c19-6a0d-4fd4-b0f8-e2cbf56300a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_b6ee371b-064f-4232-a4bd-5b74ce06da33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:to="loc_us-gaap_TreasuryStockCommonValue_b6ee371b-064f-4232-a4bd-5b74ce06da33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dcd86040-905c-495c-b485-893042a35824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_aa2d16e4-0fa9-49e6-bd6f-b9c295786c17" xlink:to="loc_us-gaap_StockholdersEquity_dcd86040-905c-495c-b485-893042a35824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_70e72cdb-edf0-4c7a-8748-dd9249e1a91e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_676b5a22-f7dd-4fc7-a311-886cfca6d180" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_70e72cdb-edf0-4c7a-8748-dd9249e1a91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2f21b5f0-af57-497c-bce8-28d29bcf144a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_7075b706-6a02-4dcf-8b29-efa23cbab084" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2f21b5f0-af57-497c-bce8-28d29bcf144a" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_7075b706-6a02-4dcf-8b29-efa23cbab084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_d62c6174-8193-4391-9ba1-4bf7cab15f76" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_7075b706-6a02-4dcf-8b29-efa23cbab084" xlink:to="loc_srt_ConsolidatedEntitiesAxis_d62c6174-8193-4391-9ba1-4bf7cab15f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_e04dfbf4-f126-46eb-a486-cd3e4c41f1c4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_d62c6174-8193-4391-9ba1-4bf7cab15f76" xlink:to="loc_srt_ConsolidatedEntitiesDomain_e04dfbf4-f126-46eb-a486-cd3e4c41f1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_6475e1a9-2637-41ed-be53-2495f7cf033c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_e04dfbf4-f126-46eb-a486-cd3e4c41f1c4" xlink:to="loc_srt_ParentCompanyMember_6475e1a9-2637-41ed-be53-2495f7cf033c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_7075b706-6a02-4dcf-8b29-efa23cbab084" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_384a70c0-3a7b-4e34-808b-6ec279978459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_384a70c0-3a7b-4e34-808b-6ec279978459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_01f939e2-7e2d-4731-92a7-cc79d62c6fda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_01f939e2-7e2d-4731-92a7-cc79d62c6fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_cafc3ced-2cbc-4196-aff0-bced62ce6760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_cafc3ced-2cbc-4196-aff0-bced62ce6760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ec641615-2b78-4b1b-a492-2ff99e101ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ec641615-2b78-4b1b-a492-2ff99e101ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_80352ad1-c48e-42d6-ba7e-dc457d483334" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_80352ad1-c48e-42d6-ba7e-dc457d483334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1919020e-9245-4517-96b6-4733937ef111" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:to="loc_us-gaap_CommonStockSharesIssued_1919020e-9245-4517-96b6-4733937ef111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_b588b40c-d265-4640-bca0-521dada236db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_dadce912-9aa8-4bd7-906a-973ac4d2ba9e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_b588b40c-d265-4640-bca0-521dada236db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_47df537e-46bc-4bc6-9710-4c0fe7e1194d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_969d3095-aa0f-49f2-9001-4bead8dd9835" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_47df537e-46bc-4bc6-9710-4c0fe7e1194d" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_969d3095-aa0f-49f2-9001-4bead8dd9835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_331c44b8-e077-491e-ad50-cec89433cd93" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_969d3095-aa0f-49f2-9001-4bead8dd9835" xlink:to="loc_srt_ConsolidatedEntitiesAxis_331c44b8-e077-491e-ad50-cec89433cd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_36548ada-e31a-48e9-818d-ab2dfa3c794a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_331c44b8-e077-491e-ad50-cec89433cd93" xlink:to="loc_srt_ConsolidatedEntitiesDomain_36548ada-e31a-48e9-818d-ab2dfa3c794a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_ddb1096c-eba7-4129-9450-56f6443f2295" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_36548ada-e31a-48e9-818d-ab2dfa3c794a" xlink:to="loc_srt_ParentCompanyMember_ddb1096c-eba7-4129-9450-56f6443f2295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_969d3095-aa0f-49f2-9001-4bead8dd9835" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_b0c9fce9-ff0a-4b8a-ac23-90152a91457c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_us-gaap_RevenuesAbstract_b0c9fce9-ff0a-4b8a-ac23-90152a91457c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ManagementFeesChargedToOperatingSubsidiaries_92b61f11-c110-4384-9d32-7c1a7e2e1268" xlink:href="hum-20231231.xsd#hum_ManagementFeesChargedToOperatingSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b0c9fce9-ff0a-4b8a-ac23-90152a91457c" xlink:to="loc_hum_ManagementFeesChargedToOperatingSubsidiaries_92b61f11-c110-4384-9d32-7c1a7e2e1268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_InvestmentAndOtherIncomeNet_fa27471c-f0b8-4b10-9b20-04404fffa08f" xlink:href="hum-20231231.xsd#hum_InvestmentAndOtherIncomeNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b0c9fce9-ff0a-4b8a-ac23-90152a91457c" xlink:to="loc_hum_InvestmentAndOtherIncomeNet_fa27471c-f0b8-4b10-9b20-04404fffa08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b1d99615-287b-4a47-91fa-81535b962222" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b0c9fce9-ff0a-4b8a-ac23-90152a91457c" xlink:to="loc_us-gaap_Revenues_b1d99615-287b-4a47-91fa-81535b962222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4623aaa7-861f-4741-bf68-b9d86c966634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4623aaa7-861f-4741-bf68-b9d86c966634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_74efcfe1-5363-4b11-ba8a-d33c990cb3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4623aaa7-861f-4741-bf68-b9d86c966634" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_74efcfe1-5363-4b11-ba8a-d33c990cb3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_49439831-7eca-432d-ae73-b8bbb261b59b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4623aaa7-861f-4741-bf68-b9d86c966634" xlink:to="loc_us-gaap_Depreciation_49439831-7eca-432d-ae73-b8bbb261b59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_233fe462-88c0-4389-b29b-e30a932c58a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4623aaa7-861f-4741-bf68-b9d86c966634" xlink:to="loc_us-gaap_InterestExpense_233fe462-88c0-4389-b29b-e30a932c58a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_47e98238-94cb-4b5e-9a82-237dc186bd81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4623aaa7-861f-4741-bf68-b9d86c966634" xlink:to="loc_us-gaap_CostsAndExpenses_47e98238-94cb-4b5e-9a82-237dc186bd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1af0be3f-10e2-4528-8cc5-11f9a0bbc16e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1af0be3f-10e2-4528-8cc5-11f9a0bbc16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries_c7133cfc-f6aa-4d9d-9fae-7fdfa9a85419" xlink:href="hum-20231231.xsd#hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries_c7133cfc-f6aa-4d9d-9fae-7fdfa9a85419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c8b44794-a702-44a0-b164-ca87f1e969cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c8b44794-a702-44a0-b164-ca87f1e969cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries_9a27a66c-5f8a-4727-94d9-2f635171b7dd" xlink:href="hum-20231231.xsd#hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries_9a27a66c-5f8a-4727-94d9-2f635171b7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_EquityInNetEarningsOfSubsidiaries_fe20429f-4e6a-44fb-a7cd-82e8a260c07b" xlink:href="hum-20231231.xsd#hum_EquityInNetEarningsOfSubsidiaries"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_hum_EquityInNetEarningsOfSubsidiaries_fe20429f-4e6a-44fb-a7cd-82e8a260c07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_565dc812-3dda-4d28-a4cd-aa210c88af86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_565dc812-3dda-4d28-a4cd-aa210c88af86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f0e4faab-18d9-45e2-9c34-72fd4f3070a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_a512d28c-34ea-4109-afea-7d34ccd80c27" xlink:to="loc_us-gaap_ProfitLoss_f0e4faab-18d9-45e2-9c34-72fd4f3070a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_cc784e16-8659-4a2c-879e-7c4d656360de" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_dc8c44db-378e-40ef-8594-1a830123a288" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_cc784e16-8659-4a2c-879e-7c4d656360de" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_dc8c44db-378e-40ef-8594-1a830123a288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1ec0017f-8e2f-43a6-8c34-1ea71c5a687a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_dc8c44db-378e-40ef-8594-1a830123a288" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1ec0017f-8e2f-43a6-8c34-1ea71c5a687a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d1b1eed5-8cca-4d8f-84dc-2eaf844f1a30" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1ec0017f-8e2f-43a6-8c34-1ea71c5a687a" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d1b1eed5-8cca-4d8f-84dc-2eaf844f1a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_f7522d50-37be-4ae5-a36f-79e934d0ffa1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_d1b1eed5-8cca-4d8f-84dc-2eaf844f1a30" xlink:to="loc_srt_ParentCompanyMember_f7522d50-37be-4ae5-a36f-79e934d0ffa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7d31242b-c77c-4b6e-a841-136a52017e6e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_dc8c44db-378e-40ef-8594-1a830123a288" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7d31242b-c77c-4b6e-a841-136a52017e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1b5e19cf-5546-4cd7-99e2-0631ba5c498b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7d31242b-c77c-4b6e-a841-136a52017e6e" xlink:to="loc_us-gaap_NetIncomeLoss_1b5e19cf-5546-4cd7-99e2-0631ba5c498b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7d31242b-c77c-4b6e-a841-136a52017e6e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_39744d99-78c2-418e-9565-1e1e3a7d009b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_39744d99-78c2-418e-9565-1e1e3a7d009b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_edcb57f6-b18d-455e-baf1-c66a47cc7553" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_edcb57f6-b18d-455e-baf1-c66a47cc7553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_055d1ed4-e572-4ac9-b868-ff139e6d6dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_055d1ed4-e572-4ac9-b868-ff139e6d6dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_80c95a39-133b-4e4d-a4bc-aea5902256e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_80c95a39-133b-4e4d-a4bc-aea5902256e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_b35effcf-5b8a-421e-a864-d70b6fea1ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_b35effcf-5b8a-421e-a864-d70b6fea1ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_ac3123f2-c009-455c-8969-a60a18cdf26d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_ac3123f2-c009-455c-8969-a60a18cdf26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_88066031-8c52-4eb8-8143-107754de3278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a650aa1a-68a9-4df5-928f-3cc140ea71ad" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_88066031-8c52-4eb8-8143-107754de3278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments_918e7be8-0f26-4b5b-9cf6-983ebc0811a3" xlink:href="hum-20231231.xsd#hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7d31242b-c77c-4b6e-a841-136a52017e6e" xlink:to="loc_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments_918e7be8-0f26-4b5b-9cf6-983ebc0811a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_595f0716-6013-4f7b-a75a-befbd4f52296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_7d31242b-c77c-4b6e-a841-136a52017e6e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_595f0716-6013-4f7b-a75a-befbd4f52296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_cc98bc1d-ce46-4f45-8bdb-01c4023e1c97" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_56ee6185-228d-4cad-860d-f57445e7a3cb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_cc98bc1d-ce46-4f45-8bdb-01c4023e1c97" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_56ee6185-228d-4cad-860d-f57445e7a3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_9f346d72-e72f-4a49-b253-40c18156f7a5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_56ee6185-228d-4cad-860d-f57445e7a3cb" xlink:to="loc_srt_ConsolidatedEntitiesAxis_9f346d72-e72f-4a49-b253-40c18156f7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_aa9c4494-b070-45a1-999f-87f71a338de0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_9f346d72-e72f-4a49-b253-40c18156f7a5" xlink:to="loc_srt_ConsolidatedEntitiesDomain_aa9c4494-b070-45a1-999f-87f71a338de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_38605569-e434-4942-b015-a0cade767a85" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_aa9c4494-b070-45a1-999f-87f71a338de0" xlink:to="loc_srt_ParentCompanyMember_38605569-e434-4942-b015-a0cade767a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_262fb949-289c-4712-b661-ee89b9d42da2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_56ee6185-228d-4cad-860d-f57445e7a3cb" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_262fb949-289c-4712-b661-ee89b9d42da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2aa91fb9-5e39-4bd8-88c8-fcfca40f509b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_262fb949-289c-4712-b661-ee89b9d42da2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2aa91fb9-5e39-4bd8-88c8-fcfca40f509b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_262fb949-289c-4712-b661-ee89b9d42da2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8c13c686-ccac-489f-89cb-ebc220364c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8c13c686-ccac-489f-89cb-ebc220364c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_CapitalContributionsToOperatingSubsidiaries_2a75f0a7-142b-4e6d-8ba2-75552e1117ab" xlink:href="hum-20231231.xsd#hum_CapitalContributionsToOperatingSubsidiaries"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:to="loc_hum_CapitalContributionsToOperatingSubsidiaries_2a75f0a7-142b-4e6d-8ba2-75552e1117ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7ff6a4f7-2d59-4b43-817a-0ff46cd2172a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7ff6a4f7-2d59-4b43-817a-0ff46cd2172a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4e02efcc-23ec-417c-9a8e-b82fae94da53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_4e02efcc-23ec-417c-9a8e-b82fae94da53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_11ace372-4886-4090-b378-58d615e24b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_11ace372-4886-4090-b378-58d615e24b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_932c3ee4-90d7-4967-b11b-59b9bc849892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_932c3ee4-90d7-4967-b11b-59b9bc849892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fe4fdb89-18ae-4435-a79c-53f896a2cddd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_248064a0-63ff-4b6a-856b-55a496c93cde" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fe4fdb89-18ae-4435-a79c-53f896a2cddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_262fb949-289c-4712-b661-ee89b9d42da2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_10a7ee60-e2aa-415c-b9c7-a886b35a63ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_10a7ee60-e2aa-415c-b9c7-a886b35a63ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_730828fb-bf22-4798-abed-0679d5a12bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_730828fb-bf22-4798-abed-0679d5a12bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_eb37bf0c-ab3f-4039-9858-8b80962bab42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromRepaymentsOfCommercialPaper"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfCommercialPaper_eb37bf0c-ab3f-4039-9858-8b80962bab42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_9e54461d-f35d-4fa9-9e0a-73cedfe44936" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_9e54461d-f35d-4fa9-9e0a-73cedfe44936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_b922b09d-8a6a-4944-8943-9ffcb2a69bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_b922b09d-8a6a-4944-8943-9ffcb2a69bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInBookOverdrafts_160106f1-1b3d-4a59-8bb8-cfc7a129d465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInBookOverdrafts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_IncreaseDecreaseInBookOverdrafts_160106f1-1b3d-4a59-8bb8-cfc7a129d465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f4cc872-cfbe-4ca4-a91c-1eace1039e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f4cc872-cfbe-4ca4-a91c-1eace1039e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_c5f08b09-ad12-4936-b93d-45620c7d23c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_PaymentsOfDividends_c5f08b09-ad12-4936-b93d-45620c7d23c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_ProceedsFromStockOptionsExercisedAndOther_67754aa3-9591-4bea-9703-be6bea76808f" xlink:href="hum-20231231.xsd#hum_ProceedsFromStockOptionsExercisedAndOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_hum_ProceedsFromStockOptionsExercisedAndOther_67754aa3-9591-4bea-9703-be6bea76808f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_310be386-afa4-4dbe-a92e-1c1ad450cb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b6777cef-698b-4f3c-ab19-a8a7ac01d890" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_310be386-afa4-4dbe-a92e-1c1ad450cb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b1064fde-dd73-4117-925f-6cadae4f7476" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_262fb949-289c-4712-b661-ee89b9d42da2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b1064fde-dd73-4117-925f-6cadae4f7476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4dfdc63-d671-46e2-b9b0-9995877f2c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_262fb949-289c-4712-b661-ee89b9d42da2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f4dfdc63-d671-46e2-b9b0-9995877f2c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef97f5ee-61e8-421f-acef-6b2307c1e95f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_262fb949-289c-4712-b661-ee89b9d42da2" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef97f5ee-61e8-421f-acef-6b2307c1e95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONNotestoCondensedFinancialStatementsDetails" xlink:type="simple" xlink:href="hum-20231231.xsd#SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONNotestoCondensedFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONNotestoCondensedFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2011906e-6f82-48ae-a105-ea51aa298ef3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DividendsToParentWithoutPriorStateRegulatoryApproval_41bcdb3a-162f-4798-a19a-d767e4e562bc" xlink:href="hum-20231231.xsd#hum_DividendsToParentWithoutPriorStateRegulatoryApproval"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2011906e-6f82-48ae-a105-ea51aa298ef3" xlink:to="loc_hum_DividendsToParentWithoutPriorStateRegulatoryApproval_41bcdb3a-162f-4798-a19a-d767e4e562bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_052ff40b-e7b2-4479-802a-efac6989aab4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2011906e-6f82-48ae-a105-ea51aa298ef3" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_052ff40b-e7b2-4479-802a-efac6989aab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_28bd8ffb-8021-4bbc-8885-9f03a1c9e6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2011906e-6f82-48ae-a105-ea51aa298ef3" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_28bd8ffb-8021-4bbc-8885-9f03a1c9e6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval_b13ff8c7-c9ce-4640-b32b-0176f01682e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_2011906e-6f82-48ae-a105-ea51aa298ef3" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval_b13ff8c7-c9ce-4640-b32b-0176f01682e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_hum_DividendsToParentWithoutPriorStateRegulatoryApproval_4a7bdbeb-4c5f-49c5-9a13-142a8b8a5f12" xlink:href="hum-20231231.xsd#hum_DividendsToParentWithoutPriorStateRegulatoryApproval"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>hum-20231231_g1.jpg
<TEXT>
begin 644 hum-20231231_g1.jpg
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M 0 "$0,1 #\ _?RBBB@ HK\]/VV/^"@7QV\=_M"?'7]C/]F?XB:3\/Y?@?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 >%_M8?\ );/@?_V/<O\ Z3-7NE>%_M8?\EL^!_\ V/<O_I,U>Z4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%?('[4?_!>K_@D]^Q=\=M=_9H_:7_:L_P"$:\;>&OLO]MZ)_P (+KMY]F^T
M6L5U#^^M;&6%]T,\3_*YQNP<,"!Y_P#\11W_  0H_P"CYO\ S&7B?_Y64 ??
M]%? '_$4=_P0H_Z/F_\ ,9>)_P#Y65Z!^RY_P7J_X)/?MH_';0OV:/V:/VK/
M^$E\;>)?M7]B:)_P@NNV?VG[/:RW4W[ZZL8H4VPP2O\ ,XSMP,L0" ?7]%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M>%_M8?\ );/@?_V/<O\ Z3-7NE>%_M8?\EL^!_\ V/<O_I,U>Z4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?R!?
M\'1W_*=?XY_]RS_ZC&DU\ 5]_P#_  ='?\IU_CG_ -RS_P"HQI-? % !7W__
M ,&N/_*=?X&?]S-_ZC&K5\ 5]_\ _!KC_P IU_@9_P!S-_ZC&K4 ?U^T444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^I?L7C?_ *#=E_X#'_&O(_VL/^2V? __ +'N7_TF:O=* ,?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V**
M ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\
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M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\
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M^Q>-_P#H-V7_ (#'_&MBB@#+L[3Q:ETCWVK6KQ!OWB);D$CV-:E%% !1110
M4444 %%%% !1110 4444 %%%% !1110!X7^UA_R6SX'_ /8]R_\ I,U>Z5X7
M^UA_R6SX'_\ 8]R_^DS5[I0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^'51_P L8X_F^X?V2OVR_P!F;]N?X1VGQO\ V6/B[I?B[P_<X26:QE*SV4V
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >%_M8?\EL^!__ &/<O_I,U>Z5X7^UA_R6SX'_ /8]R_\ I,U>
MZ4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$>W)!N2!(QR1M+R-)]O444 %%%% !117/^ /BK\./BG_ &W_ ,*Y\::?K/\
MPCGB"YT/7O[/N!)]AU*WV^?:R8^[*F]=R]MPH Z"BBB@ HHHH *^'?VMO^"-
MUAK'Q<N_VT_^":_Q<E_9^^/#YDU#5=$M@WA[QASN-OK6F@&.8.V<SJN\,QD9
M965<?<5% 'PA^S'_ ,%D=0\,_%NP_8O_ ."L/PCC^ GQENCY6A:I<W)?PAXV
MP0HFTG46)168D?Z/,V]2ZIO:0E%^[Z\^_:<_93_9W_;+^$M_\#?VG?A+I'C'
MPQJ(S+IVK09,,F"%FAD4B2WF7)VRQLKKDX89KX0_X5W_ ,%,/^")O^F?!)_$
MO[5'[,5CS-X&U"<3>/? MH.VGS' U:UC7I P#J JJ(U5Y2 ?IA17D'[%_P"W
MA^RO_P % ?A2GQ?_ &6/BO8^(M/1EBU6P&8;_1[@@YM[RU?$EO*,'AAA@-R%
ME(8^OT %%%% !1110 4444 %%%% !117@'_!2+_@I%^SC_P2_P#V<;_]H7]H
M77_[UOX9\,V<J_;_ !!?[<I:VZ'\"\A^6-<LW8$ [_X\?M5?LX_LO_\ "-?\
M-"_&CP_X/_X3#Q!%HGAG^W=06#^T+^3[D*9_#+'"KD;B,C/H%?Q!_P#!2/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%U_VUO\ 1_V4/V%O"W[.7A.ZXC\<_M#:JUWK;Q'^.'1;,;K:8<82Y+(>>?0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M -)FKW2O"_VL/^2V? __ +'N7_TF:O=* "BBB@ HHHH **** "BBB@ HHHH
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M=5QU/K7<>$?!WA'P!X<M/!W@/PMINB:181^78Z5I%C';6UNF<[8XHP%09)X
M'6@#\[_VZ/%?ABP_X.-/V(]+OO$-E#<IX)\>J\$MTBNIFTMUA!!.079'"_WB
MI SBOTBKB]>_9O\ V=_%6LW'B+Q1\!/!>I:A>2&2[OK_ ,+6DTT[GJSN\99C
M[DUV:JJJ%50 !@ #I0!\B?\ !.E/^%^_M,?M$?M[7G[ZR\0^.%^'GP^N&^=?
M[ \-&6UEEA?_ )YSZO-JK\<$)&><"O4M=_X*-?L)^$OCWXD_9@\;_M6>"O#W
MCSPE9VUWKWAWQ+K*:;+!#/"D\;H]SLCF'E2(Y\IGV!QNVYKU;P7X'\%?#?PU
M;>"_AWX/TO0-'LM_V/2=%T^.UMH-[M(^R*)51=SLS' &68D\DUA>,OV=OV?O
MB+XSL_B-\0?@7X.UWQ#IR*NGZ]K/ABTNKVU52641SR1LZ $D@ C!- 'S-_P3
M.^!WA^P_:K_:A_;8^%^E&P^'_P ;O&&A3^#D6W,,6KG3M-,5[K4,9 _<W=Y<
M3E)<?OQ!YZ[DFC=OLJCITHH *\O^*W[)7PU^,7BY_&GBC7_%%O=O D)CTGQ'
M-;0[4& =B'&?4]Z]0HH ^0OB[^RU\//A#\<O@]<>&-<\2W#:CXT,4XU77YKD
M*$A+C8'/RG(Y(ZCBOJ7_ (0?2/\ GYO?_ MJ\C_:P_Y+9\#_ /L>Y?\ TF:O
M=* ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_
MX0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\
MA!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^
M?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
M MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\
M"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH
MQ_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0
M?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!
M](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F
M]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?
MF]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK
M8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"V
MH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,
M?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2
M/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](
M_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_
M\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_
M ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VK#^)&I?"CX.^ ]5^*/
MQ6\>P^'?#FA63W>L:WK&KBWMK.!1\TDDCD!1]>I( Y-<?^W#^WI^S1_P3S^#
M,WQK_:6\<C3K1Y?LVAZ+91^?J>O7I'R6=C; AIYF) P,*H.YV106'QQ\-_V(
MOVK/^"P7CS2OVG?^"M/AFY\$_!_2[U-1^&G[*<-VV)R#F'4/$KC:;B?'(LR
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M_P""EO\ P5*\166CW(S<_"W]G.!O#VE*#]Z&349@UW>0GH4D53@<-SQ^C=%
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MQKT."$8N-<^#>HV/CBTV_P#/9EM6B>&/N0V64=<FNN^$O_!P[_P2+^*>L_\
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M"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8KX
M_P"#D7_@I%_P[O\ ^"<>O?\ "%:]]D^(7Q-\WPOX(\F7;-;>;&?ME^N.1Y%N
M6VN/NS2P>M 'W/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M7PQ_P;=?\%(O^
M'B'_  3CT'_A-=>^U_$+X9>5X7\;^=+NFN?*C'V._;/)\^W"[G/WIHI_2OO^
M@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ/\
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M52_%_P"$/P@U#Q%XF\1:@=&T36WL3+I/AV=T)6[OF'Y11' ED&"0 00#S_\
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MUX1CD!VG?JNHJO(.3M\H;@#AN]1?\,>_\%Q_VU?](_;!_;]\/?L^^%+K_6^
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M\1:3\0GURZCEBLYI;>WALETN SRW%PD-LH,J*K3AV8*IH _:WXB_$;P#\(O
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M6F_;=_T7]AO_ ()[:;\#O"5WQ#\2?VFKYHM0:(_QPZ%9EIHY .5,S/&Q(!P
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M,'X2^%7PJ^(_QR^(^B_"'X0^"]0\1>)_$6H1V.B:)I=N99[N=SA451^9)P%
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M\$OOVCK_ /9Z_:%T'^]<>&?$UG$WV#Q!8;L+=6['\ \9^:-LJW8G^WRO /\
M@I%_P3=_9Q_X*@?LXW_[/7[0N@?WKCPSXFLXE^W^'[_;A+JW<_@'C/RR+E6[
M$ '\@7_!-S_@FY^T=_P5!_:.L/V>OV>M!_NW'B;Q->1-]@\/V&[#75PP_$)&
M/FD;"KW(_H]_X(R?\&[?Q'_X(]?M':K\9O#/_!0/_A-?#WB3P^^E^)_!<GPP
M.G)?8826TZS_ -J3".6&3."8VRDLJ<;]P^P/^";O_!-W]G'_ ()?_LXV'[/7
M[/6@?W;CQ-XFO(E^W^(+_;A[JX<?B$C'RQKA5[D^_P! !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?[6'_);/@?
M_P!CW+_Z3-7NE>%_M8?\EL^!_P#V/<O_ *3-7NE !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/E?]LC_@IC8? ;Q/XO\ @O\  7X2ZA\1?B!X(\)VOB'Q;:6]U;VNF>'+.YE\
MNU^W7$LJ-YT^UVC@A620JA=@B89O2OV:_P!K1/CYXW\:?"/Q5\$?%WP_\9^
M/[/?Q#H/BF.UDCE@OEG-K=V=U:3S0W5O)]FG&X,K*T;(Z(RE1^=?_!:[]C[]
MM7]ESXT_$C_@J1^Q%+9^+O"_Q!\%Z=HWQ_\ A=J#;;JXMK#RX[;4=/;(W2QQ
MHB;!EU)8A)A*RI]Q?\$X_P!O_P#9$_X*4^ ]1_:0_9QGDM_$4=O::+X\\.ZS
M!]GUG09;=[F2&RO(<G 5[BZ*2+E'WR88E650!/&?_!3;X0^$/^"A/@'_ ()Q
M2?#7QPWBSQ]8ZI>V7B"\\.R66CQ0V%K//+Y<]QL:Z8F'8#"CQ_."9.@/T#XK
M\5>'/ OA;4O&_C#6K?3=(T;3YK[5=1NY D5K;1(9)978_=545F)[ &OS]_;=
M _XB)OV(6QR? WQ$R?\ N%&OJ/\ X**_LF^.OVX_V2/$_P"RYX"^/L_PUF\5
MK#!J'B:UT!=2D%HLJR26XA::(%9=@C?+8,;.N/FR #Q7]G#_ (+.:M^TM\;?
M#GPA\/\ _!*K]K7PWI_B6]\NV\>^-?A-_9F@VUML:07<UW+<8CB*+E>"SEE5
M5+, ?:_CY^VSX<^%'QU\-_LG?#?X?ZEX^^*GBG1+C7+3PCI%Y!;)INCP2"*3
M4[^YG8+:VQE984(#R2RMM1&P[+\<_LP?M6?\%./^"?/[<G@7_@G]_P %2/'.
MB?%GP7\7'NK/X1_'70]'2PN1J5O$9/[-U*WC4(KN@ 4X9MSJ?-F'F>2S_@G)
MK>J_$S_@XE_;F\:>*I6>X\)^'?"'AO0HI#G[-8-:^8R)GHKR0"4CH6D)H ^W
M?V4_VPOA]^U7;>*]$T?1-2\.>,/A]XB?0?B#X'U[ROM^A7X42(&,3O'-!-$R
MRPW$;,DL;9!#!T7UJOS+_9S\1:AX6_X.J/V@_A]H4C1Z7XL_9MT37=?AC.%E
MO[*?3;2WD<="RP7$B@GG#'WK]-* "BBN#^(/[3WP ^%7B-O"7Q$^*FEZ1J20
MI*UG=R,'"-RK< \&@#A_VL/^2V? _P#['N7_ -)FKW2OE3XY?M(? SXI_''X
M-P?#WXF:;JSV'C9I+Q;21CY2- 44G('!8@5],_\ "8^&/^@U!_WU0!I45F_\
M)CX8_P"@U!_WU1_PF/AC_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H
M-0?]]4 :5%9O_"8^&/\ H-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_
M 'U1_P )CX8_Z#4'_?5 &E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F
M_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU0!I45F_\)CX8_P"@U!_WU1_PF/AC
M_H-0?]]4 :5%9O\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]4 :5%9O_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?5 &E16;_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?5
M&E16;_PF/AC_ *#4'_?5'_"8^&/^@U!_WU0!I45F_P#"8^&/^@U!_P!]4?\
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M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
MA_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^S
MM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQ
MA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_
ML[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_O
MT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/
M_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_
M[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[
M3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*
MFKC_ (Y?M!? W]F;X?W7Q5_:%^+?A[P7X<LQ^_UCQ)JL5I!NP2$5I"-[G'RH
MN68\ $T =5_9VG_\^,/_ 'Z%9WB[Q!X"^'_AF]\:>/=;T?1-&TV SZCJVKW,
M5M;6L0ZO)+(0B*.Y8@5\!WW_  6-_:>_;?O9O!W_  1>_8IU/QUIK2M _P =
M_BU#/H'@NU(.#+;HX6[U(*>"D2HZ\':PJYX1_P""&FJ?M&^);+XM_P#!8K]K
M3Q-^T/KMK.+JQ\ 0.VB^"-'EZ@0Z;;,OVEE^[YLI'F*/WD;4 .^('_!<GPA\
M9?%]]\%/^"27[*WB/]IKQ?:3&VOO$>B0C3/!NC2^MUK-PHC? (8+$"L@!"R
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M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\
M?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:
M?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_
M 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9
MVG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H
M5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_
M ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_W
MZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG
M_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-
M10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!$EC91L'CLXE8="L8!%2T44
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'A?[6'_ "6SX'_]CW+_ .DS
M5[I7A?[6'_);/@?_ -CW+_Z3-7NE !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !117S?^VO\ \%9?V%/V!98_#GQV^,\$_C"\*+I'PY\*V[:KXAU&1_\
M5QQV,&73?T5Y?+C)XW4 ?2%>1?M=_MZ_L>_L'>"?^$^_:T_: \/>"[.2-FLK
M74;K?>W^.JVUI$&GN3ZB-&QWQ7R)_P +-_X+D_\ !2C]S\&_AQIW[&WPKO>!
MXK\?6::QX\U"W/\ %!IN1!II*Y!6<B5#AD<UZ[^R+_P1-_8A_96\;?\ "\O$
M'A[6/BU\6)Y%FO\ XM?&#5&UW6I)QTDA:8>7:D'(4Q(KA3M+MB@#R+_AOW_@
MJU_P46_XEG_!,S]C\?"#P!><+\=OVAK-K>:XA/\ RVTS0TW22Y'S1RS;H7!
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MCW7K14MH01'%'!:WT4,2C+'"(N6=F.69B?+_ /B%Q_X(4?\ 1C/_ )DWQ/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY)H/Q;_;"\*SZ\DGE+X6\)SOKFJ-,3A83;6"RO$Y/ $@0<]0.:\:_P"'L?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HJOJVKZ3H.G2ZOKFIV]E:0+NGNKN=8XXQG&69B !]:L4 %%%% !1
M110 4444 %%%% 'A?[6'_);/@?\ ]CW+_P"DS5[I7A?[6'_);/@?_P!CW+_Z
M3-7NE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?P!U_?Q=75K8VLE[>W,<,,,9>::5PJHH&2Q)X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"G[6>K^+GO/@_P#%?POI&BF! EEJVA/<3"0#YV+@C@GH* .;_:P_Y+9\#_\
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M+\':?XZ\-_L'ZM!8ZG;B:VBUWQ;HFEW:J>GF6M[>Q3PM_LR1JWM7]+W[$?\
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MQ16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\
M 8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_
M  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_
M -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !C_C1]B\;
M_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%
M%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\ T&[+_P !
MC_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\
M 8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45C_8O&_\
MT&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/^-'V+QO_
M -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !C_C0!L45
MC_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0;LO_  &/
M^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\ T&[+_P !
MC_C0!L45C_8O&_\ T&[+_P !C_C1]B\;_P#0;LO_  &/^- &Q16/]B\;_P#0
M;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\  8_XT?8O&_\
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MPW^%7A>+2=(M'EE6!)7EDFFE=I)KB::5FDN)Y)&:22:5FDD=V=V9B2>DHHH
M**** /"_VL/^2V? _P#['N7_ -)FKW2O"_VL/^2V? __ +'N7_TF:O=* "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK/\5^+?
M"O@/PW?>,_''B;3]&T?3+9KC4M5U:]2WMK2%1EI)99"%C0#DLQ % &A7"?M&
M_M/_ +/?[(OPQO/C+^TQ\7]#\%^&;$8FU37;T1+(^"1%$G+SRG!VQ1JSMT"F
MOS^_:G_X."AXST?7M&_X)C>#M \0Z-H4[6GBC]H_XJ7[:+\//#DO=8[B3;+J
MUP.=MO; L^5:,3*<5\;_ +/WP-_:K_X*/?%F#X]_!'P5J?[0WB]9"L?[57[3
M>BR:;X!\-Y;+#PIX7*_Z5M(RDTL942QAFAB+$T ?3?[4/_!9O]IS]HKX;W'Q
M _9GU31OV6OV?YBT<G[3?QUL-NJ:['CG_A&M .9;V0K\R.RL'4GB)UKQ_P#8
M=_9H_:5^-GB>Y^*'_!,/X ZSX:NO$9+>(_V[OVM;4ZKXMUQ77:\V@:3-GR8V
M'^KD8"-XR%D8,H-?=_[+W_!#SX ?#GXDV_[3G[9_Q US]I'XSJ%8>.OB@JS6
M>EN#N":9I>3;6,2MAD #M&1E&0'%?:\\\%I ]S<S)%%$A:221@JHH&223T %
M 'R+^QM_P1<_91_99\?']HGXC7FN?&CXTW3++J/Q?^+%Y_:FJ+*.1]C23,5@
MBDD((EWJIV&1@*^O:^*/VA_^"\O[%'PP\=R_ C]G!/$G[0WQ1^9(? 'P/TEM
M:DB<';FYNX_]&MT5N)#YC/'@EDXK@O\ A4/_  7<_P""AW[_ ../QCT#]CSX
M<WG+>$/AG<)KGC:Y@/\ RSGU5L6]D^"")+8;U((9* /J+]LC_@I3^PY^P'H8
MU?\ :M_:,\/^&+J6+?8^'S.;K5KX'@>18P![B4$X&X)M!(RPZU^*/_!P=_P<
M)_';XK_LW3?LG?"G]D/QE\*O!_Q6TXL/%GQ*Q8:YKNC1S+YOV?3%)>UM9V41
M^?*[">,RHB@AROZ_?L;_ /!'#]@#]B+7#\0_AG\&5\0>/9Y?/U#XG?$"\;6_
M$5W.?O3&[N<F%VP,^0L2G'(K\,_^"L__  1I_P""_?\ P4I_;S\=?M3ZI^P]
M<1Z1J.H?8?!NG7'Q-\, V&B6Y,=I%M_M/Y69,RR <>;-(>] 'XXU]'_\$F/V
M^/$G_!-;]O/P+^U/I<MQ)I&G:A]A\9:=;DDW^B7!$=W%M_B94Q+&#QYL,9[5
M[A_Q"X_\%U_^C&?_ #)OAC_Y9T?\0N/_  77_P"C&?\ S)OAC_Y9T ?UV^$_
M%?AOQWX5TSQQX.UJWU+2-9T^&^TK4;20/%=6TR"2*5&'WE9&5@>X(K0KX0_X
M-YOAA_P4/_9V_8,L_P!EC_@HC\$;CPIJ_P /M0:Q\%:C+XGTS4QJ6B.#)%$6
ML;J?8UNY>(!]H\KR N=K8^[Z "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%_3&\,>%P& 'VNUL(A]LU3>,$S#YRP_>*V2: /)_V'_^#6GX6?#/1KKXZ?\
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M%^SOHNC:S,K#4/%U\C7VMWS-R[2W]P7G(8DDH&"9)PHZ5[_10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&^K_ +3GQQT_QI_P7H_;Q\2?$3Q[]K+>&/V0OV:XEU_6K67K]DD6R+6.EN
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M+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\
MP+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V
M**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A
M!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$
M'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^
M;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GY
MO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "
MVH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+
M:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'
M_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!]
M(_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'T
MC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W
M_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;
MW_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#
M8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_^$'TC_GYO?\ P+:C
M_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VH V**Q_
M^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_ )^;W_P+:C_A!](_
MY^;W_P "VH V**Q_^$'TC_GYO?\ P+:C_A!](_Y^;W_P+:@#8HK'_P"$'TC_
M )^;W_P+:C_A!](_Y^;W_P "VH V**R[/PEIMC=)=PW%T6C;*A[EB/Q%:E !
M1110 4444 >:_M(?L?\ [-7[6_A2?PC^T'\&/#GB:&6#RHKO5=%MY[FU7<&_
M<RRQLT1R.JXZGUKN/"/@[PCX \.6G@[P'X6TW1-(L(_+L=*TBQCMK:W3.=L<
M48"H,D\ #K6E10!Q>O?LW_L[^*M9N/$7BCX">"]2U"\D,EW?7_A:TFFG<]6=
MWC+,?<FNR,<9C\DQJ4*X*XXQZ8IU% ',_#GX+_!WX/+?K\)/A/X9\+#5;CS]
M3'AS0;>Q^V2\_O)?)1?,;D_,V3R:M?$/X8_#;XN^&I/!GQ7^'NA^)]'ED627
M2?$.DPWML[K]UC%,K(2.QQQ6Y10!5T/0M$\,:-:^'?#6C6FG:?8P+#96%C;K
M##;Q*,*B(@"HH'    JU110 4444 >%_M8?\EL^!_P#V/<O_ *3-7NE>%_M8
M?\EL^!__ &/<O_I,U>Z4 %%%% !1110 4444 %?D#_P=:_\ !+C]NS_@I1_P
MH7_ABGX&?\)I_P (7_PE/_"3?\5-I>G?8_MG]D?9_P#C_N8/,W_99_N;MNSY
ML;ES^OU% '\@7_$+C_P77_Z,9_\ ,F^&/_EG1_Q"X_\ !=?_ *,9_P#,F^&/
M_EG7]?M% '\@7_$+C_P77_Z,9_\ ,F^&/_EG7]?M%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 >%_M8?\EL^!_\ V/<O_I,U>Z5X7^UA
M_P EL^!__8]R_P#I,U>Z4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!X7^UA_R6SX'_P#8]R_^
MDS5[I7A?[6'_ "6SX'_]CW+_ .DS5[I0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 445#J%_8Z583ZIJE[%;6UM"TMQ<3R!$BC4$
ML[,>%  ))/  H FHKXKT#_@K?XO^+/BWPSXH_9K_ &*_&_CWX9^)/!WB77M&
MU^PO=-M=4\0VNDW^EVCWFFV-S=QL]N3?OM2<PSS_ +LQQ[?O^@_''_@I]\&O
M@[^QKX(_;.T'X7?$+QU8?$H:6/ G@?P3X9-WXCUF2^@:Y2**R+J3(ENDTLB[
MOE6%^IP" ?2=%?GCI/\ P<'Z8_Q"\&_#[QU_P2;_ &P/!3>.?&.G^&-#U?QQ
M\*(M*L&U"\E$<,;3W%TJ@_><@9.V-VP0IKZD_;D_;<\*?L.?#;3/&NJ?!WQ_
M\1M:U[65TSP[X"^%OAPZOKNJ2B*2:9X;564M'##%))(^0% &>64$ ]JHKP']
M@_\ ;JU[]N#1_$>N:K^Q+\;O@W#X?N;>"&+XU>#5T6;56E5V8VL1E=Y$C"KO
M<A5S(H4L0P7WZ@ HHHH \+_:P_Y+9\#_ /L>Y?\ TF:O=*\+_:P_Y+9\#_\
ML>Y?_29J]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[2=&B<=%DCM4UBX7/(W1L.QKG_\ @I3_ ,$\_P#@H/\ M"_M >'/VMOV%/\
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M#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T
M&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\
M,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%
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M_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\
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M^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\
M^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I
M_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\
MWZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I_
M_/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G
M:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
MOJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'
MPQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^
M$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/
M^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_
M[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'P
MQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_
M (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!
M3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H
M4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^
M,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9
MVG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4
M?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_W
MZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^
M,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?
MV=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJ
MKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_
M[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&
MH/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_
M (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^
M^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/
M^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\
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M+AN$N701+;PW&VX8%9 V^2.,=@#UKM?VFOVOO"7[.?BCP-\*;3PCJGBSQ_\
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MG)Y=UI]W&CNBRQM@Y1W1U='1F5@2 >HT444 %%%% !1110 4444 %%%>$?\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^*/\ @XP
M;_@BG\?@1G_BE[3_ -.5I7VO7QO_ ,%[/!?Q*^,G_!+SXG_L\?!/X4^)O&7C
M+QQI,%EH&C>'-&EN-S)?6LLC2R@"*!5168>8ZEL$(&(( ![]\ _#'A_QO^Q[
MX*\&>+=(@U#2M7^&NFV6IV%RFZ.YMY=/CCDB<=U9&*D>AKQO_@M [>+OV ?&
M/[+OA'PW#KOC;XU6G_"#?#_PXP&;K4;P$&X/!\N*SA6:]DE/$<=HS=< ^D?
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M\#?!CX;Z!\(OACX<@TCPYX8T>VTK0M+M01':6D$:Q11+GDA44#)R3C))-;M
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M%LK0P+>7D5M!'&$5YY(X_,D\I22\BJ6Y9N]>$>%+G]I']J[X@_L^ZO\ M!_
M6Z\#V^BV>K?$;Q;H>7GM],U(!K'1-&FN" D]U'!J%Q=3!<!9]/C8*H* =_\
MM=_MA>./V5/$O@VVT;]C+XJ?%#0O$ES<PZYK?PQT>'4I/#IC$?E-/:^8LTB2
M;V^9 0HB;JQ52 ?&G_!/W]K/PO\ $3_@M[\9?#_[6W[*/B[X/_'KQ#X%L[#X
M=Z;XCN[:ZM+[P;8.9&$%Q:LT4US+<F6>1D>6+9 L:/NMY#)U7_!TL ?^"0/B
M@D=/'/A?'_@WMZ]5\-_ 7Q/^UG_P4;\!_P#!0+Q7\(=9\#^'?A/X!U?1?!\'
MBFWCMM8U^_U1HEFGEMD=VMK2W@C=$6;9,\MS(WEHB*TO ?\ !QS\-/C+^T-_
MP3OU']G3]GCX)>+/'/B_6O%&B7UMIWAW19)8X[>TOX[B5Y)VVPH=L9 0OO)8
M87&2 #[ZFFAMX7N+B58XXU+.[M@*!R22>@KYO_8(\(:%\9O@MK/[3OCO08KZ
M3XS_ ! ;Q]IT=[%N":;#)!%X<< ]"FG6&F7 '19G=AR=QU_VP]>\>_&C]C74
MO"/P6\*^*;35_B9):>$U:?0;FTO=!M=1NDLK_4)HY$#0?9;22YN [#:6B3:6
MWJ3T7[3?Q0\4?LD?LP7OB/\ 9^_9HU_XBZMH.F16'A#X>>$(D62X=4\N"-G<
MA8+= HWR')5%^578JI /G'_@M?\ !:R_;IT;X3_\$YO#EDMYKOC#XE:;XGU^
MZC3<?#?AG2I#)?:F[?\ +-G+QV<(./,DNRH.$D*_9'Q7 ;X6^)589!T"\R/^
MV#U^:'P*_P""@'_!0/X0:1K?C+5O^"&/QT\6?$_Q<8[CQ5XJU'5M,LH;ZX16
M$%I$ \ILM/MP[)# -^Q6>1S+-+-+)^A7Q5\3^+/"O[->H:EXT\,7FL^))?"K
M07NE>"]'N+PW.HO;%6CMXE#NL9ER%:0@*"-[CDT ?*'_  ;&?\H-/@3_ ->>
MO?\ J0ZG7WG7Q!_P;Q_#SXK? /\ X)7_  X_9D^/7PA\4>"_&O@A-4BUS2?$
M6C20+BYU>^NH7AFP8I@8I4)",60G# 9&?M^@ HHHH **** "BBB@ HHHH *_
M.W]E  ?\'(_[5Y Z_!OP7G_OTE?HE7YV_LM:'\6-,_X+P?'K]I'7_P!GOXA:
M9\//B%\/O#FA^$O&&H^$+J*UN[RRCB6571E\ZW3)8"29$7]V22 5R ?H%;^%
MO#MKXIN_&UOHT":M?Z?;V-YJ"I^]FMH'GDAB8]U1[F=@/65O6OBC]E#X*V/Q
MT_X+)?&?_@I=X7L5@\)Z+\/;7X2>&]4A3$?B:^MKU;K5KU#QOCMYXH+!9.5=
M[:=0<1 F]_P53_:L_;#\!ZYHG[/W[,G[#?Q;\?:#K,/G?$+QG\/GM[6:WL#N
M']G6%Q+(IBN9L8DN5&Z")CY1\YUD@C_8\_;>_:I\8^,-#^"L'_!(/QS\$/AI
MX2\,75SJ&J>(IK:1(K.TMBEMIFFV=EDR7#RM#M!.!'%( K,P*@'K'P\_XO9_
MP4/\<_$A_P![H_P;\*6W@C16ZJ-:U,6^K:NP[96T304!'(+3KQR*\*_X. _C
M?\6?A=^PEXH^&WA']BOQMXZ^'NO:9'9?$_Q7X2U#3HQX>\.%U^WO!;M(]P\X
MMDD59#;B"#<)7<A"A^D/V"OASXU^&O[+.D:Q\3O#\UMXW\8W%[XQ\;Z<^!-!
MJ^JW$E_-9$L0/]'\Y;1,X 2V0< 5Y)H/[?OQM_:1^#_BCX=VW_!+WXU^&O'E
M[8WFE6_AOX@:#;6NB2O(CQ+-+JOG&W:T 8-(4WRE0PCBE.P. >Z?L3?$_P"
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MX96YTW2-9N(+[7?%>H.69;>P@A98D6-(65O,?YWN8<&-8W+?+_PU_P""@?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6\O=F2RK''%YA 4S0Y\Q0#]&HY(YHUEBD5D90593D$'H0:6N3^ WPFTOX!_
MWP9\"]#UB\U&R\%^$].T&SU#4'W7%S%9VT=NDLI[NRQAF/J3764 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$;?^A*^('_A=S?\ Q%'_ !"'?\$;?^A*^('_ (7<W_Q% 'O_ /P_X_X(V_\
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M$;?^A*^('_A=S?\ Q%'_ !"'?\$;?^A*^('_ (7<W_Q% 'O_ /P_X_X(V_\
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M ,$ZOBW^TK\&_"GC2#Q1X.\)R:AHLNH>,)9X5F$B*"\94!QACQ7T)_P:'?\
M*&S1/^R@:]_Z.2@#]/J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
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M"9&1D.^,[ P(W;=I /I>BOS'_P""G'_!7;]K3_@F'_P4&^&'@KQ[:^#/$/P
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MHH **** "BBB@#Y _P""_'_*&S]H3_LG\W_HZ*O /^#0[_E#9HG_ &4#7O\
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M /\ Q$@?L*?]$>_: _\ #):I_P#$T?\ $2!^PI_T1[]H#_PR6J?_ !-??U%
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M*O\ @JC)\.HYW@M?V0+.VU?[+D[KAM!LI IQU8VRW( ZX! K]+_B1^Q/\1?
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MX2^&O@?\*M!CTOPUX1T.UTC0M/C)(@M;>)8HU)/+':HRQY8Y)))- '2T444
M%%%% 'B'[;W[?GP8_8$\*Z'XO^,_A3QQJMKX@U"2SLH_ _@^YUB6.1$WDRI
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MX@U3PKXL\':RFM_#CXB>'&"ZGX9U1"K+/"3C>A9(]\1(#>6A#(Z(ZUO D?\
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M?7-+\327-A9:O;GQ!&CQQW$*7,EB_G&*57,5P-L;1E3O\Q0"O_P36\"^.?\
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MF_L3^T?L?V/5+2__ ./?SX/,W_9?+_UB[=^[G;M/Y@?\1O/[+/\ T8]\0/\
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M]EG_ *,>^('_ (45C_A1_P 1O/[+/_1CWQ _\**Q_P * //_ /B!C_ZRB_\
MF$__ +]5^WW[*OPI^(_P+_9Q\%_!GXM_&#_A8'B'PMX?M]+U#QHVC'3WU?R%
M\N.>2 SSE93&J;SYC;W#/QNVC\@?^(WG]EG_ *,>^('_ (45C_A1_P 1O/[+
M/_1CWQ _\**Q_P * /V^HK\0?^(WG]EG_HQ[X@?^%%8_X4?\1O/[+/\ T8]\
M0/\ PHK'_"@#]OJ*_$'_ (C>?V6?^C'OB!_X45C_ (4?\1O/[+/_ $8]\0/_
M  HK'_"@#]OJ*_$'_B-Y_99_Z,>^('_A16/^%'_$;S^RS_T8]\0/_"BL?\*
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M_10!P'_#)_[+/_1M7P__ /"-L?\ XU1_PR?^RS_T;5\/_P#PC;'_ .-5W]%
M' ?\,G_LL_\ 1M7P_P#_  C;'_XU1_PR?^RS_P!&U?#_ /\ "-L?_C5=_10!
MP'_#)_[+/_1M7P__ /"-L?\ XU1_PR?^RS_T;5\/_P#PC;'_ .-5W]% ' ?\
M,G_LL_\ 1M7P_P#_  C;'_XU1_PR?^RS_P!&U?#_ /\ "-L?_C5=_10!P'_#
M)_[+/_1M7P__ /"-L?\ XU1_PR?^RS_T;5\/_P#PC;'_ .-5W]% ' ?\,G_L
ML_\ 1M7P_P#_  C;'_XU1_PR?^RS_P!&U?#_ /\ "-L?_C5=_10!P'_#)_[+
M/_1M7P__ /"-L?\ XU1_PR?^RS_T;5\/_P#PC;'_ .-5W]% ' ?\,G_LL_\
M1M7P_P#_  C;'_XU1_PR?^RS_P!&U?#_ /\ "-L?_C5=_10!P'_#)_[+/_1M
M7P__ /"-L?\ XU1_PR?^RS_T;5\/_P#PC;'_ .-5W]% ' ?\,G_LL_\ 1M7P
M_P#_  C;'_XU1_PR?^RS_P!&U?#_ /\ "-L?_C5=_10!P'_#)_[+/_1M7P__
M /"-L?\ XU1_PR?^RS_T;5\/_P#PC;'_ .-5W]% ' ?\,G_LL_\ 1M7P_P#_
M  C;'_XU1_PR?^RS_P!&U?#_ /\ "-L?_C5=_10!P'_#)_[+/_1M7P__ /"-
ML?\ XU1_PR?^RS_T;5\/_P#PC;'_ .-5W]% ' ?\,G_LL_\ 1M7P_P#_  C;
M'_XU1_PR?^RS_P!&U?#_ /\ "-L?_C5=_10!P'_#)_[+/_1M7P__ /"-L?\
MXU1_PR?^RS_T;5\/_P#PC;'_ .-5W]% ' ?\,G_LL_\ 1M7P_P#_  C;'_XU
M1_PR?^RS_P!&U?#_ /\ "-L?_C5=_10!P'_#)_[+/_1M7P__ /"-L?\ XU1_
MPR?^RS_T;5\/_P#PC;'_ .-5W]% ' ?\,G_LL_\ 1M7P_P#_  C;'_XU1_PR
M?^RS_P!&U?#_ /\ "-L?_C5=_10!P'_#)_[+/_1M7P__ /"-L?\ XU1_PR?^
MRS_T;5\/_P#PC;'_ .-5W]% ' ?\,G_LL_\ 1M7P_P#_  C;'_XU1_PR?^RS
M_P!&U?#_ /\ "-L?_C5=_10!P'_#)_[+/_1M7P__ /"-L?\ XU1_PR?^RS_T
M;5\/_P#PC;'_ .-5W]% ' ?\,G_LL_\ 1M7P_P#_  C;'_XU1_PR?^RS_P!&
MU?#_ /\ "-L?_C5=_10!P'_#)_[+/_1M7P__ /"-L?\ XU1_PR?^RS_T;5\/
M_P#PC;'_ .-5W]% ' ?\,G_LL_\ 1M7P_P#_  C;'_XU1_PR?^RS_P!&U?#_
M /\ "-L?_C5=_10!P'_#)_[+/_1M7P__ /"-L?\ XU1_PR?^RS_T;5\/_P#P
MC;'_ .-5W]% ' ?\,G_LL_\ 1M7P_P#_  C;'_XU1_PR?^RS_P!&U?#_ /\
M"-L?_C5=_10!P'_#)_[+/_1M7P__ /"-L?\ XU1_PR?^RS_T;5\/_P#PC;'_
M .-5W]% ' ?\,G_LL_\ 1M7P_P#_  C;'_XU1_PR?^RS_P!&U?#_ /\ "-L?
M_C5=_10!P'_#)_[+/_1M7P__ /"-L?\ XU1_PR?^RS_T;5\/_P#PC;'_ .-5
MW]% ' ?\,G_LL_\ 1M7P_P#_  C;'_XU1_PR?^RS_P!&U?#_ /\ "-L?_C5=
M_10!P'_#)_[+/_1M7P__ /"-L?\ XU1_PR?^RS_T;5\/_P#PC;'_ .-5W]%
M' ?\,G_LL_\ 1M7P_P#_  C;'_XU1_PR?^RS_P!&U?#_ /\ "-L?_C5=_10!
MP'_#)_[+/_1M7P__ /"-L?\ XU1_PR?^RS_T;5\/_P#PC;'_ .-5W]% ' ?\
M,G_LL_\ 1M7P_P#_  C;'_XU1_PR?^RS_P!&U?#_ /\ "-L?_C5=_10!P'_#
M)_[+/_1M7P__ /"-L?\ XU1_PR?^RS_T;5\/_P#PC;'_ .-5W]% ' ?\,G_L
ML_\ 1M7P_P#_  C;'_XU1_PR?^RS_P!&U?#_ /\ "-L?_C5=_10!P'_#)_[+
M/_1M7P__ /"-L?\ XU1_PR?^RS_T;5\/_P#PC;'_ .-5W]% ' ?\,G_LL_\
M1M7P_P#_  C;'_XU1_PR?^RS_P!&U?#_ /\ "-L?_C5=_10!P'_#)_[+/_1M
M7P__ /"-L?\ XU1_PR?^RS_T;5\/_P#PC;'_ .-5W]% ' ?\,G_LL_\ 1M7P
M_P#_  C;'_XU75^$/!'@OX?:,OASP%X0TO0]/61I%L-(T^.VA#M]Y@D:A<GN
M<<UJ44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656666047600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-5975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">HUMANA INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">61-0647538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 West Main Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Louisville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">KY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">40202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">580-1000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.16 2/3 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HUM<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,096,895,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,653,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Parts II and III incorporate herein by reference portions of the Registrant&#8217;s Definitive Proxy Statement to be filed pursuant to Regulation 14A with respect to the Annual Meeting of Stockholders scheduled to be held on April&#160;18, 2024. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000049071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656666046992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Louisville, Kentucky<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667495264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,694<span></span>
</td>
<td class="nump">$ 5,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investment securities</a></td>
<td class="nump">16,626<span></span>
</td>
<td class="nump">13,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables, net of allowances of $88 in 2023 and $70 in 2022</a></td>
<td class="nump">2,035<span></span>
</td>
<td class="nump">1,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">6,631<span></span>
</td>
<td class="nump">5,567<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">29,986<span></span>
</td>
<td class="nump">26,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,030<span></span>
</td>
<td class="nump">3,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term investment securities</a></td>
<td class="nump">382<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">9,550<span></span>
</td>
<td class="nump">9,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">740<span></span>
</td>
<td class="nump">749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">3,377<span></span>
</td>
<td class="nump">3,380<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">47,065<span></span>
</td>
<td class="nump">43,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Benefits payable</a></td>
<td class="nump">10,241<span></span>
</td>
<td class="nump">9,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Trade accounts payable and accrued expenses</a></td>
<td class="nump">6,569<span></span>
</td>
<td class="nump">5,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_BookOverdraftLiability', window );">Book overdraft</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Unearned revenues</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term debt</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">2,092<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,872<span></span>
</td>
<td class="nump">17,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">10,213<span></span>
</td>
<td class="nump">9,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,662<span></span>
</td>
<td class="nump">1,473<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">30,747<span></span>
</td>
<td class="nump">27,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 17)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $1 par; 10,000,000 shares authorized; none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,690,082 shares issued at December 31, 2023 and 198,666,598 shares issued at December 31, 2022</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital in excess of par value</a></td>
<td class="nump">3,346<span></span>
</td>
<td class="nump">3,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">27,540<span></span>
</td>
<td class="nump">25,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(999)<span></span>
</td>
<td class="num">(1,304)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, 76,465,862 shares at December 31, 2023 and 73,691,955 shares at December 31, 2022</a></td>
<td class="num">(13,658)<span></span>
</td>
<td class="num">(12,156)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">16,262<span></span>
</td>
<td class="nump">15,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">16,318<span></span>
</td>
<td class="nump">15,370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 47,065<span></span>
</td>
<td class="nump">$ 43,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_BookOverdraftLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Book Overdraft Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_BookOverdraftLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656665874016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Receivables, net of allowances</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par (in dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par (in dollars per share)</a></td>
<td class="nump">$ 0.1667<span></span>
</td>
<td class="nump">$ 0.1667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">198,690,082<span></span>
</td>
<td class="nump">198,666,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">76,465,862<span></span>
</td>
<td class="nump">73,691,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656665605184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Services</a></td>
<td class="text">Health Care [Member]<span></span>
</td>
<td class="text">Health Care [Member]<span></span>
</td>
<td class="text">Health Care [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">$ 101,272<span></span>
</td>
<td class="nump">$ 87,712<span></span>
</td>
<td class="nump">$ 79,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services</a></td>
<td class="nump">4,033<span></span>
</td>
<td class="nump">4,776<span></span>
</td>
<td class="nump">3,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Investment income</a></td>
<td class="nump">1,069<span></span>
</td>
<td class="nump">382<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">106,374<span></span>
</td>
<td class="nump">92,870<span></span>
</td>
<td class="nump">83,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare', window );">Benefits</a></td>
<td class="nump">88,394<span></span>
</td>
<td class="nump">75,690<span></span>
</td>
<td class="nump">69,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Operating costs</a></td>
<td class="nump">13,188<span></span>
</td>
<td class="nump">12,671<span></span>
</td>
<td class="nump">10,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">779<span></span>
</td>
<td class="nump">709<span></span>
</td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BenefitsLossesAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">102,361<span></span>
</td>
<td class="nump">89,070<span></span>
</td>
<td class="nump">79,916<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">4,013<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">3,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of Gentiva Hospice</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(237)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income), net</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="num">(532)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes and equity in net earnings</a></td>
<td class="nump">3,383<span></span>
</td>
<td class="nump">3,568<span></span>
</td>
<td class="nump">3,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">836<span></span>
</td>
<td class="nump">762<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net (losses) earnings</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,484<span></span>
</td>
<td class="nump">2,802<span></span>
</td>
<td class="nump">2,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss (income) attributable to noncontrolling interests</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Humana</a></td>
<td class="nump">$ 2,489<span></span>
</td>
<td class="nump">$ 2,806<span></span>
</td>
<td class="nump">$ 2,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per common share (in dollars per share)</a></td>
<td class="nump">$ 20.09<span></span>
</td>
<td class="nump">$ 22.20<span></span>
</td>
<td class="nump">$ 22.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per common share (in dollars per share)</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 22.08<span></span>
</td>
<td class="nump">$ 22.67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BenefitsLossesAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.5,6,7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BenefitsLossesAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred for health insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480149/944-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -SubTopic 220<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -SubTopic 220<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656665136512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Humana</a></td>
<td class="nump">$ 2,489<span></span>
</td>
<td class="nump">$ 2,806<span></span>
</td>
<td class="nump">$ 2,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Change in gross unrealized investment gains (losses)</a></td>
<td class="nump">372<span></span>
</td>
<td class="num">(1,819)<span></span>
</td>
<td class="num">(356)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Effect of income taxes</a></td>
<td class="num">(85)<span></span>
</td>
<td class="nump">418<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Total change in unrealized investment gains (losses), net of tax</a></td>
<td class="nump">287<span></span>
</td>
<td class="num">(1,401)<span></span>
</td>
<td class="num">(275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax', window );">Reclassification adjustment for net realized losses (gains) included in investment income</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Effect of income taxes</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Total reclassification adjustment, net of tax</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">305<span></span>
</td>
<td class="num">(1,346)<span></span>
</td>
<td class="num">(355)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments', window );">Comprehensive income attributable to equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Humana</a></td>
<td class="nump">$ 2,794<span></span>
</td>
<td class="nump">$ 1,460<span></span>
</td>
<td class="nump">$ 2,584<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Income (Loss), Net of Tax, Attributable To Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667734800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Total Stockholders' Equity</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Capital&#160;In Excess&#160;of Par Value</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 13,728<span></span>
</td>
<td class="nump">$ 13,728<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 2,705<span></span>
</td>
<td class="nump">$ 20,517<span></span>
</td>
<td class="nump">$ 391<span></span>
</td>
<td class="num">$ (9,918)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,934<span></span>
</td>
<td class="nump">2,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Acquisition</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(349)<span></span>
</td>
<td class="num">(349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(349)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Common stock repurchases</a></td>
<td class="num">(79)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends and dividend equivalents</a></td>
<td class="num">(364)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(364)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock unit vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">16,103<span></span>
</td>
<td class="nump">16,080<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">3,082<span></span>
</td>
<td class="nump">23,086<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="num">(10,163)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,802<span></span>
</td>
<td class="nump">2,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders', window );">Distribution from (to) noncontrolling interest holders, net</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Sale of Gentiva Hospice</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Acquisition</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(1,346)<span></span>
</td>
<td class="num">(1,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Common stock repurchases</a></td>
<td class="num">(2,096)<span></span>
</td>
<td class="num">(2,096)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,096)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends and dividend equivalents</a></td>
<td class="num">(400)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">216<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock unit vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock unit vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">15,370<span></span>
</td>
<td class="nump">15,311<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">3,246<span></span>
</td>
<td class="nump">25,492<span></span>
</td>
<td class="num">(1,304)<span></span>
</td>
<td class="num">(12,156)<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,484<span></span>
</td>
<td class="nump">2,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders', window );">Distribution from (to) noncontrolling interest holders, net</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Acquisition</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Common stock repurchases</a></td>
<td class="num">(1,586)<span></span>
</td>
<td class="num">(1,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,586)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Dividends and dividend equivalents</a></td>
<td class="num">(441)<span></span>
</td>
<td class="num">(441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(441)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Restricted stock unit vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Restricted stock unit vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock option exercises</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 16,318<span></span>
</td>
<td class="nump">$ 16,262<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 3,346<span></span>
</td>
<td class="nump">$ 27,540<span></span>
</td>
<td class="num">$ (999)<span></span>
</td>
<td class="num">$ (13,658)<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase (Decrease) From Contributions Or Distributions To Noncontrolling Interest Holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-23<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656666072832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOW - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 2,484<span></span>
</td>
<td class="nump">$ 2,802<span></span>
</td>
<td class="nump">$ 2,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of Gentiva Hospice</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(237)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesGainLoss', window );">Loss on investment securities, net</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on Kindred at Home equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net losses (earnings)</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">850<span></span>
</td>
<td class="nump">749<span></span>
</td>
<td class="nump">640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment of property and equipment</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="num">(167)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of effect of businesses acquired and dispositions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(337)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(280)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(1,318)<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="num">(491)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities', window );">Benefits payable</a></td>
<td class="nump">915<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">841<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Unearned revenues</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="num">(65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other, net</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">3,981<span></span>
</td>
<td class="nump">4,587<span></span>
</td>
<td class="nump">2,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Proceeds from sale of Gentiva Hospice, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,701<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash and cash equivalents acquired</a></td>
<td class="num">(233)<span></span>
</td>
<td class="num">(337)<span></span>
</td>
<td class="num">(4,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,004)<span></span>
</td>
<td class="num">(1,137)<span></span>
</td>
<td class="num">(1,342)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investment securities</a></td>
<td class="num">(7,552)<span></span>
</td>
<td class="num">(6,049)<span></span>
</td>
<td class="num">(7,197)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investment securities</a></td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">2,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of investment securities</a></td>
<td class="nump">3,795<span></span>
</td>
<td class="nump">2,434<span></span>
</td>
<td class="nump">3,547<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(3,492)<span></span>
</td>
<td class="num">(1,006)<span></span>
</td>
<td class="num">(6,556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_PaymentsForProceedsFromContractDeposits', window );">Receipts (withdrawals) from contract deposits, net</a></td>
<td class="nump">828<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from issuance of senior notes, net</a></td>
<td class="nump">2,544<span></span>
</td>
<td class="nump">1,982<span></span>
</td>
<td class="nump">2,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment of senior notes</a></td>
<td class="num">(1,832)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfCommercialPaper', window );">Proceeds (repayments) from issuance of commercial paper, net</a></td>
<td class="nump">211<span></span>
</td>
<td class="num">(376)<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term borrowings</a></td>
<td class="num">(100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Proceeds from term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Repayment of term loan</a></td>
<td class="num">(500)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">(2,078)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issue costs</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock repurchases</a></td>
<td class="num">(1,573)<span></span>
</td>
<td class="num">(2,096)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(431)<span></span>
</td>
<td class="num">(392)<span></span>
</td>
<td class="num">(354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInBookOverdrafts', window );">Change in book overdraft</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="num">(151)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(856)<span></span>
</td>
<td class="num">(1,914)<span></span>
</td>
<td class="nump">3,015<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease) increase in cash and cash equivalents</a></td>
<td class="num">(367)<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
<td class="num">(1,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">5,061<span></span>
</td>
<td class="nump">3,394<span></span>
</td>
<td class="nump">4,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">4,694<span></span>
</td>
<td class="nump">5,061<span></span>
</td>
<td class="nump">3,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest payments</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income tax payments, net</a></td>
<td class="nump">997<span></span>
</td>
<td class="nump">758<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract', window );"><strong>Details of businesses acquired in purchase transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired, net of cash acquired</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">460<span></span>
</td>
<td class="nump">9,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Less: Fair value of liabilities assumed</a></td>
<td class="num">(234)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(3,235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired', window );">Less: Noncontrolling interests acquired</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment', window );">Less: Remeasured existing Kindred at Home equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,360)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquired businesses, net of cash acquired</a></td>
<td class="nump">$ 233<span></span>
</td>
<td class="nump">$ 337<span></span>
</td>
<td class="nump">$ 4,187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Or Part Noncash Acquisition Noncontrolling Interest Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Or Part Noncash Acquisition Remeasurement Of Equity Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_PaymentsForProceedsFromContractDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Contract Deposits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_PaymentsForProceedsFromContractDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInBookOverdrafts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash during the period due to the net increase or decrease in book overdrafts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInBookOverdrafts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in health care insurance liability balances during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfCommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfCommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656669760960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REPORTING ENTITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">REPORTING ENTITY</a></td>
<td class="text">REPORTING ENTITY<div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Operations</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Humana Inc., headquartered in Louisville, Kentucky, is committed to putting health first &#8211; for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health &#8211; delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. References throughout these notes to consolidated financial statements to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Company,&#8221; and &#8220;Humana,&#8221; mean Humana Inc. and its subsidiaries. We derived approximately 84% of our total premiums and services revenue from contracts with the federal government in 2023, including 14% related to our federal government contracts with the Centers for Medicare and Medicaid Services, or CMS, to provide health insurance coverage for individual Medicare Advantage members in Florida. CMS is the federal government&#8217;s agency responsible for administering the Medicare program.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656792640720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. Our consolidated financial statements include the accounts of Humana Inc. and subsidiaries that the Company controls, including variable interest entities associated with medical practices for which we are the primary beneficiary. We do not own many of our medical practices but instead enter into exclusive management agreements with the affiliated Professional Associations, or P.A.s, that operate these medical practices. Based upon the provisions of these agreements, these affiliated P.A.s are variable interest entities and we are the primary beneficiary, and accordingly we consolidate the affiliated P.A.s. All significant intercompany balances and transactions have been eliminated.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Value Creation Initiatives and Impairment Charges </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities beginning in 2022, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, we recorded charges of $436&#160;million and $473&#160;million in 2023 and 2022, respectively, within operating costs in the consolidated statements of income. These charges were recorded at the corporate level and not allocated to the segments. We expect to incur additional charges through the end of 2024. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value creation initiative charges primarily relate to $237&#160;million and $248&#160;million in asset impairments in 2023 and 2022, respectively, as well as $199&#160;million and $116&#160;million in severance charges in connection with workforce optimization in 2023 and 2022, respectively. The remainder of the 2022 charges primarily relate to external consulting fees. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, we also recorded severance charges of $70&#160;million within operating costs in our consolidated statement of income as a result of our exit from the Employer Group Commercial Medical Products business and impairment charges of $91&#160;million, including $55&#160;million relating to indefinite-lived intangibles. The indefinite-</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lived intangibles impairment charges were included within operating costs in our consolidated statement of income with the remaining impairment charges included within investment income.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%">COVID-19</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The emergence and spread of the novel coronavirus, or COVID-19, beginning in the first quarter of 2020 has impacted our business. Initially during periods of increased incidences of COVID-19, a reduction in non-COVID-19 hospital admissions for non-emergent and elective medical care resulted in lower overall healthcare system utilization. At the same time, COVID-19 treatment and testing costs increased utilization. During 2022, we experienced lower overall utilization of the healthcare system than anticipated, as the reduction in COVID-19 utilization following the increased incidence associated with the Omicron variant outpaced the increase in non-COVID-19 utilization. The significant disruption in utilization during 2020 also impacted our ability to implement clinical initiatives to manage health care costs and chronic conditions of our members, and appropriately document their risk profiles, and, as such, significantly affected our 2021 revenue under the risk adjustment payment model for Medicare Advantage plans. Finally, changes in utilization patterns and actions taken in 2021 as a result of the COVID-19 pandemic, including the suspension of certain financial recovery programs for a period of time and shifting the timing of claim payments and provider capitation surplus payments, impacted our claim reserve development and operating cash flows for 2021.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 National Emergency declared in 2020 was terminated on April 10, 2023 and the Public Health Emergency expired on May 11, 2023.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include cash, time deposits, money market funds, commercial paper, other money market instruments, and certain U.S. Government securities with an original maturity of three months or less. Carrying value approximates fair value due to the short-term maturity of the investments.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Securities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities, which consist of debt and equity securities, are stated at fair value. Our debt securities have been categorized as available for sale. Debt securities available for current operations, as well as our equity securities, are classified as current assets, and debt securities available to fund our professional and other self-insurance liability requirements, as well as restricted statutory deposits, are classified as long-term assets. For the purpose of determining realized gross gains and losses for debt securities sold, that are included as a component of investment income in the consolidated statements of income, the cost of investment securities sold is based upon specific identification. Unrealized holding gains and losses for debt securities, net of applicable deferred taxes, are included in other comprehensive income or loss as a component of stockholders&#8217; equity until realized from a sale or an expected credit loss is recognized. For the purpose of determining gross gains and losses for equity securities, changes in fair value at the reporting date are included as a component of investment income in the consolidated statements of income.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the current expected credit losses model, or CECL, expected losses on available for sale debt securities are recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities. For debt securities whose fair value is less than their amortized cost which we do not intend to sell or are not required to sell, we evaluate the expected cash flows to be received as compared to amortized cost and determine if an expected credit loss has occurred. In the event of an expected credit loss, only the amount of the impairment associated with the expected credit loss is recognized in income with the remainder, if any, of the loss recognized in other comprehensive income.  To the extent we have the intent to sell the debt security or it is more likely than not we will be required to sell the debt security before recovery of our amortized cost basis, we recognize an impairment loss in income in an amount equal to the full difference between the amortized cost basis and the fair value.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential expected credit loss impairment is considered using a variety of factors, including the extent to which the fair value has been less than cost; adverse conditions specifically related to the industry, geographic area or financial condition of the issuer or underlying collateral of a debt security; changes in the quality of the debt </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">security's credit enhancement; payment structure of the debt security; changes in credit rating of the debt security by the rating agencies; failure of the issuer to make scheduled principal or interest payments on the debt security and changes in prepayment speeds. For debt securities, we take into account expectations of relevant market and economic data. For example, with respect to mortgage and asset-backed securities, such data includes underlying loan level data and structural features such as seniority and other forms of credit enhancements. We estimate the amount of the expected credit loss component of a debt security as the difference between the amortized cost and the present value of the expected cash flows of the security. The present value is determined using the best estimate of future cash flows discounted at the implicit interest rate at the date of purchase. The expected credit loss cannot exceed the full difference between the amortized cost basis and the fair value.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables and Revenue Recognition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally establish one-year commercial membership contracts with employer groups, subject to cancellation by the employer group on 30-day written notice. Our Medicare contracts with CMS renew annually. Our military services contracts with the federal government and certain contracts with various state Medicaid programs generally are multi-year contracts subject to annual renewal provisions.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Premiums Revenue</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive monthly premiums from the federal government and various states according to government specified payment rates and various contractual terms. We bill and collect premium from employer groups and members in our Medicare and other individual products monthly.  Changes in premium revenues resulting from the periodic changes in risk-adjustment scores derived from medical diagnoses for our membership are estimated by projecting the ultimate annual premium and are recognized ratably during the year, with adjustments each period to reflect changes in the ultimate premium. Receivables or payables are classified as current or long-term in our consolidated balance sheet based on the timing of the expected settlement. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premiums revenue is estimated by multiplying the membership covered under the various contracts by the contractual rates. Premiums revenue is recognized as income in the period members are entitled to receive services and is net of estimated uncollectible amounts, retroactive membership adjustments, and adjustments to recognize rebates under the minimum benefit ratios required under the Health Care Reform Law. We estimate policyholder rebates by projecting calendar year minimum benefit ratios for the small group and large group markets, as defined by the Health Care Reform Law using a methodology prescribed by Health and Human Services, or HHS, separately by state and legal entity. Medicare Advantage and Medicaid products are also subject to minimum benefit ratio requirements. Estimated calendar year rebates recognized ratably during the year are revised each period to reflect current experience. Retroactive membership adjustments result from enrollment changes not yet processed, or not yet reported by an employer group or the government. We routinely monitor the collectability of specific accounts, the aging of receivables, historical retroactivity trends, estimated rebates, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. Premiums received prior to the service period are recorded as unearned revenues.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Part D</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with CMS. The payments we receive monthly from CMS and members, which are determined from our annual bid, represent amounts for providing prescription drug insurance coverage. We recognize premiums revenue for providing this insurance coverage ratably over the term of our annual contract. Our CMS payment is subject to risk sharing through the Medicare Part D risk corridor provisions. In addition, receipts for reinsurance and low-income cost subsidies as well as receipts for certain discounts on brand name prescription drugs in the coverage gap represent payments for prescription drug costs for which we are not at risk.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk corridor provisions compare costs targeted in our bids to actual prescription drug costs, limited to actual costs that would have been incurred under the standard coverage as defined by CMS. Variances exceeding certain thresholds may result in CMS making additional payments to us or require us to refund to CMS a portion of the premiums we received. As risk corridor provisions are considered in our overall annual bid process, we estimate </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and recognize an adjustment to premiums revenue related to these provisions based upon pharmacy claims experience. We record a receivable or payable at the contract level and classify the amount as current or long-term in our consolidated balance sheets based on the timing of expected settlement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reinsurance and low-income cost subsidies represent funding from CMS in connection with the Medicare Part D program for which we assume no risk. Reinsurance subsidies represent funding from CMS for its portion of prescription drug costs which exceed the member&#8217;s out-of-pocket threshold, or the catastrophic coverage level. Low-income cost subsidies represent funding from CMS for all or a portion of the deductible, the coinsurance and co-payment amounts above the out-of-pocket threshold for low-income beneficiaries. Monthly prospective payments from CMS for reinsurance and low-income cost subsidies are based on assumptions submitted with our annual bid. A reconciliation and related settlement of CMS&#8217;s prospective subsidies against actual prescription drug costs we paid is made after the end of the year. The Health Care Reform Law mandates consumer discounts of 50% on brand name prescription drugs for Part D plan participants in the coverage gap. These discounts are funded by CMS and pharmaceutical manufacturers while we administer the application of these funds. We account for these subsidies and discounts as a deposit in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits, net in our consolidated statements of cash flows. </span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:56.896%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.472%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part D subsidy/discount payments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,530)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part D subsidy/discount reimbursements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net reimbursements (payments)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not recognize premiums revenue or benefit expenses for these subsidies or discounts. Receipt and payment activity is accumulated at the contract level and recorded in our consolidated balance sheets in other current assets or trade accounts payable and accrued expenses depending on the contract balance at the end of the reporting period.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Settlement of the reinsurance and low-income cost subsidies as well as the risk corridor payment is based on a reconciliation made approximately 9 months after the close of each calendar year. Settlement with CMS for brand name prescription drug discounts is based on a reconciliation made approximately 14 to 18 months after the close of each calendar year. We continue to revise our estimates with respect to the risk corridor provisions based on subsequent period pharmacy claims data. For additional information regarding amounts recorded to our consolidated balance sheets related to the risk corridor settlement and subsidies from CMS with respect to the Medicare Part D program, refer to Note 7 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K. </span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient services revenue </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient services include services related to pharmacy solutions, primary care, and home solutions and other services and capabilities to promote wellness and advance population health. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our pharmacy solutions business, external pharmacy revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments for drugs dispensed through our CenterWell Pharmacy (our mail-order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Services revenues related to product revenues from dispensing prescriptions are recorded when the prescription or product is shipped.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary care business recognizes revenues for certain value-based arrangements. Under these value-based arrangements, we enter into agreements with health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our patients. In exchange, we receive a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our patients. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home solutions businesses, revenues include net patient services revenue recorded based upon established billing rates, net of contractual allowances, discounts, or other implicit price concessions, and are recognized as performance obligations are satisfied, which is in the period services are rendered.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the&#160;year ended December&#160;31, 2023, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price), was not material. Further, revenue expected to be recognized in any future year related to remaining performance obligations is not material.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Administrative services fees </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative services fees cover the processing of claims, offering access to our provider networks and clinical programs, and responding to customer service inquiries from members of self-funded groups. Revenues from providing administration services, also known as administrative services only, or ASO, are recognized in the period services are performed and are net of estimated uncollectible amounts. ASO fees are estimated by multiplying the membership covered under the various contracts by the contractual rates. Under ASO contracts, self-funded employers retain the risk of financing substantially all of the cost of health benefits. However, many ASO customers purchase stop loss insurance coverage from us to cover catastrophic claims or to limit aggregate annual costs. Accordingly, we have recorded premiums revenue and benefits expense related to these stop loss insurance contracts. We routinely monitor the collectability of specific accounts, the aging of receivables, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. ASO fees received prior to the service period are recorded as unearned revenues.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under our TRICARE contracts with the Department of Defense (DoD) we provide administrative services, including offering access to our provider networks and clinical programs, claim processing, customer service, enrollment, and other services, while the federal government retains all of the risk of the cost of health benefits. We account for revenues under our contracts net of estimated health care costs similar to an administrative services fee only agreement. Our contracts include fixed administrative services fees and incentive fees and penalties. Administrative services fees are recognized as services are performed.&#160;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our TRICARE members are served by both in-network and out-of-network providers in accordance with our contracts. We pay health care costs related to these services to the providers and are subsequently reimbursed by the DoD for such payments. We account for the payments of the federal government&#8217;s claims and the related reimbursements under deposit accounting in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits, net in our consolidated statements of cash flows.  </span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:56.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost payments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,943)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost reimbursements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net reimbursements (payments)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, including premium receivables, patient services revenue receivables, and ASO fee receivables, are shown net of allowances for estimated uncollectible accounts, retroactive membership adjustments, and contractual allowances.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At&#160;December&#160;31, 2023 and 2022, accounts receivable related to services were $357 million and $291 million, respectively. For the&#160;years ended December&#160;31, 2023, 2022 and 2021, we had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the consolidated balance sheet at&#160;December&#160;31, 2023 and 2022.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets include amounts associated with Medicare Part D, rebates due from pharmaceutical manufacturers and other amounts due within one year.  We accrue pharmaceutical rebates as they are earned based on contractual terms and usage of the product.  The balance of pharmaceutical rebates receivable was $2.3 billion and $2.0&#160;billion at December&#160;31, 2023 and 2022, respectively. For additional information regarding amounts associated with Medicare Part D, refer to Note 7 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policy Acquisition Costs</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Policy acquisition costs are those costs that relate directly to the successful acquisition of new and renewal insurance policies. Such costs include commissions, costs of policy issuance and underwriting, and other costs we incur to acquire new business or renew existing business. We expense policy acquisition costs related to our employer-group prepaid health services policies as incurred. These short-duration employer-group prepaid health services policies typically have a 1-year term and may be canceled upon 30 days notice by the employer group.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at cost. Gains and losses on sales or disposals of property and equipment are included in operating costs in our consolidated income statements. Certain costs related to the development or purchase of internal-use software are capitalized. Depreciation is computed using the straight-line method over estimated useful lives ranging from 3 to 10 years for equipment, 3 to 5 years for computer software, and 10 to 20 years for buildings. Improvements to leased facilities are depreciated over the shorter of the remaining lease term or the anticipated life of the improvement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review long-lived assets, including property and equipment and other definite-lived intangible assets, for impairment whenever adverse events or changes in circumstances indicate the carrying value of the asset may not be recoverable. Losses are recognized for a long-lived asset to be held and used in our operations when the undiscounted future cash flows expected to result from the use of the asset are less than its carrying value. We recognize an impairment loss based on the excess of the carrying value over the fair value of the asset. A long-lived asset held for sale is reported at the lower of the carrying amount or fair value less costs to sell. Depreciation expense is not recognized on assets held for sale. Losses are recognized for a long-lived asset to be abandoned when the asset ceases to be used. In addition, we periodically review the estimated lives of all long-lived assets for reasonableness.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investments</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method of accounting for equity investments in companies where we are able to exercise significant influence, but not control, over operating and financial policies of the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as our ownership interest, representation on the board of directors, organizational structure, participation in policy-making decisions and material intra-entity transactions.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, under the equity method, original investments in these entities are recorded at cost and subsequently adjusted by our share of equity in income or losses after the date of acquisition as well as capital contributions to and distributions from these companies. Our proportionate share of the net income or loss of these companies is included in consolidated net income.  Investment amounts in excess of our share of an investee&#8217;s net assets are amortized over the life of the related asset creating the excess. Excess goodwill is not amortized. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered by us when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than carrying value, the investee&#8217;s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.</span></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our equity method investments, refer to Note 4 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the unamortized excess of cost over the fair value of the net tangible and other intangible assets acquired. We are required to test at least annually for impairment at a level of reporting referred to as the reporting unit, and more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. A reporting unit either is our operating segments or one level below the operating segments, referred to as a component, which comprise our reportable segments. A component is considered a reporting unit if the component constitutes a business for which discrete financial information is available that is regularly reviewed by management. We aggregate the components of an operating segment into one reporting unit if they have similar economic characteristics. Goodwill is assigned to the reporting units that are expected to benefit from the specific synergies of the business combination.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform a quantitative assessment to review goodwill for impairment to determine both the existence and amount of goodwill impairment, if any. Impairment tests are performed, at a minimum, in the fourth quarter of each year supported by our long-range business plan and annual planning process. We rely on an evaluation of future discounted cash flows to determine fair value of our reporting units. The fair value of our reporting units with significant goodwill exceeded carrying amounts. However, unfavorable changes in key assumptions or combinations of assumptions including a significant increase in the discount rate, decrease in the long-term growth rate or substantial reduction in our underlying cash flow assumptions, including revenue growth rates, medical and operating cost trends, and projected operating income could have a significant negative impact on the estimated fair value of our home solutions and primary care reporting units, which accounted for $4.4&#160;billion and $1.2&#160;billion of goodwill, respectively. Impairment tests completed for 2023, 2022, and 2021 did not result in an impairment loss. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with indefinite lives relate to Certificate of Needs (CON) and Medicare licenses acquired as part of our acquisition of Kindred at Home, or KAH, and are included within other long-term assets in the consolidated balance sheet at December&#160;31, 2023 and December&#160;31, 2022. For additional information regarding our acquisition of KAH, refer to Note 3 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K. We are required to annually compare the fair values of other indefinite-lived intangible assets to their carrying amounts. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized. Fair values of indefinite-lived intangible assets are determined based on the income approach. Impairment tests completed for 2023 and 2022 did not result in material impairment losses. These charges reflect the amount by which the carrying value exceeded its estimated fair value. Impairment tests completed for 2021 did not result in an impairment loss. The fair values of the assets were measured using Level 3 inputs, such as projected revenues and operating cash flows. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Definite-lived intangible assets primarily relate to acquired customer contracts/relationships and are included with other long-term assets in the consolidated balance sheets. Definite-lived intangible assets are amortized over the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">useful life generally using the straight-line method. We review definite-lived intangible assets for impairment under our long-lived asset policy.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefits Payable and Benefits Expense Recognition</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefits expense includes claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care and other supplemental benefits provided on or prior to the balance sheet date. Capitation payments represent monthly contractual fees disbursed to primary care and other providers who are responsible for providing medical care to members. Pharmacy costs represent payments for members&#8217; prescription drug benefits, net of rebates from drug manufacturers. Receivables for such pharmacy rebates are included in other current assets in our consolidated balance sheets. Other supplemental benefits include dental, vision, and other supplemental health products.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the costs of our benefits expense payments using actuarial methods and assumptions based upon claim payment patterns, medical cost inflation, historical developments such as claim inventory levels and claim receipt patterns, and other relevant factors, and record benefit reserves for future payments. We continually review estimates of future payments relating to claims costs for services incurred in the current and prior periods and make necessary adjustments to our reserves.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefits expense is recognized in the period in which services are provided and includes an estimate of the cost of services which have been incurred but not yet reported, or IBNR. Our reserving practice is to consistently recognize the actuarial best point estimate within a level of confidence required by actuarial standards. Actuarial standards of practice generally require a level of confidence such that the liabilities established for IBNR have a greater probability of being adequate versus being insufficient, or such that the liabilities established for IBNR are sufficient to cover obligations under an assumption of moderately adverse conditions. Adverse conditions are situations in which the actual claims are expected to be higher than the otherwise estimated value of such claims at the time of the estimate. Therefore, in many situations, the claim amounts ultimately settled will be less than the estimate that satisfies the actuarial standards of practice.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We develop our estimate for IBNR using actuarial methodologies and assumptions, primarily based upon historical claim experience. Depending on the period for which incurred claims are estimated, we apply a different method in determining our estimate. For periods prior to the most recent two months, a completion factor method uses historical paid claims patterns to estimate the percentage of claims incurred during a given period that have historically been adjudicated as of the reporting period. Changes in claim inventory levels and known changes in claim payment processes are taken into account in these estimates. For the most recent two months, the incurred claims are estimated primarily from a trend analysis based upon per member per month claims trends developed from our historical experience in the preceding months, adjusted for known changes in estimates of hospital admissions, recent hospital and drug utilization data, provider contracting changes, changes in benefit levels, changes in member cost sharing, changes in medical management processes, product mix, and workday seasonality.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The completion factor method is used for the months of incurred claims prior to the most recent two months because the historical percentage of claims processed for those months is at a level sufficient to produce a consistently reliable result. Conversely, for the most recent two months of incurred claims, the volume of claims processed historically is not at a level sufficient to produce a reliable result, which therefore requires us to examine historical trend patterns as the primary method of evaluation. Changes in claim processes, including recoveries of overpayments, receipt cycle times, claim inventory levels, outsourcing, system conversions, and processing disruptions due to weather or other events affect views regarding the reasonable choice of completion factors. Claim payments to providers for services rendered are often net of overpayment recoveries for claims paid previously, as contractually allowed. Claim overpayment recoveries can result from many different factors, including retroactive enrollment activity, audits of provider billings, and/or payment errors. Changes in patterns of claim overpayment recoveries can be unpredictable and result in completion factor volatility, as they often impact older dates of service. The receipt cycle time measures the average length of time between when a medical claim was initially incurred and </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when the claim form was received. Increases in electronic claim submissions from providers decrease the receipt cycle time. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claim may be more (less) complete than originally estimated using our completion factors, which may result in reserves that are higher (lower) than required.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical cost trends potentially are more volatile than other segments of the economy. The drivers of medical cost trends include increases in the utilization of hospital facilities, physician services, new higher priced technologies and medical procedures, and new prescription drugs and therapies, as well as the inflationary effect on the cost per unit of each of these expense components. Other external factors such as government-mandated benefits or other regulatory changes, the tort liability system, increases in medical services capacity, direct to consumer advertising for prescription drugs and medical services, an aging population, lifestyle changes including diet and smoking, catastrophes, public health emergencies, epidemics and pandemics (such as COVID-19) also may impact medical cost trends. Internal factors such as system conversions, claims processing cycle times, changes in medical management practices and changes in provider contracts also may impact our ability to accurately predict estimates of historical completion factors or medical cost trends. All of these factors are considered in estimating IBNR and in estimating the per member per month claims trend for purposes of determining the reserve for the most recent two months. Additionally, we continually prepare and review follow-up studies to assess the reasonableness of the estimates generated by our process and methods over time. The results of these studies are also considered in determining the reserve for the most recent two months. Each of these factors requires significant judgment by management.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reassess the profitability of our contracts for providing insurance coverage to our members when current operating results or forecasts indicate probable future losses. We establish a premium deficiency reserve in current operations to the extent that the sum of expected future costs, claim adjustment expenses, and maintenance costs exceeds related future premiums under contracts. For purposes of determining premium deficiencies, contracts are grouped in a manner consistent with our method of acquiring, servicing, and measuring the profitability of such contracts. Losses recognized as a premium deficiency result in a beneficial effect in subsequent periods as operating losses under these contracts are charged to the liability previously established. Because the majority of our member contracts renew annually, we would not record a material premium deficiency reserve, except when unanticipated adverse events or changes in circumstances indicate otherwise.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our benefits payable are adequate to cover future claims payments required. However, such estimates are based on knowledge of current events and anticipated future events. Therefore, the actual liability could differ materially from the amounts provided.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future policy benefits payable</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future policy benefits payable includes liabilities for long-duration insurance policies primarily related to certain blocks of insurance assumed in acquisitions, primarily life and annuities in run-off status, and are included in our consolidated balance sheet within other long-term liabilities. Most of these policies are subject to reinsurance. For additional information regarding reinsurance, refer to Note 19 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Book Overdraft</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our cash management system, checks issued but not yet presented to banks that would result in negative bank balances when presented are classified as a current liability in the consolidated balance sheets. Changes in book overdrafts from period to period are reported in the consolidated statement of cash flows as a financing activity.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets or liabilities and their reported amounts in the consolidated financial statements. These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities are recovered or settled. We also recognize the future tax benefits such as net operating and capital loss carryforwards as deferred tax assets. A valuation allowance is provided against these deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized. Future years&#8217; tax expense may be increased or decreased by adjustments to the valuation allowance or to the estimated accrual for income taxes. Deferred tax assets and deferred tax liabilities are further adjusted for changes in the enacted tax rates. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record tax benefits when it is more likely than not that the tax return position taken with respect to a particular transaction will be sustained. A liability, if recorded, is not considered resolved until the statute of limitations for the relevant taxing authority to examine and challenge the tax position has expired, or the tax position is ultimately settled through examination, negotiation, or litigation. We classify interest and penalties associated with uncertain tax positions in our provision for income taxes.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include all assets, liabilities, revenues and expenses of less than 100% owned affiliates that we control. Accordingly, we record noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interest holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interest holders&#8217; balances. Noncontrolling interests, which relate to the minority ownership held by third party investors in certain of our businesses within our Insurance and CenterWell segments, are reported below net income under the heading &#8220;Net income attributable to noncontrolling interests&#8221; in the consolidated statements of income and presented as a component of equity in the consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally recognize stock-based compensation expense, as determined on the date of grant at fair value, on a straight-line basis over the period during which an employee is required to provide service in exchange for the award (the vesting period). In addition, for awards with both time and performance-based conditions, we generally recognize compensation expense on a straight line basis over the vesting period when it is probable that the performance condition will be achieved. We estimate expected forfeitures and recognize compensation expense only for those awards which are expected to vest. We estimate the grant-date fair value of stock options using the Black-Scholes option-pricing model. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For additional information regarding our stock-based compensation plans, refer to Note 14 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Common Share</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compute basic earnings per common share on the basis of the weighted-average number of unrestricted common shares outstanding. Diluted earnings per common share is computed on the basis of the weighted-average number of unrestricted common shares outstanding plus the dilutive effect of outstanding employee stock options and restricted shares, or units, using the treasury stock method.</span></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our earnings per share, refer to Note 15 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are categorized into a fair value hierarchy based on whether the inputs to valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our own assumptions about the assumptions market participants would use. The fair value hierarchy includes three levels of inputs that may be used to measure fair value as described below.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities include securities that are traded in an active exchange market.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8211; Observable inputs other than Level 1 prices such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less frequently than exchange-traded instruments as well as debt securities whose value is determined using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes assets and liabilities whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting our own assumptions about the assumptions market participants would use as well as those requiring significant management judgment.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of actively traded debt and equity securities are based on quoted market prices. Fair value of other debt securities are based on quoted market prices of identical or similar securities or based on observable inputs like interest rates generally using a market valuation approach, or, less frequently, an income valuation approach and are generally classified as Level 2. Fair value of privately held investment grade debt securities are estimated using a variety of valuation methodologies, including both market and income approaches, where an observable quoted market does not exist and are generally classified as Level 3. For privately-held investment grade debt securities, such methodologies include reviewing the value ascribed to the most recent financing, comparing the security with securities of publicly-traded companies in similar lines of business with similar credit characteristics, and reviewing the underlying financial performance including estimating discounted cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain at least one price for each security from a third party pricing service. These prices are generally derived from recently reported trades for identical or similar securities, including adjustments through the reporting date based upon observable market information. When quoted prices are not available, the third party pricing service may use quoted market prices of comparable securities or discounted cash flow analysis, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include benchmark yields, reported trades, credit spreads, broker quotes, default rates, and prepayment speeds. We are responsible for the determination of fair value and as such we perform analysis on the prices received from the third party pricing service to determine whether the prices are reasonable estimates of fair value. Our analysis includes a review of monthly price fluctuations as well as a quarterly comparison of the prices received from the pricing service to prices reported by our third party investment adviser. In addition, on a quarterly basis we examine the underlying inputs and assumptions for a sample of individual securities across asset classes, credit rating levels, and various durations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services&#8212;Insurance (Topic 944): Effective Date and Early Application (&#8220;ASU 2020-11&#8221;). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services&#8212;Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (&#8220;ASU 2018-12&#8221;), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The new guidance relates to accounting for long-duration contracts of insurers which revises key elements of the measurement models and disclosure requirements for long-duration contracts issued by insurers, including the amortization of deferred contract acquisition costs and the measurement of liabilities for future policy benefits using current, rather than locked-in, assumptions. The new guidance, limited to our Medicare Supplement product which represents less than 1% of consolidated premiums and services revenue, became effective for us </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beginning January 1, 2023 and was applied to contracts in force on the basis of their existing carrying value amounts at the beginning of the earliest period presented. The adoption of the new standard in 2023 did not have a material impact on our consolidated results of operations, financial position or cash flows.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Pronouncements Effective in Future Periods</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting &#8212; Improvements to Reportable Segment Disclosures. The new guidance requires incremental disclosures related to a public entity&#8217;s reportable segments but does not change the definition of a segment, the method for determining segments, or the criteria for aggregating operating segments into reportable segments. The new guidance requires a public entity to disclose its significant segment expense categories and amounts for each reportable segment. The new guidance will be effective for us beginning with our annual 2024 year-end financial statements. We are currently evaluating the impact on our segment information footnote disclosures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-09 &#8212; Income Taxes (Topic 740): Improvements to Income Tax Disclosures.  The new guidance requires significant additional disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be effective for us beginning with our annual 2025 year-end financial statements, with early adoption permitted.  We are currently evaluating the impact on our income tax footnote disclosures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656665919744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS AND DIVESTITURES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">ACQUISITIONS AND DIVESTITURES</a></td>
<td class="text">ACQUISITIONS AND DIVESTITURES<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August&#160;11, 2022, we completed the sale of a 60% i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nterest in Gentiva (formerly Kindred) Hospice to Clayton, Dubilier &amp; Rice, or CD&amp;R, for cash proceeds of approximately $2.7&#160;billion, net of cash disposed, including debt repayments from Gentiva Hospice to Humana of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.9&#160;billion. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale, we recognized a pre-tax gain, net of transaction costs, of $237&#160;million which was reported as a gain on sale of Gentiva Hospice in the accompanying consolidated statement of income for the year ended December 31, 2022. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we classified Gentiva Hospice as held-for-sale and aggregated Gentiva Hospice&#8217;s assets and liabilities separately on the balance sheet. The assets, liabilities and noncontrolling interest disposed of on August 11, 2022 were as follows:</span></div><div style="padding-left:36pt;padding-right:36pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:77.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Receivables, net of allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trade accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">245&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">530&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Noncontrolling interest</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="padding-left:36pt;padding-right:36pt;text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets included $866&#160;million identifiable intangibles consisting of Medicare licenses and CON. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale of a 60% interest in Gentiva Hospice on August 11, 2022, as discussed above, Gentiva Hospice revenues and pretax earnings through the date of sale for the year ended December 31, 2022, were $958&#160;million and $150&#160;million, respectively.  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 17, 2021, we acquired the remaining 60% interest in Kindred at Home, or KAH,  from TPG Capital and Welsh, Carson, Anderson &amp; Stowe, or WCAS, two private equity funds, for an enterprise value of $8.2&#160;billion, which included our equity value of $2.4&#160;billion associated with our 40% minority ownership interest. The remeasurement to fair value of our previously held 40% equity method investment with a carrying value of approximately $1.3&#160;billion, resulted in a $1.1&#160;billion gain recognized in "Other (income) expense, net" </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the accompanying consolidated statement of income for the year ended December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We paid the approximate $5.8&#160;billion transaction price (net of our existing equity stake) through a combination of debt financing, the assumption of existing KAH indebtedness and parent company cash.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, 2022, and 2021, we acquired other health and wellness related businesses which other than the impacts to goodwill, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows.  The results of operations and financial condition of these businesses have been included in our consolidated statements of income and consolidated balance sheets from the respective acquisition dates. Acquisition-related costs recognized in each of 2023, 2022 and 2021 were not material to our results of operations. For asset acquisitions the goodwill acquired is partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the year of acquisition, were not material for disclosure purposes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656666862432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY METHOD INVESTMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">EQUITY METHOD INVESTMENT</a></td>
<td class="text">EQUITY METHOD INVESTMENT<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to our acquisition of KAH in August 2021, we accounted for our 40%&#160;investment in KAH using the equity method of accounting. Our share of income or loss was reported as equity in net (losses) earnings in our consolidated statements of income.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed the sale of a 60% interest in Gentiva Hospice on August 11, 2022 and we account for our remaining minority ownership in Gentiva Hospice using the equity method of accounting. At December&#160;31, 2023 and 2022 we owned 35% and 40%, respectively. This investment was reflected in equity method investments in our December&#160;31, 2023 and 2022 consolidated balance sheets, with our share of income or loss reported as equity in net (losses) earnings in our consolidated statements of income.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summarized balance sheets and statements of income at December&#160;31, 2023 and 2022 of Gentiva Hospice were as follows:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:55.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.746%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance sheet</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:53.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.393%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31, 2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">August 11, 2022 through December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,873&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other equity method investments</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, our Primary Care Organization entered into a strategic partnership with Welsh, Carson, Anderson &amp; Stowe, or WCAS, to accelerate the expansion of our primary care model. In May 2022, we established a second strategic partnership with WCAS to develop additional centers between 2023 and 2025. As of December 31, 2023, there were 108 primary care clinics operating under the partnership and we have capacity to open or acquire up to approximately 60 additional centers through the existing partnership agreements. In addition, the agreements include a series of put and call options through which WCAS may require us to purchase their interest in the entity, and through which we may acquire WCAS&#8217;s interest, over the next 2 to 9 years. We have the option to purchase the first cohort of clinics in 2025 for approximately $550&#160;million to $650&#160;million based on current projections. All existing cohorts can be called by us from 2025 to 2030 and could require $2.0&#160;billion to $3.0&#160;billion based on current projections. These estimates are dependent on multiple factors including the actual timing of when the put or call options are exercised, expected revenue growth at each center within the respective cohort and future capital contributions, among other factors. For additional information on inputs relevant to these put and call options, refer to Note 6 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have several individually immaterial equity method investments, including our strategic partnership with WCAS as described above, included within equity method investments in our consolidated balance sheets as of December&#160;31, 2023 and 2022 with our share of income or loss reported as equity in net (losses) earnings in our consolidated statements of income for the years ended December&#160;31, 2023, 2022 and 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 323<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481543/323-740-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org//323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667089440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT SECURITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">INVESTMENT SECURITIES</a></td>
<td class="text">INVESTMENT SECURITIES<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities classified as current and long-term were as follows at December&#160;31, 2023 and 2022, respectively:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>&#160;&#160;&#160;&#160;corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,946&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investment securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>&#160;&#160;&#160;&#160;corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(471)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,551&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(828)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,726&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,701)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investment securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,261&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own certain corporate debt securities of Gentiva Hospice. The book value and fair value are $379&#160;million and $398&#160;million, respectively, at December&#160;31, 2023. The book value and fair value were $280&#160;million and $278&#160;million, respectively, at December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross unrealized losses and fair values aggregated by investment category and length of time that individual debt securities have been in a continuous unrealized loss position were as follows at December&#160;31, 2023 and 2022, respectively:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;than&#160;12&#160;months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 months or more</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr style="height:15pt"><td colspan="36" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>&#160;&#160;&#160;&#160;corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(592)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,249&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,300)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>&#160;&#160;&#160;&#160;corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(471)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,825&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(730)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(828)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,419&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,431)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,381&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,701)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 97% of our debt securities were investment-grade quality, with a weighted average credit rating of AA- by S&amp;P at December&#160;31, 2023. Most of the debt securities that were below investment-grade were rated B+, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding approximately 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types. &#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unrealized loss from all debt securities was generated from approximately 1,560 positions out of a total of approximately 2,060 positions at December&#160;31, 2023. All issuers of debt securities we own that were trading at an unrealized loss at December&#160;31, 2023 remain current on all contractual payments. After taking into account these and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time the debt securities were purchased. At December&#160;31, 2023, we did not intend to sell any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. Additionally, we did not record any material credit allowances for debt securities that were in an unrealized loss position at December&#160;31, 2023, 2022 or 2021.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The detail of realized gains (losses) related to investment securities and included within investment income was as follows for the years ended December&#160;31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:7pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:57.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains on investment securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses on investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net recognized losses on investment securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains and losses related to equity securities for the years ended December&#160;31, 2023, 2022 and 2021 was as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.517%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains (losses) recognized on equity securities during the period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net gains (losses) recognized on equity securities sold during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses recognized on equity securities still held at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of debt securities available for sale at December&#160;31, 2023, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:75.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,279&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,302&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656666977184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE</a></td>
<td class="text">FAIR VALUE<div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our fair value measurements at December&#160;31, 2023 and 2022, respectively, for financial assets measured at fair value on a recurring basis:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:45.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total invested assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,832&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,832&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,254&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,153&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total invested assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,093&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,839&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,153&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Level 3 assets had fair values of $218 million, or 1.0% of total invested assets, and $101 million, or 0.5% of total invested assets, at December&#160;31, 2023 and 2022, respectively. During the years ended December&#160;31, 2023 and 2022, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:11.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:54.277%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.212%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December&#160;31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December&#160;31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Private<br/>Placements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January&#160;1</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gains or losses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized in other comprehensive&#160;income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers Out</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers In</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Swaps</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, we entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on our $750&#160;million of 5.875% senior notes, our $750&#160;million of 5.500% senior notes, our $500&#160;million of 3.950% senior notes and our $850&#160;million of 5.950% from fixed rates to variable rates to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities. Our swap agreements, which are considered derivative instruments, exchange the fixed interest rate under our 5.875%, 5.500%, 3.950% and 5.950% senior notes for a variable interest rate based on SOFR. Interest rate swaps with notional amounts of $650&#160;million, maturing September 1, 2032, $300&#160;million, maturing March 15, 2033, $450&#160;million  maturing August 15, 2049 and $400&#160;million, maturing March 15, 2034, were outstanding on our 5.875%, 5.500%, 3.950% and 5.950% senior notes, respectively, at December&#160;31, 2023. These swap agreements were qualified and designated as a fair value hedge. Our interest rate swaps are recognized in other assets or other liabilities, as appropriate, in our consolidated balance sheets at fair value as of the reporting date.  Our interest rate swaps are highly effective at reflecting the fair value of our hedged fixed rate senior notes payable. We utilize market-based financing rates, forward yield curves and discount rates in determining fair value of these swaps at each reporting date, a Level 2 measure within the fair value hierarchy.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The swap asset, included within other long-term assets on our consolidated balance sheet, was approximately $68&#160;million at December&#160;31, 2023. We include the gain or loss on the swap agreements in interest expense on our consolidated statement of income, the same line item as the offsetting loss or gain on the related senior notes. The gain or loss due to hedge ineffectiveness was not material for the year ended December&#160;31, 2023.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Liabilities</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our debt is recorded at carrying value in our consolidated balance sheets. The carrying value of our senior notes debt outstanding, net of unamortized debt issuance costs, was $10.8&#160;billion at December&#160;31, 2023 and $10.0 billion at December&#160;31, 2022. The fair value of our senior note debt was $10.6 billion at December&#160;31, 2023 and $9.4 billion at December&#160;31, 2022. The fair value of our senior note debt is determined based on Level 2 inputs, including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities. Carrying value approximates </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair value for our term loans and commercial paper borrowings. The commercial paper borrowings&#160;were $0.9&#160;billion at December&#160;31, 2023 and the term loan and commercial paper borrowings were $1.1 billion at December&#160;31, 2022.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Put and Call Options Measured at Fair Value</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our put and call options associated with our equity method investments are measured at fair value each period using a Monte Carlo simulation. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 27, 2021, with the signing of the definitive agreement to acquire the remaining 60% interest of KAH, the respective put and call options were terminated. As such, the $63&#160;million put and $440&#160;million call fair values as of the first quarter of 2021 were reduced to zero, resulting in $377&#160;million in other expense (income), net in our consolidated statements of income for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The put and call options fair values associated with our Primary Care Organization strategic partnership with WCAS, which are exercisable at a fixed revenue exit multiple and provide a minimum return on WCAS' investment if exercised, are measured at fair value each reporting period using a Monte Carlo simulation. The put and call options fair values, derived from the Monte Carlo simulation, were $595 million and $18 million, respectively, at December&#160;31, 2023. The put and call options fair values, derived from the Monte Carlo simulation, were $267 million and $10 million, respectively, at December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant unobservable inputs utilized in these Level 3 fair value measurements (and selected values) include the enterprise value, annualized volatility and credit spread. Enterprise value was derived from a discounted cash flow model, which utilized significant unobservable inputs for long-term revenue, to measure underlying cash flows, weighted average cost of capital and long term growth rate. The table below presents the assumptions used for December&#160;31, 2023 and 2022, respectively: </span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:59.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.837%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1% - 17.8%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7% to 20.8%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit spread</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9% - 1.1%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3% to 1.5%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue exit multiple</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5x - 2.5x </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5x - 2.5x</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average cost of capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0% - 12.5%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5% to 12.5%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term growth rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for annualized volatility, credit spread and weighted average cost of capital reflect the lowest and highest values where they differ significantly across the series of put and call options due to their expected exercise dates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain assets and liabilities are measured at fair value on a non-recurring basis subject to fair value adjustment only in certain circumstances.  As disclosed in Note 3, &#8220;Acquisitions&#8221;, we completed our acquisition of KAH during the third quarter of 2021. The net assets acquired and resulting goodwill and other intangible assets were recorded at fair value primarily using Level 3 inputs.  The net tangible assets including receivables and accrued liabilities were recorded at their carrying value which approximated their fair value due to their short term nature. The fair value of goodwill and other intangible assets were internally estimated based on the income approach.  The income approach estimates fair value based on the present value of cash flow that the assets could be expected to generate in the future. We developed internal estimates for expected cash flows in the present value calculation using inputs and significant assumptions that include historical revenues and earnings, long-term growth rate, discount rate, contributory asset charges and future tax rates, among others.  The excess purchase price over the fair value of assets and liabilities acquired is recorded as goodwill.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in Note 3, we completed the sale of a 60% interest in Gentiva Hospice on August 11, 2022. The carrying value of the assets and liabilities of Gentiva Hospice disposed approximates fair value. The amount of </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">goodwill included in the carrying value is based on the relative fair value of Gentiva Hospice as compared to the total fair value of our home solutions reporting unit included within the CenterWell segment.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, as disclosed in Note 3, we completed our acquisitions of certain health and wellness related businesses during 2023, 2022, and 2021. The values of net tangible assets acquired and the resulting goodwill and other intangible assets were recorded at fair value using Level 3 inputs. The majority of the related tangible assets acquired and liabilities assumed were recorded at their carrying values as of the respective dates of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in these acquisitions were internally estimated primarily based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets are expected to generate in the future. We developed internal estimates for the expected cash flows and discount rates in the present value calculations. Other than assets acquired and liabilities assumed in these acquisitions, there were no material assets or liabilities measured at fair value on a nonrecurring basis during 2023, 2022, or 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667006752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MEDICARE PART D<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_MedicarePartDDisclosureTextBlock', window );">MEDICARE PART D</a></td>
<td class="text">MEDICARE PART D<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with CMS. The accompanying consolidated balance sheets include the following amounts associated with Medicare Part D as of December&#160;31, 2023 and 2022. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:52.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk<br/>Corridor<br/>Settlement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CMS<br/>Subsidies/<br/>Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk<br/>Corridor<br/>Settlement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CMS<br/>Subsidies/<br/>Discounts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,825)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current (liability) asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,311)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net long-term liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total net (liability) asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,311)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_MedicarePartDDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance sheet amounts associated with Medicare Part D.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_MedicarePartDDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667033280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text">PROPERTY AND EQUIPMENT, NET<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment was comprised of the following at December&#160;31, 2023 and 2022. </span></div><div style="margin-bottom:1pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:75.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.656%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,546&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,951&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,854)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,136)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $831&#160;million in 2023, $749 million in 2022, and $640 million in 2021, including amortization expense for capitalized internally developed and purchased software of $589 million in 2023, $525 million in 2022, and $443 million in 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656666987376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND OTHER INTANGIBLE ASSETS</a></td>
<td class="text">GOODWILL AND OTHER INTANGIBLE ASSETS<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill for our reportable segments for the years ended December&#160;31, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:53.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dispositions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,670&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,550&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of our other intangible assets included in other long-term assets in the accompanying consolidated balance sheets at December&#160;31, 2023 and 2022:</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.116%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetes and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for other intangible assets was approximately $67 million in 2023, $81&#160;million in 2022, and $65&#160;million in 2021. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023 we recorded impairment charges of $55&#160;million relating to indefinite-lived intangibles.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our estimate of amortization expense for each of the five next succeeding fiscal years: </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:81.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656669622832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine if a contract contains a lease by evaluating the nature and substance of the agreement. We lease facilities, computer hardware, and other furniture and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. For new lease agreements, we combine lease and nonlease components for all of our asset classes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When portions of the lease payments are not fixed or depend on an index or rate, we consider those payments to be variable in nature. Our variable lease payments include, but are not limited to, common area maintenance, taxes and insurance which are not dependent upon an index or rate. Variable lease payments are recorded in the period in which the obligation for the payment is incurred. Most leases include options to renew, with renewal terms that can extend the lease term. The exercise of lease renewal options is at our sole discretion. Certain leases also include options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets included within <span style="-sec-ix-hidden:f-1124"><span style="-sec-ix-hidden:f-1125">other long-term assets</span></span> in our consolidated balance sheets were $510 million and $515 million at December&#160;31, 2023 and December&#160;31, 2022, respectively. Operating lease liabilities included within <span style="-sec-ix-hidden:f-1128"><span style="-sec-ix-hidden:f-1129">trade accounts payable and accrued expenses</span></span> in our consolidated balance sheets were $149 million and $152 million at December&#160;31, 2023 and December&#160;31, 2022, respectively. Additionally, operating lease liabilities included within <span style="-sec-ix-hidden:f-1132"><span style="-sec-ix-hidden:f-1133">other long-term liabilities</span></span> in our consolidated balance sheets were $444 million and $456 million at December&#160;31, 2023 and December&#160;31, 2022, respectively. The classification of our operating lease liabilities is based on the remaining lease term.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022 and 2021, total fixed operating lease costs, excluding short-term lease costs, were $145 million, $183 million and $159 million, respectively, and are included within operating costs in our consolidated statements of income. Short-term lease costs were not material for the years ended December&#160;31, 2023, 2022 and 2021. In addition, for the years ended December&#160;31, 2023, 2022 and 2021, total variable operating lease costs were</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$120 million, $101 million and $94 million, respectively, and are included within operating costs in our consolidated statements of income. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sublease facilities or partial facilities to third party tenants for space not used in our operations. For the years ended December&#160;31, 2023, 2022 and 2021, sublease rental income was</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$66 million, $52 million and $43 million, respectively, and is included within operating costs in our consolidated statements of income.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average remaining lease term is 5.4 years at December&#160;31, 2023 and December&#160;31, 2022. The weighted average discount rate is 3.9% and 3.2% at December&#160;31, 2023 and December&#160;31, 2022, respectively. For the years ended December&#160;31, 2023, 2022 and 2021, cash paid for amounts included in the measurement of lease liabilities included within our operating cash flows was $166 million, $191 million and $165 million, respectively.</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:80.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity of&#160;Lease&#160;Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate, as adjusted for collateralized borrowings, based on the information available at date of adoption or commencement date in determining the present value of lease payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667033280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BENEFITS PAYABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceDisclosureTextBlock', window );">BENEFITS PAYABLE</a></td>
<td class="text">BENEFITS PAYABLE<div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:54.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances at January&#160;1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,394&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,690&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,199&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,946)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,479)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,715)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,095)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances at December&#160;31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,241&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,289&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total estimate of benefits payable for claims incurred but not reported, or IBNR, is included within the net </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incurred claims amounts. At December&#160;31, 2023 and 2022, benefits payable included IBNR of approximately $6.6&#160;billion and $5.7&#160;billion, primarily associated with claims incurred in each respective year. The cumulative number of reported claims as of December&#160;31, 2023 was approximately 200.0&#160;million for claims incurred in 2023, 182.4&#160;million for claims incurred in 2022, and 173.7&#160;million for claims incurred in 2021.</span></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Amounts incurred related to prior years vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. We experienced favorable medical claims reserve development related to prior fiscal years of $872 million in 2023, $415 million in 2022, and $825 million in 2021.</span></div><div style="margin-bottom:12pt;margin-top:4pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical claims reserve development for 2023, 2022, and 2021 primarily reflects the consistent application of trend and completion factors estimated using an assumption of moderately adverse conditions. The favorable development recognized in 2023 and 2021 primarily resulted from trend factors developing more favorably than originally expected as well as for 2021 completion factors developing faster than expected. The favorable development recognized in 2022 resulted primarily from completion factors remaining largely unchanged, resulting in lower overall development as compared to 2023 and 2021.</span></div><div style="margin-bottom:12pt;margin-top:4pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incurred and Paid Claims Development</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion provides information about incurred and paid claims development as of December&#160;31, 2023, net of reinsurance, as well as cumulative claim frequency and the total of IBNR included within the net incurred claims amounts. The information about incurred and paid claims development for the years ended December 31, 2022 and 2021 is presented as supplementary information.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Claims frequency is measured as medical fee-for-service claims for each service encounter with a unique provider identification number. Our claims frequency measure includes claims covered by deductibles as well as claims under capitated arrangements. Claim counts may vary based on product mix and the percentage of delegated capitation arrangements.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following tables provide information about incurred and paid claims development as of December&#160;31, 2023, net of reinsurance.</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:54.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.890%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurred Claims, Net of Reinsurance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claims Incurred Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021<br/>Unaudited</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022<br/>Unaudited</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,447&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,259&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:53.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Paid Claims, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claims Incurred Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021<br/>Unaudited</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022<br/>Unaudited</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All outstanding benefit liabilities before 2021, net of reinsurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits payable, net of reinsurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479838/944-20-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//944/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(4)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479584/944-310-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(4)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479584/944-310-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656666400176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes consisted of the following for the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:1pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:55.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States and Puerto Rico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes was different from the amount computed using the federal statutory rate for the years ended December&#160;31, 2023, 2022 and 2021 due to the following:</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:55.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision at federal statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, net of federal benefit, and Puerto Rico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax exempt investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable KAH gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax effect from sale of Gentiva Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Tax Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax balances reflect the impact of temporary differences between the tax bases of assets or liabilities and their reported amounts in our consolidated financial statements, and are stated at enacted tax rates expected to be in effect when the reported amounts are actually recovered or settled. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal components of our net deferred tax balances at December&#160;31, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:70.168%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.866%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets&#160;(Liabilities)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and other accrued expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred acquisition costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jobs tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property and intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(642)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(740)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(878)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred income tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All deferred tax assets and liabilities are classified as noncurrent in our consolidated balance sheets as other long-term assets and liabilities at December 31, 2023  and 2022, respectively. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, we had approximately $7 million of federal net operating losses and approximately $1.2 billion of pre-apportioned state and Puerto Rico net operating losses to carry forward. A portion of these loss carryforwards, if not used to offset future taxable income, will expire from 2024 through 2041. The balance of the net operating loss carryforwards has no expiration date. Due to limitations and uncertainty regarding our ability to use some of the loss carryforwards and certain other deferred tax assets, a valuation allowance of $73 million was established. For the remainder of the net operating loss carryforwards and other cumulative temporary differences, based on our historical record of producing taxable income and profitability, we have concluded that future operating income will be sufficient to recover these deferred tax assets. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We file income tax returns in the United States and Puerto Rico.&#160;The U.S. Internal Revenue Service, or IRS, has completed its examinations of our consolidated income tax returns for 2021 and prior years. Our 2022 tax return is in the post-filing review period under the Compliance Assurance Process, or CAP. Our 2023 tax return is under advance review by the IRS under CAP. With a few exceptions, which are immaterial in the aggregate, we are no longer subject to state, local and foreign tax examinations for years before 2020.&#160;We are not aware of any material adjustments that may be proposed as a result of any ongoing or future examinations. We do not have material uncertain tax positions reflected in our consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656673229744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of debt outstanding was as follows at December&#160;31, 2023 and 2022:</span></div><div style="margin-bottom:1pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:61.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.877%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 3.850% due October 1, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.5 billion, 0.650% due August 3, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior notes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior notes:</span></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 3.850% due October 1, 2024</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 4.500% due April 1, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.700% due March 13, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 1.350% due February 3, 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 3.950% due March 15, 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.750% due March 1, 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.750% due December 1, 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 3.700% due March 23, 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 3.125% due August 15, 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 4.875% due April 1, 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million 2.150% due February 3, 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.875% due March 1, 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$850 million, 5.950% due March 15, 2034</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$250 million, 8.150% due June&#160;15, 2038</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$400 million, 4.625% due December&#160;1, 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 4.950% due October 1, 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$400 million, 4.800% due March 15, 2047</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 3.950% due August 15, 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.500% due March 15, 2053</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;text-indent:-9.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior notes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,213&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,534&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loans:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delayed draw term loan, due May 28, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:8.99pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,213&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,034&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the short-term and long-term debt for the years ending December 31, are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:79.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior notes, which are unsecured, may be redeemed at our option at any time at 100% of the principal amount plus accrued interest and a specified make-whole amount. The 8.150% senior notes are subject to an interest rate adjustment if the debt ratings assigned to the notes are downgraded (or subsequently upgraded). In addition, our senior notes contain a change of control provision that may require us to purchase the notes under certain circumstances. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we issued $500&#160;million of 5.750% unsecured senior notes due December 1, 2028 and $850&#160;million of our 5.950% unsecured senior notes due March 15, 2034. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $1.3&#160;billion. We used the net proceeds for general corporate purposes, which included the repayment of existing indebtedness, including borrowings under our commercial paper program.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we issued $500&#160;million of 5.700% unsecured senior notes due March 13, 2026 and $750&#160;million of 5.500% unsecured senior notes due March 15, 2053. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $1.2&#160;billion. We used the net proceeds to repay outstanding amounts under our $500&#160;million Delayed Draw Term Loan. The remaining net proceeds were used for general corporate purposes, which included the repayment of existing indebtedness, including borrowings under our commercial paper program.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $750&#160;million aggregate principal amount of 1.350% senior notes maturing in February 2027, our $600 million aggregate principal amount of 3.950% senior notes maturing in March 2027, our $750 million aggregate principal amount of 3.700% senior notes maturing in March 2029, and our $500 million aggregate principal amount of 3.125% senior notes maturing in August 2029 during the period beginning on August&#160;7, 2023 and ending on November&#160;15, 2023. For the year ended December 31, 2023, we repurchased $339&#160;million principal amount of these senior notes for approximately $310&#160;million cash.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $1.5&#160;billion aggregate principal amount of 0.650% senior notes maturing in August 2023 and our $600&#160;million aggregate principal amount of 3.850% senior notes maturing in October 2024 during the period beginning on March 13, 2023 and ending on July&#160;21, 2023. For the year ended December 31, 2023, we repurchased $361&#160;million principal amount of these senior notes for approximately $358&#160;million cash. We repaid the remaining $1.2&#160;billion aggregate principal amount of our 0.650% senior notes due on their maturity date of August&#160;3, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, we entered into interest rate swap agreements to exchange the fixed interest rate under our 5.875%, 5.500%, 3.950% and 5.950% senior notes for a variable interest rate based on SOFR, as further described in Note 6. As a result, the carrying value of these senior notes has been adjusted to reflect changes in value caused by an increase or decrease in interest rates. The cumulative, aggregate adjustment to the carrying value of the 5.875%, 5.500%, 3.950% and 5.950% senior notes was $9&#160;million, $13&#160;million, $36&#160;million and $10&#160;million respectively, at December 31, 2023.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Revolving Credit Agreements</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, we entered into an amended and restated 5-year, $2.5&#160;billion unsecured revolving credit agreement (replacing the 5-year, $2.5&#160;billion unsecured revolving credit agreement entered in June 2021) and entered into a 364-day $1.5&#160;billion unsecured revolving credit agreement (replacing the 364-day $1.5&#160;billion unsecured revolving credit agreement entered into in June 2022, which expired in accordance with its terms). </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the credit agreements, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at Term SOFR or the base rate plus a spread. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based Term SOFR, at our option. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SOFR spread, currently 103.5 basis points under the 5-year revolving credit agreement and 105.5 basis points under the 364-day revolving credit agreement, varies depending on our credit ratings ranging from 92.0 to 130.0 basis points under the 5-year revolving credit agreement and from 94.0 to 135.0 basis points under the 364-day revolving credit agreement. We also pay an annual facility fee regardless of utilization. This facility fee, currently 9.0 basis points, under the 5-year revolving credit agreement and 7.0 basis points under the 364-day revolving agreement, varies depending on our credit ratings ranging from 8.0 to 20.0 basis points under the 5-year revolving credit agreement and from 6.0 to 15.0 basis points under the 364-day revolving credit agreement.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the revolving credit agreements include standard provisions related to conditions of borrowing which could limit our ability to borrow additional funds. In addition, the credit agreements contain customary restrictive covenants and a financial covenant regarding maximum debt to capitalization of 60%, as well as customary events of default. We are in compliance with this financial covenant, with actual debt to capitalization of 41.8% as measured in accordance with the revolving credit agreements as of December&#160;31, 2023. Upon our agreement with one or more financial institutions, we may expand the aggregate commitments under the revolving credit agreements by up to $750&#160;million in the aggregate, to a maximum of $4.75&#160;billion, across the 5-year and 364-day revolving credit agreements. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, we had no borrowings and approximately $18&#160;million of letters of credit outstanding under the revolving credit agreements. Accordingly, as of December&#160;31, 2023, we had $2.482&#160;billion of remaining borrowing capacity under the 5-year revolving credit agreement and $1.5&#160;billion of remaining borrowing capacity under the 364-day revolving credit agreement (which excludes the uncommitted $750&#160;million of incremental loan facilities), none of which would be restricted by our financial covenant compliance requirement. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have other customary relationships, including financial advisory and banking, with some parties to the revolving credit agreements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Paper</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     Under our commercial paper program we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers at any time. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The maximum principal amount outstanding at any one time during the year ended&#160;December&#160;31, 2023&#160;was $3.3&#160;billion, with $871 million outstanding at December&#160;31, 2023 compared to $595 million outstanding at December 31, 2022. The outstanding commercial paper at December&#160;31, 2023 had a weighted average annual interest rate of 5.68%.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Short-Term Borrowings</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a member, through one subsidiary, of the Federal Home Loan Bank of Cincinnati, or FHLB. As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We received a short-term cash advance of $100&#160;million from FHLB with certain of our marketable securities as </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collateral and subsequently repaid the outstanding balance in December 2023. As of December&#160;31, 2023 and December&#160;31, 2022, we had no outstanding short-term FHLB borrowings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667000896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock', window );">EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Savings Plan</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have defined contribution retirement savings plans covering eligible employees which include matching contributions based on the amount of our employees&#8217; contributions to the plans. The cost of these plans amounted to approximately $278 million in 2023, $286 million in 2022, and $259 million in 2021. The Company&#8217;s cash match is invested pursuant to the participant&#8217;s contribution direction. Based on the closing price of our common stock of $457.81 on December&#160;31, 2023, approximately 8% of the retirement and savings plan&#8217;s assets were invested in our common stock, or approximately 1.3 million shares, representing approximately 1.1% of the shares outstanding as of December&#160;31, 2023. At December&#160;31, 2023, approximately 5.5 million shares of our common stock were reserved for issuance under our defined contribution retirement savings plans.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have plans under which options to purchase our common stock and restricted stock units have been granted to executive officers, directors and key employees. Awards generally require both a change in control and termination of employment within 2 years of the date of the change in control to accelerate the vesting, including those granted to retirement-eligible participants. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms and vesting schedules for stock-based awards vary by type of grant. Generally, the awards vest upon time-based conditions. We have also granted awards to certain employees that vest upon a combination of time and performance-based conditions. The stock awards of retirement-eligible participants are generally earned ratably over the service period for each tranche. Accordingly, upon retirement the earned portion of the current tranche will continue to vest on the originally scheduled vest date and any remaining unearned portion of the award will be forfeited. Our equity award program includes a retirement provision that generally treats employees with a combination of age and years of services with the Company totaling 65 or greater, with a minimum required age of 55 and a minimum requirement of 5 years of service, as retirement-eligible. Upon exercise, stock-based compensation awards are settled with authorized but unissued company stock or treasury stock. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation expense that has been charged against income for these plans was as follows for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:55.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by type:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense, net of tax</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit recognized in our consolidated financial statements is based on the amount of compensation expense recorded for book purposes, subject to limitations on the deductibility of annual compensation in excess of $500,000 per employee as mandated by the Health Care Reform Law. The actual tax benefit realized in our tax return is based on the intrinsic value, or the excess of the market value over the exercise or purchase price, of stock options exercised and restricted stock vested during the period, subject to limitations on the deductibility of annual compensation in excess of $500,000 per employee as mandated by the Health Care Reform Law. The actual tax benefit realized for the deductions taken on our tax returns from option exercises and restricted stock vesting totaled </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$30 million in 2023, $31&#160;million in 2022, and $28 million in 2021. There was no capitalized stock-based compensation expense during these years.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, there were approximately 11.0 million shares reserved for stock award plans under the Humana Inc. 2011 Stock Incentive Plan, or 2011 Plan, and approximately 14.8 million shares reserved for stock award plans under the Humana Inc. 2019 Stock Incentive Plan, or 2019 Plan. These reserved shares included giving effect to, under the 2011 Plan, 3.3 million shares of common stock available for future grants assuming all stock options were granted or 1.4 million shares available for future grants assuming all restricted stock were granted.&#160;These reserved shares included giving effect to, under the 2019 Plan, 9.7 million shares of common stock available for future grants assuming all stock options were granted or 2.9 million shares available for future grants assuming all restricted stock were granted. Shares may be issued from authorized but unissued company stock or treasury stock.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock is granted with a fair value equal to the market price of our common stock on the date of grant and generally vests in equal annual tranches over a three year period from the date of grant. Certain of our restricted stock grants also include performance-based conditions generally associated with return on invested capital and strategic membership growth. Restricted stock units have forfeitable dividend equivalent rights equal to the dividend paid on common stock. The weighted-average grant date fair value of our restricted stock was $508.23 in 2023, $430.06 in 2022, and $381.34 in 2021. Activity for our restricted stock was as follows for the year ended December&#160;31, 2023:</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:70.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(shares in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested restricted stock at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508.23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested restricted stock at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.06&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 37% of the nonvested restricted stock at December 31, 2023 included performance-based conditions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of shares vested was $236 million during 2023, $244 million during 2022, and $236 million during 2021. Total compensation expense not yet recognized related to nonvested restricted stock was $181 million at December&#160;31, 2023. We expect to recognize this compensation expense over a weighted-average period of approximately 1.7 years. There are no other contractual terms covering restricted stock once vested.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options are granted with an exercise price equal to the fair market value of the underlying common stock on the date of grant. Our stock plans, as approved by the Board of Directors and stockholders, define fair market value as the average of the highest and lowest stock prices reported on the composite tape by the New York Stock Exchange on a given date. Exercise provisions vary, but most options vest in whole or in part 1 to 3 years after grant and expire 7 years after grant.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value of each option granted during 2023, 2022, and 2021 is provided below. The fair value was estimated on the date of grant using the Black-Scholes pricing model with the weighted-average assumptions indicated below:</span></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:55.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value at grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option life (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate at grant date</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate the expected term for our employee stock options based on historical employee exercise behavior and base the risk-free interest rate on a traded zero-coupon U.S. Treasury bond with a term substantially equal to the option&#8217;s expected term.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The volatility used to value employee stock options is based on historical volatility. We calculate historical volatility using a simple-average calculation methodology based on daily price intervals as measured over the expected term of the option.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for our option plans was as follows for the year ended December&#160;31, 2023:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:70.168%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.866%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160; Under<br/>Option</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(shares in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508.80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491.82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at December&#160;31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366.69&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of  December&#160;31, 2023, outstanding stock options, substantially all of which are expected to vest, had an aggregate intrinsic value of $13 million, and a weighted-average remaining contractual term of 4.5 years. As of December&#160;31, 2023, exercisable stock options had an aggregate intrinsic value of $10 million, and a weighted-average remaining contractual term of 3.6 years. The total intrinsic value of stock options exercised during 2023 was $3 million, compared with $32 million during 2022 and $18 million during 2021. Cash received from stock option exercises totaled $9 million in 2023, $51 million in 2022, and $30 million in 2021.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense not yet recognized related to nonvested options was $9 million at December&#160;31, 2023. We expect to recognize this compensation expense over a weighted-average period of approximately 1.7 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Compensation Related Costs Share Based Payments And Compensation And Retirement Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656673216688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER COMMON SHARE COMPUTATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS PER COMMON SHARE COMPUTATION</a></td>
<td class="text">EARNINGS PER COMMON SHARE COMPUTATION<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detail supporting the computation of basic and diluted earnings per common share was as follows for the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions, except&#160;per<br/>common share results, number&#160;of<br/>shares/options in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available for common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average outstanding shares of common stock used to <br/>&#160;&#160;&#160;&#160;compute basic earnings per common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,866&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,419&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,688&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used to compute diluted earnings per&#160;common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,441&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,094&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,396&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.09&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.20&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.79&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per common share</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.00&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.08&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.67&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of antidilutive stock options and restricted stock&#160;awards <br/>&#160;&#160;&#160;&#160;excluded from computation</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656666912608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of dividend payments, excluding dividend equivalent rights, in 2021, 2022, and 2023, under our Board approved quarterly cash dividend policy:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:64.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$351</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.06</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$390</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$428</span></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><span><br/></span></div><div style="margin-bottom:1pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the Board declared a cash dividend of $0.885 per share payable on January&#160;26, 2024 to stockholders of record on December&#160;29, 2023 for an aggregate amount of $108 million. In February 2024, the Board declared a cash dividend of $0.885 per share payable on April&#160;26, 2024 to stockholders of record on March&#160;29, 2024. Declaration and payment of future quarterly dividends is at the discretion of our Board and may be adjusted as business needs or market conditions change.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchases</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors may authorize the purchase of our common shares. Under our share repurchase authorization, shares may have been purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or in privately-negotiated transactions (including pursuant to accelerated share repurchase agreements with investment banks), subject to certain regulatory restrictions on volume, pricing, and timing. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2020, we entered into separate accelerated stock repurchase agreements, the December 2020 ASR Agreements, with Citibank, N.A., or Citi, and JPMorgan Chase Bank, or JPM, to repurchase $1.75&#160;billion of our common stock as part of the $3&#160;billion repurchase program authorized by the Board of Directors on July 30, </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019. On December 23, 2020, in accordance with the December 2020 ASR Agreements, we made a payment of $1.75&#160;billion ($875&#160;million to Citi and $875&#160;million to JPM) and received an initial delivery of 3.8&#160;million shares of our common stock (1.9&#160;million shares each from Citi and JPM). We recorded the payments to Citi and JPM as a reduction to stockholders&#8217; equity, consisting of an $1.5&#160;billion increase in treasury stock, which reflects the value of the initial 3.8&#160;million shares received upon initial settlement, and a $262.5&#160;million decrease in capital in excess of par value, which reflects the value of stock held back by Citi and JPM pending final settlement of the December 2020 ASR Agreements. Upon final settlement of the December 2020 ASR agreements with Citi and JPM on May 4, 2021 and May 5, 2021, respectively, we received an additional 0.3&#160;million shares and 0.3&#160;million shares, respectively, as determined by the average daily volume weighted-averages share price of our common stock during the term of the agreement, less a discount, of $400.07 and $401.49, respectively, bringing the total shares received under the December 2020 ASR agreements to 4.4&#160;million. In addition, upon settlement we reclassified the $262.5&#160;million value of stock initially held back by Citi and JPM from capital in excess of par value to treasury stock.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 18, 2021, the Board of Directors replaced the previous share repurchase authorization of up to $3&#160;billion (of which approximately $1&#160;billion remained unused) with a new authorization for repurchases of up to $3&#160;billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 18, 2024.  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2022, we entered into separate accelerated stock repurchase agreements, the January 2022 ASR Agreements, with Mizuho Markets Americas LLC, or Mizuho, and Wells Fargo Bank, or Wells Fargo, to repurchase $1&#160;billion of our common stock as part of the $3&#160;billion repurchase program authorized by the Board of Directors on February 18, 2021. On January 12, 2022, in accordance with the January 2022 ASR Agreements, we made a payment of $1&#160;billion ($500&#160;million to Mizuho and $500&#160;million to Wells Fargo) and received an initial delivery of 2.2&#160;million shares of our common stock (1.08&#160;million shares each from Mizuho and Wells Fargo). We recorded the payments to Mizuho and Wells Fargo as a reduction to stockholders&#8217; equity, consisting of an $850&#160;million increase in treasury stock, which reflects the value of the initial 2.2&#160;million shares received upon initial settlement, and a $150&#160;million decrease in capital in excess of par value, which reflects the value of stock held back by Mizuho and Wells Fargo pending final settlement of the January 2022 ASR Agreements. Upon final settlement of the January 2022 ASR Agreements with Mizuho and Wells Fargo on March 29, 2022 and March 30, 2022, respectively, we received an additional 0.1&#160;million shares and 0.1&#160;million shares, respectively, as determined by the average daily volume weighted-averages share price of our common stock during the term of the agreement, less a discount, of $410.96 and $411.66, respectively, bringing the total shares received under the January 2022 ASR Agreements to 2.4&#160;million. In addition, upon settlement we reclassified the $150&#160;million value of stock initially held back by Mizuho and Wells Fargo from capital in excess of par value to treasury stock. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 2, 2022, we entered into separate accelerated stock repurchase agreements, the November 2022 ASR Agreements, with Goldman Sachs &amp; Co. LLC, or Goldman Sachs, and Mizuho Markets Americas LLC, or Mizuho, to repurchase $1&#160;billion of our common stock as part of the $3&#160;billion repurchase program authorized by the Board of Directors on February 18, 2021. In accordance with the November 2022 ASR Agreements, we made a payment of $1&#160;billion ($500&#160;million to Goldman Sachs on November 3, 2022 and $500&#160;million to Mizuho on November 4, 2022) and received an initial delivery of 1.5&#160;million shares of our common stock (0.760&#160;million shares each from Goldman Sachs and Mizuho). We recorded the payments to Goldman Sachs and Mizuho as a reduction to stockholders&#8217; equity, consisting of an $850&#160;million increase in treasury stock, which reflects the value of the initial 1.5&#160;million shares received upon initial settlement, and a $150&#160;million decrease in capital in excess of par value, which reflects the value of stock held back by Goldman Sachs and Mizuho pending final settlement of the November 2022 ASR Agreements. Upon final settlement of the November 2022 ASR Agreements with Goldman Sachs and Mizuho on December 15, 2022 and December 16, 2022, respectively, we received an additional 0.177&#160;million shares and 0.177&#160;million shares, respectively,  as determined by the average daily volume weighted-averages share price of our common stock during the term of the agreement, less a discount, of $534.16 and $533.87, respectively, bringing the total shares received under the November 2022 ASR Agreements to 1.8&#160;million. In addition, upon settlement we reclassified the $150&#160;million value of stock initially held back by Goldman Sachs and Mizuho from capital in excess of par value to treasury stock. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 15, 2023, the Board of Directors replaced the previous share repurchase authorization of up to $3&#160;billion (of which approximately $1&#160;billion remained unused) with a new authorization for repurchases of up to $3&#160;billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2026, which we refer to as the February 2023 repurchase authorization. During the year ended December&#160;31, 2023, we repurchased 3.1&#160;million common shares in open market transactions for $1.5&#160;billion at an average price of $482.27 under the current share repurchase authorization. During the years ended December&#160;31, 2022 and December&#160;31, 2021, we did not repurchase shares in open market transactions.  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 16, 2024, the Board of Directors replaced the February 2023 repurchase authorization (of which approximately $824&#160;million remained unused) with a new share repurchase authorization for repurchases of up to $3&#160;billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2027, which we refer to as the 2024 repurchase authorization. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding shares acquired in connection with employee stock plans, share repurchases were as follows during the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:38.546%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.129%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorization Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchase Not to Exceed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repurchases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with employee stock plans, we acquired 0.2 million common shares for $73 million in 2023, 0.2 million common shares for $96 million in 2022, and 0.2 million common shares for $79 million in 2021.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our stockholders' equity, refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Requirements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our subsidiaries operate in states that regulate the payment of dividends, loans, or other cash transfers to Humana Inc., our parent company, and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these subsidiaries, without prior approval by state regulatory authorities, or ordinary dividends, is limited based on the entity&#8217;s level of statutory income and statutory capit</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">al and surplus. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, it is generally considered an extraordinary dividend requiring prior regulatory approval. In most states, prior notification is provided before paying a dividend even if approval is not required. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although minimum required levels of equity are largely based on premium volume, product mix, and the quality of assets held, minimum requirements vary significantly at the state level. Our state regulated insurance subsidiaries had aggregate statutory capital and surplus of approximately $12.2 billion and $11.3 billion as of December&#160;31, 2023 and 2022, respectively, which exceeded aggregate minimum regulatory requirements of </span><span style="background-color:#ffffff;color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.8 billion and $8.4 billion, respectively.  The amount of ordinary dividends that may be paid to our parent company in 2024 is approximately $1.1 billion in the aggregate. The amount, timing and mix of ordinary and extraordinary dividend payments will vary due to state </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory requirements, the level of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix. Actual dividends that were paid to our parent company were approximately $1.8 billion in 2023, $1.3 billion in 2022, and $1.6 billion in 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667086960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS, GUARANTEES AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS, GUARANTEES AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS, GUARANTEES AND CONTINGENCIES<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">     Purchase Obligations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreements to purchase services, primarily information technology related services, or to make improvements to real estate, in each case that are enforceable and legally binding on us and that specify all significant terms, including: fixed or minimum levels of service to be purchased; fixed, minimum or variable price provisions; and the appropriate timing of the transaction. We have purchase obligation commitments of</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$829 million in 2024, $518 million in 2025, $354 million in 2026, $273 million in 2027, and $209 million in 2028. Purchase obligations exclude agreements that are cancellable without penalty.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our ongoing business, we do not participate or knowingly seek to participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, or SPEs, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As of December&#160;31, 2023, we were not involved in any SPE transactions.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through indemnity agreements approved by the state regulatory authorities, certain of our regulated subsidiaries generally are guaranteed by Humana Inc., our parent company, in the event of insolvency for (1)&#160;member coverage for which premium payment has been made prior to insolvency; (2)&#160;benefits for members then hospitalized until discharged; and (3)&#160;payment to providers for services rendered prior to insolvency. Our parent also has guaranteed the obligations of certain of our non-regulated subsidiaries and funding to maintain required statutory capital levels of certain regulated subsidiaries.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we enter into contractual arrangements under which we may agree to indemnify a third party to such arrangement from any losses incurred relating to the services they perform on behalf of us, or for losses arising from certain events as defined within the particular contract, which may include, for example, litigation or claims relating to past performance. Such indemnification obligations may not be subject to maximum loss clauses. Historically, payments made related to these indemnifications have been immaterial.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Contracts</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medicare products, which accounted for approximately 83% of our total premiums and services revenue for the year ended December&#160;31, 2023, primarily consisted of products covered under the Medicare Advantage and Medicare Part D Prescription Drug Plan contracts with the federal government. These contracts are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare products have been renewed for 2024, and all of our product offerings filed with CMS for 2024 have been approved.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997 (BBA) and the Benefits Improvement and Protection Act of 2000 (BIPA), generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service (FFS) program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS and the Office of the Inspector General of Health and Human Services, or HHS-OIG, perform audits of various companies&#8217; risk adjustment diagnosis data submissions. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices that influence the calculation of health status-related premium payments to MA plans.  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2012, CMS released an MA contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract&#8217;s entire health status-related risk adjusted premium amount for the year under audit.  In doing so, CMS recognized &#8220;that the documentation standard used in RADV audits to determine a contract&#8217;s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).&#8221;  To correct for this difference, CMS stated that it would apply a &#8220;Fee-for-Service Adjuster (FFS Adjuster)&#8221; as &#8220;an offset to the preliminary recovery amount.&#8221;  This adjuster would be &#8220;calculated by CMS based on a RADV-like review of records submitted to support FFS claims data.&#8221;  CMS stated that this methodology would apply to audits beginning with PY 2011.  Humana relied on CMS&#8217;s 2012 guidance in submitting MA bids to CMS.  Humana also launched a &#8220;Self-Audits&#8221; program in 2013 that applied CMS&#8217;s 2012 RADV audit methodology and included an estimated FFS Adjuster.  Humana completed Self-Audits for PYs 2011-2016 and reported results to CMS.  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, however, CMS issued a proposed rule announcing possible changes to the RADV audit methodology, including elimination of the FFS Adjuster.  CMS proposed applying its revised methodology, including extrapolated recoveries without application of a FFS Adjuster, to RADV audits dating back to PY 2011.  On January 30, 2023, CMS published a final rule related to the RADV audit methodology (Final RADV Rule).  The Final RADV Rule confirmed CMS&#8217;s decision to eliminate the FFS Adjuster. The Final RADV Rule states CMS&#8217;s intention to extrapolate results from CMS and HHS-OIG RADV audits beginning with PY 2018, rather than PY 2011 as proposed.  However, CMS&#8217;s Final RADV Rule does not adopt a specific sampling, extrapolation or audit methodology.  CMS instead stated its general plan to rely on &#8220;any statistically valid method . . . that is determined to be well-suited to a particular audit.&#8221;  </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the Final RADV Rule fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act (&#8220;APA&#8221;). CMS failed to meet its legal obligations in the federal rulemaking process to give a reasoned justification for the rule or provide a meaningful opportunity for public comment. They also chose to apply the rule retroactively rather than prospectively, as required by law. Humana&#8217;s actuarially certified bids through PY 2023 preserved Humana&#8217;s position that CMS should apply an FFS Adjuster in any RADV audit that CMS intends to extrapolate. We expect CMS to apply the Final RADV Rule, including the first application of extrapolated audit results to determine audit settlements without a FFS Adjuster, to CMS and HHS-OIG RADV audits conducted for PY 2018 and subsequent years.  The Final RADV  Rule, including the lack of a FFS Adjuster, and any related regulatory, industry or company reactions, could have a material adverse effect on our results of operations, financial position, or cash flows.  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in connection with the risk adjustment model. These reviews may also result in the identification of errors and the submission of corrections to CMS that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. We remain committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members.  It is critical that MA plans are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows. </span></div><div style="margin-bottom:9pt;margin-top:4.5pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state-based Medicaid business accounted for approximately 7% of our total premiums and services revenue for the year ended December 31, 2023 primarily serving members enrolled in Medicaid, and in certain circumstances members who qualify for both Medicaid and Medicare, under contracts with various states. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     Our military services business, which accounted for approximately 1% of our total premiums and services revenue for the year ended December 31, 2023, primarily consisted of the TRICARE T2017 East Region contract. The T2017 East Region contract comprises 32 states and approximately 6.0&#160;million TRICARE beneficiaries, under which delivery of health care services commenced on January 1, 2018. The T2017 East Region contract, which was originally set to expire on December 31, 2022, was subsequently extended by the DoD and is currently scheduled to expire on December 31, 2024, unless further extended.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, we were awarded the next generation of TRICARE Managed Care Support Contracts, or T-5, for the updated TRICARE East Region by the Defense Health Agency of the DoD.The T-5 East Region contract comprises 24 states, and Washington D.C., and covers approximately 4.6&#160;million beneficiaries. The transition period for the T-5 contract began in January 2024 and will overlap the final year of the T2017 contract. The length of the contract is <span style="-sec-ix-hidden:f-1748">one</span> transition year followed by eight annual option periods, which, if all options are exercised, would result in a total contract length of <span style="-sec-ix-hidden:f-1750">nine years.</span> </span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss of any of the contracts above or significant changes in these programs as a result of legislative or regulatory action, including reductions in premium payments to us, regulatory restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, or increases in member benefits or member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings and Certain Regulatory Matters</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, the Civil Division of the United States Department of Justice provided us with an information request in December 2014, concerning our Medicare Part C risk adjustment practices. The request relates to our oversight and submission of risk adjustment data generated by providers in our Medicare Advantage network, as well as to our business and compliance practices related to risk adjustment data generated by our providers and by us, including medical record reviews conducted as part of our data and payment accuracy compliance efforts, the use of health and well-being assessments, and our fraud detection efforts. We believe that this request for information is in connection with a wider review of Medicare Risk Adjustment generally that includes a number of Medicare Advantage plans, providers and vendors. We cooperated with the Department of Justice, and we have not heard from the Department of Justice on this matter since 2020. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on January 19, 2016, an individual filed a qui tam suit captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States of America ex rel. Steven Scott v. Humana, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, currently pending in United States District Court, Western District of Kentucky, Louisville Division. The complaint alleges certain civil violations by us in connection with the actuarial equivalence of the plan benefits under Humana&#8217;s Basic PDP plan, a prescription drug plan offered by us under Medicare Part D. The action seeks damages and penalties on behalf of the United States under the False Claims Act. The court ordered the qui tam action unsealed on September 13, 2017, so that the relator could proceed, following notice from the U.S. Government that it was not intervening at that time. On March 31, 2022, the Court denied the parties' Motions for Summary Judgement. We take seriously our obligations to comply with applicable CMS </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements and actuarial standards of practice, and continue to vigorously defend against these allegations. During 2023, we have accrued certain anticipated expenses in connection with this matter.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside.  There is no assurance that we will prevail in the lawsuit. See &#8220;Government Contracts&#8221; in this Note 17 for additional information regarding this matter.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Lawsuits and Regulatory Matters</span></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our current and past business practices are subject to review or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance, health care delivery and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, statutory capital requirements, provider contracting, risk adjustment, competitive practices, commission payments, privacy issues, utilization management practices, pharmacy benefits, access to care, sales practices, and provision of care by our healthcare services businesses, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are involved in various other lawsuits that arise, for the most part, in the ordinary course of our business operations, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate and payment disputes, including disputes over reimbursement rates required by statute, disputes arising from competitive procurement process, general contractual matters, intellectual property matters, and challenges to subrogation practices. Under state guaranty assessment laws, including those related to state cooperative failures in the industry, we may be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business as we do.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a government contractor, we may also be subject to false claims litigation, such as qui tam lawsuits brought by individuals who seek to sue on behalf of the government, alleging that the government contractor submitted false claims to the government or related overpayments from the government, including, among other allegations, those resulting from coding and review practices under the Medicare risk adjustment model. Qui tam litigation is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the individual may continue to prosecute the action on his or her own, on behalf of the government. We also are subject to other allegations of nonperformance of contractual obligations to providers, members, and others, including failure to properly pay claims, improper policy terminations, challenges to our implementation of the Medicare Part D prescription drug program and other litigation.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A limited number of the claims asserted against us are subject to insurance coverage. Personal injury claims, claims for extra contractual damages, care delivery malpractice, and claims arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record accruals for the contingencies discussed in the sections above to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters specifically described above because of the inherently unpredictable nature of legal proceedings, which also may be exacerbated by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting judgments, penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities or as a result of actions by third parties. Nevertheless, it is reasonably possible that any such outcome of litigation, judgments, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows, and may also affect our reputation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667052496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATION<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During December 2022, we realigned our businesses into two distinct segments: Insurance and CenterWell. The Insurance segment includes the businesses that were previously included in the Retail and Group and Specialty segments, as well as the Pharmacy Benefit Manager, or PBM, business which was previously included in the Healthcare Services segment. The CenterWell segment (formerly Healthcare Services) represents our payor-agnostic healthcare services offerings, including pharmacy solutions, primary care, and home solutions. In addition to the new segment classifications being utilized to assess performance and allocate resources, we believe this simpler structure will create greater collaboration across the Insurance and CenterWell businesses and will accelerate work that is underway to centralize and integrate operations within the organization. 2021 segment financial information was recast to conform to the 2022 presentation. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our two</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our military services business, primarily our T-2017 East Region contract, as well as the operations of our PBM business. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CenterWell segment includes our pharmacy solutions, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in Gentiva Hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CenterWell intersegment revenues primarily relate to the operations of CenterWell Pharmacy (our mail-order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our CenterWell intersegment revenues includes revenues earned by certain owned providers (CenterWell Senior Primary Care) derived from certain value-based arrangements with our health plans. Under these value-based arrangements, our owned providers enter into agreements with our health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our members. In exchange, the owned provider receives a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our members. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We present our consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of $20.7 billion in 2023, $19.7 billion in 2022, and $18.1 billion in 2021. In addition, depreciation and amortization expense associated with certain businesses delivering benefits to our members, primarily associated with our primary care and pharmacy operations, are included with benefits expense. The amount of this expense was $138&#160;million in 2023, $122&#160;million in 2022, and $108&#160;million in 2021. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than those described previously, the accounting policies of each segment are the same and are described in Note 2. Transactions between reportable segments primarily consist of sales of services rendered by our CenterWell segment, primarily pharmacy solutions, primary care, and home solutions, to our Insurance segment customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium and services revenues derived from our contracts with the federal government, as a percentage of our total premium and services revenues, were approximately 84% for 2023, 82% for 2022 and 83% for 2021.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,272&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,272&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,272&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,033&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,305&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,403)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,854&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,885)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,374&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,011)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,840)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,013&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net losses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,712&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,712&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,562&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,488&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,588)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,841&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,307&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,278)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,870&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,016&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,765)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,800&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of Gentiva Hospice</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net earnings (losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(982)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,568&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net earnings (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,040&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(982)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,564&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,045&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(982)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,568&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,822&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,822&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,675&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,877&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,869)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,024)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,852&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,893)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,924)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,064&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,722)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,412&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes and equity in net earnings</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings attributable to Humana</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,418&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656669622832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REINSURANCE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceTextBlock', window );">REINSURANCE</a></td>
<td class="text">REINSURANCE <div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain blocks of insurance assumed in acquisitions, primarily life and annuities in run-off status are subject to reinsurance where some or all of the underwriting risk related to these policies has been ceded to a third party. In addition, a large portion of our reinsurance takes the form of 100% coinsurance agreements where, in addition to all of the underwriting risk, all administrative responsibilities, including premium collections and claim payment, have also been ceded to a third party. We acquired these policies and related reinsurance agreements with the purchase of stock of companies in which the policies were originally written. We acquired these companies for business reasons unrelated to these particular policies, including the companies&#8217; other products and licenses necessary to fulfill strategic plans. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reinsurance agreement between two entities transfers the underwriting risk of policyholder liabilities to a reinsurer while the primary insurer retains the contractual relationship with the ultimate insured. As such, these reinsurance agreements do not completely relieve us of our potential liability to the ultimate insured. However, given the transfer of underwriting risk, our potential liability is limited to the credit exposure which exists should the reinsurer be unable to meet its obligations assumed under these reinsurance agreements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reinsurance recoverables represent the portion of future policy benefits payable and benefits payable that are covered by reinsurance. Reinsurance recoverables, included in other long-term assets, were $173 million at December&#160;31, 2023 and $181 million at December&#160;31, 2022. The amount of these reinsurance recoverables resulting from 100% coinsurance agreements was approximately $173 million at December&#160;31, 2023 and approximately $181 million at December&#160;31, 2022. Premiums ceded were $1 million in 2023, $5 million in 2022 and $6 million in 2021. Benefits ceded were $3 million in 2023, $2 million in 2022, and $2 million in 2021. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate the financial condition of our reinsurers on a regular basis. Protective Life Insurance Company with $159 million in reinsurance recoverables is well-known and well-established with a AM Best rating of A+ at December&#160;31, 2023. The remaining reinsurance recoverables of $15 million are divided between 8 other reinsurers, with $0.4 million subject to funds withheld accounts or other financial guarantees supporting the repayment of these amounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to the existence, magnitude and information about insurance that has been ceded to or assumed from another insurance company, including the methodologies and assumptions used in determining recorded amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479838/944-20-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479838/944-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479629/944-605-55-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479629/944-605-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656666942144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock', window );">SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION</a></td>
<td class="text"><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE I&#8212;PARENT COMPANY FINANCIAL INFORMATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"><tr><td style="width:1.0%"></td><td style="width:63.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.344%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions,&#160;except&#160;share<br/>amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Receivable from operating subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,277&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,625&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payable to operating subsidiaries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of notes payable to operating subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Book overdraft</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,888&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,363&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,587&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $1 par; 10,000,000 shares authorized; none issued</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,690,082 shares issued at December&#160;31, 2023 and 198,666,598 shares issued at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Capital in excess of par value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive (loss) income </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(999)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,304)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost, 76,465,862 shares at December&#160;31, 2023 and 73,691,955 shares at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,658)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,625&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,898&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the parent company financial statements.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE I&#8212;PARENT COMPANY FINANCIAL INFORMATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF INCOME</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:58.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.926%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fees charged to operating subsidiaries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,075&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment and other (loss) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,466&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,367&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Operating costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,681&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and equity in net earnings of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(860)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,215)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income before equity in net earnings of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(714)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(949)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net earnings of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net earnings of equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Humana</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,806&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,933&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the parent company financial statements.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE I&#8212;PARENT COMPANY FINANCIAL INFORMATION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:54.758%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Humana</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in gross unrealized investment gains (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,819)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of income taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total change in unrealized investment  <br/>&#160;&#160;&#160;&#160;&#160;gains (losses), net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,401)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification adjustment for net realized <br/>&#160;losses (gains) included in investment income </span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total reclassification adjustment, net of tax</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,346)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to equity method<br/>&#160;&#160;investments</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to Humana</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,794&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the parent company financial statements.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE I&#8212;PARENT COMPANY FINANCIAL INFORMATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:52.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(337)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital contributions to operating subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(792)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(484)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Purchases of property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(761)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(931)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(958)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of investment securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,695)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,317)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,732)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of senior notes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Repayments of senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,832)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds (repayments) from issuance of commercial paper, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(376)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Proceeds from issuance of term loan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of term loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Change in book overdraft</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Common stock repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,096)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(354)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,711)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,843)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,349&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to the parent company financial statements.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE I&#8212;PARENT COMPANY FINANCIAL INFORMATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></div>BASIS OF PRESENTATION<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parent company financial information has been derived from our consolidated financial statements and excludes the accounts of all operating subsidiaries. This information should be read in conjunction with our consolidated financial statements.</span></div>TRANSACTIONS WITH SUBSIDIARIES<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Services Fee</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through intercompany service agreements approved, if required, by state regulatory authorities, Humana Inc., our parent company, charges a services fee for reimbursement of certain centralized services provided to its subsidiaries including information systems, disbursement, investment and cash administration, marketing, legal, finance, and medical and executive management oversight.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash dividends received from subsidiaries and included as a component of net cash provided by operating activities were $1.8 billion in 2023, $1.3 billion in 2022, and $1.6 billion in 2021.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantee</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through indemnity agreements approved by state regulatory authorities, certain of our regulated subsidiaries generally are guaranteed by our parent company in the event of insolvency for: (1) member coverage for which premium payment has been made prior to insolvency; (2) benefits for members then hospitalized until discharged; and (3)&#160;payment to providers for services rendered prior to insolvency. Our parent has also guaranteed the obligations of our military services subsidiaries and funding to maintain required statutory capital levels of certain other regulated subsidiaries.</span></div>REGULATORY REQUIREMENTS<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our subsidiaries operate in states that regulate the payment of dividends, loans, or other cash transfers to Humana Inc., our parent company, and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these subsidiaries, without prior approval by state regulatory authorities, or ordinary dividends, is limited based on the entity&#8217;s level of statutory income and statutory capit</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">al and surplus. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, it is generally considered an extraordinary dividend requiring prior regulatory approval. In most states, prior notification is provided before paying a dividend even if approval is not required.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although minimum required levels of equity are largely based on premium volume, product mix, and the quality of assets held, minimum requirements vary significantly at the state level. Our state regulated insurance subsidiaries had aggregate statutory capital and surplus of approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.2 billion and $11.3 billion as of December&#160;31, 2023 and 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, which exceeded aggregate minimum regulatory requirements of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.8 billion</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $8.4 billion, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of ordinary dividends that may be paid to our parent company in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2024 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.1 billion </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the aggregate. The amount, timing and mix of ordinary and extraordinary dividend payments will vary due to state </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory requirements, the level of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix. Actual dividends that were paid to our parent company were approximately  $1.8 billion in 2023, $1.3 billion in 2022, and $1.6 billion in 2021.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our use of operating cash flows derived from our non-insurance subsidiaries, such as in our Healthcare Services segment, is generally not restricted by state departments of insurance (or comparable state regulators).</span></div>ACQUISITIONS<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 3 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K for a description of certain acquisitions.</span></div>INCOME TAXES<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K for a description of income taxes.</span></div>DEBT<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K for a description of debt.</span></div>STOCKHOLDERS' EQUITY<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K for a description of stockholders&#8217; equity, including stock repurchases and stockholder dividends.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.5-04(Schedule I))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480922/205-10-S99-6<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656666328736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Humana</a></td>
<td class="nump">$ 2,489<span></span>
</td>
<td class="nump">$ 2,806<span></span>
</td>
<td class="nump">$ 2,933<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656673138112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667526064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. Our consolidated financial statements include the accounts of Humana Inc. and subsidiaries that the Company controls, including variable interest entities associated with medical practices for which we are the primary beneficiary. We do not own many of our medical practices but instead enter into exclusive management agreements with the affiliated Professional Associations, or P.A.s, that operate these medical practices. Based upon the provisions of these agreements, these affiliated P.A.s are variable interest entities and we are the primary beneficiary, and accordingly we consolidate the affiliated P.A.s. All significant intercompany balances and transactions have been eliminated.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents include cash, time deposits, money market funds, commercial paper, other money market instruments, and certain U.S. Government securities with an original maturity of three months or less. Carrying value approximates fair value due to the short-term maturity of the investments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment Securities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Securities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities, which consist of debt and equity securities, are stated at fair value. Our debt securities have been categorized as available for sale. Debt securities available for current operations, as well as our equity securities, are classified as current assets, and debt securities available to fund our professional and other self-insurance liability requirements, as well as restricted statutory deposits, are classified as long-term assets. For the purpose of determining realized gross gains and losses for debt securities sold, that are included as a component of investment income in the consolidated statements of income, the cost of investment securities sold is based upon specific identification. Unrealized holding gains and losses for debt securities, net of applicable deferred taxes, are included in other comprehensive income or loss as a component of stockholders&#8217; equity until realized from a sale or an expected credit loss is recognized. For the purpose of determining gross gains and losses for equity securities, changes in fair value at the reporting date are included as a component of investment income in the consolidated statements of income.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the current expected credit losses model, or CECL, expected losses on available for sale debt securities are recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities. For debt securities whose fair value is less than their amortized cost which we do not intend to sell or are not required to sell, we evaluate the expected cash flows to be received as compared to amortized cost and determine if an expected credit loss has occurred. In the event of an expected credit loss, only the amount of the impairment associated with the expected credit loss is recognized in income with the remainder, if any, of the loss recognized in other comprehensive income.  To the extent we have the intent to sell the debt security or it is more likely than not we will be required to sell the debt security before recovery of our amortized cost basis, we recognize an impairment loss in income in an amount equal to the full difference between the amortized cost basis and the fair value.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential expected credit loss impairment is considered using a variety of factors, including the extent to which the fair value has been less than cost; adverse conditions specifically related to the industry, geographic area or financial condition of the issuer or underlying collateral of a debt security; changes in the quality of the debt </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">security's credit enhancement; payment structure of the debt security; changes in credit rating of the debt security by the rating agencies; failure of the issuer to make scheduled principal or interest payments on the debt security and changes in prepayment speeds. For debt securities, we take into account expectations of relevant market and economic data. For example, with respect to mortgage and asset-backed securities, such data includes underlying loan level data and structural features such as seniority and other forms of credit enhancements. We estimate the amount of the expected credit loss component of a debt security as the difference between the amortized cost and the present value of the expected cash flows of the security. The present value is determined using the best estimate of future cash flows discounted at the implicit interest rate at the date of purchase. The expected credit loss cannot exceed the full difference between the amortized cost basis and the fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsurancePremiumsRevenueRecognitionPolicy', window );">Premiums Revenue</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Premiums Revenue</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive monthly premiums from the federal government and various states according to government specified payment rates and various contractual terms. We bill and collect premium from employer groups and members in our Medicare and other individual products monthly.  Changes in premium revenues resulting from the periodic changes in risk-adjustment scores derived from medical diagnoses for our membership are estimated by projecting the ultimate annual premium and are recognized ratably during the year, with adjustments each period to reflect changes in the ultimate premium. Receivables or payables are classified as current or long-term in our consolidated balance sheet based on the timing of the expected settlement. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premiums revenue is estimated by multiplying the membership covered under the various contracts by the contractual rates. Premiums revenue is recognized as income in the period members are entitled to receive services and is net of estimated uncollectible amounts, retroactive membership adjustments, and adjustments to recognize rebates under the minimum benefit ratios required under the Health Care Reform Law. We estimate policyholder rebates by projecting calendar year minimum benefit ratios for the small group and large group markets, as defined by the Health Care Reform Law using a methodology prescribed by Health and Human Services, or HHS, separately by state and legal entity. Medicare Advantage and Medicaid products are also subject to minimum benefit ratio requirements. Estimated calendar year rebates recognized ratably during the year are revised each period to reflect current experience. Retroactive membership adjustments result from enrollment changes not yet processed, or not yet reported by an employer group or the government. We routinely monitor the collectability of specific accounts, the aging of receivables, historical retroactivity trends, estimated rebates, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. Premiums received prior to the service period are recorded as unearned revenues.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicare Part D</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with CMS. The payments we receive monthly from CMS and members, which are determined from our annual bid, represent amounts for providing prescription drug insurance coverage. We recognize premiums revenue for providing this insurance coverage ratably over the term of our annual contract. Our CMS payment is subject to risk sharing through the Medicare Part D risk corridor provisions. In addition, receipts for reinsurance and low-income cost subsidies as well as receipts for certain discounts on brand name prescription drugs in the coverage gap represent payments for prescription drug costs for which we are not at risk.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk corridor provisions compare costs targeted in our bids to actual prescription drug costs, limited to actual costs that would have been incurred under the standard coverage as defined by CMS. Variances exceeding certain thresholds may result in CMS making additional payments to us or require us to refund to CMS a portion of the premiums we received. As risk corridor provisions are considered in our overall annual bid process, we estimate </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and recognize an adjustment to premiums revenue related to these provisions based upon pharmacy claims experience. We record a receivable or payable at the contract level and classify the amount as current or long-term in our consolidated balance sheets based on the timing of expected settlement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reinsurance and low-income cost subsidies represent funding from CMS in connection with the Medicare Part D program for which we assume no risk. Reinsurance subsidies represent funding from CMS for its portion of prescription drug costs which exceed the member&#8217;s out-of-pocket threshold, or the catastrophic coverage level. Low-income cost subsidies represent funding from CMS for all or a portion of the deductible, the coinsurance and co-payment amounts above the out-of-pocket threshold for low-income beneficiaries. Monthly prospective payments from CMS for reinsurance and low-income cost subsidies are based on assumptions submitted with our annual bid. A reconciliation and related settlement of CMS&#8217;s prospective subsidies against actual prescription drug costs we paid is made after the end of the year. The Health Care Reform Law mandates consumer discounts of 50% on brand name prescription drugs for Part D plan participants in the coverage gap. These discounts are funded by CMS and pharmaceutical manufacturers while we administer the application of these funds. We account for these subsidies and discounts as a deposit in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits, net in our consolidated statements of cash flows. </span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:56.896%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.472%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part D subsidy/discount payments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,530)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part D subsidy/discount reimbursements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net reimbursements (payments)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not recognize premiums revenue or benefit expenses for these subsidies or discounts. Receipt and payment activity is accumulated at the contract level and recorded in our consolidated balance sheets in other current assets or trade accounts payable and accrued expenses depending on the contract balance at the end of the reporting period.</span></div>Settlement of the reinsurance and low-income cost subsidies as well as the risk corridor payment is based on a reconciliation made approximately 9 months after the close of each calendar year. Settlement with CMS for brand name prescription drug discounts is based on a reconciliation made approximately 14 to 18 months after the close of each calendar year. We continue to revise our estimates with respect to the risk corridor provisions based on subsequent period pharmacy claims data. For additional information regarding amounts recorded to our consolidated balance sheets related to the risk corridor settlement and subsidies from CMS with respect to the Medicare Part D program, refer to Note 7 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Services Revenue</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient services revenue </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient services include services related to pharmacy solutions, primary care, and home solutions and other services and capabilities to promote wellness and advance population health. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our pharmacy solutions business, external pharmacy revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments for drugs dispensed through our CenterWell Pharmacy (our mail-order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Services revenues related to product revenues from dispensing prescriptions are recorded when the prescription or product is shipped.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary care business recognizes revenues for certain value-based arrangements. Under these value-based arrangements, we enter into agreements with health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our patients. In exchange, we receive a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our patients. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our home solutions businesses, revenues include net patient services revenue recorded based upon established billing rates, net of contractual allowances, discounts, or other implicit price concessions, and are recognized as performance obligations are satisfied, which is in the period services are rendered.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the&#160;year ended December&#160;31, 2023, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price), was not material. Further, revenue expected to be recognized in any future year related to remaining performance obligations is not material.</span></div><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Administrative services fees </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative services fees cover the processing of claims, offering access to our provider networks and clinical programs, and responding to customer service inquiries from members of self-funded groups. Revenues from providing administration services, also known as administrative services only, or ASO, are recognized in the period services are performed and are net of estimated uncollectible amounts. ASO fees are estimated by multiplying the membership covered under the various contracts by the contractual rates. Under ASO contracts, self-funded employers retain the risk of financing substantially all of the cost of health benefits. However, many ASO customers purchase stop loss insurance coverage from us to cover catastrophic claims or to limit aggregate annual costs. Accordingly, we have recorded premiums revenue and benefits expense related to these stop loss insurance contracts. We routinely monitor the collectability of specific accounts, the aging of receivables, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. ASO fees received prior to the service period are recorded as unearned revenues.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under our TRICARE contracts with the Department of Defense (DoD) we provide administrative services, including offering access to our provider networks and clinical programs, claim processing, customer service, enrollment, and other services, while the federal government retains all of the risk of the cost of health benefits. We account for revenues under our contracts net of estimated health care costs similar to an administrative services fee only agreement. Our contracts include fixed administrative services fees and incentive fees and penalties. Administrative services fees are recognized as services are performed.&#160;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our TRICARE members are served by both in-network and out-of-network providers in accordance with our contracts. We pay health care costs related to these services to the providers and are subsequently reimbursed by the DoD for such payments. We account for the payments of the federal government&#8217;s claims and the related reimbursements under deposit accounting in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits, net in our consolidated statements of cash flows.  </span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:56.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost payments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,943)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost reimbursements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net reimbursements (payments)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, including premium receivables, patient services revenue receivables, and ASO fee receivables, are shown net of allowances for estimated uncollectible accounts, retroactive membership adjustments, and contractual allowances.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_OtherCurrentAssetsPolicyTextBlock', window );">Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets</span></div>Other current assets include amounts associated with Medicare Part D, rebates due from pharmaceutical manufacturers and other amounts due within one year.  We accrue pharmaceutical rebates as they are earned based on contractual terms and usage of the product.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceContractAcquisitionCostPolicyTextBlock', window );">Policy Acquisition Costs</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Policy Acquisition Costs</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Policy acquisition costs are those costs that relate directly to the successful acquisition of new and renewal insurance policies. Such costs include commissions, costs of policy issuance and underwriting, and other costs we incur to acquire new business or renew existing business. We expense policy acquisition costs related to our employer-group prepaid health services policies as incurred. These short-duration employer-group prepaid health services policies typically have a 1-year term and may be canceled upon 30 days notice by the employer group.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at cost. Gains and losses on sales or disposals of property and equipment are included in operating costs in our consolidated income statements. Certain costs related to the development or purchase of internal-use software are capitalized. Depreciation is computed using the straight-line method over estimated useful lives ranging from 3 to 10 years for equipment, 3 to 5 years for computer software, and 10 to 20 years for buildings. Improvements to leased facilities are depreciated over the shorter of the remaining lease term or the anticipated life of the improvement.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically review long-lived assets, including property and equipment and other definite-lived intangible assets, for impairment whenever adverse events or changes in circumstances indicate the carrying value of the asset may not be recoverable. Losses are recognized for a long-lived asset to be held and used in our operations when the undiscounted future cash flows expected to result from the use of the asset are less than its carrying value. We recognize an impairment loss based on the excess of the carrying value over the fair value of the asset. A long-lived asset held for sale is reported at the lower of the carrying amount or fair value less costs to sell. Depreciation expense is not recognized on assets held for sale. Losses are recognized for a long-lived asset to be abandoned when the asset ceases to be used. In addition, we periodically review the estimated lives of all long-lived assets for reasonableness.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investments</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the equity method of accounting for equity investments in companies where we are able to exercise significant influence, but not control, over operating and financial policies of the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as our ownership interest, representation on the board of directors, organizational structure, participation in policy-making decisions and material intra-entity transactions.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, under the equity method, original investments in these entities are recorded at cost and subsequently adjusted by our share of equity in income or losses after the date of acquisition as well as capital contributions to and distributions from these companies. Our proportionate share of the net income or loss of these companies is included in consolidated net income.  Investment amounts in excess of our share of an investee&#8217;s net assets are amortized over the life of the related asset creating the excess. Excess goodwill is not amortized. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered by us when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than carrying value, the investee&#8217;s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the unamortized excess of cost over the fair value of the net tangible and other intangible assets acquired. We are required to test at least annually for impairment at a level of reporting referred to as the reporting unit, and more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. A reporting unit either is our operating segments or one level below the operating segments, referred to as a component, which comprise our reportable segments. A component is considered a reporting unit if the component constitutes a business for which discrete financial information is available that is regularly reviewed by management. We aggregate the components of an operating segment into one reporting unit if they have similar economic characteristics. Goodwill is assigned to the reporting units that are expected to benefit from the specific synergies of the business combination.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform a quantitative assessment to review goodwill for impairment to determine both the existence and amount of goodwill impairment, if any. Impairment tests are performed, at a minimum, in the fourth quarter of each year supported by our long-range business plan and annual planning process. We rely on an evaluation of future discounted cash flows to determine fair value of our reporting units. The fair value of our reporting units with significant goodwill exceeded carrying amounts. However, unfavorable changes in key assumptions or combinations of assumptions including a significant increase in the discount rate, decrease in the long-term growth rate or substantial reduction in our underlying cash flow assumptions, including revenue growth rates, medical and operating cost trends, and projected operating income could have a significant negative impact on the estimated fair value of our home solutions and primary care reporting units, which accounted for $4.4&#160;billion and $1.2&#160;billion of goodwill, respectively. Impairment tests completed for 2023, 2022, and 2021 did not result in an impairment loss. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with indefinite lives relate to Certificate of Needs (CON) and Medicare licenses acquired as part of our acquisition of Kindred at Home, or KAH, and are included within other long-term assets in the consolidated balance sheet at December&#160;31, 2023 and December&#160;31, 2022. For additional information regarding our acquisition of KAH, refer to Note 3 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K. We are required to annually compare the fair values of other indefinite-lived intangible assets to their carrying amounts. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized. Fair values of indefinite-lived intangible assets are determined based on the income approach. Impairment tests completed for 2023 and 2022 did not result in material impairment losses. These charges reflect the amount by which the carrying value exceeded its estimated fair value. Impairment tests completed for 2021 did not result in an impairment loss. The fair values of the assets were measured using Level 3 inputs, such as projected revenues and operating cash flows. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Definite-lived intangible assets primarily relate to acquired customer contracts/relationships and are included with other long-term assets in the consolidated balance sheets. Definite-lived intangible assets are amortized over the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">useful life generally using the straight-line method. We review definite-lived intangible assets for impairment under our long-lived asset policy.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock', window );">Benefits Payable and Benefits Expense Recognition</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Benefits Payable and Benefits Expense Recognition</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefits expense includes claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care and other supplemental benefits provided on or prior to the balance sheet date. Capitation payments represent monthly contractual fees disbursed to primary care and other providers who are responsible for providing medical care to members. Pharmacy costs represent payments for members&#8217; prescription drug benefits, net of rebates from drug manufacturers. Receivables for such pharmacy rebates are included in other current assets in our consolidated balance sheets. Other supplemental benefits include dental, vision, and other supplemental health products.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the costs of our benefits expense payments using actuarial methods and assumptions based upon claim payment patterns, medical cost inflation, historical developments such as claim inventory levels and claim receipt patterns, and other relevant factors, and record benefit reserves for future payments. We continually review estimates of future payments relating to claims costs for services incurred in the current and prior periods and make necessary adjustments to our reserves.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefits expense is recognized in the period in which services are provided and includes an estimate of the cost of services which have been incurred but not yet reported, or IBNR. Our reserving practice is to consistently recognize the actuarial best point estimate within a level of confidence required by actuarial standards. Actuarial standards of practice generally require a level of confidence such that the liabilities established for IBNR have a greater probability of being adequate versus being insufficient, or such that the liabilities established for IBNR are sufficient to cover obligations under an assumption of moderately adverse conditions. Adverse conditions are situations in which the actual claims are expected to be higher than the otherwise estimated value of such claims at the time of the estimate. Therefore, in many situations, the claim amounts ultimately settled will be less than the estimate that satisfies the actuarial standards of practice.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We develop our estimate for IBNR using actuarial methodologies and assumptions, primarily based upon historical claim experience. Depending on the period for which incurred claims are estimated, we apply a different method in determining our estimate. For periods prior to the most recent two months, a completion factor method uses historical paid claims patterns to estimate the percentage of claims incurred during a given period that have historically been adjudicated as of the reporting period. Changes in claim inventory levels and known changes in claim payment processes are taken into account in these estimates. For the most recent two months, the incurred claims are estimated primarily from a trend analysis based upon per member per month claims trends developed from our historical experience in the preceding months, adjusted for known changes in estimates of hospital admissions, recent hospital and drug utilization data, provider contracting changes, changes in benefit levels, changes in member cost sharing, changes in medical management processes, product mix, and workday seasonality.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The completion factor method is used for the months of incurred claims prior to the most recent two months because the historical percentage of claims processed for those months is at a level sufficient to produce a consistently reliable result. Conversely, for the most recent two months of incurred claims, the volume of claims processed historically is not at a level sufficient to produce a reliable result, which therefore requires us to examine historical trend patterns as the primary method of evaluation. Changes in claim processes, including recoveries of overpayments, receipt cycle times, claim inventory levels, outsourcing, system conversions, and processing disruptions due to weather or other events affect views regarding the reasonable choice of completion factors. Claim payments to providers for services rendered are often net of overpayment recoveries for claims paid previously, as contractually allowed. Claim overpayment recoveries can result from many different factors, including retroactive enrollment activity, audits of provider billings, and/or payment errors. Changes in patterns of claim overpayment recoveries can be unpredictable and result in completion factor volatility, as they often impact older dates of service. The receipt cycle time measures the average length of time between when a medical claim was initially incurred and </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when the claim form was received. Increases in electronic claim submissions from providers decrease the receipt cycle time. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claim may be more (less) complete than originally estimated using our completion factors, which may result in reserves that are higher (lower) than required.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical cost trends potentially are more volatile than other segments of the economy. The drivers of medical cost trends include increases in the utilization of hospital facilities, physician services, new higher priced technologies and medical procedures, and new prescription drugs and therapies, as well as the inflationary effect on the cost per unit of each of these expense components. Other external factors such as government-mandated benefits or other regulatory changes, the tort liability system, increases in medical services capacity, direct to consumer advertising for prescription drugs and medical services, an aging population, lifestyle changes including diet and smoking, catastrophes, public health emergencies, epidemics and pandemics (such as COVID-19) also may impact medical cost trends. Internal factors such as system conversions, claims processing cycle times, changes in medical management practices and changes in provider contracts also may impact our ability to accurately predict estimates of historical completion factors or medical cost trends. All of these factors are considered in estimating IBNR and in estimating the per member per month claims trend for purposes of determining the reserve for the most recent two months. Additionally, we continually prepare and review follow-up studies to assess the reasonableness of the estimates generated by our process and methods over time. The results of these studies are also considered in determining the reserve for the most recent two months. Each of these factors requires significant judgment by management.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reassess the profitability of our contracts for providing insurance coverage to our members when current operating results or forecasts indicate probable future losses. We establish a premium deficiency reserve in current operations to the extent that the sum of expected future costs, claim adjustment expenses, and maintenance costs exceeds related future premiums under contracts. For purposes of determining premium deficiencies, contracts are grouped in a manner consistent with our method of acquiring, servicing, and measuring the profitability of such contracts. Losses recognized as a premium deficiency result in a beneficial effect in subsequent periods as operating losses under these contracts are charged to the liability previously established. Because the majority of our member contracts renew annually, we would not record a material premium deficiency reserve, except when unanticipated adverse events or changes in circumstances indicate otherwise.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our benefits payable are adequate to cover future claims payments required. However, such estimates are based on knowledge of current events and anticipated future events. Therefore, the actual liability could differ materially from the amounts provided.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock', window );">Future policy benefits payable</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future policy benefits payable</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future policy benefits payable includes liabilities for long-duration insurance policies primarily related to certain blocks of insurance assumed in acquisitions, primarily life and annuities in run-off status, and are included in our consolidated balance sheet within other long-term liabilities. Most of these policies are subject to reinsurance. For additional information regarding reinsurance, refer to Note 19 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_BookOverdraftPolicyPolicyTextBlock', window );">Book Overdraft</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Book Overdraft</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our cash management system, checks issued but not yet presented to banks that would result in negative bank balances when presented are classified as a current liability in the consolidated balance sheets. Changes in book overdrafts from period to period are reported in the consolidated statement of cash flows as a financing activity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets or liabilities and their reported amounts in the consolidated financial statements. These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities are recovered or settled. We also recognize the future tax benefits such as net operating and capital loss carryforwards as deferred tax assets. A valuation allowance is provided against these deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized. Future years&#8217; tax expense may be increased or decreased by adjustments to the valuation allowance or to the estimated accrual for income taxes. Deferred tax assets and deferred tax liabilities are further adjusted for changes in the enacted tax rates. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record tax benefits when it is more likely than not that the tax return position taken with respect to a particular transaction will be sustained. A liability, if recorded, is not considered resolved until the statute of limitations for the relevant taxing authority to examine and challenge the tax position has expired, or the tax position is ultimately settled through examination, negotiation, or litigation. We classify interest and penalties associated with uncertain tax positions in our provision for income taxes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Noncontrolling Interests</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include all assets, liabilities, revenues and expenses of less than 100% owned affiliates that we control. Accordingly, we record noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interest holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interest holders&#8217; balances. Noncontrolling interests, which relate to the minority ownership held by third party investors in certain of our businesses within our Insurance and CenterWell segments, are reported below net income under the heading &#8220;Net income attributable to noncontrolling interests&#8221; in the consolidated statements of income and presented as a component of equity in the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div>We generally recognize stock-based compensation expense, as determined on the date of grant at fair value, on a straight-line basis over the period during which an employee is required to provide service in exchange for the award (the vesting period). In addition, for awards with both time and performance-based conditions, we generally recognize compensation expense on a straight line basis over the vesting period when it is probable that the performance condition will be achieved. We estimate expected forfeitures and recognize compensation expense only for those awards which are expected to vest. We estimate the grant-date fair value of stock options using the Black-Scholes option-pricing model.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Common Share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Earnings Per Common Share</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compute basic earnings per common share on the basis of the weighted-average number of unrestricted common shares outstanding. Diluted earnings per common share is computed on the basis of the weighted-average number of unrestricted common shares outstanding plus the dilutive effect of outstanding employee stock options and restricted shares, or units, using the treasury stock method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are categorized into a fair value hierarchy based on whether the inputs to valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our own assumptions about the assumptions market participants would use. The fair value hierarchy includes three levels of inputs that may be used to measure fair value as described below.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 &#8211; Quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities include securities that are traded in an active exchange market.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 &#8211; Observable inputs other than Level 1 prices such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less frequently than exchange-traded instruments as well as debt securities whose value is determined using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 &#8211; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes assets and liabilities whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting our own assumptions about the assumptions market participants would use as well as those requiring significant management judgment.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of actively traded debt and equity securities are based on quoted market prices. Fair value of other debt securities are based on quoted market prices of identical or similar securities or based on observable inputs like interest rates generally using a market valuation approach, or, less frequently, an income valuation approach and are generally classified as Level 2. Fair value of privately held investment grade debt securities are estimated using a variety of valuation methodologies, including both market and income approaches, where an observable quoted market does not exist and are generally classified as Level 3. For privately-held investment grade debt securities, such methodologies include reviewing the value ascribed to the most recent financing, comparing the security with securities of publicly-traded companies in similar lines of business with similar credit characteristics, and reviewing the underlying financial performance including estimating discounted cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain at least one price for each security from a third party pricing service. These prices are generally derived from recently reported trades for identical or similar securities, including adjustments through the reporting date based upon observable market information. When quoted prices are not available, the third party pricing service may use quoted market prices of comparable securities or discounted cash flow analysis, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include benchmark yields, reported trades, credit spreads, broker quotes, default rates, and prepayment speeds. We are responsible for the determination of fair value and as such we perform analysis on the prices received from the third party pricing service to determine whether the prices are reasonable estimates of fair value. Our analysis includes a review of monthly price fluctuations as well as a quarterly comparison of the prices received from the pricing service to prices reported by our third party investment adviser. In addition, on a quarterly basis we examine the underlying inputs and assumptions for a sample of individual securities across asset classes, credit rating levels, and various durations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements and Accounting Pronouncements Effective in Future Periods</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services&#8212;Insurance (Topic 944): Effective Date and Early Application (&#8220;ASU 2020-11&#8221;). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services&#8212;Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (&#8220;ASU 2018-12&#8221;), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The new guidance relates to accounting for long-duration contracts of insurers which revises key elements of the measurement models and disclosure requirements for long-duration contracts issued by insurers, including the amortization of deferred contract acquisition costs and the measurement of liabilities for future policy benefits using current, rather than locked-in, assumptions. The new guidance, limited to our Medicare Supplement product which represents less than 1% of consolidated premiums and services revenue, became effective for us </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beginning January 1, 2023 and was applied to contracts in force on the basis of their existing carrying value amounts at the beginning of the earliest period presented. The adoption of the new standard in 2023 did not have a material impact on our consolidated results of operations, financial position or cash flows.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Pronouncements Effective in Future Periods</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting &#8212; Improvements to Reportable Segment Disclosures. The new guidance requires incremental disclosures related to a public entity&#8217;s reportable segments but does not change the definition of a segment, the method for determining segments, or the criteria for aggregating operating segments into reportable segments. The new guidance requires a public entity to disclose its significant segment expense categories and amounts for each reportable segment. The new guidance will be effective for us beginning with our annual 2024 year-end financial statements. We are currently evaluating the impact on our segment information footnote disclosures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued Accounting Standards Update No. 2023-09 &#8212; Income Taxes (Topic 740): Improvements to Income Tax Disclosures.  The new guidance requires significant additional disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be effective for us beginning with our annual 2025 year-end financial statements, with early adoption permitted.  We are currently evaluating the impact on our income tax footnote disclosures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the entity's accounting policies, methodologies, and assumptions for estimating its liability as of the balance sheet date for the cost of settling reported and unreported claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_BookOverdraftPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of policies associated with the accounting treatment of book overdraft</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_BookOverdraftPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of policies associated with the accounting treatment of future policy benefits payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_OtherCurrentAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_OtherCurrentAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceContractAcquisitionCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost related directly to successful acquisition of new and renewal of insurance contract. Information includes, but is not limited to, input, judgment, assumption, and method used to determine amortization amount, and change in input, judgment, and assumption. Cost, includes but is not limited to, deferred policy acquisition cost, deferred sale inducement cost, and present value of future profit of insurance contract acquired in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479735/944-20-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479432/944-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479432/944-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479432/944-30-50-2A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479432/944-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceContractAcquisitionCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsurancePremiumsRevenueRecognitionPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition of insurance premium. Includes, but is not limited to, basis for measurement and timing of recognition of revenue from insurance premium received from contract holder and method used in performing premium deficiency testing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -SubTopic 60<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479482/944-60-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsurancePremiumsRevenueRecognitionPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667033280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock', window );">Schedule of Health Care Cost Payments and Reimbursements</a></td>
<td class="text">We account for these subsidies and discounts as a deposit in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits, net in our consolidated statements of cash flows. <div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:56.896%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.446%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.472%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part D subsidy/discount payments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,582)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,530)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Part D subsidy/discount reimbursements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net reimbursements (payments)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>We account for the payments of the federal government&#8217;s claims and the related reimbursements under deposit accounting in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits, net in our consolidated statements of cash flows.  <div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:56.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.448%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost payments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,073)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,943)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health care cost reimbursements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net reimbursements (payments)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Health Care Cost Payments and Reimbursements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667086960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS AND DIVESTITURES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text">The assets, liabilities and noncontrolling interest disposed of on August 11, 2022 were as follows:<div style="padding-left:36pt;padding-right:36pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:77.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.928%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Receivables, net of allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,622&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Trade accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">245&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">530&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Noncontrolling interest</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656673159456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY METHOD INVESTMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Equity Method Investments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summarized balance sheets and statements of income at December&#160;31, 2023 and 2022 of Gentiva Hospice were as follows:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:55.210%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.746%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance sheet</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:53.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.393%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December 31, 2023</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">August 11, 2022 through December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,873&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656665428272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT SECURITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Investment Securities Classified as Current and Long-Term</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities classified as current and long-term were as follows at December&#160;31, 2023 and 2022, respectively:</span></div><div style="margin-bottom:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.646%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>&#160;&#160;&#160;&#160;corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,946&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investment securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>&#160;&#160;&#160;&#160;corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(471)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,809&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,551&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(828)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,726&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,701)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total investment securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,261&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of Gross Unrealized Losses and Fair Value of Securities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross unrealized losses and fair values aggregated by investment category and length of time that individual debt securities have been in a continuous unrealized loss position were as follows at December&#160;31, 2023 and 2022, respectively:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;than&#160;12&#160;months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12 months or more</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td></tr><tr style="height:15pt"><td colspan="36" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>&#160;&#160;&#160;&#160;corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(413)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,227&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(592)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,249&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(594)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,300)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,328)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government <br/>&#160;&#160;&#160;&#160;corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(471)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,157&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,400&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,625&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,825&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(730)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(828)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,419&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(270)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,431)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,381&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,701)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRealizedGainLossTableTextBlock', window );">Schedule of Realized Gains (Losses) Related to Investment Securities Included Within Investment Income</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The detail of realized gains (losses) related to investment securities and included within investment income was as follows for the years ended December&#160;31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:7pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:57.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains on investment securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses on investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross gains on equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross losses on equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(364)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net recognized losses on investment securities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Schedule of Gain (Loss) on Equity Securities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gains and losses related to equity securities for the years ended December&#160;31, 2023, 2022 and 2021 was as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.517%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gains (losses) recognized on equity securities during the period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(341)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net gains (losses) recognized on equity securities sold during the period</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses recognized on equity securities still held at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(328)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Contractual Maturities of Debt Securities Available for Sale</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of debt securities available for sale at December&#160;31, 2023, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:75.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,279&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,112&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,149&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage and asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,038&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,302&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRealizedGainLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the proceeds from sales of available-for-sale securities and the gross realized gains and gross realized losses that have been included in earnings as a result of those sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRealizedGainLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656666925712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Financial Assets Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our fair value measurements at December&#160;31, 2023 and 2022, respectively, for financial assets measured at fair value on a recurring basis:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:45.127%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.741%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.744%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,522&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,345&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,445&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,269&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total invested assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,832&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,832&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and other U.S. government corporations and agencies:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and agency obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax-exempt municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage-backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Residential</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,254&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,153&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total invested assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,093&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,839&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,153&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text">During the years ended December&#160;31, 2023 and 2022, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:<div style="margin-bottom:9pt;text-align:center;text-indent:11.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:54.277%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.212%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December&#160;31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the year ended December&#160;31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Private<br/>Placements</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance at January&#160;1</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gains or losses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Realized in earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized in other comprehensive&#160;income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers Out</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transfers In</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Assumptions Used For Inputs In Fair Value Measurement</a></td>
<td class="text">The table below presents the assumptions used for December&#160;31, 2023 and 2022, respectively: <div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:59.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.837%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Annualized volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1% - 17.8%</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7% to 20.8%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit spread</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9% - 1.1%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3% to 1.5%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue exit multiple</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5x - 2.5x </span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5x - 2.5x</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average cost of capital</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0% - 12.5%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.5% to 12.5%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term growth rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for annualized volatility, credit spread and weighted average cost of capital reflect the lowest and highest values where they differ significantly across the series of put and call options due to their expected exercise dates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656669622832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MEDICARE PART D (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock', window );">Schedule of Balance Sheet Amounts Associated With Medicare Part D</a></td>
<td class="text">The accompanying consolidated balance sheets include the following amounts associated with Medicare Part D as of December&#160;31, 2023 and 2022. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.<div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:52.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk<br/>Corridor<br/>Settlement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CMS<br/>Subsidies/<br/>Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Risk<br/>Corridor<br/>Settlement</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CMS<br/>Subsidies/<br/>Discounts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,825)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current (liability) asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,311)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net long-term liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total net (liability) asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,311)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(540)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance Sheet Account Associated With Medicare Part D</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656673239568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment was comprised of the following at December&#160;31, 2023 and 2022. </span></div><div style="margin-bottom:1pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:75.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.656%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and leasehold improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,546&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,951&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,854)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,136)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656666981200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Changes in Carrying Amount of Goodwill By Reportable Segments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill for our reportable segments for the years ended December&#160;31, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:53.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dispositions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,472&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,670&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,142&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,887&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,550&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets Included in Other Long-Term Assets</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents details of our other intangible assets included in other long-term assets in the accompanying consolidated balance sheets at December&#160;31, 2023 and 2022:</span></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.791%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.116%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Life</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of need</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare licenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer contracts/relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade names and technology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncompetes and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,693&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimate of Amortization Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our estimate of amortization expense for each of the five next succeeding fiscal years: </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:81.186%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656660880528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:80.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity of&#160;Lease&#160;Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656668019920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BENEFITS PAYABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of Activity in Benefits Payable</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:54.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances at January&#160;1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(872)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total incurred</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,394&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,690&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,199&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paid related to:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67,287)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,149)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,946)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,479)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74,715)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,095)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balances at December&#160;31</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,241&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,289&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock', window );">Schedule of Incurred and Paid Claims Development</a></td>
<td class="text">The following tables provide information about incurred and paid claims development as of December&#160;31, 2023, net of reinsurance.<div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:54.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.890%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurred Claims, Net of Reinsurance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claims Incurred Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021<br/>Unaudited</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022<br/>Unaudited</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,447&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,259&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:53.883%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.891%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Paid Claims, Net of Reinsurance</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Claims Incurred Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021<br/>Unaudited</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022<br/>Unaudited</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 &amp; Prior</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,018&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All outstanding benefit liabilities before 2021, net of reinsurance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits payable, net of reinsurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted information about claims development by accident year for short-duration insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656659979568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes consisted of the following for the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:1pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:55.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current provision:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">915&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States and Puerto Rico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred (benefit) expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Provision for Income Taxes Using Federal Statutory Rate</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes was different from the amount computed using the federal statutory rate for the years ended December&#160;31, 2023, 2022 and 2021 due to the following:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:55.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision at federal statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">States, net of federal benefit, and Puerto Rico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax exempt investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible executive compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-taxable KAH gain</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax effect from sale of Gentiva Hospice</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Tax Benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">762&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Principal Components of Net Deferred Tax Balances</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal components of our net deferred tax balances at December&#160;31, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:70.168%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.866%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets&#160;(Liabilities)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation and other accrued expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred acquisition costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jobs tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unearned revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax assets, net of valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciable property and intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(642)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(740)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(814)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(878)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred income tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656673177136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Carrying Value of Debt Outstanding</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of debt outstanding was as follows at December&#160;31, 2023 and 2022:</span></div><div style="margin-bottom:1pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:61.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.877%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term debt:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 3.850% due October 1, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.5 billion, 0.650% due August 3, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior notes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior notes:</span></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 3.850% due October 1, 2024</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 4.500% due April 1, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.700% due March 13, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 1.350% due February 3, 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 million, 3.950% due March 15, 2027</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.750% due March 1, 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 5.750% due December 1, 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 3.700% due March 23, 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 3.125% due August 15, 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 4.875% due April 1, 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million 2.150% due February 3, 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.875% due March 1, 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$850 million, 5.950% due March 15, 2034</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$250 million, 8.150% due June&#160;15, 2038</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$400 million, 4.625% due December&#160;1, 2042</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 4.950% due October 1, 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$400 million, 4.800% due March 15, 2047</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$500 million, 3.950% due August 15, 2049</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$750 million, 5.500% due March 15, 2053</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;text-indent:-9.01pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total senior notes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,213&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,534&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loans:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delayed draw term loan, due May 28, 2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:8.99pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,213&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,034&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the short-term and long-term debt for the years ending December 31, are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:79.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.094%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For the years ending December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656669606224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation expense that has been charged against income for these plans was as follows for the years ended December 31, 2023, 2022, and 2021:</span></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:55.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by type:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit recognized</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense, net of tax</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Awards Activity</a></td>
<td class="text">Activity for our restricted stock was as follows for the year ended December&#160;31, 2023:<div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"><tr><td style="width:1.0%"></td><td style="width:70.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.889%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(shares in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested restricted stock at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508.23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nonvested restricted stock at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">488.06&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Fair Value Assumptions</a></td>
<td class="text">The fair value was estimated on the date of grant using the Black-Scholes pricing model with the weighted-average assumptions indicated below:<div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:55.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.868%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value at grant date</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113.35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option life (years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate at grant date</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Activity for Option Plans</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for our option plans was as follows for the year ended December&#160;31, 2023:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:70.168%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.866%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160; Under<br/>Option</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(shares in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508.80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491.82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December&#160;31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at December&#160;31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366.69&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656669549568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER COMMON SHARE COMPUTATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Earnings Per Common Share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Detail supporting the computation of basic and diluted earnings per common share was as follows for the years ended December&#160;31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions, except&#160;per<br/>common share results, number&#160;of<br/>shares/options in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income available for common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average outstanding shares of common stock used to <br/>&#160;&#160;&#160;&#160;compute basic earnings per common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,866&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,419&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,688&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used to compute diluted earnings per&#160;common share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,441&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127,094&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,396&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.09&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.20&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.79&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per common share</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.00&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.08&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.67&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of antidilutive stock options and restricted stock&#160;awards <br/>&#160;&#160;&#160;&#160;excluded from computation</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656673132560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsDeclaredTableTextBlock', window );">Schedule of Details of Dividend Payments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of dividend payments, excluding dividend equivalent rights, in 2021, 2022, and 2023, under our Board approved quarterly cash dividend policy:</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:64.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.487%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payment Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount<br/>per&#160;Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$351</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.06</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$390</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.44</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$428</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Schedule of Share Repurchases</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding shares acquired in connection with employee stock plans, share repurchases were as follows during the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-bottom:1pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:38.546%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.602%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.129%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorization Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchase Not to Exceed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repurchases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsDeclaredTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to dividends declared, including paid and unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsDeclaredTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667227488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, By Segment</a></td>
<td class="text"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,895&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,272&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,272&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,272&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,033&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,305&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,451)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,403)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,854&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,405&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,885)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,374&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(706)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,011)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,200&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,840)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,404&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,013&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net losses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,648&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(672)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,389&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,712&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,712&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,776&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,562&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,926&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,488&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,588)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,429)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,841&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,307&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,278)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,870&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,934&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,016&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,765)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(513)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,800&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of Gentiva Hospice</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes and equity in net earnings (losses)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,528&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(982)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,568&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net earnings (losses)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,040&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(982)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,564&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss (income) attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings (loss) attributable to Humana</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,045&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(982)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,568&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Insurance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CenterWell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Eliminations/<br/>Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual Medicare Advantage</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Group Medicare Advantage</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,955&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare stand-alone PDP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Medicare</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial fully-insured</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,950&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specialty benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Supplement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State-based contracts and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total premiums</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,822&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,822&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services revenue:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Home solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Primary care</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial ASO</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Military services and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacy solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total services revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,055&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,675&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,877&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,869)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,024)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intersegment revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,852&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,893)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment income (loss)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,058&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,924)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,064&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,722)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,412&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes and equity in net earnings</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,354&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity in net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings attributable to Humana</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,418&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656661658352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REPORTING ENTITY (Details) - Premiums and services revenue - Government contracts concentration risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Federal government contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">CMS, coverage for individual Medicare Advantage members in Florida</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_FederalGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_FederalGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656661105152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_CommercialMembershipContractTerm', window );">Health services term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies', window );">Number of days notice for employer group to cancel short-duration prepaid health services policies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs', window );">Consumer discounts on brand name prescription drugs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_AccruedPharmaceuticalRebatesCurrent', window );">Pharmaceutical rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000,000<span></span>
</td>
<td class="nump">2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies', window );">Typical term (in years) of short-duration employer-group prepaid health services policies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,550,000,000<span></span>
</td>
<td class="nump">9,142,000,000<span></span>
</td>
<td class="nump">11,092,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=hum_ValueCreationInitiativesMember', window );">Value Creation Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges', window );">Restructuring and impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436,000,000<span></span>
</td>
<td class="nump">473,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Assets held for abandonment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,000,000<span></span>
</td>
<td class="nump">248,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,000,000<span></span>
</td>
<td class="nump">116,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember', window );">Exit From Employer Group Commercial Medical Products Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=hum_HomeSolutionsReportingUnitMember', window );">Home Solutions Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=hum_ProviderReportingUnitMember', window );">Provider reporting unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Long-lived assets estimated useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Long-lived assets estimated useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Long-lived assets estimated useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Long-lived assets estimated useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Long-lived assets estimated useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Long-lived assets estimated useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357,000,000<span></span>
</td>
<td class="nump">$ 291,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hum_MedicareSupplementProductMember', window );">Medicare Supplement | Revenue Benchmark | Product Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceContractAxis=CMS brand name prescription drug discounts', window );">Reinsurance Policy, Type [Axis]: CMS brand name prescription drug discounts | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SubsidyAndDiscountsSettlementPeriodAfterClose', window );">Settlement period after close</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceContractAxis=CMS brand name prescription drug discounts', window );">Reinsurance Policy, Type [Axis]: CMS brand name prescription drug discounts | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SubsidyAndDiscountsSettlementPeriodAfterClose', window );">Settlement period after close</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceContractAxis=CMS reinsurance subsidies and discounts', window );">Reinsurance Policy, Type [Axis]: CMS reinsurance subsidies and discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SubsidyAndDiscountsSettlementPeriodAfterClose', window );">Settlement period after close</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_AccruedPharmaceuticalRebatesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Pharmaceutical Rebates, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_AccruedPharmaceuticalRebatesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_CommercialMembershipContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial Membership Contract Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_CommercialMembershipContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Beginning in 2011, the Health Reform Legislation mandates consumer discounts of 50% on brand name prescription drugs for Part D plan participants in the coverage gap. These discounts are funded by CMS and pharmaceutical manufacturers while we administer the application of these funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Days Notice For Employer Group To Cancel Short Duration Prepaid Health Services Policies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_SubsidyAndDiscountsSettlementPeriodAfterClose">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsidy And Discounts, Settlement Period After Close</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_SubsidyAndDiscountsSettlementPeriodAfterClose</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Typical Term (In Years) Of Short-Duration Employer-Group Prepaid Health Services Policies</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=hum_ValueCreationInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=hum_ValueCreationInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=hum_HomeSolutionsReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=hum_HomeSolutionsReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=hum_ProviderReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=hum_ProviderReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=hum_MedicareSupplementProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=hum_MedicareSupplementProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceContractAxis=CMS brand name prescription drug discounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceContractAxis=CMS brand name prescription drug discounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceContractAxis=CMS reinsurance subsidies and discounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceContractAxis=CMS reinsurance subsidies and discounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656673114512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Part D Subsidy/Discount Payments, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SubsidyAndDiscountPayments', window );">Part D subsidy/discount payments</a></td>
<td class="num">$ (17,582)<span></span>
</td>
<td class="num">$ (16,530)<span></span>
</td>
<td class="num">$ (14,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SubsidyAndDiscountReimbursements', window );">Part D subsidy/discount reimbursements</a></td>
<td class="nump">18,353<span></span>
</td>
<td class="nump">18,498<span></span>
</td>
<td class="nump">14,628<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements', window );">Net reimbursements (payments)</a></td>
<td class="nump">$ 771<span></span>
</td>
<td class="nump">$ 1,968<span></span>
</td>
<td class="num">$ (261)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_SubsidyAndDiscountPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsidy And Discount Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_SubsidyAndDiscountPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsidy And Discount Payments In Excess Of Reimbursements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_SubsidyAndDiscountReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subsidy And Discount Reimbursements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_SubsidyAndDiscountReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656669667232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Health Care Cost Payments, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_HealthCareCostPayments', window );">Health care cost payments</a></td>
<td class="num">$ (7,073)<span></span>
</td>
<td class="num">$ (7,110)<span></span>
</td>
<td class="num">$ (6,943)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_HealthCareCostReimbursements', window );">Health care cost reimbursements</a></td>
<td class="nump">7,130<span></span>
</td>
<td class="nump">7,135<span></span>
</td>
<td class="nump">6,898<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_HealthCareCostPaymentsAndReimbursementsNet', window );">Net reimbursements (payments)</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="num">$ (45)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_HealthCareCostPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health care cost payments associated with the TRICARE South Region contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_HealthCareCostPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_HealthCareCostPaymentsAndReimbursementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between health care cost payments and reimbursements related to the TRICARE South Region contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_HealthCareCostPaymentsAndReimbursementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_HealthCareCostReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursements for health care cost payments associated with the TRICARE South Region contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_HealthCareCostReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656661000320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS AND DIVESTITURES - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>Aug. 17, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 749<span></span>
</td>
<td class="nump">$ 740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hum_KindredAtHomeMember', window );">Kindred at Home</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage', window );">Remaining ownership percentage acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_BusinessCombinationTotalEnterpriseValueOfAcquiree', window );">Enterprise value of acquiree including existing equity value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Existing equity value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Minority ownership prior to acquisition (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain', window );">Remeasurement gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest', window );">Transaction amount, net of existing equity stake</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Gentiva Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold', window );">Equity interest to be sold</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration to be received</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax', window );">Pre-tax gain, net of transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax', window );">Pretax earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Gentiva Hospice | Medicare Licenses And Certificates Of Need</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Identifiable intangibles</a></td>
<td class="nump">866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Gentiva Hospice | Term Loan Due October 2023 | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of debt</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Per Agreement, Net Of Existing Equity Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Step Acquisition, Equity Interest in Acquiree, Subsequent Acquisition, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_BusinessCombinationTotalEnterpriseValueOfAcquiree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Total Enterprise Value Of Acquiree</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_BusinessCombinationTotalEnterpriseValueOfAcquiree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Equity Interest Sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale including the portion attributable to the noncontrolling interest. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hum_KindredAtHomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hum_KindredAtHomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=hum_GentivaHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=hum_GentivaHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hum_MedicareLicensesAndCertificatesOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hum_MedicareLicensesAndCertificatesOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_TermLoanDueOctober2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_TermLoanDueOctober2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656666322784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITIONS AND DIVESTITURES - Assets, Liabilities And Noncontrolling Interest Disposed (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations - Gentiva Hospice<br> $ in Millions</strong></div></th>
<th class="th">
<div>Aug. 11, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Receivables, net of allowances</a></td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Property and equipment, net</a></td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent', window );">Goodwill</a></td>
<td class="nump">2,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets</a></td>
<td class="nump">3,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent', window );">Trade accounts payable and accrued expenses</a></td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities</a></td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest', window );">Noncontrolling interest</a></td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Noncontrolling interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=hum_GentivaHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=hum_GentivaHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656662483920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY METHOD INVESTMENT - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>primary_care_center</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by sale | Gentiva Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold', window );">Equity interest to be sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=hum_WelshCarsonAndersonAndStoweMember', window );">WCAS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters', window );">Number of primary care centers in strategic partnership | primary_care_center</a></td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened', window );">Number of additional primary care centers expected to be opened in strategic partnership | primary_care_center</a></td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=hum_WelshCarsonAndersonAndStoweMember', window );">WCAS | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity', window );">Time frame for put and call option activity per partnership agreement</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=hum_WelshCarsonAndersonAndStoweMember', window );">WCAS | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity', window );">Time frame for put and call option activity per partnership agreement</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember', window );">First Cohort of Clinics | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_StrategicPartnershipAgreementCallOptionStrikePrice', window );">Call option strike price</a></td>
<td class="nump">$ 550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember', window );">First Cohort of Clinics | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_StrategicPartnershipAgreementCallOptionStrikePrice', window );">Call option strike price</a></td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember', window );">Remaining Existing Cohorts | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_StrategicPartnershipAgreementCallOptionStrikePrice', window );">Call option strike price</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember', window );">Remaining Existing Cohorts | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_StrategicPartnershipAgreementCallOptionStrikePrice', window );">Call option strike price</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hum_KindredAtHomeMember', window );">Kindred at Home</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership (percent)</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Equity Interest Sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_StrategicPartnershipAgreementCallOptionStrikePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strategic Partnership Agreement, Call Option Strike Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_StrategicPartnershipAgreementCallOptionStrikePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strategic Partnership Agreement, Number Of Additional Primary Care Centers Expected To Be Opened</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strategic Partnership Agreement, Number Of Primary Care Centers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strategic Partnership Agreement, Timeframe For Put And Call Option Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=hum_GentivaHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=hum_GentivaHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=hum_WelshCarsonAndersonAndStoweMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=hum_WelshCarsonAndersonAndStoweMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hum_KindredAtHomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=hum_KindredAtHomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667864208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY METHOD INVESTMENT - Summarized Balance Sheets and Statements of Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance sheet</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">$ 26,183<span></span>
</td>
<td class="nump">$ 29,986<span></span>
</td>
<td class="nump">$ 26,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">17,178<span></span>
</td>
<td class="nump">18,872<span></span>
</td>
<td class="nump">17,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity</a></td>
<td class="nump">15,311<span></span>
</td>
<td class="nump">16,262<span></span>
</td>
<td class="nump">15,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract', window );"><strong>Income Statement Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,374<span></span>
</td>
<td class="nump">92,870<span></span>
</td>
<td class="nump">$ 83,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Humana</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,489<span></span>
</td>
<td class="nump">2,806<span></span>
</td>
<td class="nump">$ 2,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=hum_KindredAtHomeMember', window );">Kindred at Home</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance sheet</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">297<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">3,577<span></span>
</td>
<td class="nump">4,260<span></span>
</td>
<td class="nump">3,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">409<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="nump">2,219<span></span>
</td>
<td class="nump">2,719<span></span>
</td>
<td class="nump">2,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity</a></td>
<td class="nump">1,386<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
<td class="nump">$ 1,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract', window );"><strong>Income Statement Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">654<span></span>
</td>
<td class="nump">1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_Expenses', window );">Expenses</a></td>
<td class="nump">652<span></span>
</td>
<td class="nump">1,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Humana</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_Expenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_Expenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=hum_KindredAtHomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=hum_KindredAtHomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656660851776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVESTMENT SECURITIES - Classified as Current and Long-Term (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities Amortized Cost to Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 18,302<span></span>
</td>
<td class="nump">$ 15,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1,328)<span></span>
</td>
<td class="num">(1,701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">17,008<span></span>
</td>
<td class="nump">14,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investment securities</a></td>
<td class="nump">17,008<span></span>
</td>
<td class="nump">14,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities Amortized Cost to Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2,717<span></span>
</td>
<td class="nump">1,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">2,667<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities Amortized Cost to Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">3,946<span></span>
</td>
<td class="nump">3,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(425)<span></span>
</td>
<td class="num">(471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">3,522<span></span>
</td>
<td class="nump">3,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NontaxableMunicipalNotesMember', window );">Tax-exempt municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities Amortized Cost to Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">879<span></span>
</td>
<td class="nump">765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">858<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember', window );">Residential</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities Amortized Cost to Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities Amortized Cost to Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,471<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,345<span></span>
</td>
<td class="nump">1,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities Amortized Cost to Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,813<span></span>
</td>
<td class="nump">1,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,771<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities Amortized Cost to Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">7,011<span></span>
</td>
<td class="nump">6,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(594)<span></span>
</td>
<td class="num">(828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 6,445<span></span>
</td>
<td class="nump">$ 5,726<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_NontaxableMunicipalNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_NontaxableMunicipalNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656660908032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT SECURITIES - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentLineItems', window );"><strong>Financing Receivable, Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Book value</a></td>
<td class="nump">$ 18,302<span></span>
</td>
<td class="nump">$ 15,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 17,008<span></span>
</td>
<td class="nump">14,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities', window );">Maximum individual state general bond obligation as a percentage of total debt securities (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Securities in unrealized loss position, number of positions | position</a></td>
<td class="nump">1,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions', window );">Securities, number of positions | position</a></td>
<td class="nump">2,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CreditRatingStandardPoorsAxis=srt_StandardPoorsAAMinusRatingMember', window );">Standard &amp; Poor's, AA- Rating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentLineItems', window );"><strong>Financing Receivable, Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality', window );">Percentage of debt securities considered to be of investment-grade (percent)</a></td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by sale | Gentiva Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableRecordedInvestmentLineItems', window );"><strong>Financing Receivable, Credit Quality Indicator [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Book value</a></td>
<td class="nump">$ 379<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 398<span></span>
</td>
<td class="nump">$ 278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Securities, Number of Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Individual State General Bond Obligation, As Percentage Of Total Debt Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Total Debt Securities, Investment Grade Quality</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableRecordedInvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 79<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479294/326-20-55-79<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableRecordedInvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CreditRatingStandardPoorsAxis=srt_StandardPoorsAAMinusRatingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CreditRatingStandardPoorsAxis=srt_StandardPoorsAAMinusRatingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=hum_GentivaHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=hum_GentivaHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656662580928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less&#160;than&#160;12&#160;months</a></td>
<td class="nump">$ 3,621<span></span>
</td>
<td class="nump">$ 4,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or more</a></td>
<td class="nump">11,046<span></span>
</td>
<td class="nump">8,962<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">14,667<span></span>
</td>
<td class="nump">13,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less&#160;than&#160;12&#160;months</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or more</a></td>
<td class="num">(1,300)<span></span>
</td>
<td class="num">(1,431)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(1,328)<span></span>
</td>
<td class="num">(1,701)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less&#160;than&#160;12&#160;months</a></td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or more</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">2,330<span></span>
</td>
<td class="nump">909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less&#160;than&#160;12&#160;months</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or more</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less&#160;than&#160;12&#160;months</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or more</a></td>
<td class="nump">2,269<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">3,227<span></span>
</td>
<td class="nump">2,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less&#160;than&#160;12&#160;months</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or more</a></td>
<td class="num">(413)<span></span>
</td>
<td class="num">(367)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(425)<span></span>
</td>
<td class="num">(471)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NontaxableMunicipalNotesMember', window );">Tax-exempt municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less&#160;than&#160;12&#160;months</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or more</a></td>
<td class="nump">523<span></span>
</td>
<td class="nump">615<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">683<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less&#160;than&#160;12&#160;months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or more</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember', window );">Residential</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less&#160;than&#160;12&#160;months</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or more</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less&#160;than&#160;12&#160;months</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or more</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less&#160;than&#160;12&#160;months</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or more</a></td>
<td class="nump">1,303<span></span>
</td>
<td class="nump">1,157<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">1,321<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less&#160;than&#160;12&#160;months</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or more</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(155)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less&#160;than&#160;12&#160;months</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or more</a></td>
<td class="nump">1,364<span></span>
</td>
<td class="nump">1,011<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">1,484<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less&#160;than&#160;12&#160;months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or more</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less&#160;than&#160;12&#160;months</a></td>
<td class="nump">466<span></span>
</td>
<td class="nump">1,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or more</a></td>
<td class="nump">4,783<span></span>
</td>
<td class="nump">3,825<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">5,249<span></span>
</td>
<td class="nump">5,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less&#160;than&#160;12&#160;months</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or more</a></td>
<td class="num">(592)<span></span>
</td>
<td class="num">(730)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">$ (594)<span></span>
</td>
<td class="num">$ (828)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_NontaxableMunicipalNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_NontaxableMunicipalNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656661734640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT SECURITIES - Realized Gains (Losses) Included Within Investment Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DebtAndEquitySecuritiesRealizedGain', window );">Gross gains on investment securities</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DebtAndEquitySecuritiesRealizedLoss', window );">Gross losses on investment securities</a></td>
<td class="num">(101)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGain', window );">Gross gains on equity securities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedLoss', window );">Gross losses on equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(174)<span></span>
</td>
<td class="num">(364)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtAndEquitySecuritiesGainLoss', window );">Net recognized losses on investment securities</a></td>
<td class="num">$ (54)<span></span>
</td>
<td class="num">$ (205)<span></span>
</td>
<td class="num">$ (130)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DebtAndEquitySecuritiesRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt And Equity Securities, Realized Gain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DebtAndEquitySecuritiesRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DebtAndEquitySecuritiesRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt And Equity Securities, Realized Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DebtAndEquitySecuritiesRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndEquitySecuritiesGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndEquitySecuritiesGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656659996176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVESTMENT SECURITIES - Gains (Losses) on Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains (losses) recognized on equity securities during the period</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">$ (123)<span></span>
</td>
<td class="num">$ (341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net gains (losses) recognized on equity securities sold during the period</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized losses recognized on equity securities still held at the end of the period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (18)<span></span>
</td>
<td class="num">$ (328)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656665609392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due within one year</a></td>
<td class="nump">$ 1,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">5,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">2,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost', window );">Due after ten years</a></td>
<td class="nump">1,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost', window );">Mortgage and asset-backed securities</a></td>
<td class="nump">7,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">18,302<span></span>
</td>
<td class="nump">$ 15,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">1,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">5,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">2,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">Due after ten years</a></td>
<td class="nump">962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue', window );">Mortgage and asset-backed securities</a></td>
<td class="nump">7,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities</a></td>
<td class="nump">$ 17,008<span></span>
</td>
<td class="nump">$ 14,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656660460176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE - Financial Assets Measured on Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">$ 17,008<span></span>
</td>
<td class="nump">$ 14,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">2,667<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">3,522<span></span>
</td>
<td class="nump">3,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NontaxableMunicipalNotesMember', window );">Tax-exempt municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">858<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember', window );">Residential</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">1,345<span></span>
</td>
<td class="nump">1,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">1,771<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">6,445<span></span>
</td>
<td class="nump">5,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">4,582<span></span>
</td>
<td class="nump">4,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">17,008<span></span>
</td>
<td class="nump">14,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total invested assets</a></td>
<td class="nump">21,590<span></span>
</td>
<td class="nump">19,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | U.S. Treasury and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">2,667<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">3,522<span></span>
</td>
<td class="nump">3,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Tax-exempt municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">858<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Residential</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">1,345<span></span>
</td>
<td class="nump">1,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">1,771<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">6,445<span></span>
</td>
<td class="nump">5,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">4,582<span></span>
</td>
<td class="nump">4,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total invested assets</a></td>
<td class="nump">4,582<span></span>
</td>
<td class="nump">4,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Prices in Active Markets (Level 1) | U.S. Treasury and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Prices in Active Markets (Level 1) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Prices in Active Markets (Level 1) | Tax-exempt municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Prices in Active Markets (Level 1) | Residential</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Prices in Active Markets (Level 1) | Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Prices in Active Markets (Level 1) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Prices in Active Markets (Level 1) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">16,790<span></span>
</td>
<td class="nump">14,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total invested assets</a></td>
<td class="nump">16,790<span></span>
</td>
<td class="nump">14,153<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Other Observable Inputs (Level 2) | U.S. Treasury and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">2,667<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Other Observable Inputs (Level 2) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">3,522<span></span>
</td>
<td class="nump">3,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Other Observable Inputs (Level 2) | Tax-exempt municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">858<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Other Observable Inputs (Level 2) | Residential</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">396<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Other Observable Inputs (Level 2) | Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">1,345<span></span>
</td>
<td class="nump">1,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Other Observable Inputs (Level 2) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">1,733<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Other Observable Inputs (Level 2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">6,269<span></span>
</td>
<td class="nump">5,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total invested assets</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Unobservable Inputs (Level 3) | U.S. Treasury and agency obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Unobservable Inputs (Level 3) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Unobservable Inputs (Level 3) | Tax-exempt municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Unobservable Inputs (Level 3) | Residential</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Unobservable Inputs (Level 3) | Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Unobservable Inputs (Level 3) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Unobservable Inputs (Level 3) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_NontaxableMunicipalNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_NontaxableMunicipalNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ResidentialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656660091600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>Apr. 27, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Asset value</a></td>
<td class="nump">$ 218,000,000<span></span>
</td>
<td class="nump">$ 101,000,000<span></span>
</td>
<td class="nump">$ 68,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue', window );">Swap asset</a></td>
<td class="nump">$ 68,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_LossOnTerminationOfDerivatives', window );">Termination of put and call options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 377,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by sale | Gentiva Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold', window );">Equity interest to be sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=hum_FairValueRiskMember', window );">Fair Value Risk | Unobservable Inputs (Level 3) | Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_PutOptionMember', window );">Put option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value of financial liability</a></td>
<td class="nump">$ 595,000,000<span></span>
</td>
<td class="nump">$ 267,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember', window );">Call option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_FinancialAssetsFairValueDisclosure', window );">Fair value of financial asset</a></td>
<td class="nump">18,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities | Put option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Fair value of financial liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 63,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other long-term assets | Call option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_FinancialAssetsFairValueDisclosure', window );">Fair value of financial asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 440,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hum_KindredAtHomeMember', window );">Kindred at Home</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage', window );">Equity interest to be acquired per agreement (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="nump">871,000,000<span></span>
</td>
<td class="nump">595,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=hum_TermLoanAndCommercialPaperMember', window );">Term Loan and Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt outstanding</a></td>
<td class="nump">10,800,000,000<span></span>
</td>
<td class="nump">10,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt outstanding</a></td>
<td class="nump">10,600,000,000<span></span>
</td>
<td class="nump">$ 9,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=hum_InterestRateSwapMaturing2032Member', window );">Interest Rate Swap Maturing 2032 | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=hum_InterestRateSwapMaturing2033Member', window );">Interest Rate Swap Maturing 2033 | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=hum_InterestRateSwapMaturing2049Member', window );">Interest Rate Swap Maturing 2049 | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=hum_InterestRateSwapMaturing2034Member', window );">Interest Rate Swap Maturing 2034 | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional amount</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hum_A5.88PercentSeniorNotesDueMarch2033Member', window );">$750 million, 5.875% due March 1, 2033 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hum_A550PercentSeniorNotesDueMarch2053Member', window );">$750 million, 5.500% due March 15, 2053 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hum_A3.950PercentSeniorNotesMember', window );">3.950 Percent Senior Notes | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=hum_A5950PercentSeniorNotesDueMarch2034Member', window );">$850 million, 5.950% due March 15, 2034 | Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Definitive Agreement, Equity Interest To Be Acquired, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Equity Interest Sold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_FinancialAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Assets, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_FinancialAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_LossOnTerminationOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss On Termination Of Derivatives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_LossOnTerminationOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateFairValueHedgeAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateFairValueHedgeAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=hum_GentivaHospiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=hum_GentivaHospiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=hum_FairValueRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=hum_FairValueRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_PutOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_PutOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_CallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hum_KindredAtHomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hum_KindredAtHomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=hum_TermLoanAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=hum_TermLoanAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=hum_InterestRateSwapMaturing2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=hum_InterestRateSwapMaturing2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=hum_InterestRateSwapMaturing2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=hum_InterestRateSwapMaturing2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=hum_InterestRateSwapMaturing2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=hum_InterestRateSwapMaturing2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=hum_InterestRateSwapMaturing2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=hum_InterestRateSwapMaturing2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A5.88PercentSeniorNotesDueMarch2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A5.88PercentSeniorNotesDueMarch2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A550PercentSeniorNotesDueMarch2053Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A550PercentSeniorNotesDueMarch2053Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A3.950PercentSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A3.950PercentSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A5950PercentSeniorNotesDueMarch2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A5950PercentSeniorNotesDueMarch2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656660828672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance at January&#160;1</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract', window );"><strong>Total gains or losses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Realized in earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Unrealized in other comprehensive&#160;income</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Purchases</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Transfers Out</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Transfers In</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Balance at December&#160;31</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656665453408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE - Put and Call Options Measured at Fair Value (Details) - Options - Level 3 fair value measurement<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionOnSecuritiesMember', window );">Annualized volatility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Significant unobservable inputs</a></td>
<td class="nump">0.161<span></span>
</td>
<td class="nump">0.167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionOnSecuritiesMember', window );">Annualized volatility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Significant unobservable inputs</a></td>
<td class="nump">0.178<span></span>
</td>
<td class="nump">0.208<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionOnSecuritiesMember', window );">Credit spread | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Significant unobservable inputs</a></td>
<td class="nump">0.009<span></span>
</td>
<td class="nump">0.013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionOnSecuritiesMember', window );">Credit spread | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Significant unobservable inputs</a></td>
<td class="nump">0.011<span></span>
</td>
<td class="nump">0.015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionOnSecuritiesMember', window );">Revenue exit multiple | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Significant unobservable inputs</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionOnSecuritiesMember', window );">Revenue exit multiple | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Significant unobservable inputs</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionOnSecuritiesMember', window );">Weighted average cost of capital | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Significant unobservable inputs</a></td>
<td class="nump">0.110<span></span>
</td>
<td class="nump">0.115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionOnSecuritiesMember', window );">Weighted average cost of capital | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Significant unobservable inputs</a></td>
<td class="nump">0.125<span></span>
</td>
<td class="nump">0.125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionOnSecuritiesMember', window );">Long term growth rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput', window );">Significant unobservable inputs</a></td>
<td class="nump">0.030<span></span>
</td>
<td class="nump">0.030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetLiabilityNetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure net derivative asset (liability).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetLiabilityNetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionOnSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OptionOnSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_CreditSpreadOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_CreditSpreadOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=hum_RevenueExitMultipleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=hum_RevenueExitMultipleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputLongTermRevenueGrowthRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputLongTermRevenueGrowthRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667813408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MEDICARE PART D (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">$ 6,631<span></span>
</td>
<td class="nump">$ 5,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Trade accounts payable and accrued expenses</a></td>
<td class="num">(6,569)<span></span>
</td>
<td class="num">(5,238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">3,377<span></span>
</td>
<td class="nump">3,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="num">(1,662)<span></span>
</td>
<td class="num">(1,473)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=hum_RiskCorridorSettlementsMedicarePartDMember', window );">Risk Corridor Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Trade accounts payable and accrued expenses</a></td>
<td class="num">(232)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_NetCurrentLiabilityAsset', window );">Net current (liability) asset</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="num">(77)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_NetNoncurrentAssetLiability', window );">Net long-term liability</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_NetAssetLiability', window );">Total net (liability) asset</a></td>
<td class="num">(68)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=hum_CmsSubsidiesOrDiscountsMember', window );">CMS Subsidies/ Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">514<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Trade accounts payable and accrued expenses</a></td>
<td class="num">(1,825)<span></span>
</td>
<td class="num">(1,236)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_NetCurrentLiabilityAsset', window );">Net current (liability) asset</a></td>
<td class="num">(1,311)<span></span>
</td>
<td class="num">(540)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_NetNoncurrentAssetLiability', window );">Net long-term liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_NetAssetLiability', window );">Total net (liability) asset</a></td>
<td class="num">$ (1,311)<span></span>
</td>
<td class="num">$ (540)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_NetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Asset (Liability)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_NetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_NetCurrentLiabilityAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net current (liability) asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_NetCurrentLiabilityAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_NetNoncurrentAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Noncurrent Asset (Liability)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_NetNoncurrentAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=hum_RiskCorridorSettlementsMedicarePartDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=hum_RiskCorridorSettlementsMedicarePartDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=hum_CmsSubsidiesOrDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=hum_CmsSubsidiesOrDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656665579136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET - Property and Equipment Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 5,884<span></span>
</td>
<td class="nump">$ 6,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(2,854)<span></span>
</td>
<td class="num">(3,136)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,030<span></span>
</td>
<td class="nump">3,221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hum_BuildingsAndLeaseholdImprovementsMember', window );">Buildings and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">1,320<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 3,546<span></span>
</td>
<td class="nump">$ 3,951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=hum_BuildingsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=hum_BuildingsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667281104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation expense</a></td>
<td class="nump">$ 831<span></span>
</td>
<td class="nump">$ 749<span></span>
</td>
<td class="nump">$ 640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Amortization expense for capitalized internally developed and purchased software</a></td>
<td class="nump">$ 589<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 443<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -SubTopic 20<br> -Topic 985<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667877120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS - Changes in Carrying Amount of Goodwill by Reportable Segments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 9,142<span></span>
</td>
<td class="nump">$ 11,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">408<span></span>
</td>
<td class="nump">381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Dispositions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,331)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">9,550<span></span>
</td>
<td class="nump">9,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=hum_InsuranceSegmentMember', window );">Insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">2,472<span></span>
</td>
<td class="nump">2,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Dispositions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">2,663<span></span>
</td>
<td class="nump">2,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=hum_CenterWellSegmentMember', window );">CenterWell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">6,670<span></span>
</td>
<td class="nump">8,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Dispositions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,331)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 6,887<span></span>
</td>
<td class="nump">$ 6,670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=hum_InsuranceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=hum_InsuranceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=hum_CenterWellSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=hum_CenterWellSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656665103504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS - Details of Intangible Assets Included in Other Long-Term Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Other intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted average life (in years)</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total other intangible assets, cost</a></td>
<td class="nump">$ 2,626<span></span>
</td>
<td class="nump">$ 2,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Amortizable intangible assets, accumulated amortization</a></td>
<td class="nump">933<span></span>
</td>
<td class="nump">883<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total other intangible assets, net</a></td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">1,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=hum_CertificateOfNeedMember', window );">Certificates of need</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Medicare licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember', window );">Customer contracts/relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Other intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted average life (in years)</a></td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortizable intangible assets, cost</a></td>
<td class="nump">$ 956<span></span>
</td>
<td class="nump">929<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Amortizable intangible assets, accumulated amortization</a></td>
<td class="nump">718<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Amortizable intangible assets, net</a></td>
<td class="nump">$ 238<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names and technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Other intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted average life (in years)</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortizable intangible assets, cost</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Amortizable intangible assets, accumulated amortization</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Amortizable intangible assets, net</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Provider contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Other intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted average life (in years)</a></td>
<td class="text">11 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortizable intangible assets, cost</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Amortizable intangible assets, accumulated amortization</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Amortizable intangible assets, net</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hum_NoncompetesAndOtherMember', window );">Noncompetes and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Other intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted average life (in years)</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortizable intangible assets, cost</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Amortizable intangible assets, accumulated amortization</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Amortizable intangible assets, net</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=hum_CertificateOfNeedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=hum_CertificateOfNeedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hum_NoncompetesAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=hum_NoncompetesAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656665623184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for other intangible assets</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember', window );">Exit From Employer Group Commercial Medical Products Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656660006288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL AND OTHER INTANGIBLE ASSETS - Estimate of Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract', window );"><strong>Estimate of Amortization Expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">$ 28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656660768864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other long-term assets<span></span>
</td>
<td class="text">Other long-term assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets included within other long-term assets</a></td>
<td class="nump">$ 510<span></span>
</td>
<td class="nump">$ 515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Trade accounts payable and accrued expenses<span></span>
</td>
<td class="text">Trade accounts payable and accrued expenses<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities included within trade accounts payable and accrued expenses</a></td>
<td class="nump">$ 149<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities included within other long-term liabilities</a></td>
<td class="nump">$ 444<span></span>
</td>
<td class="nump">$ 456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed operating lease costs</a></td>
<td class="nump">145<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease rental income</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate (percent)</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease cash payments</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656664974768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Maturity of Lease Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">After 2028</a></td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Interest</a></td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 593<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656664990832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BENEFITS PAYABLE - Activity in Benefits Payable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balances, beginning of period</a></td>
<td class="nump">$ 9,264<span></span>
</td>
<td class="nump">$ 8,289<span></span>
</td>
<td class="nump">$ 8,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Acquisitions</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Incurred related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">89,266<span></span>
</td>
<td class="nump">76,105<span></span>
</td>
<td class="nump">70,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(872)<span></span>
</td>
<td class="num">(415)<span></span>
</td>
<td class="num">(825)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total incurred</a></td>
<td class="nump">88,394<span></span>
</td>
<td class="nump">75,690<span></span>
</td>
<td class="nump">69,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Paid related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="num">(79,545)<span></span>
</td>
<td class="num">(67,287)<span></span>
</td>
<td class="num">(62,149)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="num">(7,934)<span></span>
</td>
<td class="num">(7,428)<span></span>
</td>
<td class="num">(6,946)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="num">(87,479)<span></span>
</td>
<td class="num">(74,715)<span></span>
</td>
<td class="num">(69,095)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balances, end of period</a></td>
<td class="nump">$ 10,241<span></span>
</td>
<td class="nump">$ 9,264<span></span>
</td>
<td class="nump">$ 8,289<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656660977760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BENEFITS PAYABLE - Narrative (Details)<br> claim in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount', window );">Total IBNR | $</a></td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears', window );">Favorable&#160;medical&#160;claims&#160;reserve development related to prior fiscal years | $</a></td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
<td class="nump">$ 825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2023Member', window );">2023 Claims Incurred Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported', window );">Cumulative number of reported claims</a></td>
<td class="nump">200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2022Member', window );">2022 Claims Incurred Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported', window );">Cumulative number of reported claims</a></td>
<td class="nump">182.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2021Member', window );">2021 Claims Incurred Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported', window );">Cumulative number of reported claims</a></td>
<td class="nump">173.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Favorable medical claims reserve development related to prior fiscal years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Unpaid Claims And Claims Adjustment Expense, Cumulative Number Of Claims, Reported</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClaimsDevelopmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClaimsDevelopmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated costs as of the balance sheet date of settling insured claims and costs incurred in the claims settlement process for claims that have not yet been submitted to the insurance company for reimbursement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.W)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479583/944-40-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656662278032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BENEFITS PAYABLE - Incurred and Paid Claims Development (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Incurred Claims, Net of Reinsurance</a></td>
<td class="nump">$ 234,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative Paid Claims, Net of Reinsurance</a></td>
<td class="nump">224,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Benefits payable, net of reinsurance</a></td>
<td class="nump">10,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember', window );">2021 and Prior Claims Incurred Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Incurred Claims, Net of Reinsurance</a></td>
<td class="nump">69,484<span></span>
</td>
<td class="nump">$ 69,698<span></span>
</td>
<td class="nump">$ 70,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative Paid Claims, Net of Reinsurance</a></td>
<td class="nump">69,484<span></span>
</td>
<td class="nump">69,252<span></span>
</td>
<td class="nump">$ 62,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2022Member', window );">2022 Claims Incurred Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Incurred Claims, Net of Reinsurance</a></td>
<td class="nump">75,447<span></span>
</td>
<td class="nump">76,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative Paid Claims, Net of Reinsurance</a></td>
<td class="nump">74,989<span></span>
</td>
<td class="nump">$ 67,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2023Member', window );">2023 Claims Incurred Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClaimsDevelopmentLineItems', window );"><strong>Claims Development [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Incurred Claims, Net of Reinsurance</a></td>
<td class="nump">89,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Cumulative Paid Claims, Net of Reinsurance</a></td>
<td class="nump">$ 79,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClaimsDevelopmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClaimsDevelopmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reinsurance, of paid claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (b)<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undiscounted amount, after reinsurance, of incurred claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-4B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -SubTopic 40<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656673568352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Provision for Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 915<span></span>
</td>
<td class="nump">$ 755<span></span>
</td>
<td class="nump">$ 466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">States and Puerto Rico</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">862<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred (benefit) expense</a></td>
<td class="num">(164)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">$ 762<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656662227312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Provision for Income Taxes Reconciliation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax provision at federal statutory rate</a></td>
<td class="nump">$ 698<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">States, net of federal benefit, and Puerto Rico</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxExemptIncome', window );">Tax exempt investment income</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Nondeductible executive compensation</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain', window );">Non-taxable KAH gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(264)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness', window );">Tax effect from sale of Gentiva Hospice</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Unrecognized Tax Benefits</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other, net</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">$ 762<span></span>
</td>
<td class="nump">$ 485<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Non-Taxable KAH Gain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656665036576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Principal Components of Net Deferred Tax Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits', window );">Compensation and other accrued expense</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Benefits payable</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost', window );">Deferred acquisition costs</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DeferredTaxAssetJobsTaxCredit', window );">Jobs tax credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve', window );">Unearned revenues</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Investment securities</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax assets</a></td>
<td class="nump">935<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(73)<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred income tax assets, net of valuation allowance</a></td>
<td class="nump">862<span></span>
</td>
<td class="nump">851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets', window );">Depreciable property and intangible assets</a></td>
<td class="num">(642)<span></span>
</td>
<td class="num">(740)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(156)<span></span>
</td>
<td class="num">(132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="num">(814)<span></span>
</td>
<td class="num">(878)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total net deferred income tax assets (liabilities)</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total net deferred income tax assets (liabilities)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DeferredTaxAssetJobsTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Jobs Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DeferredTaxAssetJobsTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of deferred tax balance as it relates to deferred acquisition costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Portion of deferred tax balance as it relates to depreciable property and intangible assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the unearned premiums reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656673655328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowances on net operating loss carryforwards related to prior acquisitions</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses to carryforward related to prior acquisitions</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Puerto Rico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses to carryforward related to prior acquisitions</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656658910560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Debt Outstanding (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total short-term debt</a></td>
<td class="nump">$ 1,443,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,092,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">10,213,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,034,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Total senior notes</a></td>
<td class="nump">572,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">10,213,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,534,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $600 million, 3.850% due October 1, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">3.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Total senior notes</a></td>
<td class="nump">$ 572,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $1.5 billion, 0.650% due August 3, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Total senior notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,497,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $600 million, 4.500% due April 1, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 598,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $500 million, 5.700% due March 13, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 498,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $750 million, 1.350% due February 3, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">1.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 688,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $600 million, 3.950% due March 15, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 537,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $500 million, 5.750% due March 1, 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 495,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $500 million, 5.750% due December 1, 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 495,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $750 million, 3.700% due March 23, 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 590,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $500 million, 3.125% due August 15, 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">3.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 433,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $500 million, 4.875% due April 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 496,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $750 million 2.150% due February 3, 2032</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">2.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 743,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">743,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $750 million, 5.875% due March 1, 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">739,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $850 million, 5.950% due March 15, 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 840,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $250 million, 8.150% due June&#160;15, 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">8.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 261,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $400 million, 4.625% due December&#160;1, 2042</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">4.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 396,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $750 million, 4.950% due October 1, 2044</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 740,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $400 million, 4.800% due March 15, 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 396,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">396,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $500 million, 3.950% due August 15, 2049</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 529,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">493,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $750 million, 5.500% due March 15, 2053</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 728,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans Payable | Delayed draw term loan, due May 28, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="nump">$ 871,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 595,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A3850PercentSeniorNotesDueOctober2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A3850PercentSeniorNotesDueOctober2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A065PercentSeniorNotesDueAugust2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A065PercentSeniorNotesDueAugust2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A4.500PercentSeniorNotesDueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A4.500PercentSeniorNotesDueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A570PercentSeniorNotesDueMarch2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A570PercentSeniorNotesDueMarch2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A135PercentSeniorNotesDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A135PercentSeniorNotesDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A3.95PercentSeniorNotesDueMarch2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A3.95PercentSeniorNotesDueMarch2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A575PercentSeniorNotesDueMarch2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A575PercentSeniorNotesDueMarch2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A575PercentSeniorNotesDueDecember2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A575PercentSeniorNotesDueDecember2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A370PercentSeniorNotesDueMarch2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A370PercentSeniorNotesDueMarch2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A313PercentSeniorNotesDueAugust2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A313PercentSeniorNotesDueAugust2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A488PercentSeniorNotesDueApril2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A488PercentSeniorNotesDueApril2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A215PercentSeniorNotesDueFebruary2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A215PercentSeniorNotesDueFebruary2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A5.88PercentSeniorNotesDueMarch2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A5.88PercentSeniorNotesDueMarch2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A5950PercentSeniorNotesDueMarch2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A5950PercentSeniorNotesDueMarch2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A8.15PercentSeniorNotesDueJune2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A8.15PercentSeniorNotesDueJune2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A463PercentSeniorNotesDueDecember2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A463PercentSeniorNotesDueDecember2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A4.95PercentSeniorNotesDueOctober2044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A4.95PercentSeniorNotesDueOctober2044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A4.80PercentSeniorNotesDueMarch2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A4.80PercentSeniorNotesDueMarch2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A3.95PercentSeniorNotesDueAugust2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A3.95PercentSeniorNotesDueAugust2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A550PercentSeniorNotesDueMarch2053Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A550PercentSeniorNotesDueMarch2053Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_DelayedDrawTermLoanMay2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_DelayedDrawTermLoanMay2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656662165728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Maturities of Debt (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Maturities of debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2027</a></td>
<td class="nump">1,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2028</a></td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 6,930<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656660617936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Senior Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from issuance of senior notes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,544,000,000<span></span>
</td>
<td class="nump">$ 1,982,000,000<span></span>
</td>
<td class="nump">$ 2,984,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $250 million, 8.150% due June&#160;15, 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 5.750 Percent Senior Notes Due December 2028 And 5.50 Percent Senior Notes Due March 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from issuance of senior notes, net</a></td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $500 million, 5.750% due December 1, 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $850 million, 5.950% due March 15, 2034</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_LongTermDebtAggregateCarryingValueAdjustment', window );">Aggregate carrying value adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 5.70 Percent Senior Notes Due March 2026 And 5.50 Percent Senior Notes Due March 2053</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from issuance of senior notes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $500 million, 5.700% due March 13, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $750 million, 5.500% due March 15, 2053</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_LongTermDebtAggregateCarryingValueAdjustment', window );">Aggregate carrying value adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | Repurchase Plan, August 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument, repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">339,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $750 million, 1.350% due February 3, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $600 million, 3.950% due March 15, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.700 Percent Senior Notes Due March 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.125 Percent Senior Notes Due August 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.125%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | Repurchase Plan, March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt instrument, repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Debt instrument, repurchase amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 358,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $1.5 billion, 0.650% due August 3, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $600 million, 3.850% due October 1, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.85%<span></span>
</td>
<td class="nump">3.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | $750 million, 5.875% due March 1, 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_LongTermDebtAggregateCarryingValueAdjustment', window );">Aggregate carrying value adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 3.950 Percent Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_LongTermDebtAggregateCarryingValueAdjustment', window );">Aggregate carrying value adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans Payable | Delayed Draw Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_LongTermDebtAggregateCarryingValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Aggregate Carrying Value Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_LongTermDebtAggregateCarryingValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -SubTopic 470<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A8.15PercentSeniorNotesDueJune2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A8.15PercentSeniorNotesDueJune2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A575PercentSeniorNotesDueDecember2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A575PercentSeniorNotesDueDecember2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A5950PercentSeniorNotesDueMarch2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A5950PercentSeniorNotesDueMarch2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A570PercentSeniorNotesDueMarch2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A570PercentSeniorNotesDueMarch2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A550PercentSeniorNotesDueMarch2053Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A550PercentSeniorNotesDueMarch2053Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_RepurchasePlanAugust2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_RepurchasePlanAugust2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A135PercentSeniorNotesDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A135PercentSeniorNotesDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A3.95PercentSeniorNotesDueMarch2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A3.95PercentSeniorNotesDueMarch2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A3700PercentSeniorNotesDueMarch2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A3700PercentSeniorNotesDueMarch2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A3125PercentSeniorNotesDueAugust2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A3125PercentSeniorNotesDueAugust2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_RepurchasePlanMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_RepurchasePlanMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A065PercentSeniorNotesDueAugust2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A065PercentSeniorNotesDueAugust2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A3850PercentSeniorNotesDueOctober2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A3850PercentSeniorNotesDueOctober2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A5.88PercentSeniorNotesDueMarch2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A5.88PercentSeniorNotesDueMarch2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_A3.950PercentSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_A3.950PercentSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_DelayedDrawTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_DelayedDrawTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656660626704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Revolving Credit Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual', window );">Actual debt to capitalization percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum', window );">Debt to capitalization percentage, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_LineOfCreditFacilityUncommittedIncrementalCapacity', window );">Uncommitted incremental loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity', window );">Maximum borrowing capacity including uncommitted incremental loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,750,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Line of credit, outstanding borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Agreement June 2021 Five Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Agreement June 2021 One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">364 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Agreement June 2023 Five Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Facility fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.09%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,482,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Agreement June 2023 Five Year | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Facility fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.08%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Agreement June 2023 Five Year | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Facility fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Agreement June 2023 Five Year | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis points spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.035%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Agreement June 2023 Five Year | SOFR | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis points spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.92%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Agreement June 2023 Five Year | SOFR | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis points spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Agreement June 2023 One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term (in years)</a></td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">364 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Facility fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.07%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Agreement June 2023 One Year | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Facility fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.06%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Agreement June 2023 One Year | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Facility fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Agreement June 2023 One Year | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis points spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.055%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Agreement June 2023 One Year | SOFR | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis points spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.94%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Agreement June 2023 One Year | SOFR | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis points spread on variable rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.35%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Revolving Credit Agreement June 2022 One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Line of credit, outstanding borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Debt To Capitalization Percentage, Actual</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Debt To Capitalization Percentage, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility including uncommitted incremental capacity and without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_LineOfCreditFacilityUncommittedIncrementalCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Uncommitted Incremental Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_LineOfCreditFacilityUncommittedIncrementalCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_RevolvingCreditAgreementJune2021FiveYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_RevolvingCreditAgreementJune2021FiveYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_RevolvingCreditAgreementJune2021OneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_RevolvingCreditAgreementJune2021OneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_RevolvingCreditAgreementJune2023FiveYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_RevolvingCreditAgreementJune2023FiveYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=hum_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=hum_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_RevolvingCreditAgreementJune2023OneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_RevolvingCreditAgreementJune2023OneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=hum_RevolvingCreditAgreementJune2022OneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=hum_RevolvingCreditAgreementJune2022OneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656660984576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Commercial Paper and Other Short-Term Borrowings (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod', window );">Maximum amount outstanding during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt outstanding</a></td>
<td class="nump">$ 871,000,000<span></span>
</td>
<td class="nump">$ 871,000,000<span></span>
</td>
<td class="nump">595,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRate', window );">Weighted average annual interest rate (percent)</a></td>
<td class="nump">5.68%<span></span>
</td>
<td class="nump">5.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_FederalHomeLoanBankAdvancesMember', window );">Federal Home Loan Bank Advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term borrowings</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of short-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, the maximum amount borrowed at any time during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_FederalHomeLoanBankAdvancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_FederalHomeLoanBankAdvancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656660122096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employee retirement and savings plan cost</a></td>
<td class="nump">$ 278,000,000<span></span>
</td>
<td class="nump">$ 286,000,000<span></span>
</td>
<td class="nump">$ 259,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_CompanyCommonStockClosingSharePrice', window );">Company common stock closing price (in dollars per share)</a></td>
<td class="nump">$ 457.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock', window );">Plan assets invested in Company common stock (percent)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares', window );">Plan assets invested in Company common stock (in shares)</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding', window );">Shares of common stock plan assets as percentage of shares outstanding</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance', window );">Number of shares of common stock reserved for issuance under defined contribution retirement savings plan (in shares)</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod', window );">Accelerated vesting, termination of employment period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram', window );">Combination of age and years necessary for retirement provision as related to our equity award program</a></td>
<td class="text">65 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram', window );">Minimum age required for retirement eligibility as related to our equity award program</a></td>
<td class="text">55 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram', window );">Minimum number of years of service for retirement eligibility as related to our equity award program</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting', window );">Actual realized tax benefit on tax returns from option exercises and restricted stock vesting</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="nump">31,000,000<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized stock-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of shares vested</a></td>
<td class="nump">236,000,000<span></span>
</td>
<td class="nump">244,000,000<span></span>
</td>
<td class="nump">236,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of stock options outstanding</a></td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term of outstanding options (in years)</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of stock options exercisable</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term of exercisable options (in years)</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of stock options exercised</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">32,000,000<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="nump">9,000,000<span></span>
</td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation expense not yet recognized</a></td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 508.23<span></span>
</td>
<td class="nump">$ 430.06<span></span>
</td>
<td class="nump">$ 381.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions', window );">Percentage of restricted stock with performance-based conditions</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total compensation expense not yet recognized related to nonvested awards</a></td>
<td class="nump">$ 181,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense recognition over a weighted-average period (in years)</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense recognition over a weighted-average period (in years)</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hum_A2011PlanMember', window );">2011 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock shares reserved for stock award plans (in shares)</a></td>
<td class="nump">11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hum_A2011PlanMember', window );">2011 Plan | Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants assuming all stock options or restricted stock are granted (in shares)</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hum_A2011PlanMember', window );">2011 Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants assuming all stock options or restricted stock are granted (in shares)</a></td>
<td class="nump">3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hum_A2019PlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock shares reserved for stock award plans (in shares)</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hum_A2019PlanMember', window );">2019 Plan | Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants assuming all stock options or restricted stock are granted (in shares)</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hum_A2019PlanMember', window );">2019 Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants assuming all stock options or restricted stock are granted (in shares)</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Combination of age and years necessary for retirement provision as related to our equity award program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_CompanyCommonStockClosingSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Company Common Stock, Closing Share Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_CompanyCommonStockClosingSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Number Of Shares Of Common Stock Reserved For Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Plan Assets Invested In Company Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Plan Assets Invested In Company Common Stock, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Shares Of Common Stock In Plan As Percentage Of Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the aggregate tax benefit realized from the exercise of stock options and vesting of restricted stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum age required for retirement eligibility as related to our equity award program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum number of years of service for retirement eligibility as related to our equity award program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Termination Of Employment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation By Share Based Payment Award, Equity Instruments Other Than Options, Percent Of Stock With Performance Based Conditions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hum_A2011PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hum_A2011PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hum_A2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hum_A2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656664985168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit recognized</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Stock-based compensation expense, net of tax</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="nump">165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656660058560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Restricted Stock Activity (Details) - Restricted stock - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested restricted stock, beginning balance (in shares)</a></td>
<td class="nump">813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested restricted stock, ending balance (in shares)</a></td>
<td class="nump">754<span></span>
</td>
<td class="nump">813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant-Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested restricted stock, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 429.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">508.23<span></span>
</td>
<td class="nump">$ 430.06<span></span>
</td>
<td class="nump">$ 381.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">389.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">441.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested restricted stock, ending balance (in dollars per share)</a></td>
<td class="nump">$ 488.06<span></span>
</td>
<td class="nump">$ 429.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656673673712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Weighted-Average Fair Value Assumptions for Stock Options (Details) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value at grant date (in dollars per share)</a></td>
<td class="nump">$ 130.74<span></span>
</td>
<td class="nump">$ 113.35<span></span>
</td>
<td class="nump">$ 92.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">31.60%<span></span>
</td>
<td class="nump">36.10%<span></span>
</td>
<td class="nump">33.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate at grant date</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656673091376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS - Option Plans Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares&#160; Under Option</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, ending balance (in shares) | shares</a></td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 381.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">508.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">371.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">491.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">415.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 366.69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656665037984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS PER COMMON SHARE COMPUTATION (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income available for common stockholders</a></td>
<td class="nump">$ 2,489<span></span>
</td>
<td class="nump">$ 2,806<span></span>
</td>
<td class="nump">$ 2,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average outstanding shares of common stock used to compute basic earnings per common share (in shares)</a></td>
<td class="nump">123,866<span></span>
</td>
<td class="nump">126,419<span></span>
</td>
<td class="nump">128,688<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted earnings per&#160;common share (in shares)</a></td>
<td class="nump">124,441<span></span>
</td>
<td class="nump">127,094<span></span>
</td>
<td class="nump">129,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per common share (in dollars per share)</a></td>
<td class="nump">$ 20.09<span></span>
</td>
<td class="nump">$ 22.20<span></span>
</td>
<td class="nump">$ 22.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per common share (in dollars per share)</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="nump">$ 22.08<span></span>
</td>
<td class="nump">$ 22.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive stock options and restricted stock&#160;awards excluded from computation (in shares)</a></td>
<td class="nump">207<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of employee stock options and restricted stock (in shares)</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of employee stock options and restricted stock (in shares)</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="nump">644<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656761118272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Dividend Payments (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Amount per share (in dollars per share)</a></td>
<td class="nump">$ 3.44<span></span>
</td>
<td class="nump">$ 3.06<span></span>
</td>
<td class="nump">$ 2.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Total Amount</a></td>
<td class="nump">$ 428<span></span>
</td>
<td class="nump">$ 390<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656652289856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 16, 2022</div></th>
<th class="th"><div>Dec. 16, 2022</div></th>
<th class="th"><div>Dec. 15, 2022</div></th>
<th class="th"><div>Nov. 02, 2022</div></th>
<th class="th"><div>Mar. 30, 2022</div></th>
<th class="th"><div>Mar. 30, 2022</div></th>
<th class="th"><div>Mar. 29, 2022</div></th>
<th class="th"><div>Jan. 12, 2022</div></th>
<th class="th"><div>May 05, 2021</div></th>
<th class="th"><div>May 04, 2021</div></th>
<th class="th"><div>Dec. 23, 2020</div></th>
<th class="th"><div>Feb. 15, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Dec. 16, 2022</div></th>
<th class="th"><div>Mar. 30, 2022</div></th>
<th class="th"><div>May 05, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 16, 2024</div></th>
<th class="th"><div>Feb. 15, 2023</div></th>
<th class="th"><div>Nov. 04, 2022</div></th>
<th class="th"><div>Nov. 03, 2022</div></th>
<th class="th"><div>Jan. 11, 2022</div></th>
<th class="th"><div>Feb. 18, 2021</div></th>
<th class="th"><div>Dec. 22, 2020</div></th>
<th class="th"><div>Jul. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividend declared (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares received (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Increase in treasury stock from share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,586,000,000<span></span>
</td>
<td class="nump">$ 2,096,000,000<span></span>
</td>
<td class="nump">$ 79,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares', window );">Common shares acquired in connection with employee stock plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue', window );">Common shares acquired in connection with employee stock plans, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,000,000<span></span>
</td>
<td class="nump">$ 96,000,000<span></span>
</td>
<td class="nump">$ 79,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance', window );">Aggregate statutory capital and surplus in our state regulated insurance subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,200,000,000<span></span>
</td>
<td class="nump">11,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired', window );">Aggregate minimum regulatory requirements of statutory capital and surplus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800,000,000<span></span>
</td>
<td class="nump">8,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval', window );">Ordinary dividends that may be paid to parent company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DividendsToParentWithoutPriorStateRegulatoryApproval', window );">Actual dividends paid to parent company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividend declared (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=hum_A2021ShareRepurchaseAuthorizationMember', window );">2021 Share Repurchase Authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=hum_A2023ShareRepurchaseAuthorizationMember', window );">2023 Share Repurchase Authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares received (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Increase in treasury stock from share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Stock repurchase average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 482.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=hum_A2023ShareRepurchaseAuthorizationMember', window );">2023 Share Repurchase Authorization | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 824,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=hum_A2024ShareRepurchaseAuthorizationMember', window );">2024 Share Repurchase Authorization | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesDateAxis=hum_December2020AcceleratedShareRepurchaseAgreementMember', window );">December 2020 ASR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_AcceleratedShareRepurchasesAgreementAmount', window );">Accelerated share repurchase agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated share repurchase payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares received (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Increase in treasury stock from share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue', window );">Decrease in capital in excess of par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue', window );">Reclassification from capital in excess of par value to treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesDateAxis=hum_December2020AcceleratedShareRepurchaseAgreementMember', window );">December 2020 ASR | Citi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated share repurchase payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 875,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares received (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare', window );">Average daily volume weighted-average share price of common stock during term of agreement (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesDateAxis=hum_December2020AcceleratedShareRepurchaseAgreementMember', window );">December 2020 ASR | JPM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated share repurchase payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 875,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares received (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare', window );">Average daily volume weighted-average share price of common stock during term of agreement (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 401.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesDateAxis=hum_January2022AcceleratedShareRepurchaseAgreementMember', window );">January 2022 ASR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_AcceleratedShareRepurchasesAgreementAmount', window );">Accelerated share repurchase agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated share repurchase payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares received (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Increase in treasury stock from share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue', window );">Decrease in capital in excess of par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue', window );">Reclassification from capital in excess of par value to treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesDateAxis=hum_January2022AcceleratedShareRepurchaseAgreementMember', window );">January 2022 ASR | Mizuho Markets Americas LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated share repurchase payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares received (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">1,080,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare', window );">Average daily volume weighted-average share price of common stock during term of agreement (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 410.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesDateAxis=hum_January2022AcceleratedShareRepurchaseAgreementMember', window );">January 2022 ASR | Wells Fargo Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated share repurchase payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares received (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,080,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare', window );">Average daily volume weighted-average share price of common stock during term of agreement (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 411.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesDateAxis=hum_November2022AcceleratedShareRepurchaseProgramMember', window );">November 2022 ASR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_AcceleratedShareRepurchasesAgreementAmount', window );">Accelerated share repurchase agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated share repurchase payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares received (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Increase in treasury stock from share repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue', window );">Decrease in capital in excess of par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue', window );">Reclassification from capital in excess of par value to treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesDateAxis=hum_November2022AcceleratedShareRepurchaseProgramMember', window );">November 2022 ASR | Mizuho Markets Americas LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated share repurchase payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares received (in shares)</a></td>
<td class="nump">177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare', window );">Average daily volume weighted-average share price of common stock during term of agreement (in dollars per share)</a></td>
<td class="nump">$ 533.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesDateAxis=hum_November2022AcceleratedShareRepurchaseProgramMember', window );">November 2022 ASR | Goldman Sachs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated share repurchase payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares received (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,000<span></span>
</td>
<td class="nump">760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare', window );">Average daily volume weighted-average share price of common stock during term of agreement (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 534.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_AcceleratedShareRepurchasesAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accelerated Share Repurchases, Agreement Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_AcceleratedShareRepurchasesAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Reclassified From Capital In Excess Of Par Value To Treasury Stock Upon Repurchase, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DividendsToParentWithoutPriorStateRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of dividends paid to our parent company without prior approval by state regulatory authorities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DividendsToParentWithoutPriorStateRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock that were repurchased in the administration of our employee share-based compensation plans. Under the terms of these plans, we accept shares of common stock from option holders if they elect to surrender previously-owned shares upon exercise of the option to cover the exercise price of the options or, in the case of restricted shares of common stock, the withholding of shares to satisfy tax withholding obligations associated with the vesting of such shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of common stock that were repurchased in the administration of our employee share-based compensation plans. Under the terms of these plans, we accept shares of common stock from option holders if they elect to surrender previously-owned shares upon exercise of the option to cover the exercise price of the options or, in the case of restricted shares of common stock, the withholding of shares to satisfy tax withholding obligations associated with the vesting of such shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_TreasuryStockDecreaseInCapitalInExcessOfParValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock, Decrease In Capital In Excess Of Par Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_TreasuryStockDecreaseInCapitalInExcessOfParValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481138/505-30-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481138/505-30-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of dividends that can be declared or paid without approval of regulatory agency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of statutory capital and surplus (stockholders' equity) as of the balance sheet date using prescribed or permitted statutory accounting practices (rather than GAAP, if different) of the state or country.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479989/944-505-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479989/944-505-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=hum_A2021ShareRepurchaseAuthorizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=hum_A2021ShareRepurchaseAuthorizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=hum_A2023ShareRepurchaseAuthorizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=hum_A2023ShareRepurchaseAuthorizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=hum_A2024ShareRepurchaseAuthorizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=hum_A2024ShareRepurchaseAuthorizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesDateAxis=hum_December2020AcceleratedShareRepurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesDateAxis=hum_December2020AcceleratedShareRepurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=hum_CitibankNAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=hum_CitibankNAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=hum_JPMorganChaseBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=hum_JPMorganChaseBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesDateAxis=hum_January2022AcceleratedShareRepurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesDateAxis=hum_January2022AcceleratedShareRepurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=hum_MizuhoMarketsAmericasLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=hum_MizuhoMarketsAmericasLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=hum_WellsFargoBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=hum_WellsFargoBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesDateAxis=hum_November2022AcceleratedShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesDateAxis=hum_November2022AcceleratedShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=hum_GoldmanSachsCoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=hum_GoldmanSachsCoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656662239712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Share Repurchases (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 18, 2021</div></th>
<th class="th"><div>Jul. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of repurchases</a></td>
<td class="nump">$ 1,586,000,000<span></span>
</td>
<td class="nump">$ 2,096,000,000<span></span>
</td>
<td class="nump">$ 79,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember', window );">Excluding Employee Stock Plans and ASR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of repurchases</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=hum_February2023ShareRepurchaseAuthorizationMember', window );">February 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase authorization</a></td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of repurchases</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=hum_February2021ShareRepurchaseAuthorizationMember', window );">February 2021 Authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase authorization</a></td>
<td class="nump">$ 3,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of repurchases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=hum_February2023ShareRepurchaseAuthorizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=hum_February2023ShareRepurchaseAuthorizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=hum_February2021ShareRepurchaseAuthorizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=hum_February2021ShareRepurchaseAuthorizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667939328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>state </div>
<div>beneficiary </div>
<div>option_period</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>beneficiary </div>
<div>state</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary', window );">Purchase obligations in 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary', window );">Purchase obligations in 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary', window );">Purchase obligations in 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary', window );">Purchase obligations in 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary', window );">Purchase obligations in 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_TRICAREContractAxis=hum_TRICARE2017EastRegionContractMember', window );">TRICARE 2017 East Region Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_NumberOfStatesComprisingTRICAREBeneficiaries', window );">Number of states comprising TRICARE beneficiaries | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_NumberOfTRICAREBeneficiaries', window );">Number of TRICARE beneficiaries | beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_TRICAREContractAxis=hum_TRICAREManagedCareSupportContractEffective2024Member', window );">TRICARE Managed Care Support Contract, Effective 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries', window );">Number of states comprising TRICARE Managed Care Support Contract beneficiaries | state</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries', window );">Number of TRICARE Managed Care Support Contract beneficiaries | beneficiary</a></td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_TRICAREManagedCareSupportContractBaseTerm', window );">Contract base term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods', window );">Annual option periods | option_period</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_TRICAREManagedCareSupportContractTermWithOptionExercises', window );">Contract term with exercises</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=hum_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_PercentageOfTotalPremiumAndServicesRevenues', window );">Percentage of premiums and services revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=hum_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_PercentageOfTotalPremiumAndServicesRevenues', window );">Percentage of premiums and services revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=hum_MilitaryServiceMember', window );">Military services | TRICARE 2017 East Region Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_PercentageOfTotalPremiumAndServicesRevenues', window );">Percentage of premiums and services revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of States Comprising Of TRICARE Managed Care Support Contract Beneficiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_NumberOfStatesComprisingTRICAREBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of States Comprising TRICARE Beneficiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_NumberOfStatesComprisingTRICAREBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_NumberOfTRICAREBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of TRICARE Beneficiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_NumberOfTRICAREBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of TRICARE Managed Care Support Contract Beneficiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_PercentageOfTotalPremiumAndServicesRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Total Premium And Services Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_PercentageOfTotalPremiumAndServicesRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_TRICAREManagedCareSupportContractBaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>TRICARE Managed Care Support Contract, Base Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_TRICAREManagedCareSupportContractBaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>TRICARE Managed Care Support Contract, Number Of Option Periods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_TRICAREManagedCareSupportContractTermWithOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>TRICARE Managed Care Support Contract, Term With Option Exercises</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_TRICAREManagedCareSupportContractTermWithOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_TRICAREContractAxis=hum_TRICARE2017EastRegionContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_TRICAREContractAxis=hum_TRICARE2017EastRegionContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_TRICAREContractAxis=hum_TRICAREManagedCareSupportContractEffective2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_TRICAREContractAxis=hum_TRICAREManagedCareSupportContractEffective2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_MilitaryServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_MilitaryServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656665449968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_GovernmentAndHealthPlanMemberSubsidiesAmount', window );">Member co-share amounts and government subsidies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,700<span></span>
</td>
<td class="nump">$ 19,700<span></span>
</td>
<td class="nump">$ 18,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DepreciationAndAmortizationClassifiedAsBenefitExpense', window );">Depreciation and amortization classified as benefit expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">$ 108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember', window );">Government contracts concentration risk | Premiums and services revenue | Federal government contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DepreciationAndAmortizationClassifiedAsBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation and amortization expense that has been reclassified to be included with benefit expenses. The reclassification is the result of depreciation and amortization expense associated primarily from the delivery of pharmacy services by our wholly-owned pharmacy business included in our Healthcare Services segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DepreciationAndAmortizationClassifiedAsBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_GovernmentAndHealthPlanMemberSubsidiesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of member co-share amounts and government subsidies that are excluded from benefits expense because the health plans do not bear responsibility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_GovernmentAndHealthPlanMemberSubsidiesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_FederalGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_FederalGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656650896352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Segment Results (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">$ 101,272<span></span>
</td>
<td class="nump">$ 87,712<span></span>
</td>
<td class="nump">$ 79,822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">4,033<span></span>
</td>
<td class="nump">4,776<span></span>
</td>
<td class="nump">3,055<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">106,374<span></span>
</td>
<td class="nump">92,870<span></span>
</td>
<td class="nump">83,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Investment income</a></td>
<td class="nump">1,069<span></span>
</td>
<td class="nump">382<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare', window );">Benefits</a></td>
<td class="nump">88,394<span></span>
</td>
<td class="nump">75,690<span></span>
</td>
<td class="nump">69,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Operating costs</a></td>
<td class="nump">13,188<span></span>
</td>
<td class="nump">12,671<span></span>
</td>
<td class="nump">10,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">779<span></span>
</td>
<td class="nump">709<span></span>
</td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BenefitsLossesAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">102,361<span></span>
</td>
<td class="nump">89,070<span></span>
</td>
<td class="nump">79,916<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">4,013<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">3,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of Gentiva Hospice</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(237)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="num">(532)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes and equity in net earnings (losses)</a></td>
<td class="nump">3,383<span></span>
</td>
<td class="nump">3,568<span></span>
</td>
<td class="nump">3,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net losses</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Segment earnings (loss)</a></td>
<td class="nump">3,320<span></span>
</td>
<td class="nump">3,564<span></span>
</td>
<td class="nump">3,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss (income) attributable to noncontrolling interests</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent', window );">Segment earnings (loss) attributable to Humana</a></td>
<td class="nump">3,325<span></span>
</td>
<td class="nump">3,568<span></span>
</td>
<td class="nump">3,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">101,272<span></span>
</td>
<td class="nump">87,712<span></span>
</td>
<td class="nump">79,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">4,033<span></span>
</td>
<td class="nump">4,776<span></span>
</td>
<td class="nump">3,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hum_ExternalRevenuesMember', window );">External Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">105,305<span></span>
</td>
<td class="nump">92,488<span></span>
</td>
<td class="nump">82,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=hum_MedicareMember', window );">Total Medicare | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">87,895<span></span>
</td>
<td class="nump">75,157<span></span>
</td>
<td class="nump">67,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=hum_MedicareAdvantageMember', window );">Individual Medicare Advantage | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">78,837<span></span>
</td>
<td class="nump">65,591<span></span>
</td>
<td class="nump">58,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=hum_GroupMedicareAdvantageMember', window );">Group Medicare Advantage | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">6,869<span></span>
</td>
<td class="nump">7,297<span></span>
</td>
<td class="nump">6,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=hum_MedicareStandAlonePrescriptionDrugPlanMember', window );">Medicare stand-alone PDP | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">2,189<span></span>
</td>
<td class="nump">2,269<span></span>
</td>
<td class="nump">2,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=hum_CommercialFullyInsuredMember', window );">Commercial fully-insured | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">3,527<span></span>
</td>
<td class="nump">4,389<span></span>
</td>
<td class="nump">4,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=hum_SpecialtyBenefitsMember', window );">Specialty benefits | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=hum_MedicareSupplementProductMember', window );">Medicare Supplement | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">735<span></span>
</td>
<td class="nump">743<span></span>
</td>
<td class="nump">731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=hum_StateBasedContractsAndOtherMember', window );">State-based contracts and other | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">8,108<span></span>
</td>
<td class="nump">6,376<span></span>
</td>
<td class="nump">5,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=hum_HomeSolutionsMember', window );">Home solutions | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">1,342<span></span>
</td>
<td class="nump">2,333<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=hum_PrimaryCareMember', window );">Primary care | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">842<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=hum_CommercialASOMember', window );">Commercial ASO | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=hum_MilitaryAndOtherMember', window );">Military services and other | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">763<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=hum_PharmacySolutionsMember', window );">Pharmacy solutions | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">849<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">102,854<span></span>
</td>
<td class="nump">88,841<span></span>
</td>
<td class="nump">80,930<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Investment income</a></td>
<td class="nump">551<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare', window );">Benefits</a></td>
<td class="nump">89,100<span></span>
</td>
<td class="nump">75,934<span></span>
</td>
<td class="nump">69,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Operating costs</a></td>
<td class="nump">10,408<span></span>
</td>
<td class="nump">9,251<span></span>
</td>
<td class="nump">8,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BenefitsLossesAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">100,200<span></span>
</td>
<td class="nump">85,819<span></span>
</td>
<td class="nump">78,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">2,654<span></span>
</td>
<td class="nump">3,022<span></span>
</td>
<td class="nump">2,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of Gentiva Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes and equity in net earnings (losses)</a></td>
<td class="nump">2,654<span></span>
</td>
<td class="nump">3,022<span></span>
</td>
<td class="nump">2,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Segment earnings (loss)</a></td>
<td class="nump">2,648<span></span>
</td>
<td class="nump">3,040<span></span>
</td>
<td class="nump">2,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss (income) attributable to noncontrolling interests</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent', window );">Segment earnings (loss) attributable to Humana</a></td>
<td class="nump">2,654<span></span>
</td>
<td class="nump">3,045<span></span>
</td>
<td class="nump">2,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">101,272<span></span>
</td>
<td class="nump">87,712<span></span>
</td>
<td class="nump">79,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance | External Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">102,272<span></span>
</td>
<td class="nump">88,562<span></span>
</td>
<td class="nump">80,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance | Total Medicare | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">87,895<span></span>
</td>
<td class="nump">75,157<span></span>
</td>
<td class="nump">67,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance | Individual Medicare Advantage | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">78,837<span></span>
</td>
<td class="nump">65,591<span></span>
</td>
<td class="nump">58,654<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance | Group Medicare Advantage | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">6,869<span></span>
</td>
<td class="nump">7,297<span></span>
</td>
<td class="nump">6,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance | Medicare stand-alone PDP | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">2,189<span></span>
</td>
<td class="nump">2,269<span></span>
</td>
<td class="nump">2,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance | Commercial fully-insured | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">3,527<span></span>
</td>
<td class="nump">4,389<span></span>
</td>
<td class="nump">4,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance | Specialty benefits | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance | Medicare Supplement | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">735<span></span>
</td>
<td class="nump">743<span></span>
</td>
<td class="nump">731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance | State-based contracts and other | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">8,108<span></span>
</td>
<td class="nump">6,376<span></span>
</td>
<td class="nump">5,109<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance | Home solutions | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance | Primary care | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance | Commercial ASO | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance | Military services and other | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">763<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Insurance | Pharmacy solutions | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">18,405<span></span>
</td>
<td class="nump">17,307<span></span>
</td>
<td class="nump">14,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Investment income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare', window );">Benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Operating costs</a></td>
<td class="nump">16,791<span></span>
</td>
<td class="nump">15,835<span></span>
</td>
<td class="nump">12,968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">152<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BenefitsLossesAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">17,001<span></span>
</td>
<td class="nump">16,016<span></span>
</td>
<td class="nump">13,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">1,404<span></span>
</td>
<td class="nump">1,291<span></span>
</td>
<td class="nump">938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of Gentiva Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes and equity in net earnings (losses)</a></td>
<td class="nump">1,401<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
<td class="nump">938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net losses</a></td>
<td class="num">(57)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Segment earnings (loss)</a></td>
<td class="nump">1,344<span></span>
</td>
<td class="nump">1,506<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss (income) attributable to noncontrolling interests</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent', window );">Segment earnings (loss) attributable to Humana</a></td>
<td class="nump">1,343<span></span>
</td>
<td class="nump">1,505<span></span>
</td>
<td class="nump">1,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">3,033<span></span>
</td>
<td class="nump">3,926<span></span>
</td>
<td class="nump">2,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell | External Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">3,033<span></span>
</td>
<td class="nump">3,926<span></span>
</td>
<td class="nump">2,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell | Total Medicare | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell | Individual Medicare Advantage | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell | Group Medicare Advantage | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell | Medicare stand-alone PDP | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell | Commercial fully-insured | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell | Specialty benefits | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell | Medicare Supplement | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell | State-based contracts and other | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premiums</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell | Home solutions | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">1,342<span></span>
</td>
<td class="nump">2,333<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell | Primary care | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">842<span></span>
</td>
<td class="nump">568<span></span>
</td>
<td class="nump">413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell | Commercial ASO | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell | Military services and other | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | CenterWell | Pharmacy solutions | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Services revenue</a></td>
<td class="nump">849<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=hum_CorporateAndEliminationsMember', window );">Eliminations/ Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(14,885)<span></span>
</td>
<td class="num">(13,278)<span></span>
</td>
<td class="num">(11,924)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Investment income</a></td>
<td class="nump">518<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare', window );">Benefits</a></td>
<td class="num">(706)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
<td class="num">(440)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Operating costs</a></td>
<td class="num">(14,011)<span></span>
</td>
<td class="num">(12,415)<span></span>
</td>
<td class="num">(11,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BenefitsLossesAndExpenses', window );">Total operating expenses</a></td>
<td class="num">(14,840)<span></span>
</td>
<td class="num">(12,765)<span></span>
</td>
<td class="num">(11,722)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(513)<span></span>
</td>
<td class="num">(202)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of Gentiva Hospice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="num">(532)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income taxes and equity in net earnings (losses)</a></td>
<td class="num">(672)<span></span>
</td>
<td class="num">(982)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Segment earnings (loss)</a></td>
<td class="num">(672)<span></span>
</td>
<td class="num">(982)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss (income) attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent', window );">Segment earnings (loss) attributable to Humana</a></td>
<td class="num">(672)<span></span>
</td>
<td class="num">(982)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=hum_CorporateAndEliminationsMember', window );">Eliminations/ Corporate | Insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=hum_CorporateAndEliminationsMember', window );">Eliminations/ Corporate | Insurance | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=hum_CorporateAndEliminationsMember', window );">Eliminations/ Corporate | Insurance | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=hum_CorporateAndEliminationsMember', window );">Eliminations/ Corporate | CenterWell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">15,372<span></span>
</td>
<td class="nump">13,373<span></span>
</td>
<td class="nump">11,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=hum_CorporateAndEliminationsMember', window );">Eliminations/ Corporate | CenterWell | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">10,451<span></span>
</td>
<td class="nump">9,841<span></span>
</td>
<td class="nump">9,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=hum_CorporateAndEliminationsMember', window );">Eliminations/ Corporate | CenterWell | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">4,921<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
<td class="nump">2,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(15,403)<span></span>
</td>
<td class="num">(13,429)<span></span>
</td>
<td class="num">(11,893)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">(10,451)<span></span>
</td>
<td class="num">(9,841)<span></span>
</td>
<td class="num">(9,024)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="num">$ (4,952)<span></span>
</td>
<td class="num">$ (3,588)<span></span>
</td>
<td class="num">$ (2,869)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Loss From Continuing Operations Before Income Taxes Attributable To Parent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BenefitsLossesAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.5,6,7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BenefitsLossesAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred for health insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480149/944-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -SubTopic 220<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -SubTopic 220<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=hum_ExternalRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=hum_ExternalRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_MedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_MedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_GroupMedicareAdvantageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_GroupMedicareAdvantageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_MedicareStandAlonePrescriptionDrugPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_MedicareStandAlonePrescriptionDrugPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_CommercialFullyInsuredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_CommercialFullyInsuredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_SpecialtyBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_SpecialtyBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_MedicareSupplementProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_MedicareSupplementProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_StateBasedContractsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_StateBasedContractsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_HomeSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_HomeSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_PrimaryCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_PrimaryCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_CommercialASOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_CommercialASOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_MilitaryAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_MilitaryAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=hum_PharmacySolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=hum_PharmacySolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=hum_InsuranceSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=hum_InsuranceSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=hum_CenterWellSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=hum_CenterWellSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=hum_CorporateAndEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=hum_CorporateAndEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656673683296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REINSURANCE (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>reinsurer</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectsOfReinsuranceLineItems', window );"><strong>Effects of Reinsurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverables', window );">Reinsurance recoverables</a></td>
<td class="nump">$ 173.0<span></span>
</td>
<td class="nump">$ 181.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CededPremiumsWritten', window );">Premiums ceded</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">$ 6.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded', window );">Benefits ceded</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance', window );">Number of reinsurers comprising other reinsurance recoverables balance | reinsurer</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer', window );">Cash and securities in trusts held by certain reinsurers</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hum_ProtectiveLifeInsuranceCompanyMember', window );">Protective Life Insurance Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectsOfReinsuranceLineItems', window );"><strong>Effects of Reinsurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverables', window );">Reinsurance recoverables</a></td>
<td class="nump">159.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=hum_AllOthersMember', window );">All others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectsOfReinsuranceLineItems', window );"><strong>Effects of Reinsurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverables', window );">Reinsurance recoverables</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_LongDurationInsuranceProductsAxis=hum_CoinsuranceAgreementMember', window );">100% coinsurance agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectsOfReinsuranceLineItems', window );"><strong>Effects of Reinsurance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_PercentageOfCoinsuranceAgreement', window );">Percentage of coinsurance agreement</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount held in cash and securities in trust, at least equal to the recoverable from the reinsurer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reinsurers comprising other reinsurance recoverables balance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_PercentageOfCoinsuranceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Coinsurance Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_PercentageOfCoinsuranceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CededPremiumsWritten">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of written premiums ceded to other entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479655/944-605-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CededPremiumsWritten</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectsOfReinsuranceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectsOfReinsuranceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reduction of provision for policy benefits and costs incurred for policies ceded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479838/944-20-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479838/944-20-50-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479616/944-310-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=hum_ProtectiveLifeInsuranceCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=hum_ProtectiveLifeInsuranceCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=hum_AllOthersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=hum_AllOthersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_LongDurationInsuranceProductsAxis=hum_CoinsuranceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_LongDurationInsuranceProductsAxis=hum_CoinsuranceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656661038944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Balance Sheets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,694<span></span>
</td>
<td class="nump">$ 5,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investment securities</a></td>
<td class="nump">16,626<span></span>
</td>
<td class="nump">13,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables, net of allowances of $88 in 2023 and $70 in 2022</a></td>
<td class="nump">2,035<span></span>
</td>
<td class="nump">1,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">6,631<span></span>
</td>
<td class="nump">5,567<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">29,986<span></span>
</td>
<td class="nump">26,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,030<span></span>
</td>
<td class="nump">3,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">3,377<span></span>
</td>
<td class="nump">3,380<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">47,065<span></span>
</td>
<td class="nump">43,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term debt</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">2,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_BookOverdraftLiability', window );">Book overdraft</a></td>
<td class="nump">353<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,872<span></span>
</td>
<td class="nump">17,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">10,213<span></span>
</td>
<td class="nump">9,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,662<span></span>
</td>
<td class="nump">1,473<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">30,747<span></span>
</td>
<td class="nump">27,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 17)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $1 par; 10,000,000 shares authorized; none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,690,082 shares issued at December 31, 2023 and 198,666,598 shares issued at December 31, 2022</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital in excess of par value</a></td>
<td class="nump">3,346<span></span>
</td>
<td class="nump">3,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">27,540<span></span>
</td>
<td class="nump">25,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(999)<span></span>
</td>
<td class="num">(1,304)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, 76,465,862 shares at December 31, 2023 and 73,691,955 shares at December 31, 2022</a></td>
<td class="num">(13,658)<span></span>
</td>
<td class="num">(12,156)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">16,262<span></span>
</td>
<td class="nump">15,311<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">47,065<span></span>
</td>
<td class="nump">43,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investment securities</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">717<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,277<span></span>
</td>
<td class="nump">3,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,334<span></span>
</td>
<td class="nump">2,393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_InvestmentInRelatedPartiesAndSubsidiaries', window );">Investment in subsidiaries</a></td>
<td class="nump">29,666<span></span>
</td>
<td class="nump">27,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">348<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">35,625<span></span>
</td>
<td class="nump">33,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term debt</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">2,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_BookOverdraftLiability', window );">Book overdraft</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,566<span></span>
</td>
<td class="nump">1,425<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,888<span></span>
</td>
<td class="nump">9,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">10,213<span></span>
</td>
<td class="nump">9,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">19,363<span></span>
</td>
<td class="nump">18,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 17)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $1 par; 10,000,000 shares authorized; none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,690,082 shares issued at December 31, 2023 and 198,666,598 shares issued at December 31, 2022</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital in excess of par value</a></td>
<td class="nump">3,346<span></span>
</td>
<td class="nump">3,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">27,540<span></span>
</td>
<td class="nump">25,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(999)<span></span>
</td>
<td class="num">(1,304)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, 76,465,862 shares at December 31, 2023 and 73,691,955 shares at December 31, 2022</a></td>
<td class="num">(13,658)<span></span>
</td>
<td class="num">(12,156)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">16,262<span></span>
</td>
<td class="nump">15,311<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">35,625<span></span>
</td>
<td class="nump">33,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company | Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables, net of allowances of $88 in 2023 and $70 in 2022</a></td>
<td class="nump">2,050<span></span>
</td>
<td class="nump">1,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Payable to operating subsidiaries</a></td>
<td class="nump">5,768<span></span>
</td>
<td class="nump">5,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable to operating subsidiaries</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_BookOverdraftLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Book Overdraft Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_BookOverdraftLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_InvestmentInRelatedPartiesAndSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in related parties and subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_InvestmentInRelatedPartiesAndSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656665996544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Balance Sheets Share Data) (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par (in dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par (in dollars per share)</a></td>
<td class="nump">$ 0.1667<span></span>
</td>
<td class="nump">$ 0.1667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">198,690,082<span></span>
</td>
<td class="nump">198,666,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">76,465,862<span></span>
</td>
<td class="nump">73,691,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par (in dollars per share)</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par (in dollars per share)</a></td>
<td class="nump">$ 0.1667<span></span>
</td>
<td class="nump">$ 0.1667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">198,690,082<span></span>
</td>
<td class="nump">198,666,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">76,465,862<span></span>
</td>
<td class="nump">73,691,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656672421968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Income) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 106,374<span></span>
</td>
<td class="nump">$ 92,870<span></span>
</td>
<td class="nump">$ 83,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Operating costs</a></td>
<td class="nump">13,188<span></span>
</td>
<td class="nump">12,671<span></span>
</td>
<td class="nump">10,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">850<span></span>
</td>
<td class="nump">749<span></span>
</td>
<td class="nump">640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest</a></td>
<td class="nump">493<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="num">(532)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit for income taxes</a></td>
<td class="nump">836<span></span>
</td>
<td class="nump">762<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net (losses) earnings</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,484<span></span>
</td>
<td class="nump">2,802<span></span>
</td>
<td class="nump">2,934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_ManagementFeesChargedToOperatingSubsidiaries', window );">Management fees charged to operating subsidiaries</a></td>
<td class="nump">2,075<span></span>
</td>
<td class="nump">1,554<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_InvestmentAndOtherIncomeNet', window );">Investment and other (loss) income, net</a></td>
<td class="nump">42<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="num">(266)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">2,117<span></span>
</td>
<td class="nump">1,466<span></span>
</td>
<td class="nump">1,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Operating costs</a></td>
<td class="nump">2,016<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">656<span></span>
</td>
<td class="nump">581<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest</a></td>
<td class="nump">489<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">313<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">3,161<span></span>
</td>
<td class="nump">2,681<span></span>
</td>
<td class="nump">2,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="num">(184)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(672)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries', window );">Loss before income taxes and equity in net earnings of subsidiaries</a></td>
<td class="num">(860)<span></span>
</td>
<td class="num">(1,215)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit for income taxes</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(266)<span></span>
</td>
<td class="num">(259)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries', window );">(Loss) income before equity in net earnings of subsidiaries</a></td>
<td class="num">(714)<span></span>
</td>
<td class="num">(949)<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_EquityInNetEarningsOfSubsidiaries', window );">Equity in net earnings of subsidiaries</a></td>
<td class="nump">3,203<span></span>
</td>
<td class="nump">3,755<span></span>
</td>
<td class="nump">2,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in net (losses) earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 2,489<span></span>
</td>
<td class="nump">$ 2,806<span></span>
</td>
<td class="nump">$ 2,933<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_EquityInNetEarningsOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity in net earnings of subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_EquityInNetEarningsOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (loss) before equity in net earnings of subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) Before Income Taxes And Equity In Net Earnings Of Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_InvestmentAndOtherIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment and other income, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_InvestmentAndOtherIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_ManagementFeesChargedToOperatingSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Through intercompany service agreements approved, if required, by state regulatory authorities, Humana Inc., our parent company, charges a management fee for reimbursement of certain centralized services provided to its subsidiaries, including information systems, disbursement, investment and cash administration, marketing, legal, finance, and medical and executive management oversight</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_ManagementFeesChargedToOperatingSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656652175088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Comprehensive Income) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Humana</a></td>
<td class="nump">$ 2,489<span></span>
</td>
<td class="nump">$ 2,806<span></span>
</td>
<td class="nump">$ 2,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Change in gross unrealized investment gains (losses)</a></td>
<td class="nump">372<span></span>
</td>
<td class="num">(1,819)<span></span>
</td>
<td class="num">(356)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Effect of income taxes</a></td>
<td class="num">(85)<span></span>
</td>
<td class="nump">418<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Total change in unrealized investment gains (losses), net of tax</a></td>
<td class="nump">287<span></span>
</td>
<td class="num">(1,401)<span></span>
</td>
<td class="num">(275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax', window );">Reclassification adjustment for net realized losses (gains) included in investment income</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Effect of income taxes</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Total reclassification adjustment, net of tax</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">305<span></span>
</td>
<td class="num">(1,346)<span></span>
</td>
<td class="num">(355)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments', window );">Comprehensive income attributable to equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Humana</a></td>
<td class="nump">2,794<span></span>
</td>
<td class="nump">1,460<span></span>
</td>
<td class="nump">2,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Humana</a></td>
<td class="nump">2,489<span></span>
</td>
<td class="nump">2,806<span></span>
</td>
<td class="nump">2,933<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Change in gross unrealized investment gains (losses)</a></td>
<td class="nump">372<span></span>
</td>
<td class="num">(1,819)<span></span>
</td>
<td class="num">(356)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Effect of income taxes</a></td>
<td class="num">(85)<span></span>
</td>
<td class="nump">418<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Total change in unrealized investment gains (losses), net of tax</a></td>
<td class="nump">287<span></span>
</td>
<td class="num">(1,401)<span></span>
</td>
<td class="num">(275)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax', window );">Reclassification adjustment for net realized losses (gains) included in investment income</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Effect of income taxes</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Total reclassification adjustment, net of tax</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">305<span></span>
</td>
<td class="num">(1,346)<span></span>
</td>
<td class="num">(355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments', window );">Comprehensive income attributable to equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Humana</a></td>
<td class="nump">$ 2,794<span></span>
</td>
<td class="nump">$ 1,460<span></span>
</td>
<td class="nump">$ 2,584<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Income (Loss), Net of Tax, Attributable To Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656661697248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Cash Flows) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">$ 3,981<span></span>
</td>
<td class="nump">$ 4,587<span></span>
</td>
<td class="nump">$ 2,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Net Cash Provided by (Used in) Investing Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash and cash equivalents acquired</a></td>
<td class="num">(233)<span></span>
</td>
<td class="num">(337)<span></span>
</td>
<td class="num">(4,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment, net</a></td>
<td class="num">(1,004)<span></span>
</td>
<td class="num">(1,137)<span></span>
</td>
<td class="num">(1,342)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investment securities</a></td>
<td class="num">(7,552)<span></span>
</td>
<td class="num">(6,049)<span></span>
</td>
<td class="num">(7,197)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of investment securities</a></td>
<td class="nump">3,795<span></span>
</td>
<td class="nump">2,434<span></span>
</td>
<td class="nump">3,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investment securities</a></td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">2,597<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(3,492)<span></span>
</td>
<td class="num">(1,006)<span></span>
</td>
<td class="num">(6,556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from issuance of senior notes, net</a></td>
<td class="nump">2,544<span></span>
</td>
<td class="nump">1,982<span></span>
</td>
<td class="nump">2,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment of senior notes</a></td>
<td class="num">(1,832)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfCommercialPaper', window );">Proceeds (repayments) from issuance of commercial paper, net</a></td>
<td class="nump">211<span></span>
</td>
<td class="num">(376)<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInBookOverdrafts', window );">Change in book overdraft</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock repurchases</a></td>
<td class="num">(1,573)<span></span>
</td>
<td class="num">(2,096)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(431)<span></span>
</td>
<td class="num">(392)<span></span>
</td>
<td class="num">(354)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(856)<span></span>
</td>
<td class="num">(1,914)<span></span>
</td>
<td class="nump">3,015<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease) increase in cash and cash equivalents</a></td>
<td class="num">(367)<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
<td class="num">(1,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">5,061<span></span>
</td>
<td class="nump">3,394<span></span>
</td>
<td class="nump">4,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">4,694<span></span>
</td>
<td class="nump">5,061<span></span>
</td>
<td class="nump">3,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">3,042<span></span>
</td>
<td class="nump">4,868<span></span>
</td>
<td class="nump">2,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Net Cash Provided by (Used in) Investing Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash and cash equivalents acquired</a></td>
<td class="num">(233)<span></span>
</td>
<td class="num">(337)<span></span>
</td>
<td class="num">(4,187)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_CapitalContributionsToOperatingSubsidiaries', window );">Capital contributions to operating subsidiaries</a></td>
<td class="num">(792)<span></span>
</td>
<td class="num">(484)<span></span>
</td>
<td class="num">(2,580)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment, net</a></td>
<td class="num">(761)<span></span>
</td>
<td class="num">(931)<span></span>
</td>
<td class="num">(958)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investment securities</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of investment securities</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of investment securities</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,695)<span></span>
</td>
<td class="num">(1,317)<span></span>
</td>
<td class="num">(7,732)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from issuance of senior notes, net</a></td>
<td class="nump">2,537<span></span>
</td>
<td class="nump">1,976<span></span>
</td>
<td class="nump">2,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment of senior notes</a></td>
<td class="num">(1,832)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfCommercialPaper', window );">Proceeds (repayments) from issuance of commercial paper, net</a></td>
<td class="nump">211<span></span>
</td>
<td class="num">(376)<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of term loan</a></td>
<td class="num">(500)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInBookOverdrafts', window );">Change in book overdraft</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock repurchases</a></td>
<td class="num">(1,573)<span></span>
</td>
<td class="num">(2,096)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(431)<span></span>
</td>
<td class="num">(392)<span></span>
</td>
<td class="num">(354)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_ProceedsFromStockOptionsExercisedAndOther', window );">Other, net</a></td>
<td class="num">(125)<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(1,711)<span></span>
</td>
<td class="num">(3,843)<span></span>
</td>
<td class="nump">5,349<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease) increase in cash and cash equivalents</a></td>
<td class="num">(364)<span></span>
</td>
<td class="num">(292)<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">906<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 614<span></span>
</td>
<td class="nump">$ 906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_CapitalContributionsToOperatingSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital contributions to operating subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_CapitalContributionsToOperatingSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_ProceedsFromStockOptionsExercisedAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Stock Options Exercised And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_ProceedsFromStockOptionsExercisedAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInBookOverdrafts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash during the period due to the net increase or decrease in book overdrafts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInBookOverdrafts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfCommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfCommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140656667871808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Notes to Condensed Financial Statements) (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_hum_DividendsToParentWithoutPriorStateRegulatoryApproval', window );">Actual dividends paid to parent company</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance', window );">Aggregate statutory capital and surplus in our state regulated insurance subsidiaries</a></td>
<td class="nump">12.2<span></span>
</td>
<td class="nump">11.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired', window );">Aggregate minimum regulatory requirements of statutory capital and surplus</a></td>
<td class="nump">9.8<span></span>
</td>
<td class="nump">$ 8.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval', window );">Ordinary dividends that may be paid to parent company</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hum_DividendsToParentWithoutPriorStateRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of dividends paid to our parent company without prior approval by state regulatory authorities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hum_DividendsToParentWithoutPriorStateRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hum_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of dividends that can be declared or paid without approval of regulatory agency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of statutory capital and surplus (stockholders' equity) as of the balance sheet date using prescribed or permitted statutory accounting practices (rather than GAAP, if different) of the state or country.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479989/944-505-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479989/944-505-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>125
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M(Z? .Z%9_@*!43^"21)W9P-@%>*8PA+C1F+LE'@C#4FE?JH&VJ;5VL[>:F)
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MU.4K9!;A:&"L24LRXB996PX,A9+TR622''=C"9@E'AU(<K*W,_LY@OTHFGU
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M&.#]J1#Z>6).!M5),/H#4$L#!!0    ( .V&3UCW%XQ0Y04  )H9   8
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M>"TK$K[?T6#G964RU:FK7RSPKSSFOT&*>40.=R=]RCJ-@5IUR1]" @VDY<R
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MV>)OOW:":G6#-(IG4)I+5=NY7#LQ&LM70:BM#Z7Y4%H I84H6E.Y=0. FAL
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M2+?5-Q-\28LBW50O5SQ:\JP,$'^_3]/BQT;Y90?'KP"Y^A]02P,$%     @
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M(7%$V;;#T0"&3!"?**8I=DP HM3M3( &3\8!#Q9-2!Q-OM>&#W564?R!UYN
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M\141J].734\H+U);EBH$W I65'4(RBQ978="Y,KY(-Z_.QF/1F<"(T;8VHE
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MBE!%^OT20P0+J!-XYI"L,)$5SM:A>+B/"#6!PI*];H&4-;-+D@?-EYVC\BQ
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MY/'R>R]C)O@AE7@+Z_6:V21FHA'7J.(88IZ2P=8^-]G(F![W#3M4O1M,?E[
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M3R@8+N9L-T43( 0LP"%&4AI/OP]W$9T(4%S%H2_FCWVZR[3K1JSA>2$-%()
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M:C@G33*:$887(AVE)Z1?B\_*E@5,*"$A'H]HVGA\(6+?%^]U72N3TYO BY-
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MT^T_,)[/RLX./Y45_&4K\9$,^>DFW=D&6>2'".Z$^6D,[;/2](<G/.=0MYB
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MH8G. 'M3E6@K-VKG)GZ]NOP4]A+RE@+$<HH U-*F6D)>*PEOMXH.N&"G'0V
MB@C]:S0?&$G5S;;>8BPR!1,J"?]+V-0@G?D%9!X]BNNN"CH2X<>8+G(]$I5S
MU/:1/X;%^?K^='8QZXH;9J[@V.C(TOV/URJ9+_:T&O\76GF>>^P,R%?!N3];
M O*;8[5#%S!/21=WCXEI;F_/>J4?GSWP49)[30=K9>T/7JXU[;*@/,C6 C"
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M ],\Q)J%TY5__"RTPXKRTS6^786A"WB^U-IM%Z2@>PW/_@502P,$%     @
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M3TJ-^V(^YP)STG.#95"FW&PE?T29_>X/>#HTJA.\8.HQ0H!+JGGE?=V#.]\
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MC -"?GC[^GU _4"M@04-N-2D6BZ)#X+G;#IB5U!'0<>FSJN .+T_/!JP(W@
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MQE9P]$7BTIO,/#11L1UGW#U5<*YRCJ],M"'0/^<^$71CKJUDY_B:Q2-W1E9
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M(3=IZ45X,A/L[&1]JCN&KTMW!OW9@_%A,-S'VAU(W8(>'>S+MJE@+2E^*.(
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MVPV:#D1@/.2UEB(=Q:[7(G8.QA^?'I&?!F.[@G8J0E2F&>73, 0LGN#B?!2
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M/QQXH-H'HIT8V;BFO)>&6KP;EO2FHK(.]+V0TEPF-D#W2L__ 5!+ P04
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M@E&Z$YQ-7&$!;M"F*AX )42A6A!KKP<\PDV;>8S.[W7*C1U%Q6L3=-QG%U3
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MR0[PP).3E2=AL&E\]LB;:4X5\OR"7X?S6P\[WMS<;8;#S^U,=+O<3I:_19E
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M;51]];0^KKMV7*TQ@?PP['*Y$QWC](N=[%X@!5Q?C3C4ML.[(V2P\^PL;3?
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MI@K';O3DH I..<4%IX>1^._YWD&LW'4X54'V*,<1-0[+BO!(0H' 'G6U$A]
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M-(LB-6ZU\S",SQD9]FJ7M@'H>*MXL9(>,R]98,1<CN'DT:_)S?E#+S>JMI^
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MCH5QT_M;)0.3WF(1C/]Y<!LK":JWIH-M3V&#6"W93H41?C=24+'][XNWK4H
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M^AZ=U(W/I[=U.*=$UKQXLW]TJ6DO3C4+BA32$YJO3A:/[56V'+T\>^QN?0Q
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M&_G?M05\=WP!OR];Z)?_@PO$CX;^\-]02P,$%     @ [89/6 L+4 FN$
M,C(  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULI5M=<]LXLOTK**_O
MEEU%V_PFE4U2Y3B>)%7CQ!5[[SS<N@\4"4G<H0@M2=GQ_OH]W0 _)%+RS.3!
M$04"C>Y&]SG=</SV656_URLI&_%C793UNY-5TVS>7%W5Z4JND_I2;62)-PM5
MK9,&7ZOE5;VI9)+QHG5QY=IV>+5.\O+D_5L>NZ_>OU7;ILA+>5^)>KM>)]7+
M!UFHYW<GSDD[\#U?KAH:N'K_=I,LY8-L_KFYK_#MJI.2Y6M9UKDJ1247[TZN
MG3<??)K/$_XWE\_UX%F0)7.E?J<O7[)W)S8I) N9-B0AP<>3O)%%08*@QK^-
MS)-N2UHX?&ZE_\*VPY9Y4LL;5?R69\WJW4E\(C*Y2+9%\UT]?Y;&GH#DI:JH
M^5_QK.>ZLQ.1;NM&K<UB:+#.2_V9_#!^&"R([0,+7+/ 9;WU1JSEQZ1)WK^M
MU+.H:#:DT0.;RJNA7%[2H3PT%=[F6->\?[C]='?[]5%\^?K+M^]WUX]?OGU]
M>]5 ,+V^2HV0#UJ(>T"(XXH[53:K6MR6F<QV!5Q!HTXMMU7K@WM4XD>97@K/
ML81KN]X1>5YGIL?RO$-FRB4BJ1'?Y49535XNQ?]=S^NF0E#\_Y2]6IH_+8T2
MY4V]25+Y[@294,OJ29Z\__O?G-#^QQ%=_4Y7_YCT/WHD1X5,JS@A67S<5N0.
M.%RNY[(BA[N6>);(N*3(EZ7,A-HB\K<U=JAK68N\;)1HGI7(\AJN3!M1:^_6
M;\27LMY629E*D929N,&@K'Y#REV*QY4<O#4K("LMMAF$-G@]V*-9)0V4J*2
M]D^YVM;%2SLYPP//_RZ;)"]XIT^5VF[XZ6$CTSPIFI=.*TLD-605!7W2NOM5
M@GQ.7\0'6<I%WHB[I 0 5990E;C_<&=UFHCG59ZNQ#,6'M'C,SS5K-($VC[
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M/5PP392BJ399 Q/,EG+-5JR!K:ZX])3*<_+/9%BYT1T=VW3FQA4J87[B7?D
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M5D4#<']9PCOZ@@1T[U1^_"]02P,$%     @ [89/6!E.6S1G @  D08  !D
M  !X;"]W;W)K<VAE971S+W-H965T,CDN>&ULK57O3]LP$/U73AF:-FDC/^F
MI9$HV<0^,%4@ML]N<FTL'#NSG1;^^]E.FK4H5-7$E\9GWWMW]YR^I!LA'U6%
MJ.&I9EQ-O4KKYM+W55%A3=2I:)";DZ60-=$FE"M?-1))Z4 U\Z,@F/@UH=S+
M4K<WEUDJ6LTHQ[D$U=8UD<\S9&(S]4)ONW%'5Y6V&WZ6-F2%]Z@?FKDTD3^P
ME+1&KJC@('$Y]:["RSRQ^2[A%\6-VEF#G60AQ*,-?I13+[ -(<-"6P9B'FN\
M1L8LD6GC3\_I#24M<'>]9?_N9C>S+(C":\%^TU)74^_<@Q*7I&7Z3FQNL)_G
MS/(5@BGW"YLN]RSQH&B5%G4/-AW4E'=/\M3KL ,()Z\ HAX0O02\5B'N ?&Q
M@*0'.*G];A2G0TXTR5(I-B!MMF&S"R>F0YOQ*;?7?J^E.:4&I[,Y>8:U@CE*
M]PKQ B&GJF!"M1+A,SS<Y_#AY".< .5P2QDSEZ527YO2EL O^C*SKDST2IDP
M@EO!=:7@&R^QW"?P3<]#X]&V\5ETD#''XA3B\!-$012/-'1]/#P:@>?'P\,#
MT\3#-<2.+_Z?:QB3NZ-+QNFL5URJAA0X]8P9*)1K]++W[\))\'5,JK<DR]^(
M;$_&9) Q.<2>_30^27DA:@2BM:2+5I,%0] ";EHC*QF3LJ,\<Y36)==9E)Q?
MI/YZ5Z*1I/-@LI^4CR1=Q/&0U(WD[_Q9:Y0K9WH*"M%RW;W^P^[@JU?.3E[L
MSXS?=O;XCZ8SZULB5Y0K8+@TE,'I%].2[ RP"[1HG"4LA#8&XY:5^6:@M GF
M?"F$W@:VP/ 5ROX"4$L#!!0    ( .V&3UAD.J)K0P(  (H&   9    >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;)V56V^;,!2 _XK%I#VUX9;+E@%2TFY:
M'CI%:;<].W  J\9FM@GMOZ]M",NFA$IY =N<\_D[1ARBEHMG60(H]%)1)F.G
M5*I>NJY,2ZBPG/ :F'Z2<U%AI:>B<&4M &<VJ:)NX'ESM\*$.4EDU[8BB7BC
M*&&P%4@V587%ZQHH;V/'=XX+.U*4RBRX253C AY!_:RW0L_<@9*1"I@DG"$!
M>>RL_.5Z8>)MP"\"K3P9(U/)GO-G,]EDL>,9(:"0*D/ ^G: .Z#4@+3&GY[I
M#%N:Q-/QD?[-UJYKV6,)=YS^)IDJ8^>3@S+(<4/5CK??H:]G9G@II])>4=O%
MAI\=E#92\:I/U@858=T=O_3G<)*@.><3@CXAL-[=1M;R'BN<1(*W2)AH33,#
M6ZK-UG*$F9?RJ(1^2G2>2C;Z>#,0Z$G@C+ "K83 K !][$I&KM([F#@W[6GK
MCA9<H(7H@3-52O2599#]F^]JLT$O..JM@U'@/:03%/HW*/""<(07#N6&EA=>
MX)TK\P;M7]&&9>1 L@;3<U5WT.EYJ/ENEK+&*<2._C DB ,XR<</_MS[,J(\
M'92G8_1DUU! OK>?W?JGVFB5\5K]?\B=[C@PQU3"B-AL$)N-<GYP=GN%W#CT
M/;GY(#>_ZM2>0.BO"%]P&V>^Y[88W!97']RXWSCWHI][TA\J$(7M@A*EO&&J
M:Q7#ZM!H5UU_^1O>=>D'+ K")**0ZU1OLM"O4W2=KYLH7MMNL^=*]RX[+/7/
M H0)T,]SSM5Q8C88?C_)&U!+ P04    " #MAD]8<?/XZX U  "ZMP  &0
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M0#N';*(E5G=@N5D); +X+\^LXRC7P7T.EQUF!@1 #*;AMU:;P-<8A<$@6YX
MZO8-R3D0O N0OK .D5&*SV&M*/1!BB$,$91]5X.0#_0S7C,Q2T(_97A@P+&*
MT#?;FD5*[O )8)2 V2")2@+UJJE;$+! 1,SK2O@HFMMPTR#Y<M&&< 5"XGQ:
M2+^@^A#\(U$ 3]4;-RD_C=2D=_#!F3S6#L<9K",!)7X1-*YVZS(4H$F1HZZ$
MHA0Q8 [Z@=_I&EXCV7&'O<Z2RM$*@/;!,J*3!B'C&M3WN_2+8HZ' >R/#QOA
MT+@U&O$W3G>/G 7!/(846+O99UR9:]K_^+?GYV?/OE4L136H# =%@B(E2L#Q
M@*.Y+[!K!&0&JRHZGJ)H59#^$U6Q6]#@R.E/T$JV!K'J2&\S;%","%:5<%!2
M,_\R#,$S!6CQPRJK)R !Z]S4N2M)D[]\<_G3+#PFOZ,N,F(S8UIOG $IBHRZ
M7Y%( 0%>[XBFB?]$<P,+6M,J\3D\D[P7G5DV"BHF@ M'5&PG0>+GY;,;+F9'
MFH*!/IPW"BV>"$: 'P8C>P-,#"Q4[2O2_EID-XA+L$/\1?B1_VV&;SE6W$0'
M]8!&@;^$[9-VO2 (.5'6Z*13&6>P&&:FC("P^.5!/%XCR\[H@ &-KQAFI'41
M64Z_!6==@4X5-'@OA(.:.;1:XVT=HB0\-4%4_Q9P[A1U3]!5:".@_<ET]'[\
M\F'N ,II+:OH<($ <Y**K#S05WI6^)7%B#V>'JRW0%QO4+1\=K1_@ \>Z Y7
M"^_1^<1G.S'6PBUKP750I+P!/CC!!3I0"#/\!O$X#(09>I4A;*0!/@]8!<A&
MT9J6/:R#56*'5+1PW0Y5@0GRH%F]+6&UB@\U@@CUQNE3#.LJ6M9AX,10;K3(
MJU*RMAVK:TM0WNLF,C3,N<"BF93B%1"FD@83Z!"7_"U87P#&EEA:7C#MJYPB
MU=_887S6.1AK:,&O7+UJTBU,1B8C'G*P-?UH'K?!C@74@H=Z1,:2-->L+G%P
M,)J)7.*3_M9R<AP"#\6HK-'#_ZM5>+IJC<P.8?DMFITLET$AS\@DFGHYFDF&
M0>4,5CCU>+)@XI5'4K#[T2OY+8*[-'/(EM6N1\=]WH,%ISZ#E-B:=Y_(6HGA
MC^<D.R*LDAP7LK>M<_DT(R8"Z'!R\CV)VT)0D+5/LL)="?P3?A #AG1F.,%Z
M V<+,B[EP=V7=+-%&YYX"ZQY2XZ(&JFZ6P$8U&'ANI-%FGU&T6B6TO: E3B:
M2MS6HD)9IXB;-Z[D9\@/**<&@%HZ-%A0K<)1 )=;5Q6UAPSS+8R%T(;&J-"2
M\TYMUPG>.TF6D3*0#D^DY6.Z$V=0GK!E?ZX0Y6CN(*]B2;OW[BKS-G *+Z24
M4^ ["W+&Z5:18[ WP(R>%RVA IL_(GO0N=X%?"1'HOR:RTB@H $2MHZ7,PVS
MM$*F[KYDSN5_&@,]8I,^\S;ILZ/&Y >0A$4/"/(1!73OILS1/S8"HI1H%&R=
M [O<ZC/B,H%=N)PXW"H8_KA!Y.AUW[+VV ;W#!*4>51X,7(-H??&^P9U"'6)
MD= "?&!D7ZCG";DL4JHLC5?FX+SK/1 -*-?]EL?;N,T"9 $I M;E%B@,N']Q
M4^0].95K5!9;W?D\N8S8$TW5,*!:\33A]CQ<P  N:IC!LC7T!YX8?R!@*1(]
M )"T-GI7O=IYD:ZJ6@T!=L+3^M?%EI1%)8$<&38L]S<,. J-J+<+]E;Q;GC!
MQ,%B51K@#:HW6+9 B/+VWJ6-L,&PV#9Q*? FWA:>8N.6!/>!&/-3RYQS0"?$
M(=3OR;TCOM+VB-5/IIH:TW)<D4TBSO"$(\C>AXCS=^@"7XUX#W#MKB1>.4\\
MHLOY(:N)H+G!36R9<Y-_.$">U#+D1][^&:)IJP+4XBUA]?3,YBS(,6T-,8&V
M8BX=.X8A2B='P-2)8;Y"8P,PI-C-84]])53"_EAVK,_@_:ZI.4 =85<X='&N
M&BS@:47G;-R"R#5  VW:#6":N,9)BZC;H/F&)W\$HQHP[!(W]1&UWDWR4[J+
M!=D60Z)[-LW]9#&Z9^CLS-.&L/;0]$NQP-L-*'W,$]C43AN0Z_R9M0/V 9$O
MFW'A\%*]]KIQW;K.Z[)>$8-LLZ98\,OR(DY%4<#D6DZ*#.(??[P&O8%#-&@R
MP O$+GEI;H7J-)XV,!_/K"YR5&54&^&OBSRP*V)H95MCE/$W56"F@!(YON;)
M&X\K,4 5Z+=S#&$L-P42XR%>87P%H/$#"2-[N T)A;T*9Z\:0&5BG\IY4"#O
M'857 +0P/4%7O_7AH\6>3-9(,B2"&$$D$0+"3X!<>"; _HM.'A(:4L\A>H[4
MY:7Q7G:=I2MA04U@?;-D7;0P$C'W0'@X4 <P0?=[H%>!>N2/!,Q"/PFAW" >
MXK798.7,),+#<,< HB=!"UFT"$8NVXA/B4<!E/JZ\9YVQF(]8)4HC;B9^@K0
MH:)ML'PT^/LA;;KD-<*8.*G2"X4 D[SI5R&H-A&9' [#W$38M0F>\=.7/U^+
M8JFVQVZLT1!2P9-615!O.\YD=%!ZE*QQEJJ+(D<>JFJKQBN1V5"D+^<(ZG"#
MP0M-( !:GHNJ)5QU.Y02\8@=(-+$()XN":XD"E%\J@.!EZP0XD  ;EOUKJ*U
M+(,BE^TZ%0IG;QN..3P!>A .J2ER763+.'0%QY<S-LX8ZEL!3N/"ZMGAN3L1
MN4=JLB1(4':#<<>;$33DI(H^696+!@>KTHT; ]VK)QY:JW1KSLYC"(-Z>&2X
MK(E,"F0Q8$(@#!C1#D%#O7$R4(=B1R+:>#B 2"1815DX,/\LP?"^."OD41D/
MPP&[NB]S$\L!B)+CSHA<D"[(V?, A5C6$<'\ S,?*-. C1P2L@)O#-6U*(XY
MJ"I\&7Y 3-JDGXDYR:%3$''OE8:>E#]A0I(0 .RI9R\H$6!"SNO@5/%T$,@V
MGR<7[6$P2P1=W4L"7MHL60M*MBHJV+G:>F4YC_UI1E6'-8[(,O8=M5&^B8F+
M;(&,-FFV1V6WV+21\/M5.6>2&F%AU&0U495PQ8E A@_KSI&K]:N5Z/:0%CVI
M07^\,P4'$L.C]A82GC?*GKJJ)$_2>W2'' : NFK2S8#Z,&\$"5"(SR[H3I,O
MR6G;6I0[1/8\J;'X64I(I B#FMU)O3S9UAEZESR)S%2WR( OMR#OR9?H*8_.
M<9[\]#60P\6G$C88$DW.00Z?C9+5\5%E]8FR?!58Z:(65_>!K="$YHQ#JA/%
M2'[VSH&:G&8H7@-#M8O^ YS?YH;8+"%X!)B@CQS$XABX ]%3E5%JU3#1): P
M0@L6Y<_0+MTL@H)RW2U\&?%QBTHX1@#2'#.[.F&X&..1<T$5F87$ 6MB@[P9
M56TD4D#NQDJW9?+D]-]O%W((8R4;(&Y85L-:HNAZ0PFH.3EA)EP4XIL7" 1
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M+?'(^0R;UAU\BNV7D'X_S+1G>B!=@.B(#$!,9\KW^#%WF*N+J1,PQ J]D#.
M3L,>HUQ+$5B8BVQO@E9E,OQ1^LF&9$J"@J=I#6%LF:&P=P T:G+@S:Q;)O6Q
M"C)J <C=?BNQ>E*R<'(\_1/6POE/5$ YNJ8:S2&(67]-@CA0DAN+ZLR0F=2+
MLECQ'@$#V*/)IS:(F\0>^J**/0,RC$?#&[!( Y3S:2A)+G@ TEOG3F!E)^IO
M.Q UD H+,3<;]AP*=[)!")\JQ8Y%6?[4U@OV6)3DI-" O01)93&!R0Y8NJ*^
MHP##@*'BJK:'Q(VG/6,\@W$.(K@ T9U[VK_;#KV.08:8!/@T# S$2JXS?+0-
M_M+!&:/7=1) C TM_-UB[$K]A44[0(L@U&C@BMP2(2&0W.:.E.W7@/^$SUI;
M-HO (@LB_G5H21'C0R;-BP!)M;3I#9(Q;<-V@>LR8$!\[%+VJVN6/"RZ;Q"&
M85W>,^"3SPQMH,=9 O,21_"+XY0M8>*3.RF&<U\8[F/C72!9V^,_9MX;*BX?
M<6NP+P:3Q9:N80LAH]2A6K.(D60;1#(J516/"PHZC@ZC3\)[V=MM76ETVTMY
MI=JB0I]7H>)'@WE$2N7R1*PM#E3/58N3AX/7=\" 6Q](HF@/5D]0CF-Z !B8
MDT>$<'']?G:<ET5(*T>$Q"#T<;?@XAPGXB,8!:O_LO JBTR<V)316"!K\*=E
MW8>W3=[$4!X%BT);I4LIH0W+G<I2]7?5!85]:ZABGOQ8[QQ)4JJ:HQ5X74>S
M2C#/>*N)>2/O/1TWNT499V.W$;L..01#;F#@^<#T5R;(3\X(@+NMA-$\1L]:
M1U8;'JL/N8AQ,_9L3B]=8/S7A<S^A\)?'G7_K/ 7(R8RED\?KRXO/KX9AJIP
MV-<8">Y4GWKMEG04]U_7KQ^0BTFTB ,4;A,F_U6F1MAF&.9LQ-1F)@X[F[#B
M9N(5.I AQ-376M)2*CQ*9@.WD5<O>@_? -<1G[(Z%SON6B"D,J5S)6__03G"
M*<U>N_85P3*5:C?+X@LAV!%YQ+5R&<;U;USX"L@.%D?>U*/B;*R@3'-K7J$B
MF\T?H9)P8L,+.#)8RXE@ Y\B.X#U*\68R6!L!&XZ&S!J)Z \9B9&X17)++.H
MC$$&#/3JR!CUSBJ?CP$DP:4"F"VIEO244]%DG2X/X*)W 0N+U>P\7?7 5<:8
MILY(4RG[_X%?\L?!T44.R6>STV>/'O!?9V?LCGPZ>_'XT<1[ YC!"X].Z=\G
MR=/9\Q>W^R"?/(-_SI_@'(^?/#CB)'OAG60OCKJX3 [:E'_LSB_;9#;+<4-&
MH/GYF*%C9!Q@A0B<P0\-U32"7J=U4-ZZX>*@0QJ8%ZQWS>^:-J&..2?/3D.C
MC].CP'M/<N%2I.P%N5HG&WG\J\/$ZS.-2,Z..S\IQ0RT)E /6L[IOT2V-;G&
MKQLJD1]2\P.S1BXKKUN?&( ^#^8\XH@I]U[KZ$F8+_LR&@CPHG([47?@+SC"
MH*)MI:7(/+GNJ7JTM67!]693J/7+/Z&;D]>*V?T^3$?,:8>9[J@+!&GOPU^4
M:\!I"1S?QR5Y'QA):OS&?0&YAN2B/W&VGRB=VT-0&M3*JQ)_PAE<5"M0>/'N
MB4WW+EF54L3$WB$N%<Y[,:;^Z(C!)47*=9J<G9"1R\6?Y!K#2AY,%L]<J:X,
MX(%YNB?3%K5'D65Q/MI1FCL/.'U^%!%_PKC_3Z2X'B&X/S@&]ND _4)*$E";
MWFKB4-!^.SJR>?+#L)H13=:T]-$?D&#H0Z>H^^2HH\).5L^KE4?BL=B32'*0
M?O/D4KR24YH("-(;5]8\'[I+U$ZC,D>.#9Q@)XBV7G8[2JRD,H-MT7$Y*!9#
M ZY(NQ)UFO5=5*Z BARV:#I! $NJ**=H&?[=.B1K=,9BT6*U\M'^1[C6LU/R
MH822T"VKW?3C$_.;3-_X%3.QPOOPX+D=9=$75(B+GM@-ZE_.)^J4CKQORS33
M  RGP<E.71X2S(B,Q'/O:_&HW 7'D/PS"08;>ZTLEJ&**,S.*J2DS4MQU@TV
MV#K:A>(0_G@F=5M?BAGG@H02-?3\HS'O:\>D"P4"V!12%4T&=G3'\A@K!S(M
MO<GBU@6R4YJ-. /ZMA:^Q@^E/>:!$)D,]'M*]!CM7QQN:U>R5Z9O3:Z3-V-#
M! /31WQ!S+A:QOKQ;*8MO=H.UH\+##5VZ#.(=SM(99PH2HQ"/YA5TWKM? @X
MQ3-3Z&<7@]D>(]@05'P=<6':QT@X%O8<4-;/J.52C9V,-BJ2F2LV!R2OHDL<
MEN;D.&L%V6:TH*\ZZ'0!IUQ7-BC%/V=(9EK\BU@PR+K<3=,3 =XS'^8ZK%Z.
M24WL[+2M*T14$MK'9%3H>W9VM%'9RS=<VOXS,\30]&):5GWE6(B,B,*T8WY(
M.?#2&F^FUMZT"N$,-6PBQ%7?& Z2^(ZVG7!?L%\*RHBH;],2L*="+PFVR4+,
MD%#:C'$Z"#,DWU!6ZA6,J&V) ZSYSSY?B>=DE3:^*I83($A>R90B6C#]/MYP
M7.S/!8J:*HG#?79[K;WU58C$4':5F U:.F=RGB6YAW%R46-J*38W(,V5BGCK
M9@70^V<J":&^4'464I-8=E:B_IU(%FD.--;Z% &-!. :FO2$JR*B:#&H'-J?
M:F:\QQ$,9J'_S."4V2_A?(>OR*/7A1K'R"_!9A1[)1!2F"[-;:,4DP:M)W!D
MGQJFX32K[AIWIZ@9C#C%0F)KY*BBW +SI3)KLB($6S4D74MV($[FUT<Q=]<-
M5A=RM +.%VVDA$7:5AAA;GO6:%)A41GF'H$'98(@MG>^X&#"<(B\?-VDEP%6
M:5 ]3K@@L"=?^<9SSI,W/+?O424<V@_,EH>V53A$*NU!W>"/Z02:N#24-L/N
M1,D&5<5)!>&MT*9);P:\ZT7,,V=GCG*8\ >;L5DNP-I7Z--;<I^H^VH;/? .
M,:G O]_B_F'\!P>+\;7V[M RIHKU(\D_B[B?1Y*I^GO*A@2UEM.<-8TSN/&D
M>0.YWB0( <NFI-8!Z%D$BT]?X=#V2TQTE0QP\HWP@T:=U5X-H(Y$VHXF,) :
M>H+;A$5N@" Q2V34V,(F$TC_''<T/^PL-.T\.]YN\P?;J.TJZ+]';,-_9<#$
M_^SE1"MZ:*#KP!O8V7]8U4/6$%1V4ZL[T./5]\"DS2P\M-OHL.8[[<@RZ21B
MAM4_,45@*D40JB%;K_%MAVK-G @_]F!=L*%%_3^6C9<0V)'DJVP(X1?!9%AH
M^Q0G.<YV\L05#)+6F@ 8QW2KC4X+^J/L;($]D3G=>_3D;+A5TS(H]" #FPUU
M'IR,5T+JD(Z!"PRM!>*&'^EPZ85&?/1Y?!C$<$]5X,&'%++_T99I7.<,.P#M
MAUHEBQ5N&H,)"8+6U)=IXU5@B4/[!"9&&1]0C5;4BLP: 8M3KA"NDWL2YY#&
MF$*0$N0@\'(@==@G9LW]8&045G2LJN"BB$?6'IG-,/F"LVZ]U>9CK.T>=**5
MT2@]/&%["VP52@VZ?O61(P#Y[STRMXZC3XB!;:L5,&(_>*$ZH![**-.V0A1=
M8KF!*>'J2@R2+XAF/X+V\"&GA!_5J:?41[=F3*A2USI3]KFL,44%-Z!>"=*#
MR377]MM0!HJ(2Y8.Y84%H%#./$>7N6P>/E?B9,C47=E@C)LDC^H/VEZ5+6MC
M:\<-F@)L8B87R,B?,Q<*W/H8Q^&LZ>&!RN4JM(9(Y["Y"GVU3&]JTB\L5T)+
MP%9<L&-)L87)P?P<7#'IP I"Q:SUM>PA29WS#%W\<ZA56H& PPXLI" W-ADC
M\1V\U-UAN^THL.WJK*=(HR]F?.R#*?T62+)$3D9?ETL!6JXX=_8A7[GB"^]B
M"%3(3:C'E'2$K0:F]_B )]*CH[S2 0+X0M7,NW< 8G][/'_,R7*B(/WM;'[N
MOS"D-TNDS0TLLIRBNI $B.-R6AI&#QDF%$+,BUQ\'UH+./;YS*V2(-*:4#=T
MC57G)\<^L"+0-=)#D(#S#KL )?<OW[][8"K?J=U6QOGX*OXI603K([3R-0Z6
M_!WF;-BL^Y%Z'<+&_G[Q8\C_\P:/)#^SNC%L[ABJ:0ZVI8 91EE]-,OPVW/.
M"#2%DU:@!8M_:C>X<A+9"+-WF"/_2&5'"FB/J[JT2WSKA>;UJ',YZ:%46G)U
M-4NNX-?D^2RY-_D*[N,:>"J74R%^XCT ]Q@L(,CP[H+D[/3D[Y/:F->_M"XV
M5OW89A0U[S;_K6RW:"98W=4!+Y\8H;<,+4RT)3=G6-ULLM7:H.5CO)<[[&)0
M:QYY28714 ]<D&AW(E2ET/,)"@WNE'@7SJ=/HY*R(GKD#*HNE)B"_ Q6W\!C
MZZ4.)9--\+F[+/VN/.73&&>\THR.E ;#+6G;AT9S/Y'^^P@&W/:=]NRBW#)E
M[B';.Q8')H7B]6TGR0R[\,WE3%PTJ@&1S)F']!2R^W6Q;:?9T%<SH;NL]X##
MQ0>EEL[T?C\>V!(%B;3$6S%^H#V&'*Z1&YQ=@T>-X="2^^QX(^U7FNOXP11W
M^2_?B$/_8^B#/FD?_\ESA!]]1,'[:#D73Y)C9N(8Y%QM_V4H,:=@15R9-"._
M11:T-RW5P"RT1CK;^K(VVWG+1OE].P%3T" !\HEL5NPZH[TTC%<S]'X/^K)M
M$K"N6W)[FL(PQA/5T@8-N]H@@4K3C9^71^R3"G9,[F8LHI%BL-7X"*2F3$0;
MA=@D&<K% X56TM(XXSYH:6&!(;5MMZY%#&*R>%MHN]N0X1WM,0#0E%5I%'NR
M:X4\K@V,#S=6F0WP0ZJB\)&HL#?NW!7R[4*UW,*W\9_HP1P75]Z>'C=/WA\Y
M4_55YO3]+.$^"[-#N*"%3U*'-FZ/Z/-=J/_&D/H\8*7%$YXZ"4QF<^.[*TS%
M2D2PF .&F03&T"#3 N,U*0?I3%L@DY 0@C \'CHJ*VI!3DX<3=W%GR1IT$P5
M@.)[7_JVJJ%:-O2#XGN"^(P'5#GG5CT8)NMM#/$H);-$DW((3JL,'51L,2ES
M%)5BBC&5YEMK 0N'@#ZC+Q#-<*2S04LR-HYY&_,);GK,VZJE6W$FK?(02=AE
M9IQ64>=)FZOLW^;!)OJP:"S0-J4B\^/JU;N/'+#A+;#'@2^UH0JX.I&^_YH0
MJ^%UTG<\<E)GS"V6<(95BA%CO)HPU!(]S)E1R;$UEA]&N\10+<'H2\[9D<4%
MO4 ;NTQ/1+CLW9K:?!_]4K:^:RFP4%MZA8$=9J(+4T&P<%P/@VV,88?H7^U;
M^19%D7KL9XFRK+O/S,G'UN?/Q1BV.HD5E=2VI<!E8:-S:>0V;CJ,:=VC1L0T
M6='U6O54&<5:^_M(4O+(XP=L8^5[FY,O%^E]5[36O^!="P0%'8M!0>$-C=3(
M&Z13-]2!>L9V0K4W*Y2&(L1T-,QG[E7A[AJY[W8=M42WW!=6H*5S[0"%)]&,
M;Z9BWL@9@#J6/[=I/HTM^;2=1.04"BJZ8=R&$?,>;:.>U\-J?^$>P2_MZ=R>
MF1X%Y6)@0XP]MK*09K%=B(U%%P+8+;)K0!EAI,IL.-4Z(T3=U7*#RDQ<]F!2
M(6(RW]>)>M3PS#XIS5'6J^*#TAJLJ(3)<8Y4KN;AI_UNI38;J!44]LKW_,-#
M)C(.LR&TD2$BZ^9(!_EJ#K5&L U7C\A KGS+AL]Z^2L] 277%H1(E43=HD/T
MW]_\X^LS#T%8;/+#QVT03*Z,(%\B+#@M]VU\;<;6J>[&?U(MLPS*'DC%?6=:
MT)E##&CJ)1NNF75*Q0G-54!\'8$L$N:J@U,=BZ8'"Q#";YB%@!ICWP$_Y?P.
MZFP]"U5&JC"3 <V31==7J/K!AQG])/#@GD#<A6[P>ZZ-:+0$W1_TS%?H;XHO
MK.]@+4N>(H>B/*;2=YP^2"A%RUEU2X\)?#O1<G3N=R!)V&F6:AJ2I;XIPO)-
M+&5N3 Z788K6!BAC,<5[=D3\D:I0\C5V[$J9HS.0Y!"FR2R/HOG$9N5.LKKL
M-]-+CHA=4RYN7_)@E;,@!QN]#B&Z2 YKF='I8&#)].5YF):WBU46DKY"R&:"
MP1@<LF$#4@$DB(9_!KM;5>]LGY4L4GWUW)!9S;"VJ@72S0B9VWV+_M6,CR.4
M+)HJ9; OFU[L"RG:WCF^T<07M.L%:7QK'FKF[2!%+.3N 0'5J+21:C; >TR5
MCAP-QLQO!GJ[UK%SHX,E8)H:E 8X%FR4FJQ"AIKO@0U1]RU=U1;U]^9JVWJ'
M+E1>SX$AL[2*<E5)4PER=>(2"5L+8WK(:@'6C-WEFI+.'$P:#O#1/.2F?/26
M:QJ&F>D)KJBG='%LZ9BN66VQK7S6>0=1\':.V1+07-J1!JRM&_8">HTM48OD
M7)FX;]+P:>TFL%0=HZ)^^99T40Z0-K*G!*,TV*^TN1U55112(NWY!'%;35+E
M)RFLO$M#,2U&@SCVQ\(''<Q-76F5,W=X8\%CB^ 1#WW0L)O<%CG\C3P.O>+8
MT2)<BEJ(+%-J5':_I7S@!PG>F<O::F1[SD;:N.9C4++'?51R'W@?-@^@688
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M=^&9M&-X:T>20T"F-\^^/:Z)M@:%.!KM%>FH%#CN<G&;[GR$\YR'/H+GQQL
M7G=@H)Z\(JR\A'4 .:>'TO/_E*'B=89^@N?'FP"^4:K_@/T*Z\T&2.8:6U],
M+O0KQ^*D7&KV1=<>9('9;,E=18]*QPWISD)WCPOQ[AQ6;KC\1$._X0J.OD)T
M:0J^^=P,1!>=47X>S(.$7E*GL\,3VWYH?\DBDFW9ZRWU6#&)D7T)WBVCYZ3'
M'K6QSL!TT_L^..BN\_ $)*2EN#(4NW0-.43W,H)4NQQ#F-"L[_QXHSTJ%?L'
M9FI.8LA=7];F"]1SSZB/O@0J[6R]*;>RZT Y:20GFK0X\\2Z@%-ILO4^./=
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M>L<85%M* A:L5XC$- *L/':B"DI/^[8YTH6&?\XP,ZD;=CG2ND.["=.[Q;3
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M9:G!^6%)7Q34;@.M;Y6RNXE+L/]&37\!4$L#!!0    ( .V&3UAY?JGA)@,
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M2*XR4OF'UY3-.NZPJ2+Q$2K3)0)W0)>'Y0)->X&U-6V8M_N%',2&P[VV:T&
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M\N&4759*F^*?T/^[5DW3_OU-%)J-BQH;I2RQYYO) 95?3VY.V"T(K-GJ!VM
MF34$[/N5NI.ZMN$\EP-)U?D#4_.R6 GBE(:]87R:^ E^??P;1_[$OHKC!-M
MFQ6FO)V+_#L<[2U/,,W"&#/&(8\F>(HX9[?BQUOY0U8;PZIM7>3%1I3].6F2
MT0S.)RR-T@'MI^R+;(H%0BB@(8PCFA;'$Q9Z'KM2525U3E_\:9CX[.>?4N[S
M7]C8YQ#QIT$8L<NFD>: V_XT]0/&X79(H@FF7RF]45H8"2:</X) ,O5\G_$4
MBY)!/)Z&T'RK#"P_%<7BI=/ XQ@$(2TCW. I3$"'EUJ?P=^@POQ[YZ_35!Q$
MWYO=S*?)Y__MY/M3+PNZY$<3]RK(AI,?9PD+L8J)3\GG@?=B\A-DL<M4D$Q8
MPO\"!))D/SFQ0/ ? R&*PAX0* YD(,N&@.!9-":9!4(P!(08ZGT6L'%*.8VF
M"8^/XR"R.^,-RQP,$@]+Y(=3#@<?P2!Y"0"8$_ML@&RCCFRC5Y.M8YFO-7!1
M6O+Y@&?8(WQ8[ODFRJV5W'/Q(9X=MNBL;/=6RKV5)5FY(RMX7JVT!!8A,7_H
MKT2.=RO5XK:4]<JLR2>#9HJ9-7BVJ!?%7;'8'LC!6MQ)-I>RAA 3+$<M+^JM
MVCYSB&U44]C&ZC\B\@\2JN!4S= Y5*YSV(^4Q@C:7;+M$O>8_MGP_TS]V :9
M RJGG1\&E@:"S-6  /NZ+0D#;)"!R^U\#L!F( 4_L*3 D[8ZO$0-Z"F@ !L+
M\8TY!G$:N#+Q6G[8[?S=;Y $KF!T@SY9I)T<.,(+]H6#^^WX*&MPYRED8Z*_
M@(9A&KIZ<IQ PCA&0*"M:4*A11DG&N%AUI:68V0"HN4V(\0[R!:8V7(+E1?/
MFSB6H$J]KSC_\X(1^=R"@JP'F34=65<R+]O5D &T^*@6M,R>+< VTT&<$'@R
M?U=17@(,K3U6,/8CFHP!&HMQD+X>+SZ'!A\S>8)!#/>#+'65I0<4'A(V;([]
M"&#V0V[S[7EMB3D&DYA@$EAAZB#&H8573'$GZ1!.(,014Y;2!DIIF 0>026,
MO+;Z'(-*. U]N_X\L=E(IUG,'2ZPJRU4@FF0^ONJ-%!9XJZRQ*^N+%]VU/H[
MSM$@,E=8)GA?6H(WZDBG_[[.RRT.6NR/PJQ!?STI?%*5/%1_AOVZ7=/:&E&4
MY%E'^BOG6=EZIO>>'2["M >*G7?WSKN>9&&]8_<H'+W:L03C8W^Q!RETPR0=
M(9_S^+2M)&U-\4\=N]O]2L]/ZH"K#<Y]51]M&2PWV*QS8,%-:BOOT5G8B4 '
ML(W].$Z?F9+N4-G'*!B P=>GZI]+[ONQA)2#,B?LDS18]URMZGY?,!#3. HG
M%M:>91SL1V\(N4F'W.3U/1&"=7B=D"?/SM&'\#>LG?#GEM =&&V0/;@]7ZN_
M@)H.-$^0]P*&:.6?;8 N$0<3N,"@7EF_-E(7:K$[)_@\L,D(0F"'^I_3?T=]
MH\K% 1NV.D031[U?G_60+VHU")FM)72CC2.]DDK>\G$8.VQ2,*F+!>PZ *RT
M U;Z:F!=H06DZQ?J4C\*L_,07^RE38\#+^_ 571A98%P(\J#I#=H^?#E!B$Q
M[[E1/7+C:1D1C]QHX,;!5I@ZX)70BY(Z7[>R!=TLEJ+.)7,WL;O[D]PV#F Z
M35_4?8W6'&@]8=<_J(=&%GLN5>*!+8KE$K:66E7'/)_+7&P;-/E*(SM2NXFV
M[Z<D:[K&I&V6"R !@6 Y-N)Q'T-L3I_H5VW-$U%+0QM9BY+LG?3N:@[=S^"\
MU!8'5;L=;#MK:A_L+P[3)".6!G%U(F:MU7:U9DL<(]IMCY80G4PT]=%B[6?T
M!'9S# XW[@W:IB"FZQHT*/LI^^]H7=!E4BNPZXU<9W>D<TEPLH_HXB-(7[[I
M:*\H#FV:6>\Z%^W4REY:-\CGMC;N9K=[V]V+7[KKX+VXNU3_*/2*:*642TSU
M3A(</;6[J'8/1FWLY?!<&:,J.UQ+L9":!/!]J939/9"![G\++OX%4$L#!!0
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M*[4"@^M9L AO;@=\WU_X2^+6GLR!+8FU?N'%,IT%/2:$.2:.$00-KWB'><Y
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MC=1/,_IS0<,7Z'RM*:SW"U;0_ O-_P-02P,$%     @ [89/6,R^2K#? @
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M9&5R4>*= ET5!5?/4\SE[KSC=_8+]V*],7:A/S[;\C7.T?RQO5/TU6^U9*+
M4@M9@L+5>6?BCZ:1/>\._"EPIP_F8#U92OG-?EQEYQW/ L(<4V,U<!H><89Y
M;A41C.^-SDYKT@H>SO?:/SG?R9<EUSB3^8/(S.:\$W<@PQ6O<G,O=U^P\6=@
M]:4RU^X?=O798=B!M-)&%HTP(2A$68_\J8G#@4#LO2+ &@'F<->&',H+;OCX
M3,D=*'N:M-F)<]5)$SA1VJ3,C:)=07)F_/GV]N+AZOH:)C<7<+OX<GD/5S>+
MR<WGJ^GU)4SF\\O%'-XO^#)'_>&L;\BD%>RGC?IIK9Z]HMYG\%669J/ALLPP
M^UE!G["V@-D>\)2=U'B!:0\"OPO,8\$)?4$;@,#I"UX+@)393N0Y\#*#J]+P
M<BW(69AHC4;#A=!I+G6E$/Z:++511*._C\6AMA(>MV)+:Z2W/,7S#M6.1O6(
MG?&[-W[D?3SA0]CZ$)[2/IY3J685@98KF&W( ]0@2IAQI9Y%N89)(:O2V-W6
MV^DSW.-6*F,S"W-<4Z$9?<RQDZ:/.W: P6P0TCT.WN)8[W%06P%9*:KO%HQN
MP+@]*_^,7&E 2R"@]&.Q1-52P.6-)@QV2$GB5BRG5J-'E$W*&R]3A!GI0_5
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MH, 5:P0]J<UWW-73=WRY$L9_8=/&IDD >6-(53NP55!QV?[9V^X<#@##Z -
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MU"[ [J^4HKWC$G0#.?L'4$L#!!0    ( .V&3UA/*]?S6@0  %T*   9
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M%@HROD55%Q.> [)J+JN)%@?;T&V$QO;0#O?8CW-I!'!]*_"0UA/CH.WPU_\
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MNCX<B88RH*J(G7X%ET;FMV]L0A;]Q!</8![6> (72*$5N2%#;9W@9V!)1L_
M3VT[92T8R+4%T)#",?U=2<.KUF-H&I;&$+ $6.;#%;^G;7*2HH*5RU4C_B6_
MHR![M7NP^,?,7T-#Q9C";0B.^$6.998YWC$,:"KN-!6_6%,'N]/NPG3+5:%A
M:LNE, ]]^AI$[]?7'LYI06X4[<^3J QHYCG)G, EZ1$UW+CBB\4;.-+M"&G%
ME'*C24TDEL^RN:/Y"..[:4G=3W$#R%A(NQT%QQYU?E>\L?91F$+L9QZ)\KH%
M.XIL4,.,S!*@0V*)P@TG-!I%S O\_SES"&D<V9FSS/.3H5 G7:B3%X>ZVZ7I
M'2HZ<>$]%PJN>;5!F&HZEEO]]T5\>!);/)86Z\YAV4C28@6=F;18V;@X%M2Q
M)%9V-V&C1;-RX[.*4S8034GG#:QIA^R76A9HCT)3.J/MGCG?,>??Z%*H"Y&[
MJ1;VCO%=W;AYZGQ E6+0$G+T*,%"WTMM!!@+O3"FQG'@$88MMBYT;8V 2BP1
MCEP](P%X_JZTA5[2M=)=JW.]DQ7E>663(&1D^ N$B<?L*_0R>ET(??MFJ1!I
M10:M7$!95H\Y1EY,MLQY^%Y$SW>46 5E"#P(K H:3-VG[CF@HK134?IB%3W*
MY"_M=IS;JM^GFT'8%U:*W9;_\&3Y897X2M_5]UG07S*^[-1%%UEM:,BJLK=6
M!+[52Y@QC^K#OE8DH2L5=";,[U'E0KMC(""MI,SSX\-B$5*M.*9X!B^=DK0=
M!;9(L-AC6>>%[43VWM;OQ9CU"I/$2XY[2\OXX!I9(YWS]K*LZ8S:-*:]47:C
MW7U\VEY#OYFWE_E/=$V@"P)4N"17DB$=&:J](+<=(]?N4KJ0AJZXKEG2;PI4
MUH"^+Z4T^XZ=H/N5,OD/4$L#!!0    ( .V&3UB+6 ^8@0,  +4'   9
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M$Q +*9)J76&%4L<D#"*_0\#($]KQVT@"+8:.$VA1W$)^"("2".VV"2CJH3\
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ML#_.?Z;5GQ_9]&I&OF)EZV4L9/6,'L?@2PBZ0 !*XRB:J:@V_L%^5_8'T)(
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MYIT&*LRGML:WUX[0EF)4-*] J]FWX5Y-\[%2UBFNW*UK=[?X:U#=<@4A"Z@
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M-/9U.]SBEQ1(LP'7UT+HEXEI[O6W6?034$L#!!0    ( .V&3UCV>U4U#P8
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M#9$L9LQBH<4V'].60INA+W],S%R.TAJ8W]="Z->%/:"<]*/_ 5!+ P04
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M#<3]%2'\L) /R/_1&/X/4$L#!!0    ( .V&3UCYP=O*N@4  'TA   9
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MEVP5Y+>"_(%+5J$'-)/"HH1C.1F$$A2X?!S('4Z3<M;*-_%6GZXE9*A\O02
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M4?#] PI>KN =J]#(%1HE!?>0@I\K^-HS&17MAP!+W.MPMD)<20.:>M#.U-I
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M*P'X?<*8?'M1&Q2W9[U_ 5!+ P04    " #MAD]8K@@P=YT"  "U!P  &0
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MPZVZ5X'K!>I]SIC\F.A6W][4Z1]02P,$%     @ [89/6',^"< ,!   ;@\
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M:%A<;O7I'80QT._7G*O7&W,^K/\?,/L'4$L#!!0    ( .V&3UA(%'R[Y0(
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M@1 G;"[,E5Q^PUQ/R_(%4NCT%Y9Y;,V!8*Z-C'(P91#Q./MGCWD=2H!Z<P/
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MK/-)4.>#T@J4)E":I&AZS,KY)(CS2>;/S+$7=(X.=3XH35(T/3KE?!+:^?3
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MG,E4Z7G7D[J)9(WI ULF55<QPU*U<>#Z@-HO&)/'B6XMPX<A_0=02P,$%
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M6RVT_Z8,NH\<2A,HFMG*6H!&[EFDO_.NC)OJW>I0#]K2DD,C%MES 76<4)I
MT<Q<:,<9N1WGT6#SLUQOU*@RKR2Y6^1JO/EA,U/QZ'J)SHV;[IT/Z-Q0*(U!
M:1Q*$RB:F2%M0:,4.\*$NDXHC4)I#$KC4)I T<S0:-<9N>>8;D,SWX?F/2GW
MIYXI>5#UDGQ9;#IZ):CWA-)H2SOLE:+HW-XM0:4FE"90-#,=6FI&;JGI2(<K
M%U"Q":71EG8XC(TZ)I% *^90FD#1S#>3:0,Z?N/Y?Y<;"\ZBUSG+7-Z7F[Q\
M(;M;;JDM+>ZJ?-,"I5$HC4%I'$H3*)H9*"U;QP%T[#*&*E4HC4)I#$KC4)I
MT<S0:*4Z?N-5 ]YVS WTC@U4JK:T8X<61,<2#5HMA])$CX,P&UNKT''?^:Q.
M/^:F>+<P=/[J^'3^:I="@U;,H331ZS#,5CYXYZG;@AX/+)+#F3R1_6&HCF$%
M5)1":11*8U :A]($BF;&2>O6,7:^Z1CJ6:$T"J4Q*(U#:0)%,T.C7>SX#1?K
M/ZR ZE<HC;:TXQXY.GEB"EHMA])$CX,P&UM+T[%[ZFC?8074E4)IM*4=]L=)
MQW0?:,4<2A.]#L-L96TYQUYO2HV:*<$]GGHYMT8!:CVA- JE,2B-0VD"13,#
MI<7H&/N^U#%4B4)I%$IC4!J'T@2*9K[Y7UO3&/W65#?0-S90&H72&)3&H301
MV]\/&Z7V;BG6UC.&O#353?%. 51V0FD,2N-0FHA/7P_[AO:(M<F,O5Z:&IT%
M8=P]/M&30:P#%'==WG&!2DXHC4%I'$H3*)J9**U+8^Q;4&.H-X72*)3&H#0.
MI0D4S0R-MJ_Q&_;5?X "M:Q0&H72&)3&H331TH+@:("B>I&.GNE@N:J^$U;=
M0Q3LNE78A:NP*U=AEZ["KET5GPQ13A_\,H.@K6C\QV:H[J6)=8*J&^Z=#Z@A
MA=(8E,:A-(&BF1'2KC7&3E"-H=(52J-0&H/2.)0F4#0S-%K=QM]N@JH;[1T@
MJ*J-+1-4D\!J[:$5<RA-H&AF.K2'C;_%!%4WU#L74!L;6R:HQID]%U#5"J4)
M%,U<1U.KUL1O@FIP%I/[UWDDH[/D=1Y)JU*BSO6I;]P5^68%2J-0&H/2.)0F
M4#0S3EK4)MCIJ0G4V$)I%$IC4!J'T@2*9H9&2]T$/3W5#?2.C7TNYB@Y?GJ[
M[X8,NG\<2A,HFMG8VK<FD.FI;HIW"UM>B-KU4AB/;1ET+SF4)E TLYVU(DW<
MBO2S7.<OVSZ@>""+8C7[0?WK7I*IZB"L[0WUHU :;6E]7F7(H#5S*$V@:&8B
MM"%-_!:&.IJRG+T.-?\QJ0N]+I1U 0=W3=YI@5I4*(U!:1Q*$RB:F2<M6A/L
MNE )5*U":11*8U :A]($BF:&1JO5!+TNE!OH'1O[<D]1=C+6[+DA@^X?A]($
MBF8VME:B"61=*#?%NX5/%WOJF&5,^V_*H/O(H32!HIFMK-5FXK<NU-'[![,T
M-AZ%VBX+93=84-L)I5$HC4%I'$H3*)J1IE0+T12[+%0*U9Y0&H72&)3&H32!
MHIFAT=HS12\+Y09ZQP8J/EO:\2R9.#M9DQ):+X?2!(IF1D)+S12R>)2;XIT#
MZ!S4]'1]J:['L*$5<RA-H&AF$+3P3+_)^E)NJG<PH/-,TU-%:G]C%+1:#J4)
M%,V,A?:CJ=N/GLQD/^]8,LH:#J@MA=(HE,:@- ZE"13-3)#VJ2GVF?T4*DVA
M- JE,2B-0VD"13-#HZ5IBGYFWPWTC@U4FZ9]G]F'5LNA-(&BF8G01C2%/-CO
MIGC' #K'-#U](K[KCBVT8@ZE"13-#(*VI6E?6^HW4(7:4RB-IJ>"-4KLN8#Z
M52A-H&AF+K1?3=U^]<<B7U7D+G_)[Q=2#56I7.0OJ@^A9?Y,?FYNZC=;6*,!
M%:I0&H72&)3&H32!HAGQR;10S;!"-8,*52B-0FD,2N-0FD#1S-!HH9I!'OAW
M4[RS<OK@>M<D,6C%#$KC4)I T79!&%:/4M8TK_/KRZ4L9_)6+A85F30/(#2G
MD(-O22D?5%""BP_A8'CR_4UP<1M8OJ?!!=]^/]3XZ\MU/I.?\G(V5QW90CZH
MJD9GS858.9\][C_4Q5I=2@S(?5'7Q7+[XZ/,I[)L-E"_?RB*^O5#4\%S47[=
M'L[U_P%02P,$%     @ [89/6!1NL*UA"0  *FT  !D   !X;"]W;W)K<VAE
M971S+W-H965T.#4N>&ULM9UM;]M&%H7_RD"[6*1 &HFOMK.V@=@S05LT:.!L
M6BP6^X&6QC91OJCDR*X7^^,[I"B-QB:O-,JA/R26K'F&O(>ZPW-Y)9X_E=7O
M]8.4BOV99T5],7E0:OE^.JWG#S)/ZG?E4A;Z+W=EE2=*/ZSNI_6RDLFB'91G
M4W\VBZ=YDA:3R_/VN<_5Y7FY4EE:R,\5JU=YGE3/5S(KGRXFWF3SQ$UZ_Z":
M)Z:7Y\OD7GZ1ZNOR<Z4?3;>419K+HD[+@E7R[F+RP7LOXI-F0/N*7U/Y5._\
MSII=N2W+WYL'/RXN)K-FBV0FYZI!)/J_1WDMLZPAZ>WXHX-.MG,V W=_W] _
MMCNO=^8VJ>5UF?V6+M3#Q>1TPA;R+EEEZJ9\^D%V.Q0UO'F9U>V_[*E[[6S"
MYJM:E7DW6&]!GA;K_Y,_NT#L#-"<_@%^-\ _=$#0#0@.'1!V \*7 ^*! 5$W
MH-WUZ7K?V\#Q1"67YU7YQ*KFU9K6_-)&OQVMXY46S8'R157ZKZD>IRZYN/H7
M^Y[=R,<R>TR+>W9=R46JV(?[2DI]0*B:O>%2)6E6?Z=?]_4+9V_^_MWY5.FY
M&\)TWLUSM9[''YC'8Y_*0CW43!0+N>@9+_:,]PG 5._T=L_]S9Y?^23QIU7Q
MC@6SM\R?^4'/!ET?/MSO&<X/'^[UA8,>SN5<#_?Z-MX*1K ]#(*6%P[P?BZ3
MHF:?D^?D-I-]ZI+#FVSVOEXF<WDQT>FJEM6CG%S^XV]>//MG7V21,(Z$"1#,
MTB#<:A"V]&!( _V8E7>;=^#'9)YFJ7IF_VG_\*.2>?W?/FE"I#1(&$?"! AF
M21-MI8G(M\>'N5HEF5Z ;A53)9LGRU0E6?J_I%WLEK*:ZTRIU]4^>4BRJSQ(
M&$?"Q!KFS5I:<WKR>#E[%WJGY]/'GL#'V\#'9.!?K4N;=T5?I$F4:Z21,(Z$
M"1#,TN-DJ\?)*#GJ!"D-$L:1, &"6=*<;J4Y)=\J?%]R>MN<-Z;Y*N\3B&2[
M"H2$<21,K&%G5I**^U/4V3;N9V3<OQ;S,L]3I>2"I<6\:L^:]6*1Z5,J=D>D
M*Q+K&G(DC"-A8@V+=D)^$LW6/_V!]V;&N\S(T']:'\_LMJSTV&:5T >_CKA.
M2%J);+5HGEH=JP\]N:M 4!J'TD1'BW<T"O>)M&,P/=I:=$O&O%TRWK)RI6J5
M%*TV6^'J7@%(L+, 2!J'TD1'VWV3#,7=-W'WCSMU8O\G[#[3QE2VII1]3!\E
M^[=,JEYMR,F=M4'2.)0F4#1;1F/,O6"4,RX/ZMBA- ZE"13-%LBX=H]TGNOS
MKK2H5;5JWT!*5CE[DQ;L6;]UZOY2&=2R0VE\S]Y&Z]WJU>&(D7;,C1WW:#\^
MO/#WAAMJP:$TWM%V,[^_67G-$M %&#2S'71CQ;TCO?BA"\HO!;&>0,T[E,:A
M-(&BV2H: ^^-X^ ]J(6'TCB4)E T6R!CX[T#?+SC>@)U[U :A]+$GM@%<<@6
MR3.YR!A?[]'&_D8V%UHMFT(O,U!##Z5Q*$UXKSV]]WK1LJ_*&5/OTZ;^&Y>9
M@/8M].2N(D%I'$H3*)HMH[']OC?*.N-#33^4QJ$T@:+9 IGZ@$_7!XY89_80
MA[W!-3W260>HP3]FK^R8&S/OTY?9W7Q+!SO$&US3$SL'&&K0430[Z,:@^[3Q
MW*:>.RG9F^YZ2/_Q#?7E4!J'TD1'>W&Y5A]69P/+M['F/FW-7<^::)QSS*'F
M'$H3?H_5#T]]\JS)F'-_5'.^<]:D!WS2 @Y<)Z0WPUDNJ$^'T@2*9@MJ?+H_
MCD_WH3X=2N-0FD#1;(&,3_=IK^FPK$#M.93&H331T5XO*P-M0+XQX_X^,X[,
M;\-]$/1F.&L%-?%0FD#1['Y38_.#V2CY+8 :>"B-0VD"1;,%,@8^H*_;'Y[?
M:)"S)%#+#J6)CO8JO_G]Z2TP9CP8]6*]G=Z^_/+QIE<GZ#5[*(U#:0)%L]7<
M::8?YYI]@.VRQ[;98_OLQR@)!*8D$- E@:ND3FNV+-/F\RWK3UBQLF"/294V
M'X!@5:+VY3QHJ0!*XU":Z&B>9^<\;Q9$ UG/U J"?;4"<-:CO2N]-<Z:04L-
M4)I T6Q=33$BB,?)?]#B I3&H32!HMD"F>)"0'IC1/Z#EAF@- ZEB8[VZISO
M;.BDSU00 KJ",$KZ&[:V]-8X2P8M0T!I D6S=36UBN!LG/0'K3U :1Q*$RB:
M_3E+4WL(Z1:#;T]_] 3.'[J$5B&@--'17J8_+^C/?J&I+X1T?>&;LQ_53DC/
M[:P/M"0!I0D4S5;1%"Y"?Y1<%T)K$5 :A]($BF8+9&H1(=UR<$2;QQYB?Y-=
M)P2TY@"EB:-VRX[ZSD?YZ0*#6Z-'!]O33]=%&%HJ@-($BF8'W9030KJ<<'C%
MF@8Y9Q]H)0!*$V'OY_+U874RL'X;DQ^.W'&P6;_IH@V]%<Y206L"4)I T6P]
M34T@'*?A((16 J T#J4)%,T6R)0+0E3# 0URE@3J]*$T$0XU'$1G]L] MC.>
M/ARY_V WVPW7:.BM<%8.6@* T@2*9G^?CRD!1..T'T10XP^E<2A-H&BV0*8\
M$*':#VB0LR10KP^EB6B@_< ;N!(7&1L?C=Q_L)/>AMH/Z$UPU@EJ^:$T@:+9
M8AK+'XW3?A!!VP^@- ZE"13-%LA4!Z*QVP_H"9RE@M84H#01#;4?1$-);^=+
M_49N/WB1]&@C2V^,LV38;P+$?A7@&-T'D2E,1.-T'T302@.4QJ$T@:+9 IE*
M0S1V]P$]@;-4T)H#E":BH>Z#<"#[F7)"-'+W04_V&S:V],8X*P8M24!I D6S
M936%BFB<YH,(6GF TCB4)E T^PMM3>4A'KOY@)[ 52HHC4-I(AYJ/A@X]XM-
M>2$>M?O )[L/Z+F=!8)6)* T@:+9*IJR13Q.]T$,+45 :1Q*$RB:+9 I1<3P
M[@.:Z*S-T;T,'+HA D6SA3 EAQC9D$##G#4XO+V!0V<6*)H==%-@B.D"P\]2
MZ0/>)*C>4$/+ E :A]($BF:+L7,G@7'* C'VM@+8^PI@;RPP1ED@-F6!F"X+
M; 1R_Z)H&NPL$;0< *6)CF:ETM/>;Q"9[MP3*I?5?7LSKIK-RU6AUC=)VCZ[
MO>'7A_8V5R^>O_+>\_5MNPQF?1>Q3TEUK]=VELD[C9R].]&;5:UOS+5^H,IE
M>^>IVU*I,F]_?=!V1U;-"_3?[\I2;1XT$VQOCW;Y%U!+ P04    " #MAD]8
M@Q!2["H$  !Y%P  &0   'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6RUF%MO
MVS84Q[\*H0U#"JS1Q??,%A!;*EJ@P8RD71^&/=#2L2U$%#V2LM-O/U)2Y)O,
MR!WK!^MVSH_D_TB'/!SO*'OF:P"!7DB:\8FU%F)S9]L\6@/!_)9N()-/EI01
M+.0E6]E\PP#'A1-);<]Q^C;!26;YX^+>G/ECFHLTR6#.$,\)P>S[%%*ZFUBN
M]7KC,5FMA;IA^^,-7L$3B*^;.9-7=DV)$P(93VB&&"PGUKU[%[H]Y5!8_)7
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M[<I\6%:J91U!5[IXF5(A2R'=7,KR%I@*D,_GE(K'CIJ@*)B#?U!+ P04
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M#A,EU:4GFQA ]SADZ!E'>Z@+_Z;+9:U+L7E'8@6@IG'NY(R.%[: 1A%F'.V
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M:H!\OJ94G"[4!/E>TN1_4$L#!!0    ( .V&3UB(;J8/D0,  ,\*   9
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MK:-K193M4SE0O+ -Q0M7NCVQCVO=<:(P ?K]DG-U&)@%ZAYV^!]02P,$%
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M.<G498*@^&Z3!N+^DA#^.I /J([FAO\"4$L#!!0    ( .V&3UB8SB,ZO (
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M?'HFJEFH9J.:@VHNJGFHYJ-:@&HAJD6H%J-:@FHIJF6HEJ-:@6I2QPK=/U!
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MP2OAXW*S6<X?/OQ2E;?5:O> [9]_6BXW3[_93?#'<O7[P\M___\!4$L#!!0
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M\N,%4LE(( O"X GBK;XO6#5GF=K5P03@7G9.O$#BPIEALS-+.S/1SCGFT,H
M[V&V<&&VL'6SA:V:+5MJ9?[";.%7UJ9^LC-;7:O*U,J=V6V[I8]WHF\7C@J;
M'=6$A$0D:[5[P!_HK"4&<Y[*\.]AL'!AL'#;^D"PNA!F2ZW,7U@P_,JBV4\.
M!*N+:)G:BX'PLN<[!YM%$;!5LH>F7I>VL4CWC?*S^3[=(-F=<HK+TTV^B<]6
M).8HA*4,=2_;<B2R=-\L/1!TDVP]/5(A:)1\78._ *8ND+\O*17[ Y4@W[WL
M_P]02P,$%     @ [89/6.-KF1S% P  / \  !D   !X;"]W;W)K<VAE971S
M+W-H965T.3<N>&ULM5=M;^(X$/XK5FYUZDJ[34B 0@\B%9+N(2ULU>[+A]-]
M,,D 5A.;LQWHKN['G^V$;*!IMDBY+V [,\]XGAF//:,]XX]B R#14YI0,;8V
M4FZO;5M$&TBQN&1;H.K+BO$42S7E:UML.>#8**6)[3I.WTXQH98_,FMWW!^Q
M3":$PAU'(DM3S+]/(&'[L=6Q#@OW9+V1>L'V1UN\A@>07[9W7,WL$B4F*5!!
M&$4<5F/KIG,=#K6\$?A*8"\J8Z0]63+VJ">S>&PY>D.00"0U E9_.YA"DF@@
MM8U_"DRK-*D5J^,#^JWQ7?FRQ *F+/E&8KD96P,+Q;#"62+OV?Y/*/SI:;R(
M)<+\HGTAZU@HRH1D::&L=I 2FO_CIX*'BH+KOJ#@%@KNB8+WD@6O4/!>:Z%;
M*'1?J] K%(SK=NZ[(2[ $OLCSO:(:VF%I@>&?:.M^")4Y\F#Y.HK47K2?P@_
MS,/%9S1;W'ZZG]]\GGU:H/=H@3G'.H+H(@")22+>HC>(4#0G2:+B*T:V5,8U
MA!T5AB:Y(?<%0QTT9U1N! II#'&-_O07^FX#@*V\+EUW#ZY/W$;$ *)+Y'7>
M(==Q721@K=)?UFWL]3 >^O(0H(LW;QO@@G-V5<#5P(2OA^G4PQR1YI7YXAE<
M[Z5\R?U"][!E7!*Z1C.:5RM][/_ZJ,313$(J_JY+D1R[6X^M2^*UV.((QI:J
M>0+X#BS_]]\Z?>>/NK"T"1:T"1:V!'84H&X9H&X3NK_(TB5PQ%:JBNL0X64"
MAVP4Z-^&Q)SDP'T#K.^7G>^.[%V5\E]*!(V;.Y?'EL".>.R5//8:>9R#X3%B
M[\4&<T X99EF$-,8K=D..#7G0&1+06("M16QT<*YZ9Z#]:K<.U>.<\+_<ZG.
M\)E46",UZ%2DCACKEXSU&QD+0+D1D;P2:)H49:I$_,@7H@0+058$U+I 2Z"P
M(A+!DWKP"*@CK]'8N>3UGSOL#4ZHJY%Q3]([K)%Q!O6T796T7372]N%G,D7J
M@N/JZ23T* (],=QQ(A[5T;WCD)(LS7-0NTPB$.J8[X!FH+[?0@P<)]7T+!'K
M&&[<U[D,MPD6M D6M@1V%-Q!&=S!_WA=#MH,4)M@09M@84M@1P$:E@$:-IZ^
MZ?.#=K$%KM?J7EV31K1S0Y*##2O5Q+D<=$_*4JW0:5VJ%?)."I-=:1-2X&O3
MG^E:HRZV_-E<KI8MX(WI?$[6IZHUS#NYGS!Y7SG'?$VH0 FL%*1S>:5*)<][
MM7PBV=8T(TLF56MCAAO5W@+7 NK[BC%YF&@#9</L_P=02P,$%     @ [89/
M6*P%.EN9&0  TPD! !D   !X;"]W;W)K<VAE971S+W-H965T.3@N>&ULM5UM
M<]PVDOXK4[JMJZ1J%1'@>\Y652)D$U>=$U><W?VP=1]HB;:F,B_:&<I.KN['
M'V>D$9J-1@.0FE]V8_N9AT0333X F_V\^K+=_;Z_[?MA\<=ZM=F_/KL=AKMO
M+R[VU[?]NMM_L[WK-^._?-SNUMTP_G'WZ6)_M^N[F^./UJL+G675Q;I;;LXN
M7QW_[MWN\M7V?E@M-_V[W6)_OUYWNS^_[U?;+Z_/U-GI+WY=?KH=#G]Q<?GJ
MKOO4O^^'O]^]VXU_NGABN5FN^\U^N=TL=OW'UV??J6^-+O3A%T?(/Y;]ESWX
M[\5A+!^VV]\/?WAS\_HL.YQ2O^JOAP-'-_[?Y_ZJ7ZT.5..)_/N1]>SIH(<?
MPO\^L?_M./IQ-!^Z?7^U7?US>3/<OCYKSA8W_<?N?C7\NOWR4_\XHO+ =[U=
M[8__N_CR@*WKL\7U_7[8KA]_/)[!>KEY^/_NC\=(@!^HRO,#_?@#C7]0>'Z0
M/_X@C_U!\?B#XAB9AZ$<XV"ZH;M\M=M^6>P.Z)'M\!_'8!Y_/0Y_N3E<^/?#
M;OS7Y?B[X?+]#S^^_>'GWQ9O?O[;+[^^_>ZW-[_\O#A?O.\_C1=W6/S:[\?X
M[1=?F7[HEJO]U^.__?V]67SUEZ\7?UDL-XNWR]5JO'S[5Q?#>#('RHOKQP-_
M_W!@[3FPTHNWV\UPNU_\L+GI;Z8$%^,HGH:B3T/Y7K.,IK_^9I&KORYTIG/B
MA*[B?ZZ)GYOXGRMF-/G3A<F/?+GOPCQ=@KOM;EAN/BW>;![R_) N__KO$;YX
M,_3K_?]0L7_@+FCNP\WDV_U==]V_/AOO%OM^][D_N_S/_U!5]E]4W"3)C!#9
M)*;%4TP+COWRW:Y?+^_7Y&Q]^&5Y_.7A;OGY4F5*U^-,^ QCX<*:NE8(95Q4
MW3;:HB9G7SZ=?<F>_?LQ&LOK?C_>;S_WF_N>&L4#0P4.7&1YCL9 @.JZ0D-P
M07E6EO0(JJ<15.P(?ML.W>IT^N15J)RCJJS*ZP*-P(6UNJDS- 07U>195=!C
MJ)_&4+-C>+/YW.^'8VHN-]?;-7D9:FH8+1J$"\H;/)$(HJ:F!] \#:!A!_!]
MO^D_+@<R_(T;L29O<?1=5%U6+8Z^BZI:U;;TR;=/)]^R)__+7;_KCG?#Z^V>
M'D/KABQ738/&0*!T52LT!@(UWA04/0:5V6=NQH["]./-[7KY<"OO-C>+;GVX
MQ__O\2_(1VGFAKS&\XD"90AD"%#95IX! 1&A(A)[^W1Q^C]&8;JG4_R1:AI4
MG5<*#\?%-6WF)#D!J]M6^8:D[9!T(,\/R;WX:K7=C[+GXVZ[/HW/)W<T<>]5
M^-Y+H/(F<P9%H%31>,9D)85BGZZ7/XX+@<4XY?;=JE]L/RY^'.]BR\_=XJ?M
M_FY\LI"CRITSR?"07,BYSFL\)(YH.A[[.%?\\_S-9NA'E3"<YALY@,*]+*US
M50A0AF\&!"C7OGEF'^J*?ZK_,MSVN], _KK8] ,Y"O=QK'"(KPA0U>!!N)CS
M,O<H$V4?[(I_LD^SY4,_*M7^\?FX&+H_1M%RN,WU_[Y?#G\>U@WC,!=]M]N,
M-XO]PZ_Z_=?DP-V'>)XWSO4C4*4[=HJK].@!906!XA7!#Y-1/8R%'(K[,#^O
MG)$0H */P\54'F6FK"I0O"PXK3>F5X6^)NZC/<^U<UL@4&7EC(5 %<JC$I25
M"8K7"3\_7HG%5P^3\.M%-PR[Y8?[H?LPWON&[6*S'?]A,^RVXP)V?&(M'V\E
M])5S=<!YB8=+8)S!$GJ"'JFV6D+S6L)SW9SQ_G2_[C8=-3KM2H+Q<N+Q42@W
MQ2A4H3P/+FWUA>;UQ;O=]N;^FKXX_$]3U[JB;$:*;1HVJV&TGG$/0;,"*3FP
MDFQ&BFT:6"ND-"^DN(T$[0H=<B>!P%%;"02,V4O05CMI7CN==A/((; _3;[R
MDFQ&BFT:-BO7=#EG2K%:,#FPDFQ&BFT:6*L@-:\@8W:WM"O@B.TM"N7N;Q$H
M_P:7MF)0!\3@'Z..V(R+X5^972Z>(WD:2+(9*;9I_*P,U<V<^<5JW.3 2K(9
M*;9I8*TBUKPB#N^]:FJWJQR3 N>7BVMU@7?8# %K]/B$HS,LMX(WYP7OPT#>
M]C?+ZVY<9/[?@A.'/%?RBQ!)-B/%-HVCU=2YFO,%DZCJ%F4S4FS3P%K5G?,[
MAYPXS-V-O:9N6IQB!*PN58GWU A8-8I#S[Y:#EX]\O+VS>9F^7EY<P_S[+N;
MS]UFZ#X%,T[VU:/LN\<Y7C[F5G+GQ9P9)RK*1=F,%-LTL%:4Y_P>*IMQ[H9G
MW33.WBD!J\JRQ7O !*QL*M\>8F[5;\ZKWQ]WV_N[9R0;RYH\)R39C!3;-*)6
MB.?UG,DFJM!%V8P4VS2P5J'G_$8QFVS$2]_&>?%-H&K=.@\WZ@6R;X&66QV<
M\SKX*<?V0[>Y.>]6VW$BO#/O0IG&LB9/"$DV(\4VK:FQ@KS(9LRT0E2AB[(9
M*;9I8*U"+T*[WDRYDOO:6ZL&9QJ%TC@?#87*:\^;B<+JX(+7P5?;];K?72]'
M%?GQ?K7Z\WRYV=_O^IM IO&LR1-"=-M9BFT:4:O+BSEK @M192[*9J38IH$%
M=8$O* PD7ON7&NM' E7D.!\-A6I+SWJML/JW"%0&WAVJB5;#GXL/C\5=H1P3
MW8<693-2;--86B5>5'/FF*@@%V4S4FS3P%I!7O [XVR.4063F9-C%*K NI%$
ME9[W9865O04O>Y]TX_O[N[M5?YPC@203W8P693-2;--@6A%>M',FF:@6%V4S
M4FS3"G&KQ4M^<YQ+LI*H#\WQSB,%*M ;-D,R>?1B:>5NR<O=]T,W].>'CWAN
M%L?2G&Y,K&/=V/98(\=G&T^>.BE$V8P4VS2P5HB7<Y:!E*)Z7)3-2+%- VOU
M>/G\,I"2*.]0&2Y#)U!5[GZ+X:)*E7F*Y$JK>DM>]?YTJ,[<;U?WQYKF,;^X
MFA">*WD:B&X_2[%-XPB^RYFS)J04U>*B;$:*;1I8J\7+E]>$E,0G0WF!BZT(
ME,YQY8BAN%3E*?$NK?(M0\IW>?BH=O'XOIK-,M%]9U$V(\4VC:(5X.6<E2&E
MJ!@793-2;-/ 6C%>\COB45E&%'.X2>:"W IA E2 KV2FWQ5:W5OQNA?L-7[W
M_I= DO%<J7-!E,U(L4WC:#5X-6=12"6JP479C!3;-+!6@U?\9GA,DE5N.8?S
M'=45 <J=[\=(D.<Y5EFY6_%R]^URM1P.#[+]:3!P<<9FG.C6LRB;D6*;!M6*
M\&K.HI!*5)6+LADIMFE@K2JO7OZY?$44ASB?9!&@LG0RC@ 5GEK'"GPOSPO@
M=[?=.!.N_XQ>I?%\R?-!=/]9BFT:2ZO"JSD+0BI182[*9J38IH&UPKP*?3D8
MD6A$9X$"OZTF0"K#'Z(9 E5IGX"T(KB*;2SP.$\.F?;F\,*ZV]!?1O.$R3-"
M=!=:BFW:(<.J\7K.BI!:5)Z+LADIMFE@K3RO8_HL<$7\-=E=H2EQ#P\"US1-
M@>L=*5C6YIXWUK65PW6HNT),%Q57Q98E;A-!@+3&&SL42/D:P5@]7/-ZF.ND
M4A/;OZW"0OV*@-5EF^,/APE8U5:Y9P>XMN*SYG> (]JIU&[)@LH*9R.;@+4:
M7RQ#H)J\\,TF*_5J7NHE]U.IB6K?%F]G4"#WRA"ZSWM=K.ZK>=V7TD^E)C8M
MLTR[4\W%-66C<(D* :N;TO<)=PW:)H7Z)B7V4ZG=]_BZ<N]C1!>E3#MME BN
M0GEJ FJK?&I>^3RCGPK/F/QP<[407IA('7 :(JNK:EY7Q;1HJ=TM06?R!B&&
MA4P[95DAT_#;BG'-61KW=3@^_S#$L)#I^5N]T/!Z8;:V+ U1,NHF)X$BDI/B
M\B9G8R5&PTN,V+8LC:L-SBL\$!>C\,8V@?%=/ZLP&EYA)#1E:5R)H*L"/Z8)
M5)X5SE0DN/Q7Q*J-AE<;LDU9&E=+N->-P.#U)('Q73<K2)K0WM-+F[(TKJZ@
M$HSJTE@X(R2X_)?3BI2&%RG\DCE0KL-SISX'1=F,%-LTKE8I-7-N5#6B&U6B
M;$:*;1I8T/CR^5\N-=3>$]&UA<!175L(&-.UI;%RJGG)-E5@<YCG3IX:HCM6
M4FS3KJ)6Z+5S[EBUHCM6HFQ&BFT:6*M VT!19\3F<$OM63GK5P+5.*]A2)!G
M<[BU4K+EI60PZZ*ZOO '29XEHH644FS3 %N=V\[Y85,K^G99E,U(L4T#:R5W
MRTON\(9Q2^WO:??!1^":IJSP@X^"957M^6RWM8JZ#;1)#:5@4EL8_F#),T:T
MYE**;1IHJ^K;.;]_:D5EO2B;D6*;!M;*^O;YWS^U[OXDU1:&@%%M80@8TQ:F
MM?JYY?5S, =?TC>&/W;RS!$MT)1BF\8=]+R?\VNI5E3UB[(9*3;4AQ\VXG_^
M]U*GWX9:QU XJG<,A6.:QXS+3S ,7F4',_.9_64"QTV=/+)T1HP.Q5V#N,_Y
M9=6)72RZHDL",3H47>!6D#W_\ZK3;P.M9B@8T6N&9/,VFU$9<"C(8M^P>S+S
MF?UH L=-GSNBI9]B="CNP%4AF_.;K!.[6'1%5PAB="BZP.TA"]2ELIE)?&OE
MMJ8A86YO&A+F;4ZC,N#:D/%Z/)B9S^Q?$SAN^MP1W8(7HT-Q!SX3V9S?<9W8
MQ:(KNE 0HT/1!;X7&?^"@,],MT2":&5#P8A>-B3,V\Q&07>L@#U6^"5':K^;
MP!&39XTHG1&C0Q&']EUS?O:E>'>P].C*KA*DZ%!TP2HA8"7&YB1A]46TOJ%A
M3N\;&N9K?J.@<UC .BQ>QT;WQPD<,GW:B&[<B]&AD(.EPZ.AV%Q)*;M $*4S
M8G0HNF"!$/!=XY.2^"[,:95#HIQ>.3273[]"Q[6 Y5KX*?FB?CJ!PZ?/']&]
M?#$Z%'ZP?%!S5NDHWE,N/;JRBP0I.A1=L$@(N-'QV4G4X+BM=2@8T5N'@OF;
MZRAH01?PH LF:%+_G<#1TF>,Z$:^&!UR:P6+!CUG!8_B7?:2HRM*9\3H4'3!
M B%@P!=3QG/BX.K@(S"&QZ A !7.>\+%E*M&M^D)'"M]NLCNW,_BCJ> /9[2
M<];S*-Y]+SVZL@L#*3H47; PB+3NXY.1*VL_!2:(,3P&#0&H;]Y-+FGS-=S0
M)W"T] DCNUT_B[.> M9Z2L]9TZ-XY[[TZ,JN!*3H4'3!2B!@^1>7CL07B&XE
M 8%RF_O0**_A/1#=O 5=Q![/LQL !0Z=/H=DM^UG\>93P)Q/Z3E+?!3O_9<>
M7=FU@13=-+K ,5 %+ .C,C0GJGU<>W8"Y38#(E&^;D *6/8IWKHN0L.F-@P*
M'#%YZL@Z^8G1H8B#54,^:X4/;Q68'EW9=8(4'8HN6"<$C ;C$M.MS7&4;!AC
M> P: A#CO+<=G9)7_>'+U7_VJQ4](MFM>5DO/S$Z%%*P.,AGK=WAS0+3HRN[
M&)"B0]$%BX& U6#XDY 3P_1S]\(Q B9Q=8Y?7AH2-])Y>HHH8/*G>+.[N#Y"
M)Q+^#D*4X#OC<#&^XEW@IZ<"AGI<&R%%N."YIQ[N L)CT*D#V1HPTXOH'W2B
MF%S\JL;5T5<DKFSP6S=#XG1;^283\+%3O)];>ANA$^&TU,VY/@1*-4YU.(7R
MOKD')G(JX"*7TDM($59PJLXRYV)1N"I3SLL5"I<K[9MZP%Q.!=SEDOL)G0C1
M70BW5"!AVBWF)V!M[IV$0!+Q5F?/Z2D4H$Q^XA6N4#IW-BN,V%%1J(#T"KBV
MQ?064I1]FW/)(_9!60P: I Z >>VN 9#)Q;V*1#&&!Z#!@$4!>\<-E^7H=.!
M4<JZ=R,"5FKG\4W F)0%(B3@;!;;:4@1UF3G^.N]*Q+E-$VB4)7O>P7@<J8"
M-F<)'8=.5-.;>^'>4 E8F;F/"JH#1^;Y=E\!KS'%>VX)MQTZ'6URGLZ0@QC#
M8Z:#!?Y?*F  ]O+.0XIP]QHOJW/3I& E7B,8$I9E/ET#W,)4P"XLL/ .E3?)
M^H7)TADQ.A1=(*]F]0Q3LJ9ALG1&C Y%%XB\%QB'*<+MRWG8AS&&QZ!3!Z(K
M8!H63CMVNUG61DR6SHC1H>@"/3BKE9B2]1*3I3-B="BZ0*@*^(DIP@0LS[!5
MV!4):[6C:BCC,>U__ '1&3 5"^=A5%.BP&'2IXQL(>HLGF,*F(ZI65W'E*SM
MF"R=$:-#T072/& ]%K$73?B%D>E(P*AT=&%,.@+_,14P( NG8U*#HL#ADB>.
MK$F9&!T*-Q#_L_J4*5FC,EDZ(T:'H@O$?_6"#]8JKL_Q*2!!C.$QZ-2!L@YX
ME(7S\"5-B@)'3Y\XLI6ILUB9*>!EIF8U,U.R;F:R=$:,#D47+ X"CF9\6D9L
M$8<QAL>@4P?*.V!D%D[+YW8HDG4\DZ4S8G0H\&"9,*OKF9*U/9.E,V)T*+I@
M=1"P/N,S,N+5?1AC> PZ=2"]GV-X-LG(YW8FDC5&DZ4S8G33P -O-#6K.9J2
M=4>3I3-B="BZ8&$0<$AC,Y)P,W,R,HPQ/ :=.E#= 4^T<$8^MR,1?^#T.2.[
M&R]%AP(/U@SUK%^K\2YQZ=&571-(T:'H@C5!P&..S\A@Y<55!,;P&'3J0' '
M?.4BWG4D=R+B#YD^6V2WZ*7H4,C!0J&>]5,UWE<O/;JRJP$I.A1=L!H(F/#Q
MN1A1)1O&&!Z#3AU([8#77H)>C>] ).O&)TMGQ.A0S,$:H9[UJS3>&C ]NK(+
M 2FZ:72!MZ *F NRR1CA*1B!,3P&G3I0V0%?P8@'X\N:#_''3YXZHG1&C [%
M'RP5FEFK<WCGQ/3HRJX'I.A0=,%Z(."ZR"=F1'5.&&-X##IU(+8#%HOAQ$QK
M.L0?+GVFR.[(2]&A<(,%0C-KN0[O(ID>7=FU@!0=BBY8"P0,)J/*=1JB]CLO
ML'L1!=,Y+B,P))NJ?+T5@*>CXKT-HZI5X]L/R9H\RM(9,3H4;+!6:&8MVN%M
M)-.C*[LJD*)#T06K@H '95Q:NH4V#9&5+JJLG.\V"%2A?!\& ,]'Q7L?IFVX
M1G0ADK6!E*4S8G0HW&#1T,Y:L\,;3:9'5W9)($6'H@N6! &/RJBL;"-J=\(8
MPV/0$(#NYLT08[9XGM^ 2-8D4I;.B-&AV(.%0SMKY0YO0YD>7=EU@A0=BBY8
M)P3<*^.2,Z*")XPQ/ 8- 8AQWAXQ1L F]QZ2=8N4I3-B="CD8,W0SEJ[P_M1
MID=7=I$@18>B"Q8) 3?+N)PD6DT7CI41@5*9=CZ%)&"5]NI8(,AYF\3+'U;+
M]7+ST/G@8M2LNW&Z=(-G0+)[\K)VD&)TDU!JX >ILSF+<S3O-ID:75DZ(T:'
MHJM =&-:D7"?>YP8)A^_JZ)I<.\A&ICK&J\>:>"H8#V=>S2P?]2\!6)<]Z$3
MR621JW"W>@JE2OS1.(4Z]YE):&"UJ -6BUP/(DV8(Y[7^ /^*Q*F<3L 0\**
MPJ-0-+!:U-%6B]YF1"<*-+TRA;_@IX&Z4/BF3@.5:CS='C7P,-2\CU]Z/Z(3
M(3IK_+$4#7,Z,I"PUM-C0@/W0!UP#TSI2*0)_[_##:' TI@&ZKIRKQ@%5+7V
M? 6F@:>@#G@*)C<E.A%.L\&]V5&-0Q3>O29AWJ_;-/#LT[QOW7.:$@4HTY^%
MX4IIL4.B.+4@3KP2B^E(I$G?/'<Z$RC<^<90J%Q[7E=H8,&G0Q9\47V)3BS3
MER^XH0V%<C9Y*=!YF?OF+O"VT[R_VWS=B4X'GIQR5>--;A+6-KBA#P7S213@
M/:<#WG.QO8DTX1SGS,DPQO 8- R@3P+V<PEMB4Y4P<M"P*C+XL*\EP5H%=[?
M3+@GT>EH_,4+E]'R&#18H&,"5FLO[TFD"1,U\II2BH6XIB[,>TV!K D8LGF6
MX;!#-STVT5TP63HC1H?""C35K$9K6M9H39;.B-&AZ )E%S!:BUB2$P9IN;->
MHES4G 4% 2I\BU=@M*8#1FL1B1>H-PP<(7V6B&Z+B=%-(PS,U?2LYFI:UEQ-
MELZ(T:'H H4:,%>+R,$(:[4(C.$Q: ! 9 :LU>(2D'L5%#A"^A01+4D5HT,1
M!OIW5D,U+6NH)DMGQ.A0=($:#QBJQ22@JXS=AR !<A^"!,C[$ 2.:CK@J.;/
M0=Z,(L";/C=$BU#%Z%!<@:J?U3M-RWJGR=(9,3H472#N ]YI,9GG;FJJ,G?7
M?A0NSVMGDY3"J<;7:5\#_S0=\$^+2<&0$)7U29.E,V)T*,1 ZL_JDZ9E?=)D
MZ8P8W32ZP"=-!WS2(K*1<#9368%?5%Y1N+8IG/UK"I9Y7\T"IS0=<$J+S$56
MD\I:H\G2&3$Z%&*@^F>U1M.RUFBR=$:,#D47*/Z -5I,+A);TZUV4]&%Y?#-
MRFG$+DPWVF./H(%#F@XXI!U?BNT?)PO,2WI0HI6DLG1&C X%$\C\6;W1M*PW
MFBR=$:-#T05B_\7>:)KP,CM799$Y118D,"]TZR0>68_0M)[*0 WLT730'LV3
M>B$9RO.FSQ/977,I.A17H/3S.3\PT[PA7'IT946^%!V*+A#Y 5>YF"QTZQ[.
M:1U* $DA2N'\2A2XRNF JQR7@ZS\Y'F39XDHG1&C0W$%"K^8\W,RS;OFI4=7
M5MQ+T:'H G$?L->+R,%'AA*F3-&6SL8,A<O+QJD HG"ZJ5J4@A?[V[X?3#=T
MEZ_6_>Y3?S4NY?:+Z^W]9OS=881/?SN>_\=#_?RWW^FS"^?OOU??&G7X^PM+
M<_GJKOO4O^UVGY9C@J[ZCR-E]LVA*]9N^>GVZ0_#]N[UV7B)/FR'8;L^_N=M
MW]WTNP-@_/>/V^UP^L/A %^VN]^/IWWY_U!+ P04    " #MAD]8L"&D02D$
M  #D%0  &0   'AL+W=O<FMS:&5E=',O<VAE970Y.2YX;6RUF&UOJS84Q[^*
MQ>ZF>Z6I8/+8+HG4A$ZK=%M%J;J]F/;"@4-B7<"9[22WTC[\;* $"/6:R7V3
M@#GGYW/^V/C8DR/CW\060*+O:9*)J;.5<G?CNB+<0DK$%=M!II[$C*=$JEN^
M<<6. XERIS1Q?<\;NBFAF3.;Y&U+/INPO4QH!DN.Q#Y-"7^90\*.4P<[KPTK
MNME*W>#.)CNR@2>0S[LE5W=N18EH"IF@+$,<XJESBV\"/-(.N<7O%(ZB=HUT
M*FO&ONF;^VCJ>#HB2""4&D'4WP$6D"2:I.+XNX0Z59_:L7[]2O\U3UXELR8"
M%BSY@T9R.W7&#HH@)OM$KMCQ-R@3&FA>R!*1_Z)C:>LY*-P+R=+26460TJSX
M)]]+(6H./?\-![]T\%L._EL.O=*A]UZ'?NG0SY4I4LEU"(@DLPEG1\2UM:+I
MBUS,W%NE3S/]WI\D5T^I\I.SU=W]X]/SZO9Q<8<^!R )3<07] G1##W0)%&O
M1DQ<J3K2YFY80N<%U'\#BGWTP#*Y%>@NBR!J EP5816F_QKFW#<2 PBO4 __
MC'S/[Z'GIP!]_O1%C3N:B3T'WA'BXOU _Q78@0G>C\'=F$:^O>JU]')N[PWN
M71RKB2$0B]&J2))D(: _ORH[="\A%7]UO98"VN^&ZD_(C=B1$*:.^D8(X =P
M9C_]@(?>+UT"VH0%EF -,?N5F'T3?597D$/(#L#).H'.@5V0!CE)?S,/,SSJ
M3=Q#79@.FS%NV@3&B/YGOH,JWX$QWR6'E.Y3@4(XFWU%EH7_L)Y!*\=SBT$K
MP\&9"L/*HA'VL I[: Q[#AG$5!K"'IYUV7XUYQ9^*VR312/L417VR!CVXSY=
M ]<SM?H<J118NN-4T&R#F-RJQ_R-,:@6K21O_,?X-9N/SM['N)6Z,<I+IZLE
M6$/0<27HV"CH@H@M(EF$!(1[3B55*JGE2'*U&@JTA21"ZQ<U2+A:K+*:Z%VR
M%3WANF[>5;^EG#&<2Y6S!&LH=UTI=_T?$Y])R LI])7&:J&HAMQ"C4>2O71)
M9$1>NF;8A 668 TIL7<JC+R/6()+JB4]K=("6[2FHK52$UM;ATM48XD:7+<F
MKKF_B]6Q1&NJXY_4\8WJW"9)L59TZV%TOGA8V:0%MFA-X4ZE,OZ06AE;+9:M
MT@);M*:BIWH9VRN8<4<U/&C/4TO5<"G.1]36^%1<8W-UC3WO1U7?G10B&PZ0
M0B:[]3'2+AYF-FF!+5I3R5.]CX<?,G&-VXB+%;5)"VS1FHJ>MB+8O!=9 @_5
M0"0;T*)V#M).10OJM6$_:.[X8IFL[B_<VO%7"GR3'R/J/=@^D\414]5:'57>
MY@=TK?:Y/L+,C]5.F.+\\X'PC1(3)1 KI'<U4C.'%T>*Q8UDN_R0;<VD9&E^
MN042 =<&ZGG,5&E>WN@.JH/=V;]02P,$%     @ [89/6#\8\UO7"   XC
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MZ<./#FA >\T"W.5#R(Q$-NF':#XDT2!B(1F4%8?RU@Y:LR)QJ\P]Q$)B2L>
M6 A8V<5"JEF,NEGLL%A(358*NUL&LK$D"*J)B[J)JTT*!Z0C:O*2*H^-UU^
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ME],S<4 4 XEQ#(XN,$=!R(Y%V$] !4S>8T.5"V8YL^KE?.<9G[Z'[P)[I\"
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MIM;\%@JXF -1[@3%;[6BUAB@Z_K^4=&JZ6Y\(L#_1_3R>3ZJ*A\4K5J5\DL
M-LKJGPI?'KU)^1I-JM2E6L..<MU^@<LCMU"_-I95_E*[84?Q;K?*P5U!WH%N
M,JG2EFH-F^7Z3T0P#WU0!0_;5>%+ 8==%+Q#GUBME;"5:16_E''81<=;MLFN
M-.]3PSVF#7((2QF'S3K>31#AKC#O4<0ZRWI)5#=VE'([?X/H4R!6^! OA*MV
MVA=-1[,=<C;@)$DWF8^$BRUK>KK$R,=4&HC["T+X^T#N6XO?*9S?4$L#!!0
M   ( .V&3UB#B [:]@4  %P<   :    >&PO=V]R:W-H965T<R]S:&5E=#$P
M,BYX;6RM66U/XS@0_BM6;W4":=G&SCM7*I6F:"M!0;![I_L86I=&F\3=Q 7V
MWY_S0M+8$Y?E^@62])G)/#.VYW$\>F'9CWQ#*4>O29SF%X,-Y]OSX3!?;F@2
MYE_8EJ;BES7+DI"+V^QIF&\S&JY*HR0>$L-PADD8I8/QJ'QVEXU';,?C**5W
M&<IW21)FORYIS%XN!GCP]N ^>MKPXL%P/-J&3_2!\N_;NTS<#1LOJRBA:1ZQ
M%&5T?3&8X/. ^(5!B?@[HB_YWC4JJ#PR]J.XF:\N!D81$8WIDA<N0O'OF4YI
M'!>>1!P_:Z>#YIV%X?[UF_>KDKP@\QCF=,KB?Z(5WUP,O %:T76XB_D]>_E*
M:T)VX6_)XKS\BUYJK#% RUW.65(;BPB2**W^AZ]U(O8,L--C0&H#(AM8/09F
M;6"^U\"J#:PR,Q65,@]!R,/Q*&,O*"O0PEMQ42:SM!;TH[2H^P//Q*^1L./C
MA^G76?#]>H;FZ S=3>YGBV]H>GMS-UG\BZ[FB\EB.I]<H_GBZO;^9O)M?KM
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M3!&]F-(I<J**'<OSY=@!D))\ &3BGI61M+J)Z'53M7S0>OZ!#%2]8V('RQ0
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M;6B590A&1\Q\/@!@(64NKEHZ,+]TZ**3SJ!7:I'9@(50UJ&#!$"QH:O6:?G
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M8T#?MX+>^'IB-FBZ4.]_4$L#!!0    ( .V&3UBNJ>H49@,  )47   -
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MA>L&CP[%VZUES<)B_V']*L :(EA#6BP_CM)X%DZ]+)BRS][,B_R I5=!D*4
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MXF)6\O7S?]EX_@\AG_X#4$L#!!0    ( .V&3UCB50\<^ (  + ]   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V\MNVD 8AN%;0;Z >,Z'*LFJ
MFVRKW  B!J)P$G;5Y.Z+D@5\HRZZB?RNT!@QO!L_0F;^^U_#;CF]'@_C]O4T
M+M[WN\/XT&VGZ?2C[\?5=M@OQ[OC:3A<WED?S_OE=%F>-_UIN7I;;H;>&9/Z
M\^T>W>/][9Z+YX_3\#\['M?KU]7P\[CZO1\.TS\V[O\<SV_C=ABF;O&\/&^&
MZ:'KWW?7RV/_^6+O+CMWBZ>7A^[\]&*[?NX@)T%N_B O07[^H"!!8?Z@*$%Q
M_J D06G^H"Q!>?Z@(D%E_J J077^(&M41@-(:K &:&V5:POPVBK8%B"V5;(M
MP&RK:%N VE;9M@"WK<)M 7);I=L"[+:*MP7H[51O!]#;J=X.H+=K?FP#]':J
MMP/H[51O!]#;J=X.H+=3O1U ;Z=Z.X#>3O5V +V=ZNT >GO5VP/T]JJW!^CM
M56\/T-LW#TL >GO5VP/T]JJW!^CM56\/T-NKWAZ@MU>]/4!OKWI[@-Y!]0X
MO8/J'0!Z!]4[ /0.JG< Z!V:A]T O8/J'0!Z!]4[ /0.JG< Z!U4[P#0.ZC>
M :!W5+TC0.^H>D> WE'UC@"]H^H= 7I'U3L"]([-GY4 O:/J'0%Z1]4[ O2.
MJG<$Z!U5[PC0.ZG>":!W4KT30.^D>B> WDGU3@"]D^J= 'HGU3L!]$[-81.
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MC(>Z&U_SD^7?MC<_ 5!+ 0(4 Q0    ( .V&3U@'04UB@0   +$    0
M          "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ [89/
M6.%5.)_O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N
M>&UL4$L! A0#%     @ [89/6)E<G",0!@  G"<  !,              ( !
MS0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #MAD]8COWL5!D(
M   8,0  &               @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL4$L! A0#%     @ [89/6"VZ@ZP^ @  P@4  !@              ("!
M71   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( .V&3U@
MR. KJ 8  -T;   8              " @=$2  !X;"]W;W)K<VAE971S+W-H
M965T,RYX;6Q02P$"% ,4    " #MAD]8=R90("L#   5"@  &
M    @(&O&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M[89/6/<7C%#E!0  FAD  !@              ("!$!T  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( .V&3UA%;=V#1@0  /L/   8
M          " @2LC  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " #MAD]8WUI]?(P*   .9   &               @(&G)P  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ [89/6)38X$'!"@  N#<
M !@              ("!:3(  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( .V&3U@7*4&[7P0  (\)   8              " @6 ]  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #MAD]81 M&U[0H
M  #_A   &0              @('U00  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( .V&3U@2<8[JD <  )01   9              "
M@>!J  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ [89/
M6%+32._\!@  8Q$  !D              ("!IW(  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " #MAD]8CJ39P90*  !&'0  &0
M        @(':>0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( .V&3UCN^T,QJ0X  "@M   9              " @:6$  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ [89/6(Y"DHXZ!   5@D
M !D              ("!A9,  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " #MAD]8OU:)B3L#   -!P  &0              @('VEP
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( .V&3UB1&>>_
M 04  !D+   9              " @6B;  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ [89/6,AE+&[?!@  G!$  !D
M ("!H*   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #M
MAD]8 B4N@Q0(   0%0  &0              @(&VIP  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( .V&3UAP!IJ$&P@  'X3   9
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M970R-"YX;6Q02P$"% ,4    " #MAD]8C.LDF94=  ! 5   &0
M    @('0XP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M .V&3U@+"U )KA   #(R   9              " @9P! 0!X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ [89/6/TSX%7#!0  ,@X  !D
M             ("!@1(! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " #MAD]86"&J#H(.  !?*0  &0              @(%[& $ >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( .V&3U@93ELT9P(
M )$&   9              " @30G 0!X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ [89/6&0ZHFM# @  B@8  !D              ("!
MTBD! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #MAD]8
M<?/XZX U  "ZMP  &0              @(%,+ $ >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( .V&3UBB_J,(50,  #P'   9
M      " @0-B 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ [89/6!@LVZTS P  KP8  !D              ("!CV4! 'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #MAD]8>7ZIX28#  #C!@
M&0              @('Y: $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( .V&3UBEE'-(0@@  #D8   9              " @59L 0!X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ [89/6 F3K<U:
M!@  5A$  !D              ("!SW0! 'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " #MAD]8HB*,(CL$   7"0  &0
M@(%@>P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( .V&
M3UC,ODJPWP(  !0&   9              " @=)_ 0!X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ [89/6!56,.3]!   N L  !D
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M=#0S+GAM;%!+ 0(4 Q0    ( .V&3UC*>GAC\00  +$,   9
M  " @9*9 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
M[89/6(M8#YB! P  M0<  !D              ("!NIX! 'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " #MAD]8=L&N+80#   C"   &0
M            @(%RH@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( .V&3U@PP<8,1@@  " :   9              " @2VF 0!X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ [89/6 ,[#LL4 P
MU@L  !D              ("!JJX! 'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    " #MAD]8^'G5[2@*  !57P  &0              @('U
ML0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( .V&3UC^
MW\E!_P(  '\(   9              " @52\ 0!X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ [89/6 ]JCUKT @  8 @  !D
M     ("!BK\! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
M" #MAD]8<@+RJC$&  "G*0  &0              @(&UP@$ >&PO=V]R:W-H
M965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( .V&3UBN=]32?0,  *<)   9
M              " @1W) 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L!
M A0#%     @ [89/6/9[534/!@  0#$  !D              ("!T<P! 'AL
M+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " #MAD]8(.&/>O@$
M  #7&P  &0              @($7TP$ >&PO=V]R:W-H965T<R]S:&5E=#4U
M+GAM;%!+ 0(4 Q0    ( .V&3UAT"G)?6 8  /$G   9              "
M@4;8 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ [89/
M6'^#=)(B!   O \  !D              ("!U=X! 'AL+W=O<FMS:&5E=',O
M<VAE970U-RYX;6Q02P$"% ,4    " #MAD]8WT6]^\,'  #4-P  &0
M        @($NXP$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0
M   ( .V&3UB.8[E]-P,  #$*   9              " @2CK 0!X;"]W;W)K
M<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ [89/6 _:[W8. P  [@@
M !D              ("!ENX! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q0
M2P$"% ,4    " #MAD]8NRV&X(X#   *#P  &0              @(';\0$
M>&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( .V&3UBQE/Q"
M*0P  &^!   9              " @:#U 0!X;"]W;W)K<VAE971S+W-H965T
M-C(N>&UL4$L! A0#%     @ [89/6'H_F& V#0  OKL  !D
M ("!  (" 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #M
MAD]8J@WK5[<#  #U"P  &0              @(%M#P( >&PO=V]R:W-H965T
M<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( .V&3UA73MD%@P0  !,=   9
M          " @5L3 @!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#
M%     @ [89/6$T$=[U$!   510  !D              ("!%1@" 'AL+W=O
M<FMS:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " #MAD]8%)<6RZ4#  !&
M$0  &0              @(&0' ( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM
M;%!+ 0(4 Q0    ( .V&3UBW=O"FW@(  )\'   9              " @6P@
M @!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ [89/6-C6
MR^CQ P  W1   !D              ("!@2," 'AL+W=O<FMS:&5E=',O<VAE
M970V.2YX;6Q02P$"% ,4    " #MAD]8^<';RKH%  !](0  &0
M    @(&I)P( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    (
M .V&3UA%..^710,  ),+   9              " @9HM @!X;"]W;W)K<VAE
M971S+W-H965T-S$N>&UL4$L! A0#%     @ [89/6-I@?*)6 @  Y@4  !D
M             ("!%C$" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"
M% ,4    " #MAD]833)%)X,$  !)$P  &0              @(&C,P( >&PO
M=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( .V&3UBN"#!WG0(
M +4'   9              " @5TX @!X;"]W;W)K<VAE971S+W-H965T-S0N
M>&UL4$L! A0#%     @ [89/6',^"< ,!   ;@\  !D              ("!
M,3L" 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " #MAD]8
MH:,S$<L#   7$P  &0              @(%T/P( >&PO=V]R:W-H965T<R]S
M:&5E=#<V+GAM;%!+ 0(4 Q0    ( .V&3U@).*_M[@,  *$6   9
M      " @79# @!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%
M  @ [89/6!EQ- HC P  J0D  !D              ("!FT<" 'AL+W=O<FMS
M:&5E=',O<VAE970W."YX;6Q02P$"% ,4    " #MAD]8MYX%C.P#   :#0
M&0              @('U2@( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+
M 0(4 Q0    ( .V&3UAAJBH<500  !L0   9              " @1A/ @!X
M;"]W;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ [89/6$@4?+OE
M @  "@L  !D              ("!I%," 'AL+W=O<FMS:&5E=',O<VAE970X
M,2YX;6Q02P$"% ,4    " #MAD]8<_I%Z2</  !MS@  &0
M@(' 5@( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( .V&
M3UBFOS?%2 (  "0&   9              " @1YF @!X;"]W;W)K<VAE971S
M+W-H965T.#,N>&UL4$L! A0#%     @ [89/6+">M!LQ#0  &JX  !D
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M=#@X+GAM;%!+ 0(4 Q0    ( .V&3UC.7MZ.ZP,  %<2   9
M  " @1B2 @!X;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @
M[89/6(ANI@^1 P  SPH  !D              ("!.I8" 'AL+W=O<FMS:&5E
M=',O<VAE970Y,"YX;6Q02P$"% ,4    " #MAD]8WHRTO'8#  !=#   &0
M            @($"F@( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4
M Q0    ( .V&3UCQFV"?JP0  *83   9              " @:^= @!X;"]W
M;W)K<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @ [89/6)C.(SJ\ @
M< <  !D              ("!D:(" 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX
M;6Q02P$"% ,4    " #MAD]8:DN=W.LC  #.[@( &0              @(&$
MI0( >&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( .V&3UC_
M?>%AW 0  ( C   9              " @:;) @!X;"]W;W)K<VAE971S+W-H
M965T.34N>&UL4$L! A0#%     @ [89/6/$:9_L=!0  R1P  !D
M     ("!N<X" 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q02P$"% ,4
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M,"YX;6Q02P$"% ,4    " #MAD]8V7#"H\X#  "S$   &@
M@(%(_P( >&PO=V]R:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4    " #M
MAD]8@X@.VO8%  !<'   &@              @(%. P, >&PO=V]R:W-H965T
M<R]S:&5E=#$P,BYX;6Q02P$"% ,4    " #MAD]8(LA6Z[$%   9'0  &@
M            @(%\"0, >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"
M% ,4    " #MAD]8@1*H;H$(  #"+@  &@              @(%E#P, >&PO
M=V]R:W-H965T<R]S:&5E=#$P-"YX;6Q02P$"% ,4    " #MAD]8G)>^3'P#
M  "1"@  &@              @($>& , >&PO=V]R:W-H965T<R]S:&5E=#$P
M-2YX;6Q02P$"% ,4    " #MAD]8KJGJ%&8#  "5%P  #0
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:+GAM;%!+!08     <0!Q !0?   8+@,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>624</ContextCount>
  <ElementCount>569</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>175</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOW</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOW</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - REPORTING ENTITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/REPORTINGENTITY</Role>
      <ShortName>REPORTING ENTITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - ACQUISITIONS AND DIVESTITURES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/ACQUISITIONSANDDIVESTITURES</Role>
      <ShortName>ACQUISITIONS AND DIVESTITURES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - EQUITY METHOD INVESTMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/EQUITYMETHODINVESTMENT</Role>
      <ShortName>EQUITY METHOD INVESTMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - INVESTMENT SECURITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/INVESTMENTSECURITIES</Role>
      <ShortName>INVESTMENT SECURITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - FAIR VALUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/FAIRVALUE</Role>
      <ShortName>FAIR VALUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - MEDICARE PART D</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/MEDICAREPARTD</Role>
      <ShortName>MEDICARE PART D</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/PROPERTYANDEQUIPMENTNET</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETS</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - BENEFITS PAYABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/BENEFITSPAYABLE</Role>
      <ShortName>BENEFITS PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/EMPLOYEEBENEFITPLANS</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATION</Role>
      <ShortName>EARNINGS PER COMMON SHARE COMPUTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS, GUARANTEES AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - REINSURANCE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/REINSURANCE</Role>
      <ShortName>REINSURANCE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATION</Role>
      <ShortName>SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - ACQUISITIONS AND DIVESTITURES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESTables</Role>
      <ShortName>ACQUISITIONS AND DIVESTITURES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.humana.com/role/ACQUISITIONSANDDIVESTITURES</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - EQUITY METHOD INVESTMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/EQUITYMETHODINVESTMENTTables</Role>
      <ShortName>EQUITY METHOD INVESTMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.humana.com/role/EQUITYMETHODINVESTMENT</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - INVESTMENT SECURITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/INVESTMENTSECURITIESTables</Role>
      <ShortName>INVESTMENT SECURITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.humana.com/role/INVESTMENTSECURITIES</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - FAIR VALUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/FAIRVALUETables</Role>
      <ShortName>FAIR VALUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.humana.com/role/FAIRVALUE</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - MEDICARE PART D (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/MEDICAREPARTDTables</Role>
      <ShortName>MEDICARE PART D (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.humana.com/role/MEDICAREPARTD</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/PROPERTYANDEQUIPMENTNETTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.humana.com/role/PROPERTYANDEQUIPMENTNET</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETS</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.humana.com/role/LEASES</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - BENEFITS PAYABLE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/BENEFITSPAYABLETables</Role>
      <ShortName>BENEFITS PAYABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.humana.com/role/BENEFITSPAYABLE</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.humana.com/role/INCOMETAXES</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.humana.com/role/DEBT</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/EMPLOYEEBENEFITPLANSTables</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.humana.com/role/EMPLOYEEBENEFITPLANS</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONTables</Role>
      <ShortName>EARNINGS PER COMMON SHARE COMPUTATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATION</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.humana.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.humana.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - REPORTING ENTITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/REPORTINGENTITYDetails</Role>
      <ShortName>REPORTING ENTITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.humana.com/role/REPORTINGENTITY</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Part D Subsidy/Discount Payments, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPartDSubsidyDiscountPaymentsNetDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Part D Subsidy/Discount Payments, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Health Care Cost Payments, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESHealthCareCostPaymentsNetDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Health Care Cost Payments, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - ACQUISITIONS AND DIVESTITURES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails</Role>
      <ShortName>ACQUISITIONS AND DIVESTITURES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - ACQUISITIONS AND DIVESTITURES - Assets, Liabilities And Noncontrolling Interest Disposed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails</Role>
      <ShortName>ACQUISITIONS AND DIVESTITURES - Assets, Liabilities And Noncontrolling Interest Disposed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - EQUITY METHOD INVESTMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails</Role>
      <ShortName>EQUITY METHOD INVESTMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - EQUITY METHOD INVESTMENT - Summarized Balance Sheets and Statements of Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails</Role>
      <ShortName>EQUITY METHOD INVESTMENT - Summarized Balance Sheets and Statements of Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - INVESTMENT SECURITIES - Classified as Current and Long-Term (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails</Role>
      <ShortName>INVESTMENT SECURITIES - Classified as Current and Long-Term (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - INVESTMENT SECURITIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails</Role>
      <ShortName>INVESTMENT SECURITIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails</Role>
      <ShortName>INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - INVESTMENT SECURITIES - Realized Gains (Losses) Included Within Investment Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails</Role>
      <ShortName>INVESTMENT SECURITIES - Realized Gains (Losses) Included Within Investment Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - INVESTMENT SECURITIES - Gains (Losses) on Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesonEquitySecuritiesDetails</Role>
      <ShortName>INVESTMENT SECURITIES - Gains (Losses) on Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails</Role>
      <ShortName>INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - FAIR VALUE - Financial Assets Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE - Financial Assets Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - FAIR VALUE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/FAIRVALUENarrativeDetails</Role>
      <ShortName>FAIR VALUE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details</Role>
      <ShortName>FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - FAIR VALUE - Put and Call Options Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails</Role>
      <ShortName>FAIR VALUE - Put and Call Options Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - MEDICARE PART D (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/MEDICAREPARTDDetails</Role>
      <ShortName>MEDICARE PART D (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.humana.com/role/MEDICAREPARTDTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - PROPERTY AND EQUIPMENT, NET - Property and Equipment Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET - Property and Equipment Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - PROPERTY AND EQUIPMENT, NET - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Changes in Carrying Amount of Goodwill by Reportable Segments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS - Changes in Carrying Amount of Goodwill by Reportable Segments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Details of Intangible Assets Included in Other Long-Term Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS - Details of Intangible Assets Included in Other Long-Term Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Estimate of Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSEstimateofAmortizationExpenseDetails</Role>
      <ShortName>GOODWILL AND OTHER INTANGIBLE ASSETS - Estimate of Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - LEASES - Maturity of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails</Role>
      <ShortName>LEASES - Maturity of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - BENEFITS PAYABLE - Activity in Benefits Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails</Role>
      <ShortName>BENEFITS PAYABLE - Activity in Benefits Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - BENEFITS PAYABLE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails</Role>
      <ShortName>BENEFITS PAYABLE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - BENEFITS PAYABLE - Incurred and Paid Claims Development (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails</Role>
      <ShortName>BENEFITS PAYABLE - Incurred and Paid Claims Development (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - INCOME TAXES - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - INCOME TAXES - Provision for Income Taxes Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails</Role>
      <ShortName>INCOME TAXES - Provision for Income Taxes Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - INCOME TAXES - Principal Components of Net Deferred Tax Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails</Role>
      <ShortName>INCOME TAXES - Principal Components of Net Deferred Tax Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - DEBT - Debt Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/DEBTDebtOutstandingDetails</Role>
      <ShortName>DEBT - Debt Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - DEBT - Maturities of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/DEBTMaturitiesofDebtDetails</Role>
      <ShortName>DEBT - Maturities of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - DEBT - Senior Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.humana.com/role/DEBTSeniorNotesDetails</Role>
      <ShortName>DEBT - Senior Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - DEBT - Revolving Credit Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails</Role>
      <ShortName>DEBT - Revolving Credit Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - DEBT - Commercial Paper and Other Short-Term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails</Role>
      <ShortName>DEBT - Commercial Paper and Other Short-Term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - EMPLOYEE BENEFIT PLANS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - EMPLOYEE BENEFIT PLANS - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - EMPLOYEE BENEFIT PLANS - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - EMPLOYEE BENEFIT PLANS - Weighted-Average Fair Value Assumptions for Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Weighted-Average Fair Value Assumptions for Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - EMPLOYEE BENEFIT PLANS - Option Plans Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS - Option Plans Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails</Role>
      <ShortName>EARNINGS PER COMMON SHARE COMPUTATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - STOCKHOLDERS' EQUITY - Dividend Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/STOCKHOLDERSEQUITYDividendPaymentsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Dividend Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9954534 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9954535 - Disclosure - STOCKHOLDERS' EQUITY - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9954536 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIES</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9954537 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9954538 - Disclosure - SEGMENT INFORMATION - Segment Results (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails</Role>
      <ShortName>SEGMENT INFORMATION - Segment Results (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9954539 - Disclosure - REINSURANCE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/REINSURANCEDetails</Role>
      <ShortName>REINSURANCE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.humana.com/role/REINSURANCE</ParentRole>
      <Position>99</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9954540 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Balance Sheets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails</Role>
      <ShortName>SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Balance Sheets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATION</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9954541 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Balance Sheets Share Data) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails</Role>
      <ShortName>SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Balance Sheets Share Data) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATION</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9954542 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails</Role>
      <ShortName>SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATION</ParentRole>
      <Position>102</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9954543 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Comprehensive Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails</Role>
      <ShortName>SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Comprehensive Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATION</ParentRole>
      <Position>103</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9954544 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Cash Flows) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails</Role>
      <ShortName>SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Cash Flows) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATION</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="hum-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9954545 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Notes to Condensed Financial Statements) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONNotestoCondensedFinancialStatementsDetails</Role>
      <ShortName>SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Notes to Condensed Financial Statements) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATION</ParentRole>
      <Position>105</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="hum-20231231.htm">hum-20231231.htm</File>
    <File>hum-20231231.xsd</File>
    <File>hum-20231231_cal.xml</File>
    <File>hum-20231231_def.xml</File>
    <File>hum-20231231_lab.xml</File>
    <File>hum-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>hum-20231231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2083">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>132
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "hum-20231231.htm": {
   "nsprefix": "hum",
   "nsuri": "http://www.humana.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "hum-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "hum-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "hum-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "hum-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "hum-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hum-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 472,
   "keyCustom": 97,
   "axisStandard": 44,
   "axisCustom": 2,
   "memberStandard": 71,
   "memberCustom": 101,
   "hidden": {
    "total": 19,
    "http://fasb.org/us-gaap/2023": 13,
    "http://www.humana.com/20231231": 2,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 624,
   "entityCount": 1,
   "segmentCount": 175,
   "elementCount": 1036,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 2083,
    "http://xbrl.sec.gov/dei/2023": 38,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "report": {
    "R1": {
     "role": "http://www.humana.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.humana.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PremiumsEarnedNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R7": {
     "role": "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOW",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOW",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.humana.com/role/REPORTINGENTITY",
     "longName": "0000009 - Disclosure - REPORTING ENTITY",
     "shortName": "REPORTING ENTITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURES",
     "longName": "0000011 - Disclosure - ACQUISITIONS AND DIVESTITURES",
     "shortName": "ACQUISITIONS AND DIVESTITURES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.humana.com/role/EQUITYMETHODINVESTMENT",
     "longName": "0000012 - Disclosure - EQUITY METHOD INVESTMENT",
     "shortName": "EQUITY METHOD INVESTMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.humana.com/role/INVESTMENTSECURITIES",
     "longName": "0000013 - Disclosure - INVESTMENT SECURITIES",
     "shortName": "INVESTMENT SECURITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.humana.com/role/FAIRVALUE",
     "longName": "0000014 - Disclosure - FAIR VALUE",
     "shortName": "FAIR VALUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.humana.com/role/MEDICAREPARTD",
     "longName": "0000015 - Disclosure - MEDICARE PART D",
     "shortName": "MEDICARE PART D",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "hum:MedicarePartDDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "hum:MedicarePartDDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.humana.com/role/PROPERTYANDEQUIPMENTNET",
     "longName": "0000016 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETS",
     "longName": "0000017 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.humana.com/role/LEASES",
     "longName": "0000018 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.humana.com/role/BENEFITSPAYABLE",
     "longName": "0000019 - Disclosure - BENEFITS PAYABLE",
     "shortName": "BENEFITS PAYABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.humana.com/role/INCOMETAXES",
     "longName": "0000020 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.humana.com/role/DEBT",
     "longName": "0000021 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.humana.com/role/EMPLOYEEBENEFITPLANS",
     "longName": "0000022 - Disclosure - EMPLOYEE BENEFIT PLANS",
     "shortName": "EMPLOYEE BENEFIT PLANS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "hum:DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "hum:DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATION",
     "longName": "0000023 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION",
     "shortName": "EARNINGS PER COMMON SHARE COMPUTATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.humana.com/role/STOCKHOLDERSEQUITY",
     "longName": "0000024 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIES",
     "longName": "0000025 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES",
     "shortName": "COMMITMENTS, GUARANTEES AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.humana.com/role/SEGMENTINFORMATION",
     "longName": "0000026 - Disclosure - SEGMENT INFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.humana.com/role/REINSURANCE",
     "longName": "0000027 - Disclosure - REINSURANCE",
     "shortName": "REINSURANCE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReinsuranceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReinsuranceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATION",
     "longName": "0000028 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION",
     "shortName": "SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-615",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-615",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9954472 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "hum:ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "hum:ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESTables",
     "longName": "9954473 - Disclosure - ACQUISITIONS AND DIVESTITURES (Tables)",
     "shortName": "ACQUISITIONS AND DIVESTITURES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.humana.com/role/EQUITYMETHODINVESTMENTTables",
     "longName": "9954474 - Disclosure - EQUITY METHOD INVESTMENT (Tables)",
     "shortName": "EQUITY METHOD INVESTMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.humana.com/role/INVESTMENTSECURITIESTables",
     "longName": "9954475 - Disclosure - INVESTMENT SECURITIES (Tables)",
     "shortName": "INVESTMENT SECURITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.humana.com/role/FAIRVALUETables",
     "longName": "9954476 - Disclosure - FAIR VALUE (Tables)",
     "shortName": "FAIR VALUE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.humana.com/role/MEDICAREPARTDTables",
     "longName": "9954477 - Disclosure - MEDICARE PART D (Tables)",
     "shortName": "MEDICARE PART D (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "hum:BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "hum:BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETTables",
     "longName": "9954478 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables",
     "longName": "9954479 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.humana.com/role/LEASESTables",
     "longName": "9954480 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.humana.com/role/BENEFITSPAYABLETables",
     "longName": "9954481 - Disclosure - BENEFITS PAYABLE (Tables)",
     "shortName": "BENEFITS PAYABLE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.humana.com/role/INCOMETAXESTables",
     "longName": "9954482 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.humana.com/role/DEBTTables",
     "longName": "9954483 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.humana.com/role/EMPLOYEEBENEFITPLANSTables",
     "longName": "9954484 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables)",
     "shortName": "EMPLOYEE BENEFIT PLANS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONTables",
     "longName": "9954485 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Tables)",
     "shortName": "EARNINGS PER COMMON SHARE COMPUTATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.humana.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "9954486 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DividendsDeclaredTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DividendsDeclaredTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.humana.com/role/SEGMENTINFORMATIONTables",
     "longName": "9954487 - Disclosure - SEGMENT INFORMATION (Tables)",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.humana.com/role/REPORTINGENTITYDetails",
     "longName": "9954488 - Disclosure - REPORTING ENTITY (Details)",
     "shortName": "REPORTING ENTITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-58",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-59",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "longName": "9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "hum:CommercialMembershipContractTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPartDSubsidyDiscountPaymentsNetDetails",
     "longName": "9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Part D Subsidy/Discount Payments, Net (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Part D Subsidy/Discount Payments, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "hum:SubsidyAndDiscountPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "hum:SubsidyAndDiscountPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESHealthCareCostPaymentsNetDetails",
     "longName": "9954491 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Health Care Cost Payments, Net (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Health Care Cost Payments, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "hum:HealthCareCostPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "hum:HealthCareCostPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
     "longName": "9954492 - Disclosure - ACQUISITIONS AND DIVESTITURES - Narrative (Details)",
     "shortName": "ACQUISITIONS AND DIVESTITURES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:EquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-81",
      "name": "hum:BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails",
     "longName": "9954493 - Disclosure - ACQUISITIONS AND DIVESTITURES - Assets, Liabilities And Noncontrolling Interest Disposed (Details)",
     "shortName": "ACQUISITIONS AND DIVESTITURES - Assets, Liabilities And Noncontrolling Interest Disposed (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-77",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-77",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
     "longName": "9954494 - Disclosure - EQUITY METHOD INVESTMENT - Narrative (Details)",
     "shortName": "EQUITY METHOD INVESTMENT - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-77",
      "name": "hum:DisposalGroupIncludingDiscontinuedOperationEquityInterestSold",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-90",
      "name": "hum:StrategicPartnershipAgreementNumberOfPrimaryCareCenters",
      "unitRef": "primary_care_center",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails",
     "longName": "9954495 - Disclosure - EQUITY METHOD INVESTMENT - Summarized Balance Sheets and Statements of Income (Details)",
     "shortName": "EQUITY METHOD INVESTMENT - Summarized Balance Sheets and Statements of Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-86",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails",
     "longName": "9954496 - Disclosure - INVESTMENT SECURITIES - Classified as Current and Long-Term (Details)",
     "shortName": "INVESTMENT SECURITIES - Classified as Current and Long-Term (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails",
     "longName": "9954497 - Disclosure - INVESTMENT SECURITIES - Narrative (Details)",
     "shortName": "INVESTMENT SECURITIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "hum:MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails",
     "longName": "9954498 - Disclosure - INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details)",
     "shortName": "INVESTMENT SECURITIES - Gross Unrealized Losses and Fair Values of Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails",
     "longName": "9954499 - Disclosure - INVESTMENT SECURITIES - Realized Gains (Losses) Included Within Investment Income (Details)",
     "shortName": "INVESTMENT SECURITIES - Realized Gains (Losses) Included Within Investment Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "hum:DebtAndEquitySecuritiesRealizedGain",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRealizedGainLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "hum:DebtAndEquitySecuritiesRealizedGain",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRealizedGainLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesonEquitySecuritiesDetails",
     "longName": "9954500 - Disclosure - INVESTMENT SECURITIES - Gains (Losses) on Equity Securities (Details)",
     "shortName": "INVESTMENT SECURITIES - Gains (Losses) on Equity Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails",
     "longName": "9954501 - Disclosure - INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details)",
     "shortName": "INVESTMENT SECURITIES - Contractual Maturities of Debt Securities Available for Sale (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails",
     "longName": "9954502 - Disclosure - FAIR VALUE - Financial Assets Measured on Recurring Basis (Details)",
     "shortName": "FAIR VALUE - Financial Assets Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-114",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.humana.com/role/FAIRVALUENarrativeDetails",
     "longName": "9954503 - Disclosure - FAIR VALUE - Narrative (Details)",
     "shortName": "FAIR VALUE - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:InterestRateFairValueHedgeAssetAtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details",
     "longName": "9954504 - Disclosure - FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details)",
     "shortName": "FAIR VALUE - Significant Unobservable Inputs (Level 3) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails",
     "longName": "9954505 - Disclosure - FAIR VALUE - Put and Call Options Measured at Fair Value (Details)",
     "shortName": "FAIR VALUE - Put and Call Options Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-203",
      "name": "us-gaap:DerivativeAssetLiabilityNetMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-203",
      "name": "us-gaap:DerivativeAssetLiabilityNetMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.humana.com/role/MEDICAREPARTDDetails",
     "longName": "9954506 - Disclosure - MEDICARE PART D (Details)",
     "shortName": "MEDICARE PART D (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-221",
      "name": "us-gaap:OtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails",
     "longName": "9954507 - Disclosure - PROPERTY AND EQUIPMENT, NET - Property and Equipment Balances (Details)",
     "shortName": "PROPERTY AND EQUIPMENT, NET - Property and Equipment Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
     "longName": "9954508 - Disclosure - PROPERTY AND EQUIPMENT, NET - Narrative (Details)",
     "shortName": "PROPERTY AND EQUIPMENT, NET - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationNonproduction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationNonproduction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails",
     "longName": "9954509 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Changes in Carrying Amount of Goodwill by Reportable Segments (Details)",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Changes in Carrying Amount of Goodwill by Reportable Segments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails",
     "longName": "9954510 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Details of Intangible Assets Included in Other Long-Term Assets (Details)",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Details of Intangible Assets Included in Other Long-Term Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails",
     "longName": "9954511 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSEstimateofAmortizationExpenseDetails",
     "longName": "9954512 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Estimate of Amortization Expense (Details)",
     "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Estimate of Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.humana.com/role/LEASESNarrativeDetails",
     "longName": "9954513 - Disclosure - LEASES - Narrative (Details)",
     "shortName": "LEASES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails",
     "longName": "9954514 - Disclosure - LEASES - Maturity of Lease Liabilities (Details)",
     "shortName": "LEASES - Maturity of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails",
     "longName": "9954515 - Disclosure - BENEFITS PAYABLE - Activity in Benefits Payable (Details)",
     "shortName": "BENEFITS PAYABLE - Activity in Benefits Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails",
     "longName": "9954516 - Disclosure - BENEFITS PAYABLE - Narrative (Details)",
     "shortName": "BENEFITS PAYABLE - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails",
     "longName": "9954517 - Disclosure - BENEFITS PAYABLE - Incurred and Paid Claims Development (Details)",
     "shortName": "BENEFITS PAYABLE - Incurred and Paid Claims Development (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails",
     "longName": "9954518 - Disclosure - INCOME TAXES - Provision for Income Taxes (Details)",
     "shortName": "INCOME TAXES - Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails",
     "longName": "9954519 - Disclosure - INCOME TAXES - Provision for Income Taxes Reconciliation (Details)",
     "shortName": "INCOME TAXES - Provision for Income Taxes Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails",
     "longName": "9954520 - Disclosure - INCOME TAXES - Principal Components of Net Deferred Tax Balances (Details)",
     "shortName": "INCOME TAXES - Principal Components of Net Deferred Tax Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.humana.com/role/INCOMETAXESNarrativeDetails",
     "longName": "9954521 - Disclosure - INCOME TAXES - Narrative (Details)",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-262",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.humana.com/role/DEBTDebtOutstandingDetails",
     "longName": "9954522 - Disclosure - DEBT - Debt Outstanding (Details)",
     "shortName": "DEBT - Debt Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-269",
      "name": "us-gaap:LongTermDebtCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.humana.com/role/DEBTMaturitiesofDebtDetails",
     "longName": "9954523 - Disclosure - DEBT - Maturities of Debt (Details)",
     "shortName": "DEBT - Maturities of Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.humana.com/role/DEBTSeniorNotesDetails",
     "longName": "9954524 - Disclosure - DEBT - Senior Notes (Details)",
     "shortName": "DEBT - Senior Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-306",
      "name": "us-gaap:DebtInstrumentRedemptionPricePercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails",
     "longName": "9954525 - Disclosure - DEBT - Revolving Credit Agreements (Details)",
     "shortName": "DEBT - Revolving Credit Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-344",
      "name": "hum:DebtInstrumentCovenantDebtToCapitalizationPercentageActual",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-344",
      "name": "hum:DebtInstrumentCovenantDebtToCapitalizationPercentageActual",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails",
     "longName": "9954526 - Disclosure - DEBT - Commercial Paper and Other Short-Term Borrowings (Details)",
     "shortName": "DEBT - Commercial Paper and Other Short-Term Borrowings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromShortTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-350",
      "name": "us-gaap:ShorttermDebtMaximumAmountOutstandingDuringPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails",
     "longName": "9954527 - Disclosure - EMPLOYEE BENEFIT PLANS - Narrative (Details)",
     "shortName": "EMPLOYEE BENEFIT PLANS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails",
     "longName": "9954528 - Disclosure - EMPLOYEE BENEFIT PLANS - Stock-Based Compensation Expense (Details)",
     "shortName": "EMPLOYEE BENEFIT PLANS - Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails",
     "longName": "9954529 - Disclosure - EMPLOYEE BENEFIT PLANS - Restricted Stock Activity (Details)",
     "shortName": "EMPLOYEE BENEFIT PLANS - Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-366",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-354",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails",
     "longName": "9954530 - Disclosure - EMPLOYEE BENEFIT PLANS - Weighted-Average Fair Value Assumptions for Stock Options (Details)",
     "shortName": "EMPLOYEE BENEFIT PLANS - Weighted-Average Fair Value Assumptions for Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-357",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-357",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails",
     "longName": "9954531 - Disclosure - EMPLOYEE BENEFIT PLANS - Option Plans Activity (Details)",
     "shortName": "EMPLOYEE BENEFIT PLANS - Option Plans Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails",
     "longName": "9954532 - Disclosure - EARNINGS PER COMMON SHARE COMPUTATION (Details)",
     "shortName": "EARNINGS PER COMMON SHARE COMPUTATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.humana.com/role/STOCKHOLDERSEQUITYDividendPaymentsDetails",
     "longName": "9954533 - Disclosure - STOCKHOLDERS' EQUITY - Dividend Payments (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Dividend Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DividendsDeclaredTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "longName": "9954534 - Disclosure - STOCKHOLDERS' EQUITY - Narrative (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-370",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-370",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails",
     "longName": "9954535 - Disclosure - STOCKHOLDERS' EQUITY - Share Repurchases (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Share Repurchases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-384",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-419",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails",
     "longName": "9954536 - Disclosure - COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS, GUARANTEES AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "longName": "9954537 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-429",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-429",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails",
     "longName": "9954538 - Disclosure - SEGMENT INFORMATION - Segment Results (Details)",
     "shortName": "SEGMENT INFORMATION - Segment Results (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PremiumsEarnedNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.humana.com/role/REINSURANCEDetails",
     "longName": "9954539 - Disclosure - REINSURANCE (Details)",
     "shortName": "REINSURANCE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ReinsuranceRecoverables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ReinsuranceRecoverables",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails",
     "longName": "9954540 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Balance Sheets) (Details)",
     "shortName": "SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Balance Sheets) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-616",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails",
     "longName": "9954541 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Balance Sheets Share Data) (Details)",
     "shortName": "SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Balance Sheets Share Data) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-616",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails",
     "longName": "9954542 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Income) (Details)",
     "shortName": "SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Income) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-620",
      "name": "hum:ManagementFeesChargedToOperatingSubsidiaries",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails",
     "longName": "9954543 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Comprehensive Income) (Details)",
     "shortName": "SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Comprehensive Income) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-620",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails",
     "longName": "9954544 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Cash Flows) (Details)",
     "shortName": "SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Condensed Statements of Cash Flows) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-620",
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONNotestoCondensedFinancialStatementsDetails",
     "longName": "9954545 - Disclosure - SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Notes to Condensed Financial Statements) (Details)",
     "shortName": "SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION (Notes to Condensed Financial Statements) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "hum:DividendsToParentWithoutPriorStateRegulatoryApproval",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "hum-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    }
   },
   "tag": {
    "hum_A065PercentSeniorNotesDueAugust2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A065PercentSeniorNotesDueAugust2023Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$1.5 billion, 0.650% due August 3, 2023",
        "label": "0.65 Percent Senior Notes Due August 2023 [Member]",
        "documentation": "0.65 Percent Senior Notes Due August 2023"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A135PercentSeniorNotesDueFebruary2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A135PercentSeniorNotesDueFebruary2027Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$750 million, 1.350% due February 3, 2027",
        "label": "1.35 Percent Senior Notes Due February 2027 [Member]",
        "documentation": "1.35 Percent Senior Notes Due February 2027"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A2011PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A2011PlanMember",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2011 Plan",
        "label": "2011 Plan [Member]",
        "documentation": "2011 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A2019PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A2019PlanMember",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 Plan",
        "label": "A2019 Plan [Member]",
        "documentation": "A2019 Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A2021ShareRepurchaseAuthorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A2021ShareRepurchaseAuthorizationMember",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Share Repurchase Authorization",
        "label": "2021 Share Repurchase Authorization [Member]",
        "documentation": "2021 Share Repurchase Authorization"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A2023ShareRepurchaseAuthorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A2023ShareRepurchaseAuthorizationMember",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Share Repurchase Authorization",
        "label": "2023 Share Repurchase Authorization [Member]",
        "documentation": "2023 Share Repurchase Authorization"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A2024ShareRepurchaseAuthorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A2024ShareRepurchaseAuthorizationMember",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Share Repurchase Authorization",
        "label": "2024 Share Repurchase Authorization [Member]",
        "documentation": "2024 Share Repurchase Authorization"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A215PercentSeniorNotesDueFebruary2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A215PercentSeniorNotesDueFebruary2032Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$750 million 2.150% due February 3, 2032",
        "label": "2.15 Percent Senior Notes Due February 2032 [Member]",
        "documentation": "2.15 Percent Senior Notes Due February 2032"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A3.950PercentSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A3.950PercentSeniorNotesMember",
     "presentation": [
      "http://www.humana.com/role/DEBTSeniorNotesDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.950 Percent Senior Notes",
        "label": "3.950 Percent Senior Notes [Member]",
        "documentation": "3.950 Percent Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A3.95PercentSeniorNotesDueAugust2049Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A3.95PercentSeniorNotesDueAugust2049Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$500 million, 3.950% due August 15, 2049",
        "label": "3.95 Percent Senior Notes Due August 2049 [Member]",
        "documentation": "A 3.95 Percent Senior Notes Due August 2049 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A3.95PercentSeniorNotesDueMarch2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A3.95PercentSeniorNotesDueMarch2027Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$600 million, 3.950% due March 15, 2027",
        "label": "3.95 Percent Senior Notes Due March 2027 [Member]",
        "documentation": "3.95 Percent Senior Notes Due March 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A3125PercentSeniorNotesDueAugust2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A3125PercentSeniorNotesDueAugust2029Member",
     "presentation": [
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.125 Percent Senior Notes Due August 2029",
        "label": "3.125 Percent Senior Notes Due August 2029 [Member]",
        "documentation": "A 3.125 Percent Senior Notes Due August 2029 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A313PercentSeniorNotesDueAugust2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A313PercentSeniorNotesDueAugust2029Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$500 million, 3.125% due August 15, 2029",
        "label": "3.13 Percent Senior Notes Due August 2029 [Member]",
        "documentation": "3.13 Percent Senior Notes Due August 2029"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A3700PercentSeniorNotesDueMarch2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A3700PercentSeniorNotesDueMarch2029Member",
     "presentation": [
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.700 Percent Senior Notes Due March 2029",
        "label": "3.700 Percent Senior Notes Due March 2029 [Member]",
        "documentation": "3.700 Percent Senior Notes Due March 2029"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A370PercentSeniorNotesDueMarch2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A370PercentSeniorNotesDueMarch2029Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$750 million, 3.700% due March 23, 2029",
        "label": "3.70 Percent Senior Notes Due March 2029 [Member]",
        "documentation": "3.70 Percent Senior Notes Due March 2029"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A3850PercentSeniorNotesDueOctober2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A3850PercentSeniorNotesDueOctober2024Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$600 million, 3.850% due October 1, 2024",
        "label": "3.850 Percent Senior Notes Due October 2024 [Member]",
        "documentation": "3.850 Percent Senior Notes Due October 2024"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A4.500PercentSeniorNotesDueApril2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A4.500PercentSeniorNotesDueApril2025Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$600 million, 4.500% due April 1, 2025",
        "label": "4.500 Percent Senior Notes Due April 2025 [Member]",
        "documentation": "4.500 Percent Senior Notes Due April 2025"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A4.80PercentSeniorNotesDueMarch2047Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A4.80PercentSeniorNotesDueMarch2047Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$400 million, 4.800% due March 15, 2047",
        "label": "4.80 Percent Senior Notes Due March 2047 [Member]",
        "documentation": "4.80 Percent Senior Notes Due March 2047 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A4.95PercentSeniorNotesDueOctober2044Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A4.95PercentSeniorNotesDueOctober2044Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$750 million, 4.950% due October 1, 2044",
        "label": "4.95 Percent Senior Notes Due October 2044 [Member]",
        "documentation": "4.95 Percent Senior Notes Due October 2044 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A463PercentSeniorNotesDueDecember2042Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A463PercentSeniorNotesDueDecember2042Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$400 million, 4.625% due December\u00a01, 2042",
        "label": "4.63 Percent Senior Notes Due December 2042 [Member]",
        "documentation": "4.625 Percent Senior Notes Due December 2042 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A488PercentSeniorNotesDueApril2030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A488PercentSeniorNotesDueApril2030Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$500 million, 4.875% due April 1, 2030",
        "label": "4.88 Percent Senior Notes Due April 2030 [Member]",
        "documentation": "4.88 Percent Senior Notes Due April 2030"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A5.88PercentSeniorNotesDueMarch2033Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A5.88PercentSeniorNotesDueMarch2033Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$750 million, 5.875% due March 1, 2033",
        "label": "5.88 Percent Senior Notes Due March 2033 [Member]",
        "documentation": "5.88 Percent Senior Notes Due March 2033"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A550PercentSeniorNotesDueMarch2053Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A550PercentSeniorNotesDueMarch2053Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$750 million, 5.500% due March 15, 2053",
        "label": "5.50 Percent Senior Notes Due March 2053 [Member]",
        "documentation": "5.50 Percent Senior Notes Due March 2053"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member",
     "presentation": [
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.70 Percent Senior Notes Due March 2026 And 5.50 Percent Senior Notes Due March 2053",
        "label": "5.70 Percent Senior Notes Due March 2026 And 5.50 Percent Senior Notes Due March 2053 [Member]",
        "documentation": "5.70 Percent Senior Notes Due March 2026 And 5.50 Percent Senior Notes Due March 2053"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A570PercentSeniorNotesDueMarch2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A570PercentSeniorNotesDueMarch2026Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$500 million, 5.700% due March 13, 2026",
        "label": "5.70 Percent Senior Notes Due March 2026 [Member]",
        "documentation": "5.70 Percent Senior Notes Due March 2026"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member",
     "presentation": [
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.750 Percent Senior Notes Due December 2028 And 5.50 Percent Senior Notes Due March 2034",
        "label": "5.750 Percent Senior Notes Due December 2028 And 5.50 Percent Senior Notes Due March 2034 [Member]",
        "documentation": "5.750 Percent Senior Notes Due December 2028 And 5.50 Percent Senior Notes Due March 2034"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A575PercentSeniorNotesDueDecember2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A575PercentSeniorNotesDueDecember2028Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$500 million, 5.750% due December 1, 2028",
        "label": "5.75 Percent Senior Notes Due December 2028 [Member]",
        "documentation": "5.75 Percent Senior Notes Due December 2028"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A575PercentSeniorNotesDueMarch2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A575PercentSeniorNotesDueMarch2028Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$500 million, 5.750% due March 1, 2028",
        "label": "5.75 Percent Senior Notes Due March 2028 [Member]",
        "documentation": "5.75 Percent Senior Notes Due March 2028"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A5950PercentSeniorNotesDueMarch2034Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A5950PercentSeniorNotesDueMarch2034Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$850 million, 5.950% due March 15, 2034",
        "label": "5.950 Percent Senior Notes Due March 2034 [Member]",
        "documentation": "5.950 Percent Senior Notes Due March 2034"
       }
      }
     },
     "auth_ref": []
    },
    "hum_A8.15PercentSeniorNotesDueJune2038Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "A8.15PercentSeniorNotesDueJune2038Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$250 million, 8.150% due June\u00a015, 2038",
        "label": "8.15 Percent Senior Notes Due June 2038 [Member]",
        "documentation": "8.15 Percent Senior Notes Due June 2038 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_AcceleratedShareRepurchasesAgreementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "AcceleratedShareRepurchasesAgreementAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated share repurchase agreement amount",
        "label": "Accelerated Share Repurchases, Agreement Amount",
        "documentation": "Accelerated Share Repurchases, Agreement Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AcceleratedShareRepurchasesDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcceleratedShareRepurchasesDateAxis",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated Share Repurchases, Date [Axis]",
        "label": "Accelerated Share Repurchases, Date [Axis]",
        "documentation": "Information by date of execution of accelerated share repurchases."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_AcceleratedShareRepurchasesDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcceleratedShareRepurchasesDateDomain",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated Share Repurchases, Date [Domain]",
        "label": "Accelerated Share Repurchases, Date [Domain]",
        "documentation": "Date upon which the accelerated share repurchase agreement was executed."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcceleratedShareRepurchasesFinalPricePaidPerShare",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average daily volume weighted-average share price of common stock during term of agreement (in dollars per share)",
        "label": "Accelerated Share Repurchases, Final Price Paid Per Share",
        "documentation": "Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcceleratedShareRepurchasesSettlementPaymentOrReceipt",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accelerated share repurchase payment",
        "label": "Accelerated Share Repurchases, Settlement (Payment) or Receipt",
        "documentation": "Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.humana.com/role/MEDICAREPARTDDetails": {
       "parentTag": "hum_NetCurrentLiabilityAsset",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/MEDICAREPARTDDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts payable and accrued expenses",
        "negatedLabel": "Trade accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payable to operating subsidiaries",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r948"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398"
     ]
    },
    "hum_AccruedPharmaceuticalRebatesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "AccruedPharmaceuticalRebatesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmaceutical rebates",
        "label": "Accrued Pharmaceutical Rebates, Current",
        "documentation": "Accrued Pharmaceutical Rebates, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r286",
      "r775"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r181",
      "r295",
      "r770",
      "r821",
      "r822"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r24",
      "r60",
      "r644",
      "r647",
      "r693",
      "r817",
      "r818",
      "r1066",
      "r1067",
      "r1068",
      "r1082",
      "r1083",
      "r1084"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1006"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital in excess of par value",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital\u00a0In Excess\u00a0of Par Value",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r606",
      "r607",
      "r835",
      "r1082",
      "r1083",
      "r1084",
      "r1177",
      "r1203"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_AdjustmentForAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentForAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Amortization",
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r97"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r573"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r976",
      "r988",
      "r998",
      "r1024"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r991",
      "r1001",
      "r1027"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r992",
      "r1002",
      "r1019",
      "r1028",
      "r1032",
      "r1040"
     ]
    },
    "hum_AllOthersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "AllOthersMember",
     "presentation": [
      "http://www.humana.com/role/REINSURANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "All others",
        "label": "All Others [Member]",
        "documentation": "All Others"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r608"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Stock-based compensation expense, net of tax",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables, net of allowances",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r399",
      "r446"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization expense for other intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r92",
      "r97"
     ]
    },
    "hum_AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/REINSURANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and securities in trusts held by certain reinsurers",
        "label": "Amount Held In Cash And Securities In Trust At Least Equal To Recoverable From Reinsurer",
        "documentation": "Amount held in cash and securities in trust, at least equal to the recoverable from the reinsurer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of antidilutive stock options and restricted stock\u00a0awards excluded from computation (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetBackedSecuritiesMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Asset-backed securities",
        "label": "Asset-Backed Securities [Member]",
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans."
       }
      }
     },
     "auth_ref": [
      "r936",
      "r1097",
      "r1103",
      "r1104"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset impairment charges",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r98"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r290",
      "r328",
      "r368",
      "r383",
      "r389",
      "r442",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r499",
      "r501",
      "r503",
      "r504",
      "r636",
      "r641",
      "r670",
      "r766",
      "r860",
      "r948",
      "r965",
      "r1132",
      "r1133",
      "r1184"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "verboseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "terseLabel": "Current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r298",
      "r328",
      "r442",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r499",
      "r501",
      "r503",
      "r504",
      "r636",
      "r641",
      "r670",
      "r948",
      "r1132",
      "r1133",
      "r1184"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "verboseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total invested assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r442",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r499",
      "r501",
      "r503",
      "r504",
      "r636",
      "r641",
      "r670",
      "r1132",
      "r1133",
      "r1184"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r159",
      "r164",
      "r207",
      "r279",
      "r280"
     ]
    },
    "hum_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.humana.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r971",
      "r984"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.humana.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r971",
      "r984"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.humana.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r971",
      "r984"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "terseLabel": "Book value",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r452",
      "r765"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r926"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after five years through ten years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1100"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after five years through ten years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r756"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after one year through five years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r755"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after ten years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due after ten years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r757"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisRollingMaturityAbstract",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost, Rolling Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due within one year",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due within one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r754"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage and asset-backed securities",
        "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping."
       }
      }
     },
     "auth_ref": [
      "r1096",
      "r1097"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage and asset-backed securities",
        "label": "Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r753",
      "r1096"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESContractualMaturitiesofDebtSecuritiesAvailableforSaleDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "totalLabel": "Total debt securities",
        "verboseLabel": "Debt securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r452",
      "r747",
      "r1093"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investment securities",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r402",
      "r452"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities Amortized Cost to Fair Value",
        "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesGrossUnrealizedGainLossAbstract",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "hum_BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/MEDICAREPARTDTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balance Sheet Amounts Associated With Medicare Part D",
        "label": "Balance Sheet Account Associated With Medicare Part D [Table Text Block]",
        "documentation": "Balance Sheet Account Associated With Medicare Part D"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Balance Sheet Location [Axis]",
        "documentation": "Information by location on balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Balance Sheet Location [Domain]",
        "documentation": "Location in the balance sheet (statement of financial position)."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r135"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance sheet",
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BenefitsLossesAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BenefitsLossesAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Benefits, Losses and Expenses",
        "documentation": "The total amount of expense recognized during the period for future policy benefits, claims and claims adjustment costs, and for selling, general and administrative costs."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "hum_BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefits Payable and Benefits Expense Recognition",
        "label": "Benefits Payable And Benefit Expense Recognition Policy [Policy Text Block]",
        "documentation": "Describes the entity's accounting policies, methodologies, and assumptions for estimating its liability as of the balance sheet date for the cost of settling reported and unreported claims."
       }
      }
     },
     "auth_ref": []
    },
    "hum_BookOverdraftLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "BookOverdraftLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Book overdraft",
        "label": "Book Overdraft Liability",
        "documentation": "Book Overdraft Liability"
       }
      }
     },
     "auth_ref": []
    },
    "hum_BookOverdraftPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "BookOverdraftPolicyPolicyTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Book Overdraft",
        "label": "Book Overdraft Policy [Policy Text Block]",
        "documentation": "Description of policies associated with the accounting treatment of book overdraft"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "hum_BuildingsAndLeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "BuildingsAndLeaseholdImprovementsMember",
     "presentation": [
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings and leasehold improvements",
        "label": "Buildings And Leasehold Improvements [Member]",
        "documentation": "Buildings And Leasehold Improvements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r634",
      "r939",
      "r940"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r122",
      "r634",
      "r939",
      "r940"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails",
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination and Asset Acquisition [Abstract]",
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction amount, net of existing equity stake",
        "label": "Business Combination, Consideration Per Agreement, Net Of Existing Equity Interest",
        "documentation": "Business Combination, Consideration Per Agreement, Net Of Existing Equity Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Existing equity value",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value",
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minority ownership prior to acquisition (percent)",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage",
        "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remeasurement gain",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain",
        "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "hum_BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining ownership percentage acquired",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Subsequent Acquisition, Percentage",
        "documentation": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Subsequent Acquisition, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "hum_BusinessCombinationTotalEnterpriseValueOfAcquiree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "BusinessCombinationTotalEnterpriseValueOfAcquiree",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Enterprise value of acquiree including existing equity value",
        "label": "Business Combination, Total Enterprise Value Of Acquiree",
        "documentation": "Business Combination, Total Enterprise Value Of Acquiree"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CallOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CallOptionMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Call option",
        "label": "Call Option [Member]",
        "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899"
     ]
    },
    "hum_CapitalContributionsToOperatingSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "CapitalContributionsToOperatingSubsidiaries",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Capital contributions to operating subsidiaries",
        "label": "Capital Contributions To Operating Subsidiaries",
        "documentation": "Capital contributions to operating subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense for capitalized internally developed and purchased software",
        "label": "Capitalized Computer Software, Amortization",
        "documentation": "Amount of expense for amortization of capitalized computer software costs."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r254"
     ]
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Value",
        "label": "Reported Value Measurement [Member]",
        "documentation": "Measured as reported on the statement of financial position (balance sheet)."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r144"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r283",
      "r915"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r193",
      "r324"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Decrease) increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r193"
     ]
    },
    "us-gaap_CededPremiumsWritten": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CededPremiumsWritten",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/REINSURANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Premiums ceded",
        "label": "Ceded Premiums Written",
        "documentation": "Amount of written premiums ceded to other entities."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r252"
     ]
    },
    "hum_CenterWellSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "CenterWellSegmentMember",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CenterWell",
        "label": "CenterWell Segment [Member]",
        "documentation": "CenterWell Segment"
       }
      }
     },
     "auth_ref": []
    },
    "hum_CertificateOfNeedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "CertificateOfNeedMember",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of need",
        "label": "Certificate Of Need [Member]",
        "documentation": "Certificate Of Need"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "hum_CitibankNAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "CitibankNAMember",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Citi",
        "label": "Citibank NA [Member]",
        "documentation": "Citibank NA"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClaimsDevelopmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClaimsDevelopmentLineItems",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails",
      "http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Claims Development [Line Items]",
        "label": "Claims Development [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfTreasuryStockTable",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Treasury Stock [Table]",
        "label": "Class of Treasury Stock [Table]",
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109"
     ]
    },
    "hum_CmsSubsidiesOrDiscountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "CmsSubsidiesOrDiscountsMember",
     "presentation": [
      "http://www.humana.com/role/MEDICAREPARTDDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CMS Subsidies/ Discounts",
        "label": "Cms Subsidies Or Discounts [Member]",
        "documentation": "CMS Subsidies Or Discounts [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "hum_CoinsuranceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "CoinsuranceAgreementMember",
     "presentation": [
      "http://www.humana.com/role/REINSURANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "100% coinsurance agreements",
        "label": "Coinsurance Agreement [Member]",
        "documentation": "Coinsurance Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Combination of age and years necessary for retirement provision as related to our equity award program",
        "label": "Combination Of Age And Years Necessary For Retirement Provision As Related To Our Equity Award Program",
        "documentation": "Combination of age and years necessary for retirement provision as related to our equity award program"
       }
      }
     },
     "auth_ref": []
    },
    "hum_CommercialASOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "CommercialASOMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial ASO",
        "label": "Commercial ASO [Member]",
        "documentation": "Commercial ASO"
       }
      }
     },
     "auth_ref": []
    },
    "hum_CommercialFullyInsuredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "CommercialFullyInsuredMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial fully-insured",
        "label": "Commercial Fully-Insured [Member]",
        "documentation": "Commercial Fully-Insured"
       }
      }
     },
     "auth_ref": []
    },
    "hum_CommercialMembershipContractTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "CommercialMembershipContractTerm",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health services term",
        "label": "Commercial Membership Contract Term",
        "documentation": "Commercial Membership Contract Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialMortgageBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialMortgageBackedSecuritiesMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial",
        "label": "Commercial Mortgage-Backed Securities [Member]",
        "documentation": "Securities collateralized by commercial real estate mortgage loans."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1103",
      "r1104",
      "r1140"
     ]
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails",
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commercial Paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r957",
      "r958",
      "r959",
      "r962"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 17)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r152",
      "r767",
      "r847"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS, GUARANTEES AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r483",
      "r485",
      "r908",
      "r1126"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareCashPaid",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYDividendPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount per share (in dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash dividend declared (in dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r954",
      "r955",
      "r957",
      "r958",
      "r959",
      "r962",
      "r1082",
      "r1083",
      "r1177",
      "r1201",
      "r1203"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "hum_CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification from capital in excess of par value to treasury stock",
        "label": "Common Stock Reclassified From Capital In Excess Of Par Value To Treasury Stock Upon Repurchase, Value",
        "documentation": "Common Stock Reclassified From Capital In Excess Of Par Value To Treasury Stock Upon Repurchase, Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r848"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r175",
      "r848",
      "r866",
      "r1203",
      "r1204"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,690,082 shares issued at December 31, 2023 and 198,666,598 shares issued at December 31, 2022",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r769",
      "r948"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "hum_CompanyCommonStockClosingSharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "CompanyCommonStockClosingSharePrice",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company common stock closing price (in dollars per share)",
        "label": "Company Common Stock, Closing Share Price",
        "documentation": "Company Common Stock, Closing Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "hum_ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive income attributable to equity method investments",
        "verboseLabel": "Comprehensive income attributable to equity method investments",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable To Equity Method Investments",
        "documentation": "Comprehensive Income (Loss), Net of Tax, Attributable To Equity Method Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income attributable to Humana",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r305",
      "r307",
      "r315",
      "r749",
      "r784"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/MEDICAREPARTDDetails",
      "http://www.humana.com/role/REPORTINGENTITYDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r84",
      "r145",
      "r146",
      "r396",
      "r907"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/MEDICAREPARTDDetails",
      "http://www.humana.com/role/REPORTINGENTITYDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r84",
      "r145",
      "r146",
      "r396",
      "r824",
      "r907"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/REPORTINGENTITYDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r84",
      "r145",
      "r146",
      "r396",
      "r907",
      "r1054"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.humana.com/role/REPORTINGENTITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/REPORTINGENTITYDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk (percent)",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r84",
      "r145",
      "r146",
      "r396"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.humana.com/role/REPORTINGENTITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r84",
      "r85",
      "r145",
      "r231",
      "r907"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/REPORTINGENTITYDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r84",
      "r145",
      "r146",
      "r396",
      "r907"
     ]
    },
    "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Financial Information Disclosure [Abstract]",
        "label": "Condensed Financial Information Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SCHEDULE I - PARENT COMPANY FINANCIAL INFORMATION",
        "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]",
        "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r332",
      "r1049"
     ]
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Financial Statements, Captions [Line Items]",
        "label": "Condensed Financial Statements, Captions [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r332",
      "r1049"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r332",
      "r636",
      "r637",
      "r641",
      "r642",
      "r697",
      "r909",
      "r1131",
      "r1134",
      "r1135"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r332",
      "r636",
      "r637",
      "r641",
      "r642",
      "r697",
      "r909",
      "r1131",
      "r1134",
      "r1135"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r332",
      "r370",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r391",
      "r492",
      "r493",
      "r494",
      "r495",
      "r497",
      "r498",
      "r500",
      "r502",
      "r503",
      "r1132",
      "r1133"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r332",
      "r370",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r391",
      "r492",
      "r493",
      "r494",
      "r495",
      "r497",
      "r498",
      "r500",
      "r502",
      "r503",
      "r1132",
      "r1133"
     ]
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interests",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "hum_ConsumerDiscountsOnBrandNamePrescriptionDrugs": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ConsumerDiscountsOnBrandNamePrescriptionDrugs",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consumer discounts on brand name prescription drugs",
        "label": "Consumer Discounts On Brand Name Prescription Drugs",
        "documentation": "Beginning in 2011, the Health Reform Legislation mandates consumer discounts of 50% on brand name prescription drugs for Part D plan participants in the coverage gap. These discounts are funded by CMS and pharmaceutical manufacturers while we administer the application of these funds."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unearned revenues",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r549",
      "r560"
     ]
    },
    "us-gaap_ContractualRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualRightsMember",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provider contracts",
        "label": "Contractual Rights [Member]",
        "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements)."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "hum_CorporateAndEliminationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "CorporateAndEliminationsMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eliminations/ Corporate",
        "label": "Corporate And Eliminations [Member]",
        "documentation": "Corporate And Eliminations [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r936",
      "r938",
      "r1200"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails": {
       "parentTag": "hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r509",
      "r535",
      "r696",
      "r917",
      "r919"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CreditRatingStandardPoorsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CreditRatingStandardPoorsAxis",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Rating, Standard &amp; Poor's [Axis]",
        "label": "Credit Rating, Standard &amp; Poor's [Axis]"
       }
      }
     },
     "auth_ref": [
      "r924",
      "r1089",
      "r1112",
      "r1176"
     ]
    },
    "us-gaap_CreditSpreadOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditSpreadOptionMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit spread",
        "label": "Credit Spread Option [Member]",
        "documentation": "An option on the yield spread on a bond."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1056",
      "r1081",
      "r1173"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current provision",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r624",
      "r630",
      "r1081"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "States and Puerto Rico",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1056",
      "r1081",
      "r1173"
     ]
    },
    "us-gaap_CustomerContractsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerContractsMember",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer contracts/relationships",
        "label": "Customer Contracts [Member]",
        "documentation": "Entity's established relationships with its customers through contracts."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_DebtAndEquitySecuritiesGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtAndEquitySecuritiesGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss on investment securities, net",
        "totalLabel": "Net recognized losses on investment securities",
        "label": "Debt and Equity Securities, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186"
     ]
    },
    "hum_DebtAndEquitySecuritiesRealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DebtAndEquitySecuritiesRealizedGain",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails": {
       "parentTag": "us-gaap_DebtAndEquitySecuritiesGainLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross gains on investment securities",
        "label": "Debt And Equity Securities, Realized Gain",
        "documentation": "Debt And Equity Securities, Realized Gain"
       }
      }
     },
     "auth_ref": []
    },
    "hum_DebtAndEquitySecuritiesRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DebtAndEquitySecuritiesRealizedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails": {
       "parentTag": "us-gaap_DebtAndEquitySecuritiesGainLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross losses on investment securities",
        "label": "Debt And Equity Securities, Realized Loss",
        "documentation": "Debt And Equity Securities, Realized Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.humana.com/role/DEBTDebtOutstandingDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term debt",
        "totalLabel": "Total short-term debt",
        "label": "Debt, Current",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.humana.com/role/DEBT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEBT",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r326",
      "r505",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r521",
      "r528",
      "r529",
      "r531"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r169",
      "r170",
      "r234",
      "r236",
      "r332",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r517",
      "r518",
      "r519",
      "r520",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r680",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r1079"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis points spread on variable rate (percent)",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "hum_DebtInstrumentCovenantDebtToCapitalizationPercentageActual": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DebtInstrumentCovenantDebtToCapitalizationPercentageActual",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actual debt to capitalization percentage",
        "label": "Debt Instrument, Covenant, Debt To Capitalization Percentage, Actual",
        "documentation": "Debt Instrument, Covenant, Debt To Capitalization Percentage, Actual"
       }
      }
     },
     "auth_ref": []
    },
    "hum_DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt to capitalization percentage, maximum",
        "label": "Debt Instrument, Covenant, Debt To Capitalization Percentage, Maximum",
        "documentation": "Debt Instrument, Covenant, Debt To Capitalization Percentage, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate principal",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r151",
      "r506",
      "r680",
      "r929",
      "r930"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt outstanding",
        "label": "Debt Instrument, Fair Value Disclosure",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r669",
      "r929",
      "r930"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stated interest rate (percent)",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r507"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r517",
      "r518",
      "r519",
      "r520",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r530",
      "r680",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r1079"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r332",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r517",
      "r518",
      "r519",
      "r520",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r680",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r1079"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption price, percentage",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRepurchaseAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, repurchase amount",
        "label": "Debt Instrument, Repurchase Amount",
        "documentation": "Fair value amount of debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, repurchased face amount",
        "label": "Debt Instrument, Repurchased Face Amount",
        "documentation": "Face (par) amount of the original debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r103",
      "r104",
      "r148",
      "r149",
      "r151",
      "r153",
      "r214",
      "r215",
      "r332",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r512",
      "r517",
      "r518",
      "r519",
      "r520",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r530",
      "r680",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r1079"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument term (in years)",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12 months or more",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r458",
      "r926"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "12 months or more",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r458"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less\u00a0than\u00a012\u00a0months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r458",
      "r926"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less\u00a0than\u00a012\u00a0months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r458"
     ]
    },
    "hum_DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities, number of positions",
        "label": "Debt, Securities, Available-For-Sale, Securities, Number Of Positions",
        "documentation": "Debt Securities, Available-for-sale, Securities, Number of Positions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r455",
      "r926"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r456"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r926"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Securities in unrealized loss position, number of positions",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r457"
     ]
    },
    "hum_December2020AcceleratedShareRepurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "December2020AcceleratedShareRepurchaseAgreementMember",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "December 2020 ASR",
        "label": "December 2020 Accelerated Share Repurchase Agreement [Member]",
        "documentation": "December 2020 Accelerated Share Repurchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred (benefit) expense",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r223",
      "r267",
      "r629",
      "r630",
      "r1081"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred income tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173",
      "r235",
      "r618"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred income taxes",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "hum_DeferredTaxAssetJobsTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DeferredTaxAssetJobsTaxCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Jobs tax credits",
        "label": "Deferred Tax Asset, Jobs Tax Credit",
        "documentation": "Deferred Tax Asset, Jobs Tax Credit"
       }
      }
     },
     "auth_ref": []
    },
    "hum_DeferredTaxAssetsDeferredPolicyAcquisitionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DeferredTaxAssetsDeferredPolicyAcquisitionCost",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred acquisition costs",
        "label": "Deferred Tax Assets, Deferred Policy Acquisition Cost",
        "documentation": "Portion of deferred tax balance as it relates to deferred acquisition costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred income tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment securities",
        "label": "Deferred Tax Assets, Investments",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net deferred income tax assets (liabilities)",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1171"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred income tax assets, net of valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1171"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r1172"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r1172"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefits payable",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r1172"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation and other accrued expense",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r1172"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unearned revenues",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Unearned Premiums Reserve",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the unearned premiums reserve."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r1172"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESNarrativeDetails",
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowances on net operating loss carryforwards related to prior acquisitions",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total net deferred income tax assets (liabilities)",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r1171"
     ]
    },
    "hum_DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciable property and intangible assets",
        "label": "Deferred Tax Liabilities Depreciable Property And Intangible Assets",
        "documentation": "Portion of deferred tax balance as it relates to depreciable property and intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r1172"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESPrincipalComponentsofNetDeferredTaxBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee retirement and savings plan cost",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "hum_DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of common stock reserved for issuance under defined contribution retirement savings plan (in shares)",
        "label": "Defined Contribution Plan, Number Of Shares Of Common Stock Reserved For Issuance",
        "documentation": "Defined Contribution Plan, Number Of Shares Of Common Stock Reserved For Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan assets invested in Company common stock (percent)",
        "label": "Defined Contribution Plan, Plan Assets Invested In Company Common Stock",
        "documentation": "Defined Contribution Plan, Plan Assets Invested In Company Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "hum_DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan assets invested in Company common stock (in shares)",
        "label": "Defined Contribution Plan, Plan Assets Invested In Company Common Stock, Shares",
        "documentation": "Defined Contribution Plan, Plan Assets Invested In Company Common Stock, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "hum_DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock plan assets as percentage of shares outstanding",
        "label": "Defined Contribution Plan, Shares Of Common Stock In Plan As Percentage Of Shares Outstanding",
        "documentation": "Defined Contribution Plan, Shares Of Common Stock In Plan As Percentage Of Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "hum_DefinitiveAgreementEquityInterestToBeAcquiredPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DefinitiveAgreementEquityInterestToBeAcquiredPercentage",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest to be acquired per agreement (percent)",
        "label": "Definitive Agreement, Equity Interest To Be Acquired, Percentage",
        "documentation": "Definitive Agreement, Equity Interest To Be Acquired, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "hum_DelayedDrawTermLoanMay2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DelayedDrawTermLoanMay2024Member",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Delayed draw term loan, due May 28, 2024",
        "label": "Delayed Draw Term Loan May 2024 [Member]",
        "documentation": "Delayed Draw Term Loan May 2024"
       }
      }
     },
     "auth_ref": []
    },
    "hum_DelayedDrawTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DelayedDrawTermLoanMember",
     "presentation": [
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Delayed Draw Term Loan",
        "label": "Delayed Draw Term Loan [Member]",
        "documentation": "Delayed Draw Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r99"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r99"
     ]
    },
    "hum_DepreciationAndAmortizationClassifiedAsBenefitExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DepreciationAndAmortizationClassifiedAsBenefitExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization classified as benefit expense",
        "label": "Depreciation And Amortization Classified As Benefit Expense",
        "documentation": "Depreciation and amortization expense that has been reclassified to be included with benefit expenses. The reclassification is the result of depreciation and amortization expense associated primarily from the delivery of pharmacy services by our wholly-owned pharmacy business included in our Healthcare Services segment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationNonproduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationNonproduction",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation, Nonproduction",
        "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r99"
     ]
    },
    "us-gaap_DerivativeAssetLiabilityNetMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeAssetLiabilityNetMeasurementInput",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant unobservable inputs",
        "label": "Derivative Asset (Liability) Net, Measurement Input",
        "documentation": "Value of input used to measure net derivative asset (liability)."
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r837",
      "r839",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r861",
      "r862",
      "r863",
      "r864",
      "r874",
      "r875",
      "r876",
      "r877",
      "r880",
      "r881",
      "r882",
      "r883",
      "r899",
      "r901",
      "r902",
      "r903",
      "r953",
      "r955"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r134",
      "r136",
      "r137",
      "r837",
      "r839",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r861",
      "r862",
      "r863",
      "r864",
      "r874",
      "r875",
      "r876",
      "r877",
      "r880",
      "r881",
      "r882",
      "r883",
      "r899",
      "r901",
      "r902",
      "r903",
      "r919",
      "r953",
      "r955"
     ]
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notional amount",
        "label": "Derivative, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r1174",
      "r1175"
     ]
    },
    "hum_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EMPLOYEE BENEFIT PLANS",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments And Compensation And Retirement Disclosure [Text Block]",
        "documentation": "Disclosure Of Compensation Related Costs Share Based Payments And Compensation And Retirement Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-tax gain, net of transaction costs",
        "label": "Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax",
        "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r161",
      "r162"
     ]
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails",
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails",
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails",
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations",
        "terseLabel": "Disposed of by sale",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r32"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables, net of allowances",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r159",
      "r164",
      "r207"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade accounts payable and accrued expenses",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Amount classified as accounts payable and accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r159",
      "r164",
      "r204",
      "r207"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r159",
      "r164",
      "r207"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration to be received",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "hum_DisposalGroupIncludingDiscontinuedOperationEquityInterestSold": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationEquityInterestSold",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest to be sold",
        "label": "Disposal Group, Including Discontinued Operation, Equity Interest Sold",
        "documentation": "Disposal Group, Including Discontinued Operation, Equity Interest Sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent",
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r5",
      "r159",
      "r164",
      "r207"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Identifiable intangibles",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent",
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r5",
      "r159",
      "r164",
      "r207"
     ]
    },
    "hum_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Disposal Group, Including Discontinued Operation, Noncontrolling interest",
        "documentation": "Disposal Group, Including Discontinued Operation, Noncontrolling interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current",
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r159",
      "r164",
      "r204",
      "r207"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent",
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r5",
      "r159",
      "r164",
      "r207"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails": {
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent",
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r5",
      "r159",
      "r164",
      "r207"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails": {
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent",
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r5",
      "r159",
      "r164",
      "r207"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r280"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails",
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r939",
      "r940"
     ]
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYDividendPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Amount",
        "label": "Dividends",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r216"
     ]
    },
    "us-gaap_DividendsCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends",
        "label": "Dividends, Common Stock",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r216"
     ]
    },
    "us-gaap_DividendsCommonStockCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsCommonStockCash",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends and dividend equivalents",
        "label": "Dividends, Common Stock, Cash",
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_DividendsDeclaredTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsDeclaredTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Details of Dividend Payments",
        "label": "Dividends Declared [Table Text Block]",
        "documentation": "Tabular disclosure of information related to dividends declared, including paid and unpaid dividends."
       }
      }
     },
     "auth_ref": []
    },
    "hum_DividendsToParentWithoutPriorStateRegulatoryApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "DividendsToParentWithoutPriorStateRegulatoryApproval",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONNotestoCondensedFinancialStatementsDetails",
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actual dividends paid to parent company",
        "label": "Dividends To Parent Without Prior State Regulatory Approval",
        "documentation": "Amount of dividends paid to our parent company without prior approval by state regulatory authorities"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r970",
      "r971",
      "r984"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r970",
      "r971",
      "r984",
      "r1020"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1005"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic earnings per common share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r348",
      "r350",
      "r356",
      "r357",
      "r358",
      "r362",
      "r652",
      "r653",
      "r750",
      "r785",
      "r920"
     ]
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicLineItems",
     "presentation": [
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r354",
      "r356"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted earnings per common share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r350",
      "r356",
      "r357",
      "r358",
      "r362",
      "r652",
      "r653",
      "r750",
      "r785",
      "r920"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EARNINGS PER COMMON SHARE COMPUTATION",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r359",
      "r360",
      "r361"
     ]
    },
    "hum_EffectiveIncomeTaxReconciliationNonTaxableKAHGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "EffectiveIncomeTaxReconciliationNonTaxableKAHGain",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-taxable KAH gain",
        "label": "Effective Income Tax Reconciliation, Non-Taxable KAH Gain",
        "documentation": "Effective Income Tax Reconciliation, Non-Taxable KAH Gain"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectsOfReinsuranceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectsOfReinsuranceLineItems",
     "presentation": [
      "http://www.humana.com/role/REINSURANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effects of Reinsurance [Line Items]",
        "label": "Effects of Reinsurance [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense recognition over a weighted-average period (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total compensation expense not yet recognized related to nonvested awards",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1168"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense not yet recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1168"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax benefit recognized",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r602"
     ]
    },
    "hum_EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Actual realized tax benefit on tax returns from option exercises and restricted stock vesting",
        "label": "Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options And Restricted Stock Vesting",
        "documentation": "Disclosure of the aggregate tax benefit realized from the exercise of stock options and vesting of restricted stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "verboseLabel": "Employee stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityClassOfTreasuryStockLineItems",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r275",
      "r309",
      "r310",
      "r311",
      "r333",
      "r334",
      "r335",
      "r337",
      "r343",
      "r345",
      "r363",
      "r444",
      "r445",
      "r547",
      "r605",
      "r606",
      "r607",
      "r625",
      "r626",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r651",
      "r671",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r693",
      "r817",
      "r818",
      "r819",
      "r835",
      "r886"
     ]
    },
    "hum_EquityInNetEarningsOfSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "EquityInNetEarningsOfSubsidiaries",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity in net earnings of subsidiaries",
        "label": "Equity In Net Earnings Of Subsidiaries",
        "documentation": "Equity in net earnings of subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r441"
     ]
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r328",
      "r442",
      "r670"
     ]
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r328",
      "r442",
      "r670"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investment ownership (percent)",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on Kindred at Home equity method investment",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment."
       }
      }
     },
     "auth_ref": [
      "r1071",
      "r1072",
      "r1077"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investments",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r436",
      "r1064",
      "r1110"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]",
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY METHOD INVESTMENT",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r440",
      "r443",
      "r1047"
     ]
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r147",
      "r439"
     ]
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityMethodInvestmentsTextBlock",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments",
        "label": "Equity Method Investments [Table Text Block]",
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails": {
       "parentTag": "us-gaap_Investments",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r667",
      "r916"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesonEquitySecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesonEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net gains (losses) recognized on equity securities during the period",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r789",
      "r1109"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiRealizedGain",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails": {
       "parentTag": "us-gaap_DebtAndEquitySecuritiesGainLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross gains on equity securities",
        "label": "Equity Securities, FV-NI, Realized Gain",
        "documentation": "Amount of realized gain from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesonEquitySecuritiesDetails": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesonEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Net gains (losses) recognized on equity securities sold during the period",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r1109"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiRealizedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails": {
       "parentTag": "us-gaap_DebtAndEquitySecuritiesGainLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESRealizedGainsLossesIncludedWithinInvestmentIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross losses on equity securities",
        "label": "Equity Securities, FV-NI, Realized Loss",
        "documentation": "Amount of realized loss from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r1109"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesonEquitySecuritiesDetails": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESGainsLossesonEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized losses recognized on equity securities still held at the end of the period",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r788",
      "r1109"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r976",
      "r988",
      "r998",
      "r1024"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r973",
      "r985",
      "r995",
      "r1021"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Estimate of Fair Value Measurement [Member]",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r669",
      "r929",
      "r930"
     ]
    },
    "hum_ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excluding Employee Stock Plans and ASR",
        "label": "Excluding Employee Stock Plans And Accelerated Share Repurchase Agreement [Member]",
        "documentation": "Excluding Employee Stock Plans And Accelerated Share Repurchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "hum_ExitFromEmployerGroupCommercialMedicalProductsBusinessMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ExitFromEmployerGroupCommercialMedicalProductsBusinessMember",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exit From Employer Group Commercial Medical Products Business",
        "label": "Exit From Employer Group Commercial Medical Products Business [Member]",
        "documentation": "Exit From Employer Group Commercial Medical Products Business"
       }
      }
     },
     "auth_ref": []
    },
    "hum_Expenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "Expenses",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses",
        "label": "Expenses",
        "documentation": "Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ExternalCreditRatingStandardPoorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ExternalCreditRatingStandardPoorsMember",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External Credit Rating, Standard &amp; Poor's [Domain]",
        "label": "External Credit Rating, Standard &amp; Poor's [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_ExternalRevenuesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ExternalRevenuesMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External Revenues",
        "label": "External Revenues [Member]",
        "documentation": "External Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r655",
      "r656",
      "r663"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r655",
      "r656",
      "r663"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used For Inputs In Fair Value Measurement",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Assets Measured at Fair Value on Recurring Basis",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r230"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r142"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r143",
      "r144"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r656",
      "r702",
      "r703",
      "r704",
      "r929",
      "r930",
      "r936",
      "r937",
      "r938"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Basis [Axis]",
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r140",
      "r519",
      "r929",
      "r930"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Basis [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r655",
      "r656",
      "r658",
      "r659",
      "r664"
     ]
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosureItemAmountsDomain",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement [Domain]",
        "label": "Fair Value Measurement [Domain]",
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r929",
      "r930"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted\u00a0Prices in Active Markets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r562",
      "r567",
      "r656",
      "r702",
      "r936",
      "r937",
      "r938"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r562",
      "r567",
      "r656",
      "r703",
      "r929",
      "r930",
      "r936",
      "r937",
      "r938"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable Inputs (Level 3)",
        "verboseLabel": "Level 3 fair value measurement",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r656",
      "r704",
      "r929",
      "r930",
      "r936",
      "r937",
      "r938"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "hum_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossAbstract",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total gains or losses:",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) [Abstract]",
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized in earnings",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized in other comprehensive\u00a0income",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from asset measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Sales",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales",
        "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Settlements",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements",
        "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfers In",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Transfers Out",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/FAIRVALUESignificantUnobservableInputsLevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset value",
        "periodStartLabel": "Beginning balance at January\u00a01",
        "periodEndLabel": "Balance at December\u00a031",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r702",
      "r703",
      "r704",
      "r929",
      "r930",
      "r936",
      "r937",
      "r938"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring Basis",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r664"
     ]
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfAssetsAcquired",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of assets acquired, net of cash acquired",
        "label": "Fair Value of Assets Acquired",
        "documentation": "The fair value of assets acquired in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r42"
     ]
    },
    "hum_FairValueRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "FairValueRiskMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Risk",
        "label": "Fair Value Risk [Member]",
        "documentation": "Fair Value Risk"
       }
      }
     },
     "auth_ref": []
    },
    "hum_FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Favorable\u00a0medical\u00a0claims\u00a0reserve development related to prior fiscal years",
        "label": "Favorable Medical Claims Reserve Development Related To Prior Fiscal Years",
        "documentation": "Favorable medical claims reserve development related to prior fiscal years"
       }
      }
     },
     "auth_ref": []
    },
    "hum_February2021ShareRepurchaseAuthorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "February2021ShareRepurchaseAuthorizationMember",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "February 2021 Authorization",
        "label": "February 2021 Share Repurchase Authorization [Member]",
        "documentation": "February 2021 Share Repurchase Authorization"
       }
      }
     },
     "auth_ref": []
    },
    "hum_February2023ShareRepurchaseAuthorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "February2023ShareRepurchaseAuthorizationMember",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "February 2023",
        "label": "February 2023 Share Repurchase Authorization [Member]",
        "documentation": "February 2023 Share Repurchase Authorization"
       }
      }
     },
     "auth_ref": []
    },
    "hum_FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember",
     "presentation": [
      "http://www.humana.com/role/REPORTINGENTITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CMS, coverage for individual Medicare Advantage members in Florida",
        "label": "Federal Government, Centers For Medicare And Medicaid Services, Florida Medicare Advantage [Member]",
        "documentation": "Federal Government, Centers For Medicare And Medicaid Services, Florida Medicare Advantage [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_FederalGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "FederalGovernmentMember",
     "presentation": [
      "http://www.humana.com/role/REPORTINGENTITYDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal government contracts",
        "label": "Federal Government [Member]",
        "documentation": "Federal Government [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FederalHomeLoanBankAdvancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FederalHomeLoanBankAdvancesMember",
     "presentation": [
      "http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal Home Loan Bank Advances",
        "label": "Federal Home Loan Bank Advances [Member]",
        "documentation": "Borrowings from the Federal Home Loan Bank, which are primarily used to cover shortages in the required reserve balance and also in times of liquidity shortages. The member institution executes a promissory note, which is generally collateralized by government securities to the Federal Reserve or loans."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "hum_FinancialAssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "FinancialAssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of financial asset",
        "label": "Financial Assets, Fair Value Disclosure",
        "documentation": "Financial Assets, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r453",
      "r459",
      "r460",
      "r530",
      "r545",
      "r649",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r783",
      "r926",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1105",
      "r1106",
      "r1107",
      "r1108"
     ]
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of financial liability",
        "label": "Financial Liabilities Fair Value Disclosure",
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancingReceivableRecordedInvestmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancingReceivableRecordedInvestmentLineItems",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Receivable, Credit Quality Indicator [Line Items]",
        "label": "Financing Receivable, Credit Quality Indicator [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r1112"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average life (in years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortizable intangible assets, accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r477"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSEstimateofAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSEstimateofAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSEstimateofAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSEstimateofAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSEstimateofAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r476",
      "r477",
      "r479",
      "r732",
      "r733"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSEstimateofAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimate of Amortization Expense",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortizable intangible assets, cost",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r733"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortizable intangible assets, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r732"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other intangible assets:",
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r992",
      "r1002",
      "r1028"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r992",
      "r1002",
      "r1028"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r992",
      "r1002",
      "r1028"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r992",
      "r1002",
      "r1028"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r992",
      "r1002",
      "r1028"
     ]
    },
    "hum_FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future policy benefits payable",
        "label": "Future Policy And Benefits Payable Policy [Policy Text Block]",
        "documentation": "Description of policies associated with the accounting treatment of future policy benefits payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnInvestmentsTextBlock",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gain (Loss) on Equity Securities",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security."
       }
      }
     },
     "auth_ref": [
      "r1069",
      "r1070"
     ]
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on sale of Gentiva Hospice",
        "label": "Gain (Loss) on Disposition of Business",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r1077"
     ]
    },
    "hum_GentivaHospiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "GentivaHospiceMember",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails",
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gentiva Hospice",
        "label": "Gentiva Hospice [Member]",
        "documentation": "Gentiva Hospice"
       }
      }
     },
     "auth_ref": []
    },
    "hum_GoldmanSachsCoLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "GoldmanSachsCoLLCMember",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goldman Sachs",
        "label": "Goldman Sachs &amp; Co. LLC [Member]",
        "documentation": "Goldman Sachs &amp; Co. LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r461",
      "r746",
      "r927",
      "r948",
      "r1114",
      "r1121"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r927"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r90"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment loss",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r462",
      "r468",
      "r473",
      "r927"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r927"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Roll Forward]",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Dispositions",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r467",
      "r927"
     ]
    },
    "hum_GovernmentAndHealthPlanMemberSubsidiesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "GovernmentAndHealthPlanMemberSubsidiesAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Member co-share amounts and government subsidies",
        "label": "Government And Health Plan Member Subsidies Amount",
        "documentation": "Amount of member co-share amounts and government subsidies that are excluded from benefits expense because the health plans do not bear responsibility."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentContractsConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GovernmentContractsConcentrationRiskMember",
     "presentation": [
      "http://www.humana.com/role/REPORTINGENTITYDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government contracts concentration risk",
        "label": "Government Contracts Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. Risk is the materially adverse effects of termination of a significant contract or group of contracts or from future loss of a significant portion of business with a specified political body or unit thereof, such as Department of Defense, US Navy, New York City."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "hum_GroupMedicareAdvantageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "GroupMedicareAdvantageMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Group Medicare Advantage",
        "label": "Group Medicare Advantage [Member]",
        "documentation": "Group Medicare Advantage"
       }
      }
     },
     "auth_ref": []
    },
    "hum_HealthCareCostPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "HealthCareCostPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESHealthCareCostPaymentsNetDetails": {
       "parentTag": "hum_HealthCareCostPaymentsAndReimbursementsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESHealthCareCostPaymentsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Health care cost payments",
        "label": "Health Care Cost Payments",
        "documentation": "Health care cost payments associated with the TRICARE South Region contract"
       }
      }
     },
     "auth_ref": []
    },
    "hum_HealthCareCostPaymentsAndReimbursementsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "HealthCareCostPaymentsAndReimbursementsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESHealthCareCostPaymentsNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESHealthCareCostPaymentsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net reimbursements (payments)",
        "label": "Health Care Cost Payments And Reimbursements, Net",
        "documentation": "The difference between health care cost payments and reimbursements related to the TRICARE South Region contract."
       }
      }
     },
     "auth_ref": []
    },
    "hum_HealthCareCostReimbursements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "HealthCareCostReimbursements",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESHealthCareCostPaymentsNetDetails": {
       "parentTag": "hum_HealthCareCostPaymentsAndReimbursementsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESHealthCareCostPaymentsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health care cost reimbursements",
        "label": "Health Care Cost Reimbursements",
        "documentation": "Reimbursements for health care cost payments associated with the TRICARE South Region contract"
       }
      }
     },
     "auth_ref": []
    },
    "hum_HomeSolutionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "HomeSolutionsMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Home solutions",
        "label": "Home Solutions [Member]",
        "documentation": "Home Solutions"
       }
      }
     },
     "auth_ref": []
    },
    "hum_HomeSolutionsReportingUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "HomeSolutionsReportingUnitMember",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Home Solutions Reporting Unit",
        "label": "Home Solutions Reporting Unit [Member]",
        "documentation": "Home Solutions Reporting Unit"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r971",
      "r984"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of indefinite-lived intangible assets",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r1077",
      "r1124"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets held for abandonment",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r203"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r209"
     ]
    },
    "hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "IncomeLossBeforeEquityInNetEarningsOfSubsidiaries",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) income before equity in net earnings of subsidiaries",
        "label": "Income Loss Before Equity In Net Earnings Of Subsidiaries",
        "documentation": "Income (loss) before equity in net earnings of subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails": {
       "parentTag": "hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes and equity in net earnings of subsidiaries",
        "label": "Income (Loss) Before Income Taxes And Equity In Net Earnings Of Subsidiaries",
        "documentation": "Income (Loss) Before Income Taxes And Equity In Net Earnings Of Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Segment earnings (loss) attributable to Humana",
        "label": "Income Loss From Continuing Operations Before Income Taxes Attributable To Parent",
        "documentation": "Income Loss From Continuing Operations Before Income Taxes Attributable To Parent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails": {
       "parentTag": "hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Segment earnings (loss)",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r182",
      "r243",
      "r368",
      "r382",
      "r388",
      "r391",
      "r751",
      "r778",
      "r922"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before income taxes and equity in net earnings",
        "verboseLabel": "Income (loss) before income taxes and equity in net earnings (losses)",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r382",
      "r388",
      "r391",
      "r790",
      "r922"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity in net (losses) earnings",
        "negatedTerseLabel": "Equity in net losses (earnings)",
        "verboseLabel": "Equity in net losses",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r183",
      "r242",
      "r375",
      "r436",
      "r777"
     ]
    },
    "us-gaap_IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pretax earnings",
        "label": "Income (Loss) from Individually Significant Component Disposed of or Held-for-Sale, Excluding Discontinued Operations, before Income Tax",
        "documentation": "Amount before tax of income (loss) from an individually significant component disposed of or held-for-sale including the portion attributable to the noncontrolling interest. Excludes discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails",
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r939",
      "r940"
     ]
    },
    "us-gaap_IncomeStatementRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementRelatedDisclosuresAbstract",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Related Disclosures [Abstract]",
        "label": "Income Statement Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.humana.com/role/INCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r610",
      "r615",
      "r616",
      "r622",
      "r627",
      "r631",
      "r632",
      "r633",
      "r832"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails": {
       "parentTag": "hum_IncomeLossBeforeEquityInNetEarningsOfSubsidiaries",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesDetails",
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Provision for income taxes",
        "totalLabel": "Provision for income taxes",
        "terseLabel": "Benefit for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r268",
      "r344",
      "r345",
      "r376",
      "r613",
      "r628",
      "r791"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r611",
      "r612",
      "r616",
      "r617",
      "r621",
      "r623",
      "r829"
     ]
    },
    "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationDispositionOfBusiness",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax effect from sale of Gentiva Hospice",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1170"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax provision at federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nondeductible executive compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1170"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1170"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "States, net of federal benefit, and Puerto Rico",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1170"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r1170"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxExemptIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxExemptIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESProvisionforIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax exempt investment income",
        "label": "Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income (loss) exempt from income taxes."
       }
      }
     },
     "auth_ref": [
      "r1170"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payments, net",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_IncreaseDecreaseInBookOverdrafts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInBookOverdrafts",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in book overdraft",
        "label": "Increase (Decrease) in Book Overdrafts",
        "documentation": "The increase (decrease) in cash during the period due to the net increase or decrease in book overdrafts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unearned revenues",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r730",
      "r1076"
     ]
    },
    "us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInHealthCareInsuranceLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefits payable",
        "label": "Increase (Decrease) in Health Care Insurance Liabilities",
        "documentation": "The increase (decrease) in health care insurance liability balances during the period."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities, net of effect of businesses acquired and dispositions:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Receivables",
        "label": "Increase (Decrease) in Receivables",
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive effect of employee stock options and restricted stock (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r351",
      "r352",
      "r353",
      "r358",
      "r575"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r475",
      "r478"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails",
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived intangible assets",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r201"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r992",
      "r1002",
      "r1019",
      "r1028",
      "r1032",
      "r1040"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1044"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1044"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1044"
     ]
    },
    "us-gaap_InsuranceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuranceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance [Abstract]",
        "label": "Insurance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InsuranceContractAcquisitionCostPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuranceContractAcquisitionCostPolicyTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Policy Acquisition Costs",
        "label": "Insurance Contract, Acquisition Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost related directly to successful acquisition of new and renewal of insurance contract. Information includes, but is not limited to, input, judgment, assumption, and method used to determine amortization amount, and change in input, judgment, and assumption. Cost, includes but is not limited to, deferred policy acquisition cost, deferred sale inducement cost, and present value of future profit of insurance contract acquired in business combination."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r763",
      "r809",
      "r810",
      "r811"
     ]
    },
    "us-gaap_InsuranceDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuranceDisclosureTextBlock",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BENEFITS PAYABLE",
        "label": "Insurance Disclosure [Text Block]",
        "documentation": "The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r762",
      "r812",
      "r813"
     ]
    },
    "us-gaap_InsurancePremiumsRevenueRecognitionPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsurancePremiumsRevenueRecognitionPolicy",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Premiums Revenue",
        "label": "Insurance Premiums Revenue Recognition, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue recognition of insurance premium. Includes, but is not limited to, basis for measurement and timing of recognition of revenue from insurance premium received from contract holder and method used in performing premium deficiency testing."
       }
      }
     },
     "auth_ref": [
      "r264"
     ]
    },
    "hum_InsuranceSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "InsuranceSegmentMember",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance",
        "label": "Insurance Segment [Member]",
        "documentation": "Insurance Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other intangible assets, cost",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r287"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r95"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest expense",
        "terseLabel": "Interest",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r245",
      "r312",
      "r372",
      "r679",
      "r871",
      "r963",
      "r1202"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest payments",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r322",
      "r323"
     ]
    },
    "us-gaap_InterestRateFairValueHedgeAssetAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestRateFairValueHedgeAssetAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Swap asset",
        "label": "Interest Rate Fair Value Hedge Asset at Fair Value",
        "documentation": "Fair value as of the balance sheet date of all derivative assets designated as interest rate fair value hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "hum_InterestRateSwapMaturing2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "InterestRateSwapMaturing2032Member",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swap Maturing 2032",
        "label": "Interest Rate Swap Maturing 2032 [Member]",
        "documentation": "Interest Rate Swap Maturing 2032"
       }
      }
     },
     "auth_ref": []
    },
    "hum_InterestRateSwapMaturing2033Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "InterestRateSwapMaturing2033Member",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swap Maturing 2033",
        "label": "Interest Rate Swap Maturing 2033 [Member]",
        "documentation": "Interest Rate Swap Maturing 2033"
       }
      }
     },
     "auth_ref": []
    },
    "hum_InterestRateSwapMaturing2034Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "InterestRateSwapMaturing2034Member",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swap Maturing 2034",
        "label": "Interest Rate Swap Maturing 2034 [Member]",
        "documentation": "Interest Rate Swap Maturing 2034"
       }
      }
     },
     "auth_ref": []
    },
    "hum_InterestRateSwapMaturing2049Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "InterestRateSwapMaturing2049Member",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swap Maturing 2049",
        "label": "Interest Rate Swap Maturing 2049 [Member]",
        "documentation": "Interest Rate Swap Maturing 2049"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestRateSwapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestRateSwapMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate Swap",
        "label": "Interest Rate Swap [Member]",
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period."
       }
      }
     },
     "auth_ref": [
      "r913",
      "r960",
      "r961"
     ]
    },
    "us-gaap_IntersegmentEliminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntersegmentEliminationMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intersegment Eliminations",
        "label": "Intersegment Eliminations [Member]",
        "documentation": "Eliminating entries used in operating segment consolidation."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r391"
     ]
    },
    "hum_InvestmentAndOtherIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "InvestmentAndOtherIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment and other (loss) income, net",
        "label": "Investment And Other Income Net",
        "documentation": "Investment and other income, net"
       }
      }
     },
     "auth_ref": []
    },
    "hum_InvestmentInRelatedPartiesAndSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "InvestmentInRelatedPartiesAndSubsidiaries",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in subsidiaries",
        "label": "Investment In Related Parties And Subsidiaries",
        "documentation": "Investment in related parties and subsidiaries."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterestAndDividend",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment income",
        "label": "Investment Income, Interest and Dividend",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Securities",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r825",
      "r826",
      "r827",
      "r828",
      "r893",
      "r894"
     ]
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Investments",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total investment securities",
        "label": "Investments",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contractual Maturities of Debt Securities Available for Sale",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVESTMENT SECURITIES",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r246",
      "r253",
      "r274",
      "r400",
      "r403",
      "r665",
      "r666"
     ]
    },
    "us-gaap_InvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments [Member]",
        "documentation": "Assets held for their financial return, rather than for the entity's operations."
       }
      }
     },
     "auth_ref": []
    },
    "hum_JPMorganChaseBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "JPMorganChaseBankMember",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JPM",
        "label": "JPMorgan Chase Bank [Member]",
        "documentation": "JPMorgan Chase Bank"
       }
      }
     },
     "auth_ref": []
    },
    "hum_January2022AcceleratedShareRepurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "January2022AcceleratedShareRepurchaseAgreementMember",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 2022 ASR",
        "label": "January 2022 Accelerated Share Repurchase Agreement [Member]",
        "documentation": "January 2022 Accelerated Share Repurchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "hum_KindredAtHomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "KindredAtHomeMember",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kindred at Home",
        "label": "Kindred At Home [Member]",
        "documentation": "Kindred At Home [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandMember",
     "presentation": [
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r1139"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity of Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1180"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After 2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.humana.com/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r328",
      "r442",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r499",
      "r501",
      "r503",
      "r504",
      "r637",
      "r641",
      "r642",
      "r670",
      "r846",
      "r921",
      "r965",
      "r1132",
      "r1184",
      "r1185"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r238",
      "r774",
      "r948",
      "r1080",
      "r1111",
      "r1179"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Fair value of liabilities assumed",
        "label": "Liabilities Assumed",
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r75"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "terseLabel": "Current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r282",
      "r328",
      "r442",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r499",
      "r501",
      "r503",
      "r504",
      "r637",
      "r641",
      "r642",
      "r670",
      "r948",
      "r1132",
      "r1184",
      "r1185"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r165",
      "r166",
      "r167",
      "r171",
      "r328",
      "r442",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r499",
      "r501",
      "r503",
      "r504",
      "r637",
      "r641",
      "r642",
      "r670",
      "r1132",
      "r1184",
      "r1185"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r159",
      "r164",
      "r207",
      "r279",
      "r280"
     ]
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails",
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefits payable",
        "periodStartLabel": "Balances, beginning of period",
        "periodEndLabel": "Balances, end of period",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r250"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions",
        "documentation": "Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paid related to:",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": {
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Current year",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": {
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prior years",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "hum_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative number of reported claims",
        "label": "Liability For Unpaid Claims And Claims Adjustment Expense, Cumulative Number Of Claims, Reported",
        "documentation": "Liability For Unpaid Claims And Claims Adjustment Expense, Cumulative Number Of Claims, Reported"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total IBNR",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount",
        "documentation": "Estimated costs as of the balance sheet date of settling insured claims and costs incurred in the claims settlement process for claims that have not yet been submitted to the insurance company for reimbursement."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total incurred",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incurred related to:",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare licenses",
        "label": "Licensing Agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r609",
      "r1169"
     ]
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility fee (percent)",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Line Items]",
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1079"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "hum_LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity including uncommitted incremental loan facility",
        "label": "Line Of Credit Facility, Maximum Borrowing Capacity Including Uncommitted Incremental Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility including uncommitted incremental capacity and without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining borrowing capacity",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility [Table]",
        "label": "Line of Credit Facility [Table]",
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r1079"
     ]
    },
    "hum_LineOfCreditFacilityUncommittedIncrementalCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "LineOfCreditFacilityUncommittedIncrementalCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uncommitted incremental loan facility",
        "label": "Line Of Credit Facility, Uncommitted Incremental Capacity",
        "documentation": "Line Of Credit Facility, Uncommitted Incremental Capacity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LinesOfCreditCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LinesOfCreditCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit, outstanding borrowings",
        "label": "Line of Credit, Current",
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r234"
     ]
    },
    "us-gaap_LoansPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayableMember",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans Payable",
        "label": "Loans Payable [Member]",
        "documentation": "Borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "hum_LongDurationInsuranceProductsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "LongDurationInsuranceProductsAxis",
     "presentation": [
      "http://www.humana.com/role/REINSURANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Duration Insurance Products [Axis]",
        "label": "Long Duration Insurance Products [Axis]",
        "documentation": "Long-Duration Insurance Products [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_LongDurationInsuranceProductsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "LongDurationInsuranceProductsDomain",
     "presentation": [
      "http://www.humana.com/role/REINSURANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Duration Insurance Products [Domain]",
        "label": "Long Duration Insurance Products [Domain]",
        "documentation": "Long-Duration Insurance Products [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_LongTermDebtAggregateCarryingValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "LongTermDebtAggregateCarryingValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate carrying value adjustment",
        "label": "Long-Term Debt, Aggregate Carrying Value Adjustment",
        "documentation": "Long-Term Debt, Aggregate Carrying Value Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtByMaturityAbstract",
     "presentation": [
      "http://www.humana.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of debt",
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/DEBTDebtOutstandingDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total senior notes",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r292"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r332",
      "r1137"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r332",
      "r523"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r332",
      "r523"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r332",
      "r523"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r332",
      "r523"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/DEBTMaturitiesofDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r332",
      "r523"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "verboseLabel": "Long-term debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails",
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r101"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r491",
      "r1127",
      "r1128"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r487",
      "r488",
      "r491",
      "r1127",
      "r1128"
     ]
    },
    "hum_LossOnTerminationOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "LossOnTerminationOfDerivatives",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination of put and call options",
        "label": "Loss On Termination Of Derivatives",
        "documentation": "Loss On Termination Of Derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails",
      "http://www.humana.com/role/REPORTINGENTITYDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r396",
      "r935",
      "r1138",
      "r1197",
      "r1199"
     ]
    },
    "hum_ManagementFeesChargedToOperatingSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ManagementFeesChargedToOperatingSubsidiaries",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fees charged to operating subsidiaries",
        "label": "Management Fees Charged To Operating Subsidiaries",
        "documentation": "Through intercompany service agreements approved, if required, by state regulatory authorities, Humana Inc., our parent company, charges a management fee for reimbursement of certain centralized services provided to its subsidiaries, including information systems, disbursement, investment and cash administration, marketing, legal, finance, and medical and executive management oversight"
       }
      }
     },
     "auth_ref": []
    },
    "hum_MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum individual state general bond obligation as a percentage of total debt securities (percent)",
        "label": "Maximum Individual State General Bond Obligation, As Percentage Of Total Debt Securities",
        "documentation": "Maximum Individual State General Bond Obligation, As Percentage Of Total Debt Securities"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488",
      "r489",
      "r490",
      "r570",
      "r729",
      "r816",
      "r838",
      "r839",
      "r892",
      "r895",
      "r896",
      "r897",
      "r904",
      "r910",
      "r911",
      "r923",
      "r933",
      "r941",
      "r950",
      "r1136",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average cost of capital",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1178"
     ]
    },
    "us-gaap_MeasurementInputLongTermRevenueGrowthRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputLongTermRevenueGrowthRateMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long term growth rate",
        "label": "Measurement Input, Long-Term Revenue Growth Rate [Member]",
        "documentation": "Measurement input using compounded annualized rate of long-term growth in revenue."
       }
      }
     },
     "auth_ref": [
      "r1178"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annualized volatility",
        "label": "Measurement Input, Option Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1178"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "hum_MedicaidMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "MedicaidMember",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicaid",
        "label": "Medicaid [Member]",
        "documentation": "Medicaid [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_MedicareAdvantageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "MedicareAdvantageMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual Medicare Advantage",
        "label": "Medicare Advantage [Member]",
        "documentation": "Medicare Advantage [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_MedicareLicensesAndCertificatesOfNeedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "MedicareLicensesAndCertificatesOfNeedMember",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare Licenses And Certificates Of Need",
        "label": "Medicare Licenses And Certificates Of Need [Member]",
        "documentation": "Medicare Licenses And Certificates Of Need [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_MedicareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "MedicareMember",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Medicare",
        "terseLabel": "Total Medicare",
        "label": "Medicare [Member]",
        "documentation": "Medicare [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_MedicarePartDDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "MedicarePartDDisclosureTextBlock",
     "presentation": [
      "http://www.humana.com/role/MEDICAREPARTD"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MEDICARE PART D",
        "label": "Medicare Part D Disclosure [Text Block]",
        "documentation": "Balance sheet amounts associated with Medicare Part D."
       }
      }
     },
     "auth_ref": []
    },
    "hum_MedicareStandAlonePrescriptionDrugPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "MedicareStandAlonePrescriptionDrugPlanMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare stand-alone PDP",
        "label": "Medicare Stand Alone Prescription Drug Plan [Member]",
        "documentation": "Medicare Stand Alone Prescription Drug Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_MedicareSupplementProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "MedicareSupplementProductMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare Supplement",
        "label": "Medicare Supplement Product [Member]",
        "documentation": "Medicare Supplement Product"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACQUISITIONS AND DIVESTITURES",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r224"
     ]
    },
    "hum_MilitaryAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "MilitaryAndOtherMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Military services and other",
        "label": "Military And Other [Member]",
        "documentation": "Military And Other"
       }
      }
     },
     "auth_ref": []
    },
    "hum_MilitaryServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "MilitaryServiceMember",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Military services",
        "label": "Military Service [Member]",
        "documentation": "Military Service [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum age required for retirement eligibility as related to our equity award program",
        "label": "Minimum Age Required For Retirement Eligibility As Related To Our Equity Award Program",
        "documentation": "Minimum age required for retirement eligibility as related to our equity award program"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488",
      "r489",
      "r490",
      "r570",
      "r729",
      "r816",
      "r838",
      "r839",
      "r892",
      "r895",
      "r896",
      "r897",
      "r904",
      "r910",
      "r911",
      "r923",
      "r933",
      "r941",
      "r950",
      "r1136",
      "r1186",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191"
     ]
    },
    "hum_MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum number of years of service for retirement eligibility as related to our equity award program",
        "label": "Minimum Number Of Years Of Service For Retirement Eligibility As Related To Our Equity Award Program",
        "documentation": "Minimum number of years of service for retirement eligibility as related to our equity award program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interests",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r237",
      "r328",
      "r442",
      "r492",
      "r495",
      "r496",
      "r497",
      "r503",
      "r504",
      "r670",
      "r773",
      "r850"
     ]
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r216",
      "r227"
     ]
    },
    "hum_MizuhoMarketsAmericasLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "MizuhoMarketsAmericasLLCMember",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mizuho Markets Americas LLC",
        "label": "Mizuho Markets Americas LLC [Member]",
        "documentation": "Mizuho Markets Americas LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage-backed securities",
        "label": "Mortgage-Backed Securities, Issued by US Government Sponsored Enterprises [Member]",
        "documentation": "Debt securities collateralized by real estate mortgage loans (mortgages), issued by US Government Sponsored Enterprises, such as Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1103",
      "r1104",
      "r1140"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails",
      "http://www.humana.com/role/REPORTINGENTITYDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r396",
      "r935",
      "r1138",
      "r1197",
      "r1199"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.humana.com/role/REPORTINGENTITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REPORTING ENTITY",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r271"
     ]
    },
    "hum_NetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "NetAssetLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/MEDICAREPARTDDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/MEDICAREPARTDDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net (liability) asset",
        "label": "Net Asset (Liability)",
        "documentation": "Net Asset (Liability)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities",
        "verboseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities",
        "verboseLabel": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "terseLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r194",
      "r195"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_NetCurrentLiabilityAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "NetCurrentLiabilityAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/MEDICAREPARTDDetails": {
       "parentTag": "hum_NetAssetLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/MEDICAREPARTDDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net current (liability) asset",
        "label": "Net Current (Liability) Asset",
        "documentation": "Net current (liability) asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income attributable to Humana",
        "terseLabel": "Net income attributable to Humana",
        "verboseLabel": "Net income available for common stockholders",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r195",
      "r244",
      "r280",
      "r303",
      "r306",
      "r311",
      "r328",
      "r336",
      "r338",
      "r339",
      "r340",
      "r341",
      "r344",
      "r345",
      "r355",
      "r368",
      "r382",
      "r388",
      "r391",
      "r442",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r499",
      "r501",
      "r503",
      "r504",
      "r653",
      "r670",
      "r781",
      "r868",
      "r884",
      "r885",
      "r922",
      "r963",
      "r1132"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails": {
       "parentTag": "hum_IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net loss (income) attributable to noncontrolling interests",
        "terseLabel": "Net loss (income) attributable to noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r228",
      "r303",
      "r306",
      "r344",
      "r345",
      "r780",
      "r1068"
     ]
    },
    "hum_NetNoncurrentAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "NetNoncurrentAssetLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/MEDICAREPARTDDetails": {
       "parentTag": "hum_NetAssetLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/MEDICAREPARTDDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net long-term liability",
        "label": "Net Noncurrent Asset (Liability)",
        "documentation": "Net Noncurrent Asset (Liability)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements and Accounting Pronouncements Effective in Future Periods",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r992",
      "r1002",
      "r1019",
      "r1028"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "hum_NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Noncontrolling interests acquired",
        "label": "Noncash Or Part Noncash Acquisition Noncontrolling Interest Acquired",
        "documentation": "Noncash Or Part Noncash Acquisition Noncontrolling Interest Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "hum_NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: Remeasured existing Kindred at Home equity method investment",
        "label": "Noncash Or Part Noncash Acquisition Remeasurement Of Equity Investment",
        "documentation": "Noncash Or Part Noncash Acquisition Remeasurement Of Equity Investment"
       }
      }
     },
     "auth_ref": []
    },
    "hum_NoncompetesAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "NoncompetesAndOtherMember",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncompetes and other",
        "label": "Noncompetes And Other [Member]",
        "documentation": "Noncompetes and Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Sale of Gentiva Hospice",
        "label": "Noncontrolling Interest, Decrease from Deconsolidation",
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r105"
     ]
    },
    "hum_NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distribution from (to) noncontrolling interest holders, net",
        "label": "Noncontrolling Interest, Increase (Decrease) From Contributions Or Distributions To Noncontrolling Interest Holders",
        "documentation": "Noncontrolling Interest, Increase (Decrease) From Contributions Or Distributions To Noncontrolling Interest Holders"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interests",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r547",
      "r1082",
      "r1083",
      "r1084",
      "r1203"
     ]
    },
    "us-gaap_NontaxableMunicipalNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NontaxableMunicipalNotesMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Tax-exempt municipal securities",
        "label": "Nontaxable Municipal Notes [Member]",
        "documentation": "Short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments that are not taxable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of notes payable to operating subsidiaries",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "hum_November2022AcceleratedShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "November2022AcceleratedShareRepurchaseProgramMember",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "November 2022 ASR",
        "label": "November 2022 Accelerated Share Repurchase Program [Member]",
        "documentation": "November 2022 Accelerated Share Repurchase Program"
       }
      }
     },
     "auth_ref": []
    },
    "hum_NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of days notice for employer group to cancel short-duration prepaid health services policies",
        "label": "Number Of Days Notice For Employer Group To Cancel Short Duration Prepaid Health Services Policies",
        "documentation": "Number Of Days Notice For Employer Group To Cancel Short Duration Prepaid Health Services Policies"
       }
      }
     },
     "auth_ref": []
    },
    "hum_NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance",
     "presentation": [
      "http://www.humana.com/role/REINSURANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reinsurers comprising other reinsurance recoverables balance",
        "label": "Number Of Reinsurers Comprising Other Reinsurance Recoverables Balance",
        "documentation": "Number of reinsurers comprising other reinsurance recoverables balance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1087"
     ]
    },
    "hum_NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of states comprising TRICARE Managed Care Support Contract beneficiaries",
        "label": "Number Of States Comprising Of TRICARE Managed Care Support Contract Beneficiaries",
        "documentation": "Number Of States Comprising Of TRICARE Managed Care Support Contract Beneficiaries"
       }
      }
     },
     "auth_ref": []
    },
    "hum_NumberOfStatesComprisingTRICAREBeneficiaries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "NumberOfStatesComprisingTRICAREBeneficiaries",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of states comprising TRICARE beneficiaries",
        "label": "Number Of States Comprising TRICARE Beneficiaries",
        "documentation": "Number Of States Comprising TRICARE Beneficiaries"
       }
      }
     },
     "auth_ref": []
    },
    "hum_NumberOfTRICAREBeneficiaries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "NumberOfTRICAREBeneficiaries",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of TRICARE beneficiaries",
        "label": "Number Of TRICARE Beneficiaries",
        "documentation": "Number Of TRICARE Beneficiaries"
       }
      }
     },
     "auth_ref": []
    },
    "hum_NumberOfTRICAREManagedCareSupportContractBeneficiaries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "NumberOfTRICAREManagedCareSupportContractBeneficiaries",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of TRICARE Managed Care Support Contract beneficiaries",
        "label": "Number Of TRICARE Managed Care Support Contract Beneficiaries",
        "documentation": "Number Of TRICARE Managed Care Support Contract Beneficiaries"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating expenses:",
        "terseLabel": "Expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income from operations",
        "terseLabel": "Income (loss) from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r382",
      "r388",
      "r391",
      "r922"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed operating lease costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r686",
      "r947"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity of Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/LEASESMaturityofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities included within trade accounts payable and accrued expenses",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.humana.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities included within other long-term liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.humana.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cash payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r685",
      "r689"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ROU assets included within other long-term assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.humana.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.humana.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate (percent)",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r691",
      "r947"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.humana.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r947"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating losses to carryforward related to prior acquisitions",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r391"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Indexed to Issuer's Equity [Axis]",
        "label": "Option Indexed to Issuer's Equity [Axis]",
        "documentation": "Information by type of options indexed to an issuer's equity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r138",
      "r139",
      "r229"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OptionOnSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionOnSecuritiesMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Option on Securities [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of a security at a specified price during a specified period or at a specified date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/MEDICAREPARTDDetails": {
       "parentTag": "hum_NetCurrentLiabilityAsset",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/MEDICAREPARTDDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "verboseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r297",
      "r948"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/MEDICAREPARTDDetails": {
       "parentTag": "hum_NetNoncurrentAssetLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/MEDICAREPARTDDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r41",
      "r304",
      "r307",
      "r314",
      "r671",
      "r672",
      "r677",
      "r748",
      "r782",
      "r1066",
      "r1067"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r23",
      "r226",
      "r304",
      "r307"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reclassification adjustment for net realized losses (gains) included in investment income",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax",
        "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r181",
      "r302",
      "r435"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total reclassification adjustment, net of tax",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r181",
      "r302",
      "r435"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of income taxes",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax",
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in gross unrealized investment gains (losses)",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r301",
      "r435"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total change in unrealized investment gains (losses), net of tax",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r301",
      "r435"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Effect of income taxes",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r300"
     ]
    },
    "hum_OtherCurrentAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "OtherCurrentAssetsPolicyTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Current Assets",
        "label": "Other Current Assets [Policy Text Block]",
        "documentation": "Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r948"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/MEDICAREPARTDDetails": {
       "parentTag": "hum_NetNoncurrentAssetLiability",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/MEDICAREPARTDDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "negatedTerseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term assets",
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Noncurrent Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails": {
       "parentTag": "hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other expense (income), net",
        "negatedLabel": "Other expense, net",
        "negatedNetLabel": "Other income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Other Operating Activities, Cash Flow Statement",
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r978",
      "r990",
      "r1000",
      "r1026"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r981",
      "r993",
      "r1003",
      "r1029"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r981",
      "r993",
      "r1003",
      "r1029"
     ]
    },
    "srt_ParentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ParentCompanyMember",
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parent Company",
        "label": "Parent Company [Member]"
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ParentMember",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Stockholders' Equity",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total paid",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r34"
     ]
    },
    "hum_PaymentsForProceedsFromContractDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "PaymentsForProceedsFromContractDeposits",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Receipts (withdrawals) from contract deposits, net",
        "label": "Payments For (Proceeds From) Contract Deposits",
        "documentation": "Payments For (Proceeds From) Contract Deposits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Common stock repurchases",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Debt issue costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_PaymentsOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDividends",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Dividends paid",
        "negatedLabel": "Dividends paid",
        "label": "Payments of Dividends",
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investment securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r317",
      "r401"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions, net of cash and cash equivalents acquired",
        "terseLabel": "Cash paid for acquired businesses, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquiredAbstract",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Details of businesses acquired in purchase transactions:",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "negatedTerseLabel": "Purchases of property and equipment, net",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "hum_PercentageOfCoinsuranceAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "PercentageOfCoinsuranceAgreement",
     "presentation": [
      "http://www.humana.com/role/REINSURANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of coinsurance agreement",
        "label": "Percentage Of Coinsurance Agreement",
        "documentation": "Percentage Of Coinsurance Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "hum_PercentageOfTotalDebtSecuritiesInvestmentGradeQuality": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "PercentageOfTotalDebtSecuritiesInvestmentGradeQuality",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of debt securities considered to be of investment-grade (percent)",
        "label": "Percentage Of Total Debt Securities, Investment Grade Quality",
        "documentation": "Percentage Of Total Debt Securities, Investment Grade Quality"
       }
      }
     },
     "auth_ref": []
    },
    "hum_PercentageOfTotalPremiumAndServicesRevenues": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "PercentageOfTotalPremiumAndServicesRevenues",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of premiums and services revenue",
        "label": "Percentage Of Total Premium And Services Revenues",
        "documentation": "Percentage Of Total Premium And Services Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "hum_PharmacySolutionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "PharmacySolutionsMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pharmacy solutions",
        "label": "Pharmacy Solutions [Member]",
        "documentation": "Pharmacy Solutions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164",
      "r1165",
      "r1166",
      "r1167"
     ]
    },
    "us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PolicyholderBenefitsAndClaimsIncurredHealthCare",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefits",
        "label": "Policyholder Benefits and Claims Incurred, Net, Health",
        "documentation": "Amount, after effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred for health insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r1196"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Portion at Fair Value Measurement",
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r533"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r848"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r533"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $1 par; 10,000,000 shares authorized; none issued",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r768",
      "r948"
     ]
    },
    "us-gaap_PremiumsEarnedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PremiumsEarnedNet",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Premiums",
        "label": "Premiums Earned, Net",
        "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r807",
      "r823"
     ]
    },
    "hum_PrimaryCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "PrimaryCareMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Primary care",
        "label": "Primary Care [Member]",
        "documentation": "Primary Care"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of Gentiva Hospice, net",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/DEBTSeniorNotesDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of senior notes, net",
        "label": "Proceeds from Issuance of Senior Long-Term Debt",
        "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfUnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfUnsecuredDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from term loan",
        "label": "Proceeds from Issuance of Unsecured Debt",
        "documentation": "The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of investment securities",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r318",
      "r1094"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from term loan",
        "label": "Proceeds from Notes Payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other, net",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1051",
      "r1073"
     ]
    },
    "us-gaap_ProceedsFromRepaymentsOfCommercialPaper": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromRepaymentsOfCommercialPaper",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds (repayments) from issuance of commercial paper, net",
        "label": "Proceeds from (Repayments of) Commercial Paper",
        "documentation": "The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper."
       }
      }
     },
     "auth_ref": [
      "r1074",
      "r1075",
      "r1078"
     ]
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sales of investment securities",
        "terseLabel": "Proceeds from sale of investment securities",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r317",
      "r401",
      "r434"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromShortTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from short-term borrowings",
        "label": "Proceeds from Short-Term Debt",
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from stock options exercised",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r31"
     ]
    },
    "hum_ProceedsFromStockOptionsExercisedAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ProceedsFromStockOptionsExercisedAndOther",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other, net",
        "label": "Proceeds From Stock Options Exercised And Other",
        "documentation": "Proceeds From Stock Options Exercised And Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Concentration Risk",
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Products",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.humana.com/role/REINSURANCEDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r393",
      "r731",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r914",
      "r934",
      "r949",
      "r1055",
      "r1129",
      "r1130",
      "r1138",
      "r1197"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.humana.com/role/REINSURANCEDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r393",
      "r731",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r914",
      "r934",
      "r949",
      "r1055",
      "r1129",
      "r1130",
      "r1138",
      "r1197"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income",
        "terseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r303",
      "r306",
      "r320",
      "r328",
      "r336",
      "r344",
      "r345",
      "r368",
      "r382",
      "r388",
      "r391",
      "r442",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r499",
      "r501",
      "r503",
      "r504",
      "r635",
      "r638",
      "r639",
      "r653",
      "r670",
      "r751",
      "r779",
      "r834",
      "r868",
      "r884",
      "r885",
      "r922",
      "r945",
      "r946",
      "r964",
      "r1068",
      "r1132"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNET"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r263",
      "r265",
      "r266"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r285",
      "r776"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r758",
      "r776",
      "r948"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived assets estimated useful life (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "hum_ProtectiveLifeInsuranceCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ProtectiveLifeInsuranceCompanyMember",
     "presentation": [
      "http://www.humana.com/role/REINSURANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Protective Life Insurance Company",
        "label": "Protective Life Insurance Company [Member]",
        "documentation": "Protective Life Insurance Company [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_ProviderReportingUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ProviderReportingUnitMember",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provider reporting unit",
        "label": "Provider Reporting Unit [Member]",
        "documentation": "Provider Reporting Unit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PutOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PutOptionMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Put option",
        "label": "Put Option [Member]",
        "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r899",
      "r900"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488",
      "r489",
      "r490",
      "r561",
      "r570",
      "r598",
      "r599",
      "r600",
      "r705",
      "r729",
      "r816",
      "r838",
      "r839",
      "r892",
      "r895",
      "r896",
      "r897",
      "r904",
      "r910",
      "r911",
      "r923",
      "r933",
      "r941",
      "r950",
      "r955",
      "r1125",
      "r1136",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r487",
      "r488",
      "r489",
      "r490",
      "r561",
      "r570",
      "r598",
      "r599",
      "r600",
      "r705",
      "r729",
      "r816",
      "r838",
      "r839",
      "r892",
      "r895",
      "r896",
      "r897",
      "r904",
      "r910",
      "r911",
      "r923",
      "r933",
      "r941",
      "r950",
      "r955",
      "r1125",
      "r1136",
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191"
     ]
    },
    "us-gaap_ReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables, net of allowances of $88 in 2023 and $70 in 2022",
        "label": "Receivables, Net, Current",
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r1088",
      "r1090",
      "r1091",
      "r1092"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r973",
      "r985",
      "r995",
      "r1021"
     ]
    },
    "us-gaap_ReinsuranceContractAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReinsuranceContractAxis",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance Policy, Type [Axis]",
        "label": "Reinsurance Contract [Axis]",
        "documentation": "Information by reinsurance contract."
       }
      }
     },
     "auth_ref": [
      "r1192"
     ]
    },
    "us-gaap_ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/REINSURANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Benefits ceded",
        "label": "Policyholder Benefits and Claims Incurred, Ceded",
        "documentation": "Amount of reduction of provision for policy benefits and costs incurred for policies ceded."
       }
      }
     },
     "auth_ref": [
      "r1192",
      "r1196"
     ]
    },
    "us-gaap_ReinsuranceRecoverables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReinsuranceRecoverables",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/REINSURANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reinsurance recoverables",
        "label": "Reinsurance Recoverables, Including Reinsurance Premium Paid",
        "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts including premium paid under reinsurance contracts. Examples include, but are not limited to, settled and unsettled claims, incurred but not reported losses, loss adjustment expense, premium paid, policy benefits and policy reserves."
       }
      }
     },
     "auth_ref": [
      "r1193",
      "r1195",
      "r1198"
     ]
    },
    "hum_ReinsuranceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ReinsuranceTable",
     "presentation": [
      "http://www.humana.com/role/REINSURANCEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reinsurance [Table]",
        "label": "Reinsurance [Table]",
        "documentation": "Reinsurance [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReinsuranceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReinsuranceTextBlock",
     "presentation": [
      "http://www.humana.com/role/REINSURANCE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REINSURANCE",
        "label": "Reinsurance [Text Block]",
        "documentation": "The entire disclosure pertaining to the existence, magnitude and information about insurance that has been ceded to or assumed from another insurance company, including the methodologies and assumptions used in determining recorded amounts."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r761",
      "r951",
      "r952"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party, Type [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r694",
      "r695",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r865",
      "r867",
      "r891"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party, Type [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r694",
      "r695",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r865",
      "r867",
      "r891",
      "r1183"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of debt",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r830"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of term loan",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfSeniorDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      },
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of senior notes",
        "label": "Repayments of Senior Debt",
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW",
      "http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of short-term borrowings",
        "terseLabel": "Repayment of short-term borrowings",
        "label": "Repayments of Short-Term Debt",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_RepaymentsOfUnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfUnsecuredDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of term loan",
        "label": "Repayments of Unsecured Debt",
        "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ReportingUnitAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReportingUnitAxis",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting Unit [Axis]",
        "label": "Reporting Unit [Axis]",
        "documentation": "Information by reporting unit."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r927"
     ]
    },
    "us-gaap_ReportingUnitDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReportingUnitDomain",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reporting Unit [Domain]",
        "label": "Reporting Unit [Domain]",
        "documentation": "Level of reporting at which goodwill is tested for impairment."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r927"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r509",
      "r535",
      "r696",
      "r918",
      "r919"
     ]
    },
    "hum_RepurchasePlanAugust2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "RepurchasePlanAugust2023Member",
     "presentation": [
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase Plan, August 2023",
        "label": "Repurchase Plan, August 2023 [Member]",
        "documentation": "Repurchase Plan, August 2023"
       }
      }
     },
     "auth_ref": []
    },
    "hum_RepurchasePlanMarch2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "RepurchasePlanMarch2023Member",
     "presentation": [
      "http://www.humana.com/role/DEBTSeniorNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase Plan, March 2023",
        "label": "Repurchase Plan, March 2023 [Member]",
        "documentation": "Repurchase Plan, March 2023"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResidentialMortgageBackedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResidentialMortgageBackedSecuritiesMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Residential",
        "label": "Residential Mortgage-Backed Securities [Member]",
        "documentation": "Securities collateralized by residential real estate mortgage loans."
       }
      }
     },
     "auth_ref": [
      "r1095",
      "r1097",
      "r1102",
      "r1103",
      "r1104",
      "r1140"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r974",
      "r986",
      "r996",
      "r1022"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r987",
      "r997",
      "r1023"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r982",
      "r994",
      "r1004",
      "r1030"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock",
        "verboseLabel": "Restricted stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_RestructuringCostsAndAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostsAndAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and impairment charge",
        "label": "Restructuring Costs and Asset Impairment Charges",
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r216",
      "r771",
      "r820",
      "r822",
      "r831",
      "r849",
      "r948"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r333",
      "r334",
      "r335",
      "r337",
      "r343",
      "r345",
      "r444",
      "r445",
      "r605",
      "r606",
      "r607",
      "r625",
      "r626",
      "r643",
      "r645",
      "r646",
      "r648",
      "r651",
      "r817",
      "r819",
      "r835",
      "r1203"
     ]
    },
    "hum_RevenueExitMultipleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "RevenueExitMultipleMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue exit multiple",
        "label": "Revenue Exit Multiple [Member]",
        "documentation": "Revenue Exit Multiple"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services",
        "verboseLabel": "Services revenue",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r370",
      "r381",
      "r386",
      "r387",
      "r393",
      "r395",
      "r396",
      "r558",
      "r559",
      "r731"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services Revenue",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r912"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails": {
       "parentTag": "hum_IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total revenues",
        "verboseLabel": "Revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r328",
      "r369",
      "r370",
      "r381",
      "r386",
      "r387",
      "r393",
      "r395",
      "r396",
      "r442",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r499",
      "r501",
      "r503",
      "r504",
      "r670",
      "r751",
      "r1132"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_RevolvingCreditAgreementJune2021FiveYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "RevolvingCreditAgreementJune2021FiveYearMember",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Agreement June 2021 Five Year",
        "label": "Revolving Credit Agreement June 2021 Five Year [Member]",
        "documentation": "Revolving Credit Agreement June 2021 Five Year"
       }
      }
     },
     "auth_ref": []
    },
    "hum_RevolvingCreditAgreementJune2021OneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "RevolvingCreditAgreementJune2021OneYearMember",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Agreement June 2021 One Year",
        "label": "Revolving Credit Agreement June 2021 One Year [Member]",
        "documentation": "Revolving Credit Agreement June 2021 One Year"
       }
      }
     },
     "auth_ref": []
    },
    "hum_RevolvingCreditAgreementJune2022OneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "RevolvingCreditAgreementJune2022OneYearMember",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Agreement June 2022 One Year",
        "label": "Revolving Credit Agreement June 2022 One Year [Member]",
        "documentation": "Revolving Credit Agreement June 2022 One Year"
       }
      }
     },
     "auth_ref": []
    },
    "hum_RevolvingCreditAgreementJune2023FiveYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "RevolvingCreditAgreementJune2023FiveYearMember",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Agreement June 2023 Five Year",
        "label": "Revolving Credit Agreement June 2023 Five Year [Member]",
        "documentation": "Revolving Credit Agreement June 2023 Five Year"
       }
      }
     },
     "auth_ref": []
    },
    "hum_RevolvingCreditAgreementJune2023OneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "RevolvingCreditAgreementJune2023OneYearMember",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Agreement June 2023 One Year",
        "label": "Revolving Credit Agreement June 2023 One Year [Member]",
        "documentation": "Revolving Credit Agreement June 2023 One Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "hum_RiskCorridorSettlementsMedicarePartDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "RiskCorridorSettlementsMedicarePartDMember",
     "presentation": [
      "http://www.humana.com/role/MEDICAREPARTDDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk Corridor Settlement",
        "label": "Risk Corridor Settlements Medicare Part D [Member]",
        "documentation": "Risk Corridor Settlements - Medicare Part D [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r1052"
     ]
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueProductLineMember",
     "presentation": [
      "http://www.humana.com/role/REPORTINGENTITYDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Premiums and services revenue",
        "label": "Revenue, Product and Service Benchmark [Member]",
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources."
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r571",
      "r1085"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]"
       }
      }
     },
     "auth_ref": [
      "r346",
      "r571",
      "r1048",
      "r1085"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investment Securities Classified as Current and Long-Term",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESAssetsLiabilitiesAndNoncontrollingInterestDisposedDetails",
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r122",
      "r634"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Compensation Expense",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Provision for Income Taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofCashFlowsDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofComprehensiveIncomeDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Financial Statements [Table]",
        "label": "Condensed Financial Statements [Table]"
       }
      }
     },
     "auth_ref": [
      "r332",
      "r1049"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Value of Debt Outstanding",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Principal Components of Net Deferred Tax Balances",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Computation of Basic and Diluted Earnings Per Common Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "presentation": [
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r79",
      "r350",
      "r354",
      "r356"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Provision for Income Taxes Using Federal Statutory Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from External Customers by Products and Services [Table]",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r441"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Line Items]",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r438",
      "r439",
      "r441",
      "r442",
      "r670"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments [Table]",
        "label": "Schedule of Equity Method Investments [Table]",
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r328",
      "r438",
      "r439",
      "r441",
      "r442",
      "r670"
     ]
    },
    "us-gaap_ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFinancingReceivableRecordedInvestmentCreditQualityIndicatorTable",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Receivable, Credit Quality Indicator [Table]",
        "label": "Financing Receivable, Credit Quality Indicator [Table]",
        "documentation": "Disclosure of information about credit quality indicator for financing receivable."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r1112"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96",
      "r732"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets Included in Other Long-Term Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r96"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill [Table]",
        "label": "Schedule of Goodwill [Table]",
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons."
       }
      }
     },
     "auth_ref": [
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r927"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill By Reportable Segments",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r927",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123"
     ]
    },
    "hum_ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Health Care Cost Payments and Reimbursements",
        "label": "Schedule of Health Care Cost Payments and Reimbursements [Table Text Block]",
        "documentation": "Schedule of Health Care Cost Payments and Reimbursements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails",
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r201"
     ]
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity in Benefits Payable",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Long-term Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.humana.com/role/PROPERTYANDEQUIPMENTNETPropertyandEquipmentBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfRealizedGainLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRealizedGainLossTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Realized Gains (Losses) Related to Investment Securities Included Within Investment Income",
        "label": "Schedule of Realized Gain (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the proceeds from sales of available-for-sale securities and the gross realized gains and gross realized losses that have been included in earnings as a result of those sales."
       }
      }
     },
     "auth_ref": [
      "r1105"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.humana.com/role/MEDICAREPARTDDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r90"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, By Segment",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r90"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r574",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity for Option Plans",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r112"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted-Average Fair Value Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Awards Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Short-term Debt [Table]",
        "label": "Schedule of Short-Term Debt [Table]",
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Repurchases",
        "label": "Class of Treasury Stock [Table Text Block]",
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r108",
      "r109"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimate of Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "hum_SecuredOvernightFinancingRateSOFRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "SecuredOvernightFinancingRateSOFRMember",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SOFR",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "documentation": "Secured Overnight Financing Rate (SOFR)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r396",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r481",
      "r482",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r927",
      "r1055",
      "r1197"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT INFORMATION",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r380",
      "r385",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r396"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.humana.com/role/MEDICAREPARTDDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_BenefitsLossesAndExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedStatementsofIncomeDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating costs",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/DEBTSeniorNotesDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails",
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Services",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance costs",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "hum_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated vesting, termination of employment period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Termination Of Employment Period",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Termination Of Employment Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r592"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average grant date fair value (in dollars per share)",
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested restricted stock, beginning balance (in shares)",
        "periodEndLabel": "Nonvested restricted stock, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r588"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested restricted stock, beginning balance (in dollars per share)",
        "periodEndLabel": "Nonvested restricted stock, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r587",
      "r588"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Grant-Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of shares vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r599"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate at grant date",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r600"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r574",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares reserved for stock award plans (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future grants assuming all stock options or restricted stock are granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intrinsic value of stock options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r594"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r1149"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average fair value at grant date (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock options outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, beginning balance (in shares)",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r580"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares\u00a0 Under Option",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Options outstanding, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r580"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSRestrictedStockActivityDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSStockBasedCompensationExpenseDetails",
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "hum_ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of restricted stock with performance-based conditions",
        "label": "Share Based Compensation By Share Based Payment Award, Equity Instruments Other Than Options, Percent Of Stock With Performance Based Conditions",
        "documentation": "Share Based Compensation By Share Based Payment Award, Equity Instruments Other Than Options, Percent Of Stock With Performance Based Conditions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of the share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares acquired in connection with employee stock plans (in shares)",
        "label": "Share Repurchases Related To Employee Stock Based Compensation Awards Shares",
        "documentation": "Number of shares of common stock that were repurchased in the administration of our employee share-based compensation plans. Under the terms of these plans, we accept shares of common stock from option holders if they elect to surrender previously-owned shares upon exercise of the option to cover the exercise price of the options or, in the case of restricted shares of common stock, the withholding of shares to satisfy tax withholding obligations associated with the vesting of such shares."
       }
      }
     },
     "auth_ref": []
    },
    "hum_ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares acquired in connection with employee stock plans, amount",
        "label": "Share Repurchases Related To Employee Stock Based Compensation Awards Value",
        "documentation": "Cost of common stock that were repurchased in the administration of our employee share-based compensation plans. Under the terms of these plans, we accept shares of common stock from option holders if they elect to surrender previously-owned shares upon exercise of the option to cover the exercise price of the options or, in the case of restricted shares of common stock, the withholding of shares to satisfy tax withholding obligations associated with the vesting of such shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSWeightedAverageFairValueAssumptionsforStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected option life (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r597"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of stock options exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term of exercisable options (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual term of outstanding options (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "hum_ShortDurationInsuranceContractAccidentYear2021AndPriorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ShortDurationInsuranceContractAccidentYear2021AndPriorMember",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 and Prior Claims Incurred Year",
        "label": "Short-Duration Insurance Contract, Accident Year 2021 And Prior [Member]",
        "documentation": "Short-Duration Insurance Contract, Accident Year 2021 And Prior"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortDurationInsuranceContractAccidentYear2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortDurationInsuranceContractAccidentYear2021Member",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Claims Incurred Year",
        "label": "Short-Duration Insurance Contract, Accident Year 2021 [Member]",
        "documentation": "Accident year 2021 in which covered event occurs under terms of short-duration insurance contract."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_ShortDurationInsuranceContractAccidentYear2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortDurationInsuranceContractAccidentYear2022Member",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails",
      "http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Claims Incurred Year",
        "label": "Short-Duration Insurance Contract, Accident Year 2022 [Member]",
        "documentation": "Accident year 2022 in which covered event occurs under terms of short-duration insurance contract."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_ShortDurationInsuranceContractAccidentYear2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortDurationInsuranceContractAccidentYear2023Member",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails",
      "http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Claims Incurred Year",
        "label": "Short-Duration Insurance Contract, Accident Year 2023 [Member]",
        "documentation": "Accident year 2023 in which covered event occurs under terms of short-duration insurance contract."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/DEBTDebtOutstandingDetails": {
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails",
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term debt",
        "verboseLabel": "Short-term debt outstanding",
        "label": "Short-Term Debt",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r234",
      "r948",
      "r1194"
     ]
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Debt [Line Items]",
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails",
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Debt, Type [Axis]",
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails",
      "http://www.humana.com/role/DEBTDebtOutstandingDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Debt, Type [Domain]",
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_ShortTermDebtWeightedAverageInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtWeightedAverageInterestRate",
     "presentation": [
      "http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average annual interest rate (percent)",
        "label": "Short-Term Debt, Weighted Average Interest Rate, at Point in Time",
        "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment securities",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r1065"
     ]
    },
    "us-gaap_ShortdurationInsuranceContractsAccidentYearAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortdurationInsuranceContractsAccidentYearAxis",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails",
      "http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-duration Insurance Contracts, Accident Year [Axis]",
        "label": "Short-Duration Insurance Contracts, Accident Year [Axis]",
        "documentation": "Information by accident year in which a covered event occurs under the terms of the short-duration insurance contract."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShortdurationInsuranceContractsAccidentYearDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortdurationInsuranceContractsAccidentYearDomain",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails",
      "http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-duration Insurance Contracts, Accident Year [Domain]",
        "label": "Short-Duration Insurance Contracts, Accident Year [Domain]",
        "documentation": "Accident year in which a covered event occurs under the terms of the short-duration insurance contract."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTable",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails",
      "http://www.humana.com/role/BENEFITSPAYABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-duration Insurance Contracts, Claims Development [Table]",
        "label": "Short-Duration Insurance Contracts, Claims Development [Table]",
        "documentation": "Disclosure of information about undiscounted information about claims development by accident year for short-duration insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Incurred and Paid Claims Development",
        "label": "Short-Duration Insurance Contracts, Claims Development [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted information about claims development by accident year for short-duration insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails": {
       "parentTag": "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Paid Claims, Net of Reinsurance",
        "label": "Short-Duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net",
        "documentation": "Amount, after reinsurance, of paid claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails": {
       "parentTag": "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incurred Claims, Net of Reinsurance",
        "label": "Short-Duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net",
        "documentation": "Undiscounted amount, after reinsurance, of incurred claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEIncurredandPaidClaimsDevelopmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Benefits payable, net of reinsurance",
        "label": "Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net",
        "documentation": "Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r39"
     ]
    },
    "us-gaap_ShorttermDebtMaximumAmountOutstandingDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShorttermDebtMaximumAmountOutstandingDuringPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/DEBTCommercialPaperandOtherShortTermBorrowingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum amount outstanding during period",
        "label": "Short-Term Debt, Maximum Amount Outstanding During Period",
        "documentation": "For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, the maximum amount borrowed at any time during the period."
       }
      }
     },
     "auth_ref": []
    },
    "hum_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies [Line Items]",
        "label": "Significant Accounting Policies [Line Items]",
        "documentation": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Accounting Policies [Table]",
        "label": "Significant Accounting Policies [Table]",
        "documentation": "Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r325"
     ]
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer software",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "hum_SpecialtyBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "SpecialtyBenefitsMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Specialty benefits",
        "label": "Specialty Benefits [Member]",
        "documentation": "Specialty [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StandardPoorsAAMinusRatingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StandardPoorsAAMinusRatingMember",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standard &amp; Poor's, AA- Rating",
        "label": "Standard &amp; Poor's, AA- Rating [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Puerto Rico",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "hum_StateBasedContractsAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "StateBasedContractsAndOtherMember",
     "presentation": [
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State-based contracts and other",
        "label": "State-Based Contracts and Other [Member]",
        "documentation": "State-Based Contracts and Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinCarryingAmountofGoodwillbyReportableSegmentsDetails",
      "http://www.humana.com/role/SEGMENTINFORMATIONSegmentResultsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r365",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r396",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r480",
      "r481",
      "r482",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r927",
      "r1055",
      "r1197"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r56",
      "r275",
      "r309",
      "r310",
      "r311",
      "r333",
      "r334",
      "r335",
      "r337",
      "r343",
      "r345",
      "r363",
      "r444",
      "r445",
      "r547",
      "r605",
      "r606",
      "r607",
      "r625",
      "r626",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r651",
      "r671",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r693",
      "r817",
      "r818",
      "r819",
      "r835",
      "r886"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r363",
      "r731",
      "r825",
      "r836",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r848",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r867",
      "r869",
      "r870",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r886",
      "r956"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r346",
      "r571",
      "r1048",
      "r1050",
      "r1085"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r363",
      "r731",
      "r825",
      "r836",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r848",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r867",
      "r869",
      "r870",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r886",
      "r956"
     ]
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONNotestoCondensedFinancialStatementsDetails",
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary dividends that may be paid to parent company",
        "label": "Statutory Accounting Practices, Statutory Amount Available for Dividend Payments without Regulatory Approval",
        "documentation": "Amount of dividends that can be declared or paid without approval of regulatory agency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONNotestoCondensedFinancialStatementsDetails",
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate statutory capital and surplus in our state regulated insurance subsidiaries",
        "label": "Statutory Accounting Practices, Statutory Capital and Surplus, Balance",
        "documentation": "The amount of statutory capital and surplus (stockholders' equity) as of the balance sheet date using prescribed or permitted statutory accounting practices (rather than GAAP, if different) of the state or country."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r772"
     ]
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONNotestoCondensedFinancialStatementsDetails",
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate minimum regulatory requirements of statutory capital and surplus",
        "label": "Statutory Accounting Practices, Statutory Capital and Surplus Required",
        "documentation": "Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r977",
      "r989",
      "r999",
      "r1025"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock unit vesting (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r216"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.humana.com/role/EMPLOYEEBENEFITPLANSOptionPlansActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r174",
      "r175",
      "r216",
      "r584"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock unit vesting",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r174",
      "r175",
      "r216"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option exercises",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r56",
      "r216"
     ]
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase authorization",
        "label": "Stock Repurchase Program, Authorized Amount",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining authorized amount",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "documentation": "Amount remaining of a stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "terseLabel": "Shareholders' equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r178",
      "r179",
      "r197",
      "r850",
      "r866",
      "r887",
      "r888",
      "r948",
      "r965",
      "r1080",
      "r1111",
      "r1179",
      "r1203"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r130",
      "r275",
      "r276",
      "r310",
      "r333",
      "r334",
      "r335",
      "r337",
      "r343",
      "r444",
      "r445",
      "r547",
      "r605",
      "r606",
      "r607",
      "r625",
      "r626",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r651",
      "r671",
      "r673",
      "r677",
      "r693",
      "r818",
      "r819",
      "r833",
      "r850",
      "r866",
      "r887",
      "r888",
      "r905",
      "r964",
      "r1080",
      "r1111",
      "r1179",
      "r1203"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r327",
      "r532",
      "r534",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r546",
      "r547",
      "r650",
      "r889",
      "r890",
      "r906"
     ]
    },
    "hum_StrategicPartnershipAgreementCallOptionStrikePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "StrategicPartnershipAgreementCallOptionStrikePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Call option strike price",
        "label": "Strategic Partnership Agreement, Call Option Strike Price",
        "documentation": "Strategic Partnership Agreement, Call Option Strike Price"
       }
      }
     },
     "auth_ref": []
    },
    "hum_StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional primary care centers expected to be opened in strategic partnership",
        "label": "Strategic Partnership Agreement, Number Of Additional Primary Care Centers Expected To Be Opened",
        "documentation": "Strategic Partnership Agreement, Number Of Additional Primary Care Centers Expected To Be Opened"
       }
      }
     },
     "auth_ref": []
    },
    "hum_StrategicPartnershipAgreementNumberOfPrimaryCareCenters": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "StrategicPartnershipAgreementNumberOfPrimaryCareCenters",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of primary care centers in strategic partnership",
        "label": "Strategic Partnership Agreement, Number Of Primary Care Centers",
        "documentation": "Strategic Partnership Agreement, Number Of Primary Care Centers"
       }
      }
     },
     "auth_ref": []
    },
    "hum_StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Time frame for put and call option activity per partnership agreement",
        "label": "Strategic Partnership Agreement, Timeframe For Put And Call Option Activity",
        "documentation": "Strategic Partnership Agreement, Timeframe For Put And Call Option Activity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease rental income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r688",
      "r947"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r678",
      "r698"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r678",
      "r698"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r678",
      "r698"
     ]
    },
    "srt_SubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SubsidiariesMember",
     "presentation": [
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiaries",
        "label": "Subsidiaries [Member]"
       }
      }
     },
     "auth_ref": [
      "r1141",
      "r1181",
      "r1182",
      "r1183"
     ]
    },
    "hum_SubsidyAndDiscountPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "SubsidyAndDiscountPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPartDSubsidyDiscountPaymentsNetDetails": {
       "parentTag": "hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPartDSubsidyDiscountPaymentsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Part D subsidy/discount payments",
        "label": "Subsidy And Discount Payments",
        "documentation": "Subsidy And Discount Payments"
       }
      }
     },
     "auth_ref": []
    },
    "hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "SubsidyAndDiscountPaymentsInExcessOfReimbursements",
     "crdr": "credit",
     "calculation": {
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPartDSubsidyDiscountPaymentsNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPartDSubsidyDiscountPaymentsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net reimbursements (payments)",
        "label": "Subsidy And Discount Payments In Excess Of Reimbursements",
        "documentation": "Subsidy And Discount Payments In Excess Of Reimbursements"
       }
      }
     },
     "auth_ref": []
    },
    "hum_SubsidyAndDiscountReimbursements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "SubsidyAndDiscountReimbursements",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPartDSubsidyDiscountPaymentsNetDetails": {
       "parentTag": "hum_SubsidyAndDiscountPaymentsInExcessOfReimbursements",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPartDSubsidyDiscountPaymentsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Part D subsidy/discount reimbursements",
        "label": "Subsidy And Discount Reimbursements",
        "documentation": "Subsidy And Discount Reimbursements"
       }
      }
     },
     "auth_ref": []
    },
    "hum_SubsidyAndDiscountsSettlementPeriodAfterClose": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "SubsidyAndDiscountsSettlementPeriodAfterClose",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement period after close",
        "label": "Subsidy And Discounts, Settlement Period After Close",
        "documentation": "Subsidy And Discounts, Settlement Period After Close"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow disclosures:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": {
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current year",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails": {
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/BENEFITSPAYABLEActivityinBenefitsPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior years",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "hum_TRICARE2017EastRegionContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "TRICARE2017EastRegionContractMember",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRICARE 2017 East Region Contract",
        "label": "TRICARE 2017 East Region Contract [Member]",
        "documentation": "TRICARE 2017 East Region Contract"
       }
      }
     },
     "auth_ref": []
    },
    "hum_TRICAREContractAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "TRICAREContractAxis",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRICARE Contract [Axis]",
        "label": "TRICARE Contract [Axis]",
        "documentation": "TRICARE Contract"
       }
      }
     },
     "auth_ref": []
    },
    "hum_TRICAREContractDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "TRICAREContractDomain",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRICARE Contract [Domain]",
        "label": "TRICARE Contract [Domain]",
        "documentation": "TRICARE Contract [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "hum_TRICAREManagedCareSupportContractBaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "TRICAREManagedCareSupportContractBaseTerm",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract base term",
        "label": "TRICARE Managed Care Support Contract, Base Term",
        "documentation": "TRICARE Managed Care Support Contract, Base Term"
       }
      }
     },
     "auth_ref": []
    },
    "hum_TRICAREManagedCareSupportContractEffective2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "TRICAREManagedCareSupportContractEffective2024Member",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TRICARE Managed Care Support Contract, Effective 2024",
        "label": "TRICARE Managed Care Support Contract, Effective 2024 [Member]",
        "documentation": "TRICARE Managed Care Support Contract, Effective 2024"
       }
      }
     },
     "auth_ref": []
    },
    "hum_TRICAREManagedCareSupportContractNumberOfOptionPeriods": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "TRICAREManagedCareSupportContractNumberOfOptionPeriods",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual option periods",
        "label": "TRICARE Managed Care Support Contract, Number Of Option Periods",
        "documentation": "TRICARE Managed Care Support Contract, Number Of Option Periods"
       }
      }
     },
     "auth_ref": []
    },
    "hum_TRICAREManagedCareSupportContractTermWithOptionExercises": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "TRICAREManagedCareSupportContractTermWithOptionExercises",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract term with exercises",
        "label": "TRICARE Managed Care Support Contract, Term With Option Exercises",
        "documentation": "TRICARE Managed Care Support Contract, Term With Option Exercises"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOW"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of property and equipment",
        "label": "Tangible Asset Impairment Charges",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r206"
     ]
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardLineItems",
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Line Items]",
        "label": "Tax Credit Carryforward [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxCreditCarryforwardTable",
     "presentation": [
      "http://www.humana.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Table]",
        "label": "Tax Credit Carryforward [Table]",
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "hum_TermLoanAndCommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "TermLoanAndCommercialPaperMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan and Commercial Paper",
        "label": "Term Loan And Commercial Paper [Member]",
        "documentation": "Term Loan And Commercial Paper"
       }
      }
     },
     "auth_ref": []
    },
    "hum_TermLoanDueOctober2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "TermLoanDueOctober2023Member",
     "presentation": [
      "http://www.humana.com/role/ACQUISITIONSANDDIVESTITURESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan Due October 2023",
        "label": "Term Loan Due October 2023 [Member]",
        "documentation": "Term Loan Due October 2023"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_TradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeNamesMember",
     "presentation": [
      "http://www.humana.com/role/GOODWILLANDOTHERINTANGIBLEASSETSDetailsofIntangibleAssetsIncludedinOtherLongTermAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade names and technology",
        "label": "Trade Names [Member]",
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.humana.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails",
      "http://www.humana.com/role/FAIRVALUENarrativeDetails",
      "http://www.humana.com/role/FAIRVALUEPutandCallOptionsMeasuredatFairValueDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r530",
      "r545",
      "r649",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r783",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1105",
      "r1106",
      "r1107",
      "r1108"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchase average price (in dollars per share)",
        "label": "Shares Acquired, Average Cost Per Share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsShareDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.humana.com/role/SCHEDULEIPARENTCOMPANYFINANCIALINFORMATIONCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost, 76,465,862 shares at December 31, 2023 and 73,691,955 shares at December 31, 2022",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r106",
      "r109"
     ]
    },
    "hum_TreasuryStockDecreaseInCapitalInExcessOfParValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "TreasuryStockDecreaseInCapitalInExcessOfParValue",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in capital in excess of par value",
        "label": "Treasury Stock, Decrease In Capital In Excess Of Par Value",
        "documentation": "Treasury Stock, Decrease In Capital In Excess Of Par Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares received (in shares)",
        "verboseLabel": "Shares repurchased (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r175",
      "r216"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.humana.com/role/STOCKHOLDERSEQUITYShareRepurchasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Common stock repurchases",
        "terseLabel": "Increase in treasury stock from share repurchases",
        "verboseLabel": "Cost of repurchases",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r106",
      "r216"
     ]
    },
    "hum_TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Typical term (in years) of short-duration employer-group prepaid health services policies",
        "label": "Typical Term In Years Of Short Duration Employer Group Prepaid Health Services Policies",
        "documentation": "Typical Term (In Years) Of Short-Duration Employer-Group Prepaid Health Services Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasuryAndGovernmentMember",
     "presentation": [
      "http://www.humana.com/role/FAIRVALUEFinancialAssetsMeasuredonRecurringBasisDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESClassifiedasCurrentandLongTermDetails",
      "http://www.humana.com/role/INVESTMENTSECURITIESGrossUnrealizedLossesandFairValuesofSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury and agency obligations",
        "label": "US Treasury and Government [Member]",
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r936",
      "r1200"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "presentation": [
      "http://www.humana.com/role/INVESTMENTSECURITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gross Unrealized Losses and Fair Value of Securities",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "documentation": "Tabular disclosure of unrealized gains and losses on investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase obligations in 2028",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Five",
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase obligations in 2024",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year One",
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase obligations in 2027",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Four",
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase obligations in 2025",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Two",
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary",
     "crdr": "credit",
     "presentation": [
      "http://www.humana.com/role/COMMITMENTSGUARANTEESANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase obligations in 2026",
        "label": "Unrecorded Unconditional Purchase Obligation, to be Paid, Year Three",
        "documentation": "Amount of fixed and determinable portion of unrecorded unconditional purchase obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "hum_ValueCreationInitiativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "ValueCreationInitiativesMember",
     "presentation": [
      "http://www.humana.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value Creation Initiatives",
        "label": "Value Creation Initiatives [Member]",
        "documentation": "Value Creation Initiatives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.humana.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease costs",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r947"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.humana.com/role/DEBTRevolvingCreditAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Shares used to compute diluted earnings per\u00a0common share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r358"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.humana.com/role/EARNINGSPERCOMMONSHARECOMPUTATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average outstanding shares of common stock used to compute basic earnings per common share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r358"
     ]
    },
    "hum_WellsFargoBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "WellsFargoBankMember",
     "presentation": [
      "http://www.humana.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wells Fargo Bank",
        "label": "Wells Fargo Bank [Member]",
        "documentation": "Wells Fargo Bank"
       }
      }
     },
     "auth_ref": []
    },
    "hum_WelshCarsonAndersonAndStoweCohortOfClinicsOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "WelshCarsonAndersonAndStoweCohortOfClinicsOneMember",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Cohort of Clinics",
        "label": "Welsh Carson Anderson And Stowe, Cohort Of Clinics One [Member]",
        "documentation": "Welsh Carson Anderson And Stowe, Cohort Of Clinics One"
       }
      }
     },
     "auth_ref": []
    },
    "hum_WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining Existing Cohorts",
        "label": "Welsh Carson Anderson And Stowe, Cohort Of Clinics Two [Member]",
        "documentation": "Welsh Carson Anderson And Stowe, Cohort Of Clinics Two"
       }
      }
     },
     "auth_ref": []
    },
    "hum_WelshCarsonAndersonAndStoweMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.humana.com/20231231",
     "localname": "WelshCarsonAndersonAndStoweMember",
     "presentation": [
      "http://www.humana.com/role/EQUITYMETHODINVESTMENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WCAS",
        "label": "Welsh Carson Anderson And Stowe [Member]",
        "documentation": "Welsh Carson Anderson And Stowe [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-11"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "SubTopic": "20",
   "Topic": "985",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(2)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b),(d)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "e",
   "SubTopic": "470",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4B"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4B"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4B"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4C"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481620/480-10-55-63"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-3"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b),(f(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-24"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-4"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.W)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479583/944-40-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "505",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479989/944-505-50-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "505",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479989/944-505-50-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-15"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481138/505-30-25-5"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r221": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r222": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r223": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r224": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r225": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r226": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r227": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23"
  },
  "r228": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r229": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-3"
  },
  "r230": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r231": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r232": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r233": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r234": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r235": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r236": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r237": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r238": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r239": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r240": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r241": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.13(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r242": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r243": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r244": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r245": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r246": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r247": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04.5,6,7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r248": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r249": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r250": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(cc)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r251": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479655/944-605-50-1"
  },
  "r252": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479655/944-605-50-1"
  },
  "r253": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r254": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-2"
  },
  "r255": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r256": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r257": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6"
  },
  "r258": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7"
  },
  "r259": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "SubTopic": "60",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479482/944-60-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(1))",
   "SubTopic": "220",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(c))",
   "SubTopic": "220",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//323/tableOfContent"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.5-04(Schedule I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480922/205-10-S99-6"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//944/tableOfContent"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479838/944-20-50-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479838/944-20-50-4"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479838/944-20-50-7"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479735/944-20-S99-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2A"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(4)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479584/944-310-50-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(4)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479584/944-310-50-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4B"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479655/944-605-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-15"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "79",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-79"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479629/944-605-55-12"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479629/944-605-55-15"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "323",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481543/323-740-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-11"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-9"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-29"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4K"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479838/944-20-50-3"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479838/944-20-50-5"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479616/944-310-45-5"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>133
<FILENAME>0000049071-24-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000049071-24-000012-xbrl.zip
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M?>>;0DS0)\#S#+4Z,+] L-]I;O&JZ@L"RQO["UQOS"^._0]02P,$%     @
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MY\?.0+"*5A.V9AQ\M4T$;)N8?8?4=%U'@0&@P*B* M^Q4#7:@'%QP$1LII9
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MQ(K\\##E>4O$N=^Z*-<[J//:E.[&?.]:DO=V7'1;)>>M%AB:UUR)&V?60@!
M)",K52Z;Q2A"TQBK:J!X1CH)T+M)F!_<Z)@"U &E[>]("/DKU B]*<P=+5DE
M RD:16/[J(YOPS2)B=.Q"E:=')0/G"S2-_#BC'4)LPI,FF>UK(-<$8FJ2)0P
M-<9;Y>2(F:#*3!)T& ,AG+$J1I.EF.@,&E&*DO2>C<]"B@;;RYE]AD925284
MBL]LG@!11SW*=:XUQ.?O\Z;"',^-U5Z<HQ*2*M(YQF.$$V 5R/?ARCL>;$LO
M*8 CC)E^:S6#,P@C$<R-6 !J!^@'&4ZC/\\YV#$!DGX+FN9\14W-/H51Q$DI
M61:R:@N7AL?CK,T^'A2D,&*4:4W+,"=6MS.@H68<A=F4%BW+,"N>P69RWA"-
MAYD/Y$"BW&ESO^SD :D?M"'A/N_MI5Q7?JSIU8X(I9%1&U<S:[9U\$]UF7%A
ME:JJG\XHQ7"X"(^PG007X6IGL/>D2'V='983^)_B9$'1-@Y645"R?2;,)("U
MFO],J6Z$9J*P30I@U&JYBA\ CBF0E\R.2 >%H%\Y52)$M8<JVBA92"CZ>(+7
MBKJ5N9Y;XO+5,UDA"JA]D^T'WHJ6G76' #N>H2)+%B(84M#L05,9OVDSUI<9
M-Q0<S.*570X%>>OX1MT8\H2[%GL=GNTB*4#^4 $(0AD:ZQ6I\VL7Q]CKG/;Z
M#*TV,(1U21T[)J,80HS"+E[S.;&6[]=[UE(/^J.7_*Z+.S[TUJ%>C4T1<0J*
MU%!*1W'DD)A&)NA8_IP7WN@$N- <6)K7A7M8-4N7;()MO,#!*8682G< U32?
M.D9H(,,G4E4QH):2'K#LH  ""@\,=7H;^GJ578MF:5Z#1VM/E#S5A+9RTLY*
M=,VF02IV=OM4HW0;H!Z<@20FZ>DNP9=\D\S[F(8YJ/=>-\N*%/E9+85(5N%F
M'-GT$VNO3-*ET8[+J""5E]+AIBOOV L"MI5^0K-YDAK/2M,M9)5KJ(3]%AFY
MU4#!]J,DTXT,>*TPC7*A*TNWW:_=C(PGZY'Q-9V;N!SZ>]U]"7\64]HJ*!BC
M_ RV:*SD )T+>9!,?P2V@8:?(G/%?+KYTI4R'#BB6$E%D=/R0&8NTX4:!@L#
M!PYXR5!B3YE,4'^Q:R!M !.(Z[(OW@QJ%/ H"D0@(@.6+*::Q"Y'D*61V48%
MF[T-DZB23NUFDKCN8#HB<K.85*[['2WL-](8WH$_6^PES^58H\7+K@TT3Y@7
M3\FA%ZXRP^=RB"F+]YG9FN+$8E9ZO>H8<SX-]82+6B#ZDH;@7>'!HVDM!=48
M!CW]^8S4RR*?)BE518)Q]0U 2+N%R68L>K(>BT!:FXK87<TMHK0MN"JJ!P)'
M.4\YQZ@BM8>QL9W6U=-)@>HNC.HZ-]&&*<XCYDR<4>IJ$2IG8B^LS350K"A(
MH<$W=P8"5#L-$G90>7/)QT2***'/"D#[!G]!4'&&T)_%\X?X3>H7+(,H*2\6
M< ? ZP F/O#1Z@]0,F/+J\-5[#&(:=5)7O2$X>% ,44*^Q0#>ORW?8.5>9(#
M,2^-O4F16]-Q9F,;YL"$_' .3[+[H20_:X_C(;#;LLH_KW9='QJ2:2I?9R_Y
M?O6DBX<*T V."'6'?+M>G+8Q$QV2H8$[%_ %R=1_)"%Q5YJ!I+)LO="- ?U+
ML=R%Q@ "SU/2N%S]ZF:6]S6?<8 ."M GY7B;WD?F)U$NFFA=^>,*(66S+%K.
MPB!4::@YA82X(&X3C:O 'R.,E82?@& 6/DNCMZ!]SHS@$Z8.R]<J(KKWE7-Q
M:&@I$OL:@R=0*F)E(W,$Y[D1J.M5 QXT9ZMHY*Z$6_[PRW8K6K;O1+Z(-_2,
M?7RKW.#;'V#SI6YB#-LAX&3<-W>$;Z"ZC8Z>\KO)%Q,>7N9B"K3+ZHP)")88
MCJD<'PQIKGY.*U9CK%A0]:'<</ 75BF8%V-8.#ZXUDQ@(D]Z[K9>\[;L=R8:
M@[D0LB!9! \]FQ5QB/G(O(6-0UD=;UZD<S1J8# #'Z]<]JS*NYBQ.$HB'GM8
MC<=!+1>-+1()7(E2(RL8ZN^R^"?[1@OOL#!-!SF'BP>%-^%X.C<@SKPNBCXZ
M ,WFG:L<*__330IB>%#U:-+]X'";#\4Q$5'A4M:,R<*P%%_*ZK!X5K*ITWML
M:O,*2)]RI@#E2)'CR)LGN<#-'\DXLP<BT:I\3%QR!:]@0A'CU@>)4:9H"Z.B
M&JQ(PBCHC8[9-82?  YR_B2P@<><"=C225<,6Q,'T>4IQ#9<T#0DDC'7R3P2
M#0[%!/P.)Y*@'Q*$;)E%<X5[3U$!F^@ZL-&V!"@VGN&AAU\9P,YLN0[C_>H8
M*\8:]!)21@! _EH[&1 %TF3Q).7;>@C9PTB-."PIW<;$KN8Y#(UW!!0Q+1@=
MR1R2DK\8;W(!D.DNH&/.!Y]=]40_8$%B$.><Z1G<^C1KR RZUU(KLZ!^+OAT
MAV"W?9??=M/SUEJ(VBE#]=@'3":ES0'^\&^WC!*I>B>EF(DKA+5"$7_T&>Z:
MSW =]E3J,]T-K;9JZ30<2S&KI S%;TZW0-^'Y1T8QX._3@KX",_Z$KPLZ!)'
MUFRJ?(KS))MW5@"?S+*2W!H3*Y<O-6+XZM)IV@Z6M*' C)SH>C+GK<PQQ].Z
M.T,,Q-U[<K3/_H#JR"8GU-M;#8-)A9/($O<[;H8:/HG5B Q"OU=+\6<T)$R0
M$3M,BJR,&[.18M:WN^);C#AN3D[F@7=SV.4K%=;?L-05#P:FOK!%U[I3;,AN
MW;Y,R4I^D:8<K!?C8YBOXV4J4NG2N$]D/#M%6!8-,J)--9*=*[NA"+DT9=0J
M<4I.6)G)8;K5Y)'QYI&*630TP7@FMFQ%:!&)B:#Q-@D#$X$4),4XMZA0*2T)
M\I0#^!<&\+,"!5%-26/+;W>[Y'6T$*LI,5ID5 KF!JD7KL%93Z7LVUZX[ZB4
M'&]YWY6#8AK*Z_??+<J/IJ";"8=W9-VR\F5=MH2Y9++J/=MK7C;%8.V%M_Q2
MF4OE&[IQOV%VT=EVLCU>D"%(OF(K>9_2\.[%%MI]RNL2WG=,8/W5];W;@GJW
M".H2'-D*R7,KJH<W0KJ.NJ)05HKX9>BFW,8P]8M9EG-$#X?D5HU>#.=2VZ&Q
M= [2(2F< S_=543'% .=JZ6)@[>F'EU)D4DU/%.-VTEU.!L7:35BQ^K':)_#
MYSET-45'R7^8'QBFBJM=4_QG;9GC5J/P@P/M^B4KXI@5L5"M*4+87RV-ZNTI
MQ]QB:AOV;DN!:\4)Z-8#L9"T)N6^C*3A&FY<>8VN[8&@=7@HX&_W!N(/;)<B
MZJ)<@L^K&#!AT[/9%:SPSJ)0Z)++_#0<5RK.<KW7U;JR.PA-Z]GN:[&CKBL6
MC7<JI^=$]AV?L!W*U'*K6*/J($6XRH9>,E1Q\?3:D\3WZT#WA=2D4X%6*JT3
M )./L82H51]0K)!\2+>'#QKLD<;2&5C- H712F:@NKE)*>*I(;W0A)I(,,I$
M#I39W9+B5#94(G7+IV](N!QK'RL\R]6P0"E2J"VZP4F95;6E2DDY4W(7(?K)
M6H@>4:9]A'%LMMR\">!RE)/7-J*H)(N6MI3U$QJCY$"7X;+3*#SJH&1?=0VT
M$E-(BN2D07&KD^IJZ&&7J7NM=#;A BW:&<N8P56 P)K+\D*V:4=J47$^   5
MC#< ,HFH/W.$9@KL3/%#2OHM $FUT0!%36(\)N QQ1/4]XV6+W_JF/GMAJH)
MO1@=G6G]B54U4;H!RS":D'@\8G].B^"3=G<0QG\4,8N)?-]47YR1RQY\)L&;
MSBD98##R%)Z:SC+QXX!\&B>ST'=+IJ\)EN3,J+7]=F#F5R;\NL%76ZED4PN>
M)YJU$9@VLO>5I*L9&IN<JC).#7A.ZB?@"#1%!M&-TH4(X:@8G!:2%F5#'9M-
M5>[[YE'[KAF,A=4*4FXHKMA>8G2ZD1@YH&<2YNXF190#YYPAX3M=F)-);[/M
M"8;=@-1F,Q95$<DL*Q58J:(C%<^I7LR3HU/;VU2E8Q7K[.#J<P1TH\MLY.3H
MZ,2M^%!"%\!56\ME/AKN[P+KIYN,-65=];#41T1ARRJ@BZ5]/ON49XTIK4[8
M?S:EY$4".8FE#YRD4FY?(9QSC1PT$?F5:^N C$KFV%D(9.T3&]54Y!>1*2UK
MBE^H .XPI/H\R#]TFE(5C*EC']PL@I:"IRW9(YNT5#.I\<S[F/KK+,;D7[#\
M2KNUJ-MNL6U-[9_'PO+W;\>%L?24<WZI%M^O_:O)564KV(A1@(MYU:M]W<-)
MLLIX+=K?T/%+*(?TT &"4>BF3E\\E=L%_)P4R040Q)QR^?\%@Q?^IZ4U<7 0
M$>4K2=T'8)J<\>9/DY"=/31B6D25K(;(I$_-J"J8JPVC1"[K]$VF&\5YS%.=
M.]E-U4,P/8-,>8!;V@I37C[J/T#WSP+N<M*J(."')4J\>20_]R8__5*]NB;U
MBH/"^O$MW' @.7]=CK)G!/M^:=2&$AH8(COE9$-V!9O\QXIX\, (-;9K*@\-
M.2&69BOB\-^%N*T^ _&CNA94\!"4=P52$T@W&)KJK,2(SE^7A2"IFY$">C4-
M9V9PRERS,\!:38RM^-:H!DAC/SNIQ>.T2_RRY B,99U2F&,VU2;/,]:34!3<
M>W4\>.B<I_L2HFGM-&P@I;U4>J5A59&L]/F714 J3O ZH:8>92I,.VXM26J[
MIE'V5)R<+35*OF8C3_>_ B)(J,_@@LFO:DRQG)[DF)6B)),JP6J&B?B-EJ1%
MFG QF6J^MY-1_"5KE.'OGR!.ZVQ<8!'CA92YF/RR7;8$SEG6NR8E:5-IHIR+
MT, L)A*A05-8W;[\<H]3L(5W\+K@B;5K)#/SLWUK[J0F@PR)G4;U1<RC;'UT
M"U:)U:)JUVPP!V$T-Q;)-FH>*5IL771RMXV]<VU-G[)P& I'TM14U3&D:C#)
MR8Z,B,D5!AE*,ZE.%(D,6EI8;U48F7"@,.^839, QG;,I5,4D<+$(U8JR0**
M4;L)2ZUS-&?.B'YW#!$!'D5YQ\*4Q2II\HZ=*X8)<LP:YC.BBX(_08=$8L-?
M.A8D4:X-^6GLO(B$QU8L[D]L-7$;F)^M$2LQ5UESL@)3.@7C%VG._(#BO&!*
M5[2TIBN2,;B;4\+!ZECP"R9%.'?SV?'X\:VRYC/ )%G!]DR #\^)Q:G*A'4T
MB.%S&*$DA0$4\V2J8J:PR@A=?:W;'/<:BLL((2Z8:4T$$T$R*R,)H%<L8GRI
MV"(B,:NM0 :%H.##QG:-I=O1LPG[L'7=* C^L_;11X%O!HE?<!1OA1?H6^&Z
MG.N,L^VJ[>#MC@G0H+B*%F>URT<)V2T/=%>QF$IUD%Q393@*<R#6B(I)#*N3
ME(NT0W@2Z[13JYN %++ K!\NR)"DF4LOI28=XBK280EWE-I *V4(17KOE![O
M,HFFE",[\CY;\C.B>W%61+F*<Y.YDU(QG8XM1&2K3];7;3A5Q<.C/X=9+AQ9
MR,(*NV-)D/*F% K<6AA@BEE]\/_YLLEUY#0T+C.)G$ROAHV7%M!*;A VHTYY
M6^ZHU8?JNVVY_V=-T=P=HTRC),($].^X464EVG0EF@IKCYAR(S#K@4G0JVIP
M\48G;-71C>5-TEMQ?SJMX$%ISX1$V+)DCLN;O=IN12Y;0(L+8'(3DGL(5B2H
M!&6VF 3NU!SFU3VBR(9'$2B.<"#A$3_4#BP06=F^B/VLC(0T4Y_#63'C!9"D
M6 FDB8#XY;:O)DAG0 BQ=P0O[VLOX3%GZ(&NQV]/0&G9_?:5'8=U;2*A[_K#
M\][E97?0N_HP]-Y?7_W:'_:O!L.'V\:;.SFVG^GM6A'65R'[CR0Y\J<?GSP_
M\[H!GNIW+9JO#UVI"(96/QV'L2WE#8*LB82CD"73&%;RY5C-Q2+A]=05;T6T
M3L8 Y&+X+>-:JEV;:"AC8W'\@+5J!(=>G_1],IS%N6,T,YHT,9_FD"DQ$MNX
M U#=4S2RNX'F3BBG])IP%!DT>%BWX@)=?&4G#!$#I%C:TD2];BP)@/6)?#4'
MF2 *_R.Y+S.=WJ#$CVI%$H6!?)WJ)+U1L7V,HUA-/*CYG,TCM$^AZ0CC%RI?
M9G/@+\ED0G9S2="B=D-*&+N-H'#3EE*T7.4X%+H=R?3-3:7D2$P#$FP!@W4.
M,=%FV1ASG7FGA\\(;HZ/JSUWO2[:W!P@,19T-U;.&N<DTHDB]/@8*VE?U=",
M%=!VA_P[@F/(.J/$)58[^+4\?+:9XKQZ=(3>OR*1,9IM]<PD$:*D6!BL1RG+
M2!G%YDDV5HP9(GL$6P?I6[=YO2&"2&7S9!>A]_P1>A^CB!YH?RP;,V-\(%9)
M28G'3[B[&?EJC,=@;7@^NT$Z=>'ASXH9&G*SV(EW 5KH IV]FX.%JA%"AW4*
MP<NB2L5?MC8;@&G9\ X2B\?&[@]Q64CA)8*?;^RV6,OX3!EFB?)#Z"?D=<4^
M&]S>Y#V76 ]30:%J@38E&K@6ZFH$2&S*A&-#)%,RJ>RK+,8\-]*7XA_*J#QR
M35;*ML&(LR0 '*EB62EQ;EJADTJWB^C8VS'^.:1B#.,0U*/E]VPPGU1SC!M<
M1QQ:-M;8%)3^)/\_.>C%H0^:;F13NXK8\70;A3C5D;Y5->.U5%)#K K"#*W'
MC#HX.RG8930)<G&9T_&YEQ4[9AA.KZ490KD9R\!+GHBQ1C+0S*;5(.E!,WTU
MA8I9>(J)$$ C?!6+O6+38,+8.Z:XFPF4J-@9G 5C*[DTI.*=E/AL&S!4[!O(
MHZL1$F0K_Z1C*]MPN8N BZ<WA3Y_<3V,.4;/Q#<'1!%?')P>/@7(:B\AVK4V
MQ!=2\QJ+H&RW',:FMM.M!8)U91:V>9+;!<#F$\&(;C)A%IGMDLXAIHF;:F J
ML,L#3#I8TC&!@:9UN[(5+(TECR+.1(4IFU%6F(DA5]18T$3Z8<_"2,RG$W6;
MI(VZR39N<KO,N4M9_]F\R)GQDE?9J*\LH.)96>.IU(<Q]!XC4SBXE=++(BH]
MD$C5V\;<D0;5MQKI5^%><N7<$+G"Y^[E5*C8=BO%ATU]73]2X8PY(C5:+%_)
M:JFOUK/0;M'Y2ZIXD.&B7EZW%H[@)!N2TE%#V_)GP=V??GSZ_&P'3PKK=:P[
MJQ9TD]]8V:P%G>7I^C,KFW*4S)U5=  ]J0<\VJU4EA4S#&L%9 ;]*9<_)>."
M@D[&4F%C7<^2E3-:M5)9T]SQ\>%Q30;F#\T5_- W:)3QLN?@(O&66J4K*;DK
M"]E3^[4B@*8.9W/9T%J.LFG_JK "C:0U[(WWW;!LVMR;),'#5FWK3?0P0Q>5
MI6DS+F[LC=,:9#3:-ZX/HT\3A"W08Y> DL2WC7EHC]+ML7<76;M248ZEHS5B
MPKYQ;9>,U'4;N_#I@KAI/V;E.X7S&Q]QTC'%YK5IU]#AINM_RHI)$*A6M7/[
M/W"G"K=K!9D 038(R7(32KL<?'9]AW7N1U UYKF._06\M#R8) 5V&CK=;RS%
M7@]K*&OWUCJ$/D:FK4R[(Z+%CA"T)&T/\;+I1FECV$XU:F4-_3'O3AH2_<J&
MB4[G%\HE0F-DY6>,W% IIT8Y)*9C2!7'UU ]-VKM$'%C>2!<FH*F.R7IHLX*
MDSO[J[4\I'T=F-^V&LH-76T=C%O*'^$*,5JZZG'ZNFSK/?S*9M269=_%01Q)
ME1TV])*TB<+G:AH+YN"VKI;# P7+C0#:6L!M3JYM#1AS+YN0RR":3$*8TXE(
M[&"N3I!@_Z\IE3?Q4>.35"/Z-LDH7-'Y4\0^^"9*QN,E)R]QZ;EW ,P^EJ8$
M$AW[!/_8E>F C) ^9[S[5HB;8S%"Y>LBAY<B(-1Q@6W)BY1FYCKIV%>6/N*(
M.-$X33YQ?S-8KS0Z0QT6MDJ?? !PX!-I%?7$[4H]D*5=['S.O='L"TY?,JM&
MEE)BDX!H")=-UUK7=<W;^XN!@D9\07&E_CW 1!_>;#62HF.M>Y7>3V5#.&IS
M<!MF.M@G0=^XS%:ZPU72_Z1)G#-.,I84Z/6: E6P</O'[S(9;;<XZUB;WNCD
M)E5ST *]+G"WUM!,$\61HM#=.KP-#_66(Z">/C^C"LI$[_>R?6G/01W"EWM
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MY\!TO380T57C=<'(V!(,,@:EG5*Y!R 8YE/+B#5D'D6"HLVLA2P*0D60 ^V
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M"W-U@AA[I4VIO(F/&I].-:)OXY3"%9T_M<0#WX3Q:+3DY"6NN/8.@-G'PIE
MHB.?X!\[6!V0$=+GC'??RB]S+)4H?)EG\%((A#K*L85[GM#,7+ =>_#21QP1
M)QHE\6?N!0?KU4WA4(>%K=(G'P <^$121CWM=J5^T;JU[GS.?>3L"TX/-ZM&
M%@)2G6QD")=-UVKJ4.?M_<U 02.^I+A2_Q9@(@\G&XVD:%GK7JE/5M$\C_HM
M7*M4!OLDXQJ7V4HGO5+ZGVZHYXP3CW0*=+.03!4LG/( .TU&MUN<=:Q-;V0\
M2<0<%""O#=QM:VBFB>)(4.C>.KQ5AW+#$5!/7YQ1?6>B]WOIONX30MW4EWM
MUO=)J&;-RE?ZNWU._P=MMW5G!72%R!:%BBU5*#H)1Z G3$4XKO8+V>.R Y6J
M_I;*>$4O4;>O:&W1 K(76*6!VLP30[N3"KQ]E&-G2 >GE&\7Q2C2^ZKR^7=3
M%\AEYN81+F0(.NK>\8G%FZ)6O$&:(CF'ZI],(JKH:1-D !>%+B)-(II*BV)$
MW&,G$DD2+^ #\%$X7%E-N/@>-6M".0$$0F0NV#LY*RF5E"HBZ7(<NAJ2=2U0
M*+PQ>N\X^FTW_MUKY[Y;85V,O2AEB_+$?/H_I@R#FM B:U0NL)^N;E[)AA[>
M EN5N+WEMXPB%>D45L1W*_&49'\CZIKZBT4IAC76I*V-O:D'CS<[%H#5H7R:
M3=<YW'@8:*6]$9!XMQ11->I 0SSJZ12\J+V[<S%'/- UBW0?: 9Y2H&/<&I=
M_K_H)4?^DR!/5L.T+>L,).6(4MH3:?WTR_$9:_[$6,@Y;!=DLJ008[,\T1YO
MDSIE<_$U!QN0OB>2:E.X5EVZ9Y13R9K PSZ"NI934=J5 DE-9%/9X5+L1J4X
MWUI&M6-8OVM5G$R(P>G1+^TM1/RB#_V!7LF8_CF[7_$$DW,;XD),#NX\1]88
M937)UZ7"_9IB<"4X0$1DN12<YMY$@7[(:ZD%_=CMZ]#\+(]KZK]C@;>6KCFJ
MN_R4TJ+0EPN"YTK 275<&YPVR77+4)6F.1<%,1%G*QF<I1C'HM6JLS2N" 5W
M%.FZSN0@MEJ!2DW\MXV-LR'M)*]ST+QM0^/,#027IH7C,"0\!=A/=4X*=Q'#
M'&>IDV9*#5V<N+$H7@T1KZO9S2D\17W!II+=#5"TQRUYN-(*AAGM\P[WQ#Y#
MH--02(N^41QQKH!"71U+8R=DU)O-9902GAOID-J3L6.Z5(.21ZZ]Z[V1GO?:
MUJZATI)_Y>; 5MKBEN/[W6IAI2H'@0P5%Q[,0;X,6>>RS=YL"%/$#=[,9@N7
M#B.+MFZ8'=KN T58;I'9V+#-/8U63M14,1T6'J:#-<;8;YFI"7D>HIY6IKT[
MXW^T90RCH(BM"FPC@5%?K&$"6ZG8PDMN1%Z@LV0IH/AV\(^F/+?O6PU^@H2(
MX3H \%( [Y?)_C[6.W4[G9#I0'>W8SYB>E*;TM+Z6V-L=.I.K&%_M/F"?J7U
MQ*J&O=6C4ZLNG8DHE#XDP"_R:A#^FA8X9"IQPH?73K&NP>?=P')]]:.O _'[
M@N0W_79OV.EXYYW^L/NZVQEXP[?MH6>^?ML>>/U.^\)K]RZ\#SU@6H,A_(E/
M=0=>^TV_TWG7Z0WIY^';#CP[&/:[YT,L(^6=7_6&[6ZO0S_U.]U>BY[#,=_2
MD-[5^_=7_>&'7G?XNS>\PA<&'RZ'WJ?N\*UWV7G3OH2O/O0&G4OO?;][U<=G
M!MTWO6[O#1KX]!K;Y__N77VZ[%R\,:NO+.Y=^W?O%3YWWGD_A-5T+COGP_Y5
MKWO>OKR$GWXW0[7T/MJX(><Q6,7[WUNPZ/Z%_A/6XDQ+L^"4 Z_3>WW5/^^T
M7UUV\"/NL=]]T^VU+]>NN#AO.)=7W4M](+!K/%R:U+MZ77OJW7<=?+3?^=CM
M?/*ZPYJCVD(XWPV<::@2V4,([74& ^\3 O;51CL"M:RO9PH$DN3DH*8BZLBU
M"'"-=.TQ&BWI4Y"CZ;LH+QV/Q\!\DG+50IS"#K-B)R'6XG3W76H9G J@FSY0
MWVP%N!,$A7*<O3PY?F9&6C4>?*]Q[KO>X$^/GYR>66,+_/VWG<5]G/?-O]WW
M^;:'0V!FY/F]>XC6W_O?MQ_>M7MMK]L[WY17G$YHE:]LZPTWK+_X9TM@[M7O
MI6RU^U_".BOB-D#^%MA:-?&M7]/#!:ZYJ'K_M.80)\\WQDG_[VK0>?_6.S_T
M/H)4_:'?ONL&7_4_G'>\BT/O5?_JPV  :L*6T)/S*38XOZ1R)5<LSS7MP?N*
M?]XG,B4U7%>BY>FTCQ$D/CWE;06^XQ>W$A*V!=>_2D[:&N%Q\_2[)M+#L6>=
M'#\<\'\%L]Q&CG1G3K4-:F"]$/O38U@WJ=E_1&(&J//LY,RC+V<J"$)9_193
M>HKOOK,$_WU_VSI/"0ZM@G\]4B>G_GCTRR]'3Y\<C4^/Y?'H=#QZ,3H^?7H"
M5.R9./KC]-&W>U>>GWROA'*?VMC<M5;_W_Z6N\_-7>H_1W&PA/]-LUGXV_\#
M4$L#!!0    ( .Z&3UCA#K[@1B<  )3Y   >    97AH:6)I=#$P;V\M86YN
M=6%L:7-O,WER,S,N:'1M[5U;<]M&LGX_OP(GWG6D*DIK76QG[6RJ9(FQM9M(
M+DF)ZSREAL!0G!@$N!B -/?7G[[-8 "0M.0X)KE6'AR1!.;>W5]?Y_M1.4Y_
M^'ZD5?+#_WS_OWM[T5D>5V.=E5%<:%7J)*JLR6ZC=XFV[Z.]/7GJ-)_,"W,[
M*J/#)X?'T;N\>&^FBG\O39GJ'UP[W_^-/W__-^KD^T&>S'_X/C'3R"3_^,;H
MPV>#P<%Q?/3LX.#X(-&#X3/]_.CP^='@[P?#HZ/CWPZ^@5?A<7['EO-4_^.;
ML<GV1AK[?W'\?/_IX:1\.3-).7IQ\.3)7[^A1W_X?IAG)?17P/O\)S?3:6RB
MD@2FN$?S>;%WN'_X%-HK]8=R3Z7F-GL1PS1T\0VWZ-Z*\S0O7CQZ0O^]Q%_V
MAFILTOF+;V_,6-OH0L^BJWRLLF][5F5VS^K"#/E!:_ZC7QP<0"_T<<8S>0[M
MI";3;F8\ES>__'QR<1*=7YSN-^>Q-3. H?<O;LY_[4?7-Y>G_XHNW]Z<7UY$
M)Z^O^OV?X9<MG=;)Q5D]A^CB\B:ZN8Q.+W]^V[_I1Y=7T?7E3^>GY]LZNU\N
MSOI7T<V;?G0"\SOKPUQAOE?]ZYN3&_C .UGO[-N?3BX^TTP7D&S05O#6[Y4M
MS7#.#9DL@49>'#V;E%]^Q9X?PXK=O#F_[A[J/W<DQPM'$NU\F=X7K\/C1]\=
M'CYY>7);:(T"@#X?O%SG@NQ&8Y7H2-DH'T:/'SU[\E+-5)'\EH" @X^'+Z.=
M<J0C&?DZ%^\,1H2#?%TH%)WK6S+9M=UH,(]4ED0#7<ZTSJ)U+LX"4;B.I>E%
M*HKS8I(7JC1Y%B55.H_RXE9ET$A"JZ4_&.!- )LJ8$M%A(<K53,Z?OCW=2G;
M?*93/(DZVAGI0IM,#8$/1H4>ZJ* ILH<SRR^L5Z"/CI^>9J/)RJ;T]]K)>4>
M+3 1\= 4MOPM4V,A8OIR;)(DU>UO4Q4^B6U$>CQ)\[G6;E-DABNW8NW;<#G!
M(Z?U^O>ABT;7M2P'L+_=?]^=WUSTKZ_[-V^V$$N\>]._ZI]<]]:*(I H3D""
M)\+4KK0M22-\4T'C*CK/XGU@97G\'O^$%3-3';U-@;1V-H)EX5#63R>]: :,
M0TTF13Z%M0-Q&C ;E+('SU_:Z%4.>(0D@BET7.:%I26WN+JC/ 4A8A\_>OKW
ME_CMPWG^]//LF'RB+2RT1;9^BU +_W"\%85#3G_CMY.JB$?*ZLB.%+X!>Q3G
MXS'\2)O3EAXFBU0,Z"!10!+1S)0C^IG/(FS@%F[>Q>6['FJ"5_T?+Z_ZZ]U#
M6-XXSZP!@F#P)<L_*?386,U4,Z[*2J7PX%1GL+<V"B6ZU64TS(MRQ$ BA[>+
MZ#;/F<=-55JI0:J;O?0:6XS/U6<%U1R$!L,\3?,94NEW]]GD->WI^?XRN;D^
MMLWG/=&Q .L7!)[QJ6]^$)O1ZZN3%?:BS26ADRU;;E(_D;;XG*]3E.]'7PA)
M+.8X-P'A(QL!^4T"PX82HX<,0$5C52*'@66S>J(*U/'@Z%4QF4&(;2AG%*%/
M65XB0TN-KN@EE:H"-4EA2B!F)CJSS.> 94&KQ=3$VI+Z4D,NAF"778E%F@^+
MK=_(X*$35HEJ489\[2_[!\_V#A\_.G[^\BB"<1,3U"NEW,X7Q%6+C\4ICX[F
MOEX["2S$;J1*%D-NZ2<%;!2NVE\"<Q-]R3LP04DT(LV?+4]K7LXO2><K%U)_
MT$5L+,E@/,ZP.$!38Q;L()03@P.UM1@7X;[<.;(Q,G>9"'BU9<+A!O;C*Y<(
M>"0=3Q3&"]2<IL0T-2+_:B*GMV'19<S)C^H/$U!!\) 3B^"/OYTU3=(;8,CO
MX\!8"/'@UF_.WRAB7\;.-HVD06:NU6R^>2NRBLG]JMF _X4Q\.*E X[7_Q#K
M24DN+ 2',X,6B98,['7YT4 W)"J@5Z^Y J <&4NP#]$F(!*;9Z V%QJ4:0O8
M4A&ZA*8(N9+RC.V3U1V^R^#7PA)B'78Y'6GJU;A*N15X'%5RD]D2AH4(F. G
M#&2O'!DV?6$;634>,(2^9HR*2CS:WQE[WX?P-T7W.]LR\=X?#G5,RA\*>I-Y
M.TN?'":DO< 7&Z 9KM42=<X'5@>+,JR)JVGFC8PER("+"6<9=;E355G4&X%&
M\4$*C;"-)ISK$-[UOO1>-!MI4@ZA"50? ^+N"<G[CB(#6"0Q\%<Z!PZR>L#=
M$>*X"ZTL;CYU68Y4%HZ]PVRFVK)B6^BQ OH/.<\"N^@U'#/"\@>']-;!D>,"
M:"WM18.*N$B61WJ*PQWH.>!_>J"%2;:1+?2WC2WP9NH-L0IM](XO9AD'^]&R
M+;_YB-S.LW2./&56F++42!,EVA?*G,,)=%SH,I#$WE)=AA^_M6B6R&(S4:A]
MZ+AB 3\<LE$I1Q(O\NJ671;0)TP!7LECG50%]6:K>!0-BOR]+N"8J!2X B 2
M=*;<,N-H\KW>4K21ZMLNU%#.4H^=3DVB$V!;U]BES)?7AKR0B]$"\17X8X(2
M#,8[&YEX%#(J8',#C;A.5E=<FW[1<2(ZH;5053G*"PKIT"FT5^29B>$QF-4*
M&+5H8FP>G$Q2>!]V<QO/[N'JL]NR>_GEG"B3M)TCT8[9C<Y!DE1I2BA1V5&M
M+NN S=3[QK[/'0-OOH(3AC[I G=1","==SD%^2SCH^@W"8:%IYN?3@2G^J[P
M!(S4%!L$":=N0=K>XC,_*E-$/ZOB/>#L7\DFJO^-*%;:H8'[1GCF]2Z[I\()
MP!A@#C")$S04# )L=;[3W]TYW,6EP='XC_AY !!X^9EIA4%/<DL6LA>%9NC=
M"8QV+P[RLLS'+Y[4KZB!S=.J[+[RD5AJ_G=4U/&>MWIO -CA_1ZI#2]4.E-S
M^\U]0[@7D 7AI.6!HEM$44?+*>I'C8['M"><#@]$FL>D/L&QX2\"&%>J#^+X
M9)RFQGF%^A70W5C-D0P+.+>F8)I(U0R/Y@ -_"GRM0[7WHCPT7? R3'P 8GR
M!B>X"78G<3]G#%QK[_YBIM5B@\ C;26A!@[DKF!2.D7]FD0Z[DGH[UBH&H"H
M#'U5U'</$4 =,B:Q)B3-R*L]DT5N]K9$K*H%_%!Y)Y)? N*N#3[9V4I<1G1K
MV:&*'0/LC#(? -4J5A 0%="<-\KPM\2SOFVN]:4Y# L3'%I9#>NQ_Z]5\=]"
M]-:,5F%902< !$R68(1Q4U/P1#C Y"]M+>)FA:A\:,J]6YU17 R0L_\]G[BO
M4-$'1'P[ HV%/-BE(7#O']79U "6]E[P=N< Q; S -+PXABY23T*3!-!(P/:
M.D',H7U63!/0-:@PID2+838TN.*&).8P+\8,LZBS A,!+"E,%L!8%J<5,2:%
MRE%>LCPTSN3A_?6\9I,<P)W1UD?#+PL+VN59F1(7CI49["2(%\BH%WP?50X#
M*AB)!MCU7@03TZ!EP%A-!J_!7UJ-814,\]!:TNLAFG\M]J,_3#1M90[,?*K3
M?-)EJ?:]25/+H<S6T#*BV1=7*!R=?SX!!5%;,ODTE+IZU=KZ%D:( M^V(QJV
M#,2-&6U")4^)VL.@JQF,B/,+W!XS;@6N/S(3D3QO_<9<-7[<2?30$-2';F:[
M 2[2J,]J!;H?B!96 CLT !JMC_:"]="E;:O/7H&$]1V1GCO-<12V&B#AT &#
MR>>@_&B['_00O\_R6:J36QW0%L<9A@:W0L?:3)MI H0*B-K&6N%2@9H4 7KN
MD@F<R@+8C*V;I,5"$FBL+'&D]E-A0_G@=P0$9 K O46CG]LC#@5IKDN'.P#T
M."';'KR5ADI_:R'0(CF! TLF0&A3".Y>?3D3Q6+ZKT/^8.^04X!2%JSYL,C'
ML&ZWZM9Q*IRWH5-.ZSO+*T!#*D'/A@8&IM@6OFQT3,;!@F^V:O_?$9OF$6]T
MD1/3.24IHS?"'/F 2/ZP+;3-J(DPDZIP;.)*R!H8\5OH/$\6R@'D<B)@@Q=>
MZQS8\ 28>G0";*[]9B_DDL ^L[P$*481^93BA>%\\JGG)"=^32R%?!RG >(!
ML954Z$DKHFN)W.L,530K]QH:B)I/!&(%E7GT^:B87,&!!>"CK8" 29EYZN"I
MA3 O(;<N !(QC8;LC@463..=V*%/K*T*9.>6>6NS_6:D-.TC2EVO^N7%O&W!
MHX=JF+1JVWM^CX!M%^_1)PE=BN5XT4;8QDZX,$ORI%>6#+F)L7&:6[U0 BW%
ME0B/0E@9Q"=M$46NL/#^2.O&JOKY^<X)T DY IRIIG,8Q%83C6&*N&Z(^N!\
M.N\%F;7HX"8:?DK=%O/JE@TW1G"2R.*O2G1%R ,N(+9Y;/A<N(,0'#!IBZC%
M5NCV,/4@"!:CE;H- 7%K$%O#HX@( "D"H3@W; CGJ&DV^,!TIR9/&RD*RRPU
MM$@JM;DCKSLN+LPX!:16HCF\IN!$S5$]@=.IZ\&YJ#0;,HT0UO/*.&_+1[OV
MABVQ&W%^Y"*B.1T9/>2$,:1@@LK1)7F<BK;K)'"X0+MD@M]L/'5OPRX EI$@
MSZ;Q#H\/*K>4:X<AW 6[O)O(U613B4KJJ&K#"I4_M*OI&'@F(5JRY7%8CTBH
MA+7S $NKDGF^B+A08>_H"<817=@#G57?#;)W4/]<" &R10JBPEX+4.AM28<E
M:$)_B$<JNR7V2V@<83>Q4QXLD \<L#WH>"]&LS:<DS%;($/AXM=![(RV]L!%
M(OBP)71GZ@+CYJ.=@[_N.LHL\Q)8>FWUS*N2#",X=!<J7P2^4S:PUTQHZ7JL
MUVNS@%3^I)(B3SY&&#2FPZWW'6U<X/A23K,EJMLU&=3*91:>KU>E.[NOOK/
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MHZ5"#@/&@0=A,+6KC>.CB /;TX\^IK6&4QYB8$G[$L1+N3B_07^(T\JB6E/
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M+@? <5"N1D$#9=XS0IE=/RI"%Z/!TJ!59OY=2;3&!Y"A5'T)2T#'(U6H&#A
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M C<%#+QZ<!3?O5"?LR>N=<TDE:X6@!@"RO?D:F\.)O,S1N;)E:]H.*5OW=U
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M6LNLL>6/7#^IIT[#GH@/:E)/^.B2I1$EL.4@.=GE3@XDV%V%Z37V8'\N_>Z
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M\,>["_XZU-D"_C>N)OD/_P]02P,$%     @ [H9/6!X2'X.D'0  H,P  !X
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MN_05<?B;,+ %)".C&[2,<BR+A32!F43H FAHN2[P8*,S?B>!3",7CXE57K6
M[KD4SIG_, T#!YLK34:Y#>3%00JG*^A=]<E%N9 )16+.^L$,3N%4FT!B%<<2
M[7,^2DZ?=H?3=\@$6,.UODE^#Y2;*/1^41C<H%0M0Z=#4]7J(N>H5\C+Z#A6
M_\XXH:.G^TW7O"GB]8FCP(6XDR:(QQ%4%9L.[&?&EUIL3-\DMT?&I0]&OP9&
M. :>I*=T.,G);Q^*!M6X[0!\I V,@!&^312;MS(DGW[J>Z+-@OD%N76+@37^
MV?Q@AVXB)\2>O>EB27&P7S!6K&LCVCX*WU;Z I*R/HU5(\IAJ'6U?"MRT,G
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MLP?<[@-N]Y^$VSV@" ;!UQ49_'B;"'X#3!BL!4&L]"'#\/AAG;=UYWB+R6F
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M,-_=__$Z/_AG6LR2Y_\'4$L#!!0    ( .Z&3U@&939"9-D# !9P,P 0
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MT[=9QQ'#\J-1;F1?RU*\)^Y(6%K,<+1=>Q)-RBE$E(O,+2( >5F# &6#JJ:
M4B[<B @2!L&M+]RW.:>3_ZA+C.M8N1"C&DN<XS[28V7#B+#,,)%PAF8QMF?$
M8.X4W[$H/A!?S"-^LBNMN"6F42XX]J.*KB"L*$/1$V5C0!NM^\ ;AL\\QBC_
M>4Z?J.-->5PO"%>YKWO O2?*19,4X]X?1Y$ZM%8V+K411;Y&-KS5'57,>Z+<
M%BC%F'=-J*A#4&6W5MU3;%T+2_F;:X=)U/A7;T('GA.ADQYD[M%FR96+TZQ8
M<F  [!SHZ[G:R@4Q-DH+"U<\]PT;/Y;.OZ&YN*&+XPP(.9F+QP;6#MOI).Y5
M*7*;N?6'.DTJ%P621#^W@ZD7$(?GYAP2!/!"DX$EBX[,C?P/:MT.O\X0-C=>
M>(Z15!@.@,<2G=Y!?N>%8KZ%-MX5]Y4X&)\=C"E%A9UL.\=1.![NP0F^SC)#
M#N 53H2:>_%($VC^@JOZ1'[U@NGVHV"-[F$S'S&H;!3LF^>.0NI/SNEC^%K^
M??.(&]R1&7ET<MN/@U^Z<C$OC4--*/L H\#OG4?TU@P]>!K9/+>O5JRT:U::
MWYF19J:W=V9D;OTAT:Y<K++"HS)X+&"G4%?92&N%QQ_#X]HSN+3!?:/?["=J
M7;E@4(QLT*W](* AC)3OK,75?VV,?X-!N $-8)YGU \Y>6AP.[RA,M6MOB'4
M52[\G(2.^ ZWOOEG9 =V GRDP3]MU_*IU0]_W7XC#%SKDUS66MGP;Y%KG=$"
M<ZO]EA:8N_6'M("28=P!?-&*''H[Y,>:KFDX]D!&/=$@3 X[I7^E](9,:$%<
M<I)3A*JK7 A6-V+D&"[L*A><U8T8.6[=Z2H;NUU,!G[>,O <V\*CWI(2NK.$
MLM%)Y:F0)R\H&\!3DPH*[)_M*AO[T8!D&X7K<B-93[GP"*K_,]R#3OTI+,$L
MJ]9_ITXP/B-^ /Z+:U'QOX/0>U98O<0'IZ>^/2'^[-\87/@WIB$7G*+&62ZX
M3[YZ_2/5/>4<_W=O!]()- K(X9YR88CM;5JJ*)^AO))QCG?1Y\P;>WYX.SQS
M0$28P6T^A13VZ'A<3\DPBV)28&.4:8H%):,\>5#LX=FKY,)F6% NR*2^7%B-
M,DVQH&RHZ])VB8ME,>8W+LD;?AO(PH9 LVW6VMI.D+&G;'AKY<I? V>,R(A^
M)>9W:@VH&?EV:-/@*@@B:GV=_39(R#&88H#%I]8%XT'?#K91D69+)%(VG+62
M1#<P$?+"]A!&(+_L*7%NO%"?I6\VE(M+K;WV]S3@WR'.,D[1APS*Q9#6)D.J
ML)+V5% NGK,V%=@V*WT77KEPR@;P]Z>>#W8A;O[6<>F5BUXH;9GFF'AM-I0+
M%I3#-,V51LHY\6K;IKFNO;Y.<]&V::YDT->#+M@VS94*^CK)N[=-\USXIKX>
M<A&V::Y+KZQ77)TI*O+X<I[^3U-9G[_"6+%'Y'/$F'+A#9:O Y?,#N\)%EX!
M\KD6\:T[SY-M+]CQ@,S/_6L@3, ?4)>_DTV 'C]_M7CGG[@H7[+^=K]F4]V(
M";%]UI[@Z^R:SP=?<.G3/R/JFK.LU(AO3MT:W*.1X"M-WWEJJ!M$V1DUWC.D
M^)^_PB2);XYGW[ 6X))17;G3* S8'4U]H*%N[*:<T&CI PUU0TOEA,:J:C<*
M04/=<)>"T% Q1Y,K&M0-NRF(AAV8%Q4T)31;Z@8FRPG-5>9-!<T8FLH&;G=A
MRVC-)Z6'IK+Q7AW1H/0^D%QAHUP(MX*-&E:!/O&P5A6XKC"L>>"NI4.XO[(L
M%60HA3"L;EYB2WM*%<2M0G!0-Q>Q/W"H3,;%V%0W&5)A<]]-0753,PIA<Y]L
M476PV:YR,SFR2]&G:7)%A@ZID3U"1F7X+89IE2;97YCJ8P.V=4C+[),)IA+/
M* 33*O.2(S)*5'&FK4,Z0QE@:+6]L$PH53=AH2!*MPZ,RA9<C%)U\RB5+5C)
M4HE2=3,J&@)#[[)W;74S& IB02OK3V]@=JKTA5I65@5, 4P=LB>5C;>'P*SR
M);G:^WH7U>WHD)90!@U:&7;:0[-*1935M-,>FCHD0RKC;B^A665 ?I :>=93
M[.@0Z5>&-Y7?MY8K-*KPNEKFC4+0J*+M:ED\ZD#CJ(IWYVCLZ=Z7YTB'(+,R
M:- J>J,]-*LPLUKF307-&)HZQ+RKZ,U>0K.*>>>(!J7KM.0*&QWBT15L%#18
M%<)P%;BN,*QYX.Y(AW!_95DJR% *85C=O(1"Q6KV)H-YI&XN8G_@4)F,"[%Y
MK&XRI,+FGIN"Q^JF9A3"YC[9H@IAL\K-Y,@N19=_R149.J1&]@@9E>&W&*95
MFF1_8:J1#:A#6F:?3#"5>$8AF%:9EQR147 %F%R!H4,Z0QE@:+6]L$PH53=A
MH2!*JYIO!:%4W3Q*90M6LE2@]$3=C(J&P-A]H9A<L:!N!D-!+&AE_6D.S"I]
MH9:550%3 %.'[$EEX^TA,*M\2:[V_NY+Q.2*!AW2$LJ@02O#3GMH5JF(LIIV
MVD-3AV1(9=SM)31UR( 4#\TSSS5A^$!H^/G>#KY_G3W,II2/8!Q-DJ_CQ2U^
M]2MPPGA"_._9R5^Y3S0(&0_D#SV EQ^> \9YP<%&$_X_?D]\+4:1E=R:P:F\
M\CZ<5CF0"J>;X+2U/DY;.>*TJVP6Y)OGCD+J3U!1)9B05P?4M3T_U[WZ^*%Y
MM8D0[!_5N]T[ZB-D4I\]!U6./--JM+=;4RW/DJE=91,="I'[J/$6M8\THK:R
MV8.EB]^N]Q8M?UY$SPME"M%8V4#\<@9;2.*4/.U4Y%Y*;G7#VZM<SRNL$ #6
MU#T8*X-G,LU/D/OV$YAR3S3Y,AIU">)>?9F$$7K= #5].FEVU0UE:TEYC=2X
MNI%B'2G?Z>E#>74#L3I2?J5AH1#E=8ASID+97TE@!W.A9N+[,UCW>SKU_)!:
M_8D7N6'\^+D=F(Z'S^M#%!V">CH0)<^,0$_9"-;:1+D(0GL"TNIV&#^B,YOT
ME TRZ4217'E$V4#08 QBZ&&IBYZ<-[@C,&-]6$#9J,R2!4?#"7_]YA&W[UJ[
M7/=<@:YL>.1K%-@N#8*^^6=D!S9FGI*5_Z?M6CXHX_!7;[)=J=(\;'0.6R?Y
M++:R$8FOQ 'OA [&E(;?/),DJRWON W'U+_Q7-Q_ >_^9I-'V\GUS-_M%+]Z
MY5KTA5H/'BN>Z0<70/UPQO^;'=%=%/)'MDW_=F[,IFQ<8F/ZLSW/A9'^C#B.
M;K17-C)1\?Y.9+^R\8F*][=.>V7#(&KR78Z.1:NA;+1#4>#GNOC*!C;4!'Z.
MGAV\K2QKOR/@Y[KXRH8SE-K-NC(IQLE^Z^9782;PP]-[XHY$& ?_O+9=>Q)-
M\II4*E#*UNQUD&[^#C[+__$<L+W KI[I(]^5C1XI ?-%6",O>6*M  ;:1Y@K
M&[=3 N:5-"\.YKD:+<J&)Y6 >27-2P)S92.Q2L!\?42<^=2RP\'4I\1:RS]3
MF1'>K4D4,E.4#3$K >SMR^]RL8Q"P%8V?JX$L,L)/U4E=IZF2%/9Y(02P*XD
M]BXE=J[ 5C;QHP2P5\,/-[G=P[?<B%Z\P"LB)[2GSJJM;I6XWJH=TE0VI;;?
MJ-8Q,J,0JJM<I9*HWC]9G:L%4J4FE43U_LGJ7%%=92++)C)S]%7G[\"#=WA:
M%0]VZV..5%G(LLG/"N)S$*\RD(H"<:^E>*Z&2I6+K*1XR2%>925+!T2L?XBG
M^H7C^XOO/8=CK6R+5I52K%"IG*QL*9L/7%W:G 7"X,*9Y_NVY?D#&H8.;T=Q
M32W;)#Z]P]KC^H@(9=-8ZQ'C;!(,HL? MH I;WUI.^B3<&DIFW#1A!ERE4S*
MY@G4989<UU_9B/:=[\%,PMF= Y/KNQ8>39WB.](M-^3-WXAKZ2. E VQJK7F
MN>)<V9C?6FN.HN9K9,,;W5$ -WT#$Y6./<>ZFDQ][TEJ %T80-GHE";$R)4S
ME(VC;"2-KHDYMEWJS](W:L,1;67#!HH3(4].:"OK)6]$A#-O,HU"ZFO(!<IZ
MQ@H3(%<.4-8U'H0DY,6/15W2 7]%D*ZC'T0^*Z7&+VUUU9MYKKJR/O :JWY&
ML7W![]1QM%MV95U?)<"N0+?'5EM93UD-SE""1LIZUDJPT;8TM;(NM!J<L:UE
M5]995@+L0?&=K%L=95UI-3A#"1HIZVDKP49;<J\[RKK7:G#&MI9=6:<::\ .
M;=<.Z3?[B5I7+DQR9#\ZE)<8_SJ[)G]X_IE#@@PA?/RNR;H-W5"J3]ZMHZR?
MK0$A\K2B.LIZWAL3(DZ&VB:^RQWU1S[5+!W74=;+UH8<N7*'L@[UY7M(<18%
MH3>A_IF'FVE,G?A"61]; T+DRA'*>MWO(L2#3RQZ0R8:%:DX4M:I5ID">?+
MD;(N\_N$D1!"$7'N[=%8(ZUPI*P7K0$A<N4(9?WJC0B!KAPV]_(F4QI2W$_&
M^GWIPP_*>M7*DR%7;E#6IV8=?*V(;Z2/@Z>Q%=HW3?:5?U'B9T43>_!\V8/I
MYQ#2ZC),!##D9'*(/8G)-.''S!CRV!7YN+P@_\;GEU%=6==]-U1OJ4OU>4HI
MZ]7OAE)-?2BEK-N_,:50M&Q&)=![=[!6V]5[>>[B.E(V-E 6:N5II1PK&T<H
M"[7RE(3'RL8<RF!=Y,I7R@8EKM"EH@_DI1^%L/:ONHN>P]4@M,TS/#?KZ].4
M[EC9Z,.J%6>;+?#8FF<2YQ^1;P>6;6K5U_A8V9 #$R]8*^2</B[J9N!-)M3'
MNB=W9*I1<.%8V> "UF8)EZ[W@+J@;V^\,+_R,?BA^:(U: KTV]VCQAT0%WY-
M??8\HK=FZ,'+@"0=?3A,V;A"1?#M<+BRX8FEZ]\X/EJX_/UH% 7A&B'!G6-.
M(?Y6-L91D7L;W*ULD$2-M<Z3M4Z4#7&HL=9YXOI$V0#%4C'6J1\U%IL-_:EO
M.[! 1^628[GREK)ACHK>6^%O98,L2^E]=+*8VM=89Q66Y[A<U,Z5NY4-ZU34
MW@)O*QM36DKM9GNQ"W))'_V(^#-8H9-R$3Q7]E8VIE01?#L<KFQ,2:$@8KVW
M&&)2@ZS"ET+\K6Q,J2+W-KA;V9C2&];:VXO?+9<LSY.YN\I&M2IJY\_;7?WB
M:LNH?4Y-]K+R$3Q7]M8OL+9_!,^5P_6+K+57Q%IZY:)VKNRM7V1MSZB=*V_K
M%UEK-]MO)_=+1NY<F5N_N-J^D3M7[JZB:JN3KMWN6RG7=D,?YJZ":HI3.U?>
MUB^FUFJN2I&T5QVCT4R8Y\G>/?W":OM'\#PYO*=L9$T=>7Y47R+0A>_7WFZM
MAUS)K6%<K;?D6(-<_56'&O:9NY6-JJG#W=WZ$@7RC\BE *]505N%E+>R4;6*
MVEO@;?VB:IWCQ6&6)$72*9FIEBM[ZQ=7VS^"Y\KARD;6WCA=L&0_47P&M5,R
M<RU7#E<VN%81?#L<KFQ\31V+K5/OONG_=;39D=IN*!M=J\B=/W>W&U5L[?T;
MD&7JM;,J]:H0>RL;7*OHO17^KJ)KJZ.W;P=OC[0)G;<;FD;7OGG$#>[(C#PZ
M=-OD/J<.F5'KW"?/6'0,/WU-9CI5FFHWE VK[3V9<^5F98-I!7JY0?&M6-L-
M_8)>^[?S'PC>!%+EPXGZ!;WV+26=*[F5#7F]Q=^+R9UF\+YKK;!U2X&*.171
MW$!%I"'T0RJBJ6P8K:K+(@5&HYV7I=:LHFB*>]FY4EO9&-K[>7NU:EA)(!WX
M?]Y[:*^M&C+P^3'5H&E(KFCO71OQH&P0KJK9E"9X-S>":QJ.4R*GLJN:33F2
MN_1AN1S(?;*D@.NZ1]$5(K=^P3ZP4%?4?2_96>%<Z:U=K.^>3B/@*A+0.X>X
M9:WMGV<"K:E?@&_?6CGD:9&WE W&*:2QB^[,DRO!JWC<9DI#FF4*=P2?)[%^
M0;B]$.$JY.=;RD;8SGQJV>$E,6WG58_)>_KD.4^V.\K>M'U!D/EL?^13BG?P
MPX:M]J7]1+&WZ_:A<KQ^,/8XKSQ=2]E@7065I7;"<5Z)_I:RD3O]J-_<D:!H
MKB\HFGD*"F6C?A54%@N*9IZ"0MD@H'[4;]^Z938HE T?5DC9OCVA;%Q1/^*W
M=B,F6NN+B5:.8J*M;$BR0LJ2@QWYB8FVLN%)_8B_KM.Y]CC^A_@V;G&Z!]Y.
M1C&@9@3?OWVBOFN/QN&E[1+7A%'A;8/;R_MR1M+:RD99RXM47:%2!5UW;?A6
M,NU=0*U"OAIX:$H@I0H/)Y\._/#TGK@C(4#PSVO;M2?1I&@,5A;@-GF@BGN_
MS0/DI>*!LO- %?U7SK3=OCJJ6"#- E5:0P<U4/F-6V2!*KE3(F] 4Q!VJKR1
M#G*XY""L\E?*J>QW"V1=,5AEIG00A*6.#W?V*.7U#A)MZ>1/1]G\36[U4Q1:
M["H%HL.V9R6D894IR \JY=:;6L;3O]$0A/OMD-^CCP2O(K<Z^/7;HGX5M-1
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M.,LZT6=V:#\2]_M-/S<O>N\AH)S?_38$_G%W[?DCXI[A<N-NHPH)>2%!W<"
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M<TX9-N7H=[/(=-@'&NX-APZ6V5AEH_*FZHXMC*S?O/+,%Y8%6>?0UYJR84V
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M*?5?'*UM_7RP1BF'QH%\:.PG+#*BAX\^)=\/R1 F>$J<9S(+4$2FUF%BNW)
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M2(2 %8Y/L6IMB+D)6VD'2(2;I4-CZA"VL0^< \0A_&_V34?\>TO>AIX$. M
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MA2I^D6-2?-/,:Q6]4)B@C?<>M*N"%_J:=SS(^[H2S9L5;/(V_-8,(8CJ&6T
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ML<!3"LFXE2C_;8$$.@;7!F1.A =0%M7\)/LDE]1C5U+SD>1<UM4(W3311$0
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M/2XDW4D F^;'EU%MNFW?L*K,^R0OSLUW_AZE,ZQE?YN-!A10DE^$MI>C*RU
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M-^!T/[33?;AUIQN%NT46N.%\=S2AV]-S:4QFE2GL7C6%S;8'"=CN[W6*>WL
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ML-$RMF@M\&4NW.,?1$S8ER)5\3$1;( ?DD0N>BT546IIV>))K ?+TR16X:;
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MS$^/'?;IL;O2;%XD,_2 &0&5'!(,)Y86!;XM5\GS\X394@[@=L'[2.S%WR4
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M!DV<E$4]%VL5W@\KXRR4 A?YN5\.F%K\$R*Y5II0>X>K9-3>G-!M5SN[9"L
M8 US\.?+T-]]OP(<S6=9&F88\3C7@G2 8#C: H1+'M%/XP),H)"_UI7KX;'K
M*%)*<Q:4]DAX8L%[&2;<*HJMX#54S.&NLZM5[P#3_-1 0LRIXR[9U/EN55&/
M0U'^KI&X@/*<_&\N\TZ*F/U3(S!"GC044#!K!LOYL.6994U!.=@<$+&"ONVP
M4H26G-@6.\D%U.A\C:1RR=L3^KT4M(3!58['&.5UG6EA;B.S;]OIZ#XG)U$+
M)*I9*-F!0$=ETQLI@ZLZS018"$TX%'D-DORG[]Z*%^"K4Y=WUZ@A? $7V<A4
M]Y12=%_DWQ8ZZDQ$?9#8#_*, 98T/H-+TL>_W*\)LE*-318\\O!?EZ^Q,%]<
MJ^8.T9*WT*Q#E(/S>(X!Z1Z-/D\*(]6LK(=ML9AG$KE=H6[I,>$?)T+YU@,,
MV/?YPOCYBJJ@4!+!=NL$WOG"V?$W6_IJRU@!7BFT&QN/")'(/ZO7*/(\F"6E
M4R5>&,]_AZ?Z. AUQYM4(29T"%HQ+\EW,B73M-O<E!*LS<CRM4L>'IR/ZN)[
M)*SV4%@M.L0(FEO3?*8V5]C"@HW!]K-I-<^C<-/KK$$T 1$.ALMH@9Z+ 6.,
M1^56T>@SGPN2\5R9P[]%&+B,P3NI0I,4O'(G*WJ:C#LB.X6DMWTP: DZ9N+[
M..:P5V"P?S35:)!88&WAGENT<U >&.1T!EMI_.H'!QL'-Y?2.. (DC=/ !56
M.$'@7^J9B9>4E<H5]:WA8U@+;<SX*1A@@I>RTDPMJAW%7\"LLX9F- ,/,&2%
M8I/X]U$DM(N9J*,MS41MK[I]RX>/@IR4D,H16*"=M0BEV'!$_T8(3RE[!@^S
MG"%L$"-D"_0KW,VF)+NZ&B>X20RR/TI9KFAFFF76-QY\;R3HF@*@ =79",MA
MD5]CG60QV$)%6* +)6D:"H<N\8>2?YTFGPU5'?F5W.KQ@:F!=&(*25<6YNJZ
M)+97E6G_5$TQI>XT\J7F#MU"ROKR#\F76_EKLX,WZ0^?Y/Z=[=A A^:AJV[8
M7+"DP1NVU?D.-Z"ABW#2"\?43>;$9;NC5R!4OBH+97L$7IH1=V4?#D,9V<TE
MOS:RMEX Q7# 231F*$QGX]"*G:!?VKW/UJ=N1#GT*D[T4<4"[;T4!T:5$"^3
MY_#B)"?1IIX[QHV>$_)P.M9$O 7:SE0<SX$GI-&"NI/ME=)7P+R((U&TQ+?3
M/N4>E2*'/YIOK,RE$8!YL1GG83C8<EI7F.9ATH&S">9_<)44G)5! 9;/KFT:
MGK=BAI8>E926^;BZ]HM4F/A"*,_A7DE,[JY9S*E\>*V#*/4I]D&WG2^M;?73
M"6Q=U*5ZNFR(FG%%;1!5P=6W'!4*.S:-H92C4IM(NB5ISC4'*0[8J=G[@0W%
M4)P??,L;&0!@I=(K\*8*60H9VZU3@?7VDZ,):$M!/Q>YJ>B1$Z[I9GP5.C%^
M[;BSS6@5!4<-T41SI<2V:MX+='FT]>1P%7TV.&'QQFDWWVRVS?8:#9^F'J3R
MDA0T:4*&NY%R^H+Z@1I'PU=D&M[1]MM+[/SA>VEN+=?U\T@C:[9[=1^<2<&6
MUUB85[/77I;62T"S?]^,W5 <R D.9E*6YXBYW<)D8YY8BJ>BU,HK.26*P7!/
M<Q9IF^YKS*(:EBY3WS9%+"/,:#2[*9=DGOO#K<)/_6QPF@5$#Q35YOQ'4/]Y
M3:*U"?7A%+E;+SF+:%>PF\GQ%^VNP3(.>S=BVPR?O6!_NVJ:7&Q%*Z]:U \$
MH;<6CS<>@1=-IXSD/;NB^/IZU2(I 6F?RIQ=H%80D&TJ%FJH7<_?OXO;7"43
M]TWNM#A_&L/;-8689YI)9:G-1%!I[E(1UVA28("YF>I]Y.+YCA$IVW)-B>[8
M[YGAL&7DA2P;C7*:(RT<4H-LH0 ^:+J'.B P%4DO<'T("^W/:LM<OW1OEF=\
M[GC;B6]:8(K6@K ]H%@-I!CB+<[J, OX]8UV#VT/BRGAO"NLLTYO/B5C%SI2
M, I8]I*00+XQ;)0V68?M8I>@\)V.IF-I^Y+1#;0M@QR8Y[%7V+.3E6X_)44*
MDI?SJ]ZUR@[ 3X2WI?']UA .BEJ,/K/UQM<N>]@H"=/HNK3W-(Q;=[F:N?8Z
M+JLH]&4[S4)-Q2\#HB200-B%]J>NJ3NACD/S ADW,-WJ4(X7%_ [!(QT&(8>
M!I#8^(+,(EW[RXD03?1HMY\S)/4W#>_Z)QW_XJ^1/&2:J"-P]Z3P0&MC4T_E
M36TI7ZRZ'?:7%'X3V$&Y7;MB;[V=HBBCI-2.#)RBQ>$.:J"($,#1(@G8!E[9
MRY*+U9UKS-2B^2F8'Y)^6Z8G+Z1S0>T>Y8[F$,%/M;@Y+SS$I]0>?N6'2PKP
M5#890A/J6"+XA5SD7(S!XJ 4N85.WLNO,[YNS&-=X2T3')4MK<'>0QO($=R3
M(J%\71[/ZT'5XS77%TLKK$LMHH+_0\-)HTWX\5)#,UX*3-I/^4_$4S 3$_OD
ML+2&8U-:)QNUM68?7*F+J]]H.^6<EZ#^U$QP',3V%1@N+8+1$CR[*&?,YIQ=
MT=?9>1!^Y3,\FCF6OD2C?(AO7B5[?OLFC>@!PR+QSCF!7)'D?K%<:1/0Z+&&
M-L&809[M1> .SKE[#CV/9J.M?8[M,GH1C*,4RUV8K,[:<)WN?]9)4$4STA^L
MB72G+S%9!J([P48DS+GA@"'SF8L9"&[DTNB,7^HYLO97R"1AR45<$3(0JP<Y
MJ6O,"PK^SI(*6;JQ7#F[WDUT^C%.B6P+O[6]]#8:TUB$UTWM[5'89IA1'FN-
MD@"5.[P.5X1A3S:Z&WMNEA4WJ33%A+%A1:_$ ]&TJ9F6I-"R7=@I:5QY%A>-
ML_ 6&\0K'>^\&?D)W4=6#C2[9 DD@0-[>].\9L!OO4&*7XA!I9K4"1?G][0.
M+)XR+:5<@O*Q36NVQD=3]0JS0%9OGQKT4X/'#SXU^) M0CJJ(X9_\!T_E,6@
M8K)\EHPH6$#-HU?&.H)>>@^4!RI#_8N3*(I5\YJ$WCF?I#.,27Z,1I]-9>"Z
MM]DX)37'D83SG,)]P?MB$F4R=8'N:89[*](BVEI#XOR&,JL=V$J++RD3*=*%
M5I^VK4<N5!0$-^FF6XKW4%1(?*JN/_HA7!V*2>I4WA;R/XW,Y!.];]=@4RF<
MF':)4%VLW\>3<8+2G^ELF1#,W'BI#9T^KEK,C22\Z=J0,L!+?!S>]B7T;'KB
M'^")E@@Z)$DLI2<:)NW3D5#2>YI<)M(EW[D+H+,#W0S4<[1>IWH\3[_.HBM0
MM%JXK<\6S#8J)>8>#3^+N,OGX9-S8VW[EBWTUR( TLLR.Z(1+NW,7HU3J>YV
MFAP-%+17Q3[EE+RB)%(-K7L V1CN<EL:0+."&)!0.&\Y=M8HNT!^X+(.X,@%
MGX$V9AL;WPM;T6X+E!HQ1)U:,W:D\8)XGY9&:][0%K6B@K&-\>E:9;APD;M+
MZM+-HEYY2S.P[%V\;&B&38!5"LR[ /AE#3(C4SUEBT@X,&$4V:Z].ASDK%3G
M(:NT(HJF<R\O[.*EYZQ4#?)Q/&)<%U)1<&NT4X#N.JB\@9*T'1 (%\8$/_Q*
M,:H/6"]E8FID)9M#JNP_.AYY1P-ORQ]0HOX&"C 8/E,;GOP4@Y:* BG"#Z\M
M\2\0#$-[W2GZ1)&7MU@$<3H(]KHOQ65<U'/%#H 5O(RJB.<=-P'OJ"BLKD8-
M!3[CY;;0\![[?M\QUW)V@X,N81VOZ%0:^=&[7T?T^:5J^#-6_0"#V>JUE7@&
MWH):S4D,<+#Y/7Q(30AG72TV2WA*['Z3V+X)+K.%NRJ&F<.9:8:G-3S2 9,9
M=B/5J JU%4HR%5 &UU.@[@OUL@$O/1_^3;^CR@D)4V$K&S7_\HT6*X<FSV.7
M3KQ</+?T?AT8KBE&XG&*7,6$"'IIG(JZ-* RUFU6/^DG!7V3B35G55<)9&U;
M1!P*&$EZG#GFP$9M=V.'SZ=C'BR[G1X/P\/]?2\ V@5JH144(*=> U5 V2E/
MN97<Q-3#H\TPM:WQ8?7G0@-($;>T)PZC;6*PEHG'O&7FFJ(-&>%//0U:C7NM
M89]W M'USGIS+E=Z"S2K+VU:V*R2:%D:TVQ32YPX<]/&!&M:GX$1_:"<H[E2
M>-YE-"J0B%SA-QXS4HV\RPG#*76N<I ;"UEQR =ZI7#X,RGEH^?3EL'^'#]M
MC=Q<"0SK@SS293*0R1^1ZWW%#>.:Z#!@8':4%PA+EF<Q+\U[^"IPVN\!%[LZ
M,-7+S+\N,['(<!FXVDM;LPRX24I]<R&%19>((Y9PQT&)*==8(P2?/KX]/_OX
M*OATL ]>Q2M$PP'/@UL"%4"6A-SJ"[AJ.T'>/CQ@NT8S)U?4@MGXOI/!/D_B
MFJ%1"H_1%?!1 ^8M*-[G.\2WS2E@>%P*V\(#_QZ!+(6+Z?.'IX-;EF_AO'$$
M4 $'.B/)C,BQ!&8X1[<;Q6J+K@<AW8)Q:CL<$;N#:1,$S?"?&7EG%TR3EP;-
M;06K>(D]>R5''U_F+V5J2^G%3,O1%$17RB[ ZH4< :VX25BL)5T%10OMU;)D
MC,MB8HB#E5QO 3>(3E(+5C?E'94_@'^)Y+[@)G%T-A56$=;^:>\XM'Q8S]D%
MU?M]@@M-X%ME2_:.;^,G^#:/GWZ/"%FA0JGV<G ^"%=SV='@)% &:S 6OYHZ
MDKBUE!&?[ ?@HNQ"0+-07;%E*:*V[>+!%Z?1G*.<R#9\#/5D$<>Y4W3C)XMW
M7MHF>S*CN!Q@7A=E'?$,5QL@XC$DL"CX@S%><[X=(LP\P\!>7(9M(]9I,K;E
M-<T%>J:,? #O<.>J,4LSI5"228CQ7'LHH<-XR5@^P#T@II]K/-G27.,=YD/>
MP[PXGV<9LI5Z]V/'^?<,N__MAFGV!ME?-\C0!\,>+BE<7ZHD48N,?ETZ:VN.
ML1,?A-\Z7"3?WIV%4IP4*?8?7BW&">6$90H/)_'LL,U/TQ4E+6J&X((MNAR6
MF7G2'WG_YRB-R-+YN8XG8*.<<9/D\/GS9\&3GW\^>VH['7Y6W^4M8RG1N]A;
M5/0)O?L -@;N?OOA[&GH>:=S;,*B&5K7A!D5T3?_9^G#"V)#IH!8-M7- *P?
MSKTGI7XB0_%;VIXI#0OCJN/H7$MT4W&7T*)*XM)-3I?:2NTVYO5=+C1?0VC0
ME#)3#ZOQ"JKW$^2FV*8\'*Z;@FW9W=^SR5BE*<8P,AG"8J1-+ I^R"R>N_BL
M_N35P0^P_31$JR1(.EV=)IX1&9:X@BT^\1*X]E/5NYFA2S^?XHS*:81"$,X*
M?,JH]"&E' /2I_(J/2[\IZV*6.)%6W:ZH+HRMTFS&F$C<BITYDHN5RE)O@F5
ME8E!20U16*F?1),LQY%4HSQNM0CG'#)*<&RG!A0PZ!>;*$XYDX6GA6;9=Q[=
MNC0:,M"W<$.YK!+]J\8Z"=U1RVB-7UW,!+-P2-[[J-*SX:[[K.N?6C6_59;0
MOG&QVYQ2(IF-;9!3*./)O%7(:9#SZ\6&Q\;LP>/VM*_IR>O7%T\UO$.)&3^D
MQ)WTWE=[T1S?O-3!*,@C@M-$=8=4V^]*8HW0#3>0L0FI#(TWO&0;E?G?0SR3
M+7&0IC2,@X'@D%@2&>)Q93H.N;D9COY"=TF.RZZ29+=\;*5&-Z\0C6BJBP,:
MD&BT#RT@(Y.;0VCQ%&AI:AO[:IG[O/)*3H!QK7^S*(2P13(:9:-/QAK:0DLB
ME\:+TI,I::\B@W#T1CRYA$>E:4<C[19)[09J(U4,- YDQLOQBZ1(7"T1[QO;
M+/=DH1#;R=EZCTAVU@=ZFY'" "[\A8\1_N&-F]#ZIH:7!Q?^ *@W;R[VWK_]
M)7108A9F6!,:=K*C%CJWB=O%.'R>B%T)T%'4?FEL26H9?$0./W//P>QL\*](
MY^@%9W0E+?/CV<M_R9T#_P>MMFAR'TF#*/-' 5_Q8SV PA;#ZJ%Q;3@J\VQ5
M+P5L$RVM8PM>>QDXW- MA;O"I"IX!\%=@,RVF"M!+H"??1"RGN-N>LP'X)>J
MG[/'8-&T?YZ"ED@X>^!?X,IY;O6:Y]A0,Q4^W>T_PJ?,4]ORKU4$WBN%9W':
M9H5QI]5Z,EC2DV+.-&*3+&+H1;!U;S,I,"ES_?!1/LFH)Y<<B?T7]&TD7AL,
M9DTS[2+QF5KZS,EB!&MLZ5M4>)JB@+4]:3'_4S3 7/;!00[<L !Z(^/$VNS(
M^0IS!96VJ(.G _K*X8L@^)1SIF"D!/,6@:6+2!V*@<5RCG3'.?D1*;U>BXD@
M4BI@^0 TI]?J3T_UO2!&Y$;&#I=P9\4C"KDWGP9LDN6[D#WUECUUUFHA*[HT
M^DQK8U$D%#_!F?>T8WM4_^A*OE3^..5)?0\<;W1T(T'I%M&F#;L:W@'Q*846
M-;.)2QB1AO[P/W@"A\"6).<Q498FO%AX@64>/*7!I 9IR!/:=*WX'#@XZ)^(
M<>.>1!9'&M491G+=7EV8=+S'4EJ_14=/)"0.#J5/$H?88_2UO0SO)/N?RVVX
M4N>#[HGU<7P><,LCV\%0A-JMB-CPP__0FX9[\#\GVE4->V%B*UGT6Q^-&'X/
M%@ 'RH>G83#-KQ&HFP\@30>,V=_DHIRB3C'UFL&I&)&VTX%^K7QI]TXUYC@+
M$(97MMG:+5R!?3$Q,V4418MSYU3WHYU2B/4H8[VTIBB)OT;>Z$#_Q61&^M(U
MYDZ72X*KR;UC\]X%R _W->=$BZYU[G8D 7(B6ZMI9P4S/WE-=]!?/\)M3R41
MU?HU(S 4L]8QT6XZ"H-;J)%EXG8]45(._N,LZ""'U9VNU=-@71*R%]DX;%"O
M4^B<4DB$@1: YX6DBE*&^XV'U>-$NZ#VFNW@P2C.P7(#:Q(L6BPB8%5/X--N
MW=+CMD1T839L.42P)I&MN'SQ+SF_7CDWRBH1@BBO*!1!;B@9CO+L8$#_C_57
MZ4=U&!8<>S?VL!]. A_^!#LV&41,]OD#+W_P;$OS!P]*[K<'W%<=\@ 361SQ
M$Y@B#S::X&BH!8CGD5.5MJ9X75 "?P\G@F$^$<XHR:4J<(JF6F/P,%4$QY@Y
MP^CL$SEA9Q_.Y!" (*1P$ZR*SPM-C<!#REWO.0A=;9#5'@PI/$3Q.XL^LWO&
MD5.X?T)5^@'6I^1X*'E'5#&H&4^B.[<S=3&W8B(4: B7Y&;Z,3B+="1P7IYS
MBPNVAD8T?H]+P(1^HA2J(H\4S]^7BEX\EY!O[2 (,B[3Z'H@]HP5CGX(&2->
M.%DI%@M-P/U(U!X<4MP1+&83MY]AL8>)+<C2G/IV=]90).PX+WQ=9N\CW1&7
M+<U!+CY'S.FJ!D5:'-B..(&^*Y>T=T/9\Q(\4\WSB]@!-%65>HC79 XLZ_^;
M-)I$L*2*112:AH*E)D(G,K7U;.=GI026MVR',+#/PMH-KEXM=+TB@A[(UT6N
M+\H.>MB*J65;+ F;0[.:X4>+[=,5;41,:F ?>""FC"0<UH:*U;AF^X%>OPS)
M(^/W=#>;RC%/,)$9211X\#K)VP$T/(_ GYFDN71 _8KXII21ZAH)39]CQ3Z<
M%B-FC?TCAW$$%[!W[^?4'WGUC'K#)TD+^$,MF' %K^G" [F.)I,"F[Y,Z.-T
M#H(SGOH5>A$>5W?JK_Z^&'Z+V?L]!G#G%=="V<HX<83?9J.!B_1&FCKE*EHL
MAS)?(J ,738FM8O6JD7GN*W4ZX90,O[N_T:P<P6\%'1500.1,(Z1TZ F/'/1
M/.*FO1)NQ/$#$4N^KO>B&8&=.>>PP548_)933BIS?W!?\QIC*[_C!?!7+C8B
MR DZ4U9A1$X)=ME&34/FPQG+_ZE%8,3! 26<'(EHX_ >&=HDQCYFG>B-*9QT
MO%*U(0+!YN*S+4V.PC"P1$R\WN\(15)L:XHSR>W:'B2;:+*)T. M>218O,O0
M(_B=C;PT):N]1 H?]LABZ$AP;UX@_.0\-4NM&K<XV8RX)F4$)%B=L'+6I"W*
MNLBY6TL1$,]L 2-!J]'H>:]Z0(10NKAG3;@D&+ZF)J9O[/AV1<K-W@2=.GEE
M.J F6Y7^FBYL8R\IIK57N8C'C31N.8T*5=4V!6W19'B<1*N?@$L6\6\V?XPO
MHQ!'14_U.HKDA:%]N!TOQ0..M;2 ^HA"OU4.D6EFE-]J@-M@9/,;<^4]]I[;
MJB87I6IBIXDY511)K!Z>Y/6%,<"P+BR:+Z'3<_:%&JVI=\4&P",%>>[<440^
MF-E #U\JCW7)+->.#J(4RZ%C+T5M$S"V+X1:QL9<);3@H/2_T/VC,@OS1=IK
M+6\@K'")$'_M,:](&/&.U1+&#UEJ%&GV8A=F7'MU#7X?8.73GD:W2 '#D\]9
M?IUQ6X[X]XTM<)X^.HD2Q9<PO"3**$_K#%E2F/(F;0YHQ5E;FRSJRSF"DJ.A
M<7YV&)?D7=R4$@Z9VC7)5WI/:4,>B76ZBL.$F*7VW6.# FZU]JK;IE>%Q9!=
MK,$63T6,<1:C]-4M :(EWOYQ&A+)EXT(TJW5Y]31TN-7Z]@6-\N18+/GU_0>
M3UXQ&'5A+FW1.OLN7G$JHT)?@WZBMFGTE9-8$VSKS^?:<K'ST;C&O]87DTW&
MGYV0NT<QF*Q:%L&KO+BVZE%3L*DMRK*>T8P&5A;^BFY^>UXT0NW>@9;3P'O-
M;V+Y0LMB%K+W@4^\EX_WYCFB"SFI8^%FP":,P"C/N9A/A1FE^@?!KU]%+P_'
M94D0Q=P&=XEQ%RZB;N[0*-]KUB,2CM^5T2;_KF^A%WI;VVJU> =L,J51M1T5
MF8U%%VNS2[-6%/>8\=C;=5=-S81S%YIG7_JIK-@"*C4VW5NR]W)Q^&[6<=0&
MBVX#9J-Q:!Q+!:0C3>D:MP45BJ8;#OXN)C=.MS2YL<4B]Z+!S.Q KGVJ/ "U
ME:9"4OIE'*WCQ(S>1!% Q.YJ6GK\SY",6I0TPHP(V')R *BFI/5835.TS 0I
M-O:J0KRB8Q'@G+%1C%DQQJ1B%ET@_V8[=!$D2D,.J/V#,7,7HI1Q*1:Z@#(G
M#<\?%3Y(:O27N>?7-RQR>GE9-H*)WN:X;@&VW*BAKW*%H#;9V[W<UFHI0LOP
M79%7Y7F3KN#'L()S,$<VLDBFN><^=+",&GB!QS]6-7M6OGNZ-8[)*NZPD%IJ
M@M;8JJO5D4HTFK!EEUJ]69+IS#5JR";Y-;$5:44>C!TYS"T=0\6NC@MUT'ER
M 1%;3-MNM9=+@"/\;4)_V-K.UI>E+!I(:EI#5=3F[M^#T%'7IN&^[MQ,D==<
MAQ_> '/@%>E,\^O;U#G!T&KYDP?$S3^Q@?^5, EXI("=3).UFT952U2392%5
M=8H.MC5AO=7:\)9(7Q_7^S9Q/6[U7P06_7>*+*3@@Y)L0PT&KR6>\7%6FUH@
M\4",I!C6@Q:/%IKZBA,),=N*V9MPCEP*WF%/)33+?*G+1=T\L0S0+C"9AP!O
M5R>JJ)18@_>9%)_QX3\<KK1)9I>8FF1A2OYZ<YZ(EB:4LOHV]I):$RO04GQY
MWYEV=*$-6Z":MW?0ID>5:))X]X%WEK=E(&D-MDMHO(JM3W13 ;U/O848(M3:
M'TZWBI&P+NLU$,<>A^CJ&W<W(<Q^7QKPH=8V*]SF_"$'U]Z</J2MCBR%$'6?
MZP?>O'O?:)CT4:JD:X=>KYT1EPMY1&P3NV5S'L:8\3>%'7W@^+I1-\&^![_?
M>\%8ZE>DN((.MO9<6!B9%8O@ZP;2]]-!!5]"N3ZEI78D'L9;2*.<*^^Q[XV
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M9(Q4%R;8&'>5G\NX"E78*MXONXS$F&O#[#NF2#A>1JI/I-QU@HO]3C5[V9'
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M5X<!)2/)J"-8:1D8\-+K*>?&VBYK."3GVZ6ZMH[$$<HFLXA5 %$\.S>\-.X
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M[1\40U:QQ.6"?&,FRA R(5FG#EHI7@NC:K#_GNSUC0 N9HGHAO*VGH>OXV;
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M8.3?5 ?YDK=^$1BRH%X68(LX& D;49N*A8'OH7?GZGXQR^UM?N.&%2@LJ9I
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M.2 ,G31J]# [H$O[A#*Y4J"AQ%WTE=H0%1>QNY72[ 6<EQN@5\?0NT219.(
M7-L"1NW[2)/3%%U,1U2\[(7 71=?!UK(>,Q1@,)H7I-3K$?&8,\77@?.ASJG
M2B1=6--EI>0[]?J'C7?:W4+!B;H$^!H)TI@ZILH_I)*O(@X\A]LD.$OH/!$]
MU5,)ER(:_=41C0V$Y_&;:H9!=BZNX=[_?O[KR>\HM$_/S\\N/OWZ0.E.A7DC
ML0IRW=/H**LXD)1P78T6K"R0,,415HLJTSH<IR[AJ7P*0H8>V!JRZ1V&*/,
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MDN>L<X'VRR19$P#=G]O#5PT Y >#?N_5'K_5W.AZ'PA3._ZYTZP%YT8@ZV_
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M7<6,3I_PZ1=Y@^Y(S-_K.0-7<G@O<XK_]J:S]\YE'">ZL2_V"L<;)*@QX 6
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MSSQN;K92O:?'[:G5;'1:W8IMJJJ :M__\C4S'_8C_6.]! E5X=$:'%S^RX8
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M-P7:E5:V6W8Z-3J7C@;TG:;VN%B0[\ %UCZQYX/F"E\EW"\A!9C2MN *!:-
M1*/YWE#K^D('9TC^]9S=,FHZ+JH& &;46_C2AU@TY><C . O:C3X^?<@VQ=P
M/#2WON#G(9;NZ9H]% +HIT*'FH S.^,DGG+M_/I04P/5]06)I!?8 [DRSD/J
MU(%$"-PU%>'X:)R3GH>7X(/P22,X5[XS.8WY%\DNIO)ETIGFX;QB6!5O2YK&
M>)U0'82/"&VX8B+NO,1/\593)5S#^10[,1Q)2T0IB'!)N&9CDD$L0U#*)G!&
MV+$'7XQ@\0;HJJH/ MXON#_B!NX7^CO%'8'3%_#4E)R26T*.5-LH=L(8E%?
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MC5)TI@A" &V(A U?&45\&IG UWP!9&#K&W1#<G1MJ(C*2"1H.P$'4;$*%(]
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MWM-J'2^])Q5H>*#>KS9>DFA[%R??X!:.,$Z'>ME_U*GOVQ&K_)PAZ[,9B?1
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MCX[8WZYVI5*O-,2":2'YP]Z83ELT656N=4R7A/016R=P5-XO+VP%F'EA<G;
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M8:0G94YP=I'U"RGQ+K3*+%<&=2(%*D4-F8P[FH2,K/::YRA_BH$1M@:*'7L
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M2%QGT&_A=>*#K$6$ !TG$IGF$_A+^!P(N5FX&)UFHZ,NQO'QVD3>;I3R'0G
M=A?_[S,"\ /L'.\+ZB1T$W!/7=>Y$T 48(D$,[A7$@(6/,T]BG,@Q7O1 )H2
M["VZ(1AXLUD2?X=;G0FXU2!FL492K;RL SVEY-GY9?X57CY;0:B[O$0*J48K
M[_7<W@)Y#QL#1=W(]%N;,/WF<%TAT0&N-28&)?5QI+LP3NF)$=C&'I!<",0
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M,E$O&RDYYR1OI2S9)HBWSW-4]$!6V?!O^$/2W%P2-E*9N+G#73!_BODT().
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M)9?:DL98,?5F0U(C#^<>)FED6*DP"'FS0CI3U:PCSF\9CVXN%&L\:#H*-.M
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MH$-V;X54T$!5(4OU"[Q@9QEU@.( Z"JFKAEIHO2G( ;6E-NP$H>* VX )6A
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MTDSPD#D_XU#R>1 Q9R<6K6(0J.?5G6Z)GNX<MPG]>4+5&!TIB6&+%)5MM/S
M9^OY0_UJW:_.WHR\2<=EYUO#S;'%X:HY^11K\M@VSSD^7]$:*^_;_!3W\X0C
M6_L$3;-UDFG63=_:(VSV7<ZG*%I1]*^]ND;6D0EZ<^?Z4^HGJV%#V5P/:-G\
MI& U8-H=G&:ZTHT;2Q*7NW"';.(Q.X;% "2NDUA>MNBU\V#Y,?9,%@V3I^Y<
M \P^QM-T+=%M6IM;<<Q"'#!$ ^'&R]VG+=L.$]D]F:8",%*\^')J_FQ%46"[
M]'':$/SFCSLM=*/O5Y:#B$#;1YL%#O-:!(C\8*.RRLL5J"P#Q(UR3<WEIN)
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M"1+C)(+UHDBHZ*(<!9(VB\-4<,U7YA*AXQ"%:(Y,_@!/%45+V91%81@PYZS
MCYU+BS#^'?:&_VO%0,FS_%@,;@0M^+2,)100M)"Z74<,IUE5<*^ZK8XVEM#/
MPSL%[7J3J;F0_)R$( ;N S<WS(6&=C@N3B)9M5-1 >'<C_Q$D)C94Q\V?+^
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MA!%OTQ2X]*5D+M&</V05?-N<:VKXR<R-T\VC4K=\'^-X8Q=LH3L6QU[J('!
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MD(A47DE .$%W$RS;,0-?_('QQ#8,08D $*7!E10-Z;(FL5 /PBU9=!.!%AZ
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M<, D7O_(2L' D5#?[Q2AD?_O-,P*/.[9U3ADUO<K:P*;?6UYC]8B0JLTSP%
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M(X"56+"E:=\"L8T8=PA GUH/'."$K#A%%GZ4)XD%H@\V[$8T7EOSW.^,
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MQVCX[OP1TIP425+Y2]1,U&2[RU-%B#8=P#C/R)6Y0; <R_]() MP_)*Q4(2
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M[I.5:[."N\V5CN@QQ MMQN)IX.2[BB@3<U=QR4'Z!T&TD/ZT0NQ=;/'6%$-
MV9$'%(_5::2'-#)J"(V<O;'(,P6\U/M6N0)[RQ7(NT3U;((^1J;,05,N?)4=
M>9QT@=T):$ $]'27NUE&Y<ED#)0+T9VO BN%_4^_+.M<NFCN/3&B+O</+W[M
M#O1V?U^)NXVX6WM"2:-BK)?'6)5R0.HRU@@8R]3;O9-@K&=P71K8D>/C[?7;
MVX^WWV[?B^YWWS[?_/[;YX_OWG^]^P_M_?_]\_;;_WM*RX<<BDKZ'1^[(43-
MW9U]<$_V^O!<:^QZ=#&U6\./,^_6<@(E#&^9SR9N'&ES:X'WCT_Q6<Y-KY<=
M\7Q4]Q:;^*/@[<6'(+SQ+'<685<#_@\'.VQC8/$]GY1<4\'WVQ>_&FV]TSVC
M0@W%)^?*)UM,W.?D$P,O+3O])Q?V-3"^U&RM^"VT'*99HLY:ZD;*@(8/PX0Y
M<DB\NL_</>HBP/N%0Q?8YIK#]F-F5NY6/M#O8"%@K]^4ZRUU!7K(F,/SD96)
M%8(=<[7]PTG?FIZ /'X;!-^U +;CA-;D264G9\X;:T3N-)F]1AA^EB!,K982
M*N]>_&KVGEQXU1S37)''-M%9BSQZ6 CZ9!&H3-*::/[3QR%:8'B&[('YB3(\
MG]#"%'Z,R_SEQM,;\-""&0M3BE_;2JF/%=#]?94_*Y.R202SK:?G;@2#1<Q[
MJY=7QF)5Q%./0)YFA_/IE+6XJYS$TJ,=/25LTJEWN\J*/$>RV2(MGT V(VJ%
M-SJS*HV32:BS5^]U51^>Y[M:VSD0-< +M*$^'.RK5E@UXSEUDJMX2[4[R1E
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M"&$ZG%]"FLK0Z7NB*8Y!WNOOC'2K::J$-)6ARO=$4]0Y4&^VRD)3&1I<(A7
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M_/W*C-TQPXJ!MS_#%LT G#+#'(,U!L]^P;HUQPT0I\F#CQTJ8GOTS)FQ,+T
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M4D>!'NPKQ8M:)S6Q?S'K[&_FN6EBIQ,2<TEDSTDD< R7>KX-)N8AZW:0XPP
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M[TWGT7Z8L0O?9T&TTY=3TWMD:?F'+G9I-(H"#=9.18E()4.CYB>5-I!*IRC
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MXX!9^,6%8\4_4'YY"^_A6LDHW7BVQ+W]]&M,Z98?9L ^329LG-96U<$<6*^
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M@B+AN+@4B>\],2F9FY$(PL/Z8)@6$)#/U+"@-"HHPJU4^7,JMV!GL<?ED6&
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M[5-_O/R*P 6DX;I8MTN*5T,X^ )ZYXR CM"1)81$@4\0^CWRW5$CTOH0B4W
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M%<XH)I%FLQ4U+[TU 7*LG!S&FGBL-+:@5QVT^0"G[#KJD!3^]1A%A2]^A51
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M;#P#E@C+9/+CWUQ__[SNY:.U8(XXOA4T/>[L;^:YX2XTHEUH[H"@M9<%M7:
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ML&-B$Z+OL \'O9]E #J!MV^B9VC60_<M=/XH_<$?5E>?*NU)?IBQK\1^D'V
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MZ?(XG/^EZ2S]G1:@OLH&L(1;YX75R%'Z2I\)T<^7]Q^#W/#8;._#%AQ_+*D
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M?Z6OUP^_WWV2;FZQH"VN[DY5M^@+ZMS*HMA)#"T-'I/_($"8!ANX2V/Z6]
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M$$T<"]% 3@>K0]ME6A]+@(Y:Y+)K.;C*<=BCHBN7]VI].:VU8Q-/4EJ.LOJ
M+/]P6^LKG<E0*=F,2H!+L+ =#$NMKW8FBN!A#8#9\5"69:(FP3/H3$9CP:F:
M J$C<JH=S5FMCR74:A#_V*(4FNQS1)'^TMC+SBK]Y3OQ+*S 9VV4BVD_QR[7
M/CRG6^8A\T)FUD]B7OR'N$X:4Q]A\C4ME2MT!8&\RATSQ8&H"2 *(![4>8,'
M<YHPB9J"KG)-R8\+KP+6D@X&>+(/K?#>U YG1X198?>-W!>\JDD8.B:OVM5_
M(\OUX$AM# C'1HO$G1:S@AN([W+PSFF"<?!( QE;48D \'-%Q.Y&J*SN:(0*
M]#06/7O&B&OR (NJJ/V2RII S$$UK*-"IH#N13-.BBM? AVUY2>51(EK\HAR
MC93X#L$U&LHU=K;+M./RAG,($[_T/.+OE)W;)J]$.?#G=+([O-6&U>D4$1_>
M%'25Y*U'A5<!KJN+ /%&P*Q&*-O75%3Z5.D;#02/:PCXZL3CREN=BHRU^ 23
MJS_.C@BS:NQ7!5WLW<%8L+*F0.R8K&Q74UA1@6$E(57S(\I:6\)7O,$"V>P=
M+0XJY;YZ8I-7&0#>4\[DA0_P=(SOJ)@HP!(QZT:<&[2?7>QM7(Z EW2ULCE_
M C'-Y28[6(1:9S+4!3]I 3^IR(X; R"ZRD!4N&L-U]C9^-*1-Q2WOFIR#DG?
MJ];=#'MP?&.19X+ES;QP[].6%@@O/O]Z<X,RS&!0XX9BFHII"MU1V2B6_3?X
M1"Y"0:#G0:"EQ/51*31?C*MR9Z(D@]]+^U %+=8*DF=+B[4AQ7T=-"H>F<G=
M_J"DOU=0J*#06E-H?:1EKD.L),6J++4C&9,HI*F@U4;2ZM%(M1KWI(K)58/N
M:%2RFKZ@0T&'M:;#X\G,@N[@DG0Y9.E+=;<SN8\Y&$2P!1K0VYYE_V+#5F%@
MIK.")4^,NYH2@^)=K7Y7HQ.RQAOL3DMA=VQDP$TP$ V8Q'N8"W'QJL[D$YF2
MYT?B2JK<E90^%IC-B$O;-ZQ3W"_N/_;]+0HD_:-WWY,>0)?P5NZ;9-BFY/AS
MH%OZ^9,#0[6?B>U+?WMT?^7*>?+GE$>C A/PZ#.,)V)/1;WC)E]V5O6.DU1
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M-KNIL?*8B@B3LVQ0S@T/M7H)+OH!HM]"9@G*!-6<0STTF!2[R$/]8DI?*?E
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M/E=$P[D6W2\:G]=_8N?6LG1PF):[!31V%>WCL5K;NO0"PDV!\&&Z[A: \$!
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M#A&1%(P1PR]ZR0X*?\7-\-,\LEW:+K'4/N6D;YQ\G_1TY6*_?=(KW2>EWYD
MERNW3[[TB4P)#H_I2:K<E92^HM(=A%^4KN02;TFF*+L7;[U@DEP5V9Q2YKXQ
M38[OGGFWL3&);5S?Q0=XP\>%,_T1S55.,#KX#-]/8&&6*,E<V.7)IQ6^0_+G
M1'HCANM)!)B<F3]GO&$Z-^PG8#F63?^,N!!=3_B$LZAG/BEIY>&[/)! U@PT
M.]L'!$3S@N<@/J5WG,/](KT2%][B/"]=RX/;^5-GSF+AO*("F53[XJ(@70BP
M52C"[C-%I2SW%"8KJ0X:Z6=4X059L#"6'GD?_/+!M+SEPGA[;]F4H].;/JR_
M%-68#7V7OI%]S34<7>^-51V5''Z<Q5_,]9\>2(A?DY\/!SU%TU*_ZO?DU,^S
M'J7 Q.7T6W9ZE)+WJ!1[/%A,V'9RFJL*%BTN6 LYQ9+GD#N*T3K.T\^H5OT9
MF'? (K9RB!+EKELU<:7 Q&N/W+H2S:BSP6(YTTS&"I0))*@W\+ZYUHOA$VJ,
M?EL84ZK09:=+-0AEY;:Z!5OY#O0CK@5[OZSM8$7!T'E>8%C#$_DZ/Q+0<6Q4
M^AZ-A0':.NK3_VV 1N:^,?XI[Y-SV38_>-H4V^/,/KH%FS!2%:5.V;\"["T&
MNY)S<',,M*N=R:C>K:0:HZR433LZG<AE$:!/AF5[Z');. "1$[0AJOW.EBO5
M7VLMZSN!$?P'3%-0-,%.17U+5-C:<JA^-,[\&U#A%R# &WNZ6)G$O+&O^?;(
M)>+ME5J791=XR@E^KA^>AG7&4X-$2/,DQ1^V&Y,5CC\G+CM?(7-B>]8+8?MO
MV? A$=WK3BDI[G!SKN)[<T-W!:]*(^I19U(R!O,P4J"!D'BW%[?'XTSXK=;@
MH$5)$NCXY0C :! [K[SVQ.GX_+>5.YT;GBBT6POF'NY&&FEB[)!<QT*6 B''
M4^RW(@3;W%957>),67OS.#A6@"K"O5M.@L=CTG3!2UC1:AT:#Y\-#H['BDOC
M8-<Z+&?*BEND9=\3WU_D!.8(+>J(+#S:CS($7.LN!0(_1V3]N^%'K3-^&B09
MFB< 'ERX>49<3[I;^>U4UDOY1H_'ZL.5AX6_F]&$$36--@>=23("YAA^ST9O
M>CW9<_J>%^?3NQY[GBD[;I&B'O'I&UMHZG5BWS>V[V1S[U%U976%3MYPIA]'
M2G&>KPG=_!"Z>7U9_<<HSV0S42]KJ[<5LCF/@DQ5K$![F-O1*V(DV=8XO>C%
M=I95P2[NF<8B*$E04KTROM2,LB1UI:3ZZ@;)>FN[UE<+JV<<"+[TB>\M'Y9W
M6J#VU WF"Q//E[YCH_+[5V,9G>9LJ?[UKY7G6[.WNE2&XG5<L 9#5WHE$LV"
MIF&^OH,_Z!0O:"]V#Z8H&4\N8:YNZ15(3GHV_N6XTLRR07NR:"$<F)Z_PKWU
M)'@$;#;B5G)6[L;CR,\EK3@H 3/ ;TM5-9+'_3B/N+G]O,DDL/G5#0S&7>%H
M/QM3<OD,>KE?MD#1 'NT#)-%FA@GX/G96&*F;)&BDC,(X(9HN_?AAQE5+4HK
M6C3 MNR]L996ML@CM@6[9CL^\;J[++Y\K,57#K7XY690>O&QT71OV$^K[;7W
MXBO'6OP!3")E"OLO?KD9E%[\86>B]O04V*PO/JU*M</ZJ\=:_U%G,CX(^,O-
MH/3Z:PC^]/6?N<ZS1%TO$@H!*B)>#->B];#"3ZBD#,4%#-_#:F .%O5:.!Y9
MO#'9,ULXH$2 ] JO9$]PP8"W7K#P%Y,L4\.;2^3?*^L%AHJ2"S>>56S#^<7:
M2O<DK)2X(>A +LZMZ5PR:%$QV[-,*B'A)Y9:@1=1H<?6"BXF/UE],U9SC$YU
M;7RP/7 K'5C=1,8X4V1T:\=A]4P.N\-8#\N0AOULAH10K!G]#N5L^EWCG\#.
M)",BWW64/QH>H\#[N\_?>]+-VI=(85R!A$?!HT%S-"B3+%^(5![G.%X^A81Z
MR]^U&S\>@C(RRN/'7="(?:93WY.E3QV)$JWUI2K=LA/+L8,KFQAH*VJ>H(]-
M[*OA CN4AW16:NE9Y1P"5#8K;!62*SZC65VNGL TX],:Z.4KK<KCG"XHE<T,
M%)S!KOLUZ++RF,[*]WR8(U[ Y63-Q-%PU!QQ--0:)([&S1)'>C%QM%Y/=TL%
MWI[T,"=>BC\#R>+?*U ^9Q96\K51Q\,L38,5]@59%RM5.R?F$V'ZHI4BVU!9
M!#W4>;+7LZ9Y:5L8-/M[ ;+36E#ELTO?L5RZSA(DJD^Z]"[47T'I1&\A'4=0
M$,V;$WP0S#(V*,,+BMVZ9.FX5#G&VWK2UH'.K:<Y*-5D-F/+AT]UR6R!?_$B
MO^M%>G%4= ',F#*_KAPLC3?4"GK2GZ#Q^A8FCP-'<G\0_X*I!MQG!,^G6GL7
MF>"KX9K2FT46I@0J^0NWT4S+FR*?Y.H]K(I)8"+/%JT0ER@?[(53\R5B .=;
M7PM89EX+70DJ#%--)%F->&X1%UGG6U@JOZ"'[@HP].A:69XYN9!G3BKYTDK=
M@D AG#X0KXA$ED(<K!0'KV,_7>!.A+#. RP(GP#D/X%A^&C+55EV/LY<PF."
MWQ&IU-U_Z8<?EA6ZH_Z6JEB!-K&%Y_Q)@D6D,,-"2T&=)5PV?YYD2%;,!B8_
ME\3V2.H*>\A%J24+!,!J,+!"VQZLC82;*UEP 7('_-29S6 I*#VPM[M\-#;G
M' OVU!@U4Y:Y/F83" 1,=<H%X*4A[[ )?(F;##>B"@+X ^5^5K00<'97BN(^
M]++M5VI]S/ Y=*U_B41% P\:4/Z8H A(%G70X&&8B?0R-5SW#;'(>&Z^R&-8
MW+B-RZ0U"43?%E-SNY)-*(FL@&>@0/@/]>+0(7DK^@;J:6(\JJ3JO]XX;9SG
M$RS%A/2("<EX+-G+8D./>6QH%Z-&/\[,:(G-E&884MZD% :(I((2 P/;YO+;
MJO>/,WF53GY4?O*[[*@N'V=28'_KO63UD HWU/)"39"R">YQ"K0[UA<B4%Z0
M6?Q[Y2!#87JH!&KVE+NQ0FD)OWL6L#^#<2O:?L2:P3O3[T7MV7@QX'K0=;N!
M",4P Q3'_"*0WU37,5%@/L9NP+]7;  ,H.@0"UZ/\V+ZKTN>#:;K,I.>>:JO
MUCE@3*?RI'7YL/70_1R[BJD;ZR.ZBHFN8K'9W!ZMJYB:VE5LD$DV7*<[$=W$
M.#*R+&3)U/A;./!0RJG ]'@F+M56E\82+,1'QW5ISYU ;<N^@,D ZH0I*<^4
M[?+L?@[*W@,,]&/XKM*R;(@=H+*:3A<3TB@8PN7*6RUIEW50#[\.V JTE]*M
M*U^F"[MNG9B^K7P*@BMCL9#NEBQ@*FCCA>N(BI=$-:^R,ZZM_;?D<Y[BG!T^
M9\/SG*E%U2.J_R!;P<-Z_TUZ)O[<B1_5,X7K.;9*,9Y$?7U 1I83= PSI*](
M(J@J+1Q4K%8+RH%[4BN6]#KTUUZ"I@D:KT9I#2B.+B35:;%G&I[P,*^P26:@
M2#(7;^!GH@$74UAPEW#_3Z!MECT(T-><<TK ?^:K9[ I@A=?!N^]IGL<..P>
MG(_DDHTBYSQ@I'4FH[3#@-!7!I/]G\O?NWPVP9E .OHHGV4F!$*P)UUZDK>:
MSMG=)1EP7MQRX,J)>7(JZ*4^&L."9-7P##R3P>1+SBCCK!:W-)Q-94WA1UBQ
M;)!W8DNW+]ZY-#KTF%DN;/^_5X;K8X3-C%(#VV* U6K*++!R*Z#E'&[MM*DI
MR6?]<!FT?LGT2WV<,<9=MFG[T.3.!+]*;%'B WH:MUKP\*QRL,LX1L?98*'2
M._N!TRL\Z&X6G:H75&<BP&E*9Z)J6:FB >#"XX[ !_^.^=A_80[%-(]EZ)'W
M(I=\81^XG&M#-4(ZH;J?RG+7:3<I_+^YL%WN&TIM(MVY3X9M_8<93A[V;"5/
MUA3T9=>WB>O-K26[\<^KR_MXH![YB9JU1[TLH"88P3DE>2$VZ@H_+5]Z1GPN
M\0(8XM)U7BP3?I?P7/%Y]0S7^BN7'HO@P_]O/&+0F@4O(&8W5R>)SA\+:B=%
MEJ[+ A#Q(!5C*A%8Z8_K[F1+Y+6A.8PHTS!N6D\&?$CA 5M9$:;T^\<481K8
M[EN[3I>)43@M!I1^7E[_@3  MK8R2C+E?3"@'!4#:"2G'&24Q, 6D[EI8B"O
M<S./#S%Y1V@0L4&S^A@K?8Z2_3SI'8+ (QBA K<Q:OAE[8"=^A1I VCV-;9.
MMU>\B<&+@W2Q0!N3TA<P;I 'WM(E!I@ UQNWTH.C-4HSPI@48K+P\MG">96>
M'9,L BD43BIO]C,G'DG!)507-=4@/(5&C"^HLS]\&1Y3TG5&F?-"7+"6Z/$E
M*AQ38XE^"#HW?#+S.SVYSBM(2I?& ^W5;?S2-F,TG])['"ZX=6QW+=\2[^=-
MQZ=SV_HW[-@#+L,#V>Q!KFG)'N2:ENQ!CM!BG;0?"2X_;)]'T<%[B*^>.<M<
MT7@C6.92+=G?2SOU":<CW:]/^/@T3<)'6ODFX7JOKXPKZ>PMCWMC=5C=HW);
ME]>S4D:;VG\'Y":UM<WWY@1/W<[[2(V!3UI(X#)-C!=8]\S)%T[,+[PLZ:<;
M-(N_;M47TEVY2G_M+$G-SF2@"D&@#+S=$C]6DX'68$ASX6K8O&*4<H[T5^FB
MK-=9Z0\..E0L!*&E1%S]=>.D5P"O&N -#[F;XSX%7M*X_.M6QW#66$<''2MH
MD4I:K%]QY-5*U,SH?XT2-5=QNW G$;/GI%M S]I!:41)C\O828Z,#SI2-3UR
M8A\Q(L"E'W3+T)?;2QZL[B0KY/Y!ASK$H:8D2C935#30*OF>=K"TCU5ROE0M
MKYT[)'R1NY!*=((]'J53RL\=)(:L''*@&JA_J0/=W_ X8VRIA]RR<878&AQR
MH'H&MIHI+AIH6?R9<W0CC(V=J/N@S@,=G0=R2HK:+M:&?%#?@8YY@FD4+LR-
M?>!U4%M65RB\TNHU[F)O'-2:U=6]\54K"=) @^-+VKF^:%*RG2@.ZB_0!UA7
M)RM\^:@-(TZS'7\5\-L*/^6@/B!]*.!7Y\/WT]=C%Y,5DQ63S6M1T. XV]28
MQ]2PU^YZS"N-@,P-)^4EX6AXY<)YQ50[O ^KQ^'O/*7C=4Y8)N&;9%JS&7'C
M ;"+-\F8NE@_BF8GPE0)39%)C73G):;@2HLEW]!@WR#Q@A9S\WHE2EV4W\Z:
MY0RSZ%NZ4+'XVXRL84Q<,:1X&*Y$XW!;$55^!7H'5B,SHA6)55+<EI%#5P7(
M_R):ED=<%LE;/?Z+HMM9JZAHXLQ9<34;T OOG/)W3RUWNGK&ZE)3K,>"F:,F
M2QI@D>RW6*=&[4I8)$+I?Z#9K:Q4BD<_DC_0CAM3YWFY((AL3'XRHJMX'BN0
M@1M48?3GEFMN)CBR7!%,10M6@^?1\N(Q01K>D^.8K]:"A86SC#;+AM$_631)
MBMW+DR6C^ERQM5C2Q"S83)[ % 3ILSAV6(%@')L/C0KPL-+LR&[9IAG3J;LB
MZYN7& )C !L5OWBJ5U3UQN37Q0:\QD \+'_ +&8;R^B0M#)#Q=>(9AO;P*[>
M8O5]PA)$N%D\[8\.T9C.^?IL?!K>'$_L67\.#VN/!ADE'/ASMCS!R*;.:F%B
MB:&06\+TGXA-:'W.H,+EBLW^3\P'AQUTED&)>BS#'1N/$^.Z4=Y!\)CU80'C
MGO)D(XX.GMU $S5B&1!Q&46''R1MS"W/=UPT)H(<"'8S,5S,1O>ZL22)F,NC
MNUX>M$N-+M=Z7,'#WMBZ2-,YL#;^.#9[@.C/H.ZH\8RN%+K9 8C)SRF6,5RN
M7+C5(ZR0D^2 7$PIAIK%@P(J7"MXYX40JZ(BQK'9;A:+6V-CK);6@JU-6<>E
MIF77$ #=S8$'_P;VZO(F8"F8IQ7DBMPM$>CPEO7: O?.PDRUF$=YE01@BK_!
MD@/'DGYWO"4%@1U6"E\K5Y8L2!BCRTULP+>;SS7I[! B\4)>$=+86UB1?-KT
M0Y3XVE;B:R!*?(D27W4H\5778EZAIA.6=N9R?;,@J[>NC01<8T,(;K(SPZ,2
MP7"9#D*55P>-R)1"XJ@/4;Y"E8(H6QY%1:+R-#[IBJ+I3P*C]\@3*N<YPK1T
M+:D:BV#3M%CS")H\7$0@;]@55/P$1LR<& O0I)C]OUC0ZLU!!>A'5.3@ ZRE
M&V\3R%(E>=(D-S^X\0]/3C, UBP27I:G*JLDW1;!,='>A)CC&];$9_/:.KHU
M%0YU581>$8O$6ZN^'U8=HEX*J@I%.]#EI;C3GK'-H/%2+)J++1:-5]BDB935
M( -[#3#9%D]D$VZW?2HR?1B#"DV13?N'5?ZHQO2A2>0IYD]Z1X*M%A'V%:,+
M#^.U"Z,N=2MH72KL6( _;">JL!XUEH@_*\<)LND#22%S>&!*39J*_6SY?!D%
MJJ4]RK/!># U9=,<Z/+0(*0OJ_VQJ9E$-<?Z/V6LI%S LW4BK4,KFG>/YLY7
M8H(Q[))OANM_BJI1)-/E]91T>3TE7?[K]:>;J\OOU]*WR^\/TJ>=DMOU<LGM
M-9.=?Z)41",>*77J6M0-(9GN"O /G&)FL:8+QA0Y/2T(3VL+!3LAX59(GW@#
MO[!Z$'4X@.W(&YI=?;TOL\T?67'[>ZQM?SFE7.4R+(J$7:W7<)!1,0$K@"4@
M,$ZOF("S \7,9N4DMK26B5?3F#F+!2T9&K9IVZS<M+E(3!CF%%SHX6JAY]6S
M3&!7OP9\-62I\?(.\?&XQ+*!&NAP696+UPLN7NBI1?A(8/FTTM;C&WT5,G;F
M.7SEQR64B[J6]P-'C"H0_OOHXD-QDU*@$@T2G\:GNX2EHU6IK*D%BQO-@ (.
M3U.>C.7&8&C9J;GA/AM3LJ+'Z,#.[=4,L 2$CLZHSWA^$RI\\$A6B0:'XI(G
MPV7=NU9; 1T.(!_96/\"#VQ <E)%4@E4=V,%8X"!7\7A$G6FN(_*G<6M"?K0
MFYNN=(/=1\9=J9-Z"R[#_6H)I(1_8^6O3X9O=)BX!Z$$B_ LR?V+_^GMQK+&
MVUE6:I&!4Y3?&*OERV\HO9&FE*J9D?WYJ%_N25F#TGNCX4",J;%CVE[.I6 9
MDY.&4&X6[TB/%TH/C"I;FD5O9N62DM586C;U]3HM M*9D=)9%2IRBE34;]._
M@X9'3<LK!PQ>TW'I'_?$]YG:423AILAB%%O02/78>$Q[%AP47+;$H7)/__P4
M*,^5@_0,UE2 N,X@%F)D(^A?;J$<>0=V+2_DZOU29ONK2CJ"-3Q1?#US80>]
MS9B_N8H*!W'P[)TE4KL\K;_LDWE1\XR+4D68E9QRTA1>+,+UBF$LI;:RCIGK
M2K*IX F27++%HP"\ #P"/J/J>!G PVO[G<E0%H@7B&\ XM5*$(^%#S/;  G$
MUP 5 O$!X@>5(%[I3$9ZLOWS:1!_I/H[IS-D'ES#9.?@]!1W:;RQ-D&Q?!3>
MZFDW^V9C/=*-XW+KV9",^'>56@0\',+[QC;HTC8OV?;$DM^V494*<D15$E3U
M2V&"2@?VP42(P$TUBG4IW)3J[0.CQ:*@W;&2+'TC8-5T6.5HK_NR(ZS1.DH*
M>8&;IN,F1P<\*#O"<J9=1:T!K"KR?S.$Z'76'V\QI92[P=\%T=9OOS"7>-4>
M\4*DEM=08O.8I9UTF% G,>\8?HN'V\+><5H+ZRM1\RR5N+3.)-E^H3AAE=V5
M$[DG!,)V5SQ+(:PL;\=RPEU53C8-$!!L$00KT5%+LS:],]&J.E00Z*HONO95
M9?<4H3*>7J7X\NO%P<ZAXCB+WHA*J.P1OU&18=@V4CM4-,2M8T^SW0HREOI.
M-C0KR<G+;DD#_ [G#:_BL0=Q>,4UU)GUDY@7_R&NDPH[!<,$:6D,@3V!O1VC
M ')8&U:93S9W$_ Z;W@5/W+?D;4-&L7:SJ'9P:;R&BMQ<4I_:P-)K=H3>KHO
ML6.,''X^[$RTI*I:VA9LF$NA@2BI7M?, $D)KCRJC"L+&-63V131&XLS&PV8
M306G-P(E]6(V1;2__9G-N&[,IB(79>'3]9,B @_8D\K>FW!6UD</3#\7B*AM
MO851*HWIJ=672\>M",.^OBBK1(_,Q59QOJ[T&V7:"_2=5/W<G\<!WYP,DQY,
MP>-:A+)*U-<J>5RS3F:J#!O5>MJPYJHMVX$B/Q]HN72LIGWP&-."P1>\X(L*
MJVTZ*TR9*EWQI:7IC14N4+V9W6',A@*"5 5CH;I8W HVJJ:YQ()4!:D>,K1Y
MFUY2(*99&50=TRQ(69!RVTFYRA#Q K(6$Q63^:U[Q88+*A54VG8J/4RH?0%Z
M'54;8W\B6DUIQ9WL,K-[WYE"/?>*=ID9U;G+S+AH^Y'@S/2;ZRQA5]Z^+0S;
MO[1-[)ZYQ'JR6[K. .R2;6?PPV33D6_?[[Y=?W_X7^GR]I-T_?<_;KYA8[VN
M='O]D-O0H8))I U]O#G&C.81P832YJDTMP].L%:LOVZP4-(K;]KG6K0%UVRS
M\XN?W\ZE8'-Q%'*Q9I&RTN >'-JPIXU'->SC4,?>$MO7J6 %Y9SRU"4O2U&Z
MZE=VN(IV#<4+>#=M:40[AV)M.D09[A:4X?X"TE:4W:[<3&V0H5G.SAQN#YC,
MU)M_<QW/2[4W=2QD59.X2 %^ ?XMX!]5#7ZU7T6Z]7&"@ALCTCZNK 6.E/6"
M7!##(W-G84H6V*+."VL3N7<WDM1E:66,D;8?Z$L>Z:E8@*#;[R<+K6XEBL,P
M?@$!!H'Q<2&@( 3D@7I<"+1>U0^W122Y'I!6]./2BDHC()06]3<0:(K0!/KA
M4=%$XVF405W,L;9HI%?.\W+E$U?RG)G_:KA$J)^%*2"G9D#5%##L3-3NL"P%
M"/7SD!#(J0A0-01&" %]F PJK+7ZF7=((TI<5@_-G.SQJH&I=2;#[G@L"JT*
M%,91N*=+OBP*QYW)J*L.J_):GC(=K#$*Y.5TNGI>+0R?F+#72Q>VAP86G;4>
M62I",K^K1K# GV+K"[\O"/Z";3:>'9C[?^CGF315GIRP!6UW/$PR]:R 2Z%K
M'A F.;ST9# 9]%$IE4MT9CFU/EJV1,SIF&MZ_&(7DV6;DQI[#N?*5:U.O?G5
M,0R0VQT:B QD9$%]M2I7<T6[6=,P#Y'((Q)YCF?*[43/"M*SHI3T<S4]WR>>
M'Q++*.!;-ASW,+A_Z7@6WO+>):#L62^$Q_3S'8W=QZ?;CVXQ'F%F*S_[EJPT
MHF/G;>C#]?R*^,^Y&^F13^3BT27&CPMC!H-];RQ>C3</USR>D&'9P</U 5W"
MS=EO3Y7*69H=;SMVKM3O*WB$(=W8TUY>Z@I2@9H:%QW/ZAGT<2U/-)O;NX?K
M>^GA3KJZN[V_^W+SZ?+A^I/T^>;V\O;JYO*+=/\ 'V#RU3TO$/3N*DAL^B4-
M65N2HG*SGV*KIM4Z&2IN%@9]OVDJU%_*R(&<0Z_X2VX=>^DZYHH^M+P04#N3
ML9HE GA,O&39-#.K6VX2.=&2%4YB@.W'DH71I/7Q*UUJX96:0T[P6X5S&'8F
MHY2TVXTYR%WX9;I8F32%+N9J"+$&[Y6FQM+R@3S^0TRX')B*;2P6;S"3%[(
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MDT%_7!,("R]68ZX26]68J\[>X5BDO6PI8[R@$95>?>I,RR96N33M$>?*H*!
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M@9-:#OV+O00_<QYATQDWXV@.GB%9=&HKUR5F3_KJ>'Z <CYAR5FR38%E<PD
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MD(,?:[\JAR*#PT<GM%8C32A&@_+8H9U-R3_K!P;)S9NMT^I@#IU=Z<;/'(Y
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M9Q'WOG#O!0'!<"U\(3[7./XG9NC^80+M#0[<\."6!-ZH$V-,'@Y#Y$1AIF]
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M]H@PY10Y/$3*-]?"@VZ[PNUM3[B%WPIJ3[A(_0JNZC&&6O]9=_4+@>+LFXX
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MS\W^2AJP\#%DDPXSBO%9Y,^%[2]GHS^3RZE-])^7^AQ6^U%?ONIO#BK7Z-'
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MC0?PTN 7^G,("W8I158L7ES)?35E+.E?!<,CPOW,M; XB,6#E*VPY_OHP:S
M;$E3\=5:/Z.EP'.[9B5=J9PD(5Y;992I]GA''8]$>&2T!X\4GO0F#^3:)KV=
MHJMQ^O9JW*B]TB*<0@OKD@ZI7UBWA[TJM_;R]FIX<37HCS+MU<1[]AQ7D%GZ
MHH*Y.EW8C@J\5K\J&G5#)\^;?]2*_%/$JT8@BIZBG<B(H%)65!ZW^0;->EF=
MR#VZ$:C#\Y<2K9Y+@5KGI>#X@QMJNBZ\7[X:#PZ@?;6:M&_C;%<G",Q)Z.5X
M!K.9^1KGEJDHM_GST16Y+33[:PAQ0#6$DNR6:=O@EQJ<_X*+WZ,]^AV)767J
MG(]<YO;W5Y!+\>)*Z@VTFF<55#V\"J9]JYM!5&A$KTYW<U>Q3]*!2:%!]5S=
MJ:59OP9-YET=54,YZ@)<>5R^._V8^\%RQ*)T:CEB4:XA1UPY4'KZSL^9>C"E
M4MYW 9!)F32"J)QA&J&3B/.5B!()_JA$I'#^$$L&*T]C;U?FXYWX%&/Q8#[%
MJ&Z?HN3:R_L4XXLKI3],63//XV]L<\D]BF%7=5:.U2HI',PQ:76A>IY8)NGL
MV22G=:,$F]!2]KIR0BW)_+P7NR0?RBY).'6X7KM4;NVE[9(DPHK[XTR[]$VW
M9PM!9/5EHZZ^K!RO5=$XD@0>0W7#U)[[7\<F$3;)24]6#R%(]15%=Y>I8QBM
M@P5H)1S6F1+LK&"T&@[02CA3L2]G!FB_D*GM(90D,UOC[CY5CMLJF2V\FJO=
M?>H\V:2V.)\TQ@G![[(U^/1-4[/].E$N46N/\S7<KR-IF#O4,DT3OT\-*QNF
M]^(HE^C7V:UQ9+R;RVWIJ>CN4_6R28FVG!PV$6L)]'5WIF,8)NU0ADF6:@_T
ME5M[:<,DRS30EV>8J%U2NPM3.5:KI' 4C/.UQ1/N+DRULHE:HF$IATV&R";)
MT;K=A:G]=DD]6&&$/*K;+I5<>WF[--YMEX)Q7=5-TSOQA=7::B-DM1;3U%V9
M6LDF>]9&%$]!R5J7@CIILW6PN@EE4'<*JN3:2YLMA>+(Y=5-2"P!I77WJ7*\
M5L5H*7@UUY+GTMVGSH%-]JR;2&$3G"9:O86[NT\=PS =K#9"46J_3S5<&Z$,
MT3")4M)KCP'&\0Q4%<OT7OSDVDHC%+B<*W)=J!'==:I=;%);:82"K2+:J"5L
MTEV92G'!P4HC%+5VR]1P:82B80N4.LZT3&$+E#SH;DSE6*V*PAD.:E$XW8VI
ME6Q26V7$4&Q3HK*[,97B@H-51@REW:&\\F:IX<*(H7QQ)?7%@L7DLM3=F,HQ
M6R65H]02I.EN3&UD$ZVVVHCAL$ULTMV8RDS7BU?(-&J91C4GF<JNO;QIHK41
MV3>F2,V>7&7VP_MPA<7ZBK&&:CHK=3>FTV<32:NM?F:H 9O(E<&,NAO3,>S2
MP8H?1H.+JS2PP0IVJ>'BAQ$%C2C6Y"17F:'W/CQAL;[BAQ'<OE6ELF'J+DPM
M9!,I;Q!U]8J]40<:<<I&2](.9[24BRNIUHJ]DFLO;[2&H!IWQ/G^X:T)XW%N
MN+HNJ)+\5LEPP>5<&HDM<96[&U6];%);U=YHW"8VZ6Y4I;C@8%5[(^Q;J;4V
MHN3:RQLG6ALQRJS:\[N@N(%"^Z1TF:B2+%=%\8SADBZWIBBKNUC5RR:UU>Z-
MQ3:Q27=Y*L4%!ZO=&^?42.QAGQJNW1O+:)^R(WZQD2A*E9#?>W&):ZO>&],:
MB2X7=9YL4EOUWGC8)C;I;DZEN.!@U7OC4>TWIX;+]\9TL(::!V!.0WI*![A7
MDM<J:1RU3;YP=V6JDTWD06VU-&.M36S279E*<<'!@(W4NB=KE%U[:<.DBKN1
M8&.-N$H'$5&2V:JH'!4A(J2VU&5U5Z9ZV:2VF4\J!CVT#B+B!"V3>#C(/;7N
M\1EEUU[>,N&,S1VS"*-7IF&5NO+WX0N+]0'NJ=BB('4SG\Z13>3!GL4RQ<OW
MU/&9EN_1]RIRBO6B_S;7!E#JXZ76'R#+I%JT8[#'D^7J2\$A:].RA;7E$F>;
M_F4<MZEE&\2^A.U\1)(XUM(T!-S$N4N.--HS)E76DJL75^*@)XEUN7S%3NP$
M[@SOE_7&>\:YRK*>=G&E]H9R7?C>S7'>0:\A1U':<)K"TH(G?,S4U@7VFW\"
MJ<)8U<^J=V5UFF]1:_.I?R9+_8T8@F'KKX+KLT"/WX?>!$FE>'E*%0-^YKI2
M'C0^U%0;U.;@=L&[5K)0;06;FIB>,#CIX!U]KS3,N0>I?4UKWS5H"4=W236K
M 8=7]B+*C1:CZ$>X"0J&Y4V7A!FN"OYIFADZJKS\Y2BD.1\=4H,1*N"P:U)=
M=\4:3_%(0;Y.=CO9K4=V][3^9657OKC2>H/JE^TCBRYU*O[FZO"J(#T#&T*2
MFFM/ISORMWCGK>#X9K',WDJWG\VUOVYT&?A/<*WCN*C]K^>XYOPMYF=$DH%7
M_S6U<4715%'WIIK>Q,5IJ/;1\]M8CHE'^]&&*ZMKOI#?7TW#7?C2%OD>7]H@
M_(H^!?;SW.RO1-:,&41B'UYI2+@F<;#=W1;Y<V&'N>EG<CFUB?[S4I_#:C_J
MRU?]S4'AB)X4' I_NJ90&FYOO] Q9-%FSZ\U1])Q*DG_\. 1NG"[GO7S>!HY
M>"O9PI8>8V!E@+0\TF[N[I]N'H6G>^'Z_N[Q_NOMY\G3S6?AR^W=Y.[Z=O)5
M>'R"'WR[N7MZY/&"#]=,+1+CMS3.VM*;OJV0M!%FSF?^=R=N\&,Y,&U<MVZG
MA;>MU^-L00QO2>[GWW37LT$BB7,_C]JT)U3E3_"(3TMK]C-BL,"G)6#'-LA.
MMD<NFE)$AQ;SD!""-1?<!1&<A66[[)JHKXVM2R,:>OJI-Z+;CD#6:#[#"8&R
MV!-TFPBZ Q]<+JW72 2WB%122QHJ3VJV@1)+?>.0C_Y??C=,9[/4WSZ::[H?
M^J7?XV<P3+E]X_O8K[GVT;2^/%11 ?&X '\QUTU]H,_?DC\?:_WQ8)3ZJT%?
M3/UYUJ-$M3_0E)V/R@E;E(SI']4-_9+'.@6"_3OVR_5C\S$7-4\]TMU^,-=^
M_9'S6VQG^T:B,MW8%$^VO6'^M!!^;3LO?$<]WO[WO: 6V'SNQ>5XNVXH?!1:
MK^]DH[]A+1X8] ?;7,_,C;Z\7=_!8Y]>R?*%?(-W+)SR-]4AN,(]I39HXS)"
M7/ ZBJ=ZZ+Z)(VF.X>&3?^]/9OX%]OGI-3W[-[JX&ATYI;,ONY]:%02P^V@O
M=J]4S/E.V7UA$Y+*\.-:<IB5:CG?D7X?=_K], S_Q?+L\KX05F?V)/FXX&_O
M2/^KG?X_D#B8+Z2\.&@H#H/..ARFA&5!;$)3#)V-:%HH)DCF?>4"-@*7A)XF
MM^>:D,S09N1C]TPPQ6//HTV\&$P4^U*C:1KZQ(^F"PN?%4C</+)NF+M8-TQ^
M;K6].8Q[SXZU^/2$UX4Y6]!,A+=VR,RSB=$35OJ;,"4"_)V0%3$$W17 "Q*L
M#94L^)>^?A-<6!C^O326P:A4Q^AW6,2*OAB$;D9VMXLJ Q'SL6G-HCQGL_$E
M5]!I"ZVP67J.H,]FM@<;-7E[*LWGZ(*S@77.3?C%2O])+E\7UI+P[_4%4+-M
MPPU7!E(V;GCTW.F!.][T?\G,%5P+MAMNW8;W"+J!G(MK$$Q&.)K3@M^!?H&O
M.PYP-] %OHN_#!]J6*_K9ULWX'<?X&WP#H?\VX/G+-\$;\-^\UM?N 4V EWE
MTIYC:XLK*=5T$SXBS!;Z^IG@X>'/;&L)!VB]F X2VUT ]R&KVO &$SG8P?5L
M/!N^Y9#(PD!3$EN8@=K#I\Y,>^:M'%=?SXC3%\Y"L(&>=]8+RP^!.RR#8!/!
M=!QDZI(P*8="EE0&\JZ(@3^"$XZ^M(9I%F!2&2C8DY[61__74(O&.3J*B\R
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M.8>_)1?OTA$E(-YW\F(M7]#WO8;KLND*D^!B7(2-J^$=MC><<(NQT#7)2H&
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M!+H"_8FY<59A!B?%8+.<>'R#1=IFEK<TA*4)C$/UL#YE3@=\D0>'?-0M]%^
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MTIJ28$I:89^B3G@G%S@%]LQTX&-1_3J+F%M?*Z'&@7N6B]++V, #<V5C_$(
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M7=N7US,0>-MW)MCIT$]F<=O*Z\-3H:N,8\YW8-#7R^L"6[<_7)5CS=& X[Y
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MR70UXFFPGV6UH0[3VE"'*6VH6V$<O/:AS5KI$7<CCI?@.3[8\:>E/OMY"5L
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MR1U@>E+U: >( W?ZH^X BQ]@>G;Y: >(K:A9A3CO*^036(D7"]/(.);QG0$
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M%2DM[MGK).%<)2$G7511$B24!'70BL%LG21TDE AVUA1$K"CI:?))6$NCM5
MFWSOG/[O=/R^ $[/3YW%2A,9^IHUCWF! 4(L=:'9N23_9%$ZPL-SF2&YO3K0
M.)$C5QL9SM:P/'1:_Y_W49.?T_J[5>#%ZNHY6FVTZ)"&G(N)J1P14^7B2I3D
MGCJJ;++*G663UFQ+=$MC,71<N>TF'9HKL45$&O44L?*5HG5<66 E'</NP;#C
MHS+L"!E6[8W4RMV!S3/LV8? :-;5?"$"K!IKD*SYQP*!]?TP?=[C]VORI4\
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M_$Y6NHG-V^%6P\_LO6F\>N2F!/#%5,WB_)#?F(>F"VO@Q/B18\%)R _.Z;'
M,)\%TA+)K"7404P:U#:^=0K3P^BJ6^LU89NG]"/QZ:@TTXN]I1N3^B@ZI=ZV
MB"I](3O165S9E*H2&[4]8\H+I@0Q:+:M)V'J/Q>?F9XO_6;^QUM86''SDX!_
M,:&5>W!R7[]>T]0H^SV[B_Y)EDM'^ *DM<+<:>2'U7*HZO X.=3A*%]_U)Y
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M- ]$:F0%B70_S-0C5 @/!Q>"1)%2]0/-!Z]LF8XQ( OV#6P6T 4L9<C%RQ(
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M:'U1E5+$3J-<A4A Q3)!U.RZ,!O/_P7+\4@(DT 2%=Z"(:-D@'G9PO/ )4E
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MN-/=LGQT^)L6^]>,6Z R-6JV6.1,E!Z9[_CY"\;IACP(^F(3KKF[8&!AP40
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M\[E!P\+08;)Q@)!3RX)I':L5OAX1\!6<5D9C C@BI (T9H)ED9*Z+ =%7HJ
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M]*, PZPSX45>_?Y61=;)R&1 ^?9#+,JX5A8H-D_4MYMXNXLHHW5ALK*Q@-#
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MNN\GF@CYQ[EBA:$9L@W)3RLK-EF8IJ,N]>Y.0,OF=[;#OF';R;B>4@1(J=&
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M;H^U'@K73J79/0CA>O2.U-LI\\T0IFJPWU/F!BS8SV76ZF$<1EV,GIRN*-J
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ML[7,I7014NE 5* MM7?QUR;QU^D?XV5%I5<08PMKZ 6ZE&H7/?&!.3#"\Y]
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MF6^&,%6#_9XR-V#!?FZ=5@_C,"I<].1T;= &!/2%N6QD;YDM>[CIV(4::G>
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MLR^.-_REL/ NES.T$X-0?HBO8<#PIPA8?\;.+NZOKF\>_GX/VWEE2'8O9K"
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M$*E2T^8GFM2I*8V,ETU1>&:I"#BIX(O9!C2K)T8-Q&'.%OL79;4^Q4OG?J5
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MA\=3TI1UM\XN?G@S.W@!T@"&\]] >K/AKWE)5_R-/?E@@\]Y7])ZFWP*K4/
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M45!W(5U!9F(); A;1AP!G5 \EM);;$7W,>ZP @Q$76UFP7+5>+">"I67)CL
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M.!A2#D>]WVQ]Y/4S4;N[!<0NJI4+9;]B2HG^V%/1TC$.%HA4$&!Y(]OAA>T
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M_;P.3*OT_@JEL<P^^ER7"/:^\!<3.EU/K1/;C7N(KC_X$EFYEKQ8;(%$XGY
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M\?O@T;B[O_K'U<TC\/&'NRO^15[M_B#27C=B\"?I=6P7DN'>J)U6AOOGMS_
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M4-N0:M;(9C(+IQQ5PXZ.L<AA$=*7U-G;CHR&:R770</[&. =G_7/*%6"CGH
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M_GYC6F;/F^)G&\'!%RS[&8WQ\JXP+6&4U'\N-*3?$+/4LN'[7>V"J-_QE2A
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M'?ZZ_RKINIGN.$1W7/7AW;W418VI"Z8N\@L?]9*J"W_==DG7S=3%IEC4PI^
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MX86+VWI$SR-VRE,$YMBAFG<RAWAQ6VNFU4F%,4>VF&.'AMW)'-+%K1QQW%>
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MP$ER;X!4@:57_Y_>!I[),64BS$3X##;F(2),RNF:?,K=K)D(,Q%F(IS J#]
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M,JP?0>!E;!GX+U+,CFR'=%LQ@]B,?[,@PD.[=I&71NI,'='[PZM^=P.-]IF
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ME>#W8_P=&SIIG9RVSDXS5<4USUHGYZWM3AI^7"W=P\MC_N.11GS?-6>!3WL
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M4W_E&,FY47P"'X:XJE.GG[_[>)F[&>C!,O#\LY.+CX)=IP(%%42Q!!8]O/'
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MAC-8T'QS]S(:T+9"6+QE'+01)52KQ*49Q2::=H"@X]N)3.?EKL[4H^K;N2%
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MA!"R F62HW"3_ L>@PXJ6I9+ZQ/--I3W*?3K%'E[$'07RGM NT I)@6P9(B
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MQ_CP9C@.XW27#]IG3_]'X"*351>,Z",>0&+.<A>=$)$U!M?JU+7<9==J@93
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M]XZ#+7B_=XOU/0>@ULWOT%;]\,6[LE+K<:"!?7K\A8L2B=LX(@H&(:E@63*
M :LW7<]V0G(@H_7.:AZ9O-\E]K%MO/H;MU%*C[]E8,C]]UD&<$IZ4"K0/C/"
M0\[:91^41+Q?H+[Z&OIBASJ2Z6V]TX"]36S/73KNZ;X4>4I1UHRT>M(0G8?H
MI00;O!<J>O3L?A#_8V'WU.;L7.9;\+I#.W-P^+\_'I\=GQ^?GIP=G+Q^??RW
MH[/SX_./'X[.EB'<K9M68L[)9)SJ"<)D1&_Z=#R>XQ1G\V6:?NWULZG5Z82,
M[6U0]]QI-.EO24UM8[PLF/AM.KG\<E.%MW!UQA267V*^BM GXX&/)0F,CL!7
MR.^U29&G$RVXPJ(7=71T\PY:&Y"Y]47]ZJ\Z2 N'<'8RF2_$^782QK/OZ7%5
M%203C:>="]$XXID,M&N3MF!=9MJ@5D&TYEG3!?3!XNX*LP]2!O:&A'99)ZLO
MX:IP]UZY[L";Z*,K!>K$>.)B;2*JG *C;=1914V_VQ^ 'R>Z3[7\/09M XGO
M ZC+X=>7TSK)^NK4V/+BI,0 M2T7*+06?*85..,#RIP=<ZUS.K<BN$_5_#T&
MZ):2WALXJUMWAVH54_:( E2AW:085BN@!* 0I61:$ 4,>\;G?9K[5,K7=XAN
M)>]]H/0Z[>P[X0,T.GF'$C@OAICF$_&+6RC>JVR]2<6WGE"T%<%]&@G08WQN
M*>E]@//)D6>WUI ]-]4?@<"C!Y5+A%A[=6KA=$89A>3W;_!VB-855M"GBL0>
MP[<U%IKA^=8YSGJ,<\$(8X(%B34Q+S+RKHM4H'UP I$7W7P2W*:T[L]MNEVM
M$=&7I$FHTA2"FXX<0C9U0+6T*6I96W#VQG=:MPIG1SM\)VAMYT5M*OY]6*OK
MDY_WX5L]Z2$=19],Z1NW%G$5P@Q,YMQZ%@"EK:T@A*M'^+6\7[B<+;&X>;9T
M-ROITP%+W['=%4 ZO.,Y/JG7%N^.3L[/C@[IR^?'1V>'HS";#<L0<[@F-]1S
MSNO1,)M>Y&S^KNUO:QJML]&5S.V.0PR%ST%Y<,J5ZJ-;")HC8"),V))+4J)Y
M[NH3G: VN%QZ=B[V]Y\&SHA8YU"!UJP&R\Y!"+0/*4"VUD;/9&A]N+PJ;7TR
MWYLBXT%541=R:=RK[SL5;[Z># <Z)A0Q,1"I.O=<:G#">2"KCTHJKV7SZX?'
MZ.B3P6N%AJWYW:X.\1XN[Z+QJORMMI:8S5^%V7 V$)$YQCROF79UQGJ*X#U9
MS&RX,!BS5+'Y3?2:-';,DY0N+RH$,9,+,IM]'$]O]4)\A64RK;W(!L8F*Q@)
M,7IRH97!#(Y,+TAM@BO(@Q2MH\TFA*^I?;NMD.@4GC_2T=W+?5?;^$G2:]':
M=])#(NM36(;"!&D@X1"BLG7^E_4I1\M*;%VVTX3P/IF(%X'8S<7>&6*?=(AT
M<D*DVK=8U[,';F@_(7E%.;N0B3V,-:\E:^FH[NPN>9^X:R*\'4?5CVP)G%&\
M^28,IW\+HTN<3<KM=;6,LC=[=S=1=P,^-(K"[T'V'L;NDOA^,ALN^YPY'J/A
M'D(,&I3R H+B#- GYW30(HK6X?HF=+;H*OOT.P^71U^3R]GC;W^+L]GYYS#F
MXAU]\W,=VLA+=KR -<N+FP(^I0Q<^^ Y<9+[UKW6VZZ@3V<$G>/VL>:U>P)#
MTS;)FZ_AFO;3Q83L.C)2>)M4J>7O=6IM0%V'_E7N1J>4RI;%YFD^35?0)Q_V
MA0%Z*S#L"-"/4W[+0U^T#PDN)4D$@N#:U0PF!I[%"$RXXI'QK#OH*[\UV?VR
M;?=Y6G0=%UM;LG ,Y(>2LQO1"G)V8\B")1-*ZYD/G2[HI5N^;3#?K2'<!CD]
MM8OWEQ2]<KZV]W"H:4D9:R5]O7U%IWR=KNQ2OS;##Q;TTJUF?S9#2^3L.)*_
M/8MHMHQ?EWD!F&OKI.'X^[7-<E1(VV!^X]=W$\^WX4;#D/ZY,1O*AYR-#X!*
MU420(@GOMA"TA#(Q%FM8Z\&/:PU#6:]@^XE'WY;(0"7+,08&NM2NMY@5+!HB
M)\>X$0H3C_=SZAZKVU[A57US%%KAX';9=FN.-ZG;_P%1BP7S8#R3B<(C40]&
M6>$0 P7>1F7MN-="/)BOL0$,-C"1W=[G[0D':[.\T\R*.^@LVCAOT$,LAH$R
MV1(Z/4*0)@25O5/I?M..+K(LUE4<N[K6Z (PG<AF)XA9^HC)%^>U!E.;*"D3
MR!.+0D'R7A>+15JVB[R<=77,SOK_[@LR:PMGUQ=>WQW"R?C^0AK?;ZWRJHZN
ML]9>92-7]S%HW&".XC9A<A#@F$F$N>C Q^)!6QZM$>288&L_]SEZNK9JBS5;
M9FQ@F"$R37X7(^?+&^= 9U*?TF<;2NN;N57HZI-;W PSZYJVM074J7F[FTJU
MH*UF4?'D#)1<&SVR+&LR9 *NG391ZH3-+RA7HZQ/)TX[A<^60MIUS<15[^S+
M,'H7YE?+F)0GSLC*=<Y,TU**;4CHJ,*B&5=:]<):-9$(2PQ29H0DZED\1@81
ME07CBL\8=/8]*5=HS8/O<EJ>WIV.\1\8IC?9.0/IL.9Q:7 IFCJIMGJ<M-E3
M5%8%Y8R-K>NQMZ.X3P:X$_RMERW75, [2L_\3O-!F>.42#[_/)U<?OK\9OAU
M0?WL._G:>9'J8(*HXJ*@A1;"& */GAB(+##1VO5M1GR?C'VOH-I6[/M!;27Z
MBOYS'-\CWX2L6*)-)S)Y-4IQ R%[!U*XF(R(V9768P*;$=^G\[O^H;:9V/>#
MVH<T*V:3-#J#Y&0:B.8$P:<,6D<CN9(R-9^JNQW%O>IOU3M\;B?@G8.R.BV3
MR_G9</QIA%<??WL=YOB=_JBS]H9'$#J1 Z.8 Z>+!LM,":6@3KEUTDD[ZGO5
M[*I/8&TL^/U5M&*0HJCBH9AZ#!:< F^BHA]3*A9E"<TK"/9=T;I2!'*'C$%R
M3"(3F8!D,D4A*H KZ&M?/4V_8-R%UKV MJ>ZSZ%F4UPV"3DW%WAOPLZ[2Y#!
MAR15!*M-C9P#+::P0DC3F9MDO.5=UZIOM8 ^AY^]@&][&/0F%+V[!'32YTC<
M2[%F(D@;(7HC0:ALM?<N)+U7)/]H 7T.2?N#Y*8PV&]X>I=NH;7-22F(%$;7
MNR@%#KV'H%D4.HOT<%C-7D+4M3&[KS"U/YC=7N#]"5GOKH$68*U2I3;RH,W&
M)*U!J@0^15NL1QM%Z\R\MBOH<^C:"P!W (0.K[G?'!Q_^-O!VX]';X;C,$[#
M,%IV#WZ'878YQ3P9?ZCKG-)J%BS<_#9[TS=M?VG=9(U-YS3=G&;4#I.C2:5B
M()S-P1L+)H= @/ 6G$8!VG,51;8R-V_8_B0QVRK-QR>1/+9JIIC+NB $BZ;F
MT2<(B!H<*7HM;>:86E_DK4Q<KP+])KBYK].ZD=,>VOEXR7C0'&I9!JB2-7C.
M2;D745*0BAM]?UYNG]KY['9V46L0=2*E;KM0*EV*=%H"KR97"0KCO>,,,J';
MI9 PF]:7!YMVH=SMV*#6V-B:^QVZ/N^.7A\?'GPX>G_PX?SUYG[-HX_9WFGY
M,74-9AF?X/S>K)OK)M;?!M9B$E4LR?D(2M9^%P(5A)A*0L62?F"9'RLF>^85
MVV[M19?Y)6YOC8](#@7C1'>T@M#ET9&600:<&<PR>2Z;]QM\E) ^> \M97Q_
M:V_/_68Z?D'*K?;KM^B1T<L8*-ASQDI0U@D(7A%1*B>F7!"6M_8OGZ:F%U63
MG6-B>T$T*9BE-1[>'3_Q;;'203#%5(>#W!"TRV%>02'6S@,*F3.>L_L*X@G%
M]NCS&VJUJ^</G%3$-!O!NL#(8!*QP7$+6GA>E(N6^=;). ^IZ)$^VUZNSRBS
M39C>+N)98[A$-HBTH1Q$K#V!0PS+.4D*0^0"F4S*M YZ.ALITJFN:X^7KN34
M2O/=T^FL)",YL\!-G5^870"?60'$E#-+PL0'U;U/J+PV'MRS<I%:H8O$*NNC
MJIEI#EPB2Y&E5#(2+Z5;T?%<03_O58]M(:7;?0J:<+(5\I[T*X(.+DF*(+53
MM-URXN E+=86YG/.(AK^HU!KK7AB/T<MS27;A)\=1M'O/YR^/_IP_H^#D]='
M__OC\?M:&W9R='X]Z"_<FO'W*HS".&U3%K[%R[:/R%NMM-%-PM.C%.O.=\B5
ME0)LK'VR?2;G)98"&F6*R+@NL?6!Z'/T;.L6/?GL19_I@8U.6&$<)%Z[A%(\
M 3[)>D(5N:6]$%+SHO#G*>J#C6F.D_L^4$.AM/2?KQO,O<8O4TS#!8OHWR-<
M\)\<M>4U[//C2 >.7/R,RD.T/-?AA)S"U6 I%(XI9.T+;U]@UHCV7GC>G:-O
M+Y+NT([^=GKZ^N_';]^2=3D]__WHP_')^<');\>OWAX=G)T=G9]=F9)).:X#
M[#X-:]2QB%>O^_ -EU,WKR?;+7^YN:GMEI[MK?$.^=7(8+\9CFFOO!U^Q7R?
MIKH9(M/)*LM!+%M=.PTQI0)6QRSJH1P+K;,QGZ=H6UW\S-.7%L(5#,S0SC=.
M4A0>-6TZEQ)9"&6M1^YT;'T+]R.:^F2X&^+EOO)L*IIFQOL9JFYI^]M:?< X
M5R*3DR$R%_6Z 2&:Y($Y^G?A3'C9VO-;G\I>&>3]H*J%_)KA[)%U'_UY-?+W
MM\DD_S$<C0;9F\1ER% D([<@B@+D"FBPREO.&??>M'8 5Z&KPSU6Q6\=9VAS
M@"1E(J>]D%L44JQ 8*+HS+)J'3>N8X3V/;:U,6[6V$#K"J?A9LE8GJ;K(0.8
M+.32,P&B.*+-24M42@-1<6>B)_\^M[Z66)?&/AP4[@Q4G0JP,YV\<$,>TE:D
M-:KH!#EJ8H3CB6C+#H@#.KDD.45K'6OEQRG;^39+"D.V5M:F_@8HBI;@?6;@
MA([.%9\4;]V[JHMMMB_=W0!?6V^T=42X"R=[Z?H+F5) R\ PP4C7) ...P;!
M9ZZ4X#8WKUQO$97M2U]W *2F(NKPR*H>M1R=79>X3,I;##.\=0&^^>'3JD_>
M_AAIHS4T.A"JHX(03[_@E,@>?[KSZF_OP[?%2/C7M5<+*0.="H> KO94S;;.
MA^=0IZ0HGXQ/H?667)6V;=71L^_Y.,[#V2+1 C-M,?HJ!8^7]<R6LU@H9 2A
MH@/%:0-XV@; =:Q%@(D\E-:-M#8BM$\6L!.TW5==W8NS7=+HXT0.1*T$S$B>
M+ZEN(!TN((1"?^B<A<X^1MXZ!'Z"E#Z9O9V@IX5(]F_O!KP[BT?/WIG-N[^.
M75L]'K/F/'#@J I)/95:Z4U:02EE= @VV-813B^LWJWWG!#/S__ T5>\FJI;
MLWHX8P$$UN-9*6M6(04/S%&$+D4F-=HZ$WA36E^D[5L'<VO9OE9";6;^5J6V
M]F$X_V,R"#SY@DJ092Y5!RL+(=I<R[>$<DG%(%J7U:Q)XHLTE[L W"8BW _.
M"#@X2$FGB-R E2A!Z1+ !1$AEX+D#G)TH?64AK6)[%/E9O^PMK88]X*V-Y/+
MZ4!B8%S6YD>Z$)6)W-5@*1*ASZSD41K'6O=C69?&/K4,ZAW6UA;B?J V_(H#
MEWE1BGM Z3Q%1M:#)S:!%Y)IGIQG;%^^VS6-?6KNTS^HK2O$G4-MT3OKAM3L
MT&-1Q!>FR-Q;Y<$QTL)">B.MI?!<[4NUW2%T%="9_XF@VUR<'1Z"O#HZ.7IS
M?'[V_N ?!S79,LV'7XGLX?@5CK$,;TKB-C_\7_<-VQ^(;+6F5N4<5W)_,YDN
M!PT>C!?#'P_R_[E<#M8^^O,+CF<X*$;PJ%0$%3.",M82$*0"44KD-DIR\YM7
M.ZQ*W-::[GH;T)L^CK^$83X<A>%%?=_5/^Z_<?GQ^_K-99E4W3!\D*W7**(
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M)1:(EA,F'2O,MXX['Z>D3T7TC7'0@/7].O9<#(2Z6,[W6![X[O3L\^G7[^4
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M^:V8%';U>?TCAAG^Q[_\_U!+ P04    " #NAD]84M[SY27(  #110D %
M &AU;2TR,#(S,3(S,5]D968N>&UL[+U;<ULYDBW\/K^B3IW7@R[<+QW3<\*6
M756*L2V/I>HY_:3 )6%SFB+5).6ROU__)4A1%XH4;]B;-,6H")=DR=P+F6L#
MF4!BY;__WV]7W9^^PF#8Z??^]C/["_WY)^C%?NKT/O_MYS\N?B7VY__['__V
M;__^OPCY?Z\_O?OI33_>7$%O]-/) /P(TD]_=D9??AI]@9_^NS_X9^>K_^EC
MUX]R?W!%R'^,_]E)__K[H//YR^@G3KF<_MKTIX._FI"#SUX0+XTADCI.+,^,
M&$=#TDHJE<S_^?Q7'90(07K"N>5$!J>(]SP2,#9J(R@PD\8?VNWT_OG7\D?P
M0_@)A]<;CK_]V\]?1J/KO_[RRY]__OF7;V'0_4M_\/D73JGX9?K;/]_^^K<G
MO_^G&/\V<\[],O[IW:\.._-^$3^6_?+_WK\[CU_@RI-.;SCRO7C_ 'Q\&MW]
MPX=HU"^3'^*O#CM_'8[__;M^]*.Q@Y8.X:>%OU&^(]-?(^6O".-$L+]\&Z:?
M_^/??OII8CD_B(-^%SY!_NGVRS\^G3Y%VNF-?DF=JU]N?^<7W^TBXO$GC+Y?
MP]]^'G:NKKLP_;LO \@+T4^'7$"I N=_ET_[96M,7Q#((-X$(/BWT"L4KXAQ
MWJ=OC_GNLTB"[&^ZHXJ(GWYV5;S]*]^I:> G'UT![?B#R!5<!1C4A/KH<Q_@
MG(*<15@^\LO-E>_YO\3^U2]C<"=G'\[/WIV^>77Q]LWY!?[Y_NV'B_.S7\\O
MSD[^\_>S=V_>?CI_^U]_G%[\8P7D-U>(C@O&)R_X_U[CPQ_ 1YYT>ITR];S#
M;V^?4, V,A#X-H)>@LEL-(70[<='O]0M<V'_SGE='Z [_MO+FR'Y[/WUY?D(
M%Z:R1B%F.,4OAY<A6!# ,XD&/)$B.^*<I819;U4665/IG[I^.*52]L,P=O[M
M(WXIIOT%NJ/A]&_&QAX;>C&*B6$KC.O"ARY<,BU,$DF3P&0D,NI$O(%, A>>
M@K B>-O4F,8('H_GGBJO!M.1W;YV:ZT>>="_JNK/4;^:&2>>0M __]0?)!A@
MP(0_&L\%?XW=_A#2WWX>#6[@_B_[O1&R^FUW_$!\5>%S^:(:$][^ZZ8S^G[2
MO[KN]_#;X:MOG>&E$5G8Z"+1/F- %:0AP7-#& 5\N;B+3-*FB#$/4$6>/+.B
M/\.;#1R]B#-;&WP>A;9DPPRF-^.U:"50ES,Q1B4VS 54D04+8Z1G.+"]X_I-
M6;T]2D@GN0@X33++B.1<$\\P\;+:6Z.%+G!_7"H\"C_W@ EK&+L!!GST \3R
M?AR07GJG9<X1AZ,4$*D8P]$)2BR+2D1EO62QLN,?/K^FO^<%\$^=7<$E_4KV
M?.I;NJUO<5Q7_=[YJ!__>0N("NHISQ37-H?QD$^*!(-$#I9F8Q-&2]Y5=O 3
M$.U[>7.?]&L:M(&W]U5*8]OY[D??2:>]$W_=&?GN%)R)(G"3B<BT\!B0PM)H
MXJB23D4GI*T=X#T+Z ?V?#U#/V4!WY8%GV"$QH#TU@]ZG=[GX2TJ!I'Z'!AQ
MPN):E31R4WE'M#/9 ZY7D=5._.8C^8']7L&T3QTNMG[M8[RYNNF6??6ST1<8
ME 5L %]*A/,53GNQ?P6W0&U0BBMED(I.X-AE(M92B1D-E<DZA"M9[2E@57 _
M,"V:<<!3ILAMF7(Q #^\&7P?KUF3Y>L6F%-*RR@S\: MD49%XB!RHC'7Q;'3
MR 2OS(R%8'Y@)M0Q\%//JVT]_Z'?*[M*:!3\C<^GO1$,8'@W8L9CM(*3$"'A
M_!4=\4HS0HV@:'YCF$R5G?\<GD,(_*O9NX$P$6>D0E-X Y/_GTYBV"_]+G[^
M<&*+3PC\U_[@3S](EV <* V<",T1+D^4^!PEB4D9!F5]H[DR/=:$V#YC*N\N
M-^F29E/)\R\X=P[/;D;EJ+J<_U]&2Z,.'B<Y8%!.YC-QR1EBDJ*.,A$-5<UE
ME4_PM,^-1IVY. ?=SA,-S#-/1XV6Z=X4:!_[@[$/1J-!)]R,RD[[17_^G(DQ
M$W-)X42)LR*^5\QPXJ27N"@[D6A.0J;:TT\=Y(?-O!UXMX%D^>.@GSNC=_WA
M\-(:8SB7@5A>8G.A/'&<6LS=,4X+WEB6:T=!]T\_;*YL:.6*N?*7FZL%,=FL
M'7Y%2YV47RO410\,SP9O.L/[;Q<Q^?>)X2YC$! @)&*$CQCHH[$<LT"$,#JE
M[#.PV:*!V:J+UL >)NOVT]<-I//SP3T<''Z-P^AW.VE<"7CI1:0F146\P(Q6
M>AHP"\4LUW,GM<W.@:R]EJX-\C!)V8[/&M@Y>-_I]0?CU?TIU$\XU*OK\:MR
M:2DXP9DA.4$@4NE(0E*9Z!RT3S8&)G5E:JT([; )U81_GM)(;TNC11NC)2CX
M *.S?.&_71HK#36>$663QH0%C>'!X:2J9)9E[TVIVJGC*K@.FT#5/?.4/:;J
MQO7???<&7D4TP@#22;]LJXV^]--EUL9[J@6Q-F(JH7#\-CA&3'8IN*Q"2J+)
M/>P%N Z;/=4]\Y0]=EOVO.E\[23HI>&#W9(3/_R"N##C")03F@WB2B4M\=D2
M&@,P(P*-KO9\LPC+8;.DB@>>,L-M7S'Q/S?#4=G'Q5A_P:G^>%^MW'Y)99+$
M&7(<EGT"--"P,X)S&'SM1/@(@TX_?<+8[?/$<>-WX3+3B-S&\3$0#)F?)7%!
M)9*2%,Q2*O"[ZD47S8[IL)FZ5XR8LRF[]=[]V'2GP^$-I#<W@[);-\8YV3W^
M!"7[C2-(XU][5<SYVZ#LVS@+6GJ,%X/3Q:8T$LN4)<EQ)L$KST3M\'XSI(=-
MSQ:\-X=T=8X"GL(>OQ'/H<:$13M*0'F.F6_(Q%'OB#+.9IN]EE2VP[GG@;Y(
MRE7TW1S&;;VQ_QSJ\<_.)GGQVV\PB!V<RB_!)FL]YC1!,4QQM&+E;K$G&F00
M+$6A9>VE>FV0+Y=IV_ML#LNV+KU[]OB5*NVY-(IH!@9-@6%MT!2Q<L? &:F=
MKSU]K7X0OK/C7,C2&N$$T3@-H,ND(65KBN28C=*)9XB-3.J5CG/__9>95^\=
M?KO9S=U/;S^>?;HX_?#;VP\7IQ?_>%.*2[O#QW1=Z9;N@@_:^D;N*@ KW;X]
M09-CS#V81-*=X3_?W=75)(>4B$7I065'),49)40KB8HV" >,6EG_EL(B--M/
M&#.?/+EE:)/P*2E.-.4XQF B"58H8FV6029@,M>NS9^/I*W;N97\_;0<9FOS
M[LMMW2=#>?W]-?3BERL_^.?X\AFGUJA2G@A>*R(E X)1%2<NAA05-2*JVF=Y
MRS#MZLYN#;<O8](VYF^@N.HIOBFZV^K55? U=)-W&;;=7.JMZ]&E=*G@CEW0
M1@O/DDV2T$R!2 N:A%(XF(T)5#L'B=?6O-@-799<_-TM6];Q0A.5F[Y;=I.^
M0N\&/@[ZZ2:.ZYQOR]=#$BI[68K6$\,%.@3BDD^$8R*68LQ65K\V^BR@]I/B
MNOZ;S8*K&;^1RN\GK\4%_M/Q&^%45%S[2,H6-^:["H@U3! J+$U2<VUR:#X@
MF<(Y[%AD(Z,W4#_[=+3X#V]?@E6@M16!W,/:F^!C,Q<N37BVLW\;(<<#B,H+
M$UPP)&=:;L4E0T+"/W !U4KYP.O7]K=.C?4#C<:9L8[9&V#$;_VO,.B5)'E<
M?.OC:/@$[?3"K+4@4CE&L+$@Q>7. Q@"/(BL) O4U%Y35D>W!X''ID[MM^*1
MB@'(<#"Z?.__IS\XN1F.^E<PN%7@R>"L2T XE#?$@B>6:8??>D H7$:U$C_P
MXQ]P [^[Y\7\)Q] >%'!I!5O:!0T'_P5G.5'F*9W<5< M4XLL<3?"X&T&SW4
M\%"_*?-67!B>!R<S8\!Y(B "SCA1>.*MH9A,!6^=R3D^N5'S _A\05C0FLO7
ML6I%5Y?+.;\"?H;OWB\ZMTN+L29DY36)^/M$:BJ)=3*39#1U6B Z,7LT.._J
MU(*/;V^UKFCX?EVK55R0YT(Z@7)8.ORU/W@/J1/] %[UTN3+3KJMBQO^VNT/
M.LG?_4;ZZGLC_WFZPZ&<-Y111K2+D4AJ,[%"1Z*T=TXS:;.?E2)9B045L!T<
MA=KV5QOIY4<,IF ,D%U:X47B/A-#C2+294F\CXR$&)6SFAKJ&C\[?H!G#Q*&
M=\V<LVYJ](434L4ZB_,_WK]_]>D?9[^>G_[VX?37TY-7'RY>G9R<_?&AU#9\
M/'MW>G+Z]OR#'Y3A?(7-ZS V?-#6=1HU!KAE'4>97<X[GWN=C'-$;_0JQOY-
M;S0NL.EV8@>&][R#PBYM#&&FJ*597L24@R!:0I9*!"?%K*SHO/E]M:=ML[H]
M^X1)VA64R/@:"5Q[%;Y#@KI2Y1B)SQQ$MCGH)^7]:X^EE;J,AOSW</&I;,Y]
MJ=/X!)W>\&90^K1,]T[&$;N(64E ,_'L)(9EN#8ZB5&:5$GFY&F(>4[?B"WU
M%N=":7NKH@EG/Q%BW-[HE?/7VZ.ZL\%MV#3&HS45WD5+A"AX7#:XV@J+[PK7
MPF0,VMQ*^]M+4M=YSSX@KU<Q;\7#KP=XAA@O3^/DZ=GO"J J;E4M!-+^5M7V
M/GKJ\$H&;N9EGP,.=,9TS"<2P20B/8;!3C!%J-0.@G3>LI7*F_?+Z\]L5K7D
M]'7LVD1%S 3-=,N%<ZG&EZAB$?/,#).HI .1X(2RTOI8O27"(P#M[D-4<LIL
MF<O&%JV\B37=USB_N;Z>Q(:W Y[*>7.7E6*&)&,QG<W1$2NI(3'S3$WTW.99
M9\^+\9<\YD=V:6TK-M'88M#'&&;T_6.WQ":]5*Z!7!>4#T[;8Y""&QJ(9K'H
MO49%G!62,,ZR4:(TDJR]6;0"K .*XYIR1@.:Z@LA/CAP7P5B0_5-*\#;39U3
M==>N2ITM_=+FE/.P1,L[&S0N>P(,)3(RBU #)TX;[KQ2QE<OI=T9=9;40>T#
M<]9Q1T/]MZX?G.PQQQF-QA$5'>!:G#GQC":"0U;22\^LJ]V :0;"#J3X:[MI
M3MNM36W<0#WU>3^/_IP<NTV_? -?H=N_GA1C#4=W349XL"YS7QB/0"$8#,R$
M)SH%"39%*71M=:N5P1T>39KQ2P-SQNN;3K=<9)Z&V=E$ID 1 ,&)I-(3JY@G
MQB'+,9H70&LO*(\1'!X5MK!P(]V=KLN5]=[G/]"NXT616J%"E)2$(B.$D;C&
MR0O#\0@@N0"NM*]=(OL$Q $F*=L9N@&UWT> ;GF]"J2&4I Y<':3<FSIJ.?<
MOH65&YCJYT'35+/ 2E-B7YJ.)(\@'<Y&D*AR(CK+?6W1FM8<OR1A:-[OZQBW
M<HGD[_TK..]W)S+DC[!->PB)G*A-AD!V$5,A8XF-I> [!\H$BQ+8[*P_;U=R
MV7/:7\ZW=D2_(2M6WG;&L*5H8@[FP8K"2)IS)!F**J9T&%UF1PGE(6BP05$S
M*[8WS[G//.+']FLMVU4^%?SD>Y\G&Q487'B7!2.99D%D8(X$)4,Y"6/6&H[T
M6DG/9<DIX-T##RC^VMR0%<7O[T#<DFH5&!7/]!\\NOU3_ V-/^N^+2S7Q&MY
M"X='02'Z0(3"Q$T:EH@SX C-";RWS+G5&F#LVH'/',C7]=\Z!JOLM_=HJ:N;
MJUL@.H@DDP)"QS?<)"X3N$08(B@BPUD^B]5.YY;=]'OXT'8/93<V>[^&S:K?
MU?SV  B+SEL></H/OM3E%2GXF )Q3D.V3"H?ZES3_/9#.V]CF[6B%#0C@!.3
MB['T:],"RN*N&2)U.+MH3GT*QN?0O%+0;O7'6MB&JNJ&!OJZ+)7"607?48=L
M8X^NJRRUB3MVH4.6A16>"4^89@9QEMA%.T>4,B('YF.@]B#HLJT.6:-L6<<+
M#>N0?8"[4C+CDTXV8X:/@Y4B,&*I,<3: )Q;FB.O7GTY#\@>W.;;RE_/Z(YM
M9NR6]<:4C]*!XR1&6=1Q="!6&T^4D.66?/8FUN;!'NF-[2;VV,CX3WFQ=4.P
MYX5PED,[ZHZMZ<*UU*76MW_+NF-12DS$<)X,8Q7%C+F5HZ )3](B,."1-CYU
M[+'N6%/,6,?LS51DEHKT1<I6T4G/ ,=JI+-$2IJ)3QA):15,!I4A ZM?C/D,
MHCT(,#9UWM/BRUJ6;R#(&'>Q07B3GB-=WQN_!"')G+5D)  31)J,+X%0&/EX
MIR+3.3I6NY1J+I ##"RV-_A3%FS=)?()J%O>KP*KL1J;N9!V56>SM=.6T6 +
MBS=2;S,?'N#**$12I0"]2#"GHK67\!T :[140M-4NQ5>JT186G?3%@_6,73E
M^IMQSZF3 8Q7JM-BU;%TRK3H%R.B$)6B)!JKB;0Q$,^\*,=KI8>1=A!7T3!Y
M_BF[J-&HX(A^(U:L7'WS]EMG5#JDO[VZ[O:_P^"W0?_FNG3/*IW%?'=RF[$[
MO2;Y^F;8Z<%PBCM19A3&)$0'CEQG69?+JI+08(#KTL?3I16\OPV&'Y\;K7F@
MZ95A?!G@52^]&@YA='IU[3N#\1V!+W[P&8:7SCAAA32$NR1+YW1.;"Q]ZBR-
MT?D866ATM7@>7GL\:EAAJ&G7-)!VW ,ZR^_ZO<_O<&J<0!U>]%_#F\[PNL@8
MG>5+FI3@1DJBO<8WJYC&YA0(RQAI2R9"L+5[YJT,[N 8U(Q;&M&D^ JW$DA(
M<X8AF*%&EV1,%\DCX3G!?Q0(SH@J\P0\Z_JJ%(\@'!P7MC%Q Y=_%LQC7B:;
M2BINN0A$9EI"*!U)-BFQF)B@U6\ O9#5I(+!&Q G>#A#G?9&OO>Y$[HPF:).
M>[=FAVZ9M]Y^NVUT^EN_G_[L=+N7(D>3!(O$468Q:).4^&@9X4RQR(T*7-8N
MV]D&[\%1JC7G5;R"5DSS,#0O!AQ^Z5Q/M?<N8'!U&2!;%2PE+IE<L@%+;&F(
MQJ**F47$&5>YD;+L.0=#B.I&K5C_7K!]N"F(SO(;_WWXH3_J1/BU/WB4K5WT
M3\K:V#W_TA^,WMQ,MO4_#@ )GGX'WQU]F8H+32UVZ3D+2<=$LHX8<N<$.(=Z
M0W)*0@DERQ;2"B1I MM!$6OGSJM8:CAY47K#FR* WAF.C34\Z[W&P"P5C70$
M/8R#SK@W_)O!S><B/Q<5E1B84R@*U( !6Q :WQH:1:0@<O*SQ6/SIZ(U'GI0
M]&G.W!5K0<9VN G#3OJ..?X=U',8C6X5R&#0Z:=7>02#DZ((?.EU#-X*2TPH
MXF;C+CE@- F9LIAI\EK,QCYSY9K7>>A!\:(Y<S=PH'=K@.$GB-#Y6@XM/\#H
MY&8P0*R75(!S.AL,W"&7S4H@SEB,XVV.&E*BCM?N//<<GH-A277C/R6&VV;"
M0%R#&T@?,9.[\A%N1F67^1,$/X+A%%[$58T"&U.6$UE4"T.V@3# )4]39:E=
M)4A9X5$'X_8F3#MGRVRK,Y^+[]<%48FK3WO_ #\8GN5'T<^C^.CY4,AYHY7F
MDB#@(F?),G$Q9319MB:;F'U>Y0"P(J2#HM*N7#6'<LWI /XQA'S3?=?)<.D8
MYG*8VY/H<A&]Q? Z"#26$4 AN<B8JGW;8058!T.IIEPQARY;[_'>[?5$A^D^
M]8F =67#66)4S<$0&BFC0A=]WI4T!-;@Q,%NNFUDU#G>W7KK=@KD?A?P77\X
MO!1,:YD=CBB6ZAF> K%)1@):V%3F+YRU&O+U8R0'Z_DM##Z'!UN+>3W;0(N"
MU\P&3R*EL5SD2L3JR(E!9"!==B+/=L [C*YE+7&BFO'G,$/M2?NRRYDPNL$&
M9I=L5RW,9@=Y;&)V;&)V;&)V;%RU+_<=&FI<U5#KHF/CJF/CJF/CJF/CJKJ9
MQ;%QU;%QU;ZZ]-BXZMBX:K\:5VV]?7QL7'5L7'5L7-5&#+E/S#DVKCHVKCHV
MKCHVKCHVKEJ#)<?&5<?&50>8I-1N7+5US<.Q<=7\]__8N.K8N.K8N.K8N&K.
MIN2Q<=6Q<=6Q<=6/%7_5;%RU<7WAL7'5L7'57COPV+CJV+AJGNN.C:M^9.<=
M&U<=&U>UV[AJ8VF3Q?B.C:N.C:N.C:N.C:N.C:N.C:N.C:L.+/;8K+=-/1&K
MA= >'/8>&U<=&U<=&U<=&U<=&U<=&U>M>+!^;%SUPS>NVKH7YK%QU;%QU4KP
MCHVKCHVKCHVKCHVKCHVKCHVKCHVK]DR4ZMBXZMBXZMBXZMBXJ@X7CHVK%CC^
MA:PFQ\95Q\95Q\95Q\95Q\95Q\95/Q2Q=NZ\BF?^Q\95.YB7CHVKCHVKGO+B
MV+CJV+CJV+CJV+CJV+CJV+CJV+CJV+CJ!Z%44ZZ80Y=CXZI]=/RQ<=6Q<=6Q
M<=6Q<55EX\]A1OW&5:]._NN/T_/3B].S#^>O/KQY<_KWM^<7IQ=_?'K:R.DQ
MKI5Z5:WSZ5NWI]IX*%MVI)HZ?EI%]"KBPC^<PK]EE' 9T,$,UP+M<>'7DOC,
M&/$*#(V<&FOK2V<NQK-U=4#\ NFF"V=YSE.&K[\_^&Y2T"VL]@FH)3J4HP8K
M(BGE,82RJ!0NCT[JVC'HNAB;[GQ5G2=/Z@F:=,J\$I,VNV!-!SFID/'=245?
MUP^'X_E\[*A2*NR$-MPX3\"9L4P?QQF6*9+PK[7-H)*L7:ZP!%+;5RS:H4._
M.;<T4,WT#+RIB.\* !NZB+$4W&ZN9%1UZ>ITV<(?.R&.HLH&QAW!3 _?&F5+
M[QEKB;*21H;O$U6U,^D=$6;)U8W=\F4=-S3-D_LJSM??B_#!A_YH?*)5LHT;
M_&N<Q,?0IP7G -S'4N".T3\OP@J*!"DQ20C@ PV@ Z]=-;4-WO:O!U1V_W/D
M:M)W391Y]V*1H1WYT3C,>NV[I>[B_ M V8)\E=+8,[Y;QH!1VLT <.5_-. A
M?L2D$&S^.,?O+IADH^- =*:W9VI6"D,L=XY9:I2BM6\OMS.R%Q&<[2%)&JA?
M7@MPJ369WC%: 78;D=_JD'<3#^XCBYZ;R1NF0--!Q!KP66 N*!\)%&EJJ0,E
MSO.B"YDSCYPJ'AL-07?-W"6!Z0$3=QW/5[[$_!N:LO/5_]X?7M]W6G51@<JL
MM$9@GD@7) E)*R($QD*"4_OT+MF\RH5YG[WCJ+,II_0K6K2!^/(-A-%IK]QZ
M+*_.A.<R>)6")\)BE"TS]21H1@G-'#C3^-^3*NNM9YLG*%Y$W+:E\1NX'/08
MT<,5= 5<3051"S#M:-=L2Y\]2X$M#=Y$R+((GXY:FNA"N4*$DV!6AI0VS"0*
MG 23L11?C!^:",MVPUKBP3IVKAP!E *Z=WW?>W,#9W'4Q]6JN&2Z+R*I9XY+
MHGA9MV06Q+E8N@5$)9*F4JK9HI.Y-8S//&,'$4$5+_0;,&$#2W^YGCY"?&70
M=^)]1F=FN+4D>P-$QN"(US00'I,.+H./K':J,0_'BUC^MW9 Q4N:BS#=\G\5
M5 TM__,1[6;QW]YC2RBPA;D;6/P7H%,A9ZJ\QD1%"B+IN.$Q3E[<<4R#P<7
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M!O"72<]*CFS@LNX#*.LM \Y&;UEI":>H(M(P3YSF$BUG7 K9NF1J[R5NBO6
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MB@H$<1EA%16O"-J 3;7W:O:BRT/SSM_2V W<-W^ Z $G(S6<I6@)V%!NP*J
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MTGN]]_D"!E>;EY!L_JRM2T8J#;-ZB<BKK_B0<I[Z:W]0M%K. </^<09P'Q\
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MG 0##I^9P'@(#IB</<B?C7G7>F#[*5$=__2;-F[%C;L)2$6?PZBF&&F0G*:
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MW\8,\K F,-FR^9<P);?E, E3<@\N$N41( -F%*U]D-HZ-98$EKM@QCIFKWR
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M(7EV^C%7#7^:FN24-W]7Z:A)S1=_WHB9T):R=,UJ'O=<"A^SJ96^G!R",BD
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MTX61K@1'43PWG (HY0M$E@(DY@OYW&P$[U2V>S&,/H<*0QK(NV'S[<-W^;N
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M!AW FUR 6R&$C]%&X;?9D->_YJ4KMJ44&^_ BP)Y)3;.5X0Y)^-\.O^!T]5
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M?%Y:W_96='NE;R/7QCZ:0,TI01W^HJRTX)7O>CLY^QG&%RM*))^0*<\@)ZE
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MH&C!T=91Z=LYQ&+JP([L3/+&F/8D2YO '*NO;B/]/B:<X8A^]/WO.": (]J
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M^U@B*O LUX%7QD+DG"1&:4Q,3GGG6P^:: +\59GC8=3;0S-<=YD-"JJ2H_/
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MF+)(CENQG4VA2^WE6K?":,HM\\W49K7>JA(<X.X!=CH[E'V*/?RY+Z%'\M:
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M7I0)=>MPAVFX[:B=38CE@WWUZ2H>*PL/[MIM=L_;[)ZC['?+W!4---+( JN
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M!#-&#)FE"[0^.LAV)"?7FNS\X-/%:'[V]FO*&E/3E=AB=BRUS8@I^>K0H>O
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MO:Y$7*SKB7XZ,&^^"Z-RP-^WZ5JCHD'N;-9>6I/;;$:W]DH$X@Y(]8%Y?T&
MT?!Z@16+ AGAJ.E"9X]G64-M77ULIR*#!F47JM)&Q^OYP<< J5P7U1FLIFBK
M0$UX4R"#[D1F,]3L;)GDY6,8'6NM^;28E,@H_5RG,2U-N&>OQB5N%D+.O"3A
M!<K1]#YH7<'L!'^KJ(_T!&S#(28A3UB^L/NR8D@(@LW@QK&1R(VWZYO\&XLG
MEX!F4?N_VNP)^:AUYOQ!-,?'2UA7#GU@FJM OB(9MS+B($5"('=G,IQHR+E<
M^C#LF_;<"7"\M.US3=6 __/2BNN[I)MOQ/U:YM]?DH"L1X?,C\GQ]@NKU ^!
MH^F\; ZF0_5-AKX/;BE4.+9?;6V4R/UZZ]R'^6_OQYYICHQ\BNB?>3\/Z3-H
M%,@P=LZ*O]&? ,O Q/.$)1Q:NZUVYM$JP1GF<V5JOH_NQX*J'6E:<B.FBH?>
M'PP:,WREJ7$D4=-K1NN/Q20.A=XN<@V!F0!?[X,8& @F1Y/E_OTS\?^J'4C_
M^4*!]5H8&5I'HY'HC"DS,E\2I&I4U3(4\ U["V8IRD3[<(MS(G4(GYG3K9QP
MP/WM2>WCZQI5DU^A(N^N1"YN?;L,4CT)^GP#?/E>80$E9#XY%H35;BA)O3-[
MJ<" \_YVM]+C%RUO/Z),+^4B;S9?5'-W:4-<L<&-X. XLN>TIPQ CCL:SHP.
M5TPZNM9^W'O@UE$T)UO@T&"XFK:KGJCPZ.2)Z^<R3CO)N7S[G2U0[A/)9'.T
M13*?65'[%MH*F@HR'/3Q]=@Z6'C5L4>)@X_PQ=RLZ7-EQ[JVQ)[.64=O5O)?
M<&$XO_GKJY*J']#UZG//^.9$*E8F!!KD'Q3X#A),2U:%SI8TGEXX?Y5YW)?N
M6W:\\:H8.*7")/1>6I* ]"2_,H?6(P0ZI7Q[45N+"A?3CAK=_QJ=!JI$IXAH
M%7Z?HSY^TE-Z5G!Z5XS<O9<]6TYV>'>X/DES/)NL64D:P7(.8"%3\CPA@(#A
M&XEZ%L;+,J52B"LA7B]E^MFW)ONJ]'=+_:_F[.I_&K20K0E2E\%C\BH1+2PF
MF/)-\"3>GB<.2SC$.VOOW LMQ*9N\K?M;<%?Q)R+67/K[7ZLGXKVKH;E^A7!
ML@<MEDA!K[@A:8+=4Q35<.(6;E;=J?OAOU_?V<2KK)AX$>!;>>-F]_I'M'DK
M6ROE\3SOGXLROL,,S=F1_=N").AN@0G5AULHKESVXH;B#)@]6^(6-Q2';$/!
MD,L)Q0E4SIJ/]O$ZWHJ!H^34IH'R).)&XT<I!1A^$59Q1W*WAIW$F140,O:*
M:4$=\3<!OGJB(SPK6L"))@8<<)FDQWWM\9[?WI/0GK6<<4_U;R%#7]\XVHB!
MEIDN 7SSI:]!JI) AOW0BJ:W0ICQ=>,$UNGMJI:!.FU,FH/1[J@31T\9["]9
MCOD0%..)>"+9,G\;V4>!DFM8R+9 'GGD .^C\*Y(ZGI6U$:,C,"M6 SLPFY?
MDPD5]'IT2>1]OX>J$0,"'7^^W=$65>(D2JK%_C,G?@R5SEA1SIF;H0D[BYR#
MG?)T$'F)Y\*%TG<3T X4UF<*YR F@=$DK$8SDRD*N/6W42U<5"M6_3!4=T(E
M)GKP+<TN4%@0.33?/@]M&1/)P+PKWDZ1BYE:^YQ3T%$ED=<.JA.4*T)C%7B_
MWN>N;?#3L\EO^51EGH*6$VD1?-Z@VDBJ1-U/ 6L'WO?=*(.27"[S)FJ&+5Y5
ME7^[+4^^B*KUFA7R=X2AQF!H)]K@T5U#ME)%?3+X_&&/C'6?7'U?,+V"L&J$
M(_#$<1YD7D&IQ^"@/5%BX+B;%77K%YLX^S.L_/)8UNA#%)]+"UQ_,NEG1G;X
M%$:@V,X;@% W*$?G(=-AFOGR3O7-=,/.,5=SG9&[V;^.)<X="RV9M7A:,9VW
M#76[UFMZ6+ 6Y)P.F?UZBHU*% ,UI#G5TFW@68()VZ1/9B;6>.LO4M3RXQ=Y
M]&6:'R_ 5&^2BZ8R?N#&:D0RKGP7@N$W,3 UCQVT,R@V?!/U9#A&F'3FBX7F
MBR5O$)],"?'\TR 51506#:(4CPDKP1!TRE9R*X,NMV='='8Z<4EF8.X/)G'J
M4-V+]/T-1U2]C_]Z^>#1MX0['\OA;N>AF6EO! X%; -L_=>"]1Z$$F?,BO"D
M ^?0TX6C=15%-E.V9Z<K)7I/;P4%JCM%LM[\J-$2."TW4)C7MV;EL9ZQ1$E<
M'._*6\KCZ.K&UD)3RXG";U_7OJ^ZTK#]9083\(;0<']BH![^:H'3@!@(,H=,
M^]KMT:R&E$UR%T)8J*Q)U*1H*3=]A43$92F^V?L+^6E1%1M>$:X9E8^ X1C(
M-%:@;,US?H9=07 4WM]H']$Q6%V:G2A8ZAOP[FL0KE&AX8F2Q@U*<J_%_9_O
MO5(B0,ZN>7H$;[0&(9*=7]P<S<WN,%4+RSTG4B*8U&2WB=3V5VD>)?4LC?NQ
MWY)L6+!RBPV[^;L+/-J\B/THSBY4&GUXSAHF]3>@W;<%WA"N:D\(MX"*4:1O
M*U[WY"+R1JU;5(G5ZP>-G?=F?P$):Z\L&"%@1[83%I=7Q4"D&/B!'8')?7D4
M)Z_=VL]7L$=8$;/Y":D'W56H>R/B6A3%LL;*J2.#6WB8PKQ,44*'RWC!/"*Q
M&J0ZM1@2(K,\D6<X,^WJ6$XJWEF74%[]^.B:+D;3&DNG]\>OY&&=B%0*YP!J
MU%4DNX9ETNO%=,XP,R4XWWF2W(5"VKF%1Q*VLYXEC 5H]UC;#B*O?5>/#KH@
MT;T$>=M(ZA48G#W2P',59@I@*K6,--O M\4[M]9':;A>YO#2590G)-[T;=&+
M:C_I$*:9+57XX\M?UIV1:(C+-Q:]1M<A!/I8SAN*M  ]A81V"K:K-;!(<Q/V
M(:(^2O;7O3<$EN7&(]H76FFW_XWBZALW78U9HIBX; 9K0!R$47 G#EI+FG-E
MHZ##YX=G^3@F2=MY76$?&]$V1N-\?8*#T2Q?%%7\MG ?\4?WFOA3;L7XJ#MQ
M13?RMTSM'W"9E7QP(7>WO31 / <[' 4[_)08.$;ZD0UKG-^<A3D$RS;@& <Y
MARJM/=_4@4XT/=VCY+?7:<.PA#XBUYY@PH-!+>E^\W;^VC '?0C!Y8MDYMCF
MTL0W36[-<NJ7S0G^Y5^*M>NL<NZ?BZF@[S%P6?HAKT?AZY&7+<>^?D?4$4[
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M@5_)O#5P2VT%6R YKIUHF%%'[GCN.C4\)T.X0'8PQ ^I6H1.Y_'B]6"I]^F
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MZ#P-7XD$R00P<CR!"L^ \%IN\<([C!8:L_%EVD&+P'?G UTP)LJ3#^/Y@!V
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MS6^6>?P2"K,/W)7C['7QS/2PT^>S6P6?BP1_[@2,H0*>A"4[&-?FVKPW#KS
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M%4]%<A396S"[FHZP"(E\H'HA=4/__&9_WE?>R_[?/_<[]&J5Y.XRWRIT6+2
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MA>J7A #O%[$)\:5O?ZZ9"@N87_DOK-'Y?_;X_Q,>B3=)M!("Z$$=J>")?R*
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M*&7NC!;RS*!YEMR6W[V("<-3A<!/W B.)Q4">8)D^Y?0#_CA3T!CX8Q+#_E
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M8,/N!7@_.E7:$!P<O'?XTS'O+?MRK40:&[44(9*Z *1*\@$A]R<4-,9>Y9F
M)(JCP7JZ])-D=7"5CL^QUV2$I+B.+YF?GPHYW&7=XL4KC5XMB\L?^'2:_9G:
M]N$VQ9X/>;FCE[3\!]H+ PU7.PCIY 9"&OPT4YR>W&6N&8#>KQ8 Z%_F;J(7
M)S,<(CV_JLUIY_:U%&L'UPSWO6P[FO'G]@:AGQ5*OV?72]EW_ GC[@60E&5-
M;,<V/N0T5-2F !U6"X8YCW+C@;NF1AU-TJ_WG>T9^11BE+YZ^W)QL\UIN?MM
M-6LOX'&#4A@*7H8XJ+: %T=C6>I!XTTW1NSM:.89;1J[VUX^VJ]=%%.I?C3"
M5&-[MVZ1HY./V(4($>')!P2AM70^Y$Q]"ILVQ'5[<HK<8-ZSG'X6Q'R9D3@)
MCM)&AR)'@XXFA<7*WYC9EV>T?$XI03O#Q%ET=>%_N8I7_QLT8^->1]DA1VV4
M?@"(9417>MF$##^Q7-N["Q]KN<EUJ$]H*:EAONG4N WK&G<?3 )]!".7X6@B
M !5G.#SYLSP_V6IV,L<:O3P].S"QRD,LQY=!N,&@-RN=G2-@R.>QIY8S^1 (
MF59%C6:1EK[=1;EU7]3O1%RM5!DY,'[1NO3!J1;%']C8X#MF#5->HC5H0QWF
MQYS[4H7Z2X.=GK"TT"T@E@Y7Y:I>W?O!?E>9@DVZU:4M-8#,[O/YUZ?V6W!J
MC^9Q:S<J71)%PU@X-H$%[85G5VX$>KO)H'YMMS%5(Q;6B,<1'5)HO(>TYI3@
M-=>%U<[<]V8U'B.57:V'Q%[:"(6YYCUW*[)$UF!IA7@!W,'!C^-!?95.PH0%
M Y=S8K35A6XJ>Z(^).A->*9=>?F+92V)3ZFAN[PZ,H*%C>5VJ79#XLF;BWEJ
M43RIWT _;0%;@TIFHP&'^2ZXPI;?#,<MHVBFOFM.KTN1W9$Q,Q7[_*&G2[%X
M/B3M^GJA7CZ$5L6'$,V90O3!R2FVHN#SS$FN&<OM<NO6Q&HPN3.H]S*=/(+T
M>LL:/#_RR7UX,_>'Z-T=RBLGXHJ%=8O7:X]:\-313LD@A1/$C0#\'E:AZF;-
MNR_MY4WM'W\<WM3V%/A>GF_L0BI1$:K>-C;"#'9_A[Q9Z>7%@K/Y$'  P+'K
MQ^!1S 2>Y"M6>5?H9D]I#ZXARZ+=3[GE?D6=A^[^$>?=Q*=\2!3QG'*>ZK',
MC\>6#MU+M<6"NOI<1?79*&8AW3P;)D(^#<M0;I,"OP%N70W1L$WGXRR+(\Y%
MYM00/Y@^&V@VON(A(73KX,!"MZ831[8-LY;'AT3R(<HH?0:YFSJYGCHG<\M[
M="R+%#S\W9QK%7=!LY=M=N/>1].2BAC+H6*-\6#TM_O1$]7^SW>X#NMZFN"=
MW@L=@W7!)E-HXIT$>=*5-FWTD>&?^1Y;/8+>?7>5E7_A1].22;Y16H?2Z;CX
MB_[!:E B)IDDNO?6]Y_@YW/B>UY<O^TC/D 5(*9H\S3R9L==:%@6O;:KWMC_
MDGG/(6],R3C,TK<\R>?CZ4V#]V._P?]#SM.T03J5LN8X9W[:7KIZCV74CG[9
M6PK/\#Y[/_OAV4F"N77<SH=0[S@I_H^R%=?A_V7.)LCA?YUS]0EVO6S2CUGH
MVA_%__"KD/?__2^X_R#>BW^9]\E'%/ZOT[8^FO\/,KO]E?^O_'_E_RO_7_G_
MRO]7_K_R_Y7_K_Q_Y?^'_+%(111F);&I:?3D!0VZO+?NZ)\<D]/5QUD378]W
M*^5M, KZ;ZAUFI?-P5+?JP&EWI>?T-+<C[=$7R[:]=G@7>['/K\=/>X:F]2*
M5UWU_X?<O%7GWTZ9;P#]^1"13VL5B=A)9\9\:FLL0\;8(R,T&"$.G@GN?'FO
M0-'B8-+4Y)VB@/'SSPSMVGP^:J<ZS.3.HU59^GM9B,Y+^HRUQ?NE]T^%:J8'
MW"+4'@W>I7LY:IL;W<G%GG10DI#>)N#S'909$5!'K[0;FX, O =Q?_S;7SG[
M9HZ-S^8O7U$VM67<8CNCXP*[.X/<]Q//[:[K>WPOS.3-%>&?!W,' 7QNJ\TL
M63JFT@8X0XI[^$WM'5Z&?>/!Q!LM];J8:QZ*#RB9?JY^(HDB_H,7<5S%D^^@
MZ8>XO@!YZ3>#O/E4V6!^XH TG9S&50A[]:'5%WE_QC-F6^TM],W3C_L[OT>6
M>9N&%7U:CGI>L WRYU#N;SA;5,"2"2@=]B@X,DN8\.^%0>SC@"S&,N5E *%U
M#\"'])[=&UG4>>B.N>F7RQ/Z5W?ND]X(I;H>:6E>$!#FM!O8#J\V.<%WWM$&
M[64E,'HI" U4@73=8HIQ0*LI?4*/Y%&;H(&(;BV.:VHIV;SU]NN^KKC":]":
MZ+NM/YS!%7L/CC>(8R<.H8TB20 ^_?QT5"A+XM7OXRWDYRT%DQTGY"N6YP('
M+)H!WU#H]=]5J5#GNVUGU@1V3;M/EEBOE#65LGY1?3R-IP;.>HZW:8 GQX/&
MFA!*X$4O,_4K+\[+F[;:J)_9K'3-^K=.7A+DUY-Q=MD:H56/8PM6MU.EXNQU
M'J$:!8_8E.A9!]N ,G<IVEQ+MGYZZ>[*0F#M^=R9L1D3^V<-NDB7?873/JD7
MYY08L(WP.&/3%/;U4K8=. +T<-KQ\GI ':IT3T/YH4P^Q'N<2+RYQ[(YV?<X
M\5I?WS.*2;S[79=$V2O/V?_B&DM-85?T\'9= ]V,0]XT\6UM9]=NKW\YK 0?
M$D.>\F2X+7G3<)DS-L--@YEJH@6U3Q8PI@#G6_RG^@DQI31)UMDCU<;+1;M6
MU%,OOA<?5O2_S)O$DS*REDJM\VDX$<Q@I0/XDB7>E30R'3TC!";<,^T>GFCW
MC7CULLPUX#'SQF?WKB+K4#>IW,_6,S8\R5'!*HD#;04_15CX?$>Q?J"N!R'=
M9H+>'>ZX$SS!DCX8'.<Z++Y%[ZU+0,X=O6O*G=?"]_J?+FQ,O13B<F&Y!X>#
M 8]:DP$J_4DA'<&L#V.87\5[-)-49IP:B)D]7]C?U][U?BIT.RUG)O8[*L/&
M#(B=0TS6\:3SJWG]9T/0@>2U=(P%JIA66?SP7F4CB^ R8BIV\\X]>?67*1>V
M!5^]ZO#9:%JQP/#<1B]MXFD:+,DW *,,%M(&-=!6(QASE(W_;D)64[ZL9MA^
M\DA]S<V90$^),L.3^8JOMX$3@4>/-/1!%.)#MW)4!";KP5/$?()K8':BH2 2
MF.T)4J)VA/A[C:#WQ,]JJG-V>[Z\VM1R8B[XQ8]"I;C&6T=56]N3A%Y#_ICE
MSL*CR?D7Q9?H@'H/3*O5*\QT&G\%;9?\R./$F8\EO^[D5)C>I7WQ.&82#=%M
M?  ISOUA/H7D24G2!D']P24\G.G"<48;L"Y-?ONSSV9W3P8M3BLD(/!@CRZJ
M<OFTCYO:P,ZJDLBKJ'ZCVTH0F)/OL>5.<G89MMO\"D\=;(R-9%M7Z@#,2H+F
MJ[>I3:W)<KH=@5FJ/J!^K=(/QQ>"J8L8RFIGQK)[P 3.=G"DFRIL;Y>89&6>
M_<=TNO16XHD8X^[DNL"898/*A4[E@KW#%46[770+N[5%HR!_%G*[P#@6K)V\
M&0.+QBNU;0;OC@0#\SF6#ZQ,H?X-Q>=M2HI==7./..8]ANZR7Q&J;_D7MY#*
MR=%4T)#4"9L@LY^#OAQ5\"J=4&".]F E="G$7-1J5,D*)PTQ)PU* @,)^A\;
MG]7UKK3K=:!W')(@'%J[3XZ!0C!OL!+FO!UHYX:Q1.F4F#M-(T1SF1AO[*-8
MFY$^;5+#LV;OLI2<\(BC>U)M(XURWT+L_AC3O2^3@6-4,50U^QDPOA3'">3U
MD)5X$%1=[U0OI1R?_>?\!DJ7@F'OQ# J/,(S_<8&^*WDG7?.#JJ1QZC$K)YI
M*#L.%)^%XD*U1R+:FH#2K"=-\*6IR*[Q%1?5Z/J3-!X[QGI?NKBY=IX&(]4N
MR/@+=%(PJ^HL?=JA7CH\ _NTM@N9YV@Q<C[XDG.O&HQ22BH9I,3I[O5^]CKE
MW)!T>9'L9U*FS:UJ0QW=6)-@#A34)S%_ W">E#?'.H W3-V@/1IGHO?!S'(@
MS'F<*:+RQ[%:"+%[F*YTR_G!^>-'LXVUM78Z0=A_C+\LJPKL5^!X06>>U"8:
M#-17Q,N@S\Z8L'X5/$R)8$@/RKZ.J.Z6R7C\HW]N,+[AR<V;2<)2]MA=VPZF
MKNDXB2JM#.9C:0\P:D!4QPC+S@L4GH5M/M7"A^":!F70VP%XJBF9^ NIXG8_
MQ#/6L>:!GV4346&/,7'8-O_$]C9VS+#%(*:3"@2:9R*:QIDJ3W@],"5L%!G&
MW03VWOF&G4QO1\@OZ>1Z>7OW#73?'FH([$R3W'SL2:#-(ULG:,-7@@38R#D7
MTZ:V5HVE7W,4Y1I]X.FBW8G ))C5=='UUL.I@ DPY< %^^?AKUX^/][0;_?9
M>8-Q'SWPHV[8A6_D</(DE9[,S <8G%Z\[-8/EIP!\2Z;-BU65L:OOD.FGI2R
MT=N5(6/X9#6[N_WJQ^<TAT:'AFX%* @M6/Y3?O10^?5<N8) =AEM_(^RZ>]:
MR,RMK(3V4"N6V(V:3H(I(9UK8TH/&>Z54JVUBV/ZO#:);0E4K* :G)9WTEIV
M26C;"!;?01'HCL4LS*\1SQ$K<]F.QP?&1Q[5WU9P:BS6 :JT*X-K1<8[J,I8
M&GUY UJ^J)]![B* ^O.]:\:TT#L/*+&QK)[53FGEVZP#G*UMUH\9=%-=O2!;
MS:.?_0XUE$3L%?JC[Q(%>G>'JK.H&<1!== FN/G#S_PH[TS._@^GYZ RH\0^
MP9H\03'6,=ZP.\UX_I4;3VI'E'C'0XP!B%@_29MGY175T_(E Z!V8"1WS"R$
M&I!&D'K$XL-OVPY8^T70DRV\]$L:7I]);OSDM@ERR= %C>=L$)B8?ZL\YQ0W
MAC6^5#>+2]6R!IU9R?3IQ_XS6T#L[/.M%AXG#'U*2WXX+15WW](6S11?KC8*
M"4Y$KM]6)=/N4R6PM)M4\5GP!2M,X #LW41'?[VZ\3A4&5@JFJH9>5%@3@SU
M:)Z<]MPH]R[\\TGKOC[Q84O?4$,6G#T-8H%TAC^.:SM[R90&#%+,L_Y@L[G!
M#%3$A4J[<D[YS=,_GYN&Y50ROK@T)4GDDRV"M:M5/Z1"8^^2X40":-Z;CE9A
M+7?")-8SOWUTGHUJSY=FF#TN0UY&)[-@SFFFCM^9??+.B7/[>UY/&=_0>W.F
M?\GIG>,(^(V%I^ ;5SN9P8S!7*X#P\&OUZVQB!$+E0(OSAY^=5WW]&?=[<9:
MN9C(R=39A(WOQ4-<4/-+HIQHU":>E I'%_1F=X(1]+A@E_?V)Q/%AG\RD]^H
MQ/?&/3@V\?WZOG>Y;^/ZF7['A86*\\8;WO_SMJ9N@8YKX>6M>W2-BK 06ZL?
M64OS @NU -TX7KQ)A +\)%8$;<UJN_$$O?V]2:)#\F$6,HOJ63!WIF_[8SGO
MJVGW5!'HPMYKGX3'4AVOW6V%LC^LM9K PU\0D2("E(=F+7=3LQUUFBL770$H
MI<+PC%G)NPU739F?AG=V1YTF:+OJ%CY;V77$?VLSB[Q^A-L8V3$(&NCG<6,
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M>W $ P%[>]2>D&>9"13$1GLH31K)= CN'OI6>FAR\*&14KYIG,BU_4S+@K"
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M8/@7)4U):39<DVM;"3@17P1Q_%,6'4=/N9KCMVOVT+OO'Z7$=8LN2OTFLR6
MS Q6.:VYD7,07-Z3^\<[CP^14^^=/)_<<$;R/D57'A7?[B 5,Z86T:ZI')6D
M4=&+8%/&6U-8U6RK#ZTZ0'!GFR%QE+?-(X9N%?-3O=QS6FS<M\73>&UO]&>G
M]Y=*ACW+4Y>L2W*L2V9J?B*(U&ZH(N8UK%%T.9L/B5J>J$: 5^NB=X?[:<F!
M%^@2A>'/$[W-)"8^9:1-;\A?T;CA\OOHQT?7H+>QM/4JD8_)9RK4Z7#NIG)*
MB>>%)R"%X5?.N(19L/R$MJ%7&#GKL>\S^1"3B?[>*(E=/W1?&LDJ["6'H_V%
MVI3!&P'AFAM^Z/ ^.F"BT5(",T[%=CCQY&+4J'E-2' KKM=;&>W-BB^8[0XU
M^I 8M_.-^N(5/[F@?<)O3A,Y9Y>NM=LL^5W0Z+=L]-3_ZM^-V 0V=I(;0^\\
M1(U05,H&<_2 NCTI]U#F;L];;79?G5**9C)\OC?<.J=4L\5 )Z7 "X*^PX>(
M]6#?R#B*\"'CE:_XD(>RM8@+XUTP  FC#.:NEY&DW>!#9 5@!X>00/O2R&K@
M5BOWI@']KB#+:V9FB2F+#T)5GYZ\N?G>WKT[PO4WBKEBJ/_\BF^=Q4+$N1HX
MCO^UW5QU(!2[/.S_]08FB=<?!.O.M^!)=[ 6V87C O63LX.B*(/9"&BK[1W0
MLT<-=\7L;M/+UF<%>C="5-&+YU\?U[TECUU_(= G_E6)G-%J%\LH)ZL'?WV_
MK1Y;._5QYI04_E79I'BE^\FP:=_O4<<=(I!!8#7;!S0.8XWPI/58>)Y4"#U%
M*;WSHCEE"G&E4GUTZP$W1NQB[&C+*,&'U69W@9'6$3X7PJSUB9?;MKI>Y^+Q
MVE.N^)-H?./JTFN.##>8Q4Y_3)E'[V7A*?.DIK*9]N^PB3$5A;[[QK<:<LR.
MG$G;YNC[HR(\#?[Q!WMF[1$Z;%8&2GL, ]SA&EPY,(9NOC'DV():;?;]YD+M
M1F*S8=S]F.:DP)W'[.MEWQ\4B7??T+C=2&@1!H4SV-@.9VX":RL?DE(M4-P]
M4IJEWT)UT(?NMOJZI\P;1"]1(8VT$8)&+D  =T%GL=WX#.K3TEQ'=90;VYA%
M*FC36IP,3T)LXOK339T/YJ%2*!GCS&71E^ZKT%W-'DKAU@P)&\F0OKU9WZ ?
MC>F#^1@U7O]NUP:6'>5',(K:8Z/2MH/5=AO<M*=N@:2 & CWE(,/<>>(!V@B
MS7O:E3Z709D<%HE=",(9N*PD*N!)%3R!-<?,_W(#22=GJ\DT/<DQ[L,I#)C5
MS:LG$872W0^C[SE+,*XOR0I]QS>L5]9-Q:MBP[TSJ0KPB*8=7+L/:/7C]IJG
MAJZG>$K0 ZJ;$W5OH*Y@#IL=5+-6W36 OB3P]W>$L#0"%?"5$X,S7@!NO#*S
MN@4<J+^Z=&?]DB"<#SE!SL(_J[C_<MO3-B'@63!B(8G]Q(LY9.[PH:&KJFV\
MTB-0+N+IT0L.F'5R=QP,8RRGD6D/R,VP;O-L:N,R3K!P<7FAAL#</(4J%QNJ
M7*D>YZKIV+D@.>F<%G<N,%"$X="1RJ&:0B[)<R*QW1-@-Q#+=B>MS9&S[4/X
M$,G2JW0-01S"409%&9E:N+K^NUU'@*'6ZL)KEYHL!T70#J1Q]/$33X>WOJIH
M0L@OG&OI*K)/8G6-6_1U04ND4<4)&D9[JU/OM@HP>[I]"(,\)<V89\K,XC92
MO[''?&,PXH#:*6N""OY^T%XDP9R^4?QU_"6LKGJ6;,NQ [LZX.8"F^%#8KTG
ME[M@Q#V@4!6VPQBS@^L![JABEG;Y:VDI)[U'3?X.V!ED6^G5ZYF7]UKK_9E/
M(NC@NGOOQ;T$"KZY5D+$R85@ALG-B*M<);:W+&84)F]FY2!-269GFC>A0@TB
MFHFME=L@U523<147J&-(USYNU^6O5"" \_&78"ZH!?#(92DP5#.Y!ZYJ>0LM
M#/R@"+DN#ASVR6%X./4HV+FW3DWH[@JXVYBL&Z?DSPY9>XF-)>3'SN)4N:&"
M28D!.71$!E>)?N/%R/G\2(8T,[G[8GI)!.EIFG) 89A[8/!;;,7W$QWY8>>H
MYMSUQ)<"[MVQ)\[1=$' >7IPX-;:]??IF^[U5-!1S$1-J].M.ZHM+V=4W'U9
M\B-R0K'41E?\UI"*M.+VGE28P D^\V\/ADV$L8/ !([EMY:7I^1 X?8_B*QB
MG\3),VV],1IB)^V0!L&:I).OI%HY;'_P,JN:06[WAJ+WKU5A%&I36P\_V6,Z
MMYS&&V?GG ^HC+)FCWBV7QB#&@]L,?J=T0X1"DW_RX3_,N&_3/@O$_Y/,6&8
M*V8&KD&.QD]0V GCW'C.-DS?G_%N_&:W$XG;2JN^EK*MA_8XVDC6!LY[1(:\
M1;QI+@@,-_*7"K!")7/5^UD6[".L5:["?(>CQEJQI6:RVPA:-?G"'13)A;5_
MRX>EUKW/+MWE'EL2\O30&[S]<N]EC;Z7AV-<?D:N;[F#' ]PD<&'7)XQ$/R9
MB$[)^[K[ZAXZ6?$K3[FY;8CK)>OH<;PU."/W$_G$V:$,$61XW!L!'TL+P_0Z
M;ETKQFBA75C>N)_EFA;=6%7,]EBR?*MGU;=2[91+"G&N^U:(OVXX!989:&=[
M:*?66^SW-R1>@]Z+_E_@$OK?]I^\M-^-T?_'BYKCL+1*ZV(ZH0<^!:>79MB[
MR-H/2'=A+!N?O?0)>.!X8-B8=N.X[';W7813A'[85'HP0,Z T[Y!)XR[' W&
M3"RGXH&HK@:/2P^.Z1I(DD9+K,P^;RQ!"U5Z'D^L@@XA+U.)XTNS'*^O_EKZ
M:[<QCBB+WI9+-6EV_51Q5-GXH8+I=V>+K%H+=,+25YJA8B]SN8D?H)FMZ]L)
MQU$VW7P(X!V[Z/G*^" 8>)9,'*NCK?H/A_H5<)TU?U[C??>\RX=,4%1-VW;E
M?+'=L0KKQH(&Y"YU& 2]!QS@;.>]\<=NXJH ;1S?1I8UL=(\W;/4%W_0Q$IQ
M^#BJAI,\469[,D$GN*Y?NE?^>MY[\0^_WJ 30#K0R(X%]S!@.(1Z:[!6.MU<
M*J;HE!J/8-K:*!U\GC,XUTG0J4PU,K90@(C<]N_E0]2QM%?XQEZ*]X0Z;9E)
MHL'30RU86 HU#[-MY*>#79=UY#N)\YZOY\M4XY;#?E1^]I9L?B%Z(BU@HLI(
M3_1:$SD7"QQ%9H=N6*O$[$:'K-5@:=?Y$&4B4I*[(U?!Y-<M8DPUR[$X8>/C
M\8"BS_MT\HRDLZMMH)LK]OA%%,H)+WEG(A3LY5G%='(6SXQK,3X[VFK+J%<8
M]W]OY1YVWK/?^*9?]+:C9U6=71<^'I<8W*)E?*XMD07E*EK05COQ'^OH44P7
MAKG(@IQ-MX,=)8D,Y6E^U38D_#+U]R?E>CIHC\?G:M-L13_VJND>7#KJ]V)Y
MO22BIQ4V%4XD4)8G^ME3:_A@^C ZZ%6<'7T\_SQ.Z7Y3=>BIZC/39M\1C5.O
MHY(X[UTW(A7SW ,/CJ1"'[V&A-\6^E"V0DB%D\27*CB'N2XL<B=^8GRV(']6
M$TGOG]#/8[PO\Z@:F5QFPJ(0Q(R5;9$<D]_R=M<G?L1]>C'ON TS25+F0XAO
M\0V$I3F@QUR+NV_$WD:+S/BXG,BZ]TU+=63N7 GU3&N F6[PU4S_[5/=(@5]
M^3J_8S*1!7#:U5!;EGD7%C01YRH:=[?M! ,OT>I#0Q#T3VJUF4W2#VI3@K,M
M7^V75(VX<KW,4,W"Y-Q&E8)])Q\$/("L;06+6<[T\0ZJQ">0PR#DGZ="HY/V
MAZ[ZCWX?DXY-E H@%ME*Y6XH\M@",7YM20:-O+F;D,$CXWY#V#/+5\9+ZBM(
MUFWV#446Z>F9@>ZT=/R]B]C>72>?@WJSF_7S0V"=+6DMV_N.Q]6(J'&?\B'I
MI[&T*G(#?.F' .+'@I=HR'PJD7H%;?'X6U!6=M2'\Z_\CP3,IUF//IGS"U]\
M(T?Y(.\$>P@3@4<C+L.(Y"MZX&6./3H,&"RP-+"2-(D:LS>L=\;&:7XX]1@@
M7FLT*#SZ_H;^EEV_E#Z.O_Z#8,8#-C3<DORL.6@DWH&\K*7'@F7:Q\3&LW1"
MA]%F8_&?^C?$/.W>=M?O>W#B/NN6\SO[ZEI"WBXIN.KZ7P,7>=+4ARAQMB\
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M^)R!>QFIQW;%8DT.E+:9]A)N +^/ZX^LWKTR+W \59E)8S%J>Q0_!M%AU2.
M9\U##*=%A^6/"XS@CSAP)RN)5?ZQ"1_/TK82D9HQ?<03=3Q\XZ#(IA%GX-4S
M1>RLN;[-^=KEQK'I]0?U2NF#WR%)6"D5@3EU2I@85>LO1NV/7AV#2S=9 $N8
MR?R;</]+@CX]$^,@\3?A["Z\<HOH,FX\C?H6 _E6XN'5]7!!#);)=Q25..C
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M<>H1C@).*79-=H<I%V>.S6)_:;[7RNAM(U/B/?&N\A+JFQ9J*238R7P&MOI
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M)Z\*+5/]K9DX]%7@=RD\4-);^,8;XC2J4J3.^+-5C310ME]!TN2QB9H_'"H
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M #^VVOQA4G>>!6!M%>PX09)Y:W"<#ME>60T+0XYCV0,G\PM9)32O5W[BQ'Z
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MIH>*K2IIPY/-6Q9-2_&].FAZ3UG.B_ZXS=GW4IHX,0J%J9-BB)P@AD0<SF#
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M3K@N9Q%/>12E)HQB0::E$4\G.RBVPE>R&[CXHD9F1&1CP?3X:N9EF)C6=MJ
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M=W][=WW_^*_@ZL<7</U_?KNY^W[]XW$!?EP_&I^NZ8^ ]A';*+B.?\ZFQ%X
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M&BT][*E>/B[PZGP:V'./#Z.$:USF@EZJ.UX^/..2WQ6KC+[M7*-=ESB!X\L
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MB.D[4Q5A=) $N-WYY-RJ?2,S[3?MJIZ)^J# :O.63+E)R56>7_\"7"19EDB
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MTEIX]2E4)7=S"(5CBX,28_P-#J'&0'5D$M$BGSX8J5'5@@\Y@S)_M<W/H,:
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M0VM.OF3K#5DN7VY(QG\K/ZYNQ5+HSBS?JO2NO3)"AGG2-L^<&Y_M]UP'K1)
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M:JO6TSHPI3%Q!"ER9;Y8-G4SPQTAA6Q /"@XDA"GD0=3'W%("8_BT(\QC?
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MPD1297SH,R@2^0)Z ?<0#V.,N54AP'?086YDULH-22TX*%K)ZV;FM>A@K?M
MK200.XV5)52!4.66O@A2#$HMG?@-,B36>;\78W/V^>FFVX32/20N0(L%:,
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M8=1QW683?!5$?9!-6JMZ;A-;4G[:B&U4L.\1X4D:P#0B0NV\*(9)&$>0!''
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M<ZL^V*78_KHJ G+13']5SC,$#2S ]]PM&Z/,C:,EPZULDRX7H\!ZN%2,,\C
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M0/;2ZM?:H?RVR/)"^Y27_H+B,)"!D# 5.K-HFF"(4\5M?A+%(O!I&//(KLJ
M(\F,YNND]0@JX>JL&':<YVJLS!AQ2ORG3NDM]](\DQ-IGNM_JL,HZ@'\1^\
M6A.H8[@=T:LKJ28E7\=0OJ=FU\V?>1>PJ\YZO19/]9:A;(K"I3P-8ID*J)W@
M(?(0@RG%$50_A&&*:10AHQ!6FT[G9F=JF4$E-.@>=0\KPV>$NN4-@2,L1R;/
MH3 .ORTPP,7UE4%?EQ]S;V  PM'+ Y-W[<BG+-:+'TRLB*(QQ7Z"D7+]B] Y
M[!<X27T_]GV($BX@HKZ$A),8)KY/N!=BP1,CJCG>Q>R(I9'.C$%ZH.OG"S>
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M0@(1BQ)(/+7T16K)"P41D1?Z"\7/-#==_"PEL*&LKASC,5<EZ058B>.9.9U
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M^R*E3E;_(D S8MJ@O*NS\'05U6/7Z 2V2KU_YP+4>65<^R0XAMVI)X,KV3[
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MDD0'6OL,D@1'4)E3,>$<^3&UNMTXTL_<YGDM)GBJY%3VT%90NUE_#%6SB>\
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M?Y1 ?PP@;T4'9"N[I>N'_;"8;>[&!7MDHE/"@PKK5GQ 7\%/6@.0K?X"MDJ
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MC7V$VLBIM[KUN>@%J%#3?Z^E=06:12B%*_"F"H$X T2[@ 438/H"#7K?GRY
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MZ^2,L@?VQKGK!_IB\XQRS@IEG]P4Q09+X57S3^7Q_9*M'^26YTEM,9?$<XA
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M<S.%D7RN7^:N\,L"-&J^RBOK*KE-$>8?Z?IAQ;=_!A_E7Q;-C"OMJY9M#2)
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M;4'9ZNH13@O?:WYM'T%.KL?[G&N^UW2=/"Q]-X&&K=)7E/*5J@C,6>42[)2
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M-?@Q>\+I>HF(Z]'0DZL22T*(?(QA0CB'OERS8L9=1&*C;%/#\>>VR/0?""]
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M6LC*5KJ6]O,#+Y8,T=#'L0M]'!&(7"Y@',4(DD@03)*0A(E1FF7_<'/CDYV
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MU$D(0$NQ]L/7N]AV X _"BXVJR^IX$N1^&[@!!&D-/0@"@(&<9A$JG4G4WT
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M"#X<>2:-@D]"HM\O^/0C!OCB@B1PFKC0'WR=9OFWK.2JA=-7^9Q'S_%1X\-
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M6HHH+8BE$TO2=#B%S"$11 F2-,I#"@FE/G89CCC1"LT85\RY,>Y]CAD'N%%
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M8X%<7]! JV68WG!S(XHWNP^@9 :MT$!);5+UX"S4_2QA'\"1">,<=@.:YFB
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M5.3\Y_2%WS_FV>;A\9ZO_XOCO-B1)18)\3@-H<\PAHCP )) 8!A@E\4X#+V
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M.Z^Z-:T?_EBG;:"W@SPO"KT(.I@RB (_@80*"KV AY@D GM1HIMHT#/.W!:
M5E20M[*"C116/W:^#]-^?K:(U/@V<@W25DR@Y!R0:="'EGZJ@274)LHU.(&>
MG20##2AZL@SZ[IXLS4!#A6Z>@<[E9M3(>+K\)'?8Y>MW_I"JKJ'K\IN<4%61
MQ?7]!$,7>2H45.5=N9(3W1@GW(T#AP>^#B>>&F!N9%C+"'9" B6EWM=]$L1^
M$K0!S<CL9XB*]N=[3O6><Q-Y:VV[R1]V)MO)!T[R*9]3I_V&SUYG;M=4=M%U
MSBLBOY%TD,J?Y):];?U"$I1XOH""4@\BG,20<)]#ZE0?<A0$1,O1>'ZHN7W0
M=46,5ES0D5=_R3X#[GD;QQYD(W_HI]$:8.F<@4W?V+$'WT3VSH"7SLCDT0.D
MQ^HY\X#)#!\]1;JVC^8=YF$17\M\I<+KBUMQGS.Y2]V%<&L08_\3YD:*7[$<
M)<4K4(FK''U'0B7T/O0ST/5SHSW41N9%+<# 3ZMQ\'K@# HMZ7GL9*$EYU7K
MAI9H7#V\>?%77CYFS/A[/W'[W#[V-ZV,:UGU/^U3$)W_KBV@,_)'?028$3[A
M,SA<U.!Y_YF3MW@^H=2Q)L^G+AV<N29M@()_Y/5_;]95_?+;9YYCY1&I(RB7
M#B-^C%T,(\3DOL=Q7)CX"8-.PF/7=RCA@BS7U?$7TSL7U!M8ZRU/ZK>\._QX
M+WO=V0!7TAEGMNE K7<29Q&^R;+>*D'!;ZW(?U.M(&HXMV(W+9&L)K\9X&0O
M%4YGT*D3XPR .)(F9W+W9'DF?V7+((BCF!$'BD@UPW2%BE60_T0Q\I"C\L>B
ML;-,_LKF9JO(5S(8/<=$@J]'5J-#.C)W79)?\E?VKMDE.QS?+[=$RC#WS)(=
M3!;R2CH/&["78O]]GZES_JNG4GL#U;EG;DPD9=L49;6M+[,W 35MU1^#3507
M&XV=TT!8QMXNG43D'"!F^Z4CV@_;)'4?--W.Z(CX;[9#Q_X^S.[XFJZSO&KB
M)#\(7I1+EN D<@(,0R($1)0(2*C<[?C4(90$?H2Y44&W_0'F]HU^D].1K4LY
MWDK9X&DCIN'^Y@!&/>/@$G!&_E+KWEZ2I\HR3\FF5(6BU#>[AU<KN;V%_A0F
MEM;P@\=/NCR?4FY_Y3UYG7E(QM6&I1+Q*H@ AW$2!XD#@X11=83+8!*'#J2,
M<B]B-$9<JXOTWG/G]DTWHAF&772!ZO]\+U!_[/551W.CT(HC>@Z*J.@^9[)
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MO0_SH, IT5,BM625IOO?&^!5K(L%L @VO0^S4HL$,C\0B;R0*;PH<&C$J9:
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M7GOP/?2:R2OI!!2[U9>A&%8JU9;E*T JIE5R[CS)M].LS QYN1<2NIB4W6D
M-\GFG6A&<UOL&OTY">YYH?R8#SQ+\^)KON;EQPV_H^N<\,)S$&JS?(7 B7 \
M2$480!0R#)/(C2%E"0M=Y >(:YM>!O,NS=+Z4Q0XX#5=K2KGJ^+#^1? -APT
ME /W"BCJ]15WDT4X;S]9@M:RU%9$@X9J4),-*KK!QQZTBO01.60F .L;0I:
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MYH;2M:IV4-ZL\I(_YE^RMU05AKS-V%>Y5KH&T] 82].:%$WZUM$@.N>MI*F
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M,%]$1L55#>9>FMA0&6EY2RU0B0* ]N@UE1SZ:Z K3:P@:UW"U%17=[UKNJ]
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M1=BUR9Z1?3[O2]<+/B3LP0_A)G_(I0+.0<QB+.= /;7>[E?&N?+";KI-M8F
MG419!PK>-Z.[L]#33$>II4'4)8.X9PQIG31((5GN&*.$[>?&/7E=-SVFVD3
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M?/GQZOKTE].+F[-?3XL7\:U[>HL5?:\R4[XMV@R%T\E'S_IB/T!2DMS+&"?
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MN3UUW5JR-G&U:LI:TEB=YNO1'MR<'L,OW^X6/ZY]3 '3]3IYA0S7LJ*C6\S
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MB4!P.K?A@<\,5V!B=8C2:FT]+PRW(H1OA\T?[?#_\#JM LCK>ZBLKD_P*+'
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MCGFE2%PVMR720TJN\GSZ39"B3DKB@8</Y.Z8'ENR5$0>/R0R@3SD=B\!3]5
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MX)?\$N,_<[H^C-XL%A<YO?SQQZ=K#C]]JSEL1./KY?"&^82B^$NN$U>"9%J
M)XK+5"W%<E$G"O.L%@Y=#KKU(,<VE(][V](-ID> 00?@?S<C7?]5W:S?+Z8D
M^V]X^FYV?L6-]T5XHANT4AF4$1:J%P_,9.,,'7#T1>L[GD<I&O?2IQNP-E3;
MJ+?(U_??BTDBV9"@'MJ'EZS5HM92>U-9.DS(SS(1O$($'WQ +WC*HG42XM;$
MC?LDWPTXAU%F!\;RU>SL+,_CTWS);%40R""CKAZ09N0!26(.5<A%JA)<ZZOQ
M;6D;]^&_&XP.HLH.(+I,UWN E>B",\8'T"*3:Y*D!J>T!O)(,);BN2JM3><C
MY(Q;7M\-$%LIK(MC_-5L_FU6FPK<OM9;;Z7DD:R] >_0UH>P H[[##QXQ9.Q
M1?#6]TZ/$K05 NU/C\!V2NL"@]<I/W=ODZ]Y>WN5]9.%S]&Y"$%*$ESR])6(
M"C0&41P9?NN&*Y??@L!Q@_.A;^>'TU4/1_&#+/V*D_G?\?0B?YZ]."/WH[;;
M>#5;T#&PF%R_I'E,3DBO0'C)0&FK +%DT-98%Y/B7M[M:7?P<7T8R;W4834'
MT]TS^XB:[1#(=ZS"/3Y/A)/1<:% *F)-&>T@A&)!LH@Q!L6U:EZ7LR.-XT+U
MJ !Z KQ-M;D_6F?G>'H,M,9X<7:QS-7Z;3Y;+/Z8SC.>5H9_(S_J92ZS.9UK
M?YTX);U)6H!((8#*T@/62G(;+3K!@\CR;EO;@2&\'>'C^@L=XWH O?=OFA]D
MNJ837C-MA.+,:0-"A%IG$2AZH,@!/'.,,\.\,+V _1;AXSX&/$>P[Z_WW<'N
M5V"?YB^5D,]'\*MO2^'$>4NB1 8Q65_G10= S4G *%A2(0?:T$=SH&_3-NY+
M04_(;:*]#BSQW83(7[^_FYRD($/V,H#CM6.P3Q)\R!*X%=X;(T2QK7,"-M$Q
M[IW_F&@[6"L=(.M&\NV)REXP+2*PH$@6W"*XP 1X[E+(C&.0K6?&WUA^W"O[
M,7&TKPZ:Q4.#5V&\PWD=(/']@/:V6WWL0+45CY-__#(*)G)2"@TDA77F1BX$
MDL) *!.E#X&IT-KR'Z^,XOJF[?))8OKE8XYY\KWN3OJJ6H(;1;:O"/23\_^Z
M(!>T3B9)D^7G7XZ$TB84P3)(#+ZFS6;PEDQS;6FM-<94>.L$SW;4/YNBC%W0
M^/ =_5&5W<'!>VOJSKIX*Z[T6U.^=;+6%E<G.PE91]T9\$8'2%;RC,['J%IW
M GF"I%XNX(^+E,?&6!^HMKY1>/GXRV0M#$^JEHNKVA+%02"/!B+73A>G2K*M
MG<(GB>IH\/6A$-@>7GOHHS> K;[)Z7UY^:,ZV>]FYYO'A:]S_2D6CYD'\J=K
MKC\JBJ6DI:"=.9^3T Y=&1)[.]+;+2SW@<YCP!Q2CQU@]D[U_<U^0N0'7<]U
MNE&/__+'+0$M'A^CMUC:"1)XCI&L@Q.,UY&XU6]RY#<%YBV=49:YUAESQ^&L
MEZX\HSH*'8*H@ZVU$X/O\&S=PMMJLA]":C#+9$6F&*!7G$(.%X42CCG9^M%_
M3U+'#MOZ0]UC)\E $!BY(?]OM3[A._YMMO@VB>O.\9RS*'50)"E54]GH''9<
M9,@4/UN'.26_34?^39_=D>,QE$)G#:4[(CKJ2/O5B?.1Y#']\JDV:<%Y^C";
MS5=;R_+LK(T:M*ZSG5E-(@LR@O6N6)<CFK15'C.M=,/*T7?7%NY)(GH9.3O*
M =Y612-C[?5?]#ED[Q]DZ'+["!UX-%Z!Y*S.TF4& J/=Y&,@=QU+3&FKU^PG
M4+<E.>/8L\:*GPVKA9&!=5LX+WXG,[]8,;:.^:(I+(4"9,TSR2H'"*IHP."D
MX29C=EN]43R!J*?H& ]*@RA]-I &.@@-MC+V;Z]2K*.TRHI2"T;(^U08 OBD
M G#!78DJ)?IQXXA@-PI[F8(]:A0\H%([@.S.V<Z1=E[.M =#5JZ^[D?R5W4"
MH7)..F,4KOD(DF>5NSXD7@Y-5=]%>1V"\\%<N&*3+<(60%%33@JG_5TX^3<Z
M!+1>N,2[SF0<["9Q1# V4=;(MR ?\CQ6=7VA0^ASS3BZS<JU"'^;8\J79T^=
M\^B2I<B=2:=K00BG_18]&,YD#?"=PKLF<M,UR5Z+CQOW'@%NQU'+R+C['?^:
MG%V<52_F^R01_<OKT-_R-,_Q].5LFMZ'T\F7E5H73TCCQ++H A=D[[U&4'E9
MGT3.3V!1F:R51WVWV<8F.+:D:5S'\D@H'4V)'9S<CQ=&WZZW^#!;+*_TWUW4
MF.]]67^_.#'!>,>]@!1J(K+*@D)*C+5-4W;)H=+-"Q2:$#YN/OD1S_SCJWED
MP_PXP]<_N<\DSS9BM@RT]K5*U'OR?P(QZ7)(F@<IE=G""N]-P+BYZ4<RN<=1
MS_,9';"ANBTO<)JN"@(6LW+33V^9V;[?V@.EOS<0Q/%SY 7WQCEK0&=>;ZU8
M B_J(%*?92%'5@5LW5RREU$#FX^.ZSJ6Y:U>$:XH@06RS11(9N3@E:[7SCD@
M$T(JWKH!R.%4CYU<,0CZ6O@%!RBW X?WH;;G7MI2L ZW"8RDR!WY-L8G,()Q
M&;6U6K3._WR&<PS:(V++,0>[J*<#E#7MB>92#$9G!\76;<U"O8?S!3B3S 9M
M@O*MFW#^_&,.=@+4D&,.=M%N!\A^O&-^$DGJ>F%GI B@;)3@BLR@I28V(TN1
MM3[I_U7&'.R$DYW&'.RBM X0V*B_O<R\9&$U%%['I KZ(^ALP5B)60ODR%M;
MU7^/.6B(Z1%@T 'XG^B7KUGD*7L/1DM.$8"BK1P#@K,HA3-1E]2Z6OM?9LS!
M(6!MJ+8N>M-NWQG?HU(E, O.:P/*U&851@:(+I*+Y9,IKG6OY'_%,0>'@',8
M979@++?NC6^P.)UC )$1094BP#D,X.LX!RZ"PGSWSO_?8PZ.BM%!5-D!1!_M
MFJ\+<F4T^2+$CW)60 @H08L4+8\JV>:C-?\UQAP< L16"NOB&'^\8WXT7&#2
M$:13Y!K7CE/.D;77Q0MO=>&V^;W3O\J8@\-,82NE=8'!AQ]_7ZU*^F87BR>N
MG:^>0JR5Y"H["]&+0F(U]2:CM@7UGN3J7,BYM;/9D/R>1R0,?O$_%@QZ\ $>
M9'U#A^?*^36C/N<B*&1T6);)9@60Q0+2T+G#G&:Z><.<O8GMM5']P/#:&N8M
M==T!J!\W)T\)_6U>+#Y_Q2D7O]-O?EV<8,X\6"7!,*_KT[:F8XU)2,624!)&
M\OJ/FD*P*P>]PK\I[';*+A@4 \]^!ZRY?C]_.YM^J8&MYX'5Q.*$MM3A[+8F
MW=6.O\I'F[.6\;@YMKMRT.M$AWYWP$$8Z'X';.;YA#N+0E 0;4TM?*>(!8)&
M!48F:2W7.6'KN[A]Z.QU9,-X:&Z@SPZG[FSO*-X85G%+XM*P%&.RD+FU=4!7
MHF.+]K"LXZNQ>)M$Z^KQYDST:KM[<=Z/@8WN#?JN#MT=H9QXJTU4R""86DR0
MZY1872*D0*Z>"M:IT+>/?X>A7EW^HX!UT%#@$.3T,_^GK7-X5R;2:91<D*'+
MQ8&*K-[#U=0N#"0;6W)@K5M^#LK0<SV"^MM-+9'S7';35KHYL;+(PK@"QW0
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M_+;J_#W]0O' N@4*!0 43,I0"[N)FY0HXO#%@'"9&UX"*G_W4GE3X/7T2KU
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M&K(/UC,EK7:\,0YW)'%<+ X&E7NUZL/IK0-8OEZ<3\[(325?^&DY.B6]8M9
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M8F\0.D3+L\%%/C*07ITM/EV$Q211V/-^OGXE75>G9,]UT=Z#B'(Y[MD 9IF
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M/;ALZ8^DI,3_G[TW;6_K6,Y%?U'E]CQ\I&4IT3FVI"MI[]S]"4\/U3(2"E
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M*E:8:^U9/DG0N"F 8Z%M)[%W41F^R\YOTQ"GY]/5CROO8H?3PPNW4<@(F$T
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M+B["X@>Q9:_8\MIS9LA)3*P.8<M)@B^6@;>N))0VL0>#RS:B9_M/CCL#M#V
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MN%Q]#"M<S]S,5Y=Q^(+$6<A:T5D3S)"XG&408FT\,3[+P*W4?%@[]!1U/;W
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M?M/T\/.$7C#4!E!+A^.'KJL4&;/0$BR2J,AAX> T1?NA^B".<Q'2-B-?'_U
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M3@../Q9P&)_F0%EWAY;;#5C&2%N, '2B (F![F_M$.H*<U%*<@3_03'3\7#
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M](7P!6_O#9R@T,9$X4!4PZZT1^(L!& ,HXXB:,D'O0:?H&W<YL(AD=52*5W
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MX%;9SG?SJ[;DM7R6:XYO__N:\7PW7_T+;[TK^OF3+O_2?2%.--I<$FFTI!!
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M77=T6]%,U@Q<KM(COUZI&"#8.DE"<N^D(<7[0<9Y]B."$XTZ3R;%.A@<7W3
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M>O^_"_Z#>;@Y$;)L5_M$E:6P5=VQKQ@8;>ZBN-PDY5W:3W\2%*F!(JE%$DN
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MG\ _PD@*2;70')%((N*4!) 9YDC0R *FR8;BW4/[T-7"$\""8#C@W?E1FFD
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M < ^$=[:AU[- \FN]/W)DE2RQFB9O6>)>!(&:1%9;CM+E./!,U:ZQJPO;?W
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MWH2('',2N1@I)L1QV*;#'Y5/:*I;7MG >7F\AII$W)J;U4:EWL4$^Q$%;7.
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MQ>>X>,C)C(@3D1B?D!!<(NYS'XG<P U+1IP5GIOB0[^>$-"27UU,R5TIB3<
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M3__%H[^YO7T._'ERDSMJ?O@3_(KIM_@%[/*'E&)6 KBR/(6(0E ,<4(4,E2
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MU>]8MM'YN5NL2"V31N[_E4:RRB?J>8_\AK?HJQ_D7YR=Q__W__S_4$L#!!0
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M TI2_CB6T5)_F:7S^,W_ %!+ P04    " #NAD]8ISH!Y L#   N"@  &0
M &AU;2TR,#(S,3(S,7@Q,&MX97@R,RYH=&W=5EMOVS84?M^O.'/09@4LAY*H
M2QW70.LXK=',">P4>2QHZ<@B(I,"2=EU?WVI&S8LR=IA6W?Q W$.>6[?9YXC
M3G*S*Z:3'%DZ_6'RH^/ A4RJ'0H#B4)F,(5*<[&%NQ3U/3A.9S63Y5'Q;6[
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MB?93^MU0/K^/V@J2#+A]J%P4U1Y:4OATY[6O4M$8>YX[F59;HT?TM6<8Y$6
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M@1*QTVVGE7)!1&+_1X.4.],V?5"JRAU4$M/13:E7N#9)[#T3M\#A9DB<LY5
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M=3-Y<C,S+FAT;5!+ 0(4 Q0    ( .Z&3UC8E^)9E2D  .3^   >
M      "  =(R  !E>&AI8FET,3!N;BUA;FYU86QP<W4Q,#!A="YH=&U02P$"
M% ,4    " #NAD]8X0Z^X$8G  "4^0  '@              @ &C7   97AH
M:6)I=#$P;V\M86YN=6%L:7-O,WER,S,N:'1M4$L! A0#%     @ [H9/6*;_
M6Y'')P  +O\  !X              ( !)80  &5X:&EB:70Q,'!P+6%N;G5A
M;&YQ,WER,S-N+FAT;5!+ 0(4 Q0    ( .Z&3U@>$A^#I!T  *#,   >
M          "  2BL  !E>&AI8FET.3<M:'5M86YA<F5C;W5P;65N="YH=&U0
M2P$"% ,4    " #NAD]8!F4V0F39 P 6<#, $               @ $(R@
M:'5M+3(P,C,Q,C,Q+FAT;5!+ 0(4 Q0    ( .Z&3U@%_:XWER,  +&0 0 0
M              "  9JC! !H=6TM,C R,S$R,S$N>'-D4$L! A0#%     @
M[H9/6*O!LKBM00  RYH" !0              ( !7\<$ &AU;2TR,#(S,3(S
M,5]C86PN>&UL4$L! A0#%     @ [H9/6%+>\^4ER   T44) !0
M     ( !/@D% &AU;2TR,#(S,3(S,5]D968N>&UL4$L! A0#%     @ [H9/
M6$V+ &\<Y@  B6(! !,              ( !E=$% &AU;2TR,#(S,3(S,5]G
M,2YJ<&=02P$"% ,4    " #NAD]8I+'3H%+Y 0#.AQ0 %
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M>&5X,C,N:'1M4$L! A0#%     @ [H9/6"CWK)G6!P  ,R4  !H
M     ( !)O@) &AU;2TR,#(S,3(S,7@Q,&MX97@S,3$N:'1M4$L! A0#%
M  @ [H9/6.D.O.?&!P  +"4  !H              ( !-  * &AU;2TR,#(S
M,3(S,7@Q,&MX97@S,3(N:'1M4$L! A0#%     @ [H9/6 -J"'D !0  LQ,
M !D              ( !,@@* &AU;2TR,#(S,3(S,7@Q,&MX97@S,BYH=&U0
52P4&     !( $@#R!   :0T*

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>hum-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:hum="http://www.humana.com/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="hum-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <instant>2024-01-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:FederalGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:FederalGovernmentCentersForMedicareAndMedicaidServicesFloridaMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">hum:ValueCreationInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">hum:ValueCreationInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">hum:ExitFromEmployerGroupCommercialMedicalProductsBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:ReinsuranceContractAxis">
                    <us-gaap:ReinsuranceContractAxis.domain>CMS reinsurance subsidies and discounts</us-gaap:ReinsuranceContractAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:ReinsuranceContractAxis">
                    <us-gaap:ReinsuranceContractAxis.domain>CMS brand name prescription drug discounts</us-gaap:ReinsuranceContractAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:ReinsuranceContractAxis">
                    <us-gaap:ReinsuranceContractAxis.domain>CMS brand name prescription drug discounts</us-gaap:ReinsuranceContractAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">hum:HomeSolutionsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">hum:ProviderReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">hum:GentivaHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:TermLoanDueOctober2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">hum:GentivaHospiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-11</startDate>
            <endDate>2022-08-11</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">hum:GentivaHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">hum:MedicareLicensesAndCertificatesOfNeedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">hum:GentivaHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-11</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hum:KindredAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-17</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hum:KindredAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-17</startDate>
            <endDate>2021-08-17</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">hum:KindredAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">hum:KindredAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">hum:KindredAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">hum:KindredAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">hum:KindredAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">hum:KindredAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">hum:KindredAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-11</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WelshCarsonAndersonAndStoweMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WelshCarsonAndersonAndStoweMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WelshCarsonAndersonAndStoweMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WelshCarsonAndersonAndStoweCohortOfClinicsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WelshCarsonAndersonAndStoweCohortOfClinicsOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WelshCarsonAndersonAndStoweCohortOfClinicsTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">hum:GentivaHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">hum:GentivaHospiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CreditRatingStandardPoorsAxis">srt:StandardPoorsAAMinusRatingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NontaxableMunicipalNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ResidentialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">hum:FairValueRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">hum:FairValueRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A5.88PercentSeniorNotesDueMarch2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A550PercentSeniorNotesDueMarch2053Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3.950PercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A5950PercentSeniorNotesDueMarch2034Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">hum:InterestRateSwapMaturing2032Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">hum:InterestRateSwapMaturing2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">hum:InterestRateSwapMaturing2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">hum:InterestRateSwapMaturing2034Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">hum:TermLoanAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hum:KindredAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-27</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-27</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-27</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:PutOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:CallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:CreditSpreadOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:CreditSpreadOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:CreditSpreadOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:CreditSpreadOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">hum:RevenueExitMultipleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">hum:RevenueExitMultipleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">hum:RevenueExitMultipleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">hum:RevenueExitMultipleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputLongTermRevenueGrowthRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionOnSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputLongTermRevenueGrowthRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">hum:RiskCorridorSettlementsMedicarePartDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">hum:CmsSubsidiesOrDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">hum:RiskCorridorSettlementsMedicarePartDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">hum:CmsSubsidiesOrDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hum:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">hum:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">hum:CertificateOfNeedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">hum:CertificateOfNeedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">hum:NoncompetesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">hum:NoncompetesAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">hum:ShortDurationInsuranceContractAccidentYear2021AndPriorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">hum:ShortDurationInsuranceContractAccidentYear2021AndPriorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">hum:ShortDurationInsuranceContractAccidentYear2021AndPriorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3850PercentSeniorNotesDueOctober2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3850PercentSeniorNotesDueOctober2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A065PercentSeniorNotesDueAugust2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A065PercentSeniorNotesDueAugust2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A4.500PercentSeniorNotesDueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A4.500PercentSeniorNotesDueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A570PercentSeniorNotesDueMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A570PercentSeniorNotesDueMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A135PercentSeniorNotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A135PercentSeniorNotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3.95PercentSeniorNotesDueMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3.95PercentSeniorNotesDueMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A575PercentSeniorNotesDueMarch2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A575PercentSeniorNotesDueMarch2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A575PercentSeniorNotesDueDecember2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A575PercentSeniorNotesDueDecember2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A370PercentSeniorNotesDueMarch2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A370PercentSeniorNotesDueMarch2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A313PercentSeniorNotesDueAugust2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A313PercentSeniorNotesDueAugust2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A488PercentSeniorNotesDueApril2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A488PercentSeniorNotesDueApril2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A215PercentSeniorNotesDueFebruary2032Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A215PercentSeniorNotesDueFebruary2032Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A5.88PercentSeniorNotesDueMarch2033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A5950PercentSeniorNotesDueMarch2034Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A8.15PercentSeniorNotesDueJune2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A8.15PercentSeniorNotesDueJune2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A463PercentSeniorNotesDueDecember2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A463PercentSeniorNotesDueDecember2042Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A4.95PercentSeniorNotesDueOctober2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A4.95PercentSeniorNotesDueOctober2044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A4.80PercentSeniorNotesDueMarch2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A4.80PercentSeniorNotesDueMarch2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3.95PercentSeniorNotesDueAugust2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3.95PercentSeniorNotesDueAugust2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A550PercentSeniorNotesDueMarch2053Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:DelayedDrawTermLoanMay2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:DelayedDrawTermLoanMay2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A575PercentSeniorNotesDueDecember2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A5950PercentSeniorNotesDueMarch2034Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A5750PercentSeniorNotesDueDecember2028And550PercentSeniorNotesDueMarch2034Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A570PercentSeniorNotesDueMarch2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A550PercentSeniorNotesDueMarch2053Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A570PercentSeniorNotesDueMarch2026And550PercentSeniorNotesDueMarch2053Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:DelayedDrawTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A135PercentSeniorNotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3.95PercentSeniorNotesDueMarch2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3700PercentSeniorNotesDueMarch2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3125PercentSeniorNotesDueAugust2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RepurchasePlanAugust2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A065PercentSeniorNotesDueAugust2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A3850PercentSeniorNotesDueOctober2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RepurchasePlanMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:A065PercentSeniorNotesDueAugust2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2021FiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2021FiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2022OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2022OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">hum:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023OneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">hum:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">hum:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">hum:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023OneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">hum:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023OneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">hum:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2021FiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2021OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2023FiveYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">hum:RevolvingCreditAgreementJune2021OneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:FederalHomeLoanBankAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:FederalHomeLoanBankAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:FederalHomeLoanBankAdvancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hum:A2011PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hum:A2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hum:A2011PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hum:A2011PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hum:A2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hum:A2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-22</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <instant>2019-07-30</instant>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-23</instant>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:CitibankNAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-23</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:JPMorganChaseBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-23</instant>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-23</startDate>
            <endDate>2020-12-23</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:JPMorganChaseBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-23</startDate>
            <endDate>2020-12-23</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:CitibankNAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-23</startDate>
            <endDate>2020-12-23</endDate>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:CitibankNAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-04</startDate>
            <endDate>2021-05-04</endDate>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:JPMorganChaseBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-05</startDate>
            <endDate>2021-05-05</endDate>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-22</startDate>
            <endDate>2021-05-05</endDate>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:December2020AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-05</startDate>
            <endDate>2021-05-05</endDate>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <instant>2021-02-18</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-11</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-12</instant>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:MizuhoMarketsAmericasLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-12</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WellsFargoBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-12</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-12</startDate>
            <endDate>2022-01-12</endDate>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WellsFargoBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-12</startDate>
            <endDate>2022-01-12</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:MizuhoMarketsAmericasLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-12</startDate>
            <endDate>2022-01-12</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:MizuhoMarketsAmericasLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-29</startDate>
            <endDate>2022-03-29</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:WellsFargoBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-30</startDate>
            <endDate>2022-03-30</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-11</startDate>
            <endDate>2022-03-30</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:January2022AcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-29</startDate>
            <endDate>2022-03-30</endDate>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-02</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:GoldmanSachsCoLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-03</instant>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:MizuhoMarketsAmericasLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-04</instant>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-02</startDate>
            <endDate>2022-11-02</endDate>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:GoldmanSachsCoLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-02</startDate>
            <endDate>2022-11-02</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:MizuhoMarketsAmericasLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-02</startDate>
            <endDate>2022-11-02</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:GoldmanSachsCoLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-15</startDate>
            <endDate>2022-12-15</endDate>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">hum:MizuhoMarketsAmericasLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-16</startDate>
            <endDate>2022-12-16</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-02</startDate>
            <endDate>2022-12-16</endDate>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AcceleratedShareRepurchasesDateAxis">hum:November2022AcceleratedShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-15</startDate>
            <endDate>2022-12-16</endDate>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:A2021ShareRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:A2023ShareRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:A2023ShareRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:A2023ShareRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-16</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:A2024ShareRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-16</instant>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:February2023ShareRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:February2023ShareRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:February2023ShareRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:February2023ShareRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:February2021ShareRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:February2021ShareRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:February2021ShareRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:February2021ShareRepurchaseAuthorizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">hum:ExcludingEmployeeStockPlansAndAcceleratedShareRepurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="hum:TRICAREContractAxis">hum:TRICARE2017EastRegionContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="hum:TRICAREContractAxis">hum:TRICARE2017EastRegionContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="hum:TRICAREContractAxis">hum:TRICARE2017EastRegionContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="hum:TRICAREContractAxis">hum:TRICAREManagedCareSupportContractEffective2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="hum:TRICAREContractAxis">hum:TRICAREManagedCareSupportContractEffective2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:FederalGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:FederalGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GovernmentContractsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:GroupMedicareAdvantageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareStandAlonePrescriptionDrugPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialFullyInsuredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:SpecialtyBenefitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MedicareSupplementProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:StateBasedContractsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:HomeSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PrimaryCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:CommercialASOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:MilitaryAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">hum:PharmacySolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ExternalRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:InsuranceSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">hum:CenterWellSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">hum:CorporateAndEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="hum:LongDurationInsuranceProductsAxis">hum:CoinsuranceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:ProtectiveLifeInsuranceCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">hum:AllOthersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000049071</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="primary_care_center">
        <measure>hum:primary_care_center</measure>
    </unit>
    <unit id="position">
        <measure>hum:position</measure>
    </unit>
    <unit id="claim">
        <measure>hum:claim</measure>
    </unit>
    <unit id="state">
        <measure>hum:state</measure>
    </unit>
    <unit id="beneficiary">
        <measure>hum:beneficiary</measure>
    </unit>
    <unit id="option_period">
        <measure>hum:option_period</measure>
    </unit>
    <unit id="segment">
        <measure>hum:segment</measure>
    </unit>
    <unit id="reinsurer">
        <measure>hum:reinsurer</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-32">0000049071</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-35">false</dei:AmendmentFlag>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="4"
      id="f-112"
      unitRef="usdPerShare">0.1667</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="4"
      id="f-113"
      unitRef="usdPerShare">0.1667</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-7" id="f-117">http://fasb.org/us-gaap/2023#HealthCareMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-6" id="f-118">http://fasb.org/us-gaap/2023#HealthCareMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList contextRef="c-1" id="f-119">http://fasb.org/us-gaap/2023#HealthCareMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-1124">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-1125">http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-1128">http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-1129">http://fasb.org/us-gaap/2023#AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-1132">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-1133">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <hum:TRICAREManagedCareSupportContractBaseTerm contextRef="c-428" id="f-1748">P1Y</hum:TRICAREManagedCareSupportContractBaseTerm>
    <hum:TRICAREManagedCareSupportContractTermWithOptionExercises contextRef="c-428" id="f-1750">P9Y</hum:TRICAREManagedCareSupportContractTermWithOptionExercises>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-616"
      decimals="4"
      id="f-2197"
      unitRef="usdPerShare">0.1667</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-617"
      decimals="4"
      id="f-2198"
      unitRef="usdPerShare">0.1667</us-gaap:CommonStockParOrStatedValuePerShare>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">1-5975</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">HUMANA INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">61-0647538</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">500 West Main Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Louisville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">KY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">40202</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">502</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">580-1000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common stock, $0.16 2/3 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">HUM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="0" id="f-29" unitRef="usd">55096895366</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">120653315</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">Parts II and III incorporate herein by reference portions of the Registrant&#x2019;s Definitive Proxy Statement to be filed pursuant to Regulation 14A with respect to the Annual Meeting of Stockholders scheduled to be held on April&#160;18, 2024. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-6" id="f-36" unitRef="usd">4694000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-6" id="f-37" unitRef="usd">5061000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-4" decimals="-6" id="f-38" unitRef="usd">16626000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-5" decimals="-6" id="f-39" unitRef="usd">13881000000</us-gaap:ShortTermInvestments>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-4" decimals="-6" id="f-40" unitRef="usd">88000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-5" decimals="-6" id="f-41" unitRef="usd">70000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-4" decimals="-6" id="f-42" unitRef="usd">2035000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-5" decimals="-6" id="f-43" unitRef="usd">1674000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-6" id="f-44" unitRef="usd">6631000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-6" id="f-45" unitRef="usd">5567000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-6" id="f-46" unitRef="usd">29986000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-6" id="f-47" unitRef="usd">26183000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-6" id="f-48" unitRef="usd">3030000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-6" id="f-49" unitRef="usd">3221000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-4" decimals="-6" id="f-50" unitRef="usd">382000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent contextRef="c-5" decimals="-6" id="f-51" unitRef="usd">380000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:Goodwill contextRef="c-4" decimals="-6" id="f-52" unitRef="usd">9550000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-6" id="f-53" unitRef="usd">9142000000</us-gaap:Goodwill>
    <us-gaap:EquityMethodInvestments contextRef="c-4" decimals="-6" id="f-54" unitRef="usd">740000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-5" decimals="-6" id="f-55" unitRef="usd">749000000</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-6" id="f-56" unitRef="usd">3377000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-6" id="f-57" unitRef="usd">3380000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-4" decimals="-6" id="f-58" unitRef="usd">47065000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-6" id="f-59" unitRef="usd">43055000000</us-gaap:Assets>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-4" decimals="-6" id="f-60" unitRef="usd">10241000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-5" decimals="-6" id="f-61" unitRef="usd">9264000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-4" decimals="-6" id="f-62" unitRef="usd">6569000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-5" decimals="-6" id="f-63" unitRef="usd">5238000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <hum:BookOverdraftLiability contextRef="c-4" decimals="-6" id="f-64" unitRef="usd">353000000</hum:BookOverdraftLiability>
    <hum:BookOverdraftLiability contextRef="c-5" decimals="-6" id="f-65" unitRef="usd">298000000</hum:BookOverdraftLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-6" id="f-66" unitRef="usd">266000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-6" id="f-67" unitRef="usd">286000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:DebtCurrent contextRef="c-4" decimals="-6" id="f-68" unitRef="usd">1443000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="c-5" decimals="-6" id="f-69" unitRef="usd">2092000000</us-gaap:DebtCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-6" id="f-70" unitRef="usd">18872000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-6" id="f-71" unitRef="usd">17178000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-6" id="f-72" unitRef="usd">10213000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-5" decimals="-6" id="f-73" unitRef="usd">9034000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-6" id="f-74" unitRef="usd">1662000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-6" id="f-75" unitRef="usd">1473000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-4" decimals="-6" id="f-76" unitRef="usd">30747000000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-6" id="f-77" unitRef="usd">27685000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-78" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-79" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-80"
      unitRef="usdPerShare">1</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-81"
      unitRef="usdPerShare">1</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-82" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-83" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="INF" id="f-84" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-85" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-6" id="f-86" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-6" id="f-87" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-88" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-89" unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-90" unitRef="shares">198690082</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="INF" id="f-91" unitRef="shares">198666598</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-6" id="f-92" unitRef="usd">33000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-6" id="f-93" unitRef="usd">33000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-6" id="f-94" unitRef="usd">3346000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-5" decimals="-6" id="f-95" unitRef="usd">3246000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-6" id="f-96" unitRef="usd">27540000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-6" id="f-97" unitRef="usd">25492000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-6" id="f-98" unitRef="usd">-999000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-6" id="f-99" unitRef="usd">-1304000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockCommonShares contextRef="c-4" decimals="INF" id="f-100" unitRef="shares">76465862</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-5" decimals="INF" id="f-101" unitRef="shares">73691955</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-4" decimals="-6" id="f-102" unitRef="usd">13658000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-5" decimals="-6" id="f-103" unitRef="usd">12156000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-6" id="f-104" unitRef="usd">16262000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-6" id="f-105" unitRef="usd">15311000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-4" decimals="-6" id="f-106" unitRef="usd">56000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-5" decimals="-6" id="f-107" unitRef="usd">59000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-6" id="f-108" unitRef="usd">16318000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-6" id="f-109" unitRef="usd">15370000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-6" id="f-110" unitRef="usd">47065000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-6" id="f-111" unitRef="usd">43055000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:PremiumsEarnedNet contextRef="c-1" decimals="-6" id="f-114" unitRef="usd">101272000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-6" decimals="-6" id="f-115" unitRef="usd">87712000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-7" decimals="-6" id="f-116" unitRef="usd">79822000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-1" decimals="-6" id="f-120" unitRef="usd">4033000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-6" decimals="-6" id="f-121" unitRef="usd">4776000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-7" decimals="-6" id="f-122" unitRef="usd">3055000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-1" decimals="-6" id="f-123" unitRef="usd">1069000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-6" decimals="-6" id="f-124" unitRef="usd">382000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-7" decimals="-6" id="f-125" unitRef="usd">187000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:Revenues contextRef="c-1" decimals="-6" id="f-126" unitRef="usd">106374000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-6" id="f-127" unitRef="usd">92870000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="-6" id="f-128" unitRef="usd">83064000000</us-gaap:Revenues>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare contextRef="c-1" decimals="-6" id="f-129" unitRef="usd">88394000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare contextRef="c-6" decimals="-6" id="f-130" unitRef="usd">75690000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare contextRef="c-7" decimals="-6" id="f-131" unitRef="usd">69199000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-6" id="f-132" unitRef="usd">13188000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-6" decimals="-6" id="f-133" unitRef="usd">12671000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-7" decimals="-6" id="f-134" unitRef="usd">10121000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-6" id="f-135" unitRef="usd">779000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-6" decimals="-6" id="f-136" unitRef="usd">709000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-7" decimals="-6" id="f-137" unitRef="usd">596000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-1" decimals="-6" id="f-138" unitRef="usd">102361000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-6" decimals="-6" id="f-139" unitRef="usd">89070000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-7" decimals="-6" id="f-140" unitRef="usd">79916000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-6" id="f-141" unitRef="usd">4013000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-6" id="f-142" unitRef="usd">3800000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-6" id="f-143" unitRef="usd">3148000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-1" decimals="-6" id="f-144" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-6" decimals="-6" id="f-145" unitRef="usd">237000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-7" decimals="-6" id="f-146" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-6" id="f-147" unitRef="usd">493000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-6" decimals="-6" id="f-148" unitRef="usd">401000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-7" decimals="-6" id="f-149" unitRef="usd">326000000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-6" id="f-150" unitRef="usd">-137000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-6" id="f-151" unitRef="usd">-68000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-6" id="f-152" unitRef="usd">532000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-153" unitRef="usd">3383000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-6" decimals="-6" id="f-154" unitRef="usd">3568000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-7" decimals="-6" id="f-155" unitRef="usd">3354000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-156" unitRef="usd">836000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-6" id="f-157" unitRef="usd">762000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-158" unitRef="usd">485000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-159" unitRef="usd">-63000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-6" decimals="-6" id="f-160" unitRef="usd">-4000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-7" decimals="-6" id="f-161" unitRef="usd">65000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-162" unitRef="usd">2484000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-6" decimals="-6" id="f-163" unitRef="usd">2802000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-6" id="f-164" unitRef="usd">2934000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-165" unitRef="usd">-5000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-6" decimals="-6" id="f-166" unitRef="usd">-4000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-167" unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-168" unitRef="usd">2489000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-6" id="f-169" unitRef="usd">2806000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-6" id="f-170" unitRef="usd">2933000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-171"
      unitRef="usdPerShare">20.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-172"
      unitRef="usdPerShare">22.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-173"
      unitRef="usdPerShare">22.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-174"
      unitRef="usdPerShare">20.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-175"
      unitRef="usdPerShare">22.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-176"
      unitRef="usdPerShare">22.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-177" unitRef="usd">2489000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-6" id="f-178" unitRef="usd">2806000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-6" id="f-179" unitRef="usd">2933000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax contextRef="c-1" decimals="-6" id="f-180" unitRef="usd">372000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax contextRef="c-6" decimals="-6" id="f-181" unitRef="usd">-1819000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax contextRef="c-7" decimals="-6" id="f-182" unitRef="usd">-356000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="c-1" decimals="-6" id="f-183" unitRef="usd">85000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="c-6" decimals="-6" id="f-184" unitRef="usd">-418000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="c-7" decimals="-6" id="f-185" unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-6" id="f-186" unitRef="usd">287000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-6" decimals="-6" id="f-187" unitRef="usd">-1401000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-7" decimals="-6" id="f-188" unitRef="usd">-275000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax contextRef="c-1" decimals="-6" id="f-189" unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax contextRef="c-6" decimals="-6" id="f-190" unitRef="usd">-72000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax contextRef="c-7" decimals="-6" id="f-191" unitRef="usd">103000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax contextRef="c-1" decimals="-6" id="f-192" unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax contextRef="c-6" decimals="-6" id="f-193" unitRef="usd">-17000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax contextRef="c-7" decimals="-6" id="f-194" unitRef="usd">23000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-1" decimals="-6" id="f-195" unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-6" decimals="-6" id="f-196" unitRef="usd">-55000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-7" decimals="-6" id="f-197" unitRef="usd">80000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-6" id="f-198" unitRef="usd">305000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-6" id="f-199" unitRef="usd">-1346000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-6" id="f-200" unitRef="usd">-355000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-201" unitRef="usd">0</hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments>
    <hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments contextRef="c-6" decimals="-6" id="f-202" unitRef="usd">0</hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments>
    <hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments contextRef="c-7" decimals="-6" id="f-203" unitRef="usd">6000000</hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-6" id="f-204" unitRef="usd">2794000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="-6" id="f-205" unitRef="usd">1460000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-6" id="f-206" unitRef="usd">2584000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="-3" id="f-207" unitRef="shares">198649000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-8" decimals="-6" id="f-208" unitRef="usd">33000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-9" decimals="-6" id="f-209" unitRef="usd">2705000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-10" decimals="-6" id="f-210" unitRef="usd">20517000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-11" decimals="-6" id="f-211" unitRef="usd">391000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-6" id="f-212" unitRef="usd">-9918000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-6" id="f-213" unitRef="usd">13728000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-14" decimals="-6" id="f-214" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-6" id="f-215" unitRef="usd">13728000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-16" decimals="-6" id="f-216" unitRef="usd">2933000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-6" id="f-217" unitRef="usd">2933000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-18" decimals="-6" id="f-218" unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-6" id="f-219" unitRef="usd">2934000000</us-gaap:ProfitLoss>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-18" decimals="-6" id="f-220" unitRef="usd">-22000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-7" decimals="-6" id="f-221" unitRef="usd">-22000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-19" decimals="-6" id="f-222" unitRef="usd">-349000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-17" decimals="-6" id="f-223" unitRef="usd">-349000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-7" decimals="-6" id="f-224" unitRef="usd">-349000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-20" decimals="-6" id="f-225" unitRef="usd">-262000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-21" decimals="-6" id="f-226" unitRef="usd">341000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-17" decimals="-6" id="f-227" unitRef="usd">79000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-7" decimals="-6" id="f-228" unitRef="usd">79000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:DividendsCommonStockCash contextRef="c-16" decimals="-6" id="f-229" unitRef="usd">364000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-17" decimals="-6" id="f-230" unitRef="usd">364000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-7" decimals="-6" id="f-231" unitRef="usd">364000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-6" id="f-232" unitRef="usd">180000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-17" decimals="-6" id="f-233" unitRef="usd">180000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-7" decimals="-6" id="f-234" unitRef="usd">180000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-20" decimals="-6" id="f-235" unitRef="usd">-81000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-21" decimals="-6" id="f-236" unitRef="usd">81000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-7" decimals="-6" id="f-237" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-20" decimals="-6" id="f-238" unitRef="usd">16000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-21" decimals="-6" id="f-239" unitRef="usd">15000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-17" decimals="-6" id="f-240" unitRef="usd">31000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-7" decimals="-6" id="f-241" unitRef="usd">31000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-22" decimals="-3" id="f-242" unitRef="shares">198649000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-6" id="f-243" unitRef="usd">33000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-6" id="f-244" unitRef="usd">3082000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-6" id="f-245" unitRef="usd">23086000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-246" unitRef="usd">42000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-247" unitRef="usd">-10163000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-6" id="f-248" unitRef="usd">16080000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-6" id="f-249" unitRef="usd">23000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-6" id="f-250" unitRef="usd">16103000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-30" decimals="-6" id="f-251" unitRef="usd">2806000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-31" decimals="-6" id="f-252" unitRef="usd">2806000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-32" decimals="-6" id="f-253" unitRef="usd">-4000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-6" decimals="-6" id="f-254" unitRef="usd">2802000000</us-gaap:ProfitLoss>
    <hum:NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders contextRef="c-32" decimals="-6" id="f-255" unitRef="usd">-1000000</hum:NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders>
    <hum:NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders contextRef="c-6" decimals="-6" id="f-256" unitRef="usd">-1000000</hum:NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="c-32" decimals="-6" id="f-257" unitRef="usd">11000000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="c-6" decimals="-6" id="f-258" unitRef="usd">11000000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-32" decimals="-6" id="f-259" unitRef="usd">-52000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-6" decimals="-6" id="f-260" unitRef="usd">-52000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-33" decimals="-6" id="f-261" unitRef="usd">-1346000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-31" decimals="-6" id="f-262" unitRef="usd">-1346000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-6" id="f-263" unitRef="usd">-1346000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-34" decimals="-6" id="f-264" unitRef="usd">2096000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-31" decimals="-6" id="f-265" unitRef="usd">2096000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-6" decimals="-6" id="f-266" unitRef="usd">2096000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:DividendsCommonStockCash contextRef="c-30" decimals="-6" id="f-267" unitRef="usd">400000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-31" decimals="-6" id="f-268" unitRef="usd">400000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-6" decimals="-6" id="f-269" unitRef="usd">400000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-35" decimals="-6" id="f-270" unitRef="usd">216000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-31" decimals="-6" id="f-271" unitRef="usd">216000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-6" id="f-272" unitRef="usd">216000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-36" decimals="-3" id="f-273" unitRef="shares">18000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-35" decimals="-6" id="f-274" unitRef="usd">-78000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-34" decimals="-6" id="f-275" unitRef="usd">78000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-31" decimals="-6" id="f-276" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-6" decimals="-6" id="f-277" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-35" decimals="-6" id="f-278" unitRef="usd">26000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-34" decimals="-6" id="f-279" unitRef="usd">25000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-31" decimals="-6" id="f-280" unitRef="usd">51000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-6" decimals="-6" id="f-281" unitRef="usd">51000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-37" decimals="-3" id="f-282" unitRef="shares">198667000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-37" decimals="-6" id="f-283" unitRef="usd">33000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-38" decimals="-6" id="f-284" unitRef="usd">3246000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-39" decimals="-6" id="f-285" unitRef="usd">25492000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-40" decimals="-6" id="f-286" unitRef="usd">-1304000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-6" id="f-287" unitRef="usd">-12156000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-6" id="f-288" unitRef="usd">15311000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-6" id="f-289" unitRef="usd">59000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-6" id="f-290" unitRef="usd">15370000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-44" decimals="-6" id="f-291" unitRef="usd">2489000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-45" decimals="-6" id="f-292" unitRef="usd">2489000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-46" decimals="-6" id="f-293" unitRef="usd">-5000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-294" unitRef="usd">2484000000</us-gaap:ProfitLoss>
    <hum:NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders contextRef="c-46" decimals="-6" id="f-295" unitRef="usd">7000000</hum:NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders>
    <hum:NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders contextRef="c-1" decimals="-6" id="f-296" unitRef="usd">7000000</hum:NoncontrollingInterestIncreaseDecreaseFromContributionsOrDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-46" decimals="-6" id="f-297" unitRef="usd">5000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-1" decimals="-6" id="f-298" unitRef="usd">5000000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-47" decimals="-6" id="f-299" unitRef="usd">305000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-45" decimals="-6" id="f-300" unitRef="usd">305000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-6" id="f-301" unitRef="usd">305000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-48" decimals="-6" id="f-302" unitRef="usd">1586000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-45" decimals="-6" id="f-303" unitRef="usd">1586000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-1" decimals="-6" id="f-304" unitRef="usd">1586000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:DividendsCommonStockCash contextRef="c-44" decimals="-6" id="f-305" unitRef="usd">441000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-45" decimals="-6" id="f-306" unitRef="usd">441000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-1" decimals="-6" id="f-307" unitRef="usd">441000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-49" decimals="-6" id="f-308" unitRef="usd">175000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-45" decimals="-6" id="f-309" unitRef="usd">175000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-6" id="f-310" unitRef="usd">175000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-50" decimals="-3" id="f-311" unitRef="shares">23000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-49" decimals="-6" id="f-312" unitRef="usd">-80000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-48" decimals="-6" id="f-313" unitRef="usd">80000000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-1" decimals="-6" id="f-314" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-49" decimals="-6" id="f-315" unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-48" decimals="-6" id="f-316" unitRef="usd">4000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-45" decimals="-6" id="f-317" unitRef="usd">9000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-6" id="f-318" unitRef="usd">9000000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-51" decimals="-3" id="f-319" unitRef="shares">198690000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-51" decimals="-6" id="f-320" unitRef="usd">33000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-52" decimals="-6" id="f-321" unitRef="usd">3346000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-53" decimals="-6" id="f-322" unitRef="usd">27540000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-54" decimals="-6" id="f-323" unitRef="usd">-999000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-55" decimals="-6" id="f-324" unitRef="usd">-13658000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-6" id="f-325" unitRef="usd">16262000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-6" id="f-326" unitRef="usd">56000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-6" id="f-327" unitRef="usd">16318000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-328" unitRef="usd">2484000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-6" decimals="-6" id="f-329" unitRef="usd">2802000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-6" id="f-330" unitRef="usd">2934000000</us-gaap:ProfitLoss>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-1" decimals="-6" id="f-331" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-6" decimals="-6" id="f-332" unitRef="usd">237000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-7" decimals="-6" id="f-333" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:DebtAndEquitySecuritiesGainLoss contextRef="c-1" decimals="-6" id="f-334" unitRef="usd">-54000000</us-gaap:DebtAndEquitySecuritiesGainLoss>
    <us-gaap:DebtAndEquitySecuritiesGainLoss contextRef="c-6" decimals="-6" id="f-335" unitRef="usd">-205000000</us-gaap:DebtAndEquitySecuritiesGainLoss>
    <us-gaap:DebtAndEquitySecuritiesGainLoss contextRef="c-7" decimals="-6" id="f-336" unitRef="usd">-130000000</us-gaap:DebtAndEquitySecuritiesGainLoss>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c-1" decimals="-6" id="f-337" unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c-6" decimals="-6" id="f-338" unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal contextRef="c-7" decimals="-6" id="f-339" unitRef="usd">1129000000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-340" unitRef="usd">-63000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-6" decimals="-6" id="f-341" unitRef="usd">-4000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-7" decimals="-6" id="f-342" unitRef="usd">65000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-6" id="f-343" unitRef="usd">175000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-6" decimals="-6" id="f-344" unitRef="usd">216000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-6" id="f-345" unitRef="usd">180000000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-6" id="f-346" unitRef="usd">850000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-6" decimals="-6" id="f-347" unitRef="usd">749000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="-6" id="f-348" unitRef="usd">640000000</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization contextRef="c-1" decimals="-6" id="f-349" unitRef="usd">67000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization contextRef="c-6" decimals="-6" id="f-350" unitRef="usd">96000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization contextRef="c-7" decimals="-6" id="f-351" unitRef="usd">73000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-1" decimals="-6" id="f-352" unitRef="usd">206000000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-6" decimals="-6" id="f-353" unitRef="usd">248000000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-7" decimals="-6" id="f-354" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-1" decimals="-6" id="f-355" unitRef="usd">55000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-6" decimals="-6" id="f-356" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-7" decimals="-6" id="f-357" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-6" id="f-358" unitRef="usd">-167000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-6" decimals="-6" id="f-359" unitRef="usd">-100000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-7" decimals="-6" id="f-360" unitRef="usd">15000000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c-1" decimals="-6" id="f-361" unitRef="usd">337000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c-6" decimals="-6" id="f-362" unitRef="usd">54000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c-7" decimals="-6" id="f-363" unitRef="usd">280000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-6" id="f-364" unitRef="usd">1318000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-6" decimals="-6" id="f-365" unitRef="usd">463000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-7" decimals="-6" id="f-366" unitRef="usd">491000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities contextRef="c-1" decimals="-6" id="f-367" unitRef="usd">915000000</us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities contextRef="c-6" decimals="-6" id="f-368" unitRef="usd">975000000</us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities contextRef="c-7" decimals="-6" id="f-369" unitRef="usd">104000000</us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-6" id="f-370" unitRef="usd">841000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-6" decimals="-6" id="f-371" unitRef="usd">44000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-7" decimals="-6" id="f-372" unitRef="usd">176000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-6" id="f-373" unitRef="usd">-20000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-6" decimals="-6" id="f-374" unitRef="usd">32000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-7" decimals="-6" id="f-375" unitRef="usd">-65000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-1" decimals="-6" id="f-376" unitRef="usd">113000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-6" decimals="-6" id="f-377" unitRef="usd">70000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-7" decimals="-6" id="f-378" unitRef="usd">40000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-6" id="f-379" unitRef="usd">3981000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-6" decimals="-6" id="f-380" unitRef="usd">4587000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-6" id="f-381" unitRef="usd">2262000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested contextRef="c-1" decimals="-6" id="f-382" unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested contextRef="c-6" decimals="-6" id="f-383" unitRef="usd">2701000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested contextRef="c-7" decimals="-6" id="f-384" unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-6" id="f-385" unitRef="usd">233000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-6" decimals="-6" id="f-386" unitRef="usd">337000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-7" decimals="-6" id="f-387" unitRef="usd">4187000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-388" unitRef="usd">1004000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-6" decimals="-6" id="f-389" unitRef="usd">1137000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-6" id="f-390" unitRef="usd">1342000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-391" unitRef="usd">210000000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-6" decimals="-6" id="f-392" unitRef="usd">17000000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-7" decimals="-6" id="f-393" unitRef="usd">26000000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-6" id="f-394" unitRef="usd">7552000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-6" decimals="-6" id="f-395" unitRef="usd">6049000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-7" decimals="-6" id="f-396" unitRef="usd">7197000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-1" decimals="-6" id="f-397" unitRef="usd">1292000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-6" decimals="-6" id="f-398" unitRef="usd">1365000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-7" decimals="-6" id="f-399" unitRef="usd">2597000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-6" id="f-400" unitRef="usd">3795000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-6" decimals="-6" id="f-401" unitRef="usd">2434000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-7" decimals="-6" id="f-402" unitRef="usd">3547000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-6" id="f-403" unitRef="usd">-3492000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-6" decimals="-6" id="f-404" unitRef="usd">-1006000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-6" id="f-405" unitRef="usd">-6556000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <hum:PaymentsForProceedsFromContractDeposits contextRef="c-1" decimals="-6" id="f-406" unitRef="usd">-828000000</hum:PaymentsForProceedsFromContractDeposits>
    <hum:PaymentsForProceedsFromContractDeposits contextRef="c-6" decimals="-6" id="f-407" unitRef="usd">-1993000000</hum:PaymentsForProceedsFromContractDeposits>
    <hum:PaymentsForProceedsFromContractDeposits contextRef="c-7" decimals="-6" id="f-408" unitRef="usd">306000000</hum:PaymentsForProceedsFromContractDeposits>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt contextRef="c-1" decimals="-6" id="f-409" unitRef="usd">2544000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt contextRef="c-6" decimals="-6" id="f-410" unitRef="usd">1982000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt contextRef="c-7" decimals="-6" id="f-411" unitRef="usd">2984000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:RepaymentsOfSeniorDebt contextRef="c-1" decimals="-6" id="f-412" unitRef="usd">1832000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt contextRef="c-6" decimals="-6" id="f-413" unitRef="usd">1000000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt contextRef="c-7" decimals="-6" id="f-414" unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:ProceedsFromRepaymentsOfCommercialPaper contextRef="c-1" decimals="-6" id="f-415" unitRef="usd">211000000</us-gaap:ProceedsFromRepaymentsOfCommercialPaper>
    <us-gaap:ProceedsFromRepaymentsOfCommercialPaper contextRef="c-6" decimals="-6" id="f-416" unitRef="usd">-376000000</us-gaap:ProceedsFromRepaymentsOfCommercialPaper>
    <us-gaap:ProceedsFromRepaymentsOfCommercialPaper contextRef="c-7" decimals="-6" id="f-417" unitRef="usd">352000000</us-gaap:ProceedsFromRepaymentsOfCommercialPaper>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-1" decimals="-6" id="f-418" unitRef="usd">100000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-6" decimals="-6" id="f-419" unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-7" decimals="-6" id="f-420" unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-1" decimals="-6" id="f-421" unitRef="usd">100000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-6" decimals="-6" id="f-422" unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-7" decimals="-6" id="f-423" unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt contextRef="c-1" decimals="-6" id="f-424" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt contextRef="c-6" decimals="-6" id="f-425" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt contextRef="c-7" decimals="-6" id="f-426" unitRef="usd">2500000000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt contextRef="c-1" decimals="-6" id="f-427" unitRef="usd">500000000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt contextRef="c-6" decimals="-6" id="f-428" unitRef="usd">2000000000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt contextRef="c-7" decimals="-6" id="f-429" unitRef="usd">2078000000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-6" id="f-430" unitRef="usd">7000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-6" decimals="-6" id="f-431" unitRef="usd">6000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-7" decimals="-6" id="f-432" unitRef="usd">31000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-6" id="f-433" unitRef="usd">1573000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-6" decimals="-6" id="f-434" unitRef="usd">2096000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-7" decimals="-6" id="f-435" unitRef="usd">79000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividends contextRef="c-1" decimals="-6" id="f-436" unitRef="usd">431000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c-6" decimals="-6" id="f-437" unitRef="usd">392000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c-7" decimals="-6" id="f-438" unitRef="usd">354000000</us-gaap:PaymentsOfDividends>
    <us-gaap:IncreaseDecreaseInBookOverdrafts contextRef="c-1" decimals="-6" id="f-439" unitRef="usd">55000000</us-gaap:IncreaseDecreaseInBookOverdrafts>
    <us-gaap:IncreaseDecreaseInBookOverdrafts contextRef="c-6" decimals="-6" id="f-440" unitRef="usd">-28000000</us-gaap:IncreaseDecreaseInBookOverdrafts>
    <us-gaap:IncreaseDecreaseInBookOverdrafts contextRef="c-7" decimals="-6" id="f-441" unitRef="usd">6000000</us-gaap:IncreaseDecreaseInBookOverdrafts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-1" decimals="-6" id="f-442" unitRef="usd">-151000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-6" decimals="-6" id="f-443" unitRef="usd">9000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-7" decimals="-6" id="f-444" unitRef="usd">21000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-6" id="f-445" unitRef="usd">-856000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-6" decimals="-6" id="f-446" unitRef="usd">-1914000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-6" id="f-447" unitRef="usd">3015000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-6" id="f-448" unitRef="usd">-367000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-6" decimals="-6" id="f-449" unitRef="usd">1667000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-6" id="f-450" unitRef="usd">-1279000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-6" id="f-451" unitRef="usd">5061000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="-6" id="f-452" unitRef="usd">3394000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-15" decimals="-6" id="f-453" unitRef="usd">4673000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-6" id="f-454" unitRef="usd">4694000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-6" id="f-455" unitRef="usd">5061000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-29" decimals="-6" id="f-456" unitRef="usd">3394000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-6" id="f-457" unitRef="usd">394000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-6" decimals="-6" id="f-458" unitRef="usd">354000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-7" decimals="-6" id="f-459" unitRef="usd">285000000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-6" id="f-460" unitRef="usd">997000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-6" decimals="-6" id="f-461" unitRef="usd">758000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-7" decimals="-6" id="f-462" unitRef="usd">227000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:FairValueOfAssetsAcquired contextRef="c-1" decimals="-6" id="f-463" unitRef="usd">462000000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired contextRef="c-6" decimals="-6" id="f-464" unitRef="usd">460000000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired contextRef="c-7" decimals="-6" id="f-465" unitRef="usd">9804000000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:LiabilitiesAssumed1 contextRef="c-1" decimals="-6" id="f-466" unitRef="usd">234000000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1 contextRef="c-6" decimals="-6" id="f-467" unitRef="usd">70000000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1 contextRef="c-7" decimals="-6" id="f-468" unitRef="usd">3235000000</us-gaap:LiabilitiesAssumed1>
    <hum:NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired contextRef="c-1" decimals="-6" id="f-469" unitRef="usd">-5000000</hum:NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired>
    <hum:NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired contextRef="c-6" decimals="-6" id="f-470" unitRef="usd">53000000</hum:NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired>
    <hum:NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired contextRef="c-7" decimals="-6" id="f-471" unitRef="usd">22000000</hum:NoncashOrPartNoncashAcquisitionNoncontrollingInterestAcquired>
    <hum:NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment contextRef="c-1" decimals="-6" id="f-472" unitRef="usd">0</hum:NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment>
    <hum:NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment contextRef="c-6" decimals="-6" id="f-473" unitRef="usd">0</hum:NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment>
    <hum:NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment contextRef="c-7" decimals="-6" id="f-474" unitRef="usd">2360000000</hum:NoncashOrPartNoncashAcquisitionRemeasurementOfEquityInvestment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-6" id="f-475" unitRef="usd">233000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-6" decimals="-6" id="f-476" unitRef="usd">337000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-7" decimals="-6" id="f-477" unitRef="usd">4187000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-478">REPORTING ENTITY&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nature of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Humana Inc., headquartered in Louisville, Kentucky, is committed to putting health first &#x2013; for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health &#x2013; delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. References throughout these notes to consolidated financial statements to &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;Company,&#x201d; and &#x201c;Humana,&#x201d; mean Humana Inc. and its subsidiaries. We derived approximately 84% of our total premiums and services revenue from contracts with the federal government in 2023, including 14% related to our federal government contracts with the Centers for Medicare and Medicaid Services, or CMS, to provide health insurance coverage for individual Medicare Advantage members in Florida. CMS is the federal government&#x2019;s agency responsible for administering the Medicare program.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-58" decimals="2" id="f-479" unitRef="number">0.84</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-59" decimals="2" id="f-480" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-481">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. Our consolidated financial statements include the accounts of Humana Inc. and subsidiaries that the Company controls, including variable interest entities associated with medical practices for which we are the primary beneficiary. We do not own many of our medical practices but instead enter into exclusive management agreements with the affiliated Professional Associations, or P.A.s, that operate these medical practices. Based upon the provisions of these agreements, these affiliated P.A.s are variable interest entities and we are the primary beneficiary, and accordingly we consolidate the affiliated P.A.s. All significant intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Value Creation Initiatives and Impairment Charges &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our healthcare services capabilities beginning in 2022, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, we recorded charges of $436&#160;million and $473&#160;million in 2023 and 2022, respectively, within operating costs in the consolidated statements of income. These charges were recorded at the corporate level and not allocated to the segments. We expect to incur additional charges through the end of 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The value creation initiative charges primarily relate to $237&#160;million and $248&#160;million in asset impairments in 2023 and 2022, respectively, as well as $199&#160;million and $116&#160;million in severance charges in connection with workforce optimization in 2023 and 2022, respectively. The remainder of the 2022 charges primarily relate to external consulting fees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2023, we also recorded severance charges of $70&#160;million within operating costs in our consolidated statement of income as a result of our exit from the Employer Group Commercial Medical Products business and impairment charges of $91&#160;million, including $55&#160;million relating to indefinite-lived intangibles. The indefinite-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lived intangibles impairment charges were included within operating costs in our consolidated statement of income with the remaining impairment charges included within investment income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:103%"&gt;COVID-19&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The emergence and spread of the novel coronavirus, or COVID-19, beginning in the first quarter of 2020 has impacted our business. Initially during periods of increased incidences of COVID-19, a reduction in non-COVID-19 hospital admissions for non-emergent and elective medical care resulted in lower overall healthcare system utilization. At the same time, COVID-19 treatment and testing costs increased utilization. During 2022, we experienced lower overall utilization of the healthcare system than anticipated, as the reduction in COVID-19 utilization following the increased incidence associated with the Omicron variant outpaced the increase in non-COVID-19 utilization. The significant disruption in utilization during 2020 also impacted our ability to implement clinical initiatives to manage health care costs and chronic conditions of our members, and appropriately document their risk profiles, and, as such, significantly affected our 2021 revenue under the risk adjustment payment model for Medicare Advantage plans. Finally, changes in utilization patterns and actions taken in 2021 as a result of the COVID-19 pandemic, including the suspension of certain financial recovery programs for a period of time and shifting the timing of claim payments and provider capitation surplus payments, impacted our claim reserve development and operating cash flows for 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 National Emergency declared in 2020 was terminated on April 10, 2023 and the Public Health Emergency expired on May 11, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include cash, time deposits, money market funds, commercial paper, other money market instruments, and certain U.S. Government securities with an original maturity of three months or less. Carrying value approximates fair value due to the short-term maturity of the investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investment Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment securities, which consist of debt and equity securities, are stated at fair value. Our debt securities have been categorized as available for sale. Debt securities available for current operations, as well as our equity securities, are classified as current assets, and debt securities available to fund our professional and other self-insurance liability requirements, as well as restricted statutory deposits, are classified as long-term assets. For the purpose of determining realized gross gains and losses for debt securities sold, that are included as a component of investment income in the consolidated statements of income, the cost of investment securities sold is based upon specific identification. Unrealized holding gains and losses for debt securities, net of applicable deferred taxes, are included in other comprehensive income or loss as a component of stockholders&#x2019; equity until realized from a sale or an expected credit loss is recognized. For the purpose of determining gross gains and losses for equity securities, changes in fair value at the reporting date are included as a component of investment income in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the current expected credit losses model, or CECL, expected losses on available for sale debt securities are recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities. For debt securities whose fair value is less than their amortized cost which we do not intend to sell or are not required to sell, we evaluate the expected cash flows to be received as compared to amortized cost and determine if an expected credit loss has occurred. In the event of an expected credit loss, only the amount of the impairment associated with the expected credit loss is recognized in income with the remainder, if any, of the loss recognized in other comprehensive income.  To the extent we have the intent to sell the debt security or it is more likely than not we will be required to sell the debt security before recovery of our amortized cost basis, we recognize an impairment loss in income in an amount equal to the full difference between the amortized cost basis and the fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential expected credit loss impairment is considered using a variety of factors, including the extent to which the fair value has been less than cost; adverse conditions specifically related to the industry, geographic area or financial condition of the issuer or underlying collateral of a debt security; changes in the quality of the debt &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;security's credit enhancement; payment structure of the debt security; changes in credit rating of the debt security by the rating agencies; failure of the issuer to make scheduled principal or interest payments on the debt security and changes in prepayment speeds. For debt securities, we take into account expectations of relevant market and economic data. For example, with respect to mortgage and asset-backed securities, such data includes underlying loan level data and structural features such as seniority and other forms of credit enhancements. We estimate the amount of the expected credit loss component of a debt security as the difference between the amortized cost and the present value of the expected cash flows of the security. The present value is determined using the best estimate of future cash flows discounted at the implicit interest rate at the date of purchase. The expected credit loss cannot exceed the full difference between the amortized cost basis and the fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables and Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally establish one-year commercial membership contracts with employer groups, subject to cancellation by the employer group on 30-day written notice. Our Medicare contracts with CMS renew annually. Our military services contracts with the federal government and certain contracts with various state Medicaid programs generally are multi-year contracts subject to annual renewal provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Premiums Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive monthly premiums from the federal government and various states according to government specified payment rates and various contractual terms. We bill and collect premium from employer groups and members in our Medicare and other individual products monthly.  Changes in premium revenues resulting from the periodic changes in risk-adjustment scores derived from medical diagnoses for our membership are estimated by projecting the ultimate annual premium and are recognized ratably during the year, with adjustments each period to reflect changes in the ultimate premium. Receivables or payables are classified as current or long-term in our consolidated balance sheet based on the timing of the expected settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premiums revenue is estimated by multiplying the membership covered under the various contracts by the contractual rates. Premiums revenue is recognized as income in the period members are entitled to receive services and is net of estimated uncollectible amounts, retroactive membership adjustments, and adjustments to recognize rebates under the minimum benefit ratios required under the Health Care Reform Law. We estimate policyholder rebates by projecting calendar year minimum benefit ratios for the small group and large group markets, as defined by the Health Care Reform Law using a methodology prescribed by Health and Human Services, or HHS, separately by state and legal entity. Medicare Advantage and Medicaid products are also subject to minimum benefit ratio requirements. Estimated calendar year rebates recognized ratably during the year are revised each period to reflect current experience. Retroactive membership adjustments result from enrollment changes not yet processed, or not yet reported by an employer group or the government. We routinely monitor the collectability of specific accounts, the aging of receivables, historical retroactivity trends, estimated rebates, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. Premiums received prior to the service period are recorded as unearned revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Part D&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with CMS. The payments we receive monthly from CMS and members, which are determined from our annual bid, represent amounts for providing prescription drug insurance coverage. We recognize premiums revenue for providing this insurance coverage ratably over the term of our annual contract. Our CMS payment is subject to risk sharing through the Medicare Part D risk corridor provisions. In addition, receipts for reinsurance and low-income cost subsidies as well as receipts for certain discounts on brand name prescription drugs in the coverage gap represent payments for prescription drug costs for which we are not at risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk corridor provisions compare costs targeted in our bids to actual prescription drug costs, limited to actual costs that would have been incurred under the standard coverage as defined by CMS. Variances exceeding certain thresholds may result in CMS making additional payments to us or require us to refund to CMS a portion of the premiums we received. As risk corridor provisions are considered in our overall annual bid process, we estimate &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and recognize an adjustment to premiums revenue related to these provisions based upon pharmacy claims experience. We record a receivable or payable at the contract level and classify the amount as current or long-term in our consolidated balance sheets based on the timing of expected settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reinsurance and low-income cost subsidies represent funding from CMS in connection with the Medicare Part D program for which we assume no risk. Reinsurance subsidies represent funding from CMS for its portion of prescription drug costs which exceed the member&#x2019;s out-of-pocket threshold, or the catastrophic coverage level. Low-income cost subsidies represent funding from CMS for all or a portion of the deductible, the coinsurance and co-payment amounts above the out-of-pocket threshold for low-income beneficiaries. Monthly prospective payments from CMS for reinsurance and low-income cost subsidies are based on assumptions submitted with our annual bid. A reconciliation and related settlement of CMS&#x2019;s prospective subsidies against actual prescription drug costs we paid is made after the end of the year. The Health Care Reform Law mandates consumer discounts of 50% on brand name prescription drugs for Part D plan participants in the coverage gap. These discounts are funded by CMS and pharmaceutical manufacturers while we administer the application of these funds. We account for these subsidies and discounts as a deposit in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits, net in our consolidated statements of cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.896%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Part D subsidy/discount payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Part D subsidy/discount reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net reimbursements (payments)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not recognize premiums revenue or benefit expenses for these subsidies or discounts. Receipt and payment activity is accumulated at the contract level and recorded in our consolidated balance sheets in other current assets or trade accounts payable and accrued expenses depending on the contract balance at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Settlement of the reinsurance and low-income cost subsidies as well as the risk corridor payment is based on a reconciliation made approximately 9 months after the close of each calendar year. Settlement with CMS for brand name prescription drug discounts is based on a reconciliation made approximately 14 to 18 months after the close of each calendar year. We continue to revise our estimates with respect to the risk corridor provisions based on subsequent period pharmacy claims data. For additional information regarding amounts recorded to our consolidated balance sheets related to the risk corridor settlement and subsidies from CMS with respect to the Medicare Part D program, refer to Note 7 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patient services revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient services include services related to pharmacy solutions, primary care, and home solutions and other services and capabilities to promote wellness and advance population health. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our pharmacy solutions business, external pharmacy revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments for drugs dispensed through our CenterWell Pharmacy (our mail-order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Services revenues related to product revenues from dispensing prescriptions are recorded when the prescription or product is shipped.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our primary care business recognizes revenues for certain value-based arrangements. Under these value-based arrangements, we enter into agreements with health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our patients. In exchange, we receive a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our patients. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our home solutions businesses, revenues include net patient services revenue recorded based upon established billing rates, net of contractual allowances, discounts, or other implicit price concessions, and are recognized as performance obligations are satisfied, which is in the period services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the&#160;year ended December&#160;31, 2023, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price), was not material. Further, revenue expected to be recognized in any future year related to remaining performance obligations is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Administrative services fees &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Administrative services fees cover the processing of claims, offering access to our provider networks and clinical programs, and responding to customer service inquiries from members of self-funded groups. Revenues from providing administration services, also known as administrative services only, or ASO, are recognized in the period services are performed and are net of estimated uncollectible amounts. ASO fees are estimated by multiplying the membership covered under the various contracts by the contractual rates. Under ASO contracts, self-funded employers retain the risk of financing substantially all of the cost of health benefits. However, many ASO customers purchase stop loss insurance coverage from us to cover catastrophic claims or to limit aggregate annual costs. Accordingly, we have recorded premiums revenue and benefits expense related to these stop loss insurance contracts. We routinely monitor the collectability of specific accounts, the aging of receivables, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. ASO fees received prior to the service period are recorded as unearned revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under our TRICARE contracts with the Department of Defense (DoD) we provide administrative services, including offering access to our provider networks and clinical programs, claim processing, customer service, enrollment, and other services, while the federal government retains all of the risk of the cost of health benefits. We account for revenues under our contracts net of estimated health care costs similar to an administrative services fee only agreement. Our contracts include fixed administrative services fees and incentive fees and penalties. Administrative services fees are recognized as services are performed.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our TRICARE members are served by both in-network and out-of-network providers in accordance with our contracts. We pay health care costs related to these services to the providers and are subsequently reimbursed by the DoD for such payments. We account for the payments of the federal government&#x2019;s claims and the related reimbursements under deposit accounting in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits, net in our consolidated statements of cash flows.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.450%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care cost payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care cost reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net reimbursements (payments)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, including premium receivables, patient services revenue receivables, and ASO fee receivables, are shown net of allowances for estimated uncollectible accounts, retroactive membership adjustments, and contractual allowances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At&#160;December&#160;31, 2023 and 2022, accounts receivable related to services were $357 million and $291 million, respectively. For the&#160;years ended December&#160;31, 2023, 2022 and 2021, we had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the consolidated balance sheet at&#160;December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets include amounts associated with Medicare Part D, rebates due from pharmaceutical manufacturers and other amounts due within one year.  We accrue pharmaceutical rebates as they are earned based on contractual terms and usage of the product.  The balance of pharmaceutical rebates receivable was $2.3 billion and $2.0&#160;billion at December&#160;31, 2023 and 2022, respectively. For additional information regarding amounts associated with Medicare Part D, refer to Note 7 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Policy Acquisition Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Policy acquisition costs are those costs that relate directly to the successful acquisition of new and renewal insurance policies. Such costs include commissions, costs of policy issuance and underwriting, and other costs we incur to acquire new business or renew existing business. We expense policy acquisition costs related to our employer-group prepaid health services policies as incurred. These short-duration employer-group prepaid health services policies typically have a 1-year term and may be canceled upon 30 days notice by the employer group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is recorded at cost. Gains and losses on sales or disposals of property and equipment are included in operating costs in our consolidated income statements. Certain costs related to the development or purchase of internal-use software are capitalized. Depreciation is computed using the straight-line method over estimated useful lives ranging from 3 to 10 years for equipment, 3 to 5 years for computer software, and 10 to 20 years for buildings. Improvements to leased facilities are depreciated over the shorter of the remaining lease term or the anticipated life of the improvement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically review long-lived assets, including property and equipment and other definite-lived intangible assets, for impairment whenever adverse events or changes in circumstances indicate the carrying value of the asset may not be recoverable. Losses are recognized for a long-lived asset to be held and used in our operations when the undiscounted future cash flows expected to result from the use of the asset are less than its carrying value. We recognize an impairment loss based on the excess of the carrying value over the fair value of the asset. A long-lived asset held for sale is reported at the lower of the carrying amount or fair value less costs to sell. Depreciation expense is not recognized on assets held for sale. Losses are recognized for a long-lived asset to be abandoned when the asset ceases to be used. In addition, we periodically review the estimated lives of all long-lived assets for reasonableness.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the equity method of accounting for equity investments in companies where we are able to exercise significant influence, but not control, over operating and financial policies of the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as our ownership interest, representation on the board of directors, organizational structure, participation in policy-making decisions and material intra-entity transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, under the equity method, original investments in these entities are recorded at cost and subsequently adjusted by our share of equity in income or losses after the date of acquisition as well as capital contributions to and distributions from these companies. Our proportionate share of the net income or loss of these companies is included in consolidated net income.  Investment amounts in excess of our share of an investee&#x2019;s net assets are amortized over the life of the related asset creating the excess. Excess goodwill is not amortized. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered by us when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than carrying value, the investee&#x2019;s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information regarding our equity method investments, refer to Note 4 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the unamortized excess of cost over the fair value of the net tangible and other intangible assets acquired. We are required to test at least annually for impairment at a level of reporting referred to as the reporting unit, and more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. A reporting unit either is our operating segments or one level below the operating segments, referred to as a component, which comprise our reportable segments. A component is considered a reporting unit if the component constitutes a business for which discrete financial information is available that is regularly reviewed by management. We aggregate the components of an operating segment into one reporting unit if they have similar economic characteristics. Goodwill is assigned to the reporting units that are expected to benefit from the specific synergies of the business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform a quantitative assessment to review goodwill for impairment to determine both the existence and amount of goodwill impairment, if any. Impairment tests are performed, at a minimum, in the fourth quarter of each year supported by our long-range business plan and annual planning process. We rely on an evaluation of future discounted cash flows to determine fair value of our reporting units. The fair value of our reporting units with significant goodwill exceeded carrying amounts. However, unfavorable changes in key assumptions or combinations of assumptions including a significant increase in the discount rate, decrease in the long-term growth rate or substantial reduction in our underlying cash flow assumptions, including revenue growth rates, medical and operating cost trends, and projected operating income could have a significant negative impact on the estimated fair value of our home solutions and primary care reporting units, which accounted for $4.4&#160;billion and $1.2&#160;billion of goodwill, respectively. Impairment tests completed for 2023, 2022, and 2021 did not result in an impairment loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with indefinite lives relate to Certificate of Needs (CON) and Medicare licenses acquired as part of our acquisition of Kindred at Home, or KAH, and are included within other long-term assets in the consolidated balance sheet at December&#160;31, 2023 and December&#160;31, 2022. For additional information regarding our acquisition of KAH, refer to Note 3 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K. We are required to annually compare the fair values of other indefinite-lived intangible assets to their carrying amounts. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized. Fair values of indefinite-lived intangible assets are determined based on the income approach. Impairment tests completed for 2023 and 2022 did not result in material impairment losses. These charges reflect the amount by which the carrying value exceeded its estimated fair value. Impairment tests completed for 2021 did not result in an impairment loss. The fair values of the assets were measured using Level 3 inputs, such as projected revenues and operating cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Definite-lived intangible assets primarily relate to acquired customer contracts/relationships and are included with other long-term assets in the consolidated balance sheets. Definite-lived intangible assets are amortized over the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;useful life generally using the straight-line method. We review definite-lived intangible assets for impairment under our long-lived asset policy.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Benefits Payable and Benefits Expense Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Benefits expense includes claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care and other supplemental benefits provided on or prior to the balance sheet date. Capitation payments represent monthly contractual fees disbursed to primary care and other providers who are responsible for providing medical care to members. Pharmacy costs represent payments for members&#x2019; prescription drug benefits, net of rebates from drug manufacturers. Receivables for such pharmacy rebates are included in other current assets in our consolidated balance sheets. Other supplemental benefits include dental, vision, and other supplemental health products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the costs of our benefits expense payments using actuarial methods and assumptions based upon claim payment patterns, medical cost inflation, historical developments such as claim inventory levels and claim receipt patterns, and other relevant factors, and record benefit reserves for future payments. We continually review estimates of future payments relating to claims costs for services incurred in the current and prior periods and make necessary adjustments to our reserves.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Benefits expense is recognized in the period in which services are provided and includes an estimate of the cost of services which have been incurred but not yet reported, or IBNR. Our reserving practice is to consistently recognize the actuarial best point estimate within a level of confidence required by actuarial standards. Actuarial standards of practice generally require a level of confidence such that the liabilities established for IBNR have a greater probability of being adequate versus being insufficient, or such that the liabilities established for IBNR are sufficient to cover obligations under an assumption of moderately adverse conditions. Adverse conditions are situations in which the actual claims are expected to be higher than the otherwise estimated value of such claims at the time of the estimate. Therefore, in many situations, the claim amounts ultimately settled will be less than the estimate that satisfies the actuarial standards of practice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We develop our estimate for IBNR using actuarial methodologies and assumptions, primarily based upon historical claim experience. Depending on the period for which incurred claims are estimated, we apply a different method in determining our estimate. For periods prior to the most recent two months, a completion factor method uses historical paid claims patterns to estimate the percentage of claims incurred during a given period that have historically been adjudicated as of the reporting period. Changes in claim inventory levels and known changes in claim payment processes are taken into account in these estimates. For the most recent two months, the incurred claims are estimated primarily from a trend analysis based upon per member per month claims trends developed from our historical experience in the preceding months, adjusted for known changes in estimates of hospital admissions, recent hospital and drug utilization data, provider contracting changes, changes in benefit levels, changes in member cost sharing, changes in medical management processes, product mix, and workday seasonality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The completion factor method is used for the months of incurred claims prior to the most recent two months because the historical percentage of claims processed for those months is at a level sufficient to produce a consistently reliable result. Conversely, for the most recent two months of incurred claims, the volume of claims processed historically is not at a level sufficient to produce a reliable result, which therefore requires us to examine historical trend patterns as the primary method of evaluation. Changes in claim processes, including recoveries of overpayments, receipt cycle times, claim inventory levels, outsourcing, system conversions, and processing disruptions due to weather or other events affect views regarding the reasonable choice of completion factors. Claim payments to providers for services rendered are often net of overpayment recoveries for claims paid previously, as contractually allowed. Claim overpayment recoveries can result from many different factors, including retroactive enrollment activity, audits of provider billings, and/or payment errors. Changes in patterns of claim overpayment recoveries can be unpredictable and result in completion factor volatility, as they often impact older dates of service. The receipt cycle time measures the average length of time between when a medical claim was initially incurred and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;when the claim form was received. Increases in electronic claim submissions from providers decrease the receipt cycle time. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claim may be more (less) complete than originally estimated using our completion factors, which may result in reserves that are higher (lower) than required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical cost trends potentially are more volatile than other segments of the economy. The drivers of medical cost trends include increases in the utilization of hospital facilities, physician services, new higher priced technologies and medical procedures, and new prescription drugs and therapies, as well as the inflationary effect on the cost per unit of each of these expense components. Other external factors such as government-mandated benefits or other regulatory changes, the tort liability system, increases in medical services capacity, direct to consumer advertising for prescription drugs and medical services, an aging population, lifestyle changes including diet and smoking, catastrophes, public health emergencies, epidemics and pandemics (such as COVID-19) also may impact medical cost trends. Internal factors such as system conversions, claims processing cycle times, changes in medical management practices and changes in provider contracts also may impact our ability to accurately predict estimates of historical completion factors or medical cost trends. All of these factors are considered in estimating IBNR and in estimating the per member per month claims trend for purposes of determining the reserve for the most recent two months. Additionally, we continually prepare and review follow-up studies to assess the reasonableness of the estimates generated by our process and methods over time. The results of these studies are also considered in determining the reserve for the most recent two months. Each of these factors requires significant judgment by management.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reassess the profitability of our contracts for providing insurance coverage to our members when current operating results or forecasts indicate probable future losses. We establish a premium deficiency reserve in current operations to the extent that the sum of expected future costs, claim adjustment expenses, and maintenance costs exceeds related future premiums under contracts. For purposes of determining premium deficiencies, contracts are grouped in a manner consistent with our method of acquiring, servicing, and measuring the profitability of such contracts. Losses recognized as a premium deficiency result in a beneficial effect in subsequent periods as operating losses under these contracts are charged to the liability previously established. Because the majority of our member contracts renew annually, we would not record a material premium deficiency reserve, except when unanticipated adverse events or changes in circumstances indicate otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe our benefits payable are adequate to cover future claims payments required. However, such estimates are based on knowledge of current events and anticipated future events. Therefore, the actual liability could differ materially from the amounts provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Future policy benefits payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future policy benefits payable includes liabilities for long-duration insurance policies primarily related to certain blocks of insurance assumed in acquisitions, primarily life and annuities in run-off status, and are included in our consolidated balance sheet within other long-term liabilities. Most of these policies are subject to reinsurance. For additional information regarding reinsurance, refer to Note 19 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Book Overdraft&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our cash management system, checks issued but not yet presented to banks that would result in negative bank balances when presented are classified as a current liability in the consolidated balance sheets. Changes in book overdrafts from period to period are reported in the consolidated statement of cash flows as a financing activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets or liabilities and their reported amounts in the consolidated financial statements. These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;liabilities are recovered or settled. We also recognize the future tax benefits such as net operating and capital loss carryforwards as deferred tax assets. A valuation allowance is provided against these deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized. Future years&#x2019; tax expense may be increased or decreased by adjustments to the valuation allowance or to the estimated accrual for income taxes. Deferred tax assets and deferred tax liabilities are further adjusted for changes in the enacted tax rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record tax benefits when it is more likely than not that the tax return position taken with respect to a particular transaction will be sustained. A liability, if recorded, is not considered resolved until the statute of limitations for the relevant taxing authority to examine and challenge the tax position has expired, or the tax position is ultimately settled through examination, negotiation, or litigation. We classify interest and penalties associated with uncertain tax positions in our provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Noncontrolling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include all assets, liabilities, revenues and expenses of less than 100% owned affiliates that we control. Accordingly, we record noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interest holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interest holders&#x2019; balances. Noncontrolling interests, which relate to the minority ownership held by third party investors in certain of our businesses within our Insurance and CenterWell segments, are reported below net income under the heading &#x201c;Net income attributable to noncontrolling interests&#x201d; in the consolidated statements of income and presented as a component of equity in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally recognize stock-based compensation expense, as determined on the date of grant at fair value, on a straight-line basis over the period during which an employee is required to provide service in exchange for the award (the vesting period). In addition, for awards with both time and performance-based conditions, we generally recognize compensation expense on a straight line basis over the vesting period when it is probable that the performance condition will be achieved. We estimate expected forfeitures and recognize compensation expense only for those awards which are expected to vest. We estimate the grant-date fair value of stock options using the Black-Scholes option-pricing model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; For additional information regarding our stock-based compensation plans, refer to Note 14 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We compute basic earnings per common share on the basis of the weighted-average number of unrestricted common shares outstanding. Diluted earnings per common share is computed on the basis of the weighted-average number of unrestricted common shares outstanding plus the dilutive effect of outstanding employee stock options and restricted shares, or units, using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information regarding our earnings per share, refer to Note 15 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are categorized into a fair value hierarchy based on whether the inputs to valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our own assumptions about the assumptions market participants would use. The fair value hierarchy includes three levels of inputs that may be used to measure fair value as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities include securities that are traded in an active exchange market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2013; Observable inputs other than Level 1 prices such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less frequently than exchange-traded instruments as well as debt securities whose value is determined using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes assets and liabilities whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting our own assumptions about the assumptions market participants would use as well as those requiring significant management judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of actively traded debt and equity securities are based on quoted market prices. Fair value of other debt securities are based on quoted market prices of identical or similar securities or based on observable inputs like interest rates generally using a market valuation approach, or, less frequently, an income valuation approach and are generally classified as Level 2. Fair value of privately held investment grade debt securities are estimated using a variety of valuation methodologies, including both market and income approaches, where an observable quoted market does not exist and are generally classified as Level 3. For privately-held investment grade debt securities, such methodologies include reviewing the value ascribed to the most recent financing, comparing the security with securities of publicly-traded companies in similar lines of business with similar credit characteristics, and reviewing the underlying financial performance including estimating discounted cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We obtain at least one price for each security from a third party pricing service. These prices are generally derived from recently reported trades for identical or similar securities, including adjustments through the reporting date based upon observable market information. When quoted prices are not available, the third party pricing service may use quoted market prices of comparable securities or discounted cash flow analysis, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include benchmark yields, reported trades, credit spreads, broker quotes, default rates, and prepayment speeds. We are responsible for the determination of fair value and as such we perform analysis on the prices received from the third party pricing service to determine whether the prices are reasonable estimates of fair value. Our analysis includes a review of monthly price fluctuations as well as a quarterly comparison of the prices received from the pricing service to prices reported by our third party investment adviser. In addition, on a quarterly basis we examine the underlying inputs and assumptions for a sample of individual securities across asset classes, credit rating levels, and various durations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services&#x2014;Insurance (Topic 944): Effective Date and Early Application (&#x201c;ASU 2020-11&#x201d;). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services&#x2014;Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (&#x201c;ASU 2018-12&#x201d;), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The new guidance relates to accounting for long-duration contracts of insurers which revises key elements of the measurement models and disclosure requirements for long-duration contracts issued by insurers, including the amortization of deferred contract acquisition costs and the measurement of liabilities for future policy benefits using current, rather than locked-in, assumptions. The new guidance, limited to our Medicare Supplement product which represents less than 1% of consolidated premiums and services revenue, became effective for us &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;beginning January 1, 2023 and was applied to contracts in force on the basis of their existing carrying value amounts at the beginning of the earliest period presented. The adoption of the new standard in 2023 did not have a material impact on our consolidated results of operations, financial position or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Pronouncements Effective in Future Periods&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting &#x2014; Improvements to Reportable Segment Disclosures. The new guidance requires incremental disclosures related to a public entity&#x2019;s reportable segments but does not change the definition of a segment, the method for determining segments, or the criteria for aggregating operating segments into reportable segments. The new guidance requires a public entity to disclose its significant segment expense categories and amounts for each reportable segment. The new guidance will be effective for us beginning with our annual 2024 year-end financial statements. We are currently evaluating the impact on our segment information footnote disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued Accounting Standards Update No. 2023-09 &#x2014; Income Taxes (Topic 740): Improvements to Income Tax Disclosures.  The new guidance requires significant additional disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be effective for us beginning with our annual 2025 year-end financial statements, with early adoption permitted.  We are currently evaluating the impact on our income tax footnote disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-482">&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. Our consolidated financial statements include the accounts of Humana Inc. and subsidiaries that the Company controls, including variable interest entities associated with medical practices for which we are the primary beneficiary. We do not own many of our medical practices but instead enter into exclusive management agreements with the affiliated Professional Associations, or P.A.s, that operate these medical practices. Based upon the provisions of these agreements, these affiliated P.A.s are variable interest entities and we are the primary beneficiary, and accordingly we consolidate the affiliated P.A.s. All significant intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges contextRef="c-60" decimals="-6" id="f-483" unitRef="usd">436000000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:RestructuringCostsAndAssetImpairmentCharges contextRef="c-61" decimals="-6" id="f-484" unitRef="usd">473000000</us-gaap:RestructuringCostsAndAssetImpairmentCharges>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="c-60" decimals="-6" id="f-485" unitRef="usd">237000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="c-61" decimals="-6" id="f-486" unitRef="usd">248000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:SeveranceCosts1 contextRef="c-60" decimals="-6" id="f-487" unitRef="usd">199000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-61" decimals="-6" id="f-488" unitRef="usd">116000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-62" decimals="-6" id="f-489" unitRef="usd">70000000</us-gaap:SeveranceCosts1>
    <us-gaap:AssetImpairmentCharges contextRef="c-62" decimals="-6" id="f-490" unitRef="usd">91000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-62" decimals="-6" id="f-491" unitRef="usd">55000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-492">&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents include cash, time deposits, money market funds, commercial paper, other money market instruments, and certain U.S. Government securities with an original maturity of three months or less. Carrying value approximates fair value due to the short-term maturity of the investments.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-493">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investment Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment securities, which consist of debt and equity securities, are stated at fair value. Our debt securities have been categorized as available for sale. Debt securities available for current operations, as well as our equity securities, are classified as current assets, and debt securities available to fund our professional and other self-insurance liability requirements, as well as restricted statutory deposits, are classified as long-term assets. For the purpose of determining realized gross gains and losses for debt securities sold, that are included as a component of investment income in the consolidated statements of income, the cost of investment securities sold is based upon specific identification. Unrealized holding gains and losses for debt securities, net of applicable deferred taxes, are included in other comprehensive income or loss as a component of stockholders&#x2019; equity until realized from a sale or an expected credit loss is recognized. For the purpose of determining gross gains and losses for equity securities, changes in fair value at the reporting date are included as a component of investment income in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the current expected credit losses model, or CECL, expected losses on available for sale debt securities are recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities. For debt securities whose fair value is less than their amortized cost which we do not intend to sell or are not required to sell, we evaluate the expected cash flows to be received as compared to amortized cost and determine if an expected credit loss has occurred. In the event of an expected credit loss, only the amount of the impairment associated with the expected credit loss is recognized in income with the remainder, if any, of the loss recognized in other comprehensive income.  To the extent we have the intent to sell the debt security or it is more likely than not we will be required to sell the debt security before recovery of our amortized cost basis, we recognize an impairment loss in income in an amount equal to the full difference between the amortized cost basis and the fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential expected credit loss impairment is considered using a variety of factors, including the extent to which the fair value has been less than cost; adverse conditions specifically related to the industry, geographic area or financial condition of the issuer or underlying collateral of a debt security; changes in the quality of the debt &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;security's credit enhancement; payment structure of the debt security; changes in credit rating of the debt security by the rating agencies; failure of the issuer to make scheduled principal or interest payments on the debt security and changes in prepayment speeds. For debt securities, we take into account expectations of relevant market and economic data. For example, with respect to mortgage and asset-backed securities, such data includes underlying loan level data and structural features such as seniority and other forms of credit enhancements. We estimate the amount of the expected credit loss component of a debt security as the difference between the amortized cost and the present value of the expected cash flows of the security. The present value is determined using the best estimate of future cash flows discounted at the implicit interest rate at the date of purchase. The expected credit loss cannot exceed the full difference between the amortized cost basis and the fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <hum:CommercialMembershipContractTerm contextRef="c-1" id="f-494">P1Y</hum:CommercialMembershipContractTerm>
    <hum:NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies contextRef="c-1" id="f-495">P30D</hum:NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies>
    <us-gaap:InsurancePremiumsRevenueRecognitionPolicy contextRef="c-1" id="f-496">&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Premiums Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive monthly premiums from the federal government and various states according to government specified payment rates and various contractual terms. We bill and collect premium from employer groups and members in our Medicare and other individual products monthly.  Changes in premium revenues resulting from the periodic changes in risk-adjustment scores derived from medical diagnoses for our membership are estimated by projecting the ultimate annual premium and are recognized ratably during the year, with adjustments each period to reflect changes in the ultimate premium. Receivables or payables are classified as current or long-term in our consolidated balance sheet based on the timing of the expected settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premiums revenue is estimated by multiplying the membership covered under the various contracts by the contractual rates. Premiums revenue is recognized as income in the period members are entitled to receive services and is net of estimated uncollectible amounts, retroactive membership adjustments, and adjustments to recognize rebates under the minimum benefit ratios required under the Health Care Reform Law. We estimate policyholder rebates by projecting calendar year minimum benefit ratios for the small group and large group markets, as defined by the Health Care Reform Law using a methodology prescribed by Health and Human Services, or HHS, separately by state and legal entity. Medicare Advantage and Medicaid products are also subject to minimum benefit ratio requirements. Estimated calendar year rebates recognized ratably during the year are revised each period to reflect current experience. Retroactive membership adjustments result from enrollment changes not yet processed, or not yet reported by an employer group or the government. We routinely monitor the collectability of specific accounts, the aging of receivables, historical retroactivity trends, estimated rebates, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. Premiums received prior to the service period are recorded as unearned revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Medicare Part D&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with CMS. The payments we receive monthly from CMS and members, which are determined from our annual bid, represent amounts for providing prescription drug insurance coverage. We recognize premiums revenue for providing this insurance coverage ratably over the term of our annual contract. Our CMS payment is subject to risk sharing through the Medicare Part D risk corridor provisions. In addition, receipts for reinsurance and low-income cost subsidies as well as receipts for certain discounts on brand name prescription drugs in the coverage gap represent payments for prescription drug costs for which we are not at risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk corridor provisions compare costs targeted in our bids to actual prescription drug costs, limited to actual costs that would have been incurred under the standard coverage as defined by CMS. Variances exceeding certain thresholds may result in CMS making additional payments to us or require us to refund to CMS a portion of the premiums we received. As risk corridor provisions are considered in our overall annual bid process, we estimate &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and recognize an adjustment to premiums revenue related to these provisions based upon pharmacy claims experience. We record a receivable or payable at the contract level and classify the amount as current or long-term in our consolidated balance sheets based on the timing of expected settlement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reinsurance and low-income cost subsidies represent funding from CMS in connection with the Medicare Part D program for which we assume no risk. Reinsurance subsidies represent funding from CMS for its portion of prescription drug costs which exceed the member&#x2019;s out-of-pocket threshold, or the catastrophic coverage level. Low-income cost subsidies represent funding from CMS for all or a portion of the deductible, the coinsurance and co-payment amounts above the out-of-pocket threshold for low-income beneficiaries. Monthly prospective payments from CMS for reinsurance and low-income cost subsidies are based on assumptions submitted with our annual bid. A reconciliation and related settlement of CMS&#x2019;s prospective subsidies against actual prescription drug costs we paid is made after the end of the year. The Health Care Reform Law mandates consumer discounts of 50% on brand name prescription drugs for Part D plan participants in the coverage gap. These discounts are funded by CMS and pharmaceutical manufacturers while we administer the application of these funds. We account for these subsidies and discounts as a deposit in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits, net in our consolidated statements of cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.896%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Part D subsidy/discount payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Part D subsidy/discount reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net reimbursements (payments)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not recognize premiums revenue or benefit expenses for these subsidies or discounts. Receipt and payment activity is accumulated at the contract level and recorded in our consolidated balance sheets in other current assets or trade accounts payable and accrued expenses depending on the contract balance at the end of the reporting period.&lt;/span&gt;&lt;/div&gt;Settlement of the reinsurance and low-income cost subsidies as well as the risk corridor payment is based on a reconciliation made approximately 9 months after the close of each calendar year. Settlement with CMS for brand name prescription drug discounts is based on a reconciliation made approximately 14 to 18 months after the close of each calendar year. We continue to revise our estimates with respect to the risk corridor provisions based on subsequent period pharmacy claims data. For additional information regarding amounts recorded to our consolidated balance sheets related to the risk corridor settlement and subsidies from CMS with respect to the Medicare Part D program, refer to Note 7 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.</us-gaap:InsurancePremiumsRevenueRecognitionPolicy>
    <hum:ConsumerDiscountsOnBrandNamePrescriptionDrugs contextRef="c-1" decimals="INF" id="f-497" unitRef="number">0.50</hum:ConsumerDiscountsOnBrandNamePrescriptionDrugs>
    <hum:ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock contextRef="c-1" id="f-498">We account for these subsidies and discounts as a deposit in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits, net in our consolidated statements of cash flows. &lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.896%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.446%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Part D subsidy/discount payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,582)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,530)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Part D subsidy/discount reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net reimbursements (payments)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;We account for the payments of the federal government&#x2019;s claims and the related reimbursements under deposit accounting in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits, net in our consolidated statements of cash flows.  &lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.450%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care cost payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care cost reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net reimbursements (payments)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</hum:ScheduleOfHealthCareCostPaymentsAndReimbursementsTableTextBlock>
    <hum:SubsidyAndDiscountPayments contextRef="c-1" decimals="-6" id="f-499" unitRef="usd">17582000000</hum:SubsidyAndDiscountPayments>
    <hum:SubsidyAndDiscountPayments contextRef="c-6" decimals="-6" id="f-500" unitRef="usd">16530000000</hum:SubsidyAndDiscountPayments>
    <hum:SubsidyAndDiscountPayments contextRef="c-7" decimals="-6" id="f-501" unitRef="usd">14889000000</hum:SubsidyAndDiscountPayments>
    <hum:SubsidyAndDiscountReimbursements contextRef="c-1" decimals="-6" id="f-502" unitRef="usd">18353000000</hum:SubsidyAndDiscountReimbursements>
    <hum:SubsidyAndDiscountReimbursements contextRef="c-6" decimals="-6" id="f-503" unitRef="usd">18498000000</hum:SubsidyAndDiscountReimbursements>
    <hum:SubsidyAndDiscountReimbursements contextRef="c-7" decimals="-6" id="f-504" unitRef="usd">14628000000</hum:SubsidyAndDiscountReimbursements>
    <hum:SubsidyAndDiscountPaymentsInExcessOfReimbursements contextRef="c-1" decimals="-6" id="f-505" unitRef="usd">-771000000</hum:SubsidyAndDiscountPaymentsInExcessOfReimbursements>
    <hum:SubsidyAndDiscountPaymentsInExcessOfReimbursements contextRef="c-6" decimals="-6" id="f-506" unitRef="usd">-1968000000</hum:SubsidyAndDiscountPaymentsInExcessOfReimbursements>
    <hum:SubsidyAndDiscountPaymentsInExcessOfReimbursements contextRef="c-7" decimals="-6" id="f-507" unitRef="usd">261000000</hum:SubsidyAndDiscountPaymentsInExcessOfReimbursements>
    <hum:SubsidyAndDiscountsSettlementPeriodAfterClose contextRef="c-63" id="f-508">P9M</hum:SubsidyAndDiscountsSettlementPeriodAfterClose>
    <hum:SubsidyAndDiscountsSettlementPeriodAfterClose contextRef="c-64" id="f-509">P14M</hum:SubsidyAndDiscountsSettlementPeriodAfterClose>
    <hum:SubsidyAndDiscountsSettlementPeriodAfterClose contextRef="c-65" id="f-510">P18M</hum:SubsidyAndDiscountsSettlementPeriodAfterClose>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-511">&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patient services revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient services include services related to pharmacy solutions, primary care, and home solutions and other services and capabilities to promote wellness and advance population health. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our pharmacy solutions business, external pharmacy revenues include the cost of pharmaceuticals (net of rebates), a negotiated dispensing fee and customer co-payments for drugs dispensed through our CenterWell Pharmacy (our mail-order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics. Pharmacy products are billed to customers based on the number of transactions occurring during the billing period. Services revenues related to product revenues from dispensing prescriptions are recorded when the prescription or product is shipped.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our primary care business recognizes revenues for certain value-based arrangements. Under these value-based arrangements, we enter into agreements with health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our patients. In exchange, we receive a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our patients. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For our home solutions businesses, revenues include net patient services revenue recorded based upon established billing rates, net of contractual allowances, discounts, or other implicit price concessions, and are recognized as performance obligations are satisfied, which is in the period services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the&#160;year ended December&#160;31, 2023, revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price), was not material. Further, revenue expected to be recognized in any future year related to remaining performance obligations is not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Administrative services fees &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Administrative services fees cover the processing of claims, offering access to our provider networks and clinical programs, and responding to customer service inquiries from members of self-funded groups. Revenues from providing administration services, also known as administrative services only, or ASO, are recognized in the period services are performed and are net of estimated uncollectible amounts. ASO fees are estimated by multiplying the membership covered under the various contracts by the contractual rates. Under ASO contracts, self-funded employers retain the risk of financing substantially all of the cost of health benefits. However, many ASO customers purchase stop loss insurance coverage from us to cover catastrophic claims or to limit aggregate annual costs. Accordingly, we have recorded premiums revenue and benefits expense related to these stop loss insurance contracts. We routinely monitor the collectability of specific accounts, the aging of receivables, as well as prevailing and anticipated economic conditions, and reflect any required adjustments in current operations. ASO fees received prior to the service period are recorded as unearned revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under our TRICARE contracts with the Department of Defense (DoD) we provide administrative services, including offering access to our provider networks and clinical programs, claim processing, customer service, enrollment, and other services, while the federal government retains all of the risk of the cost of health benefits. We account for revenues under our contracts net of estimated health care costs similar to an administrative services fee only agreement. Our contracts include fixed administrative services fees and incentive fees and penalties. Administrative services fees are recognized as services are performed.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our TRICARE members are served by both in-network and out-of-network providers in accordance with our contracts. We pay health care costs related to these services to the providers and are subsequently reimbursed by the DoD for such payments. We account for the payments of the federal government&#x2019;s claims and the related reimbursements under deposit accounting in our consolidated balance sheets and as a financing activity under receipts (withdrawals) from contract deposits, net in our consolidated statements of cash flows.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.448%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.450%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care cost payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Health care cost reimbursements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net reimbursements (payments)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <hum:HealthCareCostPayments contextRef="c-1" decimals="-6" id="f-512" unitRef="usd">7073000000</hum:HealthCareCostPayments>
    <hum:HealthCareCostPayments contextRef="c-6" decimals="-6" id="f-513" unitRef="usd">7110000000</hum:HealthCareCostPayments>
    <hum:HealthCareCostPayments contextRef="c-7" decimals="-6" id="f-514" unitRef="usd">6943000000</hum:HealthCareCostPayments>
    <hum:HealthCareCostReimbursements contextRef="c-1" decimals="-6" id="f-515" unitRef="usd">7130000000</hum:HealthCareCostReimbursements>
    <hum:HealthCareCostReimbursements contextRef="c-6" decimals="-6" id="f-516" unitRef="usd">7135000000</hum:HealthCareCostReimbursements>
    <hum:HealthCareCostReimbursements contextRef="c-7" decimals="-6" id="f-517" unitRef="usd">6898000000</hum:HealthCareCostReimbursements>
    <hum:HealthCareCostPaymentsAndReimbursementsNet contextRef="c-1" decimals="-6" id="f-518" unitRef="usd">-57000000</hum:HealthCareCostPaymentsAndReimbursementsNet>
    <hum:HealthCareCostPaymentsAndReimbursementsNet contextRef="c-6" decimals="-6" id="f-519" unitRef="usd">-25000000</hum:HealthCareCostPaymentsAndReimbursementsNet>
    <hum:HealthCareCostPaymentsAndReimbursementsNet contextRef="c-7" decimals="-6" id="f-520" unitRef="usd">45000000</hum:HealthCareCostPaymentsAndReimbursementsNet>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="c-1" id="f-521">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, including premium receivables, patient services revenue receivables, and ASO fee receivables, are shown net of allowances for estimated uncollectible accounts, retroactive membership adjustments, and contractual allowances.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-66" decimals="-6" id="f-522" unitRef="usd">357000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-67" decimals="-6" id="f-523" unitRef="usd">291000000</us-gaap:AccountsReceivableNetCurrent>
    <hum:OtherCurrentAssetsPolicyTextBlock contextRef="c-1" id="f-524">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Assets&lt;/span&gt;&lt;/div&gt;Other current assets include amounts associated with Medicare Part D, rebates due from pharmaceutical manufacturers and other amounts due within one year.  We accrue pharmaceutical rebates as they are earned based on contractual terms and usage of the product.</hum:OtherCurrentAssetsPolicyTextBlock>
    <hum:AccruedPharmaceuticalRebatesCurrent contextRef="c-4" decimals="-8" id="f-525" unitRef="usd">2300000000</hum:AccruedPharmaceuticalRebatesCurrent>
    <hum:AccruedPharmaceuticalRebatesCurrent contextRef="c-5" decimals="-8" id="f-526" unitRef="usd">2000000000</hum:AccruedPharmaceuticalRebatesCurrent>
    <us-gaap:InsuranceContractAcquisitionCostPolicyTextBlock contextRef="c-1" id="f-527">&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Policy Acquisition Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Policy acquisition costs are those costs that relate directly to the successful acquisition of new and renewal insurance policies. Such costs include commissions, costs of policy issuance and underwriting, and other costs we incur to acquire new business or renew existing business. We expense policy acquisition costs related to our employer-group prepaid health services policies as incurred. These short-duration employer-group prepaid health services policies typically have a 1-year term and may be canceled upon 30 days notice by the employer group.&lt;/span&gt;&lt;/div&gt;</us-gaap:InsuranceContractAcquisitionCostPolicyTextBlock>
    <hum:TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies contextRef="c-1" id="f-528">P1Y</hum:TypicalTermInYearsOfShortDurationEmployerGroupPrepaidHealthServicesPolicies>
    <hum:NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies contextRef="c-1" id="f-529">P30D</hum:NumberOfDaysNoticeForEmployerGroupToCancelShortDurationPrepaidHealthServicesPolicies>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-530">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is recorded at cost. Gains and losses on sales or disposals of property and equipment are included in operating costs in our consolidated income statements. Certain costs related to the development or purchase of internal-use software are capitalized. Depreciation is computed using the straight-line method over estimated useful lives ranging from 3 to 10 years for equipment, 3 to 5 years for computer software, and 10 to 20 years for buildings. Improvements to leased facilities are depreciated over the shorter of the remaining lease term or the anticipated life of the improvement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically review long-lived assets, including property and equipment and other definite-lived intangible assets, for impairment whenever adverse events or changes in circumstances indicate the carrying value of the asset may not be recoverable. Losses are recognized for a long-lived asset to be held and used in our operations when the undiscounted future cash flows expected to result from the use of the asset are less than its carrying value. We recognize an impairment loss based on the excess of the carrying value over the fair value of the asset. A long-lived asset held for sale is reported at the lower of the carrying amount or fair value less costs to sell. Depreciation expense is not recognized on assets held for sale. Losses are recognized for a long-lived asset to be abandoned when the asset ceases to be used. In addition, we periodically review the estimated lives of all long-lived assets for reasonableness.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-68" id="f-531">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-69" id="f-532">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-70" id="f-533">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-71" id="f-534">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-72" id="f-535">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-73" id="f-536">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="c-1" id="f-537">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the equity method of accounting for equity investments in companies where we are able to exercise significant influence, but not control, over operating and financial policies of the investee. Judgment regarding the level of influence over each equity method investment includes considering key factors such as our ownership interest, representation on the board of directors, organizational structure, participation in policy-making decisions and material intra-entity transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, under the equity method, original investments in these entities are recorded at cost and subsequently adjusted by our share of equity in income or losses after the date of acquisition as well as capital contributions to and distributions from these companies. Our proportionate share of the net income or loss of these companies is included in consolidated net income.  Investment amounts in excess of our share of an investee&#x2019;s net assets are amortized over the life of the related asset creating the excess. Excess goodwill is not amortized. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate equity method investments for impairment whenever events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable. Factors considered by us when reviewing an equity method investment for impairment include the length of time (duration) and the extent (severity) to which the fair value of the equity method investment has been less than carrying value, the investee&#x2019;s financial condition and near-term prospects and the intent and ability to hold the investment for a period of time sufficient to allow for anticipated recovery. An impairment that is other-than-temporary is recognized in the period identified.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-538">&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the unamortized excess of cost over the fair value of the net tangible and other intangible assets acquired. We are required to test at least annually for impairment at a level of reporting referred to as the reporting unit, and more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. A reporting unit either is our operating segments or one level below the operating segments, referred to as a component, which comprise our reportable segments. A component is considered a reporting unit if the component constitutes a business for which discrete financial information is available that is regularly reviewed by management. We aggregate the components of an operating segment into one reporting unit if they have similar economic characteristics. Goodwill is assigned to the reporting units that are expected to benefit from the specific synergies of the business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform a quantitative assessment to review goodwill for impairment to determine both the existence and amount of goodwill impairment, if any. Impairment tests are performed, at a minimum, in the fourth quarter of each year supported by our long-range business plan and annual planning process. We rely on an evaluation of future discounted cash flows to determine fair value of our reporting units. The fair value of our reporting units with significant goodwill exceeded carrying amounts. However, unfavorable changes in key assumptions or combinations of assumptions including a significant increase in the discount rate, decrease in the long-term growth rate or substantial reduction in our underlying cash flow assumptions, including revenue growth rates, medical and operating cost trends, and projected operating income could have a significant negative impact on the estimated fair value of our home solutions and primary care reporting units, which accounted for $4.4&#160;billion and $1.2&#160;billion of goodwill, respectively. Impairment tests completed for 2023, 2022, and 2021 did not result in an impairment loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with indefinite lives relate to Certificate of Needs (CON) and Medicare licenses acquired as part of our acquisition of Kindred at Home, or KAH, and are included within other long-term assets in the consolidated balance sheet at December&#160;31, 2023 and December&#160;31, 2022. For additional information regarding our acquisition of KAH, refer to Note 3 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K. We are required to annually compare the fair values of other indefinite-lived intangible assets to their carrying amounts. If the carrying amount of an indefinite-lived intangible asset exceeds its fair value, an impairment loss is recognized. Fair values of indefinite-lived intangible assets are determined based on the income approach. Impairment tests completed for 2023 and 2022 did not result in material impairment losses. These charges reflect the amount by which the carrying value exceeded its estimated fair value. Impairment tests completed for 2021 did not result in an impairment loss. The fair values of the assets were measured using Level 3 inputs, such as projected revenues and operating cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Definite-lived intangible assets primarily relate to acquired customer contracts/relationships and are included with other long-term assets in the consolidated balance sheets. Definite-lived intangible assets are amortized over the &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;useful life generally using the straight-line method. We review definite-lived intangible assets for impairment under our long-lived asset policy.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:Goodwill contextRef="c-74" decimals="-8" id="f-539" unitRef="usd">4400000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-75" decimals="-8" id="f-540" unitRef="usd">1200000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-7" decimals="INF" id="f-541" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-6" decimals="INF" id="f-542" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="INF" id="f-543" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <hum:BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock contextRef="c-1" id="f-544">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Benefits Payable and Benefits Expense Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Benefits expense includes claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care and other supplemental benefits provided on or prior to the balance sheet date. Capitation payments represent monthly contractual fees disbursed to primary care and other providers who are responsible for providing medical care to members. Pharmacy costs represent payments for members&#x2019; prescription drug benefits, net of rebates from drug manufacturers. Receivables for such pharmacy rebates are included in other current assets in our consolidated balance sheets. Other supplemental benefits include dental, vision, and other supplemental health products.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the costs of our benefits expense payments using actuarial methods and assumptions based upon claim payment patterns, medical cost inflation, historical developments such as claim inventory levels and claim receipt patterns, and other relevant factors, and record benefit reserves for future payments. We continually review estimates of future payments relating to claims costs for services incurred in the current and prior periods and make necessary adjustments to our reserves.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Benefits expense is recognized in the period in which services are provided and includes an estimate of the cost of services which have been incurred but not yet reported, or IBNR. Our reserving practice is to consistently recognize the actuarial best point estimate within a level of confidence required by actuarial standards. Actuarial standards of practice generally require a level of confidence such that the liabilities established for IBNR have a greater probability of being adequate versus being insufficient, or such that the liabilities established for IBNR are sufficient to cover obligations under an assumption of moderately adverse conditions. Adverse conditions are situations in which the actual claims are expected to be higher than the otherwise estimated value of such claims at the time of the estimate. Therefore, in many situations, the claim amounts ultimately settled will be less than the estimate that satisfies the actuarial standards of practice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We develop our estimate for IBNR using actuarial methodologies and assumptions, primarily based upon historical claim experience. Depending on the period for which incurred claims are estimated, we apply a different method in determining our estimate. For periods prior to the most recent two months, a completion factor method uses historical paid claims patterns to estimate the percentage of claims incurred during a given period that have historically been adjudicated as of the reporting period. Changes in claim inventory levels and known changes in claim payment processes are taken into account in these estimates. For the most recent two months, the incurred claims are estimated primarily from a trend analysis based upon per member per month claims trends developed from our historical experience in the preceding months, adjusted for known changes in estimates of hospital admissions, recent hospital and drug utilization data, provider contracting changes, changes in benefit levels, changes in member cost sharing, changes in medical management processes, product mix, and workday seasonality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The completion factor method is used for the months of incurred claims prior to the most recent two months because the historical percentage of claims processed for those months is at a level sufficient to produce a consistently reliable result. Conversely, for the most recent two months of incurred claims, the volume of claims processed historically is not at a level sufficient to produce a reliable result, which therefore requires us to examine historical trend patterns as the primary method of evaluation. Changes in claim processes, including recoveries of overpayments, receipt cycle times, claim inventory levels, outsourcing, system conversions, and processing disruptions due to weather or other events affect views regarding the reasonable choice of completion factors. Claim payments to providers for services rendered are often net of overpayment recoveries for claims paid previously, as contractually allowed. Claim overpayment recoveries can result from many different factors, including retroactive enrollment activity, audits of provider billings, and/or payment errors. Changes in patterns of claim overpayment recoveries can be unpredictable and result in completion factor volatility, as they often impact older dates of service. The receipt cycle time measures the average length of time between when a medical claim was initially incurred and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;when the claim form was received. Increases in electronic claim submissions from providers decrease the receipt cycle time. If claims are submitted or processed on a faster (slower) pace than prior periods, the actual claim may be more (less) complete than originally estimated using our completion factors, which may result in reserves that are higher (lower) than required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical cost trends potentially are more volatile than other segments of the economy. The drivers of medical cost trends include increases in the utilization of hospital facilities, physician services, new higher priced technologies and medical procedures, and new prescription drugs and therapies, as well as the inflationary effect on the cost per unit of each of these expense components. Other external factors such as government-mandated benefits or other regulatory changes, the tort liability system, increases in medical services capacity, direct to consumer advertising for prescription drugs and medical services, an aging population, lifestyle changes including diet and smoking, catastrophes, public health emergencies, epidemics and pandemics (such as COVID-19) also may impact medical cost trends. Internal factors such as system conversions, claims processing cycle times, changes in medical management practices and changes in provider contracts also may impact our ability to accurately predict estimates of historical completion factors or medical cost trends. All of these factors are considered in estimating IBNR and in estimating the per member per month claims trend for purposes of determining the reserve for the most recent two months. Additionally, we continually prepare and review follow-up studies to assess the reasonableness of the estimates generated by our process and methods over time. The results of these studies are also considered in determining the reserve for the most recent two months. Each of these factors requires significant judgment by management.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reassess the profitability of our contracts for providing insurance coverage to our members when current operating results or forecasts indicate probable future losses. We establish a premium deficiency reserve in current operations to the extent that the sum of expected future costs, claim adjustment expenses, and maintenance costs exceeds related future premiums under contracts. For purposes of determining premium deficiencies, contracts are grouped in a manner consistent with our method of acquiring, servicing, and measuring the profitability of such contracts. Losses recognized as a premium deficiency result in a beneficial effect in subsequent periods as operating losses under these contracts are charged to the liability previously established. Because the majority of our member contracts renew annually, we would not record a material premium deficiency reserve, except when unanticipated adverse events or changes in circumstances indicate otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe our benefits payable are adequate to cover future claims payments required. However, such estimates are based on knowledge of current events and anticipated future events. Therefore, the actual liability could differ materially from the amounts provided.&lt;/span&gt;&lt;/div&gt;</hum:BenefitsPayableAndBenefitExpenseRecognitionPolicyPolicyTextBlock>
    <hum:FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock contextRef="c-1" id="f-545">&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Future policy benefits payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future policy benefits payable includes liabilities for long-duration insurance policies primarily related to certain blocks of insurance assumed in acquisitions, primarily life and annuities in run-off status, and are included in our consolidated balance sheet within other long-term liabilities. Most of these policies are subject to reinsurance. For additional information regarding reinsurance, refer to Note 19 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.&lt;/span&gt;&lt;/div&gt;</hum:FuturePolicyAndBenefitsPayablePolicyPolicyTextBlock>
    <hum:BookOverdraftPolicyPolicyTextBlock contextRef="c-1" id="f-546">&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Book Overdraft&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our cash management system, checks issued but not yet presented to banks that would result in negative bank balances when presented are classified as a current liability in the consolidated balance sheets. Changes in book overdrafts from period to period are reported in the consolidated statement of cash flows as a financing activity.&lt;/span&gt;&lt;/div&gt;</hum:BookOverdraftPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-547">&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets or liabilities and their reported amounts in the consolidated financial statements. These temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;liabilities are recovered or settled. We also recognize the future tax benefits such as net operating and capital loss carryforwards as deferred tax assets. A valuation allowance is provided against these deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized. Future years&#x2019; tax expense may be increased or decreased by adjustments to the valuation allowance or to the estimated accrual for income taxes. Deferred tax assets and deferred tax liabilities are further adjusted for changes in the enacted tax rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record tax benefits when it is more likely than not that the tax return position taken with respect to a particular transaction will be sustained. A liability, if recorded, is not considered resolved until the statute of limitations for the relevant taxing authority to examine and challenge the tax position has expired, or the tax position is ultimately settled through examination, negotiation, or litigation. We classify interest and penalties associated with uncertain tax positions in our provision for income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy contextRef="c-1" id="f-548">&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Noncontrolling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include all assets, liabilities, revenues and expenses of less than 100% owned affiliates that we control. Accordingly, we record noncontrolling interests in the earnings and equity of such entities. We record adjustments to noncontrolling interests for the allocable portion of income or loss to which the noncontrolling interest holders are entitled based upon their portion of the subsidiaries they own. Distributions to holders of noncontrolling interests are adjusted to the respective noncontrolling interest holders&#x2019; balances. Noncontrolling interests, which relate to the minority ownership held by third party investors in certain of our businesses within our Insurance and CenterWell segments, are reported below net income under the heading &#x201c;Net income attributable to noncontrolling interests&#x201d; in the consolidated statements of income and presented as a component of equity in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c-1" id="f-549">&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;We generally recognize stock-based compensation expense, as determined on the date of grant at fair value, on a straight-line basis over the period during which an employee is required to provide service in exchange for the award (the vesting period). In addition, for awards with both time and performance-based conditions, we generally recognize compensation expense on a straight line basis over the vesting period when it is probable that the performance condition will be achieved. We estimate expected forfeitures and recognize compensation expense only for those awards which are expected to vest. We estimate the grant-date fair value of stock options using the Black-Scholes option-pricing model.</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-550">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Earnings Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We compute basic earnings per common share on the basis of the weighted-average number of unrestricted common shares outstanding. Diluted earnings per common share is computed on the basis of the weighted-average number of unrestricted common shares outstanding plus the dilutive effect of outstanding employee stock options and restricted shares, or units, using the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-551">&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities measured at fair value are categorized into a fair value hierarchy based on whether the inputs to valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our own assumptions about the assumptions market participants would use. The fair value hierarchy includes three levels of inputs that may be used to measure fair value as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 &#x2013; Quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities include securities that are traded in an active exchange market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 &#x2013; Observable inputs other than Level 1 prices such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities include debt securities with quoted prices that are traded less frequently than exchange-traded instruments as well as debt securities whose value is determined using a pricing model with inputs that are observable in the market or can be derived principally from or corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 &#x2013; Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 includes assets and liabilities whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting our own assumptions about the assumptions market participants would use as well as those requiring significant management judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of actively traded debt and equity securities are based on quoted market prices. Fair value of other debt securities are based on quoted market prices of identical or similar securities or based on observable inputs like interest rates generally using a market valuation approach, or, less frequently, an income valuation approach and are generally classified as Level 2. Fair value of privately held investment grade debt securities are estimated using a variety of valuation methodologies, including both market and income approaches, where an observable quoted market does not exist and are generally classified as Level 3. For privately-held investment grade debt securities, such methodologies include reviewing the value ascribed to the most recent financing, comparing the security with securities of publicly-traded companies in similar lines of business with similar credit characteristics, and reviewing the underlying financial performance including estimating discounted cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We obtain at least one price for each security from a third party pricing service. These prices are generally derived from recently reported trades for identical or similar securities, including adjustments through the reporting date based upon observable market information. When quoted prices are not available, the third party pricing service may use quoted market prices of comparable securities or discounted cash flow analysis, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include benchmark yields, reported trades, credit spreads, broker quotes, default rates, and prepayment speeds. We are responsible for the determination of fair value and as such we perform analysis on the prices received from the third party pricing service to determine whether the prices are reasonable estimates of fair value. Our analysis includes a review of monthly price fluctuations as well as a quarterly comparison of the prices received from the pricing service to prices reported by our third party investment adviser. In addition, on a quarterly basis we examine the underlying inputs and assumptions for a sample of individual securities across asset classes, credit rating levels, and various durations.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-552">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, the FASB issued Accounting Standards Update No. 2020-11, Financial Services&#x2014;Insurance (Topic 944): Effective Date and Early Application (&#x201c;ASU 2020-11&#x201d;). The amendments in ASU 2020-11 make changes to the effective date and early application of Accounting Standards Update No. 2018-12, Financial Services&#x2014;Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts (&#x201c;ASU 2018-12&#x201d;), which was issued in November 2018. The amendments in ASU 2020-11 extended the original effective date by one year, and now the amendments are required for our interim and annual reporting periods beginning after December 15, 2022. The new guidance relates to accounting for long-duration contracts of insurers which revises key elements of the measurement models and disclosure requirements for long-duration contracts issued by insurers, including the amortization of deferred contract acquisition costs and the measurement of liabilities for future policy benefits using current, rather than locked-in, assumptions. The new guidance, limited to our Medicare Supplement product which represents less than 1% of consolidated premiums and services revenue, became effective for us &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;beginning January 1, 2023 and was applied to contracts in force on the basis of their existing carrying value amounts at the beginning of the earliest period presented. The adoption of the new standard in 2023 did not have a material impact on our consolidated results of operations, financial position or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Pronouncements Effective in Future Periods&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued Accounting Standards Update No. 2023-07, Segment Reporting &#x2014; Improvements to Reportable Segment Disclosures. The new guidance requires incremental disclosures related to a public entity&#x2019;s reportable segments but does not change the definition of a segment, the method for determining segments, or the criteria for aggregating operating segments into reportable segments. The new guidance requires a public entity to disclose its significant segment expense categories and amounts for each reportable segment. The new guidance will be effective for us beginning with our annual 2024 year-end financial statements. We are currently evaluating the impact on our segment information footnote disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued Accounting Standards Update No. 2023-09 &#x2014; Income Taxes (Topic 740): Improvements to Income Tax Disclosures.  The new guidance requires significant additional disclosures about income taxes, primarily focused on the disclosure of income taxes paid and the rate reconciliation table. The new guidance requires prospective application (with retrospective application permitted). The new guidance will be effective for us beginning with our annual 2025 year-end financial statements, with early adoption permitted.  We are currently evaluating the impact on our income tax footnote disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-76" decimals="2" id="f-553" unitRef="number">0.01</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="c-1" id="f-554">ACQUISITIONS AND DIVESTITURES&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August&#160;11, 2022, we completed the sale of a 60% i&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nterest in Gentiva (formerly Kindred) Hospice to Clayton, Dubilier &amp;amp; Rice, or CD&amp;amp;R, for cash proceeds of approximately $2.7&#160;billion, net of cash disposed, including debt repayments from Gentiva Hospice to Humana of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.9&#160;billion. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the sale, we recognized a pre-tax gain, net of transaction costs, of $237&#160;million which was reported as a gain on sale of Gentiva Hospice in the accompanying consolidated statement of income for the year ended December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, we classified Gentiva Hospice as held-for-sale and aggregated Gentiva Hospice&#x2019;s assets and liabilities separately on the balance sheet. The assets, liabilities and noncontrolling interest disposed of on August 11, 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;padding-right:36pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.928%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Receivables, net of allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;3,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Trade accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;padding-right:36pt;text-align:center;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets included $866&#160;million identifiable intangibles consisting of Medicare licenses and CON. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the sale of a 60% interest in Gentiva Hospice on August 11, 2022, as discussed above, Gentiva Hospice revenues and pretax earnings through the date of sale for the year ended December 31, 2022, were $958&#160;million and $150&#160;million, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 17, 2021, we acquired the remaining 60% interest in Kindred at Home, or KAH,  from TPG Capital and Welsh, Carson, Anderson &amp;amp; Stowe, or WCAS, two private equity funds, for an enterprise value of $8.2&#160;billion, which included our equity value of $2.4&#160;billion associated with our 40% minority ownership interest. The remeasurement to fair value of our previously held 40% equity method investment with a carrying value of approximately $1.3&#160;billion, resulted in a $1.1&#160;billion gain recognized in "Other (income) expense, net" &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the accompanying consolidated statement of income for the year ended December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We paid the approximate $5.8&#160;billion transaction price (net of our existing equity stake) through a combination of debt financing, the assumption of existing KAH indebtedness and parent company cash.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2023, 2022, and 2021, we acquired other health and wellness related businesses which other than the impacts to goodwill, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows.  The results of operations and financial condition of these businesses have been included in our consolidated statements of income and consolidated balance sheets from the respective acquisition dates. Acquisition-related costs recognized in each of 2023, 2022 and 2021 were not material to our results of operations. For asset acquisitions the goodwill acquired is partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the year of acquisition, were not material for disclosure purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <hum:DisposalGroupIncludingDiscontinuedOperationEquityInterestSold contextRef="c-77" decimals="2" id="f-555" unitRef="number">0.60</hum:DisposalGroupIncludingDiscontinuedOperationEquityInterestSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-77" decimals="-8" id="f-556" unitRef="usd">2700000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:RepaymentsOfDebt contextRef="c-78" decimals="-8" id="f-557" unitRef="usd">1900000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax contextRef="c-79" decimals="-6" id="f-558" unitRef="usd">237000000</us-gaap:DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-559">The assets, liabilities and noncontrolling interest disposed of on August 11, 2022 were as follows:&lt;div style="padding-left:36pt;padding-right:36pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.928%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Receivables, net of allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;3,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Trade accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents contextRef="c-77" decimals="-6" id="f-560" unitRef="usd">73000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet contextRef="c-77" decimals="-6" id="f-561" unitRef="usd">194000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets contextRef="c-77" decimals="-6" id="f-562" unitRef="usd">20000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent contextRef="c-77" decimals="-6" id="f-563" unitRef="usd">44000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent contextRef="c-77" decimals="-6" id="f-564" unitRef="usd">2331000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets contextRef="c-77" decimals="-6" id="f-565" unitRef="usd">960000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-77" decimals="-6" id="f-566" unitRef="usd">3622000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-77" decimals="-6" id="f-567" unitRef="usd">245000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities contextRef="c-77" decimals="-6" id="f-568" unitRef="usd">285000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-77" decimals="-6" id="f-569" unitRef="usd">530000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <hum:DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest contextRef="c-77" decimals="-6" id="f-570" unitRef="usd">11000000</hum:DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent contextRef="c-80" decimals="-6" id="f-571" unitRef="usd">866000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <hum:DisposalGroupIncludingDiscontinuedOperationEquityInterestSold contextRef="c-77" decimals="2" id="f-572" unitRef="number">0.60</hum:DisposalGroupIncludingDiscontinuedOperationEquityInterestSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-79" decimals="-6" id="f-573" unitRef="usd">958000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax contextRef="c-79" decimals="-6" id="f-574" unitRef="usd">150000000</us-gaap:IncomeLossFromIndividuallySignificantComponentDisposedOfOrHeldForSaleExcludingDiscontinuedOperationsBeforeIncomeTax>
    <hum:BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage contextRef="c-81" decimals="2" id="f-575" unitRef="number">0.60</hum:BusinessCombinationStepAcquisitionEquityInterestInAcquireeSubsequentAcquisitionPercentage>
    <hum:BusinessCombinationTotalEnterpriseValueOfAcquiree contextRef="c-81" decimals="-8" id="f-576" unitRef="usd">8200000000</hum:BusinessCombinationTotalEnterpriseValueOfAcquiree>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1 contextRef="c-82" decimals="-8" id="f-577" unitRef="usd">2400000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="c-81" decimals="2" id="f-578" unitRef="number">0.40</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="c-81" decimals="2" id="f-579" unitRef="number">0.40</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:EquityMethodInvestments contextRef="c-81" decimals="-8" id="f-580" unitRef="usd">1300000000</us-gaap:EquityMethodInvestments>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain contextRef="c-82" decimals="-8" id="f-581" unitRef="usd">1100000000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain>
    <hum:BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest contextRef="c-81" decimals="-8" id="f-582" unitRef="usd">5800000000</hum:BusinessCombinationConsiderationPerAgreementNetOfExistingEquityInterest>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="c-1" id="f-583">EQUITY METHOD INVESTMENT&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to our acquisition of KAH in August 2021, we accounted for our 40%&#160;investment in KAH using the equity method of accounting. Our share of income or loss was reported as equity in net (losses) earnings in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We completed the sale of a 60% interest in Gentiva Hospice on August 11, 2022 and we account for our remaining minority ownership in Gentiva Hospice using the equity method of accounting. At December&#160;31, 2023 and 2022 we owned 35% and 40%, respectively. This investment was reflected in equity method investments in our December&#160;31, 2023 and 2022 consolidated balance sheets, with our share of income or loss reported as equity in net (losses) earnings in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The summarized balance sheets and statements of income at December&#160;31, 2023 and 2022 of Gentiva Hospice were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.744%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.746%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shareholders' equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.916%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;August 11, 2022 through December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other equity method investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, our Primary Care Organization entered into a strategic partnership with Welsh, Carson, Anderson &amp;amp; Stowe, or WCAS, to accelerate the expansion of our primary care model. In May 2022, we established a second strategic partnership with WCAS to develop additional centers between 2023 and 2025. As of December 31, 2023, there were 108 primary care clinics operating under the partnership and we have capacity to open or acquire up to approximately 60 additional centers through the existing partnership agreements. In addition, the agreements include a series of put and call options through which WCAS may require us to purchase their interest in the entity, and through which we may acquire WCAS&#x2019;s interest, over the next 2 to 9 years. We have the option to purchase the first cohort of clinics in 2025 for approximately $550&#160;million to $650&#160;million based on current projections. All existing cohorts can be called by us from 2025 to 2030 and could require $2.0&#160;billion to $3.0&#160;billion based on current projections. These estimates are dependent on multiple factors including the actual timing of when the put or call options are exercised, expected revenue growth at each center within the respective cohort and future capital contributions, among other factors. For additional information on inputs relevant to these put and call options, refer to Note 6 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have several individually immaterial equity method investments, including our strategic partnership with WCAS as described above, included within equity method investments in our consolidated balance sheets as of December&#160;31, 2023 and 2022 with our share of income or loss reported as equity in net (losses) earnings in our consolidated statements of income for the years ended December&#160;31, 2023, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-83" decimals="2" id="f-584" unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <hum:DisposalGroupIncludingDiscontinuedOperationEquityInterestSold contextRef="c-77" decimals="2" id="f-585" unitRef="number">0.60</hum:DisposalGroupIncludingDiscontinuedOperationEquityInterestSold>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-84" decimals="2" id="f-586" unitRef="number">0.35</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-85" decimals="2" id="f-587" unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="c-1" id="f-588">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The summarized balance sheets and statements of income at December&#160;31, 2023 and 2022 of Gentiva Hospice were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.210%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.744%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.746%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance sheet&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shareholders' equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.916%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;August 11, 2022 through December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:AssetsCurrent contextRef="c-86" decimals="-6" id="f-589" unitRef="usd">415000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-87" decimals="-6" id="f-590" unitRef="usd">297000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-86" decimals="-6" id="f-591" unitRef="usd">4260000000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-87" decimals="-6" id="f-592" unitRef="usd">3577000000</us-gaap:AssetsNoncurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-86" decimals="-6" id="f-593" unitRef="usd">409000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-87" decimals="-6" id="f-594" unitRef="usd">269000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-86" decimals="-6" id="f-595" unitRef="usd">2719000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-87" decimals="-6" id="f-596" unitRef="usd">2219000000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:StockholdersEquity contextRef="c-86" decimals="-6" id="f-597" unitRef="usd">1547000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-87" decimals="-6" id="f-598" unitRef="usd">1386000000</us-gaap:StockholdersEquity>
    <us-gaap:Revenues contextRef="c-88" decimals="-6" id="f-599" unitRef="usd">1850000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-89" decimals="-6" id="f-600" unitRef="usd">654000000</us-gaap:Revenues>
    <hum:Expenses contextRef="c-88" decimals="-6" id="f-601" unitRef="usd">1873000000</hum:Expenses>
    <hum:Expenses contextRef="c-89" decimals="-6" id="f-602" unitRef="usd">652000000</hum:Expenses>
    <us-gaap:NetIncomeLoss contextRef="c-88" decimals="-6" id="f-603" unitRef="usd">-23000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-89" decimals="-6" id="f-604" unitRef="usd">2000000</us-gaap:NetIncomeLoss>
    <hum:StrategicPartnershipAgreementNumberOfPrimaryCareCenters
      contextRef="c-90"
      decimals="INF"
      id="f-605"
      unitRef="primary_care_center">108</hum:StrategicPartnershipAgreementNumberOfPrimaryCareCenters>
    <hum:StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened
      contextRef="c-90"
      decimals="0"
      id="f-606"
      unitRef="primary_care_center">60</hum:StrategicPartnershipAgreementNumberOfAdditionalPrimaryCareCentersExpectedToBeOpened>
    <hum:StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity contextRef="c-91" id="f-607">P2Y</hum:StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity>
    <hum:StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity contextRef="c-92" id="f-608">P9Y</hum:StrategicPartnershipAgreementTimeframeForPutAndCallOptionActivity>
    <hum:StrategicPartnershipAgreementCallOptionStrikePrice contextRef="c-93" decimals="-6" id="f-609" unitRef="usd">550000000</hum:StrategicPartnershipAgreementCallOptionStrikePrice>
    <hum:StrategicPartnershipAgreementCallOptionStrikePrice contextRef="c-94" decimals="-6" id="f-610" unitRef="usd">650000000</hum:StrategicPartnershipAgreementCallOptionStrikePrice>
    <hum:StrategicPartnershipAgreementCallOptionStrikePrice contextRef="c-95" decimals="-8" id="f-611" unitRef="usd">2000000000</hum:StrategicPartnershipAgreementCallOptionStrikePrice>
    <hum:StrategicPartnershipAgreementCallOptionStrikePrice contextRef="c-96" decimals="-8" id="f-612" unitRef="usd">3000000000</hum:StrategicPartnershipAgreementCallOptionStrikePrice>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-613">INVESTMENT SECURITIES&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment securities classified as current and long-term were as follows at December&#160;31, 2023 and 2022, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.643%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.643%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.646%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and other U.S. government &lt;br/&gt;&#160;&#160;&#160;&#160;corporations and agencies:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax-exempt municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(594)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and other U.S. government &lt;br/&gt;&#160;&#160;&#160;&#160;corporations and agencies:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(471)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax-exempt municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(828)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We own certain corporate debt securities of Gentiva Hospice. The book value and fair value are $379&#160;million and $398&#160;million, respectively, at December&#160;31, 2023. The book value and fair value were $280&#160;million and $278&#160;million, respectively, at December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross unrealized losses and fair values aggregated by investment category and length of time that individual debt securities have been in a continuous unrealized loss position were as follows at December&#160;31, 2023 and 2022, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.201%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less&#160;than&#160;12&#160;months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 months or more&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="36" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and other U.S. government &lt;br/&gt;&#160;&#160;&#160;&#160;corporations and agencies:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(413)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax-exempt municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(592)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(594)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and other U.S. government &lt;br/&gt;&#160;&#160;&#160;&#160;corporations and agencies:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(367)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(471)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax-exempt municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(730)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(828)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 97% of our debt securities were investment-grade quality, with a weighted average credit rating of AA- by S&amp;amp;P at December&#160;31, 2023. Most of the debt securities that were below investment-grade were rated B+, the higher end of the below investment-grade rating scale. Tax-exempt municipal securities were diversified among general obligation bonds of states and local municipalities in the United States as well as special revenue bonds issued by municipalities to finance specific public works projects such as utilities, water and sewer, transportation, or education. Our general obligation bonds are diversified across the United States with no individual state exceeding approximately 1% of our total debt securities. Our investment policy limits investments in a single issuer and requires diversification among various asset types. &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our unrealized loss from all debt securities was generated from approximately 1,560 positions out of a total of approximately 2,060 positions at December&#160;31, 2023. All issuers of debt securities we own that were trading at an unrealized loss at December&#160;31, 2023 remain current on all contractual payments. After taking into account these and other factors previously described, we believe these unrealized losses primarily were caused by an increase in market interest rates in the current markets since the time the debt securities were purchased. At December&#160;31, 2023, we did not intend to sell any debt securities with an unrealized loss position in accumulated other comprehensive income, and it is not likely that we will be required to sell these debt securities before recovery of their amortized cost basis. Additionally, we did not record any material credit allowances for debt securities that were in an unrealized loss position at December&#160;31, 2023, 2022 or 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The detail of realized gains (losses) related to investment securities and included within investment income was as follows for the years ended December&#160;31, 2023, 2022, and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross gains on investment securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross losses on investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross gains on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross losses on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net recognized losses on investment securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gains and losses related to equity securities for the years ended December&#160;31, 2023, 2022 and 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.517%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gains (losses) recognized on equity securities during the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net gains (losses) recognized on equity securities sold during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses recognized on equity securities still held at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of debt securities available for sale at December&#160;31, 2023, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="c-1" id="f-614">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment securities classified as current and long-term were as follows at December&#160;31, 2023 and 2022, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.643%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.483%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.643%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.646%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and other U.S. government &lt;br/&gt;&#160;&#160;&#160;&#160;corporations and agencies:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax-exempt municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(594)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and other U.S. government &lt;br/&gt;&#160;&#160;&#160;&#160;corporations and agencies:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(471)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax-exempt municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(828)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-97" decimals="-6" id="f-615" unitRef="usd">2717000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-97" decimals="-6" id="f-616" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-97" decimals="-6" id="f-617" unitRef="usd">51000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-97" decimals="-6" id="f-618" unitRef="usd">2667000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-98" decimals="-6" id="f-619" unitRef="usd">3946000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-98" decimals="-6" id="f-620" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-98" decimals="-6" id="f-621" unitRef="usd">425000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-98" decimals="-6" id="f-622" unitRef="usd">3522000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-99" decimals="-6" id="f-623" unitRef="usd">879000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-99" decimals="-6" id="f-624" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-99" decimals="-6" id="f-625" unitRef="usd">22000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-99" decimals="-6" id="f-626" unitRef="usd">858000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-100" decimals="-6" id="f-627" unitRef="usd">465000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-100" decimals="-6" id="f-628" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-100" decimals="-6" id="f-629" unitRef="usd">66000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-100" decimals="-6" id="f-630" unitRef="usd">400000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-101" decimals="-6" id="f-631" unitRef="usd">1471000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-101" decimals="-6" id="f-632" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-101" decimals="-6" id="f-633" unitRef="usd">126000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-101" decimals="-6" id="f-634" unitRef="usd">1345000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-102" decimals="-6" id="f-635" unitRef="usd">1813000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-102" decimals="-6" id="f-636" unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-102" decimals="-6" id="f-637" unitRef="usd">44000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-102" decimals="-6" id="f-638" unitRef="usd">1771000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-103" decimals="-6" id="f-639" unitRef="usd">7011000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-103" decimals="-6" id="f-640" unitRef="usd">28000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-103" decimals="-6" id="f-641" unitRef="usd">594000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-103" decimals="-6" id="f-642" unitRef="usd">6445000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-6" id="f-643" unitRef="usd">18302000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-4" decimals="-6" id="f-644" unitRef="usd">34000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-4" decimals="-6" id="f-645" unitRef="usd">1328000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-6" id="f-646" unitRef="usd">17008000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-4" decimals="-6" id="f-647" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:Investments contextRef="c-4" decimals="-6" id="f-648" unitRef="usd">17008000000</us-gaap:Investments>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-104" decimals="-6" id="f-649" unitRef="usd">1093000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-104" decimals="-6" id="f-650" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-104" decimals="-6" id="f-651" unitRef="usd">55000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-104" decimals="-6" id="f-652" unitRef="usd">1039000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-105" decimals="-6" id="f-653" unitRef="usd">3697000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-105" decimals="-6" id="f-654" unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-105" decimals="-6" id="f-655" unitRef="usd">471000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-105" decimals="-6" id="f-656" unitRef="usd">3230000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-106" decimals="-6" id="f-657" unitRef="usd">765000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-106" decimals="-6" id="f-658" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-106" decimals="-6" id="f-659" unitRef="usd">37000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-106" decimals="-6" id="f-660" unitRef="usd">728000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-107" decimals="-6" id="f-661" unitRef="usd">477000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-107" decimals="-6" id="f-662" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-107" decimals="-6" id="f-663" unitRef="usd">76000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-107" decimals="-6" id="f-664" unitRef="usd">401000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-108" decimals="-6" id="f-665" unitRef="usd">1554000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-108" decimals="-6" id="f-666" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-108" decimals="-6" id="f-667" unitRef="usd">155000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-108" decimals="-6" id="f-668" unitRef="usd">1399000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-109" decimals="-6" id="f-669" unitRef="usd">1809000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-109" decimals="-6" id="f-670" unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-109" decimals="-6" id="f-671" unitRef="usd">79000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-109" decimals="-6" id="f-672" unitRef="usd">1731000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-110" decimals="-6" id="f-673" unitRef="usd">6551000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-110" decimals="-6" id="f-674" unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-110" decimals="-6" id="f-675" unitRef="usd">828000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-110" decimals="-6" id="f-676" unitRef="usd">5726000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-5" decimals="-6" id="f-677" unitRef="usd">15946000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-5" decimals="-6" id="f-678" unitRef="usd">9000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-5" decimals="-6" id="f-679" unitRef="usd">1701000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-5" decimals="-6" id="f-680" unitRef="usd">14254000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-5" decimals="-6" id="f-681" unitRef="usd">7000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:Investments contextRef="c-5" decimals="-6" id="f-682" unitRef="usd">14261000000</us-gaap:Investments>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-111" decimals="-6" id="f-683" unitRef="usd">379000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-111" decimals="-6" id="f-684" unitRef="usd">398000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-112" decimals="-6" id="f-685" unitRef="usd">280000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-112" decimals="-6" id="f-686" unitRef="usd">278000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock contextRef="c-1" id="f-687">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross unrealized losses and fair values aggregated by investment category and length of time that individual debt securities have been in a continuous unrealized loss position were as follows at December&#160;31, 2023 and 2022, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.201%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Less&#160;than&#160;12&#160;months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12 months or more&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="36" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and other U.S. government &lt;br/&gt;&#160;&#160;&#160;&#160;corporations and agencies:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(413)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax-exempt municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(592)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(594)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and other U.S. government &lt;br/&gt;&#160;&#160;&#160;&#160;corporations and agencies:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(367)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(471)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax-exempt municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(730)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(828)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,701)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-97" decimals="-6" id="f-688" unitRef="usd">1899000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-97" decimals="-6" id="f-689" unitRef="usd">12000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-97" decimals="-6" id="f-690" unitRef="usd">431000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-97" decimals="-6" id="f-691" unitRef="usd">39000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-97" decimals="-6" id="f-692" unitRef="usd">2330000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-97" decimals="-6" id="f-693" unitRef="usd">51000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-98" decimals="-6" id="f-694" unitRef="usd">958000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-98" decimals="-6" id="f-695" unitRef="usd">12000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-98" decimals="-6" id="f-696" unitRef="usd">2269000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-98" decimals="-6" id="f-697" unitRef="usd">413000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-98" decimals="-6" id="f-698" unitRef="usd">3227000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-98" decimals="-6" id="f-699" unitRef="usd">425000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-99" decimals="-6" id="f-700" unitRef="usd">160000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-99" decimals="-6" id="f-701" unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-99" decimals="-6" id="f-702" unitRef="usd">523000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-99" decimals="-6" id="f-703" unitRef="usd">21000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-99" decimals="-6" id="f-704" unitRef="usd">683000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-99" decimals="-6" id="f-705" unitRef="usd">22000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-100" decimals="-6" id="f-706" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-100" decimals="-6" id="f-707" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-100" decimals="-6" id="f-708" unitRef="usd">373000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-100" decimals="-6" id="f-709" unitRef="usd">66000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-100" decimals="-6" id="f-710" unitRef="usd">373000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-100" decimals="-6" id="f-711" unitRef="usd">66000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-101" decimals="-6" id="f-712" unitRef="usd">18000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-101" decimals="-6" id="f-713" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-101" decimals="-6" id="f-714" unitRef="usd">1303000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-101" decimals="-6" id="f-715" unitRef="usd">126000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-101" decimals="-6" id="f-716" unitRef="usd">1321000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-101" decimals="-6" id="f-717" unitRef="usd">126000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-102" decimals="-6" id="f-718" unitRef="usd">120000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-102" decimals="-6" id="f-719" unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-102" decimals="-6" id="f-720" unitRef="usd">1364000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-102" decimals="-6" id="f-721" unitRef="usd">43000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-102" decimals="-6" id="f-722" unitRef="usd">1484000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-102" decimals="-6" id="f-723" unitRef="usd">44000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-103" decimals="-6" id="f-724" unitRef="usd">466000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-103" decimals="-6" id="f-725" unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-103" decimals="-6" id="f-726" unitRef="usd">4783000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-103" decimals="-6" id="f-727" unitRef="usd">592000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-103" decimals="-6" id="f-728" unitRef="usd">5249000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-103" decimals="-6" id="f-729" unitRef="usd">594000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-4" decimals="-6" id="f-730" unitRef="usd">3621000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-4" decimals="-6" id="f-731" unitRef="usd">28000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-4" decimals="-6" id="f-732" unitRef="usd">11046000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-4" decimals="-6" id="f-733" unitRef="usd">1300000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-4" decimals="-6" id="f-734" unitRef="usd">14667000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-4" decimals="-6" id="f-735" unitRef="usd">1328000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-104" decimals="-6" id="f-736" unitRef="usd">512000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-104" decimals="-6" id="f-737" unitRef="usd">5000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-104" decimals="-6" id="f-738" unitRef="usd">397000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-104" decimals="-6" id="f-739" unitRef="usd">50000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-104" decimals="-6" id="f-740" unitRef="usd">909000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-104" decimals="-6" id="f-741" unitRef="usd">55000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-105" decimals="-6" id="f-742" unitRef="usd">1231000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-105" decimals="-6" id="f-743" unitRef="usd">104000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-105" decimals="-6" id="f-744" unitRef="usd">1683000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-105" decimals="-6" id="f-745" unitRef="usd">367000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-105" decimals="-6" id="f-746" unitRef="usd">2914000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-105" decimals="-6" id="f-747" unitRef="usd">471000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-106" decimals="-6" id="f-748" unitRef="usd">64000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-106" decimals="-6" id="f-749" unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-106" decimals="-6" id="f-750" unitRef="usd">615000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-106" decimals="-6" id="f-751" unitRef="usd">36000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-106" decimals="-6" id="f-752" unitRef="usd">679000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-106" decimals="-6" id="f-753" unitRef="usd">38000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-107" decimals="-6" id="f-754" unitRef="usd">124000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-107" decimals="-6" id="f-755" unitRef="usd">16000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-107" decimals="-6" id="f-756" unitRef="usd">274000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-107" decimals="-6" id="f-757" unitRef="usd">60000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-107" decimals="-6" id="f-758" unitRef="usd">398000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-107" decimals="-6" id="f-759" unitRef="usd">76000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-108" decimals="-6" id="f-760" unitRef="usd">243000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-108" decimals="-6" id="f-761" unitRef="usd">13000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-108" decimals="-6" id="f-762" unitRef="usd">1157000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-108" decimals="-6" id="f-763" unitRef="usd">142000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-108" decimals="-6" id="f-764" unitRef="usd">1400000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-108" decimals="-6" id="f-765" unitRef="usd">155000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-109" decimals="-6" id="f-766" unitRef="usd">620000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-109" decimals="-6" id="f-767" unitRef="usd">32000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-109" decimals="-6" id="f-768" unitRef="usd">1011000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-109" decimals="-6" id="f-769" unitRef="usd">46000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-109" decimals="-6" id="f-770" unitRef="usd">1631000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-109" decimals="-6" id="f-771" unitRef="usd">78000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-110" decimals="-6" id="f-772" unitRef="usd">1625000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-110" decimals="-6" id="f-773" unitRef="usd">98000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-110" decimals="-6" id="f-774" unitRef="usd">3825000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-110" decimals="-6" id="f-775" unitRef="usd">730000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-110" decimals="-6" id="f-776" unitRef="usd">5450000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-110" decimals="-6" id="f-777" unitRef="usd">828000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-5" decimals="-6" id="f-778" unitRef="usd">4419000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-5" decimals="-6" id="f-779" unitRef="usd">270000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-5" decimals="-6" id="f-780" unitRef="usd">8962000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-5" decimals="-6" id="f-781" unitRef="usd">1431000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-5" decimals="-6" id="f-782" unitRef="usd">13381000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-5" decimals="-6" id="f-783" unitRef="usd">1701000000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <hum:PercentageOfTotalDebtSecuritiesInvestmentGradeQuality contextRef="c-113" decimals="2" id="f-784" unitRef="number">0.97</hum:PercentageOfTotalDebtSecuritiesInvestmentGradeQuality>
    <hum:MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities contextRef="c-1" decimals="2" id="f-785" unitRef="number">0.01</hum:MaximumIndividualStateGeneralBondObligationAsPercentageOfTotalDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions contextRef="c-4" decimals="0" id="f-786" unitRef="position">1560</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <hum:DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions contextRef="c-4" decimals="0" id="f-787" unitRef="position">2060</hum:DebtSecuritiesAvailableForSaleSecuritiesNumberOfPositions>
    <us-gaap:ScheduleOfRealizedGainLossTableTextBlock contextRef="c-1" id="f-788">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The detail of realized gains (losses) related to investment securities and included within investment income was as follows for the years ended December&#160;31, 2023, 2022, and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.222%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross gains on investment securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross losses on investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross gains on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross losses on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net recognized losses on investment securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRealizedGainLossTableTextBlock>
    <hum:DebtAndEquitySecuritiesRealizedGain contextRef="c-1" decimals="-6" id="f-789" unitRef="usd">46000000</hum:DebtAndEquitySecuritiesRealizedGain>
    <hum:DebtAndEquitySecuritiesRealizedGain contextRef="c-6" decimals="-6" id="f-790" unitRef="usd">62000000</hum:DebtAndEquitySecuritiesRealizedGain>
    <hum:DebtAndEquitySecuritiesRealizedGain contextRef="c-7" decimals="-6" id="f-791" unitRef="usd">219000000</hum:DebtAndEquitySecuritiesRealizedGain>
    <hum:DebtAndEquitySecuritiesRealizedLoss contextRef="c-1" decimals="-6" id="f-792" unitRef="usd">101000000</hum:DebtAndEquitySecuritiesRealizedLoss>
    <hum:DebtAndEquitySecuritiesRealizedLoss contextRef="c-6" decimals="-6" id="f-793" unitRef="usd">144000000</hum:DebtAndEquitySecuritiesRealizedLoss>
    <hum:DebtAndEquitySecuritiesRealizedLoss contextRef="c-7" decimals="-6" id="f-794" unitRef="usd">8000000</hum:DebtAndEquitySecuritiesRealizedLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGain contextRef="c-1" decimals="-6" id="f-795" unitRef="usd">1000000</us-gaap:EquitySecuritiesFvNiRealizedGain>
    <us-gaap:EquitySecuritiesFvNiRealizedGain contextRef="c-6" decimals="-6" id="f-796" unitRef="usd">51000000</us-gaap:EquitySecuritiesFvNiRealizedGain>
    <us-gaap:EquitySecuritiesFvNiRealizedGain contextRef="c-7" decimals="-6" id="f-797" unitRef="usd">23000000</us-gaap:EquitySecuritiesFvNiRealizedGain>
    <us-gaap:EquitySecuritiesFvNiRealizedLoss contextRef="c-1" decimals="-6" id="f-798" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedLoss contextRef="c-6" decimals="-6" id="f-799" unitRef="usd">174000000</us-gaap:EquitySecuritiesFvNiRealizedLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedLoss contextRef="c-7" decimals="-6" id="f-800" unitRef="usd">364000000</us-gaap:EquitySecuritiesFvNiRealizedLoss>
    <us-gaap:DebtAndEquitySecuritiesGainLoss contextRef="c-1" decimals="-6" id="f-801" unitRef="usd">-54000000</us-gaap:DebtAndEquitySecuritiesGainLoss>
    <us-gaap:DebtAndEquitySecuritiesGainLoss contextRef="c-6" decimals="-6" id="f-802" unitRef="usd">-205000000</us-gaap:DebtAndEquitySecuritiesGainLoss>
    <us-gaap:DebtAndEquitySecuritiesGainLoss contextRef="c-7" decimals="-6" id="f-803" unitRef="usd">-130000000</us-gaap:DebtAndEquitySecuritiesGainLoss>
    <us-gaap:GainLossOnInvestmentsTextBlock contextRef="c-1" id="f-804">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gains and losses related to equity securities for the years ended December&#160;31, 2023, 2022 and 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.515%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.517%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gains (losses) recognized on equity securities during the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Net gains (losses) recognized on equity securities sold during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized losses recognized on equity securities still held at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-1" decimals="-6" id="f-805" unitRef="usd">1000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-6" decimals="-6" id="f-806" unitRef="usd">-123000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-7" decimals="-6" id="f-807" unitRef="usd">-341000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-1" decimals="-6" id="f-808" unitRef="usd">1000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-6" decimals="-6" id="f-809" unitRef="usd">-105000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-7" decimals="-6" id="f-810" unitRef="usd">-13000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-6" id="f-811" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-6" decimals="-6" id="f-812" unitRef="usd">-18000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-7" decimals="-6" id="f-813" unitRef="usd">-328000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-814">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of debt securities available for sale at December&#160;31, 2023, regardless of their balance sheet classification, are shown below. Expected maturities may differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.995%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage and asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-4" decimals="-6" id="f-815" unitRef="usd">1243000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-4" decimals="-6" id="f-816" unitRef="usd">1239000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c-4" decimals="-6" id="f-817" unitRef="usd">5279000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-4" decimals="-6" id="f-818" unitRef="usd">5112000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost contextRef="c-4" decimals="-6" id="f-819" unitRef="usd">2936000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue contextRef="c-4" decimals="-6" id="f-820" unitRef="usd">2657000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost contextRef="c-4" decimals="-6" id="f-821" unitRef="usd">1149000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue contextRef="c-4" decimals="-6" id="f-822" unitRef="usd">962000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost contextRef="c-4" decimals="-6" id="f-823" unitRef="usd">7695000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue contextRef="c-4" decimals="-6" id="f-824" unitRef="usd">7038000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-4" decimals="-6" id="f-825" unitRef="usd">18302000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-4" decimals="-6" id="f-826" unitRef="usd">17008000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-827">FAIR VALUE&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our fair value measurements at December&#160;31, 2023 and 2022, respectively, for financial assets measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.127%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.744%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and other U.S. government corporations and agencies:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax-exempt municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total invested assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and other U.S. government corporations and agencies:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax-exempt municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total invested assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Level 3 assets had fair values of $218 million, or 1.0% of total invested assets, and $101 million, or 0.5% of total invested assets, at December&#160;31, 2023 and 2022, respectively. During the years ended December&#160;31, 2023 and 2022, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:11.25pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.277%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.211%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the year ended December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the year ended December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Private&lt;br/&gt;Placements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gains or losses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized in earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized in other comprehensive&#160;income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers Out&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers In&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2023, we entered into interest-rate swap agreements with major financial institutions to convert our interest-rate exposure on our $750&#160;million of 5.875% senior notes, our $750&#160;million of 5.500% senior notes, our $500&#160;million of 3.950% senior notes and our $850&#160;million of 5.950% from fixed rates to variable rates to align interest costs more closely with floating interest rates received on our cash equivalents and investment securities. Our swap agreements, which are considered derivative instruments, exchange the fixed interest rate under our 5.875%, 5.500%, 3.950% and 5.950% senior notes for a variable interest rate based on SOFR. Interest rate swaps with notional amounts of $650&#160;million, maturing September 1, 2032, $300&#160;million, maturing March 15, 2033, $450&#160;million  maturing August 15, 2049 and $400&#160;million, maturing March 15, 2034, were outstanding on our 5.875%, 5.500%, 3.950% and 5.950% senior notes, respectively, at December&#160;31, 2023. These swap agreements were qualified and designated as a fair value hedge. Our interest rate swaps are recognized in other assets or other liabilities, as appropriate, in our consolidated balance sheets at fair value as of the reporting date.  Our interest rate swaps are highly effective at reflecting the fair value of our hedged fixed rate senior notes payable. We utilize market-based financing rates, forward yield curves and discount rates in determining fair value of these swaps at each reporting date, a Level 2 measure within the fair value hierarchy.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The swap asset, included within other long-term assets on our consolidated balance sheet, was approximately $68&#160;million at December&#160;31, 2023. We include the gain or loss on the swap agreements in interest expense on our consolidated statement of income, the same line item as the offsetting loss or gain on the related senior notes. The gain or loss due to hedge ineffectiveness was not material for the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our debt is recorded at carrying value in our consolidated balance sheets. The carrying value of our senior notes debt outstanding, net of unamortized debt issuance costs, was $10.8&#160;billion at December&#160;31, 2023 and $10.0 billion at December&#160;31, 2022. The fair value of our senior note debt was $10.6 billion at December&#160;31, 2023 and $9.4 billion at December&#160;31, 2022. The fair value of our senior note debt is determined based on Level 2 inputs, including quoted market prices for the same or similar debt, or if no quoted market prices are available, on the current prices estimated to be available to us for debt with similar terms and remaining maturities. Carrying value approximates &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fair value for our term loans and commercial paper borrowings. The commercial paper borrowings&#160;were $0.9&#160;billion at December&#160;31, 2023 and the term loan and commercial paper borrowings were $1.1 billion at December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Put and Call Options Measured at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our put and call options associated with our equity method investments are measured at fair value each period using a Monte Carlo simulation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective April 27, 2021, with the signing of the definitive agreement to acquire the remaining 60% interest of KAH, the respective put and call options were terminated. As such, the $63&#160;million put and $440&#160;million call fair values as of the first quarter of 2021 were reduced to zero, resulting in $377&#160;million in other expense (income), net in our consolidated statements of income for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The put and call options fair values associated with our Primary Care Organization strategic partnership with WCAS, which are exercisable at a fixed revenue exit multiple and provide a minimum return on WCAS' investment if exercised, are measured at fair value each reporting period using a Monte Carlo simulation. The put and call options fair values, derived from the Monte Carlo simulation, were $595 million and $18 million, respectively, at December&#160;31, 2023. The put and call options fair values, derived from the Monte Carlo simulation, were $267 million and $10 million, respectively, at December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant unobservable inputs utilized in these Level 3 fair value measurements (and selected values) include the enterprise value, annualized volatility and credit spread. Enterprise value was derived from a discounted cash flow model, which utilized significant unobservable inputs for long-term revenue, to measure underlying cash flows, weighted average cost of capital and long term growth rate. The table below presents the assumptions used for December&#160;31, 2023 and 2022, respectively: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.837%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Annualized volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1% - 17.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7% to 20.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit spread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9% - 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3% to 1.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue exit multiple&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5x - 2.5x &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5x - 2.5x&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average cost of capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0% - 12.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5% to 12.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long term growth rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used for annualized volatility, credit spread and weighted average cost of capital reflect the lowest and highest values where they differ significantly across the series of put and call options due to their expected exercise dates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain assets and liabilities are measured at fair value on a non-recurring basis subject to fair value adjustment only in certain circumstances.  As disclosed in Note 3, &#x201c;Acquisitions&#x201d;, we completed our acquisition of KAH during the third quarter of 2021. The net assets acquired and resulting goodwill and other intangible assets were recorded at fair value primarily using Level 3 inputs.  The net tangible assets including receivables and accrued liabilities were recorded at their carrying value which approximated their fair value due to their short term nature. The fair value of goodwill and other intangible assets were internally estimated based on the income approach.  The income approach estimates fair value based on the present value of cash flow that the assets could be expected to generate in the future. We developed internal estimates for expected cash flows in the present value calculation using inputs and significant assumptions that include historical revenues and earnings, long-term growth rate, discount rate, contributory asset charges and future tax rates, among others.  The excess purchase price over the fair value of assets and liabilities acquired is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As disclosed in Note 3, we completed the sale of a 60% interest in Gentiva Hospice on August 11, 2022. The carrying value of the assets and liabilities of Gentiva Hospice disposed approximates fair value. The amount of &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;goodwill included in the carrying value is based on the relative fair value of Gentiva Hospice as compared to the total fair value of our home solutions reporting unit included within the CenterWell segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, as disclosed in Note 3, we completed our acquisitions of certain health and wellness related businesses during 2023, 2022, and 2021. The values of net tangible assets acquired and the resulting goodwill and other intangible assets were recorded at fair value using Level 3 inputs. The majority of the related tangible assets acquired and liabilities assumed were recorded at their carrying values as of the respective dates of acquisition, as their carrying values approximated their fair values due to their short-term nature. The fair values of goodwill and other intangible assets acquired in these acquisitions were internally estimated primarily based on the income approach. The income approach estimates fair value based on the present value of the cash flows that the assets are expected to generate in the future. We developed internal estimates for the expected cash flows and discount rates in the present value calculations. Other than assets acquired and liabilities assumed in these acquisitions, there were no material assets or liabilities measured at fair value on a nonrecurring basis during 2023, 2022, or 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="c-1" id="f-828">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our fair value measurements at December&#160;31, 2023 and 2022, respectively, for financial assets measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.127%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.741%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.744%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and other U.S. government corporations and agencies:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax-exempt municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total invested assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and other U.S. government corporations and agencies:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and agency obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax-exempt municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Residential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total invested assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-114" decimals="-6" id="f-829" unitRef="usd">4582000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-115" decimals="-6" id="f-830" unitRef="usd">4582000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-116" decimals="-6" id="f-831" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-117" decimals="-6" id="f-832" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-118" decimals="-6" id="f-833" unitRef="usd">2667000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-119" decimals="-6" id="f-834" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-120" decimals="-6" id="f-835" unitRef="usd">2667000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-121" decimals="-6" id="f-836" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-122" decimals="-6" id="f-837" unitRef="usd">3522000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-123" decimals="-6" id="f-838" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-124" decimals="-6" id="f-839" unitRef="usd">3522000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-125" decimals="-6" id="f-840" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-126" decimals="-6" id="f-841" unitRef="usd">858000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-127" decimals="-6" id="f-842" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-128" decimals="-6" id="f-843" unitRef="usd">858000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-129" decimals="-6" id="f-844" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-130" decimals="-6" id="f-845" unitRef="usd">400000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-131" decimals="-6" id="f-846" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-132" decimals="-6" id="f-847" unitRef="usd">396000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-133" decimals="-6" id="f-848" unitRef="usd">4000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-134" decimals="-6" id="f-849" unitRef="usd">1345000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-135" decimals="-6" id="f-850" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-136" decimals="-6" id="f-851" unitRef="usd">1345000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-137" decimals="-6" id="f-852" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-138" decimals="-6" id="f-853" unitRef="usd">1771000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-139" decimals="-6" id="f-854" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-140" decimals="-6" id="f-855" unitRef="usd">1733000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-141" decimals="-6" id="f-856" unitRef="usd">38000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-142" decimals="-6" id="f-857" unitRef="usd">6445000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-143" decimals="-6" id="f-858" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-144" decimals="-6" id="f-859" unitRef="usd">6269000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-145" decimals="-6" id="f-860" unitRef="usd">176000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-114" decimals="-6" id="f-861" unitRef="usd">17008000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-115" decimals="-6" id="f-862" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-116" decimals="-6" id="f-863" unitRef="usd">16790000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-117" decimals="-6" id="f-864" unitRef="usd">218000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-114" decimals="-6" id="f-865" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-115" decimals="-6" id="f-866" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-116" decimals="-6" id="f-867" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-117" decimals="-6" id="f-868" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-114" decimals="-6" id="f-869" unitRef="usd">21590000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-115" decimals="-6" id="f-870" unitRef="usd">4582000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-116" decimals="-6" id="f-871" unitRef="usd">16790000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-117" decimals="-6" id="f-872" unitRef="usd">218000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-146" decimals="-6" id="f-873" unitRef="usd">4832000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-147" decimals="-6" id="f-874" unitRef="usd">4832000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-148" decimals="-6" id="f-875" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-149" decimals="-6" id="f-876" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-150" decimals="-6" id="f-877" unitRef="usd">1039000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-151" decimals="-6" id="f-878" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-152" decimals="-6" id="f-879" unitRef="usd">1039000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-153" decimals="-6" id="f-880" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-154" decimals="-6" id="f-881" unitRef="usd">3230000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-155" decimals="-6" id="f-882" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-156" decimals="-6" id="f-883" unitRef="usd">3230000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-157" decimals="-6" id="f-884" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-158" decimals="-6" id="f-885" unitRef="usd">728000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-159" decimals="-6" id="f-886" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-160" decimals="-6" id="f-887" unitRef="usd">728000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-161" decimals="-6" id="f-888" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-162" decimals="-6" id="f-889" unitRef="usd">401000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-163" decimals="-6" id="f-890" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-164" decimals="-6" id="f-891" unitRef="usd">401000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-165" decimals="-6" id="f-892" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-166" decimals="-6" id="f-893" unitRef="usd">1399000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-167" decimals="-6" id="f-894" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-168" decimals="-6" id="f-895" unitRef="usd">1399000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-169" decimals="-6" id="f-896" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-170" decimals="-6" id="f-897" unitRef="usd">1731000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-171" decimals="-6" id="f-898" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-172" decimals="-6" id="f-899" unitRef="usd">1731000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-173" decimals="-6" id="f-900" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-174" decimals="-6" id="f-901" unitRef="usd">5726000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-175" decimals="-6" id="f-902" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-176" decimals="-6" id="f-903" unitRef="usd">5625000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-177" decimals="-6" id="f-904" unitRef="usd">101000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-146" decimals="-6" id="f-905" unitRef="usd">14254000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-147" decimals="-6" id="f-906" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-148" decimals="-6" id="f-907" unitRef="usd">14153000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-149" decimals="-6" id="f-908" unitRef="usd">101000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-146" decimals="-6" id="f-909" unitRef="usd">7000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-147" decimals="-6" id="f-910" unitRef="usd">7000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-148" decimals="-6" id="f-911" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-149" decimals="-6" id="f-912" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-146" decimals="-6" id="f-913" unitRef="usd">19093000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-147" decimals="-6" id="f-914" unitRef="usd">4839000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-148" decimals="-6" id="f-915" unitRef="usd">14153000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-149" decimals="-6" id="f-916" unitRef="usd">101000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-4" decimals="-6" id="f-917" unitRef="usd">218000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-178" decimals="3" id="f-918" unitRef="number">0.010</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-5" decimals="-6" id="f-919" unitRef="usd">101000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-179" decimals="3" id="f-920" unitRef="number">0.005</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-921">During the years ended December&#160;31, 2023 and 2022, the changes in the fair value of the assets measured using significant unobservable inputs (Level 3) were comprised of the following:&lt;div style="margin-bottom:9pt;text-align:center;text-indent:11.25pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.277%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.211%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the year ended December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the year ended December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Private&lt;br/&gt;Placements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance at January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gains or losses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Realized in earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized in other comprehensive&#160;income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers Out&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Transfers In&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-5" decimals="-6" id="f-922" unitRef="usd">101000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-29" decimals="-6" id="f-923" unitRef="usd">68000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-1" decimals="-6" id="f-924" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-6" decimals="-6" id="f-925" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss contextRef="c-1" decimals="-6" id="f-926" unitRef="usd">3000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss contextRef="c-6" decimals="-6" id="f-927" unitRef="usd">-14000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInOtherComprehensiveIncomeLoss>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases contextRef="c-1" decimals="-6" id="f-928" unitRef="usd">115000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases contextRef="c-6" decimals="-6" id="f-929" unitRef="usd">47000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales contextRef="c-1" decimals="-6" id="f-930" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales contextRef="c-6" decimals="-6" id="f-931" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-1" decimals="-6" id="f-932" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-6" decimals="-6" id="f-933" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 contextRef="c-1" decimals="-6" id="f-934" unitRef="usd">8000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 contextRef="c-6" decimals="-6" id="f-935" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 contextRef="c-1" decimals="-6" id="f-936" unitRef="usd">7000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 contextRef="c-6" decimals="-6" id="f-937" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-4" decimals="-6" id="f-938" unitRef="usd">218000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-5" decimals="-6" id="f-939" unitRef="usd">101000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-180" decimals="INF" id="f-940" unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-180"
      decimals="INF"
      id="f-941"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-181" decimals="INF" id="f-942" unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-181"
      decimals="INF"
      id="f-943"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-182" decimals="INF" id="f-944" unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-182"
      decimals="INF"
      id="f-945"
      unitRef="number">0.03950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-183" decimals="INF" id="f-946" unitRef="usd">850000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-183"
      decimals="INF"
      id="f-947"
      unitRef="number">0.05950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-180"
      decimals="INF"
      id="f-948"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-181"
      decimals="INF"
      id="f-949"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-182"
      decimals="INF"
      id="f-950"
      unitRef="number">0.03950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-183"
      decimals="INF"
      id="f-951"
      unitRef="number">0.05950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DerivativeNotionalAmount contextRef="c-184" decimals="-6" id="f-952" unitRef="usd">650000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-185" decimals="-6" id="f-953" unitRef="usd">300000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-186" decimals="-6" id="f-954" unitRef="usd">450000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-187" decimals="-6" id="f-955" unitRef="usd">400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-180"
      decimals="INF"
      id="f-956"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-181"
      decimals="INF"
      id="f-957"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-182"
      decimals="INF"
      id="f-958"
      unitRef="number">0.03950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-183"
      decimals="INF"
      id="f-959"
      unitRef="number">0.05950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestRateFairValueHedgeAssetAtFairValue contextRef="c-4" decimals="-6" id="f-960" unitRef="usd">68000000</us-gaap:InterestRateFairValueHedgeAssetAtFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-188" decimals="-8" id="f-961" unitRef="usd">10800000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-189" decimals="-8" id="f-962" unitRef="usd">10000000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-190" decimals="-8" id="f-963" unitRef="usd">10600000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue contextRef="c-191" decimals="-8" id="f-964" unitRef="usd">9400000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:ShortTermBorrowings contextRef="c-192" decimals="-8" id="f-965" unitRef="usd">900000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c-193" decimals="-8" id="f-966" unitRef="usd">1100000000</us-gaap:ShortTermBorrowings>
    <hum:DefinitiveAgreementEquityInterestToBeAcquiredPercentage contextRef="c-194" decimals="2" id="f-967" unitRef="number">0.60</hum:DefinitiveAgreementEquityInterestToBeAcquiredPercentage>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-195" decimals="-6" id="f-968" unitRef="usd">63000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <hum:FinancialAssetsFairValueDisclosure contextRef="c-196" decimals="-6" id="f-969" unitRef="usd">440000000</hum:FinancialAssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-197" decimals="INF" id="f-970" unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <hum:FinancialAssetsFairValueDisclosure contextRef="c-198" decimals="INF" id="f-971" unitRef="usd">0</hum:FinancialAssetsFairValueDisclosure>
    <hum:LossOnTerminationOfDerivatives contextRef="c-7" decimals="-6" id="f-972" unitRef="usd">377000000</hum:LossOnTerminationOfDerivatives>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-199" decimals="-6" id="f-973" unitRef="usd">595000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <hum:FinancialAssetsFairValueDisclosure contextRef="c-200" decimals="-6" id="f-974" unitRef="usd">18000000</hum:FinancialAssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure contextRef="c-201" decimals="-6" id="f-975" unitRef="usd">267000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <hum:FinancialAssetsFairValueDisclosure contextRef="c-202" decimals="-6" id="f-976" unitRef="usd">10000000</hum:FinancialAssetsFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-977">The table below presents the assumptions used for December&#160;31, 2023 and 2022, respectively: &lt;div style="margin-bottom:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.837%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Annualized volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.1% - 17.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7% to 20.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit spread&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9% - 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3% to 1.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue exit multiple&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5x - 2.5x &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5x - 2.5x&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average cost of capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0% - 12.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.5% to 12.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long term growth rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used for annualized volatility, credit spread and weighted average cost of capital reflect the lowest and highest values where they differ significantly across the series of put and call options due to their expected exercise dates.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-203" decimals="3" id="f-978" unitRef="number">0.161</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-204" decimals="3" id="f-979" unitRef="number">0.178</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-205" decimals="3" id="f-980" unitRef="number">0.167</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-206" decimals="3" id="f-981" unitRef="number">0.208</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-207" decimals="3" id="f-982" unitRef="number">0.009</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-208" decimals="3" id="f-983" unitRef="number">0.011</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-209" decimals="3" id="f-984" unitRef="number">0.013</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-210" decimals="3" id="f-985" unitRef="number">0.015</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-211" decimals="1" id="f-986" unitRef="number">1.5</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-212" decimals="1" id="f-987" unitRef="number">2.5</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-213" decimals="1" id="f-988" unitRef="number">1.5</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-214" decimals="1" id="f-989" unitRef="number">2.5</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-215" decimals="3" id="f-990" unitRef="number">0.110</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-216" decimals="3" id="f-991" unitRef="number">0.125</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-217" decimals="3" id="f-992" unitRef="number">0.115</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-218" decimals="3" id="f-993" unitRef="number">0.125</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-219" decimals="3" id="f-994" unitRef="number">0.030</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <us-gaap:DerivativeAssetLiabilityNetMeasurementInput contextRef="c-220" decimals="3" id="f-995" unitRef="number">0.030</us-gaap:DerivativeAssetLiabilityNetMeasurementInput>
    <hum:DisposalGroupIncludingDiscontinuedOperationEquityInterestSold contextRef="c-77" decimals="2" id="f-996" unitRef="number">0.60</hum:DisposalGroupIncludingDiscontinuedOperationEquityInterestSold>
    <hum:MedicarePartDDisclosureTextBlock contextRef="c-1" id="f-997">MEDICARE PART D&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We cover prescription drug benefits in accordance with Medicare Part D under multiple contracts with CMS. The accompanying consolidated balance sheets include the following amounts associated with Medicare Part D as of December&#160;31, 2023 and 2022. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.672%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.654%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.654%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.654%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.658%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Risk&lt;br/&gt;Corridor&lt;br/&gt;Settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CMS&lt;br/&gt;Subsidies/&lt;br/&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Risk&lt;br/&gt;Corridor&lt;br/&gt;Settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CMS&lt;br/&gt;Subsidies/&lt;br/&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current (liability) asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net long-term liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total net (liability) asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</hum:MedicarePartDDisclosureTextBlock>
    <hum:BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock contextRef="c-1" id="f-998">The accompanying consolidated balance sheets include the following amounts associated with Medicare Part D as of December&#160;31, 2023 and 2022. CMS subsidies/discounts in the table below include the reinsurance and low-income cost subsidies funded by CMS for which we assume no risk as well as brand name prescription drug discounts for Part D plan participants in the coverage gap funded by CMS and pharmaceutical manufacturers. For additional information regarding our prescription drug benefits coverage in accordance with Medicare Part D, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.672%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.654%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.654%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.654%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.658%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Risk&lt;br/&gt;Corridor&lt;br/&gt;Settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CMS&lt;br/&gt;Subsidies/&lt;br/&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Risk&lt;br/&gt;Corridor&lt;br/&gt;Settlement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CMS&lt;br/&gt;Subsidies/&lt;br/&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current (liability) asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net long-term liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total net (liability) asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(540)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</hum:BalanceSheetAccountAssociatedWithMedicarePartDTableTextBlock>
    <us-gaap:OtherAssetsCurrent contextRef="c-221" decimals="-6" id="f-999" unitRef="usd">224000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-222" decimals="-6" id="f-1000" unitRef="usd">514000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-223" decimals="-6" id="f-1001" unitRef="usd">240000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-224" decimals="-6" id="f-1002" unitRef="usd">696000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-221" decimals="-6" id="f-1003" unitRef="usd">232000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-222" decimals="-6" id="f-1004" unitRef="usd">1825000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-223" decimals="-6" id="f-1005" unitRef="usd">166000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-224" decimals="-6" id="f-1006" unitRef="usd">1236000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <hum:NetCurrentLiabilityAsset contextRef="c-221" decimals="-6" id="f-1007" unitRef="usd">-8000000</hum:NetCurrentLiabilityAsset>
    <hum:NetCurrentLiabilityAsset contextRef="c-222" decimals="-6" id="f-1008" unitRef="usd">-1311000000</hum:NetCurrentLiabilityAsset>
    <hum:NetCurrentLiabilityAsset contextRef="c-223" decimals="-6" id="f-1009" unitRef="usd">74000000</hum:NetCurrentLiabilityAsset>
    <hum:NetCurrentLiabilityAsset contextRef="c-224" decimals="-6" id="f-1010" unitRef="usd">-540000000</hum:NetCurrentLiabilityAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-221" decimals="-6" id="f-1011" unitRef="usd">17000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-222" decimals="-6" id="f-1012" unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-223" decimals="-6" id="f-1013" unitRef="usd">19000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-224" decimals="-6" id="f-1014" unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-221" decimals="-6" id="f-1015" unitRef="usd">77000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-222" decimals="-6" id="f-1016" unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-223" decimals="-6" id="f-1017" unitRef="usd">78000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-224" decimals="-6" id="f-1018" unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <hum:NetNoncurrentAssetLiability contextRef="c-221" decimals="-6" id="f-1019" unitRef="usd">-60000000</hum:NetNoncurrentAssetLiability>
    <hum:NetNoncurrentAssetLiability contextRef="c-222" decimals="-6" id="f-1020" unitRef="usd">0</hum:NetNoncurrentAssetLiability>
    <hum:NetNoncurrentAssetLiability contextRef="c-223" decimals="-6" id="f-1021" unitRef="usd">-59000000</hum:NetNoncurrentAssetLiability>
    <hum:NetNoncurrentAssetLiability contextRef="c-224" decimals="-6" id="f-1022" unitRef="usd">0</hum:NetNoncurrentAssetLiability>
    <hum:NetAssetLiability contextRef="c-221" decimals="-6" id="f-1023" unitRef="usd">-68000000</hum:NetAssetLiability>
    <hum:NetAssetLiability contextRef="c-222" decimals="-6" id="f-1024" unitRef="usd">-1311000000</hum:NetAssetLiability>
    <hum:NetAssetLiability contextRef="c-223" decimals="-6" id="f-1025" unitRef="usd">15000000</hum:NetAssetLiability>
    <hum:NetAssetLiability contextRef="c-224" decimals="-6" id="f-1026" unitRef="usd">-540000000</hum:NetAssetLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-1027">PROPERTY AND EQUIPMENT, NET&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment was comprised of the following at December&#160;31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.654%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,136)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $831&#160;million in 2023, $749 million in 2022, and $640 million in 2021, including amortization expense for capitalized internally developed and purchased software of $589 million in 2023, $525 million in 2022, and $443 million in 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-1028">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment was comprised of the following at December&#160;31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:75.786%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.654%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,136)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,030&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-225" decimals="-6" id="f-1029" unitRef="usd">16000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-226" decimals="-6" id="f-1030" unitRef="usd">17000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-227" decimals="-6" id="f-1031" unitRef="usd">1002000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-228" decimals="-6" id="f-1032" unitRef="usd">1143000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-229" decimals="-6" id="f-1033" unitRef="usd">1320000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-230" decimals="-6" id="f-1034" unitRef="usd">1246000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-231" decimals="-6" id="f-1035" unitRef="usd">3546000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-232" decimals="-6" id="f-1036" unitRef="usd">3951000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-6" id="f-1037" unitRef="usd">5884000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-6" id="f-1038" unitRef="usd">6357000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-6" id="f-1039" unitRef="usd">2854000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-6" id="f-1040" unitRef="usd">3136000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-6" id="f-1041" unitRef="usd">3030000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-6" id="f-1042" unitRef="usd">3221000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationNonproduction contextRef="c-1" decimals="-6" id="f-1043" unitRef="usd">831000000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction contextRef="c-6" decimals="-6" id="f-1044" unitRef="usd">749000000</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction contextRef="c-7" decimals="-6" id="f-1045" unitRef="usd">640000000</us-gaap:DepreciationNonproduction>
    <us-gaap:CapitalizedComputerSoftwareAmortization1 contextRef="c-1" decimals="-6" id="f-1046" unitRef="usd">589000000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1 contextRef="c-6" decimals="-6" id="f-1047" unitRef="usd">525000000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1 contextRef="c-7" decimals="-6" id="f-1048" unitRef="usd">443000000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-1049">GOODWILL AND OTHER INTANGIBLE ASSETS&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amount of goodwill for our reportable segments for the years ended December&#160;31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.635%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.189%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CenterWell&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dispositions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents details of our other intangible assets included in other long-term assets in the accompanying consolidated balance sheets at December&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.116%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of need&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer contracts/relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names and technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetes and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for other intangible assets was approximately $67 million in 2023, $81&#160;million in 2022, and $65&#160;million in 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2023 we recorded impairment charges of $55&#160;million relating to indefinite-lived intangibles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our estimate of amortization expense for each of the five next succeeding fiscal years: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-1050">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amount of goodwill for our reportable segments for the years ended December&#160;31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.635%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.189%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CenterWell&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dispositions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-233" decimals="-6" id="f-1051" unitRef="usd">2290000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-234" decimals="-6" id="f-1052" unitRef="usd">8802000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-29" decimals="-6" id="f-1053" unitRef="usd">11092000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-235" decimals="-6" id="f-1054" unitRef="usd">182000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-236" decimals="-6" id="f-1055" unitRef="usd">199000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-6" decimals="-6" id="f-1056" unitRef="usd">381000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-235" decimals="-6" id="f-1057" unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-236" decimals="-6" id="f-1058" unitRef="usd">2331000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-6" decimals="-6" id="f-1059" unitRef="usd">2331000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:Goodwill contextRef="c-237" decimals="-6" id="f-1060" unitRef="usd">2472000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-238" decimals="-6" id="f-1061" unitRef="usd">6670000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-6" id="f-1062" unitRef="usd">9142000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-239" decimals="-6" id="f-1063" unitRef="usd">191000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-240" decimals="-6" id="f-1064" unitRef="usd">217000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-1" decimals="-6" id="f-1065" unitRef="usd">408000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill contextRef="c-241" decimals="-6" id="f-1066" unitRef="usd">2663000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-242" decimals="-6" id="f-1067" unitRef="usd">6887000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-6" id="f-1068" unitRef="usd">9550000000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-1069">&lt;div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents details of our other intangible assets included in other long-term assets in the accompanying consolidated balance sheets at December&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.957%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.116%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of need&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer contracts/relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade names and technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Noncompetes and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.4 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-243" decimals="-6" id="f-1070" unitRef="usd">1092000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-243" decimals="-6" id="f-1071" unitRef="usd">1092000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-244" decimals="-6" id="f-1072" unitRef="usd">1132000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-244" decimals="-6" id="f-1073" unitRef="usd">1132000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-245" decimals="-6" id="f-1074" unitRef="usd">288000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-245" decimals="-6" id="f-1075" unitRef="usd">288000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-246" decimals="-6" id="f-1076" unitRef="usd">286000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-246" decimals="-6" id="f-1077" unitRef="usd">286000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-247" id="f-1078">P9Y4M24D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-247" decimals="-6" id="f-1079" unitRef="usd">956000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-247" decimals="-6" id="f-1080" unitRef="usd">718000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-247" decimals="-6" id="f-1081" unitRef="usd">238000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-248" decimals="-6" id="f-1082" unitRef="usd">929000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-248" decimals="-6" id="f-1083" unitRef="usd">673000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-248" decimals="-6" id="f-1084" unitRef="usd">256000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-249" id="f-1085">P6Y8M12D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-249" decimals="-6" id="f-1086" unitRef="usd">139000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-249" decimals="-6" id="f-1087" unitRef="usd">109000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-249" decimals="-6" id="f-1088" unitRef="usd">30000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-250" decimals="-6" id="f-1089" unitRef="usd">142000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-250" decimals="-6" id="f-1090" unitRef="usd">107000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-250" decimals="-6" id="f-1091" unitRef="usd">35000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-251" id="f-1092">P11Y10M24D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-251" decimals="-6" id="f-1093" unitRef="usd">67000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-251" decimals="-6" id="f-1094" unitRef="usd">62000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-251" decimals="-6" id="f-1095" unitRef="usd">5000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-252" decimals="-6" id="f-1096" unitRef="usd">73000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-252" decimals="-6" id="f-1097" unitRef="usd">63000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-252" decimals="-6" id="f-1098" unitRef="usd">10000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-253" id="f-1099">P8Y4M24D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-253" decimals="-6" id="f-1100" unitRef="usd">84000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-253" decimals="-6" id="f-1101" unitRef="usd">44000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-253" decimals="-6" id="f-1102" unitRef="usd">40000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-254" decimals="-6" id="f-1103" unitRef="usd">86000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-254" decimals="-6" id="f-1104" unitRef="usd">40000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-254" decimals="-6" id="f-1105" unitRef="usd">46000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-4" id="f-1106">P9Y2M12D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-4" decimals="-6" id="f-1107" unitRef="usd">2626000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-6" id="f-1108" unitRef="usd">933000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-6" id="f-1109" unitRef="usd">1693000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-5" decimals="-6" id="f-1110" unitRef="usd">2648000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-5" decimals="-6" id="f-1111" unitRef="usd">883000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-6" id="f-1112" unitRef="usd">1765000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-6" id="f-1113" unitRef="usd">67000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-6" decimals="-6" id="f-1114" unitRef="usd">81000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-7" decimals="-6" id="f-1115" unitRef="usd">65000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-62" decimals="-6" id="f-1116" unitRef="usd">55000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-1117">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our estimate of amortization expense for each of the five next succeeding fiscal years: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.614%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-4" decimals="-6" id="f-1118" unitRef="usd">60000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-4" decimals="-6" id="f-1119" unitRef="usd">58000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-4" decimals="-6" id="f-1120" unitRef="usd">43000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-4" decimals="-6" id="f-1121" unitRef="usd">33000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-4" decimals="-6" id="f-1122" unitRef="usd">28000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-1123">LEASES&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine if a contract contains a lease by evaluating the nature and substance of the agreement. We lease facilities, computer hardware, and other furniture and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. For new lease agreements, we combine lease and nonlease components for all of our asset classes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When portions of the lease payments are not fixed or depend on an index or rate, we consider those payments to be variable in nature. Our variable lease payments include, but are not limited to, common area maintenance, taxes and insurance which are not dependent upon an index or rate. Variable lease payments are recorded in the period in which the obligation for the payment is incurred. Most leases include options to renew, with renewal terms that can extend the lease term. The exercise of lease renewal options is at our sole discretion. Certain leases also include options to purchase the leased property. The depreciable life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets included within &lt;span style="-sec-ix-hidden:f-1124"&gt;&lt;span style="-sec-ix-hidden:f-1125"&gt;other long-term assets&lt;/span&gt;&lt;/span&gt; in our consolidated balance sheets were $510 million and $515 million at December&#160;31, 2023 and December&#160;31, 2022, respectively. Operating lease liabilities included within &lt;span style="-sec-ix-hidden:f-1128"&gt;&lt;span style="-sec-ix-hidden:f-1129"&gt;trade accounts payable and accrued expenses&lt;/span&gt;&lt;/span&gt; in our consolidated balance sheets were $149 million and $152 million at December&#160;31, 2023 and December&#160;31, 2022, respectively. Additionally, operating lease liabilities included within &lt;span style="-sec-ix-hidden:f-1132"&gt;&lt;span style="-sec-ix-hidden:f-1133"&gt;other long-term liabilities&lt;/span&gt;&lt;/span&gt; in our consolidated balance sheets were $444 million and $456 million at December&#160;31, 2023 and December&#160;31, 2022, respectively. The classification of our operating lease liabilities is based on the remaining lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2023, 2022 and 2021, total fixed operating lease costs, excluding short-term lease costs, were $145 million, $183 million and $159 million, respectively, and are included within operating costs in our consolidated statements of income. Short-term lease costs were not material for the years ended December&#160;31, 2023, 2022 and 2021. In addition, for the years ended December&#160;31, 2023, 2022 and 2021, total variable operating lease costs were&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$120 million, $101 million and $94 million, respectively, and are included within operating costs in our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sublease facilities or partial facilities to third party tenants for space not used in our operations. For the years ended December&#160;31, 2023, 2022 and 2021, sublease rental income was&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$66 million, $52 million and $43 million, respectively, and is included within operating costs in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average remaining lease term is 5.4 years at December&#160;31, 2023 and December&#160;31, 2022. The weighted average discount rate is 3.9% and 3.2% at December&#160;31, 2023 and December&#160;31, 2022, respectively. For the years ended December&#160;31, 2023, 2022 and 2021, cash paid for amounts included in the measurement of lease liabilities included within our operating cash flows was $166 million, $191 million and $165 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity of&#160;Lease&#160;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For the years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate, as adjusted for collateralized borrowings, based on the information available at date of adoption or commencement date in determining the present value of lease payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-6" id="f-1126" unitRef="usd">510000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-6" id="f-1127" unitRef="usd">515000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-6" id="f-1130" unitRef="usd">149000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-6" id="f-1131" unitRef="usd">152000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-6" id="f-1134" unitRef="usd">444000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-6" id="f-1135" unitRef="usd">456000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-6" id="f-1136" unitRef="usd">145000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-6" decimals="-6" id="f-1137" unitRef="usd">183000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-7" decimals="-6" id="f-1138" unitRef="usd">159000000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-6" id="f-1139" unitRef="usd">120000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-6" decimals="-6" id="f-1140" unitRef="usd">101000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-7" decimals="-6" id="f-1141" unitRef="usd">94000000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome contextRef="c-1" decimals="-6" id="f-1142" unitRef="usd">66000000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-6" decimals="-6" id="f-1143" unitRef="usd">52000000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-7" decimals="-6" id="f-1144" unitRef="usd">43000000</us-gaap:SubleaseIncome>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-1145">P5Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-1146">P5Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-1147" unitRef="number">0.039</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-1148" unitRef="number">0.032</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-6" id="f-1149" unitRef="usd">166000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-6" decimals="-6" id="f-1150" unitRef="usd">191000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-7" decimals="-6" id="f-1151" unitRef="usd">165000000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1152">&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity of&#160;Lease&#160;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For the years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-6" id="f-1153" unitRef="usd">169000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-6" id="f-1154" unitRef="usd">145000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-6" id="f-1155" unitRef="usd">102000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-6" id="f-1156" unitRef="usd">75000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-6" id="f-1157" unitRef="usd">54000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-6" id="f-1158" unitRef="usd">108000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-6" id="f-1159" unitRef="usd">653000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-6" id="f-1160" unitRef="usd">60000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-6" id="f-1161" unitRef="usd">593000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:InsuranceDisclosureTextBlock contextRef="c-1" id="f-1162">BENEFITS PAYABLE&lt;div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the years ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balances at January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balances at December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total estimate of benefits payable for claims incurred but not reported, or IBNR, is included within the net &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incurred claims amounts. At December&#160;31, 2023 and 2022, benefits payable included IBNR of approximately $6.6&#160;billion and $5.7&#160;billion, primarily associated with claims incurred in each respective year. The cumulative number of reported claims as of December&#160;31, 2023 was approximately 200.0&#160;million for claims incurred in 2023, 182.4&#160;million for claims incurred in 2022, and 173.7&#160;million for claims incurred in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Amounts incurred related to prior years vary from previously estimated liabilities as the claims ultimately are settled. Negative amounts reported for incurred related to prior years result from claims being ultimately settled for amounts less than originally estimated (favorable development).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously discussed, our reserving practice is to consistently recognize the actuarial best estimate of our ultimate liability for claims. Actuarial standards require the use of assumptions based on moderately adverse experience, which generally results in favorable reserve development, or reserves that are considered redundant. We experienced favorable medical claims reserve development related to prior fiscal years of $872 million in 2023, $415 million in 2022, and $825 million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:4pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The medical claims reserve development for 2023, 2022, and 2021 primarily reflects the consistent application of trend and completion factors estimated using an assumption of moderately adverse conditions. The favorable development recognized in 2023 and 2021 primarily resulted from trend factors developing more favorably than originally expected as well as for 2021 completion factors developing faster than expected. The favorable development recognized in 2022 resulted primarily from completion factors remaining largely unchanged, resulting in lower overall development as compared to 2023 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:4pt;text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;         &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incurred and Paid Claims Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following discussion provides information about incurred and paid claims development as of December&#160;31, 2023, net of reinsurance, as well as cumulative claim frequency and the total of IBNR included within the net incurred claims amounts. The information about incurred and paid claims development for the years ended December 31, 2022 and 2021 is presented as supplementary information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Claims frequency is measured as medical fee-for-service claims for each service encounter with a unique provider identification number. Our claims frequency measure includes claims covered by deductibles as well as claims under capitated arrangements. Claim counts may vary based on product mix and the percentage of delegated capitation arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The following tables provide information about incurred and paid claims development as of December&#160;31, 2023, net of reinsurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.887%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.887%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Incurred Claims, Net of Reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Claims Incurred Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;br/&gt;Unaudited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;br/&gt;Unaudited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021 &amp;amp; Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.887%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.246%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.887%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Paid Claims, Net of Reinsurance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Claims Incurred Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;br/&gt;Unaudited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;br/&gt;Unaudited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021 &amp;amp; Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All outstanding benefit liabilities before 2021, net of reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits payable, net of reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information regarding our benefits payable and benefits expense recognition, refer to Note 2 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in this Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:InsuranceDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense contextRef="c-1" id="f-1163">&lt;div style="margin-bottom:3pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a consolidated basis, which represents our Insurance segment net of eliminations, activity in benefits payable was as follows for the years ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balances at January&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(825)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Paid related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67,287)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(74,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balances at December&#160;31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-5" decimals="-6" id="f-1164" unitRef="usd">9264000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-29" decimals="-6" id="f-1165" unitRef="usd">8289000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-15" decimals="-6" id="f-1166" unitRef="usd">8143000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions contextRef="c-1" decimals="-6" id="f-1167" unitRef="usd">62000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions contextRef="c-6" decimals="-6" id="f-1168" unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions contextRef="c-7" decimals="-6" id="f-1169" unitRef="usd">42000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense contextRef="c-1" decimals="-6" id="f-1170" unitRef="usd">89266000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense contextRef="c-6" decimals="-6" id="f-1171" unitRef="usd">76105000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense contextRef="c-7" decimals="-6" id="f-1172" unitRef="usd">70024000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-1" decimals="-6" id="f-1173" unitRef="usd">-872000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-6" decimals="-6" id="f-1174" unitRef="usd">-415000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense contextRef="c-7" decimals="-6" id="f-1175" unitRef="usd">-825000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 contextRef="c-1" decimals="-6" id="f-1176" unitRef="usd">88394000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 contextRef="c-6" decimals="-6" id="f-1177" unitRef="usd">75690000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1 contextRef="c-7" decimals="-6" id="f-1178" unitRef="usd">69199000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1 contextRef="c-1" decimals="-6" id="f-1179" unitRef="usd">79545000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1 contextRef="c-6" decimals="-6" id="f-1180" unitRef="usd">67287000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1 contextRef="c-7" decimals="-6" id="f-1181" unitRef="usd">62149000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1 contextRef="c-1" decimals="-6" id="f-1182" unitRef="usd">7934000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1 contextRef="c-6" decimals="-6" id="f-1183" unitRef="usd">7428000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1 contextRef="c-7" decimals="-6" id="f-1184" unitRef="usd">6946000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense contextRef="c-1" decimals="-6" id="f-1185" unitRef="usd">87479000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense contextRef="c-6" decimals="-6" id="f-1186" unitRef="usd">74715000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense contextRef="c-7" decimals="-6" id="f-1187" unitRef="usd">69095000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-4" decimals="-6" id="f-1188" unitRef="usd">10241000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-5" decimals="-6" id="f-1189" unitRef="usd">9264000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense contextRef="c-29" decimals="-6" id="f-1190" unitRef="usd">8289000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount contextRef="c-4" decimals="-8" id="f-1191" unitRef="usd">6600000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount contextRef="c-5" decimals="-8" id="f-1192" unitRef="usd">5700000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount>
    <hum:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported
      contextRef="c-255"
      decimals="-5"
      id="f-1193"
      unitRef="claim">200000000</hum:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported>
    <hum:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported
      contextRef="c-256"
      decimals="-5"
      id="f-1194"
      unitRef="claim">182400000</hum:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported>
    <hum:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported
      contextRef="c-257"
      decimals="-5"
      id="f-1195"
      unitRef="claim">173700000</hum:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseCumulativeNumberOfClaimsReported>
    <hum:FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears contextRef="c-1" decimals="-6" id="f-1196" unitRef="usd">872000000</hum:FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears>
    <hum:FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears contextRef="c-6" decimals="-6" id="f-1197" unitRef="usd">415000000</hum:FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears>
    <hum:FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears contextRef="c-7" decimals="-6" id="f-1198" unitRef="usd">825000000</hum:FavorableMedicalClaimsReserveDevelopmentRelatedToPriorFiscalYears>
    <us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock contextRef="c-1" id="f-1199">The following tables provide information about incurred and paid claims development as of December&#160;31, 2023, net of reinsurance.&lt;div style="margin-bottom:7pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.887%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.887%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.890%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Incurred Claims, Net of Reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Claims Incurred Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;br/&gt;Unaudited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;br/&gt;Unaudited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021 &amp;amp; Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.883%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.887%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.246%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.887%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Paid Claims, Net of Reinsurance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Claims Incurred Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;br/&gt;Unaudited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;br/&gt;Unaudited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021 &amp;amp; Prior&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All outstanding benefit liabilities before 2021, net of reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits payable, net of reinsurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet contextRef="c-258" decimals="-6" id="f-1200" unitRef="usd">70066000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet contextRef="c-259" decimals="-6" id="f-1201" unitRef="usd">69698000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet contextRef="c-260" decimals="-6" id="f-1202" unitRef="usd">69484000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet contextRef="c-261" decimals="-6" id="f-1203" unitRef="usd">76105000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet contextRef="c-256" decimals="-6" id="f-1204" unitRef="usd">75447000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet contextRef="c-255" decimals="-6" id="f-1205" unitRef="usd">89328000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet contextRef="c-4" decimals="-6" id="f-1206" unitRef="usd">234259000000</us-gaap:ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet contextRef="c-258" decimals="-6" id="f-1207" unitRef="usd">62149000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet contextRef="c-259" decimals="-6" id="f-1208" unitRef="usd">69252000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet contextRef="c-260" decimals="-6" id="f-1209" unitRef="usd">69484000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet contextRef="c-261" decimals="-6" id="f-1210" unitRef="usd">67287000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet contextRef="c-256" decimals="-6" id="f-1211" unitRef="usd">74989000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet contextRef="c-255" decimals="-6" id="f-1212" unitRef="usd">79545000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet contextRef="c-4" decimals="-6" id="f-1213" unitRef="usd">224018000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet contextRef="c-4" decimals="-6" id="f-1214" unitRef="usd">10241000000</us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1215">INCOME TAXES &lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes consisted of the following for the years ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes was different from the amount computed using the federal statutory rate for the years ended December&#160;31, 2023, 2022 and 2021 due to the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax provision at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, net of federal benefit, and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax exempt investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-taxable KAH gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax effect from sale of Gentiva Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Tax Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income tax balances reflect the impact of temporary differences between the tax bases of assets or liabilities and their reported amounts in our consolidated financial statements, and are stated at enacted tax rates expected to be in effect when the reported amounts are actually recovered or settled. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal components of our net deferred tax balances at December&#160;31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.168%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.866%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&#160;(Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and other accrued expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jobs tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unearned revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net deferred income tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All deferred tax assets and liabilities are classified as noncurrent in our consolidated balance sheets as other long-term assets and liabilities at December 31, 2023  and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, we had approximately $7 million of federal net operating losses and approximately $1.2 billion of pre-apportioned state and Puerto Rico net operating losses to carry forward. A portion of these loss carryforwards, if not used to offset future taxable income, will expire from 2024 through 2041. The balance of the net operating loss carryforwards has no expiration date. Due to limitations and uncertainty regarding our ability to use some of the loss carryforwards and certain other deferred tax assets, a valuation allowance of $73 million was established. For the remainder of the net operating loss carryforwards and other cumulative temporary differences, based on our historical record of producing taxable income and profitability, we have concluded that future operating income will be sufficient to recover these deferred tax assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We file income tax returns in the United States and Puerto Rico.&#160;The U.S. Internal Revenue Service, or IRS, has completed its examinations of our consolidated income tax returns for 2021 and prior years. Our 2022 tax return is in the post-filing review period under the Compliance Assurance Process, or CAP. Our 2023 tax return is under advance review by the IRS under CAP. With a few exceptions, which are immaterial in the aggregate, we are no longer subject to state, local and foreign tax examinations for years before 2020.&#160;We are not aware of any material adjustments that may be proposed as a result of any ongoing or future examinations. We do not have material uncertain tax positions reflected in our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1216">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes consisted of the following for the years ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1217" unitRef="usd">915000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-6" decimals="-6" id="f-1218" unitRef="usd">755000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-1219" unitRef="usd">466000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1220" unitRef="usd">85000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-6" decimals="-6" id="f-1221" unitRef="usd">107000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-1222" unitRef="usd">4000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1223" unitRef="usd">1000000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-6" decimals="-6" id="f-1224" unitRef="usd">862000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-1225" unitRef="usd">470000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1226" unitRef="usd">-164000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-6" decimals="-6" id="f-1227" unitRef="usd">-100000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-1228" unitRef="usd">15000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1229" unitRef="usd">836000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-6" id="f-1230" unitRef="usd">762000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-1231" unitRef="usd">485000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1232">&lt;div style="margin-bottom:12pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes was different from the amount computed using the federal statutory rate for the years ended December&#160;31, 2023, 2022 and 2021 due to the following:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax provision at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;States, net of federal benefit, and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax exempt investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible executive compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-taxable KAH gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(264)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax effect from sale of Gentiva Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Tax Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-6" id="f-1233" unitRef="usd">698000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-6" decimals="-6" id="f-1234" unitRef="usd">750000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-7" decimals="-6" id="f-1235" unitRef="usd">718000000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-6" id="f-1236" unitRef="usd">61000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-6" decimals="-6" id="f-1237" unitRef="usd">49000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-7" decimals="-6" id="f-1238" unitRef="usd">18000000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome contextRef="c-1" decimals="-6" id="f-1239" unitRef="usd">3000000</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome contextRef="c-6" decimals="-6" id="f-1240" unitRef="usd">3000000</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationTaxExemptIncome contextRef="c-7" decimals="-6" id="f-1241" unitRef="usd">3000000</us-gaap:IncomeTaxReconciliationTaxExemptIncome>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-6" id="f-1242" unitRef="usd">19000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-6" decimals="-6" id="f-1243" unitRef="usd">30000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-7" decimals="-6" id="f-1244" unitRef="usd">33000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <hum:EffectiveIncomeTaxReconciliationNonTaxableKAHGain contextRef="c-1" decimals="-6" id="f-1245" unitRef="usd">0</hum:EffectiveIncomeTaxReconciliationNonTaxableKAHGain>
    <hum:EffectiveIncomeTaxReconciliationNonTaxableKAHGain contextRef="c-6" decimals="-6" id="f-1246" unitRef="usd">0</hum:EffectiveIncomeTaxReconciliationNonTaxableKAHGain>
    <hum:EffectiveIncomeTaxReconciliationNonTaxableKAHGain contextRef="c-7" decimals="-6" id="f-1247" unitRef="usd">264000000</hum:EffectiveIncomeTaxReconciliationNonTaxableKAHGain>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness contextRef="c-1" decimals="-6" id="f-1248" unitRef="usd">0</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness contextRef="c-6" decimals="-6" id="f-1249" unitRef="usd">-72000000</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness contextRef="c-7" decimals="-6" id="f-1250" unitRef="usd">0</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-1" decimals="-6" id="f-1251" unitRef="usd">37000000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-6" decimals="-6" id="f-1252" unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-7" decimals="-6" id="f-1253" unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-6" id="f-1254" unitRef="usd">24000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-6" decimals="-6" id="f-1255" unitRef="usd">8000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-7" decimals="-6" id="f-1256" unitRef="usd">-17000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-1257" unitRef="usd">836000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-6" id="f-1258" unitRef="usd">762000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-1259" unitRef="usd">485000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1260">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal components of our net deferred tax balances at December&#160;31, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.168%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.866%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets&#160;(Liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation and other accrued expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jobs tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unearned revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets, net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciable property and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(814)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net deferred income tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-4" decimals="-6" id="f-1261" unitRef="usd">84000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-6" id="f-1262" unitRef="usd">105000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits contextRef="c-4" decimals="-6" id="f-1263" unitRef="usd">218000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits contextRef="c-5" decimals="-6" id="f-1264" unitRef="usd">158000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c-4" decimals="-6" id="f-1265" unitRef="usd">150000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c-5" decimals="-6" id="f-1266" unitRef="usd">103000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <hum:DeferredTaxAssetsDeferredPolicyAcquisitionCost contextRef="c-4" decimals="-6" id="f-1267" unitRef="usd">43000000</hum:DeferredTaxAssetsDeferredPolicyAcquisitionCost>
    <hum:DeferredTaxAssetsDeferredPolicyAcquisitionCost contextRef="c-5" decimals="-6" id="f-1268" unitRef="usd">43000000</hum:DeferredTaxAssetsDeferredPolicyAcquisitionCost>
    <hum:DeferredTaxAssetJobsTaxCredit contextRef="c-4" decimals="-6" id="f-1269" unitRef="usd">0</hum:DeferredTaxAssetJobsTaxCredit>
    <hum:DeferredTaxAssetJobsTaxCredit contextRef="c-5" decimals="-6" id="f-1270" unitRef="usd">22000000</hum:DeferredTaxAssetJobsTaxCredit>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-4" decimals="-6" id="f-1271" unitRef="usd">16000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-6" id="f-1272" unitRef="usd">16000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve contextRef="c-4" decimals="-6" id="f-1273" unitRef="usd">5000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve contextRef="c-5" decimals="-6" id="f-1274" unitRef="usd">7000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve>
    <us-gaap:DeferredTaxAssetsInvestments contextRef="c-4" decimals="-6" id="f-1275" unitRef="usd">419000000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsInvestments contextRef="c-5" decimals="-6" id="f-1276" unitRef="usd">454000000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-6" id="f-1277" unitRef="usd">935000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-6" id="f-1278" unitRef="usd">908000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-6" id="f-1279" unitRef="usd">73000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-6" id="f-1280" unitRef="usd">57000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-4" decimals="-6" id="f-1281" unitRef="usd">862000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-6" id="f-1282" unitRef="usd">851000000</us-gaap:DeferredTaxAssetsNet>
    <hum:DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets contextRef="c-4" decimals="-6" id="f-1283" unitRef="usd">642000000</hum:DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets>
    <hum:DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets contextRef="c-5" decimals="-6" id="f-1284" unitRef="usd">740000000</hum:DeferredTaxLiabilitiesDepreciablePropertyAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-4" decimals="-6" id="f-1285" unitRef="usd">156000000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-5" decimals="-6" id="f-1286" unitRef="usd">132000000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-4" decimals="-6" id="f-1287" unitRef="usd">16000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-5" decimals="-6" id="f-1288" unitRef="usd">6000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-6" id="f-1289" unitRef="usd">814000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-6" id="f-1290" unitRef="usd">878000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-6" id="f-1291" unitRef="usd">48000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxLiabilities contextRef="c-5" decimals="-6" id="f-1292" unitRef="usd">27000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards contextRef="c-262" decimals="-6" id="f-1293" unitRef="usd">7000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-263" decimals="-8" id="f-1294" unitRef="usd">1200000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-6" id="f-1295" unitRef="usd">73000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-1296">DEBT&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of debt outstanding was as follows at December&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$600 million, 3.850% due October 1, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.5 billion, 0.650% due August 3, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$600 million, 3.850% due October 1, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$600 million, 4.500% due April 1, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$500 million, 5.700% due March 13, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$750 million, 1.350% due February 3, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$600 million, 3.950% due March 15, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$500 million, 5.750% due March 1, 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$500 million, 5.750% due December 1, 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$750 million, 3.700% due March 23, 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$500 million, 3.125% due August 15, 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$500 million, 4.875% due April 1, 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$750 million 2.150% due February 3, 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$750 million, 5.875% due March 1, 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$850 million, 5.950% due March 15, 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$250 million, 8.150% due June&#160;15, 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$400 million, 4.625% due December&#160;1, 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$750 million, 4.950% due October 1, 2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$400 million, 4.800% due March 15, 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$500 million, 3.950% due August 15, 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$750 million, 5.500% due March 15, 2053&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;text-indent:-9.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Delayed draw term loan, due May 28, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:8.99pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the short-term and long-term debt for the years ending December 31, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For the years ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our senior notes, which are unsecured, may be redeemed at our option at any time at 100% of the principal amount plus accrued interest and a specified make-whole amount. The 8.150% senior notes are subject to an interest rate adjustment if the debt ratings assigned to the notes are downgraded (or subsequently upgraded). In addition, our senior notes contain a change of control provision that may require us to purchase the notes under certain circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, we issued $500&#160;million of 5.750% unsecured senior notes due December 1, 2028 and $850&#160;million of our 5.950% unsecured senior notes due March 15, 2034. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $1.3&#160;billion. We used the net proceeds for general corporate purposes, which included the repayment of existing indebtedness, including borrowings under our commercial paper program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, we issued $500&#160;million of 5.700% unsecured senior notes due March 13, 2026 and $750&#160;million of 5.500% unsecured senior notes due March 15, 2053. Our net proceeds, reduced for the underwriters' discounts and commissions paid, were $1.2&#160;billion. We used the net proceeds to repay outstanding amounts under our $500&#160;million Delayed Draw Term Loan. The remaining net proceeds were used for general corporate purposes, which included the repayment of existing indebtedness, including borrowings under our commercial paper program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $750&#160;million aggregate principal amount of 1.350% senior notes maturing in February 2027, our $600 million aggregate principal amount of 3.950% senior notes maturing in March 2027, our $750 million aggregate principal amount of 3.700% senior notes maturing in March 2029, and our $500 million aggregate principal amount of 3.125% senior notes maturing in August 2029 during the period beginning on August&#160;7, 2023 and ending on November&#160;15, 2023. For the year ended December 31, 2023, we repurchased $339&#160;million principal amount of these senior notes for approximately $310&#160;million cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, we entered into a Rule 10b5-1 Repurchase Plan to repurchase a portion of our $1.5&#160;billion aggregate principal amount of 0.650% senior notes maturing in August 2023 and our $600&#160;million aggregate principal amount of 3.850% senior notes maturing in October 2024 during the period beginning on March 13, 2023 and ending on July&#160;21, 2023. For the year ended December 31, 2023, we repurchased $361&#160;million principal amount of these senior notes for approximately $358&#160;million cash. We repaid the remaining $1.2&#160;billion aggregate principal amount of our 0.650% senior notes due on their maturity date of August&#160;3, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2023, we entered into interest rate swap agreements to exchange the fixed interest rate under our 5.875%, 5.500%, 3.950% and 5.950% senior notes for a variable interest rate based on SOFR, as further described in Note 6. As a result, the carrying value of these senior notes has been adjusted to reflect changes in value caused by an increase or decrease in interest rates. The cumulative, aggregate adjustment to the carrying value of the 5.875%, 5.500%, 3.950% and 5.950% senior notes was $9&#160;million, $13&#160;million, $36&#160;million and $10&#160;million respectively, at December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Revolving Credit Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, we entered into an amended and restated 5-year, $2.5&#160;billion unsecured revolving credit agreement (replacing the 5-year, $2.5&#160;billion unsecured revolving credit agreement entered in June 2021) and entered into a 364-day $1.5&#160;billion unsecured revolving credit agreement (replacing the 364-day $1.5&#160;billion unsecured revolving credit agreement entered into in June 2022, which expired in accordance with its terms). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the credit agreements, at our option, we can borrow on either a competitive advance basis or a revolving credit basis. The revolving credit portion bears interest at Term SOFR or the base rate plus a spread. The competitive advance portion of any borrowings will bear interest at market rates prevailing at the time of borrowing on either a fixed rate or a floating rate based Term SOFR, at our option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The SOFR spread, currently 103.5 basis points under the 5-year revolving credit agreement and 105.5 basis points under the 364-day revolving credit agreement, varies depending on our credit ratings ranging from 92.0 to 130.0 basis points under the 5-year revolving credit agreement and from 94.0 to 135.0 basis points under the 364-day revolving credit agreement. We also pay an annual facility fee regardless of utilization. This facility fee, currently 9.0 basis points, under the 5-year revolving credit agreement and 7.0 basis points under the 364-day revolving agreement, varies depending on our credit ratings ranging from 8.0 to 20.0 basis points under the 5-year revolving credit agreement and from 6.0 to 15.0 basis points under the 364-day revolving credit agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the revolving credit agreements include standard provisions related to conditions of borrowing which could limit our ability to borrow additional funds. In addition, the credit agreements contain customary restrictive covenants and a financial covenant regarding maximum debt to capitalization of 60%, as well as customary events of default. We are in compliance with this financial covenant, with actual debt to capitalization of 41.8% as measured in accordance with the revolving credit agreements as of December&#160;31, 2023. Upon our agreement with one or more financial institutions, we may expand the aggregate commitments under the revolving credit agreements by up to $750&#160;million in the aggregate, to a maximum of $4.75&#160;billion, across the 5-year and 364-day revolving credit agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, we had no borrowings and approximately $18&#160;million of letters of credit outstanding under the revolving credit agreements. Accordingly, as of December&#160;31, 2023, we had $2.482&#160;billion of remaining borrowing capacity under the 5-year revolving credit agreement and $1.5&#160;billion of remaining borrowing capacity under the 364-day revolving credit agreement (which excludes the uncommitted $750&#160;million of incremental loan facilities), none of which would be restricted by our financial covenant compliance requirement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have other customary relationships, including financial advisory and banking, with some parties to the revolving credit agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commercial Paper&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;     Under our commercial paper program we may issue short-term, unsecured commercial paper notes privately placed on a discount basis through certain broker dealers at any time. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. The maximum principal amount outstanding at any one time during the year ended&#160;December&#160;31, 2023&#160;was $3.3&#160;billion, with $871 million outstanding at December&#160;31, 2023 compared to $595 million outstanding at December 31, 2022. The outstanding commercial paper at December&#160;31, 2023 had a weighted average annual interest rate of 5.68%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a member, through one subsidiary, of the Federal Home Loan Bank of Cincinnati, or FHLB. As a member we have the ability to obtain short-term cash advances, subject to certain minimum collateral requirements. We received a short-term cash advance of $100&#160;million from FHLB with certain of our marketable securities as &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;collateral and subsequently repaid the outstanding balance in December 2023. As of December&#160;31, 2023 and December&#160;31, 2022, we had no outstanding short-term FHLB borrowings.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c-1" id="f-1297">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of debt outstanding was as follows at December&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.877%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$600 million, 3.850% due October 1, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.5 billion, 0.650% due August 3, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$600 million, 3.850% due October 1, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$600 million, 4.500% due April 1, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$500 million, 5.700% due March 13, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$750 million, 1.350% due February 3, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$600 million, 3.950% due March 15, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$500 million, 5.750% due March 1, 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$500 million, 5.750% due December 1, 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$750 million, 3.700% due March 23, 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$500 million, 3.125% due August 15, 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$500 million, 4.875% due April 1, 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$750 million 2.150% due February 3, 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$750 million, 5.875% due March 1, 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$850 million, 5.950% due March 15, 2034&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$250 million, 8.150% due June&#160;15, 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$400 million, 4.625% due December&#160;1, 2042&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$750 million, 4.950% due October 1, 2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$400 million, 4.800% due March 15, 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$500 million, 3.950% due August 15, 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$750 million, 5.500% due March 15, 2053&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 43pt;text-align:left;text-indent:-9.01pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Delayed draw term loan, due May 28, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;text-indent:8.99pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:ShortTermBorrowings contextRef="c-192" decimals="-6" id="f-1298" unitRef="usd">871000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c-264" decimals="-6" id="f-1299" unitRef="usd">595000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-265" decimals="INF" id="f-1300" unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-265"
      decimals="INF"
      id="f-1301"
      unitRef="number">0.03850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent contextRef="c-265" decimals="-6" id="f-1302" unitRef="usd">572000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-266" decimals="-6" id="f-1303" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-267" decimals="INF" id="f-1304" unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-267"
      decimals="INF"
      id="f-1305"
      unitRef="number">0.00650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent contextRef="c-267" decimals="-6" id="f-1306" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-268" decimals="-6" id="f-1307" unitRef="usd">1497000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-269" decimals="-6" id="f-1308" unitRef="usd">572000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-270" decimals="-6" id="f-1309" unitRef="usd">1497000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtCurrent contextRef="c-4" decimals="-6" id="f-1310" unitRef="usd">1443000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="c-5" decimals="-6" id="f-1311" unitRef="usd">2092000000</us-gaap:DebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-265" decimals="INF" id="f-1312" unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-265"
      decimals="INF"
      id="f-1313"
      unitRef="number">0.03850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-265" decimals="-6" id="f-1314" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-266" decimals="-6" id="f-1315" unitRef="usd">599000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-271" decimals="INF" id="f-1316" unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-271"
      decimals="INF"
      id="f-1317"
      unitRef="number">0.04500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-271" decimals="-6" id="f-1318" unitRef="usd">598000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-272" decimals="-6" id="f-1319" unitRef="usd">597000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-273" decimals="INF" id="f-1320" unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-273"
      decimals="INF"
      id="f-1321"
      unitRef="number">0.05700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-273" decimals="-6" id="f-1322" unitRef="usd">498000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-274" decimals="-6" id="f-1323" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-275" decimals="INF" id="f-1324" unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-275"
      decimals="INF"
      id="f-1325"
      unitRef="number">0.01350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-275" decimals="-6" id="f-1326" unitRef="usd">688000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-276" decimals="-6" id="f-1327" unitRef="usd">745000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-277" decimals="INF" id="f-1328" unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-277"
      decimals="INF"
      id="f-1329"
      unitRef="number">0.03950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-277" decimals="-6" id="f-1330" unitRef="usd">537000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-278" decimals="-6" id="f-1331" unitRef="usd">597000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-279" decimals="INF" id="f-1332" unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-279"
      decimals="INF"
      id="f-1333"
      unitRef="number">0.05750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-279" decimals="-6" id="f-1334" unitRef="usd">495000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-280" decimals="-6" id="f-1335" unitRef="usd">494000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-281" decimals="INF" id="f-1336" unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-281"
      decimals="INF"
      id="f-1337"
      unitRef="number">0.05750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-281" decimals="-6" id="f-1338" unitRef="usd">495000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-282" decimals="-6" id="f-1339" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-283" decimals="INF" id="f-1340" unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-283"
      decimals="INF"
      id="f-1341"
      unitRef="number">0.03700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-283" decimals="-6" id="f-1342" unitRef="usd">590000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-284" decimals="-6" id="f-1343" unitRef="usd">743000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-285" decimals="INF" id="f-1344" unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-285"
      decimals="INF"
      id="f-1345"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-285" decimals="-6" id="f-1346" unitRef="usd">433000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-286" decimals="-6" id="f-1347" unitRef="usd">496000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-287" decimals="INF" id="f-1348" unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-287"
      decimals="INF"
      id="f-1349"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-287" decimals="-6" id="f-1350" unitRef="usd">496000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-288" decimals="-6" id="f-1351" unitRef="usd">495000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-289" decimals="INF" id="f-1352" unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-289"
      decimals="INF"
      id="f-1353"
      unitRef="number">0.02150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-289" decimals="-6" id="f-1354" unitRef="usd">743000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-290" decimals="-6" id="f-1355" unitRef="usd">743000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-180" decimals="INF" id="f-1356" unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-180"
      decimals="INF"
      id="f-1357"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-180" decimals="-6" id="f-1358" unitRef="usd">750000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-291" decimals="-6" id="f-1359" unitRef="usd">739000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-183" decimals="INF" id="f-1360" unitRef="usd">850000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-183"
      decimals="INF"
      id="f-1361"
      unitRef="number">0.05950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-183" decimals="-6" id="f-1362" unitRef="usd">840000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-292" decimals="-6" id="f-1363" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-293" decimals="INF" id="f-1364" unitRef="usd">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-293"
      decimals="INF"
      id="f-1365"
      unitRef="number">0.08150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-293" decimals="-6" id="f-1366" unitRef="usd">261000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-294" decimals="-6" id="f-1367" unitRef="usd">261000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-295" decimals="INF" id="f-1368" unitRef="usd">400000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-295"
      decimals="INF"
      id="f-1369"
      unitRef="number">0.04625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-295" decimals="-6" id="f-1370" unitRef="usd">396000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-296" decimals="-6" id="f-1371" unitRef="usd">396000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-297" decimals="INF" id="f-1372" unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-297"
      decimals="INF"
      id="f-1373"
      unitRef="number">0.04950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-297" decimals="-6" id="f-1374" unitRef="usd">740000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-298" decimals="-6" id="f-1375" unitRef="usd">740000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-299" decimals="INF" id="f-1376" unitRef="usd">400000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-299"
      decimals="INF"
      id="f-1377"
      unitRef="number">0.04800</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-299" decimals="-6" id="f-1378" unitRef="usd">396000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-300" decimals="-6" id="f-1379" unitRef="usd">396000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-301" decimals="INF" id="f-1380" unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-301"
      decimals="INF"
      id="f-1381"
      unitRef="number">0.03950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-301" decimals="-6" id="f-1382" unitRef="usd">529000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-302" decimals="-6" id="f-1383" unitRef="usd">493000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-181" decimals="INF" id="f-1384" unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-181"
      decimals="INF"
      id="f-1385"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-181" decimals="-6" id="f-1386" unitRef="usd">728000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-303" decimals="-6" id="f-1387" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-269" decimals="-6" id="f-1388" unitRef="usd">10213000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-270" decimals="-6" id="f-1389" unitRef="usd">8534000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-304" decimals="-6" id="f-1390" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-305" decimals="-6" id="f-1391" unitRef="usd">500000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-6" id="f-1392" unitRef="usd">10213000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-5" decimals="-6" id="f-1393" unitRef="usd">9034000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-1394">&lt;div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the short-term and long-term debt for the years ending December 31, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.706%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.094%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;For the years ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-4" decimals="-6" id="f-1395" unitRef="usd">1443000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-4" decimals="-6" id="f-1396" unitRef="usd">600000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-4" decimals="-6" id="f-1397" unitRef="usd">500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-4" decimals="-6" id="f-1398" unitRef="usd">1231000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c-4" decimals="-6" id="f-1399" unitRef="usd">1000000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c-4" decimals="-6" id="f-1400" unitRef="usd">6930000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c-306"
      decimals="INF"
      id="f-1401"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-293"
      decimals="INF"
      id="f-1402"
      unitRef="number">0.08150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-307" decimals="INF" id="f-1403" unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-307"
      decimals="INF"
      id="f-1404"
      unitRef="number">0.05750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-308" decimals="INF" id="f-1405" unitRef="usd">850000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-308"
      decimals="INF"
      id="f-1406"
      unitRef="number">0.05950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt contextRef="c-309" decimals="-8" id="f-1407" unitRef="usd">1300000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-310" decimals="INF" id="f-1408" unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-310"
      decimals="INF"
      id="f-1409"
      unitRef="number">0.05700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-311" decimals="INF" id="f-1410" unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-311"
      decimals="INF"
      id="f-1411"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt contextRef="c-312" decimals="-8" id="f-1412" unitRef="usd">1200000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-313" decimals="-6" id="f-1413" unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-314" decimals="-6" id="f-1414" unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-314"
      decimals="INF"
      id="f-1415"
      unitRef="number">0.01350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-315" decimals="-6" id="f-1416" unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-315"
      decimals="INF"
      id="f-1417"
      unitRef="number">0.03950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-316" decimals="-6" id="f-1418" unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-316"
      decimals="INF"
      id="f-1419"
      unitRef="number">0.03700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-317" decimals="-6" id="f-1420" unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-317"
      decimals="INF"
      id="f-1421"
      unitRef="number">0.03125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-318" decimals="-6" id="f-1422" unitRef="usd">339000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c-318" decimals="-6" id="f-1423" unitRef="usd">310000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-319" decimals="INF" id="f-1424" unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-319"
      decimals="INF"
      id="f-1425"
      unitRef="number">0.00650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-320" decimals="INF" id="f-1426" unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-320"
      decimals="INF"
      id="f-1427"
      unitRef="number">0.03850</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-321" decimals="-6" id="f-1428" unitRef="usd">361000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c-321" decimals="-6" id="f-1429" unitRef="usd">358000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-322" decimals="-8" id="f-1430" unitRef="usd">1200000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-319"
      decimals="INF"
      id="f-1431"
      unitRef="number">0.00650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-180"
      decimals="INF"
      id="f-1432"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-181"
      decimals="INF"
      id="f-1433"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-182"
      decimals="INF"
      id="f-1434"
      unitRef="number">0.03950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-183"
      decimals="INF"
      id="f-1435"
      unitRef="number">0.05950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-180"
      decimals="INF"
      id="f-1436"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-181"
      decimals="INF"
      id="f-1437"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-182"
      decimals="INF"
      id="f-1438"
      unitRef="number">0.03950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-183"
      decimals="INF"
      id="f-1439"
      unitRef="number">0.05950</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <hum:LongTermDebtAggregateCarryingValueAdjustment contextRef="c-180" decimals="-6" id="f-1440" unitRef="usd">9000000</hum:LongTermDebtAggregateCarryingValueAdjustment>
    <hum:LongTermDebtAggregateCarryingValueAdjustment contextRef="c-181" decimals="-6" id="f-1441" unitRef="usd">13000000</hum:LongTermDebtAggregateCarryingValueAdjustment>
    <hum:LongTermDebtAggregateCarryingValueAdjustment contextRef="c-182" decimals="-6" id="f-1442" unitRef="usd">36000000</hum:LongTermDebtAggregateCarryingValueAdjustment>
    <hum:LongTermDebtAggregateCarryingValueAdjustment contextRef="c-183" decimals="-6" id="f-1443" unitRef="usd">10000000</hum:LongTermDebtAggregateCarryingValueAdjustment>
    <us-gaap:DebtInstrumentTerm contextRef="c-323" id="f-1444">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-324" decimals="INF" id="f-1445" unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-325" id="f-1446">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-326" decimals="INF" id="f-1447" unitRef="usd">2500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-327" id="f-1448">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-328" decimals="INF" id="f-1449" unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-329" id="f-1450">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-330" decimals="INF" id="f-1451" unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-331"
      decimals="INF"
      id="f-1452"
      unitRef="number">0.01035</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentTerm contextRef="c-332" id="f-1453">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-333"
      decimals="INF"
      id="f-1454"
      unitRef="number">0.01055</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentTerm contextRef="c-334" id="f-1455">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-335"
      decimals="INF"
      id="f-1456"
      unitRef="number">0.00920</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-336"
      decimals="INF"
      id="f-1457"
      unitRef="number">0.01300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentTerm contextRef="c-332" id="f-1458">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-337"
      decimals="INF"
      id="f-1459"
      unitRef="number">0.00940</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-338"
      decimals="INF"
      id="f-1460"
      unitRef="number">0.01350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentTerm contextRef="c-334" id="f-1461">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="c-332"
      decimals="INF"
      id="f-1462"
      unitRef="number">0.00090</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentTerm contextRef="c-332" id="f-1463">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="c-334"
      decimals="INF"
      id="f-1464"
      unitRef="number">0.00070</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentTerm contextRef="c-334" id="f-1465">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="c-339"
      decimals="INF"
      id="f-1466"
      unitRef="number">0.00080</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="c-340"
      decimals="INF"
      id="f-1467"
      unitRef="number">0.00200</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentTerm contextRef="c-332" id="f-1468">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="c-341"
      decimals="INF"
      id="f-1469"
      unitRef="number">0.00060</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="c-342"
      decimals="INF"
      id="f-1470"
      unitRef="number">0.00150</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentTerm contextRef="c-334" id="f-1471">P364D</us-gaap:DebtInstrumentTerm>
    <hum:DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum
      contextRef="c-343"
      decimals="INF"
      id="f-1472"
      unitRef="number">0.60</hum:DebtInstrumentCovenantDebtToCapitalizationPercentageMaximum>
    <hum:DebtInstrumentCovenantDebtToCapitalizationPercentageActual
      contextRef="c-344"
      decimals="3"
      id="f-1473"
      unitRef="number">0.418</hum:DebtInstrumentCovenantDebtToCapitalizationPercentageActual>
    <hum:LineOfCreditFacilityUncommittedIncrementalCapacity contextRef="c-343" decimals="-6" id="f-1474" unitRef="usd">750000000</hum:LineOfCreditFacilityUncommittedIncrementalCapacity>
    <hum:LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity contextRef="c-343" decimals="INF" id="f-1475" unitRef="usd">4750000000</hum:LineOfCreditFacilityMaximumBorrowingCapacityIncludingUncommittedIncrementalCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-345" id="f-1476">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-346" id="f-1477">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:LinesOfCreditCurrent contextRef="c-343" decimals="INF" id="f-1478" unitRef="usd">0</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent contextRef="c-347" decimals="-6" id="f-1479" unitRef="usd">18000000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-348" decimals="-6" id="f-1480" unitRef="usd">2482000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-345" id="f-1481">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-349" decimals="-8" id="f-1482" unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-346" id="f-1483">P364D</us-gaap:DebtInstrumentTerm>
    <hum:LineOfCreditFacilityUncommittedIncrementalCapacity contextRef="c-343" decimals="INF" id="f-1484" unitRef="usd">750000000</hum:LineOfCreditFacilityUncommittedIncrementalCapacity>
    <us-gaap:ShorttermDebtMaximumAmountOutstandingDuringPeriod contextRef="c-350" decimals="-8" id="f-1485" unitRef="usd">3300000000</us-gaap:ShorttermDebtMaximumAmountOutstandingDuringPeriod>
    <us-gaap:ShortTermBorrowings contextRef="c-192" decimals="-6" id="f-1486" unitRef="usd">871000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c-264" decimals="-6" id="f-1487" unitRef="usd">595000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate
      contextRef="c-192"
      decimals="4"
      id="f-1488"
      unitRef="number">0.0568</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-351" decimals="-6" id="f-1489" unitRef="usd">100000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-351" decimals="-6" id="f-1490" unitRef="usd">100000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ShortTermBorrowings contextRef="c-352" decimals="INF" id="f-1491" unitRef="usd">0</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c-353" decimals="INF" id="f-1492" unitRef="usd">0</us-gaap:ShortTermBorrowings>
    <hum:DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock contextRef="c-1" id="f-1493">EMPLOYEE BENEFIT PLANS&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Savings Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have defined contribution retirement savings plans covering eligible employees which include matching contributions based on the amount of our employees&#x2019; contributions to the plans. The cost of these plans amounted to approximately $278 million in 2023, $286 million in 2022, and $259 million in 2021. The Company&#x2019;s cash match is invested pursuant to the participant&#x2019;s contribution direction. Based on the closing price of our common stock of $457.81 on December&#160;31, 2023, approximately 8% of the retirement and savings plan&#x2019;s assets were invested in our common stock, or approximately 1.3 million shares, representing approximately 1.1% of the shares outstanding as of December&#160;31, 2023. At December&#160;31, 2023, approximately 5.5 million shares of our common stock were reserved for issuance under our defined contribution retirement savings plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have plans under which options to purchase our common stock and restricted stock units have been granted to executive officers, directors and key employees. Awards generally require both a change in control and termination of employment within 2 years of the date of the change in control to accelerate the vesting, including those granted to retirement-eligible participants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms and vesting schedules for stock-based awards vary by type of grant. Generally, the awards vest upon time-based conditions. We have also granted awards to certain employees that vest upon a combination of time and performance-based conditions. The stock awards of retirement-eligible participants are generally earned ratably over the service period for each tranche. Accordingly, upon retirement the earned portion of the current tranche will continue to vest on the originally scheduled vest date and any remaining unearned portion of the award will be forfeited. Our equity award program includes a retirement provision that generally treats employees with a combination of age and years of services with the Company totaling 65 or greater, with a minimum required age of 55 and a minimum requirement of 5 years of service, as retirement-eligible. Upon exercise, stock-based compensation awards are settled with authorized but unissued company stock or treasury stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The compensation expense that has been charged against income for these plans was as follows for the years ended December 31, 2023, 2022, and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense by type:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax benefit recognized in our consolidated financial statements is based on the amount of compensation expense recorded for book purposes, subject to limitations on the deductibility of annual compensation in excess of $500,000 per employee as mandated by the Health Care Reform Law. The actual tax benefit realized in our tax return is based on the intrinsic value, or the excess of the market value over the exercise or purchase price, of stock options exercised and restricted stock vested during the period, subject to limitations on the deductibility of annual compensation in excess of $500,000 per employee as mandated by the Health Care Reform Law. The actual tax benefit realized for the deductions taken on our tax returns from option exercises and restricted stock vesting totaled &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$30 million in 2023, $31&#160;million in 2022, and $28 million in 2021. There was no capitalized stock-based compensation expense during these years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, there were approximately 11.0 million shares reserved for stock award plans under the Humana Inc. 2011 Stock Incentive Plan, or 2011 Plan, and approximately 14.8 million shares reserved for stock award plans under the Humana Inc. 2019 Stock Incentive Plan, or 2019 Plan. These reserved shares included giving effect to, under the 2011 Plan, 3.3 million shares of common stock available for future grants assuming all stock options were granted or 1.4 million shares available for future grants assuming all restricted stock were granted.&#160;These reserved shares included giving effect to, under the 2019 Plan, 9.7 million shares of common stock available for future grants assuming all stock options were granted or 2.9 million shares available for future grants assuming all restricted stock were granted. Shares may be issued from authorized but unissued company stock or treasury stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock is granted with a fair value equal to the market price of our common stock on the date of grant and generally vests in equal annual tranches over a three year period from the date of grant. Certain of our restricted stock grants also include performance-based conditions generally associated with return on invested capital and strategic membership growth. Restricted stock units have forfeitable dividend equivalent rights equal to the dividend paid on common stock. The weighted-average grant date fair value of our restricted stock was $508.23 in 2023, $430.06 in 2022, and $381.34 in 2021. Activity for our restricted stock was as follows for the year ended December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.887%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.889%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(shares in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested restricted stock at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested restricted stock at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 37% of the nonvested restricted stock at December 31, 2023 included performance-based conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of shares vested was $236 million during 2023, $244 million during 2022, and $236 million during 2021. Total compensation expense not yet recognized related to nonvested restricted stock was $181 million at December&#160;31, 2023. We expect to recognize this compensation expense over a weighted-average period of approximately 1.7 years. There are no other contractual terms covering restricted stock once vested.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options are granted with an exercise price equal to the fair market value of the underlying common stock on the date of grant. Our stock plans, as approved by the Board of Directors and stockholders, define fair market value as the average of the highest and lowest stock prices reported on the composite tape by the New York Stock Exchange on a given date. Exercise provisions vary, but most options vest in whole or in part 1 to 3 years after grant and expire 7 years after grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average fair value of each option granted during 2023, 2022, and 2021 is provided below. The fair value was estimated on the date of grant using the Black-Scholes pricing model with the weighted-average assumptions indicated below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value at grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected option life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate at grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We calculate the expected term for our employee stock options based on historical employee exercise behavior and base the risk-free interest rate on a traded zero-coupon U.S. Treasury bond with a term substantially equal to the option&#x2019;s expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The volatility used to value employee stock options is based on historical volatility. We calculate historical volatility using a simple-average calculation methodology based on daily price intervals as measured over the expected term of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for our option plans was as follows for the year ended December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.168%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.866%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&#160; Under&lt;br/&gt;Option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(shares in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of  December&#160;31, 2023, outstanding stock options, substantially all of which are expected to vest, had an aggregate intrinsic value of $13 million, and a weighted-average remaining contractual term of 4.5 years. As of December&#160;31, 2023, exercisable stock options had an aggregate intrinsic value of $10 million, and a weighted-average remaining contractual term of 3.6 years. The total intrinsic value of stock options exercised during 2023 was $3 million, compared with $32 million during 2022 and $18 million during 2021. Cash received from stock option exercises totaled $9 million in 2023, $51 million in 2022, and $30 million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation expense not yet recognized related to nonvested options was $9 million at December&#160;31, 2023. We expect to recognize this compensation expense over a weighted-average period of approximately 1.7 years.&lt;/span&gt;&lt;/div&gt;</hum:DisclosureOfCompensationRelatedCostsShareBasedPaymentsAndCompensationAndRetirementDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-6" id="f-1494" unitRef="usd">278000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-6" decimals="-6" id="f-1495" unitRef="usd">286000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-7" decimals="-6" id="f-1496" unitRef="usd">259000000</us-gaap:DefinedContributionPlanCostRecognized>
    <hum:CompanyCommonStockClosingSharePrice
      contextRef="c-4"
      decimals="INF"
      id="f-1497"
      unitRef="usdPerShare">457.81</hum:CompanyCommonStockClosingSharePrice>
    <hum:DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock contextRef="c-4" decimals="2" id="f-1498" unitRef="number">0.08</hum:DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStock>
    <hum:DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares contextRef="c-4" decimals="-5" id="f-1499" unitRef="shares">1300000</hum:DefinedContributionPlanPlanAssetsInvestedInCompanyCommonStockShares>
    <hum:DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding contextRef="c-4" decimals="3" id="f-1500" unitRef="number">0.011</hum:DefinedContributionPlanSharesOfCommonStockInPlanAsPercentageOfSharesOutstanding>
    <hum:DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance contextRef="c-4" decimals="-5" id="f-1501" unitRef="shares">5500000</hum:DefinedContributionPlanNumberOfSharesOfCommonStockReservedForIssuance>
    <hum:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod contextRef="c-1" id="f-1502">P2Y</hum:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedVestingTerminationOfEmploymentPeriod>
    <hum:CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram contextRef="c-1" id="f-1503">P65Y</hum:CombinationOfAgeAndYearsNecessaryForRetirementProvisionAsRelatedToOurEquityAwardProgram>
    <hum:MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram contextRef="c-1" id="f-1504">P55Y</hum:MinimumAgeRequiredForRetirementEligibilityAsRelatedToOurEquityAwardProgram>
    <hum:MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram contextRef="c-1" id="f-1505">P5Y</hum:MinimumNumberOfYearsOfServiceForRetirementEligibilityAsRelatedToOurEquityAwardProgram>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-1506">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The compensation expense that has been charged against income for these plans was as follows for the years ended December 31, 2023, 2022, and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense by type:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-354" decimals="-6" id="f-1507" unitRef="usd">168000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-355" decimals="-6" id="f-1508" unitRef="usd">207000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-356" decimals="-6" id="f-1509" unitRef="usd">171000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-357" decimals="-6" id="f-1510" unitRef="usd">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-358" decimals="-6" id="f-1511" unitRef="usd">9000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-359" decimals="-6" id="f-1512" unitRef="usd">9000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-6" id="f-1513" unitRef="usd">175000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-6" id="f-1514" unitRef="usd">216000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-6" id="f-1515" unitRef="usd">180000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-6" id="f-1516" unitRef="usd">28000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-6" decimals="-6" id="f-1517" unitRef="usd">28000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-7" decimals="-6" id="f-1518" unitRef="usd">15000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-1" decimals="-6" id="f-1519" unitRef="usd">147000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-6" decimals="-6" id="f-1520" unitRef="usd">188000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-7" decimals="-6" id="f-1521" unitRef="usd">165000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <hum:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting contextRef="c-1" decimals="-6" id="f-1522" unitRef="usd">30000000</hum:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting>
    <hum:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting contextRef="c-6" decimals="-6" id="f-1523" unitRef="usd">31000000</hum:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting>
    <hum:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting contextRef="c-7" decimals="-6" id="f-1524" unitRef="usd">28000000</hum:EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptionsAndRestrictedStockVesting>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-7" decimals="INF" id="f-1525" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-1" decimals="INF" id="f-1526" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-6" decimals="INF" id="f-1527" unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-360"
      decimals="-5"
      id="f-1528"
      unitRef="shares">11000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-361"
      decimals="-5"
      id="f-1529"
      unitRef="shares">14800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-362"
      decimals="-5"
      id="f-1530"
      unitRef="shares">3300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-363"
      decimals="-5"
      id="f-1531"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-364"
      decimals="-5"
      id="f-1532"
      unitRef="shares">9700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-365"
      decimals="-5"
      id="f-1533"
      unitRef="shares">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-354" id="f-1534">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-354"
      decimals="2"
      id="f-1535"
      unitRef="usdPerShare">508.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-355"
      decimals="2"
      id="f-1536"
      unitRef="usdPerShare">430.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-356"
      decimals="2"
      id="f-1537"
      unitRef="usdPerShare">381.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-1538">Activity for our restricted stock was as follows for the year ended December&#160;31, 2023:&lt;div style="margin-bottom:7pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.887%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.889%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(shares in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested restricted stock at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nonvested restricted stock at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-366"
      decimals="-3"
      id="f-1539"
      unitRef="shares">813000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-366"
      decimals="2"
      id="f-1540"
      unitRef="usdPerShare">429.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-354"
      decimals="-3"
      id="f-1541"
      unitRef="shares">437000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-354"
      decimals="2"
      id="f-1542"
      unitRef="usdPerShare">508.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-354"
      decimals="-3"
      id="f-1543"
      unitRef="shares">428000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-354"
      decimals="2"
      id="f-1544"
      unitRef="usdPerShare">389.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-354"
      decimals="-3"
      id="f-1545"
      unitRef="shares">68000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-354"
      decimals="2"
      id="f-1546"
      unitRef="usdPerShare">441.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-367"
      decimals="-3"
      id="f-1547"
      unitRef="shares">754000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-367"
      decimals="2"
      id="f-1548"
      unitRef="usdPerShare">488.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <hum:ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions
      contextRef="c-367"
      decimals="2"
      id="f-1549"
      unitRef="number">0.37</hum:ShareBasedCompensationByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentOfStockWithPerformanceBasedConditions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-1" decimals="-6" id="f-1550" unitRef="usd">236000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-6" decimals="-6" id="f-1551" unitRef="usd">244000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-7" decimals="-6" id="f-1552" unitRef="usd">236000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-367" decimals="-6" id="f-1553" unitRef="usd">181000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-354" id="f-1554">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-368" id="f-1555">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-369" id="f-1556">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-357" id="f-1557">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1558">The fair value was estimated on the date of grant using the Black-Scholes pricing model with the weighted-average assumptions indicated below:&lt;div style="margin-bottom:7pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.400%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.868%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value at grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected option life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate at grant date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-357"
      decimals="2"
      id="f-1559"
      unitRef="usdPerShare">130.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-358"
      decimals="2"
      id="f-1560"
      unitRef="usdPerShare">113.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-359"
      decimals="2"
      id="f-1561"
      unitRef="usdPerShare">92.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-357" id="f-1562">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-358" id="f-1563">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-359" id="f-1564">P3Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-357"
      decimals="3"
      id="f-1565"
      unitRef="number">0.316</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-358"
      decimals="3"
      id="f-1566"
      unitRef="number">0.361</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-359"
      decimals="3"
      id="f-1567"
      unitRef="number">0.338</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-357"
      decimals="3"
      id="f-1568"
      unitRef="number">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-358"
      decimals="3"
      id="f-1569"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-359"
      decimals="3"
      id="f-1570"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-357"
      decimals="3"
      id="f-1571"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-358"
      decimals="3"
      id="f-1572"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-359"
      decimals="3"
      id="f-1573"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-1574">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for our option plans was as follows for the year ended December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.168%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.866%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&#160; Under&lt;br/&gt;Option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(shares in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;371.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;415.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="-3" id="f-1575" unitRef="shares">204000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-1576"
      unitRef="usdPerShare">381.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c-1" decimals="-3" id="f-1577" unitRef="shares">63000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1578"
      unitRef="usdPerShare">508.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="-3" id="f-1579" unitRef="shares">22000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1580"
      unitRef="usdPerShare">371.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="-3" id="f-1581" unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1582"
      unitRef="usdPerShare">491.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="-3" id="f-1583" unitRef="shares">242000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-1584"
      unitRef="usdPerShare">415.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-4" decimals="-3" id="f-1585" unitRef="shares">112000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-1586"
      unitRef="usdPerShare">366.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-6" id="f-1587" unitRef="usd">13000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-1588">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-4" decimals="-6" id="f-1589" unitRef="usd">10000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-1590">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-6" id="f-1591" unitRef="usd">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-6" decimals="-6" id="f-1592" unitRef="usd">32000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-7" decimals="-6" id="f-1593" unitRef="usd">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-6" id="f-1594" unitRef="usd">9000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-6" decimals="-6" id="f-1595" unitRef="usd">51000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="-6" id="f-1596" unitRef="usd">30000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-4" decimals="-6" id="f-1597" unitRef="usd">9000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-357" id="f-1598">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1599">EARNINGS PER COMMON SHARE COMPUTATION&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Detail supporting the computation of basic and diluted earnings per common share was as follows for the years ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(dollars in millions, except&#160;per&lt;br/&gt;common share results, number&#160;of&lt;br/&gt;shares/options in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income available for common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average outstanding shares of common stock used to &lt;br/&gt;&#160;&#160;&#160;&#160;compute basic earnings per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used to compute diluted earnings per&#160;common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of antidilutive stock options and restricted stock&#160;awards &lt;br/&gt;&#160;&#160;&#160;&#160;excluded from computation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1600">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Detail supporting the computation of basic and diluted earnings per common share was as follows for the years ended December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.842%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.844%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(dollars in millions, except&#160;per&lt;br/&gt;common share results, number&#160;of&lt;br/&gt;shares/options in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income available for common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average outstanding shares of common stock used to &lt;br/&gt;&#160;&#160;&#160;&#160;compute basic earnings per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive effect of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares used to compute diluted earnings per&#160;common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic earnings per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted earnings per common share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of antidilutive stock options and restricted stock&#160;awards &lt;br/&gt;&#160;&#160;&#160;&#160;excluded from computation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-1601" unitRef="usd">2489000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-6" id="f-1602" unitRef="usd">2806000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-6" id="f-1603" unitRef="usd">2933000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-1604" unitRef="shares">123866000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-1605" unitRef="shares">126419000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-1606" unitRef="shares">128688000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-357"
      decimals="-3"
      id="f-1607"
      unitRef="shares">32000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-358"
      decimals="-3"
      id="f-1608"
      unitRef="shares">50000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-359"
      decimals="-3"
      id="f-1609"
      unitRef="shares">64000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-354"
      decimals="-3"
      id="f-1610"
      unitRef="shares">543000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-355"
      decimals="-3"
      id="f-1611"
      unitRef="shares">625000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-356"
      decimals="-3"
      id="f-1612"
      unitRef="shares">644000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-1613" unitRef="shares">124441000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-1614" unitRef="shares">127094000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-1615" unitRef="shares">129396000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1616"
      unitRef="usdPerShare">20.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-1617"
      unitRef="usdPerShare">22.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-1618"
      unitRef="usdPerShare">22.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1619"
      unitRef="usdPerShare">20.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-1620"
      unitRef="usdPerShare">22.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-1621"
      unitRef="usdPerShare">22.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-1622" unitRef="shares">207000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-6" decimals="-3" id="f-1623" unitRef="shares">205000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="-3" id="f-1624" unitRef="shares">216000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1625">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides details of dividend payments, excluding dividend equivalent rights, in 2021, 2022, and 2023, under our Board approved quarterly cash dividend policy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.117%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.487%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;br/&gt;per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$351&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$390&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$428&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2023, the Board declared a cash dividend of $0.885 per share payable on January&#160;26, 2024 to stockholders of record on December&#160;29, 2023 for an aggregate amount of $108 million. In February 2024, the Board declared a cash dividend of $0.885 per share payable on April&#160;26, 2024 to stockholders of record on March&#160;29, 2024. Declaration and payment of future quarterly dividends is at the discretion of our Board and may be adjusted as business needs or market conditions change.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Board of Directors may authorize the purchase of our common shares. Under our share repurchase authorization, shares may have been purchased from time to time at prevailing prices in the open market, by block purchases, through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, or in privately-negotiated transactions (including pursuant to accelerated share repurchase agreements with investment banks), subject to certain regulatory restrictions on volume, pricing, and timing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 22, 2020, we entered into separate accelerated stock repurchase agreements, the December 2020 ASR Agreements, with Citibank, N.A., or Citi, and JPMorgan Chase Bank, or JPM, to repurchase $1.75&#160;billion of our common stock as part of the $3&#160;billion repurchase program authorized by the Board of Directors on July 30, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2019. On December 23, 2020, in accordance with the December 2020 ASR Agreements, we made a payment of $1.75&#160;billion ($875&#160;million to Citi and $875&#160;million to JPM) and received an initial delivery of 3.8&#160;million shares of our common stock (1.9&#160;million shares each from Citi and JPM). We recorded the payments to Citi and JPM as a reduction to stockholders&#x2019; equity, consisting of an $1.5&#160;billion increase in treasury stock, which reflects the value of the initial 3.8&#160;million shares received upon initial settlement, and a $262.5&#160;million decrease in capital in excess of par value, which reflects the value of stock held back by Citi and JPM pending final settlement of the December 2020 ASR Agreements. Upon final settlement of the December 2020 ASR agreements with Citi and JPM on May 4, 2021 and May 5, 2021, respectively, we received an additional 0.3&#160;million shares and 0.3&#160;million shares, respectively, as determined by the average daily volume weighted-averages share price of our common stock during the term of the agreement, less a discount, of $400.07 and $401.49, respectively, bringing the total shares received under the December 2020 ASR agreements to 4.4&#160;million. In addition, upon settlement we reclassified the $262.5&#160;million value of stock initially held back by Citi and JPM from capital in excess of par value to treasury stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 18, 2021, the Board of Directors replaced the previous share repurchase authorization of up to $3&#160;billion (of which approximately $1&#160;billion remained unused) with a new authorization for repurchases of up to $3&#160;billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 18, 2024.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2022, we entered into separate accelerated stock repurchase agreements, the January 2022 ASR Agreements, with Mizuho Markets Americas LLC, or Mizuho, and Wells Fargo Bank, or Wells Fargo, to repurchase $1&#160;billion of our common stock as part of the $3&#160;billion repurchase program authorized by the Board of Directors on February 18, 2021. On January 12, 2022, in accordance with the January 2022 ASR Agreements, we made a payment of $1&#160;billion ($500&#160;million to Mizuho and $500&#160;million to Wells Fargo) and received an initial delivery of 2.2&#160;million shares of our common stock (1.08&#160;million shares each from Mizuho and Wells Fargo). We recorded the payments to Mizuho and Wells Fargo as a reduction to stockholders&#x2019; equity, consisting of an $850&#160;million increase in treasury stock, which reflects the value of the initial 2.2&#160;million shares received upon initial settlement, and a $150&#160;million decrease in capital in excess of par value, which reflects the value of stock held back by Mizuho and Wells Fargo pending final settlement of the January 2022 ASR Agreements. Upon final settlement of the January 2022 ASR Agreements with Mizuho and Wells Fargo on March 29, 2022 and March 30, 2022, respectively, we received an additional 0.1&#160;million shares and 0.1&#160;million shares, respectively, as determined by the average daily volume weighted-averages share price of our common stock during the term of the agreement, less a discount, of $410.96 and $411.66, respectively, bringing the total shares received under the January 2022 ASR Agreements to 2.4&#160;million. In addition, upon settlement we reclassified the $150&#160;million value of stock initially held back by Mizuho and Wells Fargo from capital in excess of par value to treasury stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 2, 2022, we entered into separate accelerated stock repurchase agreements, the November 2022 ASR Agreements, with Goldman Sachs &amp;amp; Co. LLC, or Goldman Sachs, and Mizuho Markets Americas LLC, or Mizuho, to repurchase $1&#160;billion of our common stock as part of the $3&#160;billion repurchase program authorized by the Board of Directors on February 18, 2021. In accordance with the November 2022 ASR Agreements, we made a payment of $1&#160;billion ($500&#160;million to Goldman Sachs on November 3, 2022 and $500&#160;million to Mizuho on November 4, 2022) and received an initial delivery of 1.5&#160;million shares of our common stock (0.760&#160;million shares each from Goldman Sachs and Mizuho). We recorded the payments to Goldman Sachs and Mizuho as a reduction to stockholders&#x2019; equity, consisting of an $850&#160;million increase in treasury stock, which reflects the value of the initial 1.5&#160;million shares received upon initial settlement, and a $150&#160;million decrease in capital in excess of par value, which reflects the value of stock held back by Goldman Sachs and Mizuho pending final settlement of the November 2022 ASR Agreements. Upon final settlement of the November 2022 ASR Agreements with Goldman Sachs and Mizuho on December 15, 2022 and December 16, 2022, respectively, we received an additional 0.177&#160;million shares and 0.177&#160;million shares, respectively,  as determined by the average daily volume weighted-averages share price of our common stock during the term of the agreement, less a discount, of $534.16 and $533.87, respectively, bringing the total shares received under the November 2022 ASR Agreements to 1.8&#160;million. In addition, upon settlement we reclassified the $150&#160;million value of stock initially held back by Goldman Sachs and Mizuho from capital in excess of par value to treasury stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 15, 2023, the Board of Directors replaced the previous share repurchase authorization of up to $3&#160;billion (of which approximately $1&#160;billion remained unused) with a new authorization for repurchases of up to $3&#160;billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2026, which we refer to as the February 2023 repurchase authorization. During the year ended December&#160;31, 2023, we repurchased 3.1&#160;million common shares in open market transactions for $1.5&#160;billion at an average price of $482.27 under the current share repurchase authorization. During the years ended December&#160;31, 2022 and December&#160;31, 2021, we did not repurchase shares in open market transactions.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective February 16, 2024, the Board of Directors replaced the February 2023 repurchase authorization (of which approximately $824&#160;million remained unused) with a new share repurchase authorization for repurchases of up to $3&#160;billion of our common shares exclusive of shares repurchased in connection with employee stock plans, expiring as of February 15, 2027, which we refer to as the 2024 repurchase authorization. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding shares acquired in connection with employee stock plans, share repurchases were as follows during the years ended December 31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.129%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorization Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchase Not to Exceed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with employee stock plans, we acquired 0.2 million common shares for $73 million in 2023, 0.2 million common shares for $96 million in 2022, and 0.2 million common shares for $79 million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information regarding our stockholders' equity, refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" in our 2022 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Regulatory Requirements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our subsidiaries operate in states that regulate the payment of dividends, loans, or other cash transfers to Humana Inc., our parent company, and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these subsidiaries, without prior approval by state regulatory authorities, or ordinary dividends, is limited based on the entity&#x2019;s level of statutory income and statutory capit&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;al and surplus. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, it is generally considered an extraordinary dividend requiring prior regulatory approval. In most states, prior notification is provided before paying a dividend even if approval is not required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although minimum required levels of equity are largely based on premium volume, product mix, and the quality of assets held, minimum requirements vary significantly at the state level. Our state regulated insurance subsidiaries had aggregate statutory capital and surplus of approximately $12.2 billion and $11.3 billion as of December&#160;31, 2023 and 2022, respectively, which exceeded aggregate minimum regulatory requirements of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$9.8 billion and $8.4 billion, respectively.  The amount of ordinary dividends that may be paid to our parent company in 2024 is approximately $1.1 billion in the aggregate. The amount, timing and mix of ordinary and extraordinary dividend payments will vary due to state &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;regulatory requirements, the level of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix. Actual dividends that were paid to our parent company were approximately $1.8 billion in 2023, $1.3 billion in 2022, and $1.6 billion in 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DividendsDeclaredTableTextBlock contextRef="c-1" id="f-1626">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides details of dividend payments, excluding dividend equivalent rights, in 2021, 2022, and 2023, under our Board approved quarterly cash dividend policy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.117%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.486%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.487%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payment Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;br/&gt;per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$351&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.06&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$390&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.44&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$428&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DividendsDeclaredTableTextBlock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-7"
      decimals="INF"
      id="f-1627"
      unitRef="usdPerShare">2.73</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:Dividends contextRef="c-7" decimals="-6" id="f-1628" unitRef="usd">351000000</us-gaap:Dividends>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-6"
      decimals="INF"
      id="f-1629"
      unitRef="usdPerShare">3.06</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:Dividends contextRef="c-6" decimals="-6" id="f-1630" unitRef="usd">390000000</us-gaap:Dividends>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-1"
      decimals="INF"
      id="f-1631"
      unitRef="usdPerShare">3.44</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:Dividends contextRef="c-1" decimals="-6" id="f-1632" unitRef="usd">428000000</us-gaap:Dividends>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-370"
      decimals="INF"
      id="f-1633"
      unitRef="usdPerShare">0.885</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStock contextRef="c-370" decimals="-6" id="f-1634" unitRef="usd">108000000</us-gaap:DividendsCommonStock>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-371"
      decimals="4"
      id="f-1635"
      unitRef="usdPerShare">0.885</us-gaap:CommonStockDividendsPerShareDeclared>
    <hum:AcceleratedShareRepurchasesAgreementAmount contextRef="c-372" decimals="INF" id="f-1636" unitRef="usd">1750000000</hum:AcceleratedShareRepurchasesAgreementAmount>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-373" decimals="INF" id="f-1637" unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt contextRef="c-374" decimals="-7" id="f-1638" unitRef="usd">-1750000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt contextRef="c-375" decimals="-6" id="f-1639" unitRef="usd">-875000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt contextRef="c-376" decimals="-6" id="f-1640" unitRef="usd">-875000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-377"
      decimals="-5"
      id="f-1641"
      unitRef="shares">3800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-378"
      decimals="-5"
      id="f-1642"
      unitRef="shares">1900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-379"
      decimals="-5"
      id="f-1643"
      unitRef="shares">1900000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-377" decimals="-8" id="f-1644" unitRef="usd">1500000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-377"
      decimals="-5"
      id="f-1645"
      unitRef="shares">3800000</us-gaap:TreasuryStockSharesAcquired>
    <hum:TreasuryStockDecreaseInCapitalInExcessOfParValue contextRef="c-377" decimals="-5" id="f-1646" unitRef="usd">262500000</hum:TreasuryStockDecreaseInCapitalInExcessOfParValue>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-380"
      decimals="-5"
      id="f-1647"
      unitRef="shares">300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-381"
      decimals="-5"
      id="f-1648"
      unitRef="shares">300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare
      contextRef="c-380"
      decimals="2"
      id="f-1649"
      unitRef="usdPerShare">400.07</us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare>
    <us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare
      contextRef="c-381"
      decimals="2"
      id="f-1650"
      unitRef="usdPerShare">401.49</us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-382"
      decimals="-5"
      id="f-1651"
      unitRef="shares">4400000</us-gaap:TreasuryStockSharesAcquired>
    <hum:CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue contextRef="c-383" decimals="-5" id="f-1652" unitRef="usd">262500000</hum:CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-384" decimals="INF" id="f-1653" unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-384" decimals="-9" id="f-1654" unitRef="usd">1000000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-384" decimals="INF" id="f-1655" unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <hum:AcceleratedShareRepurchasesAgreementAmount contextRef="c-385" decimals="INF" id="f-1656" unitRef="usd">1000000000</hum:AcceleratedShareRepurchasesAgreementAmount>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-384" decimals="-9" id="f-1657" unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt contextRef="c-386" decimals="-9" id="f-1658" unitRef="usd">-1000000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt contextRef="c-387" decimals="-6" id="f-1659" unitRef="usd">-500000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt contextRef="c-388" decimals="-6" id="f-1660" unitRef="usd">-500000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-389"
      decimals="-5"
      id="f-1661"
      unitRef="shares">2200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-390"
      decimals="-4"
      id="f-1662"
      unitRef="shares">1080000.00</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-391"
      decimals="-4"
      id="f-1663"
      unitRef="shares">1080000.00</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-389" decimals="-6" id="f-1664" unitRef="usd">850000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-389"
      decimals="-5"
      id="f-1665"
      unitRef="shares">2200000</us-gaap:TreasuryStockSharesAcquired>
    <hum:TreasuryStockDecreaseInCapitalInExcessOfParValue contextRef="c-389" decimals="-6" id="f-1666" unitRef="usd">150000000</hum:TreasuryStockDecreaseInCapitalInExcessOfParValue>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-392"
      decimals="-5"
      id="f-1667"
      unitRef="shares">100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-393"
      decimals="-5"
      id="f-1668"
      unitRef="shares">100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare
      contextRef="c-392"
      decimals="2"
      id="f-1669"
      unitRef="usdPerShare">410.96</us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare>
    <us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare
      contextRef="c-393"
      decimals="2"
      id="f-1670"
      unitRef="usdPerShare">411.66</us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-394"
      decimals="-5"
      id="f-1671"
      unitRef="shares">2400000</us-gaap:TreasuryStockSharesAcquired>
    <hum:CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue contextRef="c-395" decimals="-6" id="f-1672" unitRef="usd">150000000</hum:CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue>
    <hum:AcceleratedShareRepurchasesAgreementAmount contextRef="c-396" decimals="INF" id="f-1673" unitRef="usd">1000000000</hum:AcceleratedShareRepurchasesAgreementAmount>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-384" decimals="-9" id="f-1674" unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt contextRef="c-396" decimals="-9" id="f-1675" unitRef="usd">-1000000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt contextRef="c-397" decimals="-6" id="f-1676" unitRef="usd">-500000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt contextRef="c-398" decimals="-6" id="f-1677" unitRef="usd">-500000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-399"
      decimals="-5"
      id="f-1678"
      unitRef="shares">1500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-400"
      decimals="-3"
      id="f-1679"
      unitRef="shares">760000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-401"
      decimals="-3"
      id="f-1680"
      unitRef="shares">760000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-399" decimals="-6" id="f-1681" unitRef="usd">850000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-399"
      decimals="-5"
      id="f-1682"
      unitRef="shares">1500000</us-gaap:TreasuryStockSharesAcquired>
    <hum:TreasuryStockDecreaseInCapitalInExcessOfParValue contextRef="c-399" decimals="-6" id="f-1683" unitRef="usd">150000000</hum:TreasuryStockDecreaseInCapitalInExcessOfParValue>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-402"
      decimals="-3"
      id="f-1684"
      unitRef="shares">177000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-403"
      decimals="-3"
      id="f-1685"
      unitRef="shares">177000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare
      contextRef="c-402"
      decimals="2"
      id="f-1686"
      unitRef="usdPerShare">534.16</us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare>
    <us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare
      contextRef="c-403"
      decimals="2"
      id="f-1687"
      unitRef="usdPerShare">533.87</us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-404"
      decimals="-5"
      id="f-1688"
      unitRef="shares">1800000</us-gaap:TreasuryStockSharesAcquired>
    <hum:CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue contextRef="c-405" decimals="-6" id="f-1689" unitRef="usd">150000000</hum:CommonStockReclassifiedFromCapitalInExcessOfParValueToTreasuryStockUponRepurchaseValue>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-406" decimals="-9" id="f-1690" unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-406" decimals="-9" id="f-1691" unitRef="usd">1000000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-407" decimals="-9" id="f-1692" unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-408"
      decimals="-5"
      id="f-1693"
      unitRef="shares">3100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-408" decimals="-8" id="f-1694" unitRef="usd">1500000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-408"
      decimals="2"
      id="f-1695"
      unitRef="usdPerShare">482.27</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-7"
      decimals="INF"
      id="f-1696"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-6"
      decimals="INF"
      id="f-1697"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-409" decimals="-6" id="f-1698" unitRef="usd">824000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-410" decimals="-9" id="f-1699" unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock contextRef="c-1" id="f-1700">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding shares acquired in connection with employee stock plans, share repurchases were as follows during the years ended December 31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.296%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.123%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.129%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorization Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchase Not to Exceed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="39" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-411" decimals="INF" id="f-1701" unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-412"
      decimals="-4"
      id="f-1702"
      unitRef="shares">3100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-412" decimals="-6" id="f-1703" unitRef="usd">1500000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-413"
      decimals="-4"
      id="f-1704"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-413" decimals="-6" id="f-1705" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-414"
      decimals="-4"
      id="f-1706"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-414" decimals="-6" id="f-1707" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-415" decimals="INF" id="f-1708" unitRef="usd">3000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-416"
      decimals="-4"
      id="f-1709"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-416" decimals="-6" id="f-1710" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-417"
      decimals="-4"
      id="f-1711"
      unitRef="shares">4300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-417" decimals="-6" id="f-1712" unitRef="usd">2000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-418"
      decimals="-4"
      id="f-1713"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-418" decimals="-6" id="f-1714" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-419"
      decimals="-4"
      id="f-1715"
      unitRef="shares">3100000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-419" decimals="-6" id="f-1716" unitRef="usd">1500000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-420"
      decimals="-4"
      id="f-1717"
      unitRef="shares">4300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-420" decimals="-6" id="f-1718" unitRef="usd">2000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-421"
      decimals="-4"
      id="f-1719"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-421" decimals="-6" id="f-1720" unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares contextRef="c-1" decimals="-5" id="f-1721" unitRef="shares">200000</hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares>
    <hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue contextRef="c-1" decimals="-6" id="f-1722" unitRef="usd">73000000</hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue>
    <hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares contextRef="c-6" decimals="-5" id="f-1723" unitRef="shares">200000</hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares>
    <hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue contextRef="c-6" decimals="-6" id="f-1724" unitRef="usd">96000000</hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue>
    <hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares contextRef="c-7" decimals="-5" id="f-1725" unitRef="shares">200000</hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsShares>
    <hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue contextRef="c-7" decimals="-6" id="f-1726" unitRef="usd">79000000</hum:ShareRepurchasesRelatedToEmployeeStockBasedCompensationAwardsValue>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance contextRef="c-4" decimals="-8" id="f-1727" unitRef="usd">12200000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance contextRef="c-5" decimals="-8" id="f-1728" unitRef="usd">11300000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired contextRef="c-4" decimals="-8" id="f-1729" unitRef="usd">9800000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired contextRef="c-5" decimals="-8" id="f-1730" unitRef="usd">8400000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired>
    <us-gaap:StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval contextRef="c-4" decimals="-8" id="f-1731" unitRef="usd">1100000000</us-gaap:StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval>
    <hum:DividendsToParentWithoutPriorStateRegulatoryApproval contextRef="c-1" decimals="-8" id="f-1732" unitRef="usd">1800000000</hum:DividendsToParentWithoutPriorStateRegulatoryApproval>
    <hum:DividendsToParentWithoutPriorStateRegulatoryApproval contextRef="c-6" decimals="-8" id="f-1733" unitRef="usd">1300000000</hum:DividendsToParentWithoutPriorStateRegulatoryApproval>
    <hum:DividendsToParentWithoutPriorStateRegulatoryApproval contextRef="c-7" decimals="-8" id="f-1734" unitRef="usd">1600000000</hum:DividendsToParentWithoutPriorStateRegulatoryApproval>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-1735">COMMITMENTS, GUARANTEES AND CONTINGENCIES&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;     Purchase Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have agreements to purchase services, primarily information technology related services, or to make improvements to real estate, in each case that are enforceable and legally binding on us and that specify all significant terms, including: fixed or minimum levels of service to be purchased; fixed, minimum or variable price provisions; and the appropriate timing of the transaction. We have purchase obligation commitments of&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$829 million in 2024, $518 million in 2025, $354 million in 2026, $273 million in 2027, and $209 million in 2028. Purchase obligations exclude agreements that are cancellable without penalty.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Off-Balance Sheet Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of our ongoing business, we do not participate or knowingly seek to participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, or SPEs, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. As of December&#160;31, 2023, we were not involved in any SPE transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Guarantees and Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through indemnity agreements approved by the state regulatory authorities, certain of our regulated subsidiaries generally are guaranteed by Humana Inc., our parent company, in the event of insolvency for (1)&#160;member coverage for which premium payment has been made prior to insolvency; (2)&#160;benefits for members then hospitalized until discharged; and (3)&#160;payment to providers for services rendered prior to insolvency. Our parent also has guaranteed the obligations of certain of our non-regulated subsidiaries and funding to maintain required statutory capital levels of certain regulated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, we enter into contractual arrangements under which we may agree to indemnify a third party to such arrangement from any losses incurred relating to the services they perform on behalf of us, or for losses arising from certain events as defined within the particular contract, which may include, for example, litigation or claims relating to past performance. Such indemnification obligations may not be subject to maximum loss clauses. Historically, payments made related to these indemnifications have been immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Medicare products, which accounted for approximately 83% of our total premiums and services revenue for the year ended December&#160;31, 2023, primarily consisted of products covered under the Medicare Advantage and Medicare Part D Prescription Drug Plan contracts with the federal government. These contracts are renewed generally for a calendar year term unless CMS notifies us of its decision not to renew by May 1 of the calendar year in which the contract would end, or we notify CMS of our decision not to renew by the first Monday in June of the calendar year in which the contract would end. All material contracts between Humana and CMS relating to our Medicare products have been renewed for 2024, and all of our product offerings filed with CMS for 2024 have been approved.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CMS uses a risk-adjustment model which adjusts premiums paid to Medicare Advantage, or MA, plans according to health status of covered members. The risk-adjustment model, which CMS implemented pursuant to the Balanced Budget Act of 1997 (BBA) and the Benefits Improvement and Protection Act of 2000 (BIPA), generally pays more where a plan's membership has higher expected costs. Under this model, rates paid to MA plans are based on actuarially determined bids, which include a process whereby our prospective payments are based on our estimated cost of providing standard Medicare-covered benefits to an enrollee with a "national average risk profile." That baseline payment amount is adjusted to account for certain demographic characteristics and health status of our enrolled members. Under the risk-adjustment methodology, all MA plans must collect from providers and submit the necessary diagnosis code information to CMS within prescribed deadlines. The CMS risk-adjustment model uses the diagnosis data, collected from providers, to calculate the health status-related risk-adjusted premium &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;payment to MA plans, which CMS further adjusts for coding pattern differences between the health plans and the government fee-for-service (FFS) program. We generally rely on providers, including certain providers in our network who are our employees, to code their claim submissions with appropriate diagnoses, which we send to CMS as the basis for our health status-adjusted payment received from CMS under the actuarial risk-adjustment model. We also rely on these providers to document appropriately all medical data, including the diagnosis data submitted with claims. In addition, we conduct medical record reviews as part of our data and payment accuracy compliance efforts, to more accurately reflect diagnosis conditions under the risk adjustment model. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CMS and the Office of the Inspector General of Health and Human Services, or HHS-OIG, perform audits of various companies&#x2019; risk adjustment diagnosis data submissions. We refer to these audits as Risk-Adjustment Data Validation Audits, or RADV audits. RADV audits review medical records in an attempt to validate provider medical record documentation and coding practices that influence the calculation of health status-related premium payments to MA plans.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2012, CMS released an MA contract-level RADV methodology that would extrapolate the results of each CMS RADV audit sample to the audited MA contract&#x2019;s entire health status-related risk adjusted premium amount for the year under audit.  In doing so, CMS recognized &#x201c;that the documentation standard used in RADV audits to determine a contract&#x2019;s payment error (medical records) is different from the documentation standard used to develop the Part C risk-adjustment model (FFS claims).&#x201d;  To correct for this difference, CMS stated that it would apply a &#x201c;Fee-for-Service Adjuster (FFS Adjuster)&#x201d; as &#x201c;an offset to the preliminary recovery amount.&#x201d;  This adjuster would be &#x201c;calculated by CMS based on a RADV-like review of records submitted to support FFS claims data.&#x201d;  CMS stated that this methodology would apply to audits beginning with PY 2011.  Humana relied on CMS&#x2019;s 2012 guidance in submitting MA bids to CMS.  Humana also launched a &#x201c;Self-Audits&#x201d; program in 2013 that applied CMS&#x2019;s 2012 RADV audit methodology and included an estimated FFS Adjuster.  Humana completed Self-Audits for PYs 2011-2016 and reported results to CMS.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, however, CMS issued a proposed rule announcing possible changes to the RADV audit methodology, including elimination of the FFS Adjuster.  CMS proposed applying its revised methodology, including extrapolated recoveries without application of a FFS Adjuster, to RADV audits dating back to PY 2011.  On January 30, 2023, CMS published a final rule related to the RADV audit methodology (Final RADV Rule).  The Final RADV Rule confirmed CMS&#x2019;s decision to eliminate the FFS Adjuster. The Final RADV Rule states CMS&#x2019;s intention to extrapolate results from CMS and HHS-OIG RADV audits beginning with PY 2018, rather than PY 2011 as proposed.  However, CMS&#x2019;s Final RADV Rule does not adopt a specific sampling, extrapolation or audit methodology.  CMS instead stated its general plan to rely on &#x201c;any statistically valid method . . . that is determined to be well-suited to a particular audit.&#x201d;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We believe that the Final RADV Rule fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act (&#x201c;APA&#x201d;). CMS failed to meet its legal obligations in the federal rulemaking process to give a reasoned justification for the rule or provide a meaningful opportunity for public comment. They also chose to apply the rule retroactively rather than prospectively, as required by law. Humana&#x2019;s actuarially certified bids through PY 2023 preserved Humana&#x2019;s position that CMS should apply an FFS Adjuster in any RADV audit that CMS intends to extrapolate. We expect CMS to apply the Final RADV Rule, including the first application of extrapolated audit results to determine audit settlements without a FFS Adjuster, to CMS and HHS-OIG RADV audits conducted for PY 2018 and subsequent years.  The Final RADV  Rule, including the lack of a FFS Adjuster, and any related regulatory, industry or company reactions, could have a material adverse effect on our results of operations, financial position, or cash flows.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, as part of our internal compliance efforts, we routinely perform ordinary course reviews of our internal business processes related to, among other things, our risk coding and data submissions in connection with the risk adjustment model. These reviews may also result in the identification of errors and the submission of corrections to CMS that may, either individually or in the aggregate, be material. As such, the result of these reviews may have a material adverse effect on our results of operations, financial position, or cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside. We remain committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members.  It is critical that MA plans are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4.5pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our state-based Medicaid business accounted for approximately 7% of our total premiums and services revenue for the year ended December 31, 2023 primarily serving members enrolled in Medicaid, and in certain circumstances members who qualify for both Medicaid and Medicare, under contracts with various states. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;     Our military services business, which accounted for approximately 1% of our total premiums and services revenue for the year ended December 31, 2023, primarily consisted of the TRICARE T2017 East Region contract. The T2017 East Region contract comprises 32 states and approximately 6.0&#160;million TRICARE beneficiaries, under which delivery of health care services commenced on January 1, 2018. The T2017 East Region contract, which was originally set to expire on December 31, 2022, was subsequently extended by the DoD and is currently scheduled to expire on December 31, 2024, unless further extended.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, we were awarded the next generation of TRICARE Managed Care Support Contracts, or T-5, for the updated TRICARE East Region by the Defense Health Agency of the DoD.The T-5 East Region contract comprises 24 states, and Washington D.C., and covers approximately 4.6&#160;million beneficiaries. The transition period for the T-5 contract began in January 2024 and will overlap the final year of the T2017 contract. The length of the contract is &lt;span style="-sec-ix-hidden:f-1748"&gt;one&lt;/span&gt; transition year followed by eight annual option periods, which, if all options are exercised, would result in a total contract length of &lt;span style="-sec-ix-hidden:f-1750"&gt;nine years.&lt;/span&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The loss of any of the contracts above or significant changes in these programs as a result of legislative or regulatory action, including reductions in premium payments to us, regulatory restrictions on profitability, including reviews by regulatory bodies that may compare our Medicare Advantage profitability to our non-Medicare Advantage business profitability, or compare the profitability of various products within our Medicare Advantage business, and require that they remain within certain ranges of each other, or increases in member benefits or member eligibility criteria without corresponding increases in premium payments to us, may have a material adverse effect on our results of operations, financial position, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings and Certain Regulatory Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, the Civil Division of the United States Department of Justice provided us with an information request in December 2014, concerning our Medicare Part C risk adjustment practices. The request relates to our oversight and submission of risk adjustment data generated by providers in our Medicare Advantage network, as well as to our business and compliance practices related to risk adjustment data generated by our providers and by us, including medical record reviews conducted as part of our data and payment accuracy compliance efforts, the use of health and well-being assessments, and our fraud detection efforts. We believe that this request for information is in connection with a wider review of Medicare Risk Adjustment generally that includes a number of Medicare Advantage plans, providers and vendors. We cooperated with the Department of Justice, and we have not heard from the Department of Justice on this matter since 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, on January 19, 2016, an individual filed a qui tam suit captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States of America ex rel. Steven Scott v. Humana, Inc.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, currently pending in United States District Court, Western District of Kentucky, Louisville Division. The complaint alleges certain civil violations by us in connection with the actuarial equivalence of the plan benefits under Humana&#x2019;s Basic PDP plan, a prescription drug plan offered by us under Medicare Part D. The action seeks damages and penalties on behalf of the United States under the False Claims Act. The court ordered the qui tam action unsealed on September 13, 2017, so that the relator could proceed, following notice from the U.S. Government that it was not intervening at that time. On March 31, 2022, the Court denied the parties' Motions for Summary Judgement. We take seriously our obligations to comply with applicable CMS &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;requirements and actuarial standards of practice, and continue to vigorously defend against these allegations. During 2023, we have accrued certain anticipated expenses in connection with this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 1, 2023, Humana Inc. and Humana Benefit Plan of Texas, Inc. filed suit against the United States Department of Health and Human Services, and Xavier Becerra in his official capacity as Secretary, in the United States District Court, Northern District of Texas, Fort Worth Division seeking a determination that the Final RADV Rule violates the APA and should be set aside.  There is no assurance that we will prevail in the lawsuit. See &#x201c;Government Contracts&#x201d; in this Note 17 for additional information regarding this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Lawsuits and Regulatory Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Our current and past business practices are subject to review or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance, health care delivery and benefits companies. These reviews focus on numerous facets of our business, including claims payment practices, statutory capital requirements, provider contracting, risk adjustment, competitive practices, commission payments, privacy issues, utilization management practices, pharmacy benefits, access to care, sales practices, and provision of care by our healthcare services businesses, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to some of our practices. We continue to be subject to these reviews, which could result in additional fines or other sanctions being imposed on us or additional changes in some of our practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also are involved in various other lawsuits that arise, for the most part, in the ordinary course of our business operations, certain of which may be styled as class-action lawsuits. Among other matters, this litigation may include employment matters, claims of medical malpractice, bad faith, nonacceptance or termination of providers, anticompetitive practices, improper rate setting, provider contract rate and payment disputes, including disputes over reimbursement rates required by statute, disputes arising from competitive procurement process, general contractual matters, intellectual property matters, and challenges to subrogation practices. Under state guaranty assessment laws, including those related to state cooperative failures in the industry, we may be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business as we do.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a government contractor, we may also be subject to false claims litigation, such as qui tam lawsuits brought by individuals who seek to sue on behalf of the government, alleging that the government contractor submitted false claims to the government or related overpayments from the government, including, among other allegations, those resulting from coding and review practices under the Medicare risk adjustment model. Qui tam litigation is filed under seal to allow the government an opportunity to investigate and to decide if it wishes to intervene and assume control of the litigation. If the government does not intervene, the individual may continue to prosecute the action on his or her own, on behalf of the government. We also are subject to other allegations of nonperformance of contractual obligations to providers, members, and others, including failure to properly pay claims, improper policy terminations, challenges to our implementation of the Medicare Part D prescription drug program and other litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A limited number of the claims asserted against us are subject to insurance coverage. Personal injury claims, claims for extra contractual damages, care delivery malpractice, and claims arising from medical benefit denials are covered by insurance from our wholly owned captive insurance subsidiary and excess carriers, except to the extent that claimants seek punitive damages, which may not be covered by insurance in certain states in which insurance coverage for punitive damages is not permitted. In addition, insurance coverage for all or certain forms of liability has become increasingly costly and may become unavailable or prohibitively expensive in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record accruals for the contingencies discussed in the sections above to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters specifically described above because of the inherently unpredictable nature of legal proceedings, which also may be exacerbated by various factors, including: (i) the damages sought in the proceedings are unsubstantiated or &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;indeterminate; (ii) discovery is not complete; (iii) the proceeding is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties (including where it is uncertain how liability, if any, will be shared among multiple defendants); or (vii) there is a wide range of potential outcomes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting judgments, penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities or as a result of actions by third parties. Nevertheless, it is reasonably possible that any such outcome of litigation, judgments, penalties, fines or other sanctions could be substantial, and the outcome of these matters may have a material adverse effect on our results of operations, financial position, and cash flows, and may also affect our reputation.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary contextRef="c-4" decimals="-6" id="f-1736" unitRef="usd">829000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary contextRef="c-4" decimals="-6" id="f-1737" unitRef="usd">518000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary contextRef="c-4" decimals="-6" id="f-1738" unitRef="usd">354000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary contextRef="c-4" decimals="-6" id="f-1739" unitRef="usd">273000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary contextRef="c-4" decimals="-6" id="f-1740" unitRef="usd">209000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceOnFifthAnniversary>
    <hum:PercentageOfTotalPremiumAndServicesRevenues
      contextRef="c-422"
      decimals="2"
      id="f-1741"
      unitRef="number">0.83</hum:PercentageOfTotalPremiumAndServicesRevenues>
    <hum:PercentageOfTotalPremiumAndServicesRevenues
      contextRef="c-423"
      decimals="2"
      id="f-1742"
      unitRef="number">0.07</hum:PercentageOfTotalPremiumAndServicesRevenues>
    <hum:PercentageOfTotalPremiumAndServicesRevenues
      contextRef="c-424"
      decimals="2"
      id="f-1743"
      unitRef="number">0.01</hum:PercentageOfTotalPremiumAndServicesRevenues>
    <hum:NumberOfStatesComprisingTRICAREBeneficiaries
      contextRef="c-425"
      decimals="INF"
      id="f-1744"
      unitRef="state">32</hum:NumberOfStatesComprisingTRICAREBeneficiaries>
    <hum:NumberOfTRICAREBeneficiaries
      contextRef="c-426"
      decimals="-5"
      id="f-1745"
      unitRef="beneficiary">6000000</hum:NumberOfTRICAREBeneficiaries>
    <hum:NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries
      contextRef="c-427"
      decimals="INF"
      id="f-1746"
      unitRef="state">24</hum:NumberOfStatesComprisingOfTRICAREManagedCareSupportContractBeneficiaries>
    <hum:NumberOfTRICAREManagedCareSupportContractBeneficiaries
      contextRef="c-428"
      decimals="INF"
      id="f-1747"
      unitRef="beneficiary">4600000</hum:NumberOfTRICAREManagedCareSupportContractBeneficiaries>
    <hum:TRICAREManagedCareSupportContractNumberOfOptionPeriods
      contextRef="c-427"
      decimals="INF"
      id="f-1749"
      unitRef="option_period">8</hum:TRICAREManagedCareSupportContractNumberOfOptionPeriods>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1751">SEGMENT INFORMATION&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During December 2022, we realigned our businesses into two distinct segments: Insurance and CenterWell. The Insurance segment includes the businesses that were previously included in the Retail and Group and Specialty segments, as well as the Pharmacy Benefit Manager, or PBM, business which was previously included in the Healthcare Services segment. The CenterWell segment (formerly Healthcare Services) represents our payor-agnostic healthcare services offerings, including pharmacy solutions, primary care, and home solutions. In addition to the new segment classifications being utilized to assess performance and allocate resources, we believe this simpler structure will create greater collaboration across the Insurance and CenterWell businesses and will accelerate work that is underway to centralize and integrate operations within the organization. 2021 segment financial information was recast to conform to the 2022 presentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our two&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. These segment groupings are consistent with information used by our Chief Executive Officer, the Chief Operating Decision Maker, to assess performance and allocate resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits, as well as administrative services only, or ASO. In addition, our Insurance segment includes our military services business, primarily our T-2017 East Region contract, as well as the operations of our PBM business. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CenterWell segment includes our pharmacy solutions, primary care, and home solutions operations. The segment also includes our strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as our minority ownership interest in Gentiva Hospice operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our CenterWell intersegment revenues primarily relate to the operations of CenterWell Pharmacy (our mail-order pharmacy business), CenterWell Specialty Pharmacy, and retail pharmacies jointly located within CenterWell Senior Primary Care clinics. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, our CenterWell intersegment revenues includes revenues earned by certain owned providers (CenterWell Senior Primary Care) derived from certain value-based arrangements with our health plans. Under these value-based arrangements, our owned providers enter into agreements with our health plans to stand ready to deliver, integrate, direct and control the administration and management of certain health care services for our members. In exchange, the owned provider receives a premium that is typically paid on a per-member per-month basis. These value-based arrangements represent a single performance obligation where revenues are recognized in the period in which we are obligated to provide integrated health care services to our members. Fee-for-service revenue is recognized at agreed upon rates, net of contractual allowances, as the performance obligation is completed on the date of service.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We present our consolidated results of operations from the perspective of the health plans. As a result, the cost of providing benefits to our members, whether provided via a third party provider or internally through a stand-alone subsidiary, is classified as benefits expense and excludes the portion of the cost for which the health plans do not bear responsibility, including member co-share amounts and government subsidies of $20.7 billion in 2023, $19.7 billion in 2022, and $18.1 billion in 2021. In addition, depreciation and amortization expense associated with certain businesses delivering benefits to our members, primarily associated with our primary care and pharmacy operations, are included with benefits expense. The amount of this expense was $138&#160;million in 2023, $122&#160;million in 2022, and $108&#160;million in 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than those described previously, the accounting policies of each segment are the same and are described in Note 2. Transactions between reportable segments primarily consist of sales of services rendered by our CenterWell segment, primarily pharmacy solutions, primary care, and home solutions, to our Insurance segment customers. Intersegment sales and expenses are recorded at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations in the tables presenting segment results below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium and services revenues derived from our contracts with the federal government, as a percentage of our total premium and services revenues, were approximately 84% for 2023, 82% for 2022 and 83% for 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CenterWell&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eliminations/&lt;br/&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Individual Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Group Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare stand-alone PDP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial fully-insured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Specialty benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Supplement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State-based contracts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Primary care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial ASO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Military services and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmacy solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total external revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,885)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes and equity in net losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss (income) attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings (loss) attributable to Humana&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CenterWell&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eliminations/&lt;br/&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Individual Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Group Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare stand-alone PDP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial fully-insured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Specialty benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Supplement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State-based contracts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Primary care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial ASO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Military services and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmacy solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total external revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of Gentiva Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes and equity in net earnings (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net earnings (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss (income) attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings (loss) attributable to Humana&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CenterWell&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eliminations/&lt;br/&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Individual Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Group Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare stand-alone PDP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial fully-insured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Specialty benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Supplement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State-based contracts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Primary care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial ASO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Military services and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmacy solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total external revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes and equity in net earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings attributable to Humana&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-429"
      decimals="INF"
      id="f-1752"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1753"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <hum:GovernmentAndHealthPlanMemberSubsidiesAmount contextRef="c-1" decimals="-8" id="f-1754" unitRef="usd">20700000000</hum:GovernmentAndHealthPlanMemberSubsidiesAmount>
    <hum:GovernmentAndHealthPlanMemberSubsidiesAmount contextRef="c-6" decimals="-8" id="f-1755" unitRef="usd">19700000000</hum:GovernmentAndHealthPlanMemberSubsidiesAmount>
    <hum:GovernmentAndHealthPlanMemberSubsidiesAmount contextRef="c-7" decimals="-8" id="f-1756" unitRef="usd">18100000000</hum:GovernmentAndHealthPlanMemberSubsidiesAmount>
    <hum:DepreciationAndAmortizationClassifiedAsBenefitExpense contextRef="c-1" decimals="-6" id="f-1757" unitRef="usd">138000000</hum:DepreciationAndAmortizationClassifiedAsBenefitExpense>
    <hum:DepreciationAndAmortizationClassifiedAsBenefitExpense contextRef="c-6" decimals="-6" id="f-1758" unitRef="usd">122000000</hum:DepreciationAndAmortizationClassifiedAsBenefitExpense>
    <hum:DepreciationAndAmortizationClassifiedAsBenefitExpense contextRef="c-7" decimals="-6" id="f-1759" unitRef="usd">108000000</hum:DepreciationAndAmortizationClassifiedAsBenefitExpense>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-58" decimals="2" id="f-1760" unitRef="number">0.84</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-430"
      decimals="2"
      id="f-1761"
      unitRef="number">0.82</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-431"
      decimals="2"
      id="f-1762"
      unitRef="number">0.83</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1763">&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CenterWell&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eliminations/&lt;br/&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Individual Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Group Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare stand-alone PDP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial fully-insured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Specialty benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Supplement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State-based contracts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Primary care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial ASO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Military services and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmacy solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total external revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,272&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,885)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(706)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes and equity in net losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss (income) attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings (loss) attributable to Humana&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CenterWell&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eliminations/&lt;br/&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Individual Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Group Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare stand-alone PDP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial fully-insured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Specialty benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Supplement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State-based contracts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Primary care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial ASO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Military services and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmacy solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total external revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,588)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,934&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of Gentiva Hospice&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) before income taxes and equity in net earnings (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net earnings (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss (income) attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings (loss) attributable to Humana&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(982)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;CenterWell&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Eliminations/&lt;br/&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Individual Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Group Medicare Advantage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare stand-alone PDP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial fully-insured&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Specialty benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare Supplement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State-based contracts and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Home solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Primary care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial ASO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Military services and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmacy solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 48.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total services revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total external revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,869)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intersegment revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,893)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before income taxes and equity in net earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment earnings attributable to Humana&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:PremiumsEarnedNet contextRef="c-432" decimals="-6" id="f-1764" unitRef="usd">78837000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-433" decimals="-6" id="f-1765" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-434" decimals="-6" id="f-1766" unitRef="usd">78837000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-435" decimals="-6" id="f-1767" unitRef="usd">6869000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-436" decimals="-6" id="f-1768" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-437" decimals="-6" id="f-1769" unitRef="usd">6869000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-438" decimals="-6" id="f-1770" unitRef="usd">2189000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-439" decimals="-6" id="f-1771" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-440" decimals="-6" id="f-1772" unitRef="usd">2189000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-441" decimals="-6" id="f-1773" unitRef="usd">87895000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-442" decimals="-6" id="f-1774" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-443" decimals="-6" id="f-1775" unitRef="usd">87895000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-444" decimals="-6" id="f-1776" unitRef="usd">3527000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-445" decimals="-6" id="f-1777" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-446" decimals="-6" id="f-1778" unitRef="usd">3527000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-447" decimals="-6" id="f-1779" unitRef="usd">1007000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-448" decimals="-6" id="f-1780" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-449" decimals="-6" id="f-1781" unitRef="usd">1007000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-450" decimals="-6" id="f-1782" unitRef="usd">735000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-451" decimals="-6" id="f-1783" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-452" decimals="-6" id="f-1784" unitRef="usd">735000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-453" decimals="-6" id="f-1785" unitRef="usd">8108000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-454" decimals="-6" id="f-1786" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-455" decimals="-6" id="f-1787" unitRef="usd">8108000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-456" decimals="-6" id="f-1788" unitRef="usd">101272000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-457" decimals="-6" id="f-1789" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-458" decimals="-6" id="f-1790" unitRef="usd">101272000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-459" decimals="-6" id="f-1791" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-460" decimals="-6" id="f-1792" unitRef="usd">1342000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-461" decimals="-6" id="f-1793" unitRef="usd">1342000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-462" decimals="-6" id="f-1794" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-463" decimals="-6" id="f-1795" unitRef="usd">842000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-464" decimals="-6" id="f-1796" unitRef="usd">842000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-465" decimals="-6" id="f-1797" unitRef="usd">237000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-466" decimals="-6" id="f-1798" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-467" decimals="-6" id="f-1799" unitRef="usd">237000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-468" decimals="-6" id="f-1800" unitRef="usd">763000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-469" decimals="-6" id="f-1801" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-470" decimals="-6" id="f-1802" unitRef="usd">763000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-471" decimals="-6" id="f-1803" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-472" decimals="-6" id="f-1804" unitRef="usd">849000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-473" decimals="-6" id="f-1805" unitRef="usd">849000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-474" decimals="-6" id="f-1806" unitRef="usd">1000000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-475" decimals="-6" id="f-1807" unitRef="usd">3033000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-476" decimals="-6" id="f-1808" unitRef="usd">4033000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:Revenues contextRef="c-477" decimals="-6" id="f-1809" unitRef="usd">102272000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-478" decimals="-6" id="f-1810" unitRef="usd">3033000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-479" decimals="-6" id="f-1811" unitRef="usd">105305000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-480" decimals="-6" id="f-1812" unitRef="usd">31000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-481" decimals="-6" id="f-1813" unitRef="usd">4921000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-482" decimals="-6" id="f-1814" unitRef="usd">-4952000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-483" decimals="-6" id="f-1815" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-484" decimals="-6" id="f-1816" unitRef="usd">10451000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-485" decimals="-6" id="f-1817" unitRef="usd">-10451000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-486" decimals="-6" id="f-1818" unitRef="usd">31000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-487" decimals="-6" id="f-1819" unitRef="usd">15372000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-488" decimals="-6" id="f-1820" unitRef="usd">-15403000000</us-gaap:Revenues>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-489" decimals="-6" id="f-1821" unitRef="usd">551000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-490" decimals="-6" id="f-1822" unitRef="usd">0</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-491" decimals="-6" id="f-1823" unitRef="usd">518000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-1" decimals="-6" id="f-1824" unitRef="usd">1069000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:Revenues contextRef="c-489" decimals="-6" id="f-1825" unitRef="usd">102854000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-490" decimals="-6" id="f-1826" unitRef="usd">18405000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-491" decimals="-6" id="f-1827" unitRef="usd">-14885000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-6" id="f-1828" unitRef="usd">106374000000</us-gaap:Revenues>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare contextRef="c-489" decimals="-6" id="f-1829" unitRef="usd">89100000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare contextRef="c-490" decimals="-6" id="f-1830" unitRef="usd">0</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare contextRef="c-491" decimals="-6" id="f-1831" unitRef="usd">-706000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare contextRef="c-1" decimals="-6" id="f-1832" unitRef="usd">88394000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-489" decimals="-6" id="f-1833" unitRef="usd">10408000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-490" decimals="-6" id="f-1834" unitRef="usd">16791000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-491" decimals="-6" id="f-1835" unitRef="usd">-14011000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-6" id="f-1836" unitRef="usd">13188000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization contextRef="c-489" decimals="-6" id="f-1837" unitRef="usd">692000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-490" decimals="-6" id="f-1838" unitRef="usd">210000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-491" decimals="-6" id="f-1839" unitRef="usd">-123000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-6" id="f-1840" unitRef="usd">779000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-489" decimals="-6" id="f-1841" unitRef="usd">100200000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-490" decimals="-6" id="f-1842" unitRef="usd">17001000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-491" decimals="-6" id="f-1843" unitRef="usd">-14840000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-1" decimals="-6" id="f-1844" unitRef="usd">102361000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-489" decimals="-6" id="f-1845" unitRef="usd">2654000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-490" decimals="-6" id="f-1846" unitRef="usd">1404000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-491" decimals="-6" id="f-1847" unitRef="usd">-45000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-6" id="f-1848" unitRef="usd">4013000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="c-489" decimals="-6" id="f-1849" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-490" decimals="-6" id="f-1850" unitRef="usd">3000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-491" decimals="-6" id="f-1851" unitRef="usd">490000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-6" id="f-1852" unitRef="usd">493000000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-489" decimals="-6" id="f-1853" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-490" decimals="-6" id="f-1854" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-491" decimals="-6" id="f-1855" unitRef="usd">-137000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-6" id="f-1856" unitRef="usd">-137000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-489" decimals="-6" id="f-1857" unitRef="usd">2654000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-490" decimals="-6" id="f-1858" unitRef="usd">1401000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-491" decimals="-6" id="f-1859" unitRef="usd">-672000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-1860" unitRef="usd">3383000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-489" decimals="-6" id="f-1861" unitRef="usd">-6000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-490" decimals="-6" id="f-1862" unitRef="usd">-57000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-491" decimals="-6" id="f-1863" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-6" id="f-1864" unitRef="usd">-63000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-489" decimals="-6" id="f-1865" unitRef="usd">2648000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-490" decimals="-6" id="f-1866" unitRef="usd">1344000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-491" decimals="-6" id="f-1867" unitRef="usd">-672000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-1868" unitRef="usd">3320000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-489" decimals="-6" id="f-1869" unitRef="usd">-6000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-490" decimals="-6" id="f-1870" unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-491" decimals="-6" id="f-1871" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-1872" unitRef="usd">-5000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent contextRef="c-489" decimals="-6" id="f-1873" unitRef="usd">2654000000</hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent>
    <hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent contextRef="c-490" decimals="-6" id="f-1874" unitRef="usd">1343000000</hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent>
    <hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent contextRef="c-491" decimals="-6" id="f-1875" unitRef="usd">-672000000</hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent>
    <hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent contextRef="c-1" decimals="-6" id="f-1876" unitRef="usd">3325000000</hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent>
    <us-gaap:PremiumsEarnedNet contextRef="c-492" decimals="-6" id="f-1877" unitRef="usd">65591000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-493" decimals="-6" id="f-1878" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-494" decimals="-6" id="f-1879" unitRef="usd">65591000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-495" decimals="-6" id="f-1880" unitRef="usd">7297000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-496" decimals="-6" id="f-1881" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-497" decimals="-6" id="f-1882" unitRef="usd">7297000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-498" decimals="-6" id="f-1883" unitRef="usd">2269000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-499" decimals="-6" id="f-1884" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-500" decimals="-6" id="f-1885" unitRef="usd">2269000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-501" decimals="-6" id="f-1886" unitRef="usd">75157000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-502" decimals="-6" id="f-1887" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-503" decimals="-6" id="f-1888" unitRef="usd">75157000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-504" decimals="-6" id="f-1889" unitRef="usd">4389000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-505" decimals="-6" id="f-1890" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-506" decimals="-6" id="f-1891" unitRef="usd">4389000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-507" decimals="-6" id="f-1892" unitRef="usd">1047000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-508" decimals="-6" id="f-1893" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-509" decimals="-6" id="f-1894" unitRef="usd">1047000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-510" decimals="-6" id="f-1895" unitRef="usd">743000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-511" decimals="-6" id="f-1896" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-512" decimals="-6" id="f-1897" unitRef="usd">743000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-513" decimals="-6" id="f-1898" unitRef="usd">6376000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-514" decimals="-6" id="f-1899" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-515" decimals="-6" id="f-1900" unitRef="usd">6376000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-516" decimals="-6" id="f-1901" unitRef="usd">87712000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-517" decimals="-6" id="f-1902" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-518" decimals="-6" id="f-1903" unitRef="usd">87712000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-519" decimals="-6" id="f-1904" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-520" decimals="-6" id="f-1905" unitRef="usd">2333000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-521" decimals="-6" id="f-1906" unitRef="usd">2333000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-522" decimals="-6" id="f-1907" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-523" decimals="-6" id="f-1908" unitRef="usd">568000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-524" decimals="-6" id="f-1909" unitRef="usd">568000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-525" decimals="-6" id="f-1910" unitRef="usd">300000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-526" decimals="-6" id="f-1911" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-527" decimals="-6" id="f-1912" unitRef="usd">300000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-528" decimals="-6" id="f-1913" unitRef="usd">550000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-529" decimals="-6" id="f-1914" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-530" decimals="-6" id="f-1915" unitRef="usd">550000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-531" decimals="-6" id="f-1916" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-532" decimals="-6" id="f-1917" unitRef="usd">1025000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-533" decimals="-6" id="f-1918" unitRef="usd">1025000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-534" decimals="-6" id="f-1919" unitRef="usd">850000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-535" decimals="-6" id="f-1920" unitRef="usd">3926000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-536" decimals="-6" id="f-1921" unitRef="usd">4776000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:Revenues contextRef="c-537" decimals="-6" id="f-1922" unitRef="usd">88562000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-538" decimals="-6" id="f-1923" unitRef="usd">3926000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-539" decimals="-6" id="f-1924" unitRef="usd">92488000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-540" decimals="-6" id="f-1925" unitRef="usd">56000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-541" decimals="-6" id="f-1926" unitRef="usd">3532000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-542" decimals="-6" id="f-1927" unitRef="usd">-3588000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-543" decimals="-6" id="f-1928" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-544" decimals="-6" id="f-1929" unitRef="usd">9841000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-545" decimals="-6" id="f-1930" unitRef="usd">-9841000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-546" decimals="-6" id="f-1931" unitRef="usd">56000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-547" decimals="-6" id="f-1932" unitRef="usd">13373000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-548" decimals="-6" id="f-1933" unitRef="usd">-13429000000</us-gaap:Revenues>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-549" decimals="-6" id="f-1934" unitRef="usd">223000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-550" decimals="-6" id="f-1935" unitRef="usd">8000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-551" decimals="-6" id="f-1936" unitRef="usd">151000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-6" decimals="-6" id="f-1937" unitRef="usd">382000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:Revenues contextRef="c-549" decimals="-6" id="f-1938" unitRef="usd">88841000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-550" decimals="-6" id="f-1939" unitRef="usd">17307000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-551" decimals="-6" id="f-1940" unitRef="usd">-13278000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-6" id="f-1941" unitRef="usd">92870000000</us-gaap:Revenues>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare contextRef="c-549" decimals="-6" id="f-1942" unitRef="usd">75934000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare contextRef="c-550" decimals="-6" id="f-1943" unitRef="usd">0</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare contextRef="c-551" decimals="-6" id="f-1944" unitRef="usd">-244000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare contextRef="c-6" decimals="-6" id="f-1945" unitRef="usd">75690000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-549" decimals="-6" id="f-1946" unitRef="usd">9251000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-550" decimals="-6" id="f-1947" unitRef="usd">15835000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-551" decimals="-6" id="f-1948" unitRef="usd">-12415000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-6" decimals="-6" id="f-1949" unitRef="usd">12671000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization contextRef="c-549" decimals="-6" id="f-1950" unitRef="usd">634000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-550" decimals="-6" id="f-1951" unitRef="usd">181000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-551" decimals="-6" id="f-1952" unitRef="usd">-106000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-6" decimals="-6" id="f-1953" unitRef="usd">709000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-549" decimals="-6" id="f-1954" unitRef="usd">85819000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-550" decimals="-6" id="f-1955" unitRef="usd">16016000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-551" decimals="-6" id="f-1956" unitRef="usd">-12765000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-6" decimals="-6" id="f-1957" unitRef="usd">89070000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-549" decimals="-6" id="f-1958" unitRef="usd">3022000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-550" decimals="-6" id="f-1959" unitRef="usd">1291000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-551" decimals="-6" id="f-1960" unitRef="usd">-513000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-6" id="f-1961" unitRef="usd">3800000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-549" decimals="-6" id="f-1962" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-550" decimals="-6" id="f-1963" unitRef="usd">237000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-551" decimals="-6" id="f-1964" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-6" decimals="-6" id="f-1965" unitRef="usd">237000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:InterestExpense contextRef="c-549" decimals="-6" id="f-1966" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-550" decimals="-6" id="f-1967" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-551" decimals="-6" id="f-1968" unitRef="usd">401000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-6" decimals="-6" id="f-1969" unitRef="usd">401000000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-549" decimals="-6" id="f-1970" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-550" decimals="-6" id="f-1971" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-551" decimals="-6" id="f-1972" unitRef="usd">-68000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-6" id="f-1973" unitRef="usd">-68000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-549" decimals="-6" id="f-1974" unitRef="usd">3022000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-550" decimals="-6" id="f-1975" unitRef="usd">1528000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-551" decimals="-6" id="f-1976" unitRef="usd">-982000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-6" decimals="-6" id="f-1977" unitRef="usd">3568000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-549" decimals="-6" id="f-1978" unitRef="usd">18000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-550" decimals="-6" id="f-1979" unitRef="usd">-22000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-551" decimals="-6" id="f-1980" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-6" decimals="-6" id="f-1981" unitRef="usd">-4000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-549" decimals="-6" id="f-1982" unitRef="usd">3040000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-550" decimals="-6" id="f-1983" unitRef="usd">1506000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-551" decimals="-6" id="f-1984" unitRef="usd">-982000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-6" id="f-1985" unitRef="usd">3564000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-549" decimals="-6" id="f-1986" unitRef="usd">-5000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-550" decimals="-6" id="f-1987" unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-551" decimals="-6" id="f-1988" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-6" decimals="-6" id="f-1989" unitRef="usd">-4000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent contextRef="c-549" decimals="-6" id="f-1990" unitRef="usd">3045000000</hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent>
    <hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent contextRef="c-550" decimals="-6" id="f-1991" unitRef="usd">1505000000</hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent>
    <hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent contextRef="c-551" decimals="-6" id="f-1992" unitRef="usd">-982000000</hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent>
    <hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent contextRef="c-6" decimals="-6" id="f-1993" unitRef="usd">3568000000</hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent>
    <us-gaap:PremiumsEarnedNet contextRef="c-552" decimals="-6" id="f-1994" unitRef="usd">58654000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-553" decimals="-6" id="f-1995" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-554" decimals="-6" id="f-1996" unitRef="usd">58654000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-555" decimals="-6" id="f-1997" unitRef="usd">6955000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-556" decimals="-6" id="f-1998" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-557" decimals="-6" id="f-1999" unitRef="usd">6955000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-558" decimals="-6" id="f-2000" unitRef="usd">2371000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-559" decimals="-6" id="f-2001" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-560" decimals="-6" id="f-2002" unitRef="usd">2371000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-561" decimals="-6" id="f-2003" unitRef="usd">67980000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-562" decimals="-6" id="f-2004" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-563" decimals="-6" id="f-2005" unitRef="usd">67980000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-564" decimals="-6" id="f-2006" unitRef="usd">4950000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-565" decimals="-6" id="f-2007" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-566" decimals="-6" id="f-2008" unitRef="usd">4950000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-567" decimals="-6" id="f-2009" unitRef="usd">1052000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-568" decimals="-6" id="f-2010" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-569" decimals="-6" id="f-2011" unitRef="usd">1052000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-570" decimals="-6" id="f-2012" unitRef="usd">731000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-571" decimals="-6" id="f-2013" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-572" decimals="-6" id="f-2014" unitRef="usd">731000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-573" decimals="-6" id="f-2015" unitRef="usd">5109000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-574" decimals="-6" id="f-2016" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-575" decimals="-6" id="f-2017" unitRef="usd">5109000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-576" decimals="-6" id="f-2018" unitRef="usd">79822000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-577" decimals="-6" id="f-2019" unitRef="usd">0</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet contextRef="c-578" decimals="-6" id="f-2020" unitRef="usd">79822000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-579" decimals="-6" id="f-2021" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-580" decimals="-6" id="f-2022" unitRef="usd">1166000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-581" decimals="-6" id="f-2023" unitRef="usd">1166000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-582" decimals="-6" id="f-2024" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-583" decimals="-6" id="f-2025" unitRef="usd">413000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-584" decimals="-6" id="f-2026" unitRef="usd">413000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-585" decimals="-6" id="f-2027" unitRef="usd">306000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-586" decimals="-6" id="f-2028" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-587" decimals="-6" id="f-2029" unitRef="usd">306000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-588" decimals="-6" id="f-2030" unitRef="usd">547000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-589" decimals="-6" id="f-2031" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-590" decimals="-6" id="f-2032" unitRef="usd">547000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-591" decimals="-6" id="f-2033" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-592" decimals="-6" id="f-2034" unitRef="usd">623000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-593" decimals="-6" id="f-2035" unitRef="usd">623000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-594" decimals="-6" id="f-2036" unitRef="usd">853000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-595" decimals="-6" id="f-2037" unitRef="usd">2202000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax contextRef="c-596" decimals="-6" id="f-2038" unitRef="usd">3055000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:Revenues contextRef="c-597" decimals="-6" id="f-2039" unitRef="usd">80675000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-598" decimals="-6" id="f-2040" unitRef="usd">2202000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-599" decimals="-6" id="f-2041" unitRef="usd">82877000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-600" decimals="-6" id="f-2042" unitRef="usd">41000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-601" decimals="-6" id="f-2043" unitRef="usd">2828000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-602" decimals="-6" id="f-2044" unitRef="usd">-2869000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-603" decimals="-6" id="f-2045" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-604" decimals="-6" id="f-2046" unitRef="usd">9024000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-605" decimals="-6" id="f-2047" unitRef="usd">-9024000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-606" decimals="-6" id="f-2048" unitRef="usd">41000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-607" decimals="-6" id="f-2049" unitRef="usd">11852000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-608" decimals="-6" id="f-2050" unitRef="usd">-11893000000</us-gaap:Revenues>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-609" decimals="-6" id="f-2051" unitRef="usd">214000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-610" decimals="-6" id="f-2052" unitRef="usd">4000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-611" decimals="-6" id="f-2053" unitRef="usd">-31000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-7" decimals="-6" id="f-2054" unitRef="usd">187000000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:Revenues contextRef="c-609" decimals="-6" id="f-2055" unitRef="usd">80930000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-610" decimals="-6" id="f-2056" unitRef="usd">14058000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-611" decimals="-6" id="f-2057" unitRef="usd">-11924000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="-6" id="f-2058" unitRef="usd">83064000000</us-gaap:Revenues>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare contextRef="c-609" decimals="-6" id="f-2059" unitRef="usd">69639000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare contextRef="c-610" decimals="-6" id="f-2060" unitRef="usd">0</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare contextRef="c-611" decimals="-6" id="f-2061" unitRef="usd">-440000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare contextRef="c-7" decimals="-6" id="f-2062" unitRef="usd">69199000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-609" decimals="-6" id="f-2063" unitRef="usd">8340000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-610" decimals="-6" id="f-2064" unitRef="usd">12968000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-611" decimals="-6" id="f-2065" unitRef="usd">-11187000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-7" decimals="-6" id="f-2066" unitRef="usd">10121000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization contextRef="c-609" decimals="-6" id="f-2067" unitRef="usd">539000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-610" decimals="-6" id="f-2068" unitRef="usd">152000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-611" decimals="-6" id="f-2069" unitRef="usd">-95000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-7" decimals="-6" id="f-2070" unitRef="usd">596000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-609" decimals="-6" id="f-2071" unitRef="usd">78518000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-610" decimals="-6" id="f-2072" unitRef="usd">13120000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-611" decimals="-6" id="f-2073" unitRef="usd">-11722000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:BenefitsLossesAndExpenses contextRef="c-7" decimals="-6" id="f-2074" unitRef="usd">79916000000</us-gaap:BenefitsLossesAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-609" decimals="-6" id="f-2075" unitRef="usd">2412000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-610" decimals="-6" id="f-2076" unitRef="usd">938000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-611" decimals="-6" id="f-2077" unitRef="usd">-202000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-6" id="f-2078" unitRef="usd">3148000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="c-609" decimals="-6" id="f-2079" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-610" decimals="-6" id="f-2080" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-611" decimals="-6" id="f-2081" unitRef="usd">326000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-7" decimals="-6" id="f-2082" unitRef="usd">326000000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-609" decimals="-6" id="f-2083" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-610" decimals="-6" id="f-2084" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-611" decimals="-6" id="f-2085" unitRef="usd">532000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-6" id="f-2086" unitRef="usd">532000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-609" decimals="-6" id="f-2087" unitRef="usd">2412000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-610" decimals="-6" id="f-2088" unitRef="usd">938000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-611" decimals="-6" id="f-2089" unitRef="usd">4000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-7" decimals="-6" id="f-2090" unitRef="usd">3354000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-609" decimals="-6" id="f-2091" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-610" decimals="-6" id="f-2092" unitRef="usd">65000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-611" decimals="-6" id="f-2093" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-7" decimals="-6" id="f-2094" unitRef="usd">65000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-609" decimals="-6" id="f-2095" unitRef="usd">2412000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-610" decimals="-6" id="f-2096" unitRef="usd">1003000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-611" decimals="-6" id="f-2097" unitRef="usd">4000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-2098" unitRef="usd">3419000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-609" decimals="-6" id="f-2099" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-610" decimals="-6" id="f-2100" unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-611" decimals="-6" id="f-2101" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-2102" unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent contextRef="c-609" decimals="-6" id="f-2103" unitRef="usd">2412000000</hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent>
    <hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent contextRef="c-610" decimals="-6" id="f-2104" unitRef="usd">1002000000</hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent>
    <hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent contextRef="c-611" decimals="-6" id="f-2105" unitRef="usd">4000000</hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent>
    <hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent contextRef="c-7" decimals="-6" id="f-2106" unitRef="usd">3418000000</hum:IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParent>
    <us-gaap:ReinsuranceTextBlock contextRef="c-1" id="f-2107">REINSURANCE &lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain blocks of insurance assumed in acquisitions, primarily life and annuities in run-off status are subject to reinsurance where some or all of the underwriting risk related to these policies has been ceded to a third party. In addition, a large portion of our reinsurance takes the form of 100% coinsurance agreements where, in addition to all of the underwriting risk, all administrative responsibilities, including premium collections and claim payment, have also been ceded to a third party. We acquired these policies and related reinsurance agreements with the purchase of stock of companies in which the policies were originally written. We acquired these companies for business reasons unrelated to these particular policies, including the companies&#x2019; other products and licenses necessary to fulfill strategic plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reinsurance agreement between two entities transfers the underwriting risk of policyholder liabilities to a reinsurer while the primary insurer retains the contractual relationship with the ultimate insured. As such, these reinsurance agreements do not completely relieve us of our potential liability to the ultimate insured. However, given the transfer of underwriting risk, our potential liability is limited to the credit exposure which exists should the reinsurer be unable to meet its obligations assumed under these reinsurance agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reinsurance recoverables represent the portion of future policy benefits payable and benefits payable that are covered by reinsurance. Reinsurance recoverables, included in other long-term assets, were $173 million at December&#160;31, 2023 and $181 million at December&#160;31, 2022. The amount of these reinsurance recoverables resulting from 100% coinsurance agreements was approximately $173 million at December&#160;31, 2023 and approximately $181 million at December&#160;31, 2022. Premiums ceded were $1 million in 2023, $5 million in 2022 and $6 million in 2021. Benefits ceded were $3 million in 2023, $2 million in 2022, and $2 million in 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate the financial condition of our reinsurers on a regular basis. Protective Life Insurance Company with $159 million in reinsurance recoverables is well-known and well-established with a AM Best rating of A+ at December&#160;31, 2023. The remaining reinsurance recoverables of $15 million are divided between 8 other reinsurers, with $0.4 million subject to funds withheld accounts or other financial guarantees supporting the repayment of these amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReinsuranceTextBlock>
    <us-gaap:ReinsuranceRecoverables contextRef="c-4" decimals="-6" id="f-2108" unitRef="usd">173000000</us-gaap:ReinsuranceRecoverables>
    <us-gaap:ReinsuranceRecoverables contextRef="c-5" decimals="-6" id="f-2109" unitRef="usd">181000000</us-gaap:ReinsuranceRecoverables>
    <hum:PercentageOfCoinsuranceAgreement
      contextRef="c-612"
      decimals="INF"
      id="f-2110"
      unitRef="number">1</hum:PercentageOfCoinsuranceAgreement>
    <us-gaap:ReinsuranceRecoverables contextRef="c-4" decimals="-6" id="f-2111" unitRef="usd">173000000</us-gaap:ReinsuranceRecoverables>
    <us-gaap:ReinsuranceRecoverables contextRef="c-5" decimals="-6" id="f-2112" unitRef="usd">181000000</us-gaap:ReinsuranceRecoverables>
    <us-gaap:CededPremiumsWritten contextRef="c-1" decimals="-6" id="f-2113" unitRef="usd">1000000</us-gaap:CededPremiumsWritten>
    <us-gaap:CededPremiumsWritten contextRef="c-6" decimals="-6" id="f-2114" unitRef="usd">5000000</us-gaap:CededPremiumsWritten>
    <us-gaap:CededPremiumsWritten contextRef="c-7" decimals="-6" id="f-2115" unitRef="usd">6000000</us-gaap:CededPremiumsWritten>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded contextRef="c-1" decimals="-6" id="f-2116" unitRef="usd">3000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded contextRef="c-6" decimals="-6" id="f-2117" unitRef="usd">2000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded contextRef="c-7" decimals="-6" id="f-2118" unitRef="usd">2000000</us-gaap:ReinsuranceEffectOnClaimsAndBenefitsIncurredAmountCeded>
    <us-gaap:ReinsuranceRecoverables contextRef="c-613" decimals="-6" id="f-2119" unitRef="usd">159000000</us-gaap:ReinsuranceRecoverables>
    <us-gaap:ReinsuranceRecoverables contextRef="c-614" decimals="-6" id="f-2120" unitRef="usd">15000000</us-gaap:ReinsuranceRecoverables>
    <hum:NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance
      contextRef="c-1"
      decimals="INF"
      id="f-2121"
      unitRef="reinsurer">8</hum:NumberOfReinsurersComprisingOtherReinsuranceRecoverablesBalance>
    <hum:AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer contextRef="c-1" decimals="-5" id="f-2122" unitRef="usd">400000</hum:AmountHeldInCashAndSecuritiesInTrustAtLeastEqualToRecoverableFromReinsurer>
    <dei:AuditorName contextRef="c-1" id="f-2123">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-2124">Louisville, Kentucky</dei:AuditorLocation>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-615" id="f-2125">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-615" id="f-2126">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-615" id="f-2127">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-615" id="f-2128">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-2129">238</dei:AuditorFirmId>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock contextRef="c-1" id="f-2130">&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE I&#x2014;PARENT COMPANY FINANCIAL INFORMATION&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CONDENSED BALANCE SHEETS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.474%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.341%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in&#160;millions,&#160;except&#160;share&lt;br/&gt;amounts)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Receivable from operating subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payable to operating subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable to operating subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Book overdraft&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commitments and contingencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stockholders&#x2019; equity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred stock, $1 par; 10,000,000 shares authorized; none issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,690,082 shares issued at December&#160;31, 2023 and 198,666,598 shares issued at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Capital in excess of par value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive (loss) income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(999)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Treasury stock, at cost, 76,465,862 shares at December&#160;31, 2023 and 73,691,955 shares at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total stockholders' equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities and stockholders' equity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See accompanying notes to the parent company financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE I&#x2014;PARENT COMPANY FINANCIAL INFORMATION&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CONDENSED STATEMENTS OF INCOME&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.679%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.224%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.922%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.922%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.926%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Management fees charged to operating subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment and other (loss) income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(88)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Operating costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(672)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes and equity in net earnings of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(860)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,215)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Loss) income before equity in net earnings of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net earnings of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity in net earnings of equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Humana&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See accompanying notes to the parent company financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE I&#x2014;PARENT COMPANY FINANCIAL INFORMATION&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CONDENSED STATEMENTS OF COMPREHENSIVE INCOME&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.758%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.188%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to Humana&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in gross unrealized investment gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,819)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total change in unrealized investment  &lt;br/&gt;&#160;&#160;&#160;&#160;&#160;gains (losses), net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,401)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification adjustment for net realized &lt;br/&gt;&#160;losses (gains) included in investment income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total reclassification adjustment, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss), net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Comprehensive income attributable to equity method&lt;br/&gt;&#160;&#160;investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Comprehensive income attributable to Humana&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See accompanying notes to the parent company financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE I&#x2014;PARENT COMPANY FINANCIAL INFORMATION&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;CONDENSED STATEMENTS OF CASH FLOWS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.602%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.669%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net cash provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash flows from investing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Acquisitions, net of cash acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital contributions to operating subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(484)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Purchases of property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(931)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(958)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchases of investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from sale of investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturities of investment securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,317)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash flows from financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from issuance of senior notes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Repayments of senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds (repayments) from issuance of commercial paper, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(376)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Proceeds from issuance of term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repayment of term loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Change in book overdraft&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Common stock repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,096)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Dividends paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(392)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Proceeds from stock option exercises and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net cash (used in) provided by financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(Decrease) increase in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(292)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See accompanying notes to the parent company financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE I&#x2014;PARENT COMPANY FINANCIAL INFORMATION&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;NOTES TO CONDENSED FINANCIAL STATEMENTS&lt;/span&gt;&lt;/div&gt;BASIS OF PRESENTATION&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Parent company financial information has been derived from our consolidated financial statements and excludes the accounts of all operating subsidiaries. This information should be read in conjunction with our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;TRANSACTIONS WITH SUBSIDIARIES&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Services Fee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through intercompany service agreements approved, if required, by state regulatory authorities, Humana Inc., our parent company, charges a services fee for reimbursement of certain centralized services provided to its subsidiaries including information systems, disbursement, investment and cash administration, marketing, legal, finance, and medical and executive management oversight.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash dividends received from subsidiaries and included as a component of net cash provided by operating activities were $1.8 billion in 2023, $1.3 billion in 2022, and $1.6 billion in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Guarantee&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through indemnity agreements approved by state regulatory authorities, certain of our regulated subsidiaries generally are guaranteed by our parent company in the event of insolvency for: (1) member coverage for which premium payment has been made prior to insolvency; (2) benefits for members then hospitalized until discharged; and (3)&#160;payment to providers for services rendered prior to insolvency. Our parent has also guaranteed the obligations of our military services subsidiaries and funding to maintain required statutory capital levels of certain other regulated subsidiaries.&lt;/span&gt;&lt;/div&gt;REGULATORY REQUIREMENTS&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our subsidiaries operate in states that regulate the payment of dividends, loans, or other cash transfers to Humana Inc., our parent company, and require minimum levels of equity as well as limit investments to approved securities. The amount of dividends that may be paid to Humana Inc. by these subsidiaries, without prior approval by state regulatory authorities, or ordinary dividends, is limited based on the entity&#x2019;s level of statutory income and statutory capit&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;al and surplus. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, it is generally considered an extraordinary dividend requiring prior regulatory approval. In most states, prior notification is provided before paying a dividend even if approval is not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although minimum required levels of equity are largely based on premium volume, product mix, and the quality of assets held, minimum requirements vary significantly at the state level. Our state regulated insurance subsidiaries had aggregate statutory capital and surplus of approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$12.2 billion and $11.3 billion as of December&#160;31, 2023 and 2022, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively, which exceeded aggregate minimum regulatory requirements of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$9.8 billion&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $8.4 billion, respectively. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of ordinary dividends that may be paid to our parent company in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 2024 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $1.1 billion &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the aggregate. The amount, timing and mix of ordinary and extraordinary dividend payments will vary due to state &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;regulatory requirements, the level of excess statutory capital and surplus and expected future surplus requirements related to, for example, premium volume and product mix. Actual dividends that were paid to our parent company were approximately  $1.8 billion in 2023, $1.3 billion in 2022, and $1.6 billion in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our use of operating cash flows derived from our non-insurance subsidiaries, such as in our Healthcare Services segment, is generally not restricted by state departments of insurance (or comparable state regulators).&lt;/span&gt;&lt;/div&gt;ACQUISITIONS&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 3 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K for a description of certain acquisitions.&lt;/span&gt;&lt;/div&gt;INCOME TAXES&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 12 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K for a description of income taxes.&lt;/span&gt;&lt;/div&gt;DEBT&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 13 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K for a description of debt.&lt;/span&gt;&lt;/div&gt;STOCKHOLDERS' EQUITY&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 16 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K for a description of stockholders&#x2019; equity, including stock repurchases and stockholder dividends.&lt;/span&gt;&lt;/div&gt;</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-616" decimals="-6" id="f-2131" unitRef="usd">250000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-617" decimals="-6" id="f-2132" unitRef="usd">614000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-616" decimals="-6" id="f-2133" unitRef="usd">260000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-617" decimals="-6" id="f-2134" unitRef="usd">320000000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent contextRef="c-618" decimals="-6" id="f-2135" unitRef="usd">2050000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-619" decimals="-6" id="f-2136" unitRef="usd">1807000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-616" decimals="-6" id="f-2137" unitRef="usd">717000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-617" decimals="-6" id="f-2138" unitRef="usd">577000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-616" decimals="-6" id="f-2139" unitRef="usd">3277000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-617" decimals="-6" id="f-2140" unitRef="usd">3318000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-616" decimals="-6" id="f-2141" unitRef="usd">2334000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-617" decimals="-6" id="f-2142" unitRef="usd">2393000000</us-gaap:PropertyPlantAndEquipmentNet>
    <hum:InvestmentInRelatedPartiesAndSubsidiaries contextRef="c-616" decimals="-6" id="f-2143" unitRef="usd">29666000000</hum:InvestmentInRelatedPartiesAndSubsidiaries>
    <hum:InvestmentInRelatedPartiesAndSubsidiaries contextRef="c-617" decimals="-6" id="f-2144" unitRef="usd">27905000000</hum:InvestmentInRelatedPartiesAndSubsidiaries>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-616" decimals="-6" id="f-2145" unitRef="usd">348000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-617" decimals="-6" id="f-2146" unitRef="usd">282000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-616" decimals="-6" id="f-2147" unitRef="usd">35625000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-617" decimals="-6" id="f-2148" unitRef="usd">33898000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-618" decimals="-6" id="f-2149" unitRef="usd">5768000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-619" decimals="-6" id="f-2150" unitRef="usd">5421000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DebtCurrent contextRef="c-616" decimals="-6" id="f-2151" unitRef="usd">1443000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="c-617" decimals="-6" id="f-2152" unitRef="usd">2092000000</us-gaap:DebtCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-618" decimals="-6" id="f-2153" unitRef="usd">36000000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-619" decimals="-6" id="f-2154" unitRef="usd">36000000</us-gaap:NotesPayableCurrent>
    <hum:BookOverdraftLiability contextRef="c-616" decimals="-6" id="f-2155" unitRef="usd">75000000</hum:BookOverdraftLiability>
    <hum:BookOverdraftLiability contextRef="c-617" decimals="-6" id="f-2156" unitRef="usd">73000000</hum:BookOverdraftLiability>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-616" decimals="-6" id="f-2157" unitRef="usd">1566000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-617" decimals="-6" id="f-2158" unitRef="usd">1425000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-616" decimals="-6" id="f-2159" unitRef="usd">8888000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-617" decimals="-6" id="f-2160" unitRef="usd">9047000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-616" decimals="-6" id="f-2161" unitRef="usd">10213000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-617" decimals="-6" id="f-2162" unitRef="usd">9034000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-616" decimals="-6" id="f-2163" unitRef="usd">262000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-617" decimals="-6" id="f-2164" unitRef="usd">506000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-616" decimals="-6" id="f-2165" unitRef="usd">19363000000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-617" decimals="-6" id="f-2166" unitRef="usd">18587000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-616" id="f-2167" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-617" id="f-2168" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-616"
      decimals="INF"
      id="f-2169"
      unitRef="usdPerShare">1</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-617"
      decimals="INF"
      id="f-2170"
      unitRef="usdPerShare">1</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-616"
      decimals="INF"
      id="f-2171"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-617"
      decimals="INF"
      id="f-2172"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-616"
      decimals="INF"
      id="f-2173"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c-617"
      decimals="INF"
      id="f-2174"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-616" decimals="-6" id="f-2175" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-617" decimals="-6" id="f-2176" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-616"
      decimals="INF"
      id="f-2177"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-617"
      decimals="INF"
      id="f-2178"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-616"
      decimals="INF"
      id="f-2179"
      unitRef="shares">198690082</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-617"
      decimals="INF"
      id="f-2180"
      unitRef="shares">198666598</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-616" decimals="-6" id="f-2181" unitRef="usd">33000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-617" decimals="-6" id="f-2182" unitRef="usd">33000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-616" decimals="-6" id="f-2183" unitRef="usd">3346000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-617" decimals="-6" id="f-2184" unitRef="usd">3246000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-616" decimals="-6" id="f-2185" unitRef="usd">27540000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-617" decimals="-6" id="f-2186" unitRef="usd">25492000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-616" decimals="-6" id="f-2187" unitRef="usd">-999000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-617" decimals="-6" id="f-2188" unitRef="usd">-1304000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-616"
      decimals="INF"
      id="f-2189"
      unitRef="shares">76465862</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c-617"
      decimals="INF"
      id="f-2190"
      unitRef="shares">73691955</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-616" decimals="-6" id="f-2191" unitRef="usd">13658000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-617" decimals="-6" id="f-2192" unitRef="usd">12156000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity contextRef="c-616" decimals="-6" id="f-2193" unitRef="usd">16262000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-617" decimals="-6" id="f-2194" unitRef="usd">15311000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-616" decimals="-6" id="f-2195" unitRef="usd">35625000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-617" decimals="-6" id="f-2196" unitRef="usd">33898000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <hum:ManagementFeesChargedToOperatingSubsidiaries contextRef="c-620" decimals="-6" id="f-2199" unitRef="usd">2075000000</hum:ManagementFeesChargedToOperatingSubsidiaries>
    <hum:ManagementFeesChargedToOperatingSubsidiaries contextRef="c-621" decimals="-6" id="f-2200" unitRef="usd">1554000000</hum:ManagementFeesChargedToOperatingSubsidiaries>
    <hum:ManagementFeesChargedToOperatingSubsidiaries contextRef="c-622" decimals="-6" id="f-2201" unitRef="usd">1633000000</hum:ManagementFeesChargedToOperatingSubsidiaries>
    <hum:InvestmentAndOtherIncomeNet contextRef="c-620" decimals="-6" id="f-2202" unitRef="usd">42000000</hum:InvestmentAndOtherIncomeNet>
    <hum:InvestmentAndOtherIncomeNet contextRef="c-621" decimals="-6" id="f-2203" unitRef="usd">-88000000</hum:InvestmentAndOtherIncomeNet>
    <hum:InvestmentAndOtherIncomeNet contextRef="c-622" decimals="-6" id="f-2204" unitRef="usd">-266000000</hum:InvestmentAndOtherIncomeNet>
    <us-gaap:Revenues contextRef="c-620" decimals="-6" id="f-2205" unitRef="usd">2117000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-621" decimals="-6" id="f-2206" unitRef="usd">1466000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-622" decimals="-6" id="f-2207" unitRef="usd">1367000000</us-gaap:Revenues>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-620" decimals="-6" id="f-2208" unitRef="usd">2016000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-621" decimals="-6" id="f-2209" unitRef="usd">1700000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-622" decimals="-6" id="f-2210" unitRef="usd">1404000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:Depreciation contextRef="c-620" decimals="-6" id="f-2211" unitRef="usd">656000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-621" decimals="-6" id="f-2212" unitRef="usd">581000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-622" decimals="-6" id="f-2213" unitRef="usd">488000000</us-gaap:Depreciation>
    <us-gaap:InterestExpense contextRef="c-620" decimals="-6" id="f-2214" unitRef="usd">489000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-621" decimals="-6" id="f-2215" unitRef="usd">400000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-622" decimals="-6" id="f-2216" unitRef="usd">313000000</us-gaap:InterestExpense>
    <us-gaap:CostsAndExpenses contextRef="c-620" decimals="-6" id="f-2217" unitRef="usd">3161000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-621" decimals="-6" id="f-2218" unitRef="usd">2681000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-622" decimals="-6" id="f-2219" unitRef="usd">2205000000</us-gaap:CostsAndExpenses>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-620" decimals="-6" id="f-2220" unitRef="usd">184000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-621" decimals="-6" id="f-2221" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-622" decimals="-6" id="f-2222" unitRef="usd">672000000</us-gaap:OtherNonoperatingIncomeExpense>
    <hum:IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries contextRef="c-620" decimals="-6" id="f-2223" unitRef="usd">-860000000</hum:IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries>
    <hum:IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries contextRef="c-621" decimals="-6" id="f-2224" unitRef="usd">-1215000000</hum:IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries>
    <hum:IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries contextRef="c-622" decimals="-6" id="f-2225" unitRef="usd">-166000000</hum:IncomeLossBeforeIncomeTaxesAndEquityInNetEarningsOfSubsidiaries>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-620" decimals="-6" id="f-2226" unitRef="usd">-146000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-621" decimals="-6" id="f-2227" unitRef="usd">-266000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-622" decimals="-6" id="f-2228" unitRef="usd">-259000000</us-gaap:IncomeTaxExpenseBenefit>
    <hum:IncomeLossBeforeEquityInNetEarningsOfSubsidiaries contextRef="c-620" decimals="-6" id="f-2229" unitRef="usd">-714000000</hum:IncomeLossBeforeEquityInNetEarningsOfSubsidiaries>
    <hum:IncomeLossBeforeEquityInNetEarningsOfSubsidiaries contextRef="c-621" decimals="-6" id="f-2230" unitRef="usd">-949000000</hum:IncomeLossBeforeEquityInNetEarningsOfSubsidiaries>
    <hum:IncomeLossBeforeEquityInNetEarningsOfSubsidiaries contextRef="c-622" decimals="-6" id="f-2231" unitRef="usd">93000000</hum:IncomeLossBeforeEquityInNetEarningsOfSubsidiaries>
    <hum:EquityInNetEarningsOfSubsidiaries contextRef="c-620" decimals="-6" id="f-2232" unitRef="usd">3203000000</hum:EquityInNetEarningsOfSubsidiaries>
    <hum:EquityInNetEarningsOfSubsidiaries contextRef="c-621" decimals="-6" id="f-2233" unitRef="usd">3755000000</hum:EquityInNetEarningsOfSubsidiaries>
    <hum:EquityInNetEarningsOfSubsidiaries contextRef="c-622" decimals="-6" id="f-2234" unitRef="usd">2761000000</hum:EquityInNetEarningsOfSubsidiaries>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-620" decimals="-6" id="f-2235" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-621" decimals="-6" id="f-2236" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-622" decimals="-6" id="f-2237" unitRef="usd">79000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss contextRef="c-620" decimals="-6" id="f-2238" unitRef="usd">2489000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-621" decimals="-6" id="f-2239" unitRef="usd">2806000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-622" decimals="-6" id="f-2240" unitRef="usd">2933000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss contextRef="c-620" decimals="-6" id="f-2241" unitRef="usd">2489000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-621" decimals="-6" id="f-2242" unitRef="usd">2806000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-622" decimals="-6" id="f-2243" unitRef="usd">2933000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax contextRef="c-620" decimals="-6" id="f-2244" unitRef="usd">372000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax contextRef="c-621" decimals="-6" id="f-2245" unitRef="usd">-1819000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax contextRef="c-622" decimals="-6" id="f-2246" unitRef="usd">-356000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="c-620" decimals="-6" id="f-2247" unitRef="usd">85000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="c-621" decimals="-6" id="f-2248" unitRef="usd">-418000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="c-622" decimals="-6" id="f-2249" unitRef="usd">-81000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-620" decimals="-6" id="f-2250" unitRef="usd">287000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-621" decimals="-6" id="f-2251" unitRef="usd">-1401000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-622" decimals="-6" id="f-2252" unitRef="usd">-275000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax contextRef="c-620" decimals="-6" id="f-2253" unitRef="usd">-25000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax contextRef="c-621" decimals="-6" id="f-2254" unitRef="usd">-72000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax contextRef="c-622" decimals="-6" id="f-2255" unitRef="usd">103000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax contextRef="c-620" decimals="-6" id="f-2256" unitRef="usd">-7000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax contextRef="c-621" decimals="-6" id="f-2257" unitRef="usd">-17000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax contextRef="c-622" decimals="-6" id="f-2258" unitRef="usd">23000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-620" decimals="-6" id="f-2259" unitRef="usd">-18000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-621" decimals="-6" id="f-2260" unitRef="usd">-55000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax contextRef="c-622" decimals="-6" id="f-2261" unitRef="usd">80000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-620" decimals="-6" id="f-2262" unitRef="usd">305000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-621" decimals="-6" id="f-2263" unitRef="usd">-1346000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-622" decimals="-6" id="f-2264" unitRef="usd">-355000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments contextRef="c-620" decimals="-6" id="f-2265" unitRef="usd">0</hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments>
    <hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments contextRef="c-621" decimals="-6" id="f-2266" unitRef="usd">0</hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments>
    <hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments contextRef="c-622" decimals="-6" id="f-2267" unitRef="usd">6000000</hum:ComprehensiveIncomeLossNetofTaxAttributableToEquityMethodInvestments>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-620" decimals="-6" id="f-2268" unitRef="usd">2794000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-621" decimals="-6" id="f-2269" unitRef="usd">1460000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-622" decimals="-6" id="f-2270" unitRef="usd">2584000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-620" decimals="-6" id="f-2271" unitRef="usd">3042000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-621" decimals="-6" id="f-2272" unitRef="usd">4868000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-622" decimals="-6" id="f-2273" unitRef="usd">2853000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-620" decimals="-6" id="f-2274" unitRef="usd">233000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-621" decimals="-6" id="f-2275" unitRef="usd">337000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-622" decimals="-6" id="f-2276" unitRef="usd">4187000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <hum:CapitalContributionsToOperatingSubsidiaries contextRef="c-620" decimals="-6" id="f-2277" unitRef="usd">792000000</hum:CapitalContributionsToOperatingSubsidiaries>
    <hum:CapitalContributionsToOperatingSubsidiaries contextRef="c-621" decimals="-6" id="f-2278" unitRef="usd">484000000</hum:CapitalContributionsToOperatingSubsidiaries>
    <hum:CapitalContributionsToOperatingSubsidiaries contextRef="c-622" decimals="-6" id="f-2279" unitRef="usd">2580000000</hum:CapitalContributionsToOperatingSubsidiaries>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-620" decimals="-6" id="f-2280" unitRef="usd">761000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-621" decimals="-6" id="f-2281" unitRef="usd">931000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-622" decimals="-6" id="f-2282" unitRef="usd">958000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-620" decimals="-6" id="f-2283" unitRef="usd">17000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-621" decimals="-6" id="f-2284" unitRef="usd">63000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-622" decimals="-6" id="f-2285" unitRef="usd">200000000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-620" decimals="-6" id="f-2286" unitRef="usd">41000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-621" decimals="-6" id="f-2287" unitRef="usd">468000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-622" decimals="-6" id="f-2288" unitRef="usd">71000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-620" decimals="-6" id="f-2289" unitRef="usd">67000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-621" decimals="-6" id="f-2290" unitRef="usd">30000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities contextRef="c-622" decimals="-6" id="f-2291" unitRef="usd">122000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-620" decimals="-6" id="f-2292" unitRef="usd">-1695000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-621" decimals="-6" id="f-2293" unitRef="usd">-1317000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-622" decimals="-6" id="f-2294" unitRef="usd">-7732000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt contextRef="c-620" decimals="-6" id="f-2295" unitRef="usd">2537000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt contextRef="c-621" decimals="-6" id="f-2296" unitRef="usd">1976000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt contextRef="c-622" decimals="-6" id="f-2297" unitRef="usd">2953000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:RepaymentsOfSeniorDebt contextRef="c-620" decimals="-6" id="f-2298" unitRef="usd">1832000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt contextRef="c-621" decimals="-6" id="f-2299" unitRef="usd">1000000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt contextRef="c-622" decimals="-6" id="f-2300" unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:ProceedsFromRepaymentsOfCommercialPaper contextRef="c-620" decimals="-6" id="f-2301" unitRef="usd">211000000</us-gaap:ProceedsFromRepaymentsOfCommercialPaper>
    <us-gaap:ProceedsFromRepaymentsOfCommercialPaper contextRef="c-621" decimals="-6" id="f-2302" unitRef="usd">-376000000</us-gaap:ProceedsFromRepaymentsOfCommercialPaper>
    <us-gaap:ProceedsFromRepaymentsOfCommercialPaper contextRef="c-622" decimals="-6" id="f-2303" unitRef="usd">352000000</us-gaap:ProceedsFromRepaymentsOfCommercialPaper>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-620" decimals="-6" id="f-2304" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-621" decimals="-6" id="f-2305" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-622" decimals="-6" id="f-2306" unitRef="usd">2500000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-620" decimals="-6" id="f-2307" unitRef="usd">500000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-621" decimals="-6" id="f-2308" unitRef="usd">2000000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-622" decimals="-6" id="f-2309" unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:IncreaseDecreaseInBookOverdrafts contextRef="c-620" decimals="-6" id="f-2310" unitRef="usd">2000000</us-gaap:IncreaseDecreaseInBookOverdrafts>
    <us-gaap:IncreaseDecreaseInBookOverdrafts contextRef="c-621" decimals="-6" id="f-2311" unitRef="usd">5000000</us-gaap:IncreaseDecreaseInBookOverdrafts>
    <us-gaap:IncreaseDecreaseInBookOverdrafts contextRef="c-622" decimals="-6" id="f-2312" unitRef="usd">-52000000</us-gaap:IncreaseDecreaseInBookOverdrafts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-620" decimals="-6" id="f-2313" unitRef="usd">1573000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-621" decimals="-6" id="f-2314" unitRef="usd">2096000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-622" decimals="-6" id="f-2315" unitRef="usd">79000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividends contextRef="c-620" decimals="-6" id="f-2316" unitRef="usd">431000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c-621" decimals="-6" id="f-2317" unitRef="usd">392000000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c-622" decimals="-6" id="f-2318" unitRef="usd">354000000</us-gaap:PaymentsOfDividends>
    <hum:ProceedsFromStockOptionsExercisedAndOther contextRef="c-620" decimals="-6" id="f-2319" unitRef="usd">-125000000</hum:ProceedsFromStockOptionsExercisedAndOther>
    <hum:ProceedsFromStockOptionsExercisedAndOther contextRef="c-621" decimals="-6" id="f-2320" unitRef="usd">40000000</hum:ProceedsFromStockOptionsExercisedAndOther>
    <hum:ProceedsFromStockOptionsExercisedAndOther contextRef="c-622" decimals="-6" id="f-2321" unitRef="usd">29000000</hum:ProceedsFromStockOptionsExercisedAndOther>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-620" decimals="-6" id="f-2322" unitRef="usd">-1711000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-621" decimals="-6" id="f-2323" unitRef="usd">-3843000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-622" decimals="-6" id="f-2324" unitRef="usd">5349000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-620" decimals="-6" id="f-2325" unitRef="usd">-364000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-621" decimals="-6" id="f-2326" unitRef="usd">-292000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-622" decimals="-6" id="f-2327" unitRef="usd">470000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-617" decimals="-6" id="f-2328" unitRef="usd">614000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-623" decimals="-6" id="f-2329" unitRef="usd">906000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-624" decimals="-6" id="f-2330" unitRef="usd">436000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-616" decimals="-6" id="f-2331" unitRef="usd">250000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-617" decimals="-6" id="f-2332" unitRef="usd">614000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-623" decimals="-6" id="f-2333" unitRef="usd">906000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <hum:DividendsToParentWithoutPriorStateRegulatoryApproval contextRef="c-1" decimals="-8" id="f-2334" unitRef="usd">1800000000</hum:DividendsToParentWithoutPriorStateRegulatoryApproval>
    <hum:DividendsToParentWithoutPriorStateRegulatoryApproval contextRef="c-6" decimals="-8" id="f-2335" unitRef="usd">1300000000</hum:DividendsToParentWithoutPriorStateRegulatoryApproval>
    <hum:DividendsToParentWithoutPriorStateRegulatoryApproval contextRef="c-7" decimals="-8" id="f-2336" unitRef="usd">1600000000</hum:DividendsToParentWithoutPriorStateRegulatoryApproval>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance contextRef="c-4" decimals="-8" id="f-2337" unitRef="usd">12200000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance contextRef="c-5" decimals="-8" id="f-2338" unitRef="usd">11300000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired contextRef="c-4" decimals="-8" id="f-2339" unitRef="usd">9800000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired contextRef="c-5" decimals="-8" id="f-2340" unitRef="usd">8400000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired>
    <us-gaap:StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval contextRef="c-4" decimals="-8" id="f-2341" unitRef="usd">1100000000</us-gaap:StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval>
    <hum:DividendsToParentWithoutPriorStateRegulatoryApproval contextRef="c-1" decimals="-8" id="f-2342" unitRef="usd">1800000000</hum:DividendsToParentWithoutPriorStateRegulatoryApproval>
    <hum:DividendsToParentWithoutPriorStateRegulatoryApproval contextRef="c-6" decimals="-8" id="f-2343" unitRef="usd">1300000000</hum:DividendsToParentWithoutPriorStateRegulatoryApproval>
    <hum:DividendsToParentWithoutPriorStateRegulatoryApproval contextRef="c-7" decimals="-8" id="f-2344" unitRef="usd">1600000000</hum:DividendsToParentWithoutPriorStateRegulatoryApproval>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
